<SEC-DOCUMENT>0000950170-23-005113.txt : 20230228
<SEC-HEADER>0000950170-23-005113.hdr.sgml : 20230228
<ACCEPTANCE-DATETIME>20230228162012
ACCESSION NUMBER:		0000950170-23-005113
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		125
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230228
DATE AS OF CHANGE:		20230228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Repare Therapeutics Inc.
		CENTRAL INDEX KEY:			0001808158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39335
		FILM NUMBER:		23685720

	BUSINESS ADDRESS:	
		STREET 1:		7210 FREDERICK-BANTING, SUITE 100
		CITY:			ST-LAURENT
		STATE:			A8
		ZIP:			H4S 2A1
		BUSINESS PHONE:		(857) 412-7018

	MAIL ADDRESS:	
		STREET 1:		7210 FREDERICK-BANTING, SUITE 100
		CITY:			ST-LAURENT
		STATE:			A8
		ZIP:			H4S 2A1
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>rptx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-02-28T16:10:22.0925+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:rptx="http://www.reparerx.com/20221231" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_9e5deaed-1136-4770-a34f-3ccb49c019e1" name="us-gaap:CommonStockSharesAuthorizedUnlimited" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e">Unlimited</ix:nonNumeric><ix:nonNumeric id="F_9b4187e6-d52e-4cb1-9870-e5cca921222a" name="dei:DocumentFiscalPeriodFocus" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0">FY</ix:nonNumeric><ix:nonNumeric id="F_c6dce487-0fd9-46be-b529-50ace5b91fb6" name="dei:CurrentFiscalYearEndDate" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0">--12-31</ix:nonNumeric><ix:nonNumeric id="F_a034e603-6bb2-4ed0-a821-c4d7b64aa710" name="dei:EntityTaxIdentificationNumber" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0">00-0000000</ix:nonNumeric><ix:nonFraction id="F_0e6da3f2-5c56-440d-847a-a498c1b804ad" name="us-gaap:CommitmentsAndContingencies" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_1d4885b4-4eda-475c-a5da-596a44a20fc7" name="rptx:IncomeTaxExaminationYearSubjectToExamination" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0">2017 2018 2019 2020 2021 2022</ix:nonNumeric><ix:nonNumeric id="F_60c9489a-ae3e-4feb-bbbb-83c570d2da18" name="dei:EntityIncorporationStateCountryCode" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0">A8</ix:nonNumeric><ix:nonNumeric id="F_01886432-1548-4ed7-8790-7adb335816ca" name="dei:EntityCentralIndexKey" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0">0001808158</ix:nonNumeric><ix:nonNumeric id="F_2b8d184b-6872-45a6-912c-81feb34b4318" name="dei:AmendmentFlag" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0">false</ix:nonNumeric><ix:nonNumeric id="F_90ad6daa-50a2-42fb-9ca1-285b49414761" name="us-gaap:PreferredStockSharesAuthorizedUnlimited" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0">Unlimited</ix:nonNumeric><ix:nonFraction id="F_219f75ab-b85e-4e79-9264-ee3449aabe80" name="us-gaap:CommitmentsAndContingencies" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_7996140e-14fd-40cf-a2b8-d50b8f060a13" name="us-gaap:CommonStockSharesAuthorizedUnlimited" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0">Unlimited</ix:nonNumeric><ix:nonNumeric id="F_cafa14d4-bdbd-4f40-86d7-72f79346b421" name="us-gaap:PreferredStockSharesAuthorizedUnlimited" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e">Unlimited</ix:nonNumeric><ix:nonNumeric id="F_5c64d736-3755-4363-b2f0-d376d83f9242" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_4fa8599e-cef5-4581-9bfc-a45811c2a414">P32M</ix:nonNumeric><ix:nonFraction id="F_e1a9b1e0-b4b1-4ba7-bb67-f01adfdb1126" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_1c19b0ef-d0c5-4bcc-8394-10c1c635f4f6" unitRef="U_pure" decimals="5" scale="0" format="ixt:numdotdecimal">0.16496</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="rptx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_440d565d-c87e-4c67-922b-8dd7ab19917a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rptx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39535649-8458-447e-b3bd-2d67c59d8b5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bda62528-1f40-4600-97f1-d787732fa2f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rptx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_baf42153-e67f-4dc2-ba51-e440db83cb6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17e3367f-80ab-4165-a57b-7a3da73e2379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rptx:EstimatedSharesIssuableUnderTheEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb5cf079-696f-4343-a699-77c7dc62a392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8706cb3-36b5-4d0e-af7f-dd5993e51a36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86d0da1c-aaaa-4a1a-982b-05aa91d37fd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff1c845e-bbd0-4d13-bdde-c076815d4982"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3402cc5-4f44-4db4-b2f1-72ae898426a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ResearchDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98bf928f-8526-4b16-9053-723fa23a52a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9d543b1-b2e8-4033-a16b-a49687bf6b19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rptx:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69c1b260-1116-4599-800d-1afb2f09f79f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff4a68ee-b5b1-4384-8e04-39e5e83483d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MoneyMarketFundsIncludedInCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bcf5a011-b156-43a6-a346-9debd16c577f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fa8599e-cef5-4581-9bfc-a45811c2a414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6fe10c4b-5340-414c-899a-6ed2280ce2c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac38558a-83a0-47fb-bd07-2be4ac80a958"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f118fdb-411f-477e-a3a2-4b54c2f8d660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">rptx:StateAndUsFederalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42ff0858-ec4a-443e-a421-33c199818df7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rptx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48281951-8326-4dc8-8373-9afcbedac008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94ac4eab-f661-466e-ad3c-d52a1dad0918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_404f23f3-7385-4056-868c-5316d49ea62c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ProductResearchActivityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c9ad6f4-0f96-4cc2-a1f8-7552b59f9ad8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:RepareTherapeuticsIncorporationOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84f40979-c89b-461b-ba1d-ce4f4b049543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df372273-07d1-45f3-97f2-72265a4457ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82791e69-edf1-4fd6-8015-240f7998a7d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edf78ca6-0a38-4dce-a237-43ab79035e63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c1f1f11-816f-44a0-818c-677c87d99b95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12d929c7-4102-4a0a-82ac-5737d31dbf45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b7ac425-2255-44fd-ada4-9a500ac1d1b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:NewYorkUniversityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b9dcbf4-525f-41db-93e3-091d15eb10d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MoneyMarketFundsIncludedInCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d32f5d4c-c383-401d-8204-bd0f61937dfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a5e155a-5edb-4aab-8fba-3f55b166f8d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rptx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a780ab50-a50d-41cf-bc67-6e53d80a9287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9cf3be3d-b394-4173-992a-035a20692942"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36e12a3b-5472-493d-b0e7-efefbdab666c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8717ee6-9026-4027-9c4d-810f9e98e2d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:AccruedExpenseAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79831ab9-e01f-4b6c-ac9f-05479c973e07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d537aff3-5446-4d5f-b08a-5674e6242a97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fad67f8b-88f3-490b-bbfe-cdc36bfeb2fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df52d1fe-29fc-4d0d-8f6f-fd0bf0ff0418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rptx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef8a6a09-6b50-4f94-bb7e-8070837f1e1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bcff83b-674d-4098-82be-f88a301739b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rptx:PreclinicalStudiesAndClinicalTrialsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:TheUniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48b390fd-4b46-46d7-aee6-263c90700965"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51f4647b-4513-4f59-b327-5fe1b4b8ec0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f5ce4e2-c290-41fd-9af5-5d0fb88c397e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ResearchActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44a2af96-1633-4609-b79e-fb906b4b9e17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1f902aa-4006-405b-b0bd-e5a178b2bfaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-23</xbrli:startDate><xbrli:endDate>2020-06-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10a635cc-4c15-4e96-be01-4a9e22f1dbef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a124d3c-84d9-4aa0-bd9c-49a33f8564bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ProductResearchActivityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea477cfd-4c08-4194-a45f-5b0534acacdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e6d1afd-0b5e-467c-9164-fafb352d5632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:OptionsToLicenseUndruggableTargetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1eeb9ab9-2a11-42de-9a18-4d0e8bc99e37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4e66d4b-8df8-4150-855e-17cb5ce1bcb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc490bf6-e1b0-491f-b8e0-2dc975bea1ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MoneyMarketFundsIncludedInCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20ff1fa1-ce48-4c09-9244-1fba1284c839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a16f0b2-09c2-4e09-be6e-37e84f297dcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ea84029-b253-493e-8495-d6a1f2b4c88a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ClinicalTrialMaterialsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e010701-b9b6-4606-92d0-3a2915bef141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_17dcc120-3760-4de9-9e06-6064cef30d4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_678241cd-18bd-45e5-b0fa-05a4f27297f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rptx:OptionsToPurchaseCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edec0475-471a-4ae7-bedf-0d8f8f6903fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_725a0d91-5730-423e-a433-8f6615c75200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2885b753-de7f-4392-894e-f84483b20968"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:NewYorkUniversityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93008ec0-d0c8-4150-bb27-d96cc8c66909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ef6ce9a-5c8e-4c42-b1be-099fd91b49b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db2b4777-c5cc-4811-a937-f402d6499701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63512c11-8031-488d-bf0e-063cdf64bffb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7dc9fc2-b468-4689-8b15-f9d0f5c26ff5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rptx:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1cc4d13-0ecb-41c8-b252-fe8d061ccd9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bfafee29-fc89-418f-885a-bdf98c97ba34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-10</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3c5d94f-28fa-4de1-b6e2-f03d2f331b1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4efbd3ec-210d-4b1b-84fc-55cd67ef578f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_421e346c-f45c-4450-9712-2cde91dba0a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9e1d8a8-8da6-496e-93e9-56257c4a31b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rptx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba8a8b55-bc32-45e4-ac52-b062d5026bf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_434cd7cc-5862-46ac-a5bc-39dc683d789f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_209bac12-6e02-4442-87b0-25af22df7850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aecc3de1-8a93-42ff-8549-71726fd80b22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3cfc3e53-1c58-46fd-a5b8-3badfcad9efb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad4b56bf-9860-4d20-8314-347221a8f5e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BroadInstituteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rptx:SpecialtyScreeningServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-31</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c204b568-e22d-442d-991f-8208f6b49c11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ceb724a0-d094-4e75-ad7c-5458548dadc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21132067-3295-4e05-aca1-b407f86fc88d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51a377d0-935c-4a85-8c6a-d896a70f1212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2334817-ca3c-48d5-8771-4bdef45705e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ResearchDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e75a721e-63db-4a19-a404-91703f5b0417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df9028e4-3b11-4078-8748-bb04b49d52e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3dbc6dec-8dff-4b9e-b1b2-8ee0fd0bfed6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5d1add8-29f2-4667-a5b8-f33390d83a70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d5cfdbd-0c58-4551-828e-64319099c53b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2aca0240-4cad-4cad-b715-46c7dbbe4758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04d861cf-f6d2-4f55-acdf-2117513160d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06d3eba4-beff-4c6e-9e0d-74f30c8e9c98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_570d5b98-d1b3-467c-8957-e622df2b9b75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_acf39634-d069-4302-ab50-45e5dd9d130f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28941f5b-2a91-41bc-8b35-389f61385829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25443f6f-14cc-4288-8365-8cdd9a2d1076"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rptx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a6bffab-7ac1-4529-af70-4292b5a90b4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0059be0f-88d6-4e76-a6ad-ac729b891744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-31</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a43defd-03d5-46c3-9322-0c22c5e6e0fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03151e6d-e0d6-4a61-8ae6-3e23b66eafd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:CombinedLicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c1fa03b-d7de-4cdb-bb33-3af841c54489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d02b1f3e-16d6-4441-958a-8ba01e196c61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_67d17037-8967-4b35-afc2-31124ceecc4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rptx:FollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7fd1537b-f85a-4ef2-915d-82497b788de9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-23</xbrli:startDate><xbrli:endDate>2020-06-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22564969-d47a-4706-ae91-ce5a0d5d6dce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_455d4f5d-1b00-4d1c-8c1b-ced04b5ee882"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:CombinedLicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_882c43fd-0865-4bcc-8ec1-4fcf0c9a4cb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b3e7aa4-3459-470d-87c2-e0d9a02fb4d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a0b6ce9-b609-4951-87ef-6b33661b30ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a2ab1c6-eeb2-450a-825c-b2e0500e4ba4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19ce3969-55ed-4e30-9462-0263222e2f93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae5f3fdb-a581-43e3-bfb4-15c88e51dc08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27f1745b-0673-4b14-ba25-3054bf45721c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:ResearchAndDevelopmentTaxCreditsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9422e8ce-7702-44be-86dc-e5ed61056018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78e0ac1e-933a-4450-9b1d-ff16a6fd8f1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_094da959-0fa8-48bc-82fd-7da9a531e3da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43d1551f-e850-4ce0-95fc-dffbed44030c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_378a21ae-1938-4ec4-a0a9-d3c1716ef61a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eaa1c4ec-6b84-4c2f-bfb1-0f3c64fa8a22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:NewYorkUniversityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_483e024c-e743-4735-98ec-df737668fd18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_218b32a4-44d8-4f35-a8e8-8985b015f2a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:TransferOfClinicalTrialMaterialsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d97e526-4833-4dc6-8113-19ae64b7fa24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb05acb5-808b-494c-bd17-c15d87dfa489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rptx:OptionsToPurchaseCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9271e61c-f687-4b91-af75-f7655d9f62a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a420b6a-118c-4efc-bb28-d98095401947"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09a80f4e-72ef-4a70-a01e-600cbb7a0251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30716fb3-44b9-47e8-800d-7c2d957e670b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7524e4f-ecae-4724-8931-850f78dc9340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MoneyMarketFundsIncludedInCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6fb87044-e5c7-417d-afb8-2aee7d0f78a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d0b1ad6-feb9-4c5d-a621-f47ee6f509c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:NewYorkUniversityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04b847fd-b66f-4a41-bc49-b1bd4e09b5ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_956a103e-2e33-436f-86ac-ceaeba13380a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c095c251-0ca6-45ab-ae2c-2aec9d4fb280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rptx:FollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afaac43e-017a-44ba-b75d-7ea6a3b4e368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47bbe3ab-c619-4531-a810-632c68de1388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-23</xbrli:startDate><xbrli:endDate>2020-06-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b9ebcd23-ea43-4fa8-a367-3a44c77fbe15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:RepareTherapeuticsIncorporationOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96aa4796-a454-4289-a8e9-eb0a4d889465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80ef95e4-5908-4482-8697-3e73902fd846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba56d68a-153c-41be-98bc-d302dc2e8772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_301dd1df-f42b-4bd5-982c-d7e2d3733b57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2261616-9a81-42da-b0cb-ad4847fe864b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5bca2e86-6a57-4346-8aee-8fb3b26b2aca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_847f53e5-4018-4e25-b322-9a0918e5fc97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ProductRptxOptionsToLicenseDruggableTargetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d3ca020-4e0b-4919-95d8-caf1bce5c167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28dfec78-046b-45a4-9c58-7424c3330c88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e91f697c-b5f2-425a-b238-1ed83d875ffd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f5323db-0b40-4adb-a988-178988f085e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:CompletionOfContinuingTrialsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29efdcd1-f366-4daf-8b98-5eaef0a24f0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rptx:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcd5c372-fa91-4030-89f6-8275c0abec98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ProductRptxOptionsToLicenseDruggableTargetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3cd720c-8de2-4d2b-865b-f5dd9deaa416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75c9b122-048e-43f5-a14f-971257b2c683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rptx:PreclinicalStudiesAndClinicalTrialsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:TheUniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f257956-22fd-4563-8031-ee9a1b01466b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:GrantOfLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df85d4b4-de4b-4eb8-a1de-ef8901ea52bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cad33b29-12d6-4338-9a56-8e6337e0ac19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b217459-d769-49eb-838f-22205ffafcb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:ResearchAndDevelopmentTaxCreditsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c19b01e-f2cc-438a-99aa-b2fa48bdc135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11682b1d-2900-4c40-ba7d-c2e787aa1c94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bcb6ad6a-f6c4-44a8-aa2f-56e18ff3d4ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35a0d25d-897e-41e7-bd44-d80a88e5d9aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60665830-af4d-49c6-8e90-64c9fd7235be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_633aa886-db18-4e4b-ac98-428a52434cba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_609633f0-8edb-44b4-852b-0714140adf5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:OptionsToLicenseDruggableTargetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2359962d-31e5-43dc-80af-bffa2bb8add9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_def3be0b-e33c-41d8-b724-4a3e58ec67c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc472ea4-5bfc-43cf-afcc-45da63beb221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5be591d-88a6-4798-a866-48f091aca5bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a573d49c-e7e4-4254-b7c3-222222b5c736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_805bc016-191e-4564-9965-a49c941c6abe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2f83839-f843-4da9-8ac0-9aab66ecad59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:AdditionalClinicalDevelopmentPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b80891b-1319-4360-8f15-2497ed8ea0b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_179763b9-efbc-464b-afa5-88c1837ed3e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c19b0ef-d0c5-4bcc-8394-10c1c635f4f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-12</xbrli:startDate><xbrli:endDate>2020-06-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26af78f0-c117-4481-914d-922b16ea388a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rptx:EstimatedSharesIssuableUnderTheEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c1983cf-a5f8-4eb4-9f92-f0536a7871bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e79f2bb-36b7-445f-a31b-fe962378bd7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17d80998-566f-4f86-8cc7-530d916cebec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0af7e506-9a9a-47a8-b222-a900c293b675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8b79edc-32ab-46da-b385-c6a9975de00c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e186f36-a60e-4c0e-bd2b-4f70ac8527fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2cfdb5b-e3da-4229-a14c-8c3fc5b962d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ba4f675-ecb3-4e4b-9b5d-3da50cb072d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad1fe6be-ea8a-4207-b357-2558aad861b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:AccruedExpenseAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8de25cbb-79b8-4c61-83cd-426c93b13621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rptx:FollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_404b861d-d003-4142-9ce1-6483dccfba5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rptx:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4de6f4d2-6787-40e5-b77a-57e8962ad678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f916e232-9243-456b-b6ab-fa90b5090b81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bcf5428-90b7-43b9-ad8f-851d706606db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed70d3e9-a443-422c-a3ca-f76fb5ddd9dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0432e0bc-120b-4705-8281-2d047c8d1406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001808158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ClinicalTrialMaterialsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_JPY"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Positions"><xbrli:measure>rptx:Positions</xbrli:measure></xbrli:unit><xbrli:unit id="U_CAD"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Lease"><xbrli:measure>rptx:Lease</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:17.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:17.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b25607a0-2ab7-4cad-be80-c8f88a5534e1" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:17.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:17.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.996%;"></td>
    <td style="width:96.004%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b507af14-bdad-4169-90fa-eb118b8af29e" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_54019296-e3f2-4f58-a108-53d82ef57796" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_aa6027a9-1f58-46ea-8ed0-53cac794aa64" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.996%;"></td>
    <td style="width:96.004%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_844dec4b-ed66-4bdd-974e-54e4a7d7fb99" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8f3132f4-6248-472f-ac96-f4e322e8ab1d" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:23.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a6cea6ec-0ae8-4245-b027-dd23de8598b6" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:23.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repare Therapeutics Inc.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:23.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="font-size:23.0pt;font-family:&quot;Times New Roman&quot;, serif;"></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_60c9489a-ae3e-4feb-bbbb-83c570d2da18;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Qu&#xe9;bec</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_a034e603-6bb2-4ed0-a821-c4d7b64aa710;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable</span></span></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_38bca19e-2ef4-4756-97a3-9f1a2a01bff0" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7210 Frederick-Banting</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_53659468-e5c4-46b3-a991-5f62dbc3f971" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 100</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c8cf3ee0-4c02-4906-a0de-3ea9e20d64c0" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">St-Laurent</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_76abd2ae-c47a-4c27-8158-40f661a73e57" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Qu&#xe9;bec</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5f64f7b9-db49-433d-92c1-20f1e57616df" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Canada</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dbeb8a41-0341-4bbd-bc65-b57d83d646f2" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">H4S 2A1</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d8e7cbde-01a9-4549-bafd-a2a5587e9b9d" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_47b5c3a9-4592-4a5a-aea3-d7a1e4e699f7" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">412-7018</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.989%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:18.002%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:40.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_48a96e99-25ab-4ded-abfb-eb67f1dbb3fe" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Shares, no par value</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8a2fdf16-3aef-47f4-85a1-4bef87d64b7e" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RPTX</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3e7f178a-8839-494b-81a5-32e3cb7607d2" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES &#9744; </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c3377d2-5554-44fa-814d-acf65fbc96af" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">N</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  YES &#9744; </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c8c389c6-03dd-4cc6-b9b8-6f21409cdf7e" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">N</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4b287648-d7d8-484a-a768-7419ade5a4b6" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Y</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">es</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746; NO &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b8804e04-03cb-4628-9f72-4b58bd4e51ce" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Y</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">es</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746; NO &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.989%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:6.004%;"></td>
    <td style="width:28.002%;"></td>
    <td style="width:30.0%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:3.996%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_987b70bd-2e58-4ce9-a7bb-c3457e91b407" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ef454ed0-12ac-414b-8d62-0123c928c133" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8b088dc5-5196-4b93-bd59-17e85b02c6ed" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5a5f645a-6657-4318-8ee9-8f7ebef64f04" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  YES &#9744; NO </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d984c708-53ab-4a4a-8901-dadee64f97f9" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of the registrant&#x2019;s common shares held by non-affiliates was $</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f4427a8-2774-4996-9397-433755c3ca25" contextRef="C_2359962d-31e5-43dc-80af-bffa2bb8add9" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">454,878,023</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of June 30, 2022, based on a total of 32,514,512 common shares held by non-affiliates and a closing price of $13.99 as reported on The Nasdaq Stock Market on June 30, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of registrant&#x2019;s common shares outstanding as of February 24, 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">023 was </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0fef3485-773c-4153-ba89-60a10d7305bc" contextRef="C_36e12a3b-5472-493d-b0e7-efefbdab666c" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">42,077,896</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_e42f184e-61c7-4520-a0b5-6fa81a84a285" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the definitive proxy statement for the registrant&#x2019;s 2023 annual meeting of shareholders, which is to be filed within 120 days after the end of the registrant&#x2019;s fiscal year ended December 31, 2022, are incorporated by reference into Part III of this Form 10-K, to the extent described in Part III.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.799%;"></td>
    <td style="width:81.464%;"></td>
    <td style="width:5.737%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#summary_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUMMARY RISK FACTORS</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#special_note"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">162</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">162</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="summary_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUMMARY RISK FACTORS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.253%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing in our common shares involves numerous risks, including the risks described in &#x201c;Part I&#x2014;Item 1A. Risk Factors&#x201d; of this Annual Report on Form 10-K. Below are some of our principal risks, any one of which could materially adversely affect our business, financial condition, results of operations, and prospects:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will require substantial additional funding to finance our operations. If we are unable to raise capital when needed, we could be forced to delay, reduce, or terminate certain of our product development programs or other operations.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are very early in our development efforts. If we are unable to advance our product candidates into and through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business substantially depends upon the successful development of product candidates generated through the application of our SNIPRx platform, and in particular, our initial product candidates, camonsertib and RP-6306. If we or our collaborators, are unable to obtain regulatory approval for, and successfully commercialize, products developed through the application of our SNIPRx platform, our business may be materially harmed.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effects of health epidemics, including the ongoing COVID-19 pandemic, in regions where we, or the third parties on which we rely, have business operations could adversely impact our business, including our preclinical studies and clinical trials. The COVID-19 pandemic could materially affect our operations, including at our offices in Montr&#xe9;al and in the Boston Metro Area, and at our clinical trial sites, as well as the business or operations of our CROs or other third parties with whom we conduct business.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The successful development of targeted therapeutics, including our portfolio of synthetic lethality small molecule inhibitors, as well as any related diagnostics, is highly uncertain.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, on a timely basis or at all, our business will be substantially harmed.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synthetic lethality represents an emerging class of precision medicine targets, and negative perceptions of the efficacy, safety, or tolerability of this class of targets, including any that we develop, could adversely affect our ability to conduct our business, advance our product candidates or obtain regulatory approvals.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be successful in applying our SNIPRx platform to discover synthetic lethality targets with therapeutic and commercial potential or in the discovery and development of commercially viable product candidates for us or our collaborators.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates. We may find it difficult to enroll patients in our ongoing and planned clinical trials with the genomic alterations that these trials are designed to target.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face substantial competition, which may result in others developing or commercializing drugs before or more successfully than us.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to develop new products and product candidates or compete successfully with respect to acquisitions, joint ventures, licenses or other collaboration opportunities, our ability to continue to expand our product pipeline and our growth and development would be impaired. </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third parties to supply and manufacture our product candidates, and we expect to continue to rely on third parties to manufacture our products, if approved. The development of such product candidates and the commercialization of any products, if approved, could be stopped, delayed, or made less profitable if any such third party fails to provide us with sufficient quantities of product candidates or products or fails to do so at acceptable quality levels or prices or fails to maintain or achieve satisfactory regulatory compliance.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends in part on our ability to obtain intellectual property rights for our proprietary technologies and product candidates, as well as our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading price of our common shares has been and is likely to continue to be volatile and fluctuate substantially. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="special_note"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our strategy, future financial condition, future operations, research and development costs, plans and objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;aim,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;assume,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;design,&#x201d; &#x201c;due,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;goal,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;predict,&#x201d; &#x201c;positioned,&#x201d; &#x201c;potential,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The forward-looking statements in this Annual Report include, among other things, statements about:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and related preparatory work and the period during which the results of the trials will become available, as well as our research and development programs;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain regulatory approval of RP-6306 and any of our other current and future product candidates that we develop;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to identify and develop additional product candidates using our SNIPRx platform;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business disruptions affecting the initiation, patient enrollment, development and operation of our clinical trials, including a public health emergency or pandemic, such as the coronavirus disease, or COVID-19, pandemic;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the evolving impact of the COVID-19 pandemic and any variants on our operations, the continuity of our business, including our preclinical studies and clinical trials, supply chains, general economic conditions and our ability to raise additional capital;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to enroll patients in clinical trials, to timely and successfully complete those trials and to receive necessary regulatory approvals;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of completion of enrollment and availability of data from our current preclinical studies and clinical trials, including our Phase 1 clinical trials of RP-6306;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the expected timing of filings with regulatory authorities for any product candidates that we develop;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations regarding the potential market size and the rate and degree of market acceptance for any product candidates that we develop, including other current and future product candidates that we develop;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to receive any milestone or royalty payments under our collaboration and license agreements;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effects of competition with respect to RP-6306, camonsertib or any of our other current or future product candidates, as well as innovations by current and future competitors in our industry;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to fund our working capital requirements;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our intellectual property position, including the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our financial performance and our ability to effectively manage our anticipated growth;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain additional funding for our operations; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other risks and uncertainties, including those listed under the section titled &#x201c;Risk Factors&#x201d; in this Annual Report.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, and involve known and unknown risks, uncertainties and other factors including, without limitation, risks, uncertainties and assumptions regarding the impact of the COVID-19 pandemic on our business, operations, strategy, goals and anticipated timelines, our ongoing and planned preclinical activities, our ability to initiate, enroll, conduct or complete ongoing and planned clinical trials, our timelines for regulatory submissions and our financial position that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You are urged to carefully review the disclosures we make concerning these risks and other factors that may affect our business and operating results in this Annual Report. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Except as required by law, we do not intend, and undertake no obligation, to update any forward-looking information to reflect events or circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1. B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">usiness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a leading clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Synthetic lethality, or SL, represents a clinically validated approach to drug development. We use our proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. SL arises when a deficiency in either of two genes is tolerated in cells, but simultaneous deficiencies in both genes cause cell death. Cancer cells that contain a mutation in one gene of a SL pair are susceptible to therapeutic intervention targeting the other gene pair. Using our SNIPRx platform, we are developing our pipeline of SL product candidates, including our initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ATM gene (ataxia telangiectasia mutated kinase). In July 2020, we began dosing patients in our Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of camonsertib in advanced solid tumors and, in August 2021, we began dosing patients in our Phase 1b/2 ATTACC clinical trial of camonsertib to evaluate the safety and efficacy of camonsertib in combination with approved poly (ADP-ribose) polymerase, or PARP, inhibitors, olaparib and niraparib, in patients with molecularly selected cancers. We signed a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib in June 2022, which resulted in a $125 million upfront payment and up to an additional $1.172 billion in potential development, regulatory, commercial and sales milestones, plus royalties on global net product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2021, we initiated our Phase 1 MYTHIC clinical trial for RP-6306, our PKMYT1 (Protein Kinase Membrane-associated tyrosine- and threonine- specific cdc-2 inhibitory kinase) SL inhibitor, as a monotherapy for the treatment of molecularly selected advanced solid tumors, and anticipate early Phase 1 read-outs from the trial in the first half of 2023. We initiated Phase 1 combination studies of RP-6306 with gemcitabine (MAGNETIC) in December 2021, camonsertib (MYTHIC) in May 2022, and FOLFIRI (MINOTAUR) in August 2022, each for the treatment of molecularly selected advanced solid tumors, and anticipate providing an update on some of these combination studies in the fourth quarter of 2023. In the fourth quarter of 2022, we received fast track designation for RP-6306 in combination with gemcitabine for the treatment of adult patients with CCNE1 amplified, or FBXW7, or PPP2R1A mutated platinum resistant ovarian cancer. Based on promising preclinical data released at the 34th EORTC-NCI-AACR Symposium in October 2022, we are working with clinical investigators to initiate clinical testing, as part of an investigator-sponsored trial (IST), of a fourth new RP-6306 combination with carboplatin, with first patient dosing expected in the first half of 2023. In the fourth quarter of 2022, we entered into an agreement with Canadian Cancer Trials Group, or CCTG, for a planned, basket Phase 2 IST to evaluate RP-6306 in patients with selected, advanced cancers receiving standard agents. We plan to modify the trial to include a sub-study, which will evaluate RP-6306 in combination with gemcitabine in patients with CD4/6i-resistant ER+/HER2- metastatic breast cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to focus on the advancement of our preclinical programs into clinical development. We expect to initiate IND-enabling studies in the first half of 2023 for a small molecule against an undisclosed target with potential to enter the clinic in late 2023 or early 2024, which represents an acceleration from our prior expectations for this program. We are also pursuing development of an inhibitor of polymerase theta (Pol&#x3b8;) in collaboration with Ono, as Pol&#x3b8; is SL with multiple gene deficiencies found in tumors, including BRCA alterations. In 2022, we selected a proposed inhibitor, which we designated as RP-2119. In February 2023, based on our review of ongoing preclinical studies, we elected to prioritize other Pol&#x3b8; inhibiting compounds in our preclinical development portfolio, which we believe have a higher probability for clinical impact relative to RP-2119. We are now guiding toward clinical entry for a Pol&#x3b8; inhibitor in 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe our powerful SL-based approach to the development of new precision oncology therapeutics has multiple potential benefits:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ability to address previously untargetable tumor biology</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, including, for example, loss-of-function mutations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enhanced benefit-risk profile</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, by precisely targeting tumor cells with the defined mutation while sparing normal, non-cancerous cells; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Genetic stratification of patients</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, potentially enabling higher response rates; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tumor-agnostic approach</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, focusing on specific genetics and enabling the application to multiple tumor types. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A cornerstone of our company is our SNIPRx platform, which enables us to accurately identify SL gene pairs and the corresponding patients who are most likely to benefit from our therapies based on the genetic profile of their tumors. These differentiated patient selection insights have driven the development of our initial product candidate, camonsertib, which is designed as a selective inhibitor of the DNA repair protein ataxia telangiectasia and Rad3-related protein, or ATR, a kinase that is activated by DNA replication stress. Tumors containing alterations in genes encoding other DNA repair proteins, such as ataxia-telangiectasia mutated kinase, or ATM, are SL with ATR inhibition and were observed to be hypersensitive to camonsertib in our preclinical models. We believe that the preclinical selectivity and pharmacokinetic properties of camonsertib support the profile of a differentiated therapy with the potential to enhance anti-tumor activity as compared to third party ATR inhibitors currently in development. Based on our preclinical studies, we believe camonsertib has the potential to provide therapeutic benefit to identified patient populations both as a monotherapy and in combination with other therapies such as poly (ADP-ribose) polymerase, or PARP, inhibitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing a portfolio of product candidates based on targets identified using our SNIPRx platform to treat cancers with a high unmet medical need. Our second designated program, RP-6306, is focused on a novel target we discovered to be SL with amplification of cyclin E1, or CCNE1, or deleterious alterations in FBXW7, or PPP2R1A in tumors such as gynecological, colorectal and upper gastrointestinal malignancies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The core of our SNIPRx platform is the ability to identify both known and novel SL targets. Our SNIPRx platform begins with a genome-wide CRISPR-based screening approach that utilizes our proprietary isogenic cell lines, which are cell lines that are identical with the exception of a single genomic alteration, to identify SL gene pairs. Our systematic and comprehensive screening approach has been optimized to significantly reduce false negatives, providing the opportunity to identify a larger and more accurate set of SL interactions as compared to what others have reported with CRISPR-based screening technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have systematically analyzed genomic data from approximately 60,000 tumor samples and identified a set of clinically relevant tumor genomic alterations, which we refer to as tumor lesions, that are linked to genomic instability. The initial tumor lesions are present in approximately 30% of tumors. For each of these tumor lesions, we have completed a SNIPRx screen campaign to identify both previously reported and unreported targets that are SL with the tumor lesion of the campaign. The majority of our SNIPRx screen campaigns have identified multiple potential targets, which allows us to prioritize and select targets based on their potential to be amenable to small molecule inhibitors with drug-like properties. Once a SL product candidate is identified, we perform our proprietary SNIPRx Targeted Expansion of Patient Populations, or STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, screens to identify additional genomic alterations that are SL to our product candidate. Using these screens, we are able to enrich the patient population in our clinical trials and expand the patient populations that may be addressable with our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a leader in developing innovative SL therapies and have built our SNIPRx platform based on three primary pillars:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Identify</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> novel SL targets using our proprietary, genome-wide, CRISPR-enabled screening technology against clinically relevant genomic alterations in tumors with high unmet medical need; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Design and synthesize</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> potent and selective small molecule inhibitors of these targets; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expand</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">beyond the initial target population based on the additional genomic alterations identified by our proprietary STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens that are SL with our inhibitors. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are leveraging our proprietary SNIPRx platform to discover, validate and build a robust pipeline of SL-based therapeutics. Our current pipeline is represented in the diagram below.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img192321128_0.jpg" alt="img192321128_0.jpg" style="width:624px;height:297px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Corporate History and Team</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our company was founded in 2016 by field-leading academics and Versant Ventures to systematically employ SL insights and platforms and develop new precision oncology medicines. Our co-founder, Daniel Durocher, Ph.D., a principal investigator at the Lunenfeld-Tanenbaum Research Institute, was an early pioneer of genome-wide, SL screening using CRISPR, which formed the framework for our SNIPRx platform. Our other co-founders, Agnel Sfeir, Ph.D. now at Memorial Sloan Kettering Cancer Center and Frank Sicheri, Ph.D. at the Lunenfeld-Tanenbaum Research Institute, also played a key role in the development of our company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have assembled a highly qualified management team with broad experience in drug discovery and development to execute on our mission to develop novel precision oncology therapies based on SL. Our scientific co-founders and members of our management team collectively have extensive experience in oncology drug discovery and development and are pioneers in the SL field. Our management team includes industry veterans with prior experience at companies such as Pfizer, AstraZeneca, GSK, Merck, Eli Lilly and Company, Bicycle Therapeutics, Y-mAbs Therapeutics, Santhera Pharmaceuticals and Clementia Pharmaceuticals. We have an experienced research and development team focused on leveraging our deep expertise and differentiated know-how across genomic target identification, target prioritization and selection, drug discovery chemistry and clinical development to develop highly potent and selective small molecule inhibitors based on SL for the treatment of cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our goal is to be the leading biopharmaceutical company developing precision oncology, small molecule therapies based on SL. The key elements of our strategy are to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advance our initial product candidate, camonsertib, by completing ongoing clinical development and supporting collaboration partner Roche in driving broad global development and commercialization. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We designed camonsertib to have a highly selective and potent profile that may enable it to be a leading inhibitor of ATR, if approved, that is further leveraged by our differentiated STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patient selection approach. In July 2020, we began monotherapy dosing in our open-label Phase 1/2 clinical trial. In parallel with the monotherapy dose-escalation portion of the trial, in February 2021, we initiated patient recruitment of the combination therapy arm to evaluate the safety and efficacy of </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">camonsertib in combination with a PARP inhibitor, talazoparib in the same patient subgroups. In August 2021, we initiated patient recruitment in our open-label Phase 1b/2 ATTACC trial of camonsertib in combination with niraparib and olaparib, two additional PARP inhibitors. In October 2021, we presented initial Phase 1 monotherapy clinical data from our open-label Phase 1/2 TRESR trial of camonsertib in patients with solid tumors. We then presented comprehensive Phase 1 monotherapy clinical data from this trial in April 2022. In June 2022, we announced a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib for the treatment of tumors with specific synthetic-lethal genomic alterations. Under the terms of collaboration, Roche assumes all subsequent development of camonsertib with the potential to expand development into additional tumor indications and multiple combination studies.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advance RP-6306 through clinical development by leveraging our differentiated STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patient selection approach.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We designed RP-6306 to be a first-in-class, highly selective and potent small-molecule, oral inhibitor of PKMYT1, which is a novel target that we discovered to be synthetic lethal with CCNE1 amplification and other deleterious genetic alterations. In April 2021, we began dosing patients in our open-label Phase 1 MYTHIC trial of RP-6306 designed to evaluate the safety and tolerability of RP-6306 in advanced solid tumors that are characterized by genomic alterations predicted by our SNIPRx platform to be sensitive to RP-6306. In December 2021, we enrolled the first patient in our open-label Phase 1 MAGNETIC trial to evaluate the safety and tolerability of RP-6306 in combination with gemcitabine. In January 2022, we initiated patient recruitment in our open-label Phase 1 MINOTAUR trial to evaluate the safety and tolerability of RP-6306 in combination with FOLFIRI. In May 2022, we initiated patient recruitment in a new arm of the Phase 1 MYTHIC clinical trial, which is designed to evaluate the safety and tolerability of RP-6306 in combination with camonsertib in patients with advanced solid tumors. In the fourth quarter of 2022, we received fast track designation for RP-6306 in combination with gemcitabine for the treatment of adult patients with CCNE1 amplified, or FBXW7 or PPP2R1A mutated platinum resistant ovarian cancer. Based on promising preclinical data released at the 34th EORTC-NCI-AACR Symposium in October 2022, we are working with clinical investigators to initiate clinical testing of a new carboplatin combination with RP-6306 that is expected to dose the first patient in the first half of 2023. In the fourth quarter of 2022, we entered into an agreement with CCTG for a planned, basket Phase 2 IST to evaluate RP-6306 in patients with selected, advanced cancers receiving standard agents. A sub-study under the master protocol will evaluate RP-6306 in combination with gemcitabine in patients with CD4/6i-resistant ER+/HER2- metastatic breast cancer. We plan to provide an initial Phase 1 clinical data readout for RP-6306 in the first half of 2023 for monotherapy, and anticipate providing an update on some of the combination studies in the fourth quarter of 2023.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continue to advance our preclinical programs into clinical development</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In addition to camonsertib and RP-6306, we have several programs in preclinical development. We expect to initiate IND-enabling studies in the first half of 2023 for a small molecule against an undisclosed target with potential to enter the clinic in late 2023 or early 2024, which represents an acceleration from our prior expectations for this program. We are also pursuing development of an inhibitor of polymerase theta (Pol&#x3b8;) in collaboration with Ono, as Pol&#x3b8; is SL with multiple gene deficiencies found in tumors, including BRCA alterations. In 2022, we selected a proposed inhibitor, which we designated as RP-2119, and initiated IND-enabling studies. In January 2023, we amended our research services, license and collaboration agreement, or the Ono Agreement, with Ono Pharmaceutical Co., Ltd., or Ono, to extend the research term until July 31, 2023. In the first quarter of 2023, we received an approximate $1.5 million (&#165;200 million) research service payment from Ono due to the achievement of a specified research trigger for our Pol&#x3b8; program, under the companies&#x2019; 2019 agreement. In February 2023, based on our review of ongoing preclinical studies, we elected to prioritize other Pol&#x3b8; inhibiting compounds in our preclinical development portfolio, which we believe have a higher probability for clinical impact relative to RP-2119. We are now guiding toward clinical entry for a Pol&#x3b8; inhibitor in 2024.  </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Extend our leading position in SL drug discovery</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We have systematically analyzed genomic data from approximately 60,000 tumor samples and have identified a set of tumor lesions that are linked to genomic instability. This current set of tumor lesions provides us with the opportunity to be among the first to mine this substantial, largely non-overlapping genomic space for new SL gene pairs and develop a robust portfolio of novel targeted therapeutics. We intend to continue leveraging our leading position in the identification of novel oncology SL gene pairs and systematically applying our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens to expand </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the addressable patient populations for each of our product candidates. We believe our approach will allow us to continue to build a sustainable and long-term pipeline of novel product candidates for the targeted treatment of cancers with high unmet medical need.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opportunistically pursue strategic partnerships to maximize the full potential of our pipeline and SNIPRx platform</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The large number of pre-existing mutations affecting genomic stability in tumors combined with the high throughput of our SNIPRx platform has the potential to provide us with an abundance of novel targets. We believe this provides the opportunity to selectively enter into strategic partnerships and leverage our partners&#x2019; complementary capabilities. We regularly evaluate the potential of partnerships and other collaborative efforts to maximize the long-term value of our portfolio. We believe our collaboration with Bristol Myers Squibb highlights the potential broad application of our platform in the search for the next generation of precision oncology medicines.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Background</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Targeted Oncology Therapeutics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The first-generation of approved targeted therapies were predominately directed at driver mutations, which target specific types of receptor tyrosine kinases, such as, bcr-abl, EGFR and HER2, and have largely represented the focus of the targeted oncology sector for the last 20 years. A rapid evolution in the understanding of tumor biology coupled with an improved ability to segment subsets of tumors based on genomic alterations have led to the development of new generations of targeted cancer therapies for a variety of additional tumor-specific genomic abnormalities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Targeting DNA repair genes and specifically loss of function alterations is an emerging area of research with PARP inhibitors pioneering the field. The growing number of compounds in development and multiple clinical studies have begun to reveal patterns of clinical benefit alone and in combination with several other agents.  We expect both monotherapy and combination trials with these agents to emerge quickly and reshape the therapeutic landscape across many disease areas. Consistent with this trend and the specific cell cycle-related mechanisms of action for our lead assets, we have initiated comprehensive development plans for camonsertib and RP-6306 alone or in combination with multiple agents.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The speed at which the field has identified genetic changes associated with tumors has outpaced the discovery and development of precision medicines that can target those alterations. Oncology drug development has been primarily focused on genes with readily druggable alterations that confer new or enhanced protein activity, known as gain-of-function targets, such as EGFR. These include both gain-of-function alterations, such as CCNE1, as well as loss-of-function alterations, such as BRCA1. In June 2019, the New England Journal of Medicine referred to SL as a particularly attractive means to target the complex and gene-network oriented relationships associated with this previously undiscovered domain of oncology targets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The more recent ability to identify a tumor&#x2019;s genetic vulnerabilities and networks of genes responsible for more complex gene functions underlying many cancers has been enabled through new and disruptive technical breakthroughs in the field including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinically-relevant tumor genomic data: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increasing adoption and regulatory acceptance of molecular tumor testing, enabling the accurate profiling of patient tumors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated and annotated databases: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of multiple new and publicly accessible databases that consolidate, analyze, and synthesize new genetic data on tens of thousands of tumors; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tools to apply emerging genetic knowledge: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the emergence of new tools and methodologies, including CRISPR/Cas9, enabling large-scale studies of genetic networks underlying cancer biology. </span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Synthetic Lethality Opportunity and Challenge</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synthetic lethality is a powerful approach and opportunity in oncology drug development that combines two key principles in treating patients with cancer through precision oncology: (1) identifying and selecting patient</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subgroups with specific genomic alterations in tumors that are most likely to benefit from these therapies and (2) improving tolerability and reducing toxicity by not affecting normal, non-cancerous cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SL arises when deficiencies in a pair of genes occur simultaneously to result in cell death, but if that deficiency exists in only one gene, the cell will survive. As depicted below, cancer cells that contain an alteration in one gene of a SL pair are susceptible to therapeutic intervention targeting the other gene pair, resulting in cell death, whereas normal cells are not affected by the inhibition of the targeted gene and remain viable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Illustration of Synthetic Lethality Approach</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_1.jpg" alt="img192321128_1.jpg" style="width:583px;height:297px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The first clinically-validated SL gene pair was PARP-BRCA1/2, and based on the efficacy of PARP inhibitors, the SL approach to treating cancer has achieved substantial commercial validation. PARP enzymes regulate critical DNA repair pathways that cancer cells rely on as they grow and divide. PARP inhibition blocks these pathways, preventing DNA repair in cancer cells with a BRCA1/2 alteration and resulting in cancer cell death while sparing normal cells. Multiple PARP inhibitors, including olaparib (AstraZeneca), niraparib (GlaxoSmithKline), talazoparib (Pfizer), rucaparib (Clovis) and pamiparib (Beigene), have been approved for the treatment of tumors with BRCA and other DNA damage repair alterations, including ovarian, breast, prostate and pancreatic cancers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While SL offers a new route to uncover important gene targets for the treatment of cancers, identifying these SL gene pairs has been a challenge due to the lack of systematic, prospective, and large-scale methods to capture and exploit these gene-gene relationships for new drug discovery and development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Approach: An Overview of Our Drug Discovery and Development Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our SNIPRx platform integrates our deep expertise and differentiated know-how across genomic target identification, target prioritization and selection, drug discovery chemistry and clinical development. Our approach can be divided into six steps, as depicted in the graphic below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Integrated Approach to Drug Discovery and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_2.jpg" alt="img192321128_2.jpg" style="width:624px;height:237px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">1. Select tumor lesion of interest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Apply our deep understanding of tumor lesions with a bias for alterations associated with genomic instability and cancers with high unmet medical need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since 2016, we have systematically analyzed genomic data from approximately 60,000 tumor samples. We consult with leading oncology clinicians and key advisors to identify cancer types and subtypes where the current standard of care is not adequately improving patient survival. We then prioritize genetic lesions based on various criteria including mutation frequency and the feasibility of identifying lesion-positive patients. Of those, we focus on lesions that are known to directly or indirectly impact processes involved in genomic instability, such as DNA repair and cell cycle regulation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2. Execute SNIPRx screen campaign.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Utilize our SNIPRx screening technology to identify target gene candidates that induce SL in the context of our set of tumor lesions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For each of the tumor lesions we identified, each of which we refer to as an original tumor lesion, we have completed a screen campaign utilizing CRISPR technology and other tools to create proprietary isogenic cell lines, which are pairs of cell lines that are identical with the exception of a single genomic alteration. This allows us to identify, on a genome-wide basis, both known and novel targets that are SL with each original tumor lesion. Our SNIPRx platform has been optimized to both sensitivity and reproducibility, resulting in a significant decrease in false negatives compared to what has been reported with other CRISPR-based screening technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">3. Prioritize, select, and validate druggable targets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Evaluate the multiple SL targets identified for each original tumor lesion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our screen campaigns result in the identification of multiple SL targets for each original tumor lesion. We prioritize and select targets to advance into drug discovery based on a systematic and proprietary set of criteria, which include thresholds for biological validation, cellular function, known and likely toxicity, druggability with small molecules, patentability, and the potential for clinical impact versus alternative therapies. Our processes include extensive </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, genetic, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> animal validation of targets and comprehensive development of tool compounds for initial pharmacological corroboration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">4. Develop potent and selective inhibitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Develop small molecule product candidates that are highly potent and selective and advance them from lead discovery through the identification of a clinical candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have assembled an internal research team that has extensive experience in small molecule drug discovery with a proven track record of identifying development candidates and delivering them into and through the clinic. Our team has deep in-house capabilities in cell biology, molecular biology, biochemistry, enzymology, medicinal chemistry, computational chemistry, and molecular modeling. We also have proven capabilities in drug metabolism, pharmacokinetic/pharmacodynamics, and absorption, distribution, metabolism, and excretion evaluation, as well as pharmacology, including dedicated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> animal facilities to internally drive translational studies for human clinical trials. We believe these capabilities were demonstrated in the discovery and development of camonsertib and RP-6306.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">5. Perform SNIPRx Targeted Expansion of Patient Populations (STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">) screens.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expand our potential patient populations beyond those identified by the original SL pair.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once we have identified a clinical candidate, our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens utilize a set of cell lines that, when treated with our clinical candidate, elucidate genes that, when knocked down, cause sensitivity to our selected inhibitor. These screens not only confirm the SL relationship with the original tumor lesion, but also identify additional genomic alterations that confer a response to our product candidates and are mutually exclusive from the original tumor lesion. We believe the identification of these new SL pairs allows us to rationally expand our targeted patient populations by enabling us to potentially treat patients with tumors across multiple genomic alterations with the same product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">6. Conduct clinical trials in an enriched patient population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Design our clinical trials for efficient clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For our clinical trials, we plan to enroll patients with tumors that contain either the original tumor lesion or any one of the genomic alterations identified by our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens. We believe this strategy will allow us to enroll only those patients who are most likely to achieve clinical benefit from our product candidates. In addition, we are prioritizing tumor types for which there are no effective therapies currently available. We plan to evaluate multiple cohorts of patients based on specific genomic alterations, which may enable us to pursue an accelerated regulatory approval pathway for certain targeted patient populations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our SNIPRx Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The core of our SNIPRx platform is the ability to identify both known and novel SL targets. We believe that our platform and approach provide many key advantages as highlighted below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed to Address Previously Untargetable Tumor Biology. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Oncology drug development has been primarily focused on genes with readily druggable alterations that confer new or enhanced protein activity, known as gain-of-function targets, such as EGFR. The remaining targets have historically been considered undruggable. These include both gain-of-function alterations, such as CCNE1, as well as loss-of-function alterations, such as BRCA1. Our SNIPRx platform has demonstrated an ability to identify novel SL relationships, including those that address previously untargetable tumor biology. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Applies Our Proprietary Genome-wide Library. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Genome-scale screens often identify many genes coding for the same protein complex or cellular pathway, thereby increasing confidence in those hits. These screens allow us to screen the entire genome to determine the top hits across all genes, as compared to the more limited druggable gene libraries. In addition, because the definition of what is druggable is continuously evolving, by using genome-scale screens, we are able to mine the results of our existing screens as new therapeutic modalities emerge. Our genome-wide libraries, together with our industrialized and optimized screening approach and technology, result in a significant reduction in false negative hits. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Utilizes Isogenic Cell Lines.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We believe a key differentiator of our SNIPRx platform is the utilization of thoroughly characterized proprietary isogenic cell lines for our CRISPR-based genome-wide SL screen campaigns. We use normal, non-cancerous cell lines to engineer our isogenic cell models, which enable us to mine for SL interactions between two genes in models with clean genetic backgrounds that have minimal mutations and normal chromosome numbers. We have also developed a proprietary computational algorithm that is specifically designed to identify SL interactions from our isogenic screens. We believe using isogenic cell lines gives us a significant competitive advantage since most SL screening approaches used by others are based on cancer cell line panels, which we believe are less accurate due to their propensity to result in variable data. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Focuses on Niche of Genomic Instability. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the well-established network of SL interactions in DNA synthesis and repair across model organisms, we have found and believe we will continue to find clear and reproducible SL interactions through our SNIPRx platform. Genomic instability is an early event that underlies all cancer, and many of the genes we screen represent early hits in cancer that may have less heterogeneity in later stage tumors. The genomic instability space is enriched with genes encoding enzymatic activity, which provides us with ample opportunity to identify novel druggable genes for development into small molecule precision oncology therapies. We believe developing product candidates that target genomic instability may lead to durable responses with resulting clinical benefits for patients. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">One example that illustrates the power of our SNIPRx platform is a SL screen campaign that we conducted in an isogenic pair of cell lines in which one cell line had a BRCA1 mutation and the other cell line was normal for BRCA1. The results of this screen campaign are graphically depicted below. The top-right quadrant of Graphic A highlights the SL hits resulting from our screen and shows that we were able to identify PARP1 as a SL hit with BRCA1. In addition, two additional sets of genes were identified to be SL with BRCA1: (1) the genes encoding the Fanconi Anemia pathway, which are depicted in purple, and (2) the genes coding for the BLM-RMI1-RMI2 complex, which are depicted in green. The independent identification by our SNIPRx screen campaign of multiple genes within a pathway or complex greatly increases confidence that those are true SL hits. In contrast, external cell panel screens that look for SL hits by comparing a panel of cancer cell lines that have either BRCA1-mutant or normal BRCA1 cell lines do not identify these validated BRCA1 SL genes. As shown in Graphic B below, multiple cancer cell line panel screens utilizing CRISPR or shRNA all failed to identify PARP1 as a SL hit with BRCA1.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SNIPRx Screen Campaign Identifies Both Known and Novel SL Pairs Undetected by Cancer Cell Line Panels</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">A. SNIPRx BRCA1 Isogenic SL Screen</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_3.jpg" alt="img192321128_3.jpg" style="width:426px;height:253px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">B. External BRCA1 Cell Panel SL Screens</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_4.jpg" alt="img192321128_4.jpg" style="width:617px;height:149px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Clinical Stage Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Camonsertib, Also Known as RP-3500 or RG6526, an Oral ATR Inhibitor</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our initial clinical-stage product candidate, camonsertib, is a potent and selective oral small molecule inhibitor of ATR that we are developing for the treatment of tumors with mutations in ATM, which is a SL pair with ATR. ATR is a critical DNA damage response, or DDR, protein that acts as both the master regulator of the response to DNA replication stress, as well as a central effector of the DNA damage checkpoint. Based on the previously published SL relationship between ATR and ATM, ATR has been the target of prior drug discovery efforts, and ATR inhibitors in development have demonstrated promising, durable clinical responses in a small number of patients in early clinical trials. Through our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens, we believe that we have more precisely identified and expanded the patient populations that would benefit from camonsertib, which allows us to differentiate and enrich our clinical development strategy as well as address multiple types of solid tumors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Camonsertib has demonstrated an optimized anti-tumor effect, selectivity, and pharmacokinetics profile in preclinical studies that we believe supports the potential for it to be a leading ATR inhibitor, if approved. We also conducted multiple STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens in which we confirmed the SL relationship between ATR and ATM and identified an additional 19 genes that are also SL with ATR, potentially expanding the patient populations that may benefit from our product candidate. In July 2020, we began dosing in our open-label Phase 1/2 clinical trial of camonsertib in patients with advanced tumors that have alterations in the ATM gene or a subset of 16 additional genetic alterations identified through our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens. We believe the design of our trial allows us to enrich the patient population in our trials with those who are most likely to respond to camonsertib. In parallel with the monotherapy dose-escalation portion of the trial, in February 2021 we initiated patient recruitment of the combination therapy arm to evaluate the safety and efficacy of camonsertib in combination with a PARP inhibitor, talazoparib in the same patient subgroups. In August 2021, we initiated patient recruitment in our open-label Phase 1b/2 ATTACC trial of camonsertib in combination with niraparib and olaparib, two additional PARP inhibitors. In October 2021, we presented initial Phase 1 monotherapy clinical data from our open-label Phase 1/2 TRESR trial in patients with solid tumors at the AACRA-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The presentation included the recommended Phase 2 dose and schedule choice and confirmed camonsertib activity in tumors with alterations hypothesized by our SNIPRx platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, we presented comprehensive Phase 1 monotherapy clinical data from the TRESR Phase 1/2 trial, reflecting analysis of 120 patients, of which 99 patients were evaluable for efficacy as of the data cutoff date of February 14, 2022 (excluding one patient evaluated as of March 22, 2022). The study included 95 patients who received therapeutically active doses or at the recommended Phase 2 dose schedule of 3 days on / 4 days off, and reflecting the data cutoff of mid-February 2022. Monotherapy with camonsertib continued to appear safe and well tolerated. Anemia was the most common treatment-related adverse event and easily manageable. Only 24.2% of all patients in the 3 days on / 4 days off schedule experienced Grade 3 anemia, and none experienced Grade 4 anemia. Camonsertib monotherapy resulted in durable clinical benefit across tumor types and genomic alterations, with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">enriched benefit demonstrated in specific patient subsets. These updated monotherapy results showed a 43% clinical benefit rate, or CBR, which was defined as response or treatment duration of at least 16 weeks without progression, an overall response rate of 14%, and a median progression free survival, or mPFS, of 15 weeks in solid tumors across genotypes, with potential best-in-class safety and tolerability. The overall CBR in patients after PARP inhibitor failure was 47%. We observed camonsertib demonstrated robust activity in patients with ovarian cancer (n=20), demonstrating 75% CBR after dosing with camonsertib, an overall response rate of 25%, and a mPFS of 35 weeks. The ovarian cancer patient population was heavily pretreated and comprised a hard to treat population: of which 90% had previous treatment with PARP inhibitors and 85% were platinum resistant. The responders included one complete response, three partial responses as determined by RECIST 1.1 criteria, and one durable and ongoing CA-125 response in a patient with stable disease. The TRESR study comprises the largest set of tumors with detailed genomic analysis evaluated with ATR inhibitor, or ATRi, monotherapy. Genomic subsets of tumors beyond ATM included tumors harboring alterations in ATR-sensitizing genes, with responses observed in tumors harboring BRCA1/2, SETD2 and RAD51C alterations. In patients with BRCA1/2 mutated tumors (n = 37), response rate was 14% and included two patients with ovarian cancer, and one each with breast cancer, head and neck squamous cell carcinoma, and melanoma. In patients with tumors carrying BRCA1 mutations, the CBR was 48%. In patients with tumors with ATM loss-of-function, or LOF (n = 34), response rate was 9% including one RECIST 1.1 confirmed/unconfirmed response, and two prostate specific antigen responses. An additional patient with pancreatic cancer and ATM LOF had a late response, just after the data cutoff after 54 weeks of treatment. The CBR in the patients with ATM LOF was 44%  and mPFS was 17 weeks. Sequencing data demonstrated biallelic gene LOF, an emerging biomarker for synthetic lethal therapies, could potentially be leveraged to further enrich for patients most likely to benefit from camonsertib. CBR in patients with biallelic LOF was significantly higher (47%) compared to the CBR in patients with non-biallelic tumors (15%). <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, we announced a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib for the treatment of tumors with specific synthetic-lethal genomic alterations. Under the terms of the collaboration, Roche assumes all subsequent development of camonsertib with the potential to expand development into additional tumor indications and multiple combination studies. Under the terms of the agreement, we received a $125 million upfront payment in July 2022, and are eligible to receive up to $1.2 billion in potential clinical, regulatory, commercial and sales milestones, including up to $55 million in potential near-term payments, and royalties on global net sales ranging from high-single-digits to high-teens. The collaboration also provides our company with the ability to opt-in to a 50/50 U.S. co-development and profit share arrangement, including participation in U.S. co-promotion if U.S. regulatory approval is received. If we choose to exercise the co-development and profit share option, we will continue to be eligible to receive certain clinical, regulatory, commercial and sales milestone payments, in addition to full ex-U.S. royalties.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Mechanism of Action</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATR is a protein kinase that acts at multiple levels of the DDR network. It is activated when problems with ongoing DNA replication are identified, a phenomenon known as DNA replication stress. It uses its kinase activity to stabilize the DNA replication machinery locally and to suppress the initiation of DNA replication globally. As a consequence, ATR prevents the formation of DNA damage when DNA replication is stressed. In addition to these roles, ATR also restrains cell cycle progression when it is activated, a phenomenon known as the DNA damage checkpoint. ATR is one member of an extensive network of proteins that serve to recognize early stages of DNA damage, prevent replication from proceeding through these damaged sites and repair the damage. Cancer cells with alterations in genes encoding this network of DDR proteins are highly dependent on ATR for survival. ATR&#x2019;s central role in the regulation of replication stress has led to the development of multiple ATR inhibitors that have demonstrated durable responses in early clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The ATR Partner Genes and Proposed Synthetic Lethality Pairs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATM is a DDR protein related to ATR that is responsible for sensing and signaling DNA double-strand breaks. Our ATR inhibitor STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screen campaigns confirmed that ATM-deficient cells rely on ATR activity for survival. ATM orchestrates the response to double-strand break repair and thus, ATM-deficient tumors have an impaired response to DNA breaks. SL screens conducted in our laboratories have identified that at least 16 additional genes are SL with ATR inhibition, making cancer cells that are deficient in those genes highly sensitive to killing by ATR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inhibitors. An overview of the ATM-ATR SL relationship, as one of the examples of the sensitivity genes, is illustrated below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mechanism of ATM-ATR Synthetic Lethality</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_5.jpg" alt="img192321128_5.jpg" style="width:380px;height:578px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The gene encoding for ATM is frequently mutated in cancer. An analysis of sequence data collected as part of The Cancer Genome Atlas, or TCGA, found that between 1% and 4% of solid tumors, such as breast, bladder, pancreatic and lung cancers, have deficiencies in ATM, as depicted in the graphs below. Beyond ATM, 16 of 19 additional, mutually exclusive genomic alterations identified as SL with camonsertib, with average prevalence of approximately 10% across multiple tumors, were eligible for recruitment into clinical trials.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_6.jpg" alt="img192321128_6.jpg" style="width:624px;height:210px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Validation of ATR Inhibitors in ATM-Deficient Tumors and in Other Genetic Backgrounds Hypothesized to Sensitize Tumors to ATRi</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Early phase studies evaluating third party ATR inhibitors as a monotherapy support the rationale for prospective patient selection for tumors carrying genomic alterations hypothesized to sensitize tumors ATR inhibition. A Phase 1 of Bayer&#x2019;s ATR inhibitor suggested antitumor activity in solid tumors with certain DDR defects, including ATM loss (Yap, Cancer Discovery 2020). The subsequent dose expansion cohort enrolled an additional 143 patients, prospectively selected for presence of DDR gene defects. While the overall response rate was low (4%), durable responses were observed in tumors with ATM or BRCA mutations (Yap, AACR 2022). In addition, out of a cohort of 17 patients receiving EMD&#x2019;s ATR inhibitor, the single responder was a patient with metastatic colorectal cancer with loss of ATM (Yap, JCO 2020). <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Phase 1/2 TRESR study prospectively selected for patients with tumors carrying DNA damage repair loss-of-function mutations predicted to sensitize to camonsertib. Following our first clinical data release at the  AACR-ASCO-NCI meeting in October 2021, we presented comprehensive Phase 1 monotherapy data from this study at the AACR annual conference in April 2022. Camonsertib monotherapy resulted in durable responses across tumor types and genomic alterations, including ATM, BRCA1, BRCA2, RAD51C, CDK12, and SETD2. Antitumor activity was validated by molecular responses in 41% of evaluable patients.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, we announced a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib, which provided further validation of our clinical program through the addition of a strategic partner with a leading global footprint and unique expertise in precision oncology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Solution, Camonsertib</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We identified ATR as one of the SL targets through our SNIPRx screen campaign of ATM and selected ATR as a target for our initial product candidate, camonsertib, based on:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">existing third party clinical and preclinical support for the potential of ATR inhibition as a precision oncology therapy; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to design an ATR inhibitor with enhanced chemical properties, such as potency and selectivity; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(iii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens, which identified 19 additional genomic alterations beyond ATM deficiency to be SL with ATR, facilitating the expansion of the addressable patient populations. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We designed camonsertib as an oral small molecule ATR inhibitor with increased potency and a similar or improved selectivity profile compared to other known ATR inhibitors. Camonsertib has demonstrated a favorable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pharmacokinetic profile in multiple preclinical models, including rodent and canine, and a distribution, metabolism and excretion profile that suggests a low potential for drug-drug interactions in the clinic. The clinical trial of camonsertib in patients with recurrent cancers is ongoing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens have generated proprietary patient selection insights that we believe provide the rationale to expand the potential patient populations addressable by camonsertib beyond patients with tumors carrying ATM genetic defects. We have identified 19 genomic alterations, in addition to ATM deficiency, that confer sensitivity to camonsertib. This 19 gene set, which we refer to as our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-identified genes, includes several novel genes that have not been previously reported as rendering sensitivity to ATR inhibitors. In addition, many of the genes we have selected do not overlap with previously identified genes in the homologous recombination defect panel, which is utilized to identify patients for treatment with PARP inhibitors and is currently used by others to test for sensitivity to ATR inhibitors. Furthermore, our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens demonstrated that two genes previously reported by others to be sensitive to ATR inhibition were not sensitive and hence, those genes were excluded from our set of STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-identified genes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The sensitivity and accuracy of our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens enable the identification of several novel gene alterations, including certain genes that are not yet included in commercially available Next Generation Sequencing cancer panels or Clinical Laboratory Improvement Amendments, or CLIA, validated panels used in large academic centers. For our Phase 1/2 clinical trial, we identified and partnered with multiple large, leading clinical centers globally where tumor sequencing is a component of standard of care. These centers&#x2019; panels are validated and sufficiently large to accommodate screening for alterations in ATM or our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-identified genes. These panels include the majority, and in the case of whole genome or whole exome sequencing, all of these genes. For genes that are not available on certain panels at a particular clinical site, we identified surrogate genes that are co-deleted with the STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> genes and have an approximate 30% to 80% probability of concomitant loss, which we believe has and will provide sufficient enrichment for our clinical trial. By working in collaboration with our clinical partners to access their existing patient databases, we believe that we will be able to efficiently identify existing and new patients who may be eligible for our clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the prevalence of ATM deficiencies and our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-identified genomic alterations across various solid tumors, as shown in the graph below, we believe that camonsertib has the potential to benefit a significant number of patients representing a large unmet medical need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Top 10 Tumor Types with Highest Prevalence of ATM Deficiency</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or 16 STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Genomic Alterations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_7.jpg" alt="img192321128_7.jpg" style="width:521px;height:270px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our development strategy for camonsertib, we are evaluating the potential anti-tumor activity of camonsertib in combination with an approved PARP inhibitor based on the synergies we have observed in our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preclinical studies. PARP inhibitors lead to the stabilization of PARP-DNA complexes that block the progression of replication forks. ATR activity stabilizes the DNA replication forks that are destabilized by PARP inhibition and inhibition of ATR causes stalled replication forks to collapse and form cytotoxic DNA double-strand breaks. As a consequence, ATR inhibition can potentiate the cytotoxic effects of PARP inhibitors. We note that this phenomenon is particularly prominent under conditions where some cancer-relevant DDR genes, such as those identified through our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens, are inactivated, thereby creating a potential therapeutic window.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Data: Monotherapy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We observed camonsertib to have a favorable tolerability and pharmacokinetics profile across multiple preclinical studies and animal models, which we believe supports advancing the product candidate into clinical trials. In a preclinical study, we evaluated continuous daily dosing of camonsertib in a colon cancer xenograft model with CW-2 cancer cells, which contain an inactivating mutation in ATM that confers sensitivity to ATR inhibition. In this study, we injected mice with tumor cells and waited for tumor growth to approximately 200 mm</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> before initiating daily dosing over a period of 14 days with vehicle, camonsertib at its maximum tolerated dose, or MTD, of 10 mg/kg/day, or Bayer&#x2019;s ATR inhibitor product candidate, BAY1895344, at what we determined to be its MTD of 35 mg/kg/day (n=10 mice per group). Both camonsertib and BAY1895344 demonstrated statistically significant suppression of tumor growth as compared to vehicle. Importantly, we observed statistically significant higher suppression of tumor growth with camonsertib as compared to BAY1895344 (p=0.018). Body weight loss as a measurement of tolerability was similar for both compounds in this study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statistically Significant Tumor Growth Suppression in Colon Cancer Model</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_8.jpg" alt="img192321128_8.jpg" style="width:617px;height:196px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In another preclinical study using an intermittent dosing schedule, we evaluated camonsertib in comparison to BAY1895344 in a Granta-519 mantle cell lymphoma xenograft model. Similar to CW-2 cancer cells, Granta-519 cancer cells also contain an inactivating mutation in ATM that confers sensitivity to ATR inhibition. In this study, we injected mice with tumor cells and waited for tumor growth to approximately 150 mm</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> before initiating intermittent dosing with vehicle or either treatment (n=9 mice per group). We observed that both camonsertib and BAY1895344 exhibited tolerability at higher doses when administered on a three days per week schedule than their respective MTDs from the daily dosing CW-2 colon cancer study. The MTDs utilizing this intermittent dosing schedule were determined to be 30 mg/kg daily for camonsertib and 50 mg/kg twice-daily for BAY1895344. Both agents demonstrated similar and significant suppression of tumor growth in this model without body weight loss. However, significant anemia, or hematocrit reduction, was observed in mice treated with BAY1895344 (p=0.0002), whereas we did not observe these tolerability issues with camonsertib, which we believe supports our hypothesis of a favorable tolerability profile for camonsertib.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Camonsertib Exhibits Tumor Growth Suppression Without Significant Anemia</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Measured as Hematocrit in Mantle Cell Lymphoma Model</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_9.jpg" alt="img192321128_9.jpg" style="width:590px;height:203px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Data: Combination Therapy with PARP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Of our 19 STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-identified genes for camonsertib as a monotherapy, we have identified a subset of genes that are particularly sensitive to the combination of camonsertib and PARP inhibitors. The graphs below illustrate two examples of this subset of genes where synergy was demonstrated between camonsertib and PARP inhibitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Synergy Demonstrated by Combination of Camonsertib and PARP Inhibitors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_10.jpg" alt="img192321128_10.jpg" style="width:505px;height:316px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:3.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+/+: Wild Type</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-/-: Genomically altered</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We observed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> killing of cells carrying this subset of genomic alterations at low concentrations of both compounds, whereas only a minimal effect was seen on control wild-type cells. Based on this finding, we believe that the combination of camonsertib with lower doses of PARP inhibitors could lead to efficient anti-tumor activity while</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potentially addressing the tolerability issues observed with PARP inhibitors, where a majority of patients in clinical trials of niraparib and talazoparib required a dose reduction or interruption in dosing. We are currently exploring the ATR-PARP inhibitor synergy in additional ongoing studies in xenograft models.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Data: Combination Therapy with Gemcitabine</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gemcitabine is an antimetabolite chemotherapeutic agent that is commonly used in various solid tumors such as pancreatic, breast, ovarian, and non-small cell lung cancer. Gemcitabine is metabolized by the tumor cells and incorporated in their DNA, resulting in blockage of DNA polymerases and replication fork stalling. This gemcitabine-induced replication stress increases the tumor cells&#x2019; dependency on the ATR pathway and gemcitabine is therefore known to strongly enhance the cytotoxic effects of ATR inhibitors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our preclinical data demonstrate that gemcitabine shows strong synergy with camonsertib in ATM-deficient (ATM-KO) cells, whereas much higher doses are required to achieve the same degree of synergy in ATM-proficient (ATM-WT) cells (Figure A below). Consequently, camonsertib combined with gemcitabine kills ATM-KO cells at low concentrations that show little effect in WT cells (Figure B below). We therefore believe that the combination with gemcitabine may enhance the anti-tumor activity of camonsertib in ATM-deficient cancers at tolerated doses. We are currently evaluating this combination in tumor cells carrying additional STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> alterations as well as in animal models.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sensitivity of ATM-deficient cells to the combination of camonsertib and gemcitabine</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_11.jpg" alt="img192321128_11.jpg" style="width:624px;height:282px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Validation of STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Screens</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Through our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens of ATR inhibitors, we confirmed the SL relationship between ATR and ATM and identified an additional 19 genomic alterations that confer sensitivity to camonsertib. In follow-up studies with cancer cell line pairs, in which the only difference is the inactivation of the target genes, we are confirming the sensitivity of these genomic alterations to camonsertib, and this extensive validation effort is still being expanded. We are also creating xenograft models using both the parent cell lines and the inactivated cell line. In such a model using one of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-identified genes, camonsertib led to statistically significant suppression of tumor growth, whereas it had no anti-tumor effect in tumors created with wild-type parent cells, as shown in the model below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tumor Growth Suppression in a </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RNASEH2B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> -/- 5637 Bladder Isogenic Xenograft Model</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_12.jpg" alt="img192321128_12.jpg" style="width:622px;height:230px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Camonsertib Clinical Trial Program</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Design of Trials:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2020, we initiated our open-label Phase 1/2 clinical trial of camonsertib as both a monotherapy and in combination with talazoparib, an approved PARP inhibitor. The trial is designed to evaluate the oral administration of camonsertib in patients with advanced recurrent tumors of different histologies with ATM loss-of-function or a subset comprised of 16 of the 19 STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-identified genomic alterations, for which recent in-vitro studies suggested a higher confidence of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ongoing monotherapy dose escalation phase of our trial, we are evaluating the dosing regimen and safety of camonsertib to establish the recommended dose for the expansion phase of the trial. In three expansion cohorts, each of which has been designed to enroll patients based on ATM loss-of-function or different STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-identified genomic alterations, we will assess the preliminary efficacy of camonsertib at the recommended dose and schedule. In parallel with the monotherapy dose escalation phase, the trial is designed to enroll a separate arm to evaluate camonsertib in combination with talazoparib, an approved PARP inhibitor. An efficacy evaluation is performed every six weeks for the first five months and every nine weeks thereafter. As of the date of this Annual Report, we have activated twelve clinical trial sites in North America and Europe, all of which are actively enrolling patients. We observed initial signs of biological and clinical activity as monotherapy and evaluated multiple doses and schedules. We established the recommended Phase 2 dose as 160 mg once daily 3 days on / 4 days off, given continuously every week with a tolerability and safety profile that is favorable and the dominant on-target toxicity is anemia. Grade 3 anemia was reported at 15% with no grade 4 anemia and other grade 3 or 4 toxicities were at maximum 5%. Clinical responders were seen across multiple genomic alterations and tumor types. Clinical benefit rate reported at the AACR-ASCP-NCI meeting in October 2021 was 49%. In February 2021, we initiated recruitment of patients for the talazoparib combination arm of the trial. In December 2021 we entered the Phase 2 part of the trial with expansion into specific tumor and genotype cohorts. We reported complete safety and efficacy data for the monotherapy dose escalation phase of the trial at AACR in April 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The design of our Phase 1/2 clinical trial for camonsertib, now partnered with Roche, is summarized in the diagram below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img192321128_13.jpg" alt="img192321128_13.jpg" style="width:624px;height:273px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Full Dataset from the TRESR Phase 1/2 Trial Presented at AACR 2022:</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, we presented comprehensive Phase 1 monotherapy clinical data from the TRESR Phase 1/2 trial, reflecting analysis of 120 patients, of which 99 patients were evaluable for efficacy as of the data cutoff date of February 14, 2022 (excluding one patient evaluated as of March 22, 2022). The study included 95 patients who received therapeutically active doses or at the recommended Phase 2 dose schedule of 3 days on / 4 days off, and reflecting the data cutoff of mid-February 2022. Monotherapy with camonsertib continued to appear safe and well tolerated. Anemia was the most common treatment-related adverse event and easily manageable. Only 24.2% of all patients in the 3 days on / 4 days off schedule experienced Grade 3 anemia, and none experienced Grade 4 anemia. Camonsertib monotherapy resulted in durable clinical benefit across tumor types and genomic alterations, with enriched benefit demonstrated in specific patient subsets. These updated monotherapy results showed a 43% CBR, which was defined as response or treatment duration of at least 16 weeks without progression, an overall response rate of 14%, and a mPFS of 15 weeks in solid tumors across genotypes, with potential best-in-class safety and tolerability. The overall CBR in patients after PARP inhibitor failure was 47%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We observed camonsertib demonstrated robust activity in patients with ovarian cancer (n=20), demonstrating 75% CBR after dosing with camonsertib, an overall response rate of 25%, and a mPFS of 35 weeks. The ovarian cancer patient population was heavily pretreated and comprised a hard to treat population: of which 90% had previous treatment with PARP inhibitors and 85% were platinum resistant. The responders included one complete response, three partial responses as determined by RECIST 1.1 criteria, and one durable and ongoing CA-125 response in a patient with stable disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The TRESR study comprises the largest set of tumors with detailed genomic analysis evaluated with ATRi monotherapy. Genomic subsets of tumors beyond ATM included tumors harboring alterations in ATR-sensitizing genes, with responses observed in tumors harboring BRCA1/2, SETD2 and RAD51C alterations. In patients with BRCA1/2 mutated tumors (n = 37), response rate was 14% and included two patients with ovarian cancer, and one each with breast cancer, head and neck squamous cell carcinoma, and melanoma. In patients with tumors carrying BRCA1 mutations, the CBR was 48%. In patients with tumors with ATM loss-of-function, or LOF, (n = 34), response rate was 9% including one RECIST 1.1 confirmed/unconfirmed response, and two prostate specific antigen responses. An additional patient with pancreatic cancer and ATM LOF had a late response, just after the data cutoff after 54 weeks of treatment. The CBR in the patients with ATM LOF was 44%  and mPFS was 17 weeks. Sequencing data demonstrated biallelic gene LOF, an emerging biomarker for synthetic lethal therapies, could potentially be leveraged to further enrich for patients most likely to benefit from camonsertib. CBR in patients with biallelic LOF was significantly higher (47%) compared to the CBR in patients with non-biallelic tumors (15%). <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RP-6306, Our Novel, First-in-Class PKMYT1 Inhibitor Program</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Using our proprietary, CRISPR-based SNIPRx discovery platform, we identified PKMYT1 as a strong hit in a CCNE1-overexpression SL screen. PKMYT1 is a kinase that phosphorylates CDK1, thereby holding the cyclin B-CDK1 complex in an inactive state until the cell is ready to enter mitosis. RP-6306 is being developed as a highly potent and selective PKMYT1 inhibitor that preferentially kills tumor cells overexpressing CCNE1 and was shown to inhibit the growth of a broad range of CCNE1-amplified tumors in xenograft/PDX preclinical models, both as a single agent and in combination therapy settings. RP-6306 has a favorable preclinical PK profile as well as low potential for drug-drug interactions. Application of our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> genome-wide chemical screen has identified other gene alterations beyond CCNE1 amplification that are uniquely targetable by RP-6306, including tumors that have loss of FBXW7 function, a cell-cycle regulator that has been implicated as a key genetic driver in a broad range of cancers, and represent further areas of unmet medical need. We initiated patient recruitment in our open-label Phase 1 MYTHIC trial, as a monotherapy, for this program in April 2021. Our Phase 1 trial is enrolling patients suffering from recurrent tumors characterized by CCNE1 amplification and other genomic alterations which our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> preclinical studies predicted to be sensitive to RP-6306. We are evaluating more than one schedule, if necessary, at which the capsules are given in this dose escalation trial. The primary objective is to establish the recommended Phase 2 dose and schedule for RP-6306 for further studies as monotherapy and assess preliminary safety, tolerability, PK, and PD in patients. In December 2021, we enrolled the first patient in our open-label Phase 1 MAGNETIC trial to evaluate the safety and tolerability of RP-6306 in combination with gemcitabine. In January 2022, we initiated patient recruitment in our open-label Phase 1 MINOTAUR trial to evaluate the safety and tolerability of RP-6306 in combination with FOLFIRI. In May 2022, we initiated patient recruitment in a new arm of the Phase 1 MYTHIC clinical trial, which is designed to evaluate the safety and tolerability of RP-6306 in combination with camonsertib in patients with advanced solid tumors. In the fourth quarter of 2022, we received fast track designation for RP-6306 in combination with gemcitabine for the treatment of adult patients with CCNE1 amplified, or FBXW7 or PPP2R1A mutated platinum resistant ovarian cancer. Based on promising preclinical data released at the 34th EORTC-NCI-AACR Symposium in October 2022, we are working with clinical investigators to initiate clinical testing, as part of an investigator-sponsored trial (IST), of a fourth new RP-6306 combination with carboplatin, with first patient dosing expected in the first half of 2023. In the fourth quarter of 2022, we entered into an agreement with CCTG for a planned, basket Phase 2 IST to evaluate RP-6306 in patients with selected, advanced cancers receiving standard agents. We have planned a sub-study under this trial, which will allow us to evaluate RP-6306 in combination with gemcitabine in patients with CD4/6i-resistant ER+/HER2- metastatic breast cancer. We plan to provide an initial Phase 1 clinical data readout for RP-6306 in the first half of 2023 for monotherapy, and anticipate providing an update on some of the combination studies in the fourth quarter of 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Mechanism of Action</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PKMYT1, the gene targeted by RP-6306 has not previously been published as a SL gene pair with CCNE1 amplification, and we are not aware of any advanced drug discovery efforts against this target. In preclinical studies, we observed that the deletion of this gene was well tolerated in wild-type cells, but it caused lethality in isogenic cancer cells that overexpressed CCNE1.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">High levels of CCNE1 protein, an activating subunit of cyclin dependent kinase 2, or CDK2, are often observed in patients across multiple tumor types. Deregulation of cell cycle control is thought to be a prerequisite for tumor development, and several studies have demonstrated accelerated entry of cells into the S phase, or DNA synthesis phase, of the cell cycle, due to constitutive, or &#x201c;always-on,&#x201d; expression of CCNE1. Such an accelerated entry of cells into the S phase is a common sign of unregulated, cancerous growth. CCNE1 amplification can induce chromosome instability, another sign of cancer, by contributing to inappropriate initiation of DNA replication. Several studies have demonstrated that CCNE1 amplification or constitutive expression is associated with disease progression in various malignancies as well as poor clinical prognosis in patients across multiple cancers, including ovarian, breast, bladder, and colorectal cancer. For example, clinical data from patients with ovarian cancer indicate that those with CCNE1-amplified tumors have significantly shorter overall survival than those with tumors without CCNE1 amplification, as shown below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CCNE1 Amplification is Associated with Significantly Shorter Overall Survival</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in Patients with Ovarian Cancer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_14.jpg" alt="img192321128_14.jpg" style="width:279px;height:199px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CCNE1 amplification is found in 4% of tumors in the pan-cancer TCGA studies. Over 40% of uterine carcinosarcoma cancers and 10% to 20% of ovarian and stomach cancers harbor CCNE1 amplification. Together, these cancers lead to over 40,000 deaths each year in the United States. Additional cancer types also harbor CCNE1 amplification at a lower frequency, including up to 3% to 8% of esophagus, bladder, lung, and pancreatic cancers, as shown below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Top 10 Tumor Types with Highest Frequency of CCNE1 Amplification</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_15.jpg" alt="img192321128_15.jpg" style="width:597px;height:278px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Solution, RP-6306</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We identified PKMYT1 as a critical SL target for patients with CCNE1 amplification through our SNIPRx screening campaign and selected PKMYT1 as a target for our lead product candidate, RP-6306, based on:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">i.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the target validation for PKMYT1;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">ii.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to design potent and selective PKMYT1 inhibitors; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">iii.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens, which identified at least two additional genomic alterations beyond CCNE1 amplification to be SL with PKMYT1 inhibitor facilitating the expansion of the addressable patient populations.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We designed RP-6306 as an oral small molecule PKMYT1 inhibitor with significant potency and an encouraging selectivity profile as a first in class compound. RP-6306 has demonstrated a favorable pharmacokinetic profile in multiple preclinical models, including rodent and canine, and a distribution, metabolism and excretion profile that suggests a low potential for drug-drug interactions in the clinic. The clinical trial of RP-6306 in patients with recurrent cancers is ongoing.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens have generated proprietary patient selection insights that we believe provide the rationale to expand the potential patient populations addressable by RP-6306 beyond patients with tumors carrying CCNE1 amplification. We have specifically identified FBXW7 and PPP2R1A genomic alterations, in addition to CCNE1 amplification, that confer sensitivity to RP-6306. This set of genes offers extended patient populations such as about 13% of colorectal cancer and other high unmet need tumors as presented in the graph below.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Top 10 tumor types with highest prevalence of CCNE1 amplification and FBXW7 mutations deficiency</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img192321128_16.jpg" alt="img192321128_16.jpg" style="width:624px;height:169px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The proposed alterations specific to RP-6306 tumors are easily identifiable in commercially available Next Generation Sequencing cancer panels or CLIA-validated panels used in large academic centers. For our Phase 1/2 clinical trial, we identified and partnered with multiple large, leading clinical centers globally where tumor sequencing is a component of standard of care. These centers&#x2019; panels are validated and sufficiently large to accommodate screening for alterations in FBXW7 and CCNE1 or our other STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-identified genes. By working in collaboration with our clinical partners to access their existing patient databases, we are able to efficiently identify patients who may be eligible for our clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the prevalence of RP-6306 relevant genomic alterations across various solid tumors, as shown in the graph above, we believe that RP-6306 has the potential to benefit a significant number of patients representing a large unmet medical need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical data: Monotherapy</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We observed that RP-6306 has a favorable tolerability and PK profile preclinically which we believe supported advancement of the product candidate into clinical trials. We tested RP-6306 as a single agent in two preclinical cell line derived models of cancer selected to represent our target patient populations by having amplification of CCNE1. The HCC1569 breast cancer model and the OVCAR3 ovarian cancer model with CCNE1 copy numbers of 34-fold and 14-fold above ploidy, respectively. In the HCC1569 breast cancer xenograft model, RP-6306 was orally administered at doses of 2.5, 7.5 or 20 mg/kg twice daily (BID) for 28 days. RP-6306 produced a dose-dependent reduction in tumor growth reaching a statistically significant difference at all doses and a maximum effect of 77%. In the 20 mg/kg group, mice exhibited body weight loss of 3.2% at the end of study. In the OVCAR3 ovarian cancer xenograft model, RP-6306 was orally administered at doses of 2.5, 7.5 or 20 mg/kg twice daily (BID) for 28 days. RP-6306 produced a dose-dependent reduction in tumor growth reaching a statistically significant difference at all doses and a maximum effect of 82%. In the 20 mg/kg group, mice exhibited body weight loss of 6.9% at the end of study.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In preclinical studies, RP-6306 demonstrated in vivo anti-tumor activity in two cell line derived xenograft models with CCNE1 amplification. In both models, we observed statistically significant dose-dependent tumor growth suppression across a range of doses from 2.5 to 20 mg/kg BID (twice-daily administration for RP-6306).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RP-6306 Demonstrates Tumor Growth Suppression in CCNE1-Amplified Cell Line Derived Xenograft Models</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span><img src="img192321128_17.jpg" alt="img192321128_17.jpg" style="width:517px;height:240px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Data: Combination Therapies with RP-6306</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Chemotherapeutic drugs have diverse mechanisms of action, and some target DNA replication and induce DNA replication stress. During the S-phase of the cell cycle, DNA is replicated to create DNA for two daughter cells following cell division. S-phase disrupting drugs increase dependence on cell cycle checkpoints. Combining this S-phase vulnerability with RP-6306, which forces S-phase replicating cells into premature mitosis, is expected to be catastrophic to tumor cells.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gemcitabine prolongs the S-phase by both interfering with DNA polymerase and disrupting the supply of nucleotides. Clinically, gemcitabine has been used as a single agent or in combination with carboplatin, cisplatin, or paclitaxel for the treatment of pancreatic, ovarian, breast, bladder, testicular, and non-small cell lung cancer. Recent studies have tested gemcitabine in combination with DNA damage repair inhibitors (PARP and ATR inhibitors), as well as cell cycle inhibitors (WEE1, CDK4/6, and Chk1 inhibitors) across a spectrum of relapsed or refractory advanced solid tumors. Attempts to combine gemcitabine with inhibitors of these checkpoints have struggled with toxicity, impacting proliferating tumor and normal tissue with similar effect. In a setting of CCNE1, FBXW7, PPP2R1A, and potentially other RP-6306 STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> genetic alterations, however, it is expected that gemcitabine will exacerbate the replication stress environment where PKMYT1 is essential for survival and provide synthetic lethal synergy with enhanced benefit and therapeutic index.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The rationale behind combining RP-6306 and FOLFIRI in CCNE1-amplified or FBXW7-mutated tumors is similar to that of gemcitabine. The two main agents found in FOLFIRI are irinotecan (metabolized in tissues to SN-38) and fluorouracil, both of which act specifically in S-phase. SN-38 acts on the topoisomerase I-DNA complex and prevents re-ligation of the DNA strand, resulting in double-strand DNA breaks and cell death. Fluorouracil acts as a thymidylate synthase inhibitor which blocks synthesis of the pyrimidine thymidine, required for DNA replication. Combining this chemotherapy-induced S-phase vulnerability with RP-6306, which forces S-phase replicating cells into premature mitosis, is expected to be catastrophic to tumor cells.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The combination of RP-6306 and gemcitabine was evaluated in CCNE1 amplified model of ovarian cancer (OVCAR3) on a continuous BID dosing of RP-6306 at 10mg/kg and gemcitabine at 20mg/kg once weekly. The combination resulted in complete tumor regression that was significantly better than either agent alone with minimal impact on body weight loss (6.8% for the combination at the end of dosing).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RP-6306 + Gemcitabine Drives Regression and No Serious Toxicity in CCNE1-Amplified Cell Line Derived Xenograft</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><img src="img192321128_18.jpg" alt="img192321128_18.jpg" style="width:624px;height:238px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The combination of RP-6306 and irinotecan was evaluated in CCNE1-amplified model of breast cancer (HCC1569) on a continuous BID dosing of RP-6306 at 5 mg/kg and irinotecan at 30 mg/kg three times a week. The combination resulted in tumor regression that was significantly better than either agent alone with minimal impact on weight loss (1.5% for the combination at the end of dosing).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RP-6306 + Irinotecan Drives Regression and is Well Tolerated in CCNE1-Amplified Cell Line Derived Xenograft</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><img src="img192321128_19.jpg" alt="img192321128_19.jpg" style="width:624px;height:263px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The combination of low dose RP-6306 and camonsertib was evaluated in a pair of isogenic models of colorectal cancer having normal FBXW7 or FBXW7 loss-of-function. RP-6306 was administered at 5mg/kg BID and camonsertib was administered at 10mg/kg QD three times a week. Neither compound alone nor the combination substantially impacted tumor growth of FBXW7-normal tumors. In contrast, a low dose of RP-6306 in combination</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with camonsertib resulted in profound regression of FBXW7 loss-of-function tumors with 3 of 8 mice tumor free on day 22. The combination was well tolerated with a &lt; 8% maximal mean body weight loss.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RP-6306 + Camonsertib Selectively Drives Regression and is Well Tolerated in a FBXW7 Loss-of-Function Cell Line Derived Xenograft</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><img src="img192321128_20.jpg" alt="img192321128_20.jpg" style="width:581px;height:257px;" /><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Validation of STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Screens</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To identify additional genetic lesions which might have a synthetic lethal relationship with PKMYT1, several STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens were conducted. These genome wide CRISPR screens were conducted with sub-cytotoxic concentrations of PKMYT1 inhibitor and identified FBXW7 and several additional genetic alterations. FBXW7 is known to be mutated in colorectal cancers and NSCLC, among others. FBXW7 is an E3-ubiquitin ligase that targets Cyclin E1 (as well as other oncogenes) for degradation by the proteosome and has been shown to be a tumor suppressor gene. Therefore, there exists a strong mechanistic rationale for synthetic lethality with PKMYT1, and they represent a significant opportunity to expand the clinical utility of RP-6306.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In preclinical studies, RP-6306 demonstrated in vivo anti-tumor activity in two patient derived xenograft models with FBXW7 inactivating mutations. In both models, we observed statistically significant tumor growth suppression with twice daily administration for RP-6306.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RP-6306 Demonstrates Tumor Growth Suppression of FBXW7-Mutated Patient Derived Xenograft Models</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><img src="img192321128_21.jpg" alt="img192321128_21.jpg" style="width:624px;height:198px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Design of Trials</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2021, we initiated our open-label Phase 1 MYTHIC clinical trial of RP-6306 as a monotherapy. The trial is designed to evaluate the oral administration of RP-6306 in patients with advanced recurrent tumors of different histologies in tumors with detected CCNE1 amplification, deleterious alterations in FBXW7, PPP2R1A and other STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> genes, for which recent in-vitro studies suggested a higher confidence of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ongoing monotherapy dose escalation phase of our MYTHIC trial, we are evaluating the dosing regimen and safety of RP-6306. The MYTHIC trial is enrolling patients suffering from recurrent tumors characterized by CCNE1 amplification and other genomic alterations, which our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> preclinical studies predicted to be sensitive to RP-6306. We are evaluating more than one schedule at which the capsules are given, as necessary, in this dose escalation trial. The primary objective is to establish dose and schedule for RP-6306 for further studies as monotherapy and assess preliminary safety and tolerability in patients. The clinical plan beyond the dose escalation and initial explorations of dose and safety is presented below. In parallel with the monotherapy dose escalation phase, two other trials were initiated in February 2022 and December 2021, which we refer to as the MINOTAUR and MAGNETIC trials, to evaluate RP-6306 in combination with FOLFIRI and gemcitabine, respectively. In May 2022, we initiated patient recruitment in a new arm of the Phase 1 MYTHIC clinical trial, which is designed to evaluate the safety and tolerability of RP-6306 in combination with camonsertib in patients with advanced solid tumors. In the fourth quarter of 2022, we received fast track designation for RP-6306 in combination with gemcitabine for the treatment of adult patients with CCNE1 amplified, or FBXW7 or PPP2R1A mutated platinum resistant ovarian cancer. Based on promising preclinical data released at the 34th EORTC-NCI-AACR Symposium in October 2022, we are working with clinical investigators to initiate clinical testing, as part of an investigator-sponsored trial (IST), of a fourth new RP-6306 combination with carboplatin, with first patient dosing expected in the first half of 2023. In the fourth quarter of 2022, we entered into an agreement with CCTG for a planned, basket Phase 2 IST to evaluate RP-6306 in patients with selected, advanced cancers receiving standard agents. We plan to initiate a sub-study, which will allow us to evaluate RP-6306 in combination with gemcitabine in patients with CD4/6i-resistant ER+/HER2- metastatic breast cancer. We plan to provide an initial Phase 1 clinical data readout for RP-6306 in the first half of 2023 for monotherapy, and anticipate providing an update on some of the combination studies in the fourth quarter of 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The designs of our Phase 1 clinical trial and Phase 2 IST are summarized in the diagram below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><img src="img192321128_22.jpg" alt="img192321128_22.jpg" style="width:624px;height:295px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Polymerase Theta (Pol&#x3b8;) Preclinical Program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing a small molecule inhibitor of Pol&#x3b8;, a SL target associated with BRCA mutations as well as other genomic alterations, in collaboration with Ono. This program was initially added to our portfolio through a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaboration with our co-founder, Dr. Agnel Sfeir, now at Memorial Sloan Kettering Cancer Center, who initially published her observations on the SL between BRCA and Pol&#x3b8; in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nature</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in 2016.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Polymerase theta enzyme, or POLQ, is a DNA polymerase enzyme that participates in the repair of double-strand breaks in DNA. Mutations in genes such as BRCA1 and BRCA2 increase the frequency of these breaks, resulting in SL with Pol&#x3b8;. Preclinical studies have shown that inactivation of Pol&#x3b8; both on its own and in combination with PARP inhibitors reduces survival in BRCA-mutated cells, but not in BRCA wild-type cells. BRCA1 and BRCA2 mutations are routinely identified in multiple genetic profiling tests and observed in approximately 1% to 7% of patients with breast and ovarian cancer. However, the frequency of mutations in one of these BRCA genes increases in women with a family history of disease and in certain subpopulations. For example, up to 37% of patients with breast cancer with low estrogen and progesterone receptor expression have BRCA mutations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BRCA1 and BRCA2 mutations have also been shown in clinical trials to be SL with PARP inhibitors in multiple tumors, such as breast and ovarian cancer. While PARP inhibitors have proven effective in BRCA-mutant tumors, no statistically significant survival benefit has been reported in breast or pancreatic cancer to date, highlighting the potential for other SL targets, such as Pol&#x3b8;, to demonstrate meaningful efficacy as a monotherapy or in combination with PARP inhibitors. In 2022, we selected a proposed inhibitor, which we designated as RP-2119, and initiated IND-enabling studies. In February 2023, based on our review of ongoing preclinical studies, we elected to prioritize other Pol&#x3b8; inhibiting compounds in our preclinical development portfolio, which we believe have a higher probability for clinical impact relative to RP-2119. We are now guiding toward clinical entry for a Pol&#x3b8; inhibitor in 2024.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We strive to protect and enhance the proprietary technologies, inventions, and improvements that we believe are important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms, and our product candidates that are important to the development and implementation of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our patent portfolio relating to our product candidates included seven pending U.S. provisional patent applications, consisting of; two applications covering uses of ATR inhibitors; two applications covering CCNE1-SL inhibitors and their use; one application covering the manufacture of RP-6306; and two applications covering PolQ inhibitors and their use. In addition, our patent portfolio included six pending international applications under the Patent Cooperation Treaty of 1970, or the PCT, three covering camonsertib and/or its uses and three covering RP-6306 and its uses. Our portfolio also included five pending U.S. non-provisional patent applications, three covering camonsertib and its use and two covering RP-6306 derivatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, three of our four PCT applications have composition of matter or method of treatment and use claims covering camonsertib. Any application, if issued, claiming priority to any of these PCT applications is expected to expire in 2040, not including any patent term adjustment. One of our four solely owned PCT applications has composition of matter claims covering RP-6306. Any application, if issued, claiming priority to this PCT application is expected to expire in 2041, not including any patent term adjustment. Any patent issuing in our solely owned, pending U.S. non-provisional patent application having composition of matter and method of treatment and use claims covering camonsertib and its use is expected to expire in 2039, not including any patent term adjustment. Any patent issuing in our solely owned, pending U.S. non-provisional patent application having method of treatment and use claims covering certain uses of camonsertib is expected to expire in 2040, not including any patent term adjustment. Any U.S. patent, if issued, claiming priority to any one of the U.S. provisional patent applications covering uses of camonsertib is expected to expire in 2043. Any U.S. patent, if issued, claiming priority to any one of the U.S. provisional patent applications covering CCNE1-SL inhibitors and their use, is expected to expire in 2042. Any U.S. patent, if issued, claiming priority to either of the U.S. provisional patent applications covering CCNE1-SL inhibitors, including RP-6306 and its use, is expected to expire in 2043. Any U.S. patent, if issued, claiming priority to the U.S. provisional patent applications covering uses of CCNE1-SL inhibitors, including RP-6306, is expected to expire in 2043. Any U.S. patent, if issued, claiming priority to the U.S. provisional patent applications covering PolQ inhibitors and their use, is expected to expire in 2043.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> As of December 31, 2022, our patent portfolio also included two co-owned, pending international applications under the Patent Cooperation Treaty of 1970, or the PCT. The PCT applications cover uses of CCNE1-SL inhibitors, including RP-6306.  Any U.S. patent, if issued, claiming priority to the PCT applications is expected to expire in 2041 or 2042, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are granted a term of 20 years from the earliest effective non-provisional filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office, or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The PCT is an international patent law treaty that provides a unified procedure for filing patent applications to protect inventions in each of its contracting states. Thus, a single PCT application can be converted into a patent application in any of the PCT-contracting states, and is considered a simple, cost-effective means for seeking patent protection in numerous regions or countries. This nationalization (converting into an application in any of the contracting states) typically occurs 18 months after the PCT application filing date. An applicant must undertake prosecution within the allotted time in each of the contracting states or on a regional basis if it determines to undertake patent issuance in protection in such country or territory. Pursuant to its PCT application, the Company expects to pursue patent protection in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our collaborators and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our product candidates or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future product candidates may have an adverse impact on us. For more information, please see &#x201c;Risk Factors&#x2014;Risks Related to Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaborations and License Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and Worldwide License Agreement with Roche</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, we announced a worldwide license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd (collectively, Roche), or the Roche Agreement for the development and commercialization of camonsertib and specified other ATR inhibitors for the treatment of tumors with specific synthetic-lethal genomic alterations. Under the Roche Agreement, Roche assumes all subsequent development of camonsertib with the potential to expand development into additional tumor indications and multiple combination studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Roche Agreement, we received a $125 million upfront payment in July 2022, and are eligible to receive up to $1.172 billion in potential clinical, regulatory, commercial and sales milestones, including up to $55 million in potential near-term payments, and royalties on global net sales ranging from high-single-digits to high-teens. We received $5.6 million in October 2022 for the transfer of clinical trial material on hand to Roche, as agreed to pursuant to the Roche Agreement. In December 2022 we received an additional payment of $4.0 million negotiated with Roche for revisions to the clinical development plan under the Roche Agreement as agreed to by the parties on July 13, 2022. The Roche Agreement also provides our company with the ability to opt-in to a 50/50 U.S. co-development and profit share arrangement, including participation in U.S. co-promotion if U.S. regulatory approval is received, that is exercisable prior to the commencement of the first pivotal clinical trial of camonsertib. If we choose to exercise the co-development and profit share option, we will continue to be eligible to receive certain clinical, regulatory, commercial and sales milestone payments, in addition to full ex-U.S. royalties. Royalties are payable by Roche on a product by product and country by country basis until the later of 12 years following the first commercial sale of a licensed product in such country or the expiration of certain exclusivity rights.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have agreed to complete the specified ongoing clinical trials, TRESR and ATTACC, at our expense. We have also retained the right to conduct specified clinical trials of camonsertib in combination with our PKMYT1 compound, RP-6306.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Roche Agreement was subsequently amended in October 2022 to extend the timeline to negotiate in good faith the parties&#x2019; rights and obligations with respect to certain clinical trials and to clarify indications included in the development plan that are subject to milestones.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and License Agreement with Bristol-Myers Squibb Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2020, we entered into a collaboration and license agreement, or the BMS Agreement, with Bristol-Myers Squibb Company, or Bristol Myers Squibb, pursuant to which we and Bristol Myers Squibb have agreed to collaborate in the research and development of potential new product candidates for the treatment of cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are providing Bristol Myers Squibb access to a selected number of our existing early SNIPRx screening campaigns and novel campaigns. We are responsible for carrying out early-stage research activities directed to identifying and validating potential targets for licensing by Bristol Myers Squibb, in accordance with a mutually agreed upon research plan. The collaboration consists of programs directed to both druggable targets and to targets commonly considered undruggable by traditional small molecule approaches. In the event that Bristol Myers Squibb elects to obtain an exclusive license on for the subsequent development, manufacture and commercialization of a program, Bristol Myers Squibb will then be solely responsible for all such worldwide activities. The research collaboration will be overseen by a joint steering committee through completion of all research activities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The BMS Agreement has been subsequently amended in July, September and November 2020 to expand our collaboration with Bristol Myers Squibb. We amended the BMS Agreement to, among other things: (i) include additional campaigns to the list of Existing Repare Campaigns (as such term is defined in the BMS Agreement) from which Bristol Myers Squibb may select campaigns under the BMS agreement, and (ii) enable unblinding of a Bristol Myers Squibb alliance manager in order to streamline the collaboration and selection process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the BMS Agreement, Bristol Myers Squibb paid us an initial upfront fee payment of $50.0 million. In connection with entering into the BMS Agreement, we also entered into a warrant agreement with an affiliate of Bristol Myers Squibb pursuant to which we issued a warrant for total proceeds of $15.0 million, which was automatically exercised into 750,000 common shares upon closing of our IPO at which time the warrants were cancelled.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For each of the targets in the collaboration, we are entitled to receive, on a program-by-program basis, option exercise fees ranging in the low six figures depending on the nature of the applicable program. Bristol Myers Squibb has the right to retain rights to certain back-up programs in exchange for a one-time payment in the low eight figures per program. Additionally, we are entitled to receive additional fees ranging in the low to mid seven figures upon the selection of certain programs beyond a specified limit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, we received notification from Bristol Myers Squibb of their option exercise for two druggable targets directed at a single synthetic lethal lesion, pursuant to the terms of the BMS Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the BMS Agreement, we are entitled to receive up to $3.0 billion in total milestones across all potential programs. Such milestones consist of $301.0 million in total milestones per program, including $176.0 million in the aggregate for certain specified research, development, and regulatory milestones and $125.0 million in the aggregate for certain specified commercial milestones. We are also entitled to a tiered percentage royalty on annual net sales ranging from high-single digits to low-double digits, subject to certain specified reductions. Royalties are payable by Bristol Myers Squibb on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On a program-by-program basis, prior to the earlier of such program ceasing to be included under the BMS Agreement and expiration of the last to expire royalty term for such program, we, alone and with third parties, are prohibited from researching, developing, manufacturing and commercializing products that are directed to the applicable target for such program.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also have provided Bristol Myers Squibb with certain, limited rights to first negotiate with us if we determine to divest, license, or collaborate with others regarding certain existing programs, including in the event that we received an unsolicited offer to do so. The right to first negotiation expressly excludes any potential Change of Control transaction (as such term is contractually defined in the BMS Agreement).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The BMS Agreement will expire on a licensed product-by-licensed product and country-by-country basis on expiration of the applicable royalty term and in its entirety upon expiration of the last royalty term. Either party may terminate the BMS Agreement earlier upon an uncured material breach of the agreement by the other party, or the insolvency of the other party. Additionally, Bristol Myers Squibb may terminate the BMS Agreement for any or no reason on a program-by-program basis upon specified written notice.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research Services, License and Collaboration Agreement with Ono Pharmaceutical Co.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">All payments by Ono to us are presented in U.S. dollars. Future payments as disclosed in this summary have been converted to U.S. dollars at the December 31, 2022 exchange rate of $1.00 = [131.12] Japanese yen.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2019, we entered into a research services, license and collaboration agreement, or the Ono Agreement, with Ono Pharmaceutical Co., Ltd., or Ono, pursuant to which we and Ono have agreed to collaborate in the research of potential product candidates targeting Pol&#x3b8; and the development of our small molecule Pol&#x3b8; inhibitor program. We are primarily responsible for carrying out research activities to identify a product candidate for the program, to be licensed to Ono, in accordance with a mutually agreed upon research plan until the first submission of an IND in the United States or Japan. In the event that Ono elects to collaborate on the subsequent development and commercialization of a proposed product candidate, Ono will then be responsible for such activities in Japan, South Korea, Taiwan, Hong Kong, Macau and certain other Southeast Asian countries, and we will be responsible for such activities in the rest of the world. The collaboration will be overseen by a joint research committee through development candidate selection and a joint steering committee thereafter. Except as set forth below, each party will bear its own expenses in connection with research, development, and commercialization activities under the Ono Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, we entered into an amendment to the Ono Agreement whereby the Research Term, as defined in the Ono Agreement, was extended by one year at no additional cost to us. In January 2023, we and Ono entered into a second amendment to the Ono Agreement whereby the Research Term was extended until July 31, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Ono Agreement, Ono paid us an initial upfront fee payment of &#165;110 million (approximately $1.0 million). Additionally, in connection with the research activities to be conducted by us pursuant to the Ono Agreement, Ono paid us an initial upfront research service payment of &#165;790 million (approximately $7.1 million) and has agreed to make research service payments up to an aggregate of &#165;750 million (approximately $5.7 million) upon (i) certain specified research triggers and (ii) the election by Ono to collaborate on the development and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commercialization of a proposed product candidate. In October 2021 and December 2022, the Company achieved specified research triggers amounting to &#165;100 million ($0.9 million) and &#165;200 million ($1.5 million), respectively, as research service payments provided for in the Ono Agreement. The &#165;200 million ($1.5 million) is included in the collaboration revenue receivable at December 31, 2022 and was subsequently received in January 2023. Upon election by Ono to collaborate on a proposed product candidate, Ono shall be responsible for a specified percentage of research and development costs for the IND-enabling studies of the selected product candidate. As of December 31, 2022 there was $10.5 million classified as current deferred revenue related to the Ono Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Ono Agreement, we are also entitled to receive up to &#165;5.11 billion (approximately $39.0 million) in the aggregate for certain specified development and regulatory milestones, &#165;12.1 billion (approximately $92.3 million) in the aggregate for certain specified commercial milestones and a tiered percentage royalty on annual net sales in Ono&#x2019;s territory ranging from high-single digits to low teens, subject to certain specified reductions. Royalties are payable by Ono on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed product in such country and the tenth anniversary of the first commercial sale of such licensed product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the term of the Ono Agreement, we, alone and with third parties, are prohibited from researching, developing, manufacturing and commercializing products that inhibit or modulate Pol&#x3b8; as a mechanism of action in Ono&#x2019;s territory (as such term is defined in the Ono Agreement). During the term of the Ono Agreement, Ono, alone and with third parties, is prohibited from researching, developing, manufacturing and commercializing products, other than licensed products, that inhibit or modulate Pol&#x3b8; as a mechanism of action in Ono&#x2019;s territory.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The collaboration and research obligations of the Ono Agreement may be terminated upon the mutual written consent of both parties on or before the two-year anniversary of the Ono Agreement. The Ono Agreement expires on the date of expiration of all royalty obligations. Either party may terminate the Ono Agreement earlier upon an uncured material breach of the agreement by the other party, the insolvency of the other party, or the initiation of an action challenging the validity or enforceability of a party&#x2019;s patents. Additionally, Ono may terminate the Ono Agreement for any or no reason on a product-by-product and country-by-country basis upon specified written notice, as well as on a product-by-product basis for safety or efficacy reasons upon abbreviated written notice. Moreover, in the event that we are acquired by a third party and after any such acquisition the acquirer initiates a competing program in Ono&#x2019;s territory, Ono will have the right to treat such initiation as a material breach.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement with New York University</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2016, we entered into a license agreement with New York University pursuant to which we obtained a worldwide, royalty-bearing, exclusive license under certain current and/or future patents and know-how of New York University to research, develop and commercialize products that are covered by such licensed patents or otherwise modulate Pol&#x3b8;. Upon initial entry into the license agreement, we issued New York University 60,211 common shares in December 2016 as consideration for the license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2018, we subsequently amended and restated our license agreement with NYU, which we refer to, as amended and restated, as the NYU Agreement. Pursuant to the terms of the NYU Agreement, we are obligated to use reasonable diligence in connection with the research, development, and commercialization of the licensed products (as such term is defined in the NYU Agreement), including specified minimum annual spends on research and development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the NYU Agreement, we are obligated to pay New York University annual license maintenance fees in the low five figures that are creditable against any milestone payments payable in such year. Additionally, in connection with development, regulatory and commercial activities, we have agreed to make milestone payments of (i) $2.6 million in the aggregate for a product covered by a licensed patent that achieves specified development and sales milestones for the first indication, (ii) $1.3 million in the aggregate for a product covered by a licensed patent that achieves specified development and sales milestones for a second indication, (iii) $575,000 in the aggregate for a product covered by a licensed patent that achieves specified development and sales milestones for each of a third and fourth indication, (iv) $1.3 million in the aggregate for a product that is not covered by a licensed patent that achieves specified development and sales milestones for the first indication, (v) $650,000 in the aggregate for a product that is not covered by a licensed patent that achieves specified development and sales</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">milestones for a second indication, (vi) $287,500 in the aggregate for a product that is not covered by a licensed patent that achieves specified development and sales milestones for each of a third and fourth indication. We have the right to reduce these milestone payments by a specified amount of any milestones payable to a third party for a license required for the commercialization of a product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also obligated to pay New York University a low single digit royalty on net sales of any product covered by a licensed patent and a lower single digit royalty on net sales of any product that is not covered by a licensed patent, in each case subject to reduction by a specified amount of any royalties payable to a third party for a license to unblocking intellectual property. Moreover, we are obligated to pay New York University a percentage of any non-royalty consideration received by us from a sublicensee ranging in the low double digits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ono is considered a sublicensee under the terms of the NYU Agreement. Accordingly, we have paid New York University a specified percentage of the approximately $1.0 million initial upfront fee payment we received from Ono and we will be required to pay New York University a percentage between the high teens and low twenties of any future payments received under the Ono Agreement from Ono for development, regulatory and commercial milestones, as well as low single digit royalties on annual net sales in Ono&#x2019;s territory.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments in respect of net sales or sublicense in a country shall remain in force on a product-by-product, country-by-country basis, with respect to (i) products that are not covered by a licensed patent, for ten years from the date of first commercial sale in such country and (ii) products that are covered by a licensed patent, until the expiration date of the last to expire of the licensed patents covering such product or its manufacture or use in the applicable country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The NYU Agreement expires on the date of expiration of all royalty obligations. Either party may terminate the NYU Agreement earlier upon an uncured material breach of NYU Agreement by the other party or the insolvency of the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales and Marketing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We have established a wholly-owned U.S. subsidiary, Repare Therapeutics USA Inc., a Delaware corporation with operations in Cambridge, Massachusetts, to support our clinical development program and our potential commercialization efforts in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently rely, and expect to continue to rely for the foreseeable future, on third-party contract manufacturing organizations, or CMOs, to produce our product candidates for preclinical and clinical testing, as well as for future commercial manufacture of any products that we may commercialize.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We require all of our CMOs to conduct manufacturing activities in compliance with current good manufacturing practice, or cGMP, requirements. We have assembled a team of experienced employees and consultants to provide the necessary technical, quality, and regulatory oversight over our CMOs. Currently, we have manufacturing and supply agreements with our CMOs for the manufacture of RP-6306 and our preclinical candidates, including the synthesis of the active pharmaceutical ingredient, or API, as well as drug product. Roche will manufacture and supply camonsertib for ongoing and future trials, in compliance with cGMP requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All of our product candidates are small molecules and are manufactured in synthetic processes from available starting materials. The chemistry underlying our product candidates appears amenable to scale up and does not currently require unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We plan to continue to rely on third-party manufacturers for any future trials and commercialization of RP-6306, and any future product candidates, if approved, and will rely on Roche to manufacture and supply camonsertib for any future trials and commercialization, if approved. We anticipate that Roche and these CMOs will have capacity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to support commercial scale production, but we do not have any formal agreements in place at this time given our early stages of development. If needed, we believe we can identify and establish additional CMOs to provide API and finished drug product without significant disruption to our business or clinical development timelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by the rapid evolution of technologies and understanding of disease etiology, intense competition, and a strong emphasis on intellectual property. We believe that our approach, strategy, scientific capabilities, know-how and experience provide us with competitive advantages. However, we expect substantial competition from multiple sources, including major pharmaceutical, specialty pharmaceutical, and existing or emerging biotechnology companies, academic research institutions and governmental agencies and public and private research institutions worldwide. Many of our competitors, either alone or with their collaborations, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient enrollment in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result, our competitors may discover, develop, license, or commercialize products before or more successfully than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the development of precision oncology therapies for patients with genetically-defined cancers. Several biopharmaceutical companies, including Loxo Oncology, Inc. (acquired by Eli Lilly and Company), Blueprint Medicines Corporation, SpringWorks Therapeutics, Inc., Black Diamond Therapeutics, Inc., Deciphera Pharmaceuticals, Inc., Tango Therapeutics, Inc., Zentalis Pharmaceuticals, Inc., Turning Point Therapeutics, Inc. (acquired by Bristol Myers Squibb), and Exelixis, Inc. are developing precision oncology medicines. In addition, we may face competition from companies developing product candidates that are based on SL, including AstraZeneca, GlaxoSmithKline, Pfizer, Bayer, Merck Serono, Schrodinger, Inc., Exelixis, Inc., Artios Pharma Ltd., IDEAYA Biosciences, Inc, Impact Therapeutics, Aprea Therapeutics, Acrivon Therapeutics, Treadwell Therapeutics, Debiopharm Group, Varsity Pharma, Breakpoint Therapeutics, and Rhizen Pharmaceuticals AG.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, we also face competition more broadly across the oncology market for cost-effective and reimbursable cancer treatments. The most common methods of treating patients with cancer are surgery, radiation, and drug therapy, including chemotherapy, hormone therapy, biologic therapy, such as monoclonal and bispecific antibodies, immunotherapy, cell-based therapy and targeted therapy, or a combination of any such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates, if any are approved, may compete with these existing drugs and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates may not be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market may pose challenges. In addition, many companies are developing new oncology therapeutics, and we cannot predict what the standard of care will be as our product candidates progress through clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to our initial product candidate, camonsertib (now partnered with Roche), several companies are developing ATR inhibitors with multiple monotherapy and/or combination trials ongoing, including AstraZeneca (AZD6738), Bayer (BAY1895344), Merck Serono (M4344, M6620, M1774) and most recently, Artios Pharma (ATR0380), Aprea Therapeutics/Atrin Pharmaceuticals (ATRN-119), and Impact Therapeutics (IMP9064). The intensity of trials with ATR inhibitors as monotherapy and in combination with immune-oncology compounds, chemotherapy and radiation, as well as other DDR inhibitors significantly increased over the last several months.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to our PKMYT1 inhibitor product candidate, RP-6306, Exelixis, Inc. and Acrivon Therapeutics have disclosed PKMYT1 inhibitor programs in early preclinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For our preclinical Pol&#x3b8; inhibitor program, Artios Pharma (ART-4215), IDEAYA Biosciences (in collaboration with GlaxoSmithKline plc), Varsity Pharma, Breakpoint Therapeutics, and Rhizen Pharmaceuticals AG have Pol&#x3b8; programs in various stages of clinical and preclinical development.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could see a reduction or elimination in our commercial opportunity if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are more convenient to administer, are less expensive or with a more favorable label than our product candidates. Our competitors also may compete for available patient pool, slowing our accrual in trials, obtain FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture, and marketing of pharmaceutical products. These agencies and other federal, state, and local entities regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, packaging, recordkeeping, tracking, approval, import, export, distribution, advertising, and promotion of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Government Regulation of Drug Products</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#x2019;s refusal to approve a pending New Drug Application, or NDA, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The process required by the FDA before product candidates may be marketed in the United States generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nonclinical laboratory and animal tests that must be conducted in accordance with good laboratory practices, or GLPs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an investigational new drug application, or IND, which must become effective before clinical trials may begin; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval by an independent institutional review board, or IRB, for each clinical site or centrally before each trial may be initiated; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed product candidate for its intended use, performed in accordance with good clinical practices, or GCPs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an NDA and payment of user fees; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with cGMP and good clinical practices, or GCPs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of an NDA to permit commercial marketing for particular indications for use; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The testing and approval process requires substantial time, effort, and financial resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical studies include laboratory evaluation of drug substance chemistry, pharmacology, toxicity, and drug product formulation, as well as animal studies to assess potential safety and efficacy. Prior to commencing the first clinical trial with a product candidate, a sponsor must submit the results of the preclinical tests and preclinical literature, together with manufacturing information, analytical data and any available clinical data or literature, among other required information, to the FDA as part of an IND. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the conduct of the clinical trial and imposes a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in FDA authorization to commence a clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Trials</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development, as well as amendments to previously submitted clinical trials. Further, an independent IRB for each institution participating in the clinical trial must review and approve the plan for any clinical trial, its informed consent form, and other communications to study subjects before the clinical trial commences at that site. The IRB must continue to oversee the clinical trial while it is being conducted, including any changes to the study plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory authorities, an IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk, the clinical trial is not being conducted in accordance with the FDA&#x2019;s or the IRB&#x2019;s requirements, or if the drug has been associated with unexpected serious harm to subjects. Some studies also include a data safety monitoring board, which receives special access to unblinded data during the clinical trial and may advise the sponsor to halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In general, for purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1&#x2014;Studies are initially conducted to test the product candidate for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution and excretion in healthy volunteers or subjects with the target disease or condition. If possible, Phase 1 clinical trials may also be used to gain an initial indication of product effectiveness. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2&#x2014;Controlled studies are conducted with groups of subjects with a specified disease or condition to provide enough data to evaluate the preliminary efficacy, optimal dosages and dosing schedule and expanded evidence of safety. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expansive Phase 3 clinical trials. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3&#x2014;These clinical trials are generally undertaken in larger subject populations to provide statistically significant evidence of clinical efficacy and to further test for safety in an expanded subject population at multiple clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. These clinical trials may be done at trial sites outside the United States as long as the global sites are also representative of the U.S. population and the conduct of the study at global sites comports with FDA regulations and guidance, such as compliance with GCPs. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called Phase 4 studies may be made a condition to be satisfied after approval. The results of Phase 4 studies can confirm the effectiveness of a product candidate and can provide important safety information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials must be conducted under the supervision of qualified investigators in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial, and the review and approval of the study by an IRB. Investigators must also provide information to the clinical trial sponsors to allow the sponsors to make specified financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated and a statistical analysis plan. Information about some clinical trials, including a description of the trial and trial results, must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The manufacture of investigational drugs for the conduct of human clinical trials is subject to cGMP requirements. Investigational drugs and active pharmaceutical ingredients imported into the United States are also subject to regulation by the FDA relating to their labeling and distribution. Further, the export of investigational drug products outside of the United States is subject to regulatory requirements of the receiving country as well as U.S. export requirements under the FDCA. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and the IRB and more frequently if serious adverse effects occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality, and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Special FDA Expedited Review and Approval Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has various programs, including fast track designation, breakthrough therapy designation, accelerated approval, and priority review, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the fast track program, the sponsor of a new drug candidate may request that FDA designate the drug candidate for a specific indication as a fast track drug concurrent with, or after, the filing of the IND for the drug candidate. To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides additional opportunities for interaction with the FDA&#x2019;s review team and may allow for rolling review of NDA components before the completed application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. However, the FDA&#x2019;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. The FDA may decide to rescind the fast track designation if it determines that the qualifying criteria no longer apply.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, a sponsor can request breakthrough therapy designation for a drug if it is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drugs designated as breakthrough therapies are eligible for intensive guidance from the FDA on an efficient drug development program, organizational commitment to the development and review of the product including involvement of senior managers, and, like fast track products, are also eligible for rolling review of the NDA. Both fast track and breakthrough therapy products may be eligible for accelerated approval and/or priority review, if relevant criteria are met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the FDA&#x2019;s accelerated approval regulations, the FDA may approve a drug for a serious or life threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. A drug candidate approved on this basis is subject to rigorous post marketing compliance requirements, including the completion of Phase 4 or post approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post approval studies and regularly update FDA on their progress, or confirm a clinical benefit during post marketing studies, will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated approval regulations are subject to prior review by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once an NDA is submitted for a product intended to treat a serious condition, the FDA may assign a priority review designation if FDA determines that the product, if approved, would provide a significant improvement in safety or effectiveness. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under the Prescription Drug User Fee Act, or PDUFA, guidelines. Under the current PDUFA performance goals, these six and ten month review periods are measured from the 60-day filing date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review from the date of submission.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, the manufacturer of an investigational drug for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on responding to requests for expanded access. Furthermore, fast track designation, breakthrough therapy designation, accelerated approval and priority review do not change the standards for approval and may not ultimately expedite the development or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NDA Submission and Review by the FDA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assuming successful completion of the required clinical and preclinical testing, among other items, the results of product development, including chemistry, manufacture and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission of an NDA requires payment of a substantial user fee to the FDA. These user fees must be filed at the time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, under the Pediatric Research Equity Act, an NDA or supplement to an NDA for a new active ingredient, indication, dosage form, dosage regimen or route of administration must contain data that are adequate to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA must refer applications for drugs that contain active ingredients, including any ester or salt of the active ingredients, that have not previously been approved by the FDA to an advisory committee or provide in an action letter a summary of the reasons for not referring it to an advisory committee. The FDA may also refer drugs which present difficult questions of safety, purity, or potency to an advisory committee. An advisory committee is typically a panel that includes clinicians and other experts who review, evaluate, and make a recommendation as to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use and whether the manufacturing controls are adequate to assure and preserve the product&#x2019;s identity, strength, quality and purity. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontracts, are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once the FDA receives an application, it has 60 days to review the NDA to determine if it is substantially complete to permit a substantive review, before it accepts the application for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has set the review goal of 10 months from the 60-day filing date to complete its initial review of a standard NDA for a new molecular entity, or NME, and make a decision on the application. For priority review applications, the FDA has set the review goal of reviewing NME NDAs within six months of the 60-day filing date. Such deadlines are referred to as the PDUFA date. The PDUFA date is only a goal and the FDA does not always meet its PDUFA dates. The review process and the PDUFA date may also be extended if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding the submission during the review period that amends the original application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once the FDA&#x2019;s review of the application is complete, the FDA will issue either a Complete Response Letter, or CRL, or approval letter. A CRL indicates that the review cycle of the application is complete, and the application is not ready for approval. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing, or other information or analyses in order for the FDA to reconsider the application in the future. Even with the submission of additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#x2019;s satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product, or impose other conditions, including distribution restrictions or other risk management mechanisms. For example, the FDA may require a REMS as a condition of approval or following approval to mitigate any identified or suspected serious risks and ensure safe use of the drug. The FDA may prevent or limit further marketing of a product, or impose additional post-marketing requirements, based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements, FDA notification and FDA review and approval. Further, should new safety information arise, additional testing, product labeling or FDA notification may be required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may be marketed or may include contraindications, warnings, or precautions in the product labeling, which has resulted in a boxed warning. A boxed warning is the strictest warning put in the labeling of prescription drugs or drug products by the FDA when there is reasonable evidence of an association of a serious hazard with the drug. The FDA also may not approve the inclusion of all labeling claims sought by an applicant. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase 4 post-marketing studies to monitor the effect of approved products and may limit further marketing of the product based on the results of these post-marketing studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including periodic reporting, product sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval requirements imposed as a conditional of approval such as Phase 4 clinical trials, REMS and surveillance, recordkeeping and reporting requirements, including adverse experiences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual program fee requirements for approved products, as well as new application fees for supplemental applications with clinical data. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and to list their drug products and are subject to periodic announced and unannounced inspections by the FDA and these state agencies for compliance with cGMPs and other requirements, which impose procedural and documentation requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented, or FDA notification. FDA regulations also require investigation and correction of any deviations from cGMPs and specifications and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions to the approved labeling to add new safety information or other limitations, imposition of post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS program, among other consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA closely regulates the marketing and promotion of drugs. A company can make only those claims relating to safety and efficacy that are consistent with the FDA approved labeling. Physicians, in their independent professional medical judgement, may prescribe legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. However, manufacturers and third parties acting on their behalf are prohibited from marketing or promoting drugs in a manner inconsistent with the approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to comply with any of the FDA&#x2019;s requirements could result in significant adverse enforcement actions. These include a variety of administrative or judicial sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, modification of promotional materials or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, debarment, injunctions, fines, consent decrees, corporate integrity agreements, refusals of government contracts and new orders under existing contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement or civil or criminal penalties, including fines and imprisonment. It is also possible that failure to comply with the FDA&#x2019;s requirements relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse and other laws, as well as state consumer protection laws. Any of these sanctions could result in adverse publicity, among other adverse consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Marketing Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA provides periods of non-patent regulatory exclusivity, which provides the holder of an approved NDA limited protection from new competition in the marketplace for the innovation represented by its approved drug for a period of three or five years following the FDA&#x2019;s approval of the NDA. Five years of exclusivity are available to new chemical entities, or NCEs. An NCE is a drug that contains no active moiety that has been approved by the FDA in any other NDA. An active moiety is the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt, including a salt with hydrogen or coordination bonds, or other noncovalent, or not</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">involving the sharing of electron pairs between atoms, derivatives, such as a complex (i.e., formed by the chemical interaction of two compounds), chelate (i.e., a chemical compound), or clathrate (i.e., a polymer framework that traps molecules), of the molecule, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review or approve an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Regulation outside the United States</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will be subject to similar foreign laws and regulations concerning the development of our product candidates outside of the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Healthcare Laws and Regulations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business activities, including but not limited to, research, sales, promotion, distribution, medical education and other activities are subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to the FDA, including the Department of Justice, the Department of Health and Human Services, or HHS, and its various divisions, including Centers for Medicare &amp; Medicaid Services, or CMS, and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department of Defense and state and local governments. Our business activities must comply with numerous healthcare laws and regulations, including those described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, the referral of an individual for, or purchasing, leasing, ordering, or arranging for the purchase, lease or order of, any good, facility, item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other hand. The term remuneration has been interpreted broadly to include anything of value. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing, or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, amended the intent requirement of the federal Anti-Kickback Statute, and other healthcare criminal fraud statutes, so that a person or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute, or the specific intent to violate it, to have violated the statute. The ACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act, or FCA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal civil and criminal false claims laws, including the FCA, and civil monetary penalties laws prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the U.S. federal government, including the Medicare and Medicaid programs, or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#x201c;any request or demand&#x201d; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#x201c;whistleblower&#x201d; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties. Government enforcement agencies and private whistleblowers have investigated pharmaceutical companies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for or asserted liability under the FCA for a variety of alleged promotional and marketing activities, such as providing free products to customers with the expectation that the customers would bill federal programs for the products; providing consulting fees and other benefits to physicians to induce them to prescribe products; engaging in promotion for &#x201c;off-label&#x201d; uses; and submitting inflated best price information to the Medicaid Rebate Program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick, scheme or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Additionally, the ACA amended the intent requirement of some of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have committed a violation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the federal Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section 6002 of the ACA and its implementing regulations, requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (with specified exceptions) to report annually information related to specified payments or other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually specified ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates and covered subcontractors. Among other things, HITECH makes HIPAA&#x2019;s security standards directly applicable to business associates, defined as independent contractors or agents of covered entities that create, receive, maintain, or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third-party payor, including commercial insurers. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information, state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, possible exclusion from government funded</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could substantially disrupt our operations. If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate reimbursement for the procedures utilizing our product candidates, performed by health care providers, once approved, will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, determine which procedures, and the products utilized in such procedures, they will cover and establish reimbursement levels. Assuming coverage is obtained for procedures utilizing a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who undergo procedures for the treatment of their conditions, and their treating physicians, generally rely on third-party payors to reimburse all or part of the costs associated with the procedures which utilize our products. Treating physicians are unlikely to use and order our products unless coverage is provided and the reimbursement is adequate to cover all or a significant portion of the cost of the procedures which utilize our products. Therefore, coverage and adequate reimbursement for procedures which utilize new products is critical to the acceptance of such new products. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government authorities and other third-party payors are developing increasingly sophisticated methods of cost containment, such as including price controls, restrictions on coverage and reimbursement and requirements for substitution of less expensive products and procedures. Government and other third-party payors are increasingly challenging the prices charged for health care products and procedures, examining the cost effectiveness of procedures, and the products used in such procedures, in addition to their safety and efficacy, and limiting or attempting to limit both coverage and the level of reimbursement. Further, no uniform policy requirement for coverage and reimbursement exists among third-party payors in the United States, which causes significant uncertainty related to the insurance coverage and reimbursement of newly approved products, and the procedures which may utilize such newly approved products. Therefore, coverage and reimbursement can differ significantly from payor to payor and health care provider to health care provider. As a result, the coverage determination process is often a time-consuming and costly process that requires the provision of scientific and clinical support for the use of new products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There may be significant delays in obtaining coverage and reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA. Moreover, eligibility for coverage and reimbursement does not imply that a product, or the procedures which utilize such product, will be paid for in all cases or at a rate which the health care providers who purchase those products will find cost effective. Additionally, we expect pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot be sure that coverage and reimbursement will be available for any product that we commercialize, or the procedures which utilize such product, and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare Reform Measures</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals designed to change the healthcare system. Among policy-makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, the pharmaceutical industry in the United States has been affected by the passage of ACA, which, among other things: imposed new fees on entities that manufacture or import certain branded prescription drugs; expanded pharmaceutical manufacturer obligations to provide discounts and rebates to certain government programs; implemented a licensure framework for follow-on biologic products; expanded health care fraud and abuse laws; revised the methodology by which rebates owed by manufacturers to the state and federal government under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including products that are inhaled, infused, instilled, implanted or injected; imposed an additional rebate similar to an inflation penalty on new formulations of drugs; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; expanded the 340B program which caps the price at which manufacturers can sell covered outpatient pharmaceuticals to specified hospitals, clinics and community health centers; and provided incentives to programs that increase the federal government&#x2019;s comparative effectiveness research.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress.  Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025.  The IRA also eliminates the &#x201c;donut hole&#x201d; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and additional healthcare reform measures of the Biden administration will impact the ACA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2.0% per fiscal year, which went into effect in April 2013, and due to subsequent legislative amendments will remain in effect through 2031, unless additional U.S. Congressional action is taken. These Medicare sequester reductions will be suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#x2019;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. In addition, in January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, ended the use of the statutory formula for clinician payment and established a quality payment incentive program, also referred to as the Quality Payment Program. This program provides clinicians with two ways to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. At this time, it is unclear how the introduction of the Quality Payment Program will impact overall physician reimbursement under the Medicare program. Any</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, there has been particular and increasing legislative and enforcement interest in the United States with respect to drug pricing practices in recent years, particularly with respect to drugs that have been subject to relatively large price increases over relatively short time periods. Specifically, there have been several recent U.S. Congressional inquiries, Presidential executive orders and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of prescription drugs under Medicare and reform government program reimbursement methodologies for pharmaceutical products. At the federal level, in July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to Biden&#x2019;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation.  These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges.  It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry.  Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to submit a report within ninety (90) days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries.  It is unclear whether this executive order or similar policy initiatives will be implemented in the future. In addition, individual states in the United States have become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In the future, there will likely continue to be proposals relating to the reform of the U.S. healthcare system, some of which could further limit coverage and reimbursement of products.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Foreign Corrupt Practices Act</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the companies to maintain books and records that accurately and fairly reflect all transactions of the companies, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employees and Human Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 24, 2023, we had 180 full-time employees, including 63 who hold an M.D. or Ph.D. degree. Of these full-time employees, 148 were primarily engaged in research and development activities and 32 were primarily engaged in management or general and administrative activities. None of our employees is represented by a labor union and we consider our employee relations to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated under the Canada Business Corporations Act on September 6, 2016. Immediately prior to completion of our initial public offering on June 23, 2020, we were continued as a corporation under the Business Corporations Act (Qu&#xe9;bec), or the QBCA. Our principal executive offices are located at 7210 Frederick-Banting, Suite 100, St-Laurent, Quebec, H4S 2A1 and our telephone number is 857-412-7018.  In June 2017, we incorporated our wholly-owned subsidiary, Repare Therapeutics USA Inc., a Delaware corporation, which is located at 101 Main Street, Suite 1650, Cambridge, Massachusetts 02142.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Available Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain an internet website at www.reparerx.com and make available free of charge through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act of 1934 (the &#x201c;Exchange Act&#x201d;). We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). You can review our electronically filed reports and other information that we file with the SEC on the SEC&#x2019;s web site at http://www.sec.gov and on SEDAR at http://www.sedar.com. In addition, we regularly use our website to post information regarding our business, product development programs and governance, and we encourage investors to use our website, specifically the sections title &#x201c;Investors &amp; Media&#x201d; as a source of information about us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information on our website is not incorporated by reference into this Annual Report on Form 10-K and should not be considered to be part of this Annual Report on Form 10-K. Our website address is included in this Annual Report on Form 10-K as an inactive technical reference only.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">k Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing in our common shares involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our consolidated financial statements and the related notes and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; before deciding whether to invest in our common shares. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and prospects. In such an event, the market price of our common shares could decline and you may lose all or part of your investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Financial Position and Capital Needs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biopharmaceutical company founded in 2016, and our operations to date have focused primarily on raising capital, organizing and staffing our company, conducting discovery and research activities, identifying potential synthetic lethal, or SL, gene pairs, establishing and protecting our intellectual property portfolio including for our proprietary SNIPRx platform, developing and progressing our product candidates through preclinical studies and clinical development, including continuing our open-label Phase 1/2 clinical trials of camonsertib and our ongoing Phase 1 clinical trials of RP-6306, and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates and component materials. We do not have any product candidates approved for sale and have not generated any revenue from product sales. Additionally, as an organization, we have not yet demonstrated an ability to successfully complete clinical development, obtain regulatory approvals, manufacture a commercial-scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. In time, we will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investment in biopharmaceutical product development is a highly speculative undertaking and entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any product revenue to date, and we are devoting substantially all of our financial resources and efforts to research and development of our product candidates including camonsertib and RP-6306, as well as to enhancing our SNIPRx platform. To date, we have primarily funded our operations through sales of equity securities, including our IPO in June 2020 and our follow-on offering in November 2021, as well as upfront payments from collaboration and research agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred significant operating losses since our inception in 2016. Our net loss was $29.0 million, and $106.9 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $239.3 million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. It could be several years, if ever, before we have a commercialized drug. We anticipate that our expenses will increase substantially if, and as, we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue our ongoing and planned development of our product candidates, including our ongoing Phase 1 clinical trials of RP-6306; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiate preclinical studies and clinical trials for any additional product candidates that we may pursue in the future, including our earlier-stage programs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek to identify novel SL targets, develop small molecule inhibitors of these targets, nominate and develop additional product candidates and further expand our clinical product pipeline; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek regulatory approvals for any product candidates that successfully complete clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">build a portfolio of product candidates through the discovery, development, or acquisition or in-license of drugs, product candidates or technologies; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish a sales, marketing, manufacturing and distribution capability to commercialize any product candidate for which we may obtain marketing approval; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintain, protect and expand our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acquire or in-license other product candidates and technologies; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional clinical, regulatory and scientific personnel; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incur additional legal, accounting and other expenses associated with operating as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials of any product candidates that we may pursue, obtaining regulatory approval, procuring commercial-scale manufacturing, marketing, and selling any products for which we may obtain regulatory approval, as well as discovering or acquiring and then developing additional product candidates. We are only in the preliminary stages of some of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the numerous risks and uncertainties associated with drug development, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. Our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, or other regulatory authorities to perform studies in addition to those we currently expect, or if there are any delays in the initiation and completion of our clinical trials or the development of RP-6306 or any future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our common shares and could impair our ability to raise capital, maintain our research and development efforts, expand our business, or continue our operations. A decline in the value of our common shares could also cause you to lose all or part of your investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will require substantial additional funding to finance our operations. If we are unable to raise capital when needed, we could be forced to delay, reduce, or terminate certain of our product development programs or other operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have primarily funded our operations through sales of equity securities, including our IPO in June 2020 and our follow-on offering in November 2021, as well as upfront payments from collaboration and research agreements. We expect to spend substantial amounts to advance our product candidates into clinical development and to complete the clinical development of, seek regulatory approvals for and commercialize our product candidates, if approved. We will require additional capital, which we may raise through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, milestone and royalty payments under our current or future strategic alliances and licensing arrangements or other sources to enable us to complete the development and potential commercialization of our product candidates. Furthermore, we have incurred and will continue to incur additional costs associated with operating as a public company. Adequate additional financing may not be available to us on acceptable terms, or at all. Weakness and volatility in the capital markets and the economy in general could limit our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">access to capital markets and increase our costs of borrowing. Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business strategy. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and harm our product candidate development efforts. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce, or eliminate certain of our research and development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our cash and cash equivalents and marketable securities on hand was $343.9 million. We believe that our existing cash on hand, will enable us to fund our operating expenses and capital expenditure requirements into 2026. However, we will need to obtain substantial additional funding in connection with our continuing operations and planned activities. Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the continuation of our ongoing and planned development of our product candidates, including our ongoing Phase 1 clinical trials of RP-6306;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing, costs, progress and results of our ongoing clinical trials of RP-6306;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the progress of preclinical development and possible clinical trials of our current earlier-stage programs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, results and costs of our research programs and preclinical development of other product candidates that we may pursue; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the development requirements of other product candidates that we may pursue; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and amount of milestone and royalty payments that we are required to make or eligible to receive under our current or future collaboration agreements, including the Roche Agreement;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our election to opt-in to the co-development and profit share arrangement of camonsertib pursuant to the Roche Agreement;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of establishing a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA and other regulatory authorities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of expanding, maintaining and enforcing our intellectual property portfolio, including filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us or any of our product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effect of competing technological and market developments; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost and timing of completion of commercial-scale manufacturing activities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which we partner our programs, acquire or in-license other product candidates and technologies or enter into additional strategic collaborations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the revenue, if any, received from commercial sales of camonsertib, RP-6306 and any future product candidates for which we or our collaborators receive marketing approval; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the addition of equipment and physical infrastructure to support our research and development; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of operating as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive, and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, camonsertib, RP-6306</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and any future product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce, or altogether terminate our research and development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Raising additional capital will cause dilution to our shareholders, restrict our operations, or require us to relinquish rights to our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through public or private equity or debt financings, third-party funding, marketing, and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a shareholder. Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures, declaring dividends or placing limitations on our ability to acquire, sell or license intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we raise additional capital through future collaborations, strategic alliances, or third-party licensing arrangements, we may have to relinquish certain valuable rights to our intellectual property, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our clinical development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to the Development of Our Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are very early in our development efforts. If we are unable to advance our product candidates into and through clinical development, obtain regulatory approval and ultimately commercialize any of our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have no products approved for sale and our initial clinical product candidates, camonsertib and RP-6306, are still in the early stages of clinical development and will require additional clinical development, regulatory review and approval in each jurisdiction in which we intend to market it, access to sufficient commercial manufacturing capacity, and significant sales and marketing efforts before we can generate any revenue from product sales. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful clinical development and eventual commercialization, by us or our collaborators of camonsertib, RP-6306 and one or more of our other product candidates. The success of our product candidates will depend on several factors, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful completion of preclinical studies, including the identification of clinical candidates for each of our preclinical programs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval of investigational new drug, or IND, applications for our planned or future clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance by the FDA, EMA or foreign regulatory authority of our development strategy; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful initiation of clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful patient enrollment in and completion of clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safety, tolerability and efficacy profiles for our product candidates that are satisfactory to the FDA, EMA or any foreign regulatory authority for marketing approval; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates, if any product candidates are approved; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">effectively competing with other cancer therapies; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining and maintaining third-party coverage and adequate reimbursement and patients&#x2019; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintaining a continued acceptable safety profile of products following approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is no guarantee that the results obtained in current preclinical studies, our ongoing open-label Phase 1/2 clinical trials of camonsertib, our ongoing Phase 1 clinical trials of RP-6306 or any future clinical trials of any product candidate will be sufficient to obtain regulatory approval or marketing authorization for such product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of these risks are beyond our control, including the risks related to clinical development, the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, and sales efforts of any future collaborator. If we are unable to develop, receive regulatory approval for, or successfully commercialize our current or future product candidates, or if we experience delays as a result of any of these risks or otherwise, our business could be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business substantially depends upon the successful development of product candidates generated through the application of our SNIPRx platform, and in particular, our initial product candidates, camonsertib and RP-6306. If we or our collaborators are unable to obtain regulatory approval for, and successfully commercialize, products developed through the application of our SNIPRx platform, our business may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our initial clinical product candidates, camonsertib and RP-6306, were developed through the application of our SNIPRx platform. All of our product candidates to date were derived based on the same principle of SL. As such, negative results in the development of camonsertib or RP-6306 may also impact our ability to obtain regulatory approval for our other product candidates, either at all or within anticipated timeframes because, although other product candidates may target different indications, the underlying technology platform, manufacturing process and development process is the same for all of our product candidates. Accordingly, a failure in any one program may decrease trust in our technology and affect the ability to obtain regulatory approval to continue or conduct clinical programs for other product candidates. If camonsertib or RP-6306 shows unexpected adverse events or a lack of efficacy in the indications they are intended to treat, or if we or our collaborators experience other regulatory or developmental issues, our development plans and business could be significantly harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have limited experience as a company in conducting clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have limited experience as a company in conducting clinical trials. We began our first clinical trial of camonsertib in July 2020 and our first clinical trial of RP-6306 in April 2021. In part because of this lack of experience, we cannot be certain that our clinical trials will begin or be completed on time, if at all. Large-scale clinical trials would require significant additional financial and management resources and reliance on third-party clinical investigators, contract research organizations, or CROs, and consultants. Relying on third-party clinical investigators, CROs and consultants may force us to encounter delays that are outside of our control. We may be unable to identify and contract with sufficient investigators, CROs and consultants on a timely basis or at all. There can be no assurance that we will be able to negotiate and enter into any master services agreement with CROs, as necessary, on terms that are acceptable to us on a timely basis or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have filed INDs for camonsertib and RP-6306, but we may not be able to file INDs for our other product candidates on the timelines we expect. For example, we may experience manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing further clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that such regulatory authorities will not change their requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or to a new IND. Any failure to file INDs on the timelines we expect or to obtain regulatory approvals for our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The effects of health epidemics, including the ongoing COVID-19 pandemic, in regions where we, or the third parties on which we rely, have business operations could adversely impact our business, including our preclinical studies and clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business could be adversely affected by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of third party manufacturers and CROs upon whom we rely. The COVID-19 pandemic had a modest impact on our business operations. For example, we are aware that several clinical trial sites involved in our clinical trials have in the past temporarily stopped or delayed enrolling new patients, with exemptions if appropriate, and it is possible that these or other clinical sites may be similarly affected in the future. We and the third-party clinical investigators and CROs with whom we work have also experienced staffing shortages at clinical trial sites, which could adversely affect the timing of our current and ongoing clinical trials.  While it is not possible at this time to predict the duration and extent of the impact that COVID-19 will continue to have on worldwide economic activity and our business in particular, COVID-19 could adversely impact our business and ongoing and planning clinical trials, including as a result of delays or difficulties in clinical site initiation, difficulties in recruiting and retaining clinical site investigators and clinical site staff and interruption of our clinical supply chain or key clinical trial activities, such as clinical trial site monitoring, and supply chain interruptions caused by ongoing restrictions for the supply of materials for product candidates or other materials necessary to manufacture product to conduct preclinical tests.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The extent to which the COVID-19 coronavirus or any future outbreaks of contagious disease may impact our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, the results of vaccination efforts, resurgences of the virus, travel restrictions and social distancing in the United States, Canada and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States, Canada and other countries to contain and treat the disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The successful development of targeted therapeutics, including our portfolio of SL small molecule inhibitors, as well as any related diagnostics, is highly uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Successful development of targeted therapeutics, such as our portfolio of SL small molecule inhibitors, as well as any related diagnostics, is highly uncertain and is dependent on numerous factors, many of which are beyond our control. Our SNIPRx platform is based on new technologies and methods relating to precision target and biomarker identification, screening, and validation. While we believe our clinical development approach will eventually provide validation of our SNIPRx platform, we have not, to date, sought regulatory approval for any therapeutics developed through our platform. As such, it is difficult to accurately predict the developmental challenges we may incur for our current and future product candidates as we proceed through product discovery, identification, preclinical studies, and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our SNIPRx platform is novel and may not be effective at identifying SL targets for product candidates. We therefore cannot provide any assurance that we will be able to successfully identify additional novel targets or product candidates, advance any of these additional product candidates or diagnostics for their associated biomarkers through the development process. Most of our proposed targets are unproven in clinical trials and there is no guarantee that the preclinical data will translate into a clinical relevance of such novel biomarkers and targets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Targeted therapeutics that appear promising in the early phases of development may fail to reach the market for several reasons, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">research or preclinical studies may show our targeted small molecule inhibitors or antagonists to be less effective than desired or to have harmful or problematic side effects or toxicities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to accurately identify, validate or develop clinically relevant biomarkers for our targeted therapeutic product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trial results may show our targeted therapeutic small molecule inhibitors to be less effective than expected based on preclinical studies (e.g., a clinical trial could fail to meet its primary endpoint(s)) or to have unacceptable side effects or toxicities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the failure to receive the necessary regulatory approvals or a delay in receiving such approvals. Among other things, such delays may be caused by slow enrollment in clinical trials, patients dropping out of trials, length of time to achieve trial endpoints, additional time requirements for data analysis, preparation of IND applications, discussions with the FDA, an FDA request for additional preclinical or clinical data, or unexpected safety or manufacturing issues; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing costs, formulation issues, pricing or reimbursement issues, or other factors that may make our targeted therapeutic small molecule inhibitors uneconomical; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size of the patient population that have disease with the appropriate biomarkers for which we are developing our product candidates may not be large enough to support commercial viability of our product candidates, if approved; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">proprietary rights of others and their competing products and technologies that may prevent our targeted therapeutic small molecule inhibitors, or the diagnostics for biomarkers associated with such small molecule inhibitors, from being commercialized; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the development of alternative treatments or evolution in the standard of care for our targets may make our drugs less attractive; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our approach of using any of our product candidates in combination with other agents, including standard of care agents, may not materialize due to overlapping toxicity, high cost or an inability to replicate preclinical results in clinical trials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our SNIPRx platform will result in the identification, development, and regulatory approval of any products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not commercialize, market, promote or sell any product candidate without obtaining marketing approval from the FDA, EMA, or other comparable regulatory authority, and we may never receive such approvals. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans and will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. Competing clinical trials for the same populations targeted as ours may limit our enrollment, or the results of competitors with similar technologies and products may falsely undermine the potential of our SNIPRx platform. A failure of one or more clinical trials can occur at any stage of testing. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We or our collaborators may experience numerous unforeseen events prior to, during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize camonsertib, RP-6306 and any future product candidates, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching a consensus with regulatory authorities on design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulators or institutional review boards, or IRBs, may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, patients may drop out of these clinical trials at a higher rate than we anticipate or fail to return for post-treatment follow-up or we may fail to recruit suitable patients to participate in a trial; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in our combination trials due to lack of access to the drugs with which we are testing our product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trials of our product candidates may produce negative or inconclusive results; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, concerns with a class of product candidates or after an inspection of our clinical trial operations, trial sites or manufacturing facilities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">external business disruptions affecting the initiation, patient enrollment, development and operation of our clinical trials, including a public health emergency, such as the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; or </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future drug sales or other sources. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring competing drugs to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be delayed in obtaining marketing approval, if at all; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be subject to additional post-marketing testing requirements; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have regulatory authorities withdraw, or suspend, their approval of the drug or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy, or REMS; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be subject to the addition of labeling statements, such as warnings or contraindications; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be sued; or </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">experience damage to our reputation. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical trials are very expensive, time consuming and difficult to design and implement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates will require clinical testing before we are prepared to submit a new drug application, or NDA, or equivalent application required in another jurisdiction for regulatory approval. We cannot predict with any certainty if or when we might submit an NDA or equivalent application required in another jurisdiction for regulatory approval for any of our product candidates or whether any such application will be approved by the FDA or other comparable regulatory authority, as applicable. Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. For instance, the FDA or other comparable regulatory authority may not agree with our proposed endpoints for any future clinical trial of our product candidates, which may delay the commencement of our clinical trials. In addition, we may not succeed in developing and validating disease-relevant clinical endpoints based on insights regarding biological pathways for the diseases we are studying. The clinical trial process is also time consuming. We estimate that the successful completion of clinical trials for camonsertib, RP-6306 and any future product candidates will take several years to complete. Furthermore, failure can occur at any stage, and we could encounter problems that cause us to abandon or repeat clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials and we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient for the necessary regulatory approvals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We initiated our first clinical trial, an open-label Phase 1/2 clinical trial of camonsertib, in the third quarter of 2020 and initiated a Phase 1 clinical trial of RP-6306 in the second quarter of 2021. Success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Preclinical tests and Phase 1 and Phase 2 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules. Success in preclinical studies and earlier clinical trials does not ensure that later efficacy trials will be successful, nor does it predict final results. Frequently, product candidates that have shown promising results in early clinical trials have subsequently suffered significant setbacks in later clinical trials. In addition, the design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. There is a high failure rate for drugs and biologic products proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in clinical trials, including previously unreported adverse events.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. The early trials will be single arm and not comparing the results with existing (or new) standard of care. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products or had to withdraw the product after comparator or later stage trials delivered results. The changing regulatory landscape may require larger and randomized trials that will take a longer time to perform.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, some of our trials may be open-label studies, where both the patient and investigator know whether the patient is receiving the investigational product candidate or an existing approved drug, introducing bias in early interpretation of the results. Most typically, open-label clinical trials test only the investigational product candidate and sometimes do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. In addition, open-label clinical trials may be subject to an &#x201c;investigator bias&#x201d; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. Therefore, it is possible that positive results observed in open-label trials will not be replicated in later placebo-controlled trials. Further, as our trials are in patients who encountered multiple therapy failures previously, interpretation of results may be biased both towards lesser activity and at the same time towards a population that is able to tolerate and possibly benefit from novel therapies. Hence interpretation of any results from this population may not directly translate to our eventual pivotal trial population that will likely be more homogenous and less pretreated.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit, or prevent regulatory approval. Moreover, as the development of the SL pair, ATM-ATR, is still early, any clinical validation of the SL approach to treating cancer may or may not validate our approach. In addition, we may experience regulatory delays or rejections as a result of many factors, including due to changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interim, &#x201c;top-line&#x201d; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may publish interim, &#x201c;top-line&#x201d; or preliminary data from our ongoing and planned clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or &#x201c;top-line&#x201d; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common shares to fluctuate significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, on a timely basis or at all, our business will be substantially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The length of time necessary to complete clinical trials and to submit an application for marketing approval for a decision by a regulatory authority may be difficult to predict for targeted therapeutic small molecule inhibitors, in large part because of the limited regulatory history associated with them. The clinical trial requirements of the FDA and other comparable foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the product candidate. There is a limited history of multi-tumor indications, and any regulatory approvals may be conditioned upon confirmatory trials with clinical endpoints such as survival. Such trials are not only more expensive to conduct but take several years to complete. Increasing pressure from reimbursement bodies may result in poor (or no) acceptance of early trials for reimbursement. Except for certain PARP inhibitors, no products based on SL have been approved to date by regulators. As a result, the regulatory approval process for product candidates such as ours is uncertain and may be more expensive and take longer than the approval process for product candidates based on other, better known or more extensively studied technologies. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in either the United States or other comparable regions of the world or how long it will take to commercialize our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product candidate to market would adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA to the FDA or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States or elsewhere, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA or comparable foreign regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program. Depending on the extent of these or any other studies required by the FDA or comparable foreign regulatory authorities, approval of any regulatory approval applications that we submit may be delayed by several years, or may require us to expend significantly more resources than we have available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Of the large number of potential products in development, only a small percentage successfully complete the FDA or comparable foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a post-marketing risk management strategy such as a REMS or the equivalent in another jurisdiction. Regulatory authorities may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Synthetic lethality represents an emerging class of precision medicine targets, and negative perceptions of the efficacy, safety, or tolerability of this class of targets, including any that we develop, could adversely affect our ability to conduct our business, advance our product candidates or obtain regulatory approvals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aside from PARP inhibitors, such as Lynparza, Rubraca, Zejula and Talzenna, no small molecule inhibitor therapeutics for SL in DNA damage have been approved to date by the FDA or other comparable regulators. Adverse events in future clinical trials of our product candidates or in clinical trials of others developing similar products and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the resulting publicity, as well as any other adverse events in the field of SL, or other products that are perceived to be similar to SL, such as those related to gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and CROs in our product candidates, and less demand for any product that we may develop. Our pipeline of SL small molecule inhibitor product candidates could result in a greater quantity of reportable adverse events or other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delays or holds by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our SL programs, as well as our business as a whole. In addition, responses by U.S. federal or foreign governments to negative public perception may result in new legislation or regulations that could limit our ability to develop any product candidates or commercialize any approved products, obtain, or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects, and may delay or impair the development of our product candidates and commercialization of any approved products or demand for any products we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in applying our SNIPRx platform to discover SL targets with therapeutic and commercial potential or in the discovery and development of commercially viable product candidates for us or our collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our scientific approach focuses on applying our proprietary SNIPRx platform to identify SL targets across the human genome. Our drug discovery team then chooses targets identified by SNIPRx and develops potent and selective inhibitors of these targets. We use these inhibitors to further validate our SL findings before advancing them into clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe the results of our SNIPRx screen campaigns suggest that our platform is capable of identifying high quality product candidates, but past success in identifying potential product candidates does not assure future success for us with our internal drug discovery programs. Our SNIPRx platform is novel, and we may not succeed in applying our SNIPRx platform to identify targets for product candidates. We therefore cannot provide any assurance that we or our collaborators will be able to successfully identify additional product candidates or advance any of these additional product candidates. In addition, others may have discovered and prosecuted targets that we believe are undiscovered. As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our SNIPRx platform will result in the identification, development, and regulatory approval of any products. In addition, we may not succeed in applying our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens to expand the potential patient populations that can be treated with our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efforts to identify, acquire or in-license, and then develop product candidates require substantial technical, financial, and human resources, whether or not any product candidates are ultimately identified. We apply our SNIPRx technology and STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screening in our efforts to discover potential precision targets for which our product candidates may be developed. Our efforts may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development, approved products, or commercial revenues for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the methodology used may not be successful in identifying potential product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">competitors may develop alternatives that render any product candidates we develop obsolete; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any product candidates we develop may nevertheless be covered by third parties&#x2019; patents or other exclusive rights; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a product candidate may be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a product candidate may not be accepted as safe and effective by physicians, patients, the medical community or third-party payors. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates. We may find it difficult to enroll patients in our ongoing and planned clinical trials with the genomic alterations that these trials are designed to target.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of completion of our clinical trials depends in part on the speed at which we can recruit patients to participate in testing our product candidates, and we may experience delays in our clinical trials if we encounter difficulties in enrollment. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. In particular, because we are focused on patients with specific genomic alterations identified by our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens, our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. Certain genes identified by our STEP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> screens may not yet be included in commercially available panels or CLIA-validated panels used in large academic centers. We cannot be certain how many patients will have each of the genomic alterations that the applicable product candidate is designed to target or that the number of patients enrolled for each mutation will suffice for regulatory approval and inclusion of each such mutation in the approved label. We may be unsuccessful in our efforts to work with our clinical partners to identify patients who are eligible for our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same or similar populations as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#x2019; product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are engaging third parties to develop patient selection tools for use in our clinical trials, but such third parties may not be successful in developing such tools, furthering the difficulty in identifying patients with the targeted genomic alterations for our clinical trials and risking enrollment into our trials. Next Generation Sequencing panels may not include genes required for screening for our clinical trials or may not be broadly commercially available. The optimal method of diagnosis is not yet known and the availability of third party payment for diagnostic tests may limit our clinical trials as well. Further, if we are unable to include patients with the targeted genomic alterations, this could compromise our ability to seek participation in FDA&#x2019;s expedited review and development programs or otherwise seek to accelerate clinical development and regulatory timelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The enrollment of patients further depends on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risks and benefits of the product candidate under trial; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability and efficacy of competing therapies and clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of genetic sequencing information for patient tumors so that we can identify patients with the targeted genomic alterations; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patient referral practices of physicians; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proximity of patients to clinical trial sites; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the design of the clinical trial; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of any current or future license partner to execute on its development commitments and responsibilities for any product candidate to which it has acquired development rights in a given geography; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain patient consents; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reporting of the preliminary results of any of our clinical trials; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial completion. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">because some patients who might have opted to enroll in our clinical trials may instead opt to enroll in a clinical trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment and because our product candidates have not been tested in humans before, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in any future clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Serious adverse events or undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA, or other authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects, toxicities, or unexpected characteristics, including death.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If unacceptable side effects or deaths arise in the development of our product candidates, we, the IRBs at the institutions in which our studies are conducted, the FDA or any comparable foreign regulatory authority could suspend or terminate our clinical trials or the FDA or other regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Undesirable side effects or deaths in clinical trials with our product candidates may cause the FDA or comparable foreign regulatory authorities to place a clinical hold on the associated clinical trials, to require additional studies, or otherwise to delay or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by any such product, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our products, a number of potentially significant negative consequences could result, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against its manufacture and distribution; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to recall a product or change the way such product is administered to patients; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require additional warnings on the label, such as a boxed warning or contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the product could become less competitive; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a strategic collaborator for the product may choose to terminate its agreement and compromise our ability to commercialize such product in the collaborator&#x2019;s geography; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be subject to fines, injunctions, or the imposition of civil or criminal penalties; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may in the future conduct clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently expect, and may in the future choose, to conduct one or more clinical trials outside the United States, including in Europe. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; and (ii) the trials were performed by clinical investigators of recognized competence and pursuant to good clinical practice, or GCP, regulations. Additionally, the FDA&#x2019;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. Results for our clinical trials may differ by jurisdiction as a result of varying standards of care or local restrictions on reimbursement from third-party payors for clinical trials, thereby affecting the willingness of the FDA or any comparable foreign regulatory authority to accept such data. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If it is determined that companion diagnostics are needed, we may be unable to successfully develop companion diagnostics for biomarkers that enable patient selection, or experience significant delays in doing so, we may not realize the full commercial potential of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A key component of our strategy includes the use of diagnostic tools to guide patient selection of our product candidates. In some cases, a diagnostic tool may be commercially available, for example, on a tumor-profiling panel. If not already commercially available, we may be required to seek collaborations with diagnostic companies for the development of diagnostics for biomarkers associated with our product candidates. We may have difficulty in establishing or maintaining such development relationships, and we will face competition from other companies in establishing these collaborations. Furthermore, even if a diagnostic is commercially available, we may not be able to obtain reimbursement for its use without obtaining regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are also several risks associated with biomarker identification and validation. We, in collaboration with any diagnostic partners, may not be able to identify predictive biomarkers or pharmacodynamic biomarkers for one or more of our programs. We may not be able to validate potential biomarkers (e.g., certain genomic alterations) or their functional relevance preclinically in relevant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> models. Data analytics and information from databases that we rely on for identifying or validating some of our biomarker-target relationships may not accurately reflect potential patient populations or may be based on incorrect methodology. Potential biomarkers, even if validated preclinically, may not be functionally validated in human clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If it is determined that companion diagnostics are needed, we may, in collaboration with these parties, be unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so, which may adversely affect the development of our product candidates. The development of companion diagnostic products requires a significant investment of working capital, and may not result in any future income. This could require us to raise additional funds, which could dilute our current investors or impact our ability to continue our operations in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are also risks associated with diagnostics that are commercially available, including that we may not have access to reliable supply for such diagnostics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The failure to obtain required regulatory approvals for any companion diagnostic tests that may be required and that we may pursue may prevent or delay approval of our product candidates. Moreover, the commercial success of any of our product candidates may be tied to the regulatory approval, market acceptance and continued availability of a companion diagnostic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and other comparable regulatory authorities regulate </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> companion diagnostics as medical devices that will likely be subject to clinical trials in conjunction with the clinical trials for our product candidates, and which will require regulatory clearance or approval prior to commercialization. If it is determined that companion diagnostics are needed, we plan to collaborate with third parties for the development, testing and manufacturing of these companion diagnostics, the application for and receipt of any required regulatory clearances or approvals, and the commercial supply of these companion diagnostics. Our third-party collaborators may fail to obtain the required regulatory clearances or approvals, which could prevent or delay approval of our product candidates. In addition, the commercial success of any of our product candidates may be tied to and dependent upon the receipt of required regulatory clearances or approvals of the companion diagnostic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, the genomic alterations our compounds are addressing, such as ATM loss and CCNE1 amplification, are uncommon genetic alterations in tumors, or their subsets and their prognostic significance has not been fully validated for the patient populations that we are targeting. Such development risk contributes to the costs that we may need to bear in validating the alterations as well as the optimal method of diagnostic screening for our clinical trial populations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if a companion diagnostic is approved, we will rely on the continued ability of any third-party collaborator to make the companion diagnostic commercially available to us on reasonable terms in the relevant geographies. Market acceptance of the companion diagnostic may be low as a result of the cost and complexity of utilizing such companion diagnostic. Furthermore, if commercial tumor profiling panels are not able to be updated to include additional tumor-associated genes, or if clinical oncologists do not incorporate molecular or genetic sequencing into their clinical practice, we may not be successful in developing or commercializing our existing product candidates or any future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We intend to pursue the development of certain of our product candidates in combination with other therapies, and regulatory approval, safety or supply issues with these other therapies may delay or prevent the development and approval of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may explore the use of our product candidates in combination with other therapies, including those that are not yet approved. For example, pursuant to the terms of the Roche Agreement, we have retained the right to conduct specified clinical trials of camonsertib in combination with RP-6306. If we choose to develop a product candidate for use in combination with an approved therapy, we are subject to the risk that the FDA or comparable foreign regulatory authorities could revoke approval of, or that safety, efficacy, manufacturing, or supply issues could arise with, the therapy used in combination with our product candidate. If the therapies we use in combination with our product candidates are replaced as the standard of care, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials, or we may not be able to obtain adequate reimbursement from third-party payors. The occurrence of any of these risks could result in our product candidates, if approved, being removed from the market or being less successful commercially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Where we develop a product candidate for use in combination with a therapy that has not been approved by the FDA or comparable foreign regulatory authorities, we will not be able to market our product candidate for use in combination with such an unapproved therapy, unless and until the unapproved therapy receives regulatory approval. These unapproved therapies face the same risks described with respect to our product candidates currently in development, including serious adverse effects and delays in their clinical trials. In addition, other companies may also develop their products or product candidates in combination with the unapproved therapies with which we are developing our product candidates for use in combination. Any setbacks in these companies&#x2019; clinical trials, including the emergence of serious adverse effects, may delay or prevent the development and approval of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the FDA or comparable foreign regulatory authorities do not approve or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, therapies we choose to evaluate in combination with any of our product candidates, we may be unable to obtain regulatory approval of or to commercialize such product candidates in combination with these therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to the Commercialization of Our Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have never commercialized a product candidate and may experience delays or unexpected difficulties in obtaining regulatory approval for our current or future product candidates for our initial or potential additional indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never obtained regulatory approval for, or commercialized, a drug. It is possible that the FDA may refuse to accept any or all of our planned NDAs for substantive review or may conclude after review of our data that our application is insufficient to obtain regulatory approval for any product candidates. If the FDA does not approve any of our planned NDAs, it may require that we conduct additional costly clinical, nonclinical, or manufacturing validation studies before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA or other application that we submit may be significantly delayed, possibly for several years, or may require us to expend more resources than we have available. Any failure or delay in obtaining regulatory approvals would prevent us from commercializing our current or future product candidates, generating revenues, and achieving and sustaining profitability. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve any NDA or other application that we submit. If any of these outcomes occur, we may be forced to abandon the development of our product candidates, which would materially adversely affect our business and could potentially cause us to cease operations. We face similar risks for our applications in foreign jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently have no marketing and sales organization and have no experience as a company in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have no sales, marketing or distribution capabilities and have no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train, and retain marketing and sales personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable or decide not to establish internal sales, marketing, and distribution capabilities, we will pursue arrangements with third-party sales, marketing, and distribution collaborators regarding the sales and marketing of our products, if approved. However, there can be no assurance that we will be able to establish or maintain such arrangements on favorable terms or if at all, or if we are able to do so, that these third-party arrangements will provide effective sales forces or marketing and distribution capabilities. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Due to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain product candidates over other potential product candidates. These decisions may prove to have been wrong and may adversely affect our ability to develop our own programs, our attractiveness as a commercial partner and may ultimately have an impact on our commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we have limited resources and access to capital to fund our operations, we must decide which product candidates to pursue and the amount of resources to allocate to each. Our decisions concerning the allocation of research, collaboration, management, and financial resources toward particular proprietary molecules in our library,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. Similarly, our decisions to delay, terminate or collaborate with third parties in respect of certain product development programs may also prove not to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the market potential of our product candidates or misread trends in the biopharmaceutical industry, in particular for our lead product candidate, our business, financial condition and results of operations could be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The use of precision medicines as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community. Various factors will influence whether our product candidates are accepted in the market, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the clinical indications for which our product candidates are approved; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential and perceived advantages of our product candidates over current or future alternative treatments; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to demonstrate the advantages of our product candidates over other cancer medicines; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of any side effects; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of any side effects for other precision medicines and public perception of other precision medicines; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product labeling or product insert requirements of the FDA or comparable foreign regulatory authorities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations or warnings contained in the labeling approved by the FDA or comparable foreign regulatory authorities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of market introduction of our product candidates as well as competitive products; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of treatment, including with respect to diagnostic tools for our product candidates, and the availability of testing for patient selection; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the pricing of our products, if approved, and the availability of adequate coverage and reimbursement by third-party payors and government authorities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of coverage or adequate reimbursement by third-party payors and government authorities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effectiveness of our sales and marketing efforts. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our product candidates are approved for commercialization but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, although our product candidates differ in certain ways from other precision medicine approaches, serious adverse events or deaths in other clinical trials involving precision medicines, even if not ultimately attributable to our product or product candidates, could result in increased government regulation, unfavorable public perception and publicity, potential regulatory delays in the testing or licensing of our product candidates, stricter labeling requirements for those product candidates that are licensed, and a decrease in demand for any such product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The market opportunities for our product candidates may be relatively small as it will be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancer therapies are sometimes characterized as first line, second line, or third line, and the FDA often approves new therapies initially only for a particular line of use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, usually chemotherapy, antibody drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery, or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules, or a combination of these. Third line therapies can include chemotherapy, antibody drugs and small molecule tumor-targeted therapies, more invasive forms of surgery and new technologies. We expect to initially seek approval of our product candidates in most instances at least as a second or third line therapy. Subsequently, for those product candidates that prove to be sufficiently safe and beneficial, if any, we would expect to seek approval as a second line therapy and potentially as a first line therapy, but there is no guarantee that our product candidates, even if approved as a second or third or subsequent line of therapy, would be approved for an earlier line of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on various sources, including published literature and public or proprietary databases, to ascertain an estimate of the number of patients having particular genomic alterations, such as mutations, deletions or fusions. The determinable prevalence may vary depending on the source and quality of the underlying data and in some cases, insufficient data or poorly curated data may impact our ability to accurately estimate the prevalence of our target patient populations for each indication and in the aggregate across multiple indications both in the clinical trial setting, as well as in the commercial setting, if our product is approved. If the market opportunities for our product candidates are smaller than we estimate, our business, financial position, results of operations and prospects may be harmed. In addition, upon treatment with our product candidates, patients may have or develop resistance to our product candidates, reducing the addressable patient population and duration of treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others developing or commercializing drugs before or more successfully than us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical, and other resources, such a larger research and development team and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly as they develop novel approaches to treating disease indications that our product candidates are also focused on treating. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to in-license novel therapeutics that could make the product candidates that we develop obsolete. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring, or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products. We believe the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, convenience of use, price, and reimbursement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the development of precision oncology therapies for patients with genetically-defined cancers. Several</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">biopharmaceutical companies, including Loxo Oncology, Inc. (acquired by Eli Lilly and Company), Blueprint Medicines Corporation, SpringWorks Therapeutics, Inc., Black Diamond Therapeutics, Inc., Deciphera Pharmaceuticals, Inc., Tango Therapeutics, Inc., Zentalis Pharmaceuticals, Inc., Turning Point Therapeutics, Inc. (acquired by Bristol Myers Squibb), and Exelixis, Inc. are developing precision oncology medicines. In addition, we may face competition from companies developing product candidates that are based on SL, including AstraZeneca, GlaxoSmithKline, Pfizer, Bayer, Merck Serono, Schrodinger, Inc., Exelixis, Inc., Artios Pharma Ltd., IDEAYA Biosciences, Inc, Impact Therapeutics, Aprea Therapeutics, Acrivon Therapeutics, Treadwell Therapeutics, Debiopharm Group, Varsity Pharma, Breakpoint Therapeutics, and Rhizen Pharmaceuticals AG.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate that we will continue to face intense and increasing competition as new treatments enter the market and advanced technologies become available. There can be no assurance that our competitors are not currently developing, or will not in the future develop, products that are equally or more effective or are more economically attractive than any of our current or future product candidates. Competing products may gain faster or greater market acceptance than our products, if any, and medical advances or rapid technological development by competitors may result in our product candidates becoming non-competitive or obsolete before we are able to recover our research and development and commercialization expenses. If we or our product candidates do not compete effectively, it may have a material adverse effect on our business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our product candidates are approved for commercialization, we may seek to enter into agreements with third parties to market them in certain jurisdictions outside the United States. We expect that we would be subject to additional risks related to international pharmaceutical operations, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">different regulatory requirements for drug approvals and rules governing drug commercialization in foreign countries; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reduced protection for intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign reimbursement, pricing and insurance regimes; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unexpected changes in tariffs, export controls, sanctions, trade barriers and regulatory requirements; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war, such as the military conflict involving Russia and Ukraine, and terrorism, natural disasters including earthquakes, typhoons, floods and fires, or from economic or political instability, or public health emergencies, such as the novel COVID-19 coronavirus and related shelter-in-place orders, travel, social distancing and quarantine policies, boycotts, curtailment of trade and other business restrictions; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">greater difficulty with enforcing our contracts; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery and anticorruption laws in other jurisdictions; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As an organization, we have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by individual countries in Europe with which we may need to comply. If we are unable to successfully manage the challenges of international expansion and operations, our business and operating results could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and adequate reimbursement may not be available for our product candidates, which could make it difficult for us to sell profitably or at all, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market acceptance and sales of any product candidates that we commercialize, if approved, will depend in part on the extent to which reimbursement for these drugs and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and other private health insurers. Our ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate reimbursement for the procedures utilizing our product candidates, performed by health care providers, once approved, will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, determine which procedures, and the products utilized in such procedures, they will cover and establish reimbursement levels. Assuming coverage is obtained for procedures utilizing a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who undergo procedures for the treatment of their conditions, and their treating physicians, generally rely on third-party payors to reimburse all or part of the costs associated with the procedures which utilize our products. Treating physicians are unlikely to use and order our products unless coverage is provided and the reimbursement is adequate to cover all or a significant portion of the cost of the procedures which utilize our products. Therefore, coverage and adequate reimbursement for procedures which utilize new products is critical to the acceptance of such new products. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While no uniform policy for coverage and reimbursement exists in the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. Therefore, one payor&#x2019;s determination to provide coverage for a drug does not assure that other payors will also provide coverage, and adequate reimbursement, for the drug. Additionally, a third-party payor&#x2019;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a payor&#x2019;s list of covered drugs, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. Additionally, we or our collaborators may develop companion diagnostic tests for use with our product candidates. Companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical products, will apply to companion diagnostics. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize any product candidates that we develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we are successful in obtaining regulatory approval, commercial success of any approved products will also depend in large part on the availability of insurance coverage and adequate reimbursement from third-party payors, including government payors, such as the Medicare and Medicaid programs, and managed care organizations, which may be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost-effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. If government and other healthcare payors were not to provide adequate insurance coverage and reimbursement levels for any of our products once approved, market acceptance and commercial success would be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of biopharmaceutical products. Currently, we have no products that have been approved for commercial sale; however, the current and future use of product candidates by us and our collaborators in clinical trials, and the potential sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients who use the product, healthcare providers, pharmaceutical companies, our collaborators, or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our product candidates or any prospects for commercialization of our product candidates. Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a product, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased demand for our products due to negative public perception; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of clinical trial participants or difficulties in recruiting new trial participants; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiation of investigations by regulators; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs to defend or settle the related litigation; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a diversion of management&#x2019;s time and our resources; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenues from product sales; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to commercialize any of our product candidates, if approved. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we believe we maintain adequate product liability insurance for our product candidates, it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our product candidates. However, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Should any of the events described above occur, this could have a material adverse effect on our business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Regulatory Matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturers and manufacturers&#x2019; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, other marketing application, and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Comparable foreign regulatory authorities may also have programs similar to REMS. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters or holds on clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention or refusal to permit the import or export of our product candidates; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA does restrict manufacturer&#x2019;s communications on the subject of off-label use of their products. The policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, transparency, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthcare providers and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers, and third-party payors subject us to various federal and state fraud and abuse laws and other healthcare laws that may constrain the business or financial arrangements and relationships through which we research, sell, market, and distribute our product candidates, if we obtain marketing approval. Such laws include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. federal civil and criminal false claims laws, including the civil False Claims Act, which can be enforced by private individuals on behalf of the government through civil whistleblower or qui tam actions, and civil monetary penalties laws prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. Manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Health Insurance Portability and Accountability Act, or HIPAA, which created additional federal civil and criminal liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which impose certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers and their business associates, independent contractors of a covered entity that perform certain services involving the use or disclosure of individually identifiable health information, as well as their covered subcontractors. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Federal Food, Drug, and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to certain payments and other transfers of value to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to drug pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analogous laws in other jurisdictions including, but not limited to, laws relating to interactions with government officials, privacy laws, transparency laws, laws relating to reimbursement, competition, </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">consumer protection laws, laws relating to the marketing of health products and other healthcare-related laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we are also subject to federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing, or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have a material adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Enacted and future healthcare legislation may increase the difficulty and cost for us to progress our clinical programs and obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. For example, in March 2010, the Patient Protection and Affordable Care Act, or the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#x2019;s Medicaid rebate liability; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a licensure framework for follow on biologic products; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishment of a Center for Medicare &amp; Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been judicial, Congressional and executive branch challenges to certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Moreover, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025.  The IRA also eliminates the &#x201c;donut-hole&#x201d; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is also unclear how any such challenges and other litigation, and further healthcare reform measures of the Biden administration will impact the ACA and our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute will remain in effect until 2031 unless additional action is taken by Congress. These Medicare sequester reductions had been suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#x2019;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. For example, in July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to Biden&#x2019;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services, or HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain single source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented, but it is likely to have a significant impact on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to submit a report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition, and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. The price control regulations outside of the United States can have a significant impact on the profitability of a given market, and further uncertainty is introduced if and when these laws change. For example, in Canada, price control legislation for patented medicines is currently undergoing significant change that may have significant effects on profitability in Canada.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may face potential liability if we obtain identifiable patient health information from clinical trials sponsored by us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Most healthcare providers, including certain research institutions from which we may obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the HITECH. We are not currently classified as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#x2019;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#x2019;s requirements for disclosure of individually identifiable health information. In addition, in the future, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who may enroll in patient assistance programs if we choose to implement such programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The EU General Data Protection Regulation, or GDPR, also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. Further, the United Kingdom&#x2019;s decision to leave the European Union, referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear how data transfers to and from the United Kingdom will be regulated now that the United Kingdom has left the European Union.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#x2019; health information. Patients about whom we or our collaborators may obtain health information, as well as the providers who may share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#x2019; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or third-party CMOs, CROs or other contractors or consultants fail to comply with applicable federal, state/provincial or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#x2019; ability to develop and commercialize our therapeutic candidates and could harm or prevent sales of any affected therapeutics that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our therapeutics. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security or reputational damage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope and may apply regardless of the payor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we or our third-party manufacturers and suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development, or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties, or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#x2019;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Trade controls may restrict or prohibit altogether the sale or supply of certain products and services to certain governments, persons, entities, countries, and territories, including those that are the target of comprehensive sanctions, unless there are license exceptions that apply or specific licenses are obtained. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We may also have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely, and expect to continue to rely, on third parties, including independent clinical investigators, contracted laboratories and CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators, contracted laboratories and third-party CROs, to conduct our preclinical studies and clinical trials in accordance with applicable regulatory requirements and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third party contractors and CROs are required to comply with good laboratory practices, or GLPs, as applicable, and GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these GLPs and GCPs through periodic inspections of laboratories conducting GLP studies, trial sponsors, principal investigators, and trial sites. If we, our investigators, or any of our CROs or contracted laboratories fail to comply with applicable GLPs and GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional preclinical studies or clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our preclinical studies or clinical trials comply with applicable GLP or GCP regulations. In addition, our clinical trials must be conducted with product, including biologic product, produced in compliance with applicable cGMP regulations. Our failure to comply with these regulations may require us to repeat preclinical studies or clinical trials, which would delay the regulatory approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, these laboratories, investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent laboratories, investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if we make a general assignment for the benefit of our creditors or if we are liquidated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our relationships with these third-party laboratories, CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative laboratories, CROs or investigators or to do so in a timely manner or on commercially reasonable terms. If laboratories, CROs or clinical investigators do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory requirements or for other reasons, our preclinical or clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Switching or adding additional laboratories or CROs (or investigators) involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new laboratory or CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our contracted laboratories and CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, clinical investigators may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the preclinical study or clinical trial, the integrity of the data generated at the applicable preclinical study or clinical trial site may be questioned and the utility of the preclinical study or clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA. Any such delay or rejection could prevent us from commercializing our clinical-stage product candidate or any future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on third parties to supply and manufacture our product candidates, and we expect to continue to rely on third parties to manufacture our products, if approved. The development of such product candidates and the commercialization of any products, if approved, could be stopped, delayed, or made less profitable if any such third party fails to provide us with sufficient quantities of product candidates or products or fails to do so at acceptable quality levels or prices or fails to maintain or achieve satisfactory regulatory compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not currently have the infrastructure or capability internally to manufacture all our product candidates for use in the conduct of our preclinical studies and clinical trials or for commercial supply, if our products are approved. We rely on, and expect to continue to rely on, contract manufacturing organizations, or CMOs. Any replacement of our CMOs could require significant effort and expertise because there may be a limited number of qualified CMOs. This could be particularly problematic where we rely on a single-source supplier. Reliance on third-party providers may expose us to more risk than if we were to manufacture our product candidates ourselves. We are dependent on our CMOs for the production of our product candidates in accordance with relevant regulations, such as cGMP, which includes, among other things, quality control, quality assurance and the maintenance of records and documentation. Moreover, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting product development activities that could harm our competitive position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our third-party manufacturers may be subject to damage or interruption from, among other things, fire, natural or man-made disaster, war, disease outbreaks or public health pandemics, power loss, telecommunications failure, unauthorized entry, computer viruses, denial-of-service attacks, acts of terrorism, human error, vandalism or sabotage, financial insolvency, bankruptcy, and similar events. For example, the COVID-19 pandemic has impacted our supply chain, in particular our vendors&#x2019; ability to find staff, and may in the future impact our manufacturing activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we were to experience an unexpected loss of supply of or if any supplier were unable to meet our demand for any of our product candidates, we could experience delays in our research or ongoing and planned clinical trials or commercialization. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes who could meet our timelines at an acceptable cost. Moreover, our suppliers are often subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. The long transition periods necessary to switch manufacturers and suppliers, if necessary, could significantly delay our preclinical studies, our clinical trials, and the commercialization of our products, if approved, which could materially adversely affect our business, financial condition, and results of operation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In complying with the applicable manufacturing regulations of the FDA and comparable foreign regulatory authorities, we and our third-party suppliers must spend significant time, money, and effort in the areas of design and development, testing, production, record-keeping, and quality control to assure that the products meet applicable specifications and other regulatory requirements. The failure to comply with these requirements could result in an enforcement action against us, including the seizure of products and shutting down of production. We and any of these third-party suppliers may also be subject to audits by the FDA and comparable foreign regulatory authorities. If any of our third-party suppliers fails to comply with cGMP or other applicable manufacturing regulations, our ability to develop and commercialize the products could suffer significant interruptions. We face risks inherent in relying on CMOs, as any disruption, such as a fire, natural hazards, vandalism, or an outbreak of contagious disease affecting the CMO or any supplier of the CMO could significantly interrupt our manufacturing capability. In case of a disruption, we will have to establish alternative manufacturing sources. This would require substantial capital on our part, which we may not be able to obtain on commercially acceptable terms or at all. Additionally, we would likely experience months of manufacturing delays as the CMO builds or locates replacement facilities and seeks and obtains necessary regulatory approvals. If this occurs, we will be unable to satisfy manufacturing needs on a timely basis, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our current and future collaborations will be important to our business. If we are unable to enter into new collaborations as appropriate, or if these collaborations are not successful, our business could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A part of our strategy is to strategically evaluate and, as deemed appropriate, enter into partnerships in the future when strategically attractive, including potentially with major biotechnology or pharmaceutical companies. We have limited capabilities for product development and do not yet have any capability for commercialization. Accordingly, we may enter into collaborations with other companies to provide us with important technologies and funding for our programs and technology. If we fail to enter into or maintain collaborations on reasonable terms or at all, our ability to develop our existing or future research programs and product candidates could be delayed, the commercial potential of our product could change, and our costs of development and commercialization could increase. Furthermore, we may find that our programs require the use of intellectual property rights held by third parties, and the growth of our business may depend in part on our ability to acquire or in-license these intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, we are currently party to a collaboration agreement with Ono Pharmaceutical Co., or Ono, pursuant to which we and Ono have agreed to collaborate in the research of potential product candidates targeting Pol&#x3b8; and the development of our small molecule Pol&#x3b8; inhibitor program. Similarly, in May 2020, we entered into a collaboration and license agreement with Bristol Myers Squibb pursuant to which we and Bristol Myers Squibb have agreed to collaborate in the research and development of potential new product candidates for the treatment of cancer. In June 2022, we entered into a collaboration and license agreement with Roche regarding the development and commercialization of our product candidate camonsertib and other specified ATR inhibitors. These and any future collaborations we enter into may pose a number of risks, including, but not limited to, the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not perform their obligations as expected; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaborators&#x2019; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products and product candidates if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaborator may choose to deemphasize the development or commercialization of a product candidate licensed to it by us; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our collaborations do not result in the successful discovery, development, and commercialization of product candidates or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such collaboration. Moreover, we may not receive all of the milestone or royalty payments we are entitled to receive under our current and future collaboration agreements. For example, pursuant to the terms of our collaboration and license agreement with Bristol Myers Squibb, we are entitled to receive up to $301.0 million in total milestones per each program subject to the agreement. However, given the overlapping nature of the triggers for these milestone payments, as well as the uncertainty associated with achieving any of such milestones, it is unlikely that we will receive the entire $301.0 million in milestone payments with respect to each program subject to the agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report also apply to the activities of our therapeutic collaborators. Additionally, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face significant competition in seeking appropriate collaborative partners. Our ability to reach a definitive agreement for a partnership will depend, among other things, upon an assessment of the collaborator&#x2019;s resources and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expertise, the terms and conditions of the proposed partnership and the proposed collaborator&#x2019;s evaluation of a number of factors. These factors may include the design or results of preclinical studies or clinical trials, the likelihood of regulatory approval, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of any uncertainty with respect to our ownership of technology (which can exist if there is a challenge to such ownership regardless of the merits of the challenge) and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a partnership could be more attractive than the one with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization, reduce the scope of any sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our success depends in part on our ability to obtain intellectual property rights for our proprietary technologies and product candidates, as well as our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents that cover these activities. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected. Moreover, we may not be able to obtain intellectual property protection with respect to the SL pairs that we identify which are the targets of our current and future product candidates. Although we expect that the compounds underlying our product candidates will be protectable through intellectual property rights, our competitors could develop their own inhibitors based on the SL pairs we identify that might not be protected by our intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees. Roche controls prosecution of patents related to their in-license on camonsertib.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability, or scope thereof, which may result in such patents being narrowed, invalidated, or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Furthermore, for United States applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third-party or instituted by the United States patent office, or USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot be certain that we are the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority disputes. We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable, a competitor&#x2019;s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our product candidates or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property rights, or will design around the claims of patents that we have had issued that cover our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. Under the enacted Leahy-Smith America Invents Act, or America Invents Act, enacted in 2013, the United States moved from a &#x201c;first to invent&#x201d; to a &#x201c;first-to-file&#x201d; system. Under a &#x201c;first-to-file&#x201d; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO only recently developed new regulations and procedures in connection with the America Invents Act and many of the substantive changes to patent law, including the &#x201c;first-to-file&#x201d; provisions, only became effective in March 2013. In addition, the courts have yet to address many of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may be able to make or use compounds or cells that are similar to the biological compositions of our product candidates but that are not covered by the claims of our patents; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the active biological ingredients in our current product candidates will eventually become commercially available in biosimilar drug products, and no patent protection may be available with regard to formulation or method of use; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government in regards to any in-licensed patents and patent applications funded by U.S. government grants, leading to the loss of patent rights; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or our licensors, as the case may be, might not have been the first to file patent applications for these inventions; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that our pending patent applications will not result in issued patents; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that there are prior public disclosures that could invalidate our or our licensors&#x2019; patents, as the case may be, or parts of our or their patents; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that others may circumvent our owned or in-licensed patents; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the laws of foreign countries may not protect our or our licensors&#x2019;, as the case may be, proprietary rights to the same extent as the laws of the United States; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our owned or in-licensed issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we have engaged in scientific collaborations in the past, and will continue to do so in the future. Such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not develop additional proprietary technologies for which we can obtain patent protection; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that product candidates or diagnostic tests we develop may be covered by third parties&#x2019; patents or other exclusive rights; or </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patents of others may have an adverse effect on our business. </span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will have to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned patents and/or applications and any patent rights we may own or license in the future. We rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our products or technologies, we may not be able to stop a competitor from marketing products that are the same as or similar to our product candidates, which would have a material adverse effect on our business. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely in part on trade secrets to protect our technology, and our failure to obtain or maintain trade secret protection could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on trade secrets to protect some of our technology and proprietary information, especially where we believe patent protection is not appropriate or obtainable as is the case for our SNIPRx platform. However, trade secrets are difficult to protect. Litigating a claim that a third party had illegally obtained and was using our trade secrets would be expensive and time consuming, and the outcome would be unpredictable. Moreover, if our competitors independently develop similar knowledge, methods, and know-how, it will be difficult for us to enforce our rights and our business could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their drug earlier than might otherwise be the case.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent term extensions in other countries may also be subject to certain procedural or administrative requirements including adherence to certain strict timelines. A failure to meet such requirements may result in a loss of the extension in those countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may be able to make compounds or formulations that are similar to our product candidates but that are not covered by the claims of any patents, should they issue, that we own or control; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or any strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or control; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we might not have been the first to file patent applications covering certain of our inventions; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that our pending patent applications will not lead to issued patents; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issued patents that we own or control may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patents of others may have an adverse effect on our business. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may infringe our issued patents, future trademarks, copyrights, or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, trademarks, copyrights, or other intellectual property. In addition, in a patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#x2019;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patents do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common shares. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a negative impact on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends, in part, upon our ability and the ability of future collaborators, if any, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology, including interference proceedings, post grant review and inter partes review before the USPTO or equivalent foreign regulatory authority. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable, and infringed, which could have a negative impact on our ability to commercialize our current and any future product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Foreign courts will have similar burdens to overcome in order to successfully challenge a third party claim of patent infringement. If we are found to infringe a third party&#x2019;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing, and marketing our product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">candidate(s) and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing, and commercializing the infringing technology or product candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some or all of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A third party may hold intellectual property rights, including patent rights, that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable terms, or at all, and we could be forced to accept unfavorable contractual terms. If we are unable to obtain such licenses on commercially reasonable terms, our business could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We depend on intellectual property licensed from a third party and termination of this license could result in the loss of significant rights, which would harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others. In particular, we are dependent on our license agreement with New York University. Any termination of this license could result in the loss of significant rights and could harm our ability to commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disputes may also arise between us and our current licensor or future licensors regarding intellectual property subject to a license agreement, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current or future licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we, New York University or any future licensors fail to adequately protect any licensed intellectual property, our ability to commercialize products could suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims asserting that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The United States has recently enacted and implemented wide ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In some cases, we may not be able to obtain patent protection for certain technology outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, even in jurisdictions where we do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we do pursue patent protection or from selling or importing products made using our inventions in and into the United States or other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reliance on third parties requires us to share our proprietary information, which increases the possibility that such information will be misappropriated or disclosed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we rely on third parties to develop and manufacture our product candidates, or if we collaborate with third parties for the development or commercialization of our future product candidates, we must, at times, share proprietary information with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors, and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share confidential information increases the risk that such information become known by our competitors, is inadvertently incorporated into the technology of others, or is disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how, a competitor&#x2019;s discovery of our know-how or other unauthorized use or disclosure could have an adverse effect on our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors, and consultants to publish data potentially relating to our know-how. Despite our efforts to protect our know-how, we may not be able to prevent the unauthorized disclosure or use of our technical know-how by the parties to these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors, and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third-party illegally obtained and is using our proprietary information, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect proprietary information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. While we have a registered a trademark for our SNIPRx platform and SNIPDX biomarker platform technology, we have not yet selected trademarks for RP-6306 and have not yet begun the process of applying to register trademarks for RP-6306 or any other product candidate. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, any proprietary name we propose to use with RP-6306 or any future product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to the FDA. Comparable foreign regulators may have similar requirements, and it is possible that different proprietary or non-proprietary names may be required in different jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our proprietary information, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to seeking patent and trademark protection for our product candidate, we also rely on unpatented know-how, technology, and other proprietary information, to maintain our competitive position. We seek to protect our proprietary information, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated proprietary information is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, our competitors may independently develop knowledge, methods, and know-how equivalent to our proprietary information. Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our proprietary information were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive, and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension for patents covering our product candidates, our business may be materially harmed, and in any case, the terms of our patents may not be sufficient to effectively protect our product candidates and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents have a limited term. In most countries, including the United States, the expiration of a patent is generally 20 years after its first effective non-provisional filing date. However, depending upon the timing, duration, and specifics of FDA marketing approval of our product candidates, one or more of any U.S. patents we may be issued or have licensed may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA-approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our competitive position, business, financial condition, results of operations, and prospects could be harmed, possibly materially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If there are delays in obtaining regulatory approvals or other additional delays, the period of time during which we can market our product candidates under patent protection could be further reduced. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. Once the patent term has expired, we may be open to competition from similar or generic products. The launch of a generic version of one of our products in particular would be likely to result in an immediate and substantial reduction in the demand for that product, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are highly dependent on our management team, including Lloyd Segal, our President and Chief Executive Officer, Michael Zinda, Ph.D., our Chief Scientific Officer, and Maria Koehler, M.D., Ph.D., our Chief Medical Officer. Each of them may currently terminate their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development, and commercialization objectives. We do not currently maintain &#x201c;key person&#x201d; life insurance on the lives of our executives or any of our employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We expect to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 24, 2023, we had 180 full-time employees, including 148 employees engaged in research and development and 32 engaged in management or general and administrative activities. As our clinical development and commercialization plans and strategies develop, we expect we will need additional managerial, operational, sales, marketing, financial, legal and other personnel. Future growth would impose significant added responsibilities on members of management, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identifying, recruiting, integrating, maintaining and motivating additional employees; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">managing our development efforts effectively, including the ongoing Phase 1 clinical trials of RP-6306, while complying with our contractual obligations to contractors and other third parties; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. The services include substantially all aspects of clinical trial management and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our preclinical studies or clinical trials may be extended, delayed, or terminated, and we may not be able to obtain marketing approval of our product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are not able to effectively expand our organization by hiring qualified new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a significant disruption of our product development programs and our ability to operate our business effectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Cyber-attacks are increasing in their frequency, sophistication, and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering, and other means to affect service reliability and threaten the confidentiality, integrity, and availability of information. Cyber-attacks also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we have not experienced any significant system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials by us or our CROs could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Additionally, any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation, cause us not to comply with federal and/or state breach notification laws and foreign law equivalents and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information. Security breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures to protect our information technology systems and infrastructure, such measures may not prevent service interruptions or security breaches that could adversely affect our business and to the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations, and those of our CROs, CMOs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our international operations pose currency risks, which may adversely affect our operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our reporting and functional currency is the U.S. dollar. Assets and liabilities denominated in currencies other than the U.S. dollar are translated into U.S. dollars at exchange rates in effect at each balance sheet date. Income items and expenses are translated using the average exchange rate in effect for the relevant period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operating results may be affected by volatility in currency exchange rates and our ability to manage effectively our currency transaction risks. Although we report, and will continue to report, our results in U.S. dollars, a portion our expenses are incurred in Canadian dollars as a result of our operations in Canada, as well as other currencies to a lesser extent. For example, we are also exposed to currency risk through our collaboration agreement with Ono as future payments receivable under our collaboration agreement, if any, are denominated in Japanese yen.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we maintain a significant portion of our cash in Canadian dollar-denominated reserves. We do not currently manage our foreign currency exposure in a manner that would eliminate the effects of changes in foreign exchange rates. For example, we have not engaged in any active hedging techniques, and we have not employed any derivative instruments to date. Therefore, unfavorable fluctuations in the exchange rate between the Canadian dollar and U.S. dollar could have a negative impact on our business and financial results. We do, however, keep expected Canadian dollar cash requirements in Canadian dollars to form a natural hedge.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions, including civil or criminal penalties, private litigation, and adverse publicity and could negatively affect our operating results and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and any current and future collaborators may be subject to federal, state/provincial, municipal and foreign data protection laws and regulations, such as laws and regulations that address privacy and data security. In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, including Section 5 of the Federal Trade Commission Act, that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by HITECH. Depending on the facts and circumstances, we could be subject to civil, criminal, and administrative penalties if we violate HIPAA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal, and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees, and other individuals about whom we or our current or future collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#x2019; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event we decide to conduct clinical trials or continue to enroll subjects in our ongoing or future clinical trials, we may be subject to additional privacy restrictions. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#x20ac;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR increased our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. Further, the United Kingdom&#x2019;s vote in favor of exiting the European Union, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear how data transfers to and from the United Kingdom will be regulated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, California recently enacted the California Consumer Privacy Act, or CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#x2019; data collection, use and sharing practices, provide such consumers new ways to opt-out of certain sales or transfers of personal information, and provide consumers with additional causes of action. The CCPA went into effect on January 1, 2020, and the California Attorney General may bring enforcement actions for violations beginning July 1, 2020. The CCPA was amended on September 23, 2018, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. As currently written, the CCPA may impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our current or future collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#x2019; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants, and commercial partners. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in other jurisdictions, provide accurate information to the FDA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Ownership of Our Common Shares</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The trading price of our common shares has been and is likely to continue to be volatile and fluctuate substantially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading price of our common shares has been and is likely to continue to be highly volatile. Furthermore, the stock market in general and the market for biopharmaceutical and pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our shareholders may not be able to sell their common shares at or above the price they paid for their common shares. The market price of our common shares may be influenced by many factors, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ongoing COVID-19 pandemic and its impact on the global markets;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the commencement, enrollment, timing and results of our ongoing clinical trials of RP-6306, camonsertib and any future product candidates or those of our competitors;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we or our collaborators receive marketing approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our success or failure in identifying new drug candidates to pursue in clinical development; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success or failure of our SNIPRx platform in identification of new druggable SL targets; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of competitive drugs, therapies or technologies; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">development of new product candidates that may address our markets and make our product candidates less attractive; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure or discontinuation of any of our research or development programs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments related to any existing or future collaborations; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of competitive products or technologies; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of expenses related to camonsertib, RP-6306 and any future product candidates or clinical development programs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of our efforts to discover, develop, acquire or in-license additional product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to obtain or delays in obtaining adequate drug supply for any approved drug or inability to do so at acceptable prices; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant lawsuits, including patent or shareholder litigation; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the structure of healthcare payment systems, including coverage and adequate reimbursement for any approved drug; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales of common shares by us, our executive officers, directors or principal shareholders, or others; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general economic, political, and market conditions and overall fluctuations in the financial markets in the United States and abroad; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">investors&#x2019; general perception of us and our business; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the other factors described in this &#x201c;Risk Factors&#x201d; section and elsewhere in this Annual Report. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some companies that have experienced volatility in the trading price of their shares have been the subject of securities class action litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming, and could divert our management&#x2019;s attention and our resources. Furthermore, during the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market price of our common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of ownership of our common shares among our existing executive officers, directors and principal shareholders may prevent new investors from influencing significant corporate decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based upon our common shares outstanding as of December 31, 2022, our executive officers, directors, and shareholders who owned more than 5% of our outstanding common shares beneficially own shares, in the aggregate, representing approximately 66% of our common shares. If our executive officers, directors, and shareholders who owned more than 5% of our outstanding common shares acted together, they would be able to significantly influence all matters requiring shareholder approval, including the election and removal of directors and approval of any merger, consolidation, or sale of all or substantially all of our assets. The concentration of voting power and transfer restrictions could delay or prevent an acquisition of our company on terms that other shareholders may desire or result in the management of our company in ways with which other shareholders disagree.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our share price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common shares will be influenced by the research and reports that industry or financial analysts publish about us or our business. We will not have any control over these equity research analysts or the content and opinions included in their reports. The price of our shares could decline if one or more equity research analysts downgrade our shares or issue other unfavorable commentary or research about us. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our shares could decrease, which in turn could cause the trading price or trading volume of our common shares to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The sale of a substantial number of our common shares in the public market could cause the market price of our shares to drop significantly, even if our business is doing well.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of a substantial number of our common shares in the public market could occur at any time. If our shareholders sell, or the market perceived that our shareholders intend to sell, substantial amounts of our common shares in the public market, the market price of our common shares could decline significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have filed registration statements on Form S-8 to register our common shares that are issuable pursuant to our equity incentive plans. Shares registered under these registration statements on Form S-8 will be available for sale in the public market subject to vesting arrangements and exercise of options, as well as, in the case of our affiliates, the restrictions of Rule 144 under the Securities Act. Furthermore, in August 2022, we entered into the Sales Agreement with Cowen and Company, LLC as sales agent, pursuant to which we may issue and sell from time to time common shares up to a maximum aggregate amount of $125.0 million in sales deemed to be an &#x201c;at the market offering,&#x201d; as defined by the Securities Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, as of December 31, 2022, certain holders of an aggregate of 17,894,178 common shares, or their transferees, have rights, subject to some conditions, to require us to file one or more registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other shareholders. If we were to register the resale of these shares, they could be freely sold in the public market. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common shares could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our share capital in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You should not rely on an investment in our common shares to provide dividend income. We have never declared or paid cash dividends on our share capital. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements or preferred equity may preclude us from paying dividends. As a result, capital appreciation, if any, of our common shares will be your sole source of gain for the foreseeable future. Investors seeking cash dividends should not purchase our common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our articles of continuance permit us to issue an unlimited number of common shares and preferred shares without additional shareholder approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our articles of continuance permit us to issue an unlimited number of common shares. We anticipate that we will, from time to time, issue additional common shares in the future. Any further issuances of common shares will result in immediate dilution to existing shareholders and may have an adverse effect on the value of their holdings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our articles of continuance also permit us to issue an unlimited number of preferred shares, issuable in one or more series and, subject to the provisions of the Business Corporations Act (Qu&#xe9;bec), or QBCA, having such designations, rights, privileges, restrictions and conditions, including dividend and voting rights, as our board of directors may determine and which may be superior to those of the common shares. The issuance of preferred shares, while providing flexibility in connection with possible acquisitions, financings, and other corporate purposes, could, among other things, have the effect of delaying, deferring, or preventing a change in control of Repare and might adversely affect the market price of our common shares and the voting and other rights of the holders of common shares. We have no current or immediate plans to issue any preferred shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to Nasdaq listing rules, we will not be required to obtain the approval of shareholders for the issuance of additional common shares and preferred shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are a &#x201c;smaller reporting company&#x201d; and cannot predict if the reduced reporting requirements applicable to smaller reporting companies will make our common shares less attractive to investors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a &#x201c;smaller reporting company&#x201d; under the Exchange Act as of June 30, 2022. We may continue to be a smaller reporting company if either (i) the market value of our common shares held by non-affiliates is less than $250</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million or (ii) our annual revenue was less than $100.0 million during the most recently completed fiscal year and the market value of our common shares held by non-affiliates is less than $700.0 million. As a smaller reporting company, we may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. For so long as we remain a smaller reporting company, we are permitted and intend to rely on such exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot predict if investors will find our common shares less attractive because we may rely on the exemptions and reduced disclosure obligations applicable to smaller reporting companies. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and our share price may be more volatile.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as amended and the rules and regulations of The Nasdaq Global Market. Pursuant to Section 404 of the Sarbanes-Oxley Act, we are now required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting. Furthermore, if at such time we no longer qualify as a &#x201c;smaller reporting company&#x201d;, our independent registered public accounting firm will be required to issue an annual report that attests the effectiveness of our internal control over financial reporting.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. Further, we may in the future discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Moreover, our internal controls over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#x2019;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. Moreover, we are aware that the remote working arrangements implemented in connection with the COVID-19 pandemic potentially present new areas of risk, and we are carefully monitoring any impact to our internal controls and procedures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> If we are unable to assert that our internal control over financial reporting is effective, investors could lose confidence in the reliability of our financial statements, the market price of our common shares could decline and we could be subject to sanctions or investigations by The Nasdaq Global Market, the SEC or other regulatory authorities.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. Holders.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Internal Revenue Code of 1986, as amended, or the Code, we will be a passive foreign investment company, or PFIC, for any taxable year in which (1) 75% or more of our gross income consists of passive income or (2) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, passive income, including cash. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets and received directly its proportionate share of the income of such other corporation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the nature of our activities and the composition of our income and assets, we believe we were not classified as a PFIC for the taxable year ended December 31, 2022. No assurances regarding our PFIC status can be provided for any past, current, or future taxable years. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis and the applicable law is subject to varying interpretation. In particular, the characterization of our assets as active or passive may depend in part on our current and intended future business plans, which are subject to change. In addition, for our current and future taxable years, the total value of our assets for PFIC testing purposes may be determined in part by reference to the market price of our common shares from time to time, which may fluctuate considerably. Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by how, and how quickly, we spend the cash we raise in any offering. Accordingly, our U.S. counsel expresses no opinion with respect to our PFIC status.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are a PFIC, a U.S. Holder (as defined below) of our common shares would be subject to adverse U.S. federal income tax consequences, such as ineligibility for any preferential tax rates for individuals on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements under U.S. federal income tax laws and regulations. Each U.S. Holder should consult its own tax advisors with respect to the potential adverse U.S. tax consequences to it if we are or were to become a PFIC. A &#x201c;U.S. Holder&#x201d; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of our common shares and is:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a citizen or individual resident of the United States;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a trust that (a) is subject to the primary supervision of a U.S. court and the control of one or more &#x201c;United States persons&#x201d; (within the meaning of Section 7701(a)(30) of the Code) or (b) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes.</span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are a controlled foreign corporation, there could be materially adverse U.S. federal income tax consequences to certain U.S. Holders of our common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a U.S. Holder is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our common shares, such U.S. Holder may be treated as a &#x201c;United States shareholder&#x201d; with respect to each &#x201c;controlled foreign corporation&#x201d; in our group (if any) as such term is defined in the Code. We refer to this holder as a &#x201c;Ten Percent Shareholder&#x201d;.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each &#x201c;Ten Percent Shareholder&#x201d; in a non-U.S. corporation that is classified as a controlled foreign corporation, or a CFC, for U.S. federal income tax purposes generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#x2019;s pro rata share of the CFC&#x2019;s &#x2018;&#x2018;Subpart F income,&#x2019;&#x2019; global intangible low taxed income, and investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. Subpart F income generally includes dividends, interest, rents, royalties, gains from the sale of securities and income from certain</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">transactions with related parties. In addition, a Ten Percent Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain. An individual that is a Ten Percent Shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a Ten Percent Shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may subject a Ten Percent Shareholder to significant monetary penalties and may prevent the statute of limitations with respect to such Ten Percent Shareholder&#x2019;s U.S. federal income tax return for the year for which reporting was due from starting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A non-U.S. corporation generally will be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#x201c;Ten Percent Shareholder&#x201d; is a United States person (as defined by the Code) who owns or is considered to own 10% or more of the total combined voting power of all classes of stock entitled to vote or 10% or more of the total value of all classes of stock of such corporation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each U.S. Holder should consult its own tax advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten Percent Shareholder in a CFC. If we are classified as both a CFC and a PFIC, we generally will not be treated as a PFIC with respect to those U.S. Holders that meet the definition of a Ten Percent Shareholder during the period in which we are a CFC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to use our non-capital loss carryforwards to offset future taxable income may be subject to certain limitations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In general, where control of a corporation has been acquired by a person or group of persons, subsection 111(5) of the Income Tax Act (Canada), or the Canadian Tax Act, and equivalent provincial income tax legislation restrict the corporation&#x2019;s ability to carry forward non-capital losses from preceding taxation years. We have not performed a detailed analysis to determine whether an acquisition of control for the purposes of subsection 111(5) of the Canadian Tax Act has occurred after each of our previous issuances of common shares or preferred shares. In addition, if we undergo an acquisition of control, our ability to utilize non-capital losses could be limited by subsection 111(5) of the Canadian Tax Act. As of December 31, 2022, we had Canadian federal and provincial non-capital loss carry forwards of $158.5 million, which expire beginning in 2037 through 2042. In addition, we also have scientific research and experimental development expenditures of approximately $54.6 million for Canadian federal and provincial income tax purposes, which have not been deducted. These expenditures are available to reduce future taxable income and have an unlimited carry-forward period. We also have scientific research and experimental development tax credit carry forwards of approximately $9.0 million for Canadian federal income tax purposes, which expire beginning in 2036 through 2042. Research and development tax credits and expenditures are subject to verification by the tax authorities, and, accordingly, these amounts may vary. Future changes in our share ownership, some of which are outside of our control, could result in an acquisition of control for the purposes of subsection 111(5) of the Canadian Tax Act. Furthermore, our ability to utilize non-capital losses (or U.S. equivalents) of companies that we may acquire in the future may be subject to limitations. As a result, even if we attain profitability, we may be unable to use a material portion of our non-capital losses and other tax attributes, which could negatively impact our future cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes to the tax treatment of research and experimental expenditures as a result of U.S. federal tax reform could increase our tax burden and adversely affect our business and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2017, the U.S. government enacted comprehensive tax legislation, the Tax Cuts and Jobs Act of 2017, or TCJA, significantly reformed the Internal Revenue Code of 1986, as amended. As a result of this legislation beginning in 2022, our research and experimental expenditures are no longer deductible in the year they are incurred for US tax purposes. Instead, US-based research and experimental expenditures are required to be capitalized and amortized ratably over a five-year period. Any such expenditures attributable to research conducted outside the United States must be capitalized and amortized over a 15-year period. Although Congress is considering legislation that would defer the amortization requirement to later years, we have no assurance that the provision will be repealed or otherwise modified, or that any future repeal or modification would be retroactive. The requirement has materially reduced our cash flows in 2022 and is expected to materially reduce our cash flows going forward. Changes in our tax provisions or an increase in our tax liabilities, whether due to changes in applicable laws and regulations or our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interpretation or application thereof, could have a material adverse effect on our financial position, results of operations and/or cash flows.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes, or non-realization of expected benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, the Canada Revenue Agency, the U.S. Internal Revenue Service, or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#x2018;&#x2018;permanent establishment&#x2019;&#x2019; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our deductions and credits in respect of scientific research and experimental development expenditures may be challenged by tax authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax authorities in Canada and the United States may not necessarily agree with our determinations of the expenses and tax credits claimed by us, including scientific research and experimental development expenses and related tax credits. If tax authorities successfully challenge such expenses or the correctness of such income tax credits claimed, our operating results could be adversely affected. Furthermore, if the tax authorities reduce the tax credit by reducing either the rate of the credit or the eligibility of some scientific research and experimental development expenses in the future, our operating results could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have and will continue to incur significantly increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we have and will continue to incur significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Stock Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain and maintain director and officer liability insurance and we may be required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees, or as executive officers. The increased costs may require us to reduce costs in other areas of our business or increase the prices of our services. Moreover, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated bylaws designate specific courts in Canada and the United States as the exclusive forum for certain litigation that may be initiated by our shareholders, which could limit our shareholders&#x2019; ability to obtain a favorable judicial forum for disputes with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to our amended and restated bylaws, unless we consent in writing to the selection of an alternative forum, the courts of the Province of Qu&#xe9;bec and the appellate courts therefrom shall, to the fullest extent permitted by</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">law, be the sole and exclusive forum for: (a) any derivative action or proceeding brought on our behalf; (b) any action or proceeding asserting a claim for breach of fiduciary duty owed to us by any of our directors, officers or other employees; (c) any action or proceeding asserting a claim arising out of any provision of the Business Corporations Act (Qu&#xe9;bec) or the articles or our bylaws (as either may be amended from time to time); or (d) any action or proceeding asserting a claim otherwise related to our affairs, or the Canadian Forum Provision. The Canadian Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, or the U.S. Federal Forum Provision. In addition, our amended and restated bylaws provide that any person or entity holding, owning, or otherwise acquiring any interest in any of our securities is deemed to have notice of and consented to the Canadian Forum Provision and the U.S. Federal Forum Provision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Canadian Forum Provision and the U.S. Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on shareholders in pursuing any such claims. Additionally, the forum selection clauses in our amended and restated bylaws may limit our shareholders&#x2019; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our shareholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#x201c;facially valid&#x201d; under Delaware law, there is uncertainty as to whether other courts, including courts in Canada and other courts within the United States, will enforce our U.S. Federal Forum Provision. If the U.S. Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The U.S. Federal Forum Provision may also impose additional litigation costs on shareholders who assert that the provision is not enforceable or invalid. The courts of the Province of Qu&#xe9;bec and the federal district courts of the United States of America may also reach different judgments or results than would other courts, including courts where a shareholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our shareholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because we are a Canadian company, it may be difficult to serve legal process or enforce judgments against us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are incorporated and have our corporate headquarters in Qu&#xe9;bec, Canada. In addition, while many of our directors and officers reside in the United States, several of them reside outside of the United States. Accordingly, service of process upon us may be difficult to obtain within the United States. Furthermore, because substantially all of our assets are located outside the United States, any judgment obtained in the United States against us, including one predicated on the civil liability provisions of the U.S. federal securities laws, may not be collectible within the United States. Therefore, it may not be possible to enforce those actions against us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, it may be difficult to assert U.S. securities law claims in original actions instituted in Canada. Canadian courts may refuse to hear a claim based on an alleged violation of U.S. securities laws against us or these persons on the grounds that Canada is not the most appropriate forum in which to bring such a claim. Even if a Canadian court agrees to hear a claim, it may determine that Canadian law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Canadian law. Furthermore, it may not be possible to subject foreign persons or entities to the jurisdiction of the courts in Canada. Similarly, to the extent that our assets are located in Canada, investors may have difficulty collecting from us any judgments obtained in the U.S. courts and predicated on the civil liability provisions of U.S. securities provisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are governed by the corporate laws of Qu&#xe9;bec, which in some cases have a different effect on shareholders than the corporate laws of Delaware.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are governed by the QBCA and other relevant laws, which may affect the rights of shareholders differently than those of a company governed by the laws of a U.S. jurisdiction, and may, together with our charter documents, have the effect of delaying, deferring, or discouraging another party from acquiring control of us by means of a tender offer, a proxy contest or otherwise, or may affect the price an acquiring party would be willing to offer in such an</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">instance. The material differences between the QBCA and Delaware General Corporation Law, or the DGCL, that may have the greatest such effect include but are not limited to the following: (i) for material corporate transactions (such as mergers and amalgamations, other extraordinary corporate transactions or amendments to our articles), the QBCA generally requires a two-thirds majority vote by shareholders, whereas the DGCL generally only requires a majority vote; and (ii) under the QBCA, a holder of 10% or more of our common shares can requisition a special meeting of shareholders, whereas such right does not exist under the DGCL.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated bylaws and certain Canadian legislation contain provisions that may have the effect of delaying or preventing certain change in control transactions or shareholder proposals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain provisions of our amended and restated bylaws and certain Canadian legislation, together or separately, could discourage or delay certain change in control transactions or shareholder proposals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated bylaws contain provisions that establish certain advance notice procedures for nomination of candidates for election as directors at shareholders&#x2019; meetings. The QBCA requires that any shareholder proposal that includes nominations for the election of directors must be signed by one or more holders of shares representing in the aggregate not less than 5% of the shares or 5% of the shares of a class or series of shares of the corporation entitled to vote at the meeting to which the proposal is to be presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Investment Canada Act requires that a non-Canadian must file an application for review with the Minister responsible for the Investment Canada Act and obtain approval of the Minister prior to acquiring control of a &#x201c;Canadian business&#x201d; within the meaning of the Investment Canada Act, where prescribed financial thresholds are exceeded. Furthermore, limitations on the ability to acquire and hold our common shares may be imposed by the Competition Act (Canada). This legislation permits the Commissioner of Competition, or Commissioner, to review any acquisition or establishment, directly or indirectly, including through the acquisition of shares, of control over or of a significant interest in our company. Otherwise, there are no limitations either under the laws of Canada or Qu&#xe9;bec, or in our articles on the rights of non-Canadians to hold or vote our common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these provisions may discourage a potential acquirer from proposing or completing a transaction that may have otherwise presented a premium to our shareholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B. Unresolved Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Properties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our headquarters is currently located in Montr&#xe9;al, Qu&#xe9;bec, Canada and consists of 9,045 square feet of leased laboratory and office space under a lease that expires in July 2025. In September 2020, we expanded our research footprint with the addition of 20,594 square feet of combined laboratory and office space in Montr&#xe9;al, Qu&#xe9;bec, Canada through a lease agreement that expires in August 2025. The new facility expands the laboratory capacity for our CRISPR-enabled genome-wide synthetic lethal target platform, SNIPRx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, including dedicated space for work related to accelerating our preclinical assets, including those under our research collaboration with Bristol Myers Squibb. We also lease 11,312 square feet of office space in Cambridge, Massachusetts for our U.S.-based employees under a lease which expires in December 2024. We intend to renew our leases, move to new facilities or expand existing facilities to meet our growth, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Legal Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4. Mine Safety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information for our Common Shares</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common shares are traded on The Nasdaq Global Select Market under the symbol &#x201c;RPTX&#x201d; and began trading on June 20, 2020. Prior to this time, there was no public market for our common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there were approximately 21 holders of record of our common shares. This number does not reflect the beneficial holders of our common shares for whom shares are held in &#x201c;nominee&#x201d; or &#x201c;street&#x201d; name through brokerage accounts or other nominees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid cash dividends on our share capital, and we do not currently intend to pay any cash dividends on our share capital in the foreseeable future. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business. Any future determination related to dividend policy will be made at the discretion of our board of directors, subject to applicable laws, and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions, and capital requirements. In addition, our ability to pay cash dividends on our share capital in the future may be limited by the terms of any future debt or preferred securities we issue or any credit facilities we enter into.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Sales of Unregistered Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6. [Reserved]</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our audited consolidated financial statements and related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#x201c;Risk Factors&#x201d; section of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a leading clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Synthetic lethality, or SL, represents a clinically validated approach to drug development. We use our proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. SL arises when a deficiency in either of two genes is tolerated in cells, but simultaneous deficiencies in both genes cause cell death. Cancer cells that contain a mutation in one gene of a SL pair are susceptible to therapeutic intervention targeting the other gene pair. Using our SNIPRx platform, we are developing our pipeline of SL product candidates, including our initial product candidate, camonsertib (also known as RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ATM gene (ataxia telangiectasia mutated kinase). In June 2022, we entered into a worldwide license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd, collectively referred to as Roche, for the development and commercialization of camonsertib. In July 2020, we began dosing patients in our Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of camonsertib in advanced solid tumors and, in August 2021, we began dosing patients in our Phase 1b/2 ATTACC clinical trial of camonsertib to evaluate the safety and efficacy of camonsertib in combination with approved poly (ADP-ribose) polymerase, or PARP, inhibitors, olaparib and niraparib, in patients with molecularly selected cancers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2021, we initiated our Phase 1 MYTHIC clinical trial for RP-6306, our PKMYT1 (Protein Kinase Membrane-associated tyrosine- and threonine- specific cdc-2 inhibitory kinase) SL inhibitor, as a monotherapy for the treatment of molecularly selected advanced solid tumors, and anticipate early Phase 1 read-outs from the trial in the first half of 2023. We initiated Phase 1 combination studies of RP-6306 with gemcitabine (MAGNETIC) in December 2021, camonsertib (MYTHIC) in May 2022, and FOLFIRI (MINOTAUR) in August 2022, each for the treatment of molecularly selected advanced solid tumors, and anticipate providing an update on some of these combination studies in the fourth quarter of 2023. In the fourth quarter of 2022, we received fast track designation for RP-6306 in combination with gemcitabine for the treatment of adult patients with CCNE1 amplified, or FBXW7, or PPP2R1A mutated platinum resistant ovarian cancer. Based on promising preclinical data released at the 34th EORTC-NCI-AACR Symposium in October 2022, we are working with clinical investigators to initiate clinical testing, as part of an investigator-sponsored trial (IST), of a fourth new RP-6306 combination with carboplatin, with first patient dosing expected in the first half of 2023. In the fourth quarter of 2022, we entered into an agreement with Canadian Cancer Trials Group, or CCTG, for a planned, basket Phase 2 IST to evaluate RP-6306 in patients with selected, advanced cancers receiving standard agents. We plan to modify the trial to include a sub-study, which will evaluate RP-6306 in combination with gemcitabine in patients with CD4/6i-resistant ER+/HER2- metastatic breast cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to focus on the advancement of our preclinical programs into clinical development. We expect to initiate IND-enabling studies in the first half of 2023 for a small molecule against an undisclosed target with potential to enter the clinic in late 2023 or early 2024, which represents an acceleration from our prior expectations for this program. We are also pursuing development of an inhibitor of polymerase theta (Pol&#x3b8;) in collaboration with Ono, as Pol&#x3b8; is SL with multiple gene deficiencies found in tumors, including BRCA alterations. In 2022, we selected a proposed inhibitor, which we designated as RP-2119. In February 2023, based on our review of ongoing preclinical studies, we elected to prioritize other Pol&#x3b8; inhibiting compounds in our preclinical development portfolio, which we believe have a higher probability for clinical impact relative to RP-2119. We are now guiding toward clinical entry for a Pol&#x3b8; inhibitor in 2024.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception in September 2016, we have focused primarily on raising capital, organizing and staffing our company, conducting discovery and research activities, identifying potential SL gene pairs, establishing and protecting our intellectual property portfolio including for our proprietary SNIPRx platform, developing and progressing our product candidates through preclinical studies and preparing for clinical trials and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates and component materials. We do not have any product candidates approved for sale and have not generated any revenue from product sales. On June 23, 2020, we completed our initial public offering, or IPO, whereby we issued an aggregate of 12,650,000 common shares, which includes the exercise in full of the underwriters&#x2019; option to purchase up to an additional 1,650,000 common shares, at a public offering price of $20.00 per share. The aggregate net proceeds received by us from the IPO were approximately $232.0 million, after deducting underwriting commissions and offering expenses of $3.2 million. On November 1, 2021, we completed a follow-on offering, or the 2021 Offering, whereby we issued 4,600,000 common shares, including the exercise in full by the underwriters of their option to purchase up to 600,000 additional common shares, at a public offering price of $22.00 per share, for net proceeds of $94.3 million, after deducting underwriting commissions as well as offering expenses of $0.8 million. Prior to our IPO, we had funded our operations primarily through equity financings, having raised an aggregate of approximately $135.2 million of gross proceeds from the sale of our preferred shares and $15.0 million of gross proceeds from the issuance of a warrant to acquire our common shares. As of December 31, 2022, we had cash and cash equivalents and marketable securities on hand of $343.9 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception, we have incurred significant operating losses. Our net losses were $29.0 million, and $106.9 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $239.3 million. We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as we advance our product candidates, including RP-6306, through preclinical and clinical development and seek regulatory approvals, manufacture drug product and drug supply, maintain and expand our intellectual property portfolio. Our net losses are also expected to be impacted as we hire additional personnel, pay for accounting, audit, legal, regulatory and consulting services, and pay costs associated with maintaining compliance with Nasdaq listing rules and the SEC requirements, directors and officers, or D&amp;O, insurance, investor and public relations activities and other expenses associated with operating as a public company. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our preclinical studies, our clinical trials, our expenditures on other research and development activities, and our revenue and expenses recognized from collaboration and license agreements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have any products approved for sale. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates, if ever. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to raise capital or enter into such agreements as, and when, needed, could have a negative effect on our business, results of operations and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Macroeconomic Considerations</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unfavorable conditions in the economy in the United States, Canada and abroad may negatively affect the growth of our business and our results of operations. For example, macroeconomic events, including the COVID-19 pandemic, rising inflation, the U.S. Federal Reserve raising interest rates and the Russia-Ukraine war, have led to economic uncertainty globally. The effect of macroeconomic conditions may not be fully reflected in our results of operations until future periods. If, however, economic uncertainty increases or the global economy worsens, our business, financial condition and results of operations may be harmed. For further discussion of the potential impacts of macroeconomic events on our business, financial condition, and operating results, see the section titled &#x201c;Risk Factors.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent and Anticipated Developments</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advancing camonsertib, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of tumors with specific synthetic lethal genomic alterations in partnership with Roche.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial data from the Phase 1/2 trials evaluating camonsertib in combination with three poly (ADP-ribose) polymerase (PARP) inhibitors is expected to be presented in the first half of 2023 at a major medical meeting.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to report initial data from the Phase 1/2 TRESR trial evaluating camonsertib in combination with gemcitabine in the summer or fall of 2023.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluating RP-6306, a first-in-class, oral PKMYT1 inhibitor as a monotherapy and in combinations in multiple early clinical studies.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to report initial Phase 1 clinical data for RP-6306 as a monotherapy for the treatment of molecularly selected advanced solid tumors (MYTHIC) in the first half of 2023. We expect to report initial Phase 1 clinical data for RP-6306 as a combination therapy for the treatment of molecularly selected advanced solid tumors in the fourth quarter of 2023.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the fourth quarter of 2022, the U.S. Food and Drug Administration granted Fast Track designation to RP-6306 in combination with gemcitabine for the treatment of adult patients with CCNE1 amplified, or FBXW7 or PPP2R1A mutated platinum resistant ovarian cancer. Fast Track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fulfill an unmet medical need, enabling drugs to reach patients earlier.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on promising preclinical data released at the 34th EORTC-NCI-AACR Symposium in October 2022, we are working with clinical investigators to initiate clinical testing, as part of an investigator sponsored trial (IST), of a fourth new RP-6306 combination with carboplatin, with first patient dosing expected in the first half of 2023.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the fourth quarter of 2022, we entered into an agreement with CCTG for a planned, basket Phase 2 IST to evaluate RP-6306 in patients with selected, advanced cancers receiving standard agents. A sub-study under the master clinical trial protocol will evaluate RP-6306 in combination with gemcitabine in patients with CD4/6i-resistant ER+/HER2- metastatic breast cancer.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advancing preclinical programs into clinical development.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to initiate IND-enabling studies in the first half of 2023 for a small molecule against an undisclosed target with potential to enter the clinic in late 2023 or early 2024, which represents an acceleration from our prior expectations for this program.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are pursuing development of an inhibitor of Pol&#x3b8; in collaboration with Ono in Japan, South Korea, Taiwan, Hong Kong, Macau and ASEAN countries, excluding mainland China. Repare retains all rights to develop and commercialize the products outside the Ono territory. In 2022, we selected a proposed inhibitor of Pol&#x3b8;, which we designated as RP-2119. In February 2023, based on our review of ongoing preclinical studies, we elected to prioritize other Pol&#x3b8; inhibiting compounds in our preclinical development portfolio, which we believe have a higher probability for clinical impact relative to RP-2119. We are now guiding toward clinical entry for a Pol&#x3b8; inhibitor in 2024.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2023, we received an approximate $1.5 million (&#165;200 million) milestone payment from Ono. The payment reflected the achievement of a research milestone under our research services, license and collaboration agreement with Ono (Ono Agreement).</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Also, in January 2023, we and Ono amended the Ono Agreement to further extend the research term until July 31, 2023. Previously, we had entered into an amendment with Ono in October 2021 to extend the research term by one year at no additional cost to us.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have not recognized any revenue from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and License Agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 1, 2022, we entered into a collaboration and license agreement, or the Roche Agreement, with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd, or collectively, Roche, regarding the development and commercialization of our product candidate camonsertib (also known as RP-3500 or RG6526) and specified other ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) inhibitors, which we refer to as the Licensed Products. The transaction was subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions, which were met on July 13, 2022, or Effective Date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Roche Agreement, we granted Roche a worldwide, perpetual, exclusive, sublicensable license to develop, manufacture, and commercialize the Licensed Products. Roche assumes all subsequent development of camonsertib with the potential to expand development into additional tumors and multiple combination studies. We have agreed to complete specified ongoing clinical trials at our expense. We also retained the right to conduct specified clinical trials of camonsertib in combination with our PKMYT1 compound (also known as RP-6306).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Roche Agreement was subsequently amended in October 2022 to extend the timeline to negotiate in good faith the parties&#x2019; rights and obligations with respect to the Repare Trials, as defined in the Roche Agreement, and to clarify indications included in the development plan that are subject to milestones.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Roche Agreement, we received an upfront payment of $125 million in July 2022, and are eligible to receive up to $1.172 billion in potential clinical, regulatory, commercial and sales milestones, including up to $55 million in potential near-term payments, and royalties on global net sales ranging from high-single-digits to high-teens. The Roche Agreement also provides us with the ability to opt-in to a 50/50 U.S. co-development and profit share arrangement, including participation in U.S. co-promotion if U.S. regulatory approval is received. If we choose to exercise its co-development and profit share option, we will continue to be eligible to receive certain clinical, regulatory, commercial and sales milestone payments, in addition to full ex-U.S. royalties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We determined that the transaction price at the onset of the Roche Agreement was $134.6 million, being (i) the total non-refundable upfront payment received of $125.0 million, (ii) the additional $4.0 million payment received, negotiated with Roche for revisions to the clinical development plan under the Roche Agreement as agreed at the time of the Effective Date, and (iii) the $5.6 million received for the transfer of clinical trial materials.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.153%;"></td>
    <td style="width:9.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:16.845000000000002%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance obligation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transaction price</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Combined licenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105,327</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Completion of Continuing Trials</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,585</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transfer of clinical trial materials</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,714</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total transaction price</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,626</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognized $116.6 million for the year ended December 31, 2022 as revenue associated with the Roche Agreement, of which $105.3 million related to the grant of the combined licenses, $2.7 million related to the clinical trial materials transferred, and $8.6 million related to the partial recognition of deferred revenue for research and development services performed towards the completion of the Continuing Trials during the period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was $18.0 million (December 31, 2021 &#x2013; nil) of deferred revenue related to the Roche Agreement, of which $15.3 million (December 31, 2021 &#x2013; nil) was classified as current and $2.7 million  (December 31, 2021 &#x2013; nil) was classified as non-current in the consolidated balance sheet based on the period the services to complete the Continuing Trials are expected to be performed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and License Agreement with Bristol-Myers Squibb Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2020, we entered into a collaboration and license agreement, or the BMS Agreement, with the Bristol Myers Squibb Company, or Bristol Myers Squibb, pursuant to which we and Bristol Myers Squibb have agreed to collaborate in the research and development of potential new product candidates for the treatment of cancer. We are providing Bristol Myers Squibb access to a selected number of our existing screening campaigns and novel campaigns. We are responsible for carrying out early-stage research activities directed to identifying potential targets for potential licensing by Bristol Myers Squibb. The collaboration consists of programs directed to both druggable targets and to targets commonly considered undruggable to traditional small molecule approaches. In the event that Bristol Myers Squibb elects to obtain an exclusive license for the subsequent development, manufacturing and commercialization of a program, Bristol Myers Squibb will then be solely responsible for all such worldwide activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The BMS Agreement was subsequently amended in July, September and November 2020 to include additional campaigns to the list of existing campaigns from which Bristol Myers Squibb may select campaigns under the BMS Agreement and to enable unblinding of a Bristol Myers Squibb alliance manager in order to streamline the collaboration process.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the BMS Agreement, Bristol Myers Squibb paid us an initial upfront fee of $50.0 million and made an equity investment of $15.0 million in our company. We will also be eligible to receive up to $3.0 billion in total milestones across all potential programs. Such milestones consist of $301.0 million in total milestones per program subject upon the achievement of certain specified research, development, regulatory and commercial milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The $50.0 million upfront payment was recorded as deferred revenue on our consolidated balance sheet and is expected to be partially recognized at the point in time when option licenses are exercised by Bristol Myers Squibb, with the remainder being recognized on a proportional performance basis over the period of service for research services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.122%;"></td>
    <td style="width:8.978%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:16.899%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance obligation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transaction price</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Research activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,405</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Options to license druggable targets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,148</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Options to license undruggable targets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,447</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total transaction price</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021, we recognized, from our deferred revenue balance, $2.7 million and $1.1 million, respectively, as revenue associated with the BMS Agreement in relation to research activities performed during the period.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the fourth quarter of 2022, Bristol Myers Squibb waived its rights to exercise options for druggable targets directed at two separate lesions. As a result, we recognized, from our deferred revenue balance, $12.5 million as revenue for the year ended December 31, 2022 with regards to the amount allocated to the performance obligation from Bristol Meyers Squibb. In October 2021, we received notification from Bristol Myers Squibb of their option exercise for two druggable targets directed at a single synthetic lethal lesion, pursuant to the terms of the BMS Agreement. As a result, we recognized, from our deferred revenue balance, $6.5 million as revenue for the year ended December 31, 2021 with regards to the achievement of the performance obligation from Bristol Myers Squibb and the option fees received.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was $27.4 million (December 31, 2021 - $42.5 million) of deferred revenue related to the BMS Agreement, of which $27.4 million (December 31, 2021 - $2.9 million) was classified as current</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and nil (December 31, 2021 - $39.6 million) was classified as non-current on the consolidated balance sheet based on the period the services are expected to be performed and the expected timing of potential option exercises.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreement with Ono Pharmaceutical Company Ltd.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2019, we entered into a research services, license and collaboration agreement, or the Ono Agreement, with Ono Pharmaceutical Company Ltd., or Ono, pursuant to which we and Ono have agreed to collaborate in the research of potential product candidates targeting Pol&#x3b8; and the development of our small molecule Pol&#x3b8; inhibitor program. Pursuant to the terms of the agreement, we received initial upfront payments of approximately $8.1 million. These upfront payments have been recorded as deferred revenue on our consolidated balance sheet as per our revenue recognition accounting policy and will be recognized as revenue at the point in time when a product candidate is licensed to Ono pursuant to the terms of the agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, we and Ono entered into an amendment to the Ono Agreement whereby the research term, as defined in the Ono Agreement, was extended by one year. In January 2023, we and Ono entered into a second amendment to the Ono Agreement whereby the Research Term, as defined in the Ono Agreement, was extended until July 31, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021 and December 2022, the Company achieved specified research triggers amounting to &#165;100 million ($0.9 million) and &#165;200 million ($1.5 million), respectively, as research service payments provided for in the Ono Agreement. The &#165;200 million ($1.5 million) is included in the collaboration revenue receivable at December 31, 2022 and was subsequently received in January 2023. These amounts have been added to the transaction price as the consideration was no longer constrained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we classified $10.5 million (December 31, 2021 - $9.0 million) as current deferred revenue related to the Ono Agreement.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts and the development of our product candidates, partially offset by fully refundable Canadian research and development tax credits. We expense research and development costs as incurred, which include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">external research and development expenses incurred under agreements with contract research organizations, or CROs, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">employee-related expenses, including salaries, bonuses, benefits, share-based compensation, and other related costs for those employees involved in research and development efforts; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to manufacturing material for our preclinical studies and clinical trials, including fees paid to contract manufacturing organizations, or CMOs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">laboratory supplies and research materials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upfront, milestone and maintenance fees incurred under license, acquisition and other third-party agreements; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to compliance with regulatory requirements; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">facilities, depreciation, scientific advisory board and other allocated expenses, which include direct and allocated expenses for rent, maintenance of facilities and equipment, insurance, equipment and software. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our studies or other services performed. Significant judgment and estimates are made in determining the accrued expense or prepaid balances at the end of any reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We characterize research and development costs incurred prior to the identification of a product candidate as discovery costs. We characterize costs incurred once a product candidate has been identified as development costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our direct external research and development expenses consist primarily of fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct external research and development expenses also include fees incurred under license, acquisition, and option agreements. We track these external research and development costs on a program-by-program basis once we have identified a product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery activities as well as for managing our preclinical development, process development, manufacturing, and clinical development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our research and development costs:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.521%;"></td>
    <td style="width:1.859%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.337%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.87%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.412%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discovery costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct external costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,942</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,308</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory supplies and research materials</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,072</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,398</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel related costs*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,965</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,912</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facilities related costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,536</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,460</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other costs*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,032</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,665</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,547</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,743</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct external costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Camonsertib program</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,434</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,350</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RP-6306 program</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,241</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,962</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RP-2119 program</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,152</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel related costs*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,450</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,889</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facilities related costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">808</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">733</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other costs*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,868</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,494</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89,953</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,428</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R&amp;D tax credits</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,434</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,124</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119,066</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90,047</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*Certain amounts have been reclassified for presentation purposes.</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The successful development of our product candidates is highly uncertain. We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of our product candidates and manufacturing processes and conduct discovery and research activities for our preclinical programs. We cannot determine with certainty the timing of initiation, the duration, or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments, and our ongoing assessments as to each product candidate&#x2019;s commercial potential. We will need to raise substantial additional capital in the future. Our clinical development costs are expected to increase significantly as we commence clinical trials. We</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">anticipate that our expenses will increase substantially, particularly due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, rate of progress, and expenses of our ongoing research activities as well as any preclinical studies, clinical trials and other research and development activities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing an appropriate safety profile; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful enrollment in and completion of clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether our product candidates show safety and efficacy in our clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">receipt of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continued acceptable safety profile of products following any regulatory approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on other product candidates. For example, if the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or EMA, or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our ongoing and planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expense consists primarily of employee related costs, including salaries, bonuses, benefits, share-based compensation and other related costs, as well as expenses for outside professional services, including legal, accounting and audit services and other consulting fees, rent expense, directors and officers insurance expenses, investor and public relations expenses and other general administrative expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates. We also anticipate that we will continue to incur significant accounting, audit, legal, regulatory, compliance and directors and officers insurance costs as well as investor and public relations expenses associated with operating as a public company.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net consists primarily of realized and unrealized gains and losses on foreign exchange, interest income earned on cash and cash equivalents and marketable securities, and other expenses such as interest and bank charges.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Realized and unrealized gains and losses on foreign exchange consist of realized and unrealized gains and losses from holding cash and foreign currency denominated other receivables, accounts payable, accrued expenses and other current liabilities as well as operating lease liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2022 and 2021</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.951%;"></td>
    <td style="width:1.376%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.916%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.387%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.99%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.387%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.99%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">YEAR ENDED<br />DECEMBER 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CHANGE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration agreements</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131,830</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,600</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124,230</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development, net of tax credits</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119,066</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90,047</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,560</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,213</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,347</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151,626</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116,260</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,366</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(19,796</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(108,660</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,864</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Realized and unrealized gain (loss) on foreign exchange</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">308</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(144</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">452</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,631</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">259</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,372</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(43</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(41</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,896</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,822</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(13,900</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(108,586</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94,686</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit (expense)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(15,147</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,678</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(16,825</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(29,047</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(106,908</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77,861</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue was $131.8 million for the year ended December 31, 2022. Of this amount, $116.6 million related to the recognition of revenue associated with the Roche Agreement, of which $105.3 million related to the grant of the combined licenses, $2.7 million related to the clinical trial materials transferred, and $8.6 million related to the partial recognition of deferred revenue for research and development services performed towards the completion of the Continuing Trials during the period.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also recognized $15.2 million for the year ended December 31, 2022 as revenue associated with the BMS Agreement. Of this amount, $12.5 million relates to the recognition of deferred revenue related to druggable targets as Bristol Myers Squibb waived its rights to exercise options for druggable targets directed at two separate lesions, and $2.7 million was a result of the partial recognition of the deferred revenue from the BMS Agreement, in proportion to the level of research and development services performed during the period.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue was $7.6 million for the year ended December 31, 2021. Of this amount, $6.5 million related to the recognition of deferred revenue from the exercise by Bristol Myers Squibb of their option exercise for druggable targets directed at synthetic lethal lesion, pursuant to the terms of the BMS Agreement, and the related option fees received, and $1.1 million was a result of the partial recognition of the deferred revenue from the BMS Agreement, in proportion to the level of research and development services performed during the period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses, Net of Tax Credits</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses were $119.1 million for the year ended December 31, 2022, compared to $90.0 million for the year ended December 31, 2021. The increase of $29.1 million in research and development expenses was primarily due to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $13.1 million increase in direct external costs related to the advancement of the RP-6306 program, and the advancement of preclinical programs into IND-enabling studies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $12.6 million increase in personnel-related costs, including a $4.3 million increase in share-based compensation, primarily related to increased headcount in support of our discovery and development activities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $0.3 million decrease in laboratory supplies and research materials; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $3.7 million increase in other research and development costs, including travel, depreciation, facilities, and external costs not involved in the RP-6306, camonsertib or the advancement of preclinical programs into IND-enabling studies.</span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses were $32.6 million for the year ended December 31, 2022, compared to $26.2 million for the year ended December 31, 2021. The increase of $6.4 million in general and administrative expenses consisted of:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $4.0 million increase in personnel related costs, including a $2.5 million increase in share-based compensation, primarily related to increased headcount as we scale the organization;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $2.8 million increase in professional fees associated with the Roche collaboration and the establishment of our at-the-market facility program with Cowen and Company, LLC, as well as timing of audit and Sarbanes-Oxley Act of 2002 related compliance efforts;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $0.8 million increase in other general and administrative expenses mainly related to facilities and IT costs; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $1.2 million decrease in our D&amp;O insurance premium.</span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income, net was $5.9 million for the year ended December 31, 2022, compared to $0.1 million for the year ended December 31, 2021. The increase of $5.8 million in other income was primarily attributable to higher sums invested in cash and cash equivalents and marketable securities as well as higher interest rates.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Tax (Expense) Benefit</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense was $15.1 million for the year ended December 31, 2022, primarily due to the taxable income in our U.S. subsidiary and utilization of federal and state research and development tax credit carry forwards.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit was $1.7 million for the year ended December 31, 2021, primarily due to U.S. federal and state research and development tax credits generated, offset by taxable income in our U.S. subsidiary.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The decrease of $16.8 million in the income tax benefit was primarily driven by the Tax Cuts and Jobs Act effective January 1, 2022 requiring capitalization and amortization of all IRC 174 costs associated with research and development costs, offset by the utilization of federal and state research and development tax credit carry forwards.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have not recognized any revenue from product sales and have incurred operating losses and negative cash flows from our operations. We have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all. On June 23, 2020, we completed our IPO whereby we issued an aggregate of 12,650,000 common shares, which includes the exercise in full of the underwriters&#x2019; option to purchase up to an additional 1,650,000 common shares, at a public offering price of $20.00 per share. The aggregate net proceeds received by us from the IPO were $232.0 million, after deducting underwriting commissions, and offering expenses of $3.2 million. In November 2021, we completed a follow-on offering whereby we issued 4,600,000 common shares, including the exercise in full by the underwriters of their option to purchase up to 600,000 additional common shares, at a public offering price of $22.00 per share, for net proceeds of $94.3 million, after deducting underwriting commissions as well as offering expenses of $0.8 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2022, we entered into a Common Shares Sale Agreement, or the Sales Agreement, with Cowen and Company, LLC as sales agent, pursuant to which we may issue and sell common shares from time to time, or the ATM Shares. The ATM Shares to be sold under the Sales Agreement, if any, will be issued and sold pursuant to our shelf registration statement on Form S-3 (File No. 333-257668), up to a maximum aggregate amount of $125.0 million. No shares have been issued under the Sales Agreement as of the date of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to our IPO, we had funded our operations primarily through equity financings, having raised an aggregate of approximately $135.2 million of gross proceeds from the sale of our preferred shares and $15.0 million of gross proceeds from the issuance of a warrant to acquire our common shares. We have also partnered with Ono for our Pol&#x3b8; inhibitor program and Bristol Myers Squibb for research and development of potential new product candidates for the treatment of cancer and received initial upfront and additional payments of approximately $60.5 million in the aggregate. In June 2022, we entered into a collaboration and license agreement with Roche for camonsertib and have received initial payments under the terms of the collaboration in the aggregate amount of $134.6 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through preclinical and clinical development, seek regulatory approval and pursue commercialization of any approved product candidates and we will continue to incur additional costs associated with operating as a public company. We expect that our research and development and general and administrative costs will increase in connection with our planned research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to deduct U.S.-based research and development expenditures in the current fiscal year and requires taxpayers to amortize them over five years pursuant to Internal Revenue Code Section 174. This provision has increased our 2022 cash payments of income taxes significantly as compared to 2021. Although Congress is considering legislation that would defer the amortization requirement to later years, we have no assurance that the provision will be repealed or otherwise modified. If the requirement is not modified, it will materially reduce our cash flows. Changes in our tax provisions or an increase in our tax liabilities, whether due to changes in applicable laws and regulations or our interpretation or application thereof, could have a material adverse effect on our financial position, results of operations and/or cash flows.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our cash and cash equivalents and marketable securities on hand was $343.9 million. We believe that our existing cash and cash equivalents, and marketable securities on hand will be sufficient to fund our anticipated operating and capital expenditure requirements into 2026. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we expect. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing, and distribution, depending on where we choose to commercialize. We may also require additional capital to pursue in-licenses or acquisitions of other product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the numerous risks and uncertainties associated with research, development, and commercialization of our product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the initiation, timing, costs, progress and results of our product candidates, including our ongoing Phase 1 clinical trials of RP-6306;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the progress of preclinical development and possible clinical trials of our current earlier-stage programs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, results and costs of our research programs and preclinical development of any additional product candidates that we may pursue; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the development requirements of other product candidates that we may pursue; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and amount of milestone and royalty payments that we are required to make or eligible to receive under our current or future collaboration agreements, including the Roche Agreement; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA and other regulatory authorities; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we or our collaborators receive marketing approval; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of expanding, maintaining and enforcing our intellectual property portfolio, including filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us or any of our product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effect of competing technological and market developments; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost and timing of completion of commercial-scale manufacturing activities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which we partner our programs, acquire or in-license other product candidates and technologies or enter into additional strategic collaborations; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the revenue, if any, received from commercial sales of camonsertib, RP-6306 and any future product candidates for which we or our collaborators receive marketing approval; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of operating as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common shareholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common shares. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our cash flows for each of the years presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.046%;"></td>
    <td style="width:1.495%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.956000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.505%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.956000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.505%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.030000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.505%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">YEAR ENDED<br />DECEMBER 31,</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CHANGE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="12" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">322</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(85,796</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,118</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(175,778</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,676</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(174,102</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">880</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95,557</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(94,677</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of exchange rate fluctuations on cash held</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(330</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(54</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(276</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(174,906</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,031</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(182,937</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by operating activities was $0.3 million for the year ended December 31, 2022, reflecting a net loss of $29.0 million, offset by a net change of $4.4 million in our net operating assets and non-cash charges of $25.0 million. The non-cash charges primarily consist of share-based compensation for option grants to employees, as well as depreciation expense and non-cash lease expense offset by the net accretion/amortization of marketable securities and deferred tax assets. The change in our net operating assets was due to a decrease of $1.9 million in prepaid expenses and research development tax credits receivable, as well as an increase of $7.9 million in accrued</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses and other current liabilities, income taxes payable and deferred revenue, offset by an increase of $2.7 million in collaboration revenue receivable and other receivables, as well as a $2.8 million decrease in accounts payable and operating lease liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities was $85.8 million for the year ended December 31, 2021, reflecting a net loss of $106.9 million, offset by a net change of $7.0 million in our net operating assets and non-cash charges of $14.1 million. The non-cash charges primarily consist of share-based compensation for option grants to employees, as well as depreciation expense and non-cash lease expense offset by deferred tax assets. The change in our net operating assets was due to a decrease of $3.6 million in other receivables, as well as an increase of $11.9 million in accounts payable, income tax payable and accrued expenses and other current liabilities, offset by an increase of $0.9 million in research and development tax credits receivable and other non-current assets, as well as a $7.6 million decrease in operating lease liabilities and deferred revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The $86.1 million decrease in cash used in operating activities for the year ended December 31, 2022 compared to December 31, 2021 is primarily due to the $134.6 million upfront payment received under the Roche Agreement offset by an increase in operating expenses, specifically direct external costs and personnel-related costs, as we advance the development of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities was $175.8 million for the year ended December 31, 2022 and resulted primarily from purchases of marketable securities offset by proceeds from maturities of marketable securities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities was $1.7 million for the year ended December 31, 2021 and resulted primarily from purchases of property and equipment.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities was $0.9 million for the year ended December 31, 2022, consisting of net proceeds from the exercise of stock options and issuance of common shares under the ESPP.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities was $95.6 million for the year ended December 31, 2021, consisting primarily of $94.3 million from the November 2021 issuance of shares in the follow-on offering, net of underwriting commissions and offering expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Material Cash Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we anticipate the aggregate of our cash and cash equivalents and marketable securities will be sufficient to fund our contractual obligations, as well as cash requirements to support our ongoing operations and capital expenditures. Our contractual obligations as of December 31, 2022 primarily consist of:</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and Research Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and research agreement obligations primarily relate to a strategic collaboration agreement that we entered into with the University of Texas M. D. Anderson Cancer Center, or MDACC, in March 2020. The collaboration consists of preclinical studies and clinical trials designed by us and MDACC with the research to be completed by MDACC. We have agreed to commit $10.0 million in the aggregate to fund the collaboration, with payments to be made over a period of five years, of which $5.4 million was paid as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also entered into an agreement with the Broad Institute, Inc., or Broad, in July 2022, under which Broad will perform specialty screening services at our request over the course of a three-year term in exchange for payments of $0.8 million per year, beginning in July 2022, totaling $2.3 million in the aggregate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Purchase and Other Obligations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the normal course of business, we enter into contracts with CROs and other third parties for preclinical studies and clinical trials, research and development supplies and other testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and provide for termination 30 to 90 days&#x2019; prior written notice, and therefore are cancellable contracts. The amount and timing of such payments are not known as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have further entered into license agreements under which we are obligated to make milestone and royalty payments and incur annual maintenance fees. The future milestone or royalty payment obligations under the agreement are contingent upon future events, such as achieving certain clinical and commercial milestones or generating product sales. As of December 31, 2022, we were unable to estimate the timing or likelihood of achieving these clinical and commercial milestones or generating future product sales. See the section titled &#x201c;License and Collaboration Agreements&#x201d; elsewhere in this Annual Report as well as Note 7 to our annual consolidated financial statements appearing elsewhere in this Annual Report for a description of our license agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indemnification agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and executive officers that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments we could be required to make under these indemnification agreements is, in many cases, unlimited. To date, we have not incurred any material costs as a result of such indemnifications. We are not aware of any indemnification arrangements could have a material effect on our financial position, results of operations or cash flows, and we have not accrued any liabilities related to such obligations in our consolidated financial statements as of December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This management&#x2019;s discussion and analysis is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reported periods. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, will be reflected in the consolidated financial statements prospectively from the date of change in estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While our accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report, we believe the following accounting policies used in the preparation of our consolidated financial statements require the most significant judgments and estimates. See Note 2 to our annual consolidated financial statements included elsewhere in this Annual Report for a description of our other significant accounting policies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the year ended December 31, 2022, our revenue was generated from our Bristol Myers Squibb collaboration agreement and the Roche collaboration and license agreement. We also have a collaboration agreement with Ono, from which revenue has yet to be recognized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize revenue in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers, or ASC 606. We enter into collaboration and license agreements, which are within the scope of ASC 606, to discover, develop, manufacture, and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (i) licenses to compounds directed to specific targets (referred to as &#x201c;exclusive licenses&#x201d;) and (ii) research and development activities to be performed on behalf of the collaboration partner related to the licensed targets. Payments to us under these agreements may include non-refundable license fees, customer option exercise fees, payments for research activities, reimbursement of certain costs, payments based upon the achievement of certain milestones and royalties on any resulting net product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, we perform the following five steps: (i) we identify the contract(s) with a customer; (ii) we identify the performance obligations in the contract; (iii) we determine the transaction price; (iv) we allocate the transaction price to the performance obligations in the contract; and (v) we recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the accounting for these arrangements, we must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. We use judgment to determine whether milestones or other variable consideration, except for sales-based royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. In determining the stand-alone selling price of a license to our proprietary technology or a material right provided by a customer option, we consider market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating estimated stand-alone selling price, we evaluate whether changes in the key assumptions used to determine estimated stand-alone selling price will have a significant effect on the allocation of arrangement consideration between performance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within one year following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within one year following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive Licenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; If the license to our intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, we recognize revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, we consider relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, we consider whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the license is the predominant promise, and it is determined that the license represents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">functional intellectual property, revenue is recognized at the point in time when control of the license is transferred. If it is determined that the license does not represent functional intellectual property, revenue is recognized over time using an appropriate method of measuring progress. We have recognized revenue related to such licenses from our Roche collaboration and license agreement.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Services</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; The obligations under our collaboration and license agreements generally include research and development services to be performed by us to benefit the collaboration partner. For performance obligations that include research and development services, we generally recognize revenue allocated to such performance obligations based on an appropriate measure of progress. We utilize judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. The measure of progress, and thereby periods of which revenue should be recognized, are subject to estimates by management and may change over the course of the contract. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense. We have recognized revenue related to such research and development services from our Bristol Myers Squibb collaboration agreement and our Roche collaboration and license agreement.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Options</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; Our arrangements may provide a collaborator with the right to acquire additional goods or services in the future. Under these agreements, fees may be due to us (i) at the inception of the arrangement as an upfront fee or payment or (ii) upon the exercise of the customer option. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. We evaluate the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. We allocate the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires. We have recognized revenue related to such customer options from our Bristol Myers Squibb collaboration agreement.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Milestone Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the control of the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. We evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, we reevaluate the probability of achievement of all milestones subject to constraint and, if necessary, adjusts our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to our efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, we generally allocate the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. To date, we have not recognized any revenue related to the achievement of such milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalties</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our licensing arrangements.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued and Prepaid Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued and prepaid research and development expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued and prepaid expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid balance accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We measure share-based compensation based on the grant date fair value of the share-based awards and recognize share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period of the respective award. For non-employee awards, compensation expense is recognized as the services are provided, which is generally ratably over the vesting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense is classified in our consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. We recognize share-based compensation expense for the portion of awards that have vested. Forfeitures are accounted for as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected share price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and our expected dividend yield. The fair value of each restricted share unit is estimated on the date of grant based on the fair value of our common share on that same date. Prior to our IPO, as there was no public market for our common shares, we determined the volatility for awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies blended with the historical volatility of the Company's common shares. We expect to continue using such methodology until we have adequate historical data regarding the volatility of the trading price of our common shares on Nasdaq. The expected term of our options granted to employees has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. With the adoption of ASU 2018-07, we applied the nonpublic entity practical expedient for calculating the expected term of non-employee awards, using the midpoint between the vesting date and the contractual term, which is consistent with the method used for employee awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approximately equal to the expected term of the award. We have not paid, and do not anticipate paying, cash dividends on our common shares; therefore, the expected dividend yield is assumed to be zero.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See note 2 to our annual consolidated financial statements appearing elsewhere in this Annual Report for a description of recently adopted accounting pronouncements applicable to our financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under SEC rules and regulations, because we are considered to be a &#x201c;smaller reporting company&#x201d;, we are not required to provide the information required by this item in this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Financial Statement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPARE THERAPEUTICS INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.996%;"></td>
    <td style="width:6.004%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent_accounting"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a14e52bc-28e0-4d3d-b7aa-f85ec3b68012" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1263</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Shareholders&#x2019; Equity for the years ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_of_independent_accounting"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">egistered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the Shareholders and the Board of Directors of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Repare Therapeutics Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Repare Therapeutics Inc. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(the &#x201c;Company&#x201d;) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, shareholders&#x2019; equity, and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021 and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basis for Opinion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Critical Audit Matters</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">    Accrued and Prepaid Research and Development Expenses</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:17.338%;"></td>
    <td style="width:82.662%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Description of the matter</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:right;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As described in note 2 to the consolidated financial statements, the Company has entered into various research and development contracts with third parties and is required to record its accrued and prepaid research and development expenses resulting from these contracts at the end of each reporting period. When evaluating the adequacy of the accrued and prepaid expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. As of December 31, 2022, the Company has recorded $15.1 million of accrued research and development expenses and has also recorded total prepaid expenses of $5.7 million, which included amounts for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:17.338%;"></td>
    <td style="width:82.662%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:right;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">prepayments of research and development expenses. The Company&#x2019;s determination of the amount of accrued or prepaid expenses at each reporting period requires significant judgment and estimates by management in certain circumstances, as estimates are based on management&#x2019;s knowledge of the level of service performed by the third parties to date.</span></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Auditing the Company&#x2019;s accrued and prepaid research and development expenses is challenging and required significant auditor effort in performing appropriate procedures to evaluate the completeness and accuracy of the information management utilizes in these estimates.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">How we addressed the matter in our audit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:right;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls over the Company&#x2019;s process used in accounting for accrued and prepaid research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To test the accrued and prepaid research and development expenses, our audit procedures included, among others, testing the accuracy and completeness of the underlying data used by management to estimate the accrual or prepaid balance. To corroborate management&#x2019;s estimates, we inspected a sample of contracts with third parties, discussed and obtained information regarding the progress of clinical trials from the Company&#x2019;s research and development personnel that oversee the clinical trials, and inspected a sample of data obtained from the third parties. We confirmed information directly with a sample of the third parties, such as the services provided and costs incurred, and the number of sites in the clinical trials. We also inspected subsequent invoices received from the third parties and cash disbursements made to these parties, to the extent such invoices were received, or payments were made prior to the date that the consolidated financial statements were issued.</span></p></td>
   </tr>
  </table>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">    Determining Standalone Selling Prices for the Roche Agreement</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:17.338%;"></td>
    <td style="width:82.662%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Description of the matter</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:right;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As described in Note 12 to the consolidated financial statements, the Company entered into a collaboration and license agreement (the &#x201c;Roche Agreement&#x201d;) with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd (collectively, &#x201c;Roche&#x201d;). The Company accounted for the Roche Agreement under ASC 606, Revenue from Contracts with Customers and identified several performance obligations, being (i) the combination of the exclusive perpetual license to the licensed products and the non-exclusive license to certain companion diagnostics (the &#x201c;License&#x201d;), (ii) the research and development activities related to the completion of the continuing trials (the &#x201c;Continuing Trials&#x201d;), as well as (iii) the transfer of clinical trial materials on hand. The transaction price of $134.6 million was allocated to each performance obligation based on their relative standalone selling prices, which included $105.3 million being allocated to the License and recognized at a point in time upon the transfer of the License to Roche, and $26.6 million allocated to the Continuing Trials which will be deferred and recognized over the period of time to complete the Continuing Trials. The standalone selling price of the License was determined by applying a probability adjusted discounted cashflow model which forecasts future cash flows related to the License. The standalone selling price of the Continuing Trials was based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin.</span></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Auditing management&#x2019;s estimates of standalone selling prices for the performance obligations related to the License and the Continuing Trials was challenging as certain assumptions used by management required significant judgment and estimation. These assumptions include the probability of success and the discount rate for the License and the cost per patient for the Continuing Trials. Changes to these assumptions can have a material effect on the allocation of the transaction price to the performance obligations as well as the amount and timing of revenue recognized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:17.338%;"></td>
    <td style="width:82.662%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">How we addressed the matter in our audit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:right;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To audit the Company&#x2019;s estimates of the standalone selling prices for the License and the Continuing Trials as described above, we performed audit procedures that included, among others, obtaining and assessing management&#x2019;s analysis to support their conclusion of the allocation of the transaction price under ASC 606. We involved our valuation professionals to assist in the assessment of the estimation methodology used by management and to assess the discount rate used by management by comparing it to current industry trends using available information from other comparable companies. We compared the probability of success used by the Company in developing the estimate of standalone selling price of the License with external data. We obtained management&#x2019;s schedules for cost per patient and tested the accuracy and completeness of the underlying data, and compared inputs with approved budgets and with historical data for comparable clinical trials.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ </span><span style="font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_76731d4f-5e46-4f4d-9e96-5f6385eaf30d" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2017.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_cc2af8f9-da5f-4006-8266-be1e415abbcf" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Montr&#xe9;al, Canada</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">February 28, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repare Therapeutics Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">alance Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands of U.S. dollars, except share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.78%;"></td>
    <td style="width:1.576%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.949%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.576%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.12%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASSETS</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0de40c7-0f1e-4619-9024-a469497b2af2" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">159,521</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b63e317-3acb-456b-8c46-e485f262f501" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">334,427</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72b3094e-323e-4146-a8a9-6db220ec6b0c" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">184,420</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1df37d46-c2bc-44a2-bf72-08c80a731aef" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,439</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credits receivable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df62af64-3faf-4dc6-b236-88640397bbf0" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:ResearchAndDevelopmentTaxCreditsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d13f017-80e2-4dfb-a323-eec75e728360" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="rptx:ResearchAndDevelopmentTaxCreditsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,580</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue receivable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b794dd1a-7ee9-47b3-8a50-cf54a4bc44c2" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ReceivablesLongTermContractsOrPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,525</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05c1f336-8f2d-40ab-b027-77314b1a9970" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:ReceivablesLongTermContractsOrPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other receivables</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83c2b54e-3507-4c8a-9ab0-9a402480584c" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,518</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1dbc0bda-a0d3-4924-95a0-7fb581ea432a" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">654</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23481c33-1368-4da6-b419-7552ff699977" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,715</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3ae9703-4c73-4ae6-9832-396779250cbc" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eff6fc6c-f9cc-42d7-8fb5-a0dbba12ab4c" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">353,979</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54d3834d-c31c-43eb-87dd-0d1fc9a5f5f9" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">351,414</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40d3bf1e-52b0-487b-94a6-1b5a0155462a" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57c827d4-b11d-4614-b62f-8ada745e9d79" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,604</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89564830-d0a2-4701-a898-67d8dcdf1f3f" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_105eb0b0-0cc5-4004-a6f4-ef9602768326" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,491</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15b65668-a697-4310-b56e-1fae5c4a092c" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">497</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad489842-b3b7-46cd-ab1e-78cd94f966bd" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">586</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3b5c357-226f-4eb3-9ceb-8c67203e4782" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a10d97f7-3de6-416f-9f42-fb7e7fe1bfe9" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,620</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TOTAL ASSETS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a588ce74-dd72-49be-9286-5668bd2ed5b9" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">364,075</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0633582b-eefc-4c97-a074-4fd9c9776c08" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">368,715</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIABILITIES AND SHAREHOLDERS&#x2019; EQUITY</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d8ee6a5-db3a-4823-bd46-94ea91d10164" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">461</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98f6f8c7-ccb9-48ad-b73d-c362d533f6b9" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,302</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_460681da-66a6-4df1-aa8a-e78d460584fa" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,645</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aefac0a4-0f0e-4ca7-b1df-9934a545eb2c" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,622</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88647044-2037-4c9c-96ff-7e4451ea351a" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,171</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c40079c8-5278-4634-ad04-ffa253424b97" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,721</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue, current portion</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cd1468c-8583-4504-8393-2af7934a941f" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6bb7f9b4-c28a-40cb-8572-7c0d0963095d" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,921</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04d69c69-b4ef-41bc-a78e-9037b95440da" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,240</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af804d48-b990-4233-8be7-08985d3e39e7" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">523</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1ebaacd-e561-4bcc-92fa-b4d69fdba100" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,619</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65fc4493-757e-4114-8844-86ea341efe7f" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,089</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31848297-1712-4d29-a842-ee45f5665aa5" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,257</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1442be17-977c-41a8-9c16-fa02b0348158" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,592</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue, net of current portion</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f0dc5c8-2c94-4f50-8a5a-7a7736610045" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,682</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee17284d-ea5f-4ad9-aaad-fb22a0118888" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,613</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TOTAL LIABILITIES</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93a3d81c-bdee-4134-abcf-9b520c10fdd9" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,558</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f1d4bdb-ec31-478f-9460-d1a791350a0a" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">80,294</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_219f75ab-b85e-4e79-9264-ee3449aabe80;"><span style="-sec-ix-hidden:F_0e6da3f2-5c56-440d-847a-a498c1b804ad;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments</span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and Contingencies</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SHAREHOLDERS&#x2019; EQUITY:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred shares, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c881e2c-139d-4ed1-92fc-eccf1f1171dd" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:PreferredStockNoParValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d89f0cdc-130d-4a58-a3dc-6d4a00078958" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:PreferredStockNoParValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value per share; </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_90ad6daa-50a2-42fb-9ca1-285b49414761;"><span style="-sec-ix-hidden:F_cafa14d4-bdbd-4f40-86d7-72f79346b421;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unlimited</span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized as <br />&#160;&#160;of December 31, 2022 and December 31, 2021, respectively; </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_247bc6e0-fb71-4e09-870c-26e012b720ae" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_84264e65-beb4-4e9c-b3f3-ce1b11cacdc7" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_7a7c7de4-f72a-4aad-96b4-d87e694c53c0" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_7dc49a28-7aff-4ba4-8e39-84dbd8cc1ec0" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued <br />&#160;&#160;and outstanding as of December 31, 2022 and December 31, 2021, respectively</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5dbc4233-d9bf-416f-a046-d999d9fa26c6" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_639dfb29-a548-4206-ae77-cd4dc6b4f653" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common shares, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c834d01-1f07-467a-a12d-bea8010c70e1" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:CommonStockNoParValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2955696c-1735-4119-be06-2505ba7fca6b" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:CommonStockNoParValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value per share; </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_7996140e-14fd-40cf-a2b8-d50b8f060a13;"><span style="-sec-ix-hidden:F_9e5deaed-1136-4770-a34f-3ccb49c019e1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unlimited</span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized as <br />&#160;&#160;&#160;of  December 31, 2022 and December 31, 2021; </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d00a1f1-34b7-4ba0-b907-c213d801a9ba" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_9660d7c5-2295-4526-a39d-bd49ac07e8fb" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">42,036,193</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c60ca675-7a4d-49a1-aeff-2a522e44b1e0" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_8ba6f1aa-9ece-44ca-aa53-fe99cc4d0d82" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">41,850,162</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;<br />&#160;&#160;&#160;shares issued and outstanding as of December 31, 2022 and December 31, 2021,<br />&#160;&#160;&#160;respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c8d3be0-3c35-41e3-b1dd-3717e1308fc4" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">482,032</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7fbc695-0fe9-4a62-a647-857cbec81d6d" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">480,699</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_578984f1-d19c-4dc9-81ef-506ca258b322" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,226</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa6b6285-18c4-4e93-b115-e2acf6943a67" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,988</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51ea4728-dc46-4fe9-ae68-cb4ec30b96f4" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">428</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3549b956-d677-4b1c-8c2f-3dad01ebd4cc" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b789594-d1a7-4660-8049-3a4abf9c76ea" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">239,313</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bbf1ea5b-562c-4a75-8196-5548876643c6" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">210,266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TOTAL SHAREHOLDERS&#x2019; EQUITY</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37024716-79b4-4ddd-acf3-cb93dcf3d6a9" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">279,517</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f373b91-ce81-4384-9031-8cc60a08c37c" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">288,421</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TOTAL LIABILITIES AND SHAREHOLDERS&#x2019; EQUITY</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00fee654-7bff-4d56-b576-c1cb522ad205" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">364,075</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dd972c7-ab86-47d5-a3a7-6e05352655ff" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">368,715</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repare Therapeutics Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Opera</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tions and Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands of U.S. dollars, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.599%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.049%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.123%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration agreements</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28efb5a6-79d8-487a-be68-17db9f53225e" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:RevenueFromCollaborationAgreements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131,830</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d23bb8d-fa67-4801-bef7-0ad038e8dbea" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:RevenueFromCollaborationAgreements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development, net of tax credits</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4aada8ef-ec15-4d22-9b28-c343d042e41b" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">119,066</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed6ab41a-f53f-4bd3-85d8-6c56302a7790" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">90,047</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79f3b090-04d7-41c7-af60-403d6f1f6ef3" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,560</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d401f4b2-b5d1-4b54-bf79-3127716e572e" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e11e8323-2d6b-4564-9e1d-2fc1df701e1b" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">151,626</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af356dd3-8209-4655-b31d-50dda72e6ce4" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">116,260</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9275fe46-baa6-41c4-b8da-19ca7f51d78f" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">19,796</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af6a6b38-37ad-4542-a12e-666415323d1e" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">108,660</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Realized and unrealized gain (loss) on foreign exchange</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29568da7-ab27-4fbf-a858-827d06fb9e83" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">308</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19560f43-2838-404c-aa56-c15740a08aef" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">144</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca8f2730-eaea-4456-a342-b0dd5432d00a" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,631</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e05a97a-5380-4470-b4ca-f3db3b593739" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2c27148-d2e1-4f94-8fa1-acd665c5addc" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:OtherNonoperatingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ad5db8e-f64e-4e3c-9f86-4d800bb36c23" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:OtherNonoperatingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99acda49-4410-4ebf-a69d-2b8f1138ec7f" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,896</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0c7359b-6b33-4f3b-adab-7bc6c4f67e09" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb2e201f-b2cc-42f5-9701-b79f7aa6a372" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">13,900</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ca4c068-dece-4a07-b815-2bc17e14e671" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">108,586</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax (expense) benefit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30cd8e8a-04ef-40e1-a9a5-97f1302e3ff1" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,147</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54a5dc9b-96bd-44b0-a561-2544e3a89b41" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,678</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0defccc-06eb-443d-9b32-b5a1dffa8de0" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">29,047</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_388d91e7-da0a-4fc2-8852-e0a88ca9b260" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">106,908</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive loss:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on available-for-sale marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a50e9b8a-35c2-4a02-81de-eb4ac586191b" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">428</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_744f36ac-e18c-40c0-8037-b937d1f7cc4a" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cca7e00d-44a1-4836-bad1-b1524ccc4d18" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">428</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5f79fa9-4075-47b3-bb5e-b8870edf8fd3" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e78a9c26-c2de-423a-98e5-c6d4c95fd0d1" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">29,475</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5490188c-517d-498c-a85e-79ba284d1d71" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">106,908</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share attributable to common shareholders&#x2014;basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b565843c-7023-4b9b-a47d-50f7d8e41d6f" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_6209e164-b42e-4945-b321-f46d34a50b0b" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.69</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d4b85a9-29e9-4dc4-9c4a-9fc3796d8830" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_d9bbac0d-8e9f-4860-8827-592c3f0e38d5" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.83</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding&#x2014;basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15cf1b86-5302-4e7a-9d22-60ea6047a5be" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_0040d686-6394-4f75-a98a-d2a812b7a5a1" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">41,922,042</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc00c1bb-555d-49cb-a58c-6d11a245d409" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_daabc04f-a5c3-4b25-9287-9002e95c1879" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">37,818,115</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repare Therapeutics Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_convertible_pref"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Shareholders&#x2019; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands of U.S. dollars, except share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:22.503%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.417%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.023%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.023%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.023%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.023%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.023%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Other Comprehensive</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Shareholders'</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paid-in Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, January 1, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_680e8300-82ed-48de-9da2-7a6362ae3bf0" contextRef="C_3c1983cf-a5f8-4eb4-9f92-f0536a7871bc" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">36,902,924</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4dec7916-92af-4f75-af62-986a8dceae01" contextRef="C_3c1983cf-a5f8-4eb4-9f92-f0536a7871bc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">384,313</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ece9126-a297-4d81-8713-f42ed3bc15ef" contextRef="C_0a2ab1c6-eeb2-450a-825c-b2e0500e4ba4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,875</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0be4a614-c6b0-4d6d-a319-85f5c7e1d85b" contextRef="C_4a0b6ce9-b609-4951-87ef-6b33661b30ce" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">103,358</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_569bd4f0-eb6a-4029-95e4-5ead1f68e21d" contextRef="C_179763b9-efbc-464b-afa5-88c1837ed3e7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">286,830</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of vested stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5af53bad-1965-4a91-b231-0df88b35fed2" contextRef="C_956a103e-2e33-436f-86ac-ceaeba13380a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">333,996</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e19b099-109b-4f20-9d60-b975858e9bc5" contextRef="C_956a103e-2e33-436f-86ac-ceaeba13380a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,578</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84e3df28-a464-4a7c-9665-eaed7467c1cc" contextRef="C_df372273-07d1-45f3-97f2-72265a4457ed" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">592</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7064e2e4-b50f-4c20-a84d-b8ed015ca295" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">986</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8f1b550-a7ad-4690-9f23-22e14337a731" contextRef="C_df372273-07d1-45f3-97f2-72265a4457ed" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,829</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c62c49ec-524b-4aee-84bf-3d31ad1ed179" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,829</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common shares upon<br />&#160;&#160;&#160;follow-on offering, net of<br />&#160;&#160;&#160;issuance costs of $</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76862b28-3f59-4019-af85-e278de0f2820" contextRef="C_29efdcd1-f366-4daf-8b98-5eaef0a24f0d" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">840</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f318df8-1ff7-4c85-bc35-ca7b32efa7f9" contextRef="C_67d17037-8967-4b35-afc2-31124ceecc4c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,600,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e70b9b4a-4f9e-40fd-bee1-adcd5c01d66c" contextRef="C_67d17037-8967-4b35-afc2-31124ceecc4c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,288</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94f2a2b2-1bbe-4650-8f7d-f1035840a98f" contextRef="C_29efdcd1-f366-4daf-8b98-5eaef0a24f0d" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,288</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common shares</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37eb26ce-00cf-4af6-9572-5cda8b007021" contextRef="C_956a103e-2e33-436f-86ac-ceaeba13380a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,299</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d06b7073-3107-4a8a-9e85-549c8b61af24" contextRef="C_956a103e-2e33-436f-86ac-ceaeba13380a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">113</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c58a37a-f82a-448b-895f-70193db22f69" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">113</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common shares under<br />&#160;&#160;&#160;the 2020 Employee Share<br />&#160;&#160;&#160;Purchase Plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9dd142b-98fd-4d40-a7bf-09c1c418bcef" contextRef="C_df85d4b4-de4b-4eb8-a1de-ef8901ea52bf" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,943</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09bfb667-366b-4020-bdf8-5c6ae0d7a920" contextRef="C_df85d4b4-de4b-4eb8-a1de-ef8901ea52bf" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">407</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc6b5d0d-504a-4497-a547-9f65e859ca9b" contextRef="C_483e024c-e743-4735-98ec-df737668fd18" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">124</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_471e6cce-8868-4009-892e-64a83345fd99" contextRef="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">283</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_531ea8e0-fe81-4197-97ac-8300c3ce983a" contextRef="C_79831ab9-e01f-4b6c-ac9f-05479c973e07" name="rptx:NetIncomeLossAndComprehensiveIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">106,908</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfbf66c9-e00d-4889-a8d1-c888aae13676" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:NetIncomeLossAndComprehensiveIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">106,908</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c35c489d-c2c3-476a-b2c1-376aa868088b" contextRef="C_28dfec78-046b-45a4-9c58-7424c3330c88" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">41,850,162</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc47ebc8-070d-47d4-a6a7-9a9ce5f27927" contextRef="C_28dfec78-046b-45a4-9c58-7424c3330c88" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">480,699</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd0bb5f8-df53-4d2f-99fb-ab886d77ff54" contextRef="C_43d1551f-e850-4ce0-95fc-dffbed44030c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,988</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e02d88e6-2c7a-4dbc-8123-163848174537" contextRef="C_ac38558a-83a0-47fb-bd07-2be4ac80a958" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">210,266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b57b830-7a72-4edf-8049-33a4faf98532" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">288,421</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of vested stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f21b4c8-3a77-407f-bbfd-279994ed1288" contextRef="C_7a43defd-03d5-46c3-9322-0c22c5e6e0fc" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">148,116</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45d3a258-ac48-499a-ace8-0065e71ec6f1" contextRef="C_7a43defd-03d5-46c3-9322-0c22c5e6e0fc" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">708</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33fa51fc-b396-4d66-87e2-0711266f7040" contextRef="C_4e010701-b9b6-4606-92d0-3a2915bef141" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">261</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e5cb57d-c649-4f7f-aceb-72fd1739e2bb" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_938b2d6b-0fff-4a01-809f-9f8432c87e2c" contextRef="C_4e010701-b9b6-4606-92d0-3a2915bef141" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,691</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3feae2e4-e63d-442d-8fe9-5e8cb7ba77ea" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,691</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common shares under<br />&#160;&#160;&#160;the 2020 Employee Share<br />&#160;&#160;&#160;Purchase Plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0deece05-2a45-4a85-ac81-a114ed745ab2" contextRef="C_1a6bffab-7ac1-4529-af70-4292b5a90b4d" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,915</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db54954c-f253-4a9a-8ee2-af3e445cd7c1" contextRef="C_1a6bffab-7ac1-4529-af70-4292b5a90b4d" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">625</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6a6d695-0905-4345-9a5a-668ee304e019" contextRef="C_9a420b6a-118c-4efc-bb28-d98095401947" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">192</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e734b927-c6fa-496b-909b-9dc4479c020a" contextRef="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">433</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42969dcf-f6ec-471d-be32-80a9bfc97de7" contextRef="C_82791e69-edf1-4fd6-8015-240f7998a7d0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">428</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20fb8e07-729d-4d35-ade3-40a51e4effe7" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">428</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b26ef36-73f7-4dab-a770-37d1f1540334" contextRef="C_b8b79edc-32ab-46da-b385-c6a9975de00c" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">29,047</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e858b1fb-4dcb-489b-862e-611c0dc358a5" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">29,047</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_851165db-49bb-4dce-98df-a67f6e3ebd6e" contextRef="C_def3be0b-e33c-41d8-b724-4a3e58ec67c7" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">42,036,193</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21100982-8d98-49ce-9cab-9479f4e80742" contextRef="C_def3be0b-e33c-41d8-b724-4a3e58ec67c7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">482,032</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_050d60e0-dc16-4ed1-81e8-1a35365c4f74" contextRef="C_c2cfdb5b-e3da-4229-a14c-8c3fc5b962d8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,226</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7dd9aad6-b165-4bbb-9e81-0f9c7fc1e26b" contextRef="C_51f4647b-4513-4f59-b327-5fe1b4b8ec0e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">428</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11c804ca-59aa-4f16-a01d-4d40edec72e5" contextRef="C_63512c11-8031-488d-bf0e-063cdf64bffb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">239,313</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4c581fd-233e-4129-96ef-7ee935d20300" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">279,517</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repare Therapeutics Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Stateme</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nts of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands of U.S. dollars)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.905%;"></td>
    <td style="width:1.515%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.927%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.515%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.139999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash Flows From Operating Activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss for the year</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd59ea78-0f52-4e51-8e08-bb1aa5ccb4fd" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">29,047</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d412620e-e6fb-447a-91f6-6752c5112214" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">106,908</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecc1f7b4-c760-499b-83c4-3305dcf0bd3d" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,691</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_290ee402-4cd6-435e-9c66-7fce1b53f7e4" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,829</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d3b6c65-7350-48cd-84b5-0c3f5bd23657" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,978</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6a1ec44-8916-4caf-9c72-bebdf4223f4e" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,471</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash lease expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a260d32-4733-4bee-b8df-ea203df5a241" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ProvisionForLoanAndLeaseLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,206</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f1d7219-395f-42ba-89fd-e4c5f9bbbbc3" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:ProvisionForLoanAndLeaseLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,873</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c3c2e7d-df44-4572-856e-774b576adc98" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de325a78-cc2b-4de2-a088-60a5c19e24e7" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign exchange loss (gain)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d9606b1-415d-417f-8285-74786432102b" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:ForeignCurrencyTransactionGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">298</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45826a29-b046-4637-9540-6c154ffbae54" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:ForeignCurrencyTransactionGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net (accretion)/amortization of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7758ec16-2328-45ec-96b8-19f668ff47c2" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,233</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91479586-fe73-4544-b3f6-3e2708ef8802" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">113</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax asset</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee2e0a16-ab69-4d11-8755-1f4fc04d1154" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,620</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72421a48-a920-48c7-a942-7c00c2d2a893" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,208</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0e54639-1522-49fa-8ea0-d8a98b3c8718" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">593</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40d46361-7b16-4610-9ea5-3254e8476461" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credits receivable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca7a2bfd-3afe-43b0-9ee6-a99c15e1fcbf" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,287</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b11b4768-de5a-416d-bac6-758752b8c235" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">556</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue receivable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8324fd93-03b3-4a03-b0b3-93026a5dd7f5" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncreaseDecreaseInCollaborationRevenueReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,525</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70dbe2d3-ac20-408e-86ce-fb7d0569acff" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:IncreaseDecreaseInCollaborationRevenueReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other receivables</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe9921d4-5e6e-4143-988d-8c990d58d10b" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncreaseDecreaseInOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,147</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4a5ff77-1eb2-419f-a7e6-99601443c805" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncreaseDecreaseInOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,554</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e315a9d-24a2-45ad-8d78-a70e8b8d4682" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1863d6b-369d-423e-8215-ec0e93a3d542" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">298</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eafe4f0c-54af-44f2-8389-6206fa9ee504" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c1afb41-2743-4cdf-8a4d-ee61738768c7" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3532898-a26f-4e6f-8a37-176fcedf1ad1" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,020</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf7be4b1-dc74-42b5-bc71-708f40965f0e" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,166</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0df88618-8d64-43ac-bd75-0b0ef2444467" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncreaseDecreaseInOperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">615</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb98bda8-7f7c-4ced-893b-157bdbeeb85f" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:IncreaseDecreaseInOperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">98</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed1b1b6e-e7f9-4537-8aae-233b3722076f" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncreaseDecreaseInIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3095fa78-8109-45de-a618-bae528d4c08d" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncreaseDecreaseInIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">505</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd0642a4-134a-4643-ac55-80d59fc42238" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncreaseDecreaseInOperatingLeaseLiabilityNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,146</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_629945ff-764f-42eb-be3b-e0da19efe707" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:IncreaseDecreaseInOperatingLeaseLiabilityNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,118</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75afe671-67db-4da2-8e89-9ff744adb1b1" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,250</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9068de1-6c53-4a8c-bc8f-2743a9b28d25" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,473</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83cff550-c3d8-4de4-8932-2946aa551311" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">322</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a223a11-fe41-4f28-a8ae-3f56104d8e7b" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">85,796</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash Flows From Investing Activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f7d63e4-3bb2-4c0f-8fc9-f2bff3dde5f4" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">602</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4ac418c-9fe1-406d-8185-2e47ea9967cb" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,690</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds on disposal of property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a25d6a3e-09bd-4dc1-9772-7699144bc771" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ad34990-72e6-444d-9304-ecdc6d4d561c" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from maturities of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_772d3876-1d7e-46bb-a5a6-4bb2183cbf91" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a7d2112-dfc0-4990-9f7f-76969b3984eb" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,450</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b726749-f419-466c-a1fe-128a35e90580" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">256,576</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84f2ff9b-0840-416b-9573-92cfb178efcc" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,476</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f56d254-2f06-4326-8946-bf767a50273b" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">175,778</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e305361-79ab-420e-b26c-18d6e181a877" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,676</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash Flows From Financing Activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c51c4d87-4d53-4212-bd48-557abb13a640" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e97d4c49-69ce-47c6-a3fc-ce986f460d3c" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">986</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common shares under the 2020 Employee Share Purchase Plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24c0a31e-67ef-4a38-a89a-4db00fc3e17c" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">433</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22d206ca-f2d2-4780-a0c6-00a67ca329df" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">283</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net proceeds from issuance of common shares in follow-on offering</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8bd2f13-63b6-4fff-8726-daaa83f7de37" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f489d960-4205-4995-9295-d1f1f9ac665e" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,288</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5762335-3871-43b3-8724-c6058abe153f" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">880</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78fb91b3-635a-4029-b1a0-aaf6be175dc7" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95,557</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of exchange rate fluctuations on cash held</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af81be2d-68c1-4a2e-bb71-5786443143fc" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">330</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1156713c-2c77-413d-997e-dce4c0bd7f93" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">54</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net (Decrease) Increase In Cash And Cash Equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9f46a74-414b-46e9-8781-a2b78937789b" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">174,906</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d859dd98-884e-4e7a-8643-aaebaf10c127" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,031</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents cash at beginning of year</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d444525-f2cb-425c-bb34-3888c5bf77d8" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">334,427</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66d541fe-01fb-48d4-8263-2a3381e718bf" contextRef="C_179763b9-efbc-464b-afa5-88c1837ed3e7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">326,396</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents at end of year</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b7091ea-9877-42ed-830f-a7a8de900265" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">159,521</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_555f5430-7b3e-44b4-9a9f-27a2f9768988" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">334,427</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental Disclosure Of Cash Flow Information:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash interest received</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1339c83d-38e5-46d4-819f-c40a10517fe8" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,966</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75764ec5-e3e5-4b92-b3b6-838a04c74f90" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">240</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash taxes paid, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb496e0a-57dc-40f0-ba07-994609aa9b2a" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeTaxesPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,810</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50054d93-0efa-484c-bdb9-13b2c1901ae8" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncomeTaxesPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment purchases incurred but not yet paid</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6243ad6-890a-4df3-a6dc-32c668026f3e" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd1d71d7-702a-48a0-8c43-a939bf44a232" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets obtained in exchange for new operating lease liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18e74b9b-ef06-44ff-b60b-7fe936afb54c" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a63c9f2-21a8-461d-801a-525987b7b050" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,690</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPARE THERAPEUTICS INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Amounts in U.S. dollars, except per share data, unless otherwise specified)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3c633de7-e6dc-4603-8472-91c628ddba9d" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Organization and Nature of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repare Therapeutics Inc. (&#x201c;Repare&#x201d; or the &#x201c;Company&#x201d;) is a precision medicine oncology company focused on the development of synthetic lethality-based therapies to patients with cancer. The Company was incorporated under the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Canada Business Corporations Act</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2e2acdee-a7ad-4e70-82a0-301587318e19" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="dei:EntityIncorporationDateOfIncorporation" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 6, 2016</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. On June 23, 2020, immediately prior to the completion of its initial public offering (the &#x201c;IPO&#x201d;), the Company was continued as a corporation under the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business Corporations Act (Qu&#xe9;bec)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 12, 2020, the Company effected a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_14d31809-db5d-4b73-ac28-dd84a504a2ef" contextRef="C_1c19b0ef-d0c5-4bcc-8394-10c1c635f4f6" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1-for-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_e1a9b1e0-b4b1-4ba7-bb67-f01adfdb1126;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.062</span></span></span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reverse stock split of the Company&#x2019;s share capital. Accordingly, all common shares, Series A and B convertible preferred shares, stock options and per share amounts in these consolidated financial statements have been retroactively adjusted to reflect the reverse stock split on a retroactive basis for all periods presented.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 23, 2020, the Company completed its IPO of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b566739e-82de-43f5-a99a-b1ea14264af9" contextRef="C_e1f902aa-4006-405b-b0bd-e5a178b2bfaa" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,650,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of its common shares, including the exercise in full by the underwriters of their option to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2cfff554-3005-4b1e-8e17-b82984d892b3" contextRef="C_7fd1537b-f85a-4ef2-915d-82497b788de9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,650,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional common shares, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_475db824-9d6b-4db7-89ab-247dec172c0e" contextRef="C_47bbe3ab-c619-4531-a810-632c68de1388" name="rptx:GrossProceedsFromInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">253.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company&#x2019;s shares began trading on the Nasdaq Global Select Market under the ticker symbol &#x201c;RPTX&#x201d; on June 19, 2020. The Company received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdc534aa-b2fc-43a1-92b7-5f18d7d2e471" contextRef="C_47bbe3ab-c619-4531-a810-632c68de1388" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">232.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by the Company. Upon closing of the IPO, all outstanding convertible preferred shares converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10e9e5e9-04c4-40c4-bb18-f099663f2fd0" contextRef="C_47bbe3ab-c619-4531-a810-632c68de1388" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">21,558,393</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares and the outstanding warrant was automatically exercised into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22fcaab2-df12-4d03-b21c-c5891031b7dc" contextRef="C_ba8a8b55-bc32-45e4-ac52-b062d5026bf6" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">750,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the Company completed a follow-on offering of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_818b5f21-3aaf-4b1c-987a-ea2c5c6ec8cf" contextRef="C_8de25cbb-79b8-4c61-83cd-426c93b13621" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,600,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of its common shares, including the exercise in full by the underwriters of their option to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97e097bd-f237-4eaa-8b75-472c4249408a" contextRef="C_e4e66d4b-8df8-4150-855e-17cb5ce1bcb9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">600,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional common shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38bdd1e8-9b76-40b4-a057-b6c01b58868a" contextRef="C_c095c251-0ca6-45ab-ae2c-2aec9d4fb280" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">22.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, for net proceeds of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_053d2195-a6f3-4622-9b6b-02ec4070f2ce" contextRef="C_8de25cbb-79b8-4c61-83cd-426c93b13621" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">94.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, after deducting underwriting commissions as well as offering expenses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe469a77-f5ed-4432-90c8-8bac5d7cab9a" contextRef="C_404b861d-d003-4142-9ce1-6483dccfba5d" name="rptx:UnderwritingCommissionsAndEstimatedOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payable by the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception, the Company has incurred operating losses. As of December 31, 2022, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f6416e6-b748-41ad-9cf7-7a61bb72ad1c" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">239.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company does not have any products approved for sale and has financed its operations primarily through equity financings and funding from its collaboration and license agreements. Based on its current operating plan, the Company expects that its existing cash and cash equivalents and marketable securities on hand will be sufficient to fund its operating and capital expenditures into 2026.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There can be no assurance that the Company will be able to obtain additional debt or equity financing, or generate product revenue or revenue from collaboration agreements, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#x2019;s business, results of operations and financial condition.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ba389a2e-2047-432d-8b0e-c0bde3dcc39f" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fee877e3-5968-424e-b959-40567b5a2d86" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and as amended by Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c35a59cd-a5ab-4eab-81c9-62ad1fccdd68" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accompanying consolidated financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Repare Therapeutics USA Inc. (&#x201c;Repare USA&#x201d;), which was incorporated under the laws of Delaware on June 1, 2017. The financial statements of Repare USA are prepared for the same reporting period as the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">parent </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">company, using consistent accounting policies. All intra-group transactions, balances, income, and expenses are eliminated in full upon consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4399e4a5-7464-4a5f-b1bd-fb169755b054" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:SmallerReportingCompanyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller Reporting Company</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company qualifies as a &#x201c;smaller reporting company&#x201d; under the Exchange Act as of December 31, 2022 because the market value of its common shares held by non-affiliates was less than $560 million as of June 30, 2022 and its revenue for the year ended December 31, 2021 was less than $100 million. As a smaller reporting company, the Company may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. For so long as the Company remains a smaller reporting company, it is permitted and the Company intends to rely on such exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5fe81733-1ffd-4a06-8cea-4268b8d69215" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign Currencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The functional currency for the Company and Repare USA is the U.S. dollar (&#x201c;USD&#x201d;). Accordingly, transactions denominated in currencies other than the functional currency are measured and recorded in the functional currency at the exchange rate in effect on the date of the transactions. At each consolidated balance sheet date, monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using the exchange rate in effect at that date. Non-monetary assets and liabilities and revenue and expense items denominated in foreign currencies are translated into the functional currency using the exchange rate prevailing at the dates of the respective transactions. Any gains or losses arising on remeasurement are included in the consolidated statement of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ffdb7106-2bdf-4ad5-93a3-533d618397a8" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Segment Information</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#x2019;s singular focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d466ed84-5d08-48fd-b32e-25c622304296" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, right-of-use assets and lease liabilities and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eca0d058-2702-4cf5-87ab-78f93681b760" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0033c5f1-fff7-44c3-8cd2-153a5ff96177" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company classifies marketable debt securities with a remaining maturity of greater than three months when purchased as available-for-sale. Marketable debt securities with a remaining maturity date greater than one year are classified as non-current where the Company has the intent and ability to hold these securities for at least the next 12 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s marketable securities consist of U.S. treasury bills and U.S. treasury notes with original maturities greater than 90 days. All of the Company&#x2019;s marketable securities have a contractual maturity of one year or less. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company considers its investment portfolio of U.S. treasury bills and U.S. treasury notes to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on observable inputs, other than quoted market prices. Unrealized gains and losses are reported in accumulated other comprehensive items in shareholders&#x2019; equity. Amortization and accretion of premiums and discounts are recorded in interest income (expense). Realized gains or losses on debt securities are included in other income (expense).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#x2019;s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss on the consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive loss. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in other (expense) income, net within the consolidated statement of operations. Losses are charged against the allowance when the Company believes the uncollectibility of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_db9fa0e2-2ec7-4e25-b34d-dc141547bc84" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_db9fa0e2-2ec7-4e25-b34d-dc141547bc84_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Our investment portfolio comprises money market funds, U.S. treasury bills and U.S. treasury notes. Our investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company maintains deposits in accredited financial institutions which exceed insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s exposure to foreign exchange risk is primarily related to fluctuations between the Canadian dollar and the U.S. dollar. There are balances in Canadian dollars which are subject to foreign currency fluctuations relating to the impact of translating to U.S. dollars for financial statement presentation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><ix:continuation id="F_db9fa0e2-2ec7-4e25-b34d-dc141547bc84_1"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dc58231c-2712-4ff8-a057-7b98ca524ecd" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"><ix:nonNumeric id="F_2ffe40b6-d86a-4ba5-a525-067387abf024" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></ix:nonNumeric></ix:nonNumeric></span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e3934388-4323-412c-b012-61dcd45365ab" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in shareholders&#x2019; equity that result from transactions and economic events other than those with shareholders. Other comprehensive loss consists of unrealized losses on available-for-sale marketable securities. Total comprehensive loss for all periods presented has been disclosed in the consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_913aab03-1110-4216-8fe1-d500bc7fe77a" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	Level 2 &#x2013; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An entity may choose to measure financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair values of the Company&#x2019;s cash and cash equivalents, collaboration revenue receivable, other receivables, other assets and accounts payable and accrued expenses approximate their carrying values.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s marketable securities are carried at fair value, determined according to Level 2 inputs in the fair value hierarchy described above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_18967427-34d9-47de-87d2-94b7bc230949" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and Equipment, Net</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_72b0a24e-09b1-437c-a3a9-364abb9fd773" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment is stated at historical cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.498%;"></td>
          <td style="width:1.004%;"></td>
          <td style="width:49.498%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset Category</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful Lives</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_11e02b5f-b68a-4975-b6a0-5ad5be566092" contextRef="C_d02b1f3e-16d6-4441-958a-8ba01e196c61" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c8b6ebb0-9de1-44a6-96fc-6c7dbc579ec7" contextRef="C_b1cc4d13-0ecb-41c8-b252-fe8d061ccd9a" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_662c7343-0baa-4bb7-9515-fb95f3b1d503" contextRef="C_80ef95e4-5908-4482-8697-3e73902fd846" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_04d4909d-87a1-4497-9a67-dffa30adbb59" contextRef="C_5ef6ce9a-5c8e-4c42-b1be-099fd91b49b2" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the shorter of the lease term and the useful life</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. Expenditures for maintenance and repairs are recorded to expense as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_db088e45-d88b-4613-b0b6-f64e49280618" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of assets may not be recoverable. Recoverability of these assets is measured by comparing their carrying value to the future net undiscounted cash flows the assets are expected to generate over their remaining economic life. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying value of the assets exceeds their fair value. Indefinite-lived intangible assets are tested for impairment annually, or more frequently if indicators of impairment are present. To date, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6707f54-89c6-4c60-8668-3f5cefc39378" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such impairment losses have been recorded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e9cb4726-9509-4706-bd66-df558bd76f6f" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the consolidated balance sheet as a right-of-use asset and current and non-current lease liabilities, as applicable.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9fa2c9f2-0bad-47ef-b53f-33eb5c6ce6f1" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company enters into collaboration and license agreements, which are within the scope of ASC 606, to discover, develop, manufacture, and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (i) licenses to compounds directed to specific targets (referred to as &#x201c;exclusive licenses&#x201d;) and (ii) research and development activities to be performed on behalf of the collaboration partner related to the licensed targets. Payments to the Company under these agreements may include non-refundable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">license fees, customer option exercise fees, payments for research activities, reimbursement of certain costs, payments based upon the achievement of certain milestones and royalties on any resulting net product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company first evaluates license and/or collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;), based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for collaborative arrangements (or elements within the contract that are deemed part of a collaborative arrangement), which represent a collaborative relationship and not a customer relationship, outside the scope of ASC 606.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s collaborations primarily represent revenue arrangements. For the arrangements or arrangement components that are subject to revenue accounting guidance, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company applies the five-step model. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration, except for sales-based royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In determining the stand-alone selling price of a license to the Company&#x2019;s proprietary technology or a material right provided by a customer option, the Company considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating its estimated stand-alone selling price, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling price will have a significant effect on the allocation of arrangement consideration between performance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within one year following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within one year following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive Licenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the license is the predominant promise, and it is determined that the license represents functional intellectual property (&#x201c;IP&#x201d;), revenue is recognized at the point in time when control of the license is transferred. If it is determined that the license does not represent functional IP, revenue is recognized over time using an appropriate method of measuring progress.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Services</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; The obligations under the Company&#x2019;s collaboration and license agreements generally include research and development services to be performed by the Company to benefit the collaboration partner. For performance obligations that include research and development services, the Company generally</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods of which revenue should be recognized, are subject to estimates by management and may change over the course of the contract. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Options</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; The Company&#x2019;s arrangements may provide a collaborator with the right to acquire additional goods or services in the future. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment or (ii) upon the exercise of the customer option. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Milestone Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalties</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a complete discussion of accounting for collaboration revenues, s</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ee Note 12.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_175756c1-f13c-41cc-972a-6344860480cb" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. The Company&#x2019;s research and development expenses consist primarily of costs incurred in performing research and development activities, including salaries and other compensation, share-based compensation, fees paid to external service providers, laboratory supplies and costs for facilities and equipment, partially offset by fully refundable research and development tax credits. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are expensed as the goods are delivered or the services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_364849a0-d94c-4df7-ab76-bf3365460da2" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and Prepaid Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into various research and development contracts. The payments to these agreements are recorded as research and development expenses as incurred. The Company records accrued liabilities and prepaid expenses for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgements and estimates are made in determining the accrued and prepaid balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8d9d6d73-1b34-4a98-8db1-cec89b42ee87" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for all share-based awards granted to employees and non-employees as share-based compensation expense at fair value.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized over the employees&#x2019; requisite service period, which is the vesting period, on a straight-line basis. Forfeitures are accounted for as they occur.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each restricted share unit is estimated on the date of grant based on the fair value of our common share on that same date. The fair value of each stock option grant or purchases under our 2020 Employee Share Purchase Plan (&#x201c;ESPP&#x201d;) is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected share price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option and the Company&#x2019;s expected dividend yield. As there was no public market for its common shares prior to its IPO in June 2020, the Company determined the volatility for stock option awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies blended with the historical volatility of the Company's common shares. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price. For purchases under our ESPP, only the historical volatility of the Company's common shares is used when developing an estimate of expected volatility. The expected term of the Company&#x2019;s stock options granted to employees and non-employees has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. In connection with the adoption of ASU No. 2018-07, Compensation&#x2014;Stock Compensation (&#x201c;ASU No. 2018-07&#x201d;), the Company calculated the expected term of non-employee awards using the midpoint between the vesting date and the contractual term, which is consistent with the method used for employee awards. For purchases under our ESPP, the expected term is based on the length of the offering period. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award, for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common shares; therefore, the expected dividend yield is assumed to be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d5a4cd8-ee31-46af-a963-d10ce1772cea" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. Any consideration paid by employees on exercising stock options or the purchases under our ESPP and the corresponding portion previously credited to additional paid-in capital are credited to share capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c8af7464-363e-47de-9120-6bf4e71d2c78" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:ShareIssuanceCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share Issuance Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share issuance costs applicable to the issuance of equity instruments are recorded as a reduction of the financing equity proceeds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_501fa323-b9ec-44d9-bd28-7ea345a36977" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted-average number of common shares outstanding during the reporting period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of common shares and potentially dilutive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">securities </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, shares issuable under the ESPP and options to purchase common shares considered to be potentially dilutive securities were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all reporting periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5fa69eac-72df-475c-bccc-fd3fca656c11" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#x2019;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on differences between the consolidated financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_24484398-75f2-4c51-a582-ccdc47f8e84a" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:ResearchAndDevelopmentTaxCreditsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and Development Tax Credits</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes the benefit of refundable Canadian research and development tax credits as a reduction of research and development costs when there is reasonable assurance that the amount claimed will be recovered.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d4f0687a-bf12-4e08-a0b2-18ef2a0c6515" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13). Certain amendments thereto were also issued by the FASB. ASU 2016-13 and the related amendments implement an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. The Company adopted ASU 2016-13 and the related amendments thereto on January 1, 2022. The adoption of ASU 2016-13 and the related amendments thereto did not have a material impact on the Company&#x2019;s consolidated financial statements or disclosures as of and for the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_500be597-f031-4549-9d93-10e7d767b71b" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:RecentlyIssuedAccountingPronouncementsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no new accounting pronouncements issued which could have a significant effect on the Company's consolidated financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6155466b-3762-4487-8855-36124c0df958" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a7cbf7d5-222c-4c16-8241-207ddbc3b832" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.844%;"></td>
        <td style="width:1.028%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.256%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.028%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.256%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.028%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.256%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.028%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.278%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Money market funds included in cash and cash <br />&#160;&#160;&#160;equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_deda845f-7443-4578-8ab7-1605f759a9e8" contextRef="C_ff4a68ee-b5b1-4384-8e04-39e5e83483d2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,995</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab4dad1b-cf11-4660-88f9-435b0c60daf5" contextRef="C_fc490bf6-e1b0-491f-b8e0-2dc975bea1ea" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,995</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8db5da9-5c8e-4692-be4f-681ad33decb1" contextRef="C_094da959-0fa8-48bc-82fd-7da9a531e3da" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,362</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce7d3179-c07e-46dc-b0fd-7c13257975f9" contextRef="C_2e186f36-a60e-4c0e-bd2b-4f70ac8527fa" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7a1590d-dc2e-4a9f-a8c6-f70478c2c014" contextRef="C_06d3eba4-beff-4c6e-9e0d-74f30c8e9c98" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,362</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b16732e0-6262-4aba-af79-5707cdbb637f" contextRef="C_17d80998-566f-4f86-8cc7-530d916cebec" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,058</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5947c8d-7fd4-4e8b-bff9-58ab777df16f" contextRef="C_b5d1add8-29f2-4667-a5b8-f33390d83a70" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a14d2c6-8d8c-4d50-a8ba-1f74be4821e3" contextRef="C_df9028e4-3b11-4078-8748-bb04b49d52e5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,058</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36344168-ac79-46a8-aeca-fd68a42bca79" contextRef="C_28941f5b-2a91-41bc-8b35-389f61385829" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">184,420</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f36a447-9ac1-4d70-a8b7-0a7fd3c9ae67" contextRef="C_ba56d68a-153c-41be-98bc-d302dc2e8772" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_715c9956-0beb-48c0-901f-52e47c8d2ea6" contextRef="C_0af7e506-9a9a-47a8-b222-a900c293b675" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">184,420</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04e08bf9-9831-4b95-a3a8-5322090b2292" contextRef="C_baf42153-e67f-4dc2-ba51-e440db83cb6e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">227,415</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00c37e62-294d-4c33-9764-055d8f50473b" contextRef="C_aecc3de1-8a93-42ff-8549-71726fd80b22" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,995</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d96afcdd-8b2e-4d07-8b4a-2347893493fa" contextRef="C_2d3ca020-4e0b-4919-95d8-caf1bce5c167" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">184,420</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Money market funds included in cash and cash <br />&#160;&#160;&#160;equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_751efc18-a744-4bed-89f8-c6ae235cc8f5" contextRef="C_c7524e4f-ecae-4724-8931-850f78dc9340" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98ed075a-98a9-4a43-ac58-f2e8b4d8e9c6" contextRef="C_3b9dcbf4-525f-41db-93e3-091d15eb10d2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fd29ada-f275-441e-b794-a3bb42f48dab" contextRef="C_b3c5d94f-28fa-4de1-b6e2-f03d2f331b1c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1bc83dd-df90-494a-9ab9-cdb7252085de" contextRef="C_12d929c7-4102-4a0a-82ac-5737d31dbf45" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7db79a2-b38d-49d9-b3b0-397649439805" contextRef="C_0d97e526-4833-4dc6-8113-19ae64b7fa24" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c55d1f7-1e26-4fe9-b50b-67ee61be7ee9" contextRef="C_44a2af96-1633-4609-b79e-fb906b4b9e17" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5454ce8d-897d-4278-b382-778d0ddc718c" contextRef="C_20ff1fa1-ce48-4c09-9244-1fba1284c839" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5675b08d-50b6-4ca3-8196-98eccc7cb072" contextRef="C_f8706cb3-36b5-4d0e-af7f-dd5993e51a36" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure the fair value. In determining the fair values at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15e0d143-4fcb-42a1-b524-67cd640cca91" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:FairValueAssetsTransfersBetweenAllLevels" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4817b4bd-36cb-48b3-95de-a1bbaf3682e9" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="rptx:FairValueAssetsTransfersBetweenAllLevels" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transfers between fair value measure levels.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">142</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d942644b-65db-4da6-ad9f-ad7f18afe0d7" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Cash and Cash Equivalents and Marketable Securities</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_32774934-5a90-4cbf-9d65-e7dec4b0fa33" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, cash and cash equivalents and marketable securities were comprised of the following:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.588%;"></td>
        <td style="width:0.288%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.814%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.264%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.814%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.288%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.56%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.072%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.31%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Cash</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_792631e9-6e73-4e3f-a2a4-7764d9d35e29" contextRef="C_d537aff3-5446-4d5f-b08a-5674e6242a97" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">116,526</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bca0e672-0fe4-42c7-885d-60dd73b229c6" contextRef="C_d537aff3-5446-4d5f-b08a-5674e6242a97" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">116,526</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48121dea-944e-4d5d-a3de-ee8a354c8400" contextRef="C_ff1c845e-bbd0-4d13-bdde-c076815d4982" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,995</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5650fbeb-da3c-4515-bc17-33ac8442a93e" contextRef="C_ff1c845e-bbd0-4d13-bdde-c076815d4982" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc2232b5-6e10-4c20-b7c6-078e6894c867" contextRef="C_ff1c845e-bbd0-4d13-bdde-c076815d4982" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3dd945d-4cdc-4c7c-b3a3-c1991f14b0d1" contextRef="C_ff1c845e-bbd0-4d13-bdde-c076815d4982" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,995</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20a3549c-fbe0-45a3-8663-7e0460aab520" contextRef="C_51a377d0-935c-4a85-8c6a-d896a70f1212" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">159,521</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2471d1b-7d88-4971-934c-9ff275d75414" contextRef="C_51a377d0-935c-4a85-8c6a-d896a70f1212" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee5ae3ba-34ce-4f62-8c6f-f9264acac843" contextRef="C_51a377d0-935c-4a85-8c6a-d896a70f1212" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9bbb47b5-4de7-4490-83cf-07c27b247584" contextRef="C_51a377d0-935c-4a85-8c6a-d896a70f1212" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">159,521</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce0e3b5d-71ad-423e-853c-af968339a325" contextRef="C_fad67f8b-88f3-490b-bbfe-cdc36bfeb2fc" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,641</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0086962-a934-44b0-b3f9-12ea0be72674" contextRef="C_fad67f8b-88f3-490b-bbfe-cdc36bfeb2fc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88d998ef-f631-4694-8e17-5442d1aa58f1" contextRef="C_fad67f8b-88f3-490b-bbfe-cdc36bfeb2fc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_897971a9-ce69-4512-b4c7-7ecddc75890f" contextRef="C_fad67f8b-88f3-490b-bbfe-cdc36bfeb2fc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,362</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b186167-b3c2-4531-9473-9787468902b2" contextRef="C_bcb6ad6a-f6c4-44a8-aa2f-56e18ff3d4ea" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,207</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cd63be6-ae09-478a-a133-d4b66cf74f1a" contextRef="C_bcb6ad6a-f6c4-44a8-aa2f-56e18ff3d4ea" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4af84f6b-5213-438c-8f8d-2915364994c9" contextRef="C_bcb6ad6a-f6c4-44a8-aa2f-56e18ff3d4ea" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">153</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4100937c-90f1-46d3-a4d2-937045ea9380" contextRef="C_bcb6ad6a-f6c4-44a8-aa2f-56e18ff3d4ea" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,058</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9eb931a5-02e0-47a8-9f51-4641f9a44d30" contextRef="C_2c1f1f11-816f-44a0-818c-677c87d99b95" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">184,848</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc95c371-71a3-4972-bb2f-9a6d5809fba1" contextRef="C_2c1f1f11-816f-44a0-818c-677c87d99b95" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2ee18fd-fefd-4551-aedd-983073b54b4f" contextRef="C_2c1f1f11-816f-44a0-818c-677c87d99b95" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">433</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7dfb5288-8e34-40b4-bf5b-1fc5e1d27469" contextRef="C_2c1f1f11-816f-44a0-818c-677c87d99b95" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">184,420</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2466dca-e8a6-465f-ba17-8df85d2f403a" contextRef="C_09a80f4e-72ef-4a70-a01e-600cbb7a0251" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">331,892</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79354b55-c8d2-4fae-9bdc-21157eee2f8c" contextRef="C_09a80f4e-72ef-4a70-a01e-600cbb7a0251" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">331,892</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e92f792-1462-4f70-ae27-09d469b58d48" contextRef="C_725a0d91-5730-423e-a433-8f6615c75200" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49262e02-30bf-4944-abce-33072d0a8b0f" contextRef="C_725a0d91-5730-423e-a433-8f6615c75200" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25727c41-c4a7-476e-81e9-286889527184" contextRef="C_725a0d91-5730-423e-a433-8f6615c75200" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83704238-554e-4fcf-8617-8bcb944c7408" contextRef="C_725a0d91-5730-423e-a433-8f6615c75200" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6c5416a-0893-4b77-8589-0839df79ea50" contextRef="C_7e79f2bb-36b7-445f-a31b-fe962378bd7e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">334,427</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74bf028b-a486-4a46-a1a9-ec9055301ec7" contextRef="C_7e79f2bb-36b7-445f-a31b-fe962378bd7e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0327574-ff3e-4991-9d71-ad063e955efb" contextRef="C_7e79f2bb-36b7-445f-a31b-fe962378bd7e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6d3d097-6b87-42bc-87fe-52e8223b82ba" contextRef="C_7e79f2bb-36b7-445f-a31b-fe962378bd7e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">334,427</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e70d4201-54b9-4058-ac62-4a931541afc6" contextRef="C_cb5cf079-696f-4343-a699-77c7dc62a392" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b4bb48e-f619-4dbd-9765-fddf121943c7" contextRef="C_cb5cf079-696f-4343-a699-77c7dc62a392" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53c8255b-c9e5-4a2c-93c2-2750db089855" contextRef="C_cb5cf079-696f-4343-a699-77c7dc62a392" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a71738e0-6f29-417c-9917-0bb7943174cd" contextRef="C_cb5cf079-696f-4343-a699-77c7dc62a392" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bcd7666-fcb5-4ada-9da5-dbb75b88e9cd" contextRef="C_4de6f4d2-6787-40e5-b77a-57e8962ad678" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_387cc116-9c2b-4191-8556-f60d5d392fae" contextRef="C_4de6f4d2-6787-40e5-b77a-57e8962ad678" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ae028b7-4f9f-4b83-a1e0-1281fb25a1b8" contextRef="C_4de6f4d2-6787-40e5-b77a-57e8962ad678" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9dcd62db-f919-4860-9551-b16df86ec7ab" contextRef="C_4de6f4d2-6787-40e5-b77a-57e8962ad678" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest receivable was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4a3be18-b986-49a5-b0e1-2a5ef79189cd" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:AccruedInvestmentIncomeReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70ce94c6-6422-4243-99b2-455351d0c731" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:AccruedInvestmentIncomeReceivable" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively, and is included in other receivables.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47a8f803-1c3e-480b-a988-49da206b7267" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Positions" decimals="INF" format="ixt:numdotdecimal">28</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7065fd8f-6976-4ae7-8ca8-d6474aa67aad" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Positions" decimals="INF" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> available-for-sale marketable securities with an aggregate fair value of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be73f293-8091-4be3-9fb1-ef8754aa7159" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">157.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d523e318-599d-46fb-8ccf-1d107fb642e0" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that were in an unrealized loss position as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. These marketable securities have been in an unrealized loss position for less than twelve months. The unrealized losses as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. The Company does not intend to sell these securities and it is more likely than not that it will hold these investments for a period of time sufficient to recover the amortized cost. As a result, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9862e7e-2ef1-429b-8516-275a1af49628" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f67c83fe-d740-4806-af86-ca5ff33b6289" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">record</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">143</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">allowance for credit losses or other impairment charges for its marketable securities for the year ended December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b218752-df1c-46a4-987f-c066418ef2bf" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:UnrealizedGainLossOnDerivatives" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f17ac80f-f357-4905-873f-97060d057ebf" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:UnrealizedGainLossOnDerivatives" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in net unrealized losses in other comprehensive loss for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The maturities of the Company&#x2019;s marketable securities as of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> are less than one year.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_83ffc622-77e4-4693-91d5-5555324fc3f0" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b0d78a34-a0ae-4b12-8b61-5e23df876a06" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.61%;"></td>
        <td style="width:1.604%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.043%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.615%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.128%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e8566f7-b3ad-4154-86d1-f12c889e8f5d" contextRef="C_22564969-d47a-4706-ae91-ce5a0d5d6dce" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">473</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50cf299c-74ec-4f40-a73c-5fb0bf3f7c7f" contextRef="C_8c1fa03b-d7de-4cdb-bb33-3af841c54489" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">469</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36d3a60c-2be4-484f-b641-9f6ea20da775" contextRef="C_48b390fd-4b46-46d7-aee6-263c90700965" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">514</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64f83168-ab3d-4d11-ae6b-091b6e069a8a" contextRef="C_e75a721e-63db-4a19-a404-91703f5b0417" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">509</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58eb5e1d-a515-494d-a2cf-225831d3ef79" contextRef="C_5c19b01e-f2cc-438a-99aa-b2fa48bdc135" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,075</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_757dabff-328d-453e-bedb-0c2b70a61706" contextRef="C_c204b568-e22d-442d-991f-8208f6b49c11" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,536</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ced9a2fe-4fbb-40c7-8e8e-cb571073d56c" contextRef="C_4efbd3ec-210d-4b1b-84fc-55cd67ef578f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,519</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4d340a0-e476-4d55-9507-22b561cfcc66" contextRef="C_0b3e7aa4-3459-470d-87c2-e0d9a02fb4d5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,465</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0dd68ef-2a2f-4560-b6e7-e987b212054a" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,581</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c336e51c-ddbc-4134-ae5c-b78757a4eb3b" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,979</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cf87a77-36c1-4e0a-b675-13405891d69f" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,353</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c33c33c0-c369-4141-add0-d168ed226f61" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_665be909-f1a2-4630-9b96-bdc77668ba37" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_822e1fa3-fa4f-4d21-937b-ec67efa5268a" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,604</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e01830ae-88b1-44a5-9318-34531a2a40c4" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:ScheduleOfDepreciationExpenseTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense recognized was allocated as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.844000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.163%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b92bc943-7f65-4fff-893b-6b5070006a16" contextRef="C_afaac43e-017a-44ba-b75d-7ea6a3b4e368" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,837</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dab248e7-9aa2-49e1-854d-2793650c0d43" contextRef="C_30716fb3-44b9-47e8-800d-7c2d957e670b" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,325</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administration</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b372b05-7fed-4de7-ace2-07c3653d3359" contextRef="C_301dd1df-f42b-4bd5-982c-d7e2d3733b57" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">141</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f8b0d76-8698-418a-bf09-034e49c6c537" contextRef="C_48281951-8326-4dc8-8373-9afcbedac008" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">146</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8c55cac-5efa-4e5b-98ee-1fe19493ca43" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,978</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a96163f-c1d7-42db-94c4-504a33724189" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,471</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c6170a9f-41d3-4a3e-a305-103df1366739" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Accrued Expenses and Other Current Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_76a008d8-ca78-465d-bec8-59899a1fcfd5" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.844000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.163%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation and benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ce12c6b-947d-40e6-a3ea-34e47d480102" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,616</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39e05642-505e-44f5-8e14-b121f59cac05" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,867</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_037a7399-2b6c-4aaf-b9d7-58ebc8928ef5" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,078</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e4d5b93-85aa-404c-85a8-d8bbd0785741" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="rptx:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3fbb868-f438-4200-8bc4-70455a764752" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">680</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b87e9d86-f13c-4c25-b7bf-20d082100b83" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued property and equipment purchases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff8563f4-7b8c-4f8a-8246-e412ac5830a8" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:AccruedPropertyAndEquipmentPurchases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba3ffd9e-68b4-4347-882d-8ffc29741a33" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="rptx:AccruedPropertyAndEquipmentPurchases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,719</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2de2660-c2fc-402e-8e65-a3dd2a994614" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">271</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cf761b6-d179-4c2b-b596-5850aec01695" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">377</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21ff22cc-531c-4655-bb7a-1ba9e5e4b9a5" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:AccruedExpensesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,645</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5de99437-6329-4959-b4d1-792fb3b7ec5b" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="rptx:AccruedExpensesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,622</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_685e782b-5215-4853-813a-a04b42e0839e" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:LicenseAgreementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. License Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2016, as further amended in February 2017 and amended and restated in July 2018, the Company entered into a license agreement (the &#x201c;NYU Agreement&#x201d;) with New York University, pursuant to which the Company obtained a worldwide, royalty-bearing, exclusive license under certain patents and know-how of New York University to research, develop and commercialize products covered by such licensed patents. The Company is required to pay New York University an annual non-refundable license fee, which is creditable against future milestone and royalty payments. The Company is required to pay amounts up to approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da945872-f009-4a45-b18f-940a5bc6ca61" contextRef="C_2885b753-de7f-4392-894e-f84483b20968" name="rptx:LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones" unitRef="U_USD" scale="6" decimals="-5"><ix:nonFraction id="F_c5bbc78e-443b-4d85-8470-417db148e1a1" contextRef="C_eaa1c4ec-6b84-4c2f-bfb1-0f3c64fa8a22" name="rptx:LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones" unitRef="U_USD" scale="6" decimals="-5">6.7</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the aggregate upon</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">achievement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of certain clinical and commercial milestones and pay a low single digit royalty on future net sales of any product covered by a licensed product and a lower-single digit royalty on future net sales of any product not covered by a licensed product. The NYU Agreement expires on the date of expiration of all royalty obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any potential future milestone or royalty payment amounts have </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f6a7c46-a2c4-4356-bfcd-c8b071b706f0" contextRef="C_8d0b1ad6-feb9-4c5d-a621-f47ee6f509c7" name="rptx:AccrualPotentialMilestoneAndRoyaltyPayments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2ef713e9-e7c2-4880-895b-b2d300049e2f" contextRef="C_5b7ac425-2255-44fd-ada4-9a500ac1d1b0" name="rptx:AccrualPotentialMilestoneAndRoyaltyPayments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t been accrued at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> due to the uncertainty related to the successful achievement of these milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3958ba3d-8c91-412d-9a56-9b276e8bd3ac" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has historically entered into lease arrangements for its facilities and certain equipment. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c87c1c6d-006f-44b8-aa92-7ed51109d254" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:NumberOfOperatingLeases" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating leases with required future minimum payments. The Company&#x2019;s leases generally do not include </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1a894885-00d0-4aca-9a12-3811d417d077" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">termination</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or purchase options.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2017, and as further amended in 2021, the Company entered into a lease agreement for office and laboratory space in Montr&#xe9;al, Qu&#xe9;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">bec, for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_19caa646-f87a-4a57-84ba-dfc7b73166ed" contextRef="C_4a5e155a-5edb-4aab-8fba-3f55b166f8d0" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term, ending in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_66b44b3b-b1ff-4bd0-9c2a-581d06b714b3" contextRef="C_df52d1fe-29fc-4d0d-8f6f-fd0bf0ff0418" name="rptx:LesseeOperatingLeaseExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In August 2021, the lease was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fee16209-de14-41b5-b344-5ddb59abb950" contextRef="C_42ff0858-ec4a-443e-a421-33c199818df7" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a1db1fec-e1d8-443c-a5a1-05b20922cc8e" contextRef="C_42ff0858-ec4a-443e-a421-33c199818df7" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extended</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through July 2025</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2017, and as further amended throughout 2018, 2019, 2020, 2021 and 2022, the Company entered into a lease agreement for office and laboratory space located in Montr&#xe9;al, Qu&#xe9;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">bec, for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4ccb494e-c9fe-42c1-a9ce-be5917789e72" contextRef="C_25443f6f-14cc-4288-8365-8cdd9a2d1076" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term ending in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_21bdc6ce-7870-4d95-987e-01fedb8fd130" contextRef="C_440d565d-c87e-4c67-922b-8dd7ab19917a" name="rptx:LesseeOperatingLeaseExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 2020</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ebf818ad-31d2-4f2f-afe2-9e1138456ed6" contextRef="C_440d565d-c87e-4c67-922b-8dd7ab19917a" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_74aa88db-e93b-4f3d-bac2-02357c493744" contextRef="C_440d565d-c87e-4c67-922b-8dd7ab19917a" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extended</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through December 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company entered into a new lease agreement, effective January 2023, which will result in $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c43c8cf2-ec97-45d4-9e83-a58dd0ca6b20" contextRef="C_4fa8599e-cef5-4581-9bfc-a45811c2a414" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of minimum lease payments over the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_5c64d736-3755-4363-b2f0-d376d83f9242;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">thirty-two</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> month lease term.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, the Company entered into a lease agreement for office space in Cambridge, Massachusetts, for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cc3deb85-4222-4422-9268-f902df5d9c1b" contextRef="C_a780ab50-a50d-41cf-bc67-6e53d80a9287" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term ending in</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6b113d51-aa16-4dcf-bf20-5dd60b01dbf2" contextRef="C_3dbc6dec-8dff-4b9e-b1b2-8ee0fd0bfed6" name="rptx:LesseeOperatingLeaseExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> December 2024</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which commenced in December 2021. The Company has an option for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_09f5621e-f9a0-4d8c-b1c7-c51d673881e5" contextRef="C_a780ab50-a50d-41cf-bc67-6e53d80a9287" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewal, which has not been recognized in the Company&#x2019;s right-of-use asset or lease liability.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2019, and as further amended in July 2021, the Company entered into a lease agreement for office and laboratory space for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_85cb8c3c-a3be-4ae1-b504-65e0cdd0a6b9" contextRef="C_c9e1d8a8-8da6-496e-93e9-56257c4a31b4" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term located in Montr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xe9;al, Qu&#xe9;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">bec which commenced in September 2020. The Company has an option for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c2915a26-db49-43a7-a257-0bb1a26d5dc8" contextRef="C_c9e1d8a8-8da6-496e-93e9-56257c4a31b4" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewal, which has not been recognized in the Company&#x2019;s right-of-use asset or lease liability. As required under the terms of the lease agreement, the Company incurred prepaid rent of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22f9b9e9-0af1-4098-9416-d3d2365797ff" contextRef="C_c9e1d8a8-8da6-496e-93e9-56257c4a31b4" name="us-gaap:PrepaidRent" unitRef="U_USD" scale="6" decimals="-5">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million prior to commencement of the lease term, with the current portion previously accounted for within prepaid expenses and other current assets and the long-term portion accounted for within other assets. As well, as required under the terms of the amended lease agreement, the Company incurred prepaid rent of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b53d18c-f1e8-48a7-96c0-8393799e3c86" contextRef="C_bda62528-1f40-4600-97f1-d787732fa2f1" name="us-gaap:PrepaidRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million prior to commencement of the lease term which was accounted for within prepaid expenses. As of the commencement of the lease term, this prepaid rent has been reclassified to the right-of-use asset.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c38dea62-a1c5-4166-9761-601e0cfc1479" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating leases for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.844000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.163%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ced4dfe6-ac07-4701-9892-2fb45ef71092" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,456</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34136395-8992-4054-ae1c-905446d5ca6b" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,101</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fef83314-0856-4d9d-bfef-7d84d2c13bdf" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91f00097-e198-4cbb-9b17-511a82affda8" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3">25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42fc6b92-b301-4df7-a04f-a9e46d792c83" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">278</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48dad2b4-2fb6-433d-bfdd-e69b0d86fe55" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3">163</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec72bba5-e3b3-48cb-b9f4-09a1a9b8cb67" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,767</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9cacbe76-10f0-4831-b710-619c4b8ed3f9" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,289</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fa8afbef-993a-4b2f-b6c6-781371e9a065" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:SummaryOfOtherOperatingLeaseInformationTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.818%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.501%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.605%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.48%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except as specified otherwise)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Operating Lease Information</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows for operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d88a417-9a66-47ff-aedf-9edfba6e3446" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,948</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf3a44eb-6790-416f-888b-fa432e3c8bac" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,240</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets obtained in exchange for lease obligations</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2783493c-2bd6-4e8c-8a96-cc30b91dc848" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67b6451c-e085-4c84-aefa-d229593928ea" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,690</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_358d98cf-1db6-4cea-aa4a-5cfc0d1e286c" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.43</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_aef00da5-4e8e-4ef6-92a4-614520558323" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.35</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95c697c0-297c-40e6-923c-367907296e56" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9667be7-2623-48c4-abd5-6f6edb2fe7bd" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease costs for the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> include contingent rental usage, common area maintenance and other operating charges. As the Company&#x2019;s leases do </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b158aa4-4bb5-4dcc-bd7d-6fc0560d1493" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:ImplicitInterestRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_02e3c648-50bf-4da4-b212-23b54f05b72e" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:ImplicitInterestRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d3989b4f-7a43-4484-9e7b-d4dfcd086521" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments under the Company&#x2019;s operating leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.883%;"></td>
        <td style="width:1.93%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.187%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br />2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity of Lease Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3850c38e-5549-42db-a2f5-f100e3399578" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,342</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de59f857-1d16-4df9-9f8d-2fad770ee795" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,395</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a34392f0-fe1e-4f25-8c6d-c3a2993bd3b8" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">957</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac12cc35-96e0-45fe-8fbb-5de3c082e0ad" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,694</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14c21209-7a4b-4c19-aa2e-b048b7ff5332" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14444dc1-d102-4fb1-a898-a61820f9dbae" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,428</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3490e5c2-c0ce-4d1e-b45b-38152d320eba" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. Shareholders&#x2019; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Shares</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective upon the closing of the IPO, the Company authorized for issue an unlimited number of preferred shares, issuable in series, having such designations, rights, privileges, restrictions and conditions, including dividend and voting rights as the board of directors of the Company may determine, and such rights and privileges, including dividend and voting rights, may be superior to those of the common shares. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad4091c4-0097-41af-9bdf-e3e02ff27d7d" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4e888e13-6bff-4e71-bb1d-1bd3ec7abee0" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9c1e91cd-0862-44fe-8237-4526aad014d2" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b3d03ac3-18f8-4372-b8ac-bb896a41438e" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> preferred shares were issued and outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Shares</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The articles of continuance of the Company authorize an unlimited number of common shares, voting and participating, without par value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cc003efb-daf8-4111-8d5a-570078a1efb1" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each common share entitles the holder to one vote on all matters submitted to the shareholders for a vote.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The holders of common shares are entitled to receive dividends, as may be declared by the board of directors, if any. Through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8668c655-6604-411b-b118-9a7a31e151f9" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:DividendsCommonStockCash" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cash dividends have been declared or paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 1, 2021, the Company completed a follow-on offering of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02813acb-aa5c-41fb-af4b-79127abf1853" contextRef="C_8de25cbb-79b8-4c61-83cd-426c93b13621" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,600,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of its common shares, including the exercise in full by the underwriters of their option to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc4d7590-882b-4502-8f9c-cc57a42b59a8" contextRef="C_e4e66d4b-8df8-4150-855e-17cb5ce1bcb9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">600,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional common shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9dc88657-ddbd-46df-83f1-75c5f7dfc012" contextRef="C_c095c251-0ca6-45ab-ae2c-2aec9d4fb280" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">22.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, for net proceeds of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82484bca-acdc-4767-a920-b9180ebd5424" contextRef="C_8de25cbb-79b8-4c61-83cd-426c93b13621" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">94.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, after deducting underwriting commissions as well as offering expenses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d049447-dfb8-41c1-b6c6-9e3fb5148508" contextRef="C_404b861d-d003-4142-9ce1-6483dccfba5d" name="rptx:UnderwritingCommissionsAndEstimatedOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payable by the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 2022, the Company entered into a common shares sale agreement (&#x201c;the Sales Agreement&#x201d;), with Cowen and Company, LLC (&#x201c;Cowen&#x201d;) as sales agent, pursuant to which we may issue and sell common shares from time to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">146</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">time, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or the ATM Shares. The ATM Shares to be sold under the Sales Agreement, if any, will be issued and sold pursuant to our shelf registration statement on Form S-3 (File No. 333-257668), up to a maximum aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36655176-ec8a-4e22-a49e-83195f9b365a" contextRef="C_a9d543b1-b2e8-4033-a16b-a49687bf6b19" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">125.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a24a6e01-22c7-4dc3-8c9e-7a5d7b373e0d" contextRef="C_d7dc9fc2-b468-4689-8b15-f9d0f5c26ff5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares have been issued under the Sales Agreement as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1f3a37b0-bebb-4e2b-93e3-836190a4ecc4" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Share-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Employee Share Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, the Company&#x2019;s board of directors adopted, and the Company&#x2019;s shareholders approved the 2020 Employee Share Purchase Plan (&#x201c;ESPP&#x201d;). The maximum number of common shares that may be issued under the ESPP was initially </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2732bfd-c767-4598-b85e-9b6397b3266f" contextRef="C_db2b4777-c5cc-4811-a937-f402d6499701" name="rptx:CommonStockCapitalSharesInitiallyReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">327,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Additionally, the number of shares reserved and available for issuance under the ESPP will automatically increase each January 1, beginning on January 1, 2021 and each January 1 thereafter through January 31, 2030, by the lesser of (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_669efacf-95a9-488d-b4d6-575506610091" contextRef="C_9cf3be3d-b394-4173-992a-035a20692942" name="rptx:AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of common shares outstanding on December 31 of the preceding calendar year, (2) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82b3a2ae-d139-42e6-8a9e-fe353a9caa76" contextRef="C_9cf3be3d-b394-4173-992a-035a20692942" name="rptx:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,300,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares, or (3) such smaller number of common shares as the Company&#x2019;s board of directors may designate. As of January 1, 2023, the number of common shares that may be issued under the ESPP is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4578cc6f-8c44-4f40-83ef-d1352c753ca8" contextRef="C_1b80891b-1319-4360-8f15-2497ed8ea0b5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,487,035</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ESPP enables eligible employees to purchase common shares of the Company at the end of each offering period at a price equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1b99a36-df4a-4fa6-b7a6-1f4bb6ceb016" contextRef="C_9cf3be3d-b394-4173-992a-035a20692942" name="rptx:PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Participation in the ESPP is voluntary. Eligible employees become participants in the ESPP by enrolling in the plan and authorizing payroll deductions. At the end of each offering period, accumulated payroll deductions are used to purchase the Company&#x2019;s shares at the discounted price. The Company makes </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4edaf743-981e-47b4-8059-db98fd133ebd" contextRef="C_acf39634-d069-4302-ab50-45e5dd9d130f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> contributions to the ESPP. A participant may withdraw from the ESPP or suspend contributions to the ESPP. If the participant elects to withdraw during an offering, all contributions are refunded as soon as administratively practicable. If a participant elects to withdraw or suspend contributions, they will not be able to re-enroll in the current offering but may elect to participate in future offerings. The ESPP purchases only whole shares of the Company&#x2019;s shares. The Company&#x2019;s first ESPP offering period began February 16, 2021 and ended on August 15, 2021, with a second offering period commencing on August 16, 2021. Subsequent offering periods will be on a rolling six-month basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021 the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b780417-245f-4f18-9656-00e7ae982482" contextRef="C_421e346c-f45c-4450-9712-2cde91dba0a4" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,915</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93f00897-d4a6-43e1-8d60-a6052d5c2f31" contextRef="C_633aa886-db18-4e4b-ac98-428a52434cba" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,943</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares under the ESPP, respectively, at an average price per share of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23b3326d-931a-46f6-8242-b762ab5316d7" contextRef="C_421e346c-f45c-4450-9712-2cde91dba0a4" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">11.43</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a506f37-875c-4d7b-ba11-86b0ea1b4fa6" contextRef="C_633aa886-db18-4e4b-ac98-428a52434cba" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">28.46</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. Cash received from purchases under the ESPP for the years ended December 31, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b77c2925-7504-4150-a29d-c17d486c59c0" contextRef="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0" name="us-gaap:ProceedsFromRepurchaseOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a2e7dd1-29d7-4c8b-800f-4187e524512a" contextRef="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735" name="us-gaap:ProceedsFromRepurchaseOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. In February 2023, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27618ee6-907e-45ed-965a-fe123dd4fc58" contextRef="C_a5be591d-88a6-4798-a866-48f091aca5bb" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">41,703</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares under the ESPP at an average price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9198747c-a40d-4e44-8622-099b5d223576" contextRef="C_a5be591d-88a6-4798-a866-48f091aca5bb" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">9.80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_716cfb44-5114-4f42-8adf-a8a9bf93ec04" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions that the Company used in the Black Scholes option-pricing model to determine the grant date fair value under the ESPP offering were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.663%;"></td>
        <td style="width:1.159%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.51%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.159%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.51%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fb9e6c4-dc8b-4bb8-a8c1-0ce77fde9ed8" contextRef="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.36</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d16cca0c-80ce-48a7-adfb-6512dbdafe83" contextRef="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.05</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_de38f535-1955-424d-a616-98f382c949ae" contextRef="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_61f9f831-6aa1-41bc-9b0c-05f0469172c8" contextRef="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c85d1af0-d6c8-427d-924d-3a6aec98f2b0" contextRef="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">85.37</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3fe11fda-8f75-4fcd-bc75-3228057fa873" contextRef="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">61.91</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a7149b5-8464-4570-9217-83d76558692c" contextRef="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed4f9b4b-a383-4e5b-bcd5-46acff1b41ea" contextRef="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average grant date fair value under the ESPP offering during the years ended December 31, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8956377b-ea51-4384-b080-a7410dce2120" contextRef="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.91</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48e6abf6-012c-4ab5-930e-1a04e7c0381f" contextRef="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.94</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option Plan and 2020 Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2016, as further amended in December 2017 and September 2019, the Company adopted the Repare Therapeutics Inc. Option Plan (the &#x201c;Option Plan&#x201d;) for the issuance of stock options and other share-based awards to directors, officers, employees or consultants. The Option Plan authorized up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffc568e1-77a5-4b36-ae05-850bc8b04658" contextRef="C_b9ebcd23-ea43-4fa8-a367-3a44c77fbe15" name="rptx:ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,074,135</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common shares to be issued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">147</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, the Company&#x2019;s board of directors adopted, and the Company&#x2019;s shareholders approved the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;). The 2020 Plan became effective on the effective date of the IPO, at which time the Company ceased making awards under the Option Plan. The 2020 Plan allows the Company&#x2019;s compensation committee to make equity-based and cash-based incentive awards to the Company&#x2019;s officers, employees, directors and consultants including but not limited to stock options and restricted share units. A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3783e132-1e92-4307-bb7c-fc1aaf842c42" contextRef="C_96aa4796-a454-4289-a8e9-eb0a4d889465" name="rptx:CommonStockCapitalSharesInitiallyReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,600,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares were initially reserved for issuance under the 2020 Plan, plus the number of shares (not to exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47e21fe8-ac27-482e-84c7-680d0f012744" contextRef="C_96aa4796-a454-4289-a8e9-eb0a4d889465" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,807,448</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares) consisting of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5a0997d-1fe3-47ff-b9af-bb5e0b6a6731" contextRef="C_6c9ad6f4-0f96-4cc2-a1f8-7552b59f9ad8" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">298,605</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares that were available for issuance of awards under the Option Plan at the time the 2020 Plan became effective, which ceased to be available for future issuance under the Option Plan at such time and (ii) any shares subject to outstanding options or other share awards that were granted under the Option Plan that terminate or expire prior to exercise or settlement; are forfeited because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares reserved and available for issuance under the 2020 Plan will automatically increase each January 1, beginning on January 1, 2021 and each January 1 thereafter through January 1, 2030, by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed33f74b-a687-4520-8750-cc829f242605" contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a" name="rptx:AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear" unitRef="U_pure" scale="-2" decimals="2">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding number of common shares on the immediately preceding December 31, or such lesser number of shares as determined by the Company&#x2019;s board of directors. As of January 1, 2023, the number of common shares reserved for issuance under the 2020 Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3360ddee-3866-450f-9ddd-dd5699378d09" contextRef="C_a573d49c-e7e4-4254-b7c3-222222b5c736" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,025,525</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Plan is administered by the board of directors. The exercise prices, vesting and other restrictions are determined by the board of directors, except that the exercise price per share of stock option may not be less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54f2b426-098c-4506-bdcf-db25d6051d8e" contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a" name="rptx:ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare" unitRef="U_pure" scale="-2" decimals="INF">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair value of the common share on the date of grant, determined based on the average of the daily volume-weighted average trading price of shares on each of the five trading days immediately preceding the date of grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options awarded under the 2020 Plan expire </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_154e9f42-7a34-406a-a954-c70254d0ec8d" contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> after the grant and generally have vesting conditions of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ac4bb2c-44f6-4e14-bee9-97af5df9275a" contextRef="C_ea477cfd-4c08-4194-a45f-5b0534acacdc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on the first anniversary of the date of grant and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22132e17-e1e9-43f5-93fa-e25f21731df4" contextRef="C_ae5f3fdb-a581-43e3-bfb4-15c88e51dc08" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2">75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on a monthly basis at a rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8d71bc01-dd9b-4b99-b8cd-bd6103de3a8b" contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a" name="rptx:ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless otherwise decided by the Company&#x2019;s board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option Activity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a322185c-5655-4b15-acc8-0445fd111a25" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions that the Company used in the Black Scholes option-pricing model to determine the grant date fair value of stock options granted to employees and non-employees were as follows, presented on a weighted-average basis:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.663%;"></td>
        <td style="width:1.159%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.51%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.159%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.51%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_962f85dc-e6d6-4a5a-83f7-f101b88cad02" contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4">2.17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0ccc714-9a8e-4cc6-a0ee-8b161dd2e59f" contextRef="C_93008ec0-d0c8-4150-bb27-d96cc8c66909" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4">0.80</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cd3f8662-e96c-440f-aa8d-22fcb83eb716" contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.99</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7c62d082-031d-4143-aa19-e8d80a6c9350" contextRef="C_93008ec0-d0c8-4150-bb27-d96cc8c66909" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d317206a-a9bb-4602-9137-004dd61368cd" contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4">78.95</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1eb04d2-2373-4956-9943-53ded99464c1" contextRef="C_93008ec0-d0c8-4150-bb27-d96cc8c66909" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4">75.99</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c5afacd-2970-4371-a877-2baeb7fa4eba" contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4">0.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36f38555-e25a-4b3e-9c4f-21776aa7b1d3" contextRef="C_93008ec0-d0c8-4150-bb27-d96cc8c66909" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4">0.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average grant date fair value of stock options granted during the years ended December 31, 2022, 2021 and 2020 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f8ba0ac-1aa5-4a82-9da1-6a5c0800b064" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.54</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea95cb83-b23d-4324-8bc8-c4b61c36239a" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">22.49</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6418eb3a-4bb4-4786-96b1-a67349bd81a9" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#x2019;s share option activity:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.132%;"></td>
        <td style="width:0.402%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.456999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.182%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.290000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.298%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.134%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.805%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.303%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />average<br />exercise<br />price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />average<br />remaining<br />contractual<br />term<br />(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intrinsic value (in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e71705a-15a3-4ac1-a824-dac2b596ac64" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,322,591</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bcf97ca3-accd-4945-a4fc-fe0108a7f130" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c4b8cd3-a080-4fa2-a666-902831d3196e" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.15</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97afd906-5235-4b24-801f-fa9c8893309d" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,722</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c157ac71-89d7-4ff2-874d-0e3adbeefd1a" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,346,567</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8d494c0-9f1e-4a78-adf0-f007990d855c" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.41</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff3eaae8-9a96-449b-bd51-e55e0798da59" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">148,116</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3d66aa3-2f63-46a7-b446-91b06d1d30fb" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.02</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4203aca6-b54a-4cb2-ba23-884d0c13f9ff" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">488,140</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a049e1c9-5352-4a26-9a32-0672d7ad3748" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">22.15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f163cefd-ddf3-4161-a1bb-1928280875ff" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,032,902</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7501f2c1-5fcd-4383-b2d0-ebfa0db335b9" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.38</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b9e0729b-6eeb-41d9-a8da-248ca9367425" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.90</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bec71ee-78a9-4fe2-9cea-067f21fde02b" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f726448a-e639-47fb-bd24-d50e4b8bbb6d" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,592,087</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2776ace7-1ecb-4fa5-bc73-820dbf92d1ce" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">11.41</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c9697ffa-5892-4d31-bb48-428ffdbe9a95" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.94</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ff40e93-76f2-4859-a97a-3d26cf53c873" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,538</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options unvested, December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57c2ce23-59e4-497a-9cc9-659f7edc76d7" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,440,815</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74942d9f-6ad8-46c7-93d6-d4238f928459" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">16.79</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f673a122-4230-4e89-b3eb-79b568aa9cf4" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.65</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21e8b927-a3cc-44c0-b141-5b624b320cc4" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,712</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">148</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common shares for those stock options that had an exercise price lower than the fair value of the Company&#x2019;s common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value of options exercised during the years ended December 31, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_033a084d-5949-43f7-994a-fab8bde83c4a" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89a01753-2181-4e69-876c-54b1d746ebe7" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total fair value of options vested during the years ended December 31, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78112d9c-7d6b-4624-90df-e9ff272225ea" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:FairValueOfVestedOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3e59ee7-7000-479e-b7cd-563e62978f7c" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:FairValueOfVestedOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2efe3ac8-65c8-4fe7-bbe2-8f834b48aa72" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">148,116</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options were exercised at a weighted-average exercise price of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d73f962-6579-41fe-8eee-e949198164e8" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.02</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, for aggregate proceeds of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4460ae5-9403-46cb-8298-813e9c1e73e4" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As a result, an amount of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a331945a-8862-447f-b72c-f935f7fa7dac" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> previously included in additional paid-in-capital related to the exercised options has been credited to common shares and deducted from additional paid-in-capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January and February 2023, the Company granted an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e1295c7-b8d9-41d1-8a56-415630ddf493" contextRef="C_434cd7cc-5862-46ac-a5bc-39dc683d789f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,495,240</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options at a weighted average exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb0fdae1-94a2-49d8-853d-6d4cacca0236" contextRef="C_434cd7cc-5862-46ac-a5bc-39dc683d789f" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">12.42</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23a94621-e43f-4775-b8e2-351ed9a65fa1" contextRef="C_3cfc3e53-1c58-46fd-a5b8-3badfcad9efb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">626,260</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted share units to employees under the 2020 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7f38f313-0b9c-4eb2-b771-ce34adc85422" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense for all awards was allocated as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.844000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.163%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a1fed79-8753-460e-83df-9869de3bee35" contextRef="C_afaac43e-017a-44ba-b75d-7ea6a3b4e368" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,020</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed15206d-7acc-4672-b182-a9aee98db635" contextRef="C_30716fb3-44b9-47e8-800d-7c2d957e670b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,681</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64eb4361-e416-49e2-a943-be5a9c1c7164" contextRef="C_301dd1df-f42b-4bd5-982c-d7e2d3733b57" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,671</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_918c4f7a-a494-49ce-abe9-5d963d756831" contextRef="C_48281951-8326-4dc8-8373-9afcbedac008" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,148</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14824014-61fa-4998-b6c6-58f0ba6d0e46" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,691</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d344d51c-22c6-4e85-bd87-266e2ceb6be1" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,829</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense by type of award was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.844000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.163%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0462ff58-9d88-4636-ba65-d0fa2317a667" contextRef="C_19ce3969-55ed-4e30-9462-0263222e2f93" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab766815-0487-40ad-8086-684a63ac5736" contextRef="C_35a0d25d-897e-41e7-bd44-d80a88e5d9aa" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,632</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8e4cdc7-85fa-4bce-8fdb-0c99bc98926f" contextRef="C_10a635cc-4c15-4e96-be01-4a9e22f1dbef" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">291</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d0beca8-a55b-4b1d-977a-99ee464aa619" contextRef="C_17dcc120-3760-4de9-9e06-6064cef30d4d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">197</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac79e78c-1be8-4eb8-8d55-ae2ed76d2851" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,691</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5480416-2ad5-45b2-9b56-219d5e496582" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,829</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfd35817-2ef9-4671-8e60-09055825fb7c" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">42.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of unrecognized share-based compensation expense related to unvested stock options. The unrecognized share-based compensation expense is expected to be recognized over a weighted-average remaining vesting period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_54ed3dc7-1d1a-4f1a-9e3d-a8d6c57ebe70" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bdd1d3d4-6247-4a54-a1b8-c6b047044083" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Employee Savings Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has offered its employees in the United States the ability to participate in a 401(k). The Company has also offered its employees in Canada the ability to participate in a registered retirement savings plan. As of January 1, 2021, the Company started making non-matching employer contributions into both of these plans on behalf of participants equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34c972a1-eef7-4096-bc1a-d9641ada0bb0" contextRef="C_570d5b98-d1b3-467c-8957-e622df2b9b75" name="rptx:DefinedContributionPlanEmployerNonMatchingContributionPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their base salary. The Company has recorded an expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99956717-4abd-4c5e-b911-326912a9c1dc" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d38743b3-0f8c-45af-87b9-b46ce0bc7f6b" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in matching contributions for the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_2ebf2a68-c770-477b-b64b-89df3750a4aa" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Collaborations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Roche Collaboration and License Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, the Company entered into a collaboration and license agreement (the &#x201c;Roche Agreement&#x201d;) with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd (collectively, &#x201c;Roche&#x201d;) regarding the development and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commercialization of the Company&#x2019;s product candidate camonsertib (also known as RP-3500 or RG6526) and specified other Ataxia-Telangiectasia and Rad3-related protein kinase (&#x201c;ATR&#x201d;) inhibitors (the &#x201c;Licensed Products&#x201d;). The transaction was subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions, which were met on July 13, 2022 (&#x201c;Effective Date&#x201d;). Pursuant to the Roche Agreement, the Company granted Roche a worldwide, perpetual, exclusive, sublicensable license to develop, manufacture, and commercialize the Licensed Products, as well as a non-exclusive, sublicensable license to certain related companion diagnostics. The Company has agreed to complete specified ongoing clinical trials in accordance with the development plan in the Roche Agreement, as well as ongoing investigator sponsored trials (together, the &#x201c;Continuing Trials&#x201d;) at the Company&#x2019;s expense. Roche assumes all subsequent development of camonsertib with the potential to expand development into additional tumors and multiple combination studies. The Company retained the right to conduct specified clinical trials (the &#x201c;Repare Trials&#x201d;) of camonsertib in combination with the Company&#x2019;s PKMYT1 compound (also known as RP-6306). The Roche Agreement also provides the Company, at its sole discretion, with the ability to opt-in to a 50/50 U.S. co-development and profit share arrangement, including participation in U.S. co-promotion if U.S. regulatory approval is received. If the Company chooses to exercise its co-development and profit share option, it will continue to be eligible to receive certain clinical, regulatory, commercial and sales milestone payments, in addition to full ex-U.S. royalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Roche Agreement was subsequently amended in October 2022 to extend the timeline to negotiate in good faith the parties&#x2019; rights and obligations with respect to the Repare Trials, as defined in the Roche Agreement, and to clarify indications included in the development plan that are subject to milestones.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Roche Agreement, the Company received an upfront, nonrefundable payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9d6e089-b8b7-400d-8722-a3db2b3044ce" contextRef="C_21132067-3295-4e05-aca1-b407f86fc88d" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">125.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in July 2022. The Company also received an additional payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_541a579e-f2a5-40c0-9be5-0f91843cc375" contextRef="C_c2f83839-f843-4da9-8ac0-9aab66ecad59" name="rptx:CollaborationRevenueReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million negotiated with Roche for revisions to the clinical development plan under the Roche Agreement as agreed to by the parties at the time of the Effective Date. The Company further received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5f15c9e-978b-49e9-9f02-e8d3b9d1ffec" contextRef="C_0432e0bc-120b-4705-8281-2d047c8d1406" name="rptx:CollaborationRevenueReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the transfer of clinical trial material on hand to Roche, as agreed to pursuant to the Roche Agreement. The Company is eligible to receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_927d6f56-99ad-49c1-86d8-ddacaac25291" contextRef="C_fc472ea4-5bfc-43cf-afcc-45da63beb221" name="rptx:MilestonesPayments" unitRef="U_USD" scale="9" decimals="-6" format="ixt:numdotdecimal">1.172</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion in potential clinical, regulatory, commercial and sales milestones, as well as royalties on global net sales ranging from high-single-digits to high-teens, subject to certain specified reductions. Royalties are payable by Roche on a product by product and country by country basis until the later of 12 years following the first commercial sale of a licensed product in such country or the expiration of certain exclusivity rights.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Roche Agreement will expire upon the last to expire royalty term or, as applicable, the end of the U.S. co-development and profit share arrangement. Additionally, Roche may terminate the agreement for convenience in its entirety or on a product by product or country by country basis subject to certain notice periods. Either party may terminate earlier upon the other party&#x2019;s uncured material breach of the agreement or insolvency. Subject to the terms of the Roche Agreement, effective upon termination of the Roche Agreement, the Company is entitled to retain specified licenses to be able to continue to exploit the Licensed Products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed the Roche Agreement in accordance with ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and concluded that Roche is a customer within the context of the agreement. At inception, the Company identified several performance obligations under the agreement, being (i) the combination of the exclusive perpetual license to the Licensed Products and the non-exclusive license to certain companion diagnostics, (ii) the research and development activities related to the completion of the Continuing Trials, as well as (iii) the transfer of clinical trial materials on hand. The Company determined that the exclusive license to the Licensed Products and the non-exclusive license to certain companion diagnostics should be combined into one distinct performance obligation as they were not capable of being distinct from each other within the context of the agreement given both are highly interdependent of each other. The Company determined that the combined licenses, the completion of the Continuing Trials and the transfer of clinical trial materials were all capable of being distinct and were distinct within the context of the Roche Agreement given such activities are independent of each other and Roche could benefit from either separately.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the transaction price at the onset of the agreement is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86eade20-f6e3-488b-8799-f7280981a6a7" contextRef="C_39535649-8458-447e-b3bd-2d67c59d8b5a" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">134.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, being the total non-refundable upfront payment received of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c59da578-adec-4e4f-81af-40968f82ef0e" contextRef="C_21132067-3295-4e05-aca1-b407f86fc88d" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">125.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, the additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b921cb96-c8ff-4b77-b36a-e780054b65c2" contextRef="C_39535649-8458-447e-b3bd-2d67c59d8b5a" name="rptx:CollaborationRevenueReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million payment received and the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_946e24b6-7963-42ec-ad45-214a242f2765" contextRef="C_0432e0bc-120b-4705-8281-2d047c8d1406" name="rptx:CollaborationRevenueReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million received for the transfer of clinical trial materials. Additional consideration is to be paid to the Company upon the achievement of multiple clinical, regulatory and sales milestones. The Company utilized the most likely method approach and concluded that these amounts were constrained based on the probability of achievement. As such, the Company excluded this additional consideration from the transaction price.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has allocated the transaction price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4b98b1d-4bee-4a93-a1ff-ccd722d7b992" contextRef="C_39535649-8458-447e-b3bd-2d67c59d8b5a" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">134.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to each performance obligation based on the relative stand-alone selling price of each performance obligation at inception. The Company has determined the estimated stand-alone selling price at contract inception of the combined licenses by applying a probability adjusted discounted cashflow model which forecasts future cash flows related to the licenses. The Company considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success, discount rate and the time needed to commercialize a product pursuant to the license. The Company has determined the estimated stand-alone selling price at contract inception of the research and development activities required to complete the Continuing Trials based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to complete the Continuing Trials included the length of time required, the internal hours as well as external costs expected to be incurred, the number of patients and the number of clinical and investigator sponsored trials. The Company has determined the stand-alone selling price of the clinical trial materials transferred based on the purchase price from external vendors, without applying a markup as the materials have a built-in margin from the external vendors. </span><span><ix:nonNumeric id="F_1df85dc8-30fd-43dc-a4ff-9fe29708e9b1" contextRef="C_ceb724a0-d094-4e75-ad7c-5458548dadc5" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" escape="true" continuedAt="F_1df85dc8-30fd-43dc-a4ff-9fe29708e9b1_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the relative stand-alone selling price, the allocation of the transaction price to the separate performance obligations was as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_1df85dc8-30fd-43dc-a4ff-9fe29708e9b1_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.153%;"></td>
        <td style="width:9.002%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.845000000000002%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transaction price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Combined licenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36a58c1c-888b-4f75-978c-509f4664a093" contextRef="C_03151e6d-e0d6-4a61-8ae6-3e23b66eafd4" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">105,327</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Completion of Continuing Trials</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1aba1e6-42f6-4a29-9fb3-e2f7dab87927" contextRef="C_3f5323db-0b40-4adb-a988-178988f085e5" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,585</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transfer of clinical trial materials</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2e8996b-7377-4645-9dc9-7242745ea20b" contextRef="C_218b32a4-44d8-4f35-a8e8-8985b015f2a3" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,714</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total transaction price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac89b97a-e7a3-465d-a6c3-78c2300b30dd" contextRef="C_94ac4eab-f661-466e-ad3c-d52a1dad0918" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134,626</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue associated with the combined licenses was recognized at a point in time upon the transfer of the licenses to Roche on the effective date of the Roche Agreement as the Company concluded that the combined licenses were a functional intellectual property license that Roche could benefit from as of the time of grant. Revenue associated with the completion of the Continuing Trials has been deferred and will be recognized on a proportional performance basis over the period of time to complete the Continuing Trials, being estimated at within </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_175938c0-ef22-4a5b-8b64-cde920401af9" contextRef="C_60665830-af4d-49c6-8e90-64c9fd7235be" name="rptx:EstimatedPeriodOfCompletionOfTrialsToGetRevenue" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months of the effective date, using input-based measurements of total costs of research and development incurred to estimate the proportion performed. Progress towards completion is remeasured at the end of each reporting period. Revenue associated with the transfer of clinical trial materials was recognized at a point in time upon delivery of the clinical trial materials to Roche in the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecdf1736-a513-4026-b7f3-501d82ad7cb0" contextRef="C_21132067-3295-4e05-aca1-b407f86fc88d" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">116.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, 2022 as revenue associated with the Roche Agreement, of which </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ce18d2f-6b3a-4c6e-bbb8-7e776f586b8a" contextRef="C_455d4f5d-1b00-4d1c-8c1b-ced04b5ee882" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">105.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> related to the grant of the combined licenses, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f5724a8-f370-4028-9ae8-0645f2c23c62" contextRef="C_4ea84029-b253-493e-8495-d6a1f2b4c88a" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> related to the clinical trial materials transferred, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7b56fad-0c90-461c-aca7-914c68b76c29" contextRef="C_d3cd720c-8de2-4d2b-865b-f5dd9deaa416" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> related to the partial recognition of deferred revenue for research and development services performed towards the completion of the Continuing Trials during the period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6916cb26-67bc-4ec4-a026-a6412199f2ad" contextRef="C_39535649-8458-447e-b3bd-2d67c59d8b5a" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (December 31, 2021 - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbc2660b-19c3-4f93-94e7-e2db4418cba5" contextRef="C_882c43fd-0865-4bcc-8ec1-4fcf0c9a4cb3" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) of deferred revenue related to the Roche Agreement, of which </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69acf790-605e-4658-82c7-e2863453aab7" contextRef="C_39535649-8458-447e-b3bd-2d67c59d8b5a" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (December 31, 2021 - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52ddf445-e2ae-494b-989b-fa153b3355b5" contextRef="C_882c43fd-0865-4bcc-8ec1-4fcf0c9a4cb3" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) was classified as current and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_962968cd-e63b-47de-a0dd-9c8e941d6c1e" contextRef="C_39535649-8458-447e-b3bd-2d67c59d8b5a" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (December 31, 2021 - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75d84c27-5be8-4322-a1f3-0993cb8dcee4" contextRef="C_882c43fd-0865-4bcc-8ec1-4fcf0c9a4cb3" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) was classified as non-current in the consolidated balance sheet based on the period the services to complete the Continuing Trials are expected to be performed.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bristol Myers Squibb</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2020, the Company entered into a collaboration and license agreement (the &#34;BMS Agreement&#34;) with Bristol-Myers Squibb Company (&#x201c;Bristol-Myers Squibb&#x201d;), pursuant to which the Company and Bristol Myers Squibb have agreed to collaborate in the research and development of potential new product candidates for the treatment of cancer. The Company is providing Bristol Myers Squibb access to a selected number of its existing screening campaigns and novel campaigns. The Company is responsible for carrying out early-stage research activities directed to identifying potential targets for potential licensing by Bristol Myers Squibb, in accordance with a mutually agreed upon research plan and will be solely responsible for such costs. The collaboration consists of programs directed to both druggable targets and to targets commonly considered undruggable to traditional small molecule approaches. Upon Bristol Myers Squibb&#x2019;s election to exercise its option to obtain exclusive worldwide licenses for the subsequent development, manufacturing and commercialization of a program, Bristol Myers Squibb will then be solely responsible for all such worldwide activities and costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The BMS Agreement was subsequently amended in July, September and November 2020 to include additional campaigns to the list of existing campaigns from which Bristol Myers Squibb may select campaigns under the agreement and to enable unblinding of a Bristol Myers Squibb alliance manager in order to streamline the collaboration and selection process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the BMS Agreement, Bristol Myers Squibb paid the Company an initial nonrefundable upfront fee payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da34742b-9626-4df5-b226-50a23a776f6b" contextRef="C_2aca0240-4cad-4cad-b715-46c7dbbe4758" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in June 2020. The Company is entitled to receive, on a program-by-program basis, option exercise fees ranging in the low six figures depending on the nature of the applicable program. Bristol Myers Squibb also has the right to retain rights to certain back-up programs in exchange for a one-time payment in the low eight figures per program. The Company is also entitled to receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36429b38-97c2-440b-a486-6a9d069adcc1" contextRef="C_2a16f0b2-09c2-4e09-be6e-37e84f297dcd" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">301.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in total milestones on a program-by-program basis, consisting of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a84d3b2-8aac-4be0-ae7f-968355597e45" contextRef="C_f2334817-ca3c-48d5-8771-4bdef45705e6" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">176.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate for certain specified research, development and regulatory milestones and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6425d77-9243-4c79-bce6-6dc768d8d5e9" contextRef="C_ef8a6a09-6b50-4f94-bb7e-8070837f1e1b" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">125.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate for certain specified commercial milestones. The Company is further entitled to a tiered percentage royalty on annual net sales ranging from high-single digits to low-double digits, subject to certain specified reductions. Royalties are payable by Bristol Myers Squibb on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On a program-by-program basis, prior to the earlier of such program ceasing to be included under the BMS Agreement and expiration of the last to expire royalty term for such program, the Company, alone and with third parties, is prohibited from researching, developing, manufacturing and commercializing products that are directed to the applicable target for such program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has provided Bristol Myers Squibb with certain, limited rights to first negotiation if the Company determines to divest, license or collaborate with others regarding certain existing programs, including in the event that the Company receives an unsolicited offer to do so. The right of first negotiation expressly excludes any potential change of control transaction, as defined in the agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The collaboration term will expire </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4d35b2de-6e03-41ac-9082-abda559f19c4" contextRef="C_805bc016-191e-4564-9965-a49c941c6abe" name="rptx:CollaborationTermExpirationPeriod" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months after the effective date of the agreement. The BMS Agreement will expire, assuming that Bristol Myers Squibb has exercised at least one option for a program, on a licensed product-by-licensed product and country-by-country basis on expiration of the applicable royalty term and in its entirety upon expiration of the last royalty term. Either party may terminate earlier upon an uncured material breach of the BMS agreement by the other party, or the insolvency of the other party. Additionally, Bristol Myers Squibb may terminate the BMS Agreement for any or no reason on a program-by-program basis upon specified written notice.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed the BMS Agreement in accordance with ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and concluded that Bristol Myers Squibb is a customer based on the agreement structure. At inception, the Company identified several performance obligations under the BMS Agreement, being (i) research activities for each campaign over the collaboration term, as well as (ii) a selected number of material rights associated with options to obtain exclusive development, manufacturing, and commercial licenses to targets identified. The Company determined that the options to obtain the exclusive development, manufacturing and commercialization licenses were material rights under ASC 606 because there are minimal amounts to be paid to the Company upon exercise of such options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the transaction price at the onset of the BMS Agreement is the total non-refundable upfront payment received of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3e8b722-4175-474d-8cfc-6ba9d98adeb5" contextRef="C_5d5cfdbd-0c58-4551-828e-64319099c53b" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Additional consideration is to be paid to the Company upon the exercise of options to license targets and future milestone payments. The Company utilized the most likely method approach and concluded that these amounts were constrained as they represent option fees and milestone payments that can only be achieved subsequent to option exercises. As such, the Company excluded this additional consideration from the transaction price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has allocated the transaction price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d979240-e402-46f3-90a9-d60dfb41b746" contextRef="C_5d5cfdbd-0c58-4551-828e-64319099c53b" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to each performance obligation based on the relative stand-alone selling price of each performance obligation at inception, which was determined based on each performance obligation&#x2019;s estimated stand-alone selling price. The Company has determined the estimated stand-alone selling price at contract inception of the research activities based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to perform the research activities included the length of time required, the internal hours expected to be incurred on the services and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">number and costs of various studies that will be performed to complete the research plan. The Company determined the estimated stand-alone selling price at contract inception of the material rights associated with options to obtain exclusive licenses to druggable targets and undruggable targets based on the fees Bristol Myers Squibb would pay to exercise these options, the probability-weighted value of expected future cash flows associated with each license related to each target and the probability that these options would be exercised by Bristol Myers Squibb. In developing such estimates, the Company also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a product candidate pursuant to the associated license. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0cf56f0a-25f4-4823-b2d5-e8472ebeb3d1" contextRef="C_78e0ac1e-933a-4450-9b1d-ff16a6fd8f1c" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" escape="true" continuedAt="F_0cf56f0a-25f4-4823-b2d5-e8472ebeb3d1_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the relative stand-alone selling price, the allocation of the transaction price to the separate performance obligations was as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_0cf56f0a-25f4-4823-b2d5-e8472ebeb3d1_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.122%;"></td>
        <td style="width:8.978%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.899%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transaction price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Research activities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c00a4de4-33da-48bf-aaa1-501d743ed5dd" contextRef="C_8f5ce4e2-c290-41fd-9af5-5d0fb88c397e" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,405</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Options to license druggable targets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41daf8d5-b035-4e36-aeb6-27b170d4fe73" contextRef="C_609633f0-8edb-44b4-852b-0714140adf5c" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,148</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Options to license undruggable targets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c20b8f3e-e114-4b59-b0a7-1cac297d40c3" contextRef="C_9e6d1afd-0b5e-467c-9164-fafb352d5632" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,447</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total transaction price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed9c4837-d886-45ab-9f88-32c7d230209a" contextRef="C_86d0da1c-aaaa-4a1a-982b-05aa91d37fd6" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue associated with the options has been deferred and will be recognized at the point in time when options to license are exercised by Bristol Myers Squibb or upon expiry of such options. Revenue associated with the research activities has been deferred and will be recognized on a proportional performance basis over the period of service for research activities, being the collaboration term, using input-based measurements of total costs of research incurred to estimated proportion performed. Progress towards completion is remeasured at the end of each reporting period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021, the Company recognized from deferred revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c74b1e91-abab-454c-9375-055e9833d805" contextRef="C_6a124d3c-84d9-4aa0-bd9c-49a33f8564bb" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_976348fb-e2ea-4a66-a343-ead498b206be" contextRef="C_404f23f3-7385-4056-868c-5316d49ea62c" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, as revenue associated with the BMS Agreement in relation to research activities performed during the period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the fourth quarter of fiscal 2022, Bristol Myers Squibb waived its rights to exercise options for druggable targets directed at two separate lesions. As a result, the Company recognized from deferred revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e934b717-4850-478c-ade5-3caabc8dec3a" contextRef="C_dcd5c372-fa91-4030-89f6-8275c0abec98" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as revenue for the year ended December 31, 2022 with regards to the amount allocated to the performance obligation from Bristol Meyers Squibb. In October 2021, the Company received notification from Bristol Myers Squibb of their option exercise for two druggable targets directed at a single synthetic lethal lesion, pursuant to the terms of the BMS Agreement. As a result, the Company recognized from deferred revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a144ac8-44a3-4615-831c-643e0c10db33" contextRef="C_847f53e5-4018-4e25-b322-9a0918e5fc97" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as revenue for the year ended December 31, 2021 with regards to the achievement of the performance obligation from Bristol Meyers Squibb and the option fees received.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08c58008-f030-4ff5-8a14-2e35aa8b9f69" contextRef="C_11682b1d-2900-4c40-ba7d-c2e787aa1c94" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">27.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (December 31, 2021 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_350fc9ba-0e36-487d-8269-e84556332d57" contextRef="C_6fb87044-e5c7-417d-afb8-2aee7d0f78a4" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">42.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) of deferred revenue related to the BMS Agreement, of which </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04f661ba-a9b7-4757-8ac7-b693f37ae395" contextRef="C_11682b1d-2900-4c40-ba7d-c2e787aa1c94" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">27.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (December 31, 2021 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_052b5c60-8e02-4577-8ebc-cfebb3eaf3b4" contextRef="C_6fb87044-e5c7-417d-afb8-2aee7d0f78a4" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) was classified as current and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d747680-851c-44f9-a7b5-bb53fc5f9d2c" contextRef="C_11682b1d-2900-4c40-ba7d-c2e787aa1c94" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (December 31, 2021 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_922e7413-5a34-4500-8110-32879d853e0f" contextRef="C_6fb87044-e5c7-417d-afb8-2aee7d0f78a4" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">39.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) as non-current in the consolidated balance sheet based on the period the services are expected to be performed and the expected timing of potential option exercises.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ono</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2019, the Company entered into a research services, license and collaboration agreement (the &#x201c;Ono Agreement&#x201d;) with Ono Pharmaceutical Co., Ltd. (&#x201c;Ono&#x201d;), a Japanese pharmaceutical company, pursuant to which the Company and Ono have agreed to collaborate in the research of potential product candidates targeting Pol&#x3b8; and the development of the Company&#x2019;s small molecule Pol&#x3b8; inhibitor program. The Company is primarily responsible for carrying out research activities to identify a product candidate, to be licensed to Ono, in accordance with a mutually agreed upon research plan during a research term that will end upon the earlier of the date of the first submission of an Investigational New Drug application (&#x201c;IND&#x201d;) in the United States or Japan, or the end of the research term. In the event that Ono elects to collaborate on the subsequent development and commercialization of the proposed product candidate, Ono will be then responsible for such activities in Japan, South Korea, Taiwan, Hong-Kong, Macau and the Association of Southeast Asian Nations (collectively, the &#x201c;Ono territory&#x201d;), and the Company will be responsible for all such activities in the rest of the world outside the Ono territory, including the United States, Canada and European Union.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, the Company and Ono entered into an amendment to the Ono Agreement whereby the research term, as defined in the Ono Agreement, was extended by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_749ac560-66d1-4b10-b427-d30dde09e9dd" contextRef="C_bfafee29-fc89-418f-885a-bdf98c97ba34" name="rptx:CollaborationTermExtendedPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c475b2b1-f720-4023-b318-47d955d99e21" contextRef="C_edf78ca6-0a38-4dce-a237-43ab79035e63" name="rptx:SecondAmendmentAgreement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2023, the Company and Ono entered into a second amendment to the Ono Agreement whereby the Research Term, as defined in the Ono Agreement, was extended until July 31, 2023.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Ono Agreement, the Company received non-refundable upfront payments of &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b6216e7-076a-4f71-80a6-e06c62cfbd3e" contextRef="C_84f40979-c89b-461b-ba1d-ce4f4b049543" name="us-gaap:ProceedsFromCollaborators" unitRef="U_JPY" scale="6" decimals="-6" format="ixt:numdotdecimal">900</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9ca6bd6-178b-4603-a647-fd4f127edae7" contextRef="C_84f40979-c89b-461b-ba1d-ce4f4b049543" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million), consisting of an initial upfront fee payment of &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0cb386d-3fe9-4c27-8a84-5f6dbb04487f" contextRef="C_84f40979-c89b-461b-ba1d-ce4f4b049543" name="rptx:InitialUpfrontFeePayment" unitRef="U_JPY" scale="6" decimals="-6" format="ixt:numdotdecimal">110</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_016e36a1-8a8e-4d03-bb53-a9141e13fff0" contextRef="C_84f40979-c89b-461b-ba1d-ce4f4b049543" name="rptx:InitialUpfrontFeePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) and an initial upfront research service payment of &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fba85479-cf9d-47a3-bb1e-fc6445ccbbf1" contextRef="C_a3402cc5-4f44-4db4-b2f1-72ae898426a4" name="us-gaap:ProceedsFromCollaborators" unitRef="U_JPY" scale="6" decimals="-6" format="ixt:numdotdecimal">790</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2cc38b89-00d3-4a9e-bb67-1a51e9235485" contextRef="C_a3402cc5-4f44-4db4-b2f1-72ae898426a4" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million). Additionally, in connection with the research activities to be conducted pursuant to the Ono Agreement, the Company is eligible to receive additional research service payments of up to an aggregate of &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d83bb115-5725-4880-8357-97b5219ab780" contextRef="C_378a21ae-1938-4ec4-a0a9-d3c1716ef61a" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_JPY" scale="6" decimals="-6" format="ixt:numdotdecimal">750</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85965057-60b9-427f-98f9-fe95c917dc6f" contextRef="C_378a21ae-1938-4ec4-a0a9-d3c1716ef61a" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) upon the occurrence of certain specified research triggers. The Company is also entitled to receive clinical, regulatory and commercial milestone payments of up to &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d648d45d-8c81-42e9-a42f-bef2d14d6519" contextRef="C_04b847fd-b66f-4a41-bc49-b1bd4e09b5ba" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_JPY" scale="9" decimals="-7" format="ixt:numdotdecimal">17.21</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_858d9139-7bf6-4db4-95bf-5a8e8164b228" contextRef="C_04b847fd-b66f-4a41-bc49-b1bd4e09b5ba" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">149.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) in the aggregate, plus a tiered percentage royalty on annual net sales in Ono&#x2019;s Territory ranging from high-single digits to low teens, subject to certain specified reductions. All future milestone payments and royalties are payable in U.S. dollars after conversion from Japanese yen at the then applicable rate. Additionally, upon election by Ono to collaborate on the proposed product candidate, Ono shall be responsible for a specified percentage of research and development costs for the IND-enabling studies of the selected product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed the arrangement in accordance with ASC 606 and concluded that Ono is a customer based on the arrangement structure. The Company identified a single performance obligation under the arrangement consisting of the combination of the license to develop and commercialize a selected product candidate targeting Pol&#x3b8; and associated research services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the license and research services are not distinct within the context of the contract, and the license is the predominant good or service. Accordingly, revenue is recognized in accordance with guidance for licenses, and because the license represents functional IP, it is recognized at the point in time control of the license is transferred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the transaction price at the onset of the arrangement is the total upfront payments received in the aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_677f2d62-05bf-4cd3-ab9a-083c48ebc40a" contextRef="C_378a21ae-1938-4ec4-a0a9-d3c1716ef61a" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which is recorded as deferred revenue. The future milestone payments represent variable consideration that is fully constrained at inception of the arrangement as the achievement of the milestone events are highly uncertain. The Company will reevaluate the likelihood of achievement of the milestones at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price. In October 2021 and December 2022, the Company achieved specified research triggers amounting to &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f3185f2-db08-491a-a996-d8f578b598f6" contextRef="C_0059be0f-88d6-4e76-a6ad-ac729b891744" name="us-gaap:DeferredRevenueAdditions" unitRef="U_JPY" scale="6" decimals="-6" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d91f0f6b-e0c7-4b57-a615-49916e71f17f" contextRef="C_0059be0f-88d6-4e76-a6ad-ac729b891744" name="us-gaap:DeferredRevenueAdditions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) and &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08706b6a-7693-4cec-8424-1911c54dd182" contextRef="C_7ba4f675-ecb3-4e4b-9b5d-3da50cb072d2" name="us-gaap:DeferredRevenueAdditions" unitRef="U_JPY" scale="6" decimals="-6" format="ixt:numdotdecimal">200</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c59c4e71-9642-45e0-a599-d0ed8948c644" contextRef="C_7ba4f675-ecb3-4e4b-9b5d-3da50cb072d2" name="us-gaap:DeferredRevenueAdditions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million), respectively, as research service payments provided for in the Ono Agreement. The &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2560a45-6f3d-411a-8055-9b4aa0e191e7" contextRef="C_378a21ae-1938-4ec4-a0a9-d3c1716ef61a" name="rptx:CollaborationReceivable" unitRef="U_JPY" scale="6" decimals="-6" format="ixt:numdotdecimal">200</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d89645d8-49d7-4553-878b-d0261ed4fca6" contextRef="C_378a21ae-1938-4ec4-a0a9-d3c1716ef61a" name="rptx:CollaborationReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) is included in the collaboration revenue receivable at December 31, 2022 and was subsequently received in January 2023. These amounts have been added to the transaction price as the consideration was no longer constrained. Should a product candidate be presented for selection in 2023 and Ono exercises its selection option, the Company would be entitled to receive &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a3fdd33-9427-4dcd-91ae-8c00ed5e6179" contextRef="C_d32f5d4c-c383-401d-8204-bd0f61937dfb" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_JPY" scale="6" decimals="-6" format="ixt:numdotdecimal">450</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ff3f018-a36f-4a90-825f-67a8b95c8bbd" contextRef="C_d32f5d4c-c383-401d-8204-bd0f61937dfb" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) as well as &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2a2d231-d3cc-4889-9033-0bf042e2d317" contextRef="C_9f257956-22fd-4563-8031-ee9a1b01466b" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_JPY" scale="6" decimals="-6" format="ixt:numdotdecimal">110</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f590742-a625-4f6f-9d7c-dddcf1a28caf" contextRef="C_9f257956-22fd-4563-8031-ee9a1b01466b" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) upon corresponding grant of license, for a total of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_667b03ef-5693-491a-8ad8-1da9bd8b5ed9" contextRef="C_9f257956-22fd-4563-8031-ee9a1b01466b" name="rptx:RevenueRemainingPerformanceObligationNetAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the Company classified $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_620562a3-4206-4ddc-88ec-e84ad6be6f4a" contextRef="C_378a21ae-1938-4ec4-a0a9-d3c1716ef61a" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2df493a-3f62-457f-a2b1-b5b6e5c13ed3" contextRef="C_69c1b260-1116-4599-800d-1afb2f09f79f" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) as current deferred revenue related to the Ono Agreement.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_575ff9ee-1c50-42b7-9386-777f1af85738" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. Income Taxes</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_11dff0f8-84a2-485a-bc4f-6eb983c42c75" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before the provision for income taxes consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.61%;"></td>
        <td style="width:1.604%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.043%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.615%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.128%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Canada</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb72ebf6-ab3b-412c-9082-4cc5267234b6" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">17,550</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecf1dd42-1f1a-437a-87f3-e473c4d1bcf0" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">110,433</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b03053c8-9fb3-4304-ad60-f2a596131bca" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,650</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dd47305-ceb9-4961-890a-08c2a4435d76" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,847</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac971dea-308c-4f60-a8be-609068ff6e2f" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">13,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e0ace4b-05f5-4b75-8f8a-3d74f51b000f" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">108,586</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">154</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_df27257c-06c5-44dd-ba45-c8f7d7f3fa62" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the provision for income taxes are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.844000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.163%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current income tax provision - foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39ca7506-2083-464f-8f71-896515a31c63" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,527</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ab58bfa-9834-4725-8a2f-9c9ea47cc89b" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">530</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income tax benefit - foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a77a19b-196b-40c1-9eb5-d784eaac83f0" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,620</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eac2fa1a-9858-4281-a057-637d6fc7ccbd" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,208</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b97de9c-0594-4c4d-8503-fd462590a718" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,147</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_719ba709-43b7-44a2-996c-6bf6eaa46d2c" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,678</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e25d0588-126e-4dc3-b622-0fa5d03f031c" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation between tax expense and the product of accounting income multiplied by the statutory income tax rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.818%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.501%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.605%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.48%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7efd9dbc-eed9-42ea-87d3-c60194dfcf4f" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">13,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9476d429-bfb5-4483-9dfa-fe0832c61fe8" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">108,586</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax at statutory rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d1129ae-3fe0-4519-a7df-1abbf7bdb0b5" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">26.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8090adce-bdbb-48a2-8692-da2459acf98f" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">26.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computed income tax recovery</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b04bb110-1315-44ba-8306-054b676416b0" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,684</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60847106-feb0-4d08-8d4c-55a8345be624" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,775</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect on income tax resulting from:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal investment tax credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e81730d-0121-4cbe-8f9e-38d62b0f261f" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,899</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5ac372d-a5c0-4c87-b384-0df1bf547bd1" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,093</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting charges not deductible for tax purposes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b292296-7625-4f1d-bb12-381b18c337aa" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">679</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a126834-b48d-4b48-9b53-b03cbf7fa6d6" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,078</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capital gain income</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_498e2627-12d5-4cd7-a94c-0ad2f308d0a7" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncomeTaxReconciliationCapitalGainIncomeEquityCompensation" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">13,956</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa30dad6-2da2-4943-bc64-8aa0d6c581db" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:IncomeTaxReconciliationCapitalGainIncomeEquityCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6692a99b-9bbb-453d-b542-e0b538f83053" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,492</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_322b77f0-e498-4a51-922a-f1b1d7c95654" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,220</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ba12067-1e6b-4eb6-af6b-b38b99303647" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncomeTaxReconciliationStateTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">777</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c2f6825-b5cd-4f55-a376-bd735e232f33" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:IncomeTaxReconciliationStateTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_feab9bb7-3a4e-4b42-8980-57608d4466c7" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">142</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_376895eb-8fe4-4ebd-9e62-51a5fb57c928" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">644</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_804612b7-a186-439c-9911-a159e9a8404a" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,434</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a59e5bcd-3f02-4dfc-868c-d20a5f4567d7" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,285</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71c102d7-3503-4d65-af4f-2fcc484f6b97" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,147</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60fe9412-a074-4cb6-945e-eef9e0a6c2b1" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,678</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's applicable statutory tax rate is the Canadian combined rate applicable in the jurisdictions in which the Company operates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had tax losses of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f902c92f-47d5-46a2-b4e6-6dd03d833cb3" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncomeTaxLosses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">158.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which are available to offset future taxable income in Canada. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6b5c35ae-7953-4af0-a629-c56001987bcc" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock" escape="true" continuedAt="F_6b5c35ae-7953-4af0-a629-c56001987bcc_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not recognized the tax benefit of these losses. These losses expire as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_6b5c35ae-7953-4af0-a629-c56001987bcc_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.968%;"></td>
        <td style="width:1.938%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.093%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2042</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5de9dfbd-8250-480c-bc3d-a226f3148bc4" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncomeTaxLossesExpireOne" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,279</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_543ebe95-147c-4780-81c6-2b4001b2f825" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncomeTaxLossesExpireTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93,834</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2040</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8a8a312-edd4-4668-b4e8-35bffee3e5a0" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncomeTaxLossesExpireThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2039</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77756e40-050b-4473-9dd0-dbaa6e9e3192" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncomeTaxLossesExpireFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,394</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2038</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_210dcbf1-f525-4eaf-806b-79ed172c6fd4" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncomeTaxLossesExpireFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,111</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_329f7204-18a0-4f79-83e0-7ff50cf82e72" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncomeTaxLossesExpireSix" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">883</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_052de913-b7d6-42ca-ae7f-21d3aa576cdb" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncomeTaxLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">158,501</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had Scientific Research and Experimental Development (&#x201c;SR&amp;ED&#x201d;) expenditures of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_939ed3dd-c8b3-46eb-bae4-af40ec6b6744" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:ScientificResearchAndExperimentalDevelopmentExpenditures" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">54.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for Canadian federal and Qu&#xe9;bec purposes, which have not been deducted. These expenditures are available to reduce future taxable income and have an unlimited carryforward period. SR&amp;ED expenditures are subject to verification by the tax authorities and, accordingly, the amounts may vary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had non-refundable Canadian federal investment tax credits of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42788497-2ada-4037-8fa6-b80761c100cc" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:InvestmentTaxCredits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which may be utilized to reduce Canadian federal income taxes payable. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2d3a9de2-5537-4605-8efc-86ca0bc4addc" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:SummaryOfInvestmentTaxCreditsExpireTableTextBlock" escape="true" continuedAt="F_2d3a9de2-5537-4605-8efc-86ca0bc4addc_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company has not </span></ix:nonNumeric></span><span style=""></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_2d3a9de2-5537-4605-8efc-86ca0bc4addc_1" continuedAt="F_2d3a9de2-5537-4605-8efc-86ca0bc4addc_2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the tax benefits related to the non-refundable investment tax credits. The investment tax credits </span></ix:continuation></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expire as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_2d3a9de2-5537-4605-8efc-86ca0bc4addc_2">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.919%;"></td>
        <td style="width:1.919%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.162%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2042</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63a9b84f-6312-4847-a18f-242c8424b42d" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:InvestmentTaxCreditsExpireOne" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,392</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46253b8f-5b82-40c7-99b9-73e3d4f344d5" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:InvestmentTaxCreditsExpireTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,253</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2040</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3d54c0c-d084-462e-b951-5d8c6245e4ee" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:InvestmentTaxCreditsExpireThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,702</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2039</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1dc0977f-ad2d-4a18-bd83-d1bc5305e0f6" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:InvestmentTaxCreditsExpireFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,362</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2038</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7e1bbec-d733-4224-a5a2-12fbdf45107a" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:InvestmentTaxCreditsExpireFive" unitRef="U_USD" scale="3" decimals="-3">776</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13cf81bd-c88d-4bb3-ad27-717914ebfe55" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:InvestmentTaxCreditsExpireSix" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">455</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2036</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_793c1865-85c9-43c9-a2ee-f44205c00250" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:InvestmentTaxCreditsExpireSeven" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd7f2b00-cd98-4fef-bcfb-32a4e6d3f162" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:InvestmentTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,964</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_701f2598-0d02-45ac-9896-3b5bb72aea22" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s deferred tax assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.539%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.117%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.117%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fc2dd07-afff-4d24-9343-a6e7e80d2410" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,003</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0601b1a5-cc43-40a4-968b-c8baddb2ad93" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,093</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net research and development expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_723a799f-5b1c-4d53-af98-49728cc7d9cc" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,468</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_842ef5c2-1d63-49c8-9897-5a925a421936" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,656</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share issuance costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a4d86d2-37b3-4e03-961f-8ced01e9910d" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,369</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6099783-5df1-43a2-8398-87c1d66c05cb" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,538</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net federal investment tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91e3a16c-c085-4f81-a01a-9cbaeb2d7844" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:DeferredTaxAssetsNetFederalInvestmentTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,589</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1255a91-b628-4dc2-acd4-987a67aa2f67" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="rptx:DeferredTaxAssetsNetFederalInvestmentTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,805</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d0ba5de-f0a9-4743-bec0-05f454b2d519" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_713cd1b0-9c00-4393-ade5-e5a62f2cf527" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,775</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax basis of property and equipment in excess of carrying values</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5db4e780-9f1a-4966-94ca-1a9b1525568f" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">376</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7fda231-1cfd-40de-9751-6e0be3e04ec5" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b890586-59b4-4f58-a997-dac2aa4ce031" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:DeferredTaxAssetsOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,429</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d89a9d02-13ea-46aa-92cd-5446168f721b" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="rptx:DeferredTaxAssetsOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,995</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7356c289-bdc4-4538-bf23-d834747932fd" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:DeferredTaxLiabilitiesOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,445</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99e13d9a-a5c1-4223-8b9b-4ae971e277d1" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="rptx:DeferredTaxLiabilitiesOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,950</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expense and other liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fe0e314-2970-4c3c-9f8f-db4da28ec3f3" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">785</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5cab24c-86c5-4328-9681-e0731edd1bae" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="rptx:DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">760</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20578975-e4ca-43a8-93d2-0e47e37ce5d1" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,783</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e78d32d-8feb-4a4e-a1f0-f17e640bae35" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,656</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e4f5caf-acf2-492e-88fd-29cc5f0e04b5" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="rptx:DeferredTaxAssetsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,492</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efdcf0b5-5e3a-4fa9-90f3-96ecc191553a" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="rptx:DeferredTaxAssetsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">988</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R&amp;D costs capitalized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f307eb9e-9cdc-483c-8c0d-54298748b37e" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,911</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7842e3e-1870-4b0a-919b-9b416b6a887e" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca9a57fa-277e-4ff6-ad0c-0026d578328f" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,040</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9bf3ea53-08ef-4c45-b2af-abf501bdc20c" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,226</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6882c01-c9cc-41f9-bcb5-2be296a0a2b5" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,040</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9e8b675-e3ed-4f0b-bb29-b215f5303bcb" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,606</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c88d62cc-7b1f-4183-a8de-27cbe6c3a912" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_571f3a20-632f-4606-8fe0-ce7e22c8f693" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,620</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and has determined that it is more likely than not that the Company will not recognize the benefit of its net deferred tax assets, and as a result, a valuation allowance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b4f3619-d94b-4167-b4ea-1124a496ed50" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">97.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3044163c-8452-4a3e-a9ab-c88dc934cfe9" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">62.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million has been established at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and December 31, 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has incurred net operating losses in Canada since inception and the Company's U.S. subsidiary operated profitably in the United States since its inception. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had U.S. federal and state research and development tax credit carry forwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ce97b7a-c9bb-4abf-aeb0-5682e325ef9b" contextRef="C_7f118fdb-411f-477e-a3a2-4b54c2f8d660" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which were utilized in the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company files income tax returns in Canada and in the United States. In the normal course of business, the Company could be subject to examination by federal and provincial or state jurisdictions, where applicable. There are currently no pending tax examinations. The Company may be subject to tax examination for fiscal years </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_1d4885b4-4eda-475c-a5da-596a44a20fc7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2017 to 2022</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> due to unexpired statute of limitation periods.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the provinces and states in which the Company operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">156</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when the Company&#x2019;s judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38c6322a-601b-4526-9033-511f619dac2c" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f3f646d1-039c-4bdd-a665-984003c85ecb" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> uncertain tax positions have been recorded in the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and comprehensive loss. As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c5ac785-44d4-4393-97df-e301b3187026" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_565d1350-9dd5-4047-bd88-e97e875ae46b" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0f4e5e36-e3b4-4ca0-afa2-05d225293258" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. Net Loss per Share</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cda8e853-aaa4-4ba1-b7a7-d31bdd813c8e" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.61%;"></td>
        <td style="width:1.604%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.043%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.615%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.128%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fcd8e087-6dfb-43d1-ae48-9d974d1b02f7" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">29,047</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c28c30ad-8351-4163-822c-5f2049716fdb" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">106,908</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average number of common shares outstanding&#x2014;basic and <br />&#160;&#160;&#160;diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d740e79-e42c-4675-913a-082108a242fb" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_1ff0b100-70fe-4689-83d6-94090610da14" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">41,922,042</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e1b2534-97af-4336-921a-db0de5bfc0cd" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_692abfe6-9271-48c9-9611-5a730051a00c" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">37,818,115</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share&#x2014;basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4d309c4-bb63-46a5-aaed-2c0c32b249e3" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_649f97e1-fbba-43bc-8d77-214b4ebf127a" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.69</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09be5b79-b9e2-4b7a-bb74-f7c5442f8ba3" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_4b82bc3b-2d1c-49c7-8f72-128792b9a7c3" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.83</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s potentially dilutive securities, which include stock options and shares issued under the ESPP, have been excluded from the computation of diluted net loss per share attributable to common shareholders as the effect would be to reduce the net loss per share attributable to common shareholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common shareholders is the same.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0f3526fb-bf45-48d9-987d-0ae9dd4685e8" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.573%;"></td>
        <td style="width:1.175%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.882%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.175%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.195%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d1a732e-2a8f-4455-8979-aa0283864402" contextRef="C_678241cd-18bd-45e5-b0fa-05a4f27297f3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,032,902</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eed3c471-1c26-474d-b24f-a72307501374" contextRef="C_fb05acb5-808b-494c-bd17-c15d87dfa489" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,322,591</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated shares issuable under the ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de7d9e78-cf80-44c3-900e-ed870627a482" contextRef="C_17e3367f-80ab-4165-a57b-7a3da73e2379" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">47,216</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac584caf-d7e0-487a-899d-6cde9b19ba43" contextRef="C_26af78f0-c117-4481-914d-922b16ea388a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">9,654</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8062bb85-8ffc-48c5-b976-f25386823e98" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. Government Assistance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company incurred research and development expenditures which are eligible for refundable investment tax credits. The refundable investment tax credits recorded are based on management&#x2019;s estimates of amounts expected to be recovered and are subject to audit by the taxation authorities. These amounts have been recorded as a reduction of research and development expenditures in the amounts of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00e8b263-c33f-4a6f-bde3-503b976caea1" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:IncreaseDecreaseInResearchAndDevelopmentExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a291e4d1-8034-43d3-8242-44c18cbf83fb" contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e" name="rptx:IncreaseDecreaseInResearchAndDevelopmentExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0629dfdc-01fd-479d-9584-2925258c81d6" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5a61653c-b3a8-492d-b207-5d4258aefa63" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#x2019;s commitments to settle contractual obligations at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, other than leases which are recognized as operating lease liabilities in the consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.919%;"></td>
        <td style="width:1.919%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.162%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89072264-a8d3-42ae-901c-bb5f6de5530f" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ContractualObligationDueInNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,090</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dac54abf-9976-453d-856a-7f60481b8b71" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ContractualObligationDueInSecondYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16f6e17c-7cf4-4026-8be9-78ead029e103" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ContractualObligationDueInThirdYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35ec2130-a8a2-431b-aab5-3f8c17fdccd8" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ContractualObligationDueInFourthYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1ad51d8-f68c-4abb-9b41-740c88b7c5d4" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ContractualObligationDueInFifthYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a31a3f99-0b60-46f4-86a5-75aff0e9e8bb" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ContractualObligationDueAfterFifthYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6c7984e-6a55-4bc0-8600-7b4ef9280b12" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,379</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and Research Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and research agreement obligations primarily relate to a strategic collaboration agreement that was entered into with the University of Texas M. D. Anderson Cancer Center (&#x201c;MDACC&#x201d;) in March 2020. The collaboration consists of preclinical studies and clinical trials designed by the Company and MDACC with the research to be completed by MDACC. The Company has agreed to commit $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_668678e9-4335-4e2e-915f-3fec1bdf5f2a" contextRef="C_75c9b122-048e-43f5-a14f-971257b2c683" name="us-gaap:LongTermPurchaseCommitmentAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in funding for various studies over a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a73400ce-dcdb-4d1c-aabc-68fac5d0e374" contextRef="C_75c9b122-048e-43f5-a14f-971257b2c683" name="rptx:ContractualObligationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74fbefde-4aab-4e3c-8cb4-76ff381061eb" contextRef="C_0bcff83b-674d-4098-82be-f88a301739b5" name="rptx:ContractualObligationsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was paid as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company entered into an agreement with the Broad Institute, Inc. (&#x201c;Broad&#x201d;), in July 2022, under which Broad will perform specialty screening services at the Company&#x2019;s request over the course of a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f2a03a11-a564-47ee-95e1-ab0f8e22b3b8" contextRef="C_ad4b56bf-9860-4d20-8314-347221a8f5e0" name="rptx:ContractualObligationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term in exchange for payments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e87b91db-57d8-4f8d-ba36-57de3d8d69b9" contextRef="C_ad4b56bf-9860-4d20-8314-347221a8f5e0" name="rptx:ContractualObligationAmountPerYear" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per year, beginning in July 2022, totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75d98dfe-3444-4d11-bd5a-89c99c4cd62f" contextRef="C_ad4b56bf-9860-4d20-8314-347221a8f5e0" name="us-gaap:LongTermPurchaseCommitmentAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Purchase and Other Obligations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the normal course of business, the Company enters into contracts with Contract Research Organizations (&#x201c;CROs&#x201d;) and other third parties for preclinical studies and clinical trials, research and development supplies and other testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and provide for termination on 30 to 90 days&#x2019; prior written notice, and therefore are cancellable contracts. These payments are not included in the table above as the amount and timing of such payments are not known as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has further entered into license agreements under which it is obligated to make milestone and royalty payments and incur annual maintenance fees. The future milestone or royalty payments under these agreements have not been included in the table above since the payment obligations are contingent upon future events, such as achieving certain clinical and commercial milestones or generating product sales. As of December 31, 2022, the Company is unable to estimate the timing or likelihood of achieving these clinical and commercial milestones or generating future product sales (see Note 7).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indemnification Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in these consolidated financial statements as at December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bfee6f6c-0514-4ce6-a0a2-885b06df9e54" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:ForeignCurrencyDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17. Currency Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is exposed to the financial risk related to the fluctuation of foreign exchange rates and the degree of volatility of those rates. The foreign currency risk is limited to the portion of the Company&#x2019;s business transactions denominated in currency other than U.S. dollars.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company incurs a portion of its expenses in Canadian dollars, as well as other currencies to a lesser extent. A change in the currency exchange rates between the U.S. dollars relative to the Canadian dollar could have a significant effect on the Company&#x2019;s consolidated results of operations, financial position, or cash flows. The Company does not enter into arrangements to hedge its currency risk exposure, although it maintains expected Canadian dollar cash requirements in Canadian dollars to form a natural hedge.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2ce13d03-0604-41e6-a53e-459bd2556008" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:ScheduleOfFinancialPositionExposureTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is exposed to currency risk through its cash, other receivables, accounts payable, accrued expenses and other current liabilities, as well as right-of-use lease liabilities denominated in Canadian dollars as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.61%;"></td>
        <td style="width:1.604%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.043%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.615%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.128%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c96ad9a-f92f-46e3-8e6d-4f2fa2fdaf8e" contextRef="C_04d861cf-f6d2-4f55-acdf-2117513160d7" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" unitRef="U_CAD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,904</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a13c4f5f-5c60-4efa-8438-f5ced7367cec" contextRef="C_9271e61c-f687-4b91-af75-f7655d9f62a4" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" unitRef="U_CAD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,583</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credits receivable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6584a3f9-b443-4dcf-b9b9-b767ce268b14" contextRef="C_27f1745b-0673-4b14-ba25-3054bf45721c" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" unitRef="U_CAD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f685fd9-3d28-447d-b250-d58b06fdb0ca" contextRef="C_3b217459-d769-49eb-838f-22205ffafcb9" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" unitRef="U_CAD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,261</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other receivables</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3365f05-3809-417c-b66a-b6f5065c8d4f" contextRef="C_edec0475-471a-4ae7-bedf-0d8f8f6903fd" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" unitRef="U_CAD" scale="3" decimals="-3" format="ixt:numdotdecimal">851</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acf6a7d6-10a9-4515-8156-0967ec7d6832" contextRef="C_7bcf5428-90b7-43b9-ad8f-851d706606db" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" unitRef="U_CAD" scale="3" decimals="-3" format="ixt:numdotdecimal">745</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d99496c-eb5d-4cb2-85d0-4535c06e6b69" contextRef="C_cad33b29-12d6-4338-9a56-8e6337e0ac19" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" unitRef="U_CAD" scale="3" decimals="-3" format="ixt:numdotdecimal">324</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a404b8df-6f8d-4050-8961-3d84039a192c" contextRef="C_f916e232-9243-456b-b6ab-fa90b5090b81" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" unitRef="U_CAD" scale="3" decimals="-3" format="ixt:numdotdecimal">665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6915171f-794d-41dd-81b8-42db276e2017" contextRef="C_a8717ee6-9026-4027-9c4d-810f9e98e2d0" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" unitRef="U_CAD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,289</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c217e8d-68c5-4950-93b7-144445b7dc72" contextRef="C_ad1fe6be-ea8a-4207-b357-2558aad861b2" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" unitRef="U_CAD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,116</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3645cc7-2fa4-49ac-a420-4b2b33c402d4" contextRef="C_e91f697c-b5f2-425a-b238-1ed83d875ffd" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" unitRef="U_CAD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,392</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d7efea9-d107-40c0-ba6f-7c59ef4fab1d" contextRef="C_ed70d3e9-a443-422c-a3ca-f76fb5ddd9dd" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" unitRef="U_CAD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,564</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net financial position exposure</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8485ada4-700c-4f9f-88ea-ed01f5a3b5fd" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" unitRef="U_CAD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5572919a-03bc-41f8-aa71-8c0fb49eddb7" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" unitRef="U_CAD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">756</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the above net exposure at December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and assuming that all other variables remain constant, a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6caf81aa-be52-43ac-9e07-17f42d900129" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="rptx:PercentageOfDepreciationUSDAgainstCanadianDollar" unitRef="U_pure" scale="-2" decimals="2">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% depreciation of the U.S. dollar against the Canadian dollar would result in an increase of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d319c11-0f52-4cc4-b643-689d8d2af40a" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the Company&#x2019;s net loss for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also exposed to currency risk through the Ono Agreement as the Company has a collaboration revenue receivable balance as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and any future payments receivable under the Ono Agreement, if any, are denominated in Japanese yen.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_aa1fa3a8-af9b-4e69-b79a-e69d3b0f44b3" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18. Geographic Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8b81ce67-ed02-42bd-b113-24fd8953b130" contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s property and equipment, net by location was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.844000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.163%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Canada</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01f23e67-76e9-4b59-9151-f76552bd2b33" contextRef="C_9422e8ce-7702-44be-86dc-e5ed61056018" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,888</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77571108-3de8-4522-8a24-134bb83f5918" contextRef="C_209bac12-6e02-4442-87b0-25af22df7850" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,675</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1103ba9f-be99-4253-a491-20a67e48aba4" contextRef="C_98bf928f-8526-4b16-9053-723fa23a52a2" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,340</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14a487ff-a3c6-4477-a012-568120395709" contextRef="C_1eeb9ab9-2a11-42de-9a18-4d0e8bc99e37" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,929</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e92d5ef-1478-43c7-a3f1-e9f4c1382689" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b61ea5d-1214-41cd-ab5d-9a65dc59857b" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,604</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s right-of-use assets by location were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.844000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.163%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Canada</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7c0e52d-21ac-4399-840a-129f9d035ab9" contextRef="C_9422e8ce-7702-44be-86dc-e5ed61056018" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,578</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9571bf2-36d0-40cd-a16b-d775ff5b2cf6" contextRef="C_209bac12-6e02-4442-87b0-25af22df7850" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,939</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e29b242e-5eeb-4a53-b835-b941e609529a" contextRef="C_98bf928f-8526-4b16-9053-723fa23a52a2" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,793</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de2cb9f9-a4a3-4559-8590-c3a81c729749" contextRef="C_1eeb9ab9-2a11-42de-9a18-4d0e8bc99e37" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,552</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total right-of-use assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_721d6695-06c0-489e-b098-fd3aa4d75d4c" contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c946c2cc-c386-4ede-9737-def122126068" contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,491</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022 the Canadian parent company recognized revenue under its collaboration agreements of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4d20f49-480d-4694-80a4-8877e5e97df5" contextRef="C_5bca2e86-6a57-4346-8aee-8fb3b26b2aca" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (2021 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a013fc6d-0057-463e-86f4-be8052b639b6" contextRef="C_e2261616-9a81-42da-b0cb-ad4847fe864b" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) with Bristol Myers Squibb, whose headquarters are located in the United States, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee11f445-cc6d-42c3-9725-740f9f569ec5" contextRef="C_bcf5a011-b156-43a6-a346-9debd16c577f" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">116.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (2021 - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e8e4618-c729-4f4e-9934-6915dfc7bd02" contextRef="C_6fe10c4b-5340-414c-899a-6ed2280ce2c6" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) with Roche, whose headquarters are located in Switzerland.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9. Changes in and Disagreements With Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A. Controls</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, no evaluation of controls and procedures can provide absolute assurance that all control issues and misstatements due to error or fraud may occur and not be, if any, have been detected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2022 based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) (2013 framework). This evaluation included review of the documentation of controls, evaluation of the design effectiveness of controls, testing of the operating effectiveness of controls and a conclusion on this evaluation. Based on the results of its assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report does not include an attestation report of our independent registered public accounting firm regarding the effectiveness of our internal control over financial reporting due to our exemption as a smaller reporting company. Management&#x2019;s report was not subject to audit by the Company&#x2019;s registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only management&#x2019;s report in this Annual Report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the last fiscal quarter of 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B. Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9c_disclosure_regarding_foreign"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">162</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Information about Our Board of Directors&#x201d; and &#x201c;Information about Our Executive Officers&#x201d;, &#x201c;Corporate Governance, &#x201c;Delinquent Section 16(a) Reports&#x201d;, and &#x201c;Corporate Governance &#x2013; Committees of the Board of Directors&#x201d; in our definitive proxy statement to be filed with the SEC on Schedule 14A in connection with our 2023 Annual Meeting of Shareholders, or the Proxy Statement, which is expected to be filed no later than 120 days after  December 31, 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our board of directors has adopted the Repare Therapeutics Inc. Code of Business Conduct and Ethics that applies to all officers, directors and employees. This includes our principal executive officer, principal financial officer and principal accounting officer or controller or persons performing similar functions. The nominating and corporate governance committee is responsible for overseeing the Code of Business Conduct and Ethics and must approve any waivers of the Code of Ethics for our employees, executive officers and directors. The Code of Business Conduct and Ethics is available on our website at ir.reparerx.com. If we make any substantive amendments to the Code of Business Conduct and Ethics or grant any waiver from a provision of the Code of Business Conduct and Ethics to the principal executive officer, principal financial officer and principal accounting officer or controller or persons performing similar functions, we will promptly disclose the nature of the amendment or waiver on our website. Information contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report on Form 10-K, and you should not consider information on our website to be part of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11. Executi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ve Compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information required by the items is incorporated by reference to the information set forth in the sections titled &#x201c;Executive Compensation&#x201d; and &#x201c;Director Compensation&#x201d; in the Proxy Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Securities Authorized for Issuance Under Equity Compensation Plans&#x201d; and &#x201c;Security Ownership of Certain Beneficial Owners and Management&#x201d; in the Proxy Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Information Regarding the Board of Directors and Corporate Governance &#x2013; Independence of the Board of Directors&#x201d; and &#x201c;Transactions with Related Persons&#x201d; in the Proxy Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ting Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information required by this item is incorporated by reference to the information set forth in the section titled &#x201c;Independent Registered Public Accounting Firm Fees and Services&#x201d; in the Proxy Statement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(a)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following documents are filed as a part of this Annual Report:</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Financial Statements;</span></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Consolidated Financial Statements are listed in the &#x201c;Index to Consolidated Financial Statements&#x201d; under Part II, Item 8 of this Annual Report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statement Schedules:</span></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All financial statement schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes herein.</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits:</span></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The documents listed in the following Exhibit Index of this Annual Report are incorporated by reference or are filed with this Annual Report on Form 10-K, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Index</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.081%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:39.936%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:8.985%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:14.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:8.985%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:13.024%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">File Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000119312520176579/d920931dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Articles of Continuance of Repare Therapeutics Inc.</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 23, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000119312520176579/d920931dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of Repare Therapeutics Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 23, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001808158/000119312520168295/d908774dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Common Share Certificate of the registrant.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 15, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000119312520155961/d908774dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Registration Rights Agreement, by and among the registrant and certain of its shareholders, dated September 3, 2019.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 29, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000119312520155961/d908774dex43.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant Agreement by and between the registrant and BMS Strategic Portfolio Investments Holdings, Inc., dated May 26, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 29, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;4.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000156459021011011/rptx-ex44_737.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Registrant&#x2019;s Securities.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 4, 2021</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000119312520155961/d908774dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repare Therapeutics Inc. Amended and Restated Option Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 29, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000119312520155961/d908774dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Option Agreement under the Repare Therapeutics Inc. Amended and Restated Option Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 29, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001808158/000119312520168295/d908774dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of 2020 Equity Incentive Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 15, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001808158/000119312520168295/d908774dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Share Option Grant Notice and Share Option Agreement under the 2020 Equity Incentive Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 15, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001808158/000119312520168295/d908774dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Restricted Share Unit Grant Notice and Restricted Share Unit Award Agreement under the 2020 Equity Incentive Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 15, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001808158/000119312520168295/d908774dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of 2020 Employee Share Purchase Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 15, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001808158/000119312520168295/d908774dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnity Agreement by and between the registrant and its directors and officers.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 15, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001808158/000119312520168295/d908774dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between the registrant and Lloyd M. Segal, dated June 12, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 15, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001808158/000119312520168295/d908774dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between the registrant and Michael Zinda, dated June 12, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 15, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001808158/000119312520168295/d908774dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between the registrant and Maria Koehler, dated June 12, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 15, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.081%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:39.936%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:8.985%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:14.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:8.985%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:13.024%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000095017022002560/rptx-ex10_11.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between the registrant and Steve Forte, dated June 12, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1. 2022</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12++</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001808158/000119312520168295/d908774dex1014.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement by and between the registrant and NEOMED Institute, dated November 26, 2019, as amended June 5, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 15, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000119312520155961/d908774dex1015.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research Services, License and Collaboration Agreement by and between the registrant and Ono Pharmaceutical Co., Ltd., dated January 31, 2019.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 29, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000119312520155961/d908774dex1016.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated License Agreement by and between the registrant and New York University, dated July 9, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 29, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000119312520155961/d908774dex1017.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and License Agreement by and between the registrant, Repare Therapeutics USA Inc. and Bristol-Myers Squibb Company, dated May 26, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 29, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000156459020040024/rptx-ex101_64.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Collaboration and License Agreement by and between the registrant, Repare Therapeutics USA Inc. and Bristol-Myers Squibb Company, dated July 22, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 13, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000156459020053203/rptx-ex101_111.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Collaboration and License Agreement by and between the registrant, Repare Therapeutics USA Inc. and Bristol-Myers Squibb Company, dated September 24, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 12, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000156459020053203/rptx-ex102_209.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Lease Agreement by and between the registrant, the registrant and NEOMED Institute, dated June 11, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 12, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000156459021011011/rptx-ex1020_738.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment to Collaboration and License Agreement by and between the registrant, Repare Therapeutics USA Inc. and Bristol-Myers Squibb Company, dated November 20, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 4, 2021</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.20++</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000156459021043943/rptx-ex101_145.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Addendum to Lease Agreement by and between the registrant, Repare Therapeutics Inc. and NEOMED Institute, dated June 1, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 12, 2021</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.21++</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000156459021043943/rptx-ex102_144.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment to Lease Agreement by and between the registrant, Repare Therapeutics Inc. and NEOMED Institute, dated June 1, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 12, 2021</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000156459021043943/rptx-ex103_146.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fourth Amendment to Lease Agreement by and between the registrant, Repare Therapeutics Inc. and The Manufacturers Life Insurance Company, dated June 22, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 12, 2021</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">166</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.081%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:39.936%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:8.985%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:14.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:8.985%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:13.024%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.23++</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000156459021043943/rptx-ex104_177.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement by and between the registrant, Repare Therapeutics Inc. and RREEF America REIT II Corp. PPP , dated July 31, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 12, 2021</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.24</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000095017021003910/rptx-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Research Services, License and Collaboration Agreement by and between the registrant and Ono Pharmaceutical Co., Ltd., dated October 29, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 12, 2021</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.25</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000095017022002560/rptx-ex10_27.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fifth Amendment to Lease Agreement by and between the registrant, Repare Therapeutics Inc. and The Manufacturers Life Insurance Company, dated January 17, 2022.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.27</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1. 2022</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.26</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000095017022002560/rptx-ex10_28.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commencement Date Memorandum to the Lease Agreement by and between the registrant, Repare Therapeutics Inc. and RREF America REIT II Corp. PPP, dated February 25, 2022.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.28</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1. 2022</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.27</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000095017022014820/rptx-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and License Agreement by and between the registrant, Repare Therapeutics Inc. and Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd. dated June 1,2022.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 4, 2022</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.28</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000095017022014820/rptx-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Shares Sales Agreement, dated August 4, 2022, by and between and between Repare Therapeutics Inc. and Cowen and Company, LLC.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 4, 2022</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.29</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000095017022023919/rptx-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Collaboration and License Agreement by and between the registrant, Repare Therapeutics Inc. and Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd. dated October 7, 2022.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 9, 2022</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.30</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000095017022023919/rptx-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Collaboration and License Agreement by and between the registrant, Repare Therapeutics Inc. and Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd. dated October 7, 2022.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39335</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 9, 2022</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.31*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rptx-ex10_31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Amending Agreement by and between the registrant, Repare Therapeutics Inc. and NEOMED Institute, dated October 27, 2022.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.32*++</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rptx-ex10_32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement by and between the registrant, Repare Therapeutics Inc. and NEOMED Institute, dated January 1, 2023.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.33*&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rptx-ex10_33.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Research Services, License and Collaboration Agreement by and  between the registrant, Repare Therapeutics Inc. and Ono Pharmaceutical., Ltd, dated January 31, 2023.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1808158/000119312520155961/d908774dex211.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsidiaries of the registrant.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238822</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 29, 2020</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">167</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.081%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:39.936%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:8.985%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:14.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:8.985%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:13.024%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rptx-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Ernst &amp; Young LLP, an Independent Registered Public Accounting Firm.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#power_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney (incorporated by reference to the signature pages of this Annual Report on Form 10-K).</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rptx-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rptx-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rptx-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">** This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#134; Certain portions of this exhibit (indicated by asterisks) have been omitted because they are not material and would likely cause competitive harm to Repare Therapeutics Inc. if publicly disclosed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+ Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">++ Certain schedules and exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16. Form</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNAT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.915%;"></td>
    <td style="width:11.004%;"></td>
    <td style="width:4.156%;"></td>
    <td style="width:39.925%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPARE THERAPEUTICS INC.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Lloyd M. Segal</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lloyd M. Segal</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.147%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="power_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER OF </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATTORNEY</span></p>
  <p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lloyd Segal and Steve Forte, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and either of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.994%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:41.998%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:20.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Lloyd M. Segal</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer and Director</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lloyd M. Segal</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Steve Forte</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Executive Vice President, Chief Financial Officer</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Steve Forte</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Thomas Civik</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Chair of the Board of Directors</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thomas Civik</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ David Bonita, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">David Bonita, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jerel Davis, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jerel Davis, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Todd Foley</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Todd Foley</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Samarth Kulkarni, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Samarth Kulkarni, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Briggs Morrison, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Briggs Morrison, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ann D. Rhoads</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ann D. Rhoads</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Carol A. Schafer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carol A. Schafer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">170</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>rptx-ex10_31.htm
<DESCRIPTION>EX-10.31
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">EXHIBIT 10.31</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.806%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">LEASE AMENDING AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.231%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">THIS AGREEMENT </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">is entered into in the city of Montreal (Quebec) as of this October 27</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.111%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">BY AND BETWEEN</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">NEOMED INSTITUTE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, a corporation governed by the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Canada</font></p>
  <p style="margin-left:29.827%;text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Not-for-profit Corporations Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, having its principal place of business at 7171, Frederick-Banting, City of Montreal, Province of Quebec, H4S 1Z9, herein acting and represented by Matthew Carlyle, Chief Financial Officer, duly authorized as he so declares;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.074%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Hereinafter referred to as the &#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#34;)</font></p>
  <p style="margin-left:0.92%;text-indent:-41.784%;padding-left:28.893%;font-size:10.0pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.037%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">AND</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">REPARE THERAPEUTICS </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a legal person duly incorporated under the Business Corporations Act (Qu&eacute;bec), with its head office at 7210, Frederick-Banting, Suite #100, in the City of Montreal, judicial district of Montreal, Province of Quebec, Canada H4S 2A1 herein acting and represented by Christopher Kendall, VP Finance and FP&amp;A, duly authorized as he so declares;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.083%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Hereinafter referred to as the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Lessee&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and collectively with</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the Lessor the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;)</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">WHEREAS:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:0.0%;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.731%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.248972917318583%;">A.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By a lease agreement dated November 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2020 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Original Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;) between the Lessor and the Lessee, the Lessee leased for and during a term of twenty-four (24) months terminating on October 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Initial Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;), for various premises (the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Leased Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;) comprising a total rentable area of approximately two thousand, one hundred, thirty (2,130) square feet of the Building known as NEOMED INSTITUTE located at 7171, Frederick-Banting, City of Montreal, Province of Quebec, H4S 1Z9, as more particularly set out in the Original Lease.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:0.0%;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.731%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.248972917318583%;">B.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By an addendum to the Original Lease signed on June 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">First Addendum</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;) between the Lessor and the Lessee, the Lessee leased additional space to the Leased Premises for a total of approximately two thousand, five hundred, sixty-eight (2,568) square feet of the Building known as NEOMED INSTITUTE located at 7171, Frederick-Banting, City of Montreal, Province of Quebec, H4S 1Z9, as more particularly set out in the Original Lease.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:0.0%;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.731%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.248972917318583%;">C.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By an addendum to the Original Lease signed on October 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Second Addendum</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;) between the Lessor and the Lessee, the Lessee leased additional space to the Leased Premises for a total of approximately two thousand, eight hundred, thirty-two (2,832) square feet of the Building known as NEOMED INSTITUTE located at 7171, Frederick- Banting, City of Montreal, Province of Quebec, H4S 1Z9, as more particularly set out in the Original Lease.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.926%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.204%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.25263944122575%;">D.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Original Lease and the Addendums are hereinafter collectively known as the &#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#34;.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.926%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.204%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.25263944122575%;">E.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Initial Term and the Extended Term are hereinafter collectively known as the &#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#34;.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.926%;text-indent:0.0%;display:flex;margin-top:4.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.204%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.25263944122575%;">F.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Parties have agreed to amend the Lease as more particularly set out herein.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.231%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">NOW THEREFORE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, in consideration of the covenants, rights and obligations contained in this Agreement, the Parties hereto agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.926%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.204%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.25263944122575%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PREAMBLE</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The preamble shall form an integral part hereof, as if recited at length.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.926%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.204%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.25263944122575%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">AMENDMENTS TO LEASE</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.259%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.87%;min-width:5.204%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.551466274095646%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Section 2 of Schedule A of the Lease is modified such that each termination date is deleted and replaced by December 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2022, and each period is increased by two months.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.926%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.204%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.25263944122575%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">GENERAL PROVISIONS</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.259%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.731%;min-width:5.204%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.551466274095646%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Parties confirm that the Lease is in full force and effect, as modified by this Lease Amending Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.259%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.731%;min-width:5.204%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.551466274095646%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">All capitalized terms and expressions used in this Lease Amending Agreement have the same meaning as in the Lease, unless a contrary intention is expressed in this Lease Amending Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.259%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.731%;min-width:5.204%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.551466274095646%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This Lease Amending Agreement shall enure to the benefit of the Parties hereto and their respective heirs, executors, administrators, successors and assigns.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.259%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.731%;min-width:5.204%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.551466274095646%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Parties hereby acknowledge and agree that the execution hereof may be communicated by electronic transmission and that such agreement shall be deemed to be an original hereof, and shall be legal and binding upon the Parties hereto. This Lease Amending Agreement may be executed by counterparts each of which will be deemed to be an original and all of which taken together will be deemed to constitute one and the same instrument.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.773%;text-indent:-50.939%;padding-left:31.8%;font-size:10.0pt;margin-top:36.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">BALANCE OF THIS PAGE LEFT INTENTIONALLY BLANK SEE NEXT PAGE FOR SIGNATURES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, each of the parties has caused this Agreement to be executed on the date indicated hereinabove.</font></p>
  <p style="margin-left:1.92%;text-indent:0.0%;font-size:10.0pt;margin-top:7.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Lessor)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">NEOMED INSTITUTE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:44.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:1in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Matthew Carlyle</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:1in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By: Matthew Carlyle, CFO</font></p></td>
   </tr>
  </table>
  <p style="margin-left:46.24%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:15.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Lessee)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">REPARE THERAPEUTICS INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:45.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7210, Frederick-Banting</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Suite #100</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Montreal (Quebec)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">H4S 2A1</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Christopher Kendall</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By: Christopher Kendall,</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;VP Finance and FP&amp;A</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>rptx-ex10_32.htm
<DESCRIPTION>EX-10.32
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">EXHIBIT 10.32</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">AGREEMENT OF LEASE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">MADE AND ENTERED INTO IN THE CITY OF MONTREAL, PROVINCE OF QUEBEC, THIS 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DAY OF JANUARY 2023.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:24.818%;"></td>
    <td style="width:75.182%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">BY AND BETWEEN:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">NEOMED INSTITUTE,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;a corporation governed by the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Canada Not-for-profit Corporations Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, having its principal place of business at 7171, Frederick-Banting, City of Montreal, Province of Quebec, H4S 1Z9, herein acting and represented by Matthew Carlyle, CFO, duly authorized as he so declares;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">LESSOR</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">AND:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">REPARE THERAPEUTICS INC.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Business Corporations Act (Qu&eacute;bec), with its head office at 7210, Frederick-Banting, Suite #100, in the City of Montreal, judicial district of Montreal, Province of Quebec, Canada H4S 2A1 herein acting and represented by Christopher Kendall, VP Finance and FP&amp;A, duly authorized as he so declares;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">LESSEE</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">WHICH HAVE ENTERED INTO THE FOLLOWING LEASE AGREEMENT:</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE I</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>DEFINITIONS</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following expressions wherever used herein shall have the following meanings:</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201c;ADDITIONAL RENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">means the additional rent payable by the Lessee pursuant to the provisions of Section 3.2 herein, as well as all sums of money which are required to be paid by the Lessee pursuant to the provisions of this Lease other than the Base Rent.  </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">BASE RENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> means the base rent payable by the Lessee pursuant to the provisions of Section 3.1 herein.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">BUILDING</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">means the building known and designated as Neomed Institute located at 7171, Frederick-Banting, City of Montreal, Province of Quebec, H4S 1Z9.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">BUSINESS DAY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">means any day other than Saturday, Sunday or legal holidays in the Province of Quebec.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">BUSINESS HOURS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d; means from 7h00 to 19h00, Montreal time, Monday to Friday.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">ENVIRONMENTAL LAWS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d; means all legally binding laws, regulations, by-laws, orders, approvals, notices, permits and directives of a governmental authority having jurisdiction over the Property or the nature of the business of the Lessee, relating to the environment, public health and safety.    </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> &#x201c;INTEREST RATE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> means five percent (5%) per annum in excess of the prime interest rate to be charged from time to time by Bank of Montreal for commercial demand loans in Canada in Canadian funds granted to its most creditworthy borrowers, compounded monthly and reckoned from their respective due dates.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">LEASE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> means the present Lease Agreement.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201c;LEASED PREMISES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">means and comprises the premises having a total rentable square footage of three thousand four hundred and forty-five (3 445) square feet situated in the Building located on the Property, as shown on Schedule &#x201c;B&#x201d; and &#x2018;&#x2019;F&#x2019;&#x2019; attached hereto, together with 10 parking spaces, of which one parking space shall be reserved in the front parking spaces of the NEOMED INSTITUTE. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.10</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">LESSEE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> means Repare Therapeutics Inc.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">its permitted successors and assigns.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.11</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">LESSEE&#x2019;S PROPORTIONATE SHARE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> is established at seven Percent (7,0%) and means the fraction having as its numerator, the rentable square footage of the Leased Premises, and as its denominator, the rentable square footage of the Building, including the rentable area of the Leased Premises, which is deemed to be 49 220 rentable square feet.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.12</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">LESSOR</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d; means Neomed Institute, its successors and assigns.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.13</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">LESSOR&#x2019;S REPAIRS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">means the maintenance, repairs and replacements to (i) the structural elements of the Building, (ii) the roof of the Building, including the roof membrane, (iii) the exterior walls of the Building, (iv) the foundation of the Building (including footings and floor slab) (v) the exterior utility equipment, and (vi) repairs or restoration necessitated by a casualty (such as fire, flood or vandalism), unless any such repairs are required due to the negligence or fault of the Lessee.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.14</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">LESSOR&#x2019;S WORK</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d; has the meaning provided therefor at Section 4.1. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.15</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">OPERATING EXPENSES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d; means all costs, charges, impositions, expenses and outlays incurred by the Lessor in connection with the ownership, operation, maintenance, repair, renovation, replacement, insuring, management or administration of the Property and any and all installations, systems and equipment thereof. By way of example only, but without limiting the generality of the foregoing, Operating Expenses shall include all of Lessor&#x2019;s costs of maintaining the Property in a good and proper state of upkeep and repair as a prudent owner would do, including, without limiting the generality of the foregoing, the cost of all repairs, renovations, demisements, alterations, improvements and replacements effected in respect of the Property, including minor roof repairs, except for structural repairs, repairs to the foundations of any buildings, footings and floor slab, all other Lessor&#x2019;s Repairs mentioned in Section 1.14 herein, but including all snow removal and landscaping, the cost of labour, materials, services (inclusive of utilities and all applicable taxes thereto) attributable to common areas and facilities of the Property (excluding any part of such costs charged separately to lessees), utility taxes, insurance premiums and other insurance costs, deductible payments, administrative costs directly related to the operation of the Property, and all salaries, benefits and contributions in respect of the employees and other personnel engaged for the Property, any and all security services (if any), the cost of any modification, modernization, improvement or addition to the Property or to any equipment or installations or service therein or thereon, where same is required by law or where it is for the benefit or safety of the users of the Property, all reasonable expenses incurred by the Lessor in obtaining or attempting to obtain a reduction of Property Taxes, any taxes which are in </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">whole or in part computed as a function of the capital employed in respect of the Property, levied upon the Lessor as owner of the Property, whether characterized as a tax on capital or large corporations tax, and an annual management fee equal to Fifteen percent (15%) of the applicable annual Additional Rent. In regard to capital and/or structural repairs or replacements to the Building or the systems thereof, the cost of such repair or replacement shall be amortized over its useful life in accordance with generally accepted accounting principles and charged to Lessee hereunder. Furthermore, Operating Expenses includes all costs, charges, impositions, expenses and outlays incurred by the Lessor in connection with the utilities provided in the Building, the common facilities and the Leased Premises, including, but not limited to, electricity, heating and air conditioning, natural gas, reverse osmosis purified water and vacuum system in the laboratories.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following costs shall be excluded or deducted, as the case may be, from the Operating Expenses and the Lessee shall not be required to pay:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.8968727694042435%;">i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">costs related to financing or refinancing of the Property, including payments of interest on Lessor&#x2019;s debt;</font></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.8968727694042435%;">ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">any expense incurred by the Lessor for the exclusive benefit of any other lessee of the Property; or in connection with services or other benefits of a type which are not provided to Lessee but which are provided to another lessee or occupant or in connection with the leasing of space in the Property, including brokers fees or commission, legal fees and expenses, marketing and promotion costs, any lessee inducements, the cost of lease take-overs, the cost of market studies and any other fees and expenses of a similar nature;</font></div></div>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.8968727694042435%;">iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">any costs related to the acquisition of the Property;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.8968727694042435%;">iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">any reserve for bad debt or other loss of rentals;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.8968727694042435%;">v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">any costs or expenses attributable to any latent defect or construction defect in the Property or costs incurred in connection with repairs, alterations, additions, improvements, or replacements made to rectify or correct any defect in the design, materials, or workmanship of the Property;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.8968727694042435%;">vi)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost of any work which is paid for by a person other than the Lessor under a warranty obligation owed to the Lessor by such third party;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.8968727694042435%;">vii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">costs of alterations of other lessee&#x2019;s spaces, whether for initial occupancy or thereafter;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.8968727694042435%;">viii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">costs of selling, syndicating, mortgaging, or hypothecating any of Lessor&#x2019;s interest in the Property;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.8968727694042435%;">ix)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">costs incurred in connection with any disputes, including, but not limited to, any disputes between Lessor and its employees, between Lessor and property management, or between Lessor and other lessees or prospective lessees or occupants; and</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.8968727694042435%;">x)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">interest, fines, late fees, collection costs, legal fees, or penalties assessed as a result of Lessor&#x2019;s failure to make payments in a timely manner or to comply with applicable laws, including regarding the payment of taxes, or to comply with the terms of any lease, hypothec, deed of trust, ground lease, private restriction, or other agreement, except in each case where such failure of the Lessor results from the failure of the Lessee to timely comply with its obligations under this Lease.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.16</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">PARKING AREA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> means the area adjacent to the Leased Premises shown cross-hatched in blue on Schedule &#x201c;C&#x201d; attached hereto which is to be used as provided for in Article 12.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">of this Lease.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.17</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">PROPERTY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">means:</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A certain emplacement fronting on Frederick-Banting Street in the Borough of Saint-Laurent, City of Montreal, Province of Quebec, known and designated as being Lot ONE MILLION ONE HUNDRED SIXTY-THREE THOUSAND SEVEN HUNDRED NINETY-SIX (1 163 796) of the Cadastre of Quebec, Registration Division of Montreal, together with the Building (as defined above) and any other improvements thereon erected and the parking facilities serving the Building and any other improvements and bearing Civic Number 7171, Frederick-Banting, Borough of Saint-Laurent, City of Montreal, Quebec, H4S 1Z9, as same may be modified from time to time.</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.18</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">PROPERTY TAXES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> means all taxes whether special or general, rates, dues and assessments whatsoever, whether under the provisions of the Charter and by By-laws of the City of Montreal, or the Borough of Saint-Laurent, or of any other competent authority whether municipal, governmental or otherwise now charged or hereafter to be charged upon or in respect of the Property or any part thereof (excepting any income or profit taxes of the Lessor), and including, but not so as to limit the foregoing, all property taxes and assessments whatsoever, all municipal taxes, whether general or special, all local improvement taxes, all business taxes, school taxes, water taxes, garbage taxes, and similar taxes. Provided, however, that Property Taxes shall and does not include any business taxes, water taxes, garbage taxes or any other tax assessed directly to, and paid for by, lessees of the Property and not the Lessor.  In addition to the foregoing, Property Taxes shall and does not include any and all charges that are or may be charged by the relevant governmental authority in respect to water consumed by, on or about the Property.  If any such mode or method of taxation or charge is altered or varied from that in force at the beginning of the Term or should any such new tax or charge be levied or imposed on the Lessor or should the Lessor be substituted therefor then any such new tax, charge or levy shall be included in Property Taxes. Moreover, for greater certainty, if any Property Taxes are re-assessed, the Lessee&#x2019;s Proportionate Share of such Property Taxes shall be adjusted to take into account such re-assessment.  </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.19</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">REMAINDER PROPORTIONATE SHARE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d; means the proportion, expressed as a percentage, which when added to the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2019;s Proportionate Share represents One Hundred Percent (100%). For greater certainty, the &#x201c;Remainder Proportionate Share&#x201d; is intended to represent the proportion of the rentable area of Building not forming part of the Leased Premises, as comprised from time to time. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.20</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">RENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> means the Base Rent and the Additional Rent.</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.21</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">TERM</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> means the period of two (2) years and eight (8) months commencing January 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2023 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Commencement Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;) and terminating August 30</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2025 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expiration of the Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;), unless terminated prior thereto under the provisions hereof.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1.22</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">YEAR</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> means a calendar year occurring in whole or in part during the Term.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Arial;justify-content:flex-start;">ARTICLE II</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">GRANT AND NET LEASE INTENT<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">2.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessor hereby leases the Leased Premises to the Lessee, hereto present and accepting, for the Term, at the Rent, and subject to the terms and conditions herein set forth.  The Lessee acknowledges that the Lease is intended to be a net net net Lease in accordance with the custom and usage prevailing for industrial buildings in the Province of Quebec </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and accordingly, the Base Rent payable by the Lessee in virtue of these presents shall be completely net net net to the Lessor. The Lessor shall not, be responsible for any costs, expenses, impositions, outlays, or any other disbursements of any nature whatsoever arising from or relating to the Leased Premises, </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">to their use or occupation, their contents or to the business conducted therein, and </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the Lessee shall be responsible for all of these costs, expenses, outlays, or disbursements to the entire exoneration of the Lessor, unless expressly provided to the contrary herein.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE III</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>RENT</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">3.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Subject to Section 3.11 herein, the Lessee binds and obliges itself to pay to the Lessor, in lawful money of Canada, </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and in addition to any Additional Rent as may be provided for hereunder without deduction, reduction, abatement or set-off whatsoever, and without necessity of any demand therefor, the following (net net net) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Base Rent: </font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">3.1.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the First (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)  year of the Term, commencing January 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2023 and terminating on December 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2023, a Base Rent at the rate of twenty Dollars ($20,00) per square foot for rooms #2217, 2272, 2208A &amp; 2208B per annum, being a sum of two thousand and eight Dollars and thirty-three Cents ($2 008,33) per month, plus applicable taxes in accordance with Section 3.7 herein, payable in advance, without deduction or abatement, by way of equal and consecutive monthly instalments on the first day of each month;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">3.1.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the First (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)  year of the Term, commencing January 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2023 and terminating on December 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2023, a Base Rent at the rate of nine Dollars and twenty-five cents ($9,25) per square foot for rooms #2215, 2216, 2218, 2219, 2220A &amp; 2220B per annum, being a sum of four hundred and ninety-seven Dollars and ninety-six Cents ($497,96) per month, plus applicable taxes in accordance with Section 3.7 herein, payable in advance, without deduction or abatement, by way of equal and consecutive monthly instalments on the first day of each month;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">3.1.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the Second (2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)  year of the Term, commencing January 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2024 and terminating on December 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2024, a Base Rent at the rate of twenty Dollars ($20,00) per square foot for rooms #2215, 2216, 2217, 2218, 2219, 2272, 2208A, 2208B, 2220A &amp; 2220B per annum, being a sum of three </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="margin-left:13.333%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">thousand and eighty-five Dollars ($3 085,00) per month, plus applicable taxes in accordance with Section 3.7 herein, payable in advance, without deduction or abatement, by way of equal and consecutive monthly instalments on the first day of each month;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">3.1.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the Third (3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">rd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)  year of the Term, commencing January 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2025 and terminating on August 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2025, a Base Rent at the rate of twenty Dollars and sixty Cents ($20,60) per square foot for rooms #2215, 2216, 2217, 2218, 2219, 2272, 2208A, 2208B, 2220A &amp; 2220B per annum, being a sum of three thousand one hundred and seventy-seven Dollars and fifty-five Cents ($3 177,55) per month, plus applicable taxes in accordance with Section 3.7 herein, payable in advance, without deduction or abatement, by way of equal and consecutive monthly instalments on the first day of each month;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">3.1.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the First (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) and Second (2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) years of the Term, commencing January 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2023 and terminating on December 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2024, a Base Rent at the rate of nine Dollars and twenty-five cents ($9,25) per square foot for rooms #1208, 1210 &amp; 2116 per annum, being a sum of five hundred and one Dollars and eighty-one Cents ($501,81) per month, plus applicable taxes in accordance with Section 3.7 herein, payable in advance, without deduction or abatement, by way of equal and consecutive monthly instalments on the first day of each month;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">3.1.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the Third (3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">rd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) year of the Term, commencing January 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2025 and terminating on August 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2025, a Base Rent at the rate of nine Dollars and fifty-three cents ($9,53) per square foot for rooms #1208, 1210 &amp; 2116 per annum, being a sum of five hundred and seventeen Dollars ($517,00) per month, plus applicable taxes in accordance with Section 3.7 herein, payable in advance, without deduction or abatement, by way of equal and consecutive monthly instalments on the first day of each month;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">3.1.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the First (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) and Second (2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) years of the Term, commencing January 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2023 and terminating on December 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2024, a Base Rent at the rate of twenty-five Dollars ($25,00) per square foot for rooms #2232, 2232A,  2233, 2243AL, 2243L &amp; 2251 per annum, being a sum of one thousand nine hundred and sixty-four Dollars and fifty-eight Cents ($1 964,58) per month, plus applicable taxes in accordance with Section 3.7 herein, payable in advance, without deduction or abatement, by way of equal and consecutive monthly instalments on the first day of each month;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">3.1.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the Third (3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">rd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) year of the Term, commencing January 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2025 and terminating on August 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2025, a Base Rent at the rate of twenty-five Dollars and seventy-five Cents ($25,75) per square foot for rooms #2232, 2232A,  2233, 2243AL, 2243L &amp; 2251 per annum, being a sum of two thousand and thirty-two Dollars and fifty-two Cents ($2 032,52) per month, plus applicable taxes in accordance with Section 3.7 herein, payable in advance, without deduction or abatement, by way of equal and consecutive monthly instalments on the first day of each month;</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">3.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the Term, the Lessee will pay to the Lessor the Rent, in advance, in equal monthly instalments, on the first day of every month during the Term. As such, the Lessee hereby authorizes the Lessor to withdraw, from the account described in Schedule A, every first (1st) day of each month during the Term the monthly instalment of the Rent. The first payment of the Rent will be made on the first day of the Term. If the Term begins on any day other than the first, or ends on any day other than the last, of a calendar month, Rent for the fractions of a month at the beginning and at the end of the Term will be adjusted pro rata, on the basis of the actual number of days in those calendar months.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">3.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Subject to Section 3.12 herein, in addition to the Base Rent, the Lessee binds and obliges itself to pay to the Lessor, in lawful money of Canada, in each year, </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">without deduction, reduction, abatement or set-off whatsoever, and without necessity of any demand therefor,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">an Additional Rent being the aggregate of:</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">3.3.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessee&#x2019;s Proportionate Share of Property Taxes payable in accordance with the provisions of Section 3.4 below; and</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">3.3.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessee&#x2019;s Proportionate Share of the Operating Expenses for such year in accordance with Section 3.5 below.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Additional Rent for the First (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">), Second (2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) &amp; Third (3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">rd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) years of the Term is currently estimated at twenty-nine Dollars and eleven cents ($29,11) per square foot for rooms ##1208, 1210 &amp; 2116, including the management fee equal to Fifteen percent (15%) of the applicable annual Base Rent.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Additional Rent for the First (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">), Second (2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) &amp; Third (3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">rd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) years of the Term is currently estimated at thirty-eight Dollars and nineteen Cents ($38,19) per square foot for rooms #2232, 2233, 2251, 2232A, 2243AL &amp; 2243L, including the management fee equal to Fifteen percent (15%) of the applicable annual Base Rent.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Additional Rent for the First (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">), Second (2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) &amp; Third (3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">rd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) years of the Term is currently estimated at fifty-six Dollars and fifty-nine cents ($56.59) per square foot for rooms #2217, 2272, 2208A &amp; 2208B, including the management fee equal to Fifteen percent (15%) of the applicable annual Base Rent.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Additional Rent for the First (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) year of the Term is currently estimated at fifty Dollars ($50,00) per square foot for rooms #2215, 2216, 2218, 2219, 2220A &amp; 2220B, including the management fee equal to Fifteen percent (15%) of the applicable annual Base Rent.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Additional Rent for the Second (2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) year of the Term is currently estimated at fifty-four Dollars ($54,00) per square foot for rooms #2215, 2216, 2218, 2219, 2220A &amp; 2220B, including the management fee equal to Fifteen percent (15%) of the applicable annual Base Rent.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Additional Rent for the Third (3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">rd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) year of the Term is currently estimated at fifty-six Dollars and fifty-nine cents ($56.59) per square foot for rooms #2215, 2216, 2218, 2219, 2220A &amp; 2220B, including the management fee equal to Fifteen percent (15%) of the applicable annual Base Rent.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The foregoing estimate is provided to the Lessee for indicative purposes only and shall in no way limit, affect or otherwise circumscribe the provisions of this Lease concerning the calculation and payment of Additional Rent, and for greater certainty, it is understood that while the aforesaid</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">management fee, which is based on applicable annual Base Rent, is determinable in advance, the other elements of Additional Rent are only known as on an </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">ex post facto</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> basis.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">3.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Throughout the Term, Lessee shall pay, as Additional Rent, Lessee's Proportionate Share of the Property Taxes as herein below described:</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">3.4.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On or about the Commencement Date, Lessor shall invoice Lessee for Lessee&#x2019;s Proportionate Share of the Property Taxes for the then current tax year(s) or, should actual bills not yet have been received for such taxation year(s), Lessor shall estimate the amount of the Lessee's Proportionate Share of Property Taxes for the then current taxation year(s) and shall invoice Lessee therefor in equal, consecutive, monthly instalments which Lessee shall pay to Lessor in advance on the first day of each calendar month. When actual bills for all or any portion of the Property Taxes are received, Lessor shall furnish Lessee with a statement setting forth such portion thereof that is payable by Lessee pursuant to this ARTICLE III. If such amount is greater or less than the payments on account thereof theretofore made by Lessee in respect of the applicable period pursuant to this ARTICLE III, appropriate adjustments shall be made forthwith;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">3.4.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to Lessee&#x2019;s obligation to pay Lessor&#x2019;s invoices for Property Taxes when the actual bills are received as aforesaid, commencing with the month next following such invoicing Lessee shall make monthly instalments on account of future Property Taxes on the same basis as for the preceding tax year or on the basis of Lessor&#x2019;s revised reasonable estimate, as the case may be, and so on from time to time; and</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">3.4.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the first and last years of the Term (in the event same comprise less than complete tax years), the amount Lessee is required to pay on account of Lessee&#x2019;s Proportionate Share of Property Taxes shall be subject to a per diem adjustment.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">3.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Throughout the Term, Lessee shall pay, as Additional Rent, Lessee's Proportionate Share of the Operating Expenses. Prior to the commencement of each Year, or as soon thereafter as reasonably possible, the Lessor shall furnish to the Lessee an estimate of the Lessee&#x2019;s Proportionate Share of Operating Expenses. The Lessee shall pay to the Lessor on the first day of each month in advance during each Year, as Additional Rent, an amount equal to ONE-TWELFTH (1/12) of such estimated Operating Expenses applicable to such Year.  Should the first year of the Term not commence on January 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, or should the last year of the Term not terminate on December 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, then prior to the commencement of the Term, or of the last year of the Term, as the case may be, or as soon thereafter as is reasonably possible, the Lessor shall furnish the Lessee an estimate of the Lessee&#x2019;s Proportionate Share of Operating Expenses for the part of the Year in question and the Lessee shall pay to the Lessor on the first day of each month in advance during the part of the Year in question, an amount  equal to such estimates divided by the number of months during the partial Year in question.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">3.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As soon as is practicable, after</font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the end of each Year, or after the Expiration of the Term in the case the final Year, the Lessor shall furnish the Lessee with a statement </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">indicating the Lessee's Proportionate Share of the actual charges for Operating Expenses incurred for such Year </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(or part of Year, as the case may be), accompanied by a statement of the Lessor&#x2019;s chartered </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">accountant confirming  such amounts, for such Year (or part of Year, as the case may be).  The Lessee shall pay to the Lessor forthwith an amount equal to the excess of such actual charges incurred over the amount theretofore paid by the Lessee for such Year (or part of Year, as the case may be) as Additional Rent on account of Operating Expenses.  However, should the total amount paid by the Lessee to the Lessor for such Year (or part of Year, as the case may be) as Additional Rent on account of Operating Expenses exceed the Lessee&#x2019;s Proportionate Share of actual charges incurred for Operating Expenses for such applicable period, the Lessee shall receive a credit, or a reimbursement in the case of the final year, for the excess.  The appropriate adjustments shall be made between the parties hereto within thirty (30) days following the date on which the Lessor shall have furnished the Lessee with such statement.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">3.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any refunds, credits or subsidies of Property Taxes for vacant premises or resulting from reductions of such taxes attributable to there being or having been vacant premises in the Property shall not be deducted from or otherwise reduce Property Taxes and the amounts of any credits (applicable against Property Taxes or other indebtedness) or reductions of such taxes for vacant premises attributable to there being or having been vacant premises on the Property shall be included in Property Taxes, as if such refunds, credits, subsidies or reductions had not been granted, it being the intention of the parties that such refunds, credits, reductions and subsidies shall be for the sole benefit of the Lessor.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">3.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee undertakes to pay to the Lessor concurrently with the payment in respect of which such taxes are assessed, all goods and services tax (G.S.T.) and Quebec sales taxes (Q.S.T.), and all other goods and services and value added taxes in respect of the Rent, and all other sums payable by the Lessee pursuant to the Lease.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Such amounts shall not be considered as forming consideration for the rental of space or the provision by the Lessor of any service under this Lease, but shall be deemed for all other purposes to be Rent and the Lessor shall have all of the same remedies for and rights of recovery of such amounts as it has for the recovery of Rent under this Lease.  </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">3.9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee agrees that it shall have no right to claim any set off, compensation or deduction in respect of any Rent, or any other sums payable by the Lessee to the Lessor pursuant to the Lease, for any reason whatsoever.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">3.10</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">It is the intention of the parties that the lease of the Leased Premises to the Lessee pursuant to this Lease and the Rent payable by the Lessee hereunder shall be free and clear of all taxes, costs and charges arising from or relating to the Leased Premises and the Lessee shall pay all costs, charges and expenses of every kind and nature regarding the Lessee&#x2019;s operations in the Leased Premises or any part of the Property.  For greater certainty, but without limiting the generality of the foregoing, the Lessee shall be responsible for the payment, to the complete exoneration of the Lessor, of all business taxes, if any, relating to the business carried on by the Lessee in the Leased Premises or any other similar replacement taxes and/or rates which may be levied or imposed upon the business carried on in the Leased Premises or which may be payable by the Lessee as occupant thereof, whether so levied or imposed on the Lessee or the Lessor, as well as water taxes or any other tax assessed directly to, and paid for by, tenants of the Building and not the Lessor. If the mode of collecting such taxes be so altered as to make the Lessor liable therefor instead of the Lessee, the Lessee undertakes to reimburse the Lessor the amounts to be paid by the Lessor as Additional Rent on demand.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">3.11</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee agrees that should its bank refuse to honour and pay any cheque which the Lessee may have given to the Lessor in respect of any Rent, or any other sums payable by the Lessee to the Lessor pursuant to the Lease, or for any reason whatsoever, then the Lessor shall </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">have the right to charge the Lessee for a service charge to cover the cost and inconvenience suffered by the Lessor, which the parties hereto fix at Fifty Dollars ($50.00) for the first cheque which has not been honoured and paid, One Hundred Dollars ($100.00) for the second cheque which has not been honoured and paid, and One Hundred and Fifty Dollars ($150.00) for each cheque thereafter which has not been honoured and paid.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">3.12</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee&#x2019;s obligation to pay Rent shall survive the expiration or earlier termination of this Lease. Any Rent or other sum received or accepted by the Lessor and paid by anyone other than the Lessee on behalf of the Lessee shall not release or in any way affect the covenants of the Lessee set out in this Lease and shall not be deemed to constitute or evidence the Lessor&#x2019;s consent to a sublease or assignment under ARTICLE VIII herein. Any Rent or other sum received by the Lessor from or for the account of the Lessee while the Lessee is in default under this Lease may be applied at the Lessor&#x2019;s option to the satisfaction in whole or in part of any of the obligations of the Lessee then due under this Lease in such manner as the Lessor sees fit regardless of any designation or instruction of the Lessee to the contrary.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE IV</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>ACCEPTANCE OF LEASED PREMISES</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">4.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee accepts the Leased Premises &#x201c;as is&#x201d; and &#x201c;where is&#x201d;, save only for the Lessor&#x2019;s work, as set out in Schedule &#x201c;D&#x201d; attached hereto (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessor&#x2019;s Work</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;). The Lessor&#x2019;s Work shall be completed by the Lessor, at its own cost, on or prior to the Commencement Date. The Lessor&#x2019;s Work shall be deemed to be complete on the date that all Lessor&#x2019;s Work has been performed, other than any details of construction, mechanical adjustment or any other similar matter, the non-completion of which does not materially interfere with the performance by Lessee of its work. However, and notwithstanding the foregoing, the Lessor shall not be liable for damages in the event Lessor's Work, if any, in the Leased Premises has not been completed by a particular date, it being understood that this Lease shall remain in full force and effect except that Base Rent and all other sums payable hereunder shall be calculated as and from the date that the Lessor's Work has been substantially completed or would have been substantially completed had the Lessee not delayed the Lessor in the completion of Lessor's Work. The Lessor shall use commercial reasonable efforts to complete the Lessor&#x2019;s Work with all due dispatch prior to the Commencement Date.  The Lessee shall allow the Lessor to execute the Lessor&#x2019;s Work during the Fixturing Period (as defined below) without interference. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">4.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee acknowledges that the Lease is intended to be a net net net lease in which the Lessee is obligated to pay for and maintain the Leased Premises in the manner herein provided. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">4.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Subject to the provisions herein, the Lessee acknowledges having seen and examined the Leased Premises and declares itself to be fully content and satisfied therewith, and save and except for the completion of the Lessor&#x2019;s Work, the Lessee accepts the Property in its present state and condition, &#34;as is&#34; and &#34;where is&#34; and all repairs, renovations, demisements, alterations, improvements and replacements to the Leased Premises (except for Lessor&#x2019;s Repairs) as the Lessee may require from time to time during the Term, including such repairs as may be required or may be deemed advisable or necessary to enable the Lessee to obtain or maintain the permits referred to in Section ARTICLE VII below, shall be performed by the Lessor but at the sole cost and expense of the Lessee for which the Lessor will invoice the cost thereof plus an administration fee of fifteen percent (15%).  </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE V</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>PLACE OF PAYMENT AND ELECTION OF DOMICILE</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">5.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee shall pay the Rent, and all other sums which may be owing by the Lessee to the Lessor pursuant to the Lease, without notice, demand or formality whatsoever, at the office of the Lessor, at 7171, Frederick-Banting, City of Montreal, Province of Quebec, H4S 1Z9, or as directed by the Lessor.  All notices to be given to either of the parties hereto pursuant to the Lease shall be in writing and shall be validly given if either delivered personally or sent by prepaid certified mail addressed, in the case of the Lessor, at the above mentioned address, together with a copy to the Attention of Matthew Carlyle, and, to the Lessee, to the Attention: Christopher Kendall at 7210, Frederick-Banting, Suite #100, City of Montreal, Province of Quebec, H4S 2A1. Any such notice, if so mailed, shall be deemed to have been given on the fifth (5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) Business Day following the date of the mailing thereof.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE VI</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>HEATING, AIR-CONDITIONING AND UTILITIES</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">6.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessor shall be responsible for the heating and air-conditioning of the Leased Premises and for all gas, electricity and other utilities (excluding telephone) consumed in respect of the heating of the Leased Premises and for making necessary arrangements for the supply thereof. The Lessor shall pay directly to all utilities suppliers, including without limitation, Hydro-Quebec and Energir, or to any electric utility, natural gas supplier and supplier of any other utilities or, as the case may be, to their respective succeeding company, for all electricity, gas and other utilities consumed within the Leased Premises, the cost of which shall, for greater certainty, form part of Operating Expenses.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">6.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessor shall maintain, repair and from time to time replace the equipment relating to such utilities, the cost of which shall, for greater certainty form part of Operating Expenses.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">6.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessor shall heat and air-condition the Leased Premises during Normal Business Hours, excluding holidays to a reasonable degree of temperature during the appropriate seasons, but the Lessee shall hold the Lessor free and harmless from all damages, costs, losses or expenses caused directly or indirectly to the property or operations of the Lessee on the Leased Premises caused from any failure or lack of heat or air-conditioning in the Leased Premises.  The Lessor must however maintain the heating and air conditioning equipment in good working order and take necessary measures to repair same when notified by the Lessee. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE VII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>USE</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">7.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Leased Premises shall be used and occupied by the Lessee only for </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">scientific research, development activities and/or office space in connection thereof including marketing and market development</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the whole in compliance with and in conformity to all applicable governmental rules, regulations and by-laws.  The Lessee shall not use the Leased Premises, nor allow the same to be used, for any purpose other than that mentioned above, without receiving the prior written consent of the Lessor, which consent shall not be unreasonably delayed or withheld. The Lessee declares that it has obtained, and shall be solely responsible for obtaining of all necessary permits to enable it to operate in the Leased Premises, and it releases and discharges the Lessor from any and all obligations in respect thereof.  Nothing herein shall </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">be so interpreted as to imply that this Lease is in any way conditional upon the Lessee obtaining any permits or licenses for the exploitation of such business from any municipal, provincial or other authority or that the Leased Premises may otherwise be used for or be suitable for same, the Lessor making no representation and expressly disclaiming any responsibility with respect to same, and the Lessee acknowledging that the risks related to all such matters are being borne exclusively by the Lessee and at own risk and peril. The Lessee agrees and acknowledges that neither it nor any person, firm, corporation, employee, contractor or sub-contractor, whose services are retained by the Lessee, will carry on any activity in, on or about the Leased Premises that would be contrary to or in derogation from any and all federal, provincial or municipal laws, rules, regulations or by-laws including, but not restricted to, all applicable Environmental Laws.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">7.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Notwithstanding any provision to the contrary, the Lessee shall not run any business or use, allow or tolerate the use of the Leased Premises or any part thereof for any activity that in the opinion of the Lessor would tarnish the character, quality or reputation of the Lessor or the Property, or for any fraudulent or immoral practice, or carry out in the Leased Premises any activity that would be dangerous or harmful or would do anything whatsoever that could hinder the peaceable enjoyment of the other lessees or occupants of the Property or make noise or create foul odours that could inconvenience the other lessee or occupants or neighbours, or create or tolerate any losses or damages, alteration or deterioration of the Leased Premises or the Property or overload the floors in such a way as to jeopardize the structure of the Building. The Lessee, shall not, in any manner whatsoever, hold the Lessor liable for any damages or inconveniences that the Lessee may suffer due to the fault or actions of any other lessee or occupant of the Building, and the Lessee expressly waives all claims and recourses it may or could have in respect of the Lessor pursuant to Sections 1859 and 1861 of the Civil Code of Quebec. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE VIII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>SUB-LEASE AND ASSIGNMENT</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">8.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Should the Lessee desire to sub-lease the Leased Premises or any part thereof, or to assign any of its rights under this Lease, then and so often as such event shall occur, the Lessee shall give to the Lessor written notice of such desire accompanied by a copy of the offer to sub-lease, or a copy of the offer to assign, together in all cases with such financial or other information in respect of the proposed sub-lessee or assignee as the Lessor may so request.  The Lessor shall, acting reasonably, within thirty (30) days of receiving all the foregoing notify the Lessee in writing either (i) that it consents to such sub-lease or assignment, or (ii) that it does not consent to such sub-lease or assignment, or (iii) that it elects to terminate the Lease as of a date being ninety (90) days following the date of the Lessor&#x2019;s notification to the Lessee.  In such latter event, the Lease shall be deemed to have terminated as of the expiration of such ninety (90) day period, unless, within ten (10) days next following the Lessor&#x2019;s notice electing to terminate, the Lessee shall have withdrawn, by way of written notice to such effect to the Lessor, its request to sublease or assign.  Where the Lessee shall have withdrawn its request as aforesaid, the Lease shall continue in force unamended.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Where any request for sublease or assignment relates to a portion only of the Leased Premises, then, in such a case, where the Lessor shall exercise his option to terminate the present Lease as aforesaid, then the Lease shall be terminated only with respect to that portion of the Leased Premises to which the proposed sublease or assignment related. It is expressly agreed and understood that the rights so conferred to the Lessor have been freely given to the Lessor by the Lessee for valid commercial reasons. Conversely, in such circumstances where the Lessor does not elect to exercise its termination rights pursuant to subparagraph (iii) of the present section, Lessor agrees that in its consent to any request of the Lessee to a sublet or assignment pursuant to the present section shall not be unreasonably withheld, conditioned or delayed. </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">8.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Save as stipulated in Section 8.3, if, at any time during the Term, effective control of the Lessee is acquired or exercised by any person(s) or entity(ies) not having effective control of the Lessee on the date of execution of this Lease, whether pursuant to a sale of shares or other transaction or by operation of law, same shall be deemed an assignment of lease and shall be subject to the provisions of Section 8.1.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">8.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Provided that the Lessee is Repare Therapeutics Inc. or a Permitted Transferee (as defined below) thereof, that it is operating its business in the whole Leased Premises in accordance with the terms of this Lease and that it is not in default thereunder (save for a default of minor importance within the meaning of Article 1604 of the Civil Code of Qu&eacute;bec), the Lessee will have the right to sublease all or any portion of the Leased Premises and/or to assign the Lease to any entity which (i) is and thereafter remains for the remainder of the Term and any extension or renewal thereof, an affiliate of the Lessee, or of the Lessee's parent company (as &#x201c;affiliate&#x201d; and &#x201c;parent company&#x201d; are defined in the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Canada Business Corporations Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) or (ii) the resulting entity following a merger, amalgamation or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">bona fide </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">reorganization of the Lessee pursuant to which such resulting entity is the successor in and to all or substantially all of the Lessee&#x2019;s assets and activities in Canada or (iii) purchases all or substantially all of the Lessee&#x2019;s shares or assets in Canada (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Permitted Transferee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;), without the Lessor's consent, provided the following conditions are met: </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:5.204%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.204%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a written notice is given to the Lessor within fifteen (15) days of the effective date of assignment or sublease;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:5.204%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.204%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessee provides the Lessor with all relevant and reasonable documentation and information the Lessor may ask and that is available, demonstrating that the proposed assignee or sublessee complies with the foregoing conditions;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:5.204%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.204%;">c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessee and assignee or sublessee execute an agreement with the Lessor, satisfactory to the Lessor, setting forth the terms and conditions of the assignment or sublease;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:5.204%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:5.204%;">d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessee provides the Lessor with a copy of any such sublease or assignment to the Permitted Transferee;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessor will not have the right, in the circumstances of such assignment or sublet to a Permitted Transferee, to (i) recapture any portion of the Leased Premises; (ii) to delay the Lessee's subleasing efforts; (iii) sublease the Leased Premises for the Lessee; or (iv) set any other conditions that may serve to interfere with the Lessee's rights to mitigate damages, or otherwise unreasonably inhibit the Lessee's ability to sublease or assign the Lease to such Permitted Transferee.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">8.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Where the Lessor fails to respond to the Lessee&#x2019;s request to an assignment or a sublet, the Lessor shall be deemed to have refused consent.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">8.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the case of any assignment of this Lease, the assignee must unconditionally and irrevocably assume all of the Lessee&#x2019;s obligations under this Lease. In the case of any sublease granted for all or a portion of the Leased Premises, the sublessee must unconditionally and irrevocably assume all of the Lessee&#x2019;s obligations under this Lease as they apply to the portion of the Leased Premises to be sublet, for the term of such sublease.  Notwithstanding the assignment or subletting, the Lessee shall remain solidarily responsible with the assignee or sublessee, without benefit of division or discussion, for the payment of the Rent and the performance of all the other obligations of the Lessee under this Lease.  In no case shall an </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">assignment of this Lease effect novation or release the assigning Lessee from its obligations hereunder, even if the assignment is consented to by the Lessor.  At the Lessor&#x2019;s sole option, effective whenever the Lessor gives written notice to such effect to the Lessee and to the assignee or sublessee, as the case may be, and without any further formality, all rentals, sub-rentals and other amounts payable by the assignee or sublessee to the Lessee, shall be irrevocably and unconditionally assigned to the Lessor such that all sums shall be paid directly to the Lessor by the assignee or sublessee and the amount so paid will be credited against the Lessee&#x2019;s Rent under this Lease.  It is understood and agreed, however, that if the Lessor does not collect any such rentals, sub-rentals or other amounts from any assignee or sublessee, the Lessee will have no claim or defense against the Lessor in any manner whatsoever.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If this Lease is repudiated, disclaimed, disavowed, resiliated or otherwise terminated by whomsoever in connection with or as a result of the bankruptcy or insolvency of the original Lessee or any assignee or sublessee, the original Lessee and any assignee or sublessee, other than the bankrupt or insolvent person or entity, will enter into a lease upon notice from the Lessor given within sixty (60) days of the Lessor&#x2019;s knowledge of such repudiation, disclaimer, disavowal, resiliation or other termination, for a term expiring on the date this Lease would have expired but for the repudiation, disclaimer, disavowal, resiliation or other termination and upon the terms and conditions which would have applied during the remainder of the Term had this Lease not been repudiated, disclaimed, disavowed, resiliated or otherwise terminated.</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">8.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any assignment of this Lease, agreed to by the Lessor, must be prepared by the Lessor or its attorneys, and all legal fees relating to this assignment must be assumed by the Lessee. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">8.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessee hereby waives the provisions of Articles 1871, 1872 and 1873 of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Civil Code of Quebec </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">together with the provisions of Article 1870 of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Civil Code of Quebec, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">but in this latter case, only to the extent of any inconsistency with the provisions of the present Lease. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE IX</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>MAINTENANCE, REPAIRS AND ALTERATIONS  </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">9.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee shall protect all water, drain and gas pipes, water closets, sinks and accessories thereof, in and about the Leased Premises from all and any damage that the same may be subject to from any cause whatsoever; the Lessee shall keep the same free from all un-cleanliness or obstruction that might prevent the good working of the same. The Lessee shall ensure that the water-closets, sinks, drains and other sanitary conveniences of the Leased Premises shall be used only for those purposes for which each of said facilities were designed, and for no other purpose.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">9.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee shall deploy all reasonable commercial efforts to ensure that all equipment shall be kept at a sufficient distance from all walls, columns, doors, electrical panels and thermostats and shall further ensure that all exit doors and utility rooms are readily accessible at all times.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">9.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee shall ensure that it shall not render any portion of the Property in contravention of any of the governmental rules, regulations and by-laws, laws, orders, decisions, ordinances and rulings. The Lessee covenants and agrees to indemnify and hold the Lessor free and harmless from any penalty imposed for, or damages arising from, the breach of any of such rules, regulations and by-laws, laws, orders, decisions, ordinances, rulings by the Lessee or those for whom the Lessee is responsible.  </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">9.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessor, its agents and representatives shall have the right at all reasonable times, upon twenty-four (24) hours&#x2019; written notice, during the Term to enter the Leased Premises to examine the condition thereof or for any other reasons the Lessor deems necessary, acting reasonably.  </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">9.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee shall not make any alterations, improvements or additions to the Leased Premises.  Any alterations, improvements or additions that may be required by the Lessee  shall be performed by the Lessor and its contractors and the costs thereof plus an administration fee of fifteen percent (15%) of the aggregate of such costs shall be charged to Lessee as Additional Rent and shall be paid to the Lessor within ten (10) Business Days of Lessor&#x2019;s demand to that effect.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">9.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Should any Lessor&#x2019;s Repairs be deemed necessary at any time during the Term by the Lessor, the Lessor shall make and complete the same with all due diligence, and the Lessee shall permit the same to be performed without demanding any reduction of the Rent, and without any claim for damages or compensation, provided that such repairs be effected and completed with due diligence and in a manner so as to minimize disruption to the Lessee&#x2019;s operations.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">9.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee upon becoming aware of any repairs and maintenance to the Leased Premises, which shall be necessary, shall promptly furnish the Lessor with written notification thereof.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">9.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Should any repairs and maintenance to the Leased Premises be required by the fault or negligence of the Lessee or those for whom it is in law responsible, the Lessee shall reimburse the Lessor as Additional Rent the cost of all such Lessor&#x2019;s Repairs plus an administration fee of fifteen percent (15%) of the aggregate of all such costs, within ten (10) Business Days of Lessor&#x2019;s demand to that effect.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">9.9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee agrees that should any alarm (including, but not limited to, fire alarm, any sprinkler alarm or the sprinkler system) within the Leased Premises go off due to the fault or negligence of the Lessee, then the Lessee shall be responsible for, and shall indemnify and reimburse the Lessor for, all costs, expenses, fines, charges or otherwise resulting therefrom.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">9.10</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Upon Expiration or earlier termination of the Lease, the Lessee shall surrender vacant possession of the Leased Premises to the Lessor in good condition, reasonable wear and tear only excepted, in clean broom-swept condition, free of all effects of the Lessee. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE X</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>GARBAGE REMOVAL AND EXTERMINATORS</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">10.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee shall not place or leave, or permit to be placed or left, in or upon any part of the exterior of the Leased Premises or the Parking Area, any debris, garbage or refuse except as allowed by the Lessor at specific times of pick up and deposited in areas indicated by the Lessor in proper receptacles provided and placed for that purpose by the Lessee. In the case of perishable refuse or garbage, the same shall be kept in a properly refrigerated area provided by the Lessee. The Lessee shall pay for the cost of any garbage, debris and refuse removal service that may be required other than that provided by the municipality without charge should the municipality provide such a service. In the event that the Lessee fails to comply with the foregoing provisions, the Lessor, subject to Section 23.1, may rectify the situation and collect all expenses and disbursements from the Lessee as Additional Rent.</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XI</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>ENVIRONMENTAL CONCERNS</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">11.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee undertakes, with respect to the Leased Premises:</font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:7.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:8.784681696846436%;">11.1.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To comply with the Environmental Laws and to ensure on a regular basis the respect of such laws by its employees, agents, representatives and other persons or entities for whom it is responsible at law, and its suppliers, customers, representatives, invitees and other persons or entities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">who have access to the Leased Premises or any part thereof;</font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:7.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:8.784681696846436%;">11.1.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">That neither it nor its employees, agents, representatives and other persons or entities for whom it is responsible at law, nor its suppliers, customers, invitees or other  or other persons or entities who have access to the Leased Premises or any part thereof shall place, keep or store in, on, under or about the Leased Premises, except in compliance with Environmental Laws, any hazardous materials or any toxic, dangerous or radioactive substances, including any chemical or other products included in the definition of &#x201c;hazardous materials,&#x201d; &#x201c;hazardous waste,&#x201d; &#x201c;highly hazardous waste,&#x201d; &#x201c;quasi-hazardous waste,&#x201d; &#x201c;toxic substances,&#x201d; &#x201c;toxic pollutants,&#x201d; &#x201c;contaminants,&#x201d; &#x201c;pollutants,&#x201d; &#x201c;harmful products,&#x201d; or terms with similar meanings in any Environmental Law (hereinafter referred to as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Hazardous Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;), that are brought onto the Leased Premises after the Commencement Date.</font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:7.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:8.784681696846436%;">11.1.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">That it, its employees, agents, representatives and other persons or entities for whom it is responsible at law, and its suppliers, customers, invitees or other persons or entities who have access to the Leased Premises or any part thereof shall take all necessary and reasonable preventive measures in accordance with Environmental Laws to minimize the risk of leaks or spills from any Hazardous Materials used, generated, manufactured or stored in the Leased Premises by the Lessee which may in any way contaminate the Leased Premises;</font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:7.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:8.784681696846436%;">11.1.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">That it shall submit the list of Hazardous Materials used in carrying out its activities, if any, at the Commencement Date and updates thereto to the Lessor for approval once a year;</font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:7.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:8.784681696846436%;">11.1.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">That if it produces or introduces in or around the Leased Premises, any Hazardous Materials whatsoever or if the conduct of its business entails the production or presence of any Hazardous Materials whatsoever in and around the Leased Premises, then, and notwithstanding any provision to the contrary in this Lease or the law, such Hazardous Materials will be and remain its exclusive property or the exclusive property of its customers on behalf of whom it provides services and shall not become the property of the Lessor, notwithstanding the extent to which the Hazardous Materials or products containing Hazardous Materials are integrated into the Leased Premises and notwithstanding the expiration or early termination of the Lease;</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">17</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:7.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:8.784681696846436%;">11.1.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">That upon expiration or early termination of the Lease, it shall, at its expense, remove and dispose of all Hazardous Materials and all storage and other containers, in accordance with the Environmental Laws to the extent required by the Lessor;</font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:7.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:8.784681696846436%;">11.1.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">That neither it nor its employees, agents, representatives and other persons or entities for whom it is responsible at law, nor its suppliers, customers, invitees or other persons or entities who have access to the Leased Premises or any part thereof shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">in any way contaminate the Leased Premises in violation of Environmental Laws;</font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:7.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:8.784681696846436%;">11.1.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To notify the Lessor in writing of any contravention of the Environmental Laws that is in any way related to the environmental condition or quality of the Leased Premises and of any situation which, with the passage of time or otherwise, would be reasonably susceptible of leading to such a contravention, with all due dispatch in each case after the Lessee becomes aware of same;</font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:7.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:8.784681696846436%;">11.1.9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To remedy without delay any situation for which Lessee, or its employees, agents, representatives, or other persons or entities for whom it is responsible at law, or its suppliers, customers, invitees and other persons or entities who have access to the Leased Premises or any part thereof, are responsible, and which constitutes, or, which with the passage of time or otherwise, would be reasonably susceptible of leading to, a violation of Environmental Laws;</font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:7.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:8.784681696846436%;">11.1.10</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To provide the Lessor, upon request, with any available information and any documents relating to the Lessee&#x2019;s compliance with Environmental Laws as it pertains to the environmental condition or quality of the Leased Premises, including, without limitation, any relevant compliance report that is available to the Lessee; </font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:7.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:8.784681696846436%;">11.1.11</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To give the Lessor or a representative designated by the Lessor free access to the Leased Premises upon reasonable prior notice so that the Lessor may verify, subject to the obligation of the Lessor to minimize any inconvenience to the Lessee&#x2019;s activities and operations as may be caused thereby and subject to the duration and frequency of such access visits being reasonable, the Lessee&#x2019;s complying with the obligations stipulated herein; and</font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:7.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:8.784681696846436%;">11.1.12</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To indemnify and hold the Lessor harmless against aIl costs, liabilities, demands and penalties as may be incurred by the Lessor and relating directly or indirectly to any noncompliance with any Environmental Laws, or relating directly or indirectly to any breach of this ARTICLE XI, by the Lessee, its employees, agents, representatives, or other persons or entities for whom it is responsible at law, or its suppliers , customers, invitees and other persons or entities who have access to the Leased Premises or any part thereof, including, without limitation, legal costs (judicial and extra-judicial) expert fees, penalties, fines, damages and the cost of remedial work needed to conform to the Environmental Laws.</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">11.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> The </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shall indemnify, defend and save harmless the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> for and against any and all costs, claims, proceedings, liabilities, obligations, losses, demands, penalties, legal costs (judicial and extra-judicial) expert fees, penalties, fines, damages and the cost of remedial work of any kind or any nature whatsoever in connection therewith asserted against or incurred by the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> with respect to any order, decision, decree, judgment, ruling, claim or the like from or by any governmental authority under any Environmental Laws or other third party claims, in each case to the extent relating to, arising from, or in connection with any environmental conditions at, on, within, about, adjacent to, near, concerning, or affecting the Leased Premises, including but not limited to any Hazardous Materials or contamination and/or release or migration occurring at, on, upon, into, within, under, migrating to or from, about, adjacent to, near, or affecting the Leased Premises and that first occurred at any time from and after the Commencement Date and during the Term that is caused or permitted by the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> or the operations of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> or its employees, agents, contractors and those for whom it is responsible or those acting under its authority or control.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>PARKING AREA</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">12.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee may occupy nine (9) parking spaces in the zone indicated in Schedule &#x201c;C&#x201d;, and one (1) parking space in the front parking spaces of the NEOMED INSTITUTE, for its employees and visitors. The front parking space will have to be paid for by the Lessee as Additional Rent at a cost of five hundred Dollars ($500) per month during the Term. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Arial;justify-content:flex-start;">ARTICLE XIII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">13.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Throughout the Term, the Lessee shall take out and keep in force at its sole cost and expense:</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">13.1.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An &#x201c;all risks&#x201d; insurance policy for two million dollars ($2,000,000) against fire, equipment breakage, operating losses and other claims generally covered by such a policy, at all times covering the full replacement value of the Lessee&#x2019;s assets in the Leased Premises, leasehold and other improvements made by the Lessee to the Leased Premises as well as any other asset for which the Lessee is legally responsible or assets installed by the Lessee or on its behalf on the Property.</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">13.1.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A public liability insurance policy covering bodily injury, property damage, any liability assumed by the Lessee pursuant hereto and any liability arising from activities carried out by the Lessee and any other person in the Leased Premises, and work performed by the Lessee or by any other person, including persons for whom the Lessee is legally responsible, in any part of the Property.</font></div></div>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This policy shall be taken out for an inclusive limit of no less than two million dollars ($2,000,000) for each claim involving bodily injury, death or property damage, or for a higher amount, which amount the Lessor may reasonably require, from time to time.</font></p>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">13.1.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A business interruption insurance in such amounts as will reimburse the Lessee for direct or indirect loss of earnings attributable to all perils insured </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="margin-left:13.333%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">against by the Lessee hereunder, including without limitation loss of Rent for a minimum period of indemnity of three (3) months.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">13.1.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">All insurance required to cover environmental risks.</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">13.1.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any other insurance policy that the Lessor may reasonably require, from time to time.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">13.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">All insurance policies shall (i) be in form satisfactory to the Lessor, (ii) be placed with insurers reasonably acceptable to the Lessor, and (iii) provide that they will not be modified, cancelled or permitted to lapse unless the insurer notifies the Lessor in writing at least thirty (30) days prior to the date of modification, cancellation or lapse.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">13.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Each insurance policy shall name the Lessor and any other party required by the Lessor as an additional insured, as its/their interest may appear.  Each comprehensive general liability insurance policy shall contain a provision of cross-liability and severability of interests as between Lessor and Lessee.  All other insurance policies including, without limitation, the Lessee&#x2019;s all risk property damage insurance shall contain a waiver of subrogation rights which the Lessee&#x2019;s insurers may have against the Lessor, the Lessor&#x2019;s insurers, and persons under the Lessor&#x2019;s care and control.  The Lessee hereby releases and waives any and all claims against the Lessor and those for whom the Lessor is in law responsible with respect to occurrences required to be insured against by the Lessee hereunder or otherwise insured by Lessee.  The Lessee shall from time to time furnish the Lessor, upon the Lessor&#x2019;s request, with certificates of insurance reflecting (or, where the Lessor specifically requires, certified copies of) all such insurance policies and renewals thereof.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">13.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee agrees that should the Lessee fail to take out or keep in force such insurance at any time during the Term, the Lessor shall have the right to do so and to pay the premiums therefor.  In such event, the Lessee shall reimburse the Lessor the amounts paid as premiums and applicable taxes thereon as Additional Rent on demand.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">13.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Notwithstanding the express or implicit obligation of the Lessor to insure and notwithstanding any obligation on the part of the Lessee to contribute to the payment of Lessor&#x2019;s premiums as contemplated by the provisions of this Lease, Lessee acknowledges that no insurable interest is conferred upon the Lessee under any of the Lessor's insurance policies and that the Lessee shall have no right to recover any proceeds thereunder or to claim any right or title to such proceeds.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">13.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee shall not keep, use or store, or allow to be kept, used or stored, in the Leased Premises any materials, nor shall the Lessee commit or allow to be committed any acts, which will increase the cost or rate of insurance on the Property against fire or other perils.  Should the cost or rate of insurance on the Property or any portion thereof be increased by reason of the Lessee&#x2019;s use or occupation of the Leased Premises or by reason of any violation of any of the foregoing provisions, the Lessee undertakes to reimburse the Lessor an amount equal to such increase and applicable taxes thereon. The Lessee further undertakes to indemnify the Lessor from all demands made by any lessee of the Property should their cost or rate of insurance be increased by reason of the Lessee&#x2019;s use or occupation of the Leased Premises or by reason of any violation of the foregoing by the Lessee. All monies payable by the Lessee to the Lessor pursuant hereto shall be deemed Additional Rent payable on demand.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">13.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If the occupancy of the Leased Premises or the conduct of business therein or any acts or omissions of the Lessee in the Leased Premises or any part thereof, causes or results in any </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">increase in premiums of the insurance carried from time to time by the Lessor with respect to the Property, the Lessee shall pay any such increase in premiums and applicable taxes thereon as Additional Rent ten (10) Business Days after invoices for such additional premiums and applicable taxes thereon are rendered by the Lessor.  In determining whether increased premiums are caused by or result from the use and occupancy of the Leased Premises, a schedule issued by the organization computing the insurance rate on the Property showing the various components of such rate shall be conclusive evidence of the several items and charges which make up such rate. The Lessee shall comply promptly with all requirements and recommendations of the Insurer&#x2019;s Advisory Organization of Canada (or any successor thereof), or of any insurer now or hereafter in effect pertaining to or affecting the Leased Premises and the Property. The Lessee hereby acknowledges that said payment does not form part of the fixed Operating Expenses as per these presents.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">13.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee will indemnify the Lessor and save it harmless from any and all losses or claims, actions, demands, liabilities and expenses in connection with loss of life, personal injury and/or damage to or loss of property: (a) occasioned or caused wholly or in part by any act or omission of the Lessee or anyone for whom it is in law responsible; or (b) arising from any breach by the Lessee of any provisions of this Lease.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">13.9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessor will indemnify the Lessee and save it harmless from any and all losses or claims, actions, demands, liabilities and expenses in connection with loss of life, personal injury and/or damage to or loss of property: (a) occasional or caused wholly or in part by any act or omission of the Lessor or anyone for whom it is in law responsible; or (b) arising from any breach by the Lessor of any provisions of this Lease.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">13.10</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Each of the Lessor and the Lessee releases the other and waives all claims against the other and those for whom the other is in law responsible with respect to occurrences insured against or required to be insured against by the releasing party, whether any such claims arise as a result of the negligence or otherwise of the other or those for whom it is in law responsible, subject to the following:</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">13.10.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">such release and waiver shall be effective only to the extent of proceeds of insurance received by the releasing party or proceeds which would have been received if the releasing party had obtained all insurance required to be obtained by it under this Lease (whichever is greater) and, for this purpose, the Lessee&#x2019;s or the Lessor&#x2019;s deductible amounts under the Lessee&#x2019;s or Lessor&#x2019;s insurance shall be deemed to be proceeds of insurance received; and</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">13.10.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">to the extent that both parties have insurance or are required to have insurance for any occurrence, the Lessee&#x2019;s insurance shall be primary.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XIV</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>DAMAGE OR DESTRUCTION</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Provided, and it is hereby expressly agreed that if and whenever during the Term hereby leased, or any renewal thereof, the Property or the Leased Premises shall be destroyed or damaged by fire, lightning or tempest, or any of the other perils required to be insured against under the provisions of this Lease, then and in every such event:</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">14.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If the damage or destruction is such that the Leased Premises, or the Property, is rendered wholly or partially unfit for occupancy or it is impossible or unsafe to use and occupy and if in either event the damage in the opinion of the Lessor, notice of which is to be given to the Lessee within thirty (30) days of the Lessor being given access to the affected portions of the Property by the competent authorities following the happening of such damage or destruction, cannot be repaired with reasonable diligence within two hundred and seventy (270) days from the happening of such damage or destruction, then either the Lessor or the Lessee may within ten (10) days next succeeding the giving of the aforementioned notice by the Lessor, terminate this Lease by giving to the other notice in writing of such termination, in which event this Lease and the term hereby leased shall cease and be at an end as of the date of such destruction or damage and the Rent and all other payments for which the Lessee is liable under the terms of this Lease shall be apportioned and paid in full to the date of such destruction or damage. In the event that neither the Lessor nor the Lessee so terminate this Lease, the Lessor shall repair the Property with all reasonable speed and the Rent hereby reserved shall abate from the date of the happening of the damage until the damage shall be made good to the extent of enabling the Lessee to use and occupy the Leased Premises. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">14.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If the damage be such that the Leased Premises is wholly unfit for occupancy, or if it is impossible or unsafe to use or occupy it, but, if in either event, the damage, in the opinion of the Lessor, can be repaired with reasonable diligence within two hundred and seventy (270) days of the happening of such damage, the Lessor is to give notice of its decision to repair to the Lessee within thirty (30) days from the Lessor being given access to the affected portions of the Property by the competent authorities following the happening of such damage and the Rent hereby reserved shall abate from the date of the happening of such damage until the damage shall be made good to the extent of enabling the Lessee to use and occupy the Leased Premises and the Lessor shall repair the damage with all reasonable speed unless the damage or destruction is due to the acts or omissions of the Lessee or for those whom the Lessee is at law responsible in which case there shall be no abatement of Rent.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">14.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If, in the opinion of the Lessor, the damage can be made good, as aforesaid, within two hundred and seventy (270) days of the happening of such destruction or damage and the damage is such that the Leased Premises are capable of being partially used for the purposes for which it is hereby leased, then until such damage has been repaired the Rent shall abate in the proportion that the Leased Premises is rendered unfit for occupancy bears to the whole of the Leased Premises and the Lessor shall repair the damage with all reasonable speed unless the damage or destruction is due to the acts or omissions of the Lessee or for those whom the Lessee is at law responsible in which case there shall be no abatement of Rent.  Nothing herein contained shall be construed to oblige the Lessor to repair or reconstruct any alterations, improvements or property of the Lessee. On the contrary, all other improvements in and to the Leased Premises shall be the responsibility of Lessee who shall be obliged to repair and re-fixture to a standard at least equivalent to that which existed prior to the date of damage or destruction, to the extent of the proceeds of insurance received by Lessee in respect to its property and improvements.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">14.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Should any hypothecary creditor who may have an interest in any insurance proceeds refuse to permit the use of such proceeds for the repair, replacement, rebuilding and/or restoration as hereinabove provided and for the payment of amounts expended for such purposes, then the Lessor's obligation to repair or rebuild as provided for hereinabove shall cease and shall be null and void and the Lease shall be cancelled effective as of the date of the damage, unless the Lessor, at the Lessor's sole option, chooses to repair and rebuild in which latter event, Rent shall abate from the date of the happening of such damage, until the damage shall be made good to the extent of enabling the Lessee to use and occupy the Leased Premises.</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">14.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Should the Lessor fail to complete such repair or restoration to the Leased Premises for any reason whatsoever within the delay set forth in Paragraph 14.1 above, the Lessee may terminate the Lease by written notification to the Lessor to be given within thirty (30) days following the expiration of the two hundred and seventy (270) day period mentioned above, which termination shall become effective at the expiry of such thirty (30) days unless the repair/restoration shall have then been substantially completed.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">14.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In no event shall the Lessor be liable to the Lessee for any loss or damage caused by damage or destruction, or caused by any delay in the restoration or repair, subject to Lessee&#x2019;s right to terminate the Lease pursuant to section 14.5 herein.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XV</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>SIGNS</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">15.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee has no right to install any sign on the exterior of the Building or on any part of the Property. The Lessee shall have the right from time to time during the Term to display and maintain a sign at the entrance of its Leased Premises to advertise its business, subject to the Lessor&#x2019;s prior written approval with respect to the appearance, construction and size of the sign, and which approval shall not be unreasonably withheld. Any such sign shall be dignified in appearance and shall comply with all applicable laws, by-laws, rules and regulations. The Lessor will remove the sign at the termination of the Lease, and the costs of any repair resulting from the removal of such sign shall be at the sole cost of the Tenant.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XVI</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>INTEREST</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">16.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee shall pay to the Lessor interest calculated at the Interest Rate on all overdue payments of Base Rent, of Additional Rent, and of all other sums which may be owing by the Lessee to the Lessor pursuant to the Lease, calculated from the due date of the amount in question to the date of payment, compounded monthly.  Overdue interest shall also bear interest at the Interest Rate.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XVII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>NO TACIT RENEWAL</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">17.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Subject to the Lessee&#x2019;s option to renew provided herein, the Lease shall terminate </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">ipso facto</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> without notice or demand at the Expiration of the Term or upon earlier termination in accordance with this Lease, and any continued occupation of the Leased Premises by the Lessee shall not have the effect of extending the Term or renewing the Lease for any period of time, the whole notwithstanding the provisions of Article 1879 of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Civil Code of Quebec</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Should the Lessee continue occupation of the Leased Premises beyond the Expiration of the Term, the Lessee shall be presumed to occupy the Leased Premises under a tenancy from month to month in consideration of a monthly Rent equal to the aggregate of  (i) Two Hundred (200%) of the monthly Base Rent payable by the Lessee to the Lessor during the last month of the Term, plus (ii) the Additional Rent payable by the Lessee to the Lessor during the last month of the Term, plus (iii) all other sums payable by the Lessee to the Lessor pursuant to the provisions of the Lease.  The foregoing month to month tenancy is without prejudice to the Lessor&#x2019;s rights to evict the Lessee by force, by injunctive proceedings or otherwise.</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XVIII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>OVERLOADING</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">18.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee shall not bring or cause to be brought into the Leased Premises any machinery, equipment or other effects that by reason of their weight, size or otherwise might damage the Leased Premises or overload the electrical, mechanical or plumbing systems of the Leased Premises, or the floors, ceilings, walls, columns, or any other part of the Leased Premises.  The Lessee hereby assumes responsibility for all damage resulting therefrom.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XIX</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>GLASS AND WINDOW PANES</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">19.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessor shall replace any glass or window panes in the Leased Premises that may be broken, cracked or damaged during the Term and the cost thereof shall be included in the Operating Expenses.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XX</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>NO ABATEMENT OR REDUCTION OF RENT</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">20.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There shall be no abatement from, nor reduction of, nor compensation of any kind or nature whatsoever, with respect to the Base Rent, the Additional Rent, or any other sums payable by the Lessee to the Lessor pursuant to the Lease by reason of (i) partial or temporary interruption, failure or stoppage of light, plumbing service, sprinkler service, electric service, wiring, or anything whatsoever in and about the Leased Premises resulting from any cause whatsoever, (ii) gas, fire, water, steam, smoke, rain or snow leaking or flowing in or flooding the Leased Premises, or (iii) any delays with respect to snow removal; whether the same result to the Lessee, its employees, suppliers, customers, or to any other person, or to any property belonging to the Lessee or any other person, in or about the Leased Premises, provided the Lessor diligently proceeds to remedy the situation in question where it is its obliged to do so.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXI</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>NON-RESPONSIBILITY  OF  LESSOR</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">21.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Except for the Lessor&#x2019;s fault or negligence and to the extent permitted by law, the Lessor shall not be liable for any damages, consequential or otherwise, injury or death, and the Lessee agrees to indemnify and keep the Lessor free and harmless from any damages, losses and costs in respect of any claims for damage to property or injury or death to persons occurring in, upon or about the Leased Premises, sustained by the Lessee, its employees, agents, representatives, or other persons or entities for whom it is responsible at law, or its suppliers, customers, invitees and other persons or entities who have access to the Leased Premises or any part thereof, resulting from (i) the causes mentioned in Section 20.1 above. The Lessee agrees not to hold the Lessor in any way responsible for any damage or annoyance which the Lessee may sustain through the negligence, misconduct, or otherwise of any lessees or occupants who may occupy any other premises forming part of the Property.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>ENTRY INTO THE LEASED PREMISES</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">22.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee agrees to allow prospective purchasers and prospective hypothecary creditors to visit the Leased Premises during Business Hours upon twenty-four (24) hours&#x2019; written notice except in cases of emergency, whereupon entry shall be immediate.  During the last twelve (12) </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">24</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">months of the Term, the Lessee agrees to allow person or persons who may be desirous of leasing the Leased Premises to visit the same during Business Hours upon twenty-four (24) hours&#x2019; written notice, and to allow for rent signs or notices to be posted on or near the Leased Premises.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXIII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>DEFAULT  PROVISIONS</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">23.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Should the Lessee fail to fulfil any covenant or obligation incurred or assumed by it in this Lease, after having received a ten (10) day prior written notice from the Lessor to such effect, or should same not be capable of being remedied in ten (10) days, if the Lessee does not diligently commence to remedy same within the ten (10) day delay or does not complete such rectification thereafter in a diligent manner, the Lessor shall have the right to cure the default on behalf of the Lessee and to charge Lessee for all sums so paid plus an administration fee of Fifteen percent (15%) on all such incurred costs, and Lessee shall forthwith repay them to the Lessor as Additional Rent.  The Lessor, in addition to any other rights, shall have the same remedies and may take the same steps for the recovery of all sums which the Lessee is to pay or reimburse the Lessor pursuant to the Lease, as it may have for the recovery of rental arrears under the terms of this Lease. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">23.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In any of the following events, namely:</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">23.2.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If the Lessee shall fail to pay to the Lessor any instalment of Base Rent or Additional Rent or any other monies owing by the Lessee to the Lessor pursuant to the Lease (it being understood that the Lessee shall no longer be entitled to the benefit of any notice of non-payment as contemplated by section 23.1 in the event that Lessee has failed to pay any such amount to Lessor when due on two (2) or more occasions falling within any period of three hundred and sixty-five (365) consecutive days, and shall on any subsequent occasion be considered in default hereunder on any subsequent occurrence of non-payment without any grace or cure period in respect thereof);</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">23.2.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If the Lessee be declared dissolved, bankrupt, or wound-up, or shall make any general assignment for the benefit of its creditors, or take or attempt to take the benefit of any insolvency, winding-up or bankruptcy legislation, or if a petition in bankruptcy or in winding-up, or for reorganization be filed by or against the Lessee, or if a receiver or trustee be appointed for or enter into physical possession of the property of the Lessee, or any part thereof, and if such receiver or trustee is not removed within ten (10) days of his appointment;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">23.2.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If the Lessee shall assign, sublease or permit the use of the Leased Premises by others except in the manner as herein permitted;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">23.2.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If the Lessee shall fail to take possession of the Leased Premises, or if the Lessee shall abandon the Leased Premises;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">23.2.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If any insurance carried by the Lessor or by any lessee of the Property be cancelled in consequence of the business carried on by the Lessee or in consequence of anything brought into or stored in the Leased Premises by the Lessee;</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">23.2.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If the Lessee shall default in the performance of any of its other obligations under the Lease;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">23.2.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If any execution be issued against the property of the Lessee in or on the Property pursuant to a judgment against the Lessee unless Lessee has taken steps to satisfy the judgment or is bona fide contesting such execution and such execution has been finally satisfied, stayed or quashed within thirty (30) days from its issuance;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">this Lease, may be terminated forthwith at the option of the Lessor upon written notice to the Lessee. It is expressly agreed that such right of termination is without prejudice to Lessor&#x2019;s other rights and recourses in the circumstances.  In such event, the Lease shall expire and be at an end, and anything herein before to the contrary notwithstanding, as of the date set forth in the Lessor&#x2019;s aforementioned written notice, and the then current month&#x2019;s Base Rent and Additional Rent, plus the next ensuing twelve (12) months&#x2019; Base Rent and Additional Rent shall thereupon immediately become due and payable, without prejudice to the Lessor&#x2019;s other rights and recourses in the circumstances, including without limitation, the Lessor&#x2019;s right to obtain greater damages.  Furthermore, in such event, the Lessor without any further formality or judgment, may re-enter and take possession of the Leased Premises as though the Lessee or its employees, agents or representatives, or such other occupant or occupants of the Leased Premises were over-holding lessees and, to remove therefrom any persons or property occupying the Leased Premises, and to bolt the Leased Premises and change the locks thereof.  The Lessor shall have the right to re-let the Leased Premises to whomsoever it may choose without further notice or demand being necessary, and may recover from the Lessee all expenses of such re-letting (including any repairs or improvements necessitated thereby), in addition to the amounts mentioned above.</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">23.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to the foregoing and without prejudice to the Lessor&#x2019;s other rights and recourses hereunder, in the event of the bankruptcy of the Lessee, there shall immediately become due and exigible in favour of the Lessor, on account of accelerated rent, an amount equal to Base Rent and Additional Ren for a period of three (3) months next following the bankruptcy or for such longer period of time as may be allowed by any applicable bankruptcy or insolvency legislation in force from time to time. Furthermore, in the event of Lessee's continued occupancy of the Leased Premises after the filing of a proposal or a notice of intention to file a proposal pursuant to the provisions of the Bankruptcy and Insolvency Act, and any amendments thereto or replacements therefore or under any other insolvency legislation and said continued occupancy commences on a day which is not the first day of any calendar month, any Rent or other amounts payable on a monthly basis hereunder for such month and for any other partial month of the Term shall be calculated on a per diem basis and be paid in advance.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">23.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the event that the Lessor is required to retain the services of a solicitor to enforce the fulfilment by the Lessee of any obligation undertaken by it under the Lease, then in each such event the Lessor shall be entitled to demand from the Lessee, in addition to and without prejudice to judicial costs otherwise payable by the Lessee, and whether or not judicial proceedings are in fact instituted, an amount equal to all reasonable legal costs, expenses and disbursements incurred by the Lessor to enforce the fulfilment by the Lessee of any such obligation plus the cost of all inspections and environmental assessments, plus all costs incurred to enforce the fulfilment of any such obligation, plus an indemnity equal to FIFTEEN PERCENT (15%) of the amount otherwise owing by the Lessee to the Lessor.  Such indemnity is to indemnify the Lessor for additional administrative expenses incurred in connection with the enforced fulfilment by the </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">26</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessee of its obligations hereunder. Such legal costs, expenses and disbursements, and such indemnity shall be payable on demand as Additional Rent.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">23.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee hereby waives the provisions of Article 1883 of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Civil Code of Quebec</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXIV</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>EXPROPRIATION</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">24.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If during the Term, the whole or a substantial portion of the Leased Premises is expropriated which renders the remainder of the Leased Premises unsuitable for the purpose intended in this Lease, the Lease shall cease and terminate as of the date on which vacant occupancy of the Leased Premises or the portion thereof in question is required by the expropriating party, and the Lessee shall pay to the Lessor the Rent and all other sums which may be owing by the Lessee to the Lessor pursuant to the Lease to such date.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">24.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the event that Thirty percent (30%) or more of the Property be expropriated, whether or not the Leased Premises are affected, then the Lessor shall have the right to terminate the Lease as of the date on which vacant occupancy of the Property or the portion thereof in question is required by the expropriating party, provided the Lessor furnishes the Lessee with a one hundred and eighty (180) day prior written notice of such termination.  In such event, the Lease shall terminate as of such date and the Lessee shall pay to the Lessor the Rent and all other sums which may be owing by the Lessee to the Lessor pursuant to the Lease to such date.  Should the Lessor fail to furnish the Lessee with the aforementioned notice, the Lease shall continue in full force and effect.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">24.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If the expropriation of a part of the Leased Premises does not render the remainder of the Leased Premises unsuitable for the purpose intended in this Lease, then the Rent and all other sums payable by the Lessee to the Lessor pursuant to this Lease shall abate from the date on which occupancy of the portion so expropriated is taken by the expropriating party, in the proportion that the area of the part of the Leased Premises so expropriated bears to the area of the entire Leased Premises.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">24.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessor and Lessee agree that the entire expropriation proceeds payable in respect of the expropriation of the Leased Premises or any part thereof, or payable in respect of the expropriation of the Property or any part thereof, shall be paid and belong to the Lessor, subject to the provisions of section 24.5 below which may be awarded or recoverable by the Lessee. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">24.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the event that the expropriation affects the Leased Premises but does not result in the termination of the Lease but yet requires the reconstruction or replacement of some portion of the Leased Premises, such reconstruction or replacement shall be carried out by the Lessor at its expense in a good and workmanlike manner, and as expeditiously as reasonably practical, provided that the cost thereof does not exceed the amount of compensation award payable to the Lessor in respect of the cost of such reconstruction or replacement.  The Lessee hereby expressly waives any right or claim to any part thereof.  The Lessee shall have the right to claim and to recover from the expropriating authority (though not from the Lessor) such compensation as may be separately awarded or recoverable by the Lessee in its own right on account of any and all damages to the Lessee&#x2019;s business by reason of such expropriation or on account of any and all costs, losses, disbursements or otherwise which the Lessee may suffer as the result of such expropriation. </font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">27</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">24.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In no event shall the Lessor be liable to the Lessee for any loss or damage caused by expropriation for any reason whatsoever.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXV</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>SECURITY</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">25.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee clearly acknowledges and understands that any security services engaged by the Lessor at the Property are strictly and exclusively for the Lessor itself.  Consequently, the Lessee acknowledges that any security services at the Property may be altered or eliminated at any time during the Term and the Lessee acknowledges and agrees that the Lessor shall not in any way be liable for any damages, costs or losses of any nature whatsoever, however caused, including but not limited to due to the fault or negligence of the Lessor or any person for whom it is responsible at law and resulting from any deficiency or failure in the security services in effect for the Property or due to the lack thereof.  </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">25.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee undertakes and agrees not to temper with, alter, remove or otherwise disable any and all security equipment in the Leased Premises and in the Property, including, but not limited to fire prevention and detection equipment.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXVI</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>RULES AND REGULATIONS</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">26.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee undertakes to observe and apply the regulation appended hereto as Schedule &#x201c;E&#x201d;. The Lessor shall have the right, at any time and from time to time, to make or vary such reasonable rules and regulations as may be desirable, in the sole opinion of the Lessor (but not inconsistent with the provisions of this Lease), for the safety, care, cleanliness, operation and maintenance of the Leased Premises, the Parking Area, and the Property, and for the preservation of good order therein provided that such rules and regulations apply to all of the lessees of the Property. The Lessor shall furnish the Lessee with written notice of such rules and regulations, and all such rules and regulations shall be faithfully observed and performed by the Lessee, its employees, agents and representatives. The Lessor shall not be responsible to the Lessee for the non-observance or violation of any such rules or regulations by any other lessee.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">26.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee covenants with the Lessor that it will not do, or omit to do, or permit to be done or omitted, anything upon or in respect of the Leased Premises, the doing or omission of which (as the case may be) shall be or result in any nuisance, noise, disturbance or discomfort to other lessees, nor shall it create any noxious odours, unreasonable noise, dust, fumes or smoke.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">26.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Notwithstanding the foregoing, the Lessor shall ensure that the quiet and peaceful enjoyment of the Leased Premises by the Lessee is not interrupted, disturbed or hindered by demands or claims from the Lessor or from any party for whom the Lessor is in law responsible.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXVII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>MORTGAGES AND SUBORDINATION</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">27.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lease and all the rights of the Lessee hereunder are and shall be subject and subordinate at all times to any and all mortgages, hypothecs or trust deeds affecting the Property which have been executed or which may at any time hereafter be executed, and any and all extensions and renewals thereof and substitutions therefor.</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">28</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">27.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee covenants and agrees that if, by reason of default by the Lessor under any hypothec, trust deed or other charge to which the Lease is subject or subordinate, the Lessor&#x2019;s title is terminated, the Lessee will attorn to the hypothecary creditor or trustee or the acquirer of the Property pursuant to any action taken under any such hypothec, trust deed or other charge and the Lessee will recognize such person as the Lessee&#x2019;s Lessor under this Lease.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">27.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee agrees to execute and deliver, at any time and from time to time, upon the request of the Lessor or of the holder of any such hypothec, trust deed or other charge, any instrument which may be necessary or appropriate to evidence such attornment.  Notwithstanding the foregoing, Lessee&#x2019;s obligation to execute any such attornment instrument requested by the holder of any such hypothec, trust deed or other charge, shall be conditioned upon Lessee&#x2019;s receipt of a commercially reasonable non-disturbance agreement.  </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">27.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee shall upon request of the Lessor furnish to each creditor under a hypothec, trust deed or other charge, a written statement that the Lease is in full force and effect and that the Lessor has complied with all its obligations under the Lease (or state those with which it has not complied) and any other reasonable written statement, document or estoppel certificate requested by any such creditor.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXVIII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>RELEASE OF LESSOR</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">28.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the event of any sale or other alienation of Lessor&#x2019;s rights in the Property to an arm&#x2019;s length third party acquirer, the Lessor shall be entirely released and relieved of all covenants and obligations of the Lessor hereunder as of the date of such sale/alienation, provided such acquirer agrees to assume and carry out any and all covenants and obligations of the Lessor hereunder.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXIX</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>AMENDMENT OF LEASE</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">29.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">No assent or consent to changes in or waiver of any part of this Lease shall be deemed or taken as made unless the same be done in writing and attached or endorsed hereon by the Lessor and the Lessee.  No covenant or term of the Lease stipulated in favour of a party hereto shall be waived, except by express written consent of such party, whose forbearance or indulgence in any regard whatsoever shall not constitute a waiver of the covenant, term or condition to be performed by the other party and until complete performance by a party of such covenant, term or condition, the other party shall be entitled to invoke any remedies available under the Lease or by law despite forbearance or indulgence.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXX</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>NO REPRESENTATIONS OR WARRANTIES</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">30.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee agrees that the Lessor has made no representations or warranties to the Lessee whatsoever except as may be provided for in the Lease, and that the Lease constitutes the total agreement between the parties hereto.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">30.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee acknowledges that the Lease has been freely negotiated by the Lessee, and that it has had the opportunity to engage legal counsel to review the Lease and to advise it prior to the Lessee&#x2019;s execution of same.</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">29</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">30.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Notwithstanding the foregoing, the Lessor hereby represents and guarantees that that the Leased Premises and all building systems therein shall as at the Commencement Date be in good working order and condition.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">30.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The signatories hereby declare being duly authorized to sign the present Lease Agreement and bind the company that they represent.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXXI</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>SEVERABILITY</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">31.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Should any term or provision of the Lease be deemed illegal, unenforceable, or contrary to public order and good morals, under the laws of the Province of Quebec, such provision(s) shall be considered severable, and the remainder of this Lease and its conditions shall remain in full force and effect as though such provision(s) had never been included.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXXII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>SUCCESSORS AND ASSIGNS</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">32.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lease shall be binding upon, and inure to the benefit of, the respective heirs, successors, administrators and assigns of the Lessor and the Lessee, provided that nothing in this Article shall be construed as permitting the Lessee to sublet, assign or transfer any interest in the Lease other than as specifically provided in the Lease.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXXIII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>FORCE MAJEURE</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">33.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the event that either the Lessor or the Lessee shall be delayed or hindered in or prevented from the performance of any act required hereunder by reason of causes beyond the reasonable control of the performing party, including without limitation, strikes; lock-outs; labour troubles; inability to procure materials; failure of power; pandemics; epidemics; restrictive governmental laws or regulations; declarations of a state of emergency by the applicable governmental authority which prevent the Leased Premises from being open; public health emergencies where the Leased Premises are required or recommended by the applicable governmental authority or public health agency having jurisdiction to close along with the closure of other similar businesses within the municipality in which the Leased Premises are located; riots; insurrection; war or acts of war (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Force Majeure Event</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;), then performance of such act shall be excused for the period of the delay caused by the Force Majeure Event and the period for the performance of any such act shall be extended for a period equivalent to the period of such delay caused by the Force Majeure Event. However, in no event shall financial inability be considered to be a cause of Force Majeure nor shall it permit any delay or waiver of the payment of Base Rent or Additional Rent. Moreover, in the event that the Lessee&#x2019;s fixturing is delayed due to a Force Majeure for a period of up to 90 days, and provided that the Lessee notifies the Lessor of the Force Majeure Event and takes commercially reasonable action to mitigate any delay, the Fixturing Period shall be extended on a day for day basis, and the Commencement Date  and Expiration of the Term (and the dates provided increases in Base Rent as contemplated in section 3.1) shall be extended accordingly.  An event or circumstance contemplated in this Section 34.1 shall be deemed not to be an eviction or disturbance of the Lessee&#x2019;s enjoyment of the Leased Premises and the occurrence thereof shall not render the Lessor liable in damages to the Lessee or entitle the Lessee to claim any diminution in Rent but, upon such occurrence, the Lessor shall without delay take all reasonable steps to terminate the event or circumstance in question.</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">30</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Arial;justify-content:flex-start;">ARTICLE XXXIV</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">APPROVAL OF LESSOR</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">34.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Wherever the Lessor's consent is required to be given hereunder or wherever the Lessor must approve any act or performance by the Lessee, such consent or approval, as the case may be, shall be given in writing by the Lessor before same shall be deemed to be effective and, shall not be unreasonably withheld, conditioned or delayed.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Arial;justify-content:flex-start;">ARTICLE XXXV</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">TIME TO BE OF THE ESSENCE</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">35.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Time shall be of the essence of this Lease.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXXVI</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>PUBLICATION OF LEASE</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">36.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This Lease shall not be published at length but only by notice pursuant to the provisions of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Civil Code of Quebec</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and then only if the form and the terms of such notice have first been approved by the Lessor in writing, which approval shall not be unreasonable withheld.  The form shall not contain any financial provisions or conditions.  All costs of publication shall be assumed by the Lessee. The Lessee shall, at the expiration or earlier termination of this Lease, radiate all registrations of any such notice of lease failing which the Lessor will have the right to cause such radiation and to charge to the Lessee the cost thereof.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXXVII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>SCHEDULES</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">37.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Schedules attached to this Lease are included in and form an integral part of this Lease.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">37.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This Lease and such rules and regulations as may be adopted and promulgated by the Lessor and provided to the Lessee, from time to time constitute the entire agreement between the parties.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXXVIII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>INTERPRETATION</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">38.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The singular number shall be deemed to include the plural and any gender shall be deemed to include the neuter, masculine or feminine where required. Where there is more than one Lessee, they shall be jointly and solidarily bound to the fulfilment of their obligations hereunder. The headings herein are for convenience only and shall not constitute a part of the Lease. The definition of any words used in any Article of the Lease shall apply to such words when used in any other Article hereof whenever the context is consistent.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XXXIX</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>GOVERNING LAW</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">39.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lease shall be construed and governed by the laws of the Province of Quebec and the Parties irrevocably submit to the exclusive jurisdiction of the courts of the Province of Quebec for the settlement of any dispute that may arise in connection with the present Lease.</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XL</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>LEGAL COSTS AND BROKERAGE COMMISSIONS</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">40.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessor and the Lessee shall each pay their own legal fees in respect of the negotiation and execution of this Lease.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">40.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee represents and warrants that no broker, agent or other intermediary was involved in this transaction and in the negotiation and preparation of this Lease. Consequently, the Lessee shall indemnify and hold the Lessor harmless from any action instituted by brokers or agents for payments of fees or commissions associated with the transaction. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XLI</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>CIVIL CODE WAIVERS</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">41.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessee hereby waives any rights which it may have or enjoy at any time pursuant to Article 1854 (2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> paragraph), 1859, 1861, 1867 (second paragraph, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">fine), 1868 (second paragraph, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">fine), 1881 and 1883 of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Civil Code of Quebec</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> or any replacement legislation.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XLII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>CONTESTATION OF TAXES</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">42.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Lessor shall have no obligation to contest, appeal, object to or litigate the levying or imposition of any Property Taxes and/or any valuation imposed with respect thereto, and Lessor may settle, compromise, consent to, waive or otherwise determine, in its sole discretion, all matters and things relating thereto.  </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Arial;justify-content:flex-start;">ARTICLE XLIII</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIALITY</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">43.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The parties will maintain all Confidential Information (as hereinafter defined) in confidence and will not disclose such information to any other party without written consent. &#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Confidential Information</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#34; includes the terms of this Lease and any and all information whether in oral, written or other form, which is communicated by Lessee to Lessor relating to Lessee&#x2019;s proposed development and use of the Leased Premises, including but not limited to, architectural plans, specifications, site plans and drawings (regardless of whether such information is labelled as confidential), but shall not include any information:</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">43.1.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">is in or comes into the public domain otherwise than by any breach of the present Lease;</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">43.1.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the recipient can show that such information was in its possession by virtue of being recorded in its files or being in its use prior to receipt from the other party; or</font></div></div>
  <div style="margin-left:13.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.692662720527998%;">43.1.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">is received by a party hereto from a third party acting in good faith, legally in possession of such information, without restrictions as to its disclosure or use of the kind provided for by this Lease.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Confidential Information may be released (i) to the parties&#x2019; employees, partners, legal counsel, consultants and lenders who have a reasonable need for such Confidential Information, provided that such individuals agree to maintain the confidential nature of the information; (ii) as may</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">otherwise be required by law; or (iii) as may be necessary for a party to give effect to or otherwise enforce its rights under the present Lease. This provision will be binding upon execution of this Lease or the Lease is terminated.</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">ARTICLE XLIV</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"><br>AUDIT RIGHTS</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">44.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lessee will have the right to audit the Operating Expenses and the Property Taxes. Lessee will initiate any audit by giving written notice to Lessor of Lessee&#x2019;s intent to audit. Lessee's notice shall be given within ninety (90) days after Lessee's receipt from Lessor of (i) an annual recalculation of the Operating Expenses and the Property Taxes, and (ii) Lessor's notice to Lessee stating the Operating Expenses and Property Taxes for any calendar year and the audit shall occur within one hundred and twenty (120) days after Lessor&#x2019;s receipt of Lessee&#x2019;s written notice, failing which Lessee shall be prescribed from auditing the period in question and shall be deemed to have accepted Lessor&#x2019;s calculations. Lessee's audit may be conducted only by employees or consultants of Lessee or chartered accountants retained by the Lessee for such purposes, and under no circumstances shall same be conducted by any person or entity acting on a success or recovery basis. Lessee shall provide Lessor with a copy of the audit within thirty (30) business days of receipt. Where the Lessor disagrees with any results of such audit, and the parties are unable to settle same within thirty (30) business days following Lessor&#x2019;s receipt thereof, then in such case, Lessor may, at any time within ten (10) business days following expiry of the aforesaid thirty (30) business day period, submit the unsettled or disputed matters for determination to a national or regional firm of chartered accountants who otherwise act for neither Lessor or Lessee for final determination, and the decision of such chartered accountants shall be binding upon the parties.  The fees of such accountants shall be borne by the unsuccessful party.  If the audit, finally determined, determines that Lessee overpaid Operating Expenses and/or Property Taxes, Lessor will immediately reimburse Lessee for the expenses that Lessee paid in excess of the audited Operating Expenses and Property Taxes and will reimburse the Lessee&#x2019;s reasonable expenses for conducting such audit in the event Lessee paid an amount of five percent (5%) or greater than the amount of the Operating Expenses Lessee should have paid.  If the audit determines that Lessee underpaid the Operating Expenses and/or Property Taxes, Lessee will make payment to Lessor within thirty (30) days of Lessee&#x2019;s receipt of the audit.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:center;align-items:baseline;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Arial;justify-content:flex-start;">ARTICLE XLV</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">     </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">LANGUAGE DECLARATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50.1  		The Parties hereto have requested that the present Agreement of Lease be drawn up in the English language.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Les Parties aux pr&eacute;sentes ont exig&eacute; que la pr&eacute;sente Convention de Bail soit r&eacute;dig&eacute;e dans la langue anglaise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> the Parties hereto have signed these presents at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">   Montreal    </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, Province of Quebec, on the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">   1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">   </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> day of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  January   </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> 20</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">33</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:57.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:18.894%;"></td>
    <td style="width:68.529%;"></td>
    <td style="width:12.577%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">NEOMED INSTITUTE</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(LESSOR)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PER</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Matthew Carlyle</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Matthew Carlyle</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">EVP &amp; CFO</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">REPARE THERAPEUTICS INC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(LESSEE)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PER</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Christopher Kendall</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Christopher Kendall</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VP Finance &amp; FP&amp;A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SCHEDULE &#x201c;A&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">AUTOMATIC WITHDRAWAL INFORMATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">N/A &#x2013; already on file</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">35</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SCHEDULE &#x201c;B&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PLAN OF LEASED PREMISES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SCHEDULE &#x201c;B&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PLAN OF LEASED PREMISES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Ground Floor</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">37</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SCHEDULE &#x201c;C&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PLAN OF PARKING AREAS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SCHEDULE &#x201c;D&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">LESSOR&#x2019;S WORK</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">NA</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SCHEDULE &#x201c;E&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rules and Regulations</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">See attached document</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SCHEDULE &#x201c;F&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Square Footage of Leased Premises</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.326%;"></td>
    <td style="width:33.337%;"></td>
    <td style="width:33.337%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Room #</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Room Type</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Square feet</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1208</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Office</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">237</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1210</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Office</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">331</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2116</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Office</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">83</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2215</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Office in lab suite</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">97</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2216</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Office in lab suite</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">97</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2217</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Biology lab</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">321</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2218</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Office in lab suite</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">97</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2219</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Office in lab suite</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">97</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2232</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vivarium</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">156</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2233</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vivarium</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">156</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2251</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vivarium</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">212</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2272</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Biology lab</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">530</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2208A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Biology lab</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">159</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2208B</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Biology lab</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">195</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2220A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Office in lab suite</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">78</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2220B</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Office in lab suite</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">180</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2232A</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vivarium</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">149</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2243AL</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vivarium</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">119</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2243L</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Vivarium</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">151</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Total</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3445</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>4
<FILENAME>rptx-ex10_33.htm
<DESCRIPTION>EX-10.33
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT 10.33</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ii) customarily and actually treated by the registrant as private or confidential.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECOND AMENDMENT<br>TO<br>RESEARCH SERVICES, LICENSE AND COLLABORATION AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Second Amendment to Research Services, License and Collaboration Agreement (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) is entered into as of January 31, 2023 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) by and between Repare Therapeutics, Inc., a corporation organized and existing under the laws of Canada and having its principal place of business at 7210 Frederick-Banting, St-Laurent, Quebec, H4S 2A1, Canada (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repare</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and Ono Pharmaceutical Co., Ltd., a corporation organized and existing under the laws of Japan and having an address of 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka 541-8564, Japan (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ono</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Repare and Ono may each be referred to herein as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or collectively as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, Repare and Ono entered into that certain Research Services, License and Collaboration Agreement, dated as of January 31, 2019, as amended by First Amendment, dated as of October 29, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;); and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, the Parties wish to amend the Agreement to extend the Research Term and revise the Licensed Drug Candidate selection process;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW, THEREFORE, the Parties, intending to be legally bound, hereby agree as follows:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized terms used in this Second Amendment that are not defined herein shall have the meanings ascribed to them in the Agreement.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 1.142 of the Agreement is hereby deleted in its entirety and replaced with the following:</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.142	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the period commencing on the Effective Date and ending upon the earlier of (a) July 31, 2023, or (b) the date of submission of the first IND in the United States or in Japan.  Any extension of the Research Term will require the mutual written agreement of both Parties.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3.3 of the Agreement is hereby deleted in its entirety and replaced with the following:</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DC Selection Meeting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Parties shall hold a meeting at the date and time agreed upon by the Parties, but no later than the earlier of (a) the date of submission of the first IND in the United States or in Japan or (b) [***], in order to discuss the selection of one potential Licensed Drug Candidate among the Drug Candidates to move toward further Development and Commercialization by the Parties (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DC Selection Meeting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding anything to the contrary in the Agreement, except as the Parties may otherwise agree in writing, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Second Amendment shall be deemed incorporated into and made a part of the Agreement.  The provisions of this Second Amendment shall constitute an amendment to the Agreement, and, to the extent that any term or provision of this Second Amendment may be deemed expressly inconsistent with any term or provision in the Agreement, this Second Amendment shall govern and control.  Except as expressly modified by the terms of this Second Amendment, all of the terms, conditions, and provisions of the Agreement are hereby ratified, and the Agreement remains in full force and effect.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Second Amendment may be executed in two (2) or more counterparts, including by facsimile or PDF signature pages or other electronic means, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[THE REMAINDER OF THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK]</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this Second Amendment to Research Services, License and Collaboration Agreement to be executed by their respective duly authorized officers as of the Second Amendment Effective Date.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:48.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.578%;"></td>
    <td style="width:85.422%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPARE THERAPEUTICS, INC.</font></p><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Lloyd M. Segal</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lloyd M. Segal</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President &amp; CEO</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:48.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.578%;"></td>
    <td style="width:85.422%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ONO PHARMACEUTICAL CO., LTD</font></p><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Takao Yoshida</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Takao Yoshida</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Senior Director, Research Center of Oncology</font></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>5
<FILENAME>rptx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-239400, 333-255048 and 333-263469) pertaining to the 2020 Equity Incentive Plan and the 2020 Employee Share Purchase Plan of Repare Therapeutics Inc. and in the Registration Statement (Form S-3 No. 333-257668) of Repare Therapeutics Inc. and the related Prospectus of our report dated February 28, 2023, with respect to the consolidated financial statements of Repare Therapeutics Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Montr&eacute;al, Canada</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>6
<FILENAME>rptx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Lloyd M. Segal, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2022 of Repare Therapeutics Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15(d)-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.996%;"></td>
    <td style="width:1.998%;"></td>
    <td style="width:4.103%;"></td>
    <td style="width:34.904%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Lloyd M. Segal</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lloyd M. Segal</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>7
<FILENAME>rptx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Steve Forte, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2022 of Repare Therapeutics Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15(d)-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.91%;"></td>
    <td style="width:2.938%;"></td>
    <td style="width:3.248%;"></td>
    <td style="width:34.904%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Steve Forte</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Steve Forte</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Vice President, Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>rptx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#34;Exchange Act&#34;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), Lloyd M. Segal, President and Chief Executive Officer of Repare Therapeutics Inc. (the &#34;Company&#34;), and Steve Forte, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</font></p>
  <div style="margin-left:6.565%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.567185744100177%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the &#34;Report&#34;) fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:6.565%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.567185744100177%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.91%;"></td>
    <td style="width:2.938%;"></td>
    <td style="width:3.248%;"></td>
    <td style="width:34.904%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Lloyd M. Segal</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lloyd M. Segal</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Steve Forte</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Steve Forte</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Vice President, Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img192321128_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -8!PD# 2(  A$! Q$!_\0
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M+_P)?_(G&?\ "U_!/_0:_P#)6;_XBC_A:_@G_H-?^2LW_P 179T46GW7W?\
M!#GPW\DO_ E_\B<9_P +7\$_]!K_ ,E9O_B*T]$\<>'/$=XUII6II/<*N_RS
M&\9(]MP&?PKH*Y[Q7X83Q!:Q36\QM-6LV\RRO%ZQOZ'U4]Q2?.M=_P"O4<?J
MLGRV<?.Z=OERHZ&BN<\*>)3K<$UG?Q"UUJQ/EWEJ>Q[.OJIZ@_\ UB>CJTTU
M='/4IRIR<9;A1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_R1V=%<9_PJCP3_ - 7_P FIO\ XNC_ (51X)_Z O\ Y-3?_%T7GV7W_P#
M#DPW\\O_  %?_)'9T5QG_"J/!/\ T!?_ ":F_P#BZ/\ A5'@G_H"_P#DU-_\
M71>?9??_ , .3#?SR_\  5_\D=G17&?\*H\$_P#0%_\ )J;_ .+H_P"%4>"?
M^@+_ .34W_Q=%Y]E]_\ P Y,-_/+_P !7_R1V=%<9_PJCP3_ - 7_P FIO\
MXNC_ (51X)_Z O\ Y-3?_%T7GV7W_P# #DPW\\O_  %?_)'9T5QG_"J/!/\
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M#$3I\SO5J)I>=W\O-C-%T^Y\9ZO%XGUF)H]-@;=I-@X[?\]G'J>P[?J>\I
MH    X ':EJXQY3GK5G4?9+9=D%%%%48A1110 4444 %%%% !1110 4444 <
M9\._N>*/^QAN_P#V6NSKC/AW]SQ1_P!C#=_^RUV=13^%'3C/X\OZZ!1115G,
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%0WEI!?V4]G<IYEO<1M%*F2-RL,$9'(X-35!>7'V2U>?9NVXXSC.3B@:;3NA
M;.T@L+*"SMD\NWMXUBB3).U5& ,GD\"IJ** ;;=V%%%% @HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"GI^E66E?:OL4'E?:KA[J;YB=TC8W-R3C.!P.*N
M5!;7'VCSODV^7*T?7.<=ZGHM8;DY.[84444""BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHJ"VN/M'G?)M\N5H^N<X[T 3T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK[,_[^-OZUK:YXDTGPWI\=]JUV+>VDD$22"-GRQ!(&%!/13S19A=&K17,?\
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MU<E5DV,N2#@\, >M7Z0R"SN/M=JD^S;NSQG.,'%3U1T?_D%P_P# O_0C5Z@
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MJKLFG:I97CJ,LMO<)(0/?:35^@ HHHH **** "BBB@ HHHH **** "J.C_\
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M/E0'(R=A<YXR.".N:/B7I^@Z3X0\/:9K)U RVL0@MK^S@5MA1%4[E9Q@-@'
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MW'0@?0G' KNH?!NG6_@IO"L$UU'8M&T;2JZ^:0S%FYVXYR1TZ5R/_"B/"_\
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M[N@SW..M=]4R:944T%%%%24%%%% !1110 4444 %%%% !5'1_P#D%P_\"_\
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ML]1L=0M?M5E>6]S;Y(\V&573CKR#BH;/7=(U"X:WLM5L;F9?O1PW".P_ '-
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M10 51NO^0I8?]M/_ $&KU4;K_D*6'_;3_P!!H O4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 51TW_ )>_^OE_Z5>JCIO_ "]_]?+_ -*
M+U%%% !1110 4444 %%%% !5.XTG3KN]AO;G3[6:[@QY4\D*L\>#D;6(R.?2
MKE% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %4='_ .07#_P+_P!"-7JHZ/\
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MY-3?_%T?\*M\&?\ 0&_\FIO_ (NJM'O_ %]YG>KV7W_\ ["BN/\ ^%6^#/\
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MX_\ X5;X,_Z W_DU-_\ %T?\*M\&?] ;_P FIO\ XNBT>_\ 7WA>KV7W_P#
M.PHKC_\ A5O@S_H#?^34W_Q='_"K?!G_ $!O_)J;_P"+HM'O_7WA>KV7W_\
M .PHKC_^%6^#/^@-_P"34W_Q='_"K?!G_0&_\FIO_BZ+1[_U]X7J]E]__ .P
MHKC_ /A5O@S_ * W_DU-_P#%T?\ "K?!G_0&_P#)J;_XNBT>_P#7WA>KV7W_
M / .PHKC_P#A5O@S_H#?^34W_P 71_PJWP9_T!O_ ":F_P#BZ+1[_P!?>%ZO
M9??_ , ["BN/_P"%6^#/^@-_Y-3?_%T?\*M\&?\ 0&_\FIO_ (NBT>_]?>%Z
MO9??_P  ["BN/_X5;X,_Z W_ )-3?_%T?\*M\&?] ;_R:F_^+HM'O_7WA>KV
M7W_\ ["J.L?\@N;_ (#_ .A"N=_X5;X,_P"@-_Y-3?\ Q=5-2^&7A"WL)98M
M(VNN,'[3*>X_VZ+1[A>KV7W_ / .[HKSO_A7'A/_ *!7_DQ+_P#%4?\ "N/"
M?_0*_P#)B7_XJE[O?^OO(]I4_E7W_P# /1**\[_X5QX3_P"@5_Y,2_\ Q5'_
M  KCPG_T"O\ R8E_^*H]WO\ U]X>TJ?RK[_^ >B45YW_ ,*X\)_] K_R8E_^
M*H_X5QX3_P"@5_Y,2_\ Q5'N]_Z^\/:5/Y5]_P#P#T2BO._^%<>$_P#H%?\
MDQ+_ /%4?\*X\)_] K_R8E_^*H]WO_7WA[2I_*OO_P" >B45YW_PKCPG_P!
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M/"?_ $"O_)B7_P"*H]WO_7WC]I4_E7W_ / /1**\[_X5QX3_ .@5_P"3$O\
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M_"N/"?\ T"O_ "8E_P#BJ/=[_P!?>'M*G\J^_P#X!Z)17G?_  KCPG_T"O\
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M)_\ 0)_\F)?_ (JC_A6_A/\ Z!/_ ),2_P#Q5'+'N'-5[+[_ /@'H=%>>?\
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M_P"%6^#/^@-_Y-3?_%T6CW_K[PO5[+[_ /@'845Q_P#PJWP9_P! ;_R:F_\
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M4 %%%% $\7_'K/\ \!_G4%3Q?\>L_P#P'^=04#84444""BBB@ HHHH ****
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M@SJ'_@4_^-'_  D6N?\ 09U#_P "G_QK-HHNP]I/NS2_X2+7/^@SJ'_@4_\
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M% !1110 4444 %4='_Y!</\ P+_T(U>JCH__ ""X?^!?^A&@"]1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %4=8_P"07-_P'_T(5>JCK'_(+F_X#_Z$* *5%%%28!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $\7_'K/_P !_G4%3Q?\>L__
M  '^=04#84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \O^
M)_33?^NMQ_[3I+.TTZ\^%EFFIZF=/B&I.5D%NTVYMIXP",<9.?:E^)_33?\
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M_0&T_P#\!4_PH_X1W0_^@-I__@*G^%'L'W#^R9_S(^?:*^@O^$=T/_H#:?\
M^ J?X4?\([H?_0&T_P#\!4_PH]@^X?V3/^9'S[17T%_PCNA_] ;3_P#P%3_"
MC_A'=#_Z VG_ /@*G^%'L'W#^R9_S(^?:*^@O^$=T/\ Z VG_P#@*G^%'_".
MZ'_T!M/_ / 5/\*/8/N']DS_ )D?/M%?0\GAO0A;PD:+IV3NR?LJ<\_2HO\
MA'=#_P"@-I__ ("I_A2]@^X?V3/^9'S[17T%_P ([H?_ $!M/_\  5/\*/\
MA'=#_P"@-I__ ("I_A3]@^X?V3/^9'S[17T%_P ([H?_ $!M/_\  5/\*/\
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M\+ M?^@#KW_@&/\ XJNOHH]I2_D_$/9UOY_P.0_X6!:_] '7O_ ,?_%4?\+
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M-'(C(Z$JRL,$$=013[>WGNYA#;0R32L"0D:EF.!D\#V!- 6Z$5%%% @HHHH
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M&DDT'3X[74X/WD/S,Z2D<[&5B00>E5I]=LM=^"&IR6EI%9/;VY@N+2)-BPR
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MB27BQ@3.@P"U%:*<556E^GZKR"A*49NDW>W7]'Y_H7****YCJ"BBB@ HHHH
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M"W2,G\0*?J&C:7JWE_VEIMG>^5GR_M,"R;,XSC<#C.!^57:* *U]IUCJ=O\
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M,,''OS5/0M#MO#^GFSM))GC,ADS*03D@#L!Z5IT4[&G)%RYK:A11104%%%%
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M110 4444 %%%% !1110 4444 %%%% !1110 51T?_D%P_P# O_0C5ZJ.C_\
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M?_#_ ()\UT5]-2?\>T'_  +^=0TO8>8?V1_?_#_@GS717TI13]AYA_9']_\
M#_@GS717TI11[#S#^R/[_P"'_!/FNBOI2BCV'F']D?W_ ,/^"?-=%?2E%'L/
M,/[(_O\ X?\ !/FNBOI2BCV'F']D?W_P_P""?-=%?2E%'L/,/[(_O_A_P3YK
MHKZ4HH]AYA_9']_\/^"?-=%?2E%'L/,/[(_O_A_P3YKHKZ4HH]AYA_9']_\
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MW6M:E\(-)N%U]+*:25_M>I7LQ+I")G!VLV?FQ@#)[8XZ@:!,]-K(LO$5I?\
MB34]#BCG%UIRQM,[*-C!U##:<Y/!YR!7F5[KUAH.NZ*^@>-=1U=YKZ."[M+F
M[-PC1,<%@<84_3U'I73^'/\ DK_C3_KE9_\ HH46#F.]HHHJ2@HHHH ****
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MBZA:?$?Q/JT]OLL;V.V6WEWJ=Y2,!N <C!]0*ZZBE<?*%%%%(84444 %%%%
M!1110 4444 %4='_ .07#_P+_P!"-7JHZ/\ \@N'_@7_ *$: +U%%% !1110
M!A^,/$7_  BGA:]UO[+]J^S;/W/F;-VYU3[V#C[V>G:O,8_V@"4$LGA258<X
M,BWF1_Z+ _6NR^+_ /R2W6?^V'_H^.O.O!'C_P -:!\,+C2=2=I[QS-_H?DL
MPD##@$XVX/UH&>N^$?&&F>,]*-]IQ=3&VR:&48>-L9P?4>AKSO2?CK<:I)&/
M^$4\I&E$;/\ VB&VYQSCRQGK3_@+H5_8Z;J>JW43Q6][Y:VX88\P+NRWT^;
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MQ.W/TQ0!1_X:'_ZE;_RH?_:Z[?X>?$/_ (3W^TO^)7]A^Q>5_P O'F[]^_\
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M\_Y'A_\ PCNN?] ;4/\ P%?_  H_X1W7/^@-J'_@*_\ A7N'_"1:'_T&=/\
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M ("O_A1_PCNN?] ;4/\ P%?_  KW#_A(M#_Z#.G_ /@4G^-'_"1:'_T&=/\
M_ I/\:/8Q[A_9U'^?\CP_P#X1W7/^@-J'_@*_P#A1_PCNN?] ;4/_ 5_\*]P
M_P"$BT/_ *#.G_\ @4G^-'_"1:'_ -!G3_\ P*3_ !H]C'N']G4?Y_R/#_\
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M_P#A1_PCNN?] ;4/_ 5_\*]P_P"$BT/_ *#.G_\ @4G^-'_"1:'_ -!G3_\
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MLECU2&!)Y)4)S(N[#;AG'0Y_"NC\):[+K?P'UE;B8RW%E8W=L[,>2!$2N?\
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M+R3,,,6Z8([8]/\ &NHJX*T4=F%BXT8IA1115'0%%%% !1110 4444 %%%%
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M4Y1;36Q3HK0AT+5[A0T&E7TH*"0%+=VRIZ-P.A]:C72-3>T>[73KMK9,[IA
MQ1<=<MC Q19AR2[%.BNG_P"$5-QX-T_5;"&\N;ZYN'C>&)=X"KGD*!GL.]<[
M/;3VL[07$$D,R\&.1"K#\#S0U8<Z<H6OU(J*NW.C:I9VXN+K3;R"$]))8&5?
MS(Q5*@AIK<****!!1110 4444 =3X/\ %\WAZY$$Y:33Y&^=.IC/]Y?ZBO9K
M:YAN[>.XMY%DAD7<KJ<@BOG"NI\'^,)O#UR()RTFG2-\Z=3&?[R_U%;4ZEM&
M>G@<=[/]W4^'\CVNBHK>XAN[>.XMY%DAD7<CJ<@BI:Z3WT[ZH****8!1110
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M1>4:8LN%]-Z\GKGVJEX1T2ZTO7-7GNM,,+7%W=2I<^7!AT>8LHWJQD.00<,
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MVYKS_P KX;>?YGGZUMSGRL+M^G3/ZUDW9W1Y56JH57.#B^9+=_UH=A\(@_\
M8^IL@<6AN_W(;_=&?TVUZ)7.^#]7T/4M,:#087AM;4A-C)MP3SZG/UKHJN*L
MCMPL5&C%)W"BBBJ.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^S@LYYT55@^S0HY"29QG('!RV0?85QU]XLUS4K2>UO+]I;>;;OC,:!?E.1@
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M_/W98GW/>KNI^*]<UBU^RWU^SP%MQC1%C#'U(4#/XT^9&L:\$M+JU].]^_\
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M% !1110 4444 %4='_Y!</\ P+_T(U>JCH__ ""X?^!?^A&@"]1110 4444
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M?] ;4/\ P%?_  H_X1W7/^@-J'_@*_\ A7T%11[!=P_LF'\S/GW_ (1W7/\
MH#:A_P" K_X4?\([KG_0&U#_ ,!7_P *^@J*/8+N']DP_F9\^_\ ".ZY_P!
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M@O7BCL+AYT+PK$QD4=2N#D?E0)['">(M>\(:_H5E?ZHEX]H9G2'8I5MP SD
MUR_F_##_ )]]2_-O\:OOXS\ 26,=DV@7IMHG+I'Y285CU/\ K/:J_P#PDOPW
M_P"A:N_^_2__ !RL&[]CQ:E2,Y<SE!^J.S\ MX<:SO?^$<2X2+S%\WSLYW8X
MQDUV%<GX%U'P_J%I>-X?TZ6RC1U$JR*!N..#PQKK*UCL>IAK>R5K?+8*S=;T
MC^VK);;^T=0L-L@?S;&?RG. 1@G!XYZ>PK2HJMC9I-69Q_\ P@'_ %-WBO\
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MVG[3++_RUV;=NWV.?O?I6%_PMG_J"?\ DU_]A5.LEHV95*V%IRY)O7YG0?\
M"$?]31XE_P#!A_\ 8T?\(1_U-'B7_P &'_V-<_\ \+9_Z@G_ )-?_84?\+9_
MZ@G_ )-?_84O;Q[D?6L'W_,Z#_A"/^IH\2_^##_[&C_A"/\ J:/$O_@P_P#L
M:Y__ (6S_P!03_R:_P#L*/\ A;/_ %!/_)K_ .PH]O'N'UK!]_S.@_X0C_J:
M/$O_ (,/_L:/^$(_ZFCQ+_X,/_L:Y_\ X6S_ -03_P FO_L*/^%L_P#4$_\
M)K_["CV\>X?6L'W_ #.@_P"$(_ZFCQ+_ .##_P"QH_X0C_J:/$O_ (,/_L:Y
M_P#X6S_U!/\ R:_^PH_X6S_U!/\ R:_^PH]O'N'UK!]_S.@_X0C_ *FCQ+_X
M,/\ [&C_ (0C_J:/$O\ X,/_ +&N?_X6S_U!/_)K_P"PH_X6S_U!/_)K_P"P
MH]O'N'UK!]_S.@_X0C_J:/$O_@P_^QH_X0C_ *FCQ+_X,/\ [&N?_P"%L_\
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M_"$?]31XE_\ !A_]C1_PA'_4T>)?_!A_]C7/_P#"V?\ J"?^37_V%'_"V?\
MJ"?^37_V%'MX]P^M8/O^9T'_  A'_4T>)?\ P8?_ &-'_"$?]31XE_\ !A_]
MC7/_ /"V?^H)_P"37_V%'_"V?^H)_P"37_V%'MX]P^M8/O\ F=!_PA'_ %-'
MB7_P8?\ V-'_  A'_4T>)?\ P8?_ &-<_P#\+9_Z@G_DU_\ 84?\+9_Z@G_D
MU_\ 84>WCW#ZU@^_YG0?\(1_U-'B7_P8?_8T?\(1_P!31XE_\&'_ -C7/_\
M"V?^H)_Y-?\ V%'_  MG_J"?^37_ -A1[>/</K6#[_F=!_PA'_4T>)?_  8?
M_8T?\(1_U-'B7_P8?_8US_\ PMG_ *@G_DU_]A1_PMG_ *@G_DU_]A1[>/</
MK6#[_F=!_P (1_U-'B7_ ,&'_P!C1_PA'_4T>)?_  8?_8US_P#PMG_J"?\
MDU_]A1_PMG_J"?\ DU_]A1[>/</K6#[_ )G0?\(1_P!31XE_\&'_ -C1_P (
M1_U-'B7_ ,&'_P!C7/\ _"V?^H)_Y-?_ &%'_"V?^H)_Y-?_ &%'MX]P^M8/
MO^9TMQX&V3LO_"4^)SC')U#GI_NU%_PA'_4T>)?_  8?_8UA2_%WS92_]AXS
MV^U__84S_A;/_4$_\FO_ +"CV\>X?6L'W_,Z#_A"/^IH\2_^##_[&C_A"/\
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MS_U!/_)K_P"PH]O'N'UK!]_S.@_X0C_J:/$O_@P_^QH_X0C_ *FCQ+_X,/\
M[&N?_P"%L_\ 4$_\FO\ ["C_ (6S_P!03_R:_P#L*/;Q[A]:P??\SH/^$(_Z
MFCQ+_P"##_[&C_A"/^IH\2_^##_[&N?_ .%L_P#4$_\ )K_["C_A;/\ U!/_
M ":_^PH]O'N'UK!]_P SH/\ A"/^IH\2_P#@P_\ L:/^$(_ZFCQ+_P"##_[&
MN?\ ^%L_]03_ ,FO_L*/^%L_]03_ ,FO_L*/;Q[A]:P??\SH/^$(_P"IH\2_
M^##_ .QH_P"$(_ZFCQ+_ .##_P"QKG_^%L_]03_R:_\ L*/^%L_]03_R:_\
ML*/;Q[A]:P??\SH/^$(_ZFCQ+_X,/_L:/^$(_P"IH\2_^##_ .QKG_\ A;/_
M %!/_)K_ .PKLO#WB*S\16/GVYV2+Q)"3DH?ZCWIQJJ3LF:4JN&JRY8/7YF;
M_P (1_U-'B7_ ,&'_P!C1_PA'_4T>)?_  8?_8UU5%7S,Z?8P['*_P#"$?\
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MBO\ \&7_ -C785DW/BCP_9W#V]UKNF03QG#QRW<:LI]""<BCFD'L:?8Q?^$
M_P"IN\5_^#+_ .QH_P"$ _ZF[Q7_ .#+_P"QKH[#5],U4,=.U&TO OWOL\ZR
M8^NTFI;>^M+N2>.VNH)I('V3+'(&,;>C =#[&CFD'L:?8Y?_ (0#_J;O%?\
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MR_\ L:/^$ _ZF[Q7_P"#+_[&NPHHYV'L8=CC_P#A /\ J;O%?_@R_P#L:/\
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MIL-.F)$,KDR8."552Q'X@8K7OO'NJV^I21Z1+#::;$Y6&VBA384!XSQSGO\
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MVC.0?FQG-"C<*-#VD7+73LK_ *H\6HKJ_&UI#<>.YK/3K7RI)'CC9 A16E(
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M+4C:T2[AG&><GOWI65KF:ITW!SYGIIMWOY^1YW1112.<**** "BBB@ HHHH
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M<L[=78]6-:=%%6=D8J*45L%%%% PHHHH **** "BBB@ HHHH **** "BBB@
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MK-#_ .?K4/\ OXG_ ,11_P *LT/_ )^M0_[^)_\ $5YI_P )%KG_ $&=0_\
M I_\:/\ A(M<_P"@SJ'_ (%/_C1SP[!]9PO_ #[/2_\ A5FA_P#/UJ'_ '\3
M_P"(H_X59H?_ #]:A_W\3_XBO-/^$BUS_H,ZA_X%/_C1_P )%KG_ $&=0_\
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M-/\ A(M<_P"@SJ'_ (%/_C1_PD6N?]!G4/\ P*?_ !HYX=@^LX7_ )]GI?\
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MS<*I^:*>9G5AZ8)_6CGI]AK$X2^M,] _X59H?_/UJ'_?Q/\ XBC_ (59H?\
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MIMD^S+"J/MD^7Y>2"<<GFM?5+_Q7X--EJFJ:S!JVFRSI!=P"T6$P;SC<A')
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MB@ HHHH **** "J.C_\ (+A_X%_Z$:O51T?_ )!</_ O_0C0!>HHHH ****
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M#6N?\)#I(O\ [-]GR[)LW[^G?.!6O132?5G13IU8RO.=UZ)'FWC#_DIF@_\
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M^ESZWJUOIUL\:33L55I"0HX)YP">WI3]=T2[\/:M+IUYL,L84[HR2K C(()
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M=J\GV%'.@6,B[-Z)JYZ=17FGAKPW=^)K_P#X2#7R7B<[HHF_Y:>G'9!V'?\
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MSWL#@?9_O*F_Y!1116YZ84444 %%%% !4T?_ ![3_P# ?YU#4T?_ ![3_P#
M?YTF!#1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JQH_\
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MA3N%0$X)[G-9:_#;;X3M]#_M;/DZD+_SOLW7DG9MW>_7/X4)H&F9WQ!T'2=
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M5=IJ7P^_M#XAVGBO^U/+^S[/]%^SYW;01]_=QU]*7_A7_P#Q<_\ X3/^T_\
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M@]3$?4>U>P12QSQ)+$ZO&XRK*<@BMH2C)'IX:K2KQNDK]44/^$=T/_H#:?\
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M::SJ]IJOVV_LKZU0QK-9RA"R$YVMD'(S2NMAV>YYM\3Q%!XHF.CO=+-+9?\
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MSDG%>@#X;Z7%/<&TU/6;.TN9#)+8VUX4A8GKP!D9]C5JT\ Z+9:#JNB1"?\
ML[4I6F>$N,1$X^X0,@#:N,YZ4[H5F9OB74+&WN/#%L-$.KZV^9-/@,WE*A5
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MR+?H)E@B6,D2[QQST').<^G>H?#WAJ]N?@;KLZ1.9+BX6XA0#EXXBN2/R?\
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MRS,I (SR,*/6FHM.YK"A*G6YT[IK6_X&W1115G83Q?\ 'K/_ ,!_G4%3Q?\
M'K/_ ,!_G4% V%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /+_ (G]--_ZZW'_ +3KB7U6]?2(]*:;-E'*9EBVKPY&,YQGH?6O2?'/A_5-
M=%G_ &;:^?Y,LWF?O%7&=F/O$>AKC_\ A /$_P#T#/\ R/%_\564XRYM$>)C
M:55UY.$79VV3[(YJKUYK%_J%W!=74_F30(D<;;%&U5^Z, 8.*U_^$ \3_P#0
M,_\ (\7_ ,51_P (!XG_ .@9_P"1XO\ XJHY9=CE5"NM%%_<S#U#4+K5+^6]
MO9?-N)3EWVA<G&.@ ':EO=1N]1-N;N7S/L\"V\7R@;8U^Z.!SCU/-;?_  @'
MB?\ Z!G_ )'B_P#BJ/\ A /$_P#T#/\ R/%_\51RR[ Z&(=[Q>ODS%TW4KO1
M]0BO[";R;F+.Q]H;&00>"".A-266M:CI]C>65K<M';7BA9X]H.\#/J,CJ>F*
MUO\ A /$_P#T#/\ R/%_\51_P@'B?_H&?^1XO_BJ.678:HXA;1?W,HV?B;5[
M""S@MKL)'9R-+ IB1MCL"">1SU/6LN::2XGDGF8O+(Q=V/<DY)KHO^$ \3_]
M S_R/%_\51_P@'B?_H&?^1XO_BJ.678'1Q#5G%_<S)O-9U"_@LH;FX+I8IY=
MOA54HO'&0,GH.M:D?CWQ-%&B#5&;8,*[PQNX_P"!%2?UIW_" >)_^@9_Y'B_
M^*H_X0#Q/_T#/_(\7_Q5'+/S&H8I.Z4OQ,Z#Q'K%OJQU1+^5KXJ5,TF'.#U'
MS C%4;2[GL+N*[M96BGA8.CKU!%;_P#P@'B?_H&?^1XO_BJ/^$ \3_\ 0,_\
MCQ?_ !5'++L+V.(?V7]S*</BO6H-;GUB.]Q?SILDE\I#N7CC;C'\([=JO_\
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M .*IO_" >)_^@9_Y'B_^*HY9=B70KM6<7]S*6F>*=:T>W-O8W[QP$Y\IT61
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M[0,_C34\4:S'K4FL)>D7\B!'E$:?,H &"N-O11V[5>_X0#Q/_P! S_R/%_\
M%4?\(!XG_P"@9_Y'B_\ BJ.6?9C=/%-W:E?YD%MXT\06:3)!J&U)96F9##&R
MAV.25!7"\\\8IC>+M=>]L[Q]0=[FS+F"1T5F7?\ >ZCGKWSCMBK7_" >)_\
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M.C_\@N'_ (%_Z$: +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML_\ P'^=05/%_P >L_\ P'^=04#84444""BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH Y3Q%XM_X180_Z%]I^TRR_P#+79MV[?8Y^]^E87_"V?\
MJ"?^37_V%5_B?TTW_KK<?^TZ\]K.=22E9,\C&8RM3K.$)::=%V/2O^%L_P#4
M$_\ )K_["C_A;/\ U!/_ ":_^PKS6BI]K/N<W]H8G^;\%_D>E?\ "V?^H)_Y
M-?\ V%'_  MG_J"?^37_ -A7FM%'M9]P_M#$_P WX+_(]*_X6S_U!/\ R:_^
MPH_X6S_U!/\ R:_^PKS6BCVL^X?VAB?YOP7^1Z5_PMG_ *@G_DU_]A1_PMG_
M *@G_DU_]A7FM%'M9]P_M#$_S?@O\CTK_A;/_4$_\FO_ +"C_A;/_4$_\FO_
M +"O-:*/:S[A_:&)_F_!?Y'I7_"V?^H)_P"37_V%'_"V?^H)_P"37_V%>:T4
M>UGW#^T,3_-^"_R/2O\ A;/_ %!/_)K_ .PH_P"%L_\ 4$_\FO\ ["O-:*/:
MS[A_:&)_F_!?Y'I7_"V?^H)_Y-?_ &%'_"V?^H)_Y-?_ &%>:T4>UGW#^T,3
M_-^"_P CTK_A;/\ U!/_ ":_^PH_X6S_ -03_P FO_L*\UHH]K/N']H8G^;\
M%_D>FM\7=T2)_8?W<\_:^N?^ 4S_ (6S_P!03_R:_P#L*\UHI>UGW#^T,3_-
M^"_R/2O^%L_]03_R:_\ L*/^%L_]03_R:_\ L*\UHI^UGW#^T,3_ #?@O\CT
MK_A;/_4$_P#)K_["C_A;/_4$_P#)K_["O-:*/:S[A_:&)_F_!?Y'I7_"V?\
MJ"?^37_V%'_"V?\ J"?^37_V%>:T4>UGW#^T,3_-^"_R/2O^%L_]03_R:_\
ML*/^%L_]03_R:_\ L*\UHH]K/N']H8G^;\%_D>E?\+9_Z@G_ )-?_84?\+9_
MZ@G_ )-?_85YK11[6?</[0Q/\WX+_(]*_P"%L_\ 4$_\FO\ ["C_ (6S_P!0
M3_R:_P#L*\UHH]K/N']H8G^;\%_D>E?\+9_Z@G_DU_\ 84?\+9_Z@G_DU_\
M85YK11[6?</[0Q/\WX+_ "/2O^%L_P#4$_\ )K_["C_A;/\ U!/_ ":_^PKS
M6BCVL^X?VAB?YOP7^1Z5_P +9_Z@G_DU_P#84?\ "V?^H)_Y-?\ V%>:T4>U
MGW#^T,3_ #?@O\CTK_A;/_4$_P#)K_["C_A;/_4$_P#)K_["O-:*/:S[A_:&
M)_F_!?Y'ILOQ=\V4O_8>,]OM?_V%,_X6S_U!/_)K_P"PKS6BE[6?</[0Q/\
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M'6/^07-_P'_T(4 4J***DP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** )XO^/6?_@/\Z@J>+_CUG_X#_.H*!L****!!1110 4444 %%%%
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MBHBW,BJJC  #'  KNM,@EMOAYIUYIWARSU2\DN9$E,MAY[!03@\#/8"LS5?
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MX1TTZKL>:T5Z5_PJ;_J-_P#DK_\ 9T?\*F_ZC?\ Y*__ &=3[*?8YO[/Q/\
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M2O\ ]G3]E/L']GXG^7\5_F>:T5Z5_P *F_ZC?_DK_P#9T?\ "IO^HW_Y*_\
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M@L!R/GJ[]@HHHK<]4**** "BBB@ HHHH **** "BBB@ HHHH *FC_P"/:?\
MX#_.H:FC_P"/:?\ X#_.DP(:***8!1110 4444 %%%% !1110 4444 %%%%
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MC_\ A/\ _J4?%?\ X+?_ +*C_A/_ /J4?%?_ (+?_LJ["BBZ[!R3_F_ X_\
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M\5_^"W_[*NPHHNNP<D_YOP./_P"$_P#^I1\5_P#@M_\ LJ/^$_\ ^I1\5_\
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M3\4?^"X__%5Z#11[O8/92_F_ \^_X3"7_H4_%'_@N/\ \51_PF$O_0I^*/\
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M+C_\57H-%'N]@]E+^;\#S[_A,)?^A3\4?^"X_P#Q5'_"82_]"GXH_P#!<?\
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M_P 57H%%',NP<D_YOP//_P#A,9?^A3\4?^"X_P#Q5'_"8R_]"GXH_P#!<?\
MXJO0**.9=@Y)_P WX'G_ /PF,O\ T*?BC_P7'_XJC_A,9?\ H4_%'_@N/_Q5
M>@44<R[!R3_F_ \__P"$QE_Z%/Q1_P""X_\ Q5'_  F,O_0I^*/_  7'_P"*
MKT"BCF78.2?\WX'G_P#PF,O_ $*?BC_P7'_XJC_A,9?^A3\4?^"X_P#Q5>@4
M4<R[!R3_ )OP.#?QK(T,:#PEXIRN<_\ $N]?^!5'_P )C+_T*?BC_P %Q_\
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M/_\ J4?%?_@M_P#LJ["BE==@Y)_S?@<?_P )_P#]2CXK_P#!;_\ 94?\)_\
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M1_PG_P#U*/BO_P %O_V5=A11==@Y)_S?@<?_ ,)__P!2CXK_ /!;_P#94?\
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M\5_^"W_[*NPHHNNP<D_YOP./_P"$_P#^I1\5_P#@M_\ LJ/^$_\ ^I1\5_\
M@M_^RKL**+KL')/^;\#C_P#A/_\ J4?%?_@M_P#LJ/\ A/\ _J4?%?\ X+?_
M +*NPHHNNP<D_P";\#C_ /A/_P#J4?%?_@M_^RH_X3__ *E'Q7_X+?\ [*NP
MHHNNP<D_YOP./_X3_P#ZE'Q7_P""W_[*C_A/_P#J4?%?_@M_^RKL**+KL')/
M^;\#C_\ A/\ _J4?%?\ X+?_ +*C_A/_ /J4?%?_ (+?_LJ["BBZ[!R3_F_
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M<5*+NF%%%%,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<A4>42<X7.<Y./2L7XD_\A#P;_V'K?\ G6'XD\.0^*?BMJ.G2/Y4W]A++;S
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M@JR$XP.<[L]L?C7+ZA)J'BGX@7F@1:M>:;INEV\<D_V*3RY9I7&0-_4* ?\
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M "BBB@ HHHH **** "BBB@ HHHH *HZ;_P O?_7R_P#2KU4=-_Y>_P#KY?\
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MNK-QTXP?Z\5-(TKQ/=>,]3UO6-/BM8KK2_L\$4<ZR>4=_$9.>3U8D#'S=:]
MHI7'8\NT_P $:]!X!\-K"L5MK^BW$LZ0S.&1PTC$H64D<J1_+CMO)>>.=7O[
M*$Z5#H-I'('NYVN8[EI5'5$4 XSZGG^1[.BBXN4XK4&\6VNHZA;S:%:^(])G
M??;*9HH6A7'W&#C# >O)_D+'@#PU=>'-+OA>1P6\M[>/="UMVS';JV $![X
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MGCWJN72Y/-K8]&JEK.H?V3H>H:EY7F_9+:2?R]VW?L4MC.#C..N*NUB>,?\
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M% !1110 4444 %4='_Y!</\ P+_T(U>JCH__ ""X?^!?^A&@"]1110 4444
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M_M"?D?\ ?->J405NEBL)",;\L'$****L[ HHHH **** "BBB@ HHHH ****
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M/H:V/"?AV7P_8W)N[O[7J%[<-<W4X&%+MV4=E';_ "*WZ*+A8****0PHHHH
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MT_\ 0:O4<WD'LO[S./\ ^+D?]2I_Y,4?\7(_ZE3_ ,F*["BCF\@]E_>9Q_\
MQ<C_ *E3_P F*/\ BY'_ %*G_DQ7844<WD'LO[S./_XN1_U*G_DQ1_Q<C_J5
M/_)BNPHHYO(/9?WF<?\ \7(_ZE3_ ,F*/^+D?]2I_P"3%=A11S>0>R_O,X__
M (N1_P!2I_Y,4?\ %R/^I4_\F*["BCF\@]E_>9Q__%R/^I4_\F*/^+D?]2I_
MY,5V%%'-Y![+^\SC_P#BY'_4J?\ DQ1_Q<C_ *E3_P F*["BCF\@]E_>9Q__
M !<C_J5/_)BC_BY'_4J?^3%=A11S>0>R_O,X_P#XN1_U*G_DQ1_Q<C_J5/\
MR8KL**.;R#V7]YG"6/\ PL/_ $GRO^$7_P!>V[=]H^]QG'M5O_BY'_4J?^3%
M=%IO_+W_ -?+_P!*O4<WD'LO[S./_P"+D?\ 4J?^3%'_ !<C_J5/_)BNPHHY
MO(/9?WF<?_Q<C_J5/_)BC_BY'_4J?^3%=A11S>0>R_O,X_\ XN1_U*G_ ),4
M?\7(_P"I4_\ )BNPHHYO(/9?WF<?_P 7(_ZE3_R8H_XN1_U*G_DQ7844<WD'
MLO[S./\ ^+D?]2I_Y,4?\7(_ZE3_ ,F*["BCF\@]E_>9Q_\ Q<C_ *E3_P F
M*/\ BY'_ %*G_DQ7844<WD'LO[S./_XN1_U*G_DQ1_Q<C_J5/_)BNPHHYO(/
M9?WF<?\ \7(_ZE3_ ,F*/^+D?]2I_P"3%=A11S>0>R_O,X__ (N1_P!2I_Y,
M4?\ %R/^I4_\F*["BCF\@]E_>9Q__%R/^I4_\F*/^+D?]2I_Y,5V%%'-Y![+
M^\SC_P#BY'_4J?\ DQ1_Q<C_ *E3_P F*["BCF\@]E_>9Q__ !<C_J5/_)BC
M_BY'_4J?^3%=A11S>0>R_O,X_P#XN1_U*G_DQ1_Q<C_J5/\ R8KL**.;R#V7
M]YG'_P#%R/\ J5/_ "8H_P"+D?\ 4J?^3%=A11S>0>R_O,X__BY'_4J?^3%'
M_%R/^I4_\F*["BCF\@]E_>9Q_P#Q<C_J5/\ R8H_XN1_U*G_ ),5V%%'-Y![
M+^\SC_\ BY'_ %*G_DQ1_P 7(_ZE3_R8KL**.;R#V7]YG'_\7(_ZE3_R8H_X
MN1_U*G_DQ7844<WD'LO[S./_ .+D?]2I_P"3%'_%R/\ J5/_ "8KL**.;R#V
M7]YG'_\ %R/^I4_\F*/^+D?]2I_Y,5V%%'-Y![+^\SC_ /BY'_4J?^3%'_%R
M/^I4_P#)BNPHHYO(/9?WF<?_ ,7(_P"I4_\ )BC_ (N1_P!2I_Y,5V%%'-Y!
M[+^\SC_^+D?]2I_Y,4?\7(_ZE3_R8KL**.;R#V7]YG'_ /%R/^I4_P#)BC_B
MY'_4J?\ DQ7844<WD'LO[S./_P"+D?\ 4J?^3%'_ !<C_J5/_)BNPHHYO(/9
M?WF<?_Q<C_J5/_)BC_BY'_4J?^3%=A11S>0>R_O,X_\ XN1_U*G_ ),4?\7(
M_P"I4_\ )BNPHHYO(/9?WF<?_P 7(_ZE3_R8H_XN1_U*G_DQ7844<WD'LO[S
M./\ ^+D?]2I_Y,4?\7(_ZE3_ ,F*["BCF\@]E_>9Q_\ Q<C_ *E3_P F*/\
MBY'_ %*G_DQ7844<WD'LO[S./_XN1_U*G_DQ1_Q<C_J5/_)BNPHHYO(/9?WF
M<?\ \7(_ZE3_ ,F*/^+D?]2I_P"3%=A11S>0>R_O,X__ (N1_P!2I_Y,4?\
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M1110 4444 %%%% !1110 4444 %4=8_Y!<W_  '_ -"%7JHZQ_R"YO\ @/\
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M_P#D%P_\"_\ 0C0!>HHKYP\/>./BEXINY;;1]2%S-#'YKH8+9/ER!U90.I%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG:>'=)T^\,K-$)&F1<DJ.%4*222<5T7B=9_!GP"LM&N?DO;K$++GE"[M*P_
M94_6O2] \/Z+I]E:7-EI%A;3M"A,L-NB,25&>0,UY!\==0DU+Q1H^@6V6>*/
M=M'>21@ /R4?G6AN<_KVEZ9%\'/#\T%[:R:C%<O+-"DREU67/50<\;(Q7K-A
MK USX$7-X3F0:+<0R9/.](V0D_7;G\:Y?7?@9I.G^'+^\LK_ %"6]M[=I41V
M0H[*,XP%!YQZUD_#361+\,/&NBNWS064]S&#_=:%E;'T*C_OJ@#G_AS\1H?
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M1?Q!_P! +4__  $D_P */^$7\0?] +4__ 23_"HLSF]G/LS)HK6_X1?Q!_T
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M_P ([XS_ .A\_P#*1#_C1_PCOC/_ *'S_P I$/\ C78457,_Z1G[&/=_>_\
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M#Y_Y2(?\:/\ A'?&?_0^?^4B'_&NPHHYG_2#V,>[^]_YG'_\([XS_P"A\_\
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MZ6$K2^./,08RG]DQ#/([YKNZHZQ_R"YO^ _^A"CF8>QCW?WO_,YW_A'?&?\
MT/G_ )2(?\:/^$=\9_\ 0^?^4B'_ !KL**.9_P!(/8Q[O[W_ )G'_P#".^,_
M^A\_\I$/^-'_  COC/\ Z'S_ ,I$/^-=A11S/^D'L8]W][_S./\ ^$=\9_\
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M9_\ 0^?^4B'_ !H_X1WQG_T/G_E(A_QKL**.9_T@]C'N_O?^9Q__  COC/\
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MS_RD0_XUV%%',_Z0>QCW?WO_ #./_P"$=\9_]#Y_Y2(?\:/^$=\9_P#0^?\
ME(A_QKL**.9_T@]C'N_O?^9Q_P#PCOC/_H?/_*1#_C1_PCOC/_H?/_*1#_C7
M844<S_I![&/=_>_\SC_^$=\9_P#0^?\ E(A_QH_X1WQG_P!#Y_Y2(?\ &NPH
MHYG_ $@]C'N_O?\ F<?_ ,([XS_Z'S_RD0_XT?\ ".^,_P#H?/\ RD0_XUV%
M%',_Z0>QCW?WO_,X_P#X1WQG_P!#Y_Y2(?\ &C_A'?&?_0^?^4B'_&NPHHYG
M_2#V,>[^]_YG'_\ ".^,_P#H?/\ RD0_XT?\([XS_P"A\_\ *1#_ (UV%%',
M_P"D'L8]W][_ ,SC_P#A'?&?_0^?^4B'_&C_ (1WQG_T/G_E(A_QKL**.9_T
M@]C'N_O?^9Q__".^,_\ H?/_ "D0_P"-'_".^,_^A\_\I$/^-=A11S/^D'L8
M]W][_P SC_\ A'?&?_0^?^4B'_&C_A'?&?\ T/G_ )2(?\:["BCF?](/8Q[O
M[W_F<?\ \([XS_Z'S_RD0_XT?\([XS_Z'S_RD0_XUV%%',_Z0>QCW?WO_,X_
M_A'?&?\ T/G_ )2(?\:/^$=\9_\ 0^?^4B'_ !KL**.9_P!(/8Q[O[W_ )G'
M_P#".^,_^A\_\I$/^-'_  COC/\ Z'S_ ,I$/^-=A11S/^D'L8]W][_S./\
M^$=\9_\ 0^?^4B'_ !H_X1WQG_T/G_E(A_QKL**.9_T@]C'N_O?^9Q__  CO
MC/\ Z'S_ ,I$/^-'_".^,_\ H?/_ "D0_P"-=A11S/\ I![&/=_>_P#,X_\
MX1WQG_T/G_E(A_QH_P"$=\9_]#Y_Y2(?\:["BCF?](/8Q[O[W_F<?_PCOC/_
M *'S_P I$/\ C1_PCOC/_H?/_*1#_C7844<S_I![&/=_>_\ ,X__ (1WQG_T
M/G_E(A_QH_X1WQG_ -#Y_P"4B'_&NPHHYG_2#V,>[^]_YG'_ /".^,_^A\_\
MI$/^-'_".^,_^A\_\I$/^-=A11S/^D'L8]W][_S./_X1WQG_ -#Y_P"4B'_&
MC_A'?&?_ $/G_E(A_P :["BCF?\ 2#V,>[^]_P"9Q_\ PCOC/_H?/_*1#_C1
M_P ([XS_ .A\_P#*1#_C7844<S_I![&/=_>_\SC_ /A'?&?_ $/G_E(A_P :
M/^$=\9_]#Y_Y2(?\:["BCF?](/8Q[O[W_F<?_P ([XS_ .A\_P#*1#_C1_PC
MOC/_ *'S_P I$/\ C7844<S_ *0>QCW?WO\ S./_ .$=\9_]#Y_Y2(?\:/\
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M4N"!N ( (P3CWKK:J-[:G5AY2<7S--WZ!1115&X4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %4=8_P"07-_P'_T(5>JCK'_(+F_X
M#_Z$* +U%%5=2U"#2M+NM0N6Q#;1-*_T49_.@#Q;XHO=^,?B!:>%]-.\V<+,
M0.1YA7><_P# 0H^I-=-\%->.H>%)=)F;_2--DV@'KY;9*_D=P_ 5Y[X'\0:U
M9^(=3\3Q>%;_ %N:\+H9(%?;$S,&89"-S]T8XP/K5CPCK=QH'Q:\^\TNXT>W
MU=V1[6Y# H)&RI&Y1QO'7'3-:M:6,D];GLOBKQMHO@Z")]3F<RRY,<$*[I'
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MF*&DDQ)MM'H=%%%0:!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLP:CJWBS4]2>#&Q=S1Y Z*6WL<>PQ6KXU^'5AXPF@O%NI+#4H  EU$N[(!R
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW5/%.I>.,VFD>%HIXL[1/<Q^85_X%P$_,UZCJ\MG!I%U-J$:26D49>5'7<&
MYQ@]>E>8VFM^/_$,;7?AZUBLM-4E88T2(+@=@7'/X<5G-]#S\9)\RA=V?1*[
M-3P-\/;_ $#55U74+J$2!&46\0+=1W;@?EFO1ZXCP3XNU#4[^ZT37;<0:I;+
MOSMV[USSD>HR.G!!]J[>JA:VAOA(TE2_=;?J%%%%4=)XS%\2K:?6[_0OB'I-
M@L4#F.-TM&=58'DD,6.",$%1_.N+\:2^$;C5M/\ ^$$BN!>&4%FB#JI;(V;
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M!<W_  '_ -"%7JHZQ_R"YO\ @/\ Z$* +U%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9(SM/N*;30DTRU1112&%%%% !1110 4444 %%%% !1110 51UC_D%S?\!_\
M0A5ZJ.L?\@N;_@/_ *$* .=_X5;X,_Z W_DU-_\ %T?\*M\&?] ;_P FIO\
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M_P#%T?\ "K?!G_0&_P#)J;_XNNPHHYY=P]A2_E7W''_\*M\&?] ;_P FIO\
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M_H#?^34W_P 71_PJWP9_T!O_ ":F_P#BZ["BCGEW#V%+^5?<<?\ \*M\&?\
M0&_\FIO_ (NC_A5O@S_H#?\ DU-_\77844<\NX>PI?RK[CC_ /A5O@S_ * W
M_DU-_P#%T?\ "K?!G_0&_P#)J;_XNNPHHYY=P]A2_E7W''_\*M\&?] ;_P F
MIO\ XNC_ (5;X,_Z W_DU-_\77844<\NX>PI?RK[CC_^%6^#/^@-_P"34W_Q
M='_"K?!G_0&_\FIO_BZ["BCGEW#V%+^5?<<?_P *M\&?] ;_ ,FIO_BZ/^%6
M^#/^@-_Y-3?_ !==A11SR[A["E_*ON./_P"%6^#/^@-_Y-3?_%T?\*M\&?\
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M&?\ 0&_\FIO_ (NNPHHYY=P]A2_E7W''_P#"K?!G_0&_\FIO_BZ/^%6^#/\
MH#?^34W_ ,77844<\NX>PI?RK[CC_P#A5O@S_H#?^34W_P 71_PJWP9_T!O_
M ":F_P#BZ["BCGEW#V%+^5?<<?\ \*M\&?\ 0&_\FIO_ (NC_A5O@S_H#?\
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M_P#A5O@S_H#?^34W_P 71_PJWP9_T!O_ ":F_P#BZ["BCGEW#V%+^5?<<?\
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MN>!Z5-,_Y.1N_K)_Z(KG/#>KVWASQ)JR^+O#MSJNMS2 P[XA(V\$YX;L>,,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>>F?O5SG_%V_\_9*RE9O9GF8GEG-2<)?);V9O:?HVHS?%74M6N8MMI! (X9
M,!R57 'K@;L^]=Q7!^%?^%@?VXG_  D/_(/V-N_U'WL<?<YKO*N.QU86W*VD
MU=MZA1115'2>7^"_".N:3\4_$.LWUCY6GW?VGR)O-1M^^=67@,2,J">17J%%
M%-NXDK!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51UC_
M )!<W_ ?_0A5ZJ.L?\@N;_@/_H0H O5X_P#M'?\ )/-/_P"PK'_Z*EKV"O'_
M -H[_DGFG_\ 85C_ /14M &1H'P!\-:UX0TK4VU+5HKN]L8;AL/&8U=T#'"[
M,XR>F?QJI\(;_4_!WQ,U+X?W]UYUJ3)Y0SP)%&\,H/0,F21]/2O1/"'CCPII
M_@#0([KQ+I$4L&F6R2Q->1[T81*"I7.<@\8QFO,O <R^,OVB=0\2:>KG3[;S
M91(5P"OE^2N<]-V<@=>#Z&@#K/".K>'KCXWZ]8V?AC[)JL8N/.U+[?))YV'7
M=^Z(VKDX/'3%2ZC\;7?6;S3_  QX0U+7ULW*33P%@H()&0%1SC(X)QFN;\ _
M\G)^*/I=?^C$JQ/\,-:TKQ%J-S\.O&MO#([^;/I[3X:/)) 8#<& R<;E% 'H
MW@/Q]'XWMKECI%]IMQ;-MDCN$)0]CM? !(/!'!%<QK'QMCCURYTKPSX9U#Q#
M+:DK/);$A1C@D;48D \9P!Z5G?#GX@^*->U?7/".N"WGU&SM9C'>6X ^=2$P
MQ7Y2,L,$ =*S_P!F^YM(+/7["1TCU#SD=HG^5R@!'0\\'.?3/O0!Z%X!^)FE
M^/$NH8;>6QU"UYFM)R"0N<;@>XSP> 0>W2N;U/XXP-J]QI_A;PUJ'B)K<GS9
M;8D)@=2NU')&>Y %=%<ZUX=U?1_$^E>%+RP;6_LMT&BME"2&;:06Z?-\Y'S#
M/)KBOV<+W3E\+ZM9^;"NI"],LB$@.8MB!3[@$/\ 3/O0!VG@KXGZ;XWBO+>S
MM9;76+5"SZ?<L%)QQPWIG /&1GI1\.?B-'X]CU))--.FWMA*$DMFG\PX.><[
M5[A@1CM[UYSI$MOJ?[4\]UHI62TB20W4D)RC$6^QCQP?WA4?7FJWB;4)/A-\
M8]3U6%"+'6;&:9%"Y7S2I('U\U1GT#T >F:#\2?^$B^(VJ>%K+2=UMIP?S=0
M^T\94A2-FW^\2/O= 36)JWQMC76KK3O#/AC4/$(M#BXGMB0BXZD;48D=>3@'
M'''-4O@KX<N+3X<:KK3AVU'6O,=&_B*J&5?Q+%S^(KSOX36GCFZL=1@\(>(]
M*TPI*&N+>[13*QQPW,3G;U'7@YXH ]]\"^/M*\>:=-<6*R07-NP2YM9L;XB<
MX/'4'!P?8UY]IO[0,VKP-'IO@J^O=2#$BTM9VE_=@#+EA'D<G&,'ZCC-OX4>
M"]=T7QAJ^OZCKNBZE%?PN)_[-GWYG,BMN("*H_CZ>O2N?_9F13)XGD*C>HM5
M!] ?-S_(?E0!WOA_XGSZG\09/!^JZ =*O!!YL;&[\W<=JN%QL&#M))P3RI'/
M6I_%_P 2?^$:\8Z-X9L])_M&^U(KG_2?*$09]JD_*V>C$], 5QOQMM)?#GBG
MPSX\LT.ZVG6"YV_Q '<H_%?,4_A4'P\(\>?&O7O&)R]AIX\JS8@@'(V(1G_8
M5R1V+"@#W:O./&/Q;M_#OB+_ (1[2=$O-=U=5#26]L2-F1G'"L2<<\#OUKT>
MO%[KQ;K/BKXN7_AK0KC3=#:PCD0ZE-:+-<OM*AE7=QR3T]%)]J .A\#_ !;M
MO%NORZ!?:-=:/JR*S""9MP.WJO(4AL<X(Z9JEK/QKMM#\;:EX;N-"N9FM0%@
M>VE\R2XD(4A!'MX^\>=QZ>^*X7P<HC_:5EC_ +7?5V1)$>]?;F5Q!AON\<'*
MX'I5[3$5_P!J^]+*&V[R,C.#]F'- '6^&?C1%J_BV/PWK/AV\T.]F;9")W).
MXC(#*54KGMP>2*TO'WQ7L/!.H6^E0Z?/JNKS@,MK"VW:"<+EL$Y)Z  GZ<9X
M+XGL8?VB/!CQX5F%D&('7-RZG].*CDEAT[]JMYM5=(XY<>1),<+EK<*F"??Y
M1[T <M\9/&I\71:%%<Z-?:/J5EYYN+.\0@J'\O:P) )!VMV'2OJNOG/]I2[L
M9=6T&VADC:]ABF,X4Y948IL!_$/7T90!P=[\2?[,^*5MX,OM)\F*[56M[_[3
MD/N4D?)MXRP*?>ZT>/\ XDCP5J6D:9;:2=4O]2<JD(N/*V\A5YVMG)./P-<S
M\?M%G&CZ7XLL/DO-'N5W.!R$9AM/X.%_[Z-8/@NZ/Q/^-\OB=T/]GZ3:H848
M?=;;A5_[[,C_ (4 >@^.?BE:>#M2M='M]+N=6UJX0.MG;'& >F3@DDX.  3Q
MVXSG>%/C)%KGBF/PWK'AZ]T/4ILB..=BWS8W -E5*DCIQ6;XK\8:GJ/Q>MO!
MFB?V9IMU"H_XFMW;+-*CM%OQ&#P/E;&.Y)[5QLL,EM^T5H5O<:_)K=U$T:SW
M3JJ[7PQV!5X  (X]2: -?Q3_ ,G0Z'_NP_\ H+5O:AJWAY/V@[33I/#'F:RP
M7;JWV^0;?W)(_<XVGCC]:P?%/_)T.A_[L/\ Z"U)JO\ R==8_1/_ $G- ':>
M-/C!:>&?$*^'],T>YUO5^-\$#;0I(R%!"L2V.< ?C7E'C/Q;'XM^*'A*X.G7
M>FW=M-!#=6=VA5XG\_..0,C!'8?2M_P)+%I_[2/B>/5)$CGG-TMMYIP26E5D
M SW\O./:JWQ:N[&Y^.7AE+5XWG@>UCN2ASM;SR0I]P"/S% 'IOCKXI6?@[5+
M;1[73+G5]8N%#I:6YQ@'IDX)R<'  )X^F<WPI\9(M<\4Q^&]8\/7NAZE-D1Q
MSL6^;&X!LJI4D=.*S?%?C#4]1^+UMX,T3^S--NH5'_$UN[99I4=HM^(P>!\K
M8QW)/:N-EADMOVBM"M[C7Y-;NHFC6>Z=57:^&.P*O  !''J30!5\?>+-8?XW
M6-RVAWQ;2KD1VE@7?-V$D;$D8V\;\#& >G4UUWQ&\4:-+'X1O?$W@B6XO;R-
MW2";4);=[,[DRI 4;CT/('2J'C\A?VDO"Y8@#%KR?^NCT?M#,&\0^$BI!&9>
M1_OQT >H>._B+H_@&SA>_$MQ=W&?(M8<;GQU))X YZ_D#7(6OQU6VO[>'Q/X
M2U/0K:Y/[JYEW,"/[V&13CW&:YWXCO'I_P"T)X;OM995TS9 4DE&44!FZ]AA
MSD^F0:Z?X_W^ECX="VFEA>\GN(WLUR"W!RSCVVY&>G/O0!O_ !%^(Z> M(T_
M4(M.74X[V0HNVY\L ;=P8':V<URVI_'R.QEBNHO".J2:'+)LCU*4F)9?= 5P
M>AXW _2N,^)T%Q;?!3P'#=*ZS*HRK]0/+R ?3C'%=[\6(HU^ R*L:A8XK/8
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M2S<'@94G@\=C2>*? _Q&\3VMG8>(_&GAB>-W\ZUC>01,Y QE2L(+##?3I[4
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ML9&&1@1E6'8BKUOK/AP?"2.\:>T.C#3!$P!&W_5X,>/[V>-O7->/> 8+B/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS[Y' Z GH![  5S_ (C^"'@[Q'J,E^\5W87$K%Y38RJBNQZDJRL!^ %>CT4
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M3T(ZUV]% "    # '0"JFJ:58ZWIL^G:E:QW-G.NV2*0<,.OX$'D$<@U<HH
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M!0/3'3%4]-T'1M&9VTO2;"Q:3[YM;9(BWUV@9H NQ11P0I#$@2.-0JJ.@ X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*_\  V/_ !H_X2WPW_T,&E?^!L?^-%F'/'N;%%8__"6^&_\ H8-*_P# V/\
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M*_\  V/_ !H_X2WPW_T,&E?^!L?^-%F'/'N;%%8__"6^&_\ H8-*_P# V/\
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MG)>'36OHTCA9(U_=;PI!<D\]2",CL*T_^$L\-G_F8-)_\#8_\:KC7_" L/L
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MCV#_ (1+PW_T+^E?^ 4?^%'_  B7AO\ Z%_2O_ */_"BBB[#DCV#_A$O#?\
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MAO\ Z%_2O_ */_"BBB[#DCV#_A$O#?\ T+^E?^ 4?^%'_")>&_\ H7]*_P#
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M_P# */\ PHHHNPY(]@_X1+PW_P!"_I7_ (!1_P"%'_")>&_^A?TK_P  H_\
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M^%'_  B7AO\ Z%_2O_ */_"BBB[#DCV#_A$O#?\ T+^E?^ 4?^%'_")>&_\
MH7]*_P# */\ PHHHNPY(]@_X1+PW_P!"_I7_ (!1_P"%'_")>&_^A?TK_P
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M1_X4?\(EX;_Z%_2O_ */_"BBB[#DCV#_ (1+PW_T+^E?^ 4?^%'_  B7AO\
MZ%_2O_ */_"BBB[#DCV#_A$O#?\ T+^E?^ 4?^%'_")>&_\ H7]*_P# */\
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MCV#_ (1+PW_T+^E?^ 4?^%'_  B7AO\ Z%_2O_ */_"BBB[#DCV#_A$O#?\
MT+^E?^ 4?^%'_")>&_\ H7]*_P# */\ PHHHNPY(]@_X1+PW_P!"_I7_ (!1
M_P"%'_")>&_^A?TK_P  H_\ "BBB[#DCV#_A$O#?_0OZ5_X!1_X4?\(EX;_Z
M%_2O_ */_"BBB[#DCV#_ (1+PW_T+^E?^ 4?^%'_  B7AO\ Z%_2O_ */_"B
MBB[#DCV#_A$O#?\ T+^E?^ 4?^%'_")>&_\ H7]*_P# */\ PHHHNPY(]@_X
M1+PW_P!"_I7_ (!1_P"%'_")>&_^A?TK_P  H_\ "BBB[#DCV#_A$O#?_0OZ
M5_X!1_X4?\(EX;_Z%_2O_ */_"BBB[#DCV#_ (1+PW_T+^E?^ 4?^%'_  B7
MAO\ Z%_2O_ */_"BBB[#DCV#_A$O#?\ T+^E?^ 4?^%'_")>&_\ H7]*_P#
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M_P# */\ PHHHNPY(]@_X1+PW_P!"_I7_ (!1_P"%'_")>&_^A?TK_P  H_\
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M^%'_  B7AO\ Z%_2O_ */_"BBB[#DCV#_A$O#?\ T+^E?^ 4?^%'_")>&_\
MH7]*_P# */\ PHHHNPY(]@_X1+PW_P!"_I7_ (!1_P"%'_")>&_^A?TK_P
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>9"8;"SM[2)FWE((EC4M@#. .O _*K-%%(I*VQ__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img192321128_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_1.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1HT4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &AB^9H X0DE-! 0      %X< 5H  QLE1QP"   " /\< E  "')R-3 Y
M,# X' (% #U-:6-R;W-O9G0@5V]R9" M(%)E<&%R92 M($E03R M(%,M,5]#
M;V]L97D@1')A9G0@-"XR+C(P7RYD;V-X.$))300E       0]/II!77\:'ES
MX)M602<)N3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              FP   2^          $
M 0             $O@   FP                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   FP     4F=H=&QO;F<   2^    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      /FP    $   "@    4@
M >   )G    /?P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 4@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
M]/220K\BK'K-EA,2 UH$N<X_18QOYSW)BY*@YC<MV.\83F,R?::W6"6:.;OW
M_P!:O<@'*SG:BFJL'AMCR7'X^FW8W_P12;U"MI<W+'V5[072\@L('TG5V^W=
MM_.9_.(T4(6GZQ0);A@@ZB;#('\H%OTOZG_D$T_6'TF^W%]5SB7B7;6-FMK
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MY4LDDYLD3]GHWUM/&YY>
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJ94\OOKY$P;PVA#3Y^.G0)^/5KBH428!))G23.F^F^E5(2-PD;;P-]O'A7T
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MOT? ?AI30/C&]D_CPRJ_1\!^&E- ^,;V3^/#*K]'P'X:4T#XQO9/X\,JOT?
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M$:E34OQ?I#A2FI?B_2'"E-2_%^D.%*:E^+](<*'Q[JYU* "(E   !$1$P@
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M(&UQ)%$DIF(5,HH0A3&0D8PZQWT'(1DCLNPJM+5TC(XD*$RE1$%!.Q2=28/
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MKBZD#<*6-=M(]_JG37B:F$I&H6HB=0!SGGSU[:&0;F]$R:1@^]T$H;].D--
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M1@JG*-].'O/?QX\/:U,A$2$22(1-)(H)I)I@!")ID "D(0I0 "%*4 *!2@
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MT4"&,@A.Q9O\\5B3,4NBL9/LB&9N /M U< SDD"^6QS)5+4/(5:/)?8DY"5
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MIZ.,<I0.9C,,4)!H)P*82E.+=PF)@ 1 #:@ B :XYM22E2DG=)*3W@Q6Q29
M)W(!/O$UF]W$>P._%*K3=Q'L#OPI3=Q'L#OPI3=Q'L#OPI3=Q'L#OPI3=ZA'
ML_\ XL#V:4KSKY8DRO:,T\H,K4%2FCH1G+9DS[80,*AY%X=:K4U8!VN:%)-J
M2]@JF<#FYU1HH44^:+M[3"TP5N$2H H!XZD0>)X ?"0:P[@9E93J!!CW'0^,
M_(B<Z?%)14.V3(GL"*1 $0  _B!PT#773A][PQFJB5<YW[-X[=3O[N=6O".
MC^?W56SE"VRN29W]+L-C<0$(1@M'%&*4.I.R5JEX_G&P0C%FW>2+^0K,>Y:R
MK))JQ>E3DY%H^41*YBFRI:I3F@;20)(]4;D9B2,NVFAUJBE!,$S!(!(!($J
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MECED][+=TMVP<TD%;J \S)XD.LK"5$" X=2#%>F0E^3OX: '_C ,=4%P2 (
MUXDP9C0G[#QFNG^WRT/Q\*XT'X@^[ZS%<_SE_P 5*:#\0?=]9AG^<O\ BI30
M?B#[OK,,_P Y?\5*:#\0?=]9AG^<O^*E-!^(/N^LPS_.7_%2@@.@^@/N^LPS
M_.7_ !4J@O+,E%K#9LFLIT#$%I(3$QF%/ID-J<4JJ5E#UQH\0VC%.T>R=C?R
MS8QR[I&K(*I'U0,!>?QMTJ+-L-0\J5$ :=7!0DB94"HD^JI,&3)VKFL:4FXO
M\*L5)"FFU/XH]ZLE2K/JF;5M4F$I4]>&X2I #@79SF( "8AS*03Y(<2IR@Z*
ML9O#R:S9+-;*T&,JK!WD-@@#;*^M%L'K6IYAL$"%(M)/P9UZSL4@932R,B1G
M)%Y3$_\ ZFFEXW92FW/]KB&&I2X6;I804FX8*6W QB""0E1REFZ;(0Z$K2ET
M?8OHC0YZ;[7"_1!TL5GO\-LU)Z"=/.L81B/19I*RZY@.,+NW O%^B3ZBI5M;
MH6[B&"/J4[AI7:.7-HO\:)RI*URD\DZO99^6)46J[9S%7-K'K+)/5,PRJ.V<
M=#P""/ESQXJQ;)IW!I'MF[YT162K+H0.+-R0V_Z&XPSTAP9C$QD0X"IF[25#
M.P^A90L J,*2J.M3ZP46U)@$Z5ROIS]$=WZ&_27C'0YQU=W8-_1,0P._69-_
M@^(MJ=MGBH)2'%V[K=Q97)0D?^(M72E$*372B%,QZO%LV65T':IJ+C4TSHL+
M53Z;3(60; /[^0JHO:Y949%X4RBHR:T0\.+M07+IB\YU1/'6=7.YRD@J.8
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MPZB)E7$>@LJ81U]9CF'77KQIEP750!&8F-AS[:UX&I' 02>T#AI]WQWHORA
M38YDY0R)"CSC3.3*I;4H:&V/A[ $6(79 /\ *(G43'>("4Y@$! -!T]R8N[9
M>W]NA)CD5 <]]M#O';7(8ZH(7:.E(/5XA:N '?K#<M-A4\"D.*([5$'2O3D1
M#Y^GAT#H(?Q.GB/'7<&.L1.<:F,JQ,<$J UD'?>.V1''H])!!F<RM=_6*51M
ML"2!]E<;0</T?#B_!YGX>55IM!P_1\.$'F?AY4IM!P_1\.$'F?AY4IM!P_1\
M.$'F?AY4IM!P_1\.$'F?AY4IJ'#]'PX0>9/A]P!TWT(I7G1G.8'O*]CVRO\
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M;Z;@I !+EF[+-^C+E5GZM@BZ2@B"Y;('&LQDK=FMDKC)0CA-03MTS%$#%$!
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MT+U(60E?$0-B1MI$#;4U:=;SH(3H1J#K/$Z=L\_A5.\E,VW!5'=7M3-S!6>
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M(=)=!4@J)K)*%$ATE4S@)5$E"&,4Y# (&*(@(:;\6%@**DE(&829,R0 .XD
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M_P!C#W8:\AXGRI3:/]C#W8:\AXGRI3:/]C#W8:\AXGRI3:/]C#W8:G<)/O\
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M(((T[_L[:52C(GD7T;(_E*\I;E$0I6@R>?3NOK1[ B0@:KI%0-)7A-NH<@F
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M?RO:_P ,*4VOY7M?X84IM?RO:_PPI3:_E>U_AA2L#8Q_VN#>.YPCTB(_&Z-
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M:U-*BD* _. U.V^NNTB=)YU<4" 4I2D "$*4"E*4HE*4H   4 *4
M-P  >K%[*2/6"5&9F2/N.W?4*;(_8#>'$M>0\3Y4ILC]@-X<->0\3Y4ILC]@
M-X<->0\3Y4ILC]@-X<->0\3Y4ILC]@-X<->0\3Y4ILC]@-X<->0\3Y4ILC]@
M-X<->0\3Y4ILC]@-X<->0\3Y4IL#]@-W8@IS*8(,Q.F8Z<_9VX3M.F^E(,2
M3&I@3 YD#6!(UILCQ]QN[$@2H @"")&IX^ZE-D?L!O#BNO(>)\J4V1[>HWAP
M,G<#Q/E2H.JV2$)6,[+]F^V*B#NX0L0P0:ID$HL'NTH:QNMD" 367,Q@G!5
MU4Y\)'; I50VL?UB DF %$Z:B)[.R.9]TU)3I6A*#  ,$2 = 1M/=MI]TX[(
M_8#=W_U]6+O6:@92)YA0_P#HU&)D#<</+GWB:Y*!@T$!]8#_ !@U]W7]M^*%
MS<%)!@QFD2=H$IWJDZ3![--]]NPQOM4'0.1\'!9X7'.9'FA?6>MQ<4BT!/\
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M$C%$3!F-V#[L$I"!P*P)]V\:3/.K*GD\ 21STB?GYFHV/RS,TG0B>)Y/S$J
MF,)//69:C5R)-?1%5*/R_D4$S"7>)4W2Y2FU#G% #:-D_P!69=[@$DR?5&F^
MW$C>>(TCA5E=P9$H3IVG42=_G3NK]FW+7NT>H![7R?GQ&0%,*BM0O;.<>ET
M= (RGZ[4&R@F-N$3RJ $#T@VM )@K#%1+;R%*,C4#8:Z'4'83IMOK-43<C92
M1'9/;N">W[]=*F_+[E;Y*9@/&,+Y^<TJTR"I&S6KY@L#U>2=/#[( RC7SA56
MNS;LQC%*1O!S4BLH(@!$Q'4 PW;2X9G.@J )]9 .4\=-!M,>XG:KZ'VU0!(.
MT'_.K,!LB&H:=>FHZ<>@W0&OVWXQ@9G0Z2#/ CG5XJ CC.T:SW4]'[ /BQ6J
MTU+P]P^/"E-2\/</CPI34O#W#X\*4U+P]P^/"E-2\/</CPI6OV3?'=7E*/\
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MKNH)2I* <L %("A$A0)(&6*T3 !$$R@ ;N@0#3=T;MWNQ<R)!@ ?;OQF)/\
M+2L;K599)5VZJ[IX]WB*X,T2/Z)B!NZ- '30=>CU=H;]^_%2WH92([0!O'!6
M4D<QRG0U$.K!]4:Z:;DQ]WN/<=JQ#N#;KE-H0HCTAH >CZP'<.@:"&O3KPT'
M00MJ;V (3H- A&61V:R-I@@]HDUF-7SB 05 I5[25(2K.82/66K,J <Y^LH$
M)4K*=.M7K/9,L7<_*M//EM8R+5);X*OYY8[=-Y'H*)HC75)8SIO!*/4N9;N6
MB1D(9<R2+D[9!V=T_7NL7=Q9J<4%./(*#+:R%%(2,W]C)2$>R0)5 !,\:TF.
M]$L)Z4LVJ&Q9X-B##F48G;V3;9<87J6\0:MD'Z4VT3G2\6U7"!*$** EH6YK
M%C8VR BK#'IN$&\LQ;O2M7J::+YF99,AU&4@W3%4B#]H<_,NT 6/S*Y3% QR
MZ&-U%H^FZ;9>22,R0=2)]9!,9=2"F(5.@TYBOGK%L+N\&Q&[PV\"1<6SKB'%
MLJ"V+AM"\K;S2TRA;;H4VZVI"H4A23$Z5G-1ZNP.[&=!YGX>5:ZFH]78'=A!
MYGX>5*:CU=@=V$'F?AY4IJ/5V!W80>9^'E2FOS=@=V!&ADF..@\J5G6@AY.3
MTM-Y_67\(?J]?3BRK<_&.?&KB=AZX'9 YU(ZFO.J:!KZ0\?U"&- OVU?K*^T
MUU:?9'=7SJ;@/TN_$:K34W ?I=^%*:FX#]+OPI34W ?I=^'^0[3P%*JQRJLZ
MY+*ZHQ];IJJ?[IF8RSR%JBAB%6^#[!NDE\(;FHV6*JDO\'F[MLG%H.$E6SFQ
M2,,B\05CQ?\ -Y=FQ](<((EM.CF^FH.4]IW$Z:&=!5AY<#*#J>/81]\\^X[Q
M7[(S)YA7(M%PN51PY645>.WCQ51T^D'SI8[IZ^?NW G</7[YTJLZ>.UU5'#M
MRJLNNH=50QQW+I RMI$)0,J(T(3KN(U).NOW5AI3!))DGCXZ1)^ZK,2$C$UV
M-7D))TWC8UF4HK.%S@FF3:,":9 ]:BJJAB(H(I@99=8Z:**9U#E*-NIU$;_,
M^P21S!6(=E&,BG]"2LZ3EPY=)@.FVA7V+N/6;)+%U%-1_+-GB9BAS\6&HE+0
MGAQ,Q2M>//7TZ@K#='"0ZB8&Z$%7?(R^O8*1S&.78)@(:!M/C*;.XRIC>EBO
MS\_=RI69:9DVZ..!IB-B;$R]$#&A"+0\RD0N@&,5F_?/XZ36,&TJ8"OH0I=@
M2))*F.!,/GY^?NA4N0=@A;5'B]BG1';?;,W<HJ$.@Z9N2E QVCYFL5-PS=)E
M,4PHKID.)#$4*!DCD.9\_/\ .E0[F_E5$VZ$?HK,47*3ELL@LBHD50BB:J9B
MJ)G(("F<BA3"4Y#%$# .\!#$T.%'JQ*5"% F9$]^\'?XZD5'49M1!U'(0(U^
M>>U9/DAYNS#H\KD1?Y!9]:J2P+(4R9D%C*2%IH:2R;,47BQS<Z]F*:Y68QD@
M]4+S[Z*D(!ZZ.[DS2KH^KOK=*"AY(A+A5I]6-==P9F!RXF=:OV[AU0HS!@1W
M]L;\M=I$;5>?T@W  Z!T??AN[<8 ,@'GKXUE[4U-P'Z7?A2FIN _2[\*4U-P
M'Z7?A2FIN _2[\*4U-P'Z7?A2FIN _2[\*5@K/98>G5R>MEB>$CH&M0\C.S+
MU3G#%:QL6T5>O5]@FT=0R;=%0Q$B%.HJ<"IID.<Q2C4)*U)0D25& .<\/G7[
M111"02> FO*NI-;'R@,PGV;EX;+-Q>?P2H5M<PJ(4RI$5*JQB$2F$Z02CP"D
MDK,\1U%_,J'3(<T;'Q2+7H&FDVK24(C.8SD#:1[)'$DZR0(XS.FN/]HHJ,^T
M8&_Q.HTTU\:O!$1#2):I(() 38* ".@ .[I]6X?R[L"9U)).L_#Y^RJB=9B/
MB>^M!L&9[5HZ7C*PQ+8Y!LHJ@\="Z\B@8YRB(E5;.9(B+M5T\3.4Q%&D8T>&
M;JE%%^JQ.(:4^=OGYUX56M'=6C,!\!!4LC&+$H#J2 @6B13>EJ *'GU;"8QR
M?>BHD#<A]#&% HB  I7ZM;I?HT2ZR$-84"G$ZJ$RQ\V/E@$ *":4M#"1FT*&
MFWJI77QS&$2B<A-G8?.GR:5)E5O\39EC1JB+B&GR)'64AI 4N<702,4BKN,=
M)'.UE&9#'3YQ1L<5FO.)E?MVBIRIB^?GY_DKLVRJ,)^/725;D,<Q#!]Z40'4
M #H$!#\P?F&25E,1)$;$[&-^8/B9W[%54RJN+[DU9M)P4DLJ3*3,Z:;QTN@J
M)O(Z?<Y%5-E"VUL("5-G'3#@S>#MA0)Y.4JL58%U6:$/++/K-ZP'V2ZA/]HD
M<->&_/OXSH(JC3G5NA$PE1D]Y/ ;<=NS?8#U9W[]-_M]G2.-$-@3OQXGX?=6
MQKC4W ?I=^*TIJ;@/TN_"E-3<!^EWX4IJ;@/TN_"E:_9!'S=IT#Y0CNWZ[]K
MU:ZB(]72&+S'Y0=GF-ZP,2_NI_71]IK0N.\>G@IU_*_Q]^-Y(E/8D\5?H]FG
MNTKGJX_*/8?OQ+,/E2_*E-.L>P_?AF'RI?E5")Y^)'V4TW" >L!#39/H.N[3
M<.N_H'3?INQ!8"BDA0$;R5&1N. V.HY'7O0.4]Y)!UF#KL8@]E4YNE N&1%H
MFLXLC8=Q8*I8':DMG)D8PT3+.*")#O\ ,?*]$>;1C<Q$$BF/-UXIDXN_(!H<
MK6QHM'SKE;ZSN,%NG<5PMHOVST+Q7"43#P$ER\P]&B4WP "G620F[2E),.C,
MKWOH]TEP+TDX-8= /2+?-X7C.'LILN@7I#?!/]5)3/4=&^EC\%RYZ-%?5MV-
M_P#VEW@:E9 EZQ5U+<!9O9VQG*@DH++?*J9/)Y7IH1TW?YAH1RU4L,PL4CF/
MH;I-3FG#9I EV']OBW* *KRYXN&="1",G6#V#^)M8NAI.'NAQAT N.:H25\6
MER,Z'4QD6AQ(*5C*8@5\_=.>C/2+ .D]YT+Z0X9<X9<80XV<1;>!2W?*4D/6
MB[:Y!4W>86M@MW;=RTI5M=-K8+;JDA0JV66N7<;5XIJFFV(F8B92@ $*7>
M(:  :AIT:?.(=.,^V82R@), @<8/> >,1H==A$U<L[1#:$JU'JB20$YCSB(
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MX",B6KM54D2U*E;N;H7K_7)D-*:2@(5H@ GU5J&P*B%:DG*0 3H36[P/!/\
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M)KHKI'*=)9)4@*)JIG*(E.FH0P'(<HB4Q1 0'00QSIW.D:G29CLG28YULP9
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M\)13A<NDWY@;"@</2D;LO&.0;S4HN.I4H4CAQ!12'HG+(2!S.D''M_R_E5"
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MAOHJL,)O<0PZZQ,XO>.VK#%LZTR4BW0TMYQ2WO4A"7D*R@24!Q?YD*U8>4A
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MQ$0!Q!+ &@].T&FN@CNL/"3:E,ZI<!&HF"%3.G.([.)K = ZTGEF^.6K<M#
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M#6=8S'49DI; ,YX%?-O0[T%^D;TF](L7PCH%T><Q"VPW$W;*XQ"YN&[3#,/
M6HI1=7]XIA!<:9*%=6D%]\)5U32E%&>V45RZ.3A=,OF%C>YEU"HOYQBN[)5)
M^S0Y[%&MU3J@S2ET8]PY:-9%9J"#ERQ1<N?(CK^2J.#KI*;.IL>F?1^YM;>Z
M7B%O:J?1F-LZZT7VD*5#9<RN!(6I,%;8DM*)2I1*36RZ2_T;_2W@&.8C@UIT
M0QK'FL/=%N<6PO#;PX==OI2GKC9+?9:=?M&W2MI%VIMI+W5EQ#00M!.J<DKE
M7\G.N7'/.7LV<V7L$SFG-$:0AY&Q,FP298EM:'+YPV!10!410---43J .SSF
MI-0$IM+>(]*>CSJF4HQ:S40V5B'6]P=CZYD=Q'NVK3,>@GTQ N3Z..E8&\G"
MGN_0$IGW]NG&K <JC_9 ,O\ (W(RNYMY:EA,XU\P+@:AY?IQ$X"5<=S2"3X\
MM(RTNV2=J!&P LCHO&K)$[MX_69L$UF:2Z\BRT.-]*+3"\+9Q&W2F^%W<_1K
M,-NI#3Z@HI4HO)"TH2@I)60%D$9 "3([/T3_ -'OI1Z1/2#?]!L:5<="UX'@
M[F/8^]B5BIV^LK )9ZA#.'J>MU/7%RX^TA!+J&DM*+Y)"4MN2)R>+OREL[JN
MVM4N^R=I3-VS1<H(MLO[E93BLL)!\G,H;-J!T A#&,*O-:ZETYH-0'&]PA5[
MB5LW<O"WM0M.8(2ERXU,:9NL9YC\W7LD"N5])?1+HCT"QE[![&^QO'G&'G&7
M'77+/"X"# <"$V.(@A7!/6"/K&IWA9^W1%T#+V_A7GTI(P$G::O9*LRDXB-G
M(F"D(:,L+9_7Y23G'$#)0[NQP'-@6QS3>6;28.&YVJK-XT2S'$.,N):64KSI
M6M*T(6E,(5!0I*E*RK2").8A4Y@$^S7G3S%F]9?UA8&X;0W<-V]S:W:FG7+=
M3R'7&%(NF4,)N$.H9<!)MK<MK3ERK!S5)>H< ]_?A6MK 63_ #=J ;_*$=V_
M3I-UZ^\-_P"7%YC\H/?[MM:P,2_NQ_71]IK0-V_<7<.G0;K_ .MW]'^'#=Z2
MG4>R?S=M4Z=O?YUSU<:AP+[)_K<2T^L/V!Y4IJ' OLG^MPT^L/V!Y4IJ' OL
MG^MPT^L/V!Y4JFG+D;#^Y+6)H2AY/7,V**^<B &T*286?TY 1 3&T_AUG:!K
MKP#3?J.FQL39J(,Y7&5&!$95F-MMS)[IVK1=(%!JUMKA0)2SB5DF1P5=J<L4
MD]@5<I! X$[&")#RC<IN*PR$@@/\')T:>LI!Z-_Y>L?7IBQ:D*9C7U0"#S@3
MKX_#G6[LH+*$3[*= -8@1&V@D&.PCOK1,_*J2WD^##IPJRCKKE[F)2W#]$I3
MK-5YA&$21%$BG[VHX!DI*.T2'#9'R$X&$I1':SVVDW5K=614I";E#C3B\QA*
M';=3:G"F"E67,0D*2?6UU$BNGZ,XJY@6-X7B[;:7G,+Q.RQ1IIW.&758:^Q=
M):<"2E2DO+;"2I))2$D  R:\IHSD97/.1U8I7,NW,:.^I,P]KE$KD"NO*J4H
MJ)6,H6ZKR,?*L$#6VP'0@I00=&>-DH%0&BC!HY\S&KWFK7H_N\6ZUW%[G^K%
MVQ=8P:S84MW^KT(<2IO$''6EH2]=7*FTNJ#B5)2P<A3F""U^@>+_ -+CHYT'
M-EAO0'"O]+6<7M;._P#2#C&+,JL$8^7V.K5T0M["ZL;ERQP3"K.ZN;;KK<IN
M+F]RNAY;:WQ=S=R4*2JXF;/,9ER%%G[W$-3U9-"OO8><8S48REC*FS#233,N
MI&GLBP-6YV"2;=-HZ8O'*I$ E&D;&]9T1P?$L/1>7&+--M7A6+8(MU(+5VPP
MX5#$$ )A'TPDJ+6F7(M* A!"$^&?TA_27T1Z:#H]A'0.YO+GHU:V_P#7 _K)
MFY:Q+ [G$K=MI[HN^X\$?3D81U3P9Q-M2UO-+9M'%.N6J[R[W'.&_P [EI8L
MT;% L5UXN(R]AWTY96,4[ES4]"OQEPG&]=;1:+99J1_.BMY8TF7A%X6$%^BY
ML+1RAYO;N.ZMF#<W%NPEP#Z2^U;MG3VWG0A)V4<H29VF=9X'YOLV575U:VLI
M:3<73-IUQE26EO/(0EQ3<YRVA*_6 45%40K<573(C./E 6^,N4]2Z9DYYPB8
MEA,V.6M$AF+-6>>\H92SYDU7FFC=P4010BGI4S.$8"ML3F21;(1I'2*!>MQ#
MHOA>'+MT7%]?$W*E(3U;#"@A32VDNK65.-RB7 $I1*R3HE8!KTS$NA&"86NT
M;?Q3$G57:W6TN,VMH&V^I+(4XL.W*%%#A?1E2@EQ 2KU7(D=FB\JN[YNV-I3
M;94J\PLD(_@<PJS)TU676:DAH&70B[^2:;2Q5S-4B5*;>)M7Z3SFEU7QH\R*
M;E5F9S@](>C;.#,VS[5T\\E]UQE27&D)4@I1UB5R'!ZJA(B)!@R9BM'TPZ*6
MW1RTM;JUO7KL/O.VSC5PRRR4+::2XI:76WG$K20K1(1),#-N:]KJPR6BZM7X
M]P %<1\#$LU@U#0%FD>W04 -P;MM,=-?5N^;SYPRXHI^MH>WAV?=7FF;UY$0
M8 GPUV/*J+9_F))9GY/11=5%7V<F5J7-IAJ844[Y!+NS@ "!@!-JDNJ82Z"4
MJ8FUT#4-.]*KVV2.#Z%Z;RDA4?#X[C>N1QO*Z[:L*)'78A9(3$20+I#JB/\
MT-$C6!N1&WIZ;0.G01 1#?J(;M/E@(Z].X>C3U;L=6F,VI@@%1]4'59!([1L
M1WG?2NC$%(/$::3EB2.(WA*>.\Z:B/C4.!?9/];BYI]8?L#RJM-0X%]D_P!;
MAI]8?L#RI34.!?9/];AI]8?L#RI34.!?9/\ 6X:?6'[ \J4U#@7V3_6X:?6'
M[ \J4W#N "@(\"F_6J(=N*B)T4/V8^R#X:\J54?-A5JGFT"1891NZ-2JZX7L
M!FY2H2J1IVW(H1)7(%VEEX,R*SM5$RIN83GVYRE("X[?+8N<M^)3 5;#^T,\
M%S__ $M5)&R2I4E6P]^]&)6>BEZ5/)>0C'+UH6@/KVB7,.PH&Z(.@2^I92@D
M;VKN^F7]"[REWZ^B7?\ D#\W1C# @;YAJ01I,Z@\>?OX5TRB05 PK42>>@C4
M$<!\*I[R@:-9[%19*0I[&/F[?EW<[%.QL)*OFT=#O4K$S6<'6E7KA1 B32'9
M3S6;<(\^F:0;QKF+(JW5>)NFMW'+*[Q/ V%65N+R_M5=;:VSS_T=I19SVN=2
M@D$AM"U.I0E:5.%M+:2"Z55<]$W3#!.@WI-Q%KI-B;^"='ND%J_9XIC5K8OW
MU[AELX[;XF#86S8</TJ\%J+!JZ+;UO9W%VB_<MGV[1RW74>=Y(5SRTJZ6=L#
MF?!6;,M^@UD;<E8%1A8+,QG8Q:NI:JC(2,F2-;()JMV!Z4HUCX==NJW,LY5%
M<(P87DGN@&)6-N,5PZ]1B&.N))Q!EYQQJWQ0.N)<=M49E%IAIE*$IMG&4-E)
M0DD$9<OT%AG]+GH?TDQ8=#>DO1USHUZ-&E!KHIB5FI-[BW0:ZL@ZC"\>7;)M
M4WN**Q 7#RND#%Q=W9>#ZA;*"OI#C_H#D+2*G5LM(@T6ZA)ITX7GYJ0L#(D:
M[YJ2G)N2FY*/))-D]7",([?+19%E#$4439E5431,84B>FX38'#L/M;-14%@N
M+6%*"LI?<4ZZ,P"9 4I2 >*4SJHYJ^*/23TK_P!-.F^/](TI0EN\>;M[-UM"
MFDOVN&6C>'V;_5J6M32[VW83=.VRU*ZE:UM9E*A2:69F9UWFCY;5&KL#N:,%
MMDWE3JUB\T/)!"<,\KEEM;G-&2?/H]=F[B)5W&"0U-1(E.(!-JS<@>0:-&L+
M(;M&"XGCEEBEOA%ZU97[=F[=6;S[2G4+=2M+;;<)4VI(4I6Y48D3(!!SO13A
MW1^\Z7V-QTIPQS'.C>&+9O,9P-B[?L+C$;,N=2Y;6]XR\AUAR5IN"4N-I>#*
M;=3[*72XF.FW+4S70A%LI:S3:32[\Q@21KM=E&.R0M*2;H-7,IF:1P5PYA)*
MN2$4\;2-8C&K!T]=2CP$G*+Y%&.)9/,&^E.-8BNWZ(8?ACS?I$%T]AU\T\6S
M86332$E>+APD)6E*5AU-N>L(B%]8"$J^N6_Z+GH]P6\/I.Q?I3<XGZ"BAG%<
M$99=2UC_ $BN[JXN&K#H,IIHHO+.^8?2NSQ3$%+:"V6VULKM7W+DX=)M)Y7.
M7R;2(S.S%GE(%%/9J5F<+QISO[=:\LI?,>#"6A8B*;'_ (3*M%8Z0DVK4%64
M,G/0D:Y?G3:@N'7=+[BSZ&6K=GCF*LNW?T:U4]<ACJUW;Q0A3B6+5M2EZJ"P
MB I!B<P%>%=$/0_TJZ>>DW$[/T=]&GUX1:7;UVVQ]+#MG@=EB"'3965[B]\N
MW*_H;0+(<<*G'TLK,.+VLG2.6CD!=*NA8GU\KU,,_6>>25^T3D6WL"3)NX.W
M;N9-FT<.D6"KT$S.46H.EU"-54#KF36,JW1\\MNEF#7EL'U7K-L%I<4EI]Q"
M70D*RI*PDJ2VI9A1;40H)DDR2*]FZ1>@3TD='L9<PIKH]B6-FV%J7K[";&Z=
MP\ON-(=?98?<;:<?;MUK^CN7"64M..)<+2E-I#B]ZRHY57);CK[.2<KFQ1FC
MY.LIM6$VYGVZ3 S&2EDUI",25\J(FHZ47B(YV<HMSJ(I(D$%"%6$JFTPOI)T
M?8N'5N8E9(46&PIP. @2HJ<$%0!U@[D@ ;UYOZ2/0OZ7+[!,(8LN@G2!YM&(
M7+SMLS8%QY;AMVD)N%!*0IIHC,A.9:AG*DJ&8!1E;E <M_+#*7(1]G=1W<5F
MNU<VAG0ZLVKLPD$7)W)\V7>@S?RZ978,&D='M'4D_.FV7<F11*W;I&7<)B&U
MQCICA^&X&_C=LMO$64.HMF>I(0V[<NF$-%?K%($$J,$ ).^E><^C3^CSTTZ<
M^E'#_1CC5O=]"[][#'<=Q%_%K!2G[/ V$.%R^:LU/L*?+KB$V]L@N-AQY>J@
ME*C6U\F.U\HWE!5AG:Y1WE/1(]ZP*[(1O2+;:%$U5.:,DV.<V:%> X&(<VTN
M"9-#)[D=#!LWL#Q?$\7MFGW6+*T*T*44I2Y<I!"O52%(=:$E!!42=#PUBLKT
MK^B[H/Z-<7>P:UQGI#TBN6+CJ5J5_5^$H4VG.%/"+/$\NJ0$MDDG-JH$$5/J
M_P -Z9;HNHWI>N3Z%ECI1_7;56(J4KS<SR%+'GDX&5KDE.659DZ,V?B^BY)K
M8I!J_;,)--TUB7#5L21WH>=;=2T[U1"TE25MI(U!(4DH4IQ0"=(5F.:=DD:^
M/7N%8:O#G<2PUV[9-I<6[-YAUX6KIX,W ="+NWO6&;-#J XE#+S2[1I3*W&U
MI7<)4L,[<.F[<7?U&_6H&GSB&GY,92#(!) UT]4<.9X>.E<P/'CL1H=MR9[]
M)W@2*SC37F":"&FI_4/X0_RA_/@K<^[[/G7CO5U(5 @B/Y]U2*K_ )4_\H<:
M!?MJ_6/VUU2?9'S\_,ZU^>(U*F%*84KD-1U .D0$/5PU]8#PX8H=B.8(&^A/
M'3[].=4(D$5Y,T1 V4V=.9N6+O800C+A(S< F30B1ZI;G"ED@/)D]QBMHYO)
M+5[:U HNX-X4FH)[NA:=ZZS:5(S =6H&-"A)&O9ON.[2M<H%+F72#F)VW$=O
M<?>?==]1)I,1RS9TDFY92+55LZ04+SB*[=RD9)=%4@[CI*I*&3.4P"!B','K
MQ4$B8.X(GX'W_#LJI ,3KN(D@&1!F(/QJDUJHU@2L46A'V!"&M](:R["*DY:
M&5L$=/U&PGCB [78DEH599\;S+'@Y=-Y)$6DPR> LV69/$2+5SF9  )B2!J8
M  G<3W<^ZJ9!MK[(2-28 T$$F=M*U:XU*/J63]T8E45E9&39.7LS.OR)FE)B
M>DG2*0S+M1(A$TU6ZRB!F*2($1BVK1HT9E10:I%*SJ&I/W1L>$<N/,TR)@:'
M38R9\0>)U-2!<:J[L*<+)0TIYDLE:>JR,$_4:)OF(JN62\>\82K ZB0NHN0:
M.3HN2-7+)\D)$G#-ZW71*8U<QWT()(*8T.Q,]^D_>"145)3HK*)!,JUS>MN9
MF<VVO\ZIRRY,;>\9I6[-!MF+>\L\Q&UD:N+) 1#2AV>N-9L*Y%,4I:"4L]0D
M5WD%/PZ+5X1G+ N9)==\T7;(\T9N3J;;I([;V",-3:V[ULA!0"I2VUP59LI4
MA:3ZJC*2-=B#I7;6'3BXLL):P==E:7-JTA;:>N<=964..K>A0;("BEQQ12N
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M2U(>Q)BW7AY!!;7=VKBRNW>0I02$O6SSJVW(*NM80T/RHC0V*Y5VY#%TW!T
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M59VI3 NDX^?C7$>LNR5,@^:"H &0?QZZA%0;R#!T1%ZP<F35!!VW14YM0";
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ML@&H !>H-- Z/4&-*HD"3K!S:]IU)(UC65"=8UU%=^A$E ;!5"M&Y"0=1F'
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MB)@W@'SCO#]>GK ,4)''F![^'P^'90(4#I&O'[MI^>8KHN)1NW*.JH"( (@
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M5NMIG7-?)9A0JD3'OTFT4>17BR*N5'DM&[!S.VYR 1,J@:"0PB&UH&0S;.O
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MC_K*?ZB+_P#W@>CC_B^)?]DI]UDZ_P"C-RF/Z%53]N</](D_[&QO_P#-V/\
MJZ?ZB+__ '@>C?3_ /&V):?_ -DI]UDZ_P"C-RF/Z%53]N</](D_['QO]PQ_
MUE/]1%^/_P ('HW&G^U\2V_X)M3[K)U_T9N4Q_0JJ?MSA_I$G_8^-_N&/^LJ
MG^H>^_W@>C?3_P#&V):1K_L3WT^ZR=?]&;E,?T*JG[<X?Z1)'_Z'QO\ <,?]
M95?]0]__ +P/1Q_Q;$O^R4^ZR=?]&;E,?T*JG[<X?Z1)_P!CXW^X8_ZRG^H>
M_P!O]8'HW[OZVQ+_ +)3[K)U_P!&;E,?T*JG[<X?Z1)_V/C?[AC_ *RG^HB_
MG_ZX'HXG_P#*V)3'_!*?=9.O^C-RF/Z%53]N</\ 2)/^Q\;_ '#'_64_U$7_
M /O ]''_ !;$_P#LE/NLG7_1FY3']"JI^W.'^D2?]CXW^X8_ZRG^HB__ -X'
MHX_XMB?_ &2N0Y63K?\ ^K/RF0W=(4JIZ](;O^'.*'I$(TP?&X&J@6&8(Y:7
M9.Y![@1L30^@>_/_ .$#T<;@@_UMB<I((,Q_4HF8RG78FMTRJY0\/FE<9^AC
M0,R,O[+7JW%VURPS"@XB(.[@YF3D8AD[8>;9V8!8IGT4^2/SO,:"B(AM=&,S
M"\:8O[RXLC:W%K<,6[=RIJX92V RZXMM!"PZXE2LR""-"-SOIS/3?T38ST'P
M+#.DMQC71O',(Q7%KW!6;GH_?W-WU6)65I;7]PR^U<V=JIL"WNV%I6,X459=
M"DBK!;1?C![)>_&_E/(?P^=>64 Q=0](.P@>_7=A*?JCQ2/OI6<:B7F">B'\
M?UD'^.;KQ;.YCF:F%) $B3W"I(5TYT^H_P 8>/<.- OVU?K*^TUU:?9'SQKX
MT+Q]X^#$:E0-G4-!W^K>/@PI55;=_P"TJ'_P.9=OP]D]?4'YL;>Q_N[G_P T
M_P#(W\\*Q'_;3W?B^?F3O&,FK5,*5#^8>:;RI6BH4*KU![>;S<V%CFV,0C*L
M8"-C*W5!B49N=G)N0(LFS;)OYZ#BV+9JS?OG[^23!-N1HV?.VR#!,$@<OF!2
MN#YXT*'?5BMWJ5;42]V5O$G"ES#ML^?Q+N;?JQ$2TEI2%/(P3$)J815BZ\X>
M235&POB"SB1<O0.V)-"<TR#V$;'WQ\.<[U20-].^M=RPSV-F/-0,0%6"&+.5
MO,:P"Y&:\X>2A0,T#9;^2<T$2SYWSKLA-<^*B7D.HQ_,O-/+1*1EC17'<<O=
MM]VM)!V(/OK*VG/N@0U+<6N&L=<E5EXZ]NH!K)RKZ%CI-UENNY9W%J_DD(2:
M>0R-?D&JL?,.E89T=@[V$!:K+K((JQA7(^!I($ZC3>OQM_*&RXKB&84?'3C"
M=NM!IMUMJE1!5Y&GEC4>)4DIB*932T<O&KNV"@LVLTG'&DWD"+Y!628)ZD34
MDELD3($3OO[AQFHE<'@01IK\\C6I!RJJ!+5NLS=+=QEM?2UURCITY#-I1PR6
MKQ<V9QE#QTT"[B),,O%H N^7C7S)N$585(MTV9RC<R3A1O12"DQ!5R(X]W#X
MU4*$22![P/O^VI8K.<&6=RL\K3*Q<8F8LT*60,^BVIE]HQ8A\G%S1HYTJ@FR
MF2P4HLC%SHP[E^$))+(L)46;M5-$U,JOJJ]X(^ZJR#I(J2<4JM,*5'4A_P >
M.17_ /-S,_\ DL<8]Y_=E^_[!5&?RP[S]M6WT+Q]X^#&GK8TT+Q]X^#"E-"\
M?>/@PI77=@'DCK0=_DZ_K'\$;7^*'JZ\*H=CW'[#\_950,B_^)C*[?K_ .@M
M7Z__ +);]0?FQTKWMGO_ /HHK6C9/>?_ *52KBU4Z#N 1X (X4JOE-ST=WA^
M_EX:@R),IHZPV^MKYI/[%76+,%J.M,1U@GPK[ETG)?!%"?@Y" 1F.>%ZLZ3(
M_P#,Q84QY)*24%7,>Z><\MH[:H2!N0.^NN_Y3&7SJ/KDA0Y!E>DYK,NDY>2*
M;9V[AEX4MV.Y&.L!F\A%&=/8YPU;'?0ZJ:",=8&H"O&RIT"&5Q<#1)R]D[1$
M>.\_"DCF/$5N%)S@@++0,J;M/ A4ULV4H5M 1#AXI(%&?FX=]-MH%.3(R:I+
M.#LXR0%NNX;,$W2J!6Z1/*EV[=6"@9  )$0-.\^_CMX1K21S'C6--G]EPBXL
MKI>RPXUNNIQS0\HR4EY&5=6)>T7>IR,(WK[2$4</3-)6D2+-BO#.I=>4?-9E
MN5BU1B4W<A'*J=CX&A(&Y'C\>[MK49+E9910UMBXF5L\&TJ,]EO&9BP-Z"1<
M.8^1:/K)*5]VDHQ;1BQX^,A@CB/)JP2#MO'P_E(-Y@L=S0K*32@$:R.>PX]O
MV5!2@(@CUB)GW:=DC34:5GR<H>DQJN8A[D\:U2-I692.6\6Z%R[FG=N>K46L
MW@KB*B(J-5D55RL9]T"L>P0E#(Q\,ZF%7)68K%:5R*D '17:3'.8TX>=3D#2
M1IIO\_'7G4TPDU$62'C+! 2+.7A)EDWDHJ4CUTW3&08.TB+MG;1RB8R2R"Z1
MRJ)J$,("4?4.[%LB"1R)'A5:R>*4IA5%;'N/V5^')HT_<?AM1_\ O)F+_P#N
M-;.H>O\ P]>IO?[R]^NG_D^=#V\JRV?9'_J^U-3SH7C[Q\&,6KU-"\?>/@PI
M6 LFZ.#0=1\H2TZ?E" ?>ZZ]/0&\>'3B\Q^4'(#7ND5@8E_=C^NC[36@;/3T
M]/RM_3O^\^W;C? ZI]GV%?G=J-]-#V5SU<;(<!]_@Q+-^K^U_*E-GY_?X,"K
M]7]J?+[10^7V_/=4(Y-?Y@M7_P 5<U?_ )ZFL6S[*/\ U?;6ZM_R2#S$U+>(
MU>IA2H';YRS4Y>;+6*5EK,VRO4>SQ5/N5Q3G8&';,9U\SBI*4;0<5*KI.[ E
M58R98/;"N19@!3J+1\,29E&J[(LTI21),> Y>=4D#<@>^L7:.4[EHPK%RFJ7
M-Q-[EZ7YJ.^@63]>-\K:R-J85->0CI->-<-I.,CY)XJW<R4.G)QY)!L:+6=-
MW1O1J6U<-1PYG8'D*2.8\16T5S.>!D*YF#:[.DC48++[,:V4&0D7+Y1^V52K
M4VA")3C@Z,>B9@C(+N$E%6YBN4HY,3'7?J(D47)+JMIF3P_S'/8;GPE(YBNU
M)YT5&.OOP&"9KG.1$/:96YK.YAVSD*R%=B*I/$(#'S,O'OT3PMJ9RLNNK.1J
ML*Q7BU@:2 2G\$E$:<M->RDCF/&H[M7*PRM@F5&FHR8935>L^:Q,JI^15/*Q
M+ZH2J^7EQO[%1S7G<(:<DG\FC6HUA$0R3)HYF$[+'R$4L]*#=J_L95?55^R=
MN>VW;M21S'B*SGW2&79YM@*,U"J9?OLKY7,S]T09@$XQ%",MT14#1!F!V15?
M+%9"4,@8AW*4@C)MPAABSOE1!*[U7+-X?RIF3S'B*E>EWJJ9A0@6&F3+><B1
M=.H]9=))TU79R#%3FGL=(L'R#60C)%FH(%=,)!JV=H"8G.HE Y1&!"DR(D$:
MZ'M\#0$'8@]QFMKQ"JTPI4793AK-YT__ !85X_\ ,*B\ '\V*@PX-OR9W,?_
M &OOK47.Z?U$?:NIDV0X#[_!B[F_5_:_E6-39#@/O\&&;]7]K^5*:;M-_OZ?
M8U_)BTZ9C]5>QG@-]OY^ZJ'8]HJF60 ?[7YN:C_^([/\-^OJS-G]^FSN]76/
MOQP6$:)Q:?\ ]8<>($Q/_P 3?!^!/NYQI]I]-(^A^CWL]$OHO\?]#,(V]WG'
M&I[#9W_./K$/_"/ZOFQM\ITA(VUDG?Q%</RT3[S'_P!+[A7.A>/O'P893]4>
M)_%3W)_:_P 5:C?KI#9<TRRWJPJ+$A*M#O9B0\F3YYVJBT2$X-6B BD"[QVH
M*;5HB)R\\Y522VB@;4+%S<-VEO<7+ZLC+#*WEA E:^KV;1KJXM1"1KKH)!WV
MN!8->8_C.&8-AX0;W$;QJV8#JBEAO/F*GW7$I<4EEA"5OOE*24,MNK((%:*T
MS>4AXAQ.YJUA7*^-4- IPRK^=C;&K-/YT'O-P#-E %<R2EF9 R3%U$,V3XJH
M.R'C7D@5%YS&.W>K0SUM\R;%*B0WF6BX4LY2H)2&0I2ED)/JY5E64P5$$C=O
M=$F[N]8P_HMBR.DMSEO1>=59.84W:(LR@+N7KB_>3;?U<^IU0;O7WK=(+*DO
MH8*FL^M6GE$0\4X@U:TQ96Z"GF-%?QTXRFQ0;KIW7,^&RX,)4BQSG48H9523
M4(=1-95PS-%+I,CF.Z2L.XRRVI"64BX0ZBW<#B2,A3<7B+- !C10<65%/M)]
MD@$$C:X;Z.\1N;>^7?NJPR\L;O&+6YL[FTEQL8/T<NNDA4A76 9+IJVZE*DC
MJ\KB;A"W&R$JVK.+.ZCY,UZ5E+)*L23*%:L=CA:\JLY2<3):^R*L<BCAJQD
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M0Z_?X,,WZI_]7\J5G&@#Y.30P::G]8_A#_\ 5XM*T)^[3Y^=35Q,P(/Q'/\
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M< 3E$CLUCO!'+7ODD[U;4)5/M1J#VGA'GM4FY3Y&2.7,Y7Y9W86,H2%K&9L
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M4EP*DN$@@ Z9 )RG?4:$GW5C/-K6H9>6AC0;[\]SVS[JZ>F>X].4E4_)FLF
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MDJ! /LB>/'5/W^>R_"#./\5%=_K01_9#%>L3]9W^&I?2FOK.?L_XZ?"#./\
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M -DI^Y9RN_Q]9*?U 63_ ,\</ZIQS_:.&?\ #E_]93_6UZ*_]W_2O_W?9_\
M9*?N6<KO\?62G]0%D_\ /'#^J<<_VCAG_#E_]93_ %M>BO\ W?\ 2O\ ]WV?
M_9*?N6<KO\?62G]0%D_\\</ZIQS_ &CAG_#E_P#64_UM>BO_ '?]*_\ W?9_
M]DI^Y9RN_P ?62G]0%D_\\</ZIQS_:.&?\.7_P!93_6UZ*_]W_2O_P!WV?\
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M$(W\.^_G6_\ =L*=0CFKQ'E3X(1OX=]_.M_[MA3J$<U>(\J?!"-_#OOYUO\
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M\$(W\.^_G6_]VPIU".:O$>5/@A&_AWW\ZW_NV%.H1S5XCRI\$(W\.^_G6_\
M=L*=0CFKQ'E7(5&-#H7?</\ *-_[KA0L(/%7B/*N\C6V*:92%5=B :[Q41U'
;4PB.NB >L>&+B4 @'7Y/=4@VD"!.G:/*O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img192321128_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (H!; # 2(  A$! Q$!_\0
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M:L%..P4444S0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM+IDC!3O.3#[CV]17NBLKJ&4@J1D$'@BM8R4D>GAL3'$1O'<6BBBJ.D****
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MQCSHXW'IPH7C_OFN0KDG\3/EL5)_6)-]SUW7/BO;6$]K!X>MX+FU5 9&D1T
M[;%'&. .>1S2_%JVM;CP[INJF 1WCRJF3][8R,Q4^N"!^OK6;X4\&V.C:>OB
M7Q4Z0PJ!)!;O^8+#N3V7\_2N9\9^,)_%>HJP5H;&'(@A/7GJS>Y_3]3;D^7W
MCMJUY^QE[;>6R[>9S-?07PYU)]2\%V9D.7M\VY.>H7I^A%?/M>U?"]I;/PAG
M:,37#R#=GI@+_P"RTJ7Q&>5MJLUY'H=%9_VZ7^ZGY&C[=+_=3\C739GT%S0H
MK/\ MTO]U/R-'VZ7^ZGY&BS"YH45G_;I?[J?D:/MTO\ =3\C19A<T**S_MTO
M]U/R-'VZ7^ZGY&BS"YH45G_;I?[J?D:D@NGEF5&"X/H*+#N7***ISW4D<S(H
M7 ]12 N45G_;I?[J?D:/MTO]U/R-.S%<T**S_MTO]U/R-'VZ7^ZGY&BS"YH4
M5G_;I?[J?D:/MTO]U/R-%F%S0KRGXR:DX_L[2U.$.;A^>I^ZO_LU>C?;I?[J
M?D:\D^+2R2:U873+A6MS&".F0Q/_ +-6=5-1.+,9-8=V//E + ,<#/)QG%>N
MW?Q&T[2K'3M.\)6J7>#L:)HG4@#' &!EFR>>>G0YKR6"&2YGC@B7=+(P1%]2
M3@"NKL6U_P"&^H+>W.F1)+=1-$GGL&&T,I;&QNO ZUA%M'B8:K.G=QT3W=KV
M.L^,%M:-INF7K(L=^TA3'\13;D@^N#C\_>O)*]9\?:;;ZYX-M/%FV2"Z\J)F
MB+EE*N0, 'I@G.1C->34ZGQ%YA_'<NZ3/;/A'J3W7AJ>R<Y^QS83G^%N<?GN
MKT&O*/A'YEM8:G.%^661$&>GR@G_ -FKT?[=+_=3\C6]--Q1[>!DWAXW-"BL
M_P"W2_W4_(T?;I?[J?D:NS.JYH45G_;I?[J?D:/MTO\ =3\C19A<T**S_MTO
M]U/R-'VZ7^ZGY&BS"YH457MIVFW;@!C'2K%(8451DO)%D90JX!(Z4W[=+_=3
M\C3L*YH45G_;I?[J?D:/MTO]U/R-%F%S0HK/^W2_W4_(T?;I?[J?D:+,+FA4
M-W<"TLI[EAD11M(1]!FJOVZ7^ZGY&J>K3S76C7UN%7,MO(@P#GE2*&F*3LG8
M^=;RZDOKV>[F.99I&D<^Y.33].T^YU748+&TCWSSMM1?ZGV'6JI!!P1@U[!\
M*] 6#19]=01RWTX>* .2%0#U(!QDCD\\"N2,>9GRV&HNO5Y?O.RT#2++0-#_
M +*M&5G@3,[ <LY&23]?3TQ7S;7T/X4T35M+M]3;6+FWGN[VX,Q>%F(Y4#'(
M&.G3TKP[Q%X>N_#.IBPO9(9)?+$F86)7!SZ@>E746B.[,8OV<&HV2O\ +L'A
MC4GTCQ+I]ZA^Y, W/53PP_(FOI>OEFQ@:ZO[>! 2TDBH,=>3BOI;[=+_ '4_
M(U5&[3-<I;Y9+IH:%%9_VZ7^ZGY&C[=+_=3\C6UF>O<T**S_ +=+_=3\C1]N
ME_NI^1HLPN:%%9_VZ7^ZGY&C[=+_ '4_(T687-"BJMM<O-(58* !GBK5(845
MG_;I?[J?D:/MTO\ =3\C3LQ7-"BL_P"W2_W4_(T?;I?[J?D:+,+FA16?]NE_
MNI^1H^W2_P!U/R-%F%S0HK/^W2_W4_(T?;I?[J?D:+,+FA16?]NE_NI^1H^W
M2_W4_(T687-"BL_[=+_=3\C1]NE_NI^1HLPN:%%9_P!NE_NI^1H^W2_W4_(T
M687-"BL_[=+_ '4_(T?;I?[J?D:+,+FA16?]NE_NI^1H^W2_W4_(T687-"BL
M_P"W2_W4_(T?;I?[J?D:+,+FA16?]NE_NI^1H^W2_P!U/R-%F%SR/XN:D]SX
MEAL,_N[2$'&?XGY)_(+7GU=?\2T<>,[B9QCSHXW'IPH7C_OFN0KDG\3/E<6V
MZ\[]SW[68?$=KX1TFW\+KBZB2)'&8SB,1X_Y:<=<>]>6>+M3\7O'%IWB9I F
M_P V-6AC4$@$9#(.>&/?O1#\2/%4+QG^T@Z)@>6T$>T@=N%%>C^/RNI?#+[=
M=0"*XV03*C#F-V*@C\F(JVU).QZ%2<,33E*G*2Y5MT/#:^@OAQJ3ZEX*LS(<
MO;YMR<]EZ?H17S[7M7PO:6S\(9VC$UP\@W9] O\ [+2I?$8Y6VJS7D>AT5G_
M &Z7^ZGY&C[=+_=3\C739GT%S0HK/^W2_P!U/R-'VZ7^ZGY&BS"YH45G_;I?
M[J?D:/MTO]U/R-%F%S0HK/\ MTO]U/R-'VZ7^ZGY&BS"YH45G_;I?[J?D:/M
MTO\ =3\C19A<T**S_MTO]U/R-'VZ7^ZGY&BS"YH45G_;I?[J?D:/MTO]U/R-
M%F%S0HK/^W2_W4_(T?;I?[J?D:+,+FA16?\ ;I?[J?D:/MTO]U/R-%F%S0HK
M/^W2_P!U/R-'VZ7^ZGY&BS"YH45G_;I?[J?D:D@NGEF5&"X/H*+#N7***ISW
M4D<S(H7 ]12 N45G_;I?[J?D:/MTO]U/R-.S%<T**S_MTO\ =3\C1]NE_NI^
M1HLPN:%%9_VZ7^ZGY&C[=+_=3\C19A<T**S_ +=+_=3\C1]NE_NI^1HLPN:%
M%9_VZ7^ZGY&C[=+_ '4_(T687/#OB/J3ZCXTO Q^2VQ;H,] O7]2:Q- TIM;
MUZRTU20)Y0K$=0O5B/H :M>,(GA\7ZJ'!!>X:3GT8[OZU=^'<B1>/=+:0@ L
MZ\^IC8#]2*Y'K+4^6DN?$VGUE^IZGXDN-=T^"VT3P?IPWI$&>7"A84Y"@%OE
M).#UST]\UYCXOO\ Q;]G@T[Q-&P D,L3LB<G&" R<'K]>:[;XE^+-;T#4[*V
MTV7[/"\7F-)L5M[9(V\@] !_WU5WQX1J7PN6^O(52Y\NWG"X^Y(Q4,!^#,*T
MEK?4]/$Q53VD8R:<5MTL>'@X.1UKZ7\,:BVK>&=.OI.9)81O/JPX/Z@U\T5[
M[X'DELO!FF0E1_JR_P V<_,Q;^M*CN892W[22Z6.PHK/^W2_W4_(T?;I?[J?
MD:Z+,]VYH45G_;I?[J?D:/MTO]U/R-%F%S0HK/\ MTO]U/R-'VZ7^ZGY&BS"
MYH45G_;I?[J?D:/MTO\ =3\C19A<T**S_MTO]U/R-'VZ7^ZGY&BS"YH44U&+
M1JQZD TZD,**** (;O\ X]G_  _G696G=_\ 'L_X?SK,JHB844450@HHHH *
M*** "BBB@ KQ3QSX=DT769)XT)L[IB\;8X4GDK_A[5[75:_L+74[.2TO(5EA
M<8*G^8]#6<X<R.;%X95X<O7H?.E=YH7C73=+\ WVA3P7;75Q'.J.B*4!=<#)
M+ _I5G5_A=.LCR:3=(\9.1#/PP]MW0_I6&/AWXD,FTV<8']\SIC^>:Y^2<7L
M>)&AB:$GRQ\NYRU=Y\./#LEWJ0UB="MO;D^5D???'\AG\ZT=%^%ZI(LNL7*R
M*!GR(,@$^[?X?G7H<$$5M D,$:QQ(-JHHP *NG2=[R.K!X"2DJE72W0DHHHK
MI/:"BBB@ HHHH **** "BBB@#3M?^/9/Q_G1=_\ 'L_X?SHM?^/9/Q_G1=_\
M>S_A_.HZE&91115DA1110 4444 %%%% !1110!Q?Q#\.R:MIB7ULA:YM <HH
MR70]?Q'7\Z\QT"ZL;#7[.ZU.&26TADWO'& 68@9'!('7&>>E?05<7XB^'ECJ
MTKW5C(+.Y8Y88S&_X=C]/RK"I3;?,CR\9@Y3G[6EOV'WOQ/\(ZBBI?:-=W2H
M<JL]K$X!]LO7)>,/$?A?6-(BM]$T7[%<K.':3[+%'E-K C*DGJ1Q[55N/AQX
MBA<K';PSC. R3*,^_P V*N6'PPU>=\WLT%JG?!WM^0X_6LWSO2QRSEBZMXRA
MOY?J<II.EW.LZE#96J$O(>3CA1W)]J]^TZQBTW3K>RA_U<$80$]\=_QJEH7A
MS3_#UL8K*,[V^_*YRS_CZ>U:U;4Z?*M3T,%A/81O+=A1116IW!1110 4444
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MO]W^M7ZA[C1C44458@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?X>MC%9QDNW^LE?EG_\ K>U:U;4Z?*M3T<%A/81O+=A1116IW!1110 4444
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MG696G=_\>S_A_.LRJB)A6?J^LVNB6B3W7F,9)!%%%$A>25ST55'4\&M"N?\
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M])\&Z)<Z+.7NK)X_[+=1N:X9SRF.X<$Y]/PHL*YUFMZS'HMEY[1F5SNVH#@
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M45T\L=I,\)B$JQL4,Q(3=CC<1T'K0!6;1M/=K]GM4?[?M^U!R6$F%"C(/ X
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MWA>%5!&TJQ!.1C.?E'>JC^&K-]*U73C+/Y.I2R2S,&&Y2^,[>.!QQG-<W?\
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M<NFR2/*#I\GF1;2/F.TK\W'H>V*R+[P+I]]!=VOV[48+&Z=I)+2&8"+>3DD
MJ2.><9QGM47_  D>K:C?:3;:5!:1_;]-%\SW(9O*!*]E(W?> QQZY[5J>'-5
MN]3M[U+Z*)+JRNWM9##G8Y4*0R@\@$,.#1J&C$O?#5O=WL%Y%>WMG<Q0"W,M
MM(%,D8.0K94CKDY&#S5>'P9I<&D#3HWN@B71NX9O-_>PR$YRK8[=.<^^:H:Y
MXQ^QZ_-I,%]I=B;>)'EFU L0S-DA44$9XY)SW'%00^-KW4-.TJ33K>S>YNKZ
M2QE#.QB#*K'>K#JO ;IR./>GJ&AL'PA82V-_;W-Q>7,M^JK-=32#S<+RH!
M !YP!]<UM6D#6UK'"UQ+<,@P99B"[>YP /TKD[GQ-J^FV^OP7L5E)>Z;:+=0
MR0HPCD5MW#*6)&"OKS[47-SJ+W_AR758+!VN+W="(A(# #"YZ[L,W;.,=>*
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M@.PET^?36U#4QITNXBT6<".,DD\?+G@G(!)&>U4YFU@>-O#<>K"S<[;EDDM
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M@T^S:>!8?LUAG8V&)WL2%RW;ITKIJ*+A8YKQ GV3Q)X?U=A^YBEDM)F_NB4
M*3[;U4?\"IUS8>)+/5;FYTF\M+FUN2&-MJ#R#R6 P?+90<*>N,=:WYH(KF%H
M9XDEB889'4,I^H-247"QA^']&NM/N-0O]0F@DOM0D5Y5MU*QH%7:H&>3QU)Z
MTNC:/<:=K.N7DSQ-'?W"2Q!"20 @4[LCKD=LUMT4#L<?;:5XGTK5M7GT]-(E
MM[ZZ-POVB:567Y0,$!".WK5R[TW6]7L+-;\:?%<V^I07)$$CLAB1@QY*@[NO
M&,=.:Z2BBXK!1110,YK0U-[XIUW5E.;?,=E">S>6#O/_ 'TQ'X&K&M6.L7-T
MIM%TV\L6BV265^I"[\_?#!6/0XP1BMF&"*WB6*")(HU^ZB*% _ 5)0%CB[3P
M=?Z79:;-8W-M_:%C//*(F#+;E)OO1C&2JC P<'ITJ>[\/:UJ=I.][>0?:9KR
MWF6!)',,$<3 D*2,EC@DG R<>E=;11<5C U;2-0;7;76])EM_M44#6TL-R6$
M<L9(8<J"5((SG!JK>:#K6K:5(+_4H$U!+M+NS$,>8K<H>%[,X/.2?7IQ74T4
M7'8P8+;Q'=7+MJ-Q8P6WD-&+:UW/YCG^)F900!Z#UY)JFWAF]/@K2M&\VW^T
MVCV[2-N.P^6X9L'&>@XXKJJ*+BL<EKFA:UJAOK9TT>]LKC/D/>(1):@@# "J
M=V#R#D'WKI-.M/[/TRTLO-:7[/"D7F/U?:H&3[G%6:*!V"BBB@ HHHH *GM/
M^/E?Q_E4%3VG_'ROX_RI,#2K,N_^/E_P_E6G69=_\?+_ (?RJ8C9#1115B"N
M&F\'ZF;G5_+CTB0W\TDB:A<*SW$*MP% QCY1P,,/I7<T47!JYS.B^'KW3[_2
M+B=[<K9Z.+"01L22X9#D9 XPA]^:T-$TN?39M6>9HV%Y?O<Q["3A2B+@Y'7*
MFM:BBX6.<NM(U:S\0W.K:,]I(+R)$N+>[9E&Y,A75E!['&,?C36T/5[E]$GO
MKZ"XN+.\>XG8)L7:490B #G&X=>3CK72UB>(=>ET1M/C@T]KV:]N/(2-9 A!
MVD@Y(Z<<^@YH$4-:\,WNHW.O20RVZKJ&G):Q;V(VN"^2V!T^8=,U>U#1KB[N
M=!DC>(#3Y_,EW$_,/+9?EX]3WQ57_A+ULUU)-9LFL;FQ@6X:..3S1+&Q(!1L
M#/S#;@@<T^'Q)?0WMC#J^CFPBOG\J"5;@2X<@D(XP-I.#TR,T]0T*:^']?LK
M.[TC3;VUBT^XED>.Y9W6>V5VW,J@#!();!R.M:^DZ1-I^L:Q=R2*\5X\+1?,
M2^$B5#NR.N1[UD?\)CJ#QZG<P^'WDLM-N9H)Y1<@,PC8@LB[?FX&2,CT!-;%
MGKT5]K:V$$>Z%[".^2?=]Y79@!MQZ+G.>]&H*QA6?A/4].TW0);2XM?[3TN)
MX75RWDS(_5<XR.0"#C\*NW6A:QK6EWL6JWUO'/))'):1VZ;H[9D(8'<0&?)'
M.?PJK?:]/?R:6T(DM1'XA:QD"2G]ZJ+*.<8X) ..>E7-0\1ZK:I?W,'AZ26Q
MLB^^66X\IY HRS(A4[AUP<C..*-1:$<>E>(;SQ-I>IZF^FQP6*RKY-L[L6+K
MC=EE'MQV]32>.5N&M-'6TD2.X_M:#RVD7*AOFQD>E1+K6IW7CBPCM(%?3;C3
M3.%:?;\K/'F0KM/S#. ,\Y/(J"QUR-O#VAHEA-J5_=RR-:Q7<X=@8V;+M(5X
MVCH0,\@4 7#H&K:E=WE_J5S;6]T]A)96JV;,PAW]9"Q );..@&,5E1>#-56W
MTN&.UT.T%A=03NUL'WW/EL"=S%<C/)_BR<<UK3^,6LK+53?Z:8+_ $V)9I+<
M3!EDC8X#(^.1U[5/:^([TZO8V6HZ.UFFH!S;2"<2'*KN*NH VG;D]3THU#0S
M]3\+ZK<Q>)K6"2S^SZL!)$[NP=)-J+A@%(VX4G(.?:K]UI&K6?B&YU;1GM)!
M>1(EQ;W;,HW)D*ZLH/8XQC\:Z.BE<=CFFT/5[E]$GOKZ"XN+.\>XG8)L7:49
M0B #G&X=>3CK2W_ARYO=1UV;SHDBU'319QGDLK8<$D8Z?..]=)11<+%#1H;V
MWTBV@U!;<7$2",_9W+(0!@') /Z5?HHH&%%%% &M%_J4_P!T4^F1?ZE/]T4^
MLR@HHHH AN_^/9_P_G696G=_\>S_ (?SK,JHB844450@HHHH **** "BBB@
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M5TU%% R[8?\ +3\/ZU<JG8?\M/P_K5RH>Y2,F;_7R?[Q_G3*?-_KY/\ >/\
M.F51(4444P"LGQ-I<^L^'KK3[9HUEEV;3(2%&'#<X!["M:B@#)LM+GMO$NK:
MD[1F&\BMTC4$[@8P^<\8_B&.:R-,\+WME_8'F2VY_LZYNYI=K-\PE\S;MXY/
MSC.<=^M=;11<+'):UX7O=1_X27R9;=?[4MH(8-[,-I3=G=@<#YAC&:FN]*UV
M#Q5=:OI;:>\4]K' 8;EW4Y4L=V54XQGIWR>E=/11<5CDK?PG=6YTF0W,4L\.
MH2W][(05#O(K [!SP"P !["HV\*:C+::E:-/:QAM1.I6%PI8LDIDW@.N ,#I
MD'O78T47"R.<M])UB^UVQU+69+*-;!7\F"S9V#NZ[2S%@,<9P,=^M-T_1-7T
MSP58Z7:7EM%J%LJ@N5WQ2 -DJ<C.".,@9KI:*+CL<QH?AZZM?$4^LW4&G6;R
M6WD?9[#)5SN#%W)5<MP ..A/-=/110 4444 %%%% %JQ_P!<W^[_ %J_5"Q_
MUS?[O]:OU#W&C&HHHJQ!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %3VG_'ROX_RJ"I[3_CY7\?Y4F!I5F7?_'R_P"'
M\JTZS+O_ (^7_#^53$;(:***L04444 %%%% !7)>,Y+F+4?#<EG L\ZWY*Q,
M^W?^Z?(SV.,X]ZZVJUUI]K>3VL]Q%ODM9#+"=Q&UL%<\'G@GK0@9R&H^'=4\
M3G5;N\@73I)K-+6T@>17(*R>9N<KD#+!1@$\5<FAUS7[S2DO=*&FP6=RMU/(
MTZ2>8R@[50*3P2>IQ76447%8\\TR77)-/\1:?I^EI,MSJ5[''=&X54B+.02Z
MGYN.OR@Y]JTTTK4M UBRN+"P.HVT>E1:>P29(W0QL2&.X@$$'MSQTKI[.PMM
M/69;6+RQ-,\\@W$Y=SECR>Y[=*LT7"QPEAH.M"ST_P"UVJBX3Q!)?3A)5($;
M"3Y@<\C+#CKSTJEJ'AS6+Z/5HKO2)+^]G>7[->37X$"(<[,1YX(&.-O4<FO2
M**=PL<C8Z;JECJ^@WGV!I(TTH6-R!*@,#90[CS\P&T_=S5&PT#5]+T_P_?16
M2S7NG"XCGM#,JEXY&)^5L[<C /7N:[RBE<+'!ZOH>MZY9Z_?2V0@N;JR2SM+
M/S49MJL6)9@=H)+'O70ZM87-SXB\/W<,6Z"TFF:=MP&P-"RC@G)Y('%;=%%P
ML%%%% PHHHH **** "BBB@#6B_U*?[HI],B_U*?[HI]9E!1110!'/&9(608R
M?6JGV&3^\GYFK]%.X%#[#)_>3\S1]AD_O)^9J_11=BL4/L,G]Y/S-'V&3^\G
MYFK]%%V%BA]AD_O)^9H^PR?WD_,U?HHNPL4/L,G]Y/S-'V&3^\GYFK]%%V%B
MA]AD_O)^9H^PR?WD_,U?HHNPL4/L,G]Y/S-'V&3^\GYFK]%%V%BA]AD_O)^9
MH^PR?WD_,U?HHNPL4/L,G]Y/S-'V&3^\GYFK]%%V%BA]AD_O)^9H^PR?WD_,
MU?HHNPL4/L,G]Y/S-'V&3^\GYFK]%%V%BA]AD_O)^9H^PR?WD_,U?HHNPL4/
ML,G]Y/S-'V&3^\GYFK]%%V%B.%#'"J'&1Z43QF2%D&,GUJ2BD,H?89/[R?F:
M/L,G]Y/S-7Z*=V*Q0^PR?WD_,T?89/[R?F:OT4786*'V&3^\GYFC[#)_>3\S
M5^BB["Q0^PR?WD_,T?89/[R?F:OT4786*'V&3^\GYFC[#)_>3\S5^BB["Q0^
MPR?WD_,T?89/[R?F:OT4786*'V&3^\GYFC[#)_>3\S5^BB["Q0^PR?WD_,T?
M89/[R?F:OT4786*'V&3^\GYFC[#)_>3\S5^BB["Q0^PR?WD_,T?89/[R?F:O
MT4786*'V&3^\GYFC[#)_>3\S5^BB["Q0^PR?WD_,T?89/[R?F:OT4786*'V&
M3^\GYFGP6KQ3*Y*X'I5RBBX[!5.>T>29G!7!]:N44@*'V&3^\GYFC[#)_>3\
MS5^BG=BL4/L,G]Y/S-'V&3^\GYFK]%%V%BA]AD_O)^9H^PR?WD_,U?HHNPL4
M/L,G]Y/S-'V&3^\GYFK]%%V%BA]AD_O)^9H^PR?WD_,U?HHNPL4/L,G]Y/S-
M'V&3^\GYFK]%%V%BA]AD_O)^9H^PR?WD_,U?HHNPL4/L,G]Y/S-'V&3^\GYF
MK]%%V%BA]AD_O)^9H^PR?WD_,U?HHNPL4/L,G]Y/S-'V&3^\GYFK]%%V%BO;
M0-#NW$'..E6***0RC)9R-(S!EP23UI/L,G]Y/S-7Z*=PL4/L,G]Y/S-'V&3^
M\GYFK]%%V*Q0^PR?WD_,T?89/[R?F:OT4786*'V&3^\GYFC[#)_>3\S5^BB[
M"Q0^PR?WD_,T?89/[R?F:OT4786*'V&3^\GYFC[#)_>3\S5^BB["Q0^PR?WD
M_,T?89/[R?F:OT4786*'V&3^\GYFC[#)_>3\S5^BB["Q0^PR?WD_,T?89/[R
M?F:OT4786*'V&3^\GYFC[#)_>3\S5^BB["Q5MK9X9"S%2",<5:HHI#,_[#+_
M 'D_,T?89?[R?F:T**=V*QG_ &&7^\GYFC[#+_>3\S6A11=A8S_L,O\ >3\S
M1]AE_O)^9K0HHNPL9_V&7^\GYFC[#+_>3\S6A11=A8S_ +#+_>3\S1]AE_O)
M^9K0HHNPL9_V&7^\GYFC[#+_ 'D_,UH44786,_[#+_>3\S1]AE_O)^9K0HHN
MPL9_V&7^\GYFC[#+_>3\S6A11=A8S_L,O]Y/S-'V&7^\GYFM"BB["QG_ &&7
M^\GYFC[#+_>3\S6A11=A8S_L,O\ >3\S1]AE_O)^9K0HHNPL9_V&7^\GYFC[
M#+_>3\S6A11=A8S_ +#+_>3\S1]AE_O)^9K0HHNPL9_V&7^\GYFC[#+_ 'D_
M,UH44786,_[#+_>3\S1]AE_O)^9K0HHNPL9_V&7^\GYFC[#+_>3\S6A11=A8
MS_L,O]Y/S-'V&7^\GYFM"BB["QG_ &&7^\GYFC[#+_>3\S6A11=A8S_L,O\
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M>+]/U[3-/GDFM;2]O8S(EBURK28#,.!P3]TGIZ^E)3BW:Y<L-5C'G<=/\_\
MACH:*H2ZWI,&H+I\VJ64=ZQ"K;O<()"3T 4G/.>*S--\5P7FK:_9W,4=G#H[
MQJ]Q),-KA@3DY "XQZFCF6Q*HU&FTMM?QM^IT5%,AFBN((YX)$EBD4.DB,&5
ME(R"".H(I]49!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[I+.Z:1K29H)AAAM<=1SU^HXKR-]<U0ZIIFKV>HZM-:76I"(R3RK' XW8*+
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MLX[9QVK1T6+7=-M]!\&17HLKI+&6\N[A465HT$F%C3=E>"X&2#PM=CX=T?\
ML#0;;3//\_R-W[S9MW;F+=,GU]:KZUX?EU#4;35-/OS8:E:JT:RF(2H\;8RC
M+D9&0",$8JKDV.)\4W>KS^'/$NBWVHF273)+65;J.%%-Q%*W"NN, A@3E<9P
M/<5IZSKVIVFOQ>'X]0U+%O9K/<7MIIHN9I69B%&U4*H, \[>>U:4G@C[3I&L
MP7>IR3:CJQ0SWGE!0NS&P*F<!1CIGN>:FN/#&H/J%OJ]MK*6^L);_9KB;[)N
MAN$W;AF/=D$'H0U%T*S, ^)/$LFAVL8\VUO6UF.Q2ZN[$Q>?"P.)#&P&#Z@8
MY7WJU>RZU!>ZSH%UK+W,;Z0;R*Z-O&DD9#%63 7:01W(R,_C6M_PBEQ)9V4=
MUK-Q=7$&I)J$DTRY#E<_(BYPB\\ 9Q^-7;KP^MWK\VI/<$)+IS6#1!.0"V[=
MNS^&,470[,Y/PX;FTB^'\$MR+E;BRD<&6"/=$OV="J*P7( ]<Y/<FJ6J>+K_
M $VWDNQXLM+O4(9P)=,M;826X4R %/,"[@0IZDCD5T^G^#[BV30TN]56X728
MY8(]MMY9>-HQ&H/S'D =>_H*S9/A[J$GAD>'O^$C"Z;%M\E$L5#?*VY?,.[Y
MQD \;<XZT[H5G8U=#_Y'OQ7_ -N?_HHU0U[1M2@\7'7H-&MM=MWM5@^S32*D
MEN0228]XVD'//0UT=AH_V+7=5U,W&\ZAY/[O9CR_+4KUSSG.>V*SM0\,7C:W
M/J^B:RVF75TB)=*UNL\<VT84E200P'&0:5]1VT.1N)-)/A#QNMA9WFF7;6_F
M76F7"*BP,4(#H%XPV,DY.<=J]%T7_D!:?_U[1_\ H(K ;P3)<:5K4=[JSW.I
M:M ();QH0JQJ 0H6,'@#)/7)SUJ73M#\3V+6D<GBBVFM("BM$-+"ET7&5W>8
M<$@8SBAV8*Z.HHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3?".AZ1>1W5G9%9HE*1-)/))Y2G@A [$+QQQBMNBBX604444AA1110 4444
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M'!NZE!@8XX_^O@UT]%)Q3=V7"K."<8NR84444R HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"M??\ 'M^-85_:_;=.N;7./.B9,^Y%;M]_Q[?C6542.BB[
M*Z/,?#6H?V>S6-T/+G@;RW5N""*Z>XU:W2 MO'2K6N>%-/UR07#E[>[ P)X>
M"1[CO6*GP\+N!=:U<20_W$0*3^-8<LXZ(]9U</5?/)V?8H>&HWUCQE]M0$V]
MDI+/V+'@"O1JJZ=IMII5FEI90B*%>PZD^I/<U:K2$>5')B*RJSNMEH@HHHJC
M **** "BBB@ HHHH **** "BBB@ HHHH *DAD,<H(]:CHIB-U6#*&'0TM5+&
M;>FP]15NK1RR5G8****!!7RY\2,_\+#UK/\ SV'_ *"*^HZ\<^,V@V!O]'OT
MB\NZO)_(GD4_?48P2/49ZUSXF+<+]CV<CK1IXFS^TK?K^AXM7V/:_P#'I#_U
MS7^5>(Z/X*T:U^,LNBM%)/8VL N(TF;.6VJ1G&,C)/%>YU.&@XWN:YYBH5G3
M4>U_O_X8****ZCP0HHHH **\WO\ XU^&].U&ZL9K+56EMI7A<I%&5)4D'&9.
MG%=KX?U_3_$VCPZIILC/!+P0PPR,.JL/4?EZ$CFFTT)-,TZ***0PHK&UOQ+9
M:#?:5:744[R:G<"VA,2@A6) RV2,#GMFK&FZO_:5W?V_]G:A:_8Y?*\RZAV)
M/R?FC.?F7CK[BBP7-&BBLGP_XCT_Q-:W-UIK2-!!<-;EW3;N90"2!UQ\W?'T
MH UJ**S]<UBW\/Z+=:K=I*\%LNYUB +$9 X!('?UH T**K:?>QZEIMK?PJZQ
M7,*3(' #!6 (SCOS5F@ HHHH **** "BBB@ JKJ.H6NE:=/?WDHBMH$+R.>P
M%6JYKX@6=Q?^!M3@MHS+*%27RUZL$D5V ]\*:4G9-HTHP4ZD8RT3:(9O%6L6
M^FG5I?#,BZ:J>:Q^U+]H6/KN,6W'3G&[-;<VNZ3;6=O=W6I6MM!<('B>XE6,
M." 1C<1ZBJ-UXPT:#PZVLQWL,T)BWQ1K(-\C8X0#KN)XQVKGKG4S>^)"8M)T
MVWU--.B>ZEU6Y.(D?+"-5 YP<[CQ_*LW*W6YU1H>TWARVOU_S_KR.T;5-/2"
M*=KZV6&8$Q2&90KX!8[3GG !/'8&EL]3L-0MVN+*^MKF%?O20RJZCZD'%>4Z
M)%;ZA8^'HI$@FM6\1715$7]T5VR,-JDGY<]!S5OQ= EMJOB:.",Q6DEM827B
MPC&8_.8.<#_9'/MFE[5VO;^K&KP,.?V?,[__ &UCTFRU;3=2:1;#4+2Z:/AQ
M!,KE?K@\4EKK&EWMU);6FI6=Q<1_?BBG5W7Z@'(KBO&,FC)8SIHMLKZPVES^
M1+88Q'!A=V[:1P?X>#SG&*J6MA;._A>4>)-*5%N(WLH[/3-LL@Q\T>5D8@%<
MAB1@=Z;J.]B(X2#ASW:OMI_E_P #KV/0(=8TRXNA:P:C:2W+!B(4G5G(4D'@
M'/!!!]P:EO;^STZ#S[Z[@M8LX\R>0(N?J37%>%Q/I_A>_O\ 2M'CU'4&U.Y_
M=>:L+-^^*D[V'& *CO-7O;[6=*AU#PU96>M!)I(1?Z@'ABB^4%@4!#.?3&0!
MUH]II<GZHG4:6ROU5]/*^WG_ ,,=M'JFGS6!OXK^U>S')N%F4QC_ (%G%%KJ
MNG7MJ]U:7]K<6Z9WRQ3*Z+CKD@X%>5VBV=[#XA2YU2QL@-8MFBFMHB]KYX08
M!4D@J6')) SSQTJW<FVD/B#3==?3K.62S@DFU33 [Q[1+A!)'R <]?52><4O
M:LU>!BG:[Z=.CM]^_37RU/2;'5=.U,.=/O[6["'#FWF63:??!.*;;:QI=Y=R
M6EKJ5G/<Q_?ABG5G7Z@'(KS74I]2MI=0M?)TNYU2;1I_L]]I19&$:X)#QYQD
MY^4CN.*T-4.B?V!X6_L3[+]M^V6OV/[-M\S&1YF<<XV[MV>/6CVC)>"CIJ]=
MO\WY?=U['=2:QI<-^MC+J5FEXWW;=IU$A^BYS4-KK"2)J,EW]GM8;.Y:$R&Y
M1@5"J=S8^X?FQM//0]Q7#Z0_AZ+P'>2:[;K<78NY?MT7'VEY_.. .0=WW<8(
MXQ44EY;0KJ<,^GQ7<UQXG*VT=U,8XDD$,9#2$9R  >,')Q1[1[C6#C=Q5]-/
MNMMK^9W,_B;1X]&O-4AU*SN;:U0M(T-PC#/9<@X!)X'J319>)-*NM"M]7>_L
MX;:5%+.]PNU&(!*%LXR.E<"SM-XE\21S_P!F-*/#TGFKIX)C#!B0&)ZN,]<#
M@B@(T^L>$TBOK*T@.C?Z/)<VXFB,_P F\ ;E ?;CG/3-+VC*^I4[6;\_E:]O
M^">F+J-B]C]N6\MS9[=WV@2KY>/7=G&*SK3Q':W_ (@73;-H;B!K+[6MU#,'
M4_/LVC''XY_"O/GM+6VO8_-U>UO]*;78SJ"0VIAMH9?*( .692"VPGG&<9KI
M=..FGXL7@TXP[AI*_:!#C&_S1UQWV[?PQ351LB6%A!-ZO1O:W]?\-W.VHHHK
M8\X**** "BBB@ HHHH **** "BBB@ HHHH K7GW4^M5*MWGW4^M5*I".5L]
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M3DUJ'+8DHHJ"ZO;6Q0/=7$4*GIO8#/T]:S&3T52MM8TV[E$4%["\AZ)NP3]
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M?;_]\5)!H^FVTHEAL8$D'1@@R/I5VBN>R.GDCV"BBBF4%%%% !1110 4444
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MZ_\ 9?[2MO.^RRB:+YB,,/H>1[5%2+E%I'5@ZT:%>-26RO\ D<%9?\G"7_\
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M2BOZ_KH=#?:I':Z,VHQC>IC5H@?XBV-H_,BN0<0P0OJFK2N[,P#2"-G.3T
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ME+-&RC'0<X( Y^M3*]M#DQJDZ6G?7T,K3M-N=+NDO=-F\B<*5R!D$'L1W_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF(9'7:S[V8XZX^8G'_UJU*:\SIPT)PI\M1W?JW^+"BBC!IG0%%%% !111B@
MHHHH *4#)Q259LXO,ER>@IB;LKE^VB\J$<<GDU-115G*W=W"BBB@1YW\4_$.
MK:-!80Z=*]M'.6,DZ=<C&%![=<UCP>,O$)^&4]\7=KE+L6ZW97G81DM]0>,^
M]<-KWB?5/$%S+)>W4C0L^Y+<-\B>F![#O3]2U;4+>W71H;R9+"*-085<A7+
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M!80P3RYE*NS-#M0,H0H =SOD'W%)9^#O$-MXR_X2MKZS:^N)VBNK8,PB^QX
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M0*G'.!CDXSS25R(JLOP[=D0:!XCU$Z!I@GMUN]2OY91 #/@,JL2[.VWY HX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5Q^M>)Y+B1K+27PH^62Z'\D_^*_+UH\3ZT]Q,^DV3D*.+F13_P".#^OY>M4]
M/T\(H^6LY2Z(QE)R=D8D.G;?%-@""2UG<L2>23O@Y)[]:ZV&R50.*H21!/&&
MF#'_ ##[O_T9;5MO(D2[I'5!ZL<4)#44D-6%5[4_:/2H#?6_9RW^ZA/]*07U
MOW=E_P!Y&']*=AV+&T>E!4'M21RQRKF-U<>JG-.H B:!6[53GL58'BM&@C-%
M@L<I<Z?)!*L\#M%,ARKH<$5T>@^)OM<BV.H;8[L\(XX67_!O;OV] 30!P>*P
M=1TX,"<8/4$<8J=8[&=G%W1Z%5&76M*AU%=.EU.RCOG("VSSJ)#GIA<YYK*\
M,ZZUZIL+Q\WD0RK'_EJOK]1W_.N!\2:5=6WCR6YT;P_?W=U/<H\JWVDPSVDA
M.!N6XSNB '/U':M8VD:J=U='JDVL:9;7\=A/J-I%>RX,=N\ZK(^>F%)R>AII
MUO21J T\ZI9"]+;!;&X3S-V,XVYSG!!KS+4=+-OXGUV'4/!=YK=U?WL4UC>1
M@I&B< !IQS%MP>G7'/&#5T^%;G4-7\>W(TS;J$Z*FGW,L>.3"0?+<CC)X)'X
MU5D.[/0['5M-U0RC3]0M+LQ$"3[/,LFPG.,X)QT/Y4RUUO2;Z.XDM-4LKB.V
M&9VBN$<1#G[Q!^7H>OH:\;\+>%=:F@U(01:G9W0TF2T"3Z3%8QNS#A?,5\R'
M(^\5/J2,T_PCX<U.--3F:UU6"2/1YK9H9=%CM$E8KPH9'W2MD?>*DGN1D4^5
M=Q<S['L-GK>DZA<FVLM4LKF<1B4Q0W".P0XPV <XY'/N/6JMKXHTB?3;6^GO
MK6S2Y$C1+/=PG<$)#$,CLK8QDX)QWQ7 ^&O#4FE:WX$N8-&DMG^PW U&5;<J
M0YCX\TXX.2<9^E4?#WABYN;3X=6FJZ+.]O;G4C=Q7-LVV/)+)Y@(XR0",]:5
MD',SUAM9TM--74GU*S6P;I=&=1$><??SCKQUJ2TU"RO_ #/L=Y;W'E-MD\F0
M/L.,X.#P<5XO)8-H^A:,-3TF::QM_$%Q_P 2QHOGG1N(]D;8WC)X ZY]*Z[X
M6I$MQXI,%E]BA.J-LMB #$, [2!P",]!P.G:AQT&I:G;2:QID.HIITNHVB7S
MXV6S3J)&SZ+G)IK:WI*:G_9K:I9+?Y ^RFX02Y(R/DSGISTZ5YE-I;6OB35[
M:_\ !5YJ]_>:J+JSU!<QQ)$2NT&<<IMP3COT/:J.OV>IZEXC\S_A$[FVN;76
MHY/M%IIR".6W#\2-+@R.YX)"D*!R1D4<HN9GK*Z_HSW@LUU>P:Z,C0B$7*%R
MZ]5VYSN'<=:5->T:33WU"/5K![)'V-<+<H8U;C@MG /(X]Q7DE_X0DNK#6;B
M309I+V;Q8S+)]F8R-:E@=P.,^6<GD<?E3?$^D'2="\=HFF-;6$E[9&W18C%&
MXW#=LX QGTI\J#F9[!;:QIEY#/-:ZE9SQ6^?.>*=66+')W$'C\:K-XETAM,N
MM0L[^TOH;49E-M=1$+[%BP5?Q(KS6&TO$N]?U?0_!,EI:+I:6W]F7MH%6ZF$
M@)81@_. F>G7'J:S8M&U"2U\5R6N@:G:PWNE)Y$,FGK"7</AE"1+@'.< Y;&
M"<YS1RH.9GL4NNZ7;^2+K4;2VDFA,R1S7"*Q0#)8<\@ $DC(X/--G\0Z+;(C
MW&L:?$KQ+.ADN44-&3@.,GE22 #TKQW7H[:UO_$=OJ.B-J-U-HMNUM*%5O[/
MV088ODYB.X9'<\#O6S8>'1JVJ^'I+W23=V4?A*) \D!>,38X&<8W8)P.O>CE
M0<S/3YI8[BWAFAD22*0!D=&!5E(R"".HK$\0S/#H%XR$AB@3([;B%/Z&JO@:
MVNK/X?:-;WL$T%Q'&RO%,A1E^9L @\CC%:U[:I?64]K(2%E0J2.WO^%$=&4G
MU.9L['SM+>.*Y>T8KQ-$ 63'/ ((K0L'@NM*0QSR7(0;#/*FTR$?Q8P!^58]
MI>3:7<&SO5V3)^3C^\OJ*NW>N1) 3O  'K6SC=W$W+X>GIK]Y'I)-OXI"(?E
MFB=7'KCD'^?YTRZ_TGQ5=^9SY6R-0>PV@_S8U;\.6,TEQ)JMPA0.FR!6&#M/
M)8CMG Q_]>H_$%G+9W_]JPH6A=0LX49*$<!OIC@^F!1=<UAVTL3"&/3;J6^N
M]5D%K( J6\H4(AX^Z0,D\'OW-5]=MHWMW! P12QZO;30H7"/M^920#@^HJC/
M-/K=V+*TR6/^LD[1KZG^@[TXQL)N4GJ:6I74LW@JVD=CON$A20^H.,_GC]:C
M33S<:64AOI+%AAC/$%) '7[P(Q6U>Z7'<Z,VG1G8JQJL1/\ "5QM/Y@5S5IJ
M#6QDLKV,QRJ-KQMZ>WJ#ZU*M*+15VGS(WGBC>R0B02C8,2<?/QUXXYK+\/L8
M=?NH%/R20[R/=6 !_P#'C44VJ6UG8I!$=L4:A5!.>*T/#>GS1";4+I"DMP J
M(W54'//H2>WL*;5DR8W>K,R,?:O$-_+)RPF*#/8+P!^GZUHVT,=CJ,L=SJSS
M-<\PVTNP",9/"X )].?2JFLV\FE:H^HHI-I.09&'_+-^AS['U]<^U2KJUNZ+
M(P1F7[K$ D?0T64K,).2NEU*OB&%5@=U.UE^96'8CD&KWB.X>;1+$'@7,D9D
M'_ 2V/S _*LLB7Q#>BUA!\@']_(.B+W&?4]A^-=-K.FG4=+:"+"RH0\.>@8=
M!]",C\:&[-7&C)&F27=E$MO?S63*P8O"JDL/0[@>*T;R&-H6'&0.:Q;#5_()
M@G5HYHSAXWX*GWJ&6]L[&*1;92&F;<W)9G;^9^E"AJV2Y2TC;3^O+4T/"[&.
M_P!1MQ_J_DD ]"<@_H!^5=7;_P"O6L#PYITME:RW%RNVYN6#,AZHH^ZI]^23
M]:W[?_7K6=1W;*+]%%%9#"BBB@ K/UL9T6[!Z&,@UH50UO\ Y MW_N4 4FTN
MPR?]"M_^_8K+TN;2-7-ZL.GI')9W+6TJ2Q*&#+CD8SP000>];[=37%ZE=1>%
MO&,^HS';8ZG9LTO/2:!2WYF/(_X#30F:EI-I-[JFH6$%@A>Q*++(85V%F&=H
M/<@8SQQFC6'TO1M,FO[BPC:*+;N$<*ECD@<9QW-<BME#%HVCPZG9W=_J>JS3
M7\EA"ZHDSL,GS2V!M0,HQGKV-94ZFVTWQC8I9K801"R=;))O,6%F8YQC@$X4
MD"JL3<]#CCLIKVYMO[+V>1M_>O;@))N&?D/?'0^AJO=2:;:ZE96#V49EO/,\
MLK$NT;!DYKE-?N)[>^\4^3(\(EFL(I94.#'&P 8Y[<'&?>K5SI6F:'XS\/K8
MHMM&8[EGA5CMXC'S8]?4]_PHL%SJC8VG_/K!_P!^Q6:]QIOVJ_MDLA)-91++
M(B0@E@P8@+ZGY3^E<'J2VX\/_P!KV&DW*GSDDBUBZN5$\A,@Y ')!SC! XK7
MNM-LEUWQ?<+:Q":.P1U<+R&>.7<?QQS18+G5PP6L]O%-]B2/S$#;)(@&7(S@
MCL:#:6W_ #[0_P#? KD-(L[?6]26UU2,306FF6AMH')V'>IW/CN<@#-46C%S
M:VVG--+):0>(C;1'><^4(V.S=U(Y9?I18+G<M:6W_/O%_P!\"H)[:W$,F((A
M\I_@'I6/IME!I7C&\LK)/)M9+&.<PJ?E#[W7(';@"MV?_42?[I_E2*1W=B<Z
M?;$_\\E_D*GJO8_\@^V_ZY+_ "%6*D84444 %%%4]6>6/1KYX"1,MO(8R.H8
M*<?K0)NRN+I^H1:E%++ K^4DK1*[ 8DVG!9>>5SD9[X/;!+;O5(;/4+&R=)&
MEO6=8MH& 50L<Y/H*Y...WFL?!EA*%;2YX/WD9_U<L@B#(K#HW.3@]2*=?VN
MF67B'1;;3#$L:7%V9((GRL3FW8D;<_)Z[1@=\<FIYCF]M+E^[\;?YG9P2-+
MDCPR0LPR8Y"I9?8[21^1-#R.L\<8@D97!+2 KM3'3.3GGM@'ISBO.?"VGVFH
MWFA17MO'<1+H9?RI5W(3YH&2IX/4]:@M[BY2RT<VQ<SVMKJT=OSDC80$ ^@"
M@?2ES$K%/E3:_K3R\SU&FNXCC9SG"@DXKC%@T#2_"\&L1$17C6#LL]O*%GN"
M8\OS_&V1N^8'!&>U9<%NVG^(?#_EQ:=:"Z@G!BM"7EEC\C<&EDPN\EAG[O4=
M33YBGB&K:;VZ]_D=[I6I0ZOI=MJ%NLBQ7";U$@ 8#WP35RN6\,//'\-K.2U4
MM<+8L8@!DEP#CCZU4L+;0;/PS8:T61+YK0R"ZCE GN)"FYP2?]8V0>&S@CH,
M47*C6?+%OJKG:45YE;0M9:MX5N8XK"U-Y("/)<R7$Z-'EFEEPN_)(R-O7G-.
MTNRM;3PQX<U*&%5OGU2-&N!_K"K2LA7=UV[3C;TI<Q"Q3?V?Q]/+S.^U74X=
M'TV2^N%D:*,J"(P"WS,%'4CN15F*1Y#(&@DBV.54N5^<<?,,$\?7!XZ5YIJ5
MO87/@>;4[Q4_MDZALEF;B7S!-CRR>N @&%Z8 -6X=DVN2V=V VG7&OSK.C#Y
M)'$"&-6]06&<'@D"CF%]9?-MH[?C?<[>UU.&[U*^L8UD$MD4$A8#:=Z[ACGT
M^E.U+4;?2=.FOKHL(8AD[1DG)P /J2!7GKQV%KJFMZ?:1>9;SZI:6ZVZ3>5$
M6*$F-SM;"9!!4#T%4=0M?*C\3V$L6G!8H;68V]G%MAAEWX.T'^+:<$X&?2CF
M)>*DHO377\+_ .1ZW523488M4BT^1762:-I(G(&Q]OWE!SU (./0\=#CC[JS
M6Z\4:G92Z7IES:V5K$MM#=W!A2"(J2S1J(V ^88+#!&T"I&EGE\/>$IY;E;F
MZ_M"%5N%W9D4A@3E@&.4SDD#/6GS&KKO73;]'9G;T4451TA1110 4444 %%%
M% !116?J>M66DH/M,F9&&4A09=OP]/<\4";25V:%1S3PVZ%YI4C0?Q.P _6N
M)N_$>K:@2ML!90G^[\SGZD\#\!^-4!I3W$GFW#/-)_?D8LWYFH<^QFZE_A1V
M4OBC18B0=0C?'_/(&3_T$&H?^$QT/_GZE_\  67_ .)KGTTE<?=I_P#9*_W:
M7-(7-,Z*/Q5HDAXOT3WD1D'_ (\!6G!=6]TF^WGBF7^]&X8?I7#MI*X^[523
M2/+D\R/='(.CH2K#\1S1SOJ'/-;GI%%<%;:[K.FD"1Q>0C^&;AOP8<_GFNHT
MKQ!8ZL?+C8Q7 &3!+PWX=B/I5*294:B>AJU1AUK2KC4'T^'4[*2]0D/;).ID
M7'7*@Y&*O5X]HNE7.F?$&&/2_#]^;0W3F=]5TF$"$$DM)'=*=S>BCG@]ZM*Y
M;=CU2/6-,FU%].BU&T>^3.^V6=3(N/5<Y%11>(=%GDECAUC3Y'A1I)%2Y0E$
M7AF(!X [GM7FOA/2VL-1T[3KSP5>2:S:WTLL^LMF*+:68[Q*/]9\I V'@_G5
M9?!][+\--:^S:2\.KS7\CONM\3S0"4-M&[!884$+T./4T^5$\S/6;?5],N["
M2_MM1M)K.(,9+B.=6C3:,G+ X&!R:8NNZ0^FOJ2ZK8M8(=KW0N$,2G(&"^<
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M>&WCWSRI&GJ[8JNVIP#1_P"T_P#ECY7F8_I^?%<M!:3ZQ.;N^.]VY"G[J#T
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M/W 20,=.I-3P6<VI3M:VX'3][(1\L8/KZGT'\A4]G93ZG.8X#LB0XEGQPO\
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M3G^[P!CC)_#0HI6#DCV"BBBF4%%%% !1110 445S7B?77M -.LGQ=R#+N/\
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M_OVW^%8D^IM%K$MW:,61MH*L" X 'K_.@#JZ*KV5[#?6XFA;CHRGJI]#5B@
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M_P ^EQ_W[-4I5:-RDB,CKU5UP17H58LVB?;-:ENKG!ML+MC_ +Y [^WMWIW
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MU*PF@FGBO;9XH1F6195*QC&<L<\<<\]JV^L5._Y&?L:/],P?^$2F_P"@DO\
MWX_^RIR>$ 7'GW[LG<1Q[2?Q)-6=+\6Z3J.D)J#WMI;(6*LLMP@*') !YX)
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MG\Q^M>2V5K)XKO/MUU&(=*@<K%;H<;V]#C\,G\![>BZ*9'M?+";;>VG+YZ
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M_3WHA2'4XA&(_L_V92YV$L"F<MU[UT:6)&Z3-#9SR7\L1>.$81 W.]LXYQV
M-,B:"[U4SO#LMP3+*F[/ Y//N?YT^W:"]!L8K?R3*VZ-MY8[@#@-GC!R>F*0
M36EK/+;^0S(08GFW'?UY('3MT_6GU -0NEUC4E>&W\IY&VX+YSD\9X&,=/PI
M^K:A:W4<4%O;E$MP$20MU &#QCN>:201:/>(C0B>XC(9F9B%'<  >V.339[>
MVLXHYC&TRW W1([$!5P,[L=3DX[=,T*V@$US=V]OI*:9]G+2CYY)-_ <X/3'
M.!Q^?UHL[NWT[3'66W,TMWZ/C$8R.>.YS^5,E2">%M4>-MC-L,(;_EI]>NW'
M/KV]Z(T@U&#S"AA6T3YU0D[DY/&>ASQ^/M2TL!!I=]%I]Z)Y;;SP. I;&/7L
M<\9'XU[)IU[#J.GP7=OGRI5RH/;VKQM!;W0D1+?R9%1G0JY8' R0<^P/(Q7J
M/@Y2OA.P!!!VL?P+L:QQ"5KE0-VBBBN4L**** "BBB@ HHHH **** "BBB@
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M<3X5LS>ZS)?N,Q6H*H?61A_1?_0J[>B"ZBI+=A1115FH4444 %%%% !1110
M4444 %%%% !1110!!=_ZG\15*KMW_J?Q%4JI".?U'PZ[W+7>FRK%(YR\3_=8
M^H]#5/\ L?79OD?R(E[N9-WZ"I;W7+N\N'M]+(CA0[3/C)8]]OH/>JW_ !.[
M?]XNHS,1SB3# _A6ZYK:@[=3H-*TF'2H6",9)I.9)6ZM_@/:I-2TR#5+;R9L
MJRG='(OWD/J*JZ-K/]HAX)T$5W$,NHZ,/[PJ36-672X$VIYMS*<11YZ^Y]JS
MM+F\QF*=&UNW.R)H)T[-OV_F#5BR\-RR7"SZI*CA#N6"/E<_[1[_ $JGOUN[
M_>/?RQY_AB 514UOK=]ILRIJ+>?;$X,F,.GN?45H^:V@E;H=57-WGAR>*=IM
M*E1%8Y,$G !_V3V^E=$701^86&S;NW9XQZURUQK6H:G,RZ>WV>V!P),9=_?V
M%1"_0!!HNMW)V3/! G=M^\_@!70:;IL&EVOD09))W.[?><^IKG#)K=G^\6^D
MDQU28;@:WM(U9-5MV)3R[B(XECST/J/8TY\UO(-.@:MI$.JQ+ES%/'_JY5ZC
MV/J*Q/[(UV+]VOV>1?[XDV_H:U=:UDZ<4M[=!)=R#*J>B#U/^%8W_$[G_>-J
M,RD\X3"@?A3AS6#3J:.F^'6BN4N]1E6:9#E(T^XI]3ZFMYU61&1U#*PPP/0B
MN:L-=NK6Y2VU0AXW.U9P,%3VW>WO713S1VT$D\S!8XU+,Q["IGS7U'Z'-S^'
M+NTD+:9,C0GI#*<%?8'TJ-=!U>[8+=2Q6\?<JV]OPILFK:KJKDVKFTM_X0H^
M<CU)_I2"YUNP/F"[:=1UCF&0?Q[5I[PM#I[*R@T^T2VMUVQKZ]2>Y/O5R#_7
M)]:S],U*+5+,3Q@HP.V2,]4;TK0@_P!<GUK!WZC-"BBBH *\?\0ZS'J5]<B&
MSABB,F=P!W,1QN/..?IZ5[!7B<MHMO)</>+("LS1B)>&+#DY)Z 9';O71ATK
MMD3)I;T6FG)IZV\+%DWR2,#G+@''7L O/J*2SO1IE@7$$4LMPV09 ?D53['G
M)[>U)+#!=J;X,Z6Z*$D3@L&   !Z'/KVP?Q$AAU&%(X-\/V<$N)&W?(3DMD
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MD'.CI)+I5'6L^YU%5!^:LZ)=4U XM;&=@?XV78OYM@?E6K9^#99F#ZI=<?\
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MM[%%5Y@,4PW8]:KS7(VDYXIJ+$Y(T?#7_(?./^?=_P#T)*Z^;[@^M<YX4L)
MTNHRJ561=D0(Y*YR6^AP,?2NF(!Z@'ZUR8AIST.S#)J&I0<#T%5W4>@K6,49
MZHOY4WR(3UB3_OD5@;F$ZKZ"H6^\/J/YUT7V: ]8(_\ O@4GV2VSG[/%D?[
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M@ >@I:+BN8G@^)(_!NBE%P7L("Q[G]VM;=8WA,@>#-#S_P! ^W_]%K5^>Y"
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MBKR3^ K2\/:9/ TM_>*4GF&U(SU1/?W-%N2-F-R<I.3,U_WWBB^:3JL@09]
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MK^@>(M6UCQ%IZKX/NK&WCLS'=WE_ 87C8X.V-C]Y,J.,#/!.,<\/;^'-:NO
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M@-"BBBLQA7G'CU;470$#P+(&#3(K#<[$8!(]1C]:]'KPR5)[N^F*J\LK.S'
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ME@5@%F$ZY)=F_D!0G*[704I));W)]#U-M2M&$X N8&V2@< ^C#Z_S!K9M_\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5KS[J?6J;*KJ58
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M99+;QDN<EGD/5V/4_P">PK1M_P#7K452V_\ KUK)NXB_1114#"BBB@ HHHH
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M[7*@;5%%%<A84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 5KS[J?6LK4KS^S]-N+O:&,2$JI[MT _,BM6
M\^ZGUK$URU>\T2Z@B&Z0IN11W*D,!^.*N.ZN'4Y:WMY$M9KYX)KZY8[V2/&^
M0D]LD#_ZPK6%@ES81RM;O SH&,4F-R'T..,U!HE]$T"<\$5<CN[E893>M!DM
M\BQ9X7W)ZFMFI7O<ER6D;:]RKX=G>SU*73&),+J9(A_<8=0/8YS^!]:CUN5]
M1UK[!D_9[;:67LSD9R?H",?4T:(&O/$CW"C]W;Q-N;_:;@#\LFFWX-CXGF9Q
MA+@+*A]< *1^!'ZBG]H?0ELX2]]-9MIMQ''&N5NG"^7)TX'.>_IVJKJ=I)83
M)=VIV3Q'<I]?8^Q[UT$=W&T8.>U<WJ#)96KPQS33[F^02-N89Z*#WY_G2A?J
MQ2E[RY5_7_!.BO\ 5O*\/#4+<8>:-/*!YPSXQGZ9_2N=BMVL[ W2V5Q?S,P+
M)%@NQ/5CDBM?4M.EB\(16P&Z6U2-V YSMQNQ^&:9I-[&]L-K#)'!ZTE\+Y2K
MI-75T+<:;'+:AC&4+*"5;JO'0TWPQ<R137&ER,2D2^9#G^%<X*_0'&/K4Z22
M6UDRW5W]HE))+[ H'L .U5/#B&XUB[O /W4<?E ^K$@D?@ /SIO9IZD1=];6
M*^I.VKZ])"Q/V>T;RT3L6_B;Z]OP]ZL6$)N)[FWDTVYMUA.%FE"[9?=<$G\_
M6JLF[3_$-[$V 9',T9/0AN<_GD?A6Q8W<_V7-ZT)E!ZPYP1^-$D[)ICYDGRM
M?\ Q+Z-]'NTO[;AXN6 _C7NI^O\ .M[7M1>UT@/;/B6X98XG_NY&2?R!_'%8
M>N7/V@?9X1NEE.Q%'=CP*T_$EHT>AVS)EA9.C-_NA2I/X9S0]6KC6QDI;G3[
M.*2+3KF]9WVE8-I89_B.XBM*_P!*B> _(,$="*ETZ]1K< ,,XXS3&O+A+-A>
MM 9<G!ASC'X]Z/>NW<ER6BM\Q_AB\D>&>PF8LUJ1L8G)V'.!^!!'TQ726_\
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M"BBBN<L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-NAQ@@]P1V-.?-U#T*^IZ3;ZK$JR[DD3F.5/O)_B/:L0^'-50[$OK9D_O,K
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M:U*:5C>E3<7KV_K[@HHHJC<**** "BBB@ HHHH **** (+O_ %/XBJ57;O\
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MY+^6WDU"ZZ^4& )]ESP*LRZ,K6T=PL3V\I4-CHZ'TR.]5M[MQ].8[,    8
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MDY;@E8****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\01^537NKQ+"?F'3UI/#%K)))/JDJE5E41P@]2N<EOH3C'THVB[@MRD?]/\
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ML>Z8/*-WREO7'8U2OM NK:Y>YTK:R.=S6['&#WVG^E5O)UVX_=K8NAZ%I&
MK9J,G<$Y)-+9BP?O_%-F(_X&9VQV %.U0&'Q4[2?=DB0H?IP:U]&T8:8CRRR
M"6[E'SR < ?W1[5)J^DIJL"C?Y4\9S%*!T/H?:CG7,+I8@EM+'4(8A=V\,XC
M.Y!(N=I]15/6IXU@;)& *J?9M=M?W9LS+C@/$P(-2VN@7M_.LFIXBMU.?)#9
M9_8^@H2BG>X.[5GL.:WE'@!5VG<(Q(5_V=V?Y5/H\\;0+@CD5T!52FPJ-F-N
MW'&/2N6N-"OM/F9]-Q-;DY$1;#)[#U%)23NF#U+NHF_-U;FWGMX[-<F<.A9W
M] OI]:H:./.\4%X_NQPL6_'@4S[+KEX?+%H80>KRL !_C6_I&E1Z5;,@;S)I
M#NEE(^\?\*-(IZ[CO>U^AS\G[CQ1?+)U9PXSW!'%;%E96MK<W=W#D2W;*\I)
MSD@8&/2G:SHPU()-"XBNXQA'/1A_=-8WDZY#^[-@[GIN1@0?QIZ22"[5[=1W
MB"=/L\@Z\'BK&MP21^%;+<#^Y,1D]A2:?X?N9[I+K5"H5#N2W4YR>Q8_TKHY
MHH[B%X95#QN"K*>XH<DK6$M#&TN5# ,$=*LW<J+"<D5BRZ+J>F2$60^U6_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@""[_U/XBL^:))X)(9!E)%*M]#
M6A=_ZG\15*J0CBH)IM#NC97?R[?]6_9U[$&M"?6XEA)+@<=S703VT%U%Y5Q"
MDJ?W7&:IQ:!I,,@=+&+<.F<G'YUKSI[A8R- M9;W4/[4F0K#&"(=PP7)ZM]*
ME\164T=S'JENA<*NR=5&3@=&_"NCZ# Z44N=WN!QGVFQOIK2\D)\^U),3H^.
MO4'U'M3;N\FU6X%G9KOE?CCH@]3Z5TL^A:7<R&26QB+GJ0,9_*K5M:6UG'Y=
MM!'$O<(,9IJ45JD-MNR;V*S:5$=#_LL'Y/*V!O?U_.N;L[Z739C:7B^7,G!!
MZ-[CU%=G4%U9VU['LNH(Y5'3>.E*,K;BW.>O-<B2$G>!4OANQF::75+E"AD7
M9"C#!V]V/UK3@T/2[:021640<="1G'YUH4.:M9 <GXBL6MKV2^$9DM+A=LX'
M\)Z9/L:;I5Y9:?IR6UJ2(5R5#.6QGW-=<0""" 0>H-9TF@:3+(7>PBW'DXR
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9(Q(NU
MLXZ\5%]DC_VOSHHH /LD?^U^='V2/_:_.BBBX!]DC_VOSH^R1_[7YT447 /L
MD?\ M?G1]DC_ -K\Z**+@'V2/_:_.C[)'_M?G111< ^R1_[7YT?9(_\ :_.B
MBBX!]DC_ -K\Z/LD?^U^=%%%P#[)'_M?G1]DC_VOSHHHN ?9(_\ :_.C[)'_
M +7YT447 /LD?^U^=*MLB,&&<CWHHHN!-1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img192321128_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_3.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2E84&AO=&]S:&]P(#,N,  X0DE-! 0
M    *3R^$%5CA"24T$!       7AP!6@ #&R5'' (   ( _QP"4  (<G(U,#
MDP,#@< @4 /4UI8W)O<V]F="!7;W)D("T@4F5P87)E("T@25!/("T@4RTQ7T
M-O;VQE>2!$<F%F=" T+C(N,C!?+F1O8W@X0DE-!"4      !#T^FD%=?QH>7
M/@FU9!)PFY.$))300Z      #E    $     $       MP<FEN=$]U='!U=
M    4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0
M    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
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M]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
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M9T56YT1B-2;'0               !4;W @56YT1B-2;'0
M!38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M     .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;V
MYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W
M!L;VYG       X0DE- ^T      !  M     $  @"T     0 ".$))300F
M     .             #^    X0DE-! T       0   !X.$))3009
M $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M     ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@
M &       ! #(    ! %H    &       ! #4    ! "T    &       !.$
M))30/X      !P  #_____________________________ ^@     ______
M_______________________P/H     /____________________________
M\#Z     #_____________________________ ^@  #A"24T$"       $
M    $   )    "0      X0DE-!!X       0     .$))300:      ,U
M  !@             !T    Q           0
M !              ,0   !T                      !
M           !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M$       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M       $)T;VUL;VYG   !T     !29VAT;&]N9P   Q     &<VQI8V5S5F
MQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6
M-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6
M-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M   =      4F=H=&QO;F<   ,0     W5R;%1%6%0    !        ;G5L;%
M1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M$       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
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M5T;&]N9P      .$))300H       ,     C_P        .$))3001
M ! 0 X0DE-!!0       0    $.$))300,     !Z_     0   *    !?
M !X   LB   !ZC !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$
M  ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T
M(               $  /;6  $     TRU(4" @
M                                         18W!R=    5     S9&
M5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
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MXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                               %A96B
M#S40 !     1;,6%E:(                     !865H@        ;Z(  #
MCU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML
M]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !
M9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                              9&5S8P         N245#(#8Q.38V+3
M(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D
M="                             &1E<V,         +%)E9F5R96YC92
M!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "
MQ2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                !V:65W       3I/X %%\N !#/%
M #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M   0                        */     G-I9R      0U)4(&-U<G8
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M9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X"
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M1)U,O53M71UE76V-=<U^#89-
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #X :(# 1$  A$! Q$!_\0 '@
M 00# 0$!              4&!P@" P0) 0K_Q !=$  " @(! P,! P0-!@<-
M!0D#! (% 08' !$2"!,4(0D5,18B05$7(R0R4F%Q@9&QTM?P4U>3EZ'3,T)8
M@I6RT24G*#0W57:#E+?!X?$8)C5TM$-$151D<X6BI/_$ !T! 0$  @,! 0$
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MY_V?L4?7^3]/1$L\8\@[%M]IO>N[9JE?J>P:);4U<XO4[,3:JYT-YKR&P*-
ML34.O%A.(G<@.O)&6($%YQ8)$F/$B@+U@<Z;IPBIKMWJ\5<JH:7S+NSJU@ I
M:_8[+0M+@_1ZPX4.(N 5:8L&;QC")@/&#KTA!-$63QGX[:S&ZS!8X:BF8US(
MJ'&*Z1LC7&.:2@HA+!3/<T%S0]SG3$,(>X0$-< '+[M^B?Z>X%^H$^)X=BYF
M$M1CVPNS]/-2RAE5A=+M'CSJ?$<7@8^\,DT,5+%A\?M3)*:-V)A[V%_#<UM*
M^J#E8?%UMO['$-ML*FI[#<LW.SZW2N+Z]M.@:WNRU%;V&HZW:74=ZCL;6M$<
MOJ9,E3:U3LJ9J&+*<'%81XF[18DW#9ZZ3"I9F4M1,Z:HIX7-BJJ&FKFPROI:
M9\KJTU+Z4OJ(8S%)%(8G-;*=]J[.;](]CG[84>S4>VU'AD^,X90Q4.$XIB$$
MN)X-M'BVS\V(T=+C>*45#_IYV%08K'!AM=4,K:.N@%?"XT8,,SC!_(7JW]1B
MUA7:,#0F-=V%W4]"M;]RHU*[.?6=EN&]"O[2KK[%YZU2OJK%)L5MKCC4Z1(
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M8H-A!BZKYDAY5C@?>![.!=H]C-M-BU20R?&ZN8M9.P-EK7O<UDL!IZAMG/)
MD@)BF'^YA(?S7._')I#N28H7EH>W<-4TN:#$8Y&AN_< Q AX T!)%Q<+MKZ?
MO3)R*B>ON>*N*-T0SMMQO+*KNO4-Z#\LMDG M]L!X$"SC%I>3%#-J8G;-C@<
M<-1-&.,8QIMH<5A=Q*3%ZR-[:>*CWZ>KD!%- "(8+QORCB#CPQ_]NYW;7*L&
M*SW+J:O>2V-D1,,]]V-E^&T[CC8-SW#J,RTI;SPGP&MR'CD']C3C5?DYRL)6
M1VG&N48=K9K,(?=)0C>PM%\@L5</NR182S+%?'".2?&C@6,#C.)&F;AQQ.J]
MEWS*VC-5)PB\/,A>(B^QM)>0Y;O$N_\ =FAQ"H#&TCJR0,+N(R!TQ%R#O;S6
M%UR 1O9 @.%];E83]/' LT*NJGQ/HDJVEU;7]'J$9:ZCE:MU#5;]3:M;UM,.
M0^ *>CV1!*\KD88P!2S6"T.,2PC+K/\ K6*A\DG]1K.)+435<KQ/)O/J:B%U
M//.X@W,LT#WPR//O/8YS22"5F*VK!<X5$H<Z1\KG;V9DD88GO)U+G,):3J0?
M5.I_B_C6T9WARRTK6GV^2Z937.06&ZA9DNX4""#56G3;#,@IYLJQ:O>=3"FS
MYKC VS",,8,3RUFU]8QM(UE54,;02OGHPV21HI9GO;*^6&Q'#D<]C'%[;.NU
MMCD L&U-0T0M;-(!3O+X&AQ B>YP>7, T<7 $G4D!-M#@_@S5TZ_X'&^BTJ-
M#M0-ZKI0I4%5ZS< 4 ]27V8,YPC %R/7(CH8/YS@^*W$4_/V\XCURSXSB,G$
M=/B%2[B4YI97/F?[],9S4&!YOG$:@F4L/N\0EUKK*2NJ;.?+4R &+@N<^0@<
M$R<3<)) ##(=ZV7O'Q7#K?IK]/.GRA/5.&>-];D/:Z[>A9I=2J:S(MOJ!N#J
M=@%\547M658*P?A7F'X_"BXU%>(L'+B7-/CF+U0<*C$ZV<&FDHW":IED!I9"
MTRP.#W&\<A8TO!_=NMO< +*3$*V0$254[P8W1$.D<08GEKGLM?-KBUI<.9 O
M=;2^F[@%JNA4&XAT U6*BM-7A7DUNORI#7;O9Q[I;TL0Y#X1K;';0BV)M7&/
M:-;C@[*.31Q+JC',8#S(,2K!(9HZ@OX\F]QX:<TL4N]>_$93$P-=>XB)9?=-
MD%?6!V\*F4.WVR7#R/?;'PFN\VQG='0>.:[:'T^\':MO;W)^M<3Z%0\B6;ES
M86.ZU&LU=?LKSNQ0%"]8:ME5Q-G);X".=CDA98;-C)S8F><R2XY<8Q6>D903
MXC6344;8F,I9*B1\#&0$F%K8W.+0([G<L/=&0R "CZVKEA;3R5,SX&A@;$^1
MSF-#+[@#22 &W-K:#+0!;-UX!X0Y'VK7=YW_ (FX^W+<=2D*6M;-LNJ4UQ=T
MN5SY:7PA8O*&9#!9K.65QX)D:[.<G#&!<YGE2XOBE#3STE'B-92TM3?VBG@J
M)8H9KC=)DC8X-<7-]UQ(NYONFXR4BK*N"-\,-3-%%)^]D<CVM=E;.Q&HR)&H
MUT"R8X$X4;WQWE%GBG03\C62!ZQ_=R:O42V=M%I#-6R$]QE7YI,GJ\YK2ED7
M)B5_[BD3*V,"Q&XKB;:-F'MKZP4,;Q(RD%1+P&O:_B!PBWMT6D_N 6L)/?MO
M9JBMJQ"VG%3,(&.WFQ"1W##@X.!#;VR< ZVEQ>UUSX]/?!\$ U8^*M'A7KT&
MDZLNG#7T,+AUSC>TQ=Z#2#%[>(1K=0ML8L:!3M[5:WCWEXPG]>J<8Q4O=(<1
MK#(Z:KJ2\U$F\9ZZ/A5DI.\3OU,?]N9VKVW!4]MJP;B>6^]+)^[_ 'S-W)7?
M_P"TC?=<>844\7>BC@3C93</?T76=RO]\M>46-HV[9M9H3[);4/*VVW6UW^H
MO6($AE:U\<KHM0)<LY38JEEEVY%P/&,=A7[48Q7.IB*NHI8:./#V4]-3U$P@
MCEPVFBIH*EC2\[LQX0E+N4CG%H%[K9J<5K*@Q#BOCCA$!CB8]W#:^"-D;) T
MY;_N-<38V=F%)3OII]/UCL)]M=X;XZ8VAG6YZ@QL$]6JOO@VLSI\Z]*FG817
MBU)/-!G-+X>YY8JO^Y^)X5_:NM)N-XNR 4S<2K13MG%2(/:).$)Q+QQ*(R[=
MW^/_ 'KV_P"Y[_[LUPMQ"M:P1MJIQ&U_$:SB.W0\.#PX"]@0\!XY!WO6OFGC
MJ'%G&_'[EC8:/H^L:DY;U^O5-H?7JA.ID_6ZG61I=93;BD(,#!HJB ZNLC..
M<J("$H+,0"'".M4U];6-8RKJIZEL3YY(Q/*^3<?4R&6=S2\D@RR$R/L?>>2X
MYDE<,M1/,T-FE?*&N>YH>XNLZ1Q=(03<^^XESN1<2=2;L;C?_P L'J*_](>.
M?_=K1]:BX5._1$=$6LIA ADAB0$/&<8S,DL0AC.<]L8S*6<8QWSVQCOGZYSC
M&/KG'1%#%^_59Y6UF66SY)^1&WXB4;*V*>,,W&J9F-K/UGFPG*,))XP2., @
M[Y1EGMF/6S6_J%.;/O[+57=_L $M.+'+]Y/[3?\ :'7!Y>PP[?.Q^,-#J3<_
MU!@Q+'7]M+_8,8W'0^\&BF:-X3C=),CJ<AP%PYW_ 'C7_A\]+_VH'U_1CM^V
M?7OG\.MI="6F^0.@^-A?YH^\:_'_ ._I?^UK_P"\Z)NNZ?1)]Q!AD"!ZX6'9
M+OA:\ L+PS,7LL!E,)33B#,H9+&7:4XXEC';OWQVR60R!!-B?76W0V'/Y<E3
M![T5<<.:GJ&HAK=WJ$M07*X%NAV2BI7[_=V(K"/R+M14)BAL&S$7$\OF#\"5
M&1W-MY5LB-8(+/B.OF&Z6&N65K::#R)/P5 :#??&9SOK;T/J>=_!9 ]&VJU6
MQ6.Z:ZUOE)NKUM6;)#81V6EO_&VE+:MEVE[8L5-BJQ5L/WQ=EE6W$65R".A2
MT&0P"W6#9FWR;7#3R.HM:UN69\1IET3+_DWG8>8M8Y^I.9SY*1Z+CFPXMCR9
MM#.S[;;UFVJ+W.QBVYW0<+ LJ34=<U66PLW225988)FDU1<S83-0JXM-O,"5
M7P2$!3WI'-:UN\XNW6M:"7.)L  +9DG(-&9Y FP0 &S6YDD9"YOGH!GS^9\<
MI;I^7^+-DU*[WS6>1=+V?3=;6L6[_9M9V2HV&EJ U"A'K/+[],VZNL1)0<F6
M%R$B> L8E[?:</+FEI*N*5D$M+40SREHCAEADBD<7G=9NLD:UQWW>ZTV-SUL
M5F:>9L@CDAE;(ZV[&^-S)'ESK-W6. <=XY @$9VYKSF],7VJOI7]4W/UMP]J
MJ>XU&Q7T3PT*TW/7JU.GW8.N)--M@JBK6=D]6.,I">MT4;Y.K(RFN0?8=ECX
M4_7X]^GNT>SN&1XM7Q4YIB8VU#8)Q++2&:PC%0TQM%M]P8Y\3GM;(X!Q .?=
M8ALYBF&T;:V=D9A=;?$;]]T.^;-XEV@$W&X0V^[S  -O5+[LK<__ ,/1S_*H
M#/X?RC^F>_\ M^OX]>(7G]YPY_(<\_ATY6TR1]V5O_F]'.?Q_P#%%_Q_T?\
MMZ)O.N,R<[VZWU^*\8_M>_7%S%Z,J3B2JX,IJ"FNN2&=D/9;Y;Z\K=AJU=<C
M61Q15*C$?N[%I89L\M,G<BSD*"N8+K>19L ^E_IMLAA>U597C%)Y1#0PQ/92
MP/X3YG3.>TR.DS<(XPP"S!=SWMN0  ?6;+X-2XQ/4>URD,@;&1"QX8YY>7V<
M3F0UH;<D;U[YY *T?V9/JGY#]7WI;IN4^4:)2IW%+:MBTVQLZM(E=2[=B@RE
M,>S55?.1(IP-A[-79+@,5:%W56F%_8%XJ+]#MM@%)LUM#58715#YZ=D<$T?$
M<U\L0GB:_@R/;8.>W7>W6DM<TD7*ZW:'#X<+Q*6DIY#)$UK9&[Q!?'OEP,;R
M,]YI:<SF01KJ9VYLXF%RZ)#6;BUV&EUU/?-=W*VG05IF7KM:@H70(UR;WQVU
M*XH=A)76)C,IN9R*LD&((38"R+RC7AN5KG,_2WAJ.?C:^:ZG=+AD6W]X',=;
MVSSR\M=%4N]])&J*6MXB?D[8:FFV+4J'CMG6(Z99ES1\0:SM&D.ZGJ.OW&1G
MMAS#1:-9*6#=PU9+-[-M6Q;(O6JX>,H;+BZ#<N0;WOKIE;IS^ZFY:XOXBQT-
MCS&NOAIZ)R<9^D;C&@L:C:]HV>^W,M.H.IU3O57-&@[;!V#D*]=O=A%*67+7
M8K2[WVV?<!6,5-7!T>"*5@UQI!3;Y.8'BX6%QUT)L #?X:Z)N'0'D<B0?.PM
MI<:_#,*R7'W%&GT7&6I<#WU<'8M8K>*@Z3<I6U(U4U>T!7PF&]E]WGSC& 6)
MRF;.E$Y9B&SF$YDCB4\ZM5305M/-3543)Z>HC=%/#( 6R1O%GL>W(D.%P187
M&J[#"<5Q' <2H<9P>MFP[%,-JHJW#ZZF<&U%+4P$.AGA>0=V2-PWF.(.Z0"+
MFUY"O>&.*]FDI*_T/7;3-?I5CQPCAI/OA31;<2X+35EXPE"(*AX*BP&%AXCY
MA",7EX1\>M*?!L+J=TST-/(64<N'L+F EE%.&B:F8?\ ;#(&-#F-L"&@:+N\
M/V\VPP@3MP[:/%*/VG'Z3:FHX,XO/M#1.EDI,7E)!,E;3R32OBE<3NOD<[=W
MLTKPXWT.%IIEU'5::-IQW5.46CO15C$^JU%@@K5NH4O;/@FNS6I*HEC"/EE8
M$ XEX>6,\PPZA;+1S"EA$N'PO@HGA@WJ:&1C(GLB_P"(='&QCB,RUH%[+1=M
M7M"ZDQV@=C%<:/:>M@Q':&G,IW,9KJ:IFK(*JO/[IY8JNHFJ&[QMQI'/M<W#
M5>].W!5YR,GRK;\2:'9<C*'6;#N3>NH&O,.H#B-%\C4Q9]^P2&(4%'SP*XM
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MF"+#C'O0RT1I^%()8I909WS-<YKFEC;<]=^O9HZ(CHB.B(Z(CHB.B*".-_\
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MFFGW*F"H9(PTSJC>?$'EO]UL1;&X#W@3:_YL_2':/]2ZW$,=H]I:W'JS!I8
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M1XS68O4Q,ADJG1VBC)+8XXHVQ1,#B 7%K&-#G$ N=<[K18+K,5KY<4K9:V4
M.EW0&,S:QK&@-8#J; 7)(%R2;<A:/KI%UUCT*1-BHU]BJS5C!9@\YA,%@>(R
MF!@!(D$7$)=HSQB6/&<,YQYCE./E'.<2C"+@WR6<9W77M>VN?+GEJ?"RAVXX
MNLDTPO),_?CP3YB548Q(1PI.$L8DO!AH@RLB-X$G[S,/(7EA>."PQ F('(96
MY G7.V>H) -P+Y?%<W$%[$9','6ULCRY>( ',ZJ,-[8Y!X\T#<+K3M><L.0K
M6PT*FU*B&R=B+5AL6SAUZ3UFHE?4E=X)I,M.S(_>5JP@(QE862:^)R%R, )
MS(L<BXFV5\B2<_7RU6+WN)!-W6!%[6LVU[#+(<P,AE:P55ZOU/\ J.8N=%J&
M= +[&P5^IN;!;9I>1%HT V]\E+9 VJV-B971V!/CJ[U!1JB7?L%:G<2[,PO;
M7-32RA/DW6WTT&E\]!X^!^.?58 DWY>F>G2PN+D$<^HM<B?.#.3N0.3MCMUM
MP537#IVG\47CX!H[G1NT7)&UU=/9WM"O'8+Q];9$*E>R;5:M5T%44'9PI0-6
M5HA=Y1&P%@+9@$\[&]['/Q'84%R<^9-\FG3QZ@VU%CDK*[1R%<5MXY652R.
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M_P"&A_SO^K+K)G[AZ_0KCD_[3_3[IU=<RT4=$1T1'1$=$1T14$^T]NN>=?\
M0_S?<^FTFXAY-1K->))SCBD2V7DBNT.6W4(^4K/CK7[&)$[G>J[CB>T.ZO7%
M&6;5J!<2XBM2!"1%0+[.3UB<<<W>MWE70O1^.HVSTB/^GK6MZVNY4],NQ\!W
MG%'J!H=@K-3<U/;M@N]-TN/(%YR32LV6WM!BDV2@;JF@J,12][$B+WUQ^_\
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MD]5LDU+54-T1VN6(;F6$=2V@=IKU=K#[L!%=MM@I%VTDA.8+"<)X_<X&XO\
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M/(#K%9!-B;830 <8<D%U\Q/M].TO: :2I<(]SWW6FIV[^_8V:V^[N$MWB0X
MVNO7X=&#LEB\GLTKBW'L'C]L$S1!"'4&,'V=U/Q6N?+,6\1LPA>(FPOC,D9D
M#'O59I5T,6$V0- EG.(F6,(XI9CGMG$2"G.&<XS^.,9^GT[_ (];"Z-S;:Y6
MR^ MUOK8'+*_--S8=PJ-;(!=SY+#; \F@HF*!#17Q/(\L$D4H C'F<<PAB1<
M3+*,\"A/VR>*_=BC6;PO>WI_(OV-4M55HE=(+V5>7)568RS"4H2&2,H3D,HB
MBGC$QE$2$QDA+&,QG'./KCMG)1S=TV/FE#HL5 O..RO<=:5N^W:Q4S?OJ72K
M>UI*6O\ =4Q?[45Y*NH$G?@$588&W9.+KD[LA\!&*3WP8QDT# #8: C[+E-S
M?E;._(6WL[$'IYWM;H:;VOJ!Y+XYVBKJ-KT?8&+!36MW<Y+NDE-O'65FX0U#
M:]UT73D&J?<M_P!1A8&J]:K2VXORKLFCAVZB!6 KV062BO*&-.8W03I<FYMK
MS&GB?+HIO$@ W/A:XMS.GI86S%[E:M:]2'*]W>5]3LM51<3[%FT?U"R?VT/(
M=U7[%MNC@T&KVC1M-%3/@==E<[SM^SGUB^ &RR/4:(=MFEN(3>9KZ6ML+6=E
MR/U/7P\>BIO:]AUO8:6-[@YZ6ROUSS4J\*<R[3R]L6\4]Y'*M17U%5:QJ4OO
ML#^IEL]PL=?_ ")W"V/LS\;#;!5E;,^QUI]<U$M2T28D@7%29.V-B]H %L^5
M^M[G/RT2]R!ES .>MN0;H!?Q(!ZW5I&>-JYEQQTJ>O'8;H[K5/E'JG\.PU2\
MM"VKE!$ZERM@:A&)CR3*HER3DN&>,PS"&(X;Q%P!E>]MZV?(_M.8^>29&P.N
M6EAF!K;(^&FFEM5!MQPEQY7L/45QQ?PM7:Y?AE6.SG680K;&JQ"@#..:0-F'
M.6O9U76QFG!6,/=ID)$?Q@4"9@>Z^=]>O30'.^>I%M#ZJD:ZZ>>O2_.V6N73
M/-]'].W'-EB^9GJ^GE_*VR#?V3*RNP"E*TC<EV:%I3,*;2*5"R;8&&+XS&OS
MKLMVS3-D?)66C$G=]W@1GD3Y^![RT"A !M8@\K;H^ R-]=?2R;3#K=!*5!5@
MK*:CU91;6$-?K4IJUN*W7VS2JQS$4YVAQD'*\E<*L@+ <@D@2<I1EG%SB,QD
M<_7GRM;GUTOX+D#&V&I!SU\;$Z&_*^E[Y7%U,VR:]AQ"IB@]:4C;=DD,AQV%
MF:0X'6/,H#!S8!P3$<QQCM@L?$D(R[YQC,<WL+ W&9 -AR'B/,Y #EZZ*AP/
M5YI6O4%MMUP;;)TL]_#Q]K>;2>8GV.:UQ<K6^RTZS&VUXXTE=35+&R,,?)8.
MY72KTJ\)[=Y= O)PR2/*YOE;Y_>R7OJ!H=2#IZ'\Y'+)/*7JNU1W:[_0:&FV
M2_W&IW.^T-*E@O)"%[<5>UU&H5SJCUAO E :_L5B_<$1N6I#!!?4-F@4>74A
M)L7<! )YC/,<Q?Q[US6-]"0!E<"XR&1/+PO]-#:4]:]0ZMKR9KO"4PCHMY=X
MY)N=I5&6HK$.I& ,1%-2L&*;=K&+MNQ5>Y=+L547:K%/!1AAX)K)(!<2T!MQ
M>U[#/+Z?(?%,G7.[SL77ZD:"WCS //7-66UH$5M>I QEF?C5(9D27UF4DUAD
M*:>?TS*64R3S^F4\YZP6#M3YE+?11;E_^&A_SO\ JRZR9^X>OT*QD_[3_3[I
MU=<RT4=$1T1'1$=$1T1:O=AF7AWCY]O/PSG'GX]_'$O'ZY[?H[_KQXX[YZ(J
MJUW.7#6M^L*S]+%1IAZCF?>>$9^I6]VFKURD2IMDUBGW!7C",;^_58%=66TJ
M-_"$J-^O8!"G@.(K&'LX6P16@?3A8*MI$Q#(VE)@E@@\%'G!8SAWF.7;!(QS
MG$O'/;&<XQW[=.G@0?@;]_)%4_<_35?[1H_%>D#W&K75XTHJF@&[*FLX%>&O
M0H4S]B42EX&#>/<KALK:]9?+U]V!I!NUK#*ZA Y;V;C;]U_,7OS3OOO[*UJ,
M<Q8LL>4I>3D9=Y9SGM^Y%>\8X^GC'&<Y[8[R[=\_CWZAT;Y?<HE+J(CHB.B*
M(MTXW#:, M*-9$%A IRM!-(BZ[4S>.<LQP.)1#<'+SS[F08]V)3>1(SSC,B+
M%(H>*]:8<NYY<>M;.'M(UV)%]QLBPP 47E.$9$S@">2L'D.'?/E 8Y^(\3(E
M.HY(1NZ6_>%7MK6&O(D?9JV<9B0H<!,58H#1CB! 'D HI$C'N.8R1E#Z1\B*
M#=LW+;K>NRA-X) V#'@994>$92C@!RX"LQ"4Y2%CQ\O:9D7!)Q'(C$(8)Y$3
M=0N35C(,ZP6Q3(M/$7HUT)*>T#"\Y!&V)SV0LSP60"#7)$Q?&.9^WF$L9E.S
M?GEWIEKS1/\ L^4=EM*@A4,I5PLIQP>0H'^<2:\<8?R%OY$8(S-,9Q!Q\<TU
M89CF4\FQY#J)EM["R0BZ;5S8&K#",R0)V6F$XM^2^ S(>4R>$\CD;'M%+[.)
M8Q+$<&E"4R*P?'<97FFD!:3D_7-L6"BT&)D(65=&6 2$7))>_'$318B")/$T
M%\!S'MCVY=$6X&M:IHA,WK;S7E',EE26!<,Y!D^,QR--=5:!V&20\HYEF#+'
MLX)VEVS.62) ARO5#L#_  :B,J>#<@,V,"?&=)D<\0*U*MFG"?MQ[>Y")SC:
M*OF!HCQD@QR(I"OMOI]=^/!\AIG:C*8%E19.>8H9\9GEC&8P$+$LXCB99C]R
M6<Q%B>8RQ@B@WE"QU&U!7.U15,V%L7)G3$;.@.:B<9+%6L4\3A*3DB^P&0C!
MC/*X2Q)/VO;\R)Q\-YLIDMY9A[-4/ 08&(T2IDL/&!_>2[>.?;FD4.39]H>/
M*8X9S*8\RR13QG/;&<_JQWZ(HGN.5*^KLFU<UIC(5S! /6'R!CE&:\\C:DNK
M,>?>@L3$QR]TZ\B$'/ 8SCD<R$31L-RUWD%Q!&0'$%XNQ!6W(6 R9"1S,0A^
M?6&7Q(*KN<A_-D61Q2R,D\ ]LF8$4A?DVIJNMM!6DTW.=E5V+[,A2,<N%K%&
M9)Q L/.8B76#G,1!%+,80(2623S.4B+R\Y%]*OY<7W+6S)\PTT+GE;\J3MX;
MH]A7%2"L^0*_8=:6 U4:ZI;W=;^2^KZK1/JWMFZ*L;K;0VN8 K:D /F;(&V&
MZ;-  TO8 CIS)^777%S23>]A8<N8ZC0I[:#Z7<S6+"QY._*LJ^T:K87KM:OO
MBQ'VU><]FY?WW-N)=00&V]KJ[/7J3[M=]ZM&:NF8X_9 CXG2@DD-MZ__  #!
MXY9G*UAEU1HL+7OGTMR ^R97VAGJNEZ<)Z&_3ZZOM%UM+6\)HTURK8T(HA5/
MKCV+=FQ/39<8JU\R!#%4DR/#CQ53&F."6##\ICV*-PN>CD+62F6"IBCB-MYS
M^) \OWRUW#C8V\;VC-[RVP()<.#:K;.'8?\ 3S$L5?AE?B,]1M3@=%3".J%/
MAS'NPS&I7MK")''C/C@+Z9[:25X:R2+B1M<>+R>C_P!2-CZDM0<W.HHVM3VJ
MFO(:O9T%?8,V->>\"FM:!?0+D*OOU;M?9)C:@^O$BT@M :*5==9T^SA>(QXE
M3"H;%PG"0Q/9?>W7@ ^Z[=9O-(.H&1.Z;FZTMB-L(-ML#&,0TSZ)S*B6DJ*5
MS^*(YX@QY#)=R,2,<R1CP[<:026'WFIW_:+^L/C?T:T>C[=MM;<[/LN[L/45
M#IM#\2#3RE)&#S]N=YXH5ZY"L+:K+F*3#!6BO+A65GX','W>RVR.);6UDU-A
M[H8FT\;9:FHJ'/;%&UQW&-M&Q[WR/(=N-:T"S7%SA:Y^AX/A-5B\TD-,6-$+
M6R/DD.ZQ@<2UC=/W.+2VVN5SI9/7T3^K#4O4UP_7;QQ\8M>@SL5M66M?M%=$
M-MK=TA6'NKRF?6K[&2A\*AE6O)/K6+"YJNT5E,OR(D"'1Q[ *[9O$YL*Q!K!
M/$V-[)(7<2*:*5N\R6)Y <6DW:0]C'->US7-!&>OB>'U&%U3Z:I#2YK006DE
MKV'W6N%P,C8_ 9D:J&J^N#4-JH] OX+.URO)N[4^FZ@LTA1-6#0;>%5+\J;!
M.LWUTM305Y+^@6L1O8%<A;NZT$*LLCYS#JMP9YZ9D\@.0/2^>?AHNO\ =/C8
M;V>?H#<W^F75)Z'K#U'?+0-9I55M>T;=.R<UJIH*:I5I7K1W-ON.%1?+M]YJ
MZI5&VUSC^UY!K+&Q=658U,U6P,N;"R!7R"/K\CI\O+(^?E=ZVH.I\;6-B>=N
M^MTKD]2B0+;8*EN@WU,E&A?L";?S2)IV=QJ.M:GLVX:[ [')PH5;^KU^X(KV
M]G>YK=:BZA;J+7;!5108A8?_ (CX_>_BH' G2VAN;7L;@$C4>'G?()T@W&]N
M5:#<$KS8TJK9=1UC<JBBM%F:=RO6OJ^;T4+Q!EVQ=%:9@2 G1P=')<O< <?M
M4BEP<2TD<['0Y>1-[=>?(V68 <+D9;UCEGF==,K_ !ORTO9H%$J<("G-:]R?
M&:*L>S;G#WH9&?$3QR3$29&2,<2Q+'C+,.V?S>F9USTOYCO)87&]:PUUM8^.
MNOW4*>I/D;:M;X(YBNN&3*7O*&MZ5;V&N5B$16M@-Y>,8,.)UD/=S9-U2DFG
MP(P$;WVE1K2$24_:GJUDDT=+4OIF[]0R&1T3"/W/:VX%N>=K#GH%U.T$^(TF
M"8I585![1B,-!4RT43F[^_4,B>8VA@(,CKYB.X+R P7<[/Q!^SBY@]37,G,V
MTTFS['NG*6I#U&PL;Y_:+"5E#6+D5@I&FPG:V91#1+8D9?7)2 /$1Q8(\%.&
M*\A<>8V<K\3JZB=M499:=L0>7R,,9CG+F?VF7:VXL7W!)L!J;Y_%/T:VHVQQ
MG%L6I\=FJJW#8Z=\IJ:N'ANIJYLS!'!$X1L =(Q\@?3ESBQL8=NQW 7Z*M3J
MF:37JVL<G&;*PBY+@<O,8LG8,QA84^T?(2D315%+QCB4 QSB,8YQ''L!H/S?
M\_4^97W^0W<3WJ? ?GKGD% ]+3-.CLF*M SX?#VFR* FQ#(\=AYB64,SQD?U
MS#/?.8?\7,>W?JV'377Q5XFNO@,K:Y_'7_%U\M4"V 00 Q!8JS86QD*OEH6<
MBB2&1D#$ZV91G L\=\&CF.>V>TL8S'+IX'\_!8M(%[\_YY<_\J,G.%M-L*FM
MHG]:T%VFI]=<U.IJV]*@PE6:W8?%^=3H+EN)C43;RDI@\08A.?Q@YE//AC&+
M<YYZYY9=Z^"R):<[GY@WM8$V&OK8>I"3+#T_<=V@70/:?Q\>-BHFBX3&FR"T
M96NV*SVU 670W0VX?#V:ZMKQ8@SP**SLG6H3P1@F<W>=>]^\QY?)8^[U^9__
M !2G2<,:AK#"3FMZWH%$[6$.:N=J=($DXB5BD7UHLEF VT2#CF@34J(BC+ 8
M5RRZD!Q$ <8PDF]S<$6ME;7I;OZVX%B"2>8)/H-+<\[CR4KI+82343C/),*+
M 6P3.,1S/ !0%B>8XSG$<RQ#RSC&<XQG/;&<]18DW)/4W73T46Y?_AH?\[_J
MRZR9^X>OT*QD_P"T_P!/NG5US+11T1'1$=$1T1'1%X/_ &E>@^EKF/U?>G[B
M_>KSU9:'SG'ACD7D.TYN]-?,UCQ!1^G_ -/>CM/V5QR+RD_-LE-85+.XY'15
M2D**ULS-GG,N0)+Q]PBIM]C/:\2<P>N'=>:M<]8OK*YVO:KTN6&G<5ZGZUN(
MT]6V_:N ;KE6HM*_ECC'DU"Q##D'0ORKIW*PF;+7$+H+=N A\B'#(<$7ZE+:
MV0H:YZXM#27KJQ(CCAX .S(2Z\9D).*ZHC,GEB,<^(EPD*3/:(QREG$>J 20
M!J38>91-O/).E8JM.NL78IU_(!*P>FD$LZ8]_*X3^\49)I!6F]@<J_N\R8ZP
M1()P(S835"(DXK'/(Y:^&=L_5.=N>>1RTU3I3SW8L,X__FH_[5%<_P _;\,]
MN_UZ'1OE]RB4.HB.B(Z(L"DB(<R2_>PA*<OXHQCF6<]OKG/X?AC&<_7Z8SGZ
M=$52MYV^SV>=4W$*J=76OP943F0GO$(]"=<-AYC$91SG"[LX9"$6,+2),V)M
M^W$4IWY=+_Q_*)LI7-E*%FNN%/ ;-,2Q\Y:-@445;#!IE^7$/[:*PD(ZTE_B
M8%E6!"_*S F(%O???T18ZV#6;6WA]X6QM<%6(V)_,! G@[[>0Y(G7P9B:!@R
M#'!P$ G')?'"ZV<&P44'IWT[^:)YUM+575K%&D9<J"N#D2<M@&)K+IUQ]B,0
MF@S& #84'#NA(809@OG(F(3R2.2*1;C7]'TY&K9=K6+-K&(!" 1)1Q:,AA[I
MFW%_>$CF/?\ ;33+',92E 6(EGF$<D[[Y?=,O>;&OV-:LOZXC-5,)B4]L PE
M\2!# C6*TQFC(H!R-*1?$_8L2#]T>< 9%CQ=]]CZ(F3J>QEHK\$U7K$J,&U'
M'CS)*(_N]@GL/Q,IG(,N!"$7OC*HJ:493%^<0N,Y).6>9R!\_P (K$;_ $+&
MR+5DJME:;:<SF$H=F(H.@:%&,IKD_.Q@T/"&1SE'VY"F6&9P\\2Q43#K=*H:
MID)]RO%4GG"!+&E@ZK%8@ 8\!?++,.#DP26,Q-(<P@S'$ >X3QGF;_%T2CO0
MZ6]OEU:O9*3&R 4REFG::S"+.8D(9<<6@#-!9O!"$'D)!DD3!!_0<L1S-_'?
MS**O:[RR5B<A@$FRR1A)DWQXJX5LDV#Q/6RRV0/?Z0P,<AE+$LU93G/&""\G
M??)%9#AXA5==M2-"$I7PMFVP%S[<!P&>&"L#R;&<"+!/.(PF6,IB%/W%H$]M
M>&(P7Y]YG[61.RRY$UQ:GL[1!\%E.O&/&% SE QS,$B%: H2'DI!E++MDP!&
MCX1G*&9>$NU15K,ZIL5HXP=ZO0999G:B2GF:*,WA3B4ZK.'\S84RQ[LVP,&G
M!2;T(9F,(S8E&=]>QIG\;(M=9:00LU-B8J2-+)P!, "/B4]\V6 E5;8^."P]
MY1.>,&@'$QDE/,I^,XQP,M16<H+T&\4UD$BY4#8@:N=#$WO1'AI?/@=5CP'D
MHYCGG,<S$(D"PF.4?S<2D11TEP\V>PA*Y?!%%>$QR-4LN*/.P\98&.6(C%%,
M>)RP>4<%:S&6/;%+&)9)T^R*4ZFBH=%HC@JU<)5J4&K!K,9%89//$9&998,6
M4S,LDQ'O*9)2E/MB/?&,8[$5#N?N-N,?5;M6F\>\PZFH2CE3[(]06-5;E2W>
MAN,.T(P-5MF$$,@1.K(Z=JOB#B+!RHX87+$<#"Z3$J2FKJFG@J8X9(C35#LW
M6G:YL].T&(MLYK"#9Y#M<BTZCM:W9S"-I]@\9P_&*6KJJ=NT.!3L#7N91Q2M
MH,<'$+V$<.O8TN; X$O-/)4LR:7%6*X.X'XT].VBK<>\6T6::A$ZQ9ME9:+8
MVUQ:MP#!FUN+-C]O>?*)=<&)RQ 0%5EU5@A7 (4-NFI8*.%L%/&(XV7L 222
M3<ESB27$]22>6@%NGP;!<,V>H(\,PFF;2TD)<YL;"7%\CW;SY9)'.+Y)'$W+
MG$G)HR #163U^^@?0?71HVLU.Q7%QJVX:%8NV&H[/20188"M;05%>4[R-CC"
MSR%B-),XX?)0*!])<HW1#DQ OL-EMK<3V2JYJK#VP3,J8VQU--4A_"E:PET;
MMZ,M>U['$[K@='.!!%@O78+C-3@TSIJ<,>)6B.6.3>L0#=I!:000"1;,$.SM
M:ZBCTL<!\5>CS4M,X2K++(+O;5;&X"ALMC46FQ;[8[6N.DN[1Q&JM*8:M? ?
MP*2LP*  @ J,,BD8@5DVGCV.UVTV*2XMB&YQ9&MC9'$"(H(8P1'%&'$NL,RX
MO<2Y[G$G.RX<2Q&?%*A]34V#R&M#6"S&,8!NM9?><0,R=XDDF]@"&B6;6YX>
MM5=?M#4G!]Q64]!94>B63EA1E@EK7$%\M&P7UTTMM-*O#IM^)$-J2I)@JS8%
MQL'.((HXZ;^Y<VRN!?.P\ 18DVS%[>&EUH 1C(EWCER/I?I^+YK13TGIPV,1
M]1%K7%>;Q&TUK5;*GUXBX7P7FHT.R:_KE,E9)[PC9/%JM:KMLU_,DC$$51+8
M:9XA<*V"\!XF1OSZ#['/7/+++I=0$<KC6V=\B1RL?2Y-STN%-4_3)Q-;JWY#
MZ'HY0;PMYWPR4]Y#+JSEBA>'7A$>TXQ6!:LZRM=>5JLIKML(*29B:*XHQA>[
MD?D+#OYH=T6N"=0-#H;&]]?#/+D%--7J"*AA,O+5;ITE*]"LG% GD@G6"D-8
M<3ON6+121\O+WIG]S,HXG+.29E/,)OF?"_F /OHH' 9#> SOGGGS\P,M!J?5
MROKS;2<5&60)LJG ,\<Y\PR**0X%CGOW[CS+$L?7]';OU%&F[[];^?AV.7A=
M0;K&B[(M?U97$AUZM2R,\W(,K%$: 1S%@*0P%FQX-XED<_DB7Q!:1<3CDGC"
M6-C?0#J0;_++QSUS'BN9S@00"<\A>PUO:QS\,FVR&FB@[U*<Y%]-E0K::S3I
MV-GMVY;80]2>YJ=8KP5NMZ8;8;2R&4E:4SCS+H:NK&M"13S/;98"!F0,JEY6
MM!-M,FWY:CF?AGT%O%<-P!=H OK8;N9)N; V-['QOG<IH;5ZSE=8T ^[9Q&R
M97YM9XV>UJNVRO?NJG5*-MU'9]NLD%];G9+.@;H=B'253%>J.WP&MS\@&7)1
M'D(Q>V8%LB2+<[_3I;Q5U=:UCE<YG.PY'ZY]>1(M1P)O6Q<CZ#IFZ[&C*E>W
M'34=H-0?> ;<-3\^Q=BF,%E"MJY-X-6Q3.4DU8CR0DXBQF$8REQN%GV%]+WY
M'3X_*RR R)L+!UB /!WE>VF8ZJ=.HN%'1$=$1T1'1$=$6Y?_ (:'_._ZLNLF
M?N'K]"L9/^T_T^Z=77,M%'1$=$1T1'1$=$7F!Z\/LN.*?7CLNN[=LG+/-_#6
MP*:#>\,[S8<,;16Z]+E3@W:+M+8MCXJW6%G36\&:)ZU0&T!E3"[2TF&QSPT$
M^!P)WW_"[>"O0)<\5^L[8_4U;[]K9>.M(]/.M^E+TI\'Z9IV=<K>(^%ZQ[7]
MBN [->%?9+M6Q/['20%7E$HHK7TT!P))EDF<+D7I.R##(CKRSF,3+S%*4<X\
MHX)$D,YQG/TSG'E].^,X[_CC..^.B*MNT^F6EVK5N.]3:V:T$CQI4(4- UFL
MIV; 2 :)6A?< P4$?@;"P%%1VMOE(C8HWA2(D&03'!.[Q%[97U16+1A&!['&
M._?+<92SWE+O+*BN,YQF6?IC\/S<8[?3OC&.AT;Y?<HOMPRRE4V3:8<LMJHM
M,+ QWSDQ@AF08^T?SL^4XXQXX^LOPQ]<]1%!.G;?L3>QUBQK1BU7M"%@RN6(
MLP&**YCY;7P$</C1"2 HY[9]F0Y^UF,C3&7!$\]VWJQH;$%75+IR+A43C++T
M#&'B!B&$( @!.M/,\Y 2<S3-XPCF$8BG/,IP(N1/ERE.N#Y*5AD\<D#:83&)
ME5!D!9A./S,5<[4<8C@N,+KDE[<XCE#Y&)BB3ONU^_@HSY>K-,TK4-HY!9-8
M0UK4M*V7D!RM2^.X)]6A3&^)) #N,0C)F.?%()<EAAJ:\8QAXQCB@%Q &IR'
MGE;/[<^2A(&95$A^IC5FK'4:D&C\BQV'9[][4FM75(O,ZLZS;*/71)KHV&O+
MG"S:.7#LUJW9E='E-37;:0&I*D0/9<IB-CF,@",M0=;GE;QOEGDE\[9_#[Z)
M[[GZ@=)UCBR/,.X4=BKK5A]TV/&2)-BT(USO%3=@NGOD.5S1@DU-Y;6J)W;)
M5K\FHLI8KTD7F-B(:F5@CNX-:;GF;$ &U[ G]WIKTODJ,^1[\KJ8TK:NL=LY
M)UA9>\*CQ275X3OB'HK77;8VV%C&-:7-3,SE=>UU::#OW,V4[B]/9U3]FLF2
MP7#+C+;!IN<[FUNAMSU!UN+)W]#]"GLI=A?J<5Y(.25K[&9ZQZ,_<(HN5<0G
M5Q5;$0S.G,L)F&*3J$I$A[BV9#E#!(B: S$=5*Q(BLX.L)B*U@S PC%%@7QO
ME5T0E..N)C/O3A(CKGMGD3XV2?M(B)SMU+#:BMM.$952S9UFC ;G@HCD6S@0
MG!CQ RJ1XSE/)&LKY(6"T<BS$F,Y)WWW]K\<C-!' [ K,K<B,PIGIP;+DPE)
M1RIBNLIXD,041E"''8XX!D.<OKCO.12VOC>_K_'86IJWO;2U=)8D&\5HRB)[
M""\$Q+3S7J @<I9LR%D02YS)J(U0C%B4R]L3Q(,RJ3-F&R@.&L@77E;!*JK
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M:J>'5 &\!* ]X<[N3- UJMUQ@"F=B@Q=VH,*S_*W:,*TS @O,1/6JCN!P0
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M231\DAP^ [WO5/O-:TVJZG(-  (_NY.(&9&9N>I1NUN+,$ $6#GV>HGJF;V
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M*8B2F-8@\]_<SVR=_/?/^463M*5<%42ONSG,RX@J;#I8%4M*Z9/=85Q@$!R
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M/#HBZ /6-T?*TH R968%Y"@SF#>5@,88:.0L18@ SHA+B'G\R(O*<83E[V2
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MYA/[5*?.G/M;?M'N5 Y*1ITD<^!VG#%-%B9L@4DQ*>80#[:\/+RQ#+!3Q&*
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MP'$XD6Y)--BF?<6-E;W93.I"&1RA _L"E#\R8OD%QEK,XI$(3+&%OBY4*,6
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M,1S+,82+.4R9&/,L^V+S]J'?/MQQC/1$S=H!HUS:+(6]I!6Y%B*P\JM978Q
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M+B&F5Y9'&R-KGR2R. <X,8QKG'=:YSK;K6N) .W14<V(545+  9)20";!K
M2YY-C8-:";6SM86U59_1;ZY-"]9"-WJ>OZ_>ZCLVE5@,VM9LS*5@5BIM8_##
M9USR6)B?A$P&X$"T-9D3&%),9,.0F&>ZVLV+Q39"6F;72P5,%6'<"JIM\0N?
M'N\6$LD8V1DC0]KF[SGM>TY.):0-W%\%J<'?&V<QRLEW@R6(N+2YH;OL<':.
M%[C($@.(!M=7H:*^T0E,(LTF_O'!I7(\ G,\Y%C#RKU9>]F$@"ED;,2=L+@7
M)"!)9*)C'D/S_'U[NNG20S$3K0K&N7PK*K25.K(7E,&+26"C+^$L1/DZ<!)
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M3/GX_P =Y^!1-'D_EV_T'1]ZWPMEM9*_C_7WMBL !N+:1604:;+EB$8Y/P%
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M[?AC]&,8_#Z?3M]/IV[?AVQ@BXT\=F+#'_\ 51__ $JO\O5.C?+[E%U,,!5
M5A@HP ".1"F-.(Q#A''>4R3GG$80QCZYE+.,=N_ZNHBHO?VB%QL.TW"[;"X#
M37<6KP.F">-=DLB.,9'#(23.<N&SB'VG$66(BC,F<#G$GR37NK"C2LJ2QK Q
M)&OL<BM_C^:R@EVPS7#)[$L0 1P3TE6%X%CEH<QS)F8Q^4HD2U.RD];CRBS
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M[7^!7_Z5G_<],NI^ _*+E>?8K$VK&Q8IT4$5S-NNMME75457'(K##!RCB,(
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:1$=$1T1'1$=$1T1'1$=$1T1'1$=$1T1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img192321128_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_4.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:84&AO=&]S:&]P(#,N,  X0DE-! 0
M    %GR^5U8X0DE-! 0      %X< 5H  QLE1QP"   " /\< E  "')R-3 Y
M,# X' (% #U-:6-R;W-O9G0@5V]R9" M(%)E<&%R92 M($E03R M(%,M,5]#
M;V]L97D@1')A9G0@-"XR+C(P7RYD;V-X.$))300E       0]/II!77\:'ES
MX)M602<)N3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              3\   4G          $
M 0             %)P   3\                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   3\     4F=H=&QO;F<   4G    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      ,      $   "@    )P
M >   $D@   +Y  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ )P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
M],;E/>0UK6;BT/VEYG:[Z)^@I^ID?Z-O^>?_ $FJ?3+[KO7:]P+*+WTUB!(#
M0W;[FGW-]W[N]'?7B5WMOL=LM>X-87/(!<1L;6QCG;-SF_X- WT7 #6R6IG4
M79SJ
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MMM:TY4[5N[P),W?8VGJP[;[A7(V8UU>9Z4]R%CEJPX?*1\AKY@1\M<*6$I_
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MD"%K859O^V#3I%9J>C$G+'EBAUT6%,ZX,;,@Y:PNQ8*'DSPT=(89!?K+KEW
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M!C56<Q/*R_:$LTLD$3M)*9)4*!87BC+1M*:O=1B01+!&)"21'&4"EBA<J%<
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MMNK)+9=GY9]6UR6-N5?J)85U16Q8=L"SQ\=M$2QW6R%T=V0@X1V7GW)$5XV
M-8EK06',1[S_ )\;D\9K;QCJCV"W)>\M&2YA@2*74IXH81+9Q].>20 /!$;8
MI;JQA.]3%&A,+*:S67CZ_N-%.IR63Z?(NH6MBL-WJLD%O!'=V-O=17EW<^RE
M[.W,$ZPQ,;5Q.S0K$S13HX62N8?109Y08^BBY&:0L:.D,PE3U\MIW$S/=Z;E
M1LG*PQ6 B+5$,2:69@.,D)A.(.VL1;P!(\@S+>,6W&$MJDC1O$-L<RM&'*O
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MK3DDDE<O+(\KD*I>1V=RJ*$0%F))"(JHHSA54*,  5@9F=BSLSL<99B68X
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M%E*T8;;U"^)7=Y!NI3)U]J4: BZU$5#;];BH*S3EI@FZO7]@UPB%-L[9[5C
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MZ.K]GM]GO9CM]GONST\VYRGM]WG#/3M=.S@C&4]KIW?Z)TXQG/7M\>LF?O\
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MZXZ=>O#.>W/?MSVSG]*KCOGC'?/&/SK?<32CA2H]<O'ZV;I^>'<G\IUKX4J
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M2XI;93;9SZ5/3:?_ ''&/[P?+'_E1?\ *H/S&[T+9! :Z21I&23_ .$KC))
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MFH5>TF+9:J@CD,9(P"F0,LE14 <"AEQZ$ '=;# \YNM8P,9<^[;SD$#L;<
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M !YO+'^#GMG!^V(]%)\FXQYU;ZNMLD?76E$!B-P&J8(ZK1AA_P"&9VE0)@<
MB)EW 2[HQVS8I#"NGN4L>?3G&.F:YG&>CI37:QGS_P!>RK Z'<8_3=V6+UQA
M?BFQIZS]NA-G)Y^Q(')([3>8Q^??-5^K[?\ _>=+[*<$:F#DK$2,'30<J965
MNZAH9<$J8FEX39)#./35+(GT)S^.JM^CM9%Z]>S8<^E&"7<JZ=<?U$7V>U_4
MOBYZKX!]GFYYQ]CD? @RY!&?,#./+M4G3K8$CZZTL]P,+JO)'6P<MI@&&,2
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M$R$U'2I6]8R(CL5P::*GIDFP<PU.@<4^+:K18-G[^^-R3E)<56",V1(]@>5
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M=S=#J3I<L]LH@B4E,2P0\K*]O70;D>,9&O*P&  !AG L26TF.9.>D3._R04
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M'U&"=5"S+C/>O3^"]*T+5/$NFV/BN^N]'T&=KGVZ_@#1R1&.SFDMHQ*UE?B
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MS5FVXXV&/)6;%-NEUZQ,2[3(L_$,1<P9!2"<2462ML1L\-QHA"X(!_?Q!_4
M_A3MV)'R./(CGUX)_,U"N1\C9J&CZT+18-T2)6SPER\E79-IJ"J,#-  Q#+
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M9PZ^^3 ><7! )<I.0G=68_;VN2![TH .W+'I_P"7)!^> 3_"NQ8[OJO6R Q
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MM#6X5>J.UD'AM"M'6;,7^N&.4-A(S@<\L(TE3*6A71#62V/#8%P&25K5XNK
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M&KT!%7VK";/MESC;,_?J]13I,BJ486,LPZ(-+<^>##$GE' LG2!+1T:Z,*2
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M,F9IP3@T<H_$T.7AH*C0S2X]DU1A$9DN4=[E]3G4KOU;%K?R?'+OLB =V]S
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M'! WEJC<$259:%[^LJD 'Q\*':CG$A)?6Z_ZL?'^N>WID#DX(\L&OHWZ\Y_
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MF;'9I&6L$[-3UAF)29EI:9DS3SY XD@@A:W,YX4I 5;?M5OEJVA1 XZ<BB:
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M4KQ3$EXIL]/C4DXX4I,63K[Y#5O7U_@OV5UZ>KKY_H'"E>NB/T^V?SQ["_\
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MQI^S(T[F$FW8RMWYH JA:5,L]#L8VBX&\ WV9%M+PC!XPFLP-WW*&N*HJ1%
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3SGLMIPA/7HGT]$XQC_%PI7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img192321128_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_5.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &@*^9E@X0DE-! 0      %X< 5H  QLE1QP"   " /\< E  "')R-3 Y
M,# X' (% #U-:6-R;W-O9G0@5V]R9" M(%)E<&%R92 M($E03R M(%,M,5]#
M;V]L97D@1')A9G0@-"XR+C(P7RYD;V-X.$))300E       0]/II!77\:'ES
MX)M602<)N3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8             !.X   -           $
M 0             #0   !.X                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  !.X     4F=H=&QO;F<   -     !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      /A@    $   !I    H
M 3P  ,6    /:@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ H !I P$B  (1 0,1 ?_=  0 !__$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
M]522224I))1>TN8YH,$@@'72?ZI:Y)3))8@Z+U$ #[9_T\O_ -[TYZ+U$@C[
M9_T\O_WO24RZOUHU!V+A.F_<*K+@-XK>\2RBFO\ [4]0L;[JL;^;HK_6LWTJ
M/3]<5'1.HNJ:ZW)=6\B7,==E6.']>VK-QJGO_?\ 2HJJ_P!&IX/4L7 K9T_(
MQCAW4:6,9+ZPQQ/Z\VT_I+<6VW^D9+_TE%MGZ_Z7\ZMD&=1PG70VWZG5%6=]
MNCC?L/-_[F'_ +<S/_DDM/%K./15198'V-;$DN)=')_3V77._MVV(ZS^JXC\
MD,+<=F1L#@0Y[JR-T?0V($D]OL4!7^^W3;4&AQ>T-/!D1SM_ZHIVO:[Z)![Z
M&>5CCIN2R=N'0"Z?4(LL (ECMK/W=SJ_]=Z+1AYN(2[$QL>LVMAXWO@$%[J^
MW\W[_HM8@EU4E%A<6@O$.(&X#6"I)*?_T/54DDDE*22224I5W9^&R_[.ZUHN
MD-V=Y<-S&_VFHMUK::GVNDMK:7D#F&C=HL-YZ[9E>HQ^RJQ[;&MWC:QC=F_&
M<STM]CK]K_TN[]'O_J(T3J%LI<-;GR%NIG8^/ENKHLW,N =;1?7H^MS-K/4J
M?K[OTWT'-]*ZOU*KV64_HUFU=$ZC4P5UVTL8W1K:G9-+/[&/3EBJG_BZ_8K]
M-_VC)QK=I874W M.L%KZ&.$_UFJ\E9C8LA.AHU;B?LCJG^G9_P!NYG_O8M7$
MJLJQJP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>(*RN,+7X2@T165S=H.%AS9$1DAG:(23I;:WP\3C_\0 '0$!  (# 0$! 0
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MZ0HB\?U_8]]IY==PLG[*OM(M4UG"RJ;8C2/%- BBACE13$;J(.XD @F7W(:
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M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%P.D10HE.4#
M.NH" #S\_ 0$!UZ=0'6B+Q9VA]C;+FS!DZ8VQO8^VR*,\_.9]G+9B PH63F"
M'(<SB0D[8C4A(WA[O2$RSM%JQ(@JLZ.JXA#INEWD+/\ H;()&B*3(:!VN?#>
M].IT/$<5C++'>;J/9K;L-K6Z\K+[;JDL%^RV[-$E(XWC(R/SU8!B$8PMV33N
MR\@81R"D<#';2DG&P<W+DBS.VR@H&1BU8B?.R H*1DLQ45B^RV%VMK-C,<BJ
MGR3.P:K<V#%J)K!/!7TANU[74\DC8S+&";/R<PDB[FDL=P/A#V+IMM<$D@C@
M@&-T0,N#5\DCZ:6BJ00Z[:F*-\@9)N@.8+-?D26N:"WY]BO+F8=E!E(X/V_)
MTEN3=V7^Z=8:R7<5R-)Z)OQ:XCG<SUO%GVJRYFBT?+[DFU5N D:<Q;C(S,5,
M46Z)NPV\P; =KY1CW@VI73TU)ASY,;PNFIG13X<('DQU0ISY[9&/<W<IS(X"
M#>  !MP_@_QS']BH9-G_  GU/BM15XB#@>+5E2*F'$#.(V2TIJF%VX8GB-S3
M,6-!F.\YI<W>]F$W1#%+N"0X;I!]R8#:@)0'4!#AT@(#U" \0$!KXKI<$$$6
MN"#E<D#KU!&8!N#DOO-QE9P(()!X$"QORS!!%LB"+:K[**4HB41*(E$2B)1%
M0Q2FX& !#GT$-:(NLZ*9P,&Z "8--X X]6NO =?/K1%:X.WH2VHIE!P,5'0\
M-&HE;1T5%LF\?',&R?UC9FR:)I-VR!/WB2*9"%_>E"B*[<FGIIN%[ Z.;CS\
M*(J DF',0H?%1$Y)/R"]E$5>3)S;A1#CSAKST1.33'3W!> ZAPYA\W5\5$5.
M13XZD*/'APY@ZO/I1%7DDQYR /1S='51%R  #@ :!U!P#LYJ(JT1*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41<1* EW=.&FGP?/6B
M+RZVR=@F3OJY&NTKLH7(AA':TL\IWS"X(G=C+7RJU;&%V:U<F1[=(S*4+('(
M+9*7?M'>\"I&TPD]8D1.QRL>T-<R078[C^4TC0M.=ASR-PJ.:+M>!Y3"2+?E
M7R(<+V<.(!&I.9!LHWQ3M!XQ]D*QQD#9:VD,9PV/-J:SHU]&7AB#(+5=$S6>
M;M=UO?N.WZ:Y)9:'Y4Z+XRT/(A*QJ"@:.7T.Y9RTCN<"QG$-FL8HL6PZJGIS
M#(Q[G0%N]-$'6DA=&=Z.5LC0Z,ME:6YW+<KGG]I, P[:K!JW",1I::H;/#*V
M!M0TVIZ@L=T<[7,O-!T;RUQ?&0X@$7L2%"NSI&[5'L:#S)KS:/975G/ $S&0
MBD#=>-)1?($];-P1#AI P[$UM7*^A+A8L)>$=(M'@((O(]F>$CRIN@+O[_V7
M:>JV0\*C,*9LN:; -J(9)C5T.)QLPZEK8:AIFGD950,FIGR0U+26=))$]_2R
MW8V[0OA>RM/MGX(9,7DVLAJ-H-F)H8>AQ'!I9,1EI:J!XBB::2KEBJ88)H'E
MK]R-S&='"&EP:=W8OZ<9@'_ YM3?@?1_6JN<_B5VG_WILO\ VW%_AKJ/X^MD
M_P#=&U?]BN_QT^G&8!_P.;4WX'T?UJI_$KM/_O39?^VXO\-/X^MD_P#=&U?]
MBN_QT^G&8!_P.;4WX'T?UJI_$KM/_O39?^VXO\-/X^MD_P#=&U?]BN_QT^G&
M8!_P.;4WX'T?UJI_$KM/_O39?^VXO\-/X^MD_P#=&U?]BN_QT^G&8!_P.;4W
MX'T?UJI_$KM/_O39?^VXO\-/X^MD_P#=&U?]BN_QT^G%X!_P.;4WX'T?UJI_
M$KM/_O39?^VXO\-/X^MD_P#=&U?]BN_QUL/LV[>V,]J&]92Q[)L#,]K2,/;C
MBYW4AD:Q4K6AEF;:3C(LS1H^)-21G$B=:5053:\BF!FR+I7E/J.Z;EMJ-@<7
MV2I:>LQ&LP:IBJ:@TS&X;B+*R5DH8Z3\8QL;-UI:W)P+LR ;$A=9LCX2<%VR
MKY\/PRAQJFEIZ7QI[\2H6TD+H^D;%NL=TTCB_>>#NN8R[0XB]K+>?GKB-5]#
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$00 > AJ'4-$7GKMK[!ML[3J,+D2RIQSB/:7QR5-_BW
M-EN;S&88/F*AG+&"N55D!'4M;*S@RA114%5>,%TZ78E42</F#_)&_=NUURQQ
M\H9C+T$>[OS57-#@-6D$'>;DZW%M^1^/-:G6#[)'GW$L.MC+:QV+]HRXLPV8
M[5A)R[L(8X->./+U:MR(C'W5%2*3MJS24E4# NY:QYW+,BV\H062BAXQEDZ%
MFL<C0,RT$V(!.0OS R-[&XNA-[@L<02+Y7!MH3?7("VO5D%FWTV6%_B+[<OX
M"#_UU3<?^=_:/Q6/+\SZFJGTV:$_B,;<GX"3_P!=U&Y)^='WW?!3Y/YH_=;\
M4^FS0@\VPQMR#_\  @_]=TW'\91]\GX)Y/"$_=:/>57Z;+"_Q%]N7\!!_P"N
MJG<?^=_:/Q49?F?4U/ILL+_$7VY?P$'_ *ZIN/\ SO[1^*9?F?4U/ILL+_$7
MVY?P$'_KJFX_\[^T?BF7YGU-6R.S#MM1^TI>\U9K/9SVC</*P]L.+F&X,QXW
M&SK=?$0E(J+-$1L@+]V*\RJ>4*\19<F&^S9/E]_ZB #B>UX-W/#AP N>69/.
MQMF?999&[MLF[KLKV%C;(VRRMEZ;>D[YAS!\ 5165:(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(OF=ND&:"SEPJ
M1!%!(ZRRJIBD3223*)U%%%#:$333( G.<X@4I0$PB !K4$@ DFP'$Z#M4$AH
M+G$- !)<2   +DDG( #,DY#BL$-E;'*;J*8J7[9I'LXU:OH5F>Y(@KF79/R$
M48NXQ 78*/FKLBB9VKAJ59)P50@I'.!RB-2]HMY3;N&\+FPMP/\ GV\0%YC6
MT@+&FI@!E =&.EC+I 0"'1C>\II:0YKA=I%\\E]\'D2R+E(U/;UVVU/)OG1V
M+-2'G(V13=/4F2DDJT;G:.%2K.DX]%1^=NF)E2LR'<B4$"B<):X.T<UQX[IO
M:WIY$?1"R1U-/-8PSQ2AQ ;N/:XN<6N?8 .)N&M<2. L5F@" \PU990;BXXH
M.N@Z<^@Z?#T44J <.Y2G<@WSM$VU*M(]JSQ!E]ICV#59%<@XD(IQBO&U]G>2
M8KKJI"^"3O-^S*9J1!#P)LT 417!5922+6ZP"H!O?J)"G\0 0T$ $.H>(5"E
M<0*4!$0#01Y]-0_)1%30WF[3=]$30WF[3=]$30WF[3=]$30WF[3=]$30WF[3
M=]$30WF[3=]$3< >)N(CU\P?!T]%$7.B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%!FT%;5[7UBVY;'L1S'L)
MF\BLK6>2\D119K"VW-2#5C=4J+-!Y'N)!9M;:LGX*P;/V#AT[.@FF]:>Z<IX
MY@71EHU?9O8"<]<M+_$%:W%J>IJZ">EI7B.2HW(7R.%Q'#(YK9GAH\ZT9<-V
MX)N0'#4:O8RV=LEV?*X^BY\EJR\)C!GG^W;?FX=L:%06M?(9K+FK$CF%N/9&
M>=PK"UG*,[:+&.6G)(S"&@HE<CM0KL$T_**>1IC!<#N&9AL=(WNO&P7ODQMF
MW.9L.=US]'@-93^*PRFGDBHH<8IZ65C-S_5JYD#J-A#M]S?%GMEA WC9C6$N
MN3>R[.^S5EG$5QX]"3>MY*.8.L>R=W3BLNR))N6D%LYW7C9W9[F/BHZ+BW\=
M:][&A7D$_28HNY&/D^7DW+UY#^$KWAB?&YOE&UFEUORAT8;8Y#\IH(RTTYIA
M6!U^'STIZ1LD4<M++.\ON]S6814T;J=P  +8:IT3VEK07 C?+BW>7I60N@<1
MUUT_/I\/ :]0XYWS[NI=C87OU6]"YTXCL/N^*E::;,'^JWMQ_P#&;C/^CK@6
MKGS8_P#NQ[2JM_*_6/N6Y=55DHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(N(F*' 1#7J$
M0#7MZZ(<P1S7GQ[(7M.Y-V6\>8\N?%4%:,[/WEDQE93EM>:$LYC6[!U;UQ2Z
MCI!.'E(IQX65>(;IDY1P9'DE%=Y(3;IB^&OJ)::%KXVM>XO:TAP);Q)O;.V7
M#/K7$[<[25^S.&4U9AT%-43SU\=(65 E+6LDBD?O7B<P@M<T:DBQ(LM3;;VR
M=O&XH]&00LC A$UDRJ!K!7N( !@ 0 /[M><=0 .&O'4>?2O VNK7@$10CCET
MENO/>S(&JY&FVTVTJ(V2-P[";. OY-4!G?(GILKV]8XK%W7L@FV1;&2<86I>
M%CX0)"WGDBR+.E5XR*O)"2;1]S7+&PSQRQ.XN]RW([0;O5%6YEVRR15BDY1,
MY ,09_"%6V1C9(X[/>QEVA]P7.'.X\W/V<5C&WVT\.*8915>'X2(JS$*2DD=
M&:GI&-J)1$7-!E()%\@1:]KZ$+W<1'W/NC )M"ZZCS<_#C^0.:MV!:_6;K[/
M?.W*U\^/9P';Z]5WTXCL/M:I6FFR_P#ZK>W'_P 9N,_Z.N!:N?-C_P"[;[2J
MM_*_6/N6Y=55DHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(H(SCG"V<)6ZA+3*#F5F9=T,
M;:]L1@I>-)^2*@9=0B9EC%19L&:0<M)RCH0;,DA3* +.W#1JXW&!8'68_4R4
M]+N,BA DJZF7*&FA-@'.N1OR.!LR%AWG7!M:Y&AV@Q^CV?I63U(=)/4N=%14
MD6<U3*!O.  !Z.-@LZ29PW& B]RX ^/^U67.6V3:UKP<HXM7&<5:=Z-KYAB0
M,%+W++).FT1*Q)&#^8D9Z':2*1T)=50ZS>WXLPJIDW"%+KO=?B6P6"/IV0#%
M*OQAKVF281QM;=N1;'';>#3<W<7D:+XUM5B&/;84D=,Z&FP^G@K/&XC$9I*@
MF.,AF^_)FKC8F-HN-!G;4*4VA,E[*)RV9DQ)2XH^31!*S;J812[9.7?%3(0\
M*K'D/("UF4U3E%HT2<*F?MS%6:<H8CE%M\^VCV=J]FYZ=E.7XA15;FQTTK80
M7^,W'^K/#?*<[>W2V2Q;<@99KF6[2XCL\TTV)1ODZ1H=!)&"#*_-N[OFS0\B
MPM>XY99WN+PUM"Y5G[#RM<MW-;9?6Y=MMWXPLA2UU99!NK;TVSG(V,EI%.X(
MU0YU_ T$Y(C1%,4#J*HMW!SIE7-TM'X/:;HZ.;%,3FAJQT<U920[K@PO(>V'
M?)+1(UM[OS#<VD"ZF&GQ_$*JCQ9\@C,4\%;!2EC_ #896RM;/(+$N<0V]GAU
MKVL"O7FP-LRYXR=80&=+9A(=A)NTF+>_;6\8LX:/=.ER(-D[AM^6=R3F,CA4
M.FD><0FW[=N93EGS2.8I*.R;W%-A(C32U6!5<M5)$"\T%0UAJ7Q-;>1U/+&&
MLE>UH+NB# ]UCN!QR7UK"]O9VU,=+M!20T;9).C96TIDZ!CI7;L+:B-Y>6AS
MB Z82%C2/*W;A>C"*Q%2%.0=XJ@%$HE$!+IH'$!UXAH(#J'0(#S#P^:\1<6\
MX6Y$$"W4<M.U?3LN!!R!N-""+@CJ/ ^M:>;+_P#JM[<?_&;C/^CK@6LA\V/_
M +MOM*JW\K]8^Y;EU562B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB\J]J<IYW:B@(A\85
M6=OXNM]S&H'T$K9S<-T78$NLGJ.A#/4K>A4EA#Z\L>AO?6  ?6]C1XOLM65$
M8:))\4E9*_1QA@I:9L;+W_)?43.N+VWP> 7QW;;_ %C:N@II7.,<>%Q/B%[A
MDTU75]*ZV@WHH8V\+CGNJ9;;M6/)&IF%$@ZD#3W("  )2CQ#X]!TZ/1J*NKF
MZ5X+B3?3,<[9VN?1R6]I**%L#7;@)-R1KW\^LYGAHK)<F%K+NM=FM-PL9*!'
M/VTHP!^R;N_ Y%H8RC5\VY=-0$G;8XB*"Z>ZHD81$IRZB-49B4C&"-S1+&
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M*:TM+2CE*+B(EC]6?2LD]6Y!C&LD2Z"LY>N3)(D#4"DWA44,5(BAR]?@>'=
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M&]_X=[:_U^#_  +>I ]B:B@_^N'MC#\.6C_U=4GPRS$?^Q.Q [,,D_\ ,(/
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M!\$6+U&V,VVVV.(4-5/)7RUT6"PM?7TE.39E.'2U(C:74\38PT1PO#',R<;
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M$HB41*(E$2B)1$HB41*(NI59)$ICJJ%3(0!,<YQW2E* :B)C#P  #B(B.@
M]5$6HEX;9N.&MP/K"P_$W+M&9+8J&;/K1P\S0FXRWW8&(F"5\9#>.&6/+(*F
MHH47",[<:,L1,#&0BG)P*D>^X0+N\D7M<\^5M?KFH)U %R.&GKT6(*8NVILX
MJ$<YIR8WP/83HQ1^A'L^/U7%Y/VQU#;K2\LZ2S-O)-Q$HD3>-,;6_:ZA/JB:
M-S.B;JIX#@W0 GF1<9'(@=8O?O4B_5IIRY@\#U66QV)L!8AP?%N(O%UBPEJE
MD5 <3<FV0,ZN*XWNFAI"YKFD%'EP7'(G'W2CZ:DGSHYA$PK".E0YSW'-V7+K
MO?LSXDW)[<T4NF2(<NZ8-0#AH/P:?'PZZA%JMD78^Q1>MPN[^MDEP8<RRY*(
MGRMAN6"Q[L>JE .2-<R#5%>W+Y;IF*418WQ 7$S.4H$!(NN\%P\Z'RAR/U]6
M"'/J[%'Z=V[8>!PY*_;0B-JBP6W*![>,6M6%C9F8,B'*)5I[%DG(#:EX.4TS
MJ"JYL6X85\ZY$/!+/465*E4'<)R.[U&Y RX$ G7JXW49CA?N'O\ KJ4Z8BVE
ML,YM\,9V+>;->YHG0MPV%.-)"U<BVPMJ)3M[DL.Y&T9=,.=,Y3I\J[BR-%C)
MG,V<KI@!Q.:YOG"W<?9= X'0^[VJ=P. Z!QU,&H<!YN?7JTJJE<J(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB416:=N&$MF)D)ZX9>,@H6*;*O).7F9!I%Q<>T1+O+.7K]ZL@U:H)E
M]T=9=5-(@:[YRZ"%!GIGV(M,GFV(_P E**1.R9BRX,\KBL9H;)+Y=7'^ 8U4
M#J)*N5,E2\>Y=7>DV.3>%OC>W+O!;[$9ZT,<JE91&!?I'  :@6+CV#3VYJ+]
M1[C;70\EUALIW]F I'FUCF*4OR,7$JRN&<6^-L9880WB>Z83164DK?F0VZ9C
M'(H-TW&WAWY0*H>UV@"*-1OM;DQH'(G,VS'9QZQ93]=RV_L^Q[0L""96O9-L
M0%I6Y&)@E'P=MQ+&%B628<1*WCXY!LU2WC>Z,8B8&.81,<3&$3#C))-R?0BR
MK0.'#FYJ(JT1*(E$5!*!N< '3KHB@G+^S;B'-Y6+F^K3:*W)#"*ML7["*N+<
MR):#PH&%!]:M[PJC.XH59!0XJ@DV?^!K' "NVKE(3)C(<6Z6-L['0V3Z^K*!
MU87;'P,8BUL3<3M:X\:FT5MR]%XW'F>8QB3<#2&O-DT3Q]D!RFF!Q(TN>*LE
M\[$I"JW(NN<Z@V):Z^6ZZ^5O-U%[\K#2WI4$VX7[->[CZO2I.QCM=8AR/<2=
M@.GTQC7+ )F.XQ)EF)6L'('U,QR**1,5+G!C=S$@IF$)>RY.XX=0@ HF_$A@
M&H+2.1ROY)O8?#KM9 ;\_2"%L\50A@U P='2'3KI^0:JI7.B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%&N2\
MOXTP_!J7'DR][;LF&(8$R/;@E&S(7:YM (SCFIS>%R;Y4P@1!C'H.7:QQ B2
M)S#NU(:3:P)OIR[]$)MF<EJ\.?L^YK$[;9MP\O:]IKZII9PVAV<G9T X14(.
MX_LS$J(M\E744"G36;+7.WQ]$.=TP)OW)0]W<-:WSS>WY+=;]9.EN.F>ET]:
MNL'L76W<,DQNO:2O:X]IJ[V;DC]FUO\ (W88KMYV10JJ)K6PY#\E9+0S8Q2>
M#25P-;FN FX4YI@3B:HWR+[H '9G;TW^/7Q4$ ZBZW+:,6C!!%JS;I-FK=)-
M%NV0331;MT4B[J22"*92)I)IE "D(0I2D*  4  -*HI7UT1*(E$2B)1$HB41
M*(J" " @/2&@T11CD[#&+LRP1K;RA8UN7O$<H5=NWN"-0>+1SL@@*;^'?B4L
MA"R:)BD.A)13IF^1,4#)."" #4@EIN#U'K')%K";!.T3A,_A>SMF%2^[1;@!
MD\*;1<A)W*R;HID,'@MH9D:)O;_M\I2%22:-[J:WXP0W=TI&Z9C&+8.:;!PX
MZC6W'+3F>/4!Q?7UR5]M[;/M"(EV=G[0MIW3LSWN[6(R:M\FD9K8^GWAS$*3
MVHY@@E7]@3)%S*)@W8R$K!7"8QN36@45"G* L^R0Z_*X/<?C=5#KFQ%CRY_7
M[UN,S>-9!ND[9KHN6RZ9%4'#=0BR*R2A0,FJDJF)DU$SE$#$.0QBF+H(#QJF
M8)!!!',?7=KZ,U9?54"_$6ZM42I1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$7GYM=>R)8.V2[QQKCFZWSJ=OS(5P1;92V;?;
MN9:4MRU73CD7%RR;&,1=/15>*!XMMJ(21%Y.RBQ02!*/:OWJ&1D;GAQ&0:"2
M3U"]OKN*JYX;8&]SR]&O+570MQ[8F=C&+:5NQ>R=CAUN\G=-_-HN_P#.\LS.
MH71:)L".>.[ L)15'?%)Q=<[>,@COIBZM5%0ITBQY  U<>(T ].OI]2MR^O\
MNPJ2,9;(.(\?7 G?TLWG,K99.4?"LM9@EUK]O@IS;_*)P3F5*,394>85#E+#
M6/$VW$II[J168D(32"XZ#(<A]7_SRL,E%A<FV9X_6GH6TI2$* :%*&G-H4 _
M)55*Y41*(E$2B)1$HB41*(E$2B)1$HB416.X+9M^ZXE[ W+"Q,]"2:"C62B)
MF-9RD8_;+%$BK=VQ?(KM7"*A#"11-9(Y#%$2B&@C0$@W"+3=?9 D\8+N)?9-
MRM<&#C'5.\6Q=+H.,AX"DEC*\LHBECN8D$'UBIKB(D,IC*XK213U*8\:Z(F1
M$;[Y)(> X96.0=UY@7[/7= +9#MY^U:]9_\ 9%;[V.[1B'VU%@E2!EW5TV_#
M1]RXWN9I>6.+]B5I)JA=#FVG3WQ->-LW'#P*CZXFUNW=;2<>Z"/"*3N==P];
MN NR)K][<=IF 1GGGS[=!V<EC=(6WNV]L]=1SZNN_7DO2?%N3[&S-8=LY*QQ
M<+"Z;-NN,;2T'-1JN^@Y;+I@)DUDQ JS1ZU5WVSY@Z32>,':2S1VBBX143#$
MX%I+3J#8J[3O $<1=2%4*4HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1%00U 0'F$!#MHB@"YME'9HO2Y9&\KQP-B>[+MEE$E9*Y;FL
M6W9Z;>J()D20,XDI6/=NU.013321 5=$4DR))@5,H%"0YPO9Q .H!R/:HL#J
M ?0ISCHYC$L6D9&M464>P;(,V3-LF1%LT:-DBHMVS=%,"II(H(D(FDF0H%(0
MI2E   *A2OMHB41*(E$2B)1$HB414W@X@'$0YP#37C\.@>FB*F\/D&[2>M1$
MWA\@W:3UJ(F\/D&[2>M1$WA\@W:3UJ(F\/D&[2>M1$WA\@W:3UJ(F\/D&[2>
MM1$WA\@W:3UJ(H^O/%&,<CJM5L@8ZLV]U&*:R3$]VVS!W"9DDX$@KIM!EFCL
M6Q%A3(*I41("@E*)P$2ETD.+<P2.Q#GJ ?0KG9EA63CJ*&!L*S[?LR#%TN^\
M3VO#QD%%@]=;OA+H&$8BU; X<;A.66Y+E%-T!.81"HUU3319=O#Y!NTGK41-
MX?(-VD]:B)O#Y!NTGK41-X?(-VD]:B)O#Y!NTGK41-X?(-VD]:B)O#Y!NTGK
M41-X?(-VD]:B)O#Y!NTGK41-X?(-VD]:B)O#Y!NTGK41-X?(-VD]:B+EZ/GY
MJ(L,/+/2G, *CH!A - +T"(>2.GY*U+ZR8$V.0-K!K2>.>B]0B:0#89@'\KE
M^L%3QN]]\] =U/')N;?NA3T3>0_:^9/&[WWST!W4\<FYM^Z$Z)O(?M?,GC=[
M[YZ [J>.3<V_="=$WD/VOF3QN]]\] =U/')N;?NA.B;R'[7S)XW>^^>@.ZGC
MDW-OW0G1-Y#]KYD\;O??/0'=3QR;FW[H3HF\A^U\R>-WOOGH#NIXY-S;]T)T
M3>0_:^9/&[WWST!W4\<FYM^Z$Z)O(?M?,GC=[[YZ [J>.3<V_="=$WD/VOF3
MQN]]\] =U/')N;?NA.B;R'[7S)XW>^^>@.ZGCDW-OW0G1-Y#]KYD\;O??/0'
M=3QR;FW[H3HF\A^U\R>-WOOGH#NIXY-S;]T)T3>0_:^9/&[WWST!W4\<FYM^
MZ$Z)O(?M?,GC=[[YZ [J>.3<V_="=$WD/VOF3QN]]\] =U/')N;?NA.B;R'[
M7S)XW>^^>@.ZGCDW-OW0G1-Y#]KYD\;O??/0'=3QR;FW[H3HF\A^U\R>-WOO
MGH#NIXY-S;]T)T3>0_:^9/&[WWST!W4\<FYM^Z$Z)O(?M?,GC=[[YZ [J>.3
M<V_="=$WD/VOF3QN]'F4] #TAYNGFJ#63@'S;VRR&O7]>@IT3,K@#/\ 2^)]
M*Q"9NV99/.2073*04RF'5$AC&$QC@.HB4>HO3^6O=32OD:"_6US:W.U@0.W@
MM15SR0S;C T-S[>KSO\ +CV6CV\3X</"$A\X-D_4Z.:O1<=?<?@O,*JH.8#2
M.&8'_P!*>WF?_A"?WLGZE+CK[C\%/C51]EO>/E3V\S_\(3^]D_4I<=?<?@GC
M51]EO>/E3V\S_P#"$_O9/U*7'7W'X)XU4?9;WCY4]O,__"$_O9/U*7'7W'X)
MXU4?9;WCY4]O,_\ PA/[V3]2EQU]Q^">-5'V6]X^5/;S/_PA/[V3]2EQU]Q^
M">-5'V6]X^5/;S/_ ,(3^]D_4I<=?<?@GC51]EO>/E3V\S_\(3^]D_4I<=?<
M?@GC51]EO>/E3V\S_P#"$_O9/U*7'7W'X)XU4?9;WCY4]O,__"$_O9/U*7'7
MW'X)XU4?9;WCY4]O,_\ PA/[V3]2EQU]Q^">-5'V6]X^5/;S/_PA/[V3]2EQ
MU]Q^">-5'V6]X^5/;S/_ ,(3^]D_4I<=?<?@GC51]EO>/E3V\S_\(3^]D_4I
M<=?<?@GC51]EO>/E3V\S_P#"$_O9/U*7'7W'X)XU4?9;WCY4]O,__"$_O9/U
M*7'7W'X)XU4?9;WCY4]O,_\ PA/[V3]2EQU]Q^">-5'V6]X^5/;S/_PA/[V3
M]2EQU]Q^">-5'V6]X^5/;S/_ ,(3^]D_4I<=?<?@GC51]EO>/E3V\S_\(3^]
MD_4I<=?<?@GC51]EO>/E3V\3X_\ SE(.G46R>G_,"EQU]Q'M"AU74 :-UMJ#
M[@OM9WC.K"KOKI& O)[H@BF7Z[?UX"4./ .C\M ;_P"1'M4MJIC>]LN0;EVW
MMW\>064JA]4/S?7#T@'2/6/SY^FM$_SG?K'3M71-\T?7%<-!\W:'?559-!\W
M:'?1$T'S=H=]$30?-VAWT1-!\W:'?1$T'S=H=]$30?-VAWT11.^SKAZ-N6_+
M-?Y%M9I=6,;4+?.0(%>323D[3M 6?A_MAEVIC<HVBRL]'*KK0Q4DCI&4W>62
M \B.0M:_<?9Y(&O"XRR_?Q[<>^W?<V^@OF;=MN1[+WX:*1HF6C9V,CIJ(>(2
M$5+,&<I&OVQP.W>QS]NF[9/&Z@<#H.6RJ:R1PX&(<!Z:C=<T[KA8CGD??]7R
MYV:]KM#U9Y*X:AUAU_G_ "4N.?7Z.:L@B <XA47',(L.GL@V?;%RV7:$[-MH
M^XLAO9>.LR+53='6GGL%$+STLW:J(H*-TC,HALN]5,Z6;D,F3<3,=42IFD!S
MKEHN&B[CR&@-],SZ55SVM+03YQL/KZL,^W,M0\W-\QJ!<Y\.!Y\U987>61+.
ML ]J)7?.-H52^+NBK#M0KA)RIXYNZ<2>KQ4(@+9!<$G#Q*.>'35=<@U("!@4
M7()B@:S6N>7!@S: X]A)'(Y96X9]2HY[6',G/AWKLL&_[0RA:D;>]ASC:X[6
MEU91".F&B3I!NZ5A9=_ RA")OD&KHHLY>+?LCBH@0#*-S'3$Z1DU#P6N8=U_
MG:GJ#O* ] (5FN#@"-#[C99CH/F[0[Z*4T'S=H=]$30?-VAWT1-!\W:'?1$T
M'S=H=]$30?-VAWT1-!T'CV"'IX]_&H.CNP^].([>5^!T_?PNH_N, \8!S?82
M=7E'\X<U;.A_DQ^J?:;:_7+-<]B(_'DY?OYV^M>U6#=+U%]'KUL &D9W[VCC
MUFZ\";I/)+Z/7J;-Z^]OQ1-TGDE]'KTLWK[V_%$W2>27T>O2S>OO;\43=)Y)
M?1Z]+-Z^]OQ1-TGDE]'KTLWK[V_%$W2>27T>O2S>OO;\474NHBW1575,1-)%
M,ZJJ@AJ"::8"=0YM!'@4A3&$0UT .(5B=8$W):QHN2,SQOH;96]?=5S@T.).
M0!<XY^0T#-UMW,=CB>%E 6/]J?9YRI=!K)Q[E.V+KNLJ;A12"C#NSOTB-6_A
MBXJIK-D"H&(UT7 BQB'43$#)E.40U\S*REE>6QRA[KV+=YX-Q?@&D#KL>NZT
MM'M'@N(U1HZ+$(:BI8")((V^6" ;W<;".P&8(#CJVX(*GT#HZ#];P'3FUYND
M?=>8=>K2O6,^6G/+T$Z^TK<[P&6\T=6MM,B;ZYCK*Y *7W(@'$> </,/NN'Q
M\PAQJUFYD$Y"]CEIQO>W"YZCEHIN-+Y@<>^]\K\SFJ;R7$1 O 1 >'9^^Z].
M'GYPJH+2;7'M]2;PR\IOQ[/*7(.3#=UW?=:: .[KQ_Y0=?2%2ZP!)ORRMKUW
M)SZNS0E22!Q OD+\UB-]WS:.-+2G[ZO:8;0%J6NP4DYZ8<I.%D(Y@D8A%'"J
M3-)TY.4#*$*!445#B)@ I#5@EFC9&7/)8UI%W9#5S6@7SU) ]/?YJJLIZ&"2
MIJIV1P0MZ261P)#8P0";-!/8;:KY[,R)960#W*G:$VUFS6?<2]IW)R"+I+Q5
M<35A'R:\6L+I!N"JR;"6CG!E&XK("5T0I5C*%.4MH)HYM_=.<;]QXN,I-=VY
M&@ N1Z0#=5I*^CKNF\3G;.*>4PREH<#'*!O;CMX#R@QS2;: C-9QND\DOH]>
ML]F]?>WXKV)ND\DOH]>EF]?>WXHFZ3R2^CUZ6;U][?BB;I/)+Z/7I9O7WM^*
M)ND\DOH]>EF]?>WXHFZ3R2^CUZ6;U][?BB;I0Y@*'9Z]+-Z^]OQ17*-TWG !
MU(]7./*CT"/7UZU!N#ED+<#KUFV5\UDCX^CWJ450#E#Z^4/2/6/W(_/L#GW^
M<[]8^TKJF>:/3[2N&A>OTCZE55DT+U^D?4HB:%Z_2/J41-"]?I'U*(FA>OTC
MZE$30O7Z1]2B)H7K](^J%$7B9M4;+F;+COW; S/BRRWTE>\A"6S9]EL"N&#4
MN5L:7OAASCS*-K-%EW29?"8*46AKMBBOQ;D-/6FV;(;WAF\.RIZF(,AAF=:,
M.)N ?Q3S( TFV9:6VN.(.N>7BD8[?>X FV7?<WTY\,AZE\DQA/:C]N<,W:VI
MEX+L9)[*3?"U_6]D5&&Q3BBSK,@+/;9P@+ZMMO>3!!T]D7C*[TW[1:T[G/=#
M=_%MF+DI&H$0MTM,[>+G0V/2B0&]W.+7"&0&QMNN()%QIEDH >2  18'/33.
MU\N [^7'[+9V5,RN;4PDM<H9L-<%X;5E_26=4#Y7NML,7AEB?-\=9S5L1C=*
M2=OVQ)0L[;Z:[6W5$'KX)9LH[_LI)$[2AJ( Z0 Q[FXT0V#=[I"YM_/RMYWG
M&UM,P%.Y([=L2+NYEO.QN;@'MY9:K"[,P5M>8[LZWIB&MW,5VWG-[/>T=:E]
MV_=&8[J*C(3L5D>WVN#(P'YKT05M^62Q^$H>#D+<?PLDY0!TB\FV;]\L[K(9
MJ9[R'.\GIVEQ#8QGT9W[[OE;F]NZ9$Y<E7HY&@'-US)D'EUKEMA:V5\\SP]>
M0[+6$]IF)R5AJ4R-9]](VG8VTGF.YH=2ZN5;#:V/+PV=(*)B3-XJ6R?E>7AX
M=Y?2LRT0B5;VGG#:46>K+ R!<Z"-)YH&QO:QP<]T8#@QMF;P)L0>>[;>OEU7
M4L8_>8X@BSK@7)' ZVY#/*P.5\E,^8L;[0\MF[:+E+?MK+<A=<_935KLLY+M
MW()(;%..4R8MDHN=B+I@%+RC&Q)B0OU==V55Y9UP*/7#N DT735&$45:8XY(
M1% "Z-@;_*@M/2.<;6W3RL"#<CE;-6<V3>?</=<@-+2+:<=".&8Y6)Y:^XFV
M<=H)E%X7&:89VEBP6U5L^W[=%NY2:PR#.SV]J6I?,??]UVT^-ES)DI+1[R0?
MQ1IU^HO#MI)Z9M(1<2HHY? WS23P[SB.@:WHG>;O N.\#=Q&KM<B ,_0JLCD
M\G)PNXY/L<MTZVN+:@#,\=2O2G88L.[L9[+^.[*ON"=6U=$3*9,6D89Z9 SE
MHE,Y8OF=C#J&:JN$1!Y$R;%ZEN*&$$G*8' AP,4OBJ'-?,]S2"TAEBT$#)C0
M<CGD18]:],(+8VAVML_3[+ZV6V^A>OTCZE8%E30O7Z1]2B)H7K](^I1$T+U^
MD?4HB:%Z_2/J41-"]?I'U*(F@<=!#M'T>Y#C\_.$'1W8?>G$=9]Q[5'UQB'C
M -1T^HDTXZ?OCZ<P#\5;2AMT8.7F'7M-N'/Z%KKGL1_V@]BQ_4GE!\K]FMBW
M=W1?=OGK:^IMZOH+P)J3R@^5^S5O(_1]2)J3R@^5^S3R/T?4B:D\H/E?LT\C
M]'U(FI/*#Y7[-/(_1]2)J3R@^5^S3R/T?4B:D\H/E?LT\C]'U(N0 00'W0=O
MPZA];T@/-H.M4<6@Y $6X6MGK?@=,KZ:V*7L!E>[F@]0-[\#EIPM[_);)&(<
MYQ]R[6-Y6;9ESNAEMIC9BR9;#2W9)A&S-]6)CR-L'V^L[>,I+1R#E86\9*L#
MQ4FZCT9-1NJU$QR+%WM#/#.'UAAC&\Z:E?&1E>,!H>!8Y&X=?,7&5K9+Y978
M1C$=1C]91TE02_'<(K8Q &LDJ*.E;&*EL!,S1*XW+7M=N-(;NV<=<.;X4S[E
M&XK<]OEK9>M:S)_/&U;=]PP9;_=PDE&V5=-B1Z^*H^7>V==IA(R-<;=%NUAX
MV2=L6<@BNV/O,S*J+X1!5RR,<YM2&&>L+PU^0IRT]"6V(-]ZUL]."P,PC'L0
MEB-5!B5/3RXMM!4R0&I$<C:6>B;XA')T%0XL(G:!'&'.+9-X'KPEC@/:[M[&
MZC>V/HR*S]Y[,^&7&4T)7)TH\GYO(L1E2/<9-M^VY:<N1=*VKT?8L&6@HY>(
M=1#'P<6;=*10<$3<)5935S(C8U+A)1PNG!=<F=KP7M:2<MYMQJ"3KE9>2/!M
MJX:)K8#B+GU. 8>W$#+52&6HK(*UHJ883*X;E2ZD+XV[I:'-;F=X@K)[8V<L
MSWE>^/HB6@LYV'LZ.L]7Y<#"S)?*,NVO>S<=%PW'H,&MT3</>LS,-H*>RG'N
M7$5;X3\DJS1<G!8K5!\=(+14E4Z5N51% *F20!SK_B>B&XTG>! ,MQD>/(@+
MV4^!8O5U5&V6'%J/!7XU55#:::M+*JFHQ01-:)GQS22>+OK6/+*=SBX!QOY)
M*VGSE9>0I/:>QQ/2%H99OO$D?9,<RM9/&=[>UEE9&5T+X0>O[MOID6\;5-)P
MZEK)M&Y%G*-PM@:M9:,&+55D^36]4\4WC<1#9'TPAC#-QQWFU!=9\CKD>2P6
M-KD6&A718O25[L?HIGT]?6X6RA#*;Q*J;$VDQ!E2TFHJ6"2,[KH !=YD.H$9
M)*\\W6S;M;S%F;2<?>P9KN/(=V6+E*(?1*B<,[Q;D!]+7FS?V:Y@)MWE*145
M=,(9N7VO,F6/[6"%8'?1$B8@%1%SK&TE<X3F032'<EL]QLV3\<2PM:"?*: -
MT;H(&6@7$# MI9(,;%8<4FJYJ>KB=3M@8:&L$E2V2F='.:N3I'1QL<8FB&'H
MAOM<-"/4;9&L&\+#<;1)KO@W4&6[<_SET6Z9V9$0E;?7L>PXQ"4;<@LL(-E7
MT6_;$!7DE04;*ZI@7=$VZPR*2 U72-W>DG#A<VOY-B>-^&>F0OFN_P!DJ"KH
M&XVVK@,)GQB2:$N%C)":6E8'ZG+?8_2PO>V2W&U)Y0?*_9K;>1^CZEUZ:D\H
M/E?LT\C]'U(FI/*#Y7[-/(_1]2)J3R@^5^S3R/T?4B:D\H/E?LT\C]'U(FI/
M*#Y7[-/(_1]2)J3R@^5^S3R/T?4BN4<8H"OQX:):<X^^>8/-\]*H\9BVELN\
MGWCJX<%=A O<\O>I15#ZH?SF$?3WUSSQ9[A^D?:NK9YH]/M*ZZJK)1$HB41*
M(E$2B)1$HB5&\.:*O1SAIPXZAU]?SX:=&E"0.([P?9IZ4O\ 5B/:J!QYM.T
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M;(==[G(WLMIK2QI"V^U1(1JD04R &A2% H" :<P^;GUZ=:S%Y?F<AP O[_\
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M;<.[C%3B4J@&(#ABJHDBYU*LU7<QR'Q/UZ45IRG9#.Y(5V4[8BHF2. E$@B
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MB#G- CWM^UR#F#PL;V!7Z'+5B#6U:L##+*%66B8=@S=+I@($<.D&R9';@@&
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M?%$W!ZP[?VZ9\V_>=\46KVV/!KRN KM?()"X6M5_;%X[A U%-I;EQQC^6<
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M7P)NB@DY(HR!<YW#C)AF$46#4QIJ")\43G.J'QN>'-C=)O 1-&H:W+=9H ;
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M^7(,@V(/ 6_?^Y1EU:^OXZJ55GZ4:T9$?_5Y%R5%!%HS1,X=R#\Q"@+=@U3
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MVNQDF>+;&6#0R#.8/$RBH%.)8\ (8"ZQ\U71D],QQ -BYOE-)%KN ;<@$DD
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MJ/D96*C81>9C&*<F=^PB9!PW7:"JU$&XIF<%54134QQ8[A<S87QU0<RIE9#
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M5X=)''6Q]$^6FIZN,=)%+O4]6P24[]Z*1XN]CFGHR ]EP) UV2NP" Z@"@_
M &#7KT#?K,)-[-HOQ\ZQMD+G>>+ \+VOP7BL?\\N-N-B,[#.V9MJOF:OF3XB
MBC)^W>$1<+M%CM5R+E2=-E!2<M5#)+'*1PW5*9)=$P@HBH4R:I2'*):J*ACA
M=CA(-XM!8XO!+39UK..0<"T]8(6>>FJ:8QBI@F@,T,<\(FC='TL,K!)')'O
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M[":2KIMDJFGPS'G-PS:"EGQ5M4,0=5QM=13QR3!DLQDE:VHD8)GPWB9<N;Y
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MBADK!*R_)AQ.** Y(3Y94"@(II\HF"AM""H77>!T#QF9R0#<B^O5Z1=4\3D
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M3W$I%O"-#HE=%6MZ(< ZY=-<ZYDCP20P[I%CO<^5C;AR-M<RH!+1J3GRO;T
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MWPX?&(_]XB%4>\C@3D,K&^O*Y';QM=002+ &QROP';F-=/2M0LOW$2^;D>V
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M:=6<P>IL&AI:0=34L5LW+(3+X2^%RCTB1"N9!T)"E+X0\5 [A4J8 F0Z@D3
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MXX!$SCB/^Q<^O^Z]1@X]?P_&-7</?>_KSUZR.6=U=@O?.VG/KY$*4E?LI_\
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MMW*0Z*(KE Q1.BJ!5  P"( 40U\+)+$M?8.:;$9ZC06[ NZ?1%T3)X'MF@F
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M*YYWG./-Q/>5U;?-'UQ77559*(E$2B)1$HB41*(H\R%B7'&4V)&%_6?"7*1
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MHX]@UL!;UVX^GT#CDCX^CWJ8SQ;T3G'=  $PZ:&#FU'3I#HK4.HYB3:QS.I
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M/BG3-^K_  3Q4]ZOQ@[Z>)R]7>/BG3-^K_!/%3WJ_&#OIXG+U=X^*=,WZO\
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M"PK1P8E;%AY:R%C*.7NF6OE*<?IV-<#J%"1>)1;)=DD=X5!-82('W"F,<H
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MGZAJ/'MH-/\ T+>Q.[>K!R -@"1<FXL!?T*#L-X'A_\ M'PA:AH_$8#<N.@
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M5M/'=H>6#_\ C$_@+X'_ />7A!_H< ^"?1RVV/M8V:OYVR5_5M/'=H>6#_\
MC$_@+X'_ />7A!_H< ^"XFSCML<!"V=FH.?7^V^2N@->88T0#4/,'6'2(/'L
M? )(P?(9W-8/5:_7Z%'\!O _<@XEX0;9:0X!?/30]^AX]2V0V3\PW;G3#S>^
MKUB(*$N9"]LEV;+L+;</G$*"^/[]N*RO"F"\@4KTZ;XD)X9HN0AB'7W=T (
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M@,&9NHA<[3U]V+.9%;WY::9YY2^+$M"S[,CIAY.PL4I+8Y<WA)O59ZW[3?W
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MFMS[++-"3:M"XG:-IE8CF8;-H*#0;RKA-V#]->213C2)/ETWH \(JZ(L<CH
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M[I1'4VX @)MW70!XCJ(5LR !=QM<^2VUR;YWL+6%N.G8,UQ(8XAQ#7$"YTR
M'%[B UN\19N\X7SX KL =?F'#FTXZ]//KS:>>I++:M=8BX.1O?B+$]=^67-1
M;(FSB T'0WWB/-M;@01^ZQ-=0X^Z#0 ZPXCKH'3S\=/A$/.-1DTV) N"0'$
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M8MO%I+%*]B#G9\C&N7+1PX:*J+E,X:"B043)(JI<N@NLKLZR61V&53HYA4/
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MZCQ&?PSA5Q?$*.X)/E2$9D6)-@6DD=JM_%OM^?.V9Q=Q L-Z"1QMH-7&Q L
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MM2M7[6X+^:6/Z"G1Q_FV?=;\$\>K?YY5?UB7YU7VIVM]KD'_ #4Q_04Z./\
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?B^1[Y'FUWO<7N-A87<XDFPR&>F2^VI5$HB41*(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img192321128_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_6.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X2EH17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(R.C R.C R(#(Q.C,Q.C U   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,S,@  DI(  @    ,S,@  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,CHP,CHP,B Q,#HR.3HS.  R,#(R.C R.C R(#$P.C(Y.C,X      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  %[P         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ 5@$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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MIFW/RD/)G\>/Q_#'?(?$==,BB:/3Q'@[C'(^[..V5QU_2GH+4BD/B0_ZM-+
M*C[SR9!XST'3K^E2 Z_O&8]-V[^<.^=OY=:- U$)\0!AM73"O&26D!]QT_'/
MX8[UJ1[_ "D\T*)-HW!3D9[X]J0:G W2_$4WDYT^2Q%EYC>1NV9V9.W/'IBH
MMGQ1_P">FG_^.?X5W+ZI;6YT+V-M0V?%'_GII_\ XY_A1L^*/_/33_\ QS_"
MG_L?F/\ <AL^*/\ STT__P <_P *-GQ1_P">FG_^.?X4?['YA^Y.CT!?%(TR
MX_ME[0WN\^3M'R[=O&=O^U^E:T0U'S83*UOY>,2A<YSMZK_P+L>W?M7)4Y.9
M\FQA*U_=V+E4+W3[BYN4F@U*XM=H *1A2K#))X8'D\<^U9B*TVD7\NW&NW<>
MTY&R-!S^7(]C4CZ9=&Z:2/6+I$)SY6U& Y)[CWQ]!3N*PG]F7QB*'6KG)Z,(
MXP1^GT_*I+>PO8KH2RZM/-&&R86B0*?E(QD#/4@]>H].* L<#?Z%%-J-U*?B
M.+0O*[&W^T >3DGY,>:,8Z=!TKLM#T>YT_1K>W.M2WK!VD%RX+;U8<=6.0,Y
M'7M6<59WN<6'HN-1R]IS>7],T[&UFM8BDUV]R3CYG'(JU5G<%% !10 44 (1
MD$9(SW%9$>CWJ3(W]N7A16+;"J')/J2.@SP/YTQ"RZ5?L(_+UNYC960N?+1M
MX  (P1@9P>G<TZ;2KR:!XSK-TC.A3>BJ",YY''!&?KTHN%@&E7P92VMW; ,"
M08XQGVX44[^S;OS-_P#:USDR%C\BXVY)V@8QC! SC/ ]\EPL(=,O<@C6;I<8
M^4)&1D=>JYYZ=:T8@5B16<R,% +D#YO?BD!YE?Z'%/J-U*?B-]B+S.QMOM '
MDY8_)CS1TZ=*K_\ "/0_]%2_\FA_\=KTHU[)?NOZ^XZE/3X0_P"$>A_Z*E_Y
M-#_X[1_PCT/_ $5+_P FA_\ ':?UC_IS_7W#]I_<);?PJUY.L%K\2Y)YG^['
M%/N8\9X ESTK0_X5QK/_ $.^I?D__P <J98N,='32_KT$ZJ6\3M9;&>3.V\=
M/D"KC/7!!)YYZ_@0#4]M!) )!).TVYRP+#[H/;Z5Y]SF)ZANKJ"RMVN+F58H
M5(#.W09.!G\32 P[L>&=7S+/<Q.6VL?W[*02,*=N1@X]1ZTR6+PK-<"X>2!Y
M&Q('$S$'#<$8.,[F[=S3U%H$NG>%H8I(9A&J(=KI)*_R\GL3P#S['K4MA:^&
MHM35K*6#[87#!5N6))*-CC=S\A8_3FC4-#@]2@^&YU6\-]=W:WAG?SPJR8$F
MX[L87US7H[Q:;;0):R.PCCB6(*P)!55)YXYX!S]*SA:[L<6%C04I.EOU+]HD
M,=I&MN28=N4))/!Y[\U-5G<%% !10 44 %(RAE*L,@C!H RXO#>D0;/*M H1
M/+4>8V OTS69%#X0,:31RVZ(H,@)G9,!,DD@D=.<YIZBLA5_X12"*-A-$D<3
ML1NF? *DJ2<GL7/7USTYI19>$I,NLEL=[CYA<M]XC Q\W7Z4:AH++:>%3<L9
M984G<88&Y96(("=-WH ,UT-N(A;1" @PA!Y94Y&W'&#]*'<%8\FU.#X<-JMX
M=1N[M;TSN9U42$!]QW8PO3.:J_9_A9_S^WO_ 'S+_P#$UZL98OE5D=B=:V@?
M9_A9_P _M[_WS+_\35O3=%^&VKZA#865S>R7$Q(13YBYP">I7'042GBXJ[2!
MRK)7.ETOPGX4T'54U"UEF6YMB0-TA8 LC=1CTW?E74QZ?9RVZ;09(65=H)X*
M@?+7G5:TZLN:1S3FYN[+D:"*)(USM10HR<G ]Z=61(5'/(8;>258VE9$+"-/
MO-@=![F@#.&M;G51I>I?,,@FWP!QGGGBG-K&RX:(Z;?D*V-ZP94\D9^G&?QI
MV%<3^VAY;.NFZB2O5?LY!_7K4D&K+/="#[#?1DG >2W(3[I;.?PQ]2!18+GG
MUWXAT==9GM9? L<\@N&C>Y-NI\P[L%\[._6N^N);>&Z$HTN26<R;?,2 $X"9
MW;O3'R]?:H@[MG+AJD9N5H<MOQ-"';Y$>Q-B;1M7;MVC'3';Z4^J.L** "B@
M HH ** *5[J!LYHD^QW,RR9R\,9<)]<<U577':!Y/[(U(,JAMAAP3D@8'/49
MSCT!IV%<)==:.,LND:F_R%@!!R2/X>O4U)_;'SD?V??[=Y0-Y!YY(S].,Y/8
MCUHL%P;6-C[3INH=N1!D<G'K6C&_F1(^UEW*#AA@CZCUI >67_B/2+;4;J";
MP*MY+',Z/<FW0F4AB"V=G?K5?_A*M$_Z)TG_ (#)_P#$5Z<:$VD_:G6H2M\0
M?\)5HG_1.D_\!D_^(K4\-^(=*O/$%I;V_@I;"5V.VY$"KY?RGN%'TZ]Z4Z$U
M%OVEQ2A*WQ'8++:K+(8]$E$D1X;[,%W$@Y*G]#]>]:MN5:VB9(S&I0$(5VE1
MCICM]*\XY22BD,*AN3<!%-LL;-N^8/W'U['I_GD %9)]4,F'L+=4PWS"Y)/M
MQL[_ %X]Z9YVLK,X-G:21[CM83LIQDXR-IYQC/O3T%J*;C5BC$:?;!@?E!NB
M01G_ '../Y]Z?#/J37*K-801P$C,BW)9A\IS\NT?Q8'7H<^U&@:G)/JGCY=5
M:*#1+)M/$^U)21N,6[AO]9UV\]/PKJ[F74U;%M!$P$O60XRFW/KUW<9_0U$6
MWN<]"59N7M%;L7U+%%+##8Y'O2U1TA10 44 %% !4<_FBWD, 0S;#Y8?[N['
M&?;- %#S]:W1+]@M "ZB23[2>%R-Q"[>N-V!GTYI5GUC #6%INQRWVHXSD=M
MGIFGH+45Y]6!4K96S9'S)]H(P<GG=MYXQQ@?6FI<:R(%WZ=:&7;\P6Z(!;V^
M3ZT:!J/N)M5#.MM9V[@CY7DF(Q_P$ YQ]15V+S#$AE"B3:-X7IGOBD&IP5UJ
MWQ"BNYX]/T*QELED802,PRZ9.TG]X.2/:HO[9^)W_0NZ?_WT/_CM=RIX6VLF
M=*C2MN']L_$[_H7=/_[Z'_QVNOM+C66M+5[JRA69K<-.J,/EER,J!GIC/.3V
MK*M"BDO9NY%102]UFA:M<-;J;I$2;D,$/'U%35S&044 5+^WN[B.);2]^R.L
M@9F\H/N7!RN#]1S[51.G:T0/^)\ 0X.19KR,G@\^A _#-,0+IVMAU+:ZK $9
M'V->1W[]32KIVL $'7<C@+BT7/W<9//))Y].V,4:!9CET_6 QW:V&4Q[<?9%
M&&QC<,'UYQ3[>QU-+F.2?5_.C60LT0MU0%=I 7.<\$@Y]J .2;PKXFFUE[J'
MQ4ZVK3F5;82/\J;L[<9[#BNRNK6]F(^SW_D*&+']T&)^7 ')Z \^_3BHBFMS
MGH4ZD'+GE>Y=&<#/)[TM4=(44 %% !10 44 %8O]FZV(@@U\;MN"QLU)SGKU
M]..] "OINM,&"Z\%!)Q_H:D@$G Z]A@?A3EL-8Q'OUI2P/[PBT ##)X W<=>
MIST'OEZ"U$.G:S\NW7<8VYS:(02.O?H?T]>U:L2NL*+(^^0* SA<;CW..U(9
MYY>>%O%%U?W$]MXN:W@DE=XX?-<>6I)PO7M4'_"'>+O^AV;_ +^O_C7H1KT$
MM:9T*I"WPA_PAWB[_H=F_P"_K_XUW=O8WL>FV\#Z@YG2V6*27:&W.,9?GN>>
MOK6->I3DER1L14E%K16+MM'+% J33><X)R^W&1GCCZ<5+7*9!10!4O=.MM0\
MK[0'/E,60I(R$'&.H([&J,^DZ3;)";F9XP)MT;2W3 E\-P"3Z%N/\*=Q6(%M
M= B;=_:."FQ^=0;@ @#^+ID@>Y(]:06OAT0L%U%!&0,;;\C:,!1@[N.,=/7W
MHU#0EELM%M6D,][Y>Z,HXEO"!MQ@\%N/K3[*VT9;N/[->"2>-R0OVPN=Q!ZC
M<<\;L9Z#Z4:AH<[X>L_"L/BW5+BPU*>34RDQNXI1A(P7&_DH!PV!U/XUU$-C
M9IJ(=;IWN8QRAE&?N@<J/8@_D:F-DM###PIQB^1W5V:=%,Z HH ** "B@ HH
M *SM6AT^Z@2*_G\I5<,N)S$V2"!R"#W- &=):>'Y(&>74@T3,Q5_MQ 7+#(!
M!& #M^G%2+;:"3E=1SB3/%^Q^;T^]^E.[%9"&W\/M(O_ !,$#DJ %OR,GJ.
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M25N9W-2W:-K:)HAMC* H/08XJ2N,R"B@ HH ** "B@! H48 QBEH ** "B@
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M_1+=2USO@KX@>'OB)X5TOQ)X<U2#5=#U.$3VE["3LE4\8YP58-E61@&5@58
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M2?\ !4[X-:#K4UC;VGBC6H(V54O[+3XHX9"57HL\T<@PS;"&13N! !&">?\
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M&@?#:[U#2N&M[C4-56SE;(!+/$L4@&&(/RN3M.3@Y%?:WP@^-?A3XX>!=/\
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M$=E 1 P9G9E4 KSEE#?'>F_\%<K>YO;1;OX7W$&G-.D<UU:ZR)I53!,C0QM
MHDD4_+M+J,D98#FB,6QRFD?HDUTB*[$X5,[B2 !@9[^U"W4;*C Y5\;2""#D
M9[>U?/WB']K[PY%^S/?_ !C\)VH\3:;8BW$NG2W MIX9GFBB>&X.'\N1!,K-
MP5V_,I92K'8_9=_:,MOVG/AQ<>)[71)M#GMM1ETR[M))UF$<R)$^8Y !D!)E
M'**=P(Q@9*<6"FG;S/:UEW9(1L>XQG\Z3[0FYEZE>PY...<#ZU\H_$C]N2R\
M#_M/:;\'K3PA-JL\NH:9IUSJTE^MN()+MH<;(A&WF".*XC;YF4ELC &&K/\
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M\&_LJ>"M(U[3+W1M4M?MZS65_;/!,FZ^N'7,;@,,J01QT(KY'_X)F_"CQO\
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M$3-?:?%9NEK;RV,MP)5MO(1VW)!,@50<?- &"*!&*TIVDN1DU?<_>+<^BO\
M@E+\'X=3U3Q%\1]3LFE;22NCZ1/+Y3!)I%WW+"-LNDJPF&,."N5N)U&[=A?/
M/VH-#LO%W_!24:#JD)DTG5/$'A^RN[=&>/SXI(+,2KE"&!*N1D8(Y((/-?H!
M^Q[\+&^$7[./@[1+BT,>K75F=1U 36HMYEGN,S-%*F[+/&"D&2>5A4?* %'Y
MV_MA:'J^O_\ !0G5M)T"_.FZYJ.JZ+9V%[YSP?9[A[2T2.0O&"P 9D)P"0 <
M ]*N+4JDF*2<:<4^I^BG[5/P^\,>(/V8O&VFWF@V,^G:#HMUJ&E6T4(5;*>U
MMG:!HU3&S:5*;5QE"RG*LPK\Y?V=_&.O>'_V//VD8-/U&9;40:/;QP.A,"QW
M4\MK=;(G! ,D("EE^8@+\RD!AZ%\:/&?[7/Q8\,O\*O$GPTD5;B>RAO=1TG1
MF=;YU*,AENQ*UJBLXBD=H]BH4P61<@_1'[-_[%Y\'_LK^+O GBZ'34\2^,H9
M)+R;[''<'3W:%$M4<Y E>"1//&" DCML/\;)7IP]]W$U[67N:'Q#^RC\3OBU
M\)=-U+5/AG\*(O&<MR_V2?Q _A[4+^2&(!9/LHE@E6-1EE=@JAB=NX'$:JGQ
MDL?C]\:OB39^.+WX1^(?#/B:&**,77AOPQ?VI:2,EDE9F+.90-B>9O&%@0#
M'/HWP]\-_M2?L1ZIJEEHO@R7Q+H&IW$H,%O8R:K92R*R'[8!:N)8SM!4&4(S
MAQO!\M=GJGPY^/'[6GQ9^*W@W3[KP+/X/\-V]Y%/KKKH+V"36)GA292]\[AF
M1=QVPD/AFP#@5KS:W5C.,;[ES_@HY^RKXX^*WB+3?'W@NP;7Y;+2&TZ^TB#
MN(XHFEF\Z)3_ *XMYA3RU^<D)A) V8^1\%_\%!YX_L?P_P#VAOAU"]F\D5OK
M&HWEB5,,9CB:*6[T^6(@OO\ +=B"H"NI2/[H;VK]KKX@?M%_#+XC:'K?PQT"
M;Q1X+^Q)!=Z;'IBWZO>E[DL6BB NE546$AE(3=M!)S7R=\2?#_[2_P"VYXX\
M.VGB#P!+X:&DP,(6GTB?2K*V262-9YGEN6+R,"(=T<9<[8<JFXG.4-5:6QK)
M6ES1W/UGTO6K+6].LM0T^YCOK"]B6>VNK=@\4T;*&5U8<%2""#TYKY[_ &[/
MA>GQ._9C\90HT+7VB0C7;2:>XD01?9PS3'*YW%H/M**K C,@SMX*^S_#?P.W
MP^^'WACPO]L6^31=*M=,^T"+RQ-Y,*1"0)E@F0I.T$CGK6YJFCVNM:;=:?J-
MM!?65U&T4]O<1B2.9&!#(RMD$$$\5RQDXNZ.N45)69^1WPG^/R^%O^"?_P 4
M_")UJ^M-4;5+:PTUIHEE@>TU!09+2$G(3=#;W[$!4"^8K*?,<"N)^&MA<_LV
M_$3X _$"=-1T#3]=A34K^^O+1C T)O;BWN1$ACYS8-#)E=[M]H#+NW+B'6/V
M:_C/H?B+Q'\.=&\%^*-7T&37@(]3.AS0VFI2V_G6\%SYK+B-"D[M_K?+VL?G
M^56'VI_P4)_9LNO%'P7\!'P#H&K:I)X0E73+?1]*S<LFFRQ)&7V',LS(T-L
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M9T^WU231](EU?3S=(&\BY2XMT68=BX$A(!!"LJLN&567[F_8Q_:T'[5'AKQ
M;W03H.N^'S;I?_9Y3);3F5'Q)%NPZ$M%)\AW!5*#S'.[;\O?\$S?A3XW^'OQ
MXUR_\3^#M>\.Z?)X7N(4N]5TV:UB:0W=J1&&D506PK' [*:SC)Q4[[FLHJ3A
M;8T_^"NVFPVNJ?"Z_CMX%OKF+4H9;Q4"SE8_LYB7>H#%5,TN 3@>8_!WMGC?
MVX/$U_:?LN?LPZ%'=+'I-_H<5Y-9,BMYDT5C:1QMDC>-L=S/PN%Y;<&PN/7O
M^"IWP[\6_$)OAA_PB_A76_$GV/\ M,W7]CZ=-=^1O^R!=XC5B,[6Q_NFNG^,
M_P"S'XB^-G[%_P -=%L+5-/\=^'-&TV:&VU2!8YY'2S6.:QWO@P%VVDDX!>&
M,' PR.$H^[S"G&7O<I\Y_!+]H+]H3X3_  UTO1/ ?P*C/AUHEN(KV+PKJMR]
MZSH#]H>5)<3,P"_.N%V[%0*B !?V+? 7Q0T;]L#1?$NH^ _$/@G1-4EU*35+
M>UT6XT_2XXW@G=8V5D 6/S#!LC9VVM''CL1K>!/BM^UI^SSX8C\!O\-KWQ5:
MZ<HCMKJ_T*ZU%88#'\L"3VLOERHIS@98KN*#Y0@3Z'_9'\>_M#_%#XD:WK7Q
M/\/S>&_!"V3166FSZ6M@([]6ML,D<N;HJ4:8[F8IN+C/"X)$P/G#XW?L]_&;
MX _M/7WQ6\ Z%+XKMKK6;C4[2ZT[3VNB&N?.\VUGM5)EVA&D0RIM0AXB'21@
M$]K_ &:?V\_"?QV^('A[2?''A;2_#GC*WC$&BZYN2YAGNYD5+B&%F7S+4R8&
MU S!PH0R9V>9S7Q&^.W[6OPC^*WC&PL_ EQXR\.W5Y<7&A^9H+W\4%FMQ.D"
MK)8E2&>,1DK.Q?@'&22?/?@?^SK\:/V@/VF+/XM>/]"D\)6UIK4&IW4^IV#6
MC.;80F*VM[5R)=I58D$CY4!)"6D<$/7Q1]X$N6?NF'_P5=EW?M"^&T4Y\WPM
M 3N;[Z&ZNLC;[@8SUX^E?JRI1<ND3%=S$G:<G&"2.YY X[_2OS\_X*6?LX^-
M?B1XLT#QUX0TN\\206NE_P!EZC8Z=;+-<6NVXS')&@/FN9!=-D(A""W!) )-
M>K?L=_&;X_\ Q)\1WVF?$[P(^@:%I^E*YUB[TB?3[F\O=R+'D2R*IW(LK.(H
MPJN!G8&4-$KN"LRXVC/8^O-IK\B/VH-"LO%G_!20:#JL)DTG5/$'A^SN[=&>
M/SXI(+,2KE"&!*N1D8(Y((/-?KS7XZ_MAZ)J^O\ _!0K5M*T"_.FZYJ.J:+9
MV%[YS0?9[A[2T2.0O&"P 9D)P"0 < ]*FC\5BJ_PW/T3_:J^'WAC7OV8_&VF
M7F@V,^G:#HEUJ&E6T4(5;*>UMG:!HU3&S:04VKC*EE.59A7RW_P2+UF\N-)^
M*.F->2RV$$VFSQ6BS/M@DD2Y#D("57*Q0C<JKN 3.< #B_C1XR_:Y^+'AE_A
M5XD^&<BK<3V4-[J.DZ*SK?.I1D,MV)6M45G$4CM'L5"F"R+D'ZV_89_9XU7]
MGOX0FS\1?9O^$KU:X%_?"UC3=;*T:K'9O*/];Y?SOGHK3.%R/F>Y:4N6Y,7^
M]YK'P)X6^&&B_&7_ (*)>(/"/B-9I-#OO%^N/>P6\FPW*1/=SK$S?>"LT2 [
M2#@'!!(9?J#_ (*->&O#WPE_9K;3_!F@:'X4M-?\0V%IJ\.E:;;VWV^)(YY8
MT=E3YF62%"N#NRN,[2P/FWP/^%'CC2?^"CVH>*;_ ,&Z_8^&9/$WB"<:Q<Z;
M+':>4Z7HC?SBNS:Y==N#SN%?;W[47P/D_:"^"OB#P=!<V=IJ=TJ3V%Y>1;TM
MYXW#  X)3>N^)I%!8+*Q"G[I4I+F2%&#Y+]3\W/V9/C!\:_@_P##\K\-O@Q!
MJ]CJDTDUQKT?AC4KR74'1VB4/<1R!2(\,H50%7Y^ [.U1^ _#7QD\7?M>>%_
MB'J/PQU_P=+J'B.PN=1GTCP_=V-I!"TJI<2DE<J)4:0RL['?OG)X;%==\+=:
M_:P_9'T>;PC8_#K4-?TF7-]#;76FR:O;V>6<RF)[28A!(6#& /PR[E4;WW>X
M?LY_%C]IOXM_&_2)_&?AB7P=X!M8Y$U>Q_L8Z?',[0W!@D4W9:X9MZQ B!B%
M*#<%R<U+38PC&^YX/_P4*T^\^#/[7WAKX@:1:7%S+?066KQM?1LUE->6L@B:
M!2@4%0D%L6C+9_>?>7<N-'_@I3XMF^+GQP^&G@?PG/INOH=.C:R%G<*SSW.H
MS(L<4DI<1JKQQVK*3@[9<DD.E?1?_!2+X%ZC\6?A#I.L>'='EU7Q#X=U!3';
MV:3S7,EG/B.:*.&-#N8N+9SD JL3E6!)#?-G[%/P(\?>(OVG-%\3_$7PQJ^C
MV/AW3$N89M=T%H89C;6\-E:VZM(J*)(U,<HDPSYMLYR=RD9)I2ZHV<6FX]&?
M5?[3WCKX=?LO? 7PEH^O>%K7XBV]@MII>D:%K;02&46\0C-T_F1.,I&>9$C)
MW21KA5DR/E'XB?ME?&SXU?#?Q&#\'K&X^'>KVMR&U7^PKZYCM[="^9?M6\1%
MK<HS&7: '3=M7&VOHK_@H]^SKXG^-7@;0->\*PC4=3\)I=3-I4< $]S%*(BS
MPMG.]# #Y/\ RT#D EE"O\_>"_$G[6_Q.^'6F?!JQ\'R>'-%33TTZZUK6-!>
MP<Z<1]FDADEG(C(1)$SY$?G;8LC+9+3!Q2N.I&4G8['_ ()"H9/^%MD["_\
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M)8?#RTL9U2+6->FL=0"0AR\0N[^X'<D'S;:$Y4YRN.02M?3/_!33P;XA\??
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M*47_ (2GQ&45F#,W[J\.X$\D'9C !"D8K]9,=:_*+XQ?!/XT?L^?M8:S\1?
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MX*BZ5,JDQ?\ "6^&T#_PD^58' ;H3@@XSG##CFOH_P#X*P<?L[^'/^QKMO\
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MX#TCPW^S'I>NV=N$U3Q)=7%S?7$D:AF,,SVT*9"@E L.X!B?GDD((W\?(/\
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MWAZXTY[F&\CMF:*%)(8F1Y%2&V!*]'\DE]ZEP_JOQL^+W[1WQ^^']]X,\3?
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M4O#*0>#KCQ#K-\=0;4+63-O/'=I _DB7>N\RK_#GKD"OT*CMW3 ^7:!@'O\
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MQWJQ12 KM"^XD!>??IZ<XSW--%JP9SYC'?G<-QQUXQZ<>A%6J* [%9;8A@6
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MTOV5_,#EE;'.&&3GZ]N/0=NM6:*%HK!UN0>03_$00"!SG&?_ -0I%CEWAB5
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MTR:.V:ZUJTBABN)6!)2)TE<,R *6&01O3UI6=KE75['LM%%%(84444 %%%%
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MRNC;6G*MAQPK C^5:RA!1BUU,HSFY23Z&E\1/VU?@Y\*?%]_X7\5>+6TK7;
MQ"YM3IEY+L,J+(@#I$RME'5OE)P.N*Y__AXI^S[_ -#ZW_@EU#_Y'KX6_:@\
M/Z;XM_X*6'1M6L_M.FZMKFA:==PLY03P26]BLB#:-XRK,"0PP*^Z!_P3M_9\
MX_XM^W_@[U'_ .2*)1A",7+J*,YSE)1Z'K.O_&KP=X7^&$/Q$U/5OLO@R6TM
M[U=4^S2N/)G,8A8QJID^8RI_#QGYL8KR<?\ !13]GQD5QX_)5CM!&BZ@>?\
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M])>-_&EEX#\&ZYXDOX;B>TT?3[C4IX+55:9XX8VD<(K$ MA<#D#)&2!S0XM
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M^'M/^#^C^)+;0=+MO$=WXCM;>XUF.SC^V3(+2XPCS;=[+B->K?P+^&5\.?\
M@HGX[^-OQ7\)>'/!GPQAM+&XU*W&NW:O+J;0V+SP)).6C2(0!49LLX<9V\_+
M\W9?\%7_ )OV=_#V 2Z^*K9BB@EL?9+L9P/<CFHYWSHU]G[AO_\ !/#X:>$6
M_9M^'_B[_A%-#'BG_B8G^W/[-@^W?\?MQ%_K]F__ %?R=?N_+TKY2^ //_!4
MS5?^QK\2?^BK^OL__@GA*(_V._ 6<?(M^6(92!G4+@]<XZ$'Z&OC#X",(?\
M@J9JID(C'_"4^(V^8@9!2]'?W=?KVI7UFQVTBB?]LR^NOC)^W=HWPYUR]FC\
M-6FHZ1HL45G,T;Q17(@EFF&\L%F9[C:64#*0P J0A)^YM?\ V,_@[X@\ 7'A
M(?#_ $33;6:T%K'?:;91PW\.WE76YVF0N&4,6D9MY+;]X9@?D#_@H)\!?&G@
MOXTP?'/P3:W>H6ZBVO[VZMX$NGTB]M(P%N7B\OB#R[=&+R;U5XVW[%*AAO\
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M6I7]SI7Q2TQ[N5]/MY=-N(;8RN$BDD6Y#E5SM!(BB4E54L$&[. !YA\ >/\
M@J9JO_8U^)/_ $5?UZ1_P2%81_\ "V,Y&XZ3C((S@7><9ZXW#.*\U^ I$7_!
M4K5BY"?\53XC?YCC(V7@[^[K]>U6[<TT9:\L&5]3LXOVI/\ @H]?^&?'%W+=
M:/;ZY>:6MI8R.GEVMC'.T=N&)8HLC6^79"#F:<KY98$?>7Q._8O^$OQ.\+/X
M?N/".F^&69_-AU#PO96]A>1]=R"14P493M*LI4\'A@I7X=_:@^&?C_\ 93_:
M=F^,?A&PFO?#[7\NL0ZJ\!NH(GN&*75K=,JJ(2[W#1H6^9DD4I(9 Y7L;_\
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MP_X5U#X>7^C:#I>E7VL2:M+J5Q96<<,M])FU.^9U ,ARS_?S]]JY+X^,)O\
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M#?QL^)VJ_MT?$C1H_ OPOATW76C_ -.ETF-KRZNB98HXYKRY$<:B&,+&JM*
M$&[+KD!5'WE:1<FD[Q/VC6X2149/G1NCJ1MZ9!SWS[5+7&_"7P?>^!?A;X,\
M-Z@T#WVCZ+9:=</;2N\?F0P1QOL8JK.I96(9@I(/(&<5V5<9WA1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $YHYI:
M* "BN6\9>/$\&FR!T'7-;^U"0C^QK+[3Y>S;]_!&,[N/H>E4O!_Q5L?&&N7.
MC#2-:T74X+?[5]FU>S\AGBW;=R_,01GB@#MJ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "DHKQ'XA?MI?!WX5^,KWPIXG
M\8?V=K]GL^T6::;=SF/?&DB9,<3#!21#G./F SGBFDWL)M+<]OHKROQE^TEX
M-\(_ ^Z^+$4]SXA\(010S";1T5Y9%DF2' 21DPRN^'5BI4HX(#*17:>!_&UC
MX^\$Z!XHT^*>#3M:TZWU*%;H*LD<<T:R*L@#$!@&&0"0"#SWHLPNC?HW5#]J
M3(^;KTR#_GCOZ5QGQG^,&C? WX<:SXUUVTOKS2M*$)FAT](VG823)""HD=%P
M&D4DEAQG&3Q26HV=SNHW5SW@GQI8^/?!N@^)=.BN([#6K"WU&WCG5?,6.:)9
M45PI8!MK#/)&>YXSQGB#]HKPUX;^/'AGX37-EJDGB'Q!I[ZC9WD,<1LA&BSL
M59S('#8MGP A!W+SUP[,5T>J;J-U1?:E^4$$$DC''& 3Z\].W^-#7*!F7YL@
M$\J0./<\?Y-2,EW49J-91M#GA2,[N,5P^E_'#P3KGQ4UGX<66MK/XST>T%]?
M::+>5?)@*PL'\PH(V&+B'A6)_>#CKBK";L=[17!ZK\<O!.A_%31OAQ?:VL'C
M/6+0WUCIIMY6\Z +,Q?S AC48MYN&8']V>.F>T^V*JAF!4%E4$D<YQ@]??\
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MV?:C/M40G4YY^[G(SR,$C/Z&FK=+(S*N25&2,@$>F1U&:G4JQ/GVHS[5!]H
MZJP&,G) Q^M+]H#9*@NHXW*01D$@CKU!%&H$]%<]X7^(/AOQQ8RWWAS7=-U^
MRBE,#W.EWD5S&) %)0M&Q 8!T.WKAUXYK<\[D (QR3Z?G_GUJK$W1)NHW5&T
MR+MS_%PO'6E60,I;:1@]ZG4HDHKE?%WQ4\'?#][5?$_BG1O#GVKS/LYU?4(;
M03>7MW[/,9=^W>N2N0,C.*V]-UJSUG3K;4-/N(KZPNHDGMKJUD66*>-U#*Z.
MI(*D$$-G!R#T(JK$W1>W4;J9YW( 1CDD=OSZ_P"<TW[0O)4%Q_LD=<XQU]<_
MD:D"7=1NJ+SEW8 R?J,]<4>>NW)PHQGJ/Q[TK@2[J-U1&X3<!@G/?C'TSZ_X
M&D^U1[E5OD9L_*2,\?C_ "_&GJ439HS1TKE_%WQ.\(^ /LI\4^)]'\-+=%Q
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M?^ =S_\ )%'^KN8?RK[P_LZN?I+N_P!DT;O]DU^;7_#Q[XE_] ;PM_X!W/\
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MXT>+/AW^S?\ LV>"_ 5U'IOC'QU8:/I]MJVI6PFAM(E@ME8L&#D,9)H%R8I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGYBRML+Z7"SYK'U711161L%%%% !1110 4444 %%%% !24M% !1110 4444
M%%%% !1110 4E+10 4444 %%%% !1110 4444 (!1BEHH **** $VBC%+12
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M#7_H->*?_ NV_P#D>OK*BC^U<=_S]?WA]9K?S,^3?^';7PU_Z#7BG_P+MO\
MY'H_X=M?#7_H->*?_ NV_P#D>OK*BC^U<=_S]?WA]9K?S,^3?^';7PU_Z#7B
MG_P+MO\ Y'H_X=M?#7_H->*?_ NV_P#D>OK*BC^U<=_S]?WA]9K?S,^3?^';
M7PU_Z#7BG_P+MO\ Y'H_X=M?#7_H->*?_ NV_P#D>OK*BC^U<=_S]?WA]9K?
MS,^3?^';7PU_Z#7BG_P+MO\ Y'H_X=M?#7_H->*?_ NV_P#D>OK*BC^U<=_S
M]?WA]9K?S,^3?^';7PU_Z#7BG_P+MO\ Y'H_X=M?#7_H->*?_ NV_P#D>OK*
MBC^U<=_S]?WA]9K?S,^3?^';7PU_Z#7BG_P+MO\ Y'H_X=M?#7_H->*?_ NV
M_P#D>OK*BC^U<=_S]?WA]9K?S,^3?^';7PU_Z#7BG_P+MO\ Y'H_X=M?#7_H
M->*?_ NV_P#D>OK*BC^U<=_S]?WA]9K?S,^3?^';7PU_Z#7BG_P+MO\ Y'H_
MX=M?#7_H->*?_ NV_P#D>OK*BC^U<=_S]?WA]9K?S,^3?^';7PU_Z#7BG_P+
MMO\ Y'H_X=M?#7_H->*?_ NV_P#D>OK*BC^U<=_S]?WA]9K?S,^3?^';7PU_
MZ#7BG_P+MO\ Y'H_X=M?#7_H->*?_ NV_P#D>OK*BC^U<=_S]?WA]9K?S,^3
M?^';7PU_Z#7BG_P+MO\ Y'H_X=M?#7_H->*?_ NV_P#D>OK*BC^U<=_S]?WA
M]9K?S,^3?^';7PU_Z#7BG_P+MO\ Y'H_X=M?#7_H->*?_ NV_P#D>OK*BC^U
M<=_S]?WA]9K?S,^3?^';7PU_Z#7BG_P+MO\ Y'H_X=M?#7_H->*?_ NV_P#D
M>OK*BC^U<=_S]?WA]9K?S,^3?^';7PU_Z#7BG_P+MO\ Y'H_X=M?#7_H->*?
M_ NV_P#D>OK*BC^U<=_S]?WA]9K?S,^3?^';7PU_Z#7BG_P+MO\ Y'H_X=M?
M#7_H->*?_ NV_P#D>OK*BC^U<=_S]?WA]9K?S,^2V_X)M?#?MK7BC_P+MO\
MY'KZ ^%?PNT[X2>!-.\)Z3<7=QIUCYOE37DJO.?,D:1LLJJ/O,W:NTHKFK8S
M$8A*-6;:6NI$ZTZBY9,05"T;\D!22<XR1].?H!4]%<9A:^A!]G^8MPQ]\_Y_
MPY]:BCL6C9V#J6=BQ!4[0>@(&>O SZ\],U<HIW"Q7^R[=NUMN !QQW]J#:[@
M"54$'=C P6]3Q5BBBX)6(/)9F!(7 .1[<8_J:8UKYF&(5''3:3VR!Z$\&K5%
M+K<?2Q5>V=DV[\#(QS]T Y!''7_/U1;1T9%&UD&27;[W7@  8 Z?ET.<BW11
MTL'6X4444 %%%% !1110 4444 %%%% !1110 4E%1"X5F(!!*G! (XXR,_Y[
MT[7$VEN2[J*@^U1[PN<$D@9[D'&/\^E2>=G'R-S[?3_']#4Z@G<DHJ(7"G;U
M&X9&1R?PJ6F,**C\X;7;:0%YYP/\_C2+<(S,.A7&>AP3VXH EHIBRAFQ@COR
M,>G^-)YO7Y&X]OK_ (?J* '[J-U1^<"N55FY(X'IGU^F*:EV&)^1UP< L  P
MSC(Y_P#K_F,H1/14+72(KL3A4SN)( &!GO[4+=(ZHP.5?&T@@@Y&>WM3&345
M#]J1E#+EU/=?F[9SQ[?S%*;C#A=C?7CCV]:8KHEHK'\2>+M'\'Z3<:KKNIV>
MC:7;[?-OM0N$@@CW.$7=(Y"KEF"C)&2<#FK.F:W9:UIUKJ&G7$=_874:SP75
MJXDCEC8;E=6'#*1@@C/446871?HJ-9<J#M;GVS36N%VJ5!?=G;@CG )XR>>G
MZTADU%0M=(BNQ.%3.XD@ 8&>_M2_:$W*O0MV/!QSS@_2@"6BHUEW9PC8]QC/
MYT+,K9P"<'''X?XT 245%]H3<R]2O8<G''.!]:%N8W52&'S#(Y!Z=>E $M%0
M"Y1FP,Y!(/MB@74;,%!R<[>O?&<?E2U%=$]%1^;T^1N?;Z?X_H:%F5LX!.#C
MC\/\:8R2BHOM";F7J5[#DXXYP/K1YXQG:WX<GCKP* ):*C\WI\C<^WT_Q_0T
MJRAFQ@COR,>G^- #Z**2@#S/]I!O^++^(1[6_P#Z415Z5YB_Y%>9_M',&^"_
MB+U_T?\ ]*(J^8O^'F4C9*_#@8_[#?\ ]SU$YQI_$>;C,QPV7V^LSY;['W3Y
MJ_Y%'FK_ )%?"?\ P\RE_P"B=K_X.O\ [GH_X>92_P#1.U_\'7_W/67UFEW/
M,_UBRW_GY^!]V>:O^11YJ_Y%?"?_  \RE_Z)VO\ X.O_ +GH_P"'F4O_ $3M
M?_!U_P#<]'UFEW#_ %BRW_GY^!]V>:O^11YJ_P"17PG_ ,/,I?\ HG:_^#K_
M .YZ/^'F4O\ T3M?_!U_]ST?6:7</]8LM_Y^?@?=GFKWXI/.7CU/0>OM7PI_
MP\RE[_#M3_W&O_N>M;P1_P %"&\;>-M T%O :V?]K:A!8?:?[6\SREF<(7">
M0 2"PXS^/:E'$4Y=2X<09=-QBJFK\C[9HI%.5!]J89AM+]4 SNXQ72?1$E%0
MO=1QDACCC/UX)X]>A_*@7*]P5SR W4C'4#K3%=$NZC=14/VJ/J,GD#@=<G /
MTSW_ *5.I1/14/V@;B-K9 R>/Z],^U(UT-ZJ$9F)P0!C'N<_T]15$W1/14*W
M4;%0&'S$@<CG'7\NE34AA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+X?T[PY^T1+!I6FV>F0MX5)86<4<09OM2@':._'\J]?P.*^5?VD/CA_PS_\
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MY_\ <]']BX[_ )]O\/\ ,/J-?^4^Z_,'O^5'F#W_ "KX4_X><'_HG'_E<_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 97Q+\33M_X*C_  B8?.)?"LY##/3RM3P 1UZ-R<?>'M7VWCBO
MCO\ :4\$^)O"?[3OP]^.&@^&-1\<:3HMD^FZMI>BPK)?VZ,9(DEB3?OE++?2
M'8J;5\ABS+ORND;=3*=^AC_MT+YO[0G[*XR'V>*CG<>,_:].&<9YXR,#U-<#
MX+^/_P ;+C]LSQQ:+X#U#5]1@T>)I/AX_C.W6TTF+99M]KCE9?*9L-'\J*#_
M *6WHV>^\1Z;XH_:\_: ^%VLV?@'Q5X \*_#VX.L7=]XST[[')>2O)%(EM#
M6/F-NM5RX<;=Q+;<1B;,UBY\2_!/]OCX@?$*]^'7C;Q5X9UGP];V>G2>$M);
M4-[%+)2QPP5-K6LH*L0_W&V[65CII8RLSU?Q7^UEJ]]\4M;\"?#'X7ZA\3=1
M\.+G5[Y-2MK&QMG*ILCCN&WJT@9G1D?8P:.3 (1RO*>(?^"@NAZ?^S?HOQ2T
M7PO-K,EUKL?A^]T>XO?LK6%U]G>=LS")Q(JA%*D+\RR+N"MN4>+^-/V<M+\!
M?M _$35/B3\(/%'Q5\+^(]0FU30M2\(12O-:R._GS0RPVTZ-C-R8Q),03]G7
M8C>8VVI\;OA)=Z]^R#:Z9\/_ ()^)?!-LWCS^T;7P^5N=0OYH!8SQB\FA)=H
M-[*L31MP"NX%A(I*M 7-4/0?VVOB#'XO_9IT76/B/\//$'AFTG\71G3=)76[
M>VOG@^Q7$D5Q<8MYQ$2I=7MV7<C 9?'->E^)OVPM>TOX_>*/A+X4^%]]XRUO
M2;:*>VEL]6C@B??%!*WG%XMEO$JRE0Q9R76-<9E^7$_X*6>!?$7CCX$^'-,\
M-:!J'B._C\3P7,MMI-F]S)L6TO/G:- 6V[B@SR3D9ZTOP[\$>(=/_P""D'Q,
M\2W.@ZE:^&+[PS!%:ZV]H_V.>0)IX:)9L;6.4;@\_*_?H_=Y;C][FL>D_L\?
MM7:+\=?"?B:^U'3I/ ^M>%I7C\0Z9J\A3^S0-_[QIG5 %41S*VX*4:)PP P6
M\O?]OG5KGP?=?$/3?@]K4_PCL[N.UD\2W6K6MM.RF6.)WCLR#YA65O+4I(49
M@0SJ58+B?L^_!G7M:\9?M<Z/K>DZEX9L?&6J7%I8ZG>:?(D<RR2Z@@GAWE5F
M55DB?Y".3VS7B'@7X*^%OASX%ET7XD_LR_$+Q/\ $"Q68C4-#-W<:;J&]7>$
M-/;S^6@4/Y3!$E "!L%F*U-H%WF?HGXL^)EGIGP=U?XBZ1#_ &OIMOH$VO6X
MW/;_ &N)+<SQJ2R[D#)ZKD9Y':ODC]F7]G#P[^UAX'O/BS\9;63QAJGB2]N1
MIEM_:UVMKI5E'/)&;>) ZL@$PF 7>Z[!'MVEI!7U=I/P_L_$?P(M?!-]H]UX
M3L;OPVNBRZ1;7XFETR&2U$!MUGY\QT4X\P@Y(W<U\R? 'X@>/_V3_!I^&'CO
MX.^+-?@TF66?1]7\"Z=_:T%U;O<3,PD(==CA\LA;:[1N@:-2F75^PVFST77_
M (F:;^R+H'@3X.^&-(\0_%/QA>QM;:)I]S?0-<_9A)D&ZG _<PJKS)&WE! M
MLRY14+UN_"O]J2^\6?%"X^&OCGP'>_#;QR+0ZE;6=QJ,-[9WEME1F&Y3:9)<
M>82JJ0!%)EOD;'B?Q LOB7<?%GX/_M&3?#'6I5L=+FL]=\%:?,EUJ=C"[SQ1
M3!?E>=WCOO,,"PJ8_)VNRYRNYX)\,^+OVA/VRM"^+]WX+\0^ _!GA31Y=+M5
M\46BV][J%PT4JL#;%@T2_P"GN=X#H?LN,@OA#E0<TCJ_V9?VOM=_:9U:.33/
MAG?:9H5K=RP:EK1U6.6UL_\ 1UEA"%HU:>5VW(Z*,1*T1+$M@<'X:_X*&>+?
M&GP\USQMH'P+U35-(T&9DUBXAU=1;V\6$.^*0P!Y7 +F550B$)&Q;#,5Z+_@
MFCX'\1>!O@;XCT[Q-H.H^';M_$T\L=GJUF]O(\1L[0"78X4X)5P>!R&ZU\M_
MLQ_$;Q3H7[(_Q,\&:-\*O$WB]?$MW?V%GJFAVYN(;>>2S@@G2X5%W1>4IA=&
MVXE+,,J5=A?+'WO(QYI^[YGV/X@_;@T6WF^"=SX>T237-$^)VI'3XKR:Z:UF
MTTK/! Y>+RW$C+)-*#@A/W60Y!!KK/%?[1I\._M3>$?@V?#OVQ/$6D-J8UC[
M<56VPEV3'Y'EXD!^R==X/[P\8 S\L_$3]G3XA?"WX/\ [.FJ:-H5QXOU7X;W
MSZGJF@V3XO'>YOH+HP((PXE2)T>(NA)R$?84+%>ATNX\8_%C]OSX<>/G^&GB
M[PAX3M=&GLXYM=T]XFV""_423!05MW,LK((V;<46%^!*HI<D33VDCUC5/VOM
M3U+XG>*O#G@'X8:IX_TCP=-%!X@U2SOX;6XMI-TOF);V<H#W;(L,@55.7D7
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M+XA^Q1\2O$?[.'PKU+PSXF^#'Q4O=0N=;FU)9='\*2O$T;0P1@,9&5@V8FR
M,8(YKU3X>^"/$.G_ /!2#XF>);G0=2M?#%]X9@BM=;>T?['/($T\-$DV-K'*
M-P>?E<]>FT^66YC#FCL=9\+_ -M[POXX^%OCKQ3X@TN[\(:GX(W_ -OZ)=MF
M:%BTB0K$[B,-)(T4D2QL$?S%"E1N4M\D?MH?'[Q=\:OV<_"MWXC^%6K>!M(U
M'6XM0T?5'OENX+R-+:Z0^8RQQM;NPDC:(%")%$C(2H!;K=._9^^(/CO3_P!L
M71+3PYJ&EW7B/Q!!<Z,VJP/:0:KY.H7-P1!-(H#;D5 &XCS*HW ?,O(_'#5/
MB3\6OV5_AU\/;+X%^.K&\\*36-O?W5QI<I$KP6LUM!Y,>PNZN/,=W9=L1V L
M?,1C<8QB]")2<MS[=^.G[2R?"'Q!X9\(:)X8O?''CWQ&[#3-#L)XXCM1@&EN
M78EHHRGF$/L*_N)<D!<UQ=C^V9<Z;?>+O#?CGX<WW@/QSHF@77B.WTNYU.&Y
MM-3MX8MX2&Z0#+DB3<%C8*L4A)RC!>?_ &EO ?B3PK^TU\.?CAH'A;4?&^F:
M#I\FE:II6AQ*U]:JYEC2>)-WF3%EOG/EHH $!W.H8%?-?B1X+\;?M,?%CQ1\
M4(? GB7PGX<\/^ =6T?3;'Q!8B/4M7NGLKF/RTM,[TR;]L$+(K&W"Y#/MCQ4
M8O<UDYK8[:'_ (*%>()/A[I7Q(G^"NK1?#N6Z%IJ/B"'58S]F?SV0O"AC!FC
MVB(>8WE)YVZ'=D GLH?VUP/BIX(T._\  -[H_@'QM>R6GAWQA?WZJ^H;=B)(
MM@L9D2.266%$,A4E)5E( R!Y?_PK?Q?_ ,.M?^$5_P"$8US_ (2K.?[$^Q3?
M;MO]M>=CR=N__5\YQ]SYJC^)WPU\8ZDW[%'V7PSK=TNA?V>=<$>G3,-/*?V;
MN%QP!"!LF'SCHI_NX+M .:9[S\4OVI+[PK\3X?AKX%\!WOQ(\=?9Q?W-E;:C
M#9VEG;$M\TUR^[RI,;"%=0")(\-ET#?/7Q[_ &R/%7CSX!>,H?#7@_5/"OB7
MP_>KI_BZ]LO$"QS>&G6]A$!AEC"M=+<;9HR82I4QMU5D=I?VD?V>8[/]J;4O
MB%XO^&GB/XL_#OQ!I\5K+:^& YN].O%B"(1##*DDJ@6@.YMJ*;KAB4 :CJOP
MEMO$W[,OQPTOX9_ SQ)X!BO1I(MK?7KB<W^KBVF6>7_0YG=HO)3>5*,QF+ #
M+#8'[HO?.LM_VR/'?P;_ &;?"?B[QE\++B[MY8=(T^QU.X\3PS2:V9;.65KZ
M1EB=H\_9XLB0;LW'7Y:H?ML_$*/QA^S3HNL?$?X>>(/#5I/XNC.FZ2NMV]M?
M/!]BN)(KBXQ;SB(E2ZO;LNY& R^.:X#X[OXN^+G['/@?P1H_PI^(5EK_ (5O
M-%M+J+4?#KH9?+T^YCDF@"%F=%:- 2ZC_61<<G'M_P#P4L\"^(O''P)\.Z9X
M:T#4/$=_'XG@N9;;2;-[F0HMG>?.T: MMW%!GDG< >M%XBM(]R^+GQ)\8^"K
M?2H?!7PXO/B)JEZTTC0QZE%IUI!!&R+O>YF!42,94V1X)<"0CA&(^6_V@OVC
M++X]?L:_&G3[G1W\+^,?"^H6>F^(/#UQ*EV+.3^TXXU83* DJ'RG^88YC<8P
M 6T?VT_#_BCQ%\>O $7B+P-XO\>?!6VT^6[O-'\*V;W$C:D!.OF'R)%='4R6
MVTNX!7S0F<RUX!X%^$?C8_L[?M+VT7PN\4>'AKEQHC:+X>N-/NY)1 -0=S!%
MOC$EP(8W4,P!) )[TXQCRW83E)2LC]%OV;(V_P"&>/A9A54#PII9V@]/]#B
M ( XZ]J^5=(T/_AM[]J3XD:?XWBF'PW^'+_V4GA6/5;B.&YOEEN8H[N0 !=V
M!='?&R,H6!/F4.6^M/@!9W>B? GX;V%_97%G?VOAG38+BTN%V2PRI:H'1E)!
M# @C'K7S/;^&_&W[(?[1/Q \4:?\/M9^(/PT\?7BWEU<>'5-[JUE=D7,Q MQ
MM)3S9)EZ;=DL)\W<K(^=S2Q[!X9^#NA_LJ^%?&%]\-M#\1:ZNIO:&T\'PZ@)
MH%N,K #"9N8A(7C:>61FVHF>%C"BA\-?VH=4U;XS1_##XA?#Z;X<>*M2T_\
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M1;,L<X5 L)0JQC(.& 9-N7W?4-9M6-XNXM%%%24%%%% !1110 4444 %%%%
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M#I6BZ9$(;:WA)RBYR<L<LY)Y9F)9R2S$DDGI",TM%+<84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 (!5?[/*RR R;=W38>1D<\_4]AV%6:*
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MB@!N*^6/VD/@-)\?OBQ9^'5UI=%>VT5-26YEM1=#*W$J;-A91CYQW[&OJ4S
M8R"/7D<>O>O-@V?VE.A_Y%+KCC_C\]:UI5)49JI#=%PFZ<E*.Z/E_P#X=CS_
M /11U_\ !)_]T4?\.QY_^BCK_P""3_[HK[MHKU/[8QW_ #\_(Z_KM;N?"7_#
ML>?_ **.O_@D_P#NBC_AV//_ -%'7_P2?_=%?=M%']L8[_GY^0?7:W<^$O\
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MS9]%HHIWN"5@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!-U&ZH_,4<\GVQSV[?C4AQ0 M%%% !1110 FZC=43742[\L%V@
ML2Q &!U//89'/O2^>N<8/3/(Q^AY]?R-+49)NHW5$+J-LX#$KC<N.5!&02.M
M*MPD@1D^=&Z.N-O3(.>^?:C4"6BBBF(**** "BBB@ HHHH **C:8+MR#EC@#
M\,_T/Y4U+I)%# _*>C9!'IU!]>* )J*** "BBB@ HHHH **** /,OVD#GX+^
M(O\ MW_]*(J]+W"O,_VD#_Q9?Q%]+?\ ]*(J\:_X>/\ PYSQH'BC'_7K;?\
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MUW&G#<-_=R">_0#J>#T]#2U&3T444Q!1110 4444 <GXR^&_A_Q_]C.O:?\
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M9./_ .?,@^JU_P"0^L<T9KY._P"'DGPU_P"@%XJ_\!;;_P"2*/\ AY)\-?\
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M?\/)/AK_ - +Q5_X"VW_ ,D4?V3C_P#GS(/JM?\ D/K'-&:^3O\ AY)\-?\
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MF5/0@G)_NC@]<<C%43=%BBHA.&7<H+ ],8^;C/'K4M(84444 %%%% !1110
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M^">^K?"%[77+7XA:3>"VU'3!IDG^@+_:BSM/*V-L<>7$&'^;SF5=F"&KT/\
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MC&!<I31^@WP]\=)\0?!]EK_]AZWX;%T9!_9GB"R^RWT6R1D^>+)QG9N')RK
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M %_DKX.^*OPWU'0/C1XK_9WTB[U?3]+\;^,=+UK3(--L'CTV'3Y!=/=%+5)
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M?9>--"\6_&7]FMM-^(GC3QUK?]J:5/KLGBF]DO+*QOII[;?;6?F("&5X79F
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M@)\Y 4* H[ZBE=CLCQCX9_LL^&?AEXG76H=5\0>()+%7@T&U\1:F]_;Z!;L
M&ALD<9B4JJ)DEGV1*-W+[O9Z**+W!*P4444AA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 59+1F5@K@$Y(++G!Q
MC) QGOUI#9MYC'?O1L[E?KSZ>W &,=/QS;HIW%8JM9[VYV@8QQZ9SCWSQFG+
M!)MP[CM]WIQ['_/\ZL44#*K6@*_=4DYRW<9QT('L/R'I2M:EL$A68]=Y)[8X
M_P#K8JS11=@5?LIXPL:[27&T8PYSD]..IY[Y-+]E)9V)Y;&<$\'/OZ?SJS12
MV K"W?=(?,;YCG.<X], C Q^O>E^SON4F3/KU'Y<_3\CZU8HH A\E_\ GI\V
M>N#Z_7TX_6HUMY?,4NZD8&['=@>N/?CZ8XZYJU10!!]E'3MC'OTQUZ_K2+:E
M7W;R3G)Z#(]#QSBK%%,"G):S.S',9#+M^8$X]L9YZ^W0?A+]G^4;E1ST)8=0
M>H_^M[5/12$5EM-B\;0Q(+'DY/KUZ_X#KBE6"3;AV';[O3CV/^?YU8HH'H5$
MM&W*TA#,,^X&3TY'8<=LT_[,5X3@=SGGL/3T JQ13OU%96L56MY#&JCRP5.0
M>>#GJ/3C/'OCI3FMRV"0K,>N\DXXQQ_];%6**0RLL#_/\P4YR#DMVZX/3Z#T
M]Z8+%E;<LFT[@Q(R<^HY/3&1[9XZ<W**=Q614:U?*X"_(,+N8GH"!U'!Y(SU
MQ3F@D^3D,<Y)R5[=<#KSV/K[59HH&5Q;G:WW0>@ Z;1T'3_/-)]D^A 8,%R1
MT_'I[59HJ16176%_GY"G.0<ENW7!Z<]AZ>]#0O\ )R&.<DY*]NN!UY['U]JL
M44QE7[(689 (484[VR.WY\]>O;WH6U/S=.>GS$D?3TQDU:HIW%9:%=H'^3D,
M<Y)R5[=<#KSV/K[4?9R, 8 487!Z8Z#'XGFK%%+K<>ZL5_L[=2<L#D<_7\.A
M]*;]D964JV1U;)ZG_#I_WR*M44"LBO\ 91\W"X8Y/&,G P3[\=?84C68;S.
M-[;C@GD\#.>H.!C\*LT4!H5Q:[6W;R3G/89'H>.<4ODLOW<9QCD]?;/]?<U/
M11N/9W"BBB@ HHHH **** &8Z&OBW]M?X6^)_BY\0M)TKPIIG]IZC!IT-R]N
M9XH2(DFG0OF1E&,RKW['\?M+S%"D[A@=?PZUY=Y*_P##1K(8]R?\(EQN;/'V
MSIM(Z5TX:M+#U%5CNC2G4=.2E'='YY?\,2?&G_H3/_*I9?\ QZC_ (8E^-/_
M $)G_E4LO_CU?JYY1]ORH\H^WY5]#_K+C.R^[_@GI_VE5/RC_P"&)?C3_P!"
M9_Y5++_X]1_PQ+\:?^A,_P#*I9?_ !ZOU<\H^WY4>4?;\J/]9<9V7W?\$/[2
MJGY1_P##$OQI_P"A,_\ *I9?_'J/^&)?C3_T)G_E4LO_ (]7ZN>4?;\J/*/M
M^5'^LN,[+[O^"']I53\H_P#AB7XT_P#0F?\ E4LO_CU'_#$OQI_Z$S_RJ67_
M ,>K]7/*/M^5'E'V_*C_ %EQG9?=_P $/[2JGY1_\,2_&G_H3/\ RJ67_P >
MH_X8E^-/_0F?^52R_P#CU?JYY1]ORH\H^WY4?ZRXSLON_P""']I53\H_^&)?
MC3_T)G_E4LO_ (]1_P ,2_&G_H3/_*I9?_'J_5SRC[?E1Y1]ORH_UEQG9?=_
MP0_M*J?E'_PQ+\:?^A,_\JEE_P#'J/\ AB7XT_\ 0F?^52R_^/5^KGE'V_*C
MRC[?E1_K+C.R^[_@A_:54_*/_AB7XT_]"9_Y5++_ ./4?\,2_&G_ *$S_P J
MEE_\>K]7/*/M^5'E'V_*C_67&=E]W_!#^TJI^4?_  Q+\:?^A,_\JEE_\>H_
MX8E^-/\ T)G_ )5++_X]7ZN>4?;\J/*/M^5'^LN,[+[O^"']I53\H_\ AB7X
MT_\ 0F?^52R_^/4?\,2_&G_H3/\ RJ67_P >K]7/*/M^5'E'V_*C_67&=E]W
M_!#^TJI^4?\ PQ+\:?\ H3/_ "J67_QZC_AB7XT_]"9_Y5++_P"/5^KGE'V_
M*CRC[?E1_K+C.R^[_@A_:54_*/\ X8E^-/\ T)G_ )5++_X]1_PQ+\:?^A,_
M\JEE_P#'J_5SRC[?E1Y1]ORH_P!9<9V7W?\ !#^TJI^4?_#$OQI_Z$S_ ,JE
ME_\ 'J/^&)?C3_T)G_E4LO\ X]7ZN>4?;\J/*/M^5'^LN,[+[O\ @A_:54_*
M/_AB7XT_]"9_Y5++_P"/4?\ #$OQI_Z$S_RJ67_QZOU<\H^WY4>4?;\J/]9<
M9V7W?\$/[2JGY1_\,2_&G_H3/_*I9?\ QZC_ (8E^-/_ $)G_E4LO_CU?JYY
M1]ORH\H^WY4?ZRXSLON_X(?VE5/RC_X8E^-/_0F?^52R_P#CU'_#$OQI_P"A
M,_\ *I9?_'J_5SRC[?E1Y1]ORH_UEQG9?=_P0_M*J?E'_P ,2_&G_H3/_*I9
M?_'J/^&)/C3_ -"9_P"52R_^/5^KGE'V_*CRC[?E1_K+C.R^[_@B_M*J?$7[
M%G[._P 0OA'\4-4UCQ7X=;3-.N-'E@29;RWF_>/+ X3;'(S9Q$V>,<BON 5$
MUJK8SD=SM8J2?7@U-7@8S%3Q=5U:F[//JU95I<TMSE/B-X#;XA>#K_P^-=UC
MPX;H1_\ $UT"[^RWT.R5)!Y<NT[,[=IX/RDBO![']@72--U?5-5L_B_\6K/5
M=5\O[?J%OXE1+BY\M=D7F2"#=)L7A=Q.VOJ2BN6]E8PLKW/'?BM^S)X?^*?B
M:T\3C6?$GA'Q7;VO]G?V]X7UB2SNI+/>\GV=@0\93S)6D^[NRB#=CBI/@U^S
M/X=^#6K:QKEOJ6L^)_%6K,!=^(O$][]NOVB555(1*54K& @^4<G"[F.U<>O4
M47"VMSRG0?V=/#WAWX]^(OBW:WFI'Q)KMBFFW5M)+&;184%N 441APV+6/JY
M'+<<C'$:A^Q!X7AU2]N/"7C#QU\--/NYS=2Z/X+\0R6%D\Y;+3>5M8*VW;'L
M7$82*-0JX.?HVBA.P6N><?"/X"^$_@CI=[!X:LYFU#4YTNM6UC4;E[B^U.<#
M#33RMRS,2\A50J!Y)&"J7;-GX6_!O2/A)HVK6.EW%YJ,^L:I<ZWJE]J4B--?
M7LY'F2R!$6-<@(NV-%4!!\N22>^HHNPLCP[0_P!D3P9X?\=6VOV]SK$VDV-R
MU]I7@^XOBV@Z1=$DFYM;3;M20,\K*"2J&5BBKA-GN-%%#=P2L%%%%(84444
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M7_/K4E ";J-U1M,%.&&P>K$8I&G$?4=LCD<\$XZ^WTYJ;B)=U&ZHFN$3.X,
M."<?3IZ]>V:4S!6P48<X!QP?\/QIZE$M%%%,04444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 )NHW5']HC+;1RW]W'KG_ T>>O/RGC'/8@GJ#TI:C):*A%RI)!!
M&._&/IGU_P 14U,04444 %%%% !113/.&XC!R.3QQ^?X4 /HHHH ;OI<U7^U
M)N0 $ELXZ<D#.!SR<9Z<<&K%+4/06BHVF"[<AAG^?I[_ (>E24P"BBB@ HHH
MH **** "BBB@ HJ+[0N%*JS@]2/X1C.3^GYU+0 4444 %%%% !1110 4444
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M9>$+46$Q\&Z9>7":7(EJ/)86]SJ#E@0#OB:X9P"3)O?.\L13<$A1J,]C\/\
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MV3X?:?'8:AXFOTN%ANQ:6R3[;EF=8-TL&J;CN4NTCGYO.!?7_;0\0>&M:C^
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MLEG_ &:,_P"S1]30?ZF8?_G]+\#\;?\ A1_Q&52#\/\ Q2/^X+<__$5]C_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH PO$7A/3_&&DS:3KNEZ=K.E3A6FLM1@6X@
MD97#IOC<$.%8*PSC!4$8[0^%?A_X?\"::^G>&-#TSPYI\DIG>UTFTCM8_,*A
M2^V-0"< <D=AZ5T=%"T5A65[G%7OP;\%:MXH/B6_\(:!=>(_-BG&K2Z; UV)
M(P!$XF*;PR *%8'< JX(Q1XN^#G@KQ]J$=_XF\'^'_$5]%&L$=SJNEP74JQ
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MD8H ?14?G#@%2I;H#C)_7\:07"]P5SRH8<L,=0.OZ4 2T444 %%%% !1110
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M<TH50V">>U #Z*B6<9P593VXSGISQTZ]_0TGVE0&.#\J[L' _G_6@":BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BH6ND178G"IG<20 ,#/?VIS3*N,@C)QS^/^%
M$E%1B=#GGIG([C!(S^AJ2@ HHJ,3H<\],Y'<8)&?T- $E%1^<. 5*EN@.,G]
M?QI!<+W!7/*AARPQU Z_I0!+1110 45%]H3<R]2O8<G''.!]:1KI$5V)PJ9W
M$D # SW]J )J*8L@;/##''(Q3Z "BBB@ HJ+[2G?*],;N"<]..O_ .JI: "B
MBHFN%5%<\*W/) XZYY]J ):**C\X< J5+= <9/Z_C0!)140N%[@KGE0PY88Z
M@=?TH^T)N9>I7L.3CCG ^M $M%1?:$W*O0MV/!QSS@_2I: "BBB@ HJ/SE^7
MMNZ?7TJ2@ HHHH **** "BBB@ HHHH **** "BBDH X'XE:'X[U3^S#X*UJQ
MT4IY@O&ND4EL[-FW,4G3#^G45P7PWTGQ9I/QVN8_%^JV^JZJ_AK?'-;!=@C^
MT1K@@11\[E<].A%>\Y]:\P>?R_VD@QC<*?"6-W&-WVP_+G/7@U4=N6UPY>9V
M/4-M&VH?M$?]ZC[1'_>I<K[#Y9=B;;1MJ'[1'_>H^T1_WJ.5]@M+L3;:-M0_
M:(_[U'VB/^]1ROL%I=B;;1MJ'[1'_>H^T1_WJ.5]@M+L3;:-M0_:(_[U'VB/
M^]1ROL%I=B;;1MJ'[1'_ 'J/M$?]ZCE?8+2[$VVC;4/VB/\ O4?:(_[U'*^P
M6EV)MM&VH?M$?]ZC[1'_ 'J.5]@M+L3;:-M0_:(_[U'VB/\ O4<K[!:78FVT
M;:A^T1_WJ/M$?]ZCE?8+2[$VVC;4/VB/^]1]HC_O4<K[!:78FVT;:A^T1_WJ
M/M$?]ZCE?8+2[$VVC;4/VB/^]1]HC_O4<K[!:78E^]1M]*B\]%ZOG\:([I9&
M  8#GYB"!UQ6?+]J2'RO>Q8HHIC2!<<,<\<#-62/HIBR!L\,,<<C%)YO7Y&X
M]OK_ (?J* )**8L@;/##''(Q3Z $W4;JC:15QD$9..?Q_P *;YZGHK'C(P0<
M_K0!/13%D#9X88XY&*C:[1>Q/S!!C')/X\=>] $]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?/7[37[3%[\ _$7P[T/3O!8\8ZGXRO)K"QMSJ26)CN%:!
M(T#/&ZY8S 98J!@\]!65\+_VN;O7/C1-\+O'_P /;OX:^*;BV^U:<DE]'?P7
MZA'DE_?1HJ@A$=LC*YAD4LK@(WE/_!0I=67XR?LV#08K,:Q_;TPLUU NML\X
MN; P"81C?Y(? ; R,C -9OP/_P"$D\3?\% -6O/C5;V>E^-]'T%H/"UEIL!B
MTZ6$;E>:TG:4//NCFN6V,KG!FW>4;<+6T8Q<;G-*<E*Q]^B<'<=K;1QNX(/.
M.QH^T#<%VL#G!S@8X_7L./6OR&\!>&O&G[6GAOQ]XYOOA/=_$[7]1NKJRT[7
MI?&B6=IX=D,9GBBM[65@[)$UT'".^W:$0!?WF[U_XOZG\3[?X9_LV_"3X@:O
MJNCZSXNURYTWQ'/;7B"^N+5;I+9(WFB9HI5>"\5G+AR[JC,"=X9^S'[4^Y?C
M'\8-'^"/PWU?QMKEIJ%YI.EF#SX]-B229A+/'"I4,ZJ0#(&/S= >^ =OP5XT
MLO'G@W0O$UA'-#I^LZ?;ZE;I<!1(L4T:R('"L0&PW."1D'DU\/\ [8?['WPP
M^%_[./BSQ+X8TJ^TN]TO[+_9MK)JEU+;6,\MY!'<S11R2$>9-'Y4;,V5Q#$5
M ();R+]H[X-^#?AM^PQ\.=?\,Z+_ &=J_BN?0[[6+B6ZF=;F;^R[QG?$DF$(
M\^8[5VJ0W X&%&"82J-'ZJK>1M]TY;^[D ]NH/0\CKZBG+<(^[;E@,<CISS_
M "Q7Q-^W6H_X:"_95+N,#Q5P6R06-WIH!P/;\.3TKBY/A#H?QH_X*3?%?P_X
ML^WW>B+H%K<SV-O<R6T5XJ1:88X)6C(9D61Q*5SDO'$=V RE<A7M#]#1<!BN
M%8JPR&&"/IU_SB@W"K@;6W$9VXY_^OSCIZBORN^'OPIM/$7@G]I;P7K^KZ[K
MGA3X2G5)O">F7=ZT4,%TWVS_ $J00[/-D7[*,*<1_P"D3_)^];'V=^PKXAU+
MQ1^R9\/;S5;K[1/%:S62R[53;%;7,T$*_*H!VQPQKDCG&3DFB4+!&I<M?M+?
MM-W/[/\ !X>@L/"$GC#5M8CU"\2U_M..QABM;*$3W,K3.&.Y8FWA0I!$;C(.
MT-Z%\(_B!:?%3X<>&?%UF+?;JMC#<-%;W/VE;29E'G6YD 'S1N&1L@$,A! (
MQ7Q7\2OCA\*HOV^]8O\ XC&U3PSX9\+/H,%U+'/?V\U],P\V-HXD8<Q7=W \
M;J5W1D'YL!8_V*OV@/\ A$_@7\8_".CZK8ZV?A[9ZAJ_AJZNH?LYOK#%PZ.]
MH,3+'YL8=F+,X^UA3L(%')[GF+VGOVZ'UE^U+\6-8^"/P&\3>-M!M[6\U/2O
MLICAOHG>!P]S#"X*(ZMPKL>HYKI_A-XRN_''PG\&>)+V.WMKW6-#L]3N8K?=
M'%')-;K*P7()"@L<$GI7YGW/P+T*^_X)[:I\76NM;G\?:I>BZU#46U1G%X#J
MHA-O+&^4,88";+@R>:N=V,*?1OVAO&?B2']G7]ESP#X<DNFM?%FFV%K<0:3?
M_P!G7&H1?9+6W%D)FS&L<OVL@B167*(2,*<W[,GVK/T>-Y$K8)P0,D<$C/ _
M,Y ^AIPG4D##9Z8QG'&><5^9-U\'?B;\-;SQOK6@_"RZ^$/PYN/!&L6VNZ:G
MBR#6(KF5+&[DBF;<YD#"0PA/+^Z W9W%<E#\!]!M?^"?>C_&2*^UX>/='O3=
MZ=J":C(C6:?VH]OY$"@D0H/,>?* /YYW;L$QE>S7<?M6?K%]I3>%PPST..O.
M"/\ /^-'VI-I/S< G&TY('7 ZFOSR\:>(M5_:&^+G[.7PT\8ZQ?3>$?$W@VU
M\1>(+:PG>U759Y+::X*7"(WE^5OL8]JJ@*;Y2I!*LG2>$-'MOV9OV\?#WPV\
M"-<Z?X"\7:%+J5WHES>RRVUK<[9_WL"LXVO_ *#"NY]YQ(Z9QL"3[,KVA]T_
M:HL EL9&X>F.._3N*1KM%C9AE]K!2J<G)Q@?CD?GFOST_9%^$ND_M@>'?%WQ
M/^(U[K]SXR_M^XM=)U"SU:ZMQX>VI'<*;$-(=A26Y9D#[T3RU 4?/OQOVFKG
MPS\9/&_QGO?#WPLU3XE:MX/LWM-0\5WGB8V$7AYHX'79:61V^?%$\$\I4Y:2
M4SXRCQ%E[-\UA>U7+<_21;R-CCY@<9^Z?IU_SFE^U Q[T5I!C(VX.[Z'./\
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MZ?\  SX]0S:OX)\&7_P^U#P#X?US2-_@*[N-2AU$ZII]M$C[95C+O;NMNT#
M2%LY<&3>!O.5!S,^F:***S-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1^)OVT/''P?GL]-A\,^'=#BU."\C23[9+*ZV9*N=^S;_ *0_\/85]#+?0L4
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MER'($6,8ZGKWKH_VAOB\_P  O@[K_CHZ4NMC2/LY^Q?:/(,WF7"0<R;6Q_K
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MPYJ$NE:KJ5QJ5OI%I#=HH/E6\D^?.9<,&&!C*-RKJ3Z'^S;*J?L]?"Y2>?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#@_C-\'])^.'PYU7P9KEQ>6FFZEY'GSZ>Z+/^ZF29<,Z,/OQK_#7C
MOAW_ ()^^ -/U+1+GQ'K7BWX@V>@HJ:1I'BK66N;&R*E-ICA5$ &V-4,1S$R
M_>0X&/IZBJ4G%61#@I.[/)O#_P"SEH'AKX_^)OB]:7NH2>)?$%BFG75O-)']
ME2)4@4%%";]W^C1=7QUKQG5/^"8_PUO[&XTJV\3>-M*\-27[ZDF@6>KQFQBG
M9=@8120OEEC_ '8=LMLX))^:OK^BCF8<J/GSQ]^Q/X&^('A_P)8SWVM:1JG@
MVSM['3/$6CW*6VIB&!%6-&E"$$!E$BG;E'&4*AG5G?"_]BCP)\*O'>O^*;*]
MUO6[K7]*DTG5;37[M+VWODE,332S*T>Z265XV9RS$'SI   0%^@:*.9ARH^2
M9_\ @FG\-)M%U;1%U_QI!X?O;O[;!HT>M 6EA-N4>;"GE<R>4IAW2^8=CMSN
MPX]7\9?LN^"OB'\&]#^&OB*VNM0T+18((;&;[28[F%X(#!#/NC"*9%0G@J4R
M>4( %>OT4<S#E1\V6?["_AEM0N[W7/'/CWQC<2:7J&F6I\2:VMX+!;V$P3R6
MX,0"L8V90&#)\V2A*KCU?X,_!_2?@?\ #C2O!FAW%Y=Z;IIG\B?4'1I_WLSS
M,"R(H/SR-_"*[RBDVVK#44G<Y+XA?#30_BMX1OO"OBJQ_M3P]?*BW5F)Y(?,
MV2+(@W1E6&&5&RI!^7'0D5X?HW[ ?@VQ;PY;ZSXP\<^-?#^A2I-;>&?$^M+=
MZ4SQILA+6XB4;8P,*BD+C*D%"5/T[134F@Y4[GE&O_LYZ#XB^/7ASXM7&I:I
M'XAT*R-C;6D,D0M)$*W*EI%,9<MMNI.CJ/E7CBD^-W[-OA?X]#2I]>N-3T_6
M-%=I-'UK1KQ[6\TUV>-W>%@2NYC#%\S*Q7!*E3@CUBBE=CLCQ7X/_LJ^&/@W
MXEU;Q1::IKWB?QAJ:-!<>(O$^I/>7CPE8U$3$!591Y,7)7?\N-V,*,>Q_8Q\
M,Z#\6=0\?>'_ !5XR\-7NIZO'K.I:3I&L^3IU].LAE<31%"9$=V<LC,<;V"%
M%XKZ"HI\S(Y$>'_#3]DGPK\*_@SXK^&6DZKK<V@^(Q=BZN;R>%KI/M$ @?RV
M2)4'R*,94\^M4YOV+OA_?? ?3/A+J0U+5?#>FR2W%G=7%T$O(;B1YW,X>)44
MNIN9=H92GW<J><^^44<SO<KE5K'@O@/]D+1O!GQ TCQCJ'CGQYXWU71HITTQ
M?%6O-=Q6CS($DE151/F9-RD'*$,"5)52O+?\.\OAY_PI7_A6']M>)_[!_M__
M (2+[5]KMOM7G^1Y'EY^S[/*V?P[,Y[U]1T4<S!Q3/#_ (R?LE^&_C)\0]!\
M<3:]XE\*>*=&M9+2WU3PSJ(M9C&X<;2S1O@*))<;-F?-?=NXQQ?A?_@GC\//
M"GPX\<>"K76?$TNF>,&LFO[F6ZMQ<Q?9)S/#Y)2W5%&]CD,C9!KZDHH4FA.*
M9S?@?P7!X"\$^'O#-C-)<V>BV$&G0RW9W2R1Q1K&I8C W;5YXZFO,/BG^R%X
M,^*GBZ#Q>;K6O!WC:(+&/$WA'4&L+XQ!&3RV(!1OE;;O*;]JJN[ P?<Z*.9Z
MCY4[>1\QZE^P%X#\0>#_ !'HNN:SXJU^_P!=OK;4+CQ%J>K^=J226\1BB0.8
M]C((WE7#(<B3U2,I8^'?["_A;X??&"Q^)K>+?&/B;Q5;K('F\1ZG%>";?;M
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MCD$7DF8KY?EQI@$SOD'.>.:]PHHYG:P<JO<****DL**** "BBB@!G<5\!?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=,S%9B0VY@<[VR<J(YV?H?\ :EWE CE\9  SD8]>@SR!G&<&E:ZC7J<<X&>
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MDT34!X@@%[96=W*\*-=PV@<1Q*K7"21Q* %\DH79'*A^S9'MD?H(TZKGAC]
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MOA]\7]'^)FM>,;+1;6_-KX7U9M#NM2GC1+>>]109HHAO,A\HLJLS(JDL-A<
MD?*,EOXL^'/A76/ 4>IQ>#_'OQ/US4_&6MZG:W:R1> ]+D$;W+S3KR3LB,23
M*(HS(TFV6,QJ[>_?LX_$'X5>,O!/]D_"/4+630_#P33OL5K%-;R6A92ZETN%
M61R[;V\YE/F,9,EF#FAQ2",FSVFBBBLS4**** "BBB@ HHHH **** "BBB@
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M)KPO_@H<K2?L>^/U"MEAIP "DD_\3"V[#)KYCM]1\6>(?C-^SC\/]&^(6O\
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M1OCC]M?PWX+^+6N?#FV\#>._%GB31XX9KF/PSI,5XOER112!P!,'V@3(I8J
M&..>M>G_  A^,GAGXX>!M.\5>%+MKO3KQ?GB?:)K60#+0S $A77(Z$@@AE+*
MRL?B69OB'_P\F^+3_#5O"_\ ;R:):K./%1N/LWV<VVFE]H@^?S-WE8)^7&>_
M7O/^":&I:5HO@WQU\/8M#U'1/$GAC6U&OQ76H07:/>-"()&C>%$ P]FX* .
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M T+HB-]GE@>/R PBC)&QN3*007!3Z4HHYF3R(^)KS_@G3X@G^'>J_#Q/C=K
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M%%',[W%[.-K'R1XH_8+;Q'^RYX,^#B^-TLT\/:H^IOJJ:3F.Y#-=,(1;^?\
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MOIR7[6/Q9N=+\'>*O >G?#WQSXJO?$'AB[AM]3\.Z-]LL(I+B.:!(Y9%?<K
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MO^UEK>K_ +2>B?#M_B7#\8/#GB+3F>#6V\-_V'+8744$\YC5 J^:#&@+>A=
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M/4]4\*6"S0,UK>&:-K:1)+< *D+)(!O)DF!PH4'O_P!H+XG?%:']LCP)\*O
M/BRT\.Z;XAT%KNX^W:?#<QQ2!KLR7"93>9%CAWHA;RVDC0."K29.4GVA]C_:
M4^;GA6"L>@&1GO[$4?:$R =P8Y^7'IU_G7Q=\(?VC/B'\/?BQ\7_ (=?%2_A
M\:#P7HL_B6#7M+@BM+BXMHHX9/($.U(]SQSHW+ I)O4R2*59.>\*_$3]H;XD
M? ?4_CK9_$'PYI%E:+<ZG%X)M]"C>TGALG*3H]S)NFC9S;R\*6)W#$D>\>4<
MC*]HC[R\\9P%8\[<XXSQ_G\/7BAKA%7(RP]5Y'3/X<5\!?$K]K?XB^)_#O[,
MVM> ]2M/#VI>/+N>RU"PU"RCEL[BZBN+6W9) 1)*L!F:8!XV$FQUR0W35N/B
M)\?/A_\ M&0_!&[\=Z+XFU+QAI:W>D^++O28[9])11(9[C[-$@224+!<A(79
MT+"W)=5\Q&.1A[1'W.MTC!L9)#%-O?/_ .KGZ4YI@,'#$9QG']/\]:^._P!F
MGX\^/O$EC\?O#?B7Q#IFL>)?A[J%U#9^)M;CBTZPF4+/'']IBA0"*%7M&D=P
MS,%E*Y^0$^5^"/VRM8T;XX> M"L_C/'\;M$\27JZ1J5G)X6_L*33GF>".&>-
MU0%VS(S8^Z%#@G<0Z/V;#VB/T6^T*-Q960#H3W&,Y'Z_E7._$+XE>'OA7X/U
M#Q1XGOCIFAV&PW-UY+RF,.RHI*(K-]YU'3O7&:WH/Q2D^/GA_5]+\1Z59_">
M&QD75]$FA4WMU=%9]DL;"$D*,V_!D4_NVX]>$_X*'1J/V._B"&5=I_L\MU^;
M_B86W'!!Z^]1%7DEW*;M%OL?0/AOQ/IWB[P_IFN:3,UUI>IVL=Y:7!C:/S(9
M$#H^U@&7*D'# &M'[0FW/S8SC[I]<?SKY\\-Z]>^$_V#](U[298[35=)^&T5
M_:31(KK%-'I2ND@1AM;#+P""#C\*\J?]HKQ]'_P3=;XJ/XA5/'J@%M7:QML+
MG5A;9,6SRAB$[3\O;-'*PYT?:GVZ+* ')<$J%Y) (Y [CD<^X]14GVA,D Y;
MIM[D^WZ_D:^ ]4^.WQJ\3?%_X$^!_#'C2RTR?QIX L=5U&[U#3(9HTN98+J2
MXNU0)DR!8PZ1@K'OC12 C.#J^ OB+\>M:^-OCKX 3^.=%_MK2$CU0>/'TF-I
MX+#;&5BCLT5(7D<3VV=Q CS<8,G[O;7(3[1'VKXD\4Z;X1\.ZCKNK3-:Z5IU
MI+?7<XC9_*AC0N[%5!8X4$X )XKR'P;^V]\%?'WBC2_#VB^-8YM5U.7R+.*X
MT^ZMDFEYQ&))8E3<2 %!/S%E"Y+ 'Q;X.?'+Q#\>_P!@7XI:YXID^TZ[INE:
MYIUSJ&8T-X5L?.23RXXT2/:DXCP <^4&/+$#Y8U&^\0>)/V(?AQHVO\ @O4]
M(^&FE:U)?-XYTF>#4))SYMZB(]B\D;PCS9F0S22J R#[V]4-1A<F52Q^PE%9
M'AOQ5IGBWP_I6MZ5<&ZTO5+2*^L[@QL@E@D171\, 5RK X8 ^U:]8FYYA^T<
M&_X4OXBR?^??_P!*(J_.S_AM#XRL>?&./II=G_\ &:_17]I#_DB_B+Z6_P#Z
M415^/VT5Y^+G*'+9[GYYQ;BJ^']C[&;CS7O;RM_F>V?\-H?&7_H<1_X*[+_X
MS1_PVA\9?^AQ'_@KLO\ XS7B>T4;17F>UGW/SW^UL?\ \_I?>>V?\-H?&7_H
M<1_X*[+_ .,T?\-H?&7_ *'$?^"NR_\ C->)[11M%'M9]P_M;'_\_I?>>V?\
M-G_&53QXQ'_@KL__ (S7Z5_"+7-0\5?"WPCK&J2K)J&H:/9W4\B+@&:2%6<@
M>F6K\:-HK]B_@)_R0_P!_P!@"P_])TKT<'4E-VDS[OA7%U\34J1K3<K*^IZ%
M7(>*OC!X'\"ZI%IOB3Q=H?A[49H_.@L]5U."UFF0G:'5)'#%2P*@XQE377_P
MUXS??L[_  9\-_\ "4:]JW@?PN%O+JXUW5M5UVUCN%1F8R3RM-<*PCCRN]E#
M!%RQP!S7J15S](;L>LZ3KECKEC:WNGW<-]97<*W%O<VTJR131L 5=&4D,I!!
M!'!!%7:^7?V";6*S^%?BJ;3);A_ USXPU:?PI)<3R.BZ3YJI$$5SNB7>DV%?
M#DYD8$R%C]%>(_%VE>$_#VJZYJET+72]+M9+R\F"ES%#&A=VV*"QP > "3C
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ME\/;C39/!-K#Y>G/H=PD]I(H=@Q656;>=ZMN;<69RY;))I.-AQE<[RBBBH-
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M:KL&QBSD +D9]R.><>U.6X1F &[)_P!D^_7TZ&OCCP+\4OBS\+?VP-&^#WQ
M\5V7Q%T[Q)I#7^GZS'I\6FSV?EQ3N6:*)-IW/;R(4+/P8W5T(9&YV;]JCQ;X
M%UW]J/1_&_BD66J^&K22_P#"%NNEQ2&SMY'=+1R8XF#[FN-.!\[)!)SC;)M.
M1B]HC[H-PHZA@,[<X[_Y_D:/M2;BIR& SMQD]NWXC\Z^$[CXR>/_  W^SO\
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M)O'DGC37;;XO6/PLMM)^TQ>'O"R>%3J%UJB1EWB:XN&22*&1QY*%ED9 P;*
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M_&:/^&U/C)_T. _\%5E_\9KQ"BC^S<'_ ,^U]P?5Z7\J/;_^&U/C)_T. _\
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MB>:%G4!Q$\98H%::*V8NR2%1$<*<FO>:*?,Q<J/ _ 'AG]H:\^(ND7_CS7_
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M]\5?L.ZE;O\ LY6/A/4]-CTKX::BE[JKWDUQ"]\QN;6XFDACQ* 9)(9)"A<
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M?O$5&D" ,T9^8LK;/J)[=V7;OP,CO]T Y!''7_//=%M61HU&UD&<NQ^;KP
M, =/RZ'.0W)LA0L6Z***@U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU^A_ZR8#N_N_X)]#_:5'L?F_QZ_H:./7]#7Z0?\ #MSX:?\ 0;\4?^!=M_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M>8_M'_\ )%_$7TM__2B*O1S&6/( 'XUYQ^TA_P D7\1?]N__ *415Z27]_TI
MQT%:,A_X4?A^M1[EHW+0,D_"CBF!_?\ 2GT!L1K"5/ &/<T_:1]*?12>HN5+
M9""FE33Z*5AC<&C!]:=11884444Q#=M&VG44 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT;:=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO^V;J7Q0U#XY? "YU'3?#.CSS:S!<>'-/:\N99+6^+V!G@U"105DB%PT2J8
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M_A"\.DV$-W;WNO&>%;16@MI'FF,;DRI^_:(1QJ#OFB8D*C[N7T#]LOXQ^,O
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M_P!$X_\ *Y_]SU\-44?V#@/Y'][#ZC0['W+_ ,/-S_T3C_RN?_<]'_#S<_\
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MJHR<=B914MSXXM_V:?%_AO\ :T^">N6.G+JO@_P7X)B\.WWB!7AA*3);7D0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG'DH[$0.IX;:_H7PI_9<^&OP-U:]U'P-X4M]$O[Z-8;B\-U/<2A%(;:K2NY
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MW DO9+H0^9'O!E=X[8#$B( TBEA\I';ZA\,_BU^T?\<_AUXE\>>";'X:^$_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** $HI:*5@"BBBF 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^7Y?^"A?PY:2\O+'0?&^J^$K*ZAL[SQA9>'I&TJU=_)_UCL1(NWSTR#'N/\
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MO+2Z\/I8(FFQQO()'N9'!(=T&W$3=\Y(XKZ,_B%? ?\ P4@_Y&K0?^O6V_\
M0[NN[ 48XC$PI3V9TX>G&I44);,]._X>3?#7_H ^*O\ P%MO_DBC_AY-\-?^
M@#XJ_P# 6V_^2*_-VBOT3_5W ^?WGT/]G4/,_2+_ (>3?#7_ * /BK_P%MO_
M )(H_P"'DWPU_P"@#XJ_\!;;_P"2*_-VBC_5W ^?WA_9U#S/TB_X>3?#7_H
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M2,(_,QN43)6",KGNE%%%(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)G_0:\*_^!ES_P#(]'_#MWXF?]!KPK_X&7/_ ,CT?VQE_P#S^7X_Y!]<P_\
M.?*5%?5O_#MWXF?]!KPK_P"!ES_\CT?\.W?B9_T&O"O_ (&7/_R/1_;&7_\
M/Y?C_D'US#_SGRE17U;_ ,.W?B9_T&O"O_@9<_\ R/1_P[=^)G_0:\*_^!ES
M_P#(]']L9?\ \_E^/^0?7,/_ #GRE17U;_P[=^)G_0:\*_\ @9<__(]'_#MW
MXF?]!KPK_P"!ES_\CT?VQE__ #^7X_Y!]<P_\Y\I45]6_P##MWXF?]!KPK_X
M&7/_ ,CT?\.W?B9_T&O"O_@9<_\ R/1_;&7_ //Y?C_D'US#_P Y\I5^CO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )S1S2T4
M)S1S2T4 )S1S2T4 )@TF#ZTZBE884444Q"<T<TM% "44M%*P"<T<TM%,!.:.
M:6B@!N#1@TZB@!.:.:6B@!.:.:6B@!.:.:6B@!.:.:6B@ HHHH **** "DI:
M* (MR[2=P^7.?PKS;_FY+./^92_'_C\]*Z/QEX"_X3!K,_VYK&BFVW_\@>Z\
MCS=XYW94UY[X1\(-X1^/[6/]M:MK0/A?S_M&KW8GES]L^[NVCY: /:]M&VG4
M4"LANVC;3J*860W;1MIU% 60W;1MIU% 60W;1MIU% 60W;1MIU% 60W;1MIU
M% 60W;1MIU% 60W;1MIU% 60W;1MIU% 60P*>X%&T]A3Z*0QNTTZBBE:PPHH
MHIB$ I,4ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/U1_X;F^"W_0WG_P67G_ ,9H_P"&YO@M_P!#>?\ P67G_P 9K\K=[_W%_/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ/P^U;3+B6;P]=:%=P76IS(EV3/#/)9A/+4Q("3,O-O(N">#Z]\4OVKOA/\
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M4?ZLX?\ Y^/^OD']FTS]5_\ AN;X+?\ 0X'_ ,%EY_\ &:/^&YO@M_T.!_\
M!9>?_&:_*CSF_N_^/?\ UJ/.;^[_ ./?_6H_U9P__/Q_U\@_LVF?JO\ \-S?
M!;_H<#_X++S_ .,T?\-S?!;_ *' _P#@LO/_ (S7Y4><W]W_ ,>_^M1YS?W?
M_'O_ *U'^K.'_P"?C_KY!_9M,_5?_AN;X+?]#@?_  67G_QFC_AN;X+?]#@?
M_!9>?_&:_*CSF_N_^/?_ %J/.;^[_P"/?_6H_P!6</\ \_'_ %\@_LVF?JO_
M ,-S?!;_ *' _P#@LO/_ (S1_P -S?!;_H<#_P""R\_^,U^5'G-_=_\ 'O\
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M*6BL#I/,/VCV_P"+,>(AWQ;_ /I1%7Y!^7\N[</IGFOU\_:07'P8\0\=K?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2]2ATG2_B5X=M]5LK&WC>YDN+B6[BCNO,+QL(2RG57.#M*RKAE945/TL\*^
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MZMCHT$/VJW? :&3:HW(P"A@V0V.1VK3_ .%7^$?^$-_X1+_A%=#_ .$6S_R
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M0O9L_,"Z9+#]F3]DG7?$7E_\*WM/%%ZOB);K%Q:S%]19HS+;*"9CY4=[@['
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M!NH_ 7_A4,MI,OA(:=%8 02)#.S1L'6X9D0*9C*!,S%2&D)+*02#0^$O[/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MW!IU%*P"<T<TM%,!,&C!I:*!"<T<TM% Q**6B@ HHHH ;@^M&#ZTZBE88E%+
M13$)S1S2T4 )S1S2T4 )12T4 )12T4K )S1S2T4P$YHYI:* $HI:*5@&[:-M
M.HI@)S1S2T4 )S1S2T4 )S1S2T4 )S1S2T4 )S1S2T4 %%%% !1110 4444
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M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img192321128_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $. @D# 2(  A$! Q$!_\0
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M /CE',@^M4?YCTFBO-O^%V>&_P#GQU7_ +]1_P#QRC_A=GAO_GQU7_OU'_\
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MH_X1+PW_ -"_I7_@''_A4>S9P?V=+^8^5:*^JO\ A$O#?_0OZ5_X!Q_X4?\
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M)QJEQHK26\PA\]IBJ$3I(DVS=,=Q!,H)<8"@ 8&0 :[6BBA@@HHHI#"BBB@
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M?RJ%;C!Z9&<$U)XG\3ZOHVM:I81:^Z/:6$$MI')!"7NIBQ!4_)SN_NK@]Q@
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MCJO_ 'ZC_P#CE'_"[/#?_/CJO_?J/_XY7@U%'M&'UZL>\_\ "[/#?_/CJO\
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M9_T&?_)6;_XBC_A:?@S_ *#/_DK-_P#$4>Z'^R_W?P%_X59X,_Z W_DS-_\
M%T?\*L\&?] ;_P F9O\ XND_X6GX,_Z#/_DK-_\ $4?\+3\&?]!G_P E9O\
MXBCW0_V7^[^ O_"K/!G_ $!O_)F;_P"+H_X59X,_Z W_ ),S?_%TG_"T_!G_
M $&?_)6;_P"(H_X6GX,_Z#/_ )*S?_$4>Z'^R_W?P%_X59X,_P"@-_Y,S?\
MQ='_  JSP9_T!O\ R9F_^+I/^%I^#/\ H,_^2LW_ ,11_P +3\&?]!G_ ,E9
MO_B*/=#_ &7^[^ O_"K/!G_0&_\ )F;_ .+H_P"%6>#/^@-_Y,S?_%TG_"T_
M!G_09_\ )6;_ .(H_P"%I^#/^@S_ .2LW_Q%'NA_LO\ =_ 7_A5G@S_H#?\
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MAATK_P #8_\ &OE6BCVC#^T9?RGU5_PEOAO_ *&'2O\ P-C_ ,:/^$M\-_\
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M>7]G\S.(U;.=P_O?I7I$J-)&R+(T;$<.F,CZ9!'Z50TJ-HI]21YGF87(R[@
MG]U'Z #]*32>Y%2G&HN62T/,/^%%?]3'_P"27_VRC_A17_4Q_P#DE_\ ;*]A
MHI<D3#ZG0_E_%GCW_"BO^IC_ /)+_P"V4?\ "BO^IC_\DO\ [97L-%')$/J=
M#^7\6>/?\**_ZF/_ ,DO_ME'_"BO^IC_ /)+_P"V5[#11R1#ZG0_E_%GCW_"
MBO\ J8__ "2_^V4?\**_ZF/_ ,DO_ME>PT4<D0^IT/Y?Q9X]_P **_ZF/_R2
M_P#ME'_"BO\ J8__ "2_^V5[#11R1#ZG0_E_%GCW_"BO^IC_ /)+_P"V4?\
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M7,:&-9H+B2!]AY*EHV4E<C.#Q523P7X?DOUO38%95E6952>1(PZJ%5A&&"9
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M<7.^9T^=YU57R%0<?(, 8QD]L =-11=A9'*W'@+3[BROK$W^HI8W<WGFV21
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M15QC8ZJ-&-&/+$XW3?"MQ9:K<ZO;Z7H>F7:6;V]I;V8)C+M@[Y6"(3RJC '
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M_P!"_JO_ (!R?X4?\(EXD_Z%_5?_  #D_P *+R#GK]W^)L?\+3\9_P#09_\
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M $N]M(FLF4//;NBEMZ'&2.O!_*O6M;M8;S1[BWN+"6_B<#-O$RJ[88$%2S*
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MS&#/(T$5U/YTL<1/"N^YLG.3]YL @9XP$[#5[FQ1112&%%%% !1110 4444
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M!BM(KN36]-2VF)6*9KM CD=0#G!QWQ4D^NZ/:W2VMQJMC%<,5"Q27"*Y+?=
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MU_ZES_R>_P#M=>/44<\@^NU_YOP1[#_PO7_J7/\ R>_^UT?\+U_ZES_R>_\
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M79X;_P"?'5?^_4?_ ,<H_P"%V>&_^?'5?^_4?_QRES1,/;8?NCL?^$3\-_\
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M^%6^#/\ H#?^3,W_ ,71[-A_9]7NOZ^1\VTJ_>'UKZ1_X5;X,_Z W_DS-_\
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img192321128_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_8.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[14&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %.J^4U0X0DE-! 0      %X< 5H  QLE1QP"   " /\< E  "')R-3 Y
M,# X' (% #U-:6-R;W-O9G0@5V]R9" M(%)E<&%R92 M($E03R M(%,M,5]#
M;V]L97D@1')A9G0@-"XR+C(P7RYD;V-X.$))300E       0]/II!77\:'ES
MX)M602<)N3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              5\   1-          $
M 0             $30   5\                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   5\     4F=H=&QO;F<   1-    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      *;0    $   "@    ,P
M >   %^@   *40 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ ,P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M  ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !
M! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S
M-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($
M! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M&#*!H;'1U_ 9(U)76)>9N,'Q-WCA"B0E)C,X0G<G-$?_Q  < 0$  04! 0
M             0($!08' PC_Q  [$0 " 0,# @0#!P0! P0#     0(#!!$%
M(3$200834? B87$'%#*!D:&Q(\'1X4(5,S1#4H+Q4V)R_]H # ,!  (1 Q$
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M%14@1TC^QS[,62NZ'K-LJ_6&E">O5%ZCZ-)C*'9;&8%]F:?I#M-I[<E]VOM
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M@'TS< < < < < < < < < < < < < < < < < < < < < < < < < < < <
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MQZ8Q]. <OC'GSXQY_/\ ']_ ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' -,YQC'G.?&/SSP"UMEW=J&FR;K%MFS:%6GM<5H7<;^V=M@04Y2ZJ;?(Q0M
MBM")LMG(,.8E"24880(YCQIS\&2U%6ZXTM. *?%=F>OITIKD&%W5JLH9V^*F
MG=5"X%^K$LAL4*.3(7.*TR%').2+'!B)B2_F)(I$EII426E:L*C/X; J?76Y
M-5[>AFB.J]BTC9 ^N'YU6/SJ1: UFBA;&-^']H RCP:7-;@E8GQ&U/09"T/H
M0XVOW/<6G.0+EXSC/TSC/[,XS]?I]. :\ < < < < < < < < < < < < <
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M][D&ZKU6U9*UHB_V>'OS3QFM0[CN+YMLQ9PT>I%WZNP'%C8%\/N*E3. 3$Z
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M80,D52PG29T$9"X&G!Y=YHE')MRX4!V*!003H+U%KA_4MI":)I(X_HT/@'K
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MMU:CKFD8)MN<S@T,NNYM> -B7J3*@2HCI&KWH9%:!508IQT04JD=RV+^=^]
MG 0#+N,&P0XT>(&1(T :+A11X^##91'B0H4)E$>)$BQVDI:8C1F&VV6&6TI;
M::0A"$I2G&, <SS^&L+RK*4)0G*LN*5C"4XQCSG*O./&,8Q]?.?'YYQ^ AM)
M-OA&/;L=[1K4?6N\UNC66G[*NTVV#(Q *9UY"I!L!)=D$G1:@_S!.\A):"T5
M[$5Z3'5!PSB.2@K9D/*6\ABB=6%.4834^J>T'%)QZMLIMR3RO3I::X9SSQ/]
MI.B>%]2L=,O*5]7KZ@H_=Y6E*A6I2DZCAY<I2N*<HSRD\-+9^I.NJV47:1C1
M,7)8=0XU&<D1VI4&4\/D/L)?7!FJ'RID5$MC"\)>0U(=;][RIIUUO*7%>C37
M*-]M[BE=4H5:4DU*$)-9BW'KBI*,NEM92:SAL@!/[P%H^ZK1JN"#U@7E5SL&
M"TFU21^Q23N["P,K5Z#82^SQM#CU&1#<KE,:O6"]IS),0QT&HU\V84=3.;@B
M)D'N>WU6[CG>PKNOGIE=U_\ 9-_TZG:<TAKB\%;CG6!5;U13%H.S%D*L$'"K
M$6:M,O[$1%)2)LMZHV1+X:+#8;DK VW[MKM2C6O9E&D:6CE;-7H-#/T4=5I]
M^N,HY5[CN:-K&26."J]K243D.5ZKS1^RK(SKJ/?V*G G-@+;*"3W@4RQ 4<5
M]H/"!A#>Q7:V /:<US]T .U+H$-6>!9!MXM@>Q$W@]8H%CI@HI)CU:?!K=?L
MC%LGU.P031PW#?#1Y50FQB0$B]+[^N5[C;&$7/7D,3?]?5ZDVYZJT.TMVM@Z
M&V)4%VBNCA)FT#*%#39,S!YJMOL$<CPOSL2&2=,PH!%S[/#W_@CDYWVMW\'8
M2\IT^.&S1.OML[8V]5C=]7]I4REZKW [JJ>.K,X/6"@>X6^:N"=,(BN30E?;
M<"X&I/.M%HI.*!)79G;2AZMOSFMRE9V*?L,>!J^7-?JE8CDA,21NFVVJAZN&
MR)\PN-PW/MEPJ!0"TOX*QH=UZ$2LA$,%>=)QP*'K_?C1]J73G0J+U(KUT,,5
M>/=G*QB)4P%S<U*?W@]3;3.F$F9PDY!UK7)AX@^@7+ Q5RA@U9G)&<U%X!0>
MM/:$4NRS+U5[A6BPG95 L.O:T<H=/6[:IT$[M45K5O7M>)SB4>LQ!-@NEROI
M"NUV$5S!C_9-3,6T_+ @6)<N,!,O3&V:YN_7P[8U5AGQP@@:N=?4.M O(8^.
M,T*Z6"@68>2'?'DI8=A66L%XJ%-R'V9#+34EEU33R,\ NGP!P!P!P!P!P!P!
MP"G[57@-MKQ:L6@,*L5</P9(DX!.0(I008%SF7(\P<2'34.1)L*6PM;,B-(;
M6RZTI25H5C/C(&%3J<0]E[LSL/&I^G>L*JUL&D6&]SM:';@!"SZBS)U*JJ-$
MK;K"MIV)<7]=-,2K8S&K\@C1]?&FI0DNWD>-<R*R5 SC,HPA&$8SY]W.<9SZ
MY]?.?/KGUSG\\^OG/GUSP#5>&LY_3PG.?'IY_+U^G]/ .!3B&_'N*Q^ECURK
M./3&/I]<XSCZYQ]/RX]/G^VSY_CZC;OLO7M^V_[$"?9BY\]1@V,_RL;X[GYS
M^Q7=#?\ G'^/I^7(3SG9K#QNOSROD#(!Y]<8\9]<>?/CT_9G/Y\D&O .-;J$
M9SA6?'C]G]><_7]6?' -$O-JQ[V,^,>?'KC\?7T]//T\>OY?CP#EX X X X
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M'=EMTTS6 ^VLSMU?_*H.87D7V;J[-,:^3I;'RJ'3)'-F=P'#2&2BE27%MP)
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ME6-DW#(1ZP#M=R E0$<-,@/BZX#_ /A0\6]5QHC$D/?O!9F3H/?@PCL*_P!
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MD![]^^Q]!N?'CU^GI_7P#3W$X^OK]?KX_+\?U< UQXQCQCQXQ^7 (!>SN_\
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M#>MI*_KYQZ>/3QCSZ^?7T\_]\\ (:2WE6<95^E]<9SYQ_-CQCZ?A]<^. <G
M' ' ' ' ' *5NY0^$JATO5ZN_=;".'2I8>IQBPP#(L,]EE:XPI@R:=8$C');
MN$M)F$7FHC&5>^\O"<9QD#"U[/)VS/[^P6VK#N#^V+."WS.=LD[N/IS:52+
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MO;J:H4_-A&E/HIN5*/$&XQ?2L9V3?RSS@J;D'N. . . . . . . . . . .
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M8:^+X4LH'3WJ?J_4^CM,"RE2U%=;]7Z/77"FS  (98(QXY]FQ\R3]9M!4?\
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M92E*3<I2DW)MMN4GEEVEB,8KB,5%;822V226R6.RPEP57SS)' ' ' ' ' '
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MUNRI4*%I;4;;_L4J%*G1[YIPA&,'EMMOI2RVW]2JN07(X X X X X X X X
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M3'=?B*?Q(::D,.+;2AYO*@(?>S(SC/4</X_U]=T<_P V>Z.__']6> 3^X X
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M W)90CUQC/X^?.?KY\^?/Z_7/K]?7/YYX! 7V=N/&O.QOC_;Z[X_\T.R<?\
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M'GU\^,><YQC(&%C0??FFT?<IK0\+K<$F4%S94"FN=F^E%**7#J^/NUUO;%,
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MZ:1KWO/V]E^1&CAC/NPPL@_#S\Y@"X' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M3L(.9D=P]\O$Q4,WD>)R8BCIJWX;!7(L;D@TRB9F!#R_\LT!D7X X X X X
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M?_C'\WX?EP"?W ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M3VK?96"$D- +3P6U[&0AMS&Q<W"'V1<K&%-8PK"?/ ,@O ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' *?M=F"4NL6&WV4@@57JN%)V X3=:D/MC
MQ(B&]/(3%LQ6GY+J(\5AUU3<=AYY>$Y2TVM>4IR!AEVQWXW@(W7:)NE[1I?;
M^D1_7K86[,UD+73X^P:THH34<\WKK8NW]FV:P@*[6C.S]V#25+J>NI(:)@IK
MP9.M_P!K1GAI:5# N%U7[]69C2$HKV5KF^[]N.O;.-:UV)7=-=2[WL"10[0)
MI5&N+@B<.ZZ2-Z!U5^8)N8PO7;A*.PVCK!%8SY.,2"D&$A[]_4L_[//OCK2H
M=8A0&?ICNP4DM[G[9D\S*IT4[:W .IJP=M=WV"+'0;K6HB8IPA"B%&(1P<B6
MJ< .1B( NQ#,#)\*.!-S_*+ZG_U#]_/^'9W4_N1X _RB^I_]0_?S_AV=U/[D
M> >>7]I9I4"*)G#6F.]P@.&'S2I8L3]GMW-A#18P=&=F3R)";)THU'B0845E
MV3+E2'&V8[#3CKJT(0I6 .(%[3'25D#"K$!TYWJ. 3XV 9!F0_L^>Y9$66$%
M(K4X:3'3XFEWXLV 0AOLRX4N.ZXQ)CNMO-+6VM*L@>K_ )1?4_\ J'[^?\.S
MNI_<CP!_E%]3_P"H?OY_P[.ZG]R/ *;N'M1NOU JQ^[7C5?=ZGT^JBIAVRVJ
MT= ^XP&NU\*.97(GEC1DEIB+ &CH4="WI4N7(:88:2I;BTI3G/ *B3[1?5/N
MX][1'?K.?7SE'L[>ZBDY]?KC/\"7_;/G&/3@&[_*+ZG_ -0_?S_AV=U/[D>
M/\HOJ?\ U#]_/^'9W4_N1X!35F]J-U_I[09ZTZK[NUINPV(-4 +E@Z!]Q1#1
MFU6*5B$ K8M4[3,?! Z:F9Q%%"XN79LZ1G#49AQS.$\ J3'M%]4>,>=$=^_/
MC'GQ[.WNIG'GQ^&?X$?7'Y9_'@&O^47U/_J'[^?\.SNI_<CP!_E%]3_ZA^_G
M_#L[J?W(\ ]:G^T%TI<-F:UU.[2.T.OK5MVP&*GK^1N7J-V3TS5;#9P=&M^R
M9]?C7+9>LZQ6&S'W)H=O.Q1[Y1N3-C IB8C;KK7N9 G-P!P!P!P!P!P!P!P!
MP!P!P!P!P!P!P!P!P#:M.%H4A6/*5IRE6/SPK'C.,_JSC/KC\> 6LI6J]0Z.
MKU@CZYH5"U56))(Q=+)$I56!U 1+,2VL23EF+10<.!%DDY+4?#D\I(;<EO-L
MI^*\I+:4I BMT$WKUOW'6=J-]=J]L*HPU;$(;DM(;904J#,GI/9>43W$,VF!
MCE2A=U5'VADR4.U=O#P]P<TQ+$20 %\>H:P!/[@#@'4GR(\2%+ERWV8T6+'>
MD29,AU+$>/'80IUY]]Y:DH:9:;2IQUQ:L(0VE2E9]W&> 0S]G]M+K9MGK>,L
M'4Q1=S2 O8^YJO791G,Y;I0T&VM;D7,V-?)D29&57CUP>.&*Y*F/LNO!9L+.
M((]K#<-@":_ ' (S=P]BZJUCUQV<=W6,LQ[6AP*WKFR5NF0I,ZU6EO:LR/K>
M%5P#<:<)S')V(A:(HB+/?,!XHYR9B;)*P&F%26P/5ZJ[0UIN#K[JF]:=CFX6
MLY]4C"*F.LD*5 L >#4'WZ>\#-1Y4B8Y]J YP*6(G/HG$(TJ1#5*B$2,5]J:
M\!(3@&BL^$JS^6,Y_+Z8\_7QGQ^[/[. 8Z.R?9;JA9]BV/IYM=N[6VV5/6:>
MV=DK%,K%PG8'!>N6Q]/[&KK+)6MH9FF;B[<">O3HJBUW[8G%1:6VK)$@C30^
M*9 DEUN[(TWLU4;%:JD#NU4E4VZF-=W2F;% -5NYT^Y!(8LI,"'!L2>6'8?<
M#'09B.\-+D8RH16,T\ZP19G08@$AN ;%KPA.59_5C'[<Y\8]?IC]N?&. 8M-
M\]U.E1FU;1KNQ95L/F.BMTTMM@[D2),#8#.VK9;#VL]65>I$'"02'=K3+NDE
M^J/B'7?N@T:+0X18PV]%(Y%@3\TKM8)O#5U/VM7!=E"!;H,R4@";>)0$L<!M
M,E^(Y')CV94Z(EQ+\9W+$H<0)"2,3+!$02(C)<2;( NEP!P!P!P!P!P!P!P!
MP!P!P!P!P!P!P!P!P!P!P!P!P#:M/O(4G\%8SC/X^F?KCQ^O'IP",Q+IEU4,
M;4L6\2W7W493;]OBO0;9L8C10,ZVV6%(JS=(?AG3$J([**Q'J<TW5W(TY;[*
MP2$BU(S$QAK@'*S7>N/1W1-N)U2DT31>CM9AK1L.Q"-?TZ%7P R-%CNE["78
MKE6')<)F)R8V,8:API14K+^4AL(??S';P!0'0JP:2.:&S$T.[?FZD#V=N-!\
M!M,+-K>Q:AL2W;/M&S;[6+4"G#!,@:_!/WR2\'CYBN)36Y(929L_XF9TD":?
MN)_+^G/]O 'N)_+^G/\ ;P"U^Z<T;^"+:C&RS;=9UV]KB[,WRQN36QZ --?K
M)1NS&,S7F)343[-"YG3<27(TA#.6/B*8>PG+:@+;]-;WJG9O5C0=UT;-/$].
M%-5TV+K0C:(JH5BFTT&%B@ <DW%RU&4V3>A"VG)?F-'PMU67$L,I7AM($F/<
M3^7].?[> /<3^7].?[> 0,]HIL30=4ZRWFB=C'=BJU_OF(8T>X*U+79]GV,:
M=M53LI8M'JP^ -+_  98NG5VT6220GPG($,>#F.+3(D?+PY $Q=?W*L[)HM-
MV+322#50OM7!72JF$,R8R"U;M R*;!$T1YC4>6PF>+G192694=B0WAWW'F&G
M<*;2!5WN)_+^G/\ ;P![B?R_IS_;P#&CV-[(=1+C?[3IF_W2V2[MTZQK7N)<
M@VO@A,[)!2*/;([U+!SL# YEXV9+EI(Y4BD!XZCLB 2@/?,P&Y;#Z@)<=>^P
M%"[)T1R_Z_38X< ?9K11['7;G7"50N=.NM++/!;+5;76RS;,T4:%3&/\\SGX
M\=^,_%FQ)$B)*9>4!?;W$_E_3G^W@&U>,)0I6,>N$YS^/X8_5Y_JSP#%+NSN
M3TCM-^+GK)?;@<M/LW]XT6SD1FNP!0]@ANC>>MM]]=ZUKD8/@AR,S817 .Y;
M$9+"*NN-BLV(;"EFC#$0%8(38&3RJ6.%;JZ$LXU$]L980XLZ-24&$ A-(\Q!
M9GQ$$0Q>+!+")Z6'T?-C"<.*0@OY7&F1V)+;K#0%1< < < < < < < < < <
M < < < < < < < \HZ'@V$(9 $VUNC3@H@'(--N*:<<@DXCT*6VVZG])M:V'
MW$I<3^DA6<*QZXQP"#O1KI(KIY NN"NU">VSMEKFG];B#9"JBJ?D#J30-1G4
MW5-4?'B9L]@J=@0BY\K9K1\6 R?-&I$B&  Q&FH*0)[\ < M-O?4(/?NG-D:
M5LYNUUVM[/J96F6 Q1R[0*UQ IMG,0HD*7?@DF8,F7!6_#<><@R4YC2'D9;_
M $_>2!87HYT]B=+=56K5T':-PVI!L6Y]M;;CEKG!KXZ:(QM"Z$[>Y7X\2MC1
M0SW(+Q%QR?-CPH<<H8D$24$4#'2HH,>!-+WD^?'O)\_EYQY]?.,?TXSC^;/
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MC<:N5,8X\.J52&E[--&U.KPI,MD#7H@T;F=/=CN37P)+\ < < < < < < <
M< < < < < < < < < < < < < < < L3V9TG [':&VQHLF9F5R'M*BV"H9L4
M"(S/E@)12&ML<;:'R%-L$,BB.(LY8]YYEN>VPJ(MYA+V74@4!T_Z[V/KM2[Y
M O-]%[+V/M7:UIW%L:WU^FR-?5B9:;(.KM?;A5>FS+3=YP$&*K=2KPV-&(6Z
MPS9#T620D$5N3,M- 2TRI./JK&/K]<X_#Z_N_'\N :\ CIVCZZ">TNI2NHCF
MQMCZQ%%CM//2[%JURAILCKE*M(JWCQ$J+LNA[*IA>NE"86'%L@ [3RHX^&5,
M#$&'1\Z6P\!2'1+K%/Z:]4]/=:".RBNVY&IZWFO)O)8 &J[A-C,Z9-CQX5?"
M(S'%BAK4I, ;&ESS)3$5A"R9LI+4Y*< EUP#3&<9^F<9_9G@&/\ ]H9TMG=X
MM25G64.Z5NG?=C8T&_N1KU0BNR*%:<1*M;*KD1::O7;]JZQOIB)M2K "F"+T
M(5!/B!D@A&+0?C#W )<:;H;VJM1:NUA)LQ6YR-<:\IE#?N)Y$5HY;'JC71U?
M<LIIJ$VS":+GEC\E2+4-IJ(W-EO-QFT,I;3@"Y&,XS],XS^S/ &<XQ]<XQ^W
M.,?U\ Q\[GZC[,N&YMJ[[TKN\3IO95WZH?Q;ZF8F:RQ=TT:P+V*0NO\ "EF,
MJWUV-89T.&06.' );<5A@C&A$I9.;':4(= N=TIZ_P!IZP:(K>G;E9M?W(W7
MR%@G2K=KZBW.@1[3,L11TZ9L]N@W_;6ZK.?V#9[&0,6"XVN;=U-G#!-UV(&$
M1VD1L@2YX!L<QY0O'YISCTQC.?7'KCQG./P_7P#$-V<]EB.[%V?L_:WMC5P1
M+WN2ZFV.I@[!J[[YU"FV3J\O9"%.7*O_ 'S ?PC +_%V249FA&)U.DB)#+<[
M[6*NJRWD#)/HW6J=-:=U?J1%A+VU&LM?TZA-V@^Y\0U8FZG7X -)DHKWW,8G
M$<0OFI",..I;<<4A+CGNY<6!=7@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#
M@#@#@#@#@&U?JA>/S2K^K/ /G\.;Y[:ZB[.;8K5F[47;9FOZ!VWZ&Z.#4J9K
M3KU4V9=?[86NMN61TU8 >GEV&2S7!TF6"'QQLT20G");KZSD(ZB&:A@>9KWV
MSVYS8Z@V^]=3J<#U];176ZW%"%.WJ8MEN@4OL]F]!:*X)JT[4=>B%[4/M=%F
M8/ W;! @,UXB/DCC1(OF2+C@7PZP>U2M'9;J'VI['2]%YUN6T+KF;LFJ@&KA
M]\X%M!E]53=E4U$YUP#6RP8XU':CQ[(.>"NC,L28I&N&CHZ6E] $>=J^U/W'
MHNYZ,$7,IK&?3*AKNW2-REI%M'1[[N;8%7Z) >PJYS^N:[K<T2USKHG?K]28
M0&RT5\\5)3VBX3[FK@/@(QP"NM8>V7MUZJNNY!#KL+%W;<=OV%I?4@0;L*R3
M 5PWYK7?6OM46&F+)'-;5H\%#(H^PT;E1-,UF%8T5"B[(P]6D.5EUUT#KM>U
MBV)?I>Y1@NC5K6Q[0G8+0<5 D5:U[/?VMH>\=JI'7JRK<+(HD&C0SAN!!(&
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MUI[ ZB% K4;?O+F-O:I*[$*QBS!"BA%S@<J5%DCLG77V7Q:QPAAFON.EB*H
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MRIM1D-MUT>1G0@Z84:4\TH"D'>G?5%\M(//=8^O#QR57T5.49=TKKAPM)JJ
M;-7169!)5:^;?KZ*U&CUY 9QW(U(-AD5\M\BVAA('JJZM=;EQ0D%?7_1ZX59
MDF)E;AKU/0UQ:]*/XA(.2 <98!3(EXT@:.27>@H9<)?(P_FU/8B1TH ]QS0&
MDGC%IL+VGM5.GKS.KI.[G'=>U)PO<B=/+P#]1(VLBL/F989]7.BAANNS2[TN
M2#,#8!$8Y&EQ674 7$K]7KE4BS8=9 A:]%)&"UA(Q@8J (8GGSTUTD<.361[
M$=N68,D7WR!8F^E<TC->=ES'GGW%KR![O ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' -J/Y./Y_Z\\ W< < < < < < < < < <
M < < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
D < < < < < < < < < < < < < < < < < < < < < < __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img192321128_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_9.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[15T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %5B^5&0X0DE-! 0      %X< 5H  QLE1QP"   " /\< E  "')R-3 Y
M,# X' (% #U-:6-R;W-O9G0@5V]R9" M(%)E<&%R92 M($E03R M(%,M,5]#
M;V]L97D@1')A9G0@-"XR+C(P7RYD;V-X.$))300E       0]/II!77\:'ES
MX)M602<)N3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              7,   0T          $
M 0             $-    7,                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   7,     4F=H=&QO;F<   0T    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      *VP    $   "@    -P
M >   &<@   *OP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ -P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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M0U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UXP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( ,<"0P,!$0 "$0$#$0'_Q  ?  $  0,% 0$
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M[NT:7C>E>0A(ZH/G,7$Q<I%RZ&\K:Y4"0:)RC]G5';UN#(D*\;/ ,FN , 8
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MN $ ^7 ^GIQV#GD>>?3(U[?%Z7\-K?\ !+>F]M4M?'7W:^&I2!P///M1'@W
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M.61P&'RRO&4J=-5:U7#8.HY5J,J\J-9).GQ\"J17#)I3X?3>J3^B/3EU$1,
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MN(Z0<HV*?GXM*2%E',V#$#,?@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MO R5OV+$KW&@+24_3KILB>?T8\8^=6S;EG3?/IM:,:3T@!Z+$A,)/QPX, B
MAVX#L \!Q].>._?Y^@@& 5< 8 P!@# & , 8 P!@# -!$  1'L =QP"TFU+Q
M*5QI%UVHI-Y#85Y=+0E,CG*8KM&BR: +S%MFTB*('"L4R.,:9F0.Y:#)K%C:
MNP=I3UCA4G $(NOV:T]TO>'EOFU;.GC)56CT>7L+^5F8NEV>8V#LF2=F<P[2
M0B[U6[16)F9V#?G[1DZ;+5]PFU2DE4XQ"/:,FHM ?_/,[1X7JNO[AT;Z@W+1
MIEA9V>\:PQV.XEV<;68HD4$D*B3;7J3&H05:K\<76/L%:9)LHB#B6B]LC+1/
M+QZ,Q.RZBX&1$     ] #@/N# & 8U/$>\,GIY\2S5I=9;NF-CU08Z=A+#"V
MW7EM4C)2(D(0)%%$I8&>;3](>M7C65D6CU1[659 4W G:/VKA)-5.+K7E;37
M3X_'8AM*]VDE:[>BU[WH2IZ=>GK6/2WIRDZ8U6A.-:=KZJ5NIQ![+9)BRR2D
M=58&.KS!R\?2KM=%)92/C&YW2,6WC(OVXJ&:,&J8D(4FFKK5=I/G>Y"]?I@Z
M%%XFIS2VUJRXK,5?KG),'+_9.M9N G)"RSE"N!:&=W-QTJW"+I*>N=<1U.C(
M->/L%;K-7@F2<D9-,SD\CNV^)V)'H5Z:*1-/W;'95OJ-FEXBK3)7*MWIR<BW
MJNK-)/M!O'4>PGJX]9$K[C6T\^;V^7%BJ#*1D@FF,A!.SMU2AY\^TNATWZ<Z
M9^G EXG=9[!AG,5;J]$V.4?2MOI,@TCJFQL5YFRSB,]',(Z2<5N1N-TNLD,C
M/RTM%,9%Z]80:T6S3/'E EZZM]58NFC%]8X-D]D(]]+,&;N58MG3V+C$TEI*
M29MUER+.8^/1615>O$2';-4U4SKJ$*H41 ^A'341,,&4K$2;&5BY)L@]CI*-
M=(OF#]FZ3*LV=LWC4ZK=RV<)'(H@X14.DJ0Y3$.8I@$0-DG.PL*S/(S$K'Q3
M!,4RJ/9)XW8M"&5-Y$@.Y=*)(D%0P@5,#' 3B( 7D1#D#G>\H]_Q_0.?S=AY
M_0(#]P\X!TA;:^KVR,>Y<[&HK9O+S+BNQ2SBVP**4G8&BQ6[J"CE%'Y2/9AL
MN8J+B,;"J]15$$U$"G[8!V;\(H$9@U>"9BQL!8XLP:"!\V^,!$F<^YEDQC/:
M^^A'B[_L7WT4?=O>/ZR*@*?BX!RD)6.<J.TF[ULNJP<E9/DT5DU5&3P[5N^*
MT=D3,8S9R+)XT=@@L!%?=W39;R>S72,8#E LD80*!PY'G@.!#T'CY@';GT'T
M'OQSP. 5?7 & , 8 P!@# & ?!M+UQ&UN=D&C)U).F,4_>-X]BJP0>O5FS91
M9-JT6E5VL8DY7,0$T5)%R@Q(H8IG2R:(', &*+PH+C%7&A7=[$'NR;=PAK>3
M=(76I_@F\E)DT7.UZP78&I[9=%I&5M4_5I-M992(DX2CJRE?4;U&DUQ)I**R
MH&7L X], Q%='9N/%8\8_P P\?V+X=X!]P=/5S_5@=OM?P^XRWBN0OKYOS!]
MWV_:'W?/ (\;[BH&(J-NVS:=@;8IU7UI1[/;K&VUI-.FZJ\#58I_8IAVG QT
M7(R,U+DCF3A-HT9)K/7IDT&C5NJNH4IP(/\ A>;KI/6QTYT+J9HNW^HNS-$[
M/;*S,1NR916';/+!69-5!PW>P98X6,C%?#G\6J@YC'[IFJL8Z*K@LBQ>M6X&
M6<%4R<$,< .'J41$1#Y]Q^G<._IW#ZA@>WV.WMVY$ ?%9, ^&GU[<&$0'I$W
M_P !P(AR&L[)Z!]/J/W\B&433E"279>]MDM7[;/L3]Y;J-*$]=>KFK77[46O
MXGY\,9JQ@TV'*;)&;GG#N;B&T8>',_$8AND5- !.DAY ,0W]8*)2B)RIF45.
M4?,;C/&)XZ<L'#!=514:56515532K-M-6E-/5:]BO9+9(^+,9TLJ3R+#]'%@
ML)"&"QD\0L8Z?S]22JU)13MH[\>K>LE&*=TDSC1FB-<Q%5M5-91BZ4+;W!W<
MR0'SU14ZJA^$Q;*J*F4;@V$>4"D, <!PIY^3<UU,UQM3$8?$RJWK8:,8T9<$
M+14=KKA2E?FVFWVVV8CIYG^+S/+,VJUJ,\5E--PPOS%.,+<*C552"2X^MCI.
M[:7['#I;-%_4ZM:AZ9XE=]K$"D="*AO#_MK5B1111=7RDZ@M,B!CJJF.<YC&
M,(B)AX$3#P !VSN^B=>IB:&/KU7Q5*N+ZR;LDFW35VDDDMMMCW[\DV:8O.<N
MSK,\=*,L3B\WE4JN$5""E\FH1C%179&*2W=M[MGLZW,J0=/[5#D>1UQ=N.0]
M?_)J3#.RPROBL-^\4OMI?>>L-J*<GHEN^SS8\1<8 _"8T?E\/8_XL3+N8?I^
M.?+Y76]\VU[B6TV[<]5X/9^LYI/R@_/^H<Q!RE]67V63Q\,00#KKU4(^GX![
M?^SG_4.'[!]_R_BSI,L3_FWTETWKY1;U8FH_@U[2BHUQT97]%QT;T3]",>??
MH>L'VJ?S, >O8?7@ $?3\P_TXSFROM[E=^#V\_B/:IA_?!_'_-ZC\@]1'MZY
M%_'V/\ 4_>D> 'S\^;\G@.>0^H<<\A]H=OMR2&[=OL;^&WK*H*$, "!@[\_Q
M>N1?Q]C_  )VW-HK)AZF_0 C]?H _3]'?%_'V/\  <K]Z6_-[%0IBF#DH\A]
M?_CD@UP!@# & , 8 P!@&.'Q:'Y([H)W8NY6.E%*.-:-+$4DV[@"NZH]VQ1F
MEKCG#YALC4#Y9G*5U:3CGL8SV=2'4PU=*Q3>P,%GA%0 ^]X8LO5IKHAT#(4P
M[<:L%=G&$(#9_+2+1NSC+A8XTK-J[G-Q[_DS-V1VIF22+G;MQ!JFW*V;N(YL
MDE#QX$_O,7U\P?7U# (!>*<8H^'MU6  @(CJ]WQP(?[+Q _J[_=@B6S\'\"?
MA/4_^&/ZBX)-^ , 8 P!@# & , 8 P!@$;-Y]1\?H>4J3:P:\OUAA;:ZD6B-
MKK+W5J$##.H> L%LE&TRA<=F5"RF49UFKS$SQ!UZ:!ZFDWBXTSV?>-(E8#K\
M/..JTZ4V7>H9\^VWLY'X30-8QHINK%!5)B8'T93&*9W!XR,<"=?\)-IVU=PU
MA6\HLR:2<LYB:M4P1 YMAZ::WN^O3;3J28$NRUC:N& 5J)F[!"UBDPKH2 K"
MU)U#O(29&0=)$%*>N:ZC6>FRK.V#8(6LJ-JXU O;KC7%0U-382@42-6B*K74
M%VT1'N).4F5FR+AXX?JD4DYMY(2KL1<NESE.\>KG(0Q4B&*D0A"@=YP!@&.W
MQ!.E?=_5'J\]0TUNV4U?)DFXA^O$++JQ-8G&K%1T+A&1FJW%GN2!SBNW=)I(
MR#B+5<L&I%XX ,HX)H<]RS%YE1HPPN*=%TZDI3IMRC3J)KT7*44W>#V3O%ZW
M5]8\ETMR+,\]P'R;+<VJY9452$Y.&D:BB[M.45UBY-)-Q;2O&ZNI(:5U==]<
MZ@KNO[YLJ<VC8XVIQ,%)VZ?:QR+EV_:0J$8\=E,R9M7SA)TY35=F6F7TO,*'
M5Y<RKI014-L,OPU7"8:C1K5I5YTZ<82G+5R:[]VDM$W>32O)WN;W*L)7P6 P
MN%Q.)GBZ]&C3A5Q$[<52<8I2D[)7U6[O)K63<FVX7ZH\.%G1']"0L>Q9VS5^
MJZVAZ7*F:S%M@;+*.V>LZ9KMY'MIV-L"*K&CI&J;R<@X5(H23-:SR;9S*.4F
M44+;.MS\^!L"Y^XNCR6V0>DU]M98)QKZHQ]SCTH>RQDFTG%8.PZCV-J.,UP2
M>U](4R1_ 6*B+ZHX8RSAVOL")%.;1;VAV>R*+QX%E4?#[V<>?):)';-;GY=F
M6/GF?Q^O6:;,ZG8_86GK5'4:=F9.T.YJ=U1 P6FHB$AVDLX=V5S*S$K:):1=
M/SJMG0%S]A]%-JMVK]$ZGBKI6&49IO5;"A.[7*UB4>VFSOXG3EKU0U._(E-M
MXMY6Y MG/*O(UVD9['B,TE&N_;S?O# "K,]%%EL%7U5"/]@DCEZ+.[0M,XTK
M(6J @924VGU$T+=DO'QC*,LK(Y(F+K4'==8QWQ8[Q=2$N#DX^[M7,HP=@1IK
MWAY=0<PG>J/L;;A):IK:F4I$7?9.1LECM=XNKVFV:OQERFJ[.3LS7X]'7*]@
M:(UI55H28F&U<KIY\7SN()).WGW>[SV@N_K;H[W?#[6VJC>-AOY/6EKT#<-2
M1UY96BU#?9&4N%=T[56<VI"R$Y)P+*5K#?6UIM@SQ8Y@_<739-B>D,^^(R[Y
M^!\Z0Z&=RS5GM%HDK#T]LW%MUS8=1NX&NZLLD-28^I3M184\DTE5CVE^D_M,
M='1Z"7*T@RCGT,VAJV)&C6!1?/0);/=%V5UO/66R6TY!L:[KBA6*I"1.&>KW
M:SGL$2RC3I3<NZ?JPXMF3J*B)N/E$8TDXV6:OH7W@(F<ERN0(&_Z73OE@Y9/
MV^^BG8,YZSVBQP]:2M-?L>PG\CHNF:;4,]N$G9961AK!;E:DI<9J;8/8]*/L
M[]!V4CX[-NY:@3*Z?.GS:.M;R[O=]V&VM+FQZ_B65LC&Y)I5%ULETE7WUJFX
MQ65?N31=73G&$^>N5Q!1:+C6D^HK'1L+*K6B0M8$T@] ^78/J/\ &/?]/? -
M< 8 P!@# & , ^;,"(1<@('*D8&C@2JG 1(D8J)S%4.  (B5,0 Q@ .1 !#O
MSQ@&*WPQ)B&_89G7T1*M+Q:"0-.=V21@%K:*]KDX",GZ(23:%V#'5H[=*:EJ
M+--*ZF*48S^%LX]=5&.CUV"AP*VD]_\ B!6^Y:R/M?1*-)AIVW;DA+S1VM1D
MFCFOP,->MP%UI;@V>M/3U/<0ZM'KNL8M\P,$1/V2?M"UK@V P*@PK$"S?1S8
MM@J^)MXPSU?6XMIXT'T$NEX)&W1#HJ<@TT3:6\3%A* @@V,I,L%'+\'GL@:,
M!;"U<F,HJFH,-M)V5W9_#RB_1I4*EE7Q$J-VDW&#G:.MY:=CMINTT=]\838&
MUZOT#;@?UU>\:E>A<^DB+:[#U]LB4IMN;$NO5?HZK7*OP]BH\G!VZ!.ZK\U,
M0+V5BY1F#^.D7;=%8$7"A!HA.4IVE!QCIZ3NO'3S^-=2CAE2C..+XJCFTZ:I
M5$U%/23;23NG>W=MR/-#:[G<*?"S<_/]4O6NFRA(64FG35+KKZP5W[IC%LUW
M;DC"/#>1%9!THB@HFV01()W#CR(E 3'$@W7N[;7=C%:5W9MKD]5=<G;E?LW(
M_=(NVW>R-)U>1I'4-UEU"+;OYN&0JZ767U3T])NZ:R*SER>(K\#NIK%IL5S/
M"J^WBT"(KO3O/:^9V54 @>?-C.AX(&S-UO.H;Q J/*; WCO6OTN"Z+G58KVW
M]^[(V<:DENJ'4*>WS4!);?MMO=L E!A(A6581KI \E\+CDA(?W%J5&W.4HVM
M%RN^2;LNWV\KW^[(PU'#U9R5?$K#Q5"<XRE3J5%*K&_#12@I-.I9/C:X%?TF
MFG?*;XI\]>!\-[KX24U^J1J3IPWU$$=C9(D2C63:RL(JVT4O*!RID'GB#-_J
MB<"F ..2B-,IR<9>C)+9JUM.&[;WT3[U?:URY6P^#CAYS6.IRJ?))SZOY/44
MHUFI+J.-JTFU:U1>BKZ-:V\.[7]H3#@ \I$P* ?,HIE'D0^O.>'2W?B_B?G9
MBTOE%1IMWG.[:MJI-6]2LME8JB/Y0!ZB!> ^8CYP[ 'S'[/7(+=/37E::]L5
M^!E*\!5W*-_%-OY8R(/* [Z%;@@_.5XV:!&LR[SU*Y*^,1QP9V"CU!E'@W;<
MJD,_*X/_ &,W7$/0^AKDL%B[*]\3%=MOFERO=:]Q]3?D,A2ET=S/K*JIN.9.
MUXREQ-T:%](I[7XG>U[:.[/73M&P7MUJBZ)R6O5HI&1UILP\XX-8XAX6O*LZ
MW*EC$3D;#[23^+@!#E59%*1EYA!R!1 0SN<'*7RO"WT77TM;?^I'MY]GAV[^
MXXC#X50K<&,C6=XJG&-.I'C4M92?'%)<.UF[OBT5DV>-2+'_ %(C0XXYCV(\
M"/(A_8R?T[?7^01X[Y.96688Q1=U\JJIOO4I;]G98P[:N^EHQ2]6EO9N<POY
M09A![/P?LL[^XFSX<;J38=:FN7</$FG9%OKG<BK.((];1YY!PG Q!DVX/GG]
MBM15$/("JWXA/4P  @;.EP#:Z-=(N%W?7Y3>S3_ZB23;Y<]^SD[BE3ISKX:E
M6J=32X)7G*,IQ@VU*[C'TGH[VU=MK'J(<V+8"2<B9OK95P=O!QL@R(-FAD@D
M)ER*02%?\Q^/=31Q3JF^*+ +)U[$01#E0O'*.51:V>BVLO79NVW>E?MWMGQP
M^"<H*6-A&,YSC4?4UFZ<(M<%1^CZ7%K:*O)6O)6LWTO:-CWJEK_91=2Z\@'&
MRFM+.?5IKE:VC6IR5YDHM4C-&R'8-GK]E"5^6414E%$VZZLJS;JDC2@=9,2T
M];4OP]7-RLFEQT[OLTW7/5K2UB:6%P%Z/68Z$8NM.-7YFN^"DMJFBU4FDTEJ
MKZZF.C:&DNN/;W13K'4F].H=OI/?]'O6DY.X;[T1+4YK&[BLU8O#1Q5DX]O;
MV5.;UA2?M:-(D9ZN(QK)G9[ BXJ,''NH"7*P5*=1N4>JJ.R5UQ0VE=:W:>F^
MMN6ZU4O#X%\#6-CJY.3ZBJNKX=(W5WQ<>EFMG=O6QE#+/[#:-WC<M$5F5XY]
M#QS5Z6PP;'X\R60(64L!6P><L<5FJ J#%*"*R_G\J"@%#S8XY:+JZEVU;TX;
M<VM5>VE[]OB/DV":I/Y?37'"M*HG0K/JIQOU<)6BN/K%HI034=+Z'*4G[V"K
MHB>O%%44K0UBFZOX2Q!1=5U4IP<6HI!+YTBM# 7SPR@C(+ 813X$HER5.;NE
M">]K]9'1/?2]^'7LOVV12L-@EP-X^%Y4)5)1^3UUP5HOT:$G;TG)>E&HO06S
M:+A1AW1VW+QJ+-855P!'VI5^$R*F(DH*A/Q0%9,"K 3U(!_9F_'(;+T;V5TT
M^:;N_;S,&2BFU%W7)Z]EWOKH]#Z.20, 8 P!@# & , QP>*/^RBOTGVIIJ6\
MS]/M[B:KR39C46ET/<+8W&5;"YC825UC<:;LNN,($G%VNT[1!LUA8T"L6D$:
MA8FZCF/5 ZITNCO.@>&9"R5+JA_V?H;6VR;+#PFS(38A%)Z]N+7;I]>=EXB<
MDYK:EG4N+URYM$0>QR$9<[V>7CW%@+4I.=>)1(%I);JNZ]&-A5C(W0L[)B%V
MU>@DJVU-?EZV:O3](DG4I67;YQ$02T9.R-UBU_C%\:REKH=(@)"#1F7<5*O0
M!P!:?J]WUU/VSPR]WK[2Z<;K(2MI@)>&LUHB8^K:OBM:PJ,3JJ7=S%II6U+W
M!WN5CFMTL-YI<4M0H:W.I9CKPTVLU32F(EQ+"'LS/PD(B!A$  1.;L'/RX#Y
M@ _+YA_%WP25< 8 P!@# & , 8 P#01 /40#Y=QX[CZ!^? +<7G9M>H!6:<L
MLY?3$PHY0K-1@V9YBW6MTV(D==K78)H;WM\#,JR:TI(*>[Q$&S,,C.R$9&)+
MOD@/'OXZQH6Y^(QX73K9?44OH[:1-F0*=4U)6AEK*RU!!C;_ (M3-MWRW0EE
M:-XJY7/8K2IU*0:4^OJ&CJS&R+]A;+ 2KQSF8#U^?*^)Z_Z!KAI5U7U@EY)S
M:KY.)HI6&YR22:3MT@W$5$82%9D.NA7*E'KF54C*U'*BU175<24@O*3SZ3FG
MX%T< 8 P!@$ O$&\0?6?AX:(O6\=G5:[6*/K$$DM ,8"OR9H>S7"7>K1-5I+
MBY%:.8: DIV5*B551X1=:-BC+2YF3M%(J2D76NJTT>JT=KV?9IKX O;TW=3-
M"ZK=5UG<.K65L_ *YUJNVNLS5FJLO6F\Y#61C\0:N8E62230DB-B +>1%HHJ
M5B[*+5R)5/Q<76UU?L]_PU! Z7\179- ;L5;9IQ*WBQM Z9M(U]=S1&AMUZ]
M?$9;=:U66MJLE$RK>7-9:BYU55GSZ,).,8'8[EQ>'2L,T;#(.'KWQ)-A2L[#
MU&]:DJ%<GW$0Q>OIV1O,K6M<M49ROUBW0<Q/6N1I[YQ43/XZ6D*PE7@B[*12
M^+5N%3LJJ$V=XP D!T1=9]GZH"/8>T:S"GSL!K35=OFI5M)*>[/9F[5.*FI-
M!6J/T"2]7C'+U^X6I*IY:S$GH)D]=O7D2[9E8N@,AN , 8 P!@# & , 8 P!
M@# & , 8 P#J]UAY"P5*Q0<5(A$24M$/H]C*">>3"/=.D#I(.Q/5[!5+$0$%
M#%4$T+9H&3 "\LY9BOY'! (T])/3;*]-%0GZO+6]C>7EBM<M;7L\TB[Q%.WL
MI-2LG(O7,PA<-F[(*Z>D2>-(Q-_'*1"KIC&,S2Y9-^07I0)<@B0 $._< #D1
MY$./H/';T_D], Q(='8<>*QXQWVM?#M']/3U<\$+GW/[D_O*OCD_N;6UOX8^
MC'^/K5Z>PP2>9V6K5:G%R.)NN04PX13,BDO*1+!^NDB)A,*2:KI!4Y$A$QA%
M(H@F(F$3%,(B(@<-I2J7'N6[R/I]78.VBGM6KIG 139RW4^1T5T6A%$CA^,
M'3,4X>8WXW)CB8#*3X W?K&\3P?3G7W0B/\ _"ZFOZ?;@&93Q6/W-#K[_P""
M+O[_ +,;)E,_H2^K+X,MU?S4_JL\&#?]J3_VI'_HPSPJ6[\7\3\_,7^?J_XM
M7[;*H?MJ?^$3_G9!:C]"7K^",L?]3]_NIFSO^ -</\X+2N>B]"_T/&?O,?\
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M/1%TXE7,BJ^5<<'47,)0X OJFF"8" "(\CR(CQ^H. #Y^@!]W 8!OP!@# &
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MJ[5L^/(/8U<C1N] XK_K3IT%IPVU;!5K*UDBV?9=-_ *(23L4X:?U4ZM:=G
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M@9*'H%*KFNZVREBO)-!&G5$Q5:S"R*+IT9";2@G@?%8E>82?.8Z9XF&2S>1
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MQ<NYA_6&._>Z_P!MDRW?B_B<XGY0?G_4.8A'*7U9?99/+PQ/[NO57^\/;_\
MD.'SH\L_5OI+_CY1_NJI35_.TOJ_]N)ZPS>@_</ZLYPJ/STK[_Z^W7_?99?\
MMO<^\LJ_JK+/W'"?[:B<-7_.5O\ 'J?:D=5S.+!*3H@_NP>FO^&B@?Y?8YR/
M3[]3<_\ \OG_ *L#.R[]*I?6_P#UD>[!+]K+^?\ YPY\6G9%3 & , 8 P!@#
M & , XJ[%BY6:.'+-JX<,%CN&*Z[=)59FX4;K-%%VJJA#';K*-7"[8ZB1B',
M@NJB8PIJ'*(%?@A.X% ./F!0#CMQZ]OEV_BP#I#G9NO&<HYA'5XJ#>99R\9
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M;GTX[\#R(B/\?Y^,DAWY.WJN=1N5XJFOZ_)VN[V6&JE8AT/>96>GY-K%1#!
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MV$O[IT_Z*L\U%J*(?_*GO)24T7K4K8_ .EX>#EX"9W19WC8IBJLT U= 56<
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M@L'\DH.DZLJCO)\4M7Z3;MI;9N3U5UM=IJTTD_R"_=G*F8;\ 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@%!TFHJV722,!%5$CD3.8GM"D.8H@4YD_,
M3SE*80,) .03  E Q1$! #%5KKPRPHEWU3>T]H5UE.:O=[(/'2U'U?,528C(
M?9,OM*=?5"B-I[;E\H=,J45+[*2DHYN[H%HL*3BLL6J%D:Q+DD:Q Y-3\+@M
M(V3MC<%7Z[>NZ%V5O(*(7:MJ;6GIE7>7 FL8)Y6:(5XU>=++B,9%KT$_=Q[8
M(EBP%RFL91^+I<"*E$6[WY\^;*V[<GA<DZ@-?R>K=P]>'7E>:#,2M2G)*M2%
MJZ8V+1W*T6W05\J;Q1S#=*\9($/#6ZM0<T@1)X1%9Q'I(NTW#-1=NJ)(]J>
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MPI:4DUXJ_BM=?#EZ]-&'%--/5-6:O:Z]]OXZID*R?U.3T<IIE*&^.LH  /*
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M<T]BG]!^7S]>/KQD."?;NFM=FG?3UZM;,#V)/M_3A0BKK6SOI?3TM_5H"H
M   >@94E966RT0-< 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M ZQ;KA6*+7)>VV^?BJS6(!H>0G;!-/$&$1#QR0@"\A)OW)B-F3%MY@.Z>.5$
MVS5$JB[A5)%-10H&*3975UMKJ%V]&Z-Z5G%JI4-7+ZK4]C;E"BHRX5NT*5B=
MM-)0GH:QE149ZUM36J6A +'#0EK!U-A4V5B7J4:^6C[,!ENA47K>)CF\F\+(
MR*#)LC(2!&I6)'SU)!--T\(R(JN1F1TN4ZY6I5UBMRG!(%E0(!S ?4P#C.5V
MZ!0,NJBD(F*1,55"I@910P$33 3" "=0YBD(3U.8P%* B(8!C(OG7)9;KMVG
MZ<Z/V>NMJRSAU)N['9[4^L$?KR9:P1XAO9:U1K[&M"U>7M-80L<;:K"Q82LS
M+-:G&61Q&5^8EHMO$2@&3A-,1*'M $![#^5SZ_3CCT^X,AI/=)^(*X!Q_P#
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M^@'@!X[SO42 ^@#_ /=X?4! ?N'\X@:B\\4HO<T7T \<\=IWJ(Y_CKP#_$.
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MS,"8^ , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@&@F* \"8H#]!$
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M78R]F?I1]ML%IDC3#-HUEF]8<.$&+#5UDU;<Y-ZQBI5PWD[L]K162CVON!<
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MNZ<*MFZBJICHIF*!W))/R$ IN![C]W _+OW^_P#BX#@  J<!] [>G8, <!]
M^OH'K]< <!Z\!S]> ^7I^C ' ?0/T!]!#]0B'W". . ^@?HP!Y2\\^4.?KP'
M/Z< UX /0., 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 $
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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L@9 2D*3TY].._P#3_P , WX P!@# & , 8 P!@# & , 8 P!@# & , __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img192321128_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_10.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X32R17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(R.C R.C(Q(#$W.C0T.C Q   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,V,@  DI(  @    ,V,@  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,CHP,CHR,2 Q-SHT,CHS,0 R,#(R.C R.C(Q(#$W.C0R.C,Q      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  (P8         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ H $  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M<6F1Q/*K-YDJQ@*.F2!G]:QM8UC[3X=G*VDY$B[2R ,J=#DD=N:+ V<3XO\
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MZ054NM.MKV9)+E6D"?=C9SLSZE>A/UH MTPPQLVYHU+#N1S0!SNO_P#(6?\
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M$?P9>AP?@W_D6/%?_7HO_H,E-^''_(9U#_L'2?\ H25R1^R>'2WI?,A^'/\
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MV.656..>_P!X_3- &I12&%% !44UM!<%#-$CF,[EW#.#0 LNX1,T:H7 X#'
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M2.&)Y976.-%+.[' 4#J2>PH ABU"RGBCEANX)(Y6V1ND@(=N3@$=3P>/:K-
M!44=U;S2R113Q/)'PZ*X)7ZCMT/Y4 *D\,DKQ)*C21XWJ&!*YZ9':D^T0 D&
M:/(<(1N'#'H/K[4 2T4 %% !10 44 %% $<L\4&WS94CW':N]@,GT%$-Q#<I
MO@FCE4'&48,.F>WL1^= $E1)=6\D\D"3Q--']^-7!9>G4=NH_.@!);NV@W>=
M<11[0"V]P,9Z9S3HYX9BXBE1RAVN%8':?0^AH 07$#,%6:,L6*@!AR1U'U%2
MT %% !10 44 %(PW*5]1B@#DG\%QB6$_VO,GE1>7$FQ>,(R[O?&XGFHE\$1A
M5;^VYVW$;6P!GJ>,'J.Q[57,3RC8/!F88_,UV7</,+"/&#E2IP<YQ\V3[@5=
MB\)6]KJHU,:C(!DX4_=P5=0,YZ?/G'J!Z47"QJ76D)<37,DERRB=8T('0!6R
M!U[YQ^-5K?PY#%<I,+N1]C*VTXQO4\-]<97Z'VI7'8W:*0PHH ** "B@ HH
MRM>T.'7K..WFE>,(_F*R=0P!P?P//X5AMX*@CMW@&LSQD)&NX[<H%4*,9Z9Q
MG--,30P^"G*2_:-<FB>2220[,< EL<DYZ, 3[ 5:3PE:QZL+^/4G&  L>> #
M&$ SGH<9QW-.XK&CJ.AK?7AG-UY19=H7RP>S#\>&-0_\(S +1[4W;[&8L.!G
M&' !]<%\Y]0*5QV)[308K>[2Z%R\FUS( <8W-NR?QW#\A6Q2&@HH ** "B@
MHH R]4T9=2GAE,I0Q=!C(.?_ *U0R^'XS90VL<I"1R)(=X!Y5@W'U(IW%8I-
MX3W",?:%"QXVKMR  & 7G^'Y^:T)-%WZ8EJ74LDGF(YS\AYY SVR>.E%PL1W
MN@27LDQ:^F"28.S)(4AHV4@9P"-AZ?WJOZ98_P!GVGDF3S&+L[-C&23DT7"Q
M<HI#"B@ HH ** "B@ K%OO#T=]J#W3S,-X"LN!T'I30F@O/#\=R\(W!HXEVJ
MLF?48&1S@8'O5)O";.Q9[L.S)L9F3DDH%+?48R/2BX6-2XTDW%[8W)G(^R2%
MPF,@Y!'4\CK5%O#+O.))-0F?D@AB6RK$[UY/ (('X"BX6-NT@^RV4%N#N\J-
M4SZX&*FI#"B@#__9_^$QZ&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHJ"XN/)X"@GCEFPO.<9/;ICIW% $]%<5XN^,W@GP#J$>G^)?%WA
M_P /:C,HDBM=6U6&U=D)(5L.P."5;& <[6]#A;KXR^!K/PI:>*)_&/AZ#PU=
MRF"VUF;5H%LYY06!1)MVQB"D@(!R/+;C@T[,5UL=I17F0_::^$I.W_A9W@T.
M#M:/_A(;/<K?W3^\Z^U=)X/^*'A/XAK>GPKXFT7Q-]CVBX_L?4H;L0EL[ _E
M,VW.UNN/NG&<468E)/8ZFBO,?^&F_A-G_DI_@K;M+@_\)%:$LHS\P DY'_UZ
MZ71_B?X4\1>'K[7M(\2:/JNA6)<76IV>H0RVT!1-\@>16*J50JQW$?*P/2AI
MH%)/8ZFBO,6_:>^$4<@1OBAX-&>G_%06GK@CF3Z9],\X'-=]J.N6>BZ;=:AJ
M5S!IUC:0O/=75U*(X8(T7<[N[8554 DL2  ,]*+,=T:%%<WX2^(GAWQY8S7O
MAO6=.\064,GE2W6E7L5U"DF 2I=&(! 8-@X."",UT,3F2-6( )'(!R/S[T!<
M?1112&%%%% !1110 4444 %%%% !1110 445!-=>3)M9>",@_IZ>I'Y]* )Z
M*X/Q!\=OAYX2U:XTO7/'?A?1=2M\>?9:AK5M!/#D*1O1G!7AU//9E]15C7OC
M+X'\*Z;I&H:UXR\.:39:O$9M.NKW5X(8;Q %):%V8"11O0Y7/# ]Z=F2I)G:
M45YFW[37PD3&?BCX+&2 -WB*T&?8?O.O(_.NCT?XH>$_$7A^^U[2/$FCZKH=
M@7%WJ=EJ,,UM R)OD5Y%8JI12&8$C (-/E8<R.IHKS1?VF/A'SGXH^"P<XP?
M$-H/YR5T?_"T/"7_  B(\5CQ/HS>%C]W7%U&$V)_>"+_ %^[R\^9\GWOO#'6
MDU;<::>QU%%><Z;^T9\+]:OK:QT_XB^$;^^NI1#!;6NO6DLDLA( 1560DL2<
M >O'<5UGB+QAHWA'1Y=6US5;'1M+B91)?:A<K!!&&(52TC85<D@#)P2RCJ11
M9A=&U16-X;\7:1XQT>#5M U*SUO2KC=Y-_IMREQ;R[6*MLD0E6(92IYX(([5
MKJVY<B@!U%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%0SW
M'D\!03QRS87G.,GMTQT[BN0\7?&7P3X!U"/3_$OB[P_X>U&91)%:ZMJL-K(R
M$D*V'8'!*MC .=K>AP]Q-I;G:T5Q=U\9? UGX5M/$\_C'P]!X:NY#!;:S-JT
M"V<\H+ HDV[8Q!20$ Y'EMQP:Q_^&F/A+T_X6=X,#@[6C_X2&SW*W]T_O/O>
MU%F+F1Z917*^#_BAX3^(BWI\*^)M%\3?8]HN/['U&*[$);.P/Y3-MSM;KC[I
MQG%<W_PTU\)=W_)3_!6W:7!_X2.T)91GY@!)R/\ Z]%F',CTZBN6TCXH>%/$
M7A^^U[2/$FCZKH5CO%UJ=GJ$,MM 43?('D5BJE4*L<D?*P/2N9;]I[X1I($;
MXG^#1GI_Q4%IUS@CF3MQGTSSBBS#F2/3Z*SM0URST;3;K4-2N8-.L+2%Y[FZ
MNI1'#!&B[G=W;"JJ@$EB0 !GI6;X1^(?AWQ[8S7OAO6M.\064+^5+=:5>Q74
M*28!*ET8@$!@V#@X((S18=SHZ*9$YDC5B "1R <C\^]/I#"BBB@ HHHH ***
M* "BBB@ HHHH ***3/.* %HJ":Z\F3:R\$9!_3^9'Y]*XSQ!\=/AWX2U:XTO
M7?'GA?1=2M\>?9:AK5M!/#D*1O1G!7AU//9E]10!W5%<7KWQF\#^%=-TC4-:
M\9>'-)LM7B,VGW5[J\$,-X@"DM"[,!(HWH<KGA@>]9#_ +3/PC3&?BCX+&2
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M!J5GK>E7&[R;_3;E+BWFVL5;9(A*L0RE3SP01VHL.]S8HI%;<N12TAA1110
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MB Y5<,!N R <&NQCC$:[5  R3P,<DY)_.LVS5#J***DH**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHRG"*%]Z]>S11=ARHP_ _A"T\ >"M \,:?)--I^BZ?;Z;;27+!I6BAC6-"Y
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M/[3CO;G[*98E%O-*B!92!<C+<>6\<J#<FT(<@<[/LZ2X,9&4^\N5R<<]P3C
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M65BT"S9ROF$E,GC(Z\-X>9_&7_!4CQ>NLL;I?"?A93H9 "?9-\-H'^Z 7/\
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M5R7#VB5K'ZL1WB28P5.<G(;(QQSD?4?G39+H1Y9E(0'F3^$=<_E_GC./A?X
M_%SQ)\:/^"??Q.O_ !;J7]MWND:9J^E"^E0K+<0KIZ2*TQQEI 96'F 9.T%L
MON8U?V-?V4?"?QG_ &;?".O_ !)GO_&-NZWD.C:/+<365II-N;N9955(70RR
M2N&9Y9,DKY:  1@E<J2N5SN]K'WDUPRJ3Y3$X)"@\\ __JI9+K:I\M?,/8 ]
M3C('M]3ZU\+?LI_%+6/AGX<_:2\.75Y?^*=$^%-]=2Z.FH7LDEY+;PI=(EH9
M&RB($L8PJQQA0SL=ISBO$?A)XJ_9_P#B)H<GBK]H[QSJ7B[X@ZJ[2FPU!-4$
M.DVPFE9(86MEV[7SYFT':-P543G-*'4S=5[(_5E;A2V"RX/W3NZG&?Y8I'NB
MNT)&SL3C [=>3Z#@U\3?\$V?B5K/BG2_'_@F?Q$/%GAGP;>6UOH.KSVCPW%Q
M9N\X12CG<L2I#&Z(1E/-VY*JH'VN;43QG>VX'^%@"O!Z$="/U]_3-JQT1=T?
M"/QW_P""BVO:7X53Q3\./ ,UQX)744L5\7>*[=XK'4&8W *VL(D0NO[C?YK.
M"FUHWC1F%?>D&[REW?>[_P"?2OB?_@J_"MO^SOX>=2P8>*K8*RNP8$VEX,[@
M<D88\>_&.,?;,:E8P#R:J5K*QG%OF'T5YG\9?VD/A[^S^-*/CS7_ .PO[4\X
MV?\ H5Q<^:(0AE/[F-]NT2+][&<\4OPF_:,\ _'-=8/@?7/[:&CO$M\6M9[<
M0>8&*Y\U%S]Q^!G&!G ()@TN>#_MGZLOQ.^,'PC^ \=Y!]A\0:A_;?B2PDFG
M@%QIMON<1-)$1E9%ANCM/\<$1W1X!/U_;MNA4X(ST!7:0.W%?)7[)NJ0_'/X
MY?%SXV1AFTZ::'POX?,]U.TB6,"+)(RPNJ*D<[/#,!C<KM(IP=Y?TCQ]^VC\
M&_A/XNU#PIXK\8#2=?T\I]JLQIE[+Y>]%D7YXX65LJZG(/?L>*I[6)6]SW&B
MN9^'7Q'\/?%CP;I_BOPIJ']JZ!J'F?9KOR9(?,\N1HW^21588=&'('3/2NEJ
M"Q:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ***:: ,+QMXWT;X=^&-2\1>(M0ATK1=/B\ZYO+
M@D(BY  X!)8D@!0"6)  )(%?./A7]L+XB?%BQDUOX;? #5O$?A228PVFJ:MX
MCL],DGVK^];RF#C:LFZ,,KL"58<,K*O&?\%'(_\ A./%7P*^&%Z,:'XH\4JU
MY/;C%S %\NV5D+$IC9>7!.Y&&X1YP!A_H3XG?%2V^!FE^'M-T_X<^+?%FG3Q
M/;P6?@G1%NXK".%8PD4B!D6)"' 0>D9':MN56,.9\VI=^$/QL7XG?VGIVI>%
M=<\%^*M'$(U31-9M\&/S!(%F@F7,=Q 9()XUE0_-Y1;:%*D^D)<AH1(,;2,C
M<2/IVKQ7X"_M.^'/VAK[Q99Z+HGB;0[[PS)#'J5OX@L4MI4ED:53$JB1R&C:
M!MZD#!"CYLFOE;X>_&(_M5>,/%'B;QK\>IOA/X+L=1GL_#?AK2=?@T+4GB)B
M*S7&7;S%**!\Q?\ >/-L,03:RY+CYTC]$UNMS#"D(1U;@ENN ._&<_\ Z\))
M=>7U3[RY7)QSW!.,#MWYY]*^+_V/_C/K-U\:O'WP8O/%4/Q$\/:+!-J>C>+/
M[3CO;G[*98E%O-*J!92!<C+<>6\<J#<FT)Q'P4L_B3\=/CU\??"4GQ1\0>'_
M  9IOB282MINI3'5(E6YNQ:VMB\A9+2 ^6S2% "PAAC&$9J7L_,/:>1^@ZWB
MR+E4;;_M?+GG'0_A^?KQ2-<A2=P*8SG/3_/?Z5\8^"?$/BOX!_MG:-\(9O&?
MB#XA^$_%.C3:G8MXFNUN+S3;@)*QS=%"\D9^P.H3Y%'G9VLRDOR/B;XR7?QT
M_:1\:>%M8^,K?!KX8>#KH6$=O;ZE!H^JZC?1^=%(8YW;)C#K+G!*;$A_=[W+
MJ_9V%[0^^Y+I85#.,(1G?D;?S^G/T!J>-MT:MQR,_*<BOA#X&_&*^\ _M90?
M"K2OB$/C!\/?$]O_ &AI^M7NO+JMWIDZ6TKR1O<(NTEF@^6$DX5XW#*?,$GW
M=%CRU*D%3R"#G\:F2Y32,N8\ ^/_ .VKX$^!.JWOAPB[\4^.8+.2\'AS2(F=
MXT6"6??<2XV0H$B+N22Z1LLFPJ<UWG[._P 8#\>O@[H'CLZ0=!_M;[01I[7!
MG,8BN)80=Y1,[A'N^Z,;L<XR<7]HKPMI&F_!#XRZQ::796NJZGX5OS?7L%NL
M<UX(;*58A,ZX:0*"0-Q. 2.F17(_\$[A_P 8>> 3DMN;46^;'&=1N3C@ 8'3
MI3LN6Z)3?-9GT?3&D.[  /([]O7I65XJ\5:?X,\.ZSKVKR_9=)T>SEO[R?:S
MF.&-"\C!5!+856. "3C %?#G[3G[9'PB\?2?"M=$\5_:9=!\?Z3K6IJ=,O(A
M!:P>;YLO[R%=^W>ORKEV!&!4)7-&U'<^^4;<H/KZ'->+_M<?&"7X'? _Q-XI
MLI[>/6TB%EI0EGBC?[5,0BE ZMO,8)FV8.X0G.%RPM?"?]K#X7?&[Q)<>'_
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M3Z"^ _B_X'?$/X@1R_"_X>VSMIME-,GC'3_"B6%E;RAHXWLEN&CC<3^7,K;
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M?MLMU;L\J>:IB)$3/MW$(6'!X7ZX\@L/F;)R"<9P>F>,^W^><I]G*Y*N=V,
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M+\0P6=K 9&<1Q1W%_'&H+$GA47J>U?<\GW?^!#^8KXI_83_Y.,_:N_[&M/\
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MLR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IO\5.IO\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4G<TM)W-
M'YQ_\YAO\_\ 0OBOT<K\X_\ G,-_G_H7Q7Z.5O4^SZ'/2WEZBT445@= 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B>*/^/6/_KH*VZQ
M/%'_ !ZQ_P#7054=R9;'+]V^I_G11W;ZG^=%=2V("BBBF 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5V7A__ )!%O_P+_P!"-<;79>'_
M /D$6_\ P+_T(UE4V*CN:-%%%<Y84444 %%%% !1110 4444 %%%% !1110
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M_#EIX@^*&I6FHSV,^KK'*?M,+W-M!;1,=GE1OM(<[E+>:V7P%">6_P#!)?\
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M,8)C::0E%9FPL88YD=WKVCXL?M%> ?@*=)3QYKW]B'5?,^QD6EQ<^:4*[_\
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MZ8;$2"OGW]NCXLZW\(_@/<7'A^6:RU;6[Z'2(=0M9?*EM%8/++(" 23Y<$B
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MHHHH **** "BBB@ HHHH **** "BBB@ KLO#_P#R"+?_ (%_Z$:XVNR\/_\
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M(UCG[S?4_P ZV/%'_(2'_7N/_0C6.?O-]3_.NF&Q$@KQW]K[_DW/QC_VY?\
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MN_[XI/8#OH_]6GTJ1>E1Q_ZM/I4B]*XS46BBB@ HHHH **** "BBB@ HHHH
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M75KA]<$DRXN0&2,++<89]Q25B^&$9?(#;^QCIKN8*M+L?K6UQMP6'EIW9B
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M^^**/[O^^*3V [Z/_5I]*D7I4<?^K3Z5(O2N,U%HHHH **** "BBB@ HHHH
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MYJ_8'_Y(_JW_ &'Y?_2>VKZ5;[S?4U]9AOX43]YR3_D74/02BBBNH]T****
M"BBB@ HHHH **** "BBB@ HHHH *[+P__P @BW_X%_Z$:XVNR\/_ /((M_\
M@7_H1K*IL5'<T:***YRPHHHH **** "BBB@".20KP%RQ^[G.#^(!Q7Q;^U%?
M^%?"G[4W@_QA\7]&FU3X1+X;N-.TZZN[1]0TZSUMI9'=I;9"VXO;*%7]VQ9M
MI _=,T?V7,SQR,PV[003C.<<9Z'DC!_/\_EWQ=\7/VA/@]JGB:XOOAI8_%'P
MM]I>XTB\\-:@8KV*W>[F"0S0B*22:1(VMU_=1!0H)+,Q;;4;WT(E:VIRG[,4
MWA+Q?^U+XR\7?!W2)=/^%G_".1:=?WUG;-8Z;>ZV)U<%(2%Y6!@IVH,$.2JB
M56D[/4OV=O%'P%UZZ\2? 6[MX-)O]0DU'6?AQJKK#IMY^Y*E-/?RR;25B@P,
MB,GR]V(XE0\GXD_X*<_#SPEK%QI.N^"OB!HNLP*@N+2^TJUAN(MR;E#HUT,'
M#@X(QSQD8-2Z?_P4:TOQSI.H3?#GX4?$#QKJ]HL0>&WT]/)3>S#,TD#SF$D+
M(P_=MOV8[$KIRRD9J48[GV)]JVML,;9QN_#(]>O!YQZ>XS,K;E!QBO ?@;KG
MQV\3>--3U+XG>'_#_@?PNL-Q#9>'=/NA=:A)(TT#0SRRHSH55/.3<K(68L3'
MC;M][ME"V\:CC:-N/3''J?YUDU8V3N2T444AA7S%\<->D^)'[2GAOX(:AX@G
M\.^$M0\.RZYJ=O9W"0S^(/W^Q-.23Y98L+!)(_E,3)%YRD #>/IVN)^)_P &
M/!?QFTH:=XS\/6>O6R#$)N%998/G1SY<J$.F6CCW;6&X+@Y'%4M"9:H^9?%W
MPOM?V4_BE\)U^#U]>:;I?B/Q NBZO\/Y+B:]M;BTDPUUJ<4<CF1'@1(=\BDJ
MJB+.U=ZR]/\ LDZ_;^'/B=\?O .JI)9>([?QK>>)5M9I(CYUC>^6\$D>UBS<
M!&88^0W"!L%L#TGX8?LE?"GX,ZNVJ^#_  ?9:7JN-J7\SRW=Q$-K*WE2SN[1
M;E=@?+*[L_-NZ59^+?[+?PQ^.FK6&J>./"MOKFHV,+V\%UY\UO*(F;=Y9>)T
M9E#$D!B0NY\ ;C5\R(Y6>;>"M3M?B'^W9XZUW2KB&?3/!OA&V\*:@/,#^9?3
M7CW0\I5!^6,1/&Y8JRR#:%;[U>[^,/AKX5^(7V;_ (2CPUHWB,6N\VJZOI\=
MV(2V-Q42 @9VKG&/NBF> /A;X7^%?AV+0_".B6.@:=&H'EV< 5I&"JOF2M]Z
M60A$W2.2S;<L375* HP*SO;8T2/,7_9F^$BQA1\+O!/EX"[3X<M#T/R_\L^@
MR?SKYL_8!TVST7X]_M1:?IUI!86%IXEAM[>UM8ECBBC2ZU!51%4 *H   %?;
M\GW?Q'\Z^*?V$_\ DX[]JW_L:T_]+-1K3F;BS&25T?5?Q8_Y)7XS_P"P->?^
MB'K\Z6QN/UK]%OBQ_P DK\9_]@:\_P#1#U^=+8W'ZUZ^5_#(BM\0G%'%'%'%
M>]'<Q/O/]F+_ )(AX;_[>?\ TIEKI?BS_P DK\9_]@:\_P#1#US7[,7_ "1#
MPW_V\_\ I3+72_%G_DE?C/\ [ UY_P"B'KXV?\9^IVKX3\Z&QN/UI.*5L;C]
M:3BOL%LC@0<5]Y_LQ_\ )#_#?_;S_P"E,M?!G%?>?[,?_)#_  W_ -O/_I3+
M7DYE_"7J;TOB.F^+/_)*_&7_ &!KS_T0]?F3XQ\$Z1XXLC::M:QR*OF>5<1C
M;/"60KE'SQUSC!!P,C@5^FWQ9_Y)7XR_[ UY_P"B'K\YVQN/UK+++.,DPKQY
MF>%2?LPA+F66U\42P@NSH9+3>XSP"6$BY..I&W.2<#C'H'PZ^%.C?#J!C;>9
M=WLJ+'-=RG#D#L@_@&<L.N#CDXY[3BCBO9C1IQ^$Y5"S/O+]F/\ Y(?X<SSS
M<_\ I5+7?>)-<C\->']3U:6)YHK"VDN7CC(#,$0L0,\9P*X+]F+_ )(?X;_[
M>?\ TIEK:^,VI0Z;\)O&UW<'_1[71;R5V";]H$#GH,DGZ"OD9I.LT^YZ:=HW
M/(?%?[;WA+1O"^MZM;:+K-S/964]S';2K%!YABC+A6<2,4#$;=VUL>A[_$/[
M#?P(T+]K3XG>.O%GQ$N&UE-/:.\N=/A!M(KZXO&N6:1I(BI54*L=B;1^\7G:
M-C>9ZI\9->^)NJOX;\(>%I-?M]01K?[&]H[WEQA"TA"PMPBJ&SC/ W''.+W[
M+7[36N?LF_$S4?[3TAUT&Z=;37]'N(3;WD*0LZK(BR$LD\+/(HC8@,&9&"G8
MZ>A4HPC']V]3S^=RG[VQ][?M-?L(^ /B-X'O[SP1X:LO"_C2QM!)H[:+$EK:
M7$D:N\=O+"&2$"0ML\W"NOR98JH4^=?\$G?'^M:YX%\<^$I[O[9I7AV\MKBR
M+.[M&;A9A-"IW%0FZ 2*J@8:9V).[ P?CE_P5$TKQ!X)OM(^'?AG6K35=2M;
MBVDU75I$M9K!=BCS(%@D=G?YVPVY IVLN_D5Z3_P3)^"5Y\-?A-J7B35)7CU
M+Q3<QD6JW1=8+6U:18]R[?DD,CSY&XY4H.-IKB<91IWF:QM*?N;'VG&&6/#$
M,W<C@$_GQ2TD.XQ#=U]NWH/K3C7&CM.6\4?\A(?]>X_]"-8Y^\WU/\ZV/%'_
M "$A_P!>X_\ 0C6.?O-]3_.NJ&Q$@KQW]K[_ )-S\8_]N7_I9%7L5>._M??\
MFY^,?^W+_P!+(JC$?PI>AY>9?[E6_P ,OR/S9EQYC_6F<4^7'F/]:9Q7R71'
M\^=%\OR#BOTH_9!_Y-V\)_\ ;W_Z5S5^:_%?I1^R#_R;MX3_ .WO_P!*YJ]/
M+_XK]#[CA'_?9_X?U1['12A2QP ?J1QZ?SXHQ_LL?=5R*]_F6_8_7%**U;/@
M7_G*T?H/_3'7WTWWF^IKX$R?^'KA&UAP/O#'_,#_ ,<5]]M]YOE8\G[JDBMJ
MC6C,:<HZNXE%'X$?48-%0]#HM=7044?PL05Z[1SU;KM]CCG!Y-.6,MCT8$K@
M@MT;C .<Y7&!DTA)7T&T49#9VG*Y(!]>:*+@] HHHH **** "C^[_OBBC^[_
M +XI/8#OH_\ 5I]*D7I4<?\ JT^E2+TKC-1:*** "BBB@ HHHH **** "BBB
M@ J.20KP%RQ^[G.#^(!Q4E4YVDCE9AMV@@G&<XXST/)&#^?YO<5['QK^U#J'
MA7PG^U-X/\8?%_1IM4^$2^&[C3M.NKNT?4=.L];:61W:6V0MN+VRA5_=L6;:
M0/W3-&W]F&;PGXO_ &I?&7B[X.Z1+8?"S_A'(M.O[ZSM6L=-O=;$ZN"D)"\K
M"P4[4&#O)51*K2=5XN^+G[0GP>U3Q-<7WPTL?BCX6^TO<:1>>&]0,5[%;O=S
M!(9H1%))-(D;6Z_NH@H4$EF8MMYWQ)_P4Z^'GA'5[C2==\%?$#1=9@1!<6E]
MI5K#<1;DW*'1KH8.'!P1CGC(P:UM*VAAS1OJ=7J7[.WBCX"Z]=>)/@+=V\&D
MW^H2:CK/PXU5UATV\_<E2FGOY9-I*Q08&1&3Y>[$<2H?IW[5M;88VSC=^&1Z
M]>#SCT]QGX[T_P#X*-:7XZTG49OAS\*/B!XUU>T$0>&WT^/R4#LPS-) \YA)
M"R,/W;;]F.Q*^F? W7/CKXG\::GJ7Q.\/^'_  /X76&XALO#MA="ZU"21IH&
MAGFE1G0JJ><FY60LQ8F,#;MB46M6:QDGHCWY6W*#C%.J*V4+;QJ.-HVX],<>
MI_G4M06%%%% 'S#\;]>D^)'[2GAOX(:AX@G\.^$M0\.S:YJ=O9W"0S^(/](V
M)IR2?++%A8))'\IB9(O.4@ ;QQOB[X7VW[*?Q2^$Z_!Z^O-,TOQ'X@71=7^'
M\EQ->VMQ:28:ZU.*.20R(\")%OD4E5419VKO67Z:^)_P8\%_&;2AIWC/P]9Z
M];(/W)N%998/G1SY<J$.F6CCW;6&X+@Y'%<K\,/V2OA3\&=7;5?!_@^RTO5<
M;4OYGEN[B(;65O*EG=VBW*[ ^65W9^;=TK6,DC)Q;9YM^R1K]OX;^)WQ^\ Z
MJCV7B2W\:WGB46LTD1\ZQO1&\$D>UBS<!&88^0W"!L%L"QX+U.V^(?[=GCK7
M=*N(9],\&^$;;PIJ \P/YE]+>/=#RE4'B,1/&Y8JRR#:%;[U>E?%O]EOX8_'
M35K#5/''A6WUO4;&%[>"Z\^:WE$3-N\LO$Z,RAB2 Q(7<^ -QKJ_ 'PM\+_"
MOP[%H?A+1+'0-.C4#R[.$*TC!57S)6^]+(0B;I')9MN6)I<R#E>QR/[0V@_%
M/Q!X0L[?X2>(]-\+^(H]02:YO-6C\R)[01R!XU!AE&XL8V^[_![UX!_PJW]M
MLLVSXQ>#%3)V[K2,';GC.=-ZXQ7VH(=K9#$>H['D?Y_&E2((,#CZ<4E+38;C
MK>Y^6'P9TOQOHO\ P4\T>R^(VLV7B#QG%YWV_4=/0+!-G1G,>T".,<1&-3\@
MY4]>I_4Y_NO]/Z5^<_\ SF&_S_T+XK]&&^X_T_I6M1W<=.AE35E+7J?G+\4L
M?\+.\8?]AF\_]'O7,<5T_P 4L?\ "SO&'_89O/\ T>]<QQ7UM/\ A0]#G?Q!
MQ7U!^Q/U\8?]N?\ .:OE_BOJ#]B?KXP_[<_YS5QX[_=YFE/XCZAF_P!6WT/\
MJ_$?]J:-'?PR"F=QNU9F<+A3Y ;!(/&![]#Z$U^W$W^K;Z'^5?D[X[\$V7Q
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MQ-\"/V*?$7Q_^"_B;QKX8\00+KNDZI+9V_A]K9$%_+''#*_^D^8%B=A+A0R
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MJ2)/+C5>R\#Z5#]H;R]VS)^4<,,9)P0"<=#_ )[5/&VY W3/3K46-+CJ***
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MBD6%%%% !1_=_P!\44?W?]\4GL!WT?\ JT^E2+TJ./\ U:?2I%Z5QFHM%%%
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MK88EOT5#%P&( +?-P" <\YYY.>N3USFJ::-*4G*&NX4444C0**** "NR\/\
M_((M_P#@7_H1KC:[+P__ ,@BW_X%_P"A&LJFQ4=S1HHHKG+"BBB@ HHHH **
M** "J=W((7:1_E4+M&3U'5CCV ^O!JY7AG[27QV\7_!2?P^/"OPLUCXFG4_M
M'VE=)>X'V+R_*V;_ "K:;&_>^,[1^[/WN<5&/,[$RERH\IN/C7^T=\9+B6U\
M _">/X::.T]W;-XB\>2E9X08RUO.;9@&1AN7A4N8]Y"D[4>KNG_L,CXB7FG:
MY\=/'>M?$K7X 3_8\$WV31K1F@C1DBBB5'R'0-YR&(OA"R#G/A'[+/[5OQ$^
M&GP'\,^&M$_9]\3>.-*L?M2Q:]IYN/(N]UU,[8\NTD7Y6=D/SL25.><UV^I?
M$+XM_M6?$WX8:/>_!K5?AMX=\+>(+7Q7J6L^(// V6K?ZM998(0"RO(NQ0[%
MI$;,:QN:ULXF-U+8][^!W[(NG_ 'XAZQK'A7Q;K8\(ZE:S#_ (1&\E:2WMKN
M26-C<1L& ^6*)8AO1I,=9"/EKW]$6-0J@*OH*;"VY.FWDC&".]25B;H****0
MPHHJ"2Z$;,IQD>IX[=3VY(H GHKC/"?QE\">/M2FT_PQXT\.^([^&+SI+72=
M6@NID0,%+,D;DA<LHSTRP%:'BKXA>'O >GI?^)M;TOPY8O)Y*7.K7T5K%)(5
M+!$>1E#$JK'KT4^AP[,5T='3?XJQO#_C#1_%VDV^J:%J5EK>EW!;R;S3;A;B
M*7:Q1BKID'# J<' ((.",5LA@W(.><=:EC&R_=_X$/YU\4_L)_\ )QW[5O\
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MO^P->?\ HAZ_.=L;C]:RRSX9#J[B<4<4<4<5[L=S$^\_V8O^2(>&_P#MY_\
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M;L%1P^YGS=1_*5'1N>F?56EVR$,,+C.[/Y_T_.OC[QU^V;\3?#/C77](T_\
M9I\6:Y8V&HW%G;ZI;2W0COHXY-B3J%LF&UPJM]YL;MN>M5'?8B6V]CF?#_\
MP4^^!O@O28=%T/P/XHT?2[4N(K/3M,L(((R7+-M1+H*N69F. .2<\UT_@_\
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M&13MSL7..N!Z#&UIF@V>BZ?;6&GP0V.GVL*6]O9VT2Q0P1J-JHB*  H' 7H
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MY0L6 V';\RAONVW<20HX.Y6&X'V/-3)6*@[[$E%%%9FH4444 %%%% !1110
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M@?\ Y(_JW_8?E_\ 2>VKZ5;[S?4U]9AOX43]YR3_ )%U#T$HHHKJ/="BBB@
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M;MOB5O7VQ^G:I*B@;,8^7 YXP1CGWJ2L3H6PM%%%(85!)<;=X10\B\!2<9.
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M "C^[_OBBC^[_OBD]@.^C_U:?2I%Z5''_JT^E2+TKC-1:*** "BBB@ HHHH
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M^D]M7TJWWF^IKZS#?PHG[SDG_(NH>@E%%%=1[H4444 %=EX?_P"01;_\"_\
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MB'AO_MY_]*9:Z7XL_P#)*_&?_8&O/_1#US7[,7_)$/#?_;S_ .E,M=+\6?\
MDE?C/_L#7G_HAZ^-G_&?J=J^$_.AL;C]:3BE;&X_6DXK[!;(X$'%?>?[,?\
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M*_V)K#&SNFGFZ0*LHQ*X8E"(6D&X@9.Y=WNUOO\ )7S!A_XOK_GW-?'/@_\
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M?+?[$WWO%_\ VY_SFKZD7I7R6-_WAG71^ 6L3Q1_QZQ_]=!6W6)XH_X]8_\
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M_P"D]M7TJWWF^IKZS#?PHG[SDG_(NH>@E%%%=1[H4444 %=EX?\ ^01;_P#
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M\Z&QN/UI.*5L;C]:3BOL%LC@0<5]Z?LQ?\D/\-_]O/\ Z4RU\%\5]Z?LQ?\
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MWQ2>P'?1_P"K3Z5(O2HX_P#5I]*D7I7&:BT444 %%%% !1110 4444 %%%%
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M\Z*Z'\)F#=1_P'_T*OQS&*_8QNH_X#_Z%7XYC%>1F6\3\XXTWH^LOT%XI3C
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MC]F7_A6WPXDU"YUOXP>%_&WQ6\974$^O:@FNVLGVJ['[N&WMX5882,2&.,!
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M!5E*@@@Y&*V/%7PM\)^.I+)O$_AO1_$ILM_V8ZQIT-T82X0,4,BG:6V+G'7
M]!CK:3%5S,GE1GZ9H-GHNGVUAI]O#8Z?:PI;V]G;1+%#!&HVJB(H "@<!>@
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MY?\ TGMJ^E6^\WU-?-7[ _\ R1_5O^P_+_Z3VU?2K?>;ZFOK,-_"B?O.2_\
M(NH>@E%%%=-SW0HHHI@%=EX?_P"01;_\"_\ 0C7&UV7A_P#Y!%O_ ,"_]"-9
M5-BH[FC1117.6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %-_BIU-_BI,8V7[O_ A_.OBG]A/_DX[]JW_ +&M/_2S4:^UI/N_\"'\Q7Q3
M^PG_ ,G&_M7?]C6G_I9J-:+X68RW1]5_%C_DE?C/_L#7G_HAZ_.EL;C]:_1;
MXL?\DK\9?]@:\_\ 1#U^=+8W'ZU[65_!(RK?$)Q1Q1Q1Q7N+1F&Q]Y_LQ?\
M)$/#?_;S_P"E,M=+\6?^25^,_P#L#7G_ *(>N9_9C_Y(AX;_ .WG_P!*9:Z;
MXL_\DK\9_P#8&O/_ $0]?'3_ (S]3N7PGYT-C<?K2<4K8W'ZTG%?8V?*CSXA
MQ7WG^S'_ ,D/\-_]O/\ Z4RU\&<5]Y_LQ_\ )#_#?_;S_P"E,M>1F7\)>IT4
MOB.F^+/_ "2OQE_V!KS_ -$/7YSMC<?K7Z+_ !9_Y)7XR_[ UY_Z(>OSH;&X
M_6LLL7NR'6W$XHXHXHXKW%HS#8^\_P!F+_DB'AO_ +>?_2F6NE^+/_)*_&?_
M &!KS_T0]<S^S'_R1#PW_P!O/_I3+73?%G_DE?C/_L#7G_HAZ^.G_&?J=R^$
M_.AL;C]:3BE;&X_6DXK[&SY4>?$.*^]/V8O^2'^&_P#MY_\ 2F6O@OBOO3]F
M+_DA_AO_ +>?_2F6O)S+^$O4Z:6YZE36ZTZFGK7SAU'+>*/^0D/^O<?^A&L<
M_>;ZG^=;'BC_ )"0_P"O<?\ H1K'/WF^I_G73#8AA7CO[7W_ ";GXQ_[<O\
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M;V^M?I_-_JV^A_E7Y@28WM]:X<K^W\C2J-XHXHXHXKWEN<[V/J']B;[WB_\
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MONSL4I<MK'-^9&S,1(K#)&5R1U^E&Y/[WZ4B_P#!-O\ :""J#\1_#Q( !/\
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M(@YX_P#K\U[W\$_C)X4^,?@UM9\&ZG_;&F6]R]D]PT$UOB=0)&3;*BGA'0Y
M(YQGBL:A[L)J3=CT>BFJV]58< C/-.K U"BBB@ HHHH **** "BBB@ HHHH
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MN< '!/KG\NE<-K7PA\):Y\3=+^(MWI32>,=)M&L;#4DN9AY<)648\M6\MO\
M72<LA(W_ $JXMHSG9V.Z4':,@J?3-/VCW_,TU5^7KT]L4[;4:FN@;![_ )FD
M*@>OYFEVU'+(8\\# &22V/7_  I.]@T/BGXL?O/^"I'PDB&&_P"*4G 5CC!,
M>IXP1\PX#<].".^1]L1KN4;@0?3-<)K'PC\(:]\3M-^(UWIAD\7:/:/8V>J1
MW,RF* K)E1&&\I_]?+RRMC<?3CO(U.P9ZUI*5[&<(VN+L'O^9HV#W_,T;:-M
M1J7H&P>_YFOB;XL?O/\ @J1\)(N&_P"*4GPK'')CU/&"/F' ;GIP1WR/M623
MRW VD@]^?;V]ZXK5O@WX2U_XG:3\1+S2V/C'2K1K&RU);B8&*$B4%?+#^6W^
MNEY92?FJXMK<SDE*UCME!VC(*GTS3]H]_P S2*O Y_3%+MJ-370-@]_S-(5
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M?\S2*F,#/Z4NVHU-- V#W_,T;1[_ )FC;3)9#'G@8 R26QV-&HM#\Y9HR_\
MP6 *E5"%L89.&/\ PCW4^O!_\=QWK]&H8]L:@C;_ +*G@>U>9O\ L]_#Z7XQ
M/\5DT!7\>KQ_:RWLYX%O]GQY7F>7GRAM^[WSR<UZ;&OR_>)Y/)'O6M27-:QE
M3CRWN.V#W_,T;![_ )FC;1MK+4UT#8/?\S7YQ3(7_P""P!7:H0MC#)PQ_P"$
M>Z^_!_\ '<=Z_1F23RW VD@]^?;V]Z\RD_9\\ 'XPGXK?\([CQ\.%U7[9<'@
M6_V?_5"0Q@>4-N=G?/7KM3;5[F-1)V/3HHML:@C:?[HZ#VI^P>_YTD:[5ZD\
MGK3L5EJ;60FP>_YFDVCD<_F:7;3-Q$FT*3ZGL.G^/Z5.H]#XH^&+,O\ P5.^
M,6SD_P#"*6X$:L?G(CTHDD'@8RHR,_>]J^UX81'&J],#G'%</I/P@\):3\5-
M7^(MCI8B\7ZM;BROM1^U3.9(0L2A1&6,:_\ 'O%G:H^YW))KN(,/#&RG*E01
MT/\ *M).YG&-A^P>_P"9HVCW_,T;:6H+#I2T44P"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ JO<2%0?ER 5/7G&>>*L5')"),$_
M>7[K8!*_2F)['R%\#/BAH?P'^+WQG\"_$'5-,\*/J/B:Z\9:5JFHW9@MM1MK
MS;N2)Y$1&:+;&IPQ+.TJA?W+,=KX/>*--^-G[7OC[XA:!<?:O#/AO0+7P;9Z
ME:J9;359WG:[G>*8A1NA*A"JAPR.D@<!P#[[XL^%WA/Q]-:2>)_#>C>)#9[S
M;_VOIT-T82^W<4+J=N=BYQUP/08V=-T&ST73[>PT^"*QT^UA2WM[.VB6*&"-
M1M5$10 % X"]  ,8JF^Q*CW,[Q9X#\.?$+3XK/Q/H6F>(K&*9;B.UU6T2ZCC
ME"LHD59 0K@.XW  _,:Y=?V;?A*J@'X8>#6(XRV@6A)^I,?->C1PB%=J],D_
MB3D_K3ZA-I#<4V>(/^Q3\#W\:CQ4?AKH9U0#'E>2WV+'E^7_ ,>>[[/TY_U?
MWOF^]S71C]F;X2%-I^%W@G!Z_P#%.VG/.3_!WKTVDHYF+E1YP/V:_A(JA1\+
M_!N%  _XI^TZ#@?\LZ^0O^"FWP?\"^ ?@7H>I^&?!OA_P]?S>);6UEN=*TN"
MVDDB-O=,49D097<JG!XRH]*_0,BOD/\ X*:^"?$?C_X%Z#IGACP]JGB._C\2
MVMR]MI-F]S(D0M[I2Y5 <*"RC)[L*TC*5]R9)6V/=(_V:_A'&H5?A=X,51T'
M_"/VG_QND/[,_P (O,+_ /"K?!7F=F_X1ZTR,=/^6=>D+\R@]*7;4\S[E**[
M'FW_  S/\(^0?A?X,92<D-H-JW/XQTL?[-/PCCC"K\+O!:J. !X>L\#_ ,AU
MZ1MIA<^8% SZGL.G^/Z4<S[CY4?G_P#\%-OA!X%\ _ O0M3\,^#?#_AZ_F\2
MVMK+<Z5I<%M))$;>Z8HS(@RI94.#QE17UW'^S3\(XU"K\+O!@4=!_P (_:?_
M !NO"?\ @IGX/\0?$#X$Z#IWAK0=3\0WL/B:UN);;2+.2[E2(6]TI<I&"< E
M03VR*^O8\L@)&#Z53G*UKD**OL>;_P##,_PBWE_^%6^"O,[-_P (]:9&.G_+
M.C_AF?X1\@_"_P &LI.2&T"U;G\8Z]*Q[T8/K47?<OE78\WC_9I^$<:!5^%W
M@M5'  \/6>!_Y#KY#_X*;?!_P+X!^!>AZGX9\&^'_#U_-XEM;66YTK2X+:22
M(V]TQ1F1!E=RJ<'C*CTK[_DEVOMQSM+9[<'G^=?(?_!3'P?XA^(/P*T+3?#>
M@:IX@OH?$]M/+;:592W4J1""Z4OL12VT$KDXQ\P]16D92ON9RM:UCWB/]FOX
M1QJ%7X7>#%4=!_PC]I_\;I#^S/\ "+S"_P#PJWP5YG9O^$>M,C'3_EG7H\>6
M4$C::=MJ>9WW+45V/-O^&9_A'R#\+_!C*3DAM!M6Y_&.EC_9I^$<:A%^%W@M
M5'0#P]:8'_D.O2-M1R2&// P!DDMCU_PI<SZ,KE1^8W_  5,^'/A3X<GX9'P
MGX8T3PR;W^TS=?V1ID%MY^S[)LW[$&[&YL9Z;C7WLG[-?PD"\?"[P6!Z#P]:
M?_&Z^2_^"IGP\\5?$1OAE_PB_AG6/$:6:ZJ;E]'L);L0;OLGE^9Y:G:&*/C/
M7:V,X-??,)$D88'CM5RE+E6IE%>\]#SC_AF?X1;R_P#PJWP5YG9O^$>M,C'3
M_EG3E_9M^$BC'_"K_!A^N@6A/_HNO2,>]&VL[LTY5V/./^&;_A)_T2[P7_X3
M]I_\;KX$_P""I_PQ\'_#V3X9OX5\*:'X::]_M/[4=(TV"U\_9]DV;]B#=C<V
M,YQDU^H.VO@?_@JA\-?%WQ";X8_\(KX4USQ/]D_M,7/]C:=+=>1O^R;-^Q3M
MW;&QGKM/I5PE9ZD3C=:'U;'^S3\)%4*OPM\%*/0>';3_ .-T_P#X9K^$P_YI
M=X*_\)VT_P#C=>D+]T$=Z7%2Y,J,4CS,?LS_  EW2'_A6'@L!_O#_A';,=L'
MD1_3KZ4O_#-/PD[_  N\%M[GP[9__&Z]+Q32!WYI<TA\JOS=3\P/^"IGPS\(
M_#EOAD?"OA;1?#)O/[3^U?V/IL%KY^S[)LW[$&[&]L9_O&OO1?V:_A"H 'PM
M\%#_ +EVS_\ C=?*7_!4[X:^+?B$WPQ'A3PIKGB;[)_:8N?['T^6Z\C?]DV;
M]BG;G8V,]=I]*^]T VC' ^E:-WBKNYFN:[/-V_9H^$>\/_PJ[P7G&W_D7K/I
MR<?ZOU-,C_9G^$L>[_BV'@O####_ (1VS&>,'I'WX_*O3>U+BL^:6R9IRKL>
M9M^S9\(AG/PO\&9]3X=L_P#XW7R/^V9\)/ _A/X\?LT:?H7@_P /Z-8ZQXE:
MVU*WT_2H(([R+[18KLE5% ==LCC#9&';UK[]DD;S-BKN/J3Q[_C7R-^V?X-\
M0^*/CQ^S/J.B^']3U>RTCQ,T^HW-A:230V<?VFQ.^9U!$:[4D;+8&$;TK2#G
M>]S.2LK(]T3]FCX2!%!^%W@HX &?^$>M/_C=+_PS1\)/,#?\*M\%YQMY\/6?
M3DX_U?J:]$,B+R0%3^^QP.N,5,H_#VJ'*7<M+34\RC_9G^$T8?\ XMAX+(88
M8?\ ".V8SQ@](^_'Y4__ (9I^$AY_P"%7>"S]?#UG_\ &Z]* /K2%1WY-+FD
M/E2V/S^_;.^$?@CPG\>OV:=/T/P=X?T6QUCQ*UMJ-MI^EP01WD7VBQ79*J(
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M:T>Y<1C: 6SP77UK,O8X7XT?'C5_"OQ%T3X;^!/#@\5>/M;MC>;;AGAL=(M
MS)]MNY55BR!@<1C!;9MW*[Q*_$^(OBS^T)\$]#N?%OQ"\*^"?&/A2R*C4(/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !61XJU34='\-ZO>Z1I7]N:K:V<TUGIGGB#[9.J%HX?,((3>P"[
MR#C.<'%:]0R0EF9E;:Y& ><#\,T ?)_Q$_:\^+GPJ\(ZAXJ\4_L]KIOAVP,:
MW5\OC>SF$1DD6-,HD18Y=T'RAC\PR ,FK;_M(?'=_#Z:\/V8KT6ILS=F%O%M
ML+L1F/S H@$/G!\ @Q&,/N&-I;Y:Z7]LCP;XFU[P+X7UWPGI#>(M3\&>*]/\
M3MI$=P(9KR*V\S=%#\K R$2\#&2 <"1@L;\_JW_!0KX(Z+I-W%?:WJEMK-K$
MPF\.7FB7D-Y%.BDO:R%XA&LP8&,[I-FX8+ 9-;+;0P=[ZGIO[./QFU3XX?#&
M#QA?^&;?PW;WTS'3HH-9BU);FV(7RYB\2#RR6,B-&ZAXS$0PSD#U@9[U\[?L
M<^$O%/A_P;XNUKQ5I)\-ZAXT\6W_ (J319IR\]A;W0C*QS?*NV0;?NG! (W*
MK;@/H:'B-1C''3/3VK)FRV&3WD5N',CK&%&2SM@ >I/8?X&OF6/X^?%;XR:G
MKJ_"+P7H%IX7T_4)K"W\:>,=3=['5&A=8I%MH+7+[6=G*3AF0B/!(<E$^EY-
MQG/0X;((/*\ >GNW7_\ 5\=_!GXI6'[&?@6S^&'Q3T76O#VFZ5=WL6D^,(]-
M>[TS5H9+N62W ^SB5H+AU:0^0^2$AW;OF #C<F5NIVW]N?M4^'9&U"]\+_"_
MQC:Q@DZ)H6H7UC?3*S!5VSW*F)=O#MO'S!& P<"O6O@[\6M(^,'@===T:UO;
M 0W-QI]WI>JQQPWMA=02&.2WGB1F$<@P#MR3@KG&:\A_X> ?!O6%:W\,:EK'
MCG76"K#X?\/^'KV2\N6W#>(TEBC7<JAG(9L[4. 3P>D_9#\#:YX=^'OB#Q!X
MATZ30-9\;^)=0\62Z'<H3)IRW3IY<,IS\[B.)&)*QE=^PH"AS4KVU0HVOH>[
MJP901G'N,4M-5=J@>GM7,_$;QXOPZ\(ZEKQT'6_$OV$1EM,\/6?VJ]E#R*F8
MXMR[MNXL<'A58]L5F:'"_'SX[M\(9_#^BZ)X<O/&GC?Q1<-;Z-X>M28EN#'L
M\]Y;@JR11QHZ,21[G"!W3@-1\6?M1> M/GU_6_"WPY\::;9QL\^A^%KC4(M2
MG7 !$4DR%&*\-MV9<*54!F KR[XU_';5/%_C'X?^/O#/P9^+2^*?!=W=/:Z=
MJGA1TL;V&ZB6&YCDEB=I(WV >7(H8!E961@WR]]XW_;&\2KX;OSX3^ WQ2F\
M1&W9+%=:\-O!9"5BI#2M&[.549<J!SL*$J6R-DM#!O4^@_A#\2M#^,'PWT+Q
MAX;DFET75(3);_:(?)D3:[(R,O0%65EXRIVY4L"&/8UXI^QGX=/A/]F?P/I4
MFEZWHUU#;S&ZL?$5L+>\BN6N)7GR@ PAD9S&2,F,H3R37M59,V0M>!?'3XV>
M,M#^(6F?#;X7>&K#Q#XYU#3#K%Q/K$[0V.F68NH8/M$R@*9U.Z0%8W\Q1'D(
M^0I]]KX]_:1\0:S\+_VKO!?CKPWX-\;>*IAH2Z5KT&AZ*;JRGTQ[B8JL=P 2
MEQ%.5D,1&UT* O$-V]QU8I:(ZN3_ (:UVRB#_A38*AQ"I_M8#=@[=Q].G;C'
M?@U]!>%?[6_X1G2O[?\ LG]N_98_[0^P!Q;_ &G:/-\K>2WE[]VW<2<8KY\/
M[:1^4GX%?&EE8E2$\)(V[Y6."//)Z#VZ@=\5]!^%=:/B3POI&KG3[[23J%I%
M=G3]3A\FZMO,0/Y4T>3LD7=M9<G!!&>*)73LQ1L]4:M%%%26%120"1B=S*2,
M?+C_  [?UJ6B@!%4*N!TI:** "O$?B'\5_C#X;\;W^E^&/@:/%_A^$Q_9]>_
MX2ZSLA.#$C.3 Z%U*N63'.=H/ ;CVZJ5RSQRY10Q8@;6;D\=L\ <#\F[TT)G
MR1X._;"^+?Q$O_$EIH/[.UQ>W7A^_ETK4=GC"VCCBND)5H5ED@5))%*DD(S!
M0RLQ =2>P^%?[37Q \:?&:7X>>(O@V?!EQ:6JWMY<3^)[:Y>.W=7V2Q1K&!.
MGFJL3-$S!&8@\J5KS+]G_P".>B_LC?#.'X8?&..^\$ZGHE[<Q:;K"6MW>Z?K
MUN\S7'GVDJQ,6QYX1D.6&8\D,S(F]X?^(T7[4W[47@3Q;\/[*YO?AY\.[?4E
MO_$UVDD$5]=7MJBK;6T3H&D>,"-V)V[1N!QF/S-+&1]?PR"1-P]2."#TXJ2H
MX,^4N<$C@X4J/P!Z5)6/4V/!/C9\6/'%O\4/#_PR^%FF^'=1\6WUA-KNJW'B
M<SK96&FHPA0D1X,CRS'8-A8H%^9-K!ASI^!O[0D<7_)S"] 23X#L&9>?O+\_
M4# P=V1GN<UK_&3P%XY\,_&O3/B_\/M"L_&&H0Z%+X=U7P]>:F+.6>U-Q'-"
MUHS)L202F1I-[@,D:JH+$5F_\-F*%PWP-^,IVEBLB^$]VTX)('[W.>HZ>@YK
M76VAEHGJ7/ /Q4\=^!_BOH'PW^*Q\/W]UK]I>SZ!XLT9WB&J&T$8DAGM=I$4
MQC+3LX?RQN"+D@U]$09\I<G)'!^M?+_@K3?'GQP^/7ACXB>*O!%U\/?"WA2P
MNG\/6M]=Q2:GJ$]XIB+W<4880(L"@F%BLB2OC>XW*OT_;MYD*N,X;YAG'0_2
MI=BHDM8_BKQ1IO@OPYJ^OZS<_8](TFSFO[VY*.XB@B0O(^%!)PH)P 2<<"M*
M2X6&3:W&5+ ^PZD^@&1^=?,OQ=_:%M=:L_&'@C4?@W\8+FVNHKS19M3T/PQ'
M.DL3K) T\$C.RLK ED)4Y&W*X)6B.K')V15T/XI?M _'#1D\6?#WPIX+\)>$
MKP.--@^(%Q>27]Y#GY;HQ6P"1QR)MVH2QX9E=TD1CV_P7_: U7Q1X[UKX:>/
MO#@\+_$?1;07[+9O)/IVKV09(VO;.0J"(S*X'EMEEW!=S.DHC\;^!?[3VO\
M@7X8Z1X6\3?!+XJ7\^AQC2K*_P!/\)2K]MLHD5+>66*20&&9XPOF1AG7<I((
M#!5T/V?_ !9XC^+G[6GC/QEXF^'GB[P78Q>'5T?03J^EO;VTEDEWYLIN7E3F
MZ>1HV1(R$$8D!W-&':VB$S[%W;ES2]J9$NV%1C&." ,4^L.IJ<!\;OBEIWP9
M^&GB/QAJ@\RWTNU\U(3O FD)"11%T5RGF2ND>_:=NXL1A21X[I>H?M9Z]ITM
MZF@_"GPNES)*8M'UNXO;FYM(]Y"I*]L3%(=H!W(1D-DA22H[?]L#PO9>-/V>
M/&FC7=KXDO$NHK<>5X4L5O\ 4!(MS$\31VS,!(HD52ZY!,:OAEX8>8?#C]LO
MQ+I_@/0;?QM\#_BU)XIBMDAU*XT[PPTMO+,H(:53F/;OP&V;%"E]JE@ QVC<
MPEH]3VKX0CXNJVJ#XGGP:6_<_P!G_P#"(?:L8R?-\S[1_P !QM[>]>EVW^I7
M.-W.[&<;L\XS[YKR_P"#_P :#\8H]9_XH'QOX*^Q"$LGC'2OL#7 E#C$'[QP
MVTQ?-TQO4]Z]2A;=&">O0UF][&RVN/HHHH&%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>+?%_P"+FNV/C>R^'7PZ
MLM+U3XAW-B-9E?799(]/TRP$OE^=-Y8,DC2NK1)'$"0<LVU1\WM-?.?QN\->
M)_ _QR\.?&#PGX<F\:+#H\_A[Q'HUO,@NH]-$JW*SV<9 \R99 <QEB7#(JJ,
MLZU'<B6QF^ ?VD/$NO?L6Q_&6Z\.6>M:[!:75]>:5I]X;.W:.WO9(I2CRF5E
MV0Q.Y7+%B"H!+8KZ*\+:]I_BKPSI6M:3.UUI>I6L5Y:3NC(9(9%#HQ5@&!*L
M.& ([\U^?WP>U7XEWG[*]C\"]#^$WB2Q\87UK>Z=J>N^*K(Z=I5G9W=Q-YTZ
M2R,)991',N$5"<J[JKB/8WW9\*_!_P#PKOX9^$_"@NUOUT+2K72UNDC\L3"&
M)8P^W)VY"YQDXSUJI+0F+U.IK"\7>(M.\(Z!JFN:O<FQTO3+66^NKSRR_D0Q
MH7D?: Q)"ACP,X!K=KF?'GA6T\>^$_$'AF]EFCMM8L)]-FD@V>8D<T9C<IN#
M#(# \@CIP:@T>Q\Y>"O^&C/C_P"&],\6#QGX?^#VB:C&+_2=-TO1DUB\N+*9
MMT0O'N'V!EC",#$%)\UMRJWRKL_\(1^TC\/476;'XE:)\6FB'^D^&]8T"+1O
M.C'S2"UN8&)2=BFQ/-_=#S2S?=4#%\%_%?Q]^SIX1T7P+XZ^$7B'Q'!IEG'I
MNG:[\-XFU>UNH8HU0>;$[)):LJ&)/F&)'64H H%:>I?M3^.?%EG-9_#[X$>.
MF\0M&TB2>-+--$L(@ $#M*\O[Q@[+^X7:S@L0RX)K34QTL>T?!'XH:;\:/A3
MX;\:Z2GDVFKVWFF ,7$$JL4FB#%5W!)$=-P #;<C@BNYKS7]G#X4GX(?!'PE
MX)DNWOKG2[4BYN'DWA[B21I9BK;5)3S)'VY4-MVYYS7I59FRV/)/C%KGQ3TC
MQEX#@\ >'-*UOPW>ZB(O%=YJ,NR:PL_,A'F6_P"^CR^QYST?E5X['!^(GQ8^
M+WAGQ=?V'A7X'-XQT&$QFUUD^+[+3Q.#&C$>3(N]-KETYSG9D<$5[F]N&9FS
M@D>^._Y]?TKXFU[]HKX??LT_MH?$V'Q%XA$EOXLL]-N-0,5E<>9H<]K: (CJ
M$/GQSQ2QL)(2Q1@5= /F&D>QE)=ST5OC5^T!'+"3^S3P@R<>.].8+QUQLSG
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M"/QZ^+OB2^^!7CR36?%_]CP:=80Z>K6L5W:VCV\D<FH$K$+<S-\LZ[@8R[D
M86M8[&#W/I_X$?&!?C1X/U"_O-(&A:YH^JW6BZWH?VL7:V-]!)AXQ/L19?E*
M-N48&[':O48R612PVMCD'M7A/[*OPS\3_#;P'KUQXS:SA\3^*M=NO$^H:?IZ
MEH=/DN%C\RV0EWWA#'C(X!;:"X4._NL1!3(&.3V([^]9LU6PC3%9 JKN/?GI
M[5\QW_C_ .+OQX^(7C;0_AAJWA_P5X%\.7QT*?Q;>6CWVIOJ<2A[A;>V?$6Q
M&*PL)1CYBZ,Q^5?I:[17^5CG=TC;!#\'(P>OTXZ5\NK9^-?V7O&WCJ^L? 5Y
M\0_A]XHU^?Q&\WA^X2;7-/N+B*%9HWM2(_M*/,@"+&28XHG9V;"J&G8)*YH-
M\'_VA=+WWD/[0=EK[PMO32]2\$VEO;7CKD^3-)$QD1'("L\>6"YVKFNW^!/Q
M:UCQYJGB_P )^,=*LM#\>>$;FWM]6MM-N7N+>XCEA62"\BD*+MCEQ*1$Q9U"
MX8@\#B?^&P-3OMUKH_P)^+4^LW \NSCU+0%LK1IV!6,33M*RPPEBN9,$(-S'
M.#6Q^S7X&\5VOB+XA?$+QOIEMX<\3^-M0@8Z'97L=U#8V-K!Y-KET&UIF4DL
MX8AE\O"QD%1;O8S5KZ'T!&P:/(.X>N0>_M7D_P"T5X@^*6@^$[%_A'X<TGQ-
MXCDU"..[M-8D"1)9^7(7D!,T>6#B-< G(8\=QZO#Q"OT[G)H\H,P.??N/3_"
ML>ILU='D/Q7^(GQ2\)>)+:S\$?"%?'VE26J2RZ@?$]MIGE2F1U:(12H2VU0C
M;LX._':N)/QH_:"^4_\ #-*MA 06\?6&W/.0?W?LO.,\^U<7^T%\8O!_[.O[
M8O@[Q7XAU5IFU/PM_P (_>:9;6\YN+*U>\,J:@/D,4R>8CQO$A690 RK*"57
MM)/^"A/P 943_A8*N7!^;^R-0&[ACR?L_P H^4G/L,5JKV,+*Y]!>$[S4=3\
M+Z1>:QIO]C:M<6D4MYIWGK/]EF9 9(O,4 /M8D;@!G&<#I6M65X5\2:=XR\+
MZ3KVCW2WVDZI:17UG=*K*)89$#QOAOF&58'!YYYK4K,WZ"U\X_$KXA?$#XC_
M !@UCX8_##6-)\(VWA^Q@N?$OC*^M!>W%A<3CS;>UM[5RJ.[11AV9MR;)#RK
MH%?Z*,P^< ;BAP<<^A_/!KY4\4>*(?V8?VE/'OC;Q1I^IR^ /'EEILL_B2SL
MY)[?1;NTB-LD%RD0=]LN8]LN%R\B(%?#.EQW(D0>*O$OQ=_9CATWQ7XV\>:3
M\4?AVU_;6^OW%SHT>F7VB0/*$2Z@\@LLR;G5G4JSGRT6,'>63ZPM05MH@WWE
M4 _-NY'OW^M?&/QN^-GAC]L3P.GPK^%O]J^*Y->O;2'5_$%KIDT-IH%HLZS&
M>X:=(U8N('V19&\HWS9"J_VC#S&I]J);:BCO9#Z***@T"BBB@ HHHH ****
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M/V/3+B5O!EK9WB)+K,*M,8UG<RR>4[!8%W,BA=Y;! Q7M4D9;D-AA]W.<#\
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&6FN:]X6_P"$SU)-1@B\/:/'9_:9[K5VWFU2#*/Y<@PY\P<JN=H9MJ'RB/\
M:R^+S_$;_A!(OV?-GB7^R?[:^P#QK9[A9B1H!,'\KRR/,VIM+$]\;<-6T5=&
M$FD]3T;]D^'Q[+X+U_6_B)%>6.I^)?$%WK5AHVHWS7,^CZ?,$,-F^5'E[-IQ
M'@$!@"%(*K[E#N\E=WWL#->.?LQ_&Z]_:&^$]KXUN_"__",V5W<216-K)J0O
MS<1(P03%A&K+^]$J889'E;N0P->RKG&#UK*2L;1M;0BD3=(OW2N<%6&<]_7U
M KP/X'_'ZZ\9?LIP?%[Q996\$T-EJ.J:A:Z1"RHT5I/.O[M7<Y?9 #RP!;'*
MKT]]:158@'<5/(7D@XS^''K7P_X+_9^_:3\'_ &X^$%E>_"MO#LNF7VFR7=P
M^HM>!+MIC,5<($X,K!24XXW*<8:HD3W.L\#P_M%?&#0(OB/:_$#1_ ]KJW_$
MTT/P+-HL&H6YL]BO;1W-XNV9!,%#/L#. Y*[#^ZC]C_9R^,EU\8/A[/>:QIT
M>D>+-%U&YT/Q#ID$ADCM=0@?;*J.20RD%'&&;:'"[B1D[OPC\,W7@?X5^"O#
ME_+;OJ.C:/9Z=</9DF%I(H$1Q'N&XKE21G#8 R.M><_LE^!/%O@WPSXVN_&.
ME6OA_5O%/B_4/$0TF&]2\:RAG\L>7+(@\MF_=GE>H8$X;< Y;!$]_1BRJ2NT
MD<KZ>U.ID.?+!( )YP*?69H>7?''X\>&_@7I^EW.O&]O;_5KM;#2M%T>$7&H
M:A,Q4%((LC) /.2.6102S*I\BC_X*":!'-KUO)\*?BPMQH*++JT<GAR)&T^-
MD,BR3@SCRD,:LP9\#:N<UU'Q^\.:LOQ^^ _C2TT[4=6TC0]4U'3-0M=)@>6>
M+^T+40QW4@'RBWC9/WDA(V94C=SCR[QI\3_"?[,_[0_QCU+XFV\\OAGXA:/I
MMWI<D-C+<6UXMM;-:36#Y7;YK,ZG8?W8256DD0N%.JV,7N?5'PE^)%I\7OAU
MHGC&PTO5-&L=7B-Q;V>M6ZP70CWLJNR*S !P ZD,<JRGO77UXE^Q9X?\3>%?
MV7_ 6E^+[:^L]=M[64/:ZFY:X@A,\C6\;@DE"L)B7RS@H $(4KM'MM9FJ/)/
MVC->^*6A>%=/E^$GAO2/%/B-M12.ZLM:DV0+9&*0O(,S19<2+#C!/!(QSD5O
MBY\1?BAX3\006/@WX1-X_P!*DM$EEU/_ (2:TTQ4E,CA[?RI5+':JHV_H1)@
M'(.?1_%/B >&="UG5CI]]JG]FVDMW]BTR(S7-R4C+^5$@QND;9@+W++SS7Q7
M'^UOJO\ PUB+T_#[XLC0/^$)-O\ \(8VBM]K^U+?$G4?L?G;?+*?NO.SN)PO
M(Q3CN3+8]67XU?'])%+?LX2/_"Q/CW3<^^,)W.WTQCM7T-X5OM2U3PQI%[K&
MEG0]6N;2*:\TLW"W!LYF0,\/FI\LFQB5WKPVW(ZU\J_$;]JCQ-XT\ ZWX<\'
M?!KXLV7BO7+1M/TR^U+0FTR"TN)P(Q<-<F1O*$9D#@X !3ED&77Z6^%FC:IX
M;^&?A32-=U'^V-<T_2K6SU#4/->4W5S'$J32EW^9BSJS$M\Q)YYS52V)B]3J
M:***S-0HHHH **** "O,/C)XT\?>#Y-,_P"$'^&?_"PUNA-]MW:[;:6+/:J[
M#F527+[G''W?*Y^\*]/JK,J^<I95W=$/0YQD\^^!Q[?DT)GP-^QO\2OC!X;_
M &;_  CIOACX&?\ "6Z'";T0ZP/%UE8BYW7MPSCR77<NUW=,GD[ W?%>L>&_
M"_Q7^,7[1/@7QYX[\%6/PTT/P+9WWV*P_M6+5;G4KB]C,,OSPL%2-$6-LLO!
MX^??F+S[Q-^U]\:K_P"$.O?&?PGX=\%:=\+;:\,&G6NO?:9]8N8!.EMYQ6"8
M1 F9G^0LI4*>6&UW[WP/\6?CKI_[1'A_P#\2+3X=6>GZGI-SJT=]H/VY#>^5
ME1;6TD[@/.K%))$*8$+9SSQL<_4^JX.(P,,/9B2?S-25' H6)0N<=1NZ_P#U
MOI4E8'2>.R?$_59/VLO^%;BUL_[#_P"$*.OM=>4_VH7'VX0! ^[;L*9)7:22
M!SC@^??$+QU\2OBS\;M6^&/PQU6T\"67A&WM[OQ#XMO;*"_E>:>%I+6VM[9P
M5*XW,SD@AD;H%"SW/B]\)OBU)^T5#\2?AE-X-RWA=/#=S#XLEO!Q]J>=GC6W
M3C@H,[LYW9  !-[]GGX4^/\ PE\4/B;XV^(5QX:GUCQB=-6./PS+<-! MI%)
M%M(F4."59"3N;)#9VC:*V6QA+<K^ _B'\1/AI\8-(^&'Q.UK2/$]MK^GRW7A
MGQ7967V&ZOIX,275M<VREDC=4?*,H1"D7+-(Y"?1MO\ ZE3U'M_GCZ=J\$^(
M'@'Q3XO_ &JOA1XEM='2+P9X-T_4[NYUA[Q";BXNX3;BV6W +ET"J^_[I$C#
M.5VM[Y"Q:-21@_7-1(TB/K#\6>(M.\):!JNNZI,+?3-+M9+N^G6-W:*"-&=W
M 0%FPH)VJ"3SC)XK<KD/BAX-3XB> ?%?AE;XV$NL:5<Z6;M461K;SX6C#JA(
M!(+*V,C.!D]*E;E/8^8+K]MSX@P:/X?U^#X#WY\,>+-6BTSPY?7_ (DM;:?4
M'G9A;9@\IFA\Q4W#>2N"")&!#'T7X&_M#>,?B=\4_%W@[Q1\,%\"W7AFTAFO
M[HZ]#?F&2?8\$7R1!27C#ON5F \O:>:X3Q?\//'3?LF_"B6X\(21^-_AG?:3
MK4OA.PN(9VU%=.9H&C26,[(S)#^_"J'(/[M59JU_@S-XG^+G[4&M_%FZ\#ZU
MX#\(67A0>%;.U\4Q-::G=S&Y2Z>86_.R-<E"2QSB/:<F1$VT:.?8^JH\^7R<
MGD9QBJ\VY_,V\E> S$ (<9[CIPO//7VJ>'/EG(QDL>GN:1H=[;L\[2N.W)Y_
ME7.CI/ _ _A_X^>'?@IXBM/$GB/PKXF^),E]OTJ\O8I$TZ.S*P@I,L$,3,X"
MW#8"MRR L1Q6.S?M;-&A5O@N&<<*W]K YY)V@C@@>OIVKSS_ (*&>-/'P^$/
MQ \./\,VD\"*^G%?&3>(844[KNVD/^BX\T8DS%P2/XONG:/0E^.'[0;PC_C&
MF10P&?,\>:<K>_1>":W6Q@]ST;X0P_%G=K ^*J>#7B#1?V8OA-KLX^^)3,;G
MV:+&T]0YZFO48F+1J2,-CG@CG\:^>?V:?AWXXTWQ=\2_B/\ $&PM_#VO^.+N
MT"^';*<7*Z;:VB-!"&F5BC2.K9;8,?*K'!;8GT-#GRQD $\\#'XUDS5#Z***
M104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBVNO:=>Z??6]O>6%["UO<VMU"LL4L; JZ,C95E9205((YY!Y%9FI\4Z1\/\
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MMZYX-\5:;XH@T621(!J7D.RO")Y&58CLE9MYS_J\8.<'DOC3'K/PJ_:2\/\
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M_D6<"".TM,*Y5_)7>/,PI?=EAG)-MZ$*+N>E0L&7(QU(./7//ZU(O2FQH44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /A.QH@\5_O/MG_".^=]A_UC>7Y?G?/_ *O9G=_%NQQBNDK(V%HHHH ****
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MO2AKWV7^W?LL1U#["6-O]HVCS?*W?-LW[MN><8HD*)J4445!H%%%% !1110
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M16(_:5_9@\9:)\-+C3_&UY>RVD,<>FZG;M$\D=W;RNGFEQ&"(E,FTL#]WC+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,7Q1XD_X1CP_K6JG3KW5/[-M)+L66FPF:XN=D;/Y42?Q2-MP%SR67GFOBO\
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M"7XIZ:NF!_#^K2-IVJP&6:W=VMRI#R+L,P+ *P12S(BNK-]VP[O+7=][J?\
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M/^)/A\Z9\0+&"\OX]+-O;:W:Q/*LEI;2";%R9\*R1D .!S@\5Z,?VR@K!/\
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M;F&"U5#;HQ3<T<D8.9"P9LFO4OA__P -$#QIIH\;M\,SX3 E-_'X>74/M_\
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MY89'O[.*8#)\J5E5X6+&,E6;]X[L?JBW8/"K DY[GOS63-([$M%%%(H****
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MPOXF?6+72]6\,^*[+7=(@O+.:>+4;NWCE=;-C$"R;T\TAB F4 9DW;Q+H_\
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M<\]>*^+=8_8_^(ESH4WP?A\5>&].^ 5QK<FH+!:P2'78K-IS=+8HT@:,@7&
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M%RJML .[&:^\H\;>/6B01'4445!H%%%% !1110 4444 %%%% !1110 4444
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M76CX)LM<U#7;NQEAE@LQ/$+)8F(<MYJS*H= H*B123@/CHI/^"=?[/TB[&\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'@N#<1M:K&HB*REFWKL"X;<<CG)K=K(T04444#"BBB@ HHHH **** "BBB@
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M3X/L(X[>PTS6/#%GJT]M$N#L-R60D*Q(0;0$0HH!" C7I8QWO8C_ &:=.M_
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MSS^WHNIC]E+XB/HZ:@+K[+#YQTP/YAM_M$7G[MI!,?E>9OR=HCW[CMW"O8O
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M)+98L<LS$DDDFM^*-88U1<[5Z9))_,T2=V5%6'T445)04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%)F@!:*2B@!:**0F@!:*;NI:0
M"T444P"BBB@ HHHH **** "BBDS[4 +129]J* %HHHH **** "BBDW4 +13=
MU+0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%)NH 6BF[J7/M2 6BDS[44P%HHHH **** "BBB@ HHI,^U
M "T4F?:B@!:*** "BBDW4 +13=U+GVI +129]J*8"T444 %%%)NH 6BF[J6@
M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IO.:=2-2 0MM
MZU!)=;6( W8/(#<]"< >OM7R#^UE^S[\1+B3X@_$_0OCKXH\,:58Z3+JD/A;
M3GN8X$^RV8W1JZ72JOF-$S$B/@N>&[_/_P"RK\)/BQ^TY\-=3\5K^T5XT\,M
M9:M+IKVOVN[O6;9!#*'4_:DPW[[&W:>GO6\81Y;W.>4Y<UK'ZB1OO4GCJ1P<
M]#BDDF$*LS_*BC)8GCH2?I7S=#^V-\&_@K9V?@3Q5\45UCQ-X=M8=,U*_%C>
M7+7%U'&J2L[QQRKYA<'<N]BK;E/*FM;XC?&#PE\9/V3?B9XF\&:Y;:WI#>'-
M6B2X@#HR2QV<C%&1U5T< A@"H)4JW0@UGRLUYCWG[1\Q 1N/IS]/TZ^M2JVY
M<BOAK_@EOJMIHO[,7BK4[ZYM]/TZT\0W,]Q=7<OEI%&EI:-(\CL<*JJ"220
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:HH"\DYM). /7T%?-O\ P2D#?\,Y>(=X6/\ XJBX8YS_ ,^=F0<G\#TKZ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5')T/U'\Q4E-9=PZ]P: /RR^!_PQT;XT?MH?M'>"O$44
MLVCZI#KD;R6[>7- PUF!U=&((+(ZQ2+D%<A@5(R&\'^(WB?Q7\-_A/K_ .S]
MXI@F%[H'BX7VFI"LAC6$07$,JIO((AD:2&>+;&,^<\ASN K]-O@[^QR/A/\
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M6_\ @G'XJ\7> -#\'>)/COJ>L:'X=B_XDEFVB!(K:;>H\R4?:"TP6'S8HU+
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M,I(92I!# X((Q7&:K^T-\+]$U&YL-1^(_A&QO;65H)[>XU^TCDBD5S&Z,K2
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MV/Y;^9"C%UVN54Y P3@\\5U$;;USWZ&@!U%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH38[(Y3P7\+_  Y\/1KZZ!I_V%->U6?7-15II)A->S;?,E_>,VW)4':N%R.
M*S? OP-\&_#7Q#XLUSPWI TW5/%5V;_6)_M,TWVF??*^\+([*GS3RG"!0=V,
M8 %=]13NR>5')CX8^'Q\15\=?8O^*J72O[#_ +0\^4G[%YQF\K87V'YSG<5W
M>^.*ZI%VKC\:=10.P4444AA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img192321128_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *&!94# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>+]*?4M+\TVRSO &D4#<5/48)X/:MNO-O@BBQ^!;A$4*BZG<A5'0 ,.*])H
M\_U_XN:/X>UJ[TNYTC6YI+9@KRV]JK1G@'@EAZUF0_'CP]<(KPZ)XAD1ONLE
MFI!_'?74?$G5%T7X>:W>B3RI?LS1Q/C)WM\J_J:F^'^E)I'@#0[+[Q6T1R2N
M#EAO/ZM0!D^(_BOHOAG5(=.NM.U:>ZEMDN=EM;JY16S@-\PYXJGIOQK\,7VI
M065S;ZIIIG8)'+?6PCC+'H,ACBN1L_B#X<T;XP>*]4UG4F"!$L;4)$S@JN"W
M0=F!%6/%7BR'XIQ6OACPGIES<I+<QR7&HS0%(K=%.[(/KQ_09H ].\6>,M'\
M%V$%YK,LD<4TGE)Y<9<EL$]!["L?PY\6/"WBK6X=)TN>Y>[E5F4/ 5&%!)Y/
ML*YSQN/$LWQ-T<Z-X<DU.+2K)Y(WG;9 97^4%F/!*X!P.>:VO!?C74M0\0W/
MAKQ/HL6EZY#"+A/(8&.:/.,KR2#^)[],4 7O%7Q.\.^$KY=/NFN;N_*[C:V4
M7F.J^IY 'YYK6\+>+M'\8Z8;_1[DRQHVR1'7:\;=<,/\BL77I=$^'BZAXDCT
M/4+VZU&4&Y>U0S,"%)!8D_(G&...G%9/PG5;R#7/&,AM+6'7;E9$M89 1 $!
M7YCTW$G)'^- 'IE8>E>*;+6/$.KZ-:PW'G:4R+<2LJ^66<9 4@Y)Z]ATK5^V
M6YCD9)HY-BEB$8$X%?,FD?$&]T_0/$MUX?LK@7>H:B]Q?:GY>Y;2!FQ'CU;Y
MF^G\@#WG4?'NE67BF#PW;PW>HZI(,R0V2!Q /60D@+_GU%2^+?'6A^#+>-]4
MG<SS'$-K N^:7Z+_ %.!47@?POI'AC05ET^4WDEXHN+C49.9+HL-V\GTYX']
M<FN2^&-G!XH\0^(/&]^1=71OY+*Q,@_X]X4QC:#T)##]?4T :MM\8-!;4K:S
MU/3M:T7[2<13:G9^3&Q[<Y/Y]*]!!! (.0>A%<S\0=.LM3\!:U!?JGDK:22!
MV&?+902&'N" :J?"J]N-0^%^@7%TY>7[.8]Q'\*,RK^BB@#L:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** &R)YD3IN*[E(R.HKS%_@RKR,_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N.^*6DOK'PZU:&%7:>&,7,(CZ[T.X?RKL:9-$D\$D,@RDBE6'L1@T
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M1>BJ!@"IZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_"Y9/\ H1O$O_@*W^% 'J5%>6_\+ED_Z$;Q+_X"M_A1_P +ED_Z$;Q+_P"
MK?X4 >CP:786M]/?064$5W<8\Z9(P'DQ_>/4TM]IUEJ<2Q7UI#<QHX=5F0,
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M"RM[.V39!;QK%&N<X51@#\A7F?\ PN5_^A'\2?\ @*W^%'_"Y7_Z$?Q)_P"
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M_P"3E/%W_8/3^4%>P5VQV1 4444P"BBB@ HHHH **** "BBB@ HHHH ****
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MAA1110!Y'X6_Y.4\7?\ 8/3^4%>P5X_X6_Y.4\7?]@]/Y05[!7;'9$!1113
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AK?_ " -1_Z]9?\
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MJ^XPO^$-\/\ _0-B_6C_ (0WP_\ ] V+]:W:*/9P[!["E_*ON,+_ (0WP_\
M] V+]:/^$-\/_P#0-B_6MVLO7]>LO#>FB_O_ #/(\U(OW:[CN=@HX^IH]G#L
M'L*7\J^XK?\ "&^'_P#H&Q?K1_PAOA__ *!L7ZUNT4>SAV#V%+^5?<87_"&^
M'_\ H&Q?K1_PAOA__H&Q?K6[11[.'8/84OY5]QA?\(;X?_Z!L7ZT?\(;X?\
M^@;%^M;M%'LX=@]A2_E7W&%_PAOA_P#Z!L7ZT?\ "&^'_P#H&Q?K6[11[.'8
M/84OY5]QA?\ "&^'_P#H&Q?K1_PAOA__ *!L7ZUNT4>SAV#V%+^5?<87_"&^
M'_\ H&Q?K1_PAOA__H&Q?K6[11[.'8/84OY5]QB1^$=!BD61-.B#*0P//!%;
M=%%4HI;(N,(P^%6"BBBF4%%%% !1110 44$X&37FI\;>,-66_P!3\-Z%I\^B
M6<LD6;J=EGN/+/SE . .#C- 'I5%9GAW7+;Q+X>L=9M%98;N(2*K=5/0@_0@
MBL'Q-XJU:W\06_ASPS86MYJTD!N96NY"L4$0. 6V\Y)X% '8T5PNE^/+NW@U
MVW\3Z='::GHT N98[1C(D\1!PT>>>V.:RI?&WCNRT4>)KWPWIBZ$$$[P)<L;
MI(3_ !'/RY YQ0!Z?17%>*/%VIVZ^'H/"]M9W=[K+%XDO"RJL0CWECM.1VK0
M\-S^-);R8>)K/1H;81YB:PED9B^1P=W;&: .EHHHH *:Z[D9?4$4ZB@#S-_A
M9<.[-_:D7)S_ *H_XTG_  JNX_Z"D7_?H_XUZ;16'U:GV.+^S\/V_%GF7_"J
M[C_H*1?]^C_C1_PJNX_Z"D7_ 'Z/^->FT4?5J?8/[/P_;\6>9?\ "J[C_H*1
M?]^C_C1_PJNX_P"@I%_WZ/\ C7IM%'U:GV#^S\/V_%GF7_"J[C_H*1?]^C_C
M1_PJNX_Z"D7_ 'Z/^->FT4?5J?8/[/P_;\6>9?\ "J[C_H*1?]^C_C1_PJNX
M_P"@I%_WZ/\ C7IM%'U:GV#^S\/V_%GF7_"J[C_H*1?]^C_C1_PJNX_Z"D7_
M 'Z/^->B66HV>HK,UG<QSK#*T,A1L[77JI]Q5FCZM3[!_9^'[?BSS+_A5=Q_
MT%(O^_1_QH_X57<?]!2+_OT?\:]-HH^K4^P?V?A^WXL\R_X57<?]!2+_ +]'
M_&C_ (57<?\ 04B_[]'_ !KTVBCZM3[!_9^'[?BSS+_A5=Q_T%(O^_1_QH_X
M57<?]!2+_OT?\:]-HH^K4^P?V?A^WXL\R_X57<?]!2+_ +]'_&C_ (57<?\
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MC2,$(BKDY.T8R:=110 4UJ=36K.K\(T-HHHKE*"BBB@ HHHH **** "BBB@
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M&>C=:-%\,ZY>^)H?$OBNXLS=VT+0VEE9!O*@W?>8LW+,?TH UO$L_BN'[/\
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M<?\ A6]::!$UI$?[1U497_G^?_&K'_"/Q $?VCJO/_3Z_P#C0!S/_"">(_\
MHH>L_P#?N/\ PJO:>#]>O86EA^(FME!(\9S%&.48J>WJ#77'P_$QS_:.JCH.
M+U_\:RM T**339&_M#5!_I=R,"]<=)G]Z ,[_A!/$?\ T4/6?^_<?^%'_"">
M(_\ HH>L_P#?N/\ PKI?^$>B_P"@CJW_ ('2?XT?\(]%_P!!'5O_  .D_P :
M .3M/!^O7L+2P_$36]JR/&<Q1CYD8J>WJ#4__"">(_\ HH>L_P#?N/\ PK4T
M'1(Y+"=C?:D,W=PN%O' &)FZ<]>*T?\ A'HO^@CJW_@=)_C0!S7_  @GB/\
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M /'Y*W8*#^6*Z*Y'[P-_>'_UJP-54FZ=?=D/Y9K"2T/3H2]Y?UV,*X&S)/\
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M":[JN%^(G_(2\'_]AJ/_ -!- F=]1113)"BBB@ HHHH **** "BBB@ HHHH
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M:6AMQ;VK.MTF<J48<=#S4%KX#U>X^$M__HY@UR\OSJZ6Y.3N#;D1O?% '?\
MC72K:?X<ZMINP+ EBRH/[H5>/Y"L31/&UIX?^#^A^(-<,[QFWBC<Q)N8D_*.
M,CTK#USXC2>)?",F@Z9HNJ_\)%?Q"V>WDM618&;AF9B,;>N*]&\/Z%#H_A;3
M=&D1)4M8$C(<!@2!S^N: /-]2^/G@R[TN[MHUU/?+"\:YMQC)4@?Q5T'P5_Y
M)9I7_ __ $(UU&M:=8KH6H$65L"+:0@^4O\ =/M7+_!7_DEFE?\  _\ T(T
M5OBG\0E\/:;_ &3HUY#_ &_=RI BYR8 W\9]/;ZUS=]\'=4TC1Y=<L/%NI-X
MBMXS<,[R?NW<#+#UYYZUE^*_"T/BWXM>);!I!!<+90RV]QC)CD&,'Z5I75M\
M6-3T/^PKN_TF*VD7R9KQ&S*T?3TZX].: .Z^&WCVT\;>';>1[B(ZM''_ *7
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M6_Y.4\7?]@]/Y05[!7;'9$!1113 **** "BBB@ HHHH **** "BBB@ HHHH
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M):6=0U:?RXRP1(U&7D8]E'>@#:HK-U77M/T30Y-8U";R;.- Y8C).>@ [DY
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M_87NO_07H!'HU%%%,84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M +!\7]*[:@#GO#/_ "6K7?\ L#V__H5;_P 4/^28^(O^O)ZP/#/_ "6K7?\
ML#V__H5;_P 4/^28^(O^O)Z .<^'G_).M"'8V@R/7DT[Q_\ \D\U\#H+)L#T
MY%-^'G_).]!_Z]1_,T[Q_P#\D]U__KS;^8H VOA+_P DK\/_ /7N?_0VKS?X
MJZ];^&OBQ:ZG/"D_EZ3(L4;KN5I"&"@^V:](^$O_ "2OP_\ ]>Y_]#:O._B=
MX>A\4_%VTTF9MIETF0QN>B. Q4_G0 VV^&GC35M,A\4?\)%;1:I+;^=#9I;
M1!&&X1^G/':L;X<Z_)XB^-VFW=Q9QVMU%826]Q'&@5?,1&!( Z9KI+7Q+\4M
M-T./0$\,VTTT,8MH]263Y-H& V,]AC\NE8'@#PU)X5^.6F6$]Q]HNGT]Y[B3
ML9&1B<>H]Z /HZHKG_CUF_W&_E4M17/_ !ZS?[C?RH Y?X9?\D[TC_<D_P#1
MC5UM<G\,O^2=Z1_N2?\ HQJZR@ IK4ZFM6=7X1H;1117*4>.?#7_ )!&L?\
M89NOYBNPN/\ CUF_ZYM_(UQ_PU_Y!&L?]AFZ_F*["X_X]9O^N;?R->;7_BOU
M/7H?PEZ'._L_?\D[N/\ L)3?^@I5;]H/_D6="_["J?\ H#59_9^_Y)W<?]A*
M;_T%*K?M!_\ (LZ%_P!A5/\ T!J]?[9XZ.CO](TW4W5KZPMKED.5,L88BN3^
M(")%+X22-%1%UN$!5& .#VKN3U-<1\0_^/CPG_V&X?Y&O*PS?M8H]?$)>R;/
M9:***] \D**** "BBB@ HHHH \C\+?\ )RGB[_L'I_*"O8*\?\+?\G*>+O\
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M)X \\TDNG01(P>]U!G .=EP<#VK+0[U=*UBAX"U>YU#P_F\<,J3/"H50,*O
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MN[\R2W5L8+@GC&>GL:V-/\=7;_%*^\':C8PP*D/GVEPK']\O!Q@]\$]/[IH
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M:)=7E]H=C=W]NEO=S0K)+"AR$8C) -7Z "BBB@ HHHH **** "BBB@ HHHH
M***HZQ8S:GI%S96]_/832KM6Y@QOC.>HS0!PGCF&Z\1>/-&\(OJEQ8:9<6DE
MW/\ 9GV/.R, $SZ8YJOK'PFT72-)N]2T?5-4TR^M8VN([G[8S %03R&.,5E>
M+?A]:6EO:WOBCXE:G&D$F;>6XV[E8_W<<_E6%J</A36;(V>H_&+4+FV)R8I!
ME3]1B@#V7P3JUSKG@K1]3O0!<W-LKR8&,GU_'K6]6+X0-LWA+3/L=_)J%L(
M([J1=K2J. 2.U;5 !1110 4444 %%%% %#6_^0!J/_7K+_Z":X[X*_\ )+-*
M_P"!_P#H1KL=;_Y &H_]>LO_ *":X[X*_P#)+-*_X'_Z$: .>A_Y+SXA_P"P
M?%_2NVKB8?\ DO/B'_L'Q?TKMJ .>\,_\EJUW_L#V_\ Z%6_\4/^28^(O^O)
MZP/#/_):M=_[ ]O_ .A5O_%#_DF/B+_KR>@#G/AY_P D[T'_ *]1_,T[Q_\
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M1&D%@S!I%BB4@%L?Q,>U)XPLM3\4^$M.U73=-FAU/3KV.^BLKG"2/L)S&><
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M'53R#7IU>8>%+$77CGQRYNKN+&IPKB&4H#^['44 >F&HGJG_ &. <_VAJ/\
MX$&F-I "X_M#4>N<_:3FI9$D5?$O_(N7_P#UQ:K;=36+XBTH)X?OF^WZ@<1-
MP;@D59;21D_Z?J/_ ($&N>9R5"]65XJ/_%):M_UZO_*I?[)'_/\ ZC_X$&LO
MQ/I@3PIJC?;;YMMNYPTY(/UJ8[D0W.S0Y(IMP.:H+I(9\_;]1&><"X(%$VD
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M5TG[3IYL@4:> F,N!%T)&,]?UKVNJ6KZM9:%I5QJ6HSK#:VZ%W=O;L/4GL*
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MO0]:\07\=NCVZ(\\F<%N5'XG% '4:W_R -1_Z]9?_037'?!7_DEFE?\  _\
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M>(I87%Q'IQ AC+KR&V8!;'7% 'KP.0".AI:** "BBB@ HHHH **** "BBB@
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MUM_R<M8_]@L_^@-0![%J?_()O/\ K@__ *":\C^#W_).;/\ Z[2?SKUS4_\
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M%% !1110 4444 %%%% !7!>%?^2I>./^W3_T6:[VN"\*_P#)4O''_;I_Z+-
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M4O\ U^7/_HYZ$9Q-)NM(.M*>M(.HH-^AF^'O^0=+QC_3+G_T<]; Z5C^'?\
MD&S?]?ES_P"CGK8%,AA7GGB7_D;/!/&/^)M=?^@M7H=>=^)?^1L\$_\ 87NO
M_07IB/1J***!!52QTRSTS[0+*!81<3-/(%Z,[?>;';-6Z* "BBB@ HHHH **
M** "BBB@".X@BNK>6WF3?%*A1U]01@BJ&B>'M)\.6KVVD6,5K%(YD<)G+L>Y
M)Y)K3HH **** "BBB@##UOP?H'B*XBN-5TR&XGB7:DI)5U'ID$'%3V7AK1M.
MT:32++3H+>PD#!X8Q@-GKD]<^]:M% &?HVAZ9X?L?L6E6<=K;[BY5!U8]22>
M2?K4L>F646ISZDENHO9T6.2;JQ1>B^PY-6Z* "BBB@ HHHH **** "BBB@ J
M"]LK;4;22TO($GMY  \<@RK<YY'X5/10 R*&*WB6*&-(XU&%1%  ^@%/HHH
M**** "BBB@ HHHH **** *&M_P#( U'_ *]9?_037'?!7_DEFE?\#_\ 0C78
MZW_R -1_Z]9?_037'?!7_DEFE?\  _\ T(T <]#_ ,EY\0_]@^+^E=M7$P_\
MEY\0_P#8/B_I7;4 <]X9_P"2U:[_ -@>W_\ 0JW_ (H?\DQ\1?\ 7D]8'AG_
M )+5KO\ V![?_P!"K?\ BA_R3'Q%_P!>3T <Y\//^2=Z#_UZC^9IWC__ ))[
MK_\ UYM_,4WX>?\ ).]!_P"O4?S-.\?_ /)/=?\ ^O-OYB@#:^$O_)*_#_\
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M\,W6F7?B=-+N--U2ZCMC':!EDLWDSM&3]\=B?:H?".MZ?H=YX\UG4+I8=/\
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M2=.6SL[S45MX00B-<EL#!/<5$]CNPK?.9EVRK*SEE!W9Y/\ M _UKG;D!HE
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M6^A;=;RZPR1L.5;:B@D'OS_*N_H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:W_ ,@#4?\
MKUE_]!-<=\%?^26:5_P/_P!"-=CK?_( U'_KUE_]!-<=\%?^26:5_P #_P#0
MC0!ST/\ R7GQ#_V#XOZ5VU<3#_R7GQ#_ -@^+^E=M0!SWAG_ )+5KO\ V![?
M_P!"K?\ BA_R3'Q%_P!>3U@>&?\ DM6N_P#8'M__ $*M_P"*'_),?$7_ %Y/
M0!SGP\_Y)WH/_7J/YFG>/_\ DGNO_P#7FW\Q3?AY_P D[T'_ *]1_,T[Q_\
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M]9O^N;?R->;7_BOU/7H?PEZ'._L_?\D[N/\ L)3?^@I5;]H/_D6="_["J?\
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MK10 5P7A7_DJ7CC_ +=/_19KO:X+PK_R5+QQ_P!NG_HLT =TOW12TB_=%+2
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M/&J;DXI5ZFD6G+U-6<['4444$,0?>-!ZT#[QH- T)7"_$3_D)>#_ /L-Q_\
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M 4444 %%%% %#6_^0!J/_7K+_P"@FN.^"O\ R2S2O^!_^A&NQUO_ ) &H_\
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M_P!?T7\FKV7O7C7A'_DH'CS_ *_HOY-7;7_A2_KJ>?A?XJ.W'WA]:XKX(_\
M(Q>/?^PBO_H<M=J/O#ZUQ7P1_P"1B\>_]A%?_0Y:PP?VCIQVT3V.O//&'QB\
M/^$]4;2Q%<:C?ICS8K4#$?&<$GO[5U7BKQ):>$_#MSK-\LC00%01&,MEF"C]
M2*\G^!]_X<O'\07E^]M_;4]ZTK-<[0WE-R-N[W+9Q[5Z%.'-JSSFSTCP7X_T
M3QU9R2Z7*RSPX\ZVE&)$ST/N/<5U-?/6L>+?#G@_X\'4M-V_8#9^1>K9*"K2
MG/ QQVC)QW%?0BL&4,.A&:FI#E8)GDGA;_DY3Q=_V#T_E!7L%>/^%O\ DY3Q
M=_V#T_E!7L%=4=D2%%%%, HHHH **** "BBB@ HHHH **** "BBB@ JIJL;S
M:1>Q1J6=X)%51U)*G JW4=Q,EM;2SR'"1H78^P&30!XYI^M>([+X;#PNW@/7
M6N!I[VGG )MW,I&>N<<UL^$_%6NZ5H.C:+/X$UT-;00VTD^$V# "ENO3O64G
MBGQ[#X83Q[<W6GG1RPE?2EA^86Y?;D/_ 'L8-;5KK7BKQ_?PS:)G1?"Z2!OM
MLJ_O[U01]Q3]U3@\T >DT4#@44 %%%% !1110 4444 %%%% !1110 5P7A7_
M )*EXX_[=/\ T6:[VN"\*_\ )4O''_;I_P"BS0!W2_=%+2+]T4M( J-?N"I*
M8/NB@I"4444BA8_NBGU&F-@Q3\TR1K=*KR=ZG:H'[TF7 JS_ 'C7-ZYK@TK4
M=&LC!YG]I71MPV<>7A2<^_2NDF'/X5R?B71KS4];\-W5LJ&+3[UIY]S8(781
MP.YR:S9UQ;2T-$#YR#T.0:SW^1PWH:T7X.0.AS5.Y3$AQT/(K&1Z=)ZF=<1[
M9&';.1CTJ!!@GZU=F&Z)6[K\I^G:JT:[FP.[8K)H[8RT+R@ HH[*,_6M> ?O
M_P#/I69&-]S]6 K4MA^^)]":U@<%=Z&A;=?QJZE4[8<U=05T1/*J;DPIZ]33
M!3UZFK.9CJ***"&(.IH- ^\:#0-"5POQ$_Y"7@__ +#<?_H)KNJX7XB?\A+P
M?_V&X_\ T$T#9WU%%%,D**** "BBB@ HHHH **** "BBB@ KSKP5_P CMX[_
M .PK!_Z+KT6O._!/_(Z^._\ L*P?^BQ0!WC4RGM3*DV11\0'_BF]0_ZXM6JP
MY-9>N,R^'[]E8*PA.">U:IZTS*:(\5C>+^/!VL?]>K_RK<Q61XK9H_">JNC!
M7%LY#'MQ22,TM38[T'I2]Z#TIEI%*YZ'Z5RM[]P^X8?I75W(^4_2N8NTZ9[-
MBLY['?AG[QS4YVE6]"K_ *D5C3H247')C>(?7G_&MJZ4B,@CG:5_(YK*NF*O
MYF,!)2W_ 'T,C^5<,SZ2@]#E](N8KW2+6XA),;( "1@\<']16O"-MH[=V8+]
M1U/]*P/"]M-:^&K*&>-HY%5LJW498D?I72",DP6X^]U(]S_];%9-6D[';3FY
M48.6[2;^XO6P/VE%_N1<?]\Y_K6S=?Z]_P#KN_\ 2L:%@9II%Z=%^F0/Y5M7
M?%T5]96;\SC^E:KX3CE_$7H7;7_CY?Z-_*MBT_U)^HK)@&+J4CIEA6O:C$)]
MS6\#SL3L:>F_\></TK57[M9>GY^RPD_W:U%Z5U(\*J*.M9/AW_D%R_\ 7Y=?
M^CGK6'6LO069M-D+,&/VNX&1Z><],Q1H'K0.HH/6@=:1H9GAW_D&S?\ 7[<_
M^CGK8K*T!F;3Y2S!C]KN!D>GFMBM6F2PKSOQ)_R-G@G_ +"]U_Z"]>B5YYXF
M)/BWP3DY_P")M<_^@M3$>BT444""BBB@"MJ"[],NE]87'Z&O/M/T]EU"U;'2
M5#^HKT>5=\+I_>4C]*R8M,"2HVW[K UC4AS-,]'!XKV,)1[FSVK/US6[#P[I
M$^J:E-Y5M"!N(&223@ #N2> *T.U<!\4 )3X3@D/[E]>MR_H2-Q _.MCSC0T
M;XA:?JFLV^DW.GZEI=W=H9;1;Z#RQ<*!G*GUQSCK77UY_P#%1C!'X4NHCMN$
M\06J(XZA6W!AGT(X->@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 444A(5220 .23VH 6BN=MO'O
MA2\U,:;;Z_827C.8Q$LHR6'8=B:Z*@"AK?\ R -1_P"O67_T$UQWP5_Y)9I7
M_ __ $(UV.M_\@#4?^O67_T$UQWP5_Y)9I7_  /_ -"- '/0_P#)>?$/_8/B
M_I7;5Q,/_)>?$/\ V#XOZ5VU '/>&?\ DM6N_P#8'M__ $*M_P"*'_),?$7_
M %Y/6!X9_P"2U:[_ -@>W_\ 0JW_ (H?\DQ\1?\ 7D] '.?#S_DG>@_]>H_F
M:=X__P"2>Z__ ->;?S%-^'G_ "3O0?\ KU'\S3O'_P#R3W7_ /KS;^8H VOA
M+_R2OP__ ->Y_P#0VKE?$?\ R<%I/_8+E_DU=5\)?^25^'_^O<_^AM7*^(_^
M3@M)_P"P7+_)J .SKSZV_P"3EK'_ +!9_P#0&KT&O/K;_DY:Q_[!9_\ 0&H
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MVJ>@]\&I/&ETOC6^A\%:*JSB.>.;4[M>8[2-3G;N_P">AQP!TH ])K@O"O\
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M[=9/,.>#STKDOAY9W$'BCQG%<WTMQ/'J-NDDV OF'RQ\V.QH ]*:HZ&B8?\
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MFO9Z6WG1VUE&P$\^,"1]W3&20!WKO*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X;XN7MU:> ;
MB"T?RY+Z>*R,F2"JR-@D5W-<-\6["ZO? 5Q-9IYDMC/%>^7@DN(VR0,4 0>*
M/ .BQ_#6[TZVT^UBFL[/?#<)$%=9$7(?<.<Y![]ZV_!6N?VEX T75;^:.)YK
M5/,=VP"W3J?7%8'B;XAZ'<?#6XO[+4+>:YO[<P6]O&^7:9QC9MZY!-:GA_P;
M92?#?1_#NO6<=TD$$9DADS@..>WH30!JZUJ^F-H6H*NHVA)MI  )UY^4^]<C
M\&]2L+?X8:5'-?6T;C?E7F4$?,>V:U_^%3^!/^A:L_\ Q[_&C_A4_@3_ *%J
MS_\ 'O\ &@#B8+VS_P"%Y^()OMEOY36$05S,NTGCOG%=I_:-A_T$+/\ \"$_
MQIW_  J?P)_T+5G_ ./?XUY_9> _"TGQNU/17T6V.G1:;'*EN=VU7.,GK0!N
M^'-0LH_C+K<KWML(VTFW4.9EVD[NF<UN_$O5-/F^&OB".*_M7=K-PJK,I)^@
MS4W_  J?P)_T+5G_ ./?XT?\*G\"?]"U9_\ CW^- ',_#^^LH_A]H227MJCB
MU *M,H(Y/4$T_P >7UE)X UY$O;5W:S8!5G4D\CH,TGC_P"&_@[2O .MWUCH
M%K#=06KO%(N[*MZCFHOAQ\.?"&K_  \T6_O]!M9[N>#=)*V[+'<1GK0!N_"K
M5-/@^&&@QRWUK'(MN<JTR@CYF[9KE_$%]9O\>])F6\MS$-+E!D$J[0<-QG.*
M[3_A4_@3_H6K/_Q[_&C_ (5/X$_Z%JS_ /'O\: &_P!HV'_00L__  (3_&N
M@O;1?VC[*<W=OY(TP@R>:NW.QN,YQ2ZKX#\+0?&G0M&CT6V73I[&626 ;MKL
M <$\UZ!_PJ?P)_T+5G_X]_C0!MZEJ^F-I=VHU&S),+@#SU_NGWKRGX1WEI#\
M/+1);NWC<2R?*\RJ>OH37=_\*G\"?]"U9_\ CW^-5[_X5^!HM.N9$\-V8=(G
M93\W! /O0 7FHV!L+H"_M"3"_P#R\)_=/O4'PFU/3X/A=H,4U];1R+"V5>90
M1\[=LUQWP;\!^%O$'P_BO]6T6WNKHW$B&5]V2 1@<&O0/^%3^!/^A:L__'O\
M: .E_MG2_P#H)6?_ '_7_&FMK&E_]!*S_P"_Z_XUSG_"I_ G_0M6?_CW^->=
M^/O OA?2_''@JRLM&MX;:^O?+N8UW8E7*\'GW-3*/,K >R_VQIG_ $$K/_O^
MO^-']L:9_P!!*S_[_K_C7/?\*G\"?]"U9_\ CW^-'_"I_ G_ $+5G_X]_C6?
ML5W'<X/X<WMI%I6KB2[MT)UBY(#2J,C(YZ]*ZZ?4; VTP%_:9\MO^6Z^GUJ]
M_P *G\"?]"U9_P#CW^->>_"[P)X7UM_$XU'1;>X%KJTL,&_=\B G"CGI7-4P
M*G-RYCKAC'"*C8T_@+J%E;?#Z>.XO+>)SJ,IVR2JIQM3G!-5OCY?6=UX;T1;
M>[MY675$)$<JL0-C<\&NX_X5/X$_Z%JS_P#'O\:/^%3^!/\ H6K/_P >_P :
MZ_9J]SDN53J5AD_Z?:?]_P!?\:XOX@7MI+<>%?+N[=]NM0LVV53@8/)YX%4O
MC1X'\,^'?#NEW&DZ/;VDTNHI$[Q[LLA5B1R?85Z7_P *G\"?]"U9_P#CW^-<
ME/ J$E+F.NIC'.+C8Z+^V-,S_P A*S_[_K_C7C_A2]M$\>^.7>[MU1[V(HQE
M4!AANASS7??\*G\"?]"U9_\ CW^-'_"I_ G_ $+5G_X]_C6\\.IP<;[F%*I[
M.2D51J5AN'^GVG_?]?\ &N-^"]]9V_B#QT9[N",/J(*%Y5 8;Y>1D\T[P9X
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M]OV!1=SGYM@'3@ #\ZK^'= \<^&=,AT[3K3PW%;(<NVZ4O(>[,<<L?6O2Z*
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M%%6/!XQC.:Z/X5:A=7O@I(+V=Y[BQN9K,R.<EE1R%R>YVXH [:BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M" RE6 ((P0>]+10!@6W@CPQ9ZN=5M]"L8[X\^:L0X/J!T!^@K?HHH **** "
MN;@\(0P>/KKQ6+R0RW%JML;?8-H QSGKVKA?B'8>--&&I:];>-9+:P,@%K8Q
MP@L6; 6,''4FHK+P5\69[%);GQXMO.Z!O),>[:?0D+_*@#V.BO.?AG=>(;;4
M]>T+Q7JKWNJ6LD<D0;&&A(.'7 '!/KTQ7HU &7XDT5/$?AR_T>29H4O(3$TB
MC)4'OBF>%]!C\,>&;'18IVG2TCV"5U +<D]!]:Y+Q/\ $?4+'4[_ $_PYH1U
M1],0R:A<2R>7#!\I;;GNV!TJW<?$%]-G\.RZCICQZ7K%O&3?(V4@G< A&]!S
MUH [FBBN8\:>*I_#5G9QV%@U_JFH3BWL[<':K/C)+'L * 'WGA"&[\>:?XJ-
MY(LMG;O MN$&U@P/)/7O725YU!9?%J>$23:MX=MG;DP_9G?9[9'6FVGB;QAX
M:UNRL?&-M87%A?W MX-1L25$<A'RAU/0'UH ]'J*YA%Q:S0%BHD0ID=LC%2U
MYQXU;7==\<:;X4TS5YM'M)+.2[N+F(#?+@X"KGT[_6@#H_ _A"'P1X;31H+N
M2Z197D\R1 I^;M@5TE>7?\*FUK_HHFN?]\C_ .*KT32+&33-(M;*:[EO)((P
MC7$OWI".Y]Z +M<QXC\&0^(O$&@ZO)>20/I$_GI&J B0Y!P2>G2NGHH ****
M "N9\(^#H?"3:L8;R2Y_M&\>[;>@786/W1CKUKD]2^-=KI4MT+GPMKBQ6\C(
MTYB4(<'&<D]#4 ^.EH8//'A+7S#U\SR!M_/- 'K-%<[X*\7VWC;0/[7M+2XM
MH3*T2K/C+8QR,=N?TKHJ .5\=^"(/'6F6EE/?2VBVURMP&C0,6(!&.?K755Y
MAXH^+<FF2WJZ#H-QJEO83+#=WY.VWC8G!7=C)() KICXVAM_&L7AN^L+FV-T
MF;.\<?N;A@H)4'U% '4T45R?C/Q9=:"^GZ9I&G_VAKFIR%+6W9MJ!5Y=V/95
M% %O0O"D6A>(-?U:.ZDE?6)8Y7C90!$4!& >^<UT->=PV/Q9EB#RZSX<A<\F
M/[,[;?;-)I_BGQ9X?\0Z?I/C2TLI+;4IC;VNI6)(7S2,JC*>F><'_P"O0!Z+
M6!XS\+Q>,O"UUH<UR]M'<%"944,1M<-T/TK?KS#6)_%OBWX@:AH>AZR=$TS2
M(XOM$RQAI)GD4L-N>HQ_(T >B:58+I>CV6GK(9%M8(X [#!8*H7)_*K=>=#P
M'XQ!&?B1J./^O6.O1%!"@$Y('7UH 6BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@O"O
M_)4O''_;I_Z+-=[7!>%?^2I>./\ MT_]%F@#NE^Z*6D'04M( IJ_<%.I%^X*
M!H2BEHQ0,1!A!QBG4U/N#G/O3J!"&F$5)32*!ID+"LC4M#L]3U'3+^X$GGZ9
M*TUOM; W,NT[AW&*VB*Y_7-?_LC7- TW[/YG]K7#P;]V/+VINSCO2-+KJ:)3
M()'J>*@>.KNWKSW-,9 ?8U#1O&=BB5.,$ CWIJ(!G"#KWYJZ8CZ4U83S]>]*
MQI[1$*H<Y/6K4:;1[FE5 /<U*J\TTC.<[CHQU^M3@5&@Z_6I0*M'-)BB@=32
MT@ZFF0+1110(0=32TG<TM PKA/B+_P A+P?_ -AJ+_T$UW=<)\1?^0EX/_[#
M4?\ Z": .]HHHIB"BBB@ HHHH **** "BBB@ HHHH *\Z\%?\CKX[_["L'_H
ML5Z+7G7@K_D=?'?_ &%8/_18H ] :F$5(::12+3,KQ#_ ,BYJ'_7 UK=ZR_$
M0_XIS4/^N!K5[T Q16+XQ_Y$[5_^O5_Y5M"L7QC_ ,B;J_\ UZO_ "H)9MGK
M12GK24",S7A_Q(K[_KBU/N$R6'K2:\/^)#??]<6J>9?F/UI,UINS,2>+>I0]
M^1]:P]5L1>:==6TA*,\3('QG&1W%=3/%NR0/J*S-0,=O87$\X/EQ1,S$#D #
M]:QE$].E6LCF=!L9(/#NFQ+.,):QKDMCHHJ^+3YLO("?4'=4^A117/AW3)XV
M.R2TB8%E[%16@+51_%GZ"LW#4Z8XBT58SVB_T>547 V'/J>*9X5A"^%M'8X)
M^Q0D#T^05K/$%MY0BX^1N>_2JWA2 GPEHQQ_RXP_^@"M(QT.:I6O(THXR3[F
MKJ+@8]*1$"].OK4ZKP:M(Y*D[A8C_18O]T5<'2JMB/\ 1(O]VK5:'&V'>LGP
MY_R"Y?\ K\N?_1SUK=ZR?#G_ ""Y?^ORY_\ 1ST"1J4#J*6@#F@HRO#O_(-F
M_P"OVY_]'/6M63X=_P"0;-_U^W/_ *.>M:@0=Z\[\2?\C9X*_P"PO=?^@O7H
MG>O._$G_ "-?@K_L+W7_ *"] CT:BBBF 4444 07D)N;&X@&,R1L@S[C%<;9
M>";NVOX)WGB*1R*^T9['-=S17/6PU.M)2GT.'%9?0Q4XSJK6.P5C>(?#D'B.
MWAAGOM0M!$Q8-97)A9OJ1U%;-%=!W'E_C#P>VC6'A[5+&&^UE="OS<RPW,IF
ME>)\;R">25P"![4V?78?B!XP\-G0K*^$.E7+75W>SVS0B)=A C&X<ECU ["O
M4J* /)="\40_#:#4O#>L:;J&8;N:;3WM[9I5NHG8LN"!@')(YKJOAGH][H_@
MV(:E"8+V[GENY8CU0R,6"GW QFNPHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,;Q5
MX=M_%7AVZTFX<Q>: T<RCF)P<JP]P17F:>)OB%97S^'X-7\*ZG>0QY$QN-L@
M15Y9DSV')KLOBG?7FG^ +Z2S=XB[1Q33I]Z&)F =Q] :Y.R\+>']"^*?ABVT
M6UB%I=:3<F216+?:!@#<3GG(/ZT =9X"\//9)=Z_?ZO#J^JZH0TMW!_JU0?=
M2/\ V179UYMX!M;71_'7B?1="PV@PB*7"N66"X;.Z-?P&:])H \9\07]SX*D
M\8:?J.F74MAKADGLKZWB\P;V3!C?'(.>GM55=:E\?^'M \':)IM[M@%J]_?7
M$1CC@$6"0,_>)*XK:EE\;>-?%>MP:/XACT33=)N?LJJD =Y6V@DG(J]:>"_'
MT-Y!+/\ $&6:%)%9X_LJ#>H/(Z=Z /2*Y+QUX=U76(-.U#0;B&'5]*G-Q;B8
M?)+E2&1O0$5UM<;X_P!:UFR72=(T"2&'4=7N3;I<2KN$"A2S-CN<4 <[=>._
MB/8S^1+\.C,P_CMKDNA_$"IX=/\ &OCC4]+D\1Z;:Z+HMG,MV]JLOFR7$BG*
MJW]T \TRX^%.M7T@FN_B)K;S8Y* (/R!H>/Q1\/=4TN:\\1OK>AW=S'9SI=Q
MA98&<D*RD=1G&: /4*\X^)_AS5]2NM,UK3?$EGH::8LC-/<<$%L=#CI@'BO1
MZ\P\:VNF:Q\3M"TKQ,ZKHYM));:&1L1W%QG&&Z8PO(]: ./L+KQ;JEXEG9?&
M#1IKB3A(UQEOI\M>X:+;W]IHMI;ZG=+=7T<86>=1@2-W.*Y+Q=X1\"MX9N9+
MZQTZTC@@9HIX@L3QD#@J1U/3UK5^'5W?WWP\T.YU,L;M[8;R_5ADA2?JN#0!
MT]%%% !1110!P7Q6M;N31-,OH;.6^L].U&*[O;.,9,T*YR-O?!P<>U0?\+K\
M#"WS]NGWYV?9_LK^9GTVXK>\;^)KCPWI-O\ 8+9;G5+^X2SLH7.%:5N['T !
M/X5P.CV/BK_A/]:TC4K_ $F;56TC[9:SQV**D$S/M4YV[CC!]>M '4?"VUO%
MTO5=2ELGTZRU*_>ZLK!Q@PQD#G';<><=J[MEW(5SC(QFN4\!^)+_ %W3KVVU
MF&.'6=,N6M;Q(OND@95Q[$&NK9@JECT R: /GOQ!K*^%? &M>"=9L[FWO5NC
M+:W"Q%H[N-I=X?<. <9SGTKJG\11?$OQ5X:MO#]K<MIVDW:ZA=:A/$T:952%
MC7/4G-%A?_$#Q]%>:AIEQHMAHPN7BM8KRV,K2*IV[CD'N*W]"T;XAV>IVIU+
M7-%DTQ&_>P6UH4)7T7@ 4 =Y7'>-O#6J:C=Z7K_A^:)-;TEI#!'/_JYD<8=#
MZ$X&#78UQ'CO7M:AU+1_#'AUHX-3U@RXO)1E;>.-<NP'=L'B@#"N/'?Q'L[C
MR)/AT97Z;X+G>A_$"K-KI/C#QGK^CZAXGL+72-,TN=;R*TBF\R268 [2Q[ 9
MZ5'/\*=:NYA/<_$37&F'.5 4?D#BE23Q-\/_ !%HUOJ6NOKNC:M=)8 W$86:
MWF8':01U7CF@#TZO-_&.A^)8/%Z>)M&U[1])@2V$$IO 1YPR3A^Q ZCH1DUZ
M17E=WI.G^,OBWJFG>*#YEOIMM"VFZ<[D).'!WRXSR0?EH ;I>J>/-:?;IOC'
MP?=D'E88G8_EFO55SM&[&<<XKR?Q_P" _"7AOPK<ZYI<,>B:I8CSK.YMW*LT
MH^ZF">=QX_&O3M*GN;K1[*XO8?(NI8(WFB_N.5!9?P.10!;HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"GJVJV>B:5<ZGJ$PAM+9"\CGL/\>U<?8?$U)KVPCU3P[JNDV>H.([6
M\NT7RW=ONJ<'*[NV:/B^6/@-H_\ EC)>6R3^GEF09S^E-^+BJOPSNI$_UL,D
M#P$=0XD7!'O0!WU<%X5_Y*EXX_[=/_19K8U[QII7A.VL3JYN@URF5\FW>7D
M9SM''6N:\!ZK::KX^\7ZC;.PM[E+-X_-4HV/+/4'D4 >CK]T9I:B6>(*/WD?
M_?8I?/B_YZQ_]]"D!)2+]T4SSXO^>L?_ 'T*19XMH_>Q_P#?8H EHJ/SXO\
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M,DBV$ 93U!V"M0VXSU%<EIOCGPA!I-G$WBOYHX$4\D=% Z;:F/CSP?V\5?\
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M>H1F>U*VDA=,<9X&5//>O0KLRK:3&"-9)0A*(YP&/8&O'+OXB^-U\4Z?;_\
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M-:"0/?W+74V]L_.0 <>@XH YK_A4OA+_ )];K_P,D_QH_P"%2^$O^?6Z_P#
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M"5/H>*!\7/!K$ :C-DG'_'K)_P#$T ==_9EA_P ^5M_WZ7_"C^S+#_GRMO\
MOTO^%658,H8=",BEH J_V98?\^5M_P!^E_PH_LRP_P"?*V_[]+_A5JD=MJ,W
MH,T 5O[,L/\ GRMO^_2_X5S&E>&9;?Q]X@U&XL;?^SKJ&V6VX4C<H;=\O;J/
MK6?#\2VD^&MAXG_LS=?:A.;6TL(Y,^9,9&15W$=/ER:BD\3>-_#*1:EXJT[2
MY-'=U6X>QD;S+,,0 2#PX!(SB@#O/[,L/^?*V_[]+_A1_9EA_P ^5M_WZ7_"
MK0((!'0T4 5?[,L/^?*V_P"_2_X4?V98?\^5M_WZ7_"K5% %7^S+#_GRMO\
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MG'2J$OQ+U40/K<'A2YF\*H3_ *>LP\UD'641=2G?/I0!Z#9K<K90+>/&]R$
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MM7L);'4;6*YM91AXI5R#_GUJU6/XD\3Z5X3THZCJ]QY,&X(H52S.QZ!0.2:
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MK)<W4T<,$:EGDD8*JCU)-<A+\6?!,<WEC6DD&<;XHW=/^^@,4 +X<TKQ!?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*** "D8D*2!DXX%+10!Y%X9\.:%XZCN]6\6W<FH:G]LFBET^>Y*1V6UR%C"
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M2.3UITOA'QAXE,=KXMUS3O[*5U>6TTR!E^T;2"%=F.0,@=* /0@0P!'0\TM
M   '044 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\*J:9X,\-:-(LNGZ'86\JG*R+""RGV8\BMRB@ HHHH **** ,O5?#>B:X/\
MB::59W9QC=-"K,!Z!NHJ'2_"/AW1'$FFZ+8VTBG(D2%=X^C=:VJ* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[TC@"L#N!_A^M4/$ND6?A'XD>$=9T6T@LUO[@Z9=00((TD5QE20.,CD_EZ4
M>IT444 %%%% %34]3L]&TRXU&_G6"UMT+R2-T %<QIL^@_%/PX]QJ&@R-8><
MR0?;8MK2*,?O$(Y )XX/:LWXSQNW@B*23+:=%?V[WZ#JT.\9'Y[3^%=_:R02
MVD+VK1M;L@,1CQM*XXQCMB@#R>U;P7X!\?"PF\'MI:3.L5EK$@:2%V(!X+$[
M#DXR/QQ7KM<'\8Y=/3X9ZHE^ 6D"K;*#\QFW#9CZ'D^V:Z[14NXM!TZ/4&W7
MJVT:W#>L@4;C^>: +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHK$M?$&_Q7>:!=P>1.D2W%J^[(N(CPQ''#*W!'H0:VZ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y/Q_X9O?
M$.DVTVD3K!K&FW"W=D[_ '2X_A/L1Q7644 >7+\89-+B2W\1^$M;LM0 PXBM
M]\;L#C*-GD?YYJ-1K7Q0U_3)[O1;G2?#&G3"Z*7PVRWD@'RC;TVCUYKU6B@
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MFY3G+@'YN..HQUK2UGP%J%[XQN/$VE^(YM,O'M4MU5(!(F%.3N!/S _A@\T
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M!,P*PKGU^\Q'H*[F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img192321128_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X2/417AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(R.C R.C$X(#$W.C0S.C4W   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,P,   DI(  @    ,P,   H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,CHP,CHQ." Q-SHT,#HP.  R,#(R.C R.C$X(#$W.C0P.C X      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  $B@         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ 7P$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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MZ>U $T7AB"/4(KPW#F6-F((4#[V/\!6E:67V4NQE=W=B6)/6@"W10 44 %%
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M6R#]#5+PRH7P[: -N&TX(Z=3TH YE[KPY)%<I9Z5+%-Y;A9&A8#@<]:[T=*
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ML!L\<FHM)LWL-+AMGVAD&"%;('/0' X_"@#EM:L]>T[1K^\.IOJ 2!R+..,
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M[NF?0B@!JRV1FNXA<ZB7A4NP.>!G''K4+WNGKID5Y]IU,Q%RN1G<2#@Y'XT
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MFVX/O0!T*I&2) B[B.N.:$CCC!$:*F>NT8H ?10 44 %% !10 44 %% !10
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M%!04%!04%!04%!3_P  1" &&!!X# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!,T;AZUXK^V)\;KC]G_\
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M'OQ%^) \)^$+CX<^!+'Q)JVNVRW%Q/JFJBTL-+0Q*X,C;3)(27P BY.TDXH
M]@W#UHW#UKP3]GS]H#Q+X^\=>-/AW\0/"MKX5\?>%4M[FXCTR[-U8WEM.I,<
MT+D!@.,%6&1ZYR!XSX9_;2^,NM_"'4?B]'\*?#VH_#O3WO)+B.S\0NFII:VT
MSQS2A'BV,5$;-@-R!0!]PY%+6#X)\5:?X\\'Z#XETHLVF:Q90:C:M(NUC%+&
MKIN'8X89'K2MXYT!?&R^$#JEN/$S:>=4&F9/FFU$GE>=C^[O^7ZT ;M)D5B^
M-/%VG> _!^M^)=6F$&EZ1937]S(3C;'$A=C^2FO+_P!D'5O&/B;X#:%XJ\>:
MA-=Z[XE:;7/(F4*ME;3N7M[= %'RK$8^O.2: /:Z*P_!7CC0?B-X9LO$7AK5
M(-9T2]#&VOK8DQRA6*-@^S*P_"MR@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I-PI:^1OV_
MOB_\0_AJ_P (]#^'7B2'PIJ/C#Q/'HL^I2V,5WY2OM53LD5A@%\G SQUH ^N
M-P]:,U\"?%KXC?M'?L6V^@>-O''Q"T/XM>!+K58=.U6S_L.+3+JV67.)(C%P
M>%;J< XXY)'WO;RI<11RQG*.H93Z@\YH EHHHH **** "BBB@ HHHH ****
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MGI]T^M?;]9/AGPKI'@W1;71]"TRUT?2K4$06=E"L448)+':J\#+,2<=2:UJ
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M^_A@DB!@&'8C/Z5\@_$CX9_M:?M*>$[KP%XO7X>_#[PCJC*FJZAHTUQ=WDL
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MO#^N:KHVBZ]X>?1=6ET6^T[Q%:+;74-S&D;NC1J[8P)5')SD'BO5: "BBB@
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MEUX>NX18>)K?1KG2[;6;:5"0ZP3J&5D92K8XR1]3](T %%%% !1110 4444
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M'29-#T73]/>]NM1>U@2!KR]<-/.54 R2$  LQ&20!R>@K2HH **** "BBB@
MHHHH **** "BBB@!*^=_VZ?B1XJ^%OP+.N>%=87PX?[6L;;5-:\J.:XT^PEE
MV336\3Y$DHRH"8)(9L<BOHFO(?VD_@ O[0/@W2-,AUZX\,:UH6L6NOZ1JT,"
M7"V]Y!N\MGA?Y9%^8_*>^#VP0#X_\,_M._$O5O@';6>E^.6U6X\1_%&W\"Z!
MXYNM-BBU".PE/SW$MK@!9E(90'520P8@'!J])\>OBS8K/\&#XZ:7Q5_PLR'P
MA'XZ>PA^U+IDEL;G?Y6/+,X V;L8QG//->MC]@Z:_P#A[KUOJWQ#O;SXCZKX
MIMO&:^+H--AACM-3MQMA:.T!V% I92I/S;LYX%.7]A.ZE\"2FX^(EX_Q3D\6
M)XU'C9=.C 3443RE46N[:8/+^7R]W/7_ &: +_[/7[0-SX<^'7Q4/Q7\4)>1
M?#3Q/=:%=>*9K7RS=6R>6899(XEP'_>A3M7L#ZFN5_9Q^+W@_P"-W[<7Q/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK*UMO#$1R%"<=,D'_.*Z&BLJM*%:#IU5>+W3,:U&GB*<J56-XO1I[-'F>A_
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M@'0'=ZUZ/\6/A/HGQF\(R>&_$,FH)ISS1SEM,OI+.7<A)'[R,AL<],T <_\
ML[@IX5\2AA@_\);KG_IPGKU2OG'P1^P3\+?A[XFTO7=%;Q1%>Z?>+?0I-XCO
M)83*&WY>-I-K@MU!!SGFOHWI0 M%%(WW30 FX<UP^K?'+X?Z#XJC\-ZCXPT:
MRUYV""PFO$67<>BD$\$^AYKFOBAX7^+^L:^\W@GQCHNAZ-Y"J+6^TSSY?,YW
M'=GH?E_*OQV\<>$_%6E_$'4]&U^PO7\4R7CK-!)&SRSS%SRHZN&.2",YSD9K
MZG*<GI9AS<]5*RV6_P [_H?19;E=/&WYZB5ELMS]YED5NAS1N!%?-/P$\"_'
M;1M \&_\))XRTG^R+>W@%WI4^GE[Q8@O^K:;(RX& 6]03S7TGG/<U\_B:*H5
M'",U+TN>+7I1HSY5-/T/!OC5^VEX"^!?B^?P[K5CXDU6[L;./4-6N-#TI[N#
M2+5VVI-<N"-BDCMD^W2G_&#]LSP!\'[K1+.6+6O%-[JNF'7([7POI[7SPZ:,
M$WLN" D.#G=GL>*\'_X*&?&;P[?:+XL^%7B"\\2>"-033XM4T:YM;0S67BV4
M*VS3CY8+,GF,JNA*GC/0?-QVL?$I/@5\8H/&_P 4]%D\'6?B[X/6NF65K!9R
MO!!J,8W/IJ!5;8W(PAZ9&:YCG/T%\&^-=&^('@_2?%.A7\=]H6J6J7MK=KE5
M>)AN!.>G'4'IS5JS\6:)J$B1VNL6%S(\/VA5AN48F+."XP>5SWZ5\^?LH>$=
M7\"_L'^%M&U^VFL]4A\-W,DMK<)MDB$@ED5&4]"%=>#TKX0^%OP"\$W/PY_8
M\OWT/9J'B[7;ZS\0744TJ2ZA;AI 8)&##]T54(5Z;21W.0#]>8->TVZTLZE#
MJ%K+IP4N;M)E,6T=3O!Q@8/.:@C\4Z--'(\.JV<X2V^V-Y4ZMB#G$O!^YP?F
MZ<5^4/BOPS!X5^%OQ;\/V=C?6_PGT'XW0CQ#I6F>:RP:(J#SE"J<^4'\O(7T
M'H*GLO%G@7PY\2/VC-1^#-G):^&=0\!V>D:(([>:.W>ZO;E+96MDD&1&9)2W
M  +*Y'% 'WU\+_VNO!?Q8\8:3X>TNVU:SNM3\,?\)?!-J-ND4(L#-Y*LS;SM
M8GYL8QMYS7KR^*M%:QL[U=7L397CB.VN!<IY<['@!&SAB?05^67[5GP?\6K\
M?7\&> 92UIX=^$-HFJ::LC1RZOI5K=*)+*-T&0\FT9P02 1GG%=9\0/%'P@\
M0?&KX0^)O'NE;?V?;[P!Y?A2R2TFDL+35?-P]N8X5R)UC!0<9W!<<@4 ?I78
MZI9ZI'))97<%W''(T+M!('"R*<,A(/# \$=15JOCK_@EG'$O[..KF".[B@/B
MW53&M_G[0%\Q<"0DDEP!AB>X/6OL6@ HHHH **** $IC*?I[U)24 ?.&O?MA
M?".#QOK^DM8ZCK=SX>MKRXNM8M-%:>T4V@4W$,,^/WDD8<;E3."#FO??#VN:
M?XHT+3=9TBZCOM*U"WCN[2ZA/R2PNH9&7V*D&OSL^(G@'2_A[\0+SP[HO[3G
MP]\(>'K.YU@Q:7KBP2:II(U,@WD2GS0KD'=LW@%=Q!SBOO/X.:#X?\+_  I\
M'Z/X3ODU3PS8:5;6NG7T<HE6XMTC58Y-Z\-N !R/6@#LZ2EHH @FMUN%V2HL
MD?=' (/.>0?P_*EFMX[B,QS1I+'_ '74$<?6LWQ'XPT'P?:176O:WIVB6LK^
M7'-J5U';H[8SM#.0"< G ]*@D^('A>'P_!KTGB/24T.=_+BU-KV(6TC$E=JR
M[MI.01@'J#0!L26Z7$8CEC65.#MD&1P<@\YJ0*0P_P :SM9\4Z+X=T^*^U;5
M['2[&5UCCN;RY2&)V;[JAF(!)[ =:T5D210ZL&5AD,#P1ZT ?+_[#O\ R'/V
MC_\ LK&L?^BK:OJ.OES]AW_D.?M'<=?BQK&/^_5M7U'0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%(>E !F@L!3<BO//B;\<?"GPFN+2+Q#->QM=
M(TB&UL)KA0J]23&I"]>]9SG&G'FF[(RJ5(4H\U25D>BY%&17F'PU_:&\&_%K
M5'T_PY=7UQ*L!N T^GSPQE 0,AW4*>6'&:]-':BG4A5CS0=T*E6IUH\].5T/
MI*6DK0V#(I-XYILGW37A/B?]K31?"VN_V1>>#/&GVI[F2TMF71F*W;(2#Y)W
M?.#C/':L:E:%%7F['/5KTZ"YJCL>\[A2;AS7.^"/%R>./#=MK":9J6CK.67[
M'JUL;>Y3:Q7+(3QG&1[$5B_%+XO:)\*=+@EU R7NIW;>5I^CV:^9=WLG0)&@
MY],GH,]>E.56$8>TD]"I5H0I^UD[1.A\7>+]'\#:%=:SKNHPZ9IMJN^6>=L
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M[PWXKT>UUW0KY0MQ8WB;D?!R#ZA@0""""",@UTE-W#UQVH \MTW]EWX5Z/\
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MN?'J>'?#GP#&F1^+]65+7XAW!EUN%Q=/N$[HIW D$IG)"$#)X-?HO\-5N(_
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ME@C8(_=>4G&5]>^:]=KR7]F?Q%>>*/AC%?7WBOPEXQN&O)D.J>"X?*L#@CY
MNYOG'\7->M4 %>"_MK?%'Q7\)?@'J6L>!X;J7Q7<7EI8V+6=@;Z2(R3+YCB
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M/)N)LG:H S[^PH ^K:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBDW"@!:*3<*6@ HHI,T %?*__!03+>!?A4$^]_PLOP_@=?\
MEL^*^I99XX8FDDD6.-02SL< 8ZY-?B5_P49_;=\6?$'XTWW@SPUJ\%EX-\(:
MK%-82:>4E:XOH.1=&7!SM<L%"G QDY- 'Z :0O\ PU+^V!<:L?\ 2/AO\'IG
ML[+O#?\ B%UQ*X[-]F3Y?9R".IKZWP:^+O\ @DU\0X?''[*\5J-,6QO=&U:Y
MM+NZ4,3?RN1,9W8G+2$2X;G^$=,@#[3H **** "BBB@ HHHH **** "BBB@
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M5^F6S^=>6? GX)ZI\&-/O[*_^(/B#QU;7 A%M'K@A5;%8PPVPB)% #!AD?[
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M1?X+ZK\3]4TB_?XHZ%X?T#4EG"VD7AZ]DNHI(MH)9C(H(;=G@=J]&W"O@?\
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M$*I51G=\[<#C/Z<0P+"BI&H1% "HH  '8 =A4FW';GUIU #<8IU%% !1110
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M"VBR>#/[=^+>HZ9#C7OML\*:3;ASY1V*^V1SA\ K@ Y)Z5M?L1_MC?L^> _
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M-V/DC/'^KC^ZHXSSDBG_  CL]5TWP?;6.K-;R3VI\E)+>42*T8 *\CH1G'T
M-=M7E8K$.E4G3HNR[[M^K+BM+L8JA<    8K,\2>';'Q1IIL;]9'@+!B(Y6C
M;CW7FM4]ZY'XG_$!/AGX2GUV71]4UR.!U#VNCP":8*>K[2P 4=2<\5YU-3<T
MH;]#6,7.2C%:LKZ3\'?#.BZA#>6EO<QSPR><I-Y*5W9SD@M@\^M=LO:OFOX8
M_MS>$_BUXLM=!\/^&O$]S/+,L4LWV.(Q6P+;?,D*RDA >IP>E?232*BL[$*J
MC))Z"NO&1Q49I8J_-YFM7#U,,U&I&Q)16.WC#14\,CQ$VIVZZ$;=;H:@7_=>
M40"'W>F".:LZEKFGZ/\ 9?MMW%;?:ITM8/,./,E?.Q![G!Q]*X3 OT4FX&EH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@?CA\7M)^!'PQUC
MQQKEO=7FEZ7Y/FPV(5IF\R9(E*AB <-(">>@KO:\A_:P^#>J?'[X ^*/ 6D7
MEI87^KBW5+B^+B$!+B*5]VP%AE8R!CN: /.?$G['MKXRDU+^T?C[\5&TK5'D
M:?2X_$L2VYAD)+0@"+(CP=N,_=XKZ'\$>$])\"^$-$\.:# +;1=)M(;*SB#E
M]L,:!4&XGYOE Y->$1_\$Y/V=1&H;X8V); !_P!.O,?^CJ]^\*^%]-\%>'-,
MT'1K1;#2--MTM+2V5F811(NU5!8DG '4DDT :](>E+2&@#Y=_;7^(GQ(T6PT
M/PCX!\)>+M0L=<9_[=\1^$[);B\T^S!"M':[V51<29(#L?D&2 3C'E \*ZQ\
M,-4^!OQ-\ _!CQ<?"WAG1M4\.W/@MHXEUJT:9LQW#H7(<2.KLS;LC?DCG%?>
M^T_C1MH _.+X?_!WXG?LPZ?\%_&S^ -4\;7MEX<UG2M9T+07CDNK&XOKMKN'
MY21E1OV.5)VE2>>,^V_!O]E>_P!$_8V^'W@#Q=XS\3_#[4M"234]0O/"6M#3
MY8V=YI7AEF"D-&@F^;MNC!S@<_5^#M]/3VKY8_X*7:5XEUK]D'Q=9^&))/M+
M26S74$#8>>U$J^9&N.6S\IP.H!%2WRJ[)E)15V><_P#!//XF?#SP;8?'#03\
M1['4_LGC?4]2BU'6M6CENKVP$5NHOI)6P)%8HV9!QD9.,C-WX@_MH>*/C5JT
MOA3X"64L.F,S0W/CZ]M&D08."+&W(_>MZ2/A?;H:_)']G'X7ZC\4/C?X/\/0
MZ8;V"75[5+Z.8$1+!YJ^9O/8;<CGKD <D5_1;X3\!Z!X'L$LM"TFUTVU10JQ
MV\84;1T' KBQ'MZMJ="27=[V^7?^K'G8GZQ6_=8::B^KW:]%_F_DSYM^"?[+
M.H^$6O;^!IM(UC5OGU7Q/JDOVW7M18_>+SMQ$IXPD> ,<@GFO?\ PG\(?#OA
M.1;B&S^UZAU:]O&\V4G'7)SC\,5VBKMX[4[=6-'+:,)JK4O.:ZRUMZ+9?)'-
M0RC#TYJK6O4J?S2=[>BV7R2&>7TP,#TI?+ZGOTJ2BO4M8]NR(\'TI=O>GT4P
M&\TF#Z4^B@8S;R./QH&<]*?12 ****8!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 A_*OC3X_>#=%UCXJ:Y<7/[(C_$^:41!
MO%*W5@GVW]RG_/1P_P H&S)_N9%?4WQ.)'PU\6%2P;^R+O!7K_J7Z5\;_LKZ
MA^U$W[.OP\_X1NP^&%QH;:/ ;.36KK41>M'C@S!05W^N._>@#VW]A_X6ZW\(
M_@5!HNO>&[7PE<3:K?W]OH=O,D[6-M-.SPPRRKQ)(J%5+9)PJY.:^@:XSX4M
MX]D\)HWQ'@\/P>)?.<,GAN29[3RLC9@S -NZYXQ79T (>AKSOXW:U\1='\&Q
M?\*OT'3->\4W5Y#:J=9N?)L[&)B?,NI0&5I%3 ^1#N.>,]#Z)7C'[5FA?%;Q
M-\*9M%^$,MA9^(M0G6"ZU"^O#;/;6A#>886"-B5OE0-CY0Q(Y H \#C_ &U?
MB1IO@#Q#H][H?AG4/B9:^/K7X>:=J.GR3?V)<WEPF\3."?, C&[>@.<[1QFK
M#_MC?$BU\.R^"Y-#\,GXSKXZC\#+,IG_ +%R\!G%\5R)0@CS^[SNS^5(O[+?
MQ'UGX$:!X<MO"O@OP!K_ (%\36/B?PS9Z?J$][:7\T!9I%O)702;I"QR_))Q
MVJ!_V/OBC=:'+X^EN_#:?& ^/8_'":7YDITH1I ;<6)EV[^8SGS-O7\Z /<_
MV8?C=K7Q1\,>*[?QM;:;I?B[P=KUQX>UEM-=A92RQ;2LT1D.Y4=77ACP<UQO
MP]O+>^_X*$?%"6VGBN(CX)T@!HG##(GFR,BM3X(_LPRP?#3Q]IOQ:LM)US4_
MB%KMQK^O:9I[R&RB+F/R[>-B0S*@B0[C@DYZ]:X']GGX3^$/@O\ MQ?$[PYX
M)T2W\/Z-_P (=I=R+.V9F0R//+N?YB3S@=Z ,G]OS]N/QE^R3XKT&S\/VWA/
M5[;5+/SAI^H_:FOU8.RM(0C*BQ'@+DY)#>E<[^S/_P %0M-\;>&=:U[XL:QX
M4\/B*1(-.T'0(;R;5IICDG]P0^]2-N&4G!R#BOFC_@KMH=EXK_:4TL^%Y+[Q
M#X@MM#BAUG3[&V>9;'$CM 2RYPSJY)7'  /\6!Z=_P $;OA9I^BZMX[U_5TG
MC\4B&"WBTZ\TN:(VD.YB9/-D0*6<@#:A.%7)^]@.P[:71]1?\-!?'+XQ?NOA
M1\'V\*Z3+]WQ1\3)C9)M)X=+&+,S#'()(!]*<G[%>M?$YUN?CE\5O$7Q"1OF
M?P[I3G1]%&?X3#"=\@'3+/SSD<U]3 XIV[GFI).0^'7P?\$_"/2AIW@OPKI7
MAFT(PZ:=:K&TGN[#YG/NQ)KK\=:7(]:K7>H6EBA>YN8;=1U:5PH_4TTF]D,Y
MSQ)\*_!7C+4AJ&O>$-!UN_V",7>HZ;#/+M'1=[J3@9/?O5KPKX \+>!FN/\
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MCC1>BJ!@#\@*LT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 ?(WC/]O3Q!\/-#;6?$?[/7Q"TC2UFBMS=7!M-HDE=8XUXE/WG95'N:W?\
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MZ^(6HRZ+?OI>H+"UI_HUTBJS1-F7[P#J>/[PKZOOM0L].C1[NZ@M4=O+5II
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M''-=:=%X0=KBWC?.QY(Q)N56P<$CG'% 'UE17R[_ ,-\:-_T1GXT?^$1-_\
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MEC4C)YZ FNL^"_[.O@']G^QU&U\#Z$-+.HR++>7,US+=7%P5!"!Y969R%!(
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M;7F/QD^ ?ACPS\&/AWH?Q&LM5^+7QH_X10^&_#_A>UOY)(WN\%GNU7(V"#<
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M.:Z7PS^R)\)O!_Q6G^(^D>#K6T\6S3RW7VKSI6BAFE&)I8H2QCC=QU95!/-
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MIEU%?:=?01W5M<PL&26)U#(ZD=0000: +]%%% !1110 4444 %%%% !1110
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M?BCX9^)O$7CRV'P]UGPGK#>']?TFXE-R8;X$!4A*+F;>>%"@DD,,$#)Z:/\
M; ^%4GA^?67\1R6MG:ZO!H5ZMUI]S!-8WDQ(BCN(GC#Q!L?><!?>OEV'X3_'
M7PI\+?&GCJPT&;3/&/C[Q[;ZYJVAZ2+:\U/2=&&Y2+8RYB-VH88/;.1ALXH^
M"?V>]9\1>"?VJ=(\9Z-X@\,:7XNCLM0T/6/&UY"]Q))#"[0RS3HY59%E2-F7
M(VAMO:@#[1\2?M!> /!OBK7/#NM>(8=.U+0]'_M[4O.C<16MD7V"1Y,;02W
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M)9.ZL5#_ "%"<[1D<XH ^I_A+^UK\)_CAK%]I/@WQ?;ZKJ5I"URUH\$UO))
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MVT;QA>Z/;W'B;1X)K:PU)L^9;QRC$BKSC##UKI-IIU% #=O?'-&WZ>W%.HH
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MUW:R3'R!#/C$H !( X .1UK[$V^G^% 4CI0!\3_!WX>WNG?M)?M8>+9/ _\
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M!LDE,]L]*_0_X:036OPY\*0W*21W,>E6B2K-G>'$*A@V><Y!ZUT@7U%*![4
M.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img192321128_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '\!(D# 2(  A$! Q$!_\0
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MEEB9P<JI8DXR,\D]:%&+!RDCV#_A>WAC_GPU?_OS%_\ '*/^%[>&/^?#5_\
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MZ6-1!)/<-<L<*JOM^7:I-/VU:U[(I8O%-7Y5_7S.^_X3[PS_ -!/_P @2?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 8OC'_D2-?\ ^P;<?^BVJOX1A6X^'NC0.2%DTV)"
M1UP8P*U=8T_^UM#U#3?-\K[7;20>9MW;-ZE<XR,XSTS7 Z+;>-[30K"WL]7T
MD6T=NBQ"2T8L$"C&>>N*I*Z$]SK$\(:>FDZ+IHFN?)T>XCN+=MR[F9 P ?Y<
M$?,>@%4[OP#IMS/>RQWE];"[O8[]DA=-J3I_&H9#R3R<YS6;CQ__ -!C1O\
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MDB1)"K,6$:$E4!/09).![DGWKT[_ (4GJ7_07M/^_;4?\*3U+_H+VG_?MJ-
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MPMMI,NX(86#<\#(.,8XJ3_A."M^+D6ERXS*2DU\\@!<8 4$;5 R<<9]ZI_\
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M87-BBL?^U-2_Y\+3_P "V_\ C=']J:E_SX6G_@6W_P ;HY6%S8HK'_M34O\
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M%>V_A_XJ:E)J<@@AO8!Y,S\+_#U/8?*1GVKT"VMXK.UAMH$V0PHL<:Y)PH&
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M:63/GVL\BF2$=".3\I&.N:IZI?Z???"UQIUF]G'%>*CPM(T@5NIVL3TYKO\
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^&0:BJQH39TB&,]82T/_ 'PQ4?H!2>PT4="U ZKH&GZ@PPUQ;I(P_NL5!(_
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M$'SUSL&:H7?@CPW?:R-7N=)ADO0P8R%F 8CH2H.TGZBM^DW<$%%%%2 4444
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MSIWVFWL!8S1W@<I@'.5V\GDGTZ#UK-TOP!J]E'I8GN[.5[75VOY75F&]"%'
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MD!5."#R#EL< \9->MVJ-':0HXPRQJ"/0@5+12;N%@HHHI %8_BJVENO"VHK
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M$#Z3>($N06@<#=:R ?=/4E<"M:J>K?\ (&OO^O>3_P!!-)6N ?VG!_SSN_\
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M,1^94\QGP4.1R$SMQ@]ZIII^GP:9IB'Q=IHT>QOQ/;'" N5<MY;2>9AB <<
M>I!H T-(\37FHZJMO)=:9#,+AXI=+E5XKJ-1DAE+-^\^7:W"@8)YXJC#X^62
M&+43J&D&UEN!&-/63_2EC+; Y._D]&*[.G?BK@AM]9,,]QXHTV_L-,N5O#)$
MB"1"N2N^17V@>N$7(7ZU-I6C,UA!;Z9X@230DFWQ"U7]YM#9\L3*^-N[@X7.
M.,]Z U,?Q-J6J:OX-O[^(6BZ8TXB6%D;SBBS!-^_=C.X9V[>G?-;GCYKI/"<
MS6LZPMY\"N2I.5,JC P1CDC/7(R.^1!>^#KFXTRZTFVU<6^F33F<1&VWNA+A
MR@?>!LW9.,9YQG%;FNZ5_;6CS6'G"$N499"FX*5<,,C(SRH[B@"A#K5[]KUZ
MVF%NS:;!$Z.B%0[-&6.06/&1P,].YZUDVGB;7=3^6V&G0[=(@U!WDA=\NZDE
M  XP..N>,=#GC2N/#E_)=7T\&JQ0G4;=(KS_ $7=EE4KNCR_R9!Z'=2Z9X5_
MLW?_ *;YF[3(=/\ ]5C'EJ1OZ]\].WK2#4SK?Q;J$5OH^HZBEHMCJ4,DGE0H
MWF0[8C(#N+8?(4\;5QD<G&3;M]=U>*#2=0OX[(V>IR)&((5826YDYC)<L1)V
M!PJ\G(X',H\(QMI^A6<UR)(M+0HX,>//!B,9'7Y>N>]+;>&+E!IUM>:I]IL-
M-<26T0@V2,5XC\Q]Q#;1Z*N2 3[O0-23PIJ6IZUI::E?-:)%-N$<,,3!EVL5
MR6+'.<9Q@8SU-47UK7YKK76M%TX6VER[562-R\^(U<KD, AY^]@]1QQSMZ#I
M7]B:+;Z=YWG>3N_>;-N<L6Z9/K7.6NC:O=:KXFC2]:QL[RZ53OM2S.GEJ&:)
MBP )Y&2&' XX.4!;L_$&I^()+A]$6SB@MX8G_P!*1G:9Y(Q(%&UEV !@-WS<
MGIQS!8>)=7\0:@D6E+96L#6$5V7NHWE969G4IA67(RO7V/!SQ?'AF>QGG;1-
M02QBN(DBEC>W\W!10BNAW+M;: .=PX''KDVOA_4-.\4O!HTYL[2'2H;=);BV
M,R.0S]PR_..O7N>.:8%_0O%-QK&JV=LT$422V,TTJ@EF66.81$ _W>IZ9Z5D
MP:S<:EXAT6]FAC,D/]J1JD9VAA&R*.6. 2!U)Q]*VHO"LFG2V$^E7ZPW%M!)
M [7,'G+,KN'8D!EPV\9R#WZ56M_ J1PP0SZE)-'&EZDA\L*\@N",G(. 1CKC
MG/04:!J5+/QC>3ZGI]H+O3;@WQ>,_98'=+63874&4.4EQT(&T]^*I>']7FL-
M%\-37ZVUT)1=S&8PDRQ*J,QVL6.6)!R>,@XQW.]'X7U!Y]'EO-8AE&E,IB2*
MS\L.-A0[LN?FQC!& .>#D8;:>#O)CTR"YO8Y[:P,ZI&+<H7CE0KM8[SR-QY
M&?0=:- U%M]=U>*#2=0OX[(V>IR)&((5826YDYC)<L1)V!PJ\G(X'-2Q\3:S
M)INFZM=+8"SNKX6CP)&X< R-&'#EL#D [=IXSSZ:-MX8N4&G6UYJGVFPTUQ)
M;1"#9(Q7B/S'W$-M'HJY(!/NB>$]OARRTG[;G[+>+=>;Y7WL2F3;C/'7&<^]
M&@:EGQ-KHT.TMBLEM'-=7"P))=/MBCR"2[<C@ 'C(R<#-<_/XXN(H+R&UGTO
M4;J":V$<UNQ$,J2OM((#,48$$=3U!QVKJ=9TC^U8K<QSFWNK683V\P3=M< C
MD<94@D$9'U%9MWX9O-2AD^W:NTDSSP2@1Q%88UB8-M6,N<%L'+$D].PQ2#4H
MZKXFU;0TU>&Y%E=7-I:17<#Q1-&KJSE"K*78@@J>0>XHU#7;K0=5DDU*"QNI
MH=*EN?-MX#$Y(D11&&9F^4EN?P..,5?UWPI_;5S?3?;?)^U6,=ICRMVW;(7W
M=1G.<8_6IM6\,6^LZE)<74S>3)8/9-$HP?F=6WANQ&WIBF&IC^*QKR^#M6_M
M%]/E@>R8M]GC>-HGXXY9@X]_E^G/$\GB._T*54UC[++"^G27:?9HV1D:/;E"
M2Q#9###87D=.:M7WA[5M5TFYT^^UR-HI;<PCRK(+DG'SOER2>/X2HY/X3ZIX
M9@U:\MY;F8F".SFM'B"\N) H)!SP1M]#UH Q;;QRL$MFU]J.D74=S&[/#I[[
MI+9E0N ?G;>, KG"\X]>(M1N=8O)O"EW>BS%M<ZC',L4*,'A)C<JI8L0_P I
M.2 O(Z<\;L&@7SB"#4M6-U9P1M&(8HC"9@5V_O2'._ SP HSSZ553PI?;M(B
MFUD26FE3B2"/[-AW55*J)&W8+ $#< .^0<\ :D7CJWN+IM"MDDM?L\VI)&\5
MQ;F57.QR-PW %>/N^N#D8Y9_PD6I+HESKUM!9KI%K*Z+:^6WFO#&VQF#[MJG
M(8A=IX &>>-_5M*_M2737\[ROL5XMUC9NWX5EV]1C[W7GI65)X2E:TN-*34@
MFBW$S2O;>1F0!FW-&LF[ 4MD\J3@D9Z80$^C:KJ6JZSJ:%K1+"RN?( $3&23
MY P.[=A<;AV.?:LK6[G6+;QG=2V,]NWV?17FB@FA9@3OY'#CDE1SCH ,=ZZ+
M2=(&EW.IS";S!>W/V@*$V^7\BKMZ\_=Z\=:;-I$C^(X=6BN(U MC;30O#NWH
M6W#!W#:<^H- &1_PF:?VW;Q[$_LR33_M3S<[E<H9 N>A'EJ3T[CWIFEZYK^M
M@PVZZ=:W%O;12W!FB=PTDJ[U10&!4!<98D\G@<5$WP]@;0?[+^WL/],\_P X
M1<^7M\ORNO3R_ES^.*V+G0[N/4[F_P!)U".SDNXU2X26V\Y25&$=1N7:P&1S
MD'CCCEZ!J7=$U0:SHUKJ B,)F7+1DYV,"0PSWP0>>]7ZIZ5IMOH^EV^GVN\P
MP)M4N<LWJ2?4G)/UJY2&%%%% !1110 53U;_ ) U]_U[R?\ H)JY5/5O^0-?
M?]>\G_H)H6X'2T445F4%<UI/_(&L?^O>/_T$5TM<UI/_ "!K'_KWC_\ 015Q
MV$RY1113$%%%<]>^);B/3;B[L]&O)5C9E61C%L8JVT\"3?R00,*3['I4N26Y
M<*<INR.AJO>7MOI]LUQ=2B.)2!G!))/   Y))Z <FGVTKSVT4LD+PNZAC&^-
MR'T..*R?$D,[PZ?<PPO,+.]2XECC7<S( RG [D;@<>U$G970X13FHL@M?%5O
M-J^I122)%8V=O'*TDL;Q.C$L"&#8(Z# QW[Y%7D\0Z6\-Q*UPT0MT$DBSQ/$
MP4]&VN 2#T! Y/%<GJ5K>:MK&IWMKIUWY*+:2()86C-P(Y"S !@.<=CZ#U%:
M&I1KK>IO>-IM_)806+QRKY+0RRLSHP55;:3MV[LCOP,FLE.1URH4[KI]VFB_
M%F_#KNG3+<MY[1?9D#S"XB>%D4YPQ#@''!YI]CK%EJ,C1V\DGF*@DV2PO$Q4
M]& < D>XXKC[VTUC4+"]L+.?4+RQ2WA9)+ZV$4Q=9 2BEE7?E5R2P/.,DY-:
MNF0R7?B&WO-^K3I!;NIFOH4MPI<CY HB4N?ESG.!CWIJ;;L1*A!1;O\ U;TZ
M_+YG4T445L<84444 %%%% !2,,J1ZBEHH 8B!!URW<FGT44@"BBBF 451U.^
M>SCB2",2W5P_EPH3QGJ6;'10 2?_ *]5QIVK%=[ZXXF_NI;1B+_OD@M_X]4M
M]"U#2[=C6HJCIUW<S&:"]@$5S 0&*9*2*>C*3V.#QV(/7J;U-.Y,DT[,YSQ%
MXKMM)TV^>V<27=N-HW0NT0DP#L9P-H.#TW \CUK1N]?TVQN7@GN&#Q!3*4B=
MUB#="[*"$SU^8CCGI7(ZI'=V_A/6M%.G7MQ>2W$KQ-%;LZRJ[[P^\ C(!Z9S
MD5I'S],'B"SET^ZN);Z9Y;9HH&D24.@4*6 PN",'<0,<]*QYY7_KS.YT*?*O
MGUWVU]-S:N_$.EV4SQ3W#9C"M(Z0NZ1ANF]U!5<]>2..>E.O->TZPN'@N)V#
MHH>39$[B)3T+E00@X/+8Z5RSV=QI%MBR.KV^KQV<,1\FW\ZWNY%15!/#*OW=
MI)*$#VZJ;74+.\U8WC:G&]X%D1+"V26.7]V%,98QOM((Q\Q P0?6CVDA+#TW
MU_X.WE_G\CMVFB6$S-(@B"[RY8;0N,YSZ5G6_B'3+F0(DTBL8C,GFV\D>]!U
M9=RC<.1TS52>SN[7P*UG;VHENH[(1I!.5FY"XVG@!L?3!Q7/2VTL^MZ=<01Z
MS<JL%PLLUW;O&J,T6%18]JJO3J% )(Y)JI3:L13H0DG=]_P_S.KLO$>E:A-;
MQ6UP[&X4M"S0NJR8&2%8J 2!U .1@YZ&J.H>*[:.:QAL7$KW%ZEN6>%PC*6V
MML? 5B/8FLS^SKQO#WA*W2WFCEB9!+^[.8OW+@EAVY/>HO\ 26TCPWI1TN\%
MS8WEN+@BW;RXQ&=I</C:P/7()X)SBI<Y6-%0I*5UK\_77\#L;[4;738DDNI&
M7S'"(J(SL['LJJ"2>O057&O::;'[9]H/E>;Y.TQ.)/,SC9Y>-V[VQG'/2J_B
M.WMY[:W,\6H9CF#1W%@I:2!L$;L#)(()!&UNO([UA1?VL]Y9ZE=Q7-U965])
ML9[;9</$T>T.8PH)VL<<*"1SBJE-IV,J=&$H7?\ 7DOZ^1I7WBVVAN=.^SN&
MAFN6M[@/!()4(0D )@-N)QQ@YSQ6DNOZ8U@][]I(ACE\E@T3JXDX^381NW<C
MC&>:RKV635=;T.X@T^\6""[?=+-;E,CRFYP?F R<?,!STK)U#3-1;6[V]2.\
M2WAU2.8F"(,Y7R F]%92&VD]@3UQS4N<EYFBHTY63T=N_GMMO_5CK5UW36LK
MB[-P4BMSMF$D;(Z'C *, V3D8&,G(QG-9@\6VO\ ;-W#(_EV-M:1RR-)!(DB
M2,Y7!4C.,;3T[YZ5D2Z?=RW,VJPQZE=)!<VTK&Z18Y+A(]Q;9$(T.5W<9Y8C
M [9CUN"[UF_UF:STZ[$;:="D;20-&9F64N0 P!SCC!Y./0BDYRL5"A2O9_GM
MM_7Z;G3:_KJ:58W@A9&OH;1[J.)U8J54@9)'N1QG-22^(=/M B74S"7R1-*(
MH7D$2D?><J#L'7EL=*Y?Q!]IU>\OYK33[\Q'19H5:2U="TAD0[0" <X]N>V<
M4_[)>6%_J;32:LB7:1O$+.U242XC"E&)C<H01CD@8.?6FZDKZ;"CAX<BOO\
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M67-,Z53HOK^*\O-_UUT-V3Q%%;QR&[T^^MI595CBD129F8X54*L5)SQC/'?
MYK/UCQ-(FEZ@EO%<6.HVIA8QSJC'8\BKD;2RD'D=<BI=5?6M2ME6#3;FUACG
MB:1!=HD\R9^=5*-A>QSO!.".*P)_#-^SZH;+1C:07,$"Q1M,A<LDP9BYW'YB
M,G.3D=\\43E+9%4:=*Z<[+5=5W7GZ]_4ZB\\36UH;MA:7<]M9MMN;F)4V1'@
MD'+!C@$$[0>OK6;<>)IDN=?\Z.ZBLK*&)HYK=8BP!&<C<3DMD8R,8'.#UHZW
MH6I:A%J\,VF2WUS+)(;*XDNE\B*,J-N$+?*XP1D)U_BP20Z^T35)+'6[>*PD
M9K^SMQ&WF1@!T7!4Y;K[\CWI.4_Z^94*=!)7:^_S7GZ_Y'0W7B.WMI[I$M;N
MYCL\?:IH$4I#D9P<L"Q Y(4'%13>*;99[J*VLKV\-M"D\C6ZH5V,NX$%F&>!
MTZGL#51K35-..LVMK8&Z34)6F@G65%6-G4*PD#$' (S\H;(]Z32-"N]-.J0E
M-T;V-M;PR;A^\,<3*>,\<XZ^M5>=[&7)14;ORZ[[?\'^D=);W$5W;17,#AX9
MD$B,/XE(R#^52UF^'[6>R\.Z=:W2[)X;9(W7(."% QD<5I5JG=:G+-)2:044
M44R0HHHH **** ,"]TZW3Q787\MY-%O5XUA#$)))QC)]<#IWVCWSOU#=6D%[
M;M!<Q++$W56'Y'V/O5#^Q9-OEC6-3$/3R_,0_P#CY7?_ ./5%K/1&KDII<SV
M(+?SI?%EP8+Z:2WABQ<1M@HKG&Q%Z8( ))Y/S 'M6Y5>SLK;3[86]K$L40).
M!SDGJ23R3[FK%.*L34DI/0Q/^$HM/].=K:Z6VL7:.>Y95V!U/W0-VXDY&,#N
M*CNO$ABLKS_B7W=O>Q6K7,4$XCRZCJP(<C@XR"0?:J,WAZ^NM"UNS*B*6XU%
MKF#,F ZAE9<E>1G;]14;:-=79N)5TRZMRMC-$GVV_:>1I'7&U/WK*%XY)Y/'
M QFLFYG6H4-_ZZ>?4=IWB)K.P2?5)M2EF&G&]D21(-I7*@E=F.<G@$]#SS6M
M#XDM7F"7%O<V:O;M<Q27"J%DC7!8C#$C (.& //2L'4/#^J3V?EQVNYO[ ^Q
MX\Q1^^RIV]?8\]/>KNO:!>:L^GPQC9&MA<P2R;AA&=$"Y'4C*GIZ4)S2'*-"
M35VE>_R-&W\203-")+.\MEN(VDMGF50)@HW'&&)!V\X8 XSZ&JL/C*UFBLI4
MT[4?+OABU8QI^];'W<;\@]>6PO!.<<U0@T6[G>R$FF7,3VRLTDEUJ#S(7V%1
MY2^:>N3RP&!VJ6RT74(;/PG&]OAK G[2-Z_N_P!TR^O/)'3-'-/^OD)TZ"_X
M?U\_)&DOB>U:VW?9KK[3]I-H+/:OFF4#)'WMN-OS9W8QWI)?%-G;VIEFMKM)
MEN5M7MM@,J2-]W(!(((P003G/UQB3^'+\ZM<:@;>:1$U%Y1##<^3)+$\2H65
ME88((Z$C(S4G]@WLCQW,=@\.[4K:4I-=--,(HR<L[,[#N<!3T]>QS3#V=#37
M\?PW_3YEK6?%,T&DWK6ME<PWUM+#')%,(R461@ _#%2#R!@GGJ,9-=/&Q>)'
M:-HV902C8ROL<$C/T)KDM;T34;N[UN2"W+I<16GE .HWM'(68<G@X]<=:ZR)
MVDB1VC:-F4$H^,J?0X)&1[$BKC>[O_6YE54%!<O]:+];CZ***T.8**** "BB
MB@ IEJOFZ[".T,#N?JQ 'Z!J?3M(7??7\WH4A'X+N_\ 9Z.@RGXM/VAM%TT<
M_:M1C=Q_L0@S9/MNC0?\"K4K'NC]K\?1IU73M.+'TWSR8'X@0-_WU[UL5DQ,
M****1(4444 %%%% &?K.J_V/9+<_8+Z^S($\JRA\UQG/)&1QQUK0KS[XQ?\
M(FP?]?T7\FK/?3;+Q5\4];M-?DD:/3H(S90"9HP@(4LXP0<@X.??GH,4EI<+
MG=>'O$=GXEM;JXLXYXTMKE[9Q,H!+* 21@GCYA6O7SY;7=U;?#Q[6TEEFM[S
MQ$\$S";89T,:?(7/ #=R?3TS71Z+:ZAI-WXDL%TQ-)TY]*ED?3O[4CN6BE"
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ML=)O?['ECN]V5L)&D: [=RAGR4;T.TG\.AY'3IM73PMX.BT^2W5)-2;8LK.
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MD]AHQ-"/VK4]>U'J)K]H(S_L0J(B/^^UD/XUMUC^%;:2T\+:<DXQ</")9_\
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M;?4K">RNHQ);SH8Y%]01^A]ZXW_A7^H262:1/XJO)="0X%F;=!(8P<A#+G)
MX[8P, #C'=5QGQ$\77_A&PLI["&VD:>5D83JQ  &>,,*$)EG4/!K3>(++5=-
MU+[ +>U6S> 6XD62$'.T$D;>#C//:J-UX*@M? =CHMSK,<$.GW'VA[R6(*I&
M]FP06P/OXSGM73Z!?RZKX>T_4)U19;FW25P@(4$@$XR3Q69X^X\#:IQG]VO_
M *&M :'/1:1IUQK%Q#HGCR.VM-0N?M$MA9S1F1Y#RVQPVY<XZ =!W%=3I7AP
M:9XCU?5A=&0:B(AY13'E[%Q][)W9^@J;^V;E(+B:?1+ZV2&%Y2\SP$':,X^2
M1CD_2L*+4]6L],T76KO4?/34)H4GM/*18XUF(V^60-^5R/O,V1GVI@;/B;P[
M'XCTZ* W,EK<6\RW%M<QC+12+T..XYZ9%5-!\+7&FZS<ZSJ>KOJ>HS1" 2F!
M852,$' 521U YIOA^35]9TZPUMM5,:W+>:UEY"&(1'("@X#[L8.[<1GMBJ-K
MKVIR>$O#E\]SFYO+^&&=_+7YT:0@C&,#@=J0&U:>'_LOBW4==^U;OMD,<7D^
M7C9M YW9YSCTKGM)\#^(]#T]+'3O&?D6R$E4_LN-L$G)Y9B:L:?J^H)JT$.L
M:A=V5U)=M#]EN+)?LLP.2@BE5>N,?><DD$;>15.Q\3ZG>65OJ\,NHSO-.#_9
MZ:8Y@$!;;@2B/)8+\V[?C((QBGJ&AN6FAC1]=NO$&H:M&YEM(K>5I(Q$NY<
MN3G R1TQQFNDKSG7Y]2UCP/?:N=09('N-BV0C0QB-9@G+8W[\KNSNQVQ76^)
MM1N=/TZ!;(HES=W45I'*Z[A$7;&['? S@>N*0%G7;3[?H-_:?9S<&:W=!")
MA<D' #$$*?<CBO*=!T[7]3U7PY;WUMK)CTV;>WVVT$,,$:@856ZR'@#)YQT'
M6NL\0ZSJWAZ/4[5-1>Z<:<U[;SS11^9&RNJ%2%4*0=P(XSU]JUK6YU&P\5V^
MFW>HO>17=F\Q#Q(OER(R@[-H'RD-T;)&!S3!ZF1'X57PT\/F^+Y;'0(KKS8[
M-F6#YCD[#-D$J3GY>X]^:F@\,V5QX=\0I!KEO+:ZU=27 NHU5DBW-]W(;#8/
M&<BM36].U7^V[+6=+2TN7MH9(FM;IBF0Q!S&P!VN=H'(Q@URFMW$=_H^HJ;&
MYT;5EOK)[Z 2)(K%G4(P;E3P,Y !RN#G'(!K2^ KN"6.?1_$,VFSO91VEVZ6
MX?S@BA0PR<HV!U!)'8COTLFCQ2^'I-'EN+F6*2W:W>:60M*P*X+%CU/.?3VQ
M7+W.N7\VI:K;P:AJ,7]GE8(!!IK7 GD"!BTI6-@ 20,*5.,GN*FTZ\UWQ!JE
MY'_:$^DQQ65O*(%MXR\<LBL2#O4\ @\=>G([@:&=8>#X](UG04OO%D$MS8%A
M:6CPQQ%HV&"%4-N)SGYN?I5E/AU)#X;TO3;?63%=Z;=&ZANQ; C)).-A;Z=^
MW2IK&^U#Q#!IUQ+HCBUG6*2ZGMC%^]E1^!\[A@BE=W1B<X&,?-M>(K^ZMCIM
MG9R^1-?W8@\_8&,:[69B >-V%P,@CGI1J&ABOX%OTO;J2Q\3W=C;7SK->Q00
MJ&DD_B9'SF/=[9_$<5JVGA=+77]9U)KII(]3ABA,6TYC")LSO))8GKT_.L"^
MU[6=%O-8L9+]KHJ]G#9S/;!GC\XR;F*QJ-[ +P .=HXY.34O$.JZ?IVL&UN-
M1GCBLOM$%Y>Z<8&CD#!2AS&BMD$$<9Z]>QJ&@6/PVN+/^S$;Q \MOIEXMS;0
MFT55 W%F#$'+,3CYB>,'CGA;OX;SW%KK%E'KICL=1N/M/DFT#&*3<&SNW G@
M8QQ5C5]=U+PM=S?:;UM05M-EN522-$"2HRC"[ #L._H<D8ZTZUU768KNVA@E
MU#4GG@D$OVO3'MXX9@A92K>6F$+#;AB3R.>M&H:%C5O!]W/K-QJNB:[-I-Q>
M1B.["P+*LH  4@$C:P&>1^&.<FG^!;72M3T2YL[IEATN*6,1.FYI3)G+%LC'
M)]*;X<U6YEO[:VU#4[U;V2%C+8:A9+$=ZG!:)U4*R^V7X(.1@U:U:YU&3Q;I
MNEVNH/:6T]K-+*8XT9\J4QM+*0#SW!&">,X( T*8\$7$7]JR6FO7-I<WM]]M
MCE@3;Y9R?D9=V)%YZ'%6?#/A=/#-Q?WMYJ2W5[J$J^9+Y*P(3V 1>-Q).3W_
M #SFV&N:KJ5[:Z)]O,4ZSW:7%ZD2;W2"0(N%(*@MD9X(XXZ\4]5GOKW4K#3K
MC4)?-T_78X5N(DC!D5X&=68%2-Z@E> %.3QTP!H>BT5S>N>++*VTJY;2M0L;
MF^5DC6-)ED\LM(J;F4'. 6_I6;K^IZOX;BFA_M1[PSZ=<313311AXI8@#D!5
M"E2&'!!((ZTK#N=M16'9ZK:Z98VQUG7H/M-RBR@74D46,@9" !?ESZY/N:QK
MS7M3B\)>*+Y+G%S8WDT5N_EK\BJ5P,8P>IZYHL%SM:1F5$+,P55&22< "N(N
M]1UIU\5W<6K/"FD.S6\*P1E6"Q*Y5R5)(/;!!&3R>,2O?ZCX@CUAK;4&LHK.
M%%2)(T82LT0D.\L"=OS #:5/!.?0L%SL(9HKF!)X)4EBD4,DB,&5@>A!'44^
MO-="UJXET[3]-CO;^R@M-+MV+V5@UR[R.N1N_=N H Z<$DGGBM6PU76]8U?2
M[2:XGTWS+"2XN(UMU5RZ2A,@2*2H.<X(Z'\:+"N=K15*QUC3-3=UL-1M+MD&
M6$$ZR%1[X/%7:!A1110 4444 %%%% !1110 53U;_D#7W_7O)_Z":N53U;_D
M#7W_ %[R?^@FA;@=+1116905S6D_\@:Q_P"O>/\ ]!%=+7-:3_R!K'_KWC_]
M!%7'83+E%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M:]7S(HH/^>TT<9^A89_3-'C9O,\,RV ^]J,T5CCU61PK_P#CA<_A4B+YNL6,
M?9-\Q_!=O_L]0:Z?M7BO0+'JL'GW[C_=41+G\9B?^ ^U3(9K4445F0%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &3H@^U>+==O>J
MVZ06">Q"F5\?7SD'_ :?9MYJS7'_ #WF=P?;.%_\= JKX:G,/@F?5QS)?//?
M*?[P=F,7_CGEBKUM"+>UBA'2- OY#%:1V+):***H04444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4M7TN#6M*
MN-.N6D6&< ,T9 88(/&0?2KM8'C6XN+3PC?3VL\D$Z^7LEC.&7]XHH WF570
MJRAE88((R"*P[7PK:6KVB_:[R:TLWWVMI*ZF.%NQ!"AFVY(&YCC\!6-?K-!X
ME@T2&/6;NSALOM3);WY661V<KEI'E5BH ^Z#C+#CI5&QDU#4]:TG3;^_O(HD
M%XCI%> 22K&Z;!(T3'#@'!P<\'U.05SJK3PW%921+;ZAJ$=E%+YJ622*L2GK
MC(7>5R<[2V.V,<563P;9QBTB%_?_ &6SNA=6UKO3RXF#%L?=W%>2,,3@=,5S
MHN+V?4[+2'U"]^S1ZS/:^8L[*\D0AWA6<')P21GKQUS3I;C4+MM<EBCU@M83
M-;VDL-ZB0P>4H(,@>4>823N8N&R#3 ZC_A&HWG@:XU+4+FWMYQ<16T\BLJN"
M2IW;=[ $Y 9CT'I4:>$K--L/VJ\.G+.)UT\NOD!P=P_AW[=WS;=VW/;'%8%_
M)JB&?6-334OL3V\-Q%<:5?#;:852X:+<%D&=S%OGROM39=0O=8O-<GA35G6V
M<16<EG=1PQ0@1AP[*TJ;\ELG<I& !ZT ;E[X,LKV"YM3>WT-C<3?:'M(G01B
M3(8D94MR1G;G;GG%:.J0:=JP.CW4G[YT\]5C8K)'M88D!'W2&Q@]\'KS7*V!
MN]>U>]%]?WD2C2K6;RK.\9$65U?+*T;8/3L2IX)!P,9NG7TTEU#X@E:>6]C\
M,FZ/[UPLDBDCE0<$'&<8QDYQF@+G7W'A&TO;:^COKV]NIKR$0/<R,@=(P<[5
M"J% SS]W)[]JLZC#I]KK-AJUW/)',,V4"@95FE(P" "<Y4<Y KE;2\U2QBTB
M^2'5"]QQ<O?7T317.Y"W[M/-.UL@%0BCC(Q4,T#7.B^$]9EU&ZFN;S4+228/
M.QC9G.XJL9.U=IX&T#@'.<T =?JNEP3:A;7R7-]9WI_T=9[1-Y9#D[7!5EVY
MYR1P>XSRR;PQ:W-A=V]Q=74LUVT;RW;%!*3&P9, *$ ! X"XZYR228_$UQ/;
MW.@"&:2,2ZK''($8C>OER':<=1D#CVKF+":[@\-Z/K;ZE?RW<FJ+#)ON79&B
M:=HRA0G:?E[D9SCGBD!N:W8:7I227M[K5[I\=[LM[IX]N+AMNT,WR'82H.67
M;]1@5GW6D0:-J6K:G-J%SHVD+9VUO#+:NAW* P*X*L<CY<$ 'DX/6M+QO;QW
M=KH]M,NZ*;5(8W'J"&!KDM6OI=5\&3Z?,Q,VC64HO./^6REH8\_51(_Y4T#/
M3;&UMK*P@M;.,1VT482)!V4#CKS6=XDLY;S3X1#:37$L5PDJFWG6*6(C/SH7
M^4D9^ZV 03]#C6L<NM:AK8N=0O+1+#9#;K!.T8BS$K^80I&\Y.?FR,#&.M5/
M#U[=^+4EEU"^N;5[:QMVC%M,T(#R(6,K!2-W(& V5&#QR:0#O#>B0Z_9ZGJE
MU)>26VJ^2T$EQ(HN!Y6XK)\@"H03P%[*,]36C>Z#I=S<S:;J6I7MSJ&I6K1+
M+)M#B%2"P7:@1>2#R,GWQQC^ [B?S=#MO.D^SG0VD\K<=N[S@-V.F<<9K)36
M+RW%IJGFR7%S;VFK.C2,7/RR#;U[  ?@*8CT34- L=4OTNKM7DVVTEL8B1L9
M'QNSQG/RCH:J+X?L[)4N[_4[VXBLH'6)[F95%NA7#,&15.=O&YB2.>>36+ID
MNH6FH:(XCU14N24NGU"^B=)\H6#1IYK88,,X11\I/H,=+XATVTU/2)H[V'SH
MXE:54+$*6 .,@'##V.12&5-(TJUN3I^KC5;[4DCA)LWN=@VJZ@%OE1221QEL
MGD^IK1ETJ";6K?56>03V\+PJH(VE6()R,9S\H[U2\&_\B7HO_7E%_P"@BMN@
M9@_\(G9J?,@N;N"Y6ZFNH[B-EWHTIRZC*E2IXX(/0=QFE;PK:&T6)+J[2X%W
M]M-V"AE:;!&XY4KT.,;< 8P!6[10%BMJ&GVVJ6$UE=H7@E&& )!ZY!!'0@@'
M/M61)X3MKJ&Y6^OKZ\EFM6M!/,R;XHV^\%VH!D\9)!/ YKH** (X(E@MXX5)
M*QJ%!/7 &*Y_4/!EGJ$6H6[7]_#:7\AEGMH70(7(&6!*EAT!QG&>U=)10!D-
MX=M&M]9A,D^W5]WGG<,KNC"';QQP.^>:KS^$[64R>3>WMJLT"07*P.H%PBC:
M-V5)!QQE=IQ^%;]% '/Q>$K:TCMQ87]]92PVJVC30LA:6-?N[PR%<CG! !Y/
M:K-AX<L--O;:YM1(AM[5K5$+94JSAR3GDL2.N>YK7HH"P4444 %%%% !1110
M 4444 %%%% !5/5O^0-??]>\G_H)JY5/5O\ D#7W_7O)_P"@FA;@=+111690
M5S6D_P#(&L?^O>/_ -!%=+7-:3_R!K'_ *]X_P#T$5<=A,N4444Q!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 &FKYFL7,G:*%$'U8DG] M
M9]J?MGC76KKJMK%!8K[, 97_ #$J?]\BM70UW17<_P#SUN&Q]%PG\U-8_A(_
M:-&DU$\G4;J:[!]4=SY?_D,(/PJ)[@]C=HHHJ"0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K(\4W4EGX7U&6#_CX,!B@_P"NC_(G_CS"
MM>L371]JU+0=-ZB>_6>0?[$*F4'_ +[6,?C0-%Z^MHK#1M.TJ 8B5HH%'^Q&
M-W\DQ^-/HU%O-UF"/M#"SGZL<#]%:BM5L4PHHHIB"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM?V%MJ=E)
M9WD7FV\F-R;BN<$$<@@]0*LT4 4-0T>QU.2&6YCD$T.?+FAF>&10>H#H0<'T
MSBL>[\'VT^K:0\,:PZ?803($BF>.0,Y4AE9<'/#9.[)R<YR:Z>B@#-AT#2[=
M;)8K4*+)VD@P[95V!#,3GYB03DMGKFF7GAO2K^ZDN;BV8R3!1,$F=$F"]/,1
M6"OZ?,#QQTK5HH R+GPQI%W/+++;./.V^;''/)''+CIO16"MQQR#QQ3KSPWI
M5].\TULP:1%CE$4SQK*J] ZJ0' !(PP/''2M6B@"G%I=E!=SW44 2:>)(9"I
M."BYV@#H,9/2JUOX<TJU:T:"W:/[)"8(@LSX\L_PL,_./9LUJT4 95EX;TK3
M[F.XMK9E>+=Y*O,[I#NZ^6C,53T^4#CCI40\)Z*+B*86C9AF\^%//D\N*3=N
MRB;MJ\\G &:VJ* *UW86U\ULUS%O-M,)X3N(VN 0#P>>&/!XYJL- TQ=.@T\
M6W^BP3">./S&^5P^\'.<GYCG'2M*B@"M>6%M?^1]IBW_ &>99XOF(VNO0\'G
MKT/%5)/#NE21:C&UH-FI'-V [#S#C'KQQZ8K4HH RKSPYI=_,TT]N^]XQ%(8
MYY(Q*@_A<*P#CKPV>IIUYX>TN^DCDFMB&CB\@>5(\0:/^XP0@,G^RV1R>.36
MG10!C?\ "+:.+>T@2VDB6T0QP-#<21NJ'JNY6#$>Q)I]IX9T>Q,'V:Q1! LJ
M1KN8JJR'+C!.,$_EVQ6M10!EV/AW2].N(Y[:W</$I6$23/(L(/41JS$(.WR@
M<<5I21I-$\4@RCJ58>H-.HH @L[.#3[*"SM8_+MX$$<:9)VJ!@#)YJ>BB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IZM_P @
M:^_Z]Y/_ $$U<JGJW_(&OO\ KWD_]!-"W Z6BBBLR@KFM)_Y UC_ ->\?_H(
MKI:YK2?^0-8_]>\?_H(JX["9<HHHIB"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ I'8(C.QPJC)I:JZEEM/EC4X:4"(?5R%'\Z$ S4;F72?AW<W$
M7%U]B8QC_IM(/E'_ 'VPJ]I]G'IVFVMC%_J[:%(4^B@ ?RJEXKQ,VB:6H^6Y
MU"-G7T2$&;/TW1H/^!"M:LY.[!A1114DA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !6/:#[9X^D?JFG:<%'IOGDR?Q @7_OKWK8K)\*E9
M%UO5G/RW.H2A6]$A A_+,;'_ (%312)E;SM2OINWF")?HH&?_'BU355T[<;"
M*1QAY<RL/=B6/\ZM5JP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "J>K?\@:^_P"O>3_T$U<JGJW_ "!K
M[_KWD_\ 030MP.EHHHK,H*Y33KCR-,M(9+6]62.%%8?8Y3@A0#_#75T4T[ <
M[]M3_GWO?_ *;_XFC[:G_/O>_P#@%-_\37144^9"L<[]M3_GWO?_  "F_P#B
M:AFUBTMY(HYOM$;RG;&KVLH+GT *\]1^==17)>+?^1@\-?\ 7U_[/'51LW8+
M%O[:G_/O>_\ @%-_\31]M3_GWO?_  "F_P#B:Z*BIYD%CG?MJ?\ /O>_^ 4W
M_P 31]M3_GWO?_ *;_XFNBHHYD%CG?MJ?\^][_X!3?\ Q-'VU/\ GWO?_ *;
M_P")KHJ*.9!8YW[:G_/O>_\ @%-_\31]M3_GWO?_  "F_P#B:Z*BCF06.=^V
MI_S[WO\ X!3?_$T?;4_Y][W_ , IO_B:Z*BCF06.=^VI_P ^][_X!3?_ !-'
MVU/^?>]_\ IO_B:Z*BCF06.=^VI_S[WO_@%-_P#$T?;4_P"?>]_\ IO_ (FN
MBHHYD%CG?MJ?\^][_P" 4W_Q-'VU/^?>]_\  *;_ .)KHJ*.9!8YW[:G_/O>
M_P#@%-_\31]M3_GWO?\ P"F_^)KHJ*.9!8YW[:G_ #[WO_@%-_\ $T?;4_Y]
M[W_P"F_^)KHJ*.9!8YW[:G_/O>_^ 4W_ ,31]M3_ )][W_P"F_\ B:Z*BCF0
M6.=^VI_S[WO_ (!3?_$T?;4_Y][W_P  IO\ XFNBHHYD%CG?MJ?\^][_ . 4
MW_Q-'VU/^?>]_P# *;_XFNBHHYD%CG?MJ?\ /O>_^ 4W_P 31]M3_GWO?_ *
M;_XFNBHHYD%CG?MJ?\^][_X!3?\ Q-'VU/\ GWO?_ *;_P")KHJ*.9!8YW[:
MG_/O>_\ @%-_\31]M3_GWO?_  "F_P#B:Z*BCF06.=^VI_S[WO\ X!3?_$T?
M;4_Y][W_ , IO_B:Z*BCF06.=^VI_P ^][_X!3?_ !-'VU/^?>]_\ IO_B:Z
M*BCF06.=^VI_S[WO_@%-_P#$TBL;R]LXD@N@HF$CM);2( %!(Y8 =0M='11S
M!8X[7;];3QO9RW-IJ3VUMI[^7);:?/<*9)77(S&C $+%W[/[U-_PE>G_ //G
MKG_@BO?_ (U75T5-@L<I_P )7I__ #YZY_X(KW_XU1_PE>G_ //GKG_@BO?_
M (U75T4K!8Y3_A*]/_Y\]<_\$5[_ /&J/^$KT_\ Y\]<_P#!%>__ !JNKHHL
M%CE/^$KT_P#Y\]<_\$5[_P#&J/\ A*]/_P"?/7/_  17O_QJNKHHL%CE/^$K
MT_\ Y\]<_P#!%>__ !JC_A*]/_Y\]<_\$5[_ /&JZNBBP6.4_P"$KT__ )\]
M<_\ !%>__&J/^$KT_P#Y\]<_\$5[_P#&JZNBBP6.4_X2O3_^?/7/_!%>_P#Q
MJC_A*]/_ .?/7/\ P17O_P :KJZ*+!8Y3_A*]/\ ^?/7/_!%>_\ QJC_ (2O
M3_\ GSUS_P $5[_\:KJZ*+!8Y3_A*]/_ .?/7/\ P17O_P :H_X2O3_^?/7/
M_!%>_P#QJNKHHL%CE/\ A*]/_P"?/7/_  17O_QJC_A*]/\ ^?/7/_!%>_\
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M_P#B:/MJ?\^][_X!3?\ Q-=%11S(+'._;4_Y][W_ , IO_B:/MJ?\^][_P"
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M8^)_^ACU?_P.E_\ BJ/^$Q\3_P#0QZO_ .!TO_Q5'('.?7-%?(W_  F/B?\
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M_5I_\8H_L/4/^AJU?_OU:?\ QB@#:HK%_L/4/^AJU?\ []6G_P 8H_L/4/\
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M!@<8Z=#^()]\\UASM[(S5:4K\L?Q1T-%<T/"MT(%B_X2353A]Q)F/S?CG/X
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M5/SD#D.02/6NT-I;->+>-;Q&Z5#&LQ0;PIY*ANN/:J]AHVEZ4SMIVFV=FT@
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M252X^HSFJ-KJ-RVNWUO/>:2;2%-RQQ2G[1'TYD!. .OZ4#NB3^P;7_G[U?\
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M\S*>@[^U4-+UQ$T**]UK5=%4O(4\^TN,6['G #,>3@'CV-%V.Z*__"O?"/\
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M_8-K_P _>K_^#>Z_^.5F^*?%3Z'+;6-C:&\U.ZYBA&< 9QDXZ]_R-9-OXO\
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M%#'T&3S38=3L+BY:V@OK:6=/O1)*K,OU .:5V.Z,K_A!_"__ $ K'_OT*/\
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M=I'Y QC S@'@<CFCF%[)_D>?:,D5IX@\=66FX73%LI2$C.45]O;\V%8>H?\
M)$M*_P"PJW_H,M>R:?X9T;2M-N-/L;%(;:X!690S$N",'+$YZ'UJM)X+\/RZ
M)%HSZ?G3XI?.2'SI.'YYSNS_ !'OWI\R!TG8XOQ7HVG^'_&7@MM,M8[<R77E
M2%!@N \8RQ[GYSR>M9&H"/Q!?^*KNTM=*LH;0OY\]XIFGE(W ;-Y(0G;@;<8
MR!S7K.HZ%INK7EC=WUMYL]C)YMLV]EV-D'. 0#RJ]<]*H77@CPW>ZFVHW&DP
MR73MN9BS88^I7.TG\*2D.5)MNVQY/>PQ2?!;3;B2-&GCOFC21E!95)<E0>H&
M>U=+XKMK6TUGX?16D$,,7VP'9"@5<EX23@=Z[B/PAH4>AMHJV .GL_F&%I';
M#>H).1^!J.+P5X>A73UCT_:-/E,UJ/.D_=N2I)^]SRJ]<]*?,A>R=ON_ XW2
M;2RUGXI>(8]?BBN)(5VVL-S@J(_4*>/NX/XDUC63&+P_X]LK)B^CPO\ Z/AL
MJI+G[I^@'Y"O4-9\)Z%X@E674].CGE4;1)N9&QZ94@FIE\.:1'HDFC1V,::?
M("'A0E=WU(.<\=<TN9#]D_S/)=8T338/@]IFI16D:WS2(S7 'SMDL,$]<<#C
MVKTG[-H-]=Z'?:G);_VNL"-:B2Y*N21GA=WS<^QJ[/X7T:YT*+19K/=IT6"D
M/FN,8Z?,#GOZT^;PWI-Q?6%[+:;KBP4);/YCCRP.G&<'\<T.5QQIM?@6=6MY
M+K1KZWB_UDMO(B?4J0*\_P#AIXET?3?"[:;J%]!97=M+(9([EQ&3DYXSU/;'
M7BO3*P-4\$>'-9NS=7VEQ23MRSJ[1EOKM(S^-)-6LRI1=U*)S^N^.]#U3PCK
M3VT$U[# 5A=&#1I)N; .Y2#MXSC()'UK@[^QFL+WPI=EM*@-S+')%!I\>UHT
MRA!=S\S'G&23R#R:]HB\.Z1!I$FDQ:? MA(,/"%X;W/<GWZ\5EQ_#OPI$BK'
MI"+MD$BL)I-P8=/FW9Q[9Q34DB)TY2W.2TG2;#5OB]XBCU"TBNHXXMRI*NY0
M?D&<'O@FN?\ #FC:=<> ?%-Y-:1RW%N62&1QDQ@#(VYZ<U[%:Z#IEGK%SJUO
M;;+ZZ7;-+YC'<..Q.!T'057M?">B66F7FG6]ELM+PDSQ^:YWY&#R3D?@11S!
M[)_F>6W\S2^"/ UM>3.NE3W#+>-N(&T2 #)]EW?E6WX@L]/T7XA>%1X>BAM[
MB>39<Q6V #"2O) ]5+G/?&:[T>'-(&AIHIL8WTY!A8')8#G/4G.<GKFH-'\(
M:#H%PUQIFG1P3,,>869V ] 6)Q^%',@]D_R_ X3P?H6F:UXP\:_VC:1W'EWC
M(GF#(7=)+D@'OP,'J*Q]!LEUGX27-E+J=K8%-3/E-=2B-'(16V9/U)_"O7=.
MT+3=)O+Z[L;;RI[Z3S;EM[-O;).<$D#EFZ8ZU5MO"&@6FCS:1%IT?V":3S7A
M=V<%\ 9RQ)!X'0T<P>R=OO//]'DCT+Q9H]OKOANRM;V?$=I>Z;+M#9^4%D5L
M$'."36)9VE]JUUXJN+E=#:2.5_M,FJB0RPJ"1F,+TQC' ST'M7JVE^"/#>C7
MBW=AI<<=POW9&=W*_3<3C\*74O!/AS5[XWM]I44EP3EG#,FX^X4@'\:?,A>R
ME8\IU>VDF\*^#;2XO([J)[N6..:,. 8RR ??56XY'3M70_%?1-*TOPE:O8:=
M:VSF^4%HHE4X,;Y&0.^T?E7?WWAK1]26Q6ZLE9;!@ULJ,R",C&,!2!V'!]*G
MU72+#7+$V6I6RW%N2&V$D<CN"""*7-L/V6C1Y_XEMK6T^)7A&"RAAAMTSMCA
M0*@^<DX XZYJEX;L-'U'XE^*8M5AMYB))&BCG *_>.X@'N!W[<UWMOX+\/VD
MUC+!I^Q[ DVQ\Z0[,G)ZMSR3US45UX#\,WL]U/<Z6DDMT_F2N97R6YY'S?+U
M/3%',@]F[W.;^$S%8]>MX7+6$5YBWYRH'.<'Z!:]'JGIFE6.C62V>G6R6]NI
M)"+ZGN2>2?<U<J6[NYK"/+&P4444B@JI>?)/:3?W9=A^C C^>VK=5=14MI\Q
M499%\Q?JIW#]130%"=?*U2=>TBK*/K]T_P A^=%2ZG@R6=RI^4DQD^S#(_51
M^=152$PHHHIB//?$-Q'HOQ/TS5;XE+*2W,8EP2%;# _^A#\ZZ"[\;Z!:7-O
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M..: -NBBB@ HHHH **** "BBB@ HK-UC5_['AAD_L[4+WS9-FVR@\PI[L,C
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M+TQ_$OK57PUXML/%7V_[##<Q_8IO(D\]5&6]L$\<>U%@N;U%%% !1110 4A
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M+J&I7K9FN9%V9'H%R<?GZ>E=+292"BBB@ HHHH **** "BBB@ HHHH ****
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M'U'<U>BO3X:LM'OGGF-A-II1TEF9E654\Q<;B<%@'&/8 =JZR;2[*XN4N)8
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M4EI-81RK)IMUY;6[!06)B)4/NR6R=W  Q4QOKC6=4U#RUU6>W@BB6VDLKA(
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MU*PA[>896^BJ?_9BM34FGKYFMROV@MPH^KMD_P#H _.@"_\ ZS5_:&']7/\
M]A^M6ZJ67SRW<W]^8J/HH"_S!JW4,H****0!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !574F(T^95.&D C4^[':/YU:JI=_/<V</K(7/T4'^I6F@)Y'2
MVMGD(PD:$_@!6):JR6T8?[Y&YOJ>3^IK0U=O]"$7>9UC_#.3^@-5::V$PHHH
MJA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M>TK_ )!%E_UPC_\ 015NJFE?\@BR_P"N$?\ Z"*MU#W*"BBBD 4444 %%%%
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M$7 P,E803Y8R0023D$8.,Y@\W6;O1?%>J'Q%JL3:;>L+:*.X(7[^"&[D8Q@
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MXG;=)M?<=K'OT_GVX!8$SMZ*\R^*MUXD&DWUM%I]LV@,D1ENBP\Q6WKP!O\
M[VT?=[UU/@ZZ\1W6GR?\)#86UH5""W\A@=ZXZG#M[>E*P7U.DHKS^_.H>(_B
M1<Z+_:]]IUCI]JLH6RE\MY6;:<D\Y'S <YZ>YKEO^$FUW3O#&N#^T[JXNWUD
M62W'+LBD,28U)PN=N !TSQC@T[!<]IHKRS1M1UJUOM1MXH_$YTJ33Y7$VLQ$
M20S*I(*OV&![<UA?:M?M/!&A>(X_$NIM=W%Z;81R3;X@NZ3EE/WCE3R<\$#L
M*+!<]JO+2"_LI[.YC\R">-HY$R1N4C!&1R*J:-H6F>'[,VFEVBV\)8N0"6)/
MJ222:X:QO=1\->.=4TUM4OM2M5TMKP+>2;SYB\\?W1UX'J.N!4>@66N:GI>C
M^)?^$MN(;N[NOWL%Q+_HS(69=B1]"QQP/RP1FBP7.[C\0Z3)?7]D+U%GL%#W
M0<%%B4C.2Q &/QJU87]MJ=C#>V<OFV\R[HWP1N'T/->7ZO+>ZCJ7CZREU"]%
MO;6JRQ1),=JX7) '0*<<@=1FH[63^R?A[H4"ZSK2/J<RMY-DHEG91UCA)*^6
MO3U.3W!(HL%SU34+^VTNPFOKR7RK:%=TC[2V!] ":?:74-]9P7=L^^">-98W
MP1N5AD'!Y'!KQZ"_U?\ X1_QMI.IRWC"UAC=(KRY%Q)$3U'F <@@ XZ#\\VI
M5U3PSX6\->(K;7KZ=Y?L\3V4D@^SF-DX14 P"% !/))R>M%@N>FVNMZ=>ZK=
MZ9;W&^\L\&>/8PV9Z<D8/X&M"O+;S5M176?'T:ZA=!+6T#6ZB9L0G;U09^4_
M2J#R:SI?AKPQXC_X2+5)[BZNHH98)9LPLC;CC;W.%P2<DDYXHL%SV&J]]8VV
MI6,UE=Q^9;S(4D3)&0?<<BO)M7US6-4\1:ZD4GB4-8RF"RCTB+,*LN>9L'G)
M /TS]*]-\-WE[?\ AVQN=2@>"]>(>=')&4(8<$[3TSC/XTK!>Y+H^BZ=H-C]
MBTNU6WM]Q<J"22QZDDDDGIU]!5^BB@84444 %%%% !1110 4444 %%%% !11
M10 4444 7M*_Y!%E_P!<(_\ T$5;JII7_((LO^N$?_H(JW4/<H****0!1110
M 4444 %%%% !1110!FZ]_P @L?\ 7Q!_Z.2JD\$5S;R6\\:R0RH4=&&0RD8(
M/X5;U[_D%C_KX@_]')5=F5%+,0J@9))P *M;"9R-I\-]%M;N"0SZA/:VTIEM
M[">Y+6\+$Y^5<9Z^I.>^:V8?#UI!XGN=?62<W=Q (&0L-@4$<@8SGY1WJD?&
M5JT#W5OINJ7-@F2;R& &,@=6&6#,..H!K=M+N"^M(KJUE66"90Z.O1@:>I.A
M2U[0;'Q'IC6%^C&/<'1T;:\;CHRGL1DUCVGP^T>W6_-S+>ZA/?1>3-<7L^^3
M9QP& 'H/?@5U=%%QV..LOAQI5E=Z?="_U6::P<- T]P'VJ.D>-N GL #SUJW
M'X&TR+2M7TY9[OR=5E,T[%UW*2<_+\O ^N:Z:H+RZ2QL;B[E#&."-I6"]2%&
M3CWXHN%D8TOA#3YGT!FFN0=#4+;89?G "CY_EY^X.F.]4]3^'VDZEJ%S=K<Z
MA9&\_P"/N*SN/+CN/]]<'.<^W?N2:Z6SNDOK&WNX@PCGC650W4!AD9]^:CU#
M4K?3(X'N"V)[B.W3:,_.[!1^&30%D9=SX/TN>31602VZ:.VZUBA8;>W#9!)^
MZ.^>O-.F\):9<ZU?ZG<B69[ZU^R30NP\LIQTP,@_*.<UNT4!8Y*P^'NF6-]9
MW+WVJ7B63;K6WN[G?%"1T*K@8Q@8HOOAWH]]?7$YN-1@@NI!+<V4%QL@G8')
M++C//L1[8KH+;5(+K5+[3XUD$MEY?F%@-IWKN&.?3Z5=HN*R,9/#%A'XCAUN
M,RI/#:BT2)2!$$'3C&<_C45YX3L[KQ-#KZW=];7D:JCBWFVI,JG.UQC)!P,C
M(SBMZB@=CCW^&^C2:"-&>>]:U^V_;2?,7<7V[=N=OW<'Z^]6]'\$Z=I&K_VI
M]JO[Z[2/RH7O9_-\E.?E3@8')'?]372T47"P5!:6=K80""SMH;>$$GRX8PBY
M/4X%3T4 8^O^'+/Q$MFMW).@M+A;B/R6 RP['(/%7M2L4U/3+FQDEEB2XC,;
M/$0& (P<$@]O:K5% &=IVB66F:%%HT*%[..(Q;9#DN#G.<8Y.3GZUAP_#[2X
M=.TRQ^V7[PZ;=?:K?=(F=V0=I^7[N>>QY/-=;10%C#USPM8Z[?6%]++<6]Y8
MOOAGMF56]<'(.1QT^OJ:DT[PY9Z9KFI:M#).UQJ!4RJ[ JN.FT 9_,FMBB@#
M+\0Z#:^)-'DTR\DFCAD96+0D!N#D=01^E:$$2P6\<*DE8U"@GK@#%244 %%%
M% !1110 4444 %%%% !1110 4444 %%%% ":<OF:U,_:&!4'U=B3_P"@+5_3
M_G2>;_GK,Q_ ':/T451TR00V.H7QZ&5V'T0!<?FI_.M.SA,%E!$>J( ?KCFI
MD4MB:L?Q'X9TWQ1IZVFHH_[MO,AFB;;)"_\ >4]C^8K8JCJ^L66B6)O+Z4I'
MN"*JJ6:1ST55'))]!4@9.@^"=-T&YN[Q+B^OM0NE\N6]OI_-F*8 V9P!CY1V
MS[\#%SPSX;L_"FBII5C)/) CLX:=@6R3D\@ ?I52/QC;+<P1:AIFJ:8EPXCB
MGO856-F/12RLVTGL&Q71TW<2L<QX@\"Z;X@U)-1:ZU#3[X1&%Y]/G\II8S_"
MW!R/\]A5.?X8^'Y-)TVPMFO;%M.<R075K/MGW-C<2Q!Y) /3C'&!Q79T4786
M1Q<7PQT6"RUBTCNM1$6K)&MSNG#L60YW@LI.XG).<_>. .,:$O@K39KKP_<-
M/=A]#C$=L ZX< */G^7G[HZ8KI*JZ=>_VA9+<_9;FVW,Z^5<Q['&UBN2/0XR
M/4$&B["R,>V\%Z3;ZAKEVXFN/[:P+J&8@I@9X4  CKZFLW3OAEHFGZA:W+76
MIWD5FQ>TM+NYWP6[$Y!1<#&,=R??)YKM**+L+(PM/\*6.FZYJVKPRW+7&J;?
M/5V4JN!_" ,CKW)K)3X9:)'H%GI4=QJ"&RF::VO8Y@MQ"S$%MK!0.<#M^O-=
MG11=A9'+Z7X T73K74H9S=:F^IJ$N[C4)O,ED0# 7<,8QZCGISP,0Z'\/-*T
M34K>_-YJ>H2VD?E6@O[CS%MEQC$8 &..*ZZBB["R,;PWX:L_"UC/:6,L\D<]
MP]PQG8$AF ! P!QP*YT?"G15TB\TI=1U<6%S()/L_P!H4I"0V[Y 5P/3G)P*
M[NBB["R..U+X<:7J.M-J_P#:.K6E\84A26TN1$8PH RI"YR0,'.1R>*V?#?A
MK3O"VF?8=/60JSF2265MTDKG^)CQDUL44786*]Y8VFH0>1>VL%S%N#>7-&'7
M(Z'![U8HHI#,6U\,65IXLOO$<<MP;R]A6&1&9?+"J% P,9S\H[FDUOPO9:_J
M&EW=[+<8TZ;SXH491&[\8+@@DXQZCO6W13N%C$\3^%K'Q5906U[)<0FWG6>*
M:W8*Z,,]"0>.?3THLO"]E8^*=0\0QS7#7E]$D4JNR[ %"@$  $'Y1WK;HHN%
MCET\!Z7!J.M7=O/>0+K,+17=O&ZB([@07 *Y#<L<YZL>*U]!T6V\.Z):Z3:/
M*\%LI5&E(+'))Y( '?TK1HHN%C%NO#%E=^++'Q')+<"\LH6AC167RRK!@<C&
M<_,>XK:HHI %%%% !1110 4444 %%%% !1110 4444 5+C]YJ%I%V7?*?P&T
M?^A?I534&\S4HH^T49<_5C@?H&_.K<7[S4[E^T:)&/KRQ_FM9P;S;NZF[-(4
M7Z+\O\P:I Q]%%%428&N>$;'7;Z"_:YO;&^A4HMU8S>5(4_NDX/')J@WPYT+
M^Q;3383=V_V6;SXKF&7;,).,MNQC)VKVXP,8K6U;7387L&G6=F]]J,ZF18%<
M(%0'!=V/W1GCN2>U0VWB&XCU2#3M9TW[!/<Y^S2).)HI2!DKNP"&QS@CFC46
MA0@^'FDVZ:DJW>H,=1MQ!<M),'9SU+Y*YW$_ASTJV_@S3I(="B,UUMT5E>WP
MRY<C'W_EY^Z.F*TWUO28IEADU2R25G**C7"!BP." ,]001CUJ6\U*QTY4:^O
M;:U5SM0SRJ@8^@R>:-0T,Z'PKIT6M:IJC&6634XA%<0R%3&5  P!C/('<FLN
MT^&^BVMW!(9]0GM;:4RV]A/<EK>%B<_*N,]?4G/?-=,-1L6M9+H7MN;>(E9)
M1*NQ"#@@G. 15>36+5]'N]0T^>UO4@B=QY=R@1BJDX+YPO3J>G6C4>A#:^';
M.S\37^O1R3FZO8UCD1F&P!0H&!C/\([FLI/A[HR:*--$MX-ET;N&Y$H6:&0X
MY1@!CIW!_,#&XVM:?;V\<E[?6EJQB21EDN$ 4-G'.>1D$ ]#@U8-]9K9?;6N
MH!:;=WGF0;,>N[IB@-##TSP3I>G&^>:6[U*:]C\F>:_F\UVCQ]S.!QQ]?R%0
MZ5X TK2]1MKS[5J%W]D#?9(;NX\R.WSW1<#'3W]>H!K?M-4T^_;;9W]K<-LW
MXAF5SMSC/!Z9!&?:K=%PLC(T+P[:>'_MWV22=_MEPUS)YK X8]0, <5C_P#"
MNM+6TU.S2^U-+343NDMQ./+C.]6R@*\'Y0,G)Q77T47"QR5]\/=+OKVUO#>:
ME!<6MJEK#);SA&0+T8$+G=@D>G/2M7P]X:L/#5K-%9M-+)/(99[BX??)*Q[L
M<#_/N36Q11<+$-U:6U];/;7=O%<0/C=%*@=6P<C(/!Y -2JH50J@  8 ':EH
MH \Y\9V@'BRUO&T37^(2O]H:'+^\?_8=0. /7<"0>^.#P?X+BNO"NJV>KZ=)
M:VNH7;306[G$L*#[A]0P]_3G@UZ-11<5CFM.\$:=8/>327>H7UW=0&W:ZO9_
M,D2,C!53CC\JC?P'I<GAG3]!-Q>?9;&X^T1.'7>6RQPQVXQ\YZ =JZFBBX[&
M,?#5D?%#>("\QNFM_LQC)7RROTQG/XUBK\,M"%TC&;4&LHYC.FG-<9ME;V7&
M?U_3BNSHHN%C!3PCIR:EK%ZSSR-JT7E7,;,-H7&WY<#(X]S64/AKI8TVWLCJ
M6KM]EE\VUF-R/,MSQPAVX4< ].HKLZ*+A8Y*'X=Z3!#J<:76H'^TH5BN6>8.
MS$<E\E2=Q.2>W)X%,L_AOH]G<V4ANM2N(+(AH+2XN-\*N!]X+CJ3\QQQD],<
M5V%%%PLCG)?!>G37>MW+3W0?6(A%< .N%&,?)\O!^N:6Y\&:==Z!IFC2370M
M].E26)E9=[%00-QVX(^8] *Z*BBX6.5U;P#I>K:C<7GVK4+-KM0MU%9S^7'<
M8_OK@YX_SGFNDM+2WL+.&TM8EB@A0)&B]% J:B@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** +VE?\ ((LO^N$?_H(JW532O^019?\ 7"/_ -!%
M6ZA[E!1112 **** "BBB@ HHHH **** ,W7O^06/^OB#_P!')6!XKBGG\(ZO
M%;!FF>TD"JO4_*>!6_KW_(+'_7Q!_P"CDJ"K6PF9.A75F?"EA<Q21BS6S0[N
MBJH7G/IC!S]*Y>.33O$FM:'9"U,.A2:?+=06;((TE<.% *#@@*2P'OFN@E\&
M>'YI7=]/&';>\2RNL3'U,8;:?RJ]J.B:=JL$,5Y;*ZP'=$48QM&<8^5E((_
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MV3M!]!G@=NG:NNK-TK0=,T1IVTZV\EK@J93O9BY&<$[B>>3SW[UI4AH****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 54U#YHX8?^>LR+^ .X_HIJW523]YJD"=HHVD/U
M. /TW4T!4OV\S4XT[0Q%C]6.!^BG\Z94:MYMU=3=FE*CZ+\O\P3^-250F%%%
M%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/[.@_P">EU_X%2__ !5']G0?\]+K_P "I?\ XJC0"W153^SH/^>EU_X%2_\
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M(HL'*5Z*L?V3_P!/UU^4?_Q%']D_]/UU^4?_ ,118.4KT58_LG_I^NORC_\
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M\H__ (BC^R?^GZZ_*/\ ^(HL'*5Z*L?V3_T_77Y1_P#Q%']D_P#3]=?E'_\
M$46#E*]%6/[)_P"GZZ_*/_XBC^R?^GZZ_*/_ .(HL'*5Z*L?V3_T_77Y1_\
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FHL'*3:5_R"++_KA'_P"@BK=1V\*VUM% A)6- @)ZX Q4E9L#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img192321128_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #' 1<# 2(  A$! Q$!_\0
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MY?\ &E_X1V#_ )_]5_\  ^7_ !H UZ*R/^$=@_Y_]5_\#Y?\:/\ A'8/^?\
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M*""TFV.&:/>TAW9WG*X54'RC)%;46FZA9Z-J<5H6-U=7#^4\\F_8IP@8G.<
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MD# QQBNRK)UG_C\T8]_MW_M*2@#6HHHH **** "BBB@ HHHH **** "BBB@
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M@BMV@ HHHH **** "BBB@ KRWQ)\*;_7?B?:>*8]=>WM8S&S1J6$J;!C:A'
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M&TD?,">,C(K4KEK;PG+#:M;O>(R)&D,)$9SM67S,MSR>W%=30 4444 %%%%
M&/X@^YIO_80@_P#0JV*Q_$'W--_["$'_ *%6Q0 4444 5[ZQM=3LI;*]@2>V
MF7;)%(,JP]#6+!X#\*VMRES!H=G'-&P=75.01R#^%=%10!GZIILFIPB'[9)!
M'O5F5$4AL'.#D'@\?E]:DU*:X@LG:WM3<N004#A.,=<FKE1S_P#'O)_NG^5
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MY],CUK5TSP]I&HVC2&'4(9$=HI$.I3G:RG!Y#\T =717/0^#-*BA1&DU&1E
M!=]0GRWN</1#X+TJ*)4:349"/XWU"?)_)Z .AHKDKCPYH]A=VT+KJLWVV<HK
M?VA-MB^0G!^?I\I]3DU@VPTC[1-))!JC0RE)(T_M&;]W"53YOO\ ))=3CW-
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M( %VC!7;G//).:@F\-7-GX2T*#^PKB:>YWMJ#M')</&X'RDQ[U!/8$G"X]Z
M/3+SQ!IEAJ4>GW%QLNI/+VIL)SYC%4Y QR5(J6]T?3M0N(KB[LX9IHE94D9?
MF 92I&?3#'CWKR[2]!UT2^'&NM/N_,MHK&.=G7.PQW,I;)R> I4]2,$5O?$/
M2[R[U"SNK:UNKWRX66*W%N98?,SD$E75HV_V^1Q[4 =Q8V,&GV_D6ZL$W%B6
M<LS$]22>2:LUYEK<.MQ2:S:#2=0FDU(V,D,EN?,CCV;!(&?.005)]Q4ECX;O
M=(T2+Q!8Z?.^O6]W<22P/(=UU"TKCR^3@?*59?<#UH ]#%S&UX]J _F*@D)*
M';@DC[W0GCIUJ5U5T9& *L,$'N*\WA\)ZNMU> R2_;C807:71)\LWPFDD8#V
MY"X_NFJ>M:;J][8V^H7^C3RSZG<M)<0B-YS91JF(D\I74,>IR3@$F@#M(M+T
M&'5XM/1'^VPQBZ"EW.4W!5+$G# %%P#TVCTKH:\\\ Z7JME>V#ZE:W$31:/]
MFD:8='%PYVYR?X<$8)&,<UZ'0 4444 9]YHMA?W(GN8/,?9L(+':PP1R,X.-
MS8/;)JQ964&GVX@MU8)N+$LQ9F).223R35BB@ J&\NX+"SFN[F01P0H7=CV
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M3R=H5CST#CU- '0Z?I=IIB.EI&4#D$Y8MT& !GH . .@JY110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% "*JHH50 H&  .!2T44 %%%% !2!54DJH&3DX'4T44 +1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img192321128_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_15.jpg
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M 0$! 0$! 0'_P  1" $1 DD# 1$  A$! Q$!_\0 'P !  $$ @,!
M      8'" D*! 4" PL!_\0 21    8! @(&!0H"" 4$ P    ,$!08' @$(
M"5@9&E>7UM<3%)66U1$2%187&%:4F-0*."$B-E5V=[6V(SE4>-@E,5&W)F&S
M_\0 ' $!  (# 0$!              $&! 4' P@"_\0 5A$!   # @<+" 4(
M!0P" P    $"! ,1!0855)/2TQ(6%R$Q05-5D9*4$Q11<971U? '5F&!L312
M=*&SP=3A(C(S<K(V8V1F<W6DI;3CY?$U0B,D@__:  P# 0 "$0,1 #\ W^
M            !97N#WR;4-H]AI&;<==,<JMSF<+97.+HWU#(E9CP@:7R5I7%
M2GR8V5U+PP2J%:8HS11F3GKD;CKACGCIEKIX6]73TVYEM[66SC-NHRPC":-\
M(;F$8\4(M)A7&+ N [2RDPKA"RHIZB2:>QEM);6:-I+9S73QAY.SGA#<QFEA
M&^[EXE$NFBX7W.!7WL6?^$!CY4H,YD[)]5JM_P#B?U[2Z.IV!TT7"^YP*^]B
MS_P@&5*#.9.R?5-_^)_7M+HZG8'31<+[G K[V+/_  @&5*#.9.R?5-_^)_7M
M+HZG8'31<+[G K[V+/\ P@&5*#.9.R?5-_\ B?U[2Z.IV!TT7"^YP*^]BS_P
M@&5*#.9.R?5-_P#B?U[2Z.IV!TT7"^YP*^]BS_P@&5*#.9.R?5-_^)_7M+HZ
MG8'31<+[G K[V+/_  @&5*#.9.R?5-_^)_7M+HZG8'31<+[G K[V+/\ P@&5
M*#.9.R?5-_\ B?U[2Z.IV!TT7"^YP*^]BS_P@&5*#.9.R?5-_P#B?U[2Z.IV
M!TT7"^YP*^]BS_P@&5*#.9.R?5-_^)_7M+HZG8'31<+[G K[V+/_  @&5*#.
M9.R?5-_^)_7M+HZG8'31<+[G K[V+/\ P@&5*#.9.R?5-_\ B?U[2Z.IV!TT
M7"^YP*^]BS_P@&5*#.9.R?5-_P#B?U[2Z.IV!TT7"^YP*^]BS_P@&5*#.9.R
M?5-_^)_7M+HZG8'31<+[G K[V+/_  @&5*#.9.R?5-_^)_7M+HZG8'31<+[G
M K[V+/\ P@&5*#.9.R?5-_\ B?U[2Z.IV!TT7"^YP*^]BS_P@&5*#.9.R?5-
M_P#B?U[2Z.IV!TT7"^YP*^]BS_P@&5*#.9.R?5-_^)_7M+HZG8'31<+[G K[
MV+/_  @&5*#.9.R?5-_^)_7M+HZG8'31<+[G K[V+/\ P@&5*#.9.R?5-_\
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MV+/_  @&5*#.9.R?5-_^)_7M+HZG8'31<+[G K[V+/\ P@&5*#.9.R?5-_\
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M[^8S:[_DI)O]]*16,8/[2F_N6G^*5P'Z9ORW 7Z+6_MK!JS"O.*@
M
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M&;/L!>)PA\,.J^;_ +M8VA=X%Q^089!K.DIN_:[$X'L9L^P%XG"'PPZKYO\
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M&DO]L'W_  U$_P#5)F)YH>N/X2HYX^J'XS)*(2
M
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MA67^3AOA<,J5^<S]DFJ;_<<.O:ONT^Q.F7XGG.%9?Y.&^%PRI7YS/V2:IO\
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M32*1MW)5'Z*D$VTB3@T2-ZC>2<Q0R,S_ !Q>O-*3R%ES7",+HQAZ(W*Z @
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M)LN7WH[2"4L3<G3LREWK6C2F4AA9:M:F=6+^+DAZ^?F]WZXKW00
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MR=V7W'F5'FE-H++4/LIJ[LV@/N='?AP>3L^CD[LON/,J/-*;066H?935W9M
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MQQTTTTTTTTTTTTTT'[9/)R/(
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M9H3;J$W]&ZZ,;Z1EK&
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MR+RQUU/RYX
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M:NTK);>LGJXVEK92V4TLT]C86.XA+)--",(0L(37WWWS1A=Q,B0S5I
M
M        !&DO]L'W_#43_P!4F8GFAZX_A*CGCZH?C,DHA(
M
M               M^G%YYQ"Y(74)48+<#I=&-)5]/'NCPF)1)"I]$H*J1XHV
MN(OY62W0Z7H5Z(QU<V-L5>@/2*7)O_J*=0CBC>IMD3QDF996@G.BZB-G2\I[
M11:;N"+*.%--A/A3G\]!&5.>);DVU38AK&1GABJD!\5<4+&0X+\DJ903=&^Z
M[CY/GMY>1T33O;I=SGCY$#%K\B;F^-(GAJ?U$)L@M2YOR1ZW$L\WA#E&5,&2
MO47E4-QVU3US^B7O EQDS<0<HCR%66BUS4B[BA'TQNYOL]_'Z.=*FO>%MT>U
M$<2L]AY.9LL^K>C'DAB$[4ISS9<OJ%K8$RQ65&,DC0L6+K[I\DY$\'(%;=C.
MV@]S)1IRUYJ,A/:OO2J;GU<]*SEI,IU9F:"O[KH0UOK=JWMEEQ)OG<)S5Z/#
M6W:DJWN(.S6^Z->?R.C<B<$?TLC0G*"BLA==\_<U OXHN0O[)N)VQX,SX\-&
M"BEI)F?@V.:U!B?GA.5>F&1V*0\K0S+#3++3#+/3+7'3+733733745G#\TT+
M2FNC&']"TY(QA_\ :7T."_3':VMG6X#\G:6EG?2UE^XGFDONM;"Z_<QA?=?&
MZ_DOBU>OK[.OQI+/>-X_>"O[N?\ .F[T?>XQYU4YQ;Z:TUCZ^SK\:2SWC>/W
M@;N?\Z;O1]YYU4YQ;Z:TUCZ^SK\:2SWC>/W@;N?\Z;O1]YYU4YQ;Z:TUCZ^S
MK\:2SWC>/W@;N?\ .F[T?>>=5.<6^FM-8^OLZ_&DL]XWC]X&[G_.F[T?>>=5
M.<6^FM-8^OLZ_&DL]XWC]X&[G_.F[T?>>=5.<6^FM-8^OLZ_&DL]XWC]X&[G
M_.F[T?>>=5.<6^FM-8^OLZ_&DL]XWC]X&[G_ #IN]'WGG53G%OIK36/K[.OQ
MI+/>-X_>!NY_SIN]'WGG53G%OIK36/K[.OQI+/>-X_>!NY_SIN]'WGG53G%O
MIK36/K[.OQI+/>-X_>!NY_SIN]'WGG53G%OIK36?2'X4LL<F3A-[;IJ<F5RE
MT8J3E<B]04NZ1"L?5+,_S)>2W9OCXI*;T!B_)+@CQ<G962@1>DQ4+#RDQ1F>
M-XP;&,:&FC&-\?)\L?[TSZTQ#FFGQ1P%-/-&::-+-?--&,TT?_V+;CC&-\8I
MGL]WW/V]#;?9]T5I7T,9Y/!Y$BB+9&YW83K%&#&1YU56-@2E'8B[*#.DQKHB
MOY#/)#"W%0M@[GK,VR#)[+AQ2F%S^,*"\Y;YI=S&$(_/'&'JCR7\OV(S -_5
MVO1%%2*P]FD_@D"M"E8-8DLE:)\-D*2+3>=H[BQ:J]9#54<CZ=Z=ULB@5316
M.,[R;&)9)G/<G COJ^SD164XF",L..Z:^Z/HYN+CY8Q]/)"/)RK_ "H;-C=N
M0%@FD:E,!EI:] AT>%U9S%NGL/1/QK:B<'!J:I2VZ%D.Z5+BN(,0N.:5 8Z-
MBA [X($J=P(+T(C"[T_?"Y4P$
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M[U9P0
M                     C27^V#[_AJ)_P"J3,3S0]<?PE1SQ]4/QF240D
M
M                            '%5KD3>7@<O6)411AQ28LU6H)3%F*#\O
MF$$89G9X8YG'9_U"BL==<S,OZN&.NO\ 0 \DZM(LT.U2*DZK1.H-2*-4YQ9^
MA"I/E\T],=J5EEH4H)RUTQ-)S^:87EK\F>..H!JK2XJL$.JE/HM,3FJRT>IQ
M>BHQ*0822<IP3ZY>FS3DG*""C3L<-2RS#R<,\M,C,-,@Y # 'Q<N+A8/#6N2
MLHO"Z@AMFD6G6>3^O52A_>V8YI.C<I?&XE.DP:2#L#RU.#EF8;F=KCEAD5CI
MA\NF6OR:K"6$IZ&:REELI;3RD)YHQFFC"ZZ,L+N*#G&/..]5BE48/LJ>AIZR
M%;8V]I-&VM;2SC)&QGDEA"6$D(WPF\I&,;^2Z%S$YUJ.]^5&I/?F8_LAK-\%
MKF]GWYO<HG#+A+J6A\14:IUJ.]^5&I/?F8_L@WP6N;V??F]QPRX2ZEH?$5&J
M=:CO?E1J3WYF/[(-\%KF]GWYO<<,N$NI:'Q%1JG6H[WY4:D]^9C^R#?!:YO9
M]^;W'#+A+J6A\14:IUJ.]^5&I/?F8_L@WP6N;V??F]QPRX2ZEH?$5&J=:CO?
ME1J3WYF/[(-\%KF]GWYO<<,N$NI:'Q%1JG6H[WY4:D]^9C^R#?!:YO9]^;W'
M#+A+J6A\14:IUJ.]^5&I/?F8_L@WP6N;V??F]QPRX2ZEH?$5&J=:CO?E1J3W
MYF/[(-\%KF]GWYO<<,N$NI:'Q%1JG6H[WY4:D]^9C^R#?!:YO9]^;W'#+A+J
M6A\14:K8\X5^^24<0;;"HOR701@KMV)LR6032/QQS<79NR21UOCJTE?JK<RR
ME.BA3D]&X&E:8^CPQ(+UPUUURR^3=T%7-64_EII(21W<TFYEC&,+I80X[X^F
M]U;$W&*VQGP/'"=O365+/"KMZ;R5E///)N;*6RFA-NIX0C?'RD81AR<2\>O=
MP%#VW(IC$*INRH[-EE=J]4%@1>O;(ALTD4&7XKES9DBF+)&WER<HRKQ<FQR;
MM4STF0G:+F]<DUP]82'EEYJV71]#LC;GI\A6RH#[6K<E=))"OB,=1FSB,EJG
MZ5M;DWLKG&64C-ST-=) W/+LU-"]G0XGN*-U<VYN4)RUBU,2:+H^A.6QX:7H
ME0H9W-O=4Z-Q<F=6>VK$ZXE,[,RX]L>&P\U,8;@4X-3DE4MSDCSRQ4(5R90D
M5%E*"3"\0[$
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M=="Z$;^>_GXH?OO^Z[GXUXH(
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MCY2TA+">;=VT\\]T822\5]T+N*''%<@/=M@
M                                                       !:[;>
MZK;5MVGVK9?%[553[A)H>P+HZBL6;L$34O:-O>I:G7*FPEY6I,UI",]004H-
M(TSP*,.+QSUTUSQTU\K6HL+'<PM;:SLHS;J,(6D\LD8PAN;XPW487W<]S65^
M&<$X+GLY<)82HJ":VEC-92U=396$;262-T\9(6DTL9H2QFEA&,+X0C&'I4[Z
M3?AW\[.V/OD@_P 8'EY]1YU3Z:SUF!ONQ6^L.!_:%-M#I-^'?SL[8^^2#_&
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ML+.JI+>RJ::VA&:RM[">6TLK2$)HRQC)/)&,LT(32S2QC",>.$8<R9#]/<
M
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M8GHTJ1M3RC2D1A='^=_W?=R+HP0
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M4'>C](>;EJ8;EEEKKJ [@
M                                       1I+_;!]_PU$_]4F8GFAZX
M_A*CGCZH?C,DHA(
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M4GI:WLWAP)UQT;(W7,EF*HDN)X-KRXBZ/SV_OAVW<O$NO!
M
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M251@KD<G4LK4D;3Y#(%1>!1:E[>C4V;DZJ,"R\#EZD\S'##'+3'0A)@
M
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M+&$TLTN#Z26:6:6-\)I8PL81A&$80C",(PC",+X+D1[MJ
M
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M-Q?TH71OXUT ]VX
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M>3T]L(KT@0
M                      X*9L;42IR7(VY"D6O"@A6[K$R1.0J=529$F;DR
MER4%%X&KE"=O1I$!!RK,TPI$E3)2\L2""B\0YP       ,%7%3X0B[B96_74
MI1WZDIK&J:VQC^:%361T^U?-9+*'YQT5X*"I[#M&[1'HV:DZDZD+M3]3M#-#
M2?1_,SU>$,&QKIK*:%M"R\G">6[R>[OOC+&_^O+==][GV.F(\V-UO06LN$Y:
M#S*QMK.,L:2-3Y3RT\DU]\*FPW&Y\G===-????"[CQ>=5)>N>9K_ $Y*_.\:
M[>_'.X:".U4G@7M/K')[*F^(G527KGF:_P!.2OSO#>_'.X:".U.!>T^L<GLJ
M;XB=5)>N>9K_ $Y*_.\-[\<[AH([4X%[3ZQR>RIOB)U4EZYYFO\ 3DK\[PWO
MQSN&@CM3@7M/K')[*F^(G527KGF:_P!.2OSO#>_'.X:".U.!>T^L<GLJ;XB=
M5)>N>9K_ $Y*_.\-[\<[AH([4X%[3ZQR>RIOB)U4EZYYFO\ 3DK\[PWOQSN&
M@CM3@7M/K')[*F^(MAKAJ[(%'#ZVS(]O*JRB;6-2SB63'66)XD9"B\\9/F@R
MQ;_H0R22K+'5%ZEKIJJ^E<M%'I?Z$Y/S/ZVZHJ7S.GA8;ORETTTVZW.Y_K1O
MNNW4W)ZW4<4L7HXL8(EP7-5PK8RU%O;^7A81IX1\M&6.Y\G&UMOZNYY=WQW\
MD%_PRUF
M                                $:2_VP??\-1/_5)F)YH>N/X2HYX^
MJ'XS)*(2
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M3&YRUYM5U:G(R',13&T*#FN-S%R-/]&VQPN8"[[_ %?K[(>B]? "
M
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MW98EF(([!6&/$*\6K5T3.0A&Z_[87+L00
M                                                       "-)?[
M8/O^&HG_ *I,Q/-#UQ_"5'/'U0_&9)1"0
M
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M*CKAD4ISQ1/IKBN1("VA3J6X9K5B5+BGU/4%%YA(
M
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M+M,5N;5@XZJ<6[-9CHJR1Z$Y*--#M<] ?EW(
M
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M6>[J[.,OE+&TEM)-U"%/",9=U+"^$(POA?"^#.X-LZ.
M
M            (TE_M@^_X:B?^J3,3S0]<?PE1SQ]4/QF240D
M
)         ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img192321128_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_16.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X2"V17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(R.C R.C Q(#$S.C(P.C(Y   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,V-@  DI(  @    ,V-@  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,CHP,CHP,2 Q,#HR.#HT-  R,#(R.C R.C Q(#$P.C(X.C0T      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  #PH         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ 10$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M\+Q\9?W['_P'_P#KT?\ "\?&7]^Q_P# ?_Z]/ZK1%[:8?\+Q\9?W['_P'_\
MKT?\+Q\9?W['_P !_P#Z]'U6B'MIA_PO'QE_?L?_  '_ /KUVVA_$GQ!?Z-;
MW4[6WF2 [ML6!PQ'K[5%3#4HK0N%23>II)X\UEG 9[=0>I\KI^M2GQOJN'Q=
M6^1]W]Q][CZUA[*!KS,@_P"$]UO^];_]^JZCPQX@U'5;&>6:!)Y$E" )\FT$
M$Y/X_P ZFI3A&-T--W.ABN+E[G8]F4B/23>#C@'D?CCC/2K5<Q844 17#3+
MQMT5Y?X0QP*K)/J1AB+V,0D9L2*+CA1GKG;SQSB@#S#QG'XL_P"$KOCI=W<Q
M61*>6J7BQK]Q=V%W#'.:P?+\=_\ 00O/_!BO_P 76+A5;T3/ KQQ;JRY;VNR
MQ;Q^,-C_ &G4-2W9^3R]03'W6ZY?UV_AFGWB>+"(_L5_J8QD/YNH)S[\2?7]
M*.2MV9')B[=;E3R_'?\ T$+S_P &*_\ Q=5[Z+X@-9R"#4;[S3C;MU)0>O\
MOU=*%3G7,G8=.&+YUS7L9UM;_$=5;[3?ZPS;U(V:JF"O.X?ZSKTQ3;JV^)1G
MS:ZAJZQ$#B354R#W_P"6G2O9_<WV_ ].TSU/P[:>*1J=C+>O=O:\&0M<;E(Q
M]>:[/&JF,@?9$??D'+,-N.AX'.>]>?5<>;W3KBM"^N[8N[&['.#WI:Q+"B@
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MH 6BDW4;J %HI-U&Z@!:*3=1NH 6BDW4;J %HI-U&Z@!:*3=1NH 6BDW4;J
M%HI-U&Z@!:*3=1NH 6BDW4;J %HI-U&Z@!:*3=1NH 6BDW4;J %HI-U&Z@!:
M*3=1NH 6BDW4;J %HI-U&Z@!:*3=1NH 6BDW4;J %HI-U&Z@!:*3=1NH 6BD
MW49I73 6BDW4;J8"T4FZC=0 M%)NHW4 +12;J-U "T4FZC=0 M%)NHW4 +12
M;J-U "T4FZC=0 M%)NHW4 +12;J-U "T4FZC=0 M%)NHW4 +12;J-U "T4FZ
MC=0 M%)NHW4 +12;J-U "T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!0U[3Y]6T/4+&VO)
M-.N+FWDABO(AEX&92 Z\CE2<]1TZBO!(;/4_@9\1?#$OB?XCS7V@:E'=Q3MJ
M\S100!(U*EGEF<99V7G@YP,D'%?1-?('_!1KGP/H/./]?_Z-MJF4N6+D<F+K
M/#8>I62ORIO[CZ#_ .%\?#3_ **%X6_\'-O_ /%T?\+X^&G_ $4+PM_X.;?_
M .+K\;=O^V?\_C1M_P!L_P"?QKS?KOD?FO\ KG7_ .?2_$_9+_A?'PT_Z*%X
M6_\ !S;_ /Q='_"^/AI_T4+PM_X.;?\ ^+K\;=O^V?\ /XT;?]L_Y_&CZ[Y!
M_KG7_P"?2_$_9+_A?'PT_P"BA>%O_!S;_P#Q='_"^/AI_P!%"\+?^#FW_P#B
MZ_&W;_MG_/XT;?\ ;/\ G\:/KOD'^N=?_GTOQ/V2_P"%\?#3_HH7A;_P<V__
M ,71_P +X^&G_10O"W_@YM__ (NOQMV_[9_S^-&W_;/^?QH^N^0?ZYU_^?2_
M$_9+_A?'PT_Z*%X6_P#!S;__ !='_"^/AI_T4+PM_P"#FW_^+K\;=O\ MG_/
MXT;?]L_Y_&CZ[Y!_KG7_ .?2_$_9+_A?'PT_Z*%X6_\ !S;_ /Q='_"^/AI_
MT4+PM_X.;?\ ^+K\;=O^V?\ /XT;?]L_Y_&CZ[Y!_KG7_P"?2_$_9+_A?'PT
M_P"BA>%O_!S;_P#Q='_"^/AI_P!%"\+?^#FW_P#BZ_&W;_MG_/XT;?\ ;/\
MG\:/KOD'^N=?_GTOQ/V2_P"%\?#3_HH7A;_P<V__ ,71_P +X^&G_10O"W_@
MYM__ (NOQMV_[9_S^-&W_;/^?QH^N^0?ZYU_^?2_$_9+_A?'PT_Z*%X6_P#!
MS;__ !='_"^/AI_T4+PM_P"#FW_^+K\;=O\ MG_/XT;?]L_Y_&CZ[Y!_KG7_
M .?2_$_9+_A?'PT_Z*%X6_\ !S;_ /Q='_"^/AI_T4+PM_X.;?\ ^+K\;=O^
MV?\ /XT;?]L_Y_&CZ[Y!_KG7_P"?2_$_9+_A?'PT_P"BA>%O_!S;_P#Q='_"
M^/AI_P!%"\+?^#FW_P#BZ_&W;_MG_/XT;?\ ;/\ G\:/KOD'^N=?_GTOQ/V2
M_P"%\?#3_HH7A;_P<V__ ,71_P +X^&G_10O"W_@YM__ (NOQMV_[9_S^-&W
M_;/^?QH^N^0?ZYU_^?2_$_9+_A?'PT_Z*%X6_P#!S;__ !='_"^/AI_T4+PM
M_P"#FW_^+K\;=O\ MG_/XT;?]L_Y_&CZ[Y!_KG7_ .?2_$_9+_A?'PT_Z*%X
M6_\ !S;_ /Q='_"^/AI_T4+PM_X.;?\ ^+K\;=O^V?\ /XT;?]L_Y_&CZ[Y!
M_KG7_P"?2_$_9+_A?'PT_P"BA>%O_!S;_P#Q='_"^/AI_P!%"\+?^#FW_P#B
MZ_&W;_MG_/XT;?\ ;/\ G\:/KOD'^N=?_GTOQ/V2_P"%\?#3_HH7A;_P<V__
M ,71_P +X^&G_10O"W_@YM__ (NOQMV_[9_S^-+M_P!L_E_]>CZ[Y!_KE7_Y
M]+\3]D?^%\?#3_HH7A;_ ,'-O_\ %T?\+X^&G_10O"W_ (.;?_XNOQP\D;<^
M;^'^33=G7YS^7_UZ7U[R!<95VK^R7XG[(_\ "^/AI_T4+PM_X.;?_P"+H_X7
MQ\-/^BA>%O\ P<V__P 77XV[?]L_Y_&E\O@G>?R_^O3^NVZ#_P!<J]K^R7XG
M[(_\+X^&G_10O"W_ (.;?_XNC_A?'PT_Z*%X6_\ !S;_ /Q=?C>T87&)"?\
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M5I_\<K^?7>/^><?_ 'P/\*-X_P"><?\ WP/\*/\ 5^E_S\?W!_:3_E/Z"O\
MAI[X/?\ 15?!/_A16G_QRC_AI[X/?]%5\$_^%%:?_'*_GUWC_GG'_P!\#_"C
M>/\ GG'_ -\#_"C_ %?I?\_']P?VD_Y3^@K_ (:>^#W_ $57P3_X45I_\<H_
MX:>^#W_15?!/_A16G_QROY]=X_YYQ_\ ? _PHWC_ )YQ_P#? _PH_P!7Z7_/
MQ_<']I/^4_H*_P"&GO@]_P!%5\$_^%%:?_'*/^&GO@]_T57P3_X45I_\<K^?
M7>/^><?_ 'P/\*-X_P"><?\ WP/\*/\ 5^E_S\?W!_:3_E/Z"O\ AI[X/?\
M15?!/_A16G_QRC_AI[X/?]%5\$_^%%:?_'*_GUWC_GG'_P!\#_"C>/\ GG'_
M -\#_"C_ %?I?\_']P?VD_Y3^@K_ (:>^#W_ $57P3_X45I_\<H_X:>^#W_1
M5?!/_A16G_QROY]=X_YYQ_\ ? _PHWC_ )YQ_P#? _PH_P!7Z7_/Q_<']I/^
M4_H*_P"&GO@]_P!%5\$_^%%:?_'*/^&GO@]_T57P3_X45I_\<K^?7>/^><?_
M 'P/\*-X_P"><?\ WP/\*/\ 5^E_S\?W!_:3_E/Z"O\ AI[X/?\ 15?!/_A1
M6G_QRC_AI[X/?]%5\$_^%%:?_'*_GUWC_GG'_P!\#_"C>/\ GG'_ -\#_"C_
M %?I?\_']P?VD_Y3^@K_ (:>^#W_ $57P3_X45I_\<H_X:>^#W_15?!/_A16
MG_QROY]=X_YYQ_\ ? _PHWC_ )YQ_P#? _PH_P!7Z7_/Q_<']I/^4_H*_P"&
MGO@]_P!%5\$_^%%:?_'*/^&GO@]_T57P3_X45I_\<K^?7>/^><?_ 'P/\*-P
M_P"><?\ WP/\*/\ 5^E_S\?W!_:3_E/Z"O\ AI[X/?\ 15?!/_A16G_QRC_A
MI[X/?]%5\$_^%%:?_'*_GV5E9@-L(R<995 _,TJ_/&KB*/:PXR@'/)QT]OI1
M_J_27_+Q_</^T7_*?T$?\-/?![_HJO@G_P **T_^.4?\-/?![_HJO@G_ ,**
MT_\ CE?S\;#Y:OY4>TL5R$4X(V]?^^A^1I1&S.RK%&S!=V JYV_-D@=2!M)/
MM1_J]2LG[1Z^0?VB_P"4_H&_X:>^#W_15?!/_A16G_QRC_AI[X/?]%5\$_\
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MX)_\**T_^.4?\-/?![_HJO@G_P **T_^.5_/KO'_ #SC_P"^!_A1O'_/./\
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M!7_#3WP>_P"BJ^"?_"BM/_CE'_#3WP>_Z*KX)_\ "BM/_CE?SZ[Q_P \X_\
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M?[0GPNURZ:UL/B-X3O;E028;?7+61\#J=JR$XK8'Q4\%CG_A+=#_ /!C#_\
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M_P#BJ_.-5SU**,9R13%DC,*R-)%'NX"R?*<^GM^./SXI_P!DI?:%[?R/T?\
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M7\J/[+C_ #![9]C]'?\ A:W@K_H;-#_\&,/_ ,51_P +6\%?]#9H?_@QA_\
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MJW<./?I3JX5?BEX<T'P7I'BCQ3J%KX%T_4XH9E3Q//'ITD$DL7F"WD65@$F
MSN3.<JWOCI/#OBO2/%VCQ:MH>I6>L:7,SK%>Z?<)<0R;&*-M="5.&4@X/!!!
MY&*+,+HUJ1FVJ3@GV%<?I/QD\">(-2TG3M+\9:!J6HZO$]QI]G9ZI!++>1H9
M%=XE5R9%4PS LN1^Z?\ NG#/&/QD\#> ;Y;'Q/XP\/\ AR^9%G6VUC5+>VD,
M)8@2A9)%.TE6 /JI],46871V*R!G*XY'7D<>GYT^N!\1>*-5TWXE>"-*L]7\
M-VNCZD+X7UCJT[IJUVT<*F/[#'D!]K'=+N'",".N:EU3XZ?#G05D.J>//#.E
MF.YGLI%O=8MHBEQ#L\^$[G_UD?F1[EZKO7/446871W-%5_MB>7O(9<=5; (Y
M(R?;@\].*Y;2_C'X#UKQ9)X7T_QIX>O?$L4DL4FC6^K6\EY&\182(T*N7#*4
M?<,<;&SC%%F%T=C17/\ BOQ_X<\":?%J'B76]/\ #VG23"!+S5;N.UA9RK,
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M117O'GA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6<44:!FP"S2.B!<Y+.  :E_X*,:G96_[(?C*TN;J*WGU"73[:TCD<!KB7[;
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M3_A5A9C:*=Y9]_\ OD_X4>6??_OD_P"% 68VBG>6??\ [Y/^%'EGW_[Y/^%
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MKL,;,;13O+/O_P!\G_"CRS[_ /?)_P * LQM%.\L^_\ WR?\*/+/O_WR?\*
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M+?\ @EMO_B*/^%"_#+_HG?A;_P $MM_\17PW_P /&_B9_P! ;PK_ . =S_\
M)%'_  \;^)G_ $!O"O\ X!W/_P D4?6*(?ZPY/V_\E/N3_A0OPR_Z)WX6_\
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MQKXF?] ;PK_X!W'_ ,D4OK% 7^L.3VO;_P E/N3_ (4+\,O^B=^%O_!+;?\
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M^'C?Q,_Z WA7_P  [G_Y(H^L40_UAR?M_P"2GW)_PH7X9?\ 1._"W_@EMO\
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M .2J/^'N7Q>_Z%CP/_X 7?\ \E4?V%B_Y5]Z#VN"_D7W+_(_3QO@+\,E7/\
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M)1X'_P#"<L__ (U7IW/I1SZ4>TG_ #,.1=D>8_\ #,'P=_Z)1X'_ /"<L_\
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M (U7IW/I1SZ4>TG_ #,.1=D>8_\ #,'P=_Z)1X'_ /"<L_\ XU1_PS!\'?\
MHE'@?_PG+/\ ^-5Z=SZ4<^E'M)_S,.1=D>8_\,P?!W_HE'@?_P )RS_^-4?\
M,P?!W_HE'@?_ ,)RS_\ C5>G<^E'/I1[2?\ ,PY%V1YC_P ,P?!W_HE'@?\
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M#_X+(/\ XBNJVT;:+ONPY5V.5_X57X*_Z%'0?_!9!_\ $4?\*K\%?]"CH/\
MX+(/_B*ZK;1MHN^[#E78Y7_A5?@K_H4=!_\ !9!_\11_PJOP5_T*.@_^"R#_
M .(KJMM&VB[[L.5=CE?^%5^"O^A1T'_P60?_ !%'_"J_!7_0HZ#_ ."R#_XB
MNJVT;:+ONPY5V.5_X57X*_Z%'0?_  60?_$4?\*K\%?]"CH/_@L@_P#B*ZK;
M1MHN^[#E78Y7_A5?@K_H4=!_\%D'_P 11_PJOP5_T*.@_P#@L@_^(KJMM&VB
M[[L.5=CE?^%5^"O^A1T'_P %D'_Q%'_"J_!7_0HZ#_X+(/\ XBNJVT;:+ONP
MY5V.5_X57X*_Z%'0?_!9!_\ $4?\*K\%?]"CH/\ X+(/_B*ZK;1MHN^[#E78
MY7_A5?@K_H4=!_\ !9!_\139/A3X+:-@/"&@$XXSID'7_OBNLVT;:.9]V%D5
MK'3X--M8;6UACM[:%52.*)0BHH&  !QC&*L]Z6BEN[C"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHI* %HIK,%&3TR!^9Q7+^-/B?X:^';:(/$
M6I+IHUK4X=%TYFC=Q<7LI81P#8#ACL/)P/>@6VYU5%8_B3Q9IOA'PSJFOZO,
MUGIFEVLMY>2^6TAABCC,DAVH&)(52<*"3CC-9\?Q.\*GP+8>,Y]=LM/\+7UM
M;W<&JZC*+6 Q3A#"Q:7;MW^8@ ;!RP&,\4PNMCJ**B6X1L8SSG'H?H:3[4F5
M&&W$ E<<C.<?R[4ADU%0M=1KC<=N<=??I7/?\+*\._\ "QAX$:_*>*CI?]M"
MQ:"0 V?FB'S!)M\O_6';MW;N"<8YH Z>BH8;E)_N<C'7(XZ<=?<4JW"/MV\D
MC/!'H#_4?G2N@):*A^U)P,-NP"5QR,@G^AX%/60. 0#SZBF ZOD#_@HU_P B
M/H/_ &W_ /1MM7U_7R!_P4:_Y$?0?^V__HVVK*K_  Y>AYF:?[C6_P +_(_/
M':*-HHVBC:*^</YW#:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:*!K<='$9&"J,D\ >M*JHP3
M##YL8/.-Q. N?7]!W.>*:%!P",C(S],\_P"?Y5Z#\(?%W@[P')K.JZ]X8'BC
M7H[98M%M[]5FT]9'!$TES$2-P3(V =1D$H<.'%7DD=.'IPK5%&I+E1P$<8D'
M"N".H*GC(R#[CGJ.*BWQA0VY3N^Z$.\L>. %SSR./<5[C^V1#)#^TQXLWB.1
MD-B$CV=3]EA;;UR>2.,X/ QQDVO GQ>^,EOX1L;;X;Z#-9Z-8QK;S_\ ".>&
MQ.MW<)&H::>0Q/F=U\K+9&>"5&#G>%-<[39ZE/!P^LSP\I-V;6W8\'&W(&Y2
MQ&<!ATR1GWY&.,]?8X7*KDL0!7KW[4]UIUQ\2+2:UAL['7)M,@/B2UTUF:"/
M5B7:Y13N9,J0F_8S9;&26#$^<^"_['C\9:"WB$L- %_;G461I%(MO,7S2#&"
M_P!S=PGS'H,&E4I\L^4\^MA>2O[%,Q7Q#,Z2$1NAPV><8/)R.PX.>F"#5S1]
M'O\ Q+JD6G:387.JZE(3ML[&(SS, I8D(F2P"@GC/2OM>;Q?\5T^+MMITFAZ
M>OP8F=D15L+:31/[!"L@D:X4E$4VZ&3:\@YP-FQU6O+/A/=66IR?&G0/AOJ7
MV;Q-J5S;)X1$-RUO=&R2[+R)#-.RLA\H M&S!B$/RL%-:/#J+6I[DLIIPJKW
MKJ[^:MI;O=Z'SS?6,]GJ%Q8W<3VM]:N8[BUF1DDA8'#*RD9!!!&.N1CK3[K1
M[^QTVROKJQN;>RO3(+6XDA81S^6P638^-K;6(#8/!(!YXKZ/^(7@33OB!\2-
M"37]6:RT[PSX8L8?'FN*HFDM+Q$<2+).IVS7+D11#;O;<  CA60>*?$SXA7'
MQ,U:UO)+&/2]-TZTBT[2]/C=I?LEK%N6.(R-\SL V2S\L2V. *B5/E3.#$X)
M8>G*4G=)V1QVT4;11M%&T5SGB!M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
M !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%-;@+_":\L^+G
M_(P6W_7HG_H4E>I_PFO+/BY_R,%M_P!>B?\ H4E?4<,_[_'T9]%D/^\OT.$H
MHHK]B/T$****0"J-S $[<G&3F@;<X#\YZ%6!/H<$9P00<XZ$4J!"?WA(3!SM
M.,\=/QZ<<\\<U]^_LE-\95_8QU1/@B/^*N_X6%(+Q=MH-MJ-.@$G%W\G,@BZ
M8;.?>N'&XCZO%27^1TTH1GN? ;1D9(^91_$,X.<$8/?@@^V1FF=.<$_09KZ"
M_:XU[X]:IK&BZ;\<X;X7&F+-_94UQI]M#"_F"$S>5-;((IN%@)PS;"VWKD#Q
M+PQX@U+PCXDTG7='N5LM6TN\AOK.Y:-9!#-&X='VL"&VLH.""#C!!Z5I0K.K
M3YE:_D[K[[&=2,8RL9ODNS*H&XL0HP1@L3@#/0Y)'3CGK4^GZ;=ZMJ5IIVGV
MTVH7]X\<=K:VL322W#R'$:1J!EF9CM"@9)XQFONK]D?]JSX^?'K]H+POX5O?
M'<S:(LS7^K/'H-E($M8%,CI(R0J8UE.(?,)7:9EP"=H;G/AC\:K'XQ?M8?%[
MQ-;+;:'XC\5>&]4TGP/]IVV<]MJ/D0VEBB2%F%O<O%'L+AU!=V1"=RJ?.EC:
MT93A*&J5]_\ @'7[*-D?(7B3POJ_@W6KC2/$&FWFAZM;[?.L=1MW@GCW*&7,
M; -RI5NG1U/0YH_X1?6?^$;?Q"-+O6\/K>?8/[66W<VOVC9O\GS<;1(%PVPD
M-@YQP<?9'Q>^%7B#XC1_ KX;>*K\S?%'1[75)O'>K:A<QW]QI.EM=B6&:^NF
ME*&*.V>:01M."!(@&#*N?GSX\_%33O%]QI'@KPBB1?#GP2+FS\/HS-+<7$<L
MV^:^GD=%;S;B1%D,>R-8PRHBC#EMJ&-E7Y8I>OI_P>GD14HJ*;/)J***]8X@
MI5I*5:%N +]ZOHS]D;[WB[_MS_E-7SFOWJ^C/V1OO>+O^W/^4U<F)_@LZ\/_
M !4?1&T4;11M%&T5\^>X&T4;11M%&T4 &*]V_8S_ .2H7_\ V!Y__1]O7A.*
M]W_8S_Y*AJ'_ &!Y_P#T?;URXW^ RX_$C[-9MHR?4#\S3&N$50>2#Z#\J?(N
M]2N2ON*\P^,GP#T#XW'28/%5WJ\V@6;2BY\/V.HO:V6I^88RGVM4*M)Y4D:.
M@#K@CO\ =/R)W'I:W2,^WD'M_GMWZ^AH%P,@,K(Q .W@G\AG_"OCK0_A#H?[
M/?[7WPWT?X7B^TG3/$FE:@?%6B07LEY"L-O$6M;B82^8Z$SR,@EW*"0$7&Z0
M2<__ ,%"OASX^U+X?^._%VK>,5T_P#HEMI\>B^&]%:1#=S2WEH)YK\-\LFU@
M3&HR!A&&U@_F7RHSYF?<R7"NVSG?QE>NW(S@XZ4^201KN;.,@< GJ<4R.-%9
M=N5"C:%'3MV_"BX/[OWR.IQW'^<=Z@L%N%;&/3-9GB#Q=HWA'1[G5]?U2ST+
M2+8*9M1U*X2"VC#,JJ6E8A5RS*!DC)(K\\_VUIK_ ./_ (!\<_$"VU&\'PP\
M#)I]KX:^R2*UCXBU*6\CCN[T,R O'$'\E'PR,=SQR &16]V_:_BTK2O'7PB\
M3>-;%K_X1:)>ZF_B<W=B^H6,=Q+9B.PEN+9%<R8D)59"A"E\%U+ -IRF?,SZ
M@TO7+'7-/M;_ $VZAU"PNHDGM[NU<2Q31N-R.CKD,I4@@C@@@]#5?3_%FC:O
MK.HZ18ZI97FJZ:(S?V,%RCSV8D4M'YL8.Y-X!*[@,X.*^-OA/\1M4^$OP<\5
MOX7T=;S5/&/C;5'^&'A5RZ)>:?*Z-'/%;@KY%H@,URV?)0*WS,GF*Y^E?@?\
M(;+X/^&;NRAO[C5M7U?4KC7-<U2X41M?ZC<!6FF\I0$B4X4*B@ *HSEB6(XC
M4F>E4445F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0#H%QAAZ-:@K<RMU_P" 7*49ZGTAX7NK3]G_ /8PU7Q);" >,?BW/<:)9FW
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M )35RXE6I-'9A_XB9]$;11M%&T4;17SQ[8;11M%&T4;10 8KW;]C/_DJ%_\
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MY1_9\?Y'^(?ZKY7V?_@1\4_\.X/B7_T&?"O_ (&7/_R/1_P[@^)?_09\*_\
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M^1_B'^J^5]G_ .!'Q3_P[@^)?_09\*_^!ES_ /(]'_#N#XE_]!GPK_X&7/\
M\CU]K?\ #3OP=_Z*OX)_\*&S_P#CE'_#3OP=_P"BK^"?_"BL_P#XY1_9\?Y'
M^(?ZKY7V?_@1\4_\.X/B7_T&?"O_ (&7/_R/1_P[@^)?_09\*_\ @9<__(]?
M:W_#3OP=_P"BK^"?_"AL_P#XY1_PTY\'?^BK^"?_  HK/_XY1]0A_(_Q%_JQ
ME?G_ .!'Q3_P[@^)?_09\*_^!ES_ /(]'_#N#XE_]!GPK_X&7/\ \CU]K?\
M#3OP=_Z*MX)_\**S_P#CE'_#3GP=_P"BK^"?_"BL_P#XY1_9\?Y'^(_]5\K\
M_P#P(^*?^'<'Q+_Z#/A7_P #+G_Y'H_X=P?$O_H,^%?_  ,N?_D>OM;_ (:<
M^#O_ $5;P3_X45G_ /'*/^&G/@[_ -%6\$_^%%9__'*/[/A_(_Q%_JQE7G_X
M$?%/_#N#XE_]!GPK_P"!ES_\CT?\.X/B7_T&?"O_ (&7/_R/7VM_PTY\'?\
MHJ_@G_PHK/\ ^.4?\-.?!W_HJ_@G_P **S_^.4?V?'^1_B/_ %7ROL__  (^
M*?\ AW!\2_\ H,^%?_ RY_\ D>C_ (=P?$O_ *#/A7_P,N?_ )'K[6_X:<^#
MO_15_!/_ (45G_\ '*/^&G/@[_T5?P3_ .%%9_\ QRC^SX_R/\0_U7ROL_\
MP(^*?^'<'Q+_ .@SX5_\#+G_ .1Z/^'<'Q+_ .@SX5_\#+G_ .1Z^UO^&G/@
M[_T5?P3_ .%%9_\ QRC_ (:<^#O_ $5?P3_X45G_ /'*/[/C_(_Q#_5?*^S_
M / CXH;_ ()P_$O:?^)SX5_\#+G_ .1ZX[QQ_P $L?BOXFU2&>UU_P &QA8%
MCQ->W8.06/:U/]X5^A'_  TY\'3_ ,U7\$_^%%9__'*3_AIOX._]%7\$Y_[&
M*S_^.5V86G4P=3VU./O>AU8?(,OPM3GIIW]3\U?^'17QD_Z&/P/_ .!UY_\
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M_P <H_M7'=O_ "4/J.&/S5_X=%?&3_H8_ __ ('7G_R+1_PZ*^,G_0Q^!_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_? _P *;Q1Q1IW_  "_F.WK_P \H_\ O@?X4;U_YY1_]\#_  IO%'%&G?\
M +^8[>O_ #RC_P"^!_A1O7_GE'_WP/\ "F\4<4:=_P  OYCMZ_\ /*/_ +X'
M^%&]?^>4?_? _P *;Q1Q1IW_  "_F.WK_P \H_\ O@?X4;U_YY1_]\#_  IO
M%'%&G?\  +^8[>O_ #RC_P"^!_A1O7_GE'_WP/\ "F\4<4:=_P  OYCMZ_\
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M;L(-?^(NO2_8O#6@N_SZC<\;I& QB*&/,DC,T:!0%,B%U-%F+F1ZO'=+)(B
M'++O[=/SY_#-35E:']K&GV<6I3P3ZE&@6XDLXF@A>0* Q6-G<JI+9 +-QC)-
M:M(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/+/O_P!\G_"OZ"?^&7_@Y_T2CP1_X3MG_P#&J/\ AE_X.?\ 1*/!'_A.V?\
M\:H_UAA_S[#^SY_S'\^WEGW_ .^3_A1Y9]_^^3_A7]!/_#+_ ,'/^B4>"/\
MPG;/_P"-4?\ #+_P<_Z)1X(_\)VS_P#C5'^L,/\ GV']GS_F/Y]O+/O_ -\G
M_"CRS[_]\G_"OZ"?^&7_ (.?]$H\$?\ A.V?_P :H_X9?^#G_1*/!'_A.V?_
M ,:H_P!88?\ /L/[/G_,?S[>6??_ +Y/^%'EGW_[Y/\ A7]!/_#+_P '/^B4
M>"/_  G;/_XU2-^S#\'57(^$_@EO8>';+_XU1_K!#_GV']GS_F/Y]_+/O_WR
M?\*/+/O_ -\G_"OZ!?\ AF7X-D9'PG\$GM_R+EG_ /&J</V8_@XW3X3^"?\
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MG;+_ .-4?ZPP_P"?;#^SJG\Q_/OY9]_^^3_A1Y9]_P#OD_X5_01_PS!\'?\
MHD_@C_PG;+_XU1_PS!\'?^B3^"/_  G;+_XU1_K##_GVP_LZI_,?S[^6??\
M[Y/^%'EGW_[Y/^%?T$?\,P?!W_HD_@C_ ,)VR_\ C5'_  S!\'?^B3^"/_"=
MLO\ XU1_K##_ )]L/[.J?S'\^_EGW_[Y/^%'EGW_ .^3_A7]!'_#,'P=_P"B
M3^"/_"=LO_C5'_#,'P=_Z)/X(_\ "=LO_C5'^L,/^?;#^SJG\Q_/OY9]_P#O
MD_X4>6??_OD_X5_01_PS!\'?^B3^"/\ PG;+_P"-4?\ #,'P=_Z)/X(_\)VR
M_P#C5'^L,/\ GVP_LZI_,?S[^6??_OD_X4>6??\ [Y/^%?T$?\,P?!W_ *)/
MX(_\)VR_^-4?\,P?!W_HD_@C_P )VR_^-4?ZPP_Y]L/[.J?S'\^_EGW_ .^3
M_A1Y9]_^^3_A7]!'_#,'P=_Z)/X(_P#"=LO_ (U1_P ,P?!W_HD_@C_PG;+_
M .-4?ZPP_P"?;#^SJG\Q_/OY9]_^^3_A1Y9]_P#OD_X5_01_PS!\'?\ HD_@
MC_PG;+_XU1_PS!\'?^B3^"/_  G;+_XU1_K##_GVP_LZI_,?S[^6??\ [Y/^
M%'EGW_[Y/^%?T$?\,P?!W_HD_@C_ ,)VR_\ C5'_  S!\'?^B3^"/_"=LO\
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M*G_K##_GVQ?V=4_F/Y^/+/O_ -\G_"CRS[_]\G_"OZ"/^&7_ (._]$F\$_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVCSLQG*G@ZTX.S47^1\O_P##9OQF_P"AR7_P5V?_ ,9H_P"&S?C-_P!#DO\
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MM?Y1UYPQX6OUC(L+AZ^ IU*L$V[GZ%E>*K3PE.<I7>I]*?\ #QW]HG_HH/\
MY1]/_P#D>C_AX[^T3_T4'_RCZ?\ _(]?-6ZC=7O?4<)_S[7W'I_6*O\ ,?2O
M_#QW]HG_ **#_P"4?3__ )'H_P"'CO[1/_10?_*/I_\ \CU\U;J-U'U'"?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"RN<'-E$?_<=7FG_  6"Z_"($XW-JR_B39 5]')_P42_9\\S9_PL##$;@O\
M8VH<C .1_H_S<'/&>,UZWV$TCZ7[;BV=%>7'Q(^&_P"R?XGU+QCXAL=3^(^D
M:!JE_+K&FP)Y!FC2:6W9$,2*0JB/(*#D'KUKY%_9]\6?M;?M)>";_P 3>'?B
MGX<T^RLM2;3I/[4T^WAE:18HI&8>79/A2)4 ^8'@^V?L[XX>)M/\8?LI^/\
M7='F-[I&J>"[^\L[E4*B6"6PDDCD"MA@"K#@@'GI7P#^Q+^V]X%_9K^%.M^&
M_$FE>(=2O;K7)M12;1[>"2%8VMK6,*S23QX?*'Y<=QU)Q2C=Q=D5/2:UZ'NG
M[)'[6OQ%USXQ7_P:^,&G0V?B>VCFCMK[R!;W,UU&3*\,D<:^24-NWF1R)M4Q
MP@YE,H-=9^WA\1_BO\$M'\-?$#X?:TZ^'[6Y%OKFC7-K!<6YR2\4KGR_,5'R
M\3D3K@M!Y8#$M7@W[(&M:9^T5^VCJWQAUS6=%T'6U66/3O"UM?,;N9C:B!
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MPP^623]YNO7'3' [4Y/6UAP6E[DM%%%9F@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5%<'$?7;R.?Q%2U%<'$1Y R0/F..I IB>Q\3?"
MC7OCM^U%X(U7XA^$_C!HW@JWN+NXCTSPC;Z#;7JV9B3;'#>7+J9(W?"LV$8A
M9%=<*ZQ+V7[0'[7!_9_;X=Z!K]]H9\6WUQI<_BBWBL+R6UMM,D\V.[NK9@.0
MLT>$1BSXSE.=P7QM^S;X"\;SW/Q@^&7CX?#C6V$UW/XO\-W\<^EW*+(C3_:X
M]_E21AK=BZJZ(S[FE$A7!X/QIX\U;XH? []EGQ9XGL6T[7-1^(F@FX62+#3R
M*]Q$MP!L3:DZ+YJC: !, "1S6G*8:GUCX,^+?A;Q_P"!X/&VB:Q%=^$Y5FE&
MJ3*]M&D<3RQRNXE1"JJT3@EN,+GIR>'\"?MI_!?XE>(XM T#QU9SZM/_ ,>]
MM=P3V9N#N10L1G1 [EI% 0$L>< XK@?^"@1M&^%O@]?$+WJ^!?\ A,])7Q4U
MJ)EA_LO=()OM)C!(BWF+Z/Y>WYMIK/\ V_)/#_A_X!:9H.FDVOBW^U]/'@C1
M](#1W/V^&6-0MI%&/X(6E7IM0NH^\8Z7*7S,]H^)?[3OPS^#NN2Z/XR\31Z%
MJ4=@FI^1-;3.9+=I_(#(41@YW@Y1<L "Q&U21A7W[:_P3TWP+I?C";Q[9?V%
MJ=Y)86LD<$[W#3Q_ZQ&MUC,T>W*[BZ*!OC)P'7/":UX7TGQ1_P %"K&'6-*L
M=4CL/ALM_:?:H$E^R72ZN0DR9R4D&YMKC!!#8-1?!/P7X>D_;-_: U2/1=*_
MM/39-#EL;O[+&9;5[BRD-R\9VY0RL6+E<%R3D\DT<J%S,^A_#OQ1\*>*O <'
MC72]>L;CPK-:-?#5FF$<"0("9'=FQL";6#[L%2C!L$$5POPS_; ^$/Q?\41^
M'?"OC*WU#69H9)X;6:UGM3.L8!?RS-&@<JIW%5R=H9L85B/G[X3^-O#OP1^
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M</D#G';Z5,DBHRON6:^0/^"C7_(CZ#_VW_\ 1MM7U_7R!_P4:_Y$?0?^V_\
MZ-MJYZO\.7H<&:?[C6_PO\C\\=HHVBC;[4;?:OG;,_G<-HHVBC;[4;?:BS -
MHI4^5L@9I-OM2[?PHL!VGP7^';?%;XG:#X56<VT>H3,MQ(K[&$"1M)-M)5AN
M,:.!D$9(SQFO;_$WQF^+LBW4GAGP')H?PL2*26+3(_"2MI]S8-(\C23D*P82
M1R$R&-U1@20026KRW]F/QII/P[^.OA/6]:F6WTV*XDMYKAW5$B$T,D =V9E
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M;0_VBO#/BCXZ^)?A'#8:M#XCT/3DU*YN+B",6LD3K;L A$A<M_I*C!0<H_7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,G+97/RC)) QW)ZGKS4V.<UG=MW9I:RLA:***!A1110 4444 %%%% !1110
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MO8JJX[G);.?O'OU[>@ ^Y/\ AV7-_P!%*'_@C_\ NBD;_@F5/_T4D'_N!_\
MW11]5JDRX?S:4>64-/\ $?#VY_[C?F/\:-S_ -QOS'^-?<'_  [*G_Z*0/\
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MOBOI[_AS*.?^+LIG'_0M?_==>A_"'_@F'+\*UU)3\2_[6^V>2=SZ(8MFP2#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_&:_*]6=F"A!DG Y_\ K4,SK&6* ;0"RDX*Y]>./3GKVS3^O3_E'_K9C/\
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M"G3@?-QVY^OOQ]*<LP9E 5CGG/3'U!YH DHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MIKMM7.,T .HJ%;C+!2C*3CKCT/O[5+N% "T4QI JECT R:19@S 8;G/;CBCK
M8"2BF22K$N6.!D#\S@5&UVB9!#<?3KZ9[?C1N!/147VA<D?-GW!'<C^E+YP+
M%<-G&>G'YTKK89)14*W4;=#GUY'')!/7U%*MPC!3TSD@'@X'?_/K3$2T5%YX
MR?E;&T,#CKGMZ_\ ZZ<L@90<'GVH#<?14/VI"N1N/ /"GOTIRSHTA3)W#DC%
M'6P>9)136<*N2>*;YPY^5OTQCUH DHJ'[4O!VD*21NR,<?C_ )Q3UDW-C!'<
M>AH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,DSY9V\-VS3Z
MBNB1"VTX8\ ^A/&: /DW]NK]K:3]G'PS:Z%X=6$^,]<BE-K(Y5DTZW^X;DQD
M_O)&9B(U(*EE)(.W8_$^'?V3?VC-7TFW\4ZI^T)KFB>.IG;4VT ,\^G03EBZ
M0-ME\HQ@[ X$+(!N54=0-W%_MQ-_PC?[>'P2\1:BJZ;HZ+I/FZQ>,8K=5BU2
M9YQYK87$:2(S<_*K M@$9_0^+$3&+>V>-F[)(&0",GD],GTR.>];-^ZK(Y5>
M4VF]#A_A/JGBC0OA-87GQ7O-*LO$6FQ7*ZIJ%NZ0V3QPR2*EV"<*@DA196SM
M"[VRL>"B\!8_\% _@'J&H6EE'X]2&:XG6W5KK2[V"-&8@ R220JL:\@EG( 7
M+$A02/GW_@J]XXU[1?"_P^\-VFI7-OH^MRWK7]JA -T\)MS$' &656E8[,["
M=AQE4*^B?&[]C+X4^%OV5_$6GZ9H,%M?^&=&N-5M->C6--2EN+>*297FF5,R
M(YR&C*[ K?($*(5%%/<IU'JD=7^WSK=CKG[%OC74-.NH;W3KJ/39X+RW=989
MXFO[5@R,"5964C!Z$$$9'-2_\$\KB.']CWX>;=K(QU#:4!QN^WW)P.,#N.:^
M/O OB#5-6_X)5_$NWNY<PZ1K<=E8JR+&((#=6$_EAA@N#+/*VXGJV!P !8\8
M>,M7\(_\$K?A[%H>JS:?'K6L7>CZA<0?+)+9M<ZD[Q9Y."T:!NS+N4Y#$5;C
M:'*NY*E[_,^Q]CZM_P %!O@!HNI75C<_$. S6TKQ/)!IMY-"2A(8I*D)1U^4
MD,K$%1D$CFO</#OB[1_%VCV^K:#J=IK6EW 8PWVGSI/!*58HP5U)4D,I4\\$
M$=17RG\"_P!B_P"%/B#]E_PY87GAN.:]\3:-;:G=Z[(D;:E#<3QQS9AG*$QK
M&VT*GW<1_,KEY"_F7_!(W7M5O/#OQ)T*2X/]BV=SI]Y:P"(+LDFCFC=LYR,I
M;6XV<J-FX ;VJ>16N"J-GTW+^W!\%;?P;!XIF\:I!HTU^^FQR2Z?=),TZ1)*
MX$)B\PJJRQ9<*5!E09RPSVGBCX_^ O!/PWTWQ]KOB*'3?">IPV\]C?30R;[E
M9U#Q".$*968J=Q4)N !) "G'YH?\$Z_V;O _Q^OO'=WXWTR35XM"6S6TLTGE
MAB7SVE+O^Y9'W?Z,H W8PS A_EVS_M"6?B/6OVT=&^&?A7P_I_C&P\&06=AX
M8\'ZY,7L4MX],AF*.&EC\P9$CL99"7\A5<LH"4_9J]@]H[7/T.^%O[6OPC^-
M&K+I?A#QK9:CJCA3'83Q2VEQ-F-I/W<<Z(TF$1F;8#M R<9&>@^*7QU\"?!7
M1EU/QOXCM/#]M(K-#',3)/<A616\F"/=)+@R)G8K;0P+8'-?FG\1_P!F7]H;
MXB>(]#UVP^#7AKP'J>E$.EYX)O[;2_,Q+YB2$+?.-ZD B1=K<C)( 5.Q^*>B
MP?&#_@J9I?A/Q0YOM"TM;5(+5HXFC,,&GF_^S2JR$-&\S.7+9+(Y3(P,/V2[
MA[9O2Q]?:?\ MQ?!'6O#_B/5[3QU;RV'A^"*ZU(FQNA)%#)*D22+$8@\J;W1
M2T:L%WKNQN&?E;X(_P#!0Q4_:$\</X_^(0/PJS??V$1HZ@)B['V;/D0>=S!Y
MA_>=UYK[(L_V8?A-INM7FJ67@#P_937=A_9MQ:P:>J6<L/G). ]J,0LPD2-O
M,*;OE49PH ^&/V3_ (<>&/$'[>'QDT+5?#>EZAH5E_;?V?3;S3XI+6U":G;K
M$$B9-BX5G^Z!PW<&DN6S!N2:N?<GC7]K#X4?#OPSH>N^(?&%MIUGKEK%>Z?!
MY$TMW/!+&TB2"VC1I@A53\Q0#.%SD@%?AC^U=\)_C-JS:5X0\:6.K:D0#'9R
M));R7 *R-^Z655,N%B=FV!MH&6QD5\U_M8?&'X-_"GXM>'M$7X/6/Q-\?)I-
MKH]CHZQQ&TM+1G=H;-8<2J+@.(BD:P!PDPVMAMK?,LWB9[C]M[X6:G8?#"]^
M"-W=ZMI<$^CJ)K7[3')=>0\R1O%#M62,&,A$ .R3))9B2--238I56I6/:?VS
M!*W_  4,^!AQY@;^P=V"0G&K3[3T88^9O3HOX?HU#&0Q;C&<#!(. #U_'-?G
M-^V4-O\ P40^!F[EF.A$8QQ_Q-IN,XR>A]*_1V'[OXG^=9SV1=-N['U\@?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N6^*GC)OAU\,?%O
MBM;7[<="TFZU3[*7V";R86DV;L'&[;C.#C-=37F/[4'_ ";7\5_^Q3U7_P!(
MY:TII2FD^YG4;4&T?#,?_!9([5_XM'M&!\J^)>!P.!_H?2G_ /#Y3_JD9_\
M"D_^Y*_-5?N#_/84JG'6OT/^Q<'R)V=SYN6*JWW/U-^&O_!6$_$?XC>%?"8^
M%YT\Z]JUII?VO_A(3)Y/G3)'OVBV7=C=G&1G'6OT"AC$'S$@DD OW;L"<=_P
MK^?K]F<?\9(_"@]O^$LTG_TLBK^@AE#*58;E.,CVS7R><X6AA*L8TET/8P59
MUH^\>8_M(?M!:%^SC\,[CQ5K$,U[+)*MGIVGP?*UY=,KLD1?!$:;8W9G(.%4
MX#-M5OEKPOXJ_:]_:4@7Q?X2OM!^%OA"\@632[74XT>2\MVDD,<I+032[MH
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MEC_NK_WT:/LL?]U?^^C7XY_\+R^)'_10?%/_ (.KK_XY1_PO+XD?]%!\4_\
M@ZNO_CE<'UR'8^"_UNPG_/F7X'[&?98_[J_]]&C[+'_=7_OHU^.?_"\OB1_T
M4'Q3_P"#JZ_^.4?\+R^)'_10?%/_ (.KK_XY1]<AV#_6["?\^9?@?L9]EC_N
MK_WT:/LL?]U?^^C7XY_\+R^)'_10?%/_ (.KK_XY2K\<OB0QQ_PL'Q2/^XW=
M?_'*/KD.PO\ 6["?\^9?@?L7]EC_ +J_]]&C[+'_ '5_[Z-?CJWQQ^)"_P#-
M0O%!_P"XW=?_ !RD_P"%Y?$@_P#-0?%/_@[NO_CE'UV'8/\ 6["?\^9?@?L7
M]EC_ +J_]]&C[+'_ '5_[Z-?CI_PO'XD?]%!\4?^#NZ_^.4?\+Q^)'_10O%'
M_@[NO_CE/ZY#^4/];L)_SYE^!^Q?V6/^ZO\ WT:/LL?]U?\ OHU^.B_''XDL
M0/\ A8/BGG_J-W7_ ,<I1\</B2<?\7!\4\_]1NZ_^.5/UV'8;XNPBWHR_ _8
MK[+'_=7_ +Z-'V6/^ZO_ 'T:_'3_ (7E\2 ?^2@^*?\ P=W7_P <H_X7E\2/
M^B@^*?\ P=W7_P <I_7(=@_UNPG_ #YE^!^Q?V6/^ZO_ 'T:/LL?]U?^^C7X
MY_\ "\OB1_T4'Q3_ .#JZ_\ CE'_  O+XD?]%!\4_P#@ZNO_ (Y1]<AV#_6[
M"?\ /F7X'[&?98_[J_\ ?1H^RQ_W5_[Z-?CG_P +R^)'_10?%/\ X.KK_P".
M4O\ PO+XD?\ 10/%7_@[NO\ XY36,A?87^MV$_Y\R_ _8MK:-5)('_?1I!#!
MNP5_\>/^-?CK_P +R^)+$ ?$'Q3SQ_R&[K_XY7+?$C]H+XH:?X?CD@^)'BZW
MD:Z $D6NW:L%V$@9$GM73A*L<765%*S>QUX;BC#8BHJ2I.[]#]M?L\']W_QX
M_P"-'V>#^[_X\?\ &OY_/^&G/B]_T5CQQ_X45[_\=H_X:<^+W_16/''_ (45
M[_\ ':^N_P!7JW\R/H?KU'^7\#^@/[/!_=_\>/\ C1]G@_N_^/'_ !K^?S_A
MISXO?]%8\<?^%%>__':/^&G/B]_T5CQQ_P"%%>__ !VC_5ZM_,@^O4?Y?P/Z
M _L\']W_ ,>/^-'V>#^[_P"/'_&OY_/^&G/B]_T5CQQ_X45[_P#':7_AIOXO
M?]%8\<?^%%>__':/]7JW\R#Z]1_E_ _H"^SP?W?_ !X_XT?9X/[O_CQ_QK^?
MW_AIOXO?]%8\<?\ A17O_P =I/\ AISXO?\ 16/''_A17O\ \=I?ZOUOYD'U
MZC_+^!_0']G@_N_^/'_&C[/!_=_\>/\ C7\_O_#37Q>_Z*QXX_\ "BO?_CM'
M_#37Q>_Z*QXX_P#"BO?_ ([1_J_6O;F0?7Z'\OX'] 7V>#^[_P"/'_&C[/!_
M=_\ 'C_C7\_G_#3GQ>_Z*OXX_P#"CO?_ ([1_P -.?%[_HJ_CC_PHKW_ ..T
M_P#5ZM:_,A_7J/\ +^!_0']G@_N_^/'_ !H^SP?W?_'C_C7\_G_#3GQ>_P"B
MK^./_"CO?_CM+_PTU\7O^BL>./\ PHKW_P".T?ZO5E]I"^O4?Y?P/Z OL\']
MW_QX_P"-'V>#^[_X\?\ &OY_/^&G/B]_T5CQQ_X45[_\=H_X:<^+W_16/''_
M (45[_\ ':/]7JW\R#Z]1_E_ _H#^SP?W?\ QX_XTC6\&.$)^C'_ !K^?W_A
MISXO?]%8\<?^%%>__':7_AISXO;@?^%K^-S@YP?$-X0?;_6T+AZM_,@^O4>D
M?P/Z !;P\?*3GW/I]:401%L;#_WT:^/_ /@EOXV\2?$#X!Z[J/B?Q!J?B+48
M?$T]N+K5KN2ZD6-;2U(16<DA078_B:^R /SKYVM2="JZ3UL>G!1J04TOP(?L
M<7]W_P >-*MK&K9"\^Y-3;:-IK#E1KRKL1-"/0#Z40PB-L@\GKWSR3U]LG\Z
MEP:-HSFJO?0K4=1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKQ]\+_CI\2/'WC+6/A3^T#IOBZ*XU&XU*R\+^%_B#.;J"QDNB4 C+"%!$LZ
MC>$ 7"Y)4'\^U8M&7E187=6"Q*0G!'8YP0#O'!..G<XY,%BZN(O=K3H=-2BX
M:VT+OAWPSK'C#6+?2=!TN\UO5+EF$%CI\#3SR[5+L5C4%B BLQXZ ^AQ:\8>
M!?$OP]U*/3_%7A[5?#=]+ +B.UU:RDMI7C)(#*CJ"1N!7<!@D$9X-?3WP%L?
M&C_L7^-;SX.OJW_"<W'BZRM];;PS<M+J8TA+4M 8XD/FHOVJ63F)%=AOW,4C
M?&[XI\,?$WQQ^Q!X[U'XR:1K5G=^"=8L9_#.J^)+9XM5E^U7 AN[>62?][)
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M3\,W[:IID-W-9"]6WD2&:2)MLAA=U FC#?+YL>Z,D$!B00.FKB?A':^$-.\
M:%9^ GTUO"5O$8['^R;A;B#8&<.?,4MO8R*Y=BQ8OOW,6R3VU9F@4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !112$XYH 6BF[N <&C=0 ZBFE@*;YR\XR3
M_/Z4@)**C,P&!@Y/;TIC706/>8WQUZ#IQD]>V?KQTJA7)Z*C696.!GZXXI^Z
MD,6BDW4C.%7)!ZXX&: '45%'<)-]WG@'/;D9Z]ZH^)/$^D>#]%N-7UW5++1M
M*M]OG7VH7"6\$6Y@J[I'(499@!D\D@=30!IT5D^'/%6C^,-)M]5T+4[36=+N
M-WDWVGSI/!+@D':Z$J<$$=>H-:M'D M%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !2-TI:0T -8[5'7KV&>]?
M+'[5>H:IX4^._P "_&MIX0\3^+M)\/C76OX_"^F/>SQ"XMH88FP,*/F8M\S#
MA&QDC!^IV4[?EZ_7%1>0V3M(3/\ =QQV';THCHR))M6/DK05U_X^_M.?#CXC
MV/PUUGP)X;\&VNIVFI:IXNMHM/O[^26W\N*W2V!:7RXS-YB.Q"'S+C[K >92
M\*> _B;'\%?VDM-\'Q7WAGQKK'C_ %F^T.:\C>S>YMW>W.^"1UX$L:RHDPPH
M9@0ZXW#[!CM2C-DJP/ X(./0G)S_ )XIZPE<$]0 !_G'_P!:KYB>0_,C3_A+
MX>C\9_"&Y^&GP$^)'A:YTKQAI']M^)/%=K<+(]N) 6;R1*Z,K8=WF142+9T
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MBV[1Y(D=R1SN8]>Y_P#K=..V31S,?(CP+X-^%]4TO]K#]H'6KG2;VUTG5?\
MA'_L-_/:/'#=>592)+Y4APLFUMJG;G!..]?0?\50PV^QE)50%Y&.<$]:GQSF
MI9<=@KY _P""C7_(CZ#_ -M__1MM7U_7R!_P4:_Y$?0>,_Z_C_MK;5C5_AR]
M#SLT_P!QK?X7^1^>.T4;13>?^>;?F/\ &CG_ )YM^8_QKYKF1_/%AVT4;13>
M?^>;?F/\:.?^>;?F/\:.9!8=M%.C4,V.>01\N"3QTYX_.H^?^>;?F/\ &E7<
M,_NS@C!Z<@\$=?2CF06/??@['<_%;X(^)_A5H>IPZ;XD;45\06-G+<E3J\:1
M!'M^0JHR^5&X+$Y=02%5=XLZII>M_ OX'^.?!OC:3[%K?BR>QFT_0H;Q;CR!
M!-YD]TX1V2)'544-NWNT9^3"%J^?$9EP&W.<CYV12<=.>>2!QGT)&*2#%NK(
ML7'RA9"%+$ $?-SS].>@P1@[NA5ERV>Y[ZS%^R<;>_9QO?2S_4]$B^".N1_#
MOPGXY;5-)L-$\0:JFEP3S7+(;5C)*GG3DIL2$>2Q+!B<$<<X':^&?V6?BGH&
MK+JVGW.F^']-LHY+J'Q<GB"."T6V$3_Z0)8F,JQ-&.NT##C.!NQX&I?<)/+\
MF8# :,@@<=0"<@DM)W/WJD38&53$XC51PK_Q#H<9QD E?H!QVHA4@B*>)PM-
MQE*#NNTCT3X_^*-#\=?&3Q3XA\*PS66E74\=Q')';B%Y)8XUWS&+;NRS*\GS
M%3W8*6R.D\17 ^!7PZN?"<8DC\9>+-/M;G6;E%"2Z1:G#QV   =)I$4&99/E
M"[5VONW5XHI?[[([2@K@EP3A?N\^P&,>AX(QRXDI&H1&) VB/(5!US@9Z$GI
M^O-$:RC)LS6,E"<ZWVY?<K[_ / /M3X@:H=WQ,\4WFM6Y^#FL>%?L'AB&:\$
ME@;WR(%ACALO,)2198IOE$2LAB;.,-GXK; 902I!C4@Y!.2,G(_A/M3XY!&T
M1$4A,?W7\P CH0>Y/.[@G'(_NBH]SJBJ%R>=[;5#/DYR3GK14K*H3CL8L8T^
M6UO^'_X ;11M%-Y_YYM^8_QHY_YYM^8_QKGYD>38=M%&T4WG_GFWYC_&CG_G
MFWYC_&JC)70[#XP-Z_4?SKCOBQ_R+-O_ -?2_P#H#5V,:MN!\MNOJ/\ &N/^
M*REO#-MTS]H5L9&?N-7L9-_OU'R9ZV5_[Y \AHI=IHVFOW2S/TL2BEVFC::+
M,!*Z[X2_#F[^+GQ&T/P?8:EI>DW^K3&"VNM9N3;VWF[&9$+A'(=V4(@"DEW0
M <UR6TTH4CH2I]1U'N/>HG&3BU#1E1M=7/KWX1_L>^,/@Q\3/#7COXO2Z/\
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ML_"7DR2+!=6R&ZEVW#VRQJB.REI)% 7Y\8=2Q49Q\Y_#7]K[X-:KXL_X6/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#)%.V&\@5#AQ_:C][."_X=ES?]%(_\HG_W11_P[+F_Z*1_Y1/_ +HKOO\
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M_P"43_[HJU_P]V^#VYE_X1KQQE>O^@V?M_T]^])_P]X^#O\ T+7CC_P!L_\
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M ,ETO_#WCX._]"UXXS_UXV?_ ,EU='*\31FJE.D[^AM3RK*:,E.$4GZGF?\
MPYH'_16E_P#":_\ NNC_ (<T#_HK2_\ A-?_ '77I?\ P]X^#O\ T+/C?_P!
ML_\ Y+H_X>\?!W_H6?&__@#9_P#R77L.><+=/[CTN3!=SS3_ (<T#_HK2_\
MA-?_ '71_P .:!_T5I?_  FO_NNO2_\ A[Q\'?\ H6?&_P#X V?_ ,ET?\/>
M/@]_T+/C?_P!L_\ Y+I\V<=G]P<F"[GFG_#F@?\ 16E_\)K_ .ZZ/^'- _Z*
MTO\ X37_ -UUZ9_P]X^#W_0L^-__  !L_P#Y+H_X>\?![_H6?&__ ( V?_R7
M2]IF_9_<+EP/<\S_ .'- _Z*TO\ X37_ -UT?\.:!_T5I?\ PFO_ +KKTO\
MX>\_![_H6?&__@#9_P#R71_P]Y^#W_0L^-__  !L_P#Y+I\^<=G]P<N"[GFG
M_#F@?]%:7_PFO_NNC_AS0/\ HK2_^$U_]UUZ7_P]Y^#W_0L^-_\ P!L__DNC
M_A[S\'O^A9\;_P#@#9__ "71SYQV?W!RX+N>:?\ #F@?]%:7_P )K_[KH_X<
MT#_HK2_^$U_]UUZ7_P />?@]_P!"SXW_ / &S_\ DN@?\%>/@\<#_A&?&_\
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MV<RU@Z'1'A7[('[,?_#*OP]U3PN?$?\ PDWV[59-4%U]B^R^7OBBC\O;YCY
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*Z*G)+9GK8ZI2Q<HKG2<4[M*R?DA_P .?%_@'0?#\]OXH^''_":WC2L?MO\
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MX2K,BJNZ3.&()/@GB3XF/K'P_P##'@ZQL%TO2-'\VYG*R;Y+^]E)WW,A 4<
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M?[0U.=)C>F.VF66"-2)1& K"0Y,98^:03A4 X"-@JD[5#,F"$0*@.-O"C '
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M9\2O$4VKZK\4/B8I_M1M9M+*+Q$OV;3KK<6C:U1H6\GR]S",@Y0$@5Z-X/\
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MDDNQ+,68L22370UE+<TCHA:***"@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@K?\^XA_9J[G\^__  S'\8?^B4^-O_"=N_\ XW1_PS'\8?\ HE/C;_PG;O\
M^-U_01Y:_P![_P >-'EK_>_\>-'^L%;_ )]Q#^S5W/Y]_P#AF/XP_P#1*?&W
M_A.W?_QNC_AF/XP_]$I\;?\ A.W?_P ;K^@CRU_O?^/&CRU_O?\ CQH_U@K?
M\^XA_9J[G\^__#,?QA_Z)3XV_P#"=N__ (W1_P ,Q_&'_HE/C;_PG;O_ .-U
M_01Y:_WO_'C1Y:_WO_'C1_K!6_Y]Q#^S5W/Y]_\ AF/XP_\ 1*?&W_A.W?\
M\;H_X9C^,/\ T2GQM_X3MW_\;K^@CRU_O?\ CQH*+Z_^/&C_ %@K?\^XA_9J
M[G\^_P#PS'\8?^B4^-O_  G;O_XW1_PS'\8?^B4^-O\ PG;O_P"-U_0)N7J
MQ'3.[_Z]/VK[_P#?5"X@KM75.(?V;'^8_GX_X9C^,/\ T2GQM_X3MW_\;I5_
M9D^, 89^%7C8<C_F7;S_ .-U_0/Y:^O_ (]_]>C8!R.3[O1_K!6_Y]H/[.C_
M #'XG_LS_ 7XFZ'X\O;C4OASXMT^WFTME2:ZT*ZC3=YD?R[FC S\A.*^F?\
MA5?C+_H4M<_\%TW_ ,37Z+[?FX'RCD;6Y)IP=?FY.%.#UKBJ9O.H[N".RGA5
M36C/SF_X57XR_P"A2US_ ,%TW_Q-*/A7XRR/^*2USGCC39C_ "6OT9&&('.?
MQH:,2+M_^O\ SK'^U)O9%^P\SS?]G/3+W1?@[X>L=0LKBQO(_M'F07,9C=,W
M$A&5.",@@UZ9W%1)$RMDMD$<KZ' Z?K4N.:\J3YI.3ZG3;E22%HHHI#"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2FF4;M
MN&)]AD?G1,2(SM^]T%>#_%3]H:]\+^.(O _@'P-??$OQ="1-J>FV-TMI::5;
MO%))&UU=.K1123;&V1O@LJD\;H][L*Y[PLA9L;&'KG''3_']*?7EGP;^+UYX
M^;5M(\2>$[SP-XQT/R7U'0KF1;B)(9Q(;>>"Z0".>-A'*A*'*O#(K*-HSZ:+
ME6^Z"W&>F,^W/?BBS#F1-14+72*VW#$CD[5)P/7_ #_C2_:$Z'A]I;82,X'7
M^=%@NA[N(U+,<*.2::LZ.P4'+8Z @_7_ #[U']J5U(&5/\.2,-Z$<]#BN;\#
MZ]XCUI_$'_"1>&?^$;6SU:XM-./]H1W?]HV:;?*N_D_U6_+?NF^9=O-(9UE(
MS!1D]/I4/VN/H#R>@/&3SQSWXI)K@*K9! 4C+=L9Y/'/K^5 KCOM*\8#,I.
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MZWBO^?DOO?\ F=Q_PO/XE_\ 10O%/_@[NO\ XY1_PO/XE_\ 10O%/_@[NO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^';WPU_Z#?B?_P "K;_XQ1_P[>^&O_0;\3_^!5M_\8H^JR#_ %5S/LOO_P"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHIKN(UW')'L,T .HKD/%GQ?\
M W@/4HM/\2>,=!\/:A-%Y\5GJNIP6LTD>2-ZI(P)7*L,@8RI'8UT&EZY8ZYI
M=IJ6G745_IUW&DUM=VS"2*>-P"DB,.&1@00PR""".#FF*Z+]%1M,!G"LQQD
M8Y^E-6X5F*E2I'7=CCG []^U(9-144<XD"':RAAG)QQTXZ^_;CBD-TBL5.X$
M=<C'&<9_.@":BHEF#?PL.<#/?IS^M+YP'4-N_N@9(^N*5T!)147VA<D!6/3H
M/6D^U+SD$#..2/3/KZ47'9DU%,$RDJ.06Z#'U_PIV:8B*\M8;^UFMKB))[>9
M#')%(NY74C!4CN",BOE?]J_QWI'[*_\ PBWC_2_"EE>-IZW:RZ?8E+#[1YA@
MA7<ZHWW1+GE3]W'&<CZMKX=_X*N_\D7L?^!_^E-I73AH1J5X0ELVC*K)QIRD
MMTCS+_A\H?\ HD9_\*3_ .Y*/^'RA_Z)&?\ PI/_ +DK\U=Q]:-Q]:^__L?!
M?RO[V?._7L1_,?I5_P /E#_T2,_^%)_]R4?\/E#_ -$C/_A2?_<E?FKN/K1N
M/K1_8^"_E?WL/KV(_F/TJ_X?*'_HD9_\*3_[DH_X?*'_ *)&?_"D_P#N2OS5
MW'UHW'UH_L?!?RO[V'U[$?S'Z5?\/E#_ -$C/_A2?_<E'_#Y0_\ 1(S_ .%)
M_P#<E?FKN/K1N;MDFC^QL%_*_O#Z]B/YC]*O^'RA_P"B1G_PI/\ [DH_X?*'
M_HD9_P#"D_\ N2OS59]F06Y'8<YYQQCK3BKKD_P;M@<$$,?;UXYIK)L$U?E?
MWC^NXC>Y^E'_  ^4/_1(S_X4G_W)1_P^4/\ T2,_^%)_]R5^:WS>HS[D#/MS
MWI=KY(7+[?O;?X1ZGT'\^V<BI_L? _RO[P6,Q#V9^E'_  ^4/_1(S_X4G_W)
M1_P^4/\ T2,_^%)_]R5^:[*R2(A/+@%.#EO8#K^.,<]:126SL)<A=S!03M^O
M'ISGICO0\GP*T<7]X_KF)M>Y^E/_  ^4/_1(S_X4G_W)1_P^4/\ T2,_^%)_
M]R5^:QRO#':V 0K<$@_U]NOM2;CZT?V/@?Y7]Y/U[$=S]*O^'RA_Z)&?_"D_
M^Y*/^'RA_P"B1G_PI/\ [DK\U=Q]:-Q]:?\ 8^"_E?WL/KV(_F/TJ_X?*'_H
MD9_\*3_[DH_X?*'_ *)&?_"D_P#N2OS5W'UHW'UH_L?!?RO[V'U[$?S'Z5?\
M/E#_ -$C/_A2?_<E'_#Y0_\ 1(S_ .%)_P#<E?FKN/K1N/K1_8^"_E?WL3QU
M>VK/TJ/_  64W8'_  J,CD9/_"2?_<E?27[%_P"V*?VLY/%F[P@OA;_A'A:
M$ZE]M:;[0)2>?)CVX,/OG-?B(F*_2W_@C7][XO?]P?\ ]!O*\K,\MPV&PSG3
M3NF=>%Q-2K5Y9/0_2RBD)QSC--\P>A/X5\8>Z/HJ*.X63  ()&=K<$#W%/D?
MRUS@GMA1F@!U%0-=+&P#C9GIDCF@7:,CL.0N0V",#'7)S@4#)Z*A-P!G*MU
M[>N/7M3UD#' SUQ0(?1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN_\ XW1]8H_SK[P]E4_E9YI17I?_  S)\8?^B4^-O_">N_\ XW0/V8_C"?\
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MOKE1%^\:X+QQ&)$=%(NI5R6+ ;<'(R?9Z*+LGE1\QZ9^P3X8M]/L]'U3Q_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH>26/S/N;MT892K*58\@>R_ 7]H3PK^T9X%'BKPI]NCLEO)+">WU*$0SV\Z
M-L=0Q&2CQN-I/#C."& MQ:W)4E+8],HJ'[4GRY##=TRI'8'&/Q_2E68-CY&
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MW7A_7]!^,WP\.O\ B4>(5F741#_H,=KY#"W7>WR9W;SR>1BO=*^0/^"C6?\
MA!]!P >9^HR/];;5$Y<L7(Y<56^KT)UK7Y4W]Q]:[HO^>H_[Z-&Z+_GJ/^^C
M7X>;F_NQ_P#?"_X4;F_NQ_\ ?"_X5YWUS^[^)^>_ZXQ_Y\O[S]P]T7_/4?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %(W2EI#0 ?PU^<'[%_\
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MYM%W6A+1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]J9M_P!K^=8X?"1PTG*+W*J5'-)#:*=M]Q^M&W_:'ZUVG.,D^Z?I7WG\//\
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M HHHH *1FVJ3UI::R[E(X_$9H P/%GC[0_!&GK>ZW>&RM6G^SK)Y+R;I-I;
M" GHK=NU>'_$#4_ ?[1?CSP1X>$SZ]H_^F_;(42XMO\ ED)(_G 1AAH0>".P
MYR17T48"V"QR>"6!(Y'H.U/\LF3<2#Z<<C\:-]&3*,9Q<9*Z9X1_PQ%\'/\
MH59__!K>_P#QZC_AB+X.?]"K/_X-;W_X]7O.TT;34>SAV/._LS!?\^8_<>#?
M\,1?!S_H59__  :WO_QZC_AB+X.?]"K/_P"#6]_^/5[SM-&TT>SAV#^S,%_S
MYC]QX-_PQ%\'/^A5G_\ !K>__'J3_AB'X.,,'PK,1_M:K>X_]'5[UM-&T]J7
MLX=@_LW!?\^8_<?-EY_P3L_9_P!2NGN+OP%YTS$?/_;.H#HH'_/?VJ+_ (=O
M?L\?]$^X_P"PSJ'_ ,D5],8-&TUV+$UXVC&;2]3KCAZ25E&Q\S_\.WOV=_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img192321128_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_17.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X2WV17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(R.C R.C Q(#$S.C$U.C U   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,U.0  DI(  @    ,U.0  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,CHP,CHP,2 Q,SHQ,SHU-0 R,#(R.C R.C Q(#$S.C$S.C4U      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  '$D         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ =@$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M$:ON& JJ/G="1T^Z!@<<UD:-I6NW=_XSMKFYDD61GCBC-R=HW>81C"DXY!P
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M;RK)(UI:@'Y7;)=L$R?=[+_%SP":1E4G9<JW=[#+/PVT&O>&[>1L9M%=Q]D
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M&0(@"E2J_)NPRLP//\7&" 0 9>O:/H7AO0;>>YD ,-[ 8I[EQN7]XG P!T1
M.G1><G)J#Q/XYD>/[-X4N+>ZO(<S3L678L:HS$9/<X&/_P!>!$RO;W=S1N5\
M8:I93*HL+&.2+Y$R3-DCHQ^9 .QQGV(K#N/!/B&]2$M?P6R^<TAM[=VCC@RR
MX*!>"<!AA@1\QZYH(G[2_N[&GHW@)+'5+Z:]G6YMI3^[0?*6R<GS H"DYZ8
M J,_#J%(M?"7TTAU1PT:&5E6$!BVWOD9/I_C3B[$K#Q4;>OXEZ'P38)?:3/+
M!YWV*V$.Z6Z=R<# XQ@@<_W1STX%7#X5TT>);758M.M$,,+)N4E3N/0[0,'
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M3$ "> <*#Z9- #P?'"V.M?:3:%UM)18?9XQN>0#Y&)+<,>?EQC[O/454E/Q
MCO))8FM1:,Q^9DWF- 3C" [B=IR>Y*@8YH M1S>,Y#8RRQQA)VADDC1 ODYE
M0NAY);$1D!)QRJXY-=I0 44 %% !10 44 07DDT-G-+;11RSHA*)(Y16([%@
M#@>^#7)6?Q!A;2[>YU'398I9D$@BM7\X*I2-URS!.2)4& .N><#- %RV\<Z9
M?6-U<V"32BWN8K=MZ[ 2\FS(// .??CIR*S+7XK:#<RD-',JLY\HJ4<F,1"7
M>P!RHQN]?NG.#Q0!J6OC:PU"ZA@M8)B'>(.9L(0DB@JRKR3RR \#&[VQ73
M=!B@ P"<D"EH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH *B^S08
M\F/ X V#V_P'Y4 ->RM9(C$UO$4+JY7:,;E((/U! (/L*9+IMC/"\4EI"8W!
M##8!D'K^= #FL;5Y8Y6MXR\;!E;:,@@$#\@35B@ HH ** "B@ HH __9 /_A
M,>AH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I
M;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\>#IX
M;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X;6QN
M<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A
M>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B
M9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z>&UP/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX\>&UP.D-R96%T;W)4;V]L
M/E=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P,3$N,38S.#0\+WAM<#I#
M<F5A=&]R5&]O;#X\>&UP.D-R96%T941A=&4^,C R,BTP,BTP,50Q,SHQ,SHU
M-2XU.#4\+WAM<#I#<F5A=&5$871E/CPO<F1F.D1E<V-R:7!T:6]N/CPO<F1F
M.E)$1CX\+W@Z>&UP;65T83X-"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(#P_>'!A8VME="!E;F0])W<G/S[_VP!#
M  ," @," @,# P,$ P,$!0@%!00$!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+
M$!80$1,4%145# \7&!84&!(4%13_VP!# 0,$! 4$!0D%!0D4#0L-%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!3_
MP  1" +\!G(# 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%
M!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q
M%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(
M24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*C
MI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ
M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEB<"J/A[QEH?BHS_ -DZQI^J-;D+*ME=1S>63G ;:3CH>OI0KBYD;A8+U(%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH 2H+IF6)RH!;' /0GL/QJ=NE07,@AB:1AD*-V![4UN)ZZ'YQ_\
M!0C]LK6]'U^X^'7@J]^Q1VO&L:A:S 2JP'S0J>V.Y_"O(O@__P $[/B-\8]#
M3Q%K&HP^'+2[7S(?[6$T]U(A&=Q7L3G\C7C]FMQ\6OVE[=-6;[1)K7B.+[5W
MW1M(=_X$/^AK]T-/LX=/T^UM;./[/#$JQHFW&U0, ?D*ZYR]G%6.2"YFTS\;
M?CU^Q?\ $/\ 9DTV'Q#;W:7>C6YW?VMI4DL4EJ3A=[@_=^\.O7.*^J_V ?VF
MM4^-7AW6?AIXRO#J&HV]HS6VH%MDEQ:-B.0-Z.N[-?6GQ\\,V?C3X/\ C#2;
MN%9XI=+G W#*AMA*L?H0#^%?DA^PSJ]UX?\ VK_!$-K-M:XN9K6X /R21F-_
MESZY4'\*4/WB<GT";Y+1[G/V=Q?_ +-/[5,CY:UN/#^N['4RNXE@\P*ISG',
M3OFOV_TF_AU32[6^LWCFM[B,21LK JZL PP1UX)K\NO^"I'PQ_L#XJZ1XNLX
MDBMO$%F8)F5<#SX\J6SZ_.A_"OL?]@[XI#XF?LX^'9+J97O],_XETP5@6^0?
M*2.O(''J**R]I!-!1]V;3/(_^"I_Q*&C_#/0/!UO([3:M>B>ZCB?#-!#C<O7
MN6!'KMIW_!-OP+#\//@AKOCK62L-OJ,S727%P<JEI"O+YSU^1S^-?+W[<OBZ
M7XT?M5?\(_IDLES#920Z-;+#EPTS-AV7'7.>W]T^E?;G[1FGK\#_ -AW4M"T
MAA;FUTJUTXL#C#2LL<A/IG<:<HJ/*EU,[R;D^Q\)?M0?M2>+OVFOB+_8?AVY
MU"#PQ]M%KI.EZ?*4-^V3B20+S_"3M_V3Z5Z+X8_X)8_$'Q#HL6H:QXDTK2+N
M50YT]X9)6'LQ['UKF/\ @FAX3LO%7Q^:^NK2.X72=+EU.V29?E64LL8'U7S7
M^A-?KM'E=N",LV6]\@]*F;]F[(JG[ZNS\_\ ]BGX(_%WX!?'BZT/Q'9WA\(W
M-G(YO(6+V0< [ "20&)QQUK[J\:>)8/!OA/5]<NIH88-/M9+EVG.%PJDX_'I
M]2*V)(Q@L3CCKZ5\A_\ !2[XK#P3\"UT"WNQ!>>)+K[,=K#>MO&5,Q ZXQP3
MVS647[21T_PXW/S!\6W^N?%+Q1XL\8O;WE[$+AM1NVC+YACE;"DKV &.3T%?
MH+_P2O\ B@VI^%_$7@2_F$EYH\GVFV:3&XPL0#@YY +#\ZY__@GS^SK:>*/V
M=_'-_J=L GBJ-]/MII.0UNGW6!_W@/R-?-G[(7C:_P#@'^TUHMM?NT4<UX^E
MZA'+\A*R%T4$'I@A&YKJMS)HY$^5W[G[.:YO&BZ@8^7%O)M^NTXK\(/"O@:\
M^,7QP?0$U2*SNM:U:1GN+A)9E.)"1@YQT!K]W]1^;2KLD\>7(<]B,''Z5^%G
MP=\;Z?\ #OX]:+XBU9BFFZ9J37$Y"%CM7=G@?45E22LS>KNCWKXI?\$V?&_P
MO\)ZCXAT7Q/8^(/L*27+PQ1R03)$#DLISV&3GVKH?^"=W[2WBIOB59> O$.I
MW6M:%J416S?4+F266V>/. K,!@'I[UZ?\;_^"E7@?4/ &LZ9X/L-0U/5]5LW
MM+9[N Q1)O0AC@]< G\<5XY_P3A_9]\2:W\7(_']]I<EEH&F)(8[RY5HWN)S
MV52/N\]1Z5;^'4QCK+<^O_VW_ OQ+^)?@OP]H'PXEG22ZU%HM2>&8VR"''+2
M-UV@CMU/'>OEF3_@DYXFM_#=S=MXVT^?6XX=\<"V3LN[8AVJ['/."I;WK](O
M'7BVS^'O@_6/$=\DDEEI=K+>2K"/F8*"Q ]SBOA;QI_P5@T";P_./"OA34?[
M0N$ BEU62*-8]PZX0GIU^:LJ4IK2)O4C"UY'Q[^SW\2?%'P&^..FQQ7UQ;%-
M333]2L('#P3?-M(QDXQG.?;%?N%83)-&C _ZU?/53U4-@X/YU^/G[&_P O/V
M@OBY;>*?$&HZ9;65OJ+:G<6R7:?;+N0/G'DYW!0<<XQ7["VB.D05MN%+(NW^
MZ#Q^5%;FNN9BH<MFHK0GD&Z-ADKD8R.M?%7_  4(_:XO_@[IMIX*\'WL=KXF
MOT$EW> AFL8,94X[,V!@'J#7VL<8YK\1OVT]=O?&'[4/C-)9!)+#J"Z7'DYV
MB-O*'\JFBN9ZEUI\BLC<^!/[&?Q#_:;M)/$[W:Z5I-VY U'59))GF;=EV12<
M,#UR.G2MWXT?\$Z?'OP9\.W7B?2[VW\56UGNDN?L<<D,\48'WUP<_+USZ U^
MIWP=\.V?A/X:>&=+TZV2VLX-.@ 1!CYR@+G\371ZQIMMK.F7=A>Q^=:7,+PR
MQXSN5E((_(U7MKRY;&7L].:Y^;7_  3Q_:^\07'BFU^'/B^_EUBQO$QHUS>,
M#-&X1F*$]\A2!7Z/7/B71]-G>&[UBQMY(<;XYKE$9"<  @GC.X8^HK\,]%AD
M^'G[2VGVUG.UM)8>)=D)0X81M-M3\,$CZ9KV[_@I!X)U+X>_M#1^(]/>X2W\
M0P+=P.)-ICFC CD .[IPIZ?Q#UK25--KS$JCCH?KDLR-G#J<#)P?P_H?RJE>
M^(M*TV01W>IV=K)L\S9-<(AVCJV">GO7F?[+OQ.A^*GP-\)>((YO/D>R6VN&
M;J98OW;G/?YD8_C7Y9?&K7M2_:0_:\N['3[J>XM+[51I=G'#*Z>5$I.]@ <$
M?*QS[&L53^+R-Y5+6\S]HI+JW^R&X:=!;;=_G!QMVXSG/IBN2_X7%X&34A8+
MXLT;[;_SS;4(=P_#=7RG^UW^S5\4?C'XG\'>'?!NK-IW@JSTU()96N/*42(S
M\NJG<WRE0,=Q]:\N\4?\$L]4TWPC=ZM!XW:[URT@9A;?9L1R!1EAO)W<@'!]
M<41@G&[9,JC3LD?I7:ZA;7ULD]O<13Q. 5DC<,I!Z8(ZU%?:M9::B-=WEO:K
M(VQ#-*J!F )(&3R< G'L:_*W_@FO\:-?\,?%Y/AYJ&HW!T:_CGB2TFP_DRQ!
MBH5V/);'2O;/^"LS,OPH\%)YS1F367$@4.0Z^2W4)W[TN36Q2J7CS'VMJGC#
M0M%T<:K?ZQ8VVF'I=S7*+$><<,3@\^]<;\3/#^A?'[X/>(]%L==B73=4M7M_
M[3M9EDCB(PV[<#@@8&>>E?DY\+_ _P 6OVM]%TGPKI-PT_AWPW&T*&Z?;:P<
M@X8J<LY!''49!Z5]L>&_@;XD_9^_8A^*?A[Q%J%M+>?9;ZY@FMMS+%&4XP2:
MIP46M3&-24D] _8[_8IM/@5\1KCQ(_CBS\2W4%J]LEK8J!AGP&D?GKCMZD5]
MG7%Y!:P.\UPENJC)=F QS_\ 6-?E=_P2JG:X^.7B%99YF(T/_EJ6;+>9&-PR
M>&SQ7OO[9/[.WQ<_:$^*&D6&@:G#I_@."T&_[1=;(/M&Z0L6A!#L^,<].E$E
MS3LRJ<K0YF?5'_"Z? JZ@+#_ (3'1C>%M@B:^B!SZ8W=:[*"\AN;=)8YHY(W
M *NK @@]"#WK\R/&W_!+^^\,>!-1US2?&AOM5LK9[DVHMRD,A0;F4$G)X!Q[
MU2_X)D_&G6=*^)5W\/=2U&=]#O(G>SM[@!VCN(P20K$DD8[#UJ90LKH(U7)V
M:/TZU+7--T?R_M^H6MCYA(3[3,L>X@9(&2,X'-,O/$>EV.EG49]1M([ #=]I
M>=1'C.,[B<5\'?\ !6RX>'P=X A5G_>7MSYJ[F"2 1I]X*<G!Y^N*^<_A+\*
MOC+^V+X9TW2;2_:R\#:$/*M[J])CM68<,H0'>V.XJHTTU=L;J-.R1^M_AOX@
M>&_&#.NC:YINJNAP5LKR.8C_ +Y)Q6]&ZORK!AG&0<U^%_Q+\$>.?V1/B^EA
M-?K:ZW9A=0M;_37D6.\B!R(]IXV'!&.N:_:#X3>,O^%B?#CPYXF(6-]3L8KB
M2.,Y42%?FP?3.?RI3I\JNBH5.9V.SS2TQ>U/K$V"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z5
MQGQBQ_PJ?QD6&0-'NVY]H6/H?Y5V9KD/B[:37_PM\8VUNC2SS:/=QQQQJ69F
M,+@* .I)XQ[T1^-$RVL?CO\ L0^ =!^)'[0ECH/B?25U;3);>XD>UE#!7(!(
M!PR]&"GIVK]/9OV(?@>WF,?AWIT@9<%?,EY_\?KX$_X)]_#_ ,2Z-^U%I]Y?
M:)J5I:1172R33VDB(I(X!)& ?\*_6Y =W3^]_.NJO-Z<IST::5[GX@?M:^#]
M#\ _M*^)="\/:9'I&E6LJ>5:PLQ4,=GJY['TK]4?B3X8F\9?LC:EI4*L;B?P
MP JJ"6)$&< >^*_.7]M3P!XDU;]J[Q3=V7A[5;NWNKN(V\UO92NDV$CSL(7#
M=#T]#7ZU>"[(IX$T*WN86&W38(Y874@_ZH J1^F*JI+EC%K5DTXWDT]#\8_V
M,_']I\-_VC/"NJ:K,;6RN)Y+"=R=I^<;1U_V@N:_;6WF21L!U/\ $BJ?X3T/
MTK\L/VO_ -@KQ7X1\67WBWX?64^L^'KR<SR6ENC&XLY&Y)55&=N>,^AKSWP?
M^U]\?OACHEOX>M[R9+>S98TAOM,,S1<X&"T+-U]31*/M/>%&2HMIH_92:[MX
MC&DDL:O*?W:,P!<CGY1W_"OQ$_;+T&?P7^TYXQ15:-WU!;V%V!'52VX?B*^F
M?V3=$^._Q;^/^D?$'QBNKPZ19AC<7&I1B"VG1E9=L405>?FXP..M>Q_MN?L;
MWWQ[L;?Q)X32.V\9Z=%Y)AN7 2\B)(50YX#+DL"?[H%13M3=ARE[35(]Y_9S
M^(&E?$CX-^%-<TNX$T$FGPQ2_,#ME2-5<?7.:])FN(K=2TLJ1JH+$NP   R3
M7XD^#O&7QQ_95U"YL]-M==\/13/M?3;NT>6WWCAG4,,$MUW#C'2NXN/BA^TW
M^U))%H$*ZK)I4W[F0:;:?8K>,'^*1T!#CZFG.FKW3*C6459H_7]9HY,[75L8
M)VG. >E?!7_!6AED^'/@8(0Q_M>7[ISTA8?SKV3XZ>*?'WP1_9:TVY\,6LFI
M^*M,@LK200V[3\[0KMMP3UXR?7UK\YOCA\6?C9^T!I^D:?XRTB]EMM-N6N8A
M;Z,T0#$KC)"_Y&:FG:,@E+VBT1]O?\$LY$_X9_U ;US_ &Q,>O8@8/XU]B:A
M8VVI6-Q:7D2W%K.ACEB==P96&""/>OQI^#OQT^.OP/\ "[:)X4T:X-FUPUP8
M9M,<LTA11@97IZ>XK[[^/>J?$SQ)^R?INL^%;?4K7QU)]AO)1IT(2Y1<CS$"
M]>YR,=,TZD;RNF.$ERVDCVE/@WX%$I3_ (1+2 OR[2MHIPH&,'CCO^=?F!_P
M46^#?AOX5_%319O"MI'I\&JVTEU<V<;#(?)! 7J 1G'OBM!O^"@7QZ\-6Z:9
MJ6F0F_@_=E[S39$FR/[P8 ,:XG3/@G\:/VR?B))JNM6M^&G4"75KNV-O;6\+
M<%8B?O''8=*VH6C*\F95(J?NI'UO\#9KWQ5_P37UNWO;BXNIDTC4(H)[C.XH
M@(0<]0,X_"OE;_@G/H/A_P 2_'Q+7Q%;6VH)_9DDMM'<()%$ZXVMM[YP<#OB
MOU5^'?PFT;X<?##3O EE 9-&LK+[$^]<F4%3YC'U+'/YU^4_Q8^ ?Q)_9+^,
ML?B7P_97DVFVETUW9:E9V[O$D;R?+'(0, 8;&#ZU$9J\O,'#;0^YOV]OA7X3
MOOV=_$6HS:-8VE]IJK+97$,"Q%9,KELCL1D8-?.7_!)R\U";XB^.8&,B64FE
MQRR$(=GFK*BJ0O;*DD>N#7F7Q$^/WQT_:\TFQ\(PZ#/<VDD\?FV^CV<D?F.,
MG]XY& BXW'MQ7W9^Q%^RY-^SKX#N)-86.;Q1J[K+>/;\&-5.5CR>".*ANT>4
MJ*YJEVA_QT_8/^'7QRUMM<E\[0]8D.9;K3\ 2MGEF'0L1Q^->%?$3_@GY\-_
M@O\ #'Q3XPUC7=0UMM-LY);.&Z81J)L81<=SN(P/6N8^(G[97Q^^"WQ*\066
MLZ*FH:5#>2QVRW>G&.-T+9C99!@$=!D&O*?&OC?X_P#[9M_8:))H5Y<V+7'F
M0V<-L;>RC)[O(!\X&,]>U.+VN]A.\F]#J_\ @EOX5GUCX\ZMJKP[;?2],D99
M%3*AI&"A6;L<.3CV-?K"HV(![C^=> ?L??LTVW[-_P .TT^<>=X@U&7[1J$R
M#<%DP1L#=U Z5] %=RCZBHJRYI&M*+B?+W_!2,K_ ,,E^)0\C1 W%H-R#)_U
MR< 5\I_\$T_A)X-^*EWXZ;Q/X?T_75M4M!;K=QMD>8)"W\A^8K[ _;_\-ZGX
MJ_9=\266DZ;/JE_YMLZ6L$;.[ 2J2< $\5^:?P0^)'QC_9];4/\ A$]$NK0:
MCM$XNM-DDVF/ 7@KWR:UI\THV3,*O*IW:/K3]N#]C_X;>%_@O>>*_"&B6OA?
M4]-FB+1V6X1SX;&T@\GKVKD/^"4?CG5V\9>*O"K,9- DL&U*$,[.8YA*B8&>
M@*LWY5Y3XZ\2?M*_M66]MX>U;0]9O+,S+)'##IC6=L[9!4L^W[H(!/L*^X?V
M(?V1Y?V<M%U'5-?>*?Q=K6#<+%\\=L@'^K1AQUYJI^["TF.D[SNEH?%'_!2S
M+?M/7@4J"VE6X^8X!&TY'Y9K]1?@C#'9_!_P;''"L$']CVAV#C_EBE?FC_P4
M9\%:]KG[1S7>FZ'J6H6[V$$:36MI)*C,%.5!4$$CTK].OA+#-:_"WP?#)&T4
MT>D6L;QR J581(""#T(P>/:HK27(K%T;\[N?GG_P5K^TQ^,O \DV7L?L=R(U
MQQD.N1]3T_&L/X$_LV?'OQQ\*]%U?PA\1%TC0[I)#;6/V^2/RE\UP5*J."/2
MOKO]N?\ 9DO?VB? =C-H/EKXGT5VN+2.;A)593OCSZG''OBOA?X3_'SXT_L@
MV-QX5O/"=S+HJR;TL=961XX9,8?8ZC.TNI8?[PK123@DF9QARU')ZGH'B[_@
MG3\</'VIM>^(O%VGZE<M!]E$EQ>ROA2,$]/0\>^*^N_BK\3O^&2/V;=,N;E)
M-8U:PLXM-MAPR/.5"[FR0VP'DX]*^3]+_;,_:'^,VNZ98>#_  =_8EM-<1I+
M)8Z>\J[-P+-YC#Y0%!ZU])_MR? GQ!\=O@(EMHUO'<>(]-9;SR)4P92JCS N
MWJ3S@#J<5A*7,TI&B3C=H^7?AM\5/VJ?VJ+R_P!9\(Z_!H>A12""0P!;6V21
M5.Y8S(C,2.O&:^=?VG_!_P 0/!WQ,2P^)FJCQ!XG%A'*+Y;@W \E@0B[BJX;
M*OP!_'[UZ7\ ?VFOB/\ LPV^J^$+3P1-J8N[EITMM2@D$D<N "$11N.<&N8_
M:(\%_&3Q_K^F>._&WAR]%WKAV6UK;0NYM8D(V*R 97()QFNJZ3N<\XN4+VUN
M?J[X+\*V7CG]G/P]X?U&$3V&I^'(+2=3_=>!5)^HSD?2OSD^+G_!/KXF?"._
MN=>^'<]QKVBP#S(IK*X,-]  "3\HY8#%?=GBT>-M+_9)TR7P0+FW\5V6A6C6
M\,4):;S$C3>FS:3G 88QFOCB'_@HW\:/"%FFB^(/ UE)K<<2HEQ=6<PFWD<Y
M4,@R/I7.KZV.EM<J31J_L8?MR>+IOB-I7P_\>7W]K6U\XMK:^GB*RQR '*.>
M@(QCGK7K_P#P5*D$?[/-B"5R=4CRWL,C^9%?./['O[-_Q!^)'QTL/B;XDT:?
M2M&L[QM5F>]MWB>YDR2(XD.<#.._2OM[]M[X/ZI\9/@7J6DZ#!YVKV,J7\$1
M4MYHC.YT [E@> .I%+:>I-KPT/&O^"4\R+\+?%JLZJRZJ@()Y&8SBONB-E;(
M!!*G!&>E?B1\%?B]\7/V<;K6-#\,:->:?/J3;I[*\L'>0S$$ JK#/%?L9\+]
M1U;5OA_X=OO$$>S6KFSCDN@8Q&1(5R?E[5-6*3NF.E)[-'74M-'6G5SHZPHH
MHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "&JUXGF6\L><%U*
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MI TI13$0&;:#@9(&3W-6N555V(E&2I61N?\ !+FWC7]GFYG%K##=2:M*)9$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHI* %HI-P]1^=% "T44A8+C) H 6BBDR/6@!:*0,&Z'-
M8-T.: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFR+N7&-W
M(X_&@ +#'7WKR_XA?M#_  Z^&/BW3?#?B7Q?9Z+XAORAM=.E9VDE#$A3MQC!
M(('N..:\W_;H_:CO_P!F'X>Z?J&D:#)KNL:O<?8[+$GR12\8)0<N?0#OBOR3
M\8?\+(U3]J;P1KWQ526+Q-K5]97BPW)(:*W:11&!&<&,95N"/XAZT ?OVLVX
MK*'VQ,%*<@!L]N><\BO)?B-^U=\*/A?K7]D>*?'^C:-JBR>6]H)A)*C<<,%R
M5/(SD#K4O[3WQ+E^#7[.'C'Q= H-QINE,8LG'SOMC4CD<@N".>HK\M/V+_V#
M(/VQ/!WB+X@>+?%NJ6C+J+6MHUN/,,\RQHSR2!U)*Y..#R5Q0!^QOA/Q9HOC
M318-:T+5+75=*FSY=W:3^9&WJ#V!]C6#\3OC%X-^#.EB_P#&OB;3O#UI)RDU
M_*%+?,!\J9W-R0/E!QG)K\RO^"7_ (NU7X._M->-O@KJ=\;JS8W,26Z;O*-[
M;,P:1%*Y0-'NR/8^E<5XC\+WW[?_ .W]KWA74M3GLO#FE/<*OV5\O#86Q$81
M-V5#LS9+$=Z /U@^%OQ[^'WQDCDE\&>+--UXQOLFC@G_ 'BG!P-AY'0_D:[/
M7-8L-#TVZOM1O(+&SMHS+/<7$WE)&@ZLS=A7XJ?&CX3WG_!-W]J7P/J7AC6+
MS6-*N6AOE:[VK(\(E"/#*5 5C@/T[-7T/_P5U^,VK6^A?#SX>:"\L-KXB/\
M:DZY(:Z4$+% XR,JSR@D?[/M0!]CZ#^V-\%O%7B1-#T?XE:#=:J'9!;/=E2Q
M .=K-A3^?ZU[7$RA5P0=PS7XW?'K_@F';?!W]F./XAZ9XIO[SQ+I=G#?:M9S
M1+';L&*F4PGJI0-@ GYMM?=7_!-GXO:A\7/V7O#]UJT[W>I:9/+I<D[%<L(P
M-A/.3E3^E 'U72U7^V6ZNRF>,,GW@7&1]?S'YTOVZVX/VB+&0/OCJ>!0!/15
M==0M6<(+F$OD#:)!G)QC^8_.I\T +1110 4444 %%%% !1110 4444 %%%%
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MF:\A_;(_8<^*_A?XV7WQB^"GVN:^OIOM<MGI@7[;;32 K+MS\KKD@@=@2>U
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[MJ<*1CIM67A?KSG'M6=^P7,?$/_  4L\67NH?Z1,L^M2*[=$9)L*2>WR@T
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M+ QW&(21(^PD 9(+'MVH Z2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ IDGW1]1_.GTR3[H^H_G0!^-'P0_Y
M3 ZS_P!C'K'_ *(GK]EA]]?^!?SK\:?@A_RF!UG_ +&/6/\ T1/7[+#[Z_\
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MI_P-(;X+> ".1_8%A_Z3QU^;/_!;[_D,?"/_ *YZE_Z%;U^D?P%_Y(?\/?\
ML7M._P#26.@#O**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS0!]G_%_X[^ _@/H:ZKXRU^TT6"4'R$F8"6<@9Q&I.7(ZX'8$UXQX%_X*9?
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MIU !1110 4444 %%%% !1110 UG5!EF"CU)JM/?6\%PD,D\:32?<C9AN;KG
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MGT^E>Z+TI:* "BBB@ HHHH **** "BBB@ HHHH *9)]T?4?SI],D^Z/J/YT
M?C1\$/\ E,#K/_8QZQ_Z(GK]EA]]?^!?SK\:?@A_RF!UG_L8]8_]$3U^RP^^
MO_ OYT 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#XBWL.L?$[Q6X;4+BU4BWM(1REO"#R% QGMD5]%1H%^=(\%S\Q*@'\:G7I0
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MB!_P49T/Q+X@LTM=;U34=2N[V$*R>1,UO<%UV,2RG)(P>17[G#[Z_P# OYT
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MEEJMD3_QZWD6!)']!_6@#V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M _\ 8_6O\C0!]E-]X?Y]:=36^\/\^M.H **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_M+6IWNKRXNIO-9F9MQ"Y&17L<A&TY-?)?[7W[<VF? &ZA\(>%M*7QE\3=2
M2WT.U.]K9C]R255!+GCA%Y_"@#SS_@KAXF\+I\!;'PSJ$45WXSU;48&T*UA7
M?<(%E02M@<D,,@<<D]S7U)^RUX7U?P9^SU\/=#UV=I]7LM'MX[IVSG=Y8^4Y
M[C('/I7RC^S/^PYXC\1^.H_C'^T%J,FO^,)I1/:^'[C+Q6193LWCIO&1A1]W
MC/2OOJWD# R,P&3W()&.,$CC\* 'SY"L02"OS?*,GCG%?DI>_M2:#X'_ ."A
M7Q2\9ZGH6I>);^PMVT?1-+TNW,LDKJ5C+@@':-FYL]Q7ZT7$D;JZDA]I&Y5/
M/K_2O-_A]J?PO\9:MJEYX1'AW5-2@N6CU"?3XXFD5USD.1D[@?UH ^1?!7_!
M5S3+7Q);:-\2/AWJ_@>"ZD*QZA<#< O."RD D XR1P,Y/2OOO0]6L]<TNRO]
M/N([JQNH4N(+B%P5D1U#*1CU4@_0U\W?\%!/ OASQ/\ LL^/9];LX1<:=9->
MV-U*H+1W*D&->!D*2 #]:9_P30U+4]6_8U\ S:K-//<QB[B$DV06C6ZF6+KS
MM\L1[3W&.U 'U!*/E;G;Q][T]Z_.S4?^"BWC'PS\</BKX'7P\WC/4M,D6U\,
MZ3H]LPFN)!@N[C&2JC))'85^BLLBHA+%0.GS' K\SOV/M+LKK_@I%\<;F:W@
MF>U=C;S38+0EF"G;]02/QH C_P"&]OCY\"_'7AP_&GX>V>E>#]7ND1[U$\I;
M=9 2WEN>-R+EBIZA2.^:ZWQO^VA\=_BA<7^H_ CX9OK'@BU$CVFO:G93!]3"
MG!:!!M..<9!Y_2KO_!8Q8YOV;]&S'YTJZ]$%W1X8?NVZ5]<? O2+#PW\'/!=
MGIUI#9VT>F0;(TP -R*S_B30!X7^Q'^V9>?M/Z3XHTGQ)H=OX=\:>'&1+ZWB
M+"+RR<&3+;MI5@<@]Q7CWC[_ (*#_$[XG_$W5?!O[._@A?%EKI+&*[UB:$R9
M<$IN^\B*N>0Q(Z=^E>>_LP_:-&_:4_:]@\/QR1WD.D7C6D,*DDRK,VU0!U))
MP!W)KVK_ ()%6=A!^SGJ-Y');G69];N8;R=4!F8@@IN[[3O)&>M 'BOQ2_X*
M6?'#X.Z+_P (]XW^&\/AGQH+H/:WTUM*EM/$!M<[7SO)R?F0E<U^E7P_\4W&
MO?#?P_X@U&>-)KO38;V?RTVH-T8D.,^U?&/_  6"T_2IO@+X<OKB."358]=A
M%M*5 F9-K>:@[X& 3Z<5Z#\:OB6_PI_X)ZV6HPNT^HWGARRTRV^SMF4S7$4<
M:A0.2P#YP.>* *'[!D?_  L7Q1\8/C;= 1#Q9X@>TT[+;@+*VS&H!]"W(]<5
MXO\ \$Q]6L_#?Q(_:0U+5+F/3[&RU1YKBXN&"I$JRS$LQ., 5]L_LS_#9?@_
M^SWX)\).JR3Z;IB+-)LV[G==[,P]=S8-?D)\+?@/\3OVA_&7QQT'P-JL-AH4
M&JWEY?PS,P%_(L[E(#MY(8K@#OQ[T ?H;\/_ -I;XD?M._%J=OA390Z3\)])
M;RKSQ-K4#-_:CJ3N%JG\(X^]TK7_ &T/VW%_9G.F>%?#NF-XJ^(FKK&]GI?_
M #SC9BJLX'+;BKA<=2OL:O\ [!_QY\.?%WX4Q:#;:39^$_%/A=1INL>&K:-8
MUM94_=B5%'16P<D=Z^>H8DUS_@K])_PDT<=U9V>CE-,6Y7*9$+;" >N&\XCW
MSZ4 07G[:G[4?P=TF'Q1\1/A*I\+W >2>:WM94DM5V':9"1A #@G=V!KW+_@
MGC^U5XN_:F\*>+]7\56UK:MIVH10V<5I&5^1T=CNSUZ"OI3Q]8V&L^ ]>M-4
M6&?3Y=.F2<31AHB#$X8\\<>O;%?"'_!&Q(D\&_%,P1K#$=?BPN[H!'( N.Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA_GUIU5HKVWN889X9XI8)!N25'!5A@\@C@U8S0 M%%% !1110 4444 %%%%
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MQZKJ$.J1W4D<C["55&R?;_' KZ2^'6BWOAWX?>'=+O%V7EEIT4,J(,A75 "
M?J*ZNB@#X5_9A_9Y\<?#']JOXU^-_%FE1V?A/7TF:VG\X'S4\TL=P]U_QKR#
M_AFOXM? SXA:YXB_9=\5:;KO@G4G#3:7%=QO'%+C:8RN3G!YR.:_3[4K)-2L
MKFTF4M#<1M$X_P!E@0?T-?G)KG_!/_XZ_!_QSKVK_ GXDQZ1H>JR&8Z7=7,B
M%&+9/!!7N?\ .* /G7]MSX4_'O4/!.E>//C3KVF)<?V@FGZ9X7M9EP@;'[P$
M'&,GD=1WK[=^)GP/\6_&+3?V;_"R::R>#M"2TUK7KA;A=I:&!=D13JV6Z?\
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M?^C6KZZC^\_^]_04 -CC*L6";2QW-DY[8J1V*H2!D@4K,%!).!ZFFLRL@.[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&;[IRNX=""#7F?Q"_9I^%?Q4NTN/%/P_T36KB+[L]S:*#SUY7!->H,RJ/F(
MSCD_E7.^-OB!X<^'6B3:QXGUNQT+28O]9=7UPL*#G!Y)'2@#Q#3O^">_[/VF
MW_V@?#;3IF+;DCG 9 ?89KVWPIX!\,^";-[#PYH=GHL  #)9VXC#8Z<XY_.O
M/_!O[4WPG\<:/X@O_#7CO1]1TK046?5+I"Y2SC8X#N3P%)!^;IP3V->H>&?$
M.F>*-%M=5T>_M]3TRZ7S(+RU(,4J^JGH1]* -*+.W!&,=*DI*6@ HHHH ***
M* "BBB@ HHHH **** "F2?='U'\Z?3)/NCZC^= 'XT?!#_E,#K/_ &,>L?\
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M?Q3'_4"N!^E>VDA>IQ7B?[:.&_99^)R Y;^Q9CM[]J +O[)Y/_#-7PR8<_\
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MTNII(H;J&:6,E72.0,RD=00#Q1::E::@K&UNH;D+P3#('Q^1]C^5 %FBBB@
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MECO+J=&G2&8D8A6->7;D>_(H _0KSH^/G7D CGU.!2[UW;<C=Z9K\T?V4O\
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MK7<_\$IOB]X9\-_#77/AGKNI0:%XPT;5;B::#4)EA\Z-G!^4,02RD-D=1WH
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M4$X[\?G6Y10!\Y?#7]EC1?@7\6/B-\4[#6]4U"^\1P2RW%G<QJ1#M9G_ '9
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MKR,<]B:\0_;.^)'P;OO&'A_X,?&?1]1C9K-;FR\:M'&(HBP*-+GJ#\@W$_*
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M?US4[3Q)\)O$?PZAM8%DAEUQ05F<G!"-@<XSQ0![S44F.^<>U/7I44S#)4,
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M6%0J*B;-OL%   QZ5=HHH **0G')X%)O7<!N&2,@9H ^0_\ @I1_R37X=?\
M8^Z-_P"C6KZZC^\_^]_05\A_\%)Y$_X5K\.QN7/_  GVCCK_ --6/]#7UW"P
M8M@@Y((QZ8'- $M(W2A6##(.1[4M 'DOQ\^'7COXC>%8]-\ >.W^'&J>=OGU
M-=.CNC.G]W!.5KY;\:?L"?'#XCS:4_B7]I.[U9]'N4O+!G\.(GD7"\"08E .
M.O0U]_44 ?)7P_\ V;?V@/#?C;1=5UW]HZZ\2:+9W0>ZTF3P^D N(_XEWASC
M/7.*^KK?Y6=<%<,Q/!P<G(.:GHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_I7MC.J*2S!0.I)KQ/\ ;1/F?LJ_$X+\Q?1)MH7G/3I0!H?LC_\ )LGPP_[
M5K_Z+KUZO(OV25*_LS?#%6!##0K7(/4?)7KFX9QGGKB@!:*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BDS1F@!:*3-&: %HHHH *
M*** "BD+!>2<"C<.1GF@!:*3<!@DC%&X'N* %HIOF*> P)^M+F@!:*** "BB
MB@ HHHH **** "BDS2;U&<L..3S0 ZBFAE;@$'C/7M3J "BBB@ HHHH ****
M "BBB@ HHI#TH BF7<,8)Y_A)'?U%?F)\8/^"L$_PQ^*?BKPR/A-IFJ'2;UK
M5[QM2"F4C^(CR#G_ +ZK]/'4,,$$\@\'!X.:XW4O@[X%UC4);R^\%^'K^ZF<
MRRW-SI5O(SD^K,F3^= 'YCC_ (+/7/F*O_"EM)5LYYU/''<_ZGTKZ>_87_;:
M_P"&K]>\1V4G@:Q\(2:5!%(K6UR)'FSD8(\M3BO>?'?[-/PM\8>&-1TO4/!'
MAVVM+B!DDGMM-@@DC&,[A(J@KC&>O2OCC_@DKXTABNOB7X"C6UEM]%O]]G?1
MPCS9H2SJ%9QU V_I0!^C<=24U?NTZ@ HHHH **** "BBB@ HHHH **** "F2
M?='U'\Z?3)/NCZC^= 'XT?!#_E,#K/\ V,>L?^B)Z_98??7_ (%_.OQI^"'_
M "F!UG_L8]8_]$3U^RP^^O\ P+^= $E%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%(O)<#<P[9J3-0
M27$4:N[2HJ(#N9F "XZY^E 'R9X=D\S_ (*3>*%,? \&6V[YE./WS]AS7UK^
MYC^;"ICN>*^+?"OC+0#_ ,%+?%K_ -N:;L?PC;6Z-]KCPTOFN=@.>6P0<=:^
MN_%/B;2O!^A7VM:UJ%KI6EV,9EN;R\<)%$H[L2?R'<XH UY)%#8/.1TZ\=,_
M2OD_XR?M=:OJ7C";X5_ O2XO&OQ"/R7FIH0=,T5/^>DKC*LR\_)G.>.^*XG6
MOB9\2_VZ+^;P]\+'O_ _P@C<Q:EXZF0QW.JH/OI9H0"H.-H;IS7U)\$_@+X,
M^ /A.#0/!VCKIUM]^XGD_>7%S+CF260\LQ[]J /F:/\ X)R->Z+<>)M4\>ZT
M?C;/-]L/C2SE*!).,QK%T\GJ-G6N)\*ZY^T]\4/BUXT^"]Q\4]!TQ?#5M ;S
MQ#9:0Z7DT,@ WH<8$F./8\]J_14=:^./@/\ \I OCQ_V#+"@#W']GS]GOPY^
MSGX)70_#B37,US*;G4M4OFWW>H3MRTTK=V)[#@9KU92>XH7[M.H **** &R%
M@A*_>[5YY\;/%'C/PGX)N+[P-X4'C/71.D,>FO<"VW*Q 8^800  2<^U>BT4
M ?G3^T%??M.?'[P_HVE2_ F'P^FEZY:ZQ')'K\<Q?[+(Q\LC:/O>N>_&:]I\
M*_'3]H[4O%EE9ZU^SY;Z7H\]W''-J2:_%(8HB.7*#G@U]6T4 0*H693C).5W
M$$GUQ["IZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;MP,X''.<[>E?4?[#'[;/B;]K#7/$5MKGA*'PW;Z?;)/ \9D(DRP!P6&#UH
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M.: .@HK#L_'7AO4;J.VM/$.E75S)C9##>Q.[9Z8 ;)S6VK!NA![<4 +1110
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M@S]10!^HB_=IU-7[M.H **** "BBD9@HR3@>IH 6BD+ =3BDWK\HW#+=.>M
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MY^V)X;_:8^#_ .T;XG^(OP\@\1?\(S>RB19-+WWL.T #]Y"@;8/J,5'\'_\
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M>'_VPOVC/%'Q,\0^ -.^#_ARX\1:"B2WR2:P5C56^Z0??MZU]V_QU\<_ ?\
MY2!?'C_L&6% 'LOP(\5?%OQ1]O\ ^%F^!]+\(B'_ (]#INHFY\W/7<*]C7I2
M+]VG4 %%%% !12$XY/ I/,7.-PSC/7MZT .HIC2HOWG4?4TOF*6V[ANQG;GF
M@!U(6"C).!0"#T.:23.WC(Y'0>] "22*J_,P&0<9-?&__!1$&34O@$%&XCQ[
M:L0.<#!Y^E?0'QN^*NI?"+PVNL6/@K7_ !T6<JUAX>A$LR+CJ5/;WXK\]OVQ
MOVKM1^(%]\*6U'X0>-O"+:1XKM=1@&LVL?\ IY&/W$)W8+GIM&:0'ZHLPW#G
MIR?UIV0>AKY8\ _ME>(O&GC'1]%F^!'Q!T2*^D$3:C?VZ+! IR2SD?= QCG&
M. :^H(,[L;L@$]$(X[<]Z8:]2?IUHW#.,C-([!5R>E>4?M)?'*Q_9_\ A5J/
MBF[MH[^6(^7;6;.%\^0G"J/7DCIVH ]5DF2/AG53QP3CJ<#]>*&8*,L<#..?
M?BODKP4O[4OC6QT;Q1-KOA3P_I]_)%<?\(]):;I8;=QDKYAC/S8.>O:K_P"U
M!^T%XD\%>,/"7PQ^'=I92^/?$+8%U<\1V,;*P\S!3!Y!/X'TJ^4CF/J7S%SC
M<N>.,^O2E612W# _C7QEI'Q\^*GP5_: \-^!/BW?Z7X@TOQ04BT[4M-M_LZV
M\A^7#L4 8Y!& >K#UK'^(O[07Q?UKQ!\3+_P3=:3I7A3X=RI;SVEU 3<7[Y.
M]PYX'RD_+[4<K#F/N?S%*Y##'KFA9%;[K*W?@U\R^.OVK/[-^!'A/7M&M$F\
M9^,+=8]%TQ7#%IFPK3,HYV(26)QC@ ]:]J^&-KXFM?!VEIXNU*#4_$>Q6O[B
MW@2%-Q7[@521P>]2U8:D=C2TT=>N:=2*"BBB@ HHHH **** "DI::S';\O/(
M_GS0!Q7QA^*FB?!KX=ZWXN\0W M]+TR#S9/[SD\*BCN6/''OZ5^4UY^UQ^UE
M^U-XCO+[X2:?K.D>&8)'2&#0K.$HJ@]))9.-_(R,Y&:^KO\ @KQ;ZM/^RJ1I
MY=K>/6+>6_2//-N$E )QT4.4Y/&2!WKT#_@G7=^%KO\ 9*\$'PS-#*L-LZZB
M(T'G"Y\QVE$F.<ECQGG:%]10!\3_  W_ &\OCY^S5\0--\-_'[3+R[T.^D&9
MM4@6*=$SC?%(H"R ,5S@G S7ZRZ#KUEXFTK3]6TZ875C?0K/!(#QL9<@CUS7
MP/\ \%C+_P *1_ ;1K2_:%O%<NJ12:;M0>;L6-O-SW\O!SGIN4"OI+]AA=47
M]D[X8)K#NVH+I:^9YN=^"6*9S_LD4 >]T444 %%%% !112;AZT +129%('4X
M(((/3GK0 ZBFF10NXL /7-!=5ZL!^- #J*:KJV"&!!Y&#UI=PW%<C=UQWH 6
MFR?ZMOH:=39/]6WT- 'Y1?\ !;[_ )#'PC_ZYZE_Z%;U^D?P%_Y(?\/?^Q>T
M[_TECK\W/^"WW_(8^$?_ %SU+_T*WK](_@+_ ,D/^'O_ &+VG?\ I+'0!WE%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4A8+R3@4M-?[IYQVSB@!DSKY8); R.0?>OS_P#V^_BMX+/Q
M:^!R#Q%I;-HGB<37R?;$/V8;#S( <KSCKCM7J?[:GCKQ9JFN>"/@WX(U&31=
M=\;W#?;=5MY-LUII\>3*R<@@L%*D^C&NG\$_L,_!3P7X?72V\ :1X@N-J_:=
M3UBV%U=W;CDNS/DC//0^M 'C?QH\7+^VE\>O"OPC\)Z@+_X?>'Y$USQ;JFGS
M[X)V0$PVN1PP9MO&>_M7W#I5E!IMG;6ME%';V,48CAAC&!&J@ *!Z8%?!7Q.
M^&-E^P1\5M"^*7P[B.F> /$5_#I7B7020MO;^8V(Y(LKE0&Y.3T4U]^PNK;"
M/NL-P&.1GGF@":BBB@ HHHH **** "BBB@ HHHH H:Q%=3:;=QV4B0WC1,L,
MDBEE5R#M) ]#BODO6_A_^UCI.BZA>-\5?"$UK;K-.;=](<R-$%8A"W3I7V'6
M!XZ^;P;KV.<Z?<?^BVH ^&?V>M<_:J_:,^$NC^/--^)'A;1XK^2XC6SDT7<8
MMC-'OSWSM_6OM'X4Z/XOT7P9IUGXXUFWU[Q%#DSWUI;B&-^..*\$_P""8<T9
M_8W\%XD4_/=#J.OGR'%?5VX>M "T4E+0 44@8,N001ZTBR*W*L"/:@!U)FDW
MJV<,#CKSTIJR)(H*NK!AD$'.:0#\T9I.#T/--#*V"&4CZTP'TM,W ,/F&<X'
M/?TI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8Q\O7D5;_P""M%K)X8^)GP0U6:*1[+3--59653@-'-&=F?[V >.M>K?LK?\
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MV_\ X>^)H?B+X9?PY:>$KZVN-335$,,4S.=L;2;MH8_W2<T ?2/[-_[*^C?
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M70; C_P'2@#O:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRZ<%U*[V<[AEF42)VS^5;/[//[5>K_&3QAXA^&'CSPVWA+Q?;PS!HK=B8V4
MAC\Q)'!W#GGCUI\HTV4;3]O2:\UVVU&+X>:E_P *SN]472+;Q>URNQYRVS<8
M_P"X3P#G'Y5[#\</CQ;_  CTW1[33M(;Q7XFUNY6TTO1;2Y6.2?.W,F3T15;
M<6Z8'O7QKXR^!/Q$^%/PI3P9XFD\.V_PG\.:T=>'B)I\7\\:R%EB6//WBS
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ML1W37'VVX,Y8QM$ <GI]\U^P?P%7'P1^'I_ZE[3O_22.OS>_X+??\ACX1_\
M7/4O_0K>OTC^ O\ R0_X>_\ 8O:=_P"DL= '>4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4F1TSS2U#,&W95<_7O0 ]949BJNK,.H!Y')
M'\P?RI5D5AD,"/4&OF#XR?LU_%7XB?$34]9\._'C6O!/AV81F+1;.T5TB*J
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M*^\_'WPI\(_%*UL[7Q=H%IX@@M7,L"7L6\(Q&#^AKC/^&/\ X,#_ )IOH/\
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MSX9\-3^*]34R1C3;=29)$>UA+'@< 8SGVK9_:4_:^^*WBKP%J'AR\^&U_P"
M-*U!&M[^\N%>9TA/WG#@80?7KT[UTRCM8YH]?(^F?V _C!KOQF^ MKJFOWC7
MNIZ?=OITE\5!>XVQQL"QQ@D>81QZ?6O"_P!M S+^V]\&V2Y52@MRJD,"<W1&
M!V]:^@/V$K?P%8_ O2(/ FJMJ]M@27LTP"RFX9$W%DZK]WC/I7S]^VI_R>U\
M&/K9_P#I6U3!<M1IE2UI)GVU\7G'_"IO&+ LA72+QBRY!&('.1COFOSM_83_
M &2_ ?Q\^&>KZSXO@U*_U.#4I+19H[]T'E^5&ZGOSESV[&OT1^+G_))?&_\
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M5\4_'C4/&O[7'QT\&>"]<^&NG^ K;6U6_DDNSYVL1:=$V668MCRB5!VIC!.
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M'0!WE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-9U7EF
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M^SO\+;3PJ;A+[4!-+<7=[#&565F;*]?12H_X"?2M8RY5<QG'F=CYMUS]F?\
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MUP5.!U [\=:WE+F:=]CG5XW5MSA?^"<-RJ?M#_$^W\."1O"&YR/GS''(LNT
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M>W@6*(.?X% XXXJ+,T4HO8[,=:=2>]+4EA1110 4444 %%%% !4<W^K/ 8G
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M7/!^G^)/#ETUWIETNY2\11XV_B5L]P>#BNUK$W04444AA1110 4444 %%%%
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M?^2'_#W_ +%[3O\ TECH [RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$9KC?C:OB_\ ;^_;CUGP!I&MOIN@:.\EFC!B\4<,)_>3/&" Q\PX_$5]A_\
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MP7_P4;T70/%-T][XBTW4-0M=0G-S]H$DZ6MP'?>>6!(//O7[FC[Z_P# OYT
M24444 %%%)D4 +29HW ]#FH9O+97WE2B\MN/ QSS0 3'Y6PVP]-V,XS7Y_\
MBZXTG]J'XY>-]7^)NOMHGP,^'-R-)2PDO1#:ZI?X'F&8#EU7>O YS@5[I\7O
MVX/AQ\.]6E\.Z5-=^//&;C9!H'A:+[7)))VC=DW>7GU(K\G<WGQ2\=>,+S5+
M:ZT30SK5Q=OX9DN&>"&\=L%&8??*A%SZ'&:Z,/1EB*BA$X<9C*>!I2K5=D??
MM[_PQ#\7]//A&RO_  SI]RZE+6XLTDLY("!@&.0JNT#&1D]:S/V+?@U86?[1
MGQ'T_P"(?VOQAXW\&BVCT75-4F\^%--E4M$T*GY<X&"WN1UKY"U/X?Z%J]BM
MI/8PQPD8\R.)O-5^VTK^E:?[-_B7XE^&/B#X_?3?B#H_AJ.STN$:CXI\1?OI
M8+-'8)Y4><R,"53:,D;A7H8[+:F#2<NIX^59Y1S63A3T:/V$\=?$+PW\/?#U
MSK'B/6;/2[.%3</)>X&Y5&6"#(W$ =LXZU^6/QT_:8\5?ML>.KC0_"G@KQ/X
MC^&&EK)-%8:8SV::LZH2);J?&U%3&X+GG;7F7A5_"GQ!\>'QI\8_'/B3QQHZ
MW131?#!3[1J'B C.'%L#FW@8]-X' K[//@?]H#X_^$;VSMM,L_V>OAJ+1_+T
M;3H$DU>^C"G8LA S%P ,#KGO7CNVJ1]*[+5,_/;X)^*K:SL-0T2]B2PN_M+3
M1J6"C: J;03U"X*\=3S7INI^(+?P_:->7<L<44:E\2$#</09ZYKR9/%'@_PS
MX7E\(^,_#VHS:QI5[-&]Q&_E3)AOE]SD<D54T7QM\*M/OHIYM+\0:R\;;XH;
MJ3**PY&5'49QQ[5[>'S>M0I>R2NC\IQ^5PQ.*]M[*=[]%='W9_P2)2R\2:G\
M6M<N+"V:\-_9&UFE@#R1*T=QY@5NJYX_#-?I5;AER&B6,YXVG(/^%?G]_P $
MH;K^WV^+?B>TTZ:UTG6-3LQ!-) T4;M''+N6/C!"[AG'K7Z##K7CSDYR<GU/
MT[#KEI17+;3J17"%LC;N7OD=N]?)WB+_ ()B_ [Q9JU[J>HZ9K<]Q>7$EPZR
M:I(55G.X[0?NC-?7%%2M'='2?',/_!*OX"6;"6'2-:BD4\/'JCAAVX(Y%?0_
MP9^#^@? _P $VGA7PVM^NF6[O,@O[I[B0%CSEVZ_2N_HI7?5BZW0WH13J**!
MD,T6[YLX/L,UCZQX2T77[>6+4](M=3BD&V2.XMHW#CWR*WJ;(N]0/<'\CF@+
ML_)#]N;X<^'?@C^U#H&H:/I5CH6C>(M(>,QVRI%&)HB=[-SP3\H_ 5P/[J6-
M?*5R7/!B!)ZCTK].?VEO ?P?^)FFV^D?$UM&@O+BUE33I[^Y2"ZAW#+/"[$;
M<%1STK\V?$7P \(Z=^T;H?PYTSXXG_A!K_3I;Q]6FOH"UG(IPMNKAMN]L#YC
MU!.*^AR_,OJL7$^'SCAR685UB*4N7HRK\&/AGHG[1'[5GA#PEJMM'JVA:=:7
M5S?J6"EL*Q4$9&?F"_K7Z<:%^QS\%_#<PDT_X9>'(65OD>.P&_..I9CS7+_L
MK_!WX(_!XKIGP_OM.U?Q0MNPO-4^UI->W2$Y+,03E<_W>*^E%^[7CXBK&M4<
MT?3X#!K X:&'3^$YO3O!&@Z'"L5GHVGV:*,(MK8HFWC'8<U\>?MP?L;Z]\0/
M$5G\3_AR%/BFRMQ;7^E,^Q;V%3P%XP&'OZ5]QS*2IP.:^=OCO^S3XR^+'C2'
M6-!^+'B#P)I\=OY1T_3"&21\<L<]*PC)Q:E'H=E6G"M3=*IJF?F3$WQ"NO%]
MUX*L_AOXAE\=0*+J?10<M&I. 68C!7/?V/I7W[^PS^R#J_P3FU3QSXZDCF\=
MZY&(FMX0ICLH?O>4".IXY(KDK?\ X)S^,XO$UQXHB^/?BR'Q%>0"*>_,*ERG
M!"]/5C^M>[?L\_L^^+?@WKNI7NO?$O7/'=K>0K'%#J6 (G!R6Q79B,96Q"Y9
ML\S Y3A,ODYT(V;ZGO(!V]*;(NYBNW<,8QZU,I/<4R92RL N[(QC.*X%H>PC
MY6_;!_8QMOV@#:>*/#E^/#OQ"L(S';ZCLREVN#B&8>@&2#]*^$?"OP%^-7CK
MXO>(_AE8KX?TW7O#L43ZGJLI)@5)!\KQKC[V37Z _&SPU^TO>?$*XN?AGXC\
M-6/A)HHDBM-5MV>42<;F)]*\-\,_LT?M9>$?B9XD\?:;XL\%+XC\110PZ@9+
M1C'M3.-H]:Z:>(JTERQEH>=6R["XB<9U8)M'TQ^RK^S!HO[,O@M]+MKB35M=
MOF\_4M6G WSR'KCN%ST%>YK]VO#?V<]#^-^CW&M?\+;UG1]6A;'V$Z5&5(YY
MSFO<UZ5@VV[L]!::+86BBBD,0UFZ]K^E>&; WVKZE9Z59;@AN+ZX2&/<>@W,
M0,UH2;A&=BAF[ G%<1\5_A%X7^-'AI_#7C+2/[:T2:59Y(#*\:Y0@J/D(/7W
M[4 ?+?\ P40^('A37/AO\/H=.\2:)?3)XVTFY9;74(9'6%)6+R85L[ #RW09
MYKZOT_XF>#+ZYA@M?%NAW$]PX$$46I0LTI(  4!LMGVKP]?^";'[.<>]%^&=
MML8<,U_<L1WXS+Q5WP]_P3X^ /A76[#6M,^'4%KJEG.MQ#.U[=.8V0Y! ,A'
M;THLK6#6Y](*0<8-.J"'&Y258#&%;!''7&.W3O4] $;Q!N2 WL::(0.0BH?[
MR@9J:B@"+RV;@LQ'N!4BKM&*6B@ HHHH **** $HI:* &XI0*6BF*PG>EHHI
M#"BBB@ HHHH **** "FLNX8SCD']:=39"%0DG '- 'S-^W]^T%JO[._[/M]K
MWA^18->U&XCT^PF<9$3."2P'J%#$?2OSI^&_P9_;(^/GABT\:6'B76H]*U)/
M,M+F]U5;=IUS]Y4X(4\D'&#BOTD_;V^&WACXF?LR^)K+Q/JUOX?M+&(7]MJ5
MT/D@N$&(Q]6)VX]Z^(?V5?\ @JKX<^%?PQT;P7XV\/:A<C18FM[;5-+V[+B,
M'"!HSRIQD_E0!A-^QC^V=M;S?%]^$VG.-?/IQW]:_3+]F'PKXK\#_ [PCHOC
MB\EO_%%K:>5?7$LQF9Y-[G)8_P"R17RM_P /CO@[U70?$61S\MNF?YU]A_!7
MXHZ;\:OAMH'C;2()X-.UJ)KJ%+I5WJNXJ <=^/T- '>4444 %%%(W2@ I/,4
M $L,'IS534K^VTW3Y[NZG@MK6%2\LUPX2-%'+%F/   -?*7B/_@J!\ /"_B"
M71I?$MWJ3Q.4:XT^P>YMP1UPZ9!Q[4 ?7.12"1&7<&4KTSGBN&^%/QF\'?&[
MPS_;G@S7;77=-W>6[6[C=&X&=C '*MC'!]:YWXX_M/\ PY_9WTJSO/&VO)I9
MNEW06D&);B09 RD0^9AR.@- 'KA8*0"0">GO1FOG_P"!_P"W'\(OV@M<_L;P
MMXC*ZQDB/3]3B^S3RXZ[$;D_A]*]PUC6K#0M)NM3U"\AL]/M8VEFN9F 2-5Z
MDGVQ0!>$R-P'4GZT[/;O7R-)_P %1/@$GB,:,?$U](6DV?;AI[_9NN-PDQM*
MYXW=*^HO#GB+2O$^EV>JZ-?6^H:=>1B6&ZMF#I*I&00PXH V*;)_JV^AIU-D
M_P!6WT- 'Y1?\%OO^0Q\(_\ KGJ7_H5O7Z1_ 7_DA_P]_P"Q>T[_ -)8Z_-W
M_@M\#_;'PCX_Y9ZC_P"A6]?I%\!?^2'_  ]_[%[3O_26.@#O**** "BBB@ H
MHHH **** "BBB@ HHHH **0L%ZD"D+JO5@/QH 5ONFH)7W+M3#%L9 /\)."?
MRS4AE1XP4=6S@J0>#SQ^M?+?[2G[4NI>'?$5M\+_ (4:<OBOXHZMS'';D/;Z
M1!_'<7#+G:1@G8<$_C0!Q?["?BS3_A?XR^)GP1UZYM[3Q#I>OW.HV;R2!/ML
M$[EP4R?G(]LU]F:E>6NFZ?<75W=1V=K$C&2XD<*J  Y))X&*^./#O_!-3P==
M>"9)O%VLZQ??%:ZG-_=>-M*N7ANH[AN@@/01CH%/3O5F;_@GC)XEVVOC?XQ>
M//%NA+,LCZ1<W@2*Y7;@I.4Y?/<CTH B_99U:/XT?M>_&#XO:/&I\)_8K?PM
M8W8/RW<D+!WD0]''R]1FOM%>E<[X%\#Z)\.?#&G^'O#>E6NAZ'8Q^7;V%JI"
M1_0GD_4\UNR2)MY;OP >21S@?E0 LF,D%MO?CK7R!\*?VZK+Q_\ M;>)?A8T
M4,/AJ-7M-!U4N M[=V^?M"J_1^^,9.5KN?VX/C9-\&?A'-#HZ-<>,O%$RZ'H
M<$>=QFEPI8 <G:&+<>@KY^\=?LDW?@W]E;PK#X6FCM_B/X);^WUU%03-=72_
M/=(Q')5LL/PKGJ5E3DDSFJUE3:3/T$\Q-I'F;2.NWDC!YKR[XH?M-_"WX/1L
M_BSQMI&F3][>.3SIR<X V)ENN.H_2OD[X*_#7XG?MI^ =,\;^,_CCJ6G>%]5
M#2'PWX106<EK(C%&BDFZYR,X]*^B?AC^PW\&_A6Z76G^#;?5-6W;GU/6RU_<
M2-C!8LY(!Y/:NBZ:NCINFDT>87'[=7BCXAS2V?P5^#'B3QN=VU]6U:---L#Z
M,K/RX'6F?\*-_:>^,BJWC_XI67P\TICA=+\#JWVDHW!5YV'! /\ #UP1WK['
MAM;>UABBM[=(8H?E1%C"A!C& .,?A3_,0,=S*-O)SVH%J[I'XS_M0?![X0_!
MK]ISP!X2OM7U1M.@0:CXDUK6II;J:>4<QJI/\+?+G Z'/2OL>W_X*%?L]VHB
M@M?%SV\"%8HX?L<P6(+A5 X^[7SC^VUX)M_B=^VIKFB:A?W4-C9Z':3;853[
MQ1?[P]:\H?\ 9'\*>>&&JZED<[66#'ZH?Y5QUZ2J/5V/A\VXARK+\7]6QDI7
M2OHKGMWP^_:/\$Z+^W=H.K?#OQ7=S^$O'C-'KVBQVTGE?:_+=(I%7'=]AS^-
M?6/Q[_:ZA\ ^((_AS\.])D\>?%F\A*0Z3:R!H]/X($MW(,J@4'<0>>/>OS%\
M0? ^#P'XB\$1>%?$&HZ;J&JZU#I4=\5BW0&5@N]< 'C=V%?K3^SS^S%X5_9[
MT&YM](MCJ'B&\EW:EK]Z3)=7C'[SLYR0,_PBNFGI&R/H,KS"AFF#CB</>U^J
ML?-$?_!-GQC\0M7A\:?$/XOZLOCRZC/VC^R[=)+6SW<M%$K?PC/6O)?VBOV5
M?$?P4\4?#'1+/XN:WJD'BK6!I<TMQ"D+1J1R5 //%?57[>WB7XW>$?#_ (2G
M^"ND:AJVI/>3)??V?IXN61/+7:3UP"01DCGI7YQ?&GXC_M7:IK_@:3XAZ/J^
MG:I;ZDLF@K/I4<;RW1X"1@CYG/3:.3FJT6YWU<)AL1)5*T(M^9]M7?\ P3%C
MUA[>WO\ XP>)-3M;>9;@6MY:J$.QQPWMCI^%?=5C"D-A D3$*L8C1B,;L*!D
M^GW:_,7X+?%K]MG6/BSX9M/%WAO7(O#4E\J7LESH?DQB%LY+.%^4#C\N:_4)
MIE57. J@-G>.,C^E/3H.CAZ%"'+022\CSCX[_&1O@OX(D\10>'M5\5?ODB%A
MHL!FG8'JX !X&>3TK\]OVUOVUO\ A:_PAM-(?X5>,O#*QZW9ZE'?:I;>7 ZP
M2,VS=C@L%8@#TK]"_CEX\\5_#KP(^L>$/!EQX^U:.=%.EVKB-C&<;BI.> .]
M?G=^W1\=OBY\5/@[;:+XF^!6I^"M/;5+66*_N;E)UDD$A\J$,H^\^0-O7!)Z
M4[7V-E&_2Y]&>'?^"@IU;4M,TY_@?\1(7EDBA:\72W\M&.T%C\N[ SZ=.O'-
M?8]I="YCAEP0)0'52IRN1G!/0$5\=>'?VJOCG=7VFVES^S-KEO9R20QR7JWT
M95$R!OV[<@8 Z]J^R;.9I886>/R)'0.T.02A(Y!/?!XXHV*]-"?\*3(]*=12
M&>=?&KX+^&/CUX!N/"'BRTGN=$N)(IC' YCD5HVRI#8..:^&/VJO^">/PG^#
MOP \8>*]#_M^'5]-L_.MVGU(R1[MZ@ C9[U^E#99L X-?+__  4.\;:#H_[+
M?CO1[_5]/M]5N[+$%C-=(D\N)%/R(3N;CT':BR>Y,H4I6<XWL?/W[-O_  3=
M^$GQ;^!'@CQ=XB?Q*VKZOI\=U=&VU,+&6(/"@)DKCTK[F^#OP?\ #WP-\#Z?
MX0\*VLEMHMGN\KSY3))ECDDG:,\UY=^P1XXT/7OV6_AOIMCJEC=ZC8:+ EU:
MP7*/+ W/#J#E3]0.M?1?G*6"[ER>@S56Y3.'+#X#EOBAX5T+QOX!U[0O%%H=
M0T"\M76]MUZO&/F.,=^,_A7YHZ['^QU9^'-1CM?!?BV"[BMY#%)-I]V!'($)
M 9L8"ACSFOTX\=>)H?!OA'7->G198=+LIKQXV; 8(A;!/OC%?AS\9OV@?BK^
MTQK4NK7]CJEMX5R[:?HNEL+>")3D#>0H+^N.^*J$)5-(JYC7J4:<;U[6];'H
M_P"S3=?LRW7PETE_B!X;\2ZMXN9G6]FTNSNIX=F]@@#)QD+@8K]+?V2?"/PT
M\/\ PJBNOAAIEYI7A_5+A[GRM0C>.<L/ERROR*_%OX9>(/BE\&+RQU3PE%JV
MFZG8S[)7E)EM;@-TS$R\@9QD=*_:;]C_ ./B_M'?!32_%L^GKI6H":2PN[9,
MA1/&!O(7' .<_C3J8>5-^\K$8>IAY\SH6OY.Y[A&-H I[L%4GG\!DTU.E(_O
M]:R>AW+8\O\ C?\ M">#_@/IMI=>)KUXY[P-]DL;2 R7$Q'7:!Z9KA?A7^VA
MX(^)'CJ/P=+::YX8\0W*![2#7[1;5[ML9VQXZG Z&O'O^"@6DW?@WQY\/_BM
MI&IV-YJ.BS>5!X=OKA5^UOOZ1H>6SD@X!Z&N \&_$ZQ_:W_:\\(ZIXBM_P#A
M H_#-NC6>E7C&*YU"<D_=R!T)/X "ME335S)U-;'U;\5_P!L+P+\*_$%SI$E
MKKNOZM;C_3K?0+$W!M\#CS&R%!S_ +0_'I71? _]I7P9^T!H,^H^%K^=#9'_
M $JUU*,1SP]?O(&/\ZZ7QSXDT#X=^'=:\1ZO%9V=O#!YMP[",&? ;:A)Y)..
M*^)/^"<_@.^\0:W\4_B&ENVGZ'XC+6UA'ND)^8L2ZKC&!T/UHY4D1S.3L>^6
MO[=WPXNO'\7A^*/58X)KW^S8M<:R']GO<Y(\L39Y;/&T9.2.*].^,7QFT#X+
M^&X]4UAY9IKJ5;:STVQB#7-W*6  1&(R02,_XU\&ZQX(^(G@_P""5I\*-=\#
MW&FZ)H6OMJU_XR9U2R:TCD+NZN1E793@'/6NPL?CIX:7XE:;\4_BS=W=M810
M2IX)\,I;-.\5F%VOJ,\7WMT@'4C"\&FZ:W01J/9GWYH=\VHV%K=26TUE+<0I
M*UM< *\>5R00.A!X-:5<UX#\<:-\1/#>G^(- U.WU;2;Z,207-N=P8$9(..F
M*Z6L3H04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;'_@FSX4UK8WC_QMXQ\<S*X?$^H&SA) P"(HL!1[5[!X#_9#^#WPUN%F\/\
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M@.P4;<5$*48.Z,J>'ITK<J!:=31UIU;'2%%%% !1110 4444 %%%% !1110
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M[N=V&H_5X*"V7R/A+]O_ /91;5_".B^,_AQX6L8M9\-S&2XT[2[)(WN[4\,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0?\ H7],_P# 6/\ ^)H_X0W0?^A?TS_P%C_^)H _)?\ X?9?$'_H0/#?_?\
MF_\ BZ/^'V7Q!_Z$#PW_ -_YO_BZ_6C_ (0W0?\ H7],_P# 6/\ ^)H_X0W0
M?^A?TS_P%C_^)H _)?\ X?9?$'_H0/#?_?\ F_\ BZ/^'V7Q!_Z$#PW_ -_Y
MO_BZ_6C_ (0W0?\ H7],_P# 6/\ ^)H_X0W0?^A?TS_P%C_^)H _)?\ X?9?
M$'_H0/#?_?\ F_\ BZ/^'V7Q!_Z$#PW_ -_YO_BZ_6C_ (0W0?\ H7],_P#
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M7C<WNFV=^T7B+:LEQ;(QV_9HC@[@3C+9_"@#R/\ X?9?$'_HG_AO_O\ S?\
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MG"\\5^,O_!,LA?\ @H-XOR<?Z'JZ\^OVE./T-?LS)AA]WS%;C''/YUYSX-^
M?P^\"^*)_$_A_P #:)HNNW8D\R_L[!([C]X=TF7SGDCG'K]: /2D^[3JBC8*
MJ@D MT]Z?O7.-PS]: '4444 %%%% !1110 444F: &R,J+EB%&1R3CO7Y)_\
M%NR/^$Z^% SR--OB1_VUA_P-?K9(?E.#@]!QG%>>_$3X(_#_ .,-Q87OC#PA
MI/B>>P1HX)=2LUG9$;EE7GC)% &I\'V ^$O@8$@$Z)8X'_;NE=C6?I=C!I-C
M;6=K"MI96R+%%#L"K&@&%5<= !@5?W#)&>: %HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#7Y
M1?\ !:Z\F;Q1\*K-COM3;WMPT8[_ +R!?Y&OU<D^Z>^.:_-[_@LI\*K_ ,1?
M#_P?XZLK:>Z70)Y;2Y$,;-Y<=R05D? ^55>)%)/&74=Q0!].^.M!T]OV(]1T
M8Q@V4?@1HUBQT5+,;3],H*^0?^")5U)'H?Q3M6<>2+FQFV=>L<P/'M@5S'B/
M_@IIX5US]C.?P0NGW\7C>XT-]%>%$)BB_=>7]HW]P1GCWKV7_@C_ /";4/"'
MP/UWQ7?Q20S^*+Y9;97C*_N8,J#S_"Y)(/<<B@#T+]JO_@H=IO[+?Q&LO"=W
MX'U3Q3+/IT>I"\LYTBC =Y$V\@Y("J?HPKQEO^"TNA[&/_"H==X!/_(0C[?]
MLZ_1MK"&:Z,CV\;,5V;WCW$ = "1TY)I9-)M67#6\)7(S^[ [^U 'X1_MZ?M
MC6?[7%_X.NK3PE>>$UT.*Z5A?3+*9C(8NA"#^XOYBOI[X=_\%?-'\%^ O#6A
M2?##6KXZ7I-G9-,E]&!*R1!-P^3@$*#63_P6QA6UUKX5O%&(2T&H%V4@;V#0
M;.,\X^E?HQ\"M+MS\&? !^R0G=X>TYC(T:9W&V0D\#W]>] 'P_\ \/I]$_Z)
M#KO_ (,(_P#XW1_P^GT3_HD.N_\ @PC_ /C=?H]_9=O_ ,\(?^_2T?V7;_\
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M ,&$?_QNC_A]/HG_ $2'7?\ P81__&Z_1[^R[?\ YX0_]^EH_LNW_P">$/\
MWZ6@#\X?^'T^B?\ 1(==_P#!A'_\;H_X?3Z)_P!$AUW_ ,&$?_QNOT>_LNW_
M .>$/_?I:/[+M_\ GA#_ -^EH _.'_A]/HG_ $2'7?\ P81__&Z/^'T^B?\
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M?^'T^B?]$AUW_P &$?\ \;H_X?3Z)_T2'7?_  81_P#QNOT>_LNW_P">$/\
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MZ_1[^R[?_GA#_P!^EH_LNW_YX0_]^EH _.'_ (?3Z)_T2'7?_!A'_P#&Z/\
MA]/HG_1(==_\&$?_ ,;K]'O[+M_^>$/_ 'Z6C^R[?_GA#_WZ6@#\X?\ A]/H
MG_1(==_\&$?_ ,;H_P"'T^B?]$AUW_P81_\ QNOT>_LNW_YX0_\ ?I:/[+M_
M^>$/_?I: /SA_P"'T^B?]$AUW_P81_\ QNF2?\%K= CC\Q_A)K:1_P!YM1B
MZ$]=GH#^1K]'I=*M]F?(0X(;Y(U!X.:^#?\ @LC:PV?[-NASQ01B9O$,$4C?
M<!C\BX;;QUP0"/<4 <HG_!:O09%#+\(]<93T*ZC$0>2/[GJ#^1IW_#Z?1/\
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M-+O:2-%5D9L\\AQ^5 'U[124M !1110 4444 %%%% !4$UP(0S-G:JEC@<X
MS4]<?\7-9A\-_#/Q5JLLC1"UTVX<.O4-L(4_F10!X=JG_!1WX":3JE_87/C1
M([NQ=HY";9F"L,@@$=>0>E=I\&?VO/A=\?O$MQH?@?Q$NKZA;VWVN6/R)$;8
M"%+<CH"0,^I K\B_V0?AG\!_B9H/BCQ#\;_&*Z+>_P!H+%;6<>I_9YI5=5+2
M;>ZAGP3T'-?IO^R#^RK\'OA'K%[X[^%6J_VU#JUDUA+/%J*WL2J9$DP&!.#\
M@XH ^J%^[3J;&P900<BG4 %%%% !1110 4444 (:P/''C;1?AWX5U#Q%XAOX
M=,T>QC\R>ZN'"HJYQU)ZG-:]XYCAD< L5&[:/XL<X_'I7XN_M*_%[XY?M<>%
M_&>HKI?_  C7PK\(S21W,<#-%;7)CEV;=[<2L"1E03CK0!^L7P8^.?@OX^>'
M)->\&:FNH:?#.;<R,NUEDQG:>>X/ZUJ?$KXM>$?@_P"'7U_Q?KUEH.FAO+:Z
MNY  6R!M4=6.2.!ZYKXQ_P""-[(W[-?B%"K*?^$@?E5)QF./!S[?TKPC_@HK
MK.J_'K]MSPE\'XK^XM=-M9+6P*QJ2HEG(D,NS^+;'*!G_9/I0!]^_#3]MSX+
M?%SQ!%I/ASQO9S:K))Y4%O=%H#.V.B;\ D]AW[5[S'*K'&X;O[N>:_&/]O3]
MAW0?V2/"/@SQOX&UG4(9C?Q64[W5P"7N1&\@G3'3)3IV&:_4K]E_XC2_%?X"
M^ O%5P7-SJ6DPO-OPQ\Q04DR1T.Y#U]* /5J*** "BBB@ HHHH :Q'K4<C+L
MY*XXZ\CVHFQM8G. ,Y7K7P9^W9^T-\7K3XF6OP7^#^C->ZGK6E)/+?643FXM
M@S2(PW_=3"@,2>B\]Z /I;PM^U5\-O&'Q:NOAOI'B6/4_%UJ9!+:1I\JE 2X
M!]1C!KU#7-:M-!T6]U2^N!:V=G$TT\Q&=B*,DD?2OQ7_ ."=OAK5O"/[?O\
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M44 %%%% !112;AG&1GTH ^9_^"D3!?V)_BCD@?Z';CK_ -/D%>,?\$99$?\
M9L\3*K*S#Q//D \_ZB#_ !%?:/Q,^'.B?%KP7J?A/Q'9F_T+5%6.Y@60IN57
M5QA@01@J#QZ5@? WX ^#?V<O"T_ASP-82Z9H\UVUY(EQ</.S2,BI]YSD?<7I
M0!Z8O2G4Q6&[&>?2GT %%%% !1110 444E $<G<]J_&?_@F2"/\ @H+XNX_Y
M<M8_]*4K]E;I?-B90 V\;<;RF?\ @0Y'X5X;\*OV-_AA\'?B5<^//"_A^73_
M !%>+<1RW#7TLHQ,V]_D;CDCOZT >\+]VG4U#E<CD4+(L@RK!A['- #J***
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%)97$G:12YQ]* .<_P""T.H0K^SOX/M Z>>WB.*58MPW;5MYU8XZX!903V+
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M-25&J!)"?50/RS_C4E !1110 F<=>*JW=U!;V\D\TT<4"(TCRR, JJ!DL3Z
M=ZM5\W_MW>&?B)XV_9_U+PU\.+-KO5M8FCM;M(SM861!,@#$@ G '4=: %\4
M_P#!0#X$^"=:?2[_ .(&GF>)MA^RQR3H#W!9 5X]S7LG@'XF^&/BEH4>L^$]
M<LM>T]]I\ZUER!GH".Q^M?FW\!O^"1^A^(_@VVK?$V_US0O&]W&[_8X6C1+
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M_O)&#MZ]P*T_@[^TW\-/CQ)-'X)\666NW4(+-;J#',J]SL;#8Y]*_-SX#?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD
MI: "BBB@ HHHH **** "BDI: "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** $;[IKX[_P""L$;2_L;>(=JEA'J-A(^!G:HN%&3Z#) S[BOL.0%E(4X-
M>:_M$?"FW^-GP@\4^"[AU@.J636\,\B%E2;(,3''8.%/MUH ^?/^"3M_#=_L
M@Z8L8">5JMQ&WIN CX^M?'G[(TG]K?\ !5#Q-=6A#VQN]98-&=P=0'4D$=0#
M_*N2\(_\-6?L3W6M^"?#_A[4%L=1F=TF@T[[5$7(P9() ,!L;?\ ODBOJO\
MX)?_ +(OB_X:ZAKWQ/\ B'8R:=XAUDO':VMY&/M6UF)EED/\.]B"%Z\9H _1
M+^+\*=2+TI: "BBB@ HHHH *@N&VQL25 QR6&0!ZU/5>[A%Q#)$PRLBE&'J#
MP?TH _+'5/\ @ECXP^+?[17B7Q'XZ\06.G>&=4O)M1:;3R&NIB[!@C(?NGYN
M]>"_M,?L]ZG_ ,$_?C9X*U/PGXMN]06^ N8)F00S QR!9(I-IPRLK8XKT+XI
M_!?]HW]C3XVZAXN^';ZUXB\->:[6UXSO>QRV[L6$-S"<X()V]NV#G%4? _[/
M?Q[_ &]/C1I/B?XHZ??>'O"]FD:^;=6XMDAMP^_R8(FPW)'/<9&: /U_\'ZY
M_P )+X7T3590J3WUI%<M&AR%9D!8?0$X^M;M4-+L1IUK;VL<2I! GEQ!?X54
M *,>X%7Z "BBB@ HHHH AF4,IRI89[=>M9$NC6%C'?W5M8QPW,\9\ZZ6)5>7
MC^(XR:W:IZLS#3;GRRH?8<;CQ[_I0!^/7_!&Y@O[1'Q"R0/^)!-_Z4QU[;_P
M6JL9[CX6> ;N(M);P:M*9"HR%S'QD]J\X_X))_#GQ;X0_:!\;WFN>']0TBTE
MT:2%9KVSDA1I/M$9" LHR< G'7 -?<W[;/[.,_[3GP-U#PY83?9/$=LPO-+<
MG"-<)@A&8]%8 KD^M $W[+.H01_L:^ Y6D0QQ^%8MYW# VQ$-GTQW]*^"_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7G\30!KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOYM0-L7D?;MB,YY) 4?*#P&!/!K[)\1KN_X(YP88*/\ A%K-MQ/'_'TE9/\
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M_>7.,X/7%=I_P32^+_A[]G_]HCQ/IWCRXA\.PZG;MIWVJX4A(+I)A\CGJH8
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M'J#CK0!]QTM-'6G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3["\*3+"QY4(V<[1TQ7Z-T4 ?*O[+?\ P3Y^'_[,>I_VU8M=:_XD=% U*^4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^+__  4%_:1UAIO'7A;P]=>%OAF&;[#/)I7FHT8;Y'E+<'/'MCGI7V?^PO\
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M/EC$@.<@;>6' ]:\W_;G_8*^*'[17[0%OXQ\,QZ4FDK9V]L3<W 1UV')X/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img192321128_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_18.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X2BL17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(R.C R.C Q(#$S.C(X.C4P   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,P.0  DI(  @    ,P.0  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,CHP,CHP,2 Q,SHR.#HQ-P R,#(R.C R.C Q(#$S.C(X.C$W      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  %P          8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ 8@$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M]"* 'M;0.P9X(V8*5!* D ]1]*!:VXC$8@B"#HH08'&.GTXH $MH(V#)!&K
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M,;HH9%&X>@) XR0W//Z5:TZ+68IP+^X@FB;+$H-NS/\ #TYQZ\<#IWH U:*
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M_B/KS2*Z%FB@044 %% !7'?#[;#HVJ.UHUFG]HS,5DV@$;5R_!Z'KSCOP!@
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M'7OSQ6O3+B[A104%% !10 44 %85AI\Q\3WNJ3V,$#,A@253EY4!!!;GV]J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM -X&\/>!;@VGAV07IUV2]U'RK!AF"6W6XB4LTH+Q-MVQO@D9*YR/F/XO?\
M!+O6?AC\/-7\2Z-X\LM>.B6LUY=6=[I36.ZWBBDD+1LCS%Y!@## !B,EABE"
M$9;O4<YRCLM#]487;S'5G,@'? &.^/UJ>OS-_P""47Q>\4W'BS6?AK>79G\+
M6^DSZO:VUR&:2TF6XMT986)!6)O/<LI!RZ[UVEG+_I=,[*HV %B<<G _S_C4
M3CRNQI"7,KDE-;/K44+,S#<V3MZ+R/KG'^?2G7&_:NP9^;GZ?Y_SWJ"]PF9E
MC&&523]YNU<=XF^,/@GP3K5MI?B/QIX?\/:E<1>?'I^JZG!;W$D>6&Y$=P67
M*,,C(RIYX-?'W_!1#]L35OAK-!\-O FJW&G^)6B6?5]6L)(G>V@E1T6V'REH
MIV5UFW QNBB)D+;R!X=\$?\ @F;XC^*G@6P\4Z]XNM/">E:I;0W^FV%O9&^G
MDAD7<K2#=$L)*^60@+'YL-M8$'=4TDG/9G,ZCORP5S]2O#WC#1O&&C0ZQX?U
MFSUG2I@?*OM/F2ZMI,'!(DC)4X((X/'>M5IF:/@^6<XR^.GKQZ_A7YD^%OV,
M_BS^RA^T%\/_ !'X6U:3Q-X=O-8M=,U'4=(M&25;1WB\\7EO\X2(@R_,'9!Y
M*,3&^S/HO_!0S]L#5?AB]I\-O NJSZ;XHD@6XU?5+"2)GMK>5)(UME!W/'*0
MWG;@8W11$59MY 7LTW:+T'[;EC>2U/L3Q/\ &+P3X)UJVTOQ'XT\/^'M2N(O
M/CT_5=3@M[B2/+#<J,X++E&Y&1E3SP:VO#?B[1_&FDP:OX>UBRUK2ILB*^T^
MXCN;>7!P=LD9*M@@C@U^6?P1_P""9OB/XJ>!;#Q3KWBZT\)Z5JEM#?Z;86]D
M;Z>2&1=RM(-T2PEE\LA 6/S8;:P(/5>$_P!C;XM?LF_M"?#[Q#X6U.3Q3X9O
M]8M=*U74-'LG65;-WB,_VRV&\)&1YF&#.BF&-LQOLRW3A%6N3&I-ZM'Z:?:"
MV,$X.<\ 8QCU_P _2BWNO.D8 N><\@8' X!'7K[]3]!^5/\ P5;O+F3X[^%[
M+[3,VF6/AN.YCC:4O&DK75R)&VDXW%8$W'T0$]*W/^">?QY\0?"GXN7GP6\9
MW/D:3+=W-C;VMQ+'(NEZNDA\V&.4/M6&1EE78I?=-L*@>8Y9>QTYDP]LU+E:
M/T^FD,:AB<#=@]/\]<4Q)_FV;@S#D\\XQ_/I^=?-_P#P4(E:7]COQXQ+==.D
M1E^4_P#(1MO0^GY@X]:X'_@D[\_[.OB$L2?^*JN#@DX&;.SX [#D\=.:SC'W
M+LUYO?Y3[0CF+@$Y4$>H.#W']/PI6DX/S[>, G'%?A;\7/"%UX^_:\\:>%["
M6"#4-:\<7VF6TUR<(DDM](B9/) !8'@'ITKW#_AU-\782[C7_!8(?Y8UOKMC
ML/ .?LHY&#QCN>>!6WLE%*[W,_:N3:2V/U?AE:1_]8&.,;1C''4@<]S@\]J?
M<3-'&"O+9]"1^..@]Z\C_95^%&M_ _X#^&O!&N75K>ZGI8NO.N[&9Y(6\RZF
ME7:70$X#@<CBOSR^/GQT^-/[4OPU\2^,#HESX-^#&CQV4WV$@/'JTS7(M]JS
M^6#<L)7?<H'E+Y";E#A2V<*=Y6N:3J<JO8_6F*1RS!Q@=![^]2M7YO?\$>E5
M?^%LJI4[5TA?E;<3Q><DDD],#GIVK](32G'E=AQES1N(<TR>0QJ,'!S@<<?3
MVI9FV+G..?\ /:OR3_;$_:F\3?M)_%1_ACX'NI)O T]Y#I-M:QRP>5K5\LTL
M8F$R_*T+NT6T%RF$20A6R8R$')A.HH'Z3ZK^T)\-=%U"\T^_^)/A.QU"SE:"
MXM;G7+2.6*0$*R.IDRK*W!!''0^M=ZLTTBJT?1E#+O4KU[$'D?3@\_7'YJ:#
M_P $E=5N=&ANM=^)ECI^L-O-RMCI#7-O&RE@#YLDT3,=H7JGRXQR!N/?_L*_
M!7XJ?LZ_&_Q3X'\1M=7'@.YT5M2M[RRDEGTR:\$T,:M',4&V78TJ,AV.WE*Q
M5U6-EN5*-M&9JI)/WEN?=;73"V+_ +T *6)6/Y\=L+USCG&,\=,\4];DL>6
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M// &2S'&H<LQ)_Y"%SZU](5BU:31LGS),6BBB@84444 %%%% !1110 4444
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M#GGI65F:MJ-M=SV&D->8?&#]HSP!\!UTL^./$/\ 8@U1)6LC]CGN/.\L+O\
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M%V&=Q?!8,RN;'_!2+PCJGPX_:D'C.RO+RV;6K*VU+3[FW5K>.WN+>,6[11S
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MGM55E[[%1:Y3COCIKU_X4^"?Q US2YQ;:GIGA_4+VTF**XCFCMI'1BK JV&
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M"^,1XNF\\_VEJ'A::^G'F@>9)F>VE(DD)8&3Y6*LXZ,:I?M(>//C?XR.A/\
M&.RUB"&Q,XTS^U-$73BY<Q^8(2L4?F  19W D;>,9.>B$4G&S,*DFT[H_3S_
M ()W'_C#WP!_W$/_ $X7-?2 -?E[_P $]OB!\;(?&G@/PH\.M+\(<Z@$D70D
M73\^5=28^UM#O(^T#/\ K,[B!]WY:_3V%CN8'<1U^;''/2N&?QL[:?PHFHHH
MJ#4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D-+2-2>P!Z5^<G_  5XD,;?"5U^
M\K:N020 #FS[GI7Z-^E?G!_P5\ 9?A*K#<K/JV5(R#S9'D=^0/RK:E\2,:WP
M,\W_ &>_^"BW_"B?A%H'@6/P"?$DVCF<+?2ZS]G>5III)?N&!RN/,*^^WUX.
M'\!O@YXT_;R^/.H^/?&$$47AO[;'<Z[J$<1MH9E10L6GVZQN6W&$1JQ+;T1E
M=GWL@?Z=_9/_ &9_AM\9?V)_#T/B+PGI[ZIK,5_'/KUE9Q1ZHC+?W'ER)<;2
MVY=JX#94@;65D+*?CGP/XH\2?L(_M87T%S"MQ!IMY_9FJI#;Q.U]IDI27=$#
M*=LDD?DRHID5@R('R XKIBU[W+N<CO[O,]#[0_X*@_&#4O /PETCPOH^H7VF
MW_BRZDCN);/:5EL(DVSPLP&]=[SPX"#YE1U8@,5?S?\ 89_8G\ ?$#X,V_C+
MX@Z</$5QJUVZ:?$NI7,8M+:%Q"V[RC&3*TZ2;B6*[5C( ._=?_X*YZ/J%UX=
M^&^KQHK:=8W=[I\UPS+^ZN)T@DA!4,&R5@D.Y>!MY*Y4-ZS_ ,$T_'VC^*?V
M:M,\.V-Q_P 33PQ<W%GJ%H[1[E\^9[F*55!R(V68H"RC+12J,[2QR2<:=T;N
M2=2SV/@S]K3X2C]D?]I&+_A#[QK/3XQ:>(M"\S_2I+#]\VS>70*QCGADV[A(
M3'Y>]B=V?O3]L3Q<_CK_ ()\:QXI-O\ V<=;TK1M3:V23/E>==6DC1[LCD;V
M&>O?K7Q=_P %*_B!H_C;]I:X33'_ +0_X1K28=(O+B!DD07"RS22JF&8#;Y\
M:-G!5TD!7C</LG]J[PG>^ _^"==WX9U&9)]3T;1M#TFXFMF9XVEBN;*-F5F7
M<5)3() R#\P!XK6;?N]S*"UEV/B;]A?]EG3?VE/'&J77B*_>'PSX<^SRZA8V
M[NLVIO,TWEQK)_#&/+DW,"6QE5V[MZZ'_!0#]E_0OV?_ !YX9NO"%JVE^']?
MM)%MM.%Y+*;2X@\M)0C-\R1LLL1R9')8R#"JJ ]]_P $J_B9X>\(>.O&'AO6
M;^WTR]\10V;Z?-=31P+))%-*GV8$L"9I&NE98P.0K8&0*L_\%7O'VF:WXZ\"
M^%[)Y+J^T.WNKG4'61'2$W7D>4IVOE9%2,N05!"2Q$$ALBWS>ULR/==._4^E
M/!WQ!NOBE_P3AU;Q%?F>2_E\":I;SS7-PUQ).\%M/;F5Y#R[2>29#G)R]?)G
M_!)UFF_:(\0,S,3_ ,(G,<9P/^/JS[5]-?!GP]J'AW_@F'<V.J)*MS/X,UN[
M5%VRN\5R+J:$KM9@-T<J$)DE<A3@@BOE'_@EQX@L]!_:6NK6ZG6VGUC0+FQL
M(F5F\R19H)F48'7R86?+$#@]\ Y05U,UF[2@>L_\%?%'E_":/^!FU8$>P^QC
MCT_"M'1Y=87_ ()$R3:*UZM^+6Y\Q]/5C+]F_ME_M.=I!\OR!+OYP$WEN :\
MW_X*C_%_P[X]\?>%_"NBWOV^_P#"CWB:E)$H\B.6<PXA5\Y>1/(;S,#:I95S
MN#A?J']C7X@:!\+OV#O!?B7Q/J TO1;-KQ9KHQO)L,FJ3QI\J L<NZC@=\GC
M)I6Y:<6^XK\U22Z6/B']CW2_V;]3TC4;+XU-,-?N-0AATJ2\N[J.S6W*J 3)
M 1Y3%@3*\Y6,*8BK9$AK]#?AS^R;\,?"/A+QW:>"Y+VW\.>/]+2RE^QWHNHH
M[<V\J+):32*S?.MP[[G>1<D8P,"O#/C1_P $_P#X4?$[PO>>/_AEXGTSP?'Y
M-Q??;+>]2?0)"BS>8^]6_P!'7<0C.A,<<<+ 0YS7FO\ P29\?ZM#\0O%G@DR
M!]"N-&_MI87>0F":*6&+Y%+%5#K/\Y RWEQ<_+@S*\DVF.'+S*+1\P_M4?"G
M2?@?\=/%'@G1;F[N],TUK189M2GC>?$MM%*Q=D15#J96"_+R "<DDG]5_P!G
M?]BCP1^S?XXO?$WAO4_$%YJ-UI\FG.FJW,,L?E/+'*2 D"$$-$ /F.06R"<$
M?F__ ,%"8A/^V%\0H1,-TIL$V1L"^?L%N<,,'D_* OHR]Z_8_2?$VC:L=-:Q
MU6RNSJEF;^Q^SW"/]JMAY9,\6&.^,>?%\ZY4>:G/S#-U6^2(4XQ4W8VFP<9&
M:_)O_@JV G[1GAS)94'A.U)*D!N+N\P 3TR3CCG!XYQ7ZR-VK\FO^"KQQ^T9
MX<. <>$[8\C/2\NS_2L:/QFU;X3V?]D3]A?P9XV^%MMX\^*=EJ'BKQ)XKD.K
M(+C4)8A;Q,7,;EH)LO),K"1]YX+A=JLKEOF/]L[XB:I\</VK=1T&7Q"=*T32
MM3'AK31K,HM['3G5UAN;B8C[D;2J\ADY9D5 >%0+^IO[.,:Q_LY_"XAMK#PI
MI:@DDX LX_Z?RK\B/CMX5MM*_;#\8:9XXEO=#T>Y\5RW6HWUHRO+#IMU<"=9
MD8>8N1!+N&1\N[;M)4BMJ5Y29C47+%-'V%X@_9G_ &/+OP3<Z'I'CWPSHWB(
MVXBM_$!\8QW%Q',,8F:$W B8-@[T54&'8)L)4KQ'_!)/XB7UOXO\:^"&%U/8
MWE@NMQ)/.VRUEBE2&0"/&T-*MQ&6((QY"C!! C]-\-_\$S?@9XMT:#5- \:>
M)-=T:\+>3>Z=J=A/!(5)4E)$MR#M((^4YRI!/&!W/[.?[-_PA_9_\7>*_$/@
M?QCJOB76-*TR72]5TQ+Z'4YK./S5D93;6L(F$Q:!E50"3@C:QI.7NM,:C+F3
MT/C+]@OP;I?QZ_:DUG5?'5O#XBF@L=1UZZAO[&WD@N;R2X2,F>(QA<9N7E"J
MJ[7"$$!<&S_P4J^%/@7X:_&#P^O@Z'3_  ]/JFG"2_T'2[)K:*%ED*1S@I^[
M'FJK)L55VF NV?-S7GG@&SF^-'QF\?\ B_2OB'X=^$&O?;+C6M+DU/5Y;-09
M[C]Y EXBA55(9FS@!B<*$V[VC]V^!?[)&D>./C%9:[\1OCGX/^(FJ1W,%RFF
M:+KB:S>:VT",WE3M* Q1%CB^55<L@9<QXW':7NR^1@FI+YGTOI/P+L/@'^Q'
M\2=*L8=2M)]1\,ZGK%_9:K=PW4MI=R::$DA,D,:1R!/*V[@N"03T( _-O]E#
MX,ZE^T1\3-.\"C5-1T[PYY8U/6)+&=%98(595<([!7DW3^4K$.4\\MM958']
M@/VC %_9W^*>W:0WA+5B&7&&'V27&..W/_?7OQ^=7_!)M!)^T)X@4Y /A*<?
M*2#_ ,?5GW%8TW[LF:5(VG ^B?VF_"_@O]B']G3Q1<_"^UNO ^O>+KFST9=2
MM+N>X,3()'+9GF8Q 0"Z53%\P:1,8(#+\M?L._!_X+^+-+U[7?B]XB\/64<3
M):V&AZIX@&GW Q^]EN9$#QR,#E C*P4EYMRDJ#7U_P#\%2O#E]K'[,]G>V4.
MZTT?Q!:7U\RE08X#%- " >3F6>)"%#$ASQC)'R#^Q;^SC\&_C[HUY9^,/%^J
MZ+XX6^86FA6=[;V[7MIY0>.1$E@9IY%*2[U0DIY:EE 8,]4W^YOU'42]M;H8
M?[87PY^&OPK\:>%=?^"GC"SGM+[-P;#0M9%ZVCSVSQ,DJ7,<KR(T@=F&[<5>
M)RKD;47VO_@I)XRU7XA?!_X'>*8K'4;/0]:M9-3N[-"[VUO/-:VTEO%.QVJ9
M-KW*HS*#CS"%QOKM_%'_  39^ /@?38=0\0_$3Q!X=LY)HX5O=2UBPM8'D .
MU=S6RJ6(3[N<Y6OH3QM>?"/X;_#WPE\)O'VK6-MH.HZ7_9=E;^)V,:7<5G%'
MF26X"JD4JXC<.2A\P Q_, :3ELP2W1\@_LN> /V0_B;X+\+Z!K*R7GQ$N+)?
MM<.O:E>6,ES<O(J,L#H\4#;W:,1)&=Y3RBR[P^/L.^^$8^"_[)_B;P-X#N]:
MGNM,\/ZI_9-TLF=0^TR+/*IC:%$_>"1_EV*#TX]?AS]M7]@_PS\$O!>I^._"
M7B5=.TK[7%&_AW5I"SRO(\F%MY\AI-BE"(W!98XI)#(V,'Z*_P"">WQ?GO/V
M2=4U;Q9>XTSP7=WEJ;T^=-,MA!!'=?/R[MY:S.BJ@P$CC4+QS$KO6^A<;)6L
M?!W[)+? UO$7B27XY1WD5H\$1TKR6N3;O+N#R^8+4&82 %-I!*;#(7 .TU^G
M/P"_9F^$/P_\7-\0_A;*5L=1T=]+$.GZM]OTZ=?M D>979G<R;XPA(D*@)C:
M#DGRKXC?LA?!;]KZPN?'G@+Q#!H^N7LY>XUK0'^T0R3LL,CBYM-P:*;;RT:M
M$^Z4O(&;I\P?\$]?%&K_  W_ &NCX-L=6L-6TK5!?:1>OIEV;JTN%MHY98[F
M AE#Y:$[9&4X6:3N_%.\HMID)Q4TK'&_\%#$7_AL#Q[QGRFL&3=S@G3[;/7M
M[=*_17_@H!\6KWX/?LXZG>Z3?WVCZUJ]Y#I%GJMAM\RS,@:21]Y(*9ABE4.G
MS!G0C!Y'YT_\%")"_P"U]\0_E(P=/&2.O_$NM3D>HYQ^!K[G_P""I'A_4=6_
M9KL=0L;3[3#H?B*UU&[;*_N8O)GA5\$@G][/$,+S\WIDBI+X!)_&?-O_  3U
M_9%\(?'+0_%?C+QUI<FK:;;7JZ78Z<;N:W_TA426>:0Q%"PVRQA"'VD/)N4D
M*1QO[?W[,7A_X!^.O#U]X,@^S^&_$-K)%#87%Q).\-Q#L6;:9%)\EDFA()=L
M/YG&-NWZ+_X).^.M+D^'GC/P0=T6OV>J_P!JRQS.H:>&2"*+*=VV/!M<A0H\
MR/GY\5YK_P %7O'FDZWXZ\!^$K1C<ZQX>L[RZOOLK(\<'VDQ>7""&W+*$MRV
M&"X62(XP_P I%S]MR]")*/L>9;GJWQ@^*5_\9/\ @EW=>,]5^75KRUL?M<BE
M%\Z2'5887D^4(H\PQ,Y4  >81C'%?-O[ ?[/.C_M%>*->/C2>>^\'^&8OM)T
M9;R:**XO[S*"4;,';LMCO9'5V:.$,Q52*]\\6>%KWP;_ ,$E+?3KZ6.>6>PL
MM222)V=?*NM7ANHUW$#!"3HI7L5(!8#<<;_@CZHD;XK2%5WXTK!  P"U\2/I
MD]*5[4VT7O429\Y?MX? SPY\ _CL-&\*P&QT"_T>WU&TTQC(ZVBL9()(P\CN
MSY:W9\Y&/,P<@)C]=?@;KU]XL^#/@+7M5G^U:MJF@6%[>7&Q4\V:2W1W;:H"
MC+,3@  9X K\T?\ @J^NW]HCPX!T_P"$2MO_ $KNZ_1[]FO_ )-W^%W_ &*V
ME_\ I)%45-:<6RJ>E:26QZ31117,=H4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 (RAL9&?2N=\>>"=%\?^%=2T#7]*CUK2-0B:*YLIB?WBXR IR-
MIW*I!#*00&!!%='39%WK@Y_ XHNUJA-*2LS\H_B;_P $T?BIX%\6W.L_#6]M
M_$=A#J*R:3]GU$6.J6J ,PDD+[(]R-B/>DF6^\$4,P7.O/V._P!K#XK36FA>
M-+S4WTAI?/6;Q-XL%]:02JK%7\M)Y7W=5#(A(W=ADC]:TC$8P!Q]:5D5EPRY
M!K95GU1BZ.NC/F3]C[]BS1/V:K?^V;N]GUCQW>Z<+/4;SSV-K&&=9)$MUVJQ
M4LL?S/DY3*B+<R5])WF([?   W*,EBH SUR/\^XZU/'%''C8BKM&!@=!Z#\J
M<T:NI##*GJ#64I.3N:1BHJQ^7OQ"_P""5_CFX\=:U<^"];\-1>%99YI-,L-2
MO+J*>"*3<WE,%AE_U9<(K>8Q8*"V-Q4?>O[-_P )V^!OP;\+^")+@W=QIEI_
MI$WF;T:=W:2;RSL7]T)'8)N&[8%#9(->F*BJ !GCU)-$<:1@A% [G'?W-6ZD
MI*S)C347=%'7M+LM8TJXL=1LX-0L;F-X9[6YB66.6-E*NK*P(8%21@@@YP>M
M?FE^T-_P2ZUK3=4U#7/A5=VVIZ;,SR_\(M=2B&\M]Q15CM[B1@DH!:1@\S1L
MBQH-TC89?T^J/R4QTSW&23CW'O4QDX[%2BI;GY)ZG^RS^V%\1%&@>);O7+G1
M=0GCANUU;Q@EQ9Q+O5A(\0N7+;" Y 1C\F5#< ^BZU_P3A^*%S\%/#'A"R\3
M>&Y+F'6-1UK6-/ENKJ*Q>::"V@@QB%S,T:P2,'=4(\XJ-W+-^DTD(D7:PR,8
MZ_K]>.M+L&[<1S]:OVK?0CV*[GF?[-_PE_X49\&_#'@AY_M,^FVS-<S*^Y&N
M))&EGV?(O[OS9'V;ANVXW9.36W\8OA_9_%3X8>)O"-[Y:1:S83627$MH+H6T
MCH1'.(R1EHWVR#D<H,$'!KL8XTC4A %SR??W-$L"3(4D4/&P(96&001@@CN.
M:CFUN6HKEY3X-_8[_8I^*/[-?QB3Q)JNI^$KW1KNQGTW4/LES=370C81R)Y.
MZ%%)\Z*($N>$WX&<$8G[4'_!/[XA?';X]>)_'6AZYX8L]'U)[0Q0ZC/<+./*
MM8(F&$B93EHWP0W8>]?H;Y,?3'Z_G2^6N<\D_7-5[1WN1[*-K%.0&1,F-E9@
M=_E@'IZY'/MQ^E?G[XC_ ."?/Q%\'?M#W?CWX2ZQX6T+2H=434],TW4+JYMC
M&&.^:U=+:$#[,7,B"-&7]U(0V><_H9Y"8Z'J#G//'O3O+'N.<]:E3ML5RW>I
M\5_ML?L>^,/C7XTTWXB>!?$%O9^(M#L8+:+2Y)#;3*8I)YA+%=*V$<F55"D*
M,$DR# 4_+6M?LC?M9_$?^SM&\73ZSJFF-=*['Q%XHBO+2TSE#<-$;ER=JRMD
MHK$+N !) K]>/)7(.",8Q@D=*/+"C&..G))JU5\C.5%2>Y\K?L@?L5Z9^S1)
M=ZY?:BFN^-+ZT2SDN(0T5I80[8VEBA!QYF9%!,C $A% 5,N&\\_X*OZYIT/P
M;\)Z'<;6U.^UY;^.S\LX>&"VF65RVPH-KW,0PQ^;=E0=I%?<\T:1IDGRP#G<
M#C!.>?QS^M?+/Q8_8AA^,G[1VE_$CQ3XI.I:%IK6R0>&6TF%T\B%2PA>9F(D
M1IS)(P>-B5<H&'RXI3O)285(\L.2*W*O_!,?P%JG@G]FU+K546(^(-5N-:LH
MC'(DBVKQPPHSAQP'-NTB%25:-T8$Y)KZUVANH]ZKV:E5R1AFR6RFTGGK[#GH
M?7ZU9K&3YFV;0CRQ2/ /VJ_V0?"G[3.D6+WES_PC_B>Q98[37(81*QA!+-;R
MQEE\Q,%V7Y@4;Y@<%U?X$M?V*?VG_A1K-_IGA&2[AMY5A,]]X8\2)9VUX55G
M51')-'*RHS2J Z#!+%/EYK]>64.I!&0>"#2+"H8M@Y)SU/MT]!P.*UC4<=#*
M5)2=T?F1\"?V$/C5JGQB\-?$'XCZQ'93Z3K-K?7C:GJ9U#4KQ;9A*B@H[J0Q
M4)\\H*J2P5L;3]9_M1?LB^&/VH-'TZ74+A?#_BJR*K:ZW;P^:?*R6>WD0E?-
M3[Y7)5HW&X8#2*_T&UNC#!+#C'#D?UZ\]:40H%("KAA@\=?K^9_.H=1\UT7[
M-<O*S\A[7]BG]I_X3ZS?Z9X1DNXK>583/?>&/$B6=M>%59U41R31RLJLTJ@.
M@Y+%/EYKT#X%_L'_ !KU3XP>&_B!\1M82RGTG6;6^O)-2U3[?J-TMNZRH,HS
MJ5)"K\\H*KDA3P#^G A 8L <DYZGVZ>@X'%*L('/S=,?>.*IUF^A*I);,^'?
MVTOV)_'7[27Q2T?Q+X<UCP[IVG6NB0:=/;ZE=W ?S8YYY&V*D+ @K, &+ Y'
MW>]?;4C--&%>/(8$.N,CTQR.<_EC)JR(E7 "X [#@4GDJHZ9Z'YN>G2HYK[E
M*-CX2_;!_8'\1?'3XH1>-O!6IZ-IMS>6J0ZI;ZK/<H)IH1MBN$(60,&C6)&0
MJBCR@<N7)KVG]BO]GC5OV9OA/>^%];U*SU'5+W59M6F.FQR?9H=Z11B-'=5,
MGRPJQ.U<%RH!V[C] K;HA!48QT&XX'3H.W3^?K2):PQL66-5.=QQW. ,GWP
M/H,5;J-JS$J<4[GYF_%C_@F;\3_B!\5O&/B:PUWPA%::OK=YJEO%<W=VLL:R
MSM(H?%NPW#/8URC?\$I?B[;J637?!?7D1WMWGTSC[+@FOUB557)50I/)P.M*
M*/:R)]C&]T>.?LL_"G7/@=\!O#7@C6KBUU#5=+^TB2YL9I'A?S;J:5=I= W
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MW",>56%HHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P B)(C)MR<9VYQGO73;0/4\ <DGI3EQZ=*5W:P^5)W'4444B@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *2EHH *2EHH 3%%+10 FT48I:* "B
MBB@ I*6B@!,44M% ";11BEHH *2EHH *0J#2T4 (5!QQTJ/[/'G)&3G.<G/;
M].!Q4M% ";1G-&!2T4 )M%&*6B@!,"C%+10 4444 %)2T4 )M%&T4M% ";11
M@4M% ";11BEHH **** "BBB@ I*6B@!-HHQ2T4 )M%&*6B@ HHHH **** "B
MBB@ HHHH *2EHH 3%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4E+10 FT48%+10 FT48I:* $HI:* $VBC I:* $VBC I:* $VBC:*6B@!-
MHHVBEHH 3:*6BB@ HHHH **** "D90W6EHH 9Y*9R%P<8R.#CGC]::UNC,Q.
M[+#'WC[].>#R>14M% #5C16)"@$]2!^/]32TM% !1110 F!1M%+10 F!1M%+
M10 FT48%+10 FT48%+10 FT48I:* $VBC:*6B@!-HHQ2T4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 45',Q5.&VG^\1P.#UJO'=2-M^3/S E3\A"
MGH<'W]<'@\9XH N454CG=FVD.I4_QE1NQQS[=#D>H^E(MRP09+,<< +AO;.>
MYXZX_I0!<HJI)<.K!2&5B?KVR.<8YP1R1S^%+]HSD!\EF*]OEP2"?IQW]/PH
M M454,SDL"Y'(4,B$@DX]NF6]>W7KB2.4/,R[VRH^[MPIYZ@^W3K0!/1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX&AB\+C*M7>G!..MM>9+YGZ*T445UGSH4444 %%%% !1110 4444 %%%>?\
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MD>2YG&HYS-Y8Q-Y6SL+[R\2[,=\I_;561PK_  &(5B"S+K>[&!R,^P[=<'\
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MX^/Q-^%_A'QE]G.F#Q!HMGJWV%'\XVYFA28QARHW[0^TG:,XZ \4+XH\5?\
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M-V.1[8[<XH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ.9S&H;DX/
MW5QEO0<^^/2@"2BN,_X6YX,?QT?!(\9: OC7&?\ A'?[2@_M 9B$W_'N6$A_
M=9DZ?=YZ<UUD;/YVUV'W>F.N,<C\_?M[T 3T444 %%1S2^3&7VEL=E'/^?K7
M$>&OC1X1\3?$SQ%\/K+7;6X\9>'X(;G4=*"/')%'*B.CIN $J;98B6C+!3(@
M?:64$ [NBN>^('C[0/A?X.U3Q3XHU2WT;0=,B\ZZO+DD*BY    +.[,0JHH+
M.S*J@D@4[P?XNL?'7A;2O$6B7*WNC:O:QWUE=&)X]\,J!XV,; ,N59.& /7(
M'2@#?HKBO$7Q8\->$_''A?P;J>IM;^)?%9N_[#L_LTLGVO[-$)9_WB1E$V*0
M?G89[9Z5URR/M&&#+_?[]OP/?Z>E $]%<C\*OBCX;^,W@;3?&'A#55UOPYJ7
MF_9;Y;:6W$GERO$_R2JKC#QL.0.F1D$5K>,/%.G>!_"FL>(]9N?L6CZ19S:A
M?77EO)Y-O$ADE?:@+-M16. "3C !- &Q16+X/\6:;XZ\-:/XAT:Y^VZ-J]E#
MJ%E<B-D\V"5%DC?:X#+E'4X8 C/(%;5 !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!RGQ2^%OACXT>!=2\'>
M,M,_MCPWJ/E_:K'[1+!YGER+*GSQ,KC#HK<$=*\"C_X)>?LR1L"OPS&<@_\
M(>U,]/\ MYKZHHH \]\+_L_?#KPA\*K7X:V/A+3[CP);;MFA:HK:A;G=.UP=
MXN#(7Q*Q<;B<'&,8%<;\(_V(/@C\"_&4?BOP5X$@TKQ#%#)#%?3W]W>-"L@
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MU^5__!<CB/X)X&.-;/'_ '#Z_5.3[H_WA_,5^5O_  7(_P!7\$_IK?\ [CZ
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MB5IGOH+E)&DC#1*# 0APY8,21E!R:^HUC13D*H/7IZ]:1H58@D$X.<9./RH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_CQX[^.OQ-_9=^'?B_\ 9]L?[.\9^(?[/U:\LS)8RFVLI[*262+?>*(WVRO
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M^-'P$\!_M"^%[;P[\0-!7Q!H]M>+J$5L;J>WVSK&\8?="Z,<)*XP3CG.,@$
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M<CY=O\^O!&??\A8JM:M\[@%6S\QQP1G!&1C@\]_059H **** "BBB@ HHHH
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M,/ /PPT?PWXY\4?\)IXBTH36LFO,"LE] +B7[-)(",^9]G\D.26)</EY#\[
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M3(K\_?VM/VB?&/B7]GO4M(\:?"G5O!L7B?[$ND77VR&\@=Q,D[)< *DEN^Q
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M)3=NQSTSGIU_Q-*L:JQ8#YCW_I]*?32459#C%15D-6-8\[1C/6G444QGS_\
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M^84))*\D$9[@'&0/3H.E>?\ QV^!GA+]H3X:ZCX*\7V'VG2[PAXKB'Y;BRN
M#Y=S ^#MD4D\]"&96#*S*0#XD^.?CGXY>,M6_9SB^*'PNT;X<Z98_$_PXDT]
MOKJ:A+J&H9DV-;PPEEMX%5;@LDKNY\R$*YV,U?HQ;-NR5;>OW>V 0>W\OPKP
M'X3_ +&OASX>>.=.\7ZMXO\ 'OQ&\0:.)?['O/&_B*6^_LLRH\<_DHH1"949
M0^]6YB0K@Y-?0:H%QCZ=: '4444 %%%% !1110 4444 %%%% !1110 4444
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MX;R.=9$$\*RJKJ#+;7'R'<$&T>8YW;?HGRU] /I0L:IT&.,4 .HHHH ****
M"BBB@!&4-C.?P)%?,/\ P4.\.ZQXN_9_'AW2?'7@GP!;ZQJD=IJ=YX[N(;>R
MN[7R)V,"/+#+MGWI%*C*%=?)+*RE>?I^O'_VHM/U#4?A_81Z;\%M'^.MPNIQ
MN?#NMWEE:P6Z^5*#=![M&3<N0@ &[$QQP#0!^!_AWP%?^)/B]/\ #H^/_#6E
MPQ3W.E-XDU+6C%H3PV[23$K<;?\ 4R21%X_EPS/'P"<U^UO_  3N\.:QX+^
M@\-:OXY\%^/8M(U&6TT^[\!W$,]C:6HBA(@D>**,&<R&65F<,[>=N9F)-?D_
M\(K#49_V][NSB^#&C^)M0&OZVA^%UU=V:6,#+'=;[832(;=EML,RD+AC -H!
M*X_9_P#9;L]1T_P'?1:G\&=)^!L[:C(Z>'M'OK2ZBN5\J$&Z9K9%4.Q!0@C=
M^Z!)((I62V)44MD>Q% 1@C-1R1A(V91E@.,Y-34UU#K@_H<4RS\F?^":\(^$
MOQ1^$-S#;:C#H?Q4\(:S8L\%X'MKO6-/U:Y<RS1&7"^791Q1JRK@M/A<[Y6'
MZO6LGF$$J5?'SJ?X3G&/S!]?K7Y0>$[<^"_^">O[+WQF@M-0:7X=>,I[O4[S
M2KHPW$6C7.K745["D?FHLOG.+6(KU(8@E4,AK]7K;"S&,+L5%PJ[< +G Q^7
M\OK0(MT444 %%%% !1110 4444 %07BNT:[0&YY!R,\$=1TYQSS4]1S ,F#Q
M2UZ":NK'PO\ !/\ X4E'K_QB/Q+'@5M>;XA:QY/_  DWV,W(MMR;=GG_ #;,
M^8>.,EA7MOC^\\$7_P"RS\2;?X?S:)/X?M?#VJ6JP^'7@:UAE-M)(R8B.Q7_
M 'F]AQ][/>NUU']G?X7ZS?W5Y??#KPK=7MW(9Y[J;1[=Y99"VYF9BF6))).>
MN36[H_PQ\)>&O#M[X?TCPSI&F:'?;_M>FVEC%%;SEU".9(U4*Q9553D'( %<
MM.@X-[:GTF)S.C6KQQ,>>ZE%V>UE;_(X_P#9]ACA_9Y^'31D OX9TUSM&<EK
M6( Y';^@ZX%?&>E'^Q?V$?@=XKE@FN].\*^-X-<U*6 QAX[==2NT+*&8!F+R
MJN <_.,\ U^BNF:+9:-IMMIUC:PVMA;PI;PV\*!8XHU4*J*HX50  %'%0Z#X
M5T?PIH]OI.C:59Z3I=N6,5G8P+#"A8EFVHH &223QR234RHN45&.]C&CFD:-
M:=7DO>?-^>GXGQG^WG^T7\.M4^ 6J>$-'\26/B'6=;F@CM[71;F*Y,7DW$4S
MF38QVJ=@4#JQD& 5#,OV;;[WLU 4Y^Z.3^A[< ^@S@9KE[+X%_#G3M%O](M/
M 7AN#2M1\H7MC'I,"P70B.8O-0)B381E=P..U=M]GC4B15&Y>X'/_P"JMHTI
M1FY:6:.3$8BA*C"A0@[Q;;;?>W^1\A? CXG:!\%?B!\7_!OCZ[C\%:EJ'BR^
M\2Z?+K,D=O;7]C=.!&T4[-L=OW?*Y!'0Y99-MZZ\6:-\=OVNOAZW@F]@UC3?
MAY8ZC?:OJEN&>T#7D*0P01S*"C29W,5R %1L,61U'T9XI^%_A+QXUJ_B7POI
M&OM9EC;'4[&.X,6XJ6V[U.,E%SCKM&>E:/AGP?HO@S1X-)T#2+'1-)MRQAL=
M/MT@@BRQ<[8T 499BQP.IS4JC+E2;UN=4\?AY3EB84VJDHVWTVLW;T_,\)_8
MWAW_ /"Z]T9C7_A96M')RK$GR,MP!^!YXQS7T+=6Z1V\I0;"^23QW&#U!]!V
MJIH/A?2/##7_ /96F6>FF_NY+ZZ^R0)%]HG?&^:3:!N=MHRQR3@9/%7K]2]I
M(BD;V4A<C/./3O6D;TX:'%C*T<7BI5FK7M^21XW^RG^T$_[2G@'5/$[: ?#@
MMM5DL1:M<FXWJ(89 ^XHG42]-O;K7MJFOD?_ ()I^#M<\$_ _6K#7]#U/P[>
MMXAFF2SU6TDMI#']FM@&57 8KP1D]U8=J^MHQ446Y4XN6YMFM*C0QM6EAW>"
M>C^1)11170>4%%%% !1110 4444 %1SLRQDH-S]0HXW8YQGMFI*1E##!S^!Q
M0!YWXD_:%^&'@G7KS1O$OQ,\'Z!JUL5\W3]2UVTMKB+<BNN^-Y RDJRL,CE6
M4CK7@G[6'[;>F^'OASINE? [Q;X1\=_$CQ3K-MX<TVVTW6K.\DLGN X%UY(<
MJVUE5%\PB,/*A?<H*-[_ .*/V>?A7XWURYUOQ'\-/"'B#6;K8)]1U70K6ZN9
MMJ!%WR21EFPJJHR> H':O"?VH?V+M%U/P3H>M_!?P'X(\-_$'PGKUIXDL((-
M$M[--6-MO;[#)+$(RJ.S*WS,%+1J&* ^8BE>V@GL<E+^QKXTU;2;^XU/]I'X
MIW/BF[-Q</?Z9K+66E":1V=-NGYPD>&7,2RA3R%V*0!I?LL_M<W7AV;QM\.O
MVC/'/AO0_B+X1OXXO[6U#4+.QM=6LIXQ+;RPDL@=MI).(TQ&\&X%R^.;E_X*
M)>'8[4Z.WPX\<'XNAO);X:MI$AU!IC:FXWA@OS098#?M,I3]YY&W)KJ?V6_V
M78?B%)XX^+'QV^'ND:CXO\>:BE]::'XDT^UOFT738DV6D!5X!Y4^PXD'4K'#
MO"R!U'%0]KS/GV/.PKK.<O:;=#W[3?VF_A#KFI6>FZ5\5_!6IZE>3I;VUG9^
M(K*6:>1V"I&B"7+,S$* ,DDCBO2;>1I 26#CIN7&#]/Y?A7G6D_LR_![0-5L
MM4TOX4>"--U*RF2YM;RS\.6<4T$J,&21'6,%64@$,#D$ BO25C5,X')ZGJ>@
M']!7<>D-G4-'@^H'OSQ_(U\*_M_^%_A]XN_:._9HTKXH/IT/@>[7Q,=3EU34
M6T^W^2SMWA\RX5T*?O0F/F&2=O\ %BONFX/[O&X*2< DXY[8X/?%?('[57A7
M1/'W[9/[*>B^(=&T_7M#G/BL3V&J6L=S;3;=/A8!HI 0VUD5@2." 1TH \#^
M/'P5_8I^'WP?\4^)OA_XLT/1/'6EV;:AX=O_  SXUGN]034(F#VPAC6XE+ R
M^6I8)E%W-N0KO7L_C5X#B_: ^(W[$6@?&#2)]6FUS0-9G\0:?=E["22\&D6D
MSAQ"8VB87"#*KL .%QC(J/\ :8^#.D?L:_%KPI^TO\-?">CV?A?3+A-/\9Z3
M:6L&V*RG>*W%U80'8L4Y#O$QBD3YFC)0QR7!/6?M;^"_!G[0'[3G[*NAZU;V
M_B?P?X@@\2SRK87KQQW<(T^":%TFA=6*Y5'!5L,O3*D@@'._M*?LQ_#?]CWX
M8CXD?!O2+WP;\1[+6M+M]+L[37;Z4^(B]Y 6TR2W-R3<QR %S"A#GR 0<*<_
M?9!A7 16;<2%0X).<D@$^Y[UX)\,?V$O@+\)O$\'B3PM\.M-BUFW"R6UQJ%W
M<7PMV#HZ2QI<O(L<BL@(D4!UP0& )%97BCX%_M#:IXHU6_T3]ILZ%H=S=S2V
M.CKX"L+C[#;M)F*'S6<-*$4J-[<G;SG)H \8_:6\8>"O'?[1GC32_BSXRU#0
MO@A\.]'T^SU?P[]NGM8]8UO49&N8/W=H#+<HEO$) N0T;VZN!L$I.O\ L_\
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MCZ5^T40_>-]/ZG_ 5^+O[-/_ "F/UG_L=/%G_HG4:_:./[[?3^IH EI*6DH
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M110 4R2-95VL,C_(I]% $?V>-68A=I;J1Q_GJ?SI4A2-B5&">OIU)_J:?10
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MU: 75G/<^#?"-JTT1X601SP*X5AAE)4!E96&58$_JE^W+XB\*^%?V3OB3?\
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M4@BMW]A#X6_&OXG:'X]\;_#WXKW'PA\(:YKLDEK8W'AV'5CJ+ID278CN&"1
M[E0O"S!WBD4[1"@K.+=S\_X7S[,,VK5Z6-H\BA:VEK/^7S/U/HKYZ^&?P?\
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MS'I-CH?[;G[6UKI]C;6%N\WABX:.VB6)7EDL)I)GV@<LTCN[-U+.2<DU]:T
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M@NMY:.)I-RN'CCVHQ9A%N$;0\_\ $KQC\(/BQ\4OBCXG_:&\97R?"W1?$O\
MPAGA+P7-=7D*_P!HV4(.HWIL[ >9)B28A)RYPMPZR!<PJ #])[>X\YCC+J>0
MP7"]!QG\??H?I4DTAC4$ GG' SUX_G7S3^Q!X#\(>#?#OB6X^%WQ+7QQ\)M2
MNH[K0-$!$Q\-O(GFW%J)F<RX8RHY@E5&BS\P:1Y';V+XUZ]XS\,_#'7-1^'O
MABW\8^,XHT73-'N[R.UAEE:15W/)(RKM0,9"NY2VS:&4L" #K69KE=CH"H_B
M4]3C^'C&.<?G4<LPX$B!-Z9",1GJ!C'?G:.O?G'&?C3]B_2O%UE^U)^T]!XZ
MU:QUGQ@R^%YM0GTNW:"R#26,[K!$C'>T<2,L8:3#R",,V"QSF>$_@EX9_;B^
M+WQ5\8?%3^T]8\/>#_$MWX'\-^$&U*6"TT\VH@^T7AD@:-C+<2X;!Z# )EVQ
MF, ^X[4EB2<@\Y7!&.@YS]..V.G%6&57 # ,,@\^HZ5^=OA7]J&3]AB7Q9\*
M_$EUJ7C7PAX+\9:)H%CXAU6?9/IND:E92W:HZ10NT_V1+=@ H&\-A?*14BKU
M*3_@H1_P@_BA])^*?PJ\7?#[^UK0WO@^/RUU.[\1?O-JV?D0)_HUZWF0C[.[
MG87 =TRAD /K]8U5MV/FQC))-$<2Q+A=QX RS%CP,=37SG\(/VNYO%7BOQ;X
M+^)?@VY^$/C7P[IK>();'5-0BN[2XT<!=UZEZBK"JH[;7!)"X(W,5E$?!:S^
MWMXR;P?KGQ)\)_ S5_&'P:M(;R6R\76NLV\4]TL#21><=/*&>.$SIAG.62$-
M,R#!C !]CSR>6J_-M!8+GCOP.OOBD@F,S;LC9M&-IR"3SG/ITQ^-?.OQ@_::
MG\._L/7_ ,9K*&XT74-0\*6NHV-O;I'=265[?Q1I;?ZT(LBQSW$1+%<,J.=A
MR%KY[_8NT?PY^QWXZ_:0L?$FIZ?X?TCPCI'A ZM??:9);9[M]-D>YE1I/G<S
M7$CE$"J6+HBJ,A0 ?HI17R[X=_;@M8?@7J_QB^(/A.X^'/@:28#PO#>W@N-7
M\11,7,)2T"*(FE4*47S'!&^0L(4$KX.I_MI?$_P+XE\!Z+\0OV?-0\''QAXD
ML/#]EJ$?B6VU*RB\^39(TLL$9V2J60I"RCS )2''E$$ ^P**JM)(NTLQ(;HJ
MC!/4XQSV&.M>-?M,_&K7O@S'\+'T*'3;E?%?CS2?"]ZVI(SB&TNO-\R2((Z_
MO!Y8()+ #.5/8 ]OHJ"&1FF*L^2%R4P,\G@G\C['M4] !1110 4444 %%%%
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M2"03]30;="K* 5# @["5ZC':I** &JH7H,?_ %Z4]1]:6D/4?6@#\6/V:?\
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MXX^$O@CXG-8GQCX.T'Q7]A\S[+_;>FPW@@\S;YFP2*VW=L3..NU<]!0!\_\
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MTZTNH)[I%<;3 \DF$8'),;AUC=2M?5/[0D^?VY/V3F\MF)_X2X_=.X_\2N/
M'&>Y&/SKZ3NOAWX5OM)T/2[CPUI$^F:%-!<:3926,30Z=+ NV![="NV)HUX4
MH 5' Q5J^\'Z%JFMZ1K-[HNGWNL:/YO]FZC<VJ27-EYJ[9?)E8%H]Z@!MI&X
M<'- 'Q-^T%X=U+QA^V/\1O#NBVC:AJVL?L\ZG86ELTBIYL\FHR1HNYRJJ&8K
M\S$+SUQ6)'^U;\,(/^"=NO\ @W4?%-OH/C'0O!-QX*O/"VL*;?51J4-E]C*"
MT)\QE>0J0P4A S&388Y5C^V_%WP]M=5CUK5="73_  ]X[O-'FTBR\7'3HKF[
ML4;<T>-PS)''*5E\DL$)49]:^)=>^&_[0'Q%T'6_#&O?L]?#A/B+K.EW>@WG
MQMN=2LU$\3P/:M="&"$W8:2V(C7 4 NI:../,2@$>JZ/:?&CP/\ L1_!V6TM
M=10Z;IGC/668+?16MCIVF1JD=S;]/(NY9C!YCL%W*R@2$X'&_%+]E/4?VH/V
MROVEFTOQ<="O_#/_  C.H:=IEY:I=:9?7YTY3"U[$ZNKQHD5Q'AHW_X^B<,H
M:*7] OAQ\'?#/P[T[PU#I^E6\M]H'AZU\,VFN7<$1U.2P@4!(9)U4$IE0Y48
M4N2P5<"NGT_PCH>DZYJVM66C6%GK&K>3_:.H6]LB7%[Y2E8O.D W2;%)"[B=
MH) Q0!\%_&CXZ7WQR_9E^&?Q.3POJT^I?#+XBZ7J7Q T.UL&@N-.ET]'.HB*
M&5\LB-(C#YR51\RE-DNW1_:N_:/^&GQ:UO\ 9ETSP9XUTCQ)J%Y\4?#^JBSL
M)1+-';*S*SS(,M;L&N47RY@DF=V%^1\?0/QS^%OB?PGX-U;7_P!GW3O"_A3X
MCW&IQ:M?P_V/:QCQ2J&5Y+*YFPI#2&1F\W<&!!&^/>SKX3X3^ OC#XK>.O ;
M:A\ ?!_[//@WPOXDL_%6H#0]5L[C4-:NK2*X-BD?V.W\M8XY96,BR_,4G_=L
M"&R ?=*1+(K!QO#CY@W(/M@U^>7[3O\ P3F^$GA./X5/\/\ X7ZA(=0\?Z18
M>(&T^\U*]*Z/(9?M32YF<PQ\)F8;2N0-PSS^A5K-YNUE!\MD#*6!!/X8XX(Z
M_E5AE##!S^!(H \G^!7[,'PQ_9R;66^''AL: -9$7VYA?W-T)?*+^6!YTK[0
M/,D^[C.[G.!CUFF+&JD$#) P"3D]O\!3Z "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY6*@
M;3@YXR.#QTJ2D90PP1D>] '!:O\ &CP3X=\>6O@G6_&&CZ5XHNK:VGM=)O[A
M()KY9Y9(HO(#D"5FDAE4QQ[F!V9 WKN^.T_X(R?!29GC;Q5\00"Q?G4+(9[<
MYL\D]^?[W&<YKZ*_::_8R^%W[4UK:2>--+FM]=M(OLUGXATN;R;ZWAWB1H]Q
M#)(O#@"1'">9(4VLQ:OBR;_@FS^TKX!LK+0OA?\ M#7$7A:"-V6&?5=2T3[-
M,TCM(B6]L9DV%OF+!^6=CMXW, >U?#__ ()'?!_X9^//#?B[2_$OC:?4]!U*
MVU6UCO;ZS>!I8)5E02!;56*[D&0&!QW%?4_P]^,W@3XG:QK&E^#O%FC>*+G2
MHH+F];1;M;N*%9VE$698\IN)@DR@8LH"D@!E+?GUHO\ P3%^-'Q/\FR^-_[0
M.J:MX<MKZVGATFVU"^U8SD!EFQ]K*+!($9E20)*,.Y(V@JWW'^SK^S7\//V9
M?#,^A> =#;3OM(C;4-1NW:6\U"2-=BR32,.?XV"+MC4NY1%#G(!ZY1110 44
M44 %%%% !2'J/K2TAZCZT ?BQ^S3_P IC]9_['3Q9_Z)U&OVCC^^WT_J:_%S
M]FG_ )3'ZS_V.GBS_P!$ZC7[1Q_?;Z?U- $M%%% !45QDJN 2=PZ?Y_G4M(R
MANHH ^.?CI>'X5?MU? 7XA?;M1M--\7VE[X"UF3[*9K/!)FTZV+"-FCEENY!
M\^_#"!C\J+(3]@6TQF#;CR"1C&._'7GM_D8KY<_X*5>&]1NOV8[GQ?X?_M!?
M%'P_UK3_ !=I!T^%9MD]O.$:66-D<-''%--*<C \L,WRA@?H/X;^-+/XC>!?
M#?BS3XYK?3O$&E6NJVD-VJK.(IHDE4.%9@& D (!(!S@D8H Z>BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *KWW_'NY.-N#G/I@U8JKJ2^99RQC
M!9U( 89!./3O2=[.Q44FTF>8_L\?'S0OVB_!]]XE\/6.J:?8P:@]BT>K1QQR
M&18XI"5".XVXD Z]0W%>K+7R1_P37\(Z[X.^".N6?B'1-4\/WTOB*>X6SU6T
MDMGV&WML,J. =N<C./O!J^ME7YJQHMRIQE+<]'-*5+#XRK1H.\$]'\A]%%%;
MGF!1110 4444 %%%% !1110 444R0LJY7D^GK[4 /HJI)/M8,;A1&1G[H(ZY
MZ]A@@5-$SLY!S@#'([]^>_;]: ):*** &R9VD+PV.*^5?C'\:OCA)^TY:_"C
MX16W@!L^#D\5W%UXUCO>AO7MC&CVS?\ 7,@%?[W/'/U5(H9>0#CGD5\*?&GP
MGXY\9?\ !1ZUL?A_\0Q\,]7C^%"W$VK?V'!JWFP#6'1H/*F(506:-]P.1Y>/
MXC0!L?$;X\?M0_LW:';^._BEX?\ A=X@^'=E>0P:W'X'DOUU.V@E;RQ/&+MU
M1]LC1C8,EBP'R+ND3N_VGOCE\3O WQ6^$?@#X7Q>$7U;QL=65[GQC#=-!&;.
MWAF7!MW5ERKR9)5N=F,<U\S1^'?'_P 3_P!IFZ_9U_:7^*FL>)/#EW%#K_AW
M3O#^G6NGVGB>"*5W'VN:VC$L*!()LV[8!DBW),"D+2^N?MHMXV7]JS]F$_#W
M^P4\8D>*38_\)1YYTX_Z#!Y@E$!\S_5[MN/XMO:@#7\0?'/]HG]GW3X?&/QF
MT/X;:G\.HKNUL]6NO!5UJ$5YI,<]Q'%]M>.>-_/B0L08HAYC&12.%8UV/QG_
M &@_'EI\8M-^#_PH\,Z1J/C>]T)O$=SK7BR[:#2=+LUN3 "T<7[ZX9W1X]J8
MV-)$V77?MXCQ)\$?VAOV@-,3P?\ &G7?ACI?PU-]:ZAK-IX/M]1FN]6A@N(Y
MOL<CW#KY$4FPDRQ,'5D0 %2PKS_3_AKXM^+'[;W[2NA:3XWO_ ?A&4>%Y];O
M/#,C1:]/(NFG[';V]PRD6Z%O,DE?:7Q'&@PKR$ 'K7AG]H+XW^!#\0=$^*OP
MO_MOQ!H>C?VWH6J_#VSO+C2-<+;(TT\$K++'<><P!)3A-\C(D<8DEY_QQ^TC
M^T-^S_X;N?B3\4O ?@F]^&BW%N+O2?">J3MKVB17$Z*C3/,HM[IHMWDLL6S?
M(RL&1 Q$_P .?'5Q^S?^T!XF^$GC?XE:AXF\!KX-M_%VF^(O'5];?:-*+:@]
MI+;S7/EK]I\Z66-D>1AL"QQ*ASFC]KSX5>/KRQ\1^/+[QQ8^+OAEX8\KQ))\
M*-5T=;6QO(+*)99H9;^%O-DSY4DT:2QR1>:(ED1U3@ ZOXS?'[XFWGQ@L_A/
M\#_#V@ZYXHLK./5?$OB#Q-)(VD:+!('$%O,+=Q(MS*R%@G4)M8*ZL[PZ_P"S
MG\?_ !;XP\5^*?AM\5- T_PO\4/#C+<E--FQ8:WITCNL=]8B1C(T:E-D@YV,
M4#,KLT4?F?['?C.R^(W[4O[1?BG3XIX;+7M-\%:I:PW8"W$4<VD/*JR $@/L
M<9P6'4 D#-<;^U0P;]J#XP!-P$G[-NKDAEQC-]+CY<=<\X/)W'Z4 =3X5_:0
M_:1_:&\#3_$3X.>#? .F>#"+H:7IWC2^N)M6UA8994\Y?LY2"#>R>4(I'^5T
M<M(4*L?IKX,_$:^^*/POT'Q5J?AS5_!VH:E$3<:'K<0BN;.1)#&ZD$ E=REE
M+*K,I5MB$[1\F? ']F3Q_P#$#X#_  V\6:I\;O%WA#7/^$;TQO#VF^$+D1Z-
M8V\5O&;(7=HZ'[=*?EDG\Q@KEVC&V.-2?H3]C7XMZE\=_P!FOP+XQUY/+UV[
MLWM]0VNG[ZXMY9+:2<A%55\UX7D"*H50^T9V@T 8G[4_[7_AO]G/POJ%HMVV
MJ?$6XT6\U#1/#=O9O=RS&)6S<7"1$>7;1['DD=G3,<,Y3<4('1Z-^T!:Z'^R
MKH?Q?\;36]I;OX3L_$.H"S*PJ\LMJDIA@69\%WD=8XT9QN:1%SDU!^UEX3T,
M? +XQ^)?[&T\^(SX!UC3SJYM8S=FU%I-((/-QO\ +W_/LSMW<XS7S=^T@BC_
M ((]Z*,.<>#O"Q"JI;I)I[<]@..I_K0!OW_[2W[3_@/PG9_%7QI\+O"W_"LC
M,UUJ7A;1&NV\5Z7IKLX2>19&$3-$OEM(NU3C=O2 ;VB^HS\<?A_'I>H:D_CK
MPRNFZ;!:W=]>#5[<Q6D-TH:UDF8/B-)596C=CM<$%200:YW]J@D_LQ_& D;E
M_P"$,U?(0XZ64Q(QR!G/7N#[#/P[^PW\#?!_QC^+WC"^\76 UZRT/P9X">VT
M'4,3:7+<3>'41;B:U8%9I(HPZ1E]P03S'&XJ5 /T+U[XO>#/"?A6Q\2Z[XPT
M+1?#]^4%IJM_J,$-M<;X_,3RY&8*Y9 64*S;EY&1751W!D3*-YF,CC'S8)''
M8]/7CVK\_OV+_P!E3X>>/K?XUZ;XMT:Y\3>'O#7C;7O!?ASP_K5])=66A:?O
MCDD^Q(SDP3R&1=\ZGS/W:E65C(6X+PWK_B#Q9_P3;_9M\+R^)M6L;7Q]XYMO
M!.N7MG< 7<NDRWU_";=)75MJB.&) H&-B>604+*0#[^T;]H;X;^)$C_L7XD>
M#M8:2]M].0V>N6TB-=3E_(MP5D.99!')L0?,Q0X!YQY-^VQ^U!XL^ %CX9TS
MP18:3>^*M9M]8U4'7H)7L4L=+T^2[NP3%(KB9AY(C&"I.\,5X8>8_M@? ?X;
M?#_Q)^SKXB\*^!]$\(:Q!\5M#T]KO1;*&RW6\C-(ZR"+"R8\B)@S!BH!P1N<
M'$^)JWOQ&^,7[8/CA;N$Z#X(^&5WX&L9K"(R1WDDEH]]=YG,A43VTQ>)T494
M31@A2IW@'U[\-_B];:M^S_X1^(OC+5-+\/1ZGH.GZGJ%T\R6UC;RW$,;$*\K
M':I>0*H9B3E1DY&>FU3XD>&=#\(IXKU#Q)H]GX5:WANAKEQ?1167DR[?+D\X
MMLVOO0(=WS;AC-?F/^SK->_M$?$#X%>#?CIH.K:!X L?"UM<_#[PM<6K/I/B
M:ZL[812WE[)P781Q-+' Z!#%)&-P27_2_IGXF>'8OC)_P4&\*^ ?%I&K>!/#
M?@2;Q9#X9O((IM/N=2>\DLA-/%)&1-MAD79G_5LORD9D# 'TQX/^+7@SQS=V
MUGH'B_0-?O+FR;4K>'2]4AN7FM5F:!IU5&),8E5HRX&T.K+G((KK)F*QDAMO
MJ<9QQ7Q=\-?AAX2^%O\ P4VU>S\'>'=.\,Z?J'PJ^W3V>EP+!#YPU2*$LL2_
M*A\N"+*H%&?F(W,Q/TG\;?\ A:7_  BMI_PJ3_A$?^$E^W)Y_P#PFGVO[']E
MV2;MOV;Y_,W^5C/RXW9YQ0!J>&?BEX;\6>.O%O@[3=2^U>(_"HLSK%D+>5/L
MWVJ(RP'>RA'WHI/[MFVXP2#Q775^:GP;_P"&H8_VKOVA?[";X2_\)ACP\?$C
M:@-4.GC-BYMOL07]X?W>?,\SJ0-M?HCX/DUUO#&D#Q1_9X\1_8H#J7]D^9]D
M^U>6/.\GS/F\KS-^W=\VT#/- &U1110 4444 %%%% 'BG[:'PAU+X[_LQ^._
M!&C,PU;4;2.6TC5$8S3031W$<.7=%7S&A$>]F 3?N.=N#^/GQ*_:J\4V>K_L
MYZ%XO^'-QX<U[X(W%N)+6[>:SDU&.-K.2!6AEBW6[M#;0Y<[PQEWA5!"U^O'
M[<7Q8U_X(_LM^.?&/A9[>+Q!90V\%G+<P>>D;3W,5N9/+)VNRK*S*'RNY5W*
MPRI_/CX7_LD_MH?%KX<>'O%UE\=;[2=.UVQCO[6VU3QMJWVCR)06C9Q"DB#>
MA5\;B0'4'!!  /=?^"?V@^.?C)^TM\3_ -I;Q=X9F\$:;XGTN#3M%TN6W=4O
M+=UM76:-Y"KNJ0VMJ#*(_+F>=V0J$*#]"*^*OV*?V8_VB/@M\4]5UKXM?%;_
M (3GPU<:-+9V^FCQ#J-^([IIX'6;RKB)$&$CE7<#N^?&,$U]JT ,D8J!M&3D
M#BOEV7]NW0K_ /;(T;X"Z!I]OKK74=RE_P"(+>\8)IUY#!<2R6C0F+$CJ((P
MQ60!3*RG#1,#] _$CPW=^,? /B'0]/UBY\/7^I6%Q9VVL6>3+8RR1,B7"@,I
M+1LP<893E0001FOS0\%_LW^$?V7_ /@I]\$?!W@\:A/82^';R_NKW5)1+/<W
M$EOJX+,5"JA"1QH%1$XC!(+;F8 ^Y/VI?VKO"?[*?P[D\2>('.H:K,)(]*\/
MP2JD^HS@ X5BIVQ(67?,1M0,!AY&2-OGGPW_ ,%0;_2?'WA_0/BW\%/$WPCT
MSQ!<"UL-:UJX\N'S/.B1WD^TP6P6"-)-\D@9BN0-O.1]6_$CX$^!?BQXF\&^
M(?%>B?VEK'@Z^_M'0KH7,\1M+@RQN7VQNH?YH(CAPP^3I@D'X2_:<\:WO_!2
M/XF:=\#_ (4"WD\#^&=335_$OQ"D5I+2!U26)!;E6"R+MDG"\_OY!E"D*-,X
M!](_M5?MOQ_L]^,O#/@CPUX(U/XE_$+6XC>IX<TTO"T-D!(3,S+%*SL?*?"(
MAPL<KN5 4/;_ &8_VU+3]H#Q)J_@G6O!6O\ PW^)>C68U&]\-Z]"P)MBRJ'2
M1DC8G$D!(>./F9=N]06KQ?X<S-KW_!8+XJRZQ'_:::!X.B_LGS\3'3LPZ:7\
M@,"8R?M5R"5VY\^8<[V!9\1U7PS_ ,%A?A8-*)TW^W/!\HU3[(WE?VCB+4=H
MN-N/-(-M;X#[O^/>+^XNT Z+XG?\%(]:TCXL>*O!/PN^"7B3XP+X5N?L&KZG
MI#3QK!=AG5XO+CM9FP&CD4.VT,T4A4,H#-]%?LV_M(>%?VH? ,GBWPA]OCT^
M&^FT^>WU2 0W,$T81BK*K,IRDD;@JQ&)%!PP8#Y3_P"".RC6?@3X[\3W\?V_
MQ)JGC"Y-_K-QF2^NL6ULX\Z8_.YWS3N,L>99#U8Y?_P388:+\=?VLO#-@XT[
MP_I?C'_0-'MQY=G9DWFH1L(HEPB92"%2%4$K'&.BJ  ??TGW1_O#^8K\K?\
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M3^9S_,TZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (KG/EX X8@-SC SSV_
MS[=:\A^,G[4'PO\ @!]G'C_QGIV@W=WM,%B3)<WDB,&VSB"!'D6+,4@\PILW
M(!G)&?7IPVT%5#LN2%/?@]^WUK\#H] \ >)_V;?C[XR^)&HX_:.7Q/"!INIR
M_8KF+S+R+[3)%9XB#R.TEXLD95O*$*$)%C) /VVT/XT>#=8F\#06VOV_VGQI
MI;ZQX?BG1X&U&VCBAFE9 ^#O$=Q&YC8A]I9L$1N5[:SD8JJN&63;N96/S+Z
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M#X4N=)N?#UII$\>R^G@>W=DD.Z+R0[^8,SEO*P"-X*4 ?6-]\??@[^SO\"?
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MX-7ULJ_-6-%N5.,I;GHYI2I8?&5:-!W@GH_D/HHHK<\P**** "BBB@ HHHH
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M&7B;X8M\9O\ A*--_LV3Q!\2=:U_3&%U%,;BRG$'E2C8QV[O+)VN%88&5 -
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MJUK-WMJ?HI11176>"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%QC!Z<_F<?A4U-5 I)&>3GDDTZ@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ.9RBJ1W./\_CC\Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (R\2Z?X:TF+<OGZE*$#N$>3RT'624HCD1J"[;3@&O+/AO\ MZ? KXM^)8=
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M&SG'WA0!^YT?]/\ &GTR/^G^-/H **** "BBB@ HHHH **** "BBB@ HHHH
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MU[_3ZU:JK:2-(Q8E3N&>'!(]L#VP>IZ_C5JN8[@HHHH **** "BBB@ HHHH
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MS^T%?L.TR>6J[MN]\9SC<<=:_7N3[H_WA_,5^5O_  7(_P!7\$_IK?\ [CZ
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MQ5J/AZ6.PG+R&+SFD$KACN*M,UTJ.4C#+$  2C&OLF@ HHHH **** "BBB@
MHHHH **** "BBB@ JO??\>[DXVX.<^F#5BJNI+YEG+&,%G4@!AD$X].])WL[
M%12;29YC^SQ\?-"_:+\'WWB7P]8ZII]C!J#V+1ZM'''(9%CBD)4([C;B0#KU
M#<5ZLM?)'_!-?PCKO@[X(ZY9^(=$U3P_?2^(I[A;/5;22V?8;>VPRHX!VYR,
MX^\&KZV5?FK&BW*G&4MST<TI4L/C*M&@[P3T?R'T445N>8%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !364.I4Y /'!(/Z4Z
MB@#PK]MSQUXL^%W[+_C7Q3X%U6#1O%6EQ6TMI>W1MRJK]JA$RXN 49FB\P*F
M"SL55 7*@\I^SK^W)\+?'GP9\*:CXE^*_AFS\51Z;:P:XFMWL&ERG4/L\37!
M6*7RLIYC. R+L)#!20*]>^/WP9T7]H+X3ZWX \17%_::-JY@^T3:6Z)<+Y,\
M<Z[2Z.OWHE!RIX)'7%?C?\2O _[#_@'Q;/HEMXO^+GB]("5GU/P])ITMIYBR
M.C(LDL$7F<*'#Q[HV612KGI0!^S?@CXW?#SXE:M+IGA+Q[X7\4ZC# ;F2ST7
M6+:\F2(,JF0I%(Q"AG4;B,98#N*[>OBC_@G_ /LO_ CP/J%[\5O@MXV\0>,K
M/4+&;0I)=4N(BD7[Z&61'A^RPR12@PQD!^J.&P0Z-7VO0 4444 %%%% !111
M0 4444 ,D^Z/]X?S%?E;_P %R/\ 5_!/Z:W_ .X^OU2D^Z/]X?S%?E;_ ,%R
M/]7\$_IK?_N/H _5*/\ I_C3Z9'_ $_QI] !1110 4444 %%%% !1110 5%<
M.44$-@YZ <G@G%2U'-]WJ<\X"]^#0!Y3\;?B-\3O LFD)\.OA/\ \+2:Y$_V
M\?\ "2VNDFPVE/*R)E/F"0,_W?N^7SUKYCT/_@HI\2_$GC;QAX4M_@+I']L^
M#HS<:];O\3M+B%A$HS+(TCQJCK%TD*,1$3MD*L<5N_M6>%=4_:?_ &D/"'[.
M]SJ]]X<^'T?AF?QGXG?2;]([C44\]K:V@0- ^1%<+'(0_P C!V8C?%&:Z#XE
M_P#!,_X'>._AB/"^B>%X?!M]9P2C2M<L#+)=6\KNC[I_,?-XN51=LQ8A"RH8
MS@@ \'\$_P!L_P#!6?7O#_B#Q3H?_""_!+P9>R)=:/9ZT]S<ZYJKJK[&8*BI
M''&\0W[ X$TJQL3)F']*+7JQW'&2 "NWH>?KR3S[CZU\W?\ !./7E\4?L8_#
M"Z.GV.FF.RN+-8=,MVAB86]U+;^:>3^]D\OS)&XWR/(V!R!],A0&)[GWH 6B
MBB@ HHHH **CF8I&6#;<<EO0=_PKS/5_VG/A'H&K76F:G\5O!&F:A9SR6]U9
MWWB&SBFBD1BKQNIE!1E964@C(*D&@#U"HY<8&<]>U>9:7^TY\(]=U2TTW2_B
MOX*U/4;V=(+:SM/$-E+-+([!4B1!)EF9B%  SE@.:](CD9D)+;QG&]<8/T'Z
M?A3$W;423)7@<D\+_P#7[5YSX!^/W@#Q[\1=?\$^'];%YXFT=K@W]D+.>+RS
M%*L4OSL@1MKLHX8YSGUKT28KY>2<=CN&<^U?GG^QQ-M_;_\ C0@56=?[:**I
M7=M_M2'CK@9_"N.M4=.4(Q5[O4]_+,#2Q>&Q=:HVG3@FK6LW>VI^BLA95RO)
M]/7VJ'S6\S(F5E8<# /?USZ$5'-(T@$1)1@=VX'GKQG'0'!'T!_#Y%_:J\"?
M#_PGKU_X]\=_M'_$SX8VVILOEZ)X;\6&WMV,2PPR"ULTA>:3!:-I"@;:7+$*
MN,==[:G@-VU/KZ21OE E5?F'\/4=2.OI4D+EC]X, ,9XY/K7Y8?L7:9X;_:4
M\!Z3:Z]^U1\6K3XIR><;_P ,V_C62W! EG:+R$GB;SO]'AWR"-I=F26"Y K]
M!_B]XV\<>!?#=K>> /AW)\2M;:[6WFTEM;@TOR[?RW)N/.GW*<.J)MZG>2,A
M33W0*SU3/3:CF;8H.=HR/_U5\6?\-K_'5?B<OP\/[,)_X3#^R/[?;3&\>V(_
MT'SS!YHE,(C)\PJNT-NYZ=ZX#Q/^UY\</C]\4[O]G'0O K?!7QQ<;#KWB0:P
MNLR:-II@$\DT1MXD5)6CDB1)-^ TJ*&CD=9$0S=^)GQ%N/\ @HMXXU?X+_#S
M4K6#X.Z#-:S>.O%T3QR2Z@XF+P6>GAL_(TD!/VC:0?+W %55;GVGQ!_P3[^
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M6YZ.:4J6'QE6C0=X)Z/Y#Z***W/,"BBB@ HHHH **** "BBB@ HHHH ****
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MAWD0YDDV1[L!1A$4 (B*NQ_PR;\$-A3_ (4YX!VDD_\ (LV7?_ME0!1_9"\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 1R*&V\?-GY3C.#@\_P Z_*_5OAG^TG_P3W^(?B^7
MX)^%V\?_  F\1W@N;#18[2YU--.:1G=$,$4WVA)(DC\IIMQCE7RM[%]BI^IM
MUNVIL*AMXQOQ@_YZC'<"OQ6_9^_8-\>?MX7'C_X@^/\ X@2^&O$$&OR:7?\
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M]RXC'E[2V>KH.]?%R_M$ZVO[8T?Q8_X4%\;?^$>_X0'_ (1;[(/!<BWGVO\
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M-\'/%=WK;?%7XF>-S<636G]E^-/$G]HVD.Z2-_,6/RUQ*NP*'S]V1QCFO;J
M"BBB@ HHHH *KWW_ ![N3C;@YSZ8-6*JZDOF6<L8P6=2 &&03CT[TG>SL5%)
MM)GF/[/'Q\T+]HOP??>)?#UCJFGV,&H/8M'JT<<<AD6.*0E0CN-N) .O4-Q7
MJRU\D?\ !-?PCKO@[X(ZY9^(=$U3P_?2^(I[A;/5;22V?8;>VPRHX!VYR,X^
M\&KZV5?FK&BW*G&4MST<TI4L/C*M&@[P3T?R'T445N>8%%%% !1110 4444
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M]$^$GP]\.>"_#EM]ET70[*.TA#(B2.5P6DDV*JF61BTCL%&YW8GKSUOV>/D
M;<\G!([ ?T%=W1(]%;)'Y#> _P!JKP;^P7\</B9\,[$S^,OAE/KEQ=0II$#P
MW?AZZ3SHIK5H[@(UTRM';QF03["D(D5MSN@M>)OVNO"?[;7[07PG\$7 7PS\
M.]-\1VVIO:^(;%=0E\1W9,,5O9FWBC=(2[R3Q9>81%)F>3E%C;];S N_?@@X
MQPQ&><TYH5DWA@<,NT\GI_2L?8PYN=+4YOJ\.?G2U/-_C%X*\<^-_#%G8?#S
MXAK\,]:M[M)9=531;?5O-@"2*T'DS,JKEF1M_4;, #<:^=8_V*?CFGQ07XA'
M]I__ (J_^QAX>74/^%?6 'V$3^?Y/E";R_\ 6#=N"ANV['%?:H4#'M[TC*&Z
MBMSI///@CX/\<^!_#=YIWQ ^(1^)6LO=M/#JW]APZ2(H"B*L'E0DH<,CMNSG
M]YZ 5Z)2"-0VX#YO7\O\!3J "F2' '7KVI],D;"]_P *!/1$$F=O Y)X7^M>
M<> ?CY\/_'WQ"U[P/H&M"]\2Z,TYOK/['/&8C%*L4O[QT"-M=E'#'.:]%FV[
M,^O!RN<U^>_[&C!O^"@/QEQRN-;(' *C^U(,8XZ'K^5<M:HZ;A&*O=ZGOY9@
M:6*PV+K5&U[.":M:S=[:_>?HDJ!!@=*=1174>"%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $<S%0
MIR ,_-DXXP:_$'X"_ O]H;]L7QIX_P#C-\/O%&D?#:^OM4DL[_4--U";1A<2
MN(YI8(ULD>0JH^SLYE)+NP8O))YC#]O;E=T1YQ@YSQQ[\@].OX5^/O@'X/?\
M%!OA;JGBC4O#.GS:;<>*M1EUG5HS>Z'/%+>2.S23".61HXG8N<^4%R%0'A%
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M3T?R'T445N>8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLHJO#,6E<,6&2<*P QC ./;/UZ_A5BK/L HHHH **** "BBB@ HHHH ****
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MHH *0]1]:6D/4?6@#\6/V:?^4Q^L_P#8Z>+/_1.HU^T<?WV^G]37XN?LT_\
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ML^!/Q$\-?#[X=>'+#6O%5]8C5[V_UI9);*WLB\L:?)$ZN7WQ.Q;(50J !S(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-9 _49]/4=N*=10
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MWG^REXN^)GB;P_\ %/X;2'5/$^FV$6C7GAB\F2W2^LO/,@,,D@412JTC%PY
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M "/7ZGQ1HHP%4#KT]22:?Y:_W1^5 'Y6_P##!/[;?_1Q9_\ "VUS_P"1Z/\
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MZ +%%%% !4<RAH\'N0..#SQUJ2HYLLH4':6. 0,X..O_ .N@#\KO^"XW[O\
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M-=<0KK-_8O#>R?+BXG@FDMI+CY415\UH3+L50$\S;R "?;:XSX2_#?0_@_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *S]>U2ST/1[S4M1O+;3M.LH9+FZO+R80PP1(A9Y'D)PB@ DL>  36A7S
M7_P4>\4ZIX._8I^)VHZ/=?8[V2TMK!IA&KGR+F[@MIU&X$#=#-(NX<C=D$$
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MEEV[CP.J_:>_;8^''[)<FDV_B^XU#5-:U0E[?1]#BBFNTAR?W[K))&B1;EV
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MKGCCP/8^!/!_BVRDO'T[29[&2R2^6Z5[>.%897DBCCBN+E54?*1UR56O:/\
M@I^S1_L._$=D8QNITPJX;;M(U*UYSV_#GM0!Y+_P2UT;7?B$GQ6^/GBQ&;7_
M !QKC6]D\]H^+>TB^>3[+/*68V[,Z0A!\H_LY%).P!>U\;?\%7O@/X1\>+X9
MBU36M>A$XM[C7]%L%FTZU?S7C8L[.LDJJ$\S="D@=2-A?.*Y/]EO5K[P_P#\
M$D[W4=-N[C2M5LO"GBBYMKJRE9)K:19M0:-U=3E&5AD,.05[$5R__!%O1] M
M_@WX]U&)H#XIDUM(=0CAN2\ILTME:UWQ;R N^:\PVT%BKJ<^6 H!YM_P3?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"_/*-@,@*$4AS;/T'^T2>6<*0X; 5L98 ]N>X!H6X?A6PK]2,AL<\ X[X_\
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MW=^)_#?@#PRW]BW6I@?:EM;O3;B9;61\!"D2QHB_+P&8 *NR-#E&Y'W DS%
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MMEO(\;[:X6X?>"WF0A"%Y::)1YA9BDR,6_X*%&1T=1_PJT$EF'RXU?)4[<]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7<9)9?JZ2-) P(P6&TLIP<>Q'(IQ (_7@T^;R(Y$>?\ PE\/^.-%\-W!\?\
MB+3_ !'KEW<F\/\ 9>FBSMK!&52;2+DM+'&XDVROAV##=S7#_M#?!GQ-X^UK
MP+XV\$ZY:Z-XV\&W,[Z:NL0!]/NX;H1Q7$,X5#(A9% #*,XR/E+!T]UCACC)
M*C&3G&3CH!T^@%+Y:?,0O+=2."?QHYAN%U8^4O#7P3^-VO\ Q^\"_$CXD>)_
M"%S8>'9M2\KP]X<MYECLXY[/R?W,LB>9,TCG<_F8"^4-O#E4^I))C'NQ@JI
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4E+10 FT4;12T4 )M%&!2T4 )M%&*6B@
M HHHH *2EHH 3:*-HI:* $VBC%+10 4E+10 FT48I:* $VBC%+10 FT4;12T
M4 )M%&T4M% ";11BEHH 3:*,4M% ";11BEHH *2EHH 3:*,4M% ";112T4 )
M@48I:* "DI:* $VBC%+10 4444 )M%&*6B@!-HHQ2T4 %)2T4 )M%&*6B@!-
MHHI:* "BBB@ I*6B@!-HHVBEHH 3:*-HI:* $VBC%+10 FT48I:* $VBC:*6
MB@!-HHVBEHH 3:*,4M% !24M% ";112T4 %)2T4 )M%&*6B@ I*6B@!-HHI:
M* $VBC%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img192321128_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_19.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X2T(17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(R.C R.C Q(#$S.C,Q.C$V   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,S-P  DI(  @    ,S-P  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,CHP,CHP,2 Q,SHS,#HS-P R,#(R.C R.C Q(#$S.C,P.C,W      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  &UL         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ ; $  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
M   ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!
M!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25
MEI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/D
MY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'
M" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!
M"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)
M2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*C
MI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S
M]/7V]_CY^O_:  P# 0 "$0,1 #\ ]_HH R-:\0VVAM&MQ%._F12R+Y49?[FW
M@X'&=W4\#N:KP>)6N;RVMXM.E)N1))"3(HW11L%9NO!RRX7T/;D!V%?4IW'C
MFVM422XL+J-&BD<,P!!=&<&,$9!?]V3C/0Y]:LZ?XNMK_5/L MKA7,0D5Q&S
M!N8P>V< R $D<;6SC%%A<Q*OB)YIECMM.EE$D\L,3>:J[O++!SR>.5P/7(Z<
MXR[3XA6=[=VUK#I]V9IFB4J5Y3S/,()QGC;'NSTPPZ<X?*',:W_"1![:%XK*
M5IY[R2SCA9E!WIOW$G. ,1L>_:H[#Q997DEZCQ36YLU=YO,'158C(QU!QGCW
M'4&E8=Q;_P 6:?I\5C<R;C8W8<_:<$+&%4MD\>QXZGL#5[1-6BUS2(-1A1HX
MY=P"L02"K%3R..HHL">IH44AA10 44 %% '+7?C>UL+2^FO+2:)[4280$-O*
M;NXX7)4@9JY'XOTB;=Y<[,5#DX0X 4@,2>@&2!SCJ*KE9/,C.O?B#I=K9W-P
MB._EQ^=$I!7SD\N.0D'!P?WBC!]:MIXTTI9"ERTD/SE%;RV*LVZ5=H./O?N6
MX[G@9HY6',CHZ*DH** "B@ HH ** (IK6"X.9H8Y#L9/G4'Y6QN'T.!GZ54_
ML+2?-\S^S+3?YGF[O)7._.=W3KDDT[BL-3P]HL8PFDV2C#+@0+T8$,.G<$Y^
MIIPT/2U*E+&!"K(PV(%^X<ITZ@$ @>PHNPL@ET+29I'DETRT=W?S&9H5)+<\
M].O)_,TIT32F>-SIMH6CV;#Y*Y7;G;CCMDX],FB["R#^Q-*^SO;_ -FVGDO)
MYK1^2NTO_>QCK[U8ALK2WE,L-M#'(5V%D0 [<DXSZ9)/XFBX602V5K/<0W$U
MO%)-"<Q.R E#['M4D,,5O&(X8TC0$D*@P,DY/ZDTACZ* "B@ HH ** *,^C:
M9=/ON-/M96^?EXE/WOO=1W[T?V-IFV1?[/M<2[O,'E#YMQ!.?J0#]0*=V*R&
M'P_HQ# Z598= C#R%Y4  #IT  'T I9=$TR5D8V4(9)%D!5 #N5S(/\ Q\EO
MJ3ZT7861H44AA10 44 %% !534[::\TV>WMYFAFD7:LJL5*'^\".<CK0!B6^
MC^((M4>7^U1]E,\KJKR&0JA!VKMP >2.,\;>"=QK1\.WUQJ&CK/=,C3">>)F
M1=H.R5T!QD]E% &K10 44 (3@$\\>@ID$\=S;QSQ$F.10RDJ1D'IP>: )**
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MV,<EJOS1L9,$@ Y&!DY..OOTXH S4US7P!/)HA-O,^R)5)#H<D99<9P<9SP
M"*ZF@!KN$C9R&(49(4$G\ .M<GX+TJ*#0+JPNK, /.9)$>WEC5R0O.).IRO;
M Z<"@#H8](TV*831V%LLH9F#B(9RW!/U-9_A  >'\ 8 O+O '_7Q)0!NT4 ,
MED$,,DK$!44L2QP!CUKG;B\O-1:P$4<UK-YVURKL%!_B7G;N(7+<J1D <Y-
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M5"AP67<5+\X)W'[HS@C-=-X<T6YTS4-9FNI9Y!=7"O&)"NP +_  20,\8/\
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M1G=&=,K&.KD?W?>IK.2PO[1+FT\F:"4$JZ $'L?Y8_"E9E\RO8M].E%(844
M%<1X!DCFO]?F@N))K>2Z+1AU10,O(20%8G!R.N">O>@#IY-#TV66*1K1<Q,&
M15)5>!@94'!' X(QD ]0*K>'XHX)-7CBC6.-;]L*BX _=Q]J -FB@ HH **
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MG T]UXJO8(5QF25;55&>!R8JBTZQU"ZL(9&\47CS;0LWDI;,HD'W@"(NQS0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCE8G-1T9[KFBF"16;;GGZ5S'C'XJ>#?AZMJWBGQ7HOAL79(M_P"U[^*U\[!
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MW</'+&P!5T8<,I!!!'%%FMQ*2>Q;HHHI%!1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?L;?0R?#OAG[:LSV\:+F:26";]ZR>6#AE7:R':N=U)*U--;L)24JKCT/M_\
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MN8ED !*%XR0& (XSGFM>X8JF58*1SENG0]?:O$OV1_V<7_9A^'NI>&'\3?\
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M@_\ 'I%7Y.K>:A^V]^V1;07^LWJZ7KNJ3);B\=8IH-'@,MPEM&JAXXY%A63
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M^('B^7POX8\8Z7XCUJ+3SJCQ:3+]IC6W$@C+&9 8]VXC]WNWX(.W!!K\W?\
M@E+$S?M$Z[P5;_A%+EE##!XO;/.0>W_ZQ7U=^Q_^PU-^S7XBU'Q9JWB@Z]XB
MU#3!926UE:K#;0;GCDE 8G=-\\2!&(CPN[*Y;B7]DG]@U/V7?B)J7BI?&?\
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M?'W_  5;\0>$&^'O@?07GL;GQ=_::W=K;+A[J.Q:&5)7# $JCR+#@$CS#&V
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M>0@S74I W33-_%(V!T 4!550B*J!74(.,7N4E*<U*70_)'>J_P#!1#<3@?\
M"U,\\<?VL#_45ZQ_P5IT*\M?C1X.UNXM<Z-J'A\6$4QE"AY8;F9I5(!W# N8
M#D@!M_!.#CWF+_@G%*G[1'_"TS\0NOBD^)O[)_L4 C-W]H,'G?:/7Y=VT].E
M?0/[1G[/FC_M(?"^Z\)ZQ++83^8+RPU"%LFSNE5E1]F=KC:[HP/57;!5L,-7
M57-&2(C3?+*)\7_L[_L+? SXZ_#'1->L/'?B*]\0#3+635['3=2M5DT^[=#Y
MJ-$UOYD8,JR[0_#!<J2,&O2O"O[ ?P/^&/Q8\*"W\>ZT?%]A=PZUIF@WNLV
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M3)V[C7Y6^'?CEJ.B_L_>*?AM;7UX-,US6+'4Q;>5"P$40D\U'FQY@=I$T\C
M8$0/]T,P;]W)XRL!?9\^6(5CG.<YXSR<=L]L<"OPFUCX91>//VBM6\$_#MK>
M\TN^\0W&G:*;=Y+NW6V6Y989/-0R.T*1C>TOSG8#U!-:4&N7E?0RK7Y^9=3]
M,O\ @F?\*3\/?V<K76+NV>'5O%%R^I.;JT,-PEL,1V\9=B6DCPKS(<XQ<G Y
M)/UJH(K&\(>';'P=X?TS0-,@^RZ7I=K%96EN9&D,4,:!(TW,26PJ@9)STSZG
M:[UQS?--R.RG'EBD+1114F@4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#\6>'/#L?A,>+M=U*TDOKJW;4FL!:0%@D+[S;R+()&288!!4P\CYE-?.3_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
M.9/,V#..>WT/?M^%25'/&98]H9DYZKU_"@#\M/VXRG[1W_!0_P"$7PB@1O$&
MAZ*+4ZSHY MS"LK_ &K4!]H.UFS916['9)QC:GSLPK]/Y(?-D'FX6%6!PP.&
M(/ .3QC'T).:\,D_8N\(M^U5_P +]_M76CXL4$#3C-$+ _Z']DY7R]_W.?O=
M>:]YDMY&91GS(\;2K'GKR2<^F>,4 ?""?MQ?#WX=_MH>)_!7Q!^&&D_#W7?,
M?2F^(3WMO<R7<++"]I]LD6%7B@EA\E_FE<1$HK@!69/(/^"M?[0?PH^)'@;P
M=X5\+ZYI/B_Q3;:E_:?]JZ-/!>PV-H8Y(Y8'N5W!#,YA/EJ3_J0SA0$W_<'[
M2'[&/PU_:FCMF\9Z3-#J]I#]GM=>TB86U];Q^:LGE[BK+(N1)@2*P02R;0K.
MS5PGP+_X)F?!GX$>,+7Q3866K>)=;LYXKBQF\1W4<ZV,B;\/''%'&A;+*P,B
MOM:-&38R[J /B3]KCPQJ'[/?Q+_8^\:>+K62%/#_ (8T'3[_ $W3Y(Y+R&;2
M)HYKQ IQ&WRW"JC"0@LC@[1@GWS_ (*+?M@_"7QK^R3>>&O#GC'3_%>L>,/L
M+65KH\RRR01Q75O<O)=1DAK8[%"B.0"0L^-N$<I]J?%[X*^$/CQX-E\+^.]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BD9MHR<]<<#--$BLS ')7KCM0
MYF"C).!35E5ONG=]!Q4=PX7RR<CYQCL,X(&3^G'J!7QUXD_:X^(OQ1^/'B+X
M4_ +P=I6JWOA>X:/Q#XP\8-/#I5G(@D22W6.)1+N,BJB2;B683;8VB3S@ ?9
M)D4+G.1[#-*LBR<JP8>QKXV\8?&G]ISX!V__  DOQ(^'?@WQQX"AA9M4N/AM
M<W$=_I48EB#7!BNR?.41M(WEH,?NBTDD2 D_4GP]\>:!\4/".C^+/"^J6^M:
M!JEMY]G?6A)1T)P00P#*RD%65@"K*P8*PP #IZ*;N' Z9Z4*X;(!S0 ZFNPC
M4L>@]!FG5!=,B+&S%0=^%+#/S$$#'Y_SH D\Q?[W/IWH:9%SEL<X_3/\J^1_
M&?Q@\??"/]NWPCX7\0:]%=_"/XA:;)#H=O<?9;./3=2A2,N@F ,]PSN(U57*
MAVOU10QC%?5[-^[1=A&6VD\@%LC/3IWY]1WS0!:\Q2VT'GG]/_UTZODS]DOX
MQ>/?C]\=/C+XC_MZ _!CP]J;^&/#NEVJ6MQ%=7,/EB2[2Z0"4IL19 &W*POL
M!V\D5](WGQ&\*:=XPL_"=WXETFT\4WL+7-KH<][&E[/$H<F1("V]D BD.X C
M"-Z4 ="6V_\ ZJ P.?;BO ?V[OBAXD^$/[*?CGQ?X.U Z9XBTPV0MKL6\<^S
M??6\4@V2(Z-E)'7E3C/J./6M=^('A;P9JFDZ9KWB;2=%U'6)OL^FV>I7\4$U
M[+N0&.%'8&1MTL8VJ#S(@QR,@'2,P49/2D616X!YZX(P:\\^,6D^/->M_!X\
M :]8:+]E\365QK_VQ0WVS24+_:K6/]U)^\?Y "-F-K?..0>]A8*P 4HK$DAF
MR<GGCD\?>_*@"<G'7BA6#9QGCU&*YOPG\0?"OQ*TF74/"7B;1_%&GQ3&WDO-
M%OX[N%)=JML9XF(#8=&P3G# ]P:\C_9'^)WB3XD/\9QXEU#^T3X?^).M:!IF
M+>*(V]C 8C##^[1=VW>3O;<QW\L: /H&BN>\0_$3PMX1U;2-+UWQ'I6BZEK$
MWV;3+/4+R.":_EW(NR!'(,K!I(QA <%U'<5OI(LF=K!L'!]CZ4 .HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHIK2+'C<P7<<#/<^@H =130X+$9Y_S_ (TZ@ HHHH ****
M"BBB@ HHHH **** /+/VK/\ DU[XP?\ 8G:Q_P"D4U? G_!#O[WQI_W-#_E?
MU]]_M6?\FO?&#_L3M8_](IJ^!/\ @AW][XT_[FA_ROZ /U.HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***0MC% "T4FX'/M2-(JC).!0 ZN3^*4?C23P+J(^'G]@GQA
M^[^PCQ,9QI_^L7S/-,'[S_5[]NW^+;GBNI616. >?IC/3IZ]13Z /A?XM?&+
M]K;X,_\ "&/K]C\&+M_%?B6Q\+6!TZ/59&ANKDR>6\GF.H"!48$C)RPX(S7>
ME/VU6W#'P')/7/\ ;6UN>">?0#CW-/\ V]O^;=/^RR>'/_;BOJ6/O]!0!'!'
MY<CG;(NXDDL00>@!ZGL/\:GHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ^9/\ @H=^TAK_ .S#^SZWB/PO:P2^(-4U.+1K.[N0'2Q>2&:0W'EGB1E6
M%@JM\H9E9@RJ5;Y*/[*7[=<BIXSD^,8_MV,KJA\.KXENU#3#$OV0VPA%DWS'
M9LW"WZC<4Y'V-^W9X!^&/Q0^"]OX7^*/BJW\$6.H:FHT;Q!=3>5'9:FEO<21
M.Q;$9!C2=2LC*'#%599&C-?&>C?\$]?VD=<TNST33?VB8=2^$]Y$EG;FU\1Z
MD\4^C,NQ#%:*I@96@.5A$IC(VKYA7F@#W?\ 99U71?\ @HQ^S''=_&7P=I.O
MZMHNI2Z*]]L,4TQC2WF-Q&T>Q[9Y-T:R+$R*QC)X4JB\'XD_9S_:-_8INIM3
M^ 7B&X^)/PSLX?,'@?Q&XNKF ^7</-Y<:B/*;W9U%JT<KR2(K12A-S?7'[+/
M[-_A_P#99^%=KX.T.XFO6:9KW4-1N"5:^O75$EFV;BJ*1'&JH,[54 EF+,WK
MLA$\+!&W;@>4?!Z'H10 RV8>8ZABQY+'CKDCL.O'Z<=ZLUQVH_%;PAX?\;Z#
MX,O]>L;7Q5K0<:=HBS![F9$CFD:3RERRQA;:;]XX"[DVYW$*>O60-C'(/?%
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M_@AW][XT_P"YH?\ *_H _4ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ*8LRR,R@\J<$8(]/\13Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7JE>5_LH_P#)KOP>_P"Q.T?_ -(8:]4H **** "BBB@ HHHH **** "BBB@
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MC^Z:_,GX:_MI_M6Z#X1E^/?BWPWIOB[X,7?F_P"@PW&GZ?';9NS;Q^2RAKI
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M\_91_P"37?@]_P!B=H__ *0PUZI7E?[*/_)KOP>_[$[1_P#TAAKU2@ HHHH
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M\1-)#8>+_"NIWUS/J&FWD!E5(IDG=BJ@O/M90N_+!@KQLB 'UK1110 4444
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M92"PW6-S="4PWFH^9GR(GVX,D?WL9SQG!H ]Y\9?M[>._@SK7A27XT? 2_\
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MO,S"<,YW,%970@'UU^R?^U-X0_:K^'Z:_P"')6M-5M,1:QH-PX:XTR=N0K'
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MMF^O].AUZ>2WU>&VE_U$0EC+V\)^5)'1(&0O))C&_< #J/\ AG/_ (* 8/\
MQ.?'P['_ (N)%GT_Y_\ J,]Z_6?X':;K^C?!_P "V'BQIV\56V@6,&K-=7 N
M)3>+;Q^?ND!82'S"^6#,#ZFOSI3_ (+>.64O\&%9P@W$>*=HSWY-GQV_R:_2
M/X2^-C\2OACX2\7&Q_LS_A(-'L]7^Q[_ #/(^T0I+Y9? W$;\9P.E '74C,%
MY-+5#7M4L=$T>\U#5+R#3]+M(9)[N\NI5BA@A1"SR2.W"*J@DL2 ,<D"@"YY
MR;B,\CD\'B@S1J0"Z@GISU[U^0/@KP7\4O\ @K'XP\8:SXA\93?#[X;:+-$F
MF:1':RW=E'.58QQQ1AXHIIHXY'\V=CYG^D1C8J2(L?J'[$W@[XV?LL_M3:G\
M(]6MO%'B_P"$\T=Q;VFM&VNET6T8(UW'<HTJ,D3N7>*2)'53+,=S.8U) /TN
M,R#=EAA>3[?YQ1Y@XX;G_9-?DY^T9J/Q'_;P_;*\0? OP9XO_LKX?>'28M1C
MC9XK6..!K<7LUS"Q5KN1+K;%&F FY$92H,DIY<>'_B+_ ,$L_P!H?P/8:EXX
M?5OA%XHN0+Z1XG6SE@W0)?2FQ221HKF%3&RR1Y)5452P,D8 /V)6XC92=V%_
MO,"!U(ZGZ4Y9E;N1USD$=#@U^?/_  4X_:#\=^&?$GPW^#GPOUZZTWQ?XLG6
M6[33I7M;XK)<)#911719$C2:7SPQ# @0IDHC$/\ -/Q=_8;^+/[!O@G3?C#X
M-^)!>^L3;QZ\=%0VOV+S)(0B#>^+VV,XC5D>-0W[LM$5W% #]G58-G&>/48I
MU>7?LV_%B#XX? _P9X_CDA:36M.26\%K%)'%'=JQCN8E$F7VQSI,H))&!D%@
M0:]/6177(/&2/R.* /+OVK/^37OC!_V)VL?^D4U? G_!#O[WQI_W-#_E?U]]
M?M6,/^&7OC!SS_PAVL8_\ IJ^!O^"'HV2_&E&X;9H?'X7] 'ZFT444 %%%%
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MUJ.G#Q)9QR7<.G:@(AK,M[-)90VDK'9B,>7+D-)LD\X;P/+5A]>?MJ?M3_\
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M/0)?&&H:9\7_ (#V;66C/?6.EI9ZEHUI'"L,>Z-<*N790#(\ROY"H9+=I5W
M'WOX/TW4]%\,Z/I^MZQ_;^LVUE%%>ZI]E6V^W3JBK).(D^6/>X9]BY"[\ X
MK;K,\.ZG9:[I%GJNF7L6I:=?01W-M=V\ZS12QNH9'CD4E74J1AE)!ZY.<UI,
MP7KQ0 M%,$JDL/FRIP?E/^2/?Z^E#2JJDG=C(7[I[_\ Z^M #B<5X[^U+^TI
MX<_9A^$]UXQUR&>_D>=++3-/MF,9O;QU9XX_-P1&FV-V=R" J-\KDA&]<GDC
MVJ6.T YW$?=X//M]37QU^V)IVC2_M5_LHZKXKL;A?#EOKVI6POQ!/Y$.I/'
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M= %]_P (XWAG1CXG^U-;F%=8\M!9"WP/-\LV?FDY_C\PMP8:^1=-_P""N'Q
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M50HR>  !@5V6DZ'9^']+M--TRQ@T[3[*!8+2ULXECBMXU4*D<2C"HJJH 4
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M!G2VD$<>&^=FB,A*/M^S_!_P_P##_P /-)GT_P +^'=+\-6<D[736FBV<=K
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M-[\<X_*O@C_@A[C=\:<*JX&B8VCC&+[^>,T ?J;1110 4444 %%%% !1110
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MZ/>H9=X&1OR.E 'T99R><SMYF]1T&"" >03T[$=N,?6K51HK>8Q/3MG'^?\
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M5C<S 7-_<2310JD,0^>3#SQ;BH(0.&8JN30!UE%0)>0R0B5'\Q""04!;..N
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MX&ZAX@UCX-^ ]1\61SQ>*KO0+"XU=+J#[/,MX]M&TXDBPOEMYA8%=HP01@4
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MO_<:_P#;&OU-;[I^E?EE_P %OO\ 6?!7_N-?^V- 'WU^RC_R:[\'O^Q.T?\
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MGP"^%WP#^/'PH\*^/=,^#/@&&UUJQ$TMJWAFU8VTZL4FA#/;IO\ +E66,N%
M;8&7Y2*(2YEJ<&09D\RPG/-6DG9IKJ>C_P##5_P2[?&+P"?IXGLC_P"U:](T
MG6+#7M,L]1TR]M]1T^\A6XMKNTE66*>)@&5T=20RD$$$'!!!KS;_ (92^"@9
M2OP=\ HP.0P\,6.1[C]U7HVB:+8^'=+M-,TRR@T[3;.)+>VM+6)8XH8D4*D:
M(H 554!0 ,  59]*7Z1ONGZ4M-8_*?\ "@#X%_X*+,H_:@_8Y!3?N\7.HY P
M3>Z6,\@UZ=^V5^UQK?[+_CCX6V-AX7?Q;8^*UU2WFTS3X7>_FNHH[=;2&W96
M&WS+B>-6.QR%)*JS84^8_P#!116D_:@_8W=58JOC$[CC[N;W2\9].M,_X*+;
M9OVG?V/%#@$>,'W#S-C<WVE8_E0!S_Q8_;$_:C_9^^#U[XI^)'PW\#^'=1EU
MZPTK2XXRUQ!/$]M?23LZP7KL'1K:VVDE1AWX) *^O?MR_MD:[^R+XK^$HLM*
ML=1\/^(;^Y76XWM9)KP6T,EKO^R!9HT\TK/*1YF06*<<-7 _\%EEW?LM^$U1
M<!?%]JJJK9'_ !XWW ]?\^]+_P %&"[?M/?L>>40I7QBP.[ '-[I6.2/;T/0
M]: ,OX@?ME?M6? F1_%OQ#^!6@6OPW2\\AUTW5EEO(4E++ 9+B.>9%PQB4RO
M J,2J@1F10/>/V@OVVO#GP5^&_@/Q'H>DZA\0-6\=>0?"^CZ9#- ^IQR>2=^
M6C=T^2>'"%#(SRHH7EGCS?\ @IP!)^Q#\1B"OEL=,!8XP/\ B:6F"< Y'4]?
M7\/FS2;B3P9^T!^P9XLUO6IK/PKJ'@:VT.PM"99MFH/IOE%A& 53SS>V,7F+
MR?+._8(P: .RU3]L+]J#X%V:>)_CK\$-'7P%YD-E=ZAX3NHWNK22210)6 NY
MU90/,4(PC1I)(T\T;\'RC_@H7XU^)^L?M5?!"]T?P_HVJ^';?6;>[^&]_:WD
M<BZ].XTZ202R?:"OEFX,2*Q6(%#D,P.X?:/[?OCCPQX+_9+^(DGBM;>[AU/2
MWTVPLI5BE,E_*"MLT:2E0[1R?Z0"/F5;=Y%!* #Y#^-&99/^";2AE1,:5M4M
MP/ET4@%@>><8X';\0#WCQM^V3\5/AMX#^&_A?5OAQIVO?M%>-GO!#X7TB]C^
MQ6$:2.D%Q+MGE.QD\IO]8J$)<$RQ^617&ZM^V+^T]\";!?%?QR^"&F0?#_S8
M;.[O_"=]$\]DTCHHE8&YG4A1Y@ <(CN\2&9.CX/[:'@W6O%7[?'P\TK3_B!X
M@^#X\2^#QH]AXETN)XDN;E+RXE:R:5;B#<3F(! TGSO;C9B4.J_%3]AGQSX2
M\ ^(=9\>?MG>*[+PE:V3IJ1U""]DMI;=P4:)XVU!_.,A95$0#&0LJ!27 H ^
MEOVF/VH+_P"%^@^ K3X;Z!;_ !'\<^/9GM_#&GVMPQM9H1#YC7GFJI5X4WP$
M_O(PR2%]ZJI(\'A_;B^._P !?%WARY_:5^&.D^%? &MR-8KKOAIS=?8Y]JLK
MR;+F<$ "0E" [KO:,N861^6U#P[:?#/]O_\ 9-C_ +9M-2\*Q?#N'0=-\5JB
MP6.J2QV=_ GDRAF0F0S6I5$=B/M$0&?,4M]N?'KX]>#OV;_!MCXE\:WUQI^E
MW6JV^EH]K;22GSI6+%F"#[B*DLKM_=1PH9B(W /!OC]^UM\3[/XZ:C\'O@'X
M!TSQOXST?2XM:UFZUN[:&*UCDY\@)(\ 9L36D@=9B,2%-F58KS/P\_;:^,W@
M/XX>#?AY^T1\,],\&Q>,+A+71M9TJ5GC$Q#IL;9)<+*[SM!'@/'Y2S!VRK*1
M9\;?&KX[?M(?%SXB^ OV>_$GA+P9I'P]O;2QU/6]:AEDN[Z[83K/%&LEO-&L
M:2QLA7826A#+*5D*CY]_:*^&WC3X;_MG?LY2>-OC5/\ %37=6\46$_V%[06"
MZ9 MY9Q+(EK%,T<23,A'R1H&:!B2[9( /HOXA?MJ?$_1/VD_B7\&/ 7PRM_'
MOBK3[>QE\/>6YM88H6T]9KFYU"=Y-KJDTUNJ*!"&#%/,#L@8^ _[87QD_P"&
MD-,^#/QV^'^D^%/$7B#3FU#1I_#\RRHJH+EV^T#[1,"CK;RA2K*ZF/E6$FY>
MJ^ ^EVUU^WE^U7J'V&W?488O#-LEU(BM+'')IQ+H" 2$<PQEEXR57T%6_CYN
M;]M[]DZ0"1(U_P"$K+*P $?_ !+(R,XX'7O_ /K /J%F\N!W9=J*A8AR".GW
M>!T%?.'BOX _"+X7_%[QW^T?X\EL)O.LK!TGU^);B#1Y+91%YEJ #F241VFP
M!6F#HRHW[XI7TG,P\ESM8XSQ]T],<'(P?>O"_#/QQ^'_ .T5XZ^)7P=U?PU<
M/J7A::./5-&\3V-OY6IQB5BMQ!"SN9(08X7$C*,>= >"P- 'R[\%]2T/]H+_
M (**O\2O@E';Z?\ #S0- \OQ9J-M;'3!K=W=B\=2(=BR3,TTB,TDJ#YK,L6R
M(]^O^R[HMA^T!^W5^T3XW\9V-OK6H^ ]2@\/:!9W$8FM;"..[N!'/$DP9HIU
M-DLFZ-U&^>X< &3Y:7[2'AK1?@9^VI^S<OP8T6P\(^)M?O9K+Q#IOAJ!(!=:
M1]HMRS75I&NWRBGVQO-9,@0,V[,"-'L_L-"/P%^VE^U=X2UMVM/$6J:LNNV5
MFP\UI;#[3<N)?-4LOW;ZT^1B'_>8VY5\ %#]J?2;+]GS]NC]GCQKX+M(-$U'
MQWJ=QX?\06EK$L%MJ,4EW;K)/,L(0RSL;UI-SEOWD,#$?(<UM+_;L^-?CGXL
M?&+X7^ OAQH/B[QGX<U>XM=(S*MK;1Z;;7LEO<37C370,DA#6RHD>P;I))#D
M+L.O^W0Y\;?MI?LH>%-"W7_B'2=7D\07MBGR&.P6ZM9C+N;"L-EA=$*I+'RL
M $LH9/\ @G6H'[4'[8BB3?CQBI/IN-[J>X@8R/N^O;Z4 4_!W[?7Q@37O%_P
MH\6?#71V_:%MYX8O#_AW2[L0V-PLMF]TTES,]R\:+#&BN0L^93.D:A"'D'5?
M 7]K[XOQ_M(Z9\'?CQX#TCPSXB\1:8VIZ-)X?F5T5(TG8M<8N)5(<02@,I4J
MT0!4AP4Y[X0+YG_!8CXXL&P!X0MF#+CG$&C@]0?IV^M)\8,_\/?/@@JRJ%7P
M?.!M*G($6LG&#TXR,T ;OQ&_:P^/?B_XE>+_  Y^S[\+-(\9:/X.U(Z-JWB'
M7;AHX;J[54\R&)9);8!XG\Y'"F7(,394.F_7_9G_ &QO'?QA_:(O_A5XQ\&6
MWA#5/#OA6:\\0V;H[3KJT=Y%&?L[^:RM:R0312)E2<L=LLB ._+_ /!)339O
M!OP=^(W@W5I(;;QAH7C.\MM4TQKN.6XM&$-O%D["=REX9@'!*LT;[6.#C4^'
MOC3PMXR_X*I^/(/#Z6\IT?X=G2=6GMQ$RW=XE_:NQ+(S&0QQRQ0$MA@863&$
M&0#3\>067Q@_X*-_#SPM<76FWNG?#/PO=>*9[66 74CW]Q*ENL,VZ0B)HQ]D
MNH_ER-JN#^\1EP/@#\:O"'[._P //VF/&OC'4AI^F6OQB\1)'%'A[F\G(@*6
ML"DC?*^'P <*-[,RJK,.B_8&^W^/O%_QV^,]WJDVHZ=XU\4_V=HDTVG&T%UI
MNGB2*VN49E4NICE$7W 0;4[RS%L?&>J?L?\ CCXX:]^T3\1_#FO6TJ^#?B#K
MLND>#[C3VU,:I=QS^?,?)8,@9XOLZ(OERB<H$=509(!]T?LU?M!?%+XB?#CQ
M+\6_BEH^A?#WX9QV<^IZ19VME<S:J]DBF7[7-)YA#(L8.-MN#+G>JHNP/XYH
M'[;'[2GQ574_'OPP^!FG:O\ !RVO)3;&_<KJU];0G]Z8Q]I4R2R;651%#*JN
M_E@RM&V>\^+'Q>'[77_!.7QSXL\!W*^'+J;1YI-0TXWX$EG]E=9KVS=H@2?,
MMXI @(42QW$9=51R*]/_ &._BCX4\1?LB^ ];L_$%I/INA>'K2PUBZ\U88K"
MXMK6-+E)M^WRMA7>2V!M8."48$@'$_L'_MDZW^UMXI^+!O-)L=,\.:#=VC:"
MT=N\5Y-:SO=;6N299$,FR"+(CP Q8<C&/KVOSQ_X)?\ BK2?&GQZ_:NUW0KA
M+O1M6\1V^H6%TB,@FMY;K4I$8*RJPX<'! QNY&>OZ'4 %%%% !1110 4444
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M !1110 4444 >6?M6?\ )KWQ@_[$[6/_ $BFKX$_X(=_>^-/^YH?\K^OOO\
M:L_Y->^,'_8G:Q_Z135\"?\ !#O[WQI_W-#_ )7] 'ZG4444 %%%% !1110
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M /!2#]IRZ\>7.EZM\ VU]]&,1UK0]$T75+:]M!-"6@\QG:7[.2?WF98R'0,
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MQIX-\ _$+]I+QW9_!J&_TGX8:%\-QX3/B_2[@VNIW5]>7"SF^S+%'(ESE;E
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MAIEY+<2Q!/L\K1JT#K;LSKYOS80;594DC_1R:-9%&X9(.0>X.",CWQFOGO\
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MXAU%_$9\-KJ7B'XE:S(/,TS1C<-"_P!EC$F_S=V88D!W0Q+"JOD>?#T6K?\
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M+/\ @HUHO@O0KG6?$7P0^-F@:-:%?M&I:AX42W@A+,$4-(]P%&YF51D\E@*
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MKX<U(2_9;UK>2#S?+E>)QY<@5UVO&Z\@9QD9!!KJ[C/EC&,Y'5<CVS]#S^%
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M.@N(-+U_3;?5;2.[15F2*>)9$5PC,N[##."1Z$]:_%W5OVPO"=K_ ,$Z-#^
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M<8D?S0 "5!X^4L 22 ,XZD [?_!0#X&>//AW=:7\2O&,?PQ\-^(M;U65I(_
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M:_\ V?O%/P3_ &0=)D\;>)M4^/&G^'_B%8>(M6N-9O)K:X.F&!K4VPDDGFD
M:9XQF/)'GEMN%)'V-J7[1GP9UKX-W?C"^\:^&+SX=7L$EM/+<3I)!/OMVE>T
M>W(WM.822UIM\TYVE,F@#C/AK^SO\&?B-^R+:?#KPC?7VO\ PL\0V2317\.K
M32S^;O$GG(7^6%UN(O,:#RTC642!H<LZ5YU^UY^V-X(_8U\&0_"*P\&W.NZD
MWA:%=&TR]B$VC+9EGM8H+MFF,TBJD+;U(;S1\I8;R5\>_8M^)WB+]E3_ ()U
M^(?B=-X4MO$6E/XJDO8+9M5-KY]E(UK8F2,I%-\PND*>6X3Y5=AT57^V]/\
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M5MT68@S%P C8PO\ @E^NS]AOX;#H?^)GQC '_$TNZ /JBBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"*?.T $C)Q\IP>AK\C/VF/CU^Q'\4O%&LR77@KQ
M?-J]UL8^+O!=A%8+<2EQ/)+Y=Q-&))-[O'))-!O.XX)V1LOZ;_M">&=2\:?
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M2@!P1UZUA_\ !$.0S7'QI;"@;-%/R+M')U!NGKR: /U*HHHH **** "BBB@
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MT+]G7X4Z)X'\-VUKY5I!&U[?01- ^I794+<7<@+,0[E1A=S;%"("%50/!O\
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MY1GC8JK!70X)SA@>XH Z.BFK(K?=.>,Y'3\Z=0 4444 %%%% !1110 4444
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MTD8.95<RKMPWF",*OS1[)/A1OVDM"N(/GLKY[QE 5=ZI$LV,%_,W\#)Z[<<
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M/GFQ-)"&,8=BL>X ^6J ]#4YK&E&HO9APO+&2PK>+3\KGH?_  U?\$>WQB\
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M,K*Y.9/T^\=?$3PM\.])AU+Q5XDTCPUI\LP@BNM:OXK."24HS",/(P!)5&(
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M_::^'O[,WA6#6_'>LFQ^U&9-/TZWB:6\OY(XR[)#&/\ @*^8Y6-6D0,Z[@:
M/4_/3U],<'N<#^=>&?'7]LSX7_ W5+?P]JFJ3^)/&MU-';VW@[PS -0U6>20
MQA(S$&"QLRS(ZK*R&1<[ YXKQ?2_%W[0_P"V/IL=UX(M+7]G_P"%&IK)+;^(
MK\B[U_5+9UGC26W@0J+=640L?FC==ZR0SN.OLOP1_8O^&7P*U.?7-+T:ZU_Q
ME=3R7-SXP\27/V[6)99&D+R"<X$3,L\B.T2H9% W[SR0#YK^)_P?_:*_;N\"
MWEOXKTK0/@OX*,(OM+\.ZI;#5-8NKOR+<PM/.8]UHI+3*SQK',@:2-X9 2:Z
M*U_;A\>_L^Z)J>E?'[X0^++F_P##*QVMQX]\(Z>MUI.IC<56X9W\J.$L&A(4
M,<O(P*P_<'W$RE"963!7A=O) [X_P^E?+?\ P4V;;^Q'\2U"!4QIJ_(0"<ZE
M:@JO'IU/^!P <'JF@?$']O3XI>&'U_P'?> ?@'X.UF#4+C1_&UD+76M?OH[=
MV4M;O%(/LZM*L3(659(Y)?G9CMA^XX8V5\NOS;>6#$CKT&?Y\=OPCC9$FDE?
M ;&UFP1@ \?ASUSVJT&!8@>F>G'YT +1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $<S +R
M0I[,<<<=:YKQI\0O#'PVT^'4?%7B71_">G22+ ESK-]%:1/*59EC5Y6 +;4<
M[1R0I/8UTDZ[E7Y=Q!Z\#''7ZU\._ME_\$]M=_:V^.VF>*/^$PM/"7ANR\-P
MZ<)'M6OKHW:W4\F!#NC54V3 ^9YN[*[=I!R #Q?]L3XY?L3^(K?6(QX/_P"$
MW\8/_::C5/!<!TW&HL%4SS71*)<[Y"&679=+\KOM8,/,^-O@]\/?BUXT\>W>
MH_L\^'O&^DV$ZMIXU&PU,HL+"*.:6&?4UCMH0"Z+($8(.8PH+%2?UH^#'_!-
MSX$_!U=0N'\,Q^.;E@Z_;/&:0ZAY<;"-O+$/E+" /+5E?R]X$CKNVG%?4:_)
M@!CM/RL2_(;( /(.3TZG\Z /SK_X)Z?MW>/?B%\9-5^$OQAF^T^(I_M+:;=3
MZ<+&[M[F!5,UA+!%&%4!$EDW.$*-'(A+ET"?H]'(LBJRG(89'&*^5F_8A)_;
M</[0R^+U8[LGPW_9 R1_9PL3_I!F]!O^YZXZG/U/&C*^2 !R/7OQS]!^M $M
M%%% !1110 4444 %%%% "-]T_2ORR_X+??ZSX*_]QK_VQK]36^Z?I7Y9?\%O
MO]9\%?\ N-?^V- 'WM^RP#_PRS\'RJ[F'@[1B%XY/V&'UKPO]OW0C\-=2^%W
M[0EC:2?VAX"UV"TUV[LX;5I)-"NBT%Q&WG -(<RB.,!OW9NIF[[U]X_91_Y-
M=^#W_8G:/_Z0PUTWQ8^'.A_%SX<Z]X.\1VAO=&UFU:TG18XW=-W"RIO5E#QM
MMD5B#M9%;M0!Y]\>O@?X;_:R^#5OH[:Y+'%,8=:T#Q'I-RLOD701O)NX]C!)
M49)6&-V"LF4*-M=?S1\5?!+XX?"OX@>'?A[K'A'3_$_B/Q&9QI.H:/K$$%OJ
M"VUO'/<%?-V&)D#$DS! S?<4\Y^P/V6O&GQH\1?LGZ1X9\('PTOQ.^'^OW'@
MW76\<)(]DJ6F\"*)K%LNR(]E'O;AMDI.XX8U/%WP7_:T\<?%;P#X[OKCX++K
M?@D:@VGV\4VKI#,MY"()//4QDG"K\N&'(K>E7J4?@=CS\7E^&QT5'$0YK!^Q
MW^P[XB^'_C"U^*GQ8NK5O&=I;&'1-!TFX=K;2%EB*RM,V<2W!\V6(J"\8!+!
MW)0Q_;UF&R26RO.T8[9//OV_R:^=/"\'[73>)M$_X223X,_\([]KA&J_V6-7
M%W]EWKYWDEVV&39OV;A@'&:^CX(RFXL/F)ZYZ\#W_P XJ)SE4ES2>IU4J,*,
M%3IJT5T)JCFR4(4X)Z'TJ2F2,%QGN:S-CY=_:<T'7K_QY8S:?^RQX:^.,2Z:
M@_X2+6-2TJUFMG$DA^RHMU$\A5?]8"#MS,WO7PYH/C:V\2_MM7VB6?[*W@.^
MU>Q\.OH4OPY&OZ1]E2Z2X6:6[21H?(DN4BS&T:*9 B/D@1N%_4/X^?%S2_@?
M\(?%'CC5-TEOHUFTL< 9T\^=B(X(2ZHQ3S)7CCWE2%W;CPIQ^/OA_P '^)?A
MOX/TGXL6DMU)\4-(U-O%5S=7MQ,L]VK'S+N"=\QN0T>3(I9SS,H_UA-3*2BT
M>;C,=1P;IQJO63LC]"O@?JA^'.O:OKWC;]FSP3^SAX=L],*S>,;?6]):-G>>
M%5M'-ND957?#99L%HT7!9EKF/^&N?B5^U%>:II/[,W@^WATBPDDT^Z^)?C9F
MAL[:41S_ .HMQND=B!;2*[*Y4N@FMU#!JC_9[_97T;]H[PWX-^,'QD\=7OQM
MU:_M8M1T_3+MD@T;29&2V,D"VD#>6TD<MN8I?NI(0RR0[@37VCI&CP:%I%II
MVF6<-A8V<*V]I96Z"*&WB50J1JJDA0HP!@8 7  K31ZH]#LT]#\7(?A3\5O"
M?[3GC;Q3XQ\!?$CXC:K9ZE=6UKXDL?"MRT=]MD:%+E,'9Y7E(!'&NY KJ 0L
M:@]C;?$2]U_5-8\.6WP?^(VIWVFPQ0:QIJ>&7:>VCFC8QBXB#%H@\98J&"AQ
MR"0*_0?XG?!GXY^+/'6IZKX2_:#/@CP],(_L6A?\(98W_P!CQ&JO^_D<.Y=U
M9SN'&\J.!D>7:#^Q7\</"_C?QEXOTS]IA;?7_%PM1K5TO@&Q;[6+:)HK<"-I
MRB!$;;\H7/.[)P1BX)NYXF,R;#8[$+$U6^9;6;2^X\:_87_96\-_%3P#XQ\&
M_%KX):A96&@ZNEWH.NZ[I3Z/J5[:3"X'V=YXHX9)O+969LRR*#/&,)Y25[7)
M^Q?\6/A7I=U!\'OVCO$NB:=#IB06FA^,K.#6X5EA63R8XI77;:P %$Q% S +
MGY\(B^[? SX>_$WP+)K7_"QOBM_PL\7'D_8&_P"$<MM)-GC?YO\ J6;S ^8\
M9QMV'KFO4+M@J+G &X?>./IS]<5HCVE&T5%]#\L/VGOVVOBAH_A/Q=\&/&%M
M\.I?$7B*2313XL\'>(XYK*Q@;R4NH+FTD\V>)@)+B)I)3$WS,44F,L?FO]G/
MXM^)?V8_BE?7GPZ\4^&I[3Q#K$GA>:/Q9?,;"&$3Q&WU&X,,J,556E7S]I6-
M#-C_ %@%=%XX^-7PB^)?[1GQ"\=:I'H>G:)=W+6.CVD>BY2ZB5\R7\JI;J7E
MG<-(3-F51.R,2%0U!XI\=? 3Q%X=O].C;1]/NIH3'!>6VA2QO#(2-DNY8PVU
M#\VT'G&#GH<'*7-;H?.8K-*V'Q:IJC.4>Z6A]N>$?V6I_P!L"U;Q/\7OCA!\
M2]*M=2C,7A3X:ZG"OARS>.25C"SJI:1O*G1=YV3HA(\V3Y'7Z^^&OPF\)?!W
MPS#X=\$^&M/\.:+$!FVL8Q'YSA%3S)6Y:60JB@R2$NV/F)-?.O\ P2[\?:'X
M\_97TL:)X>L= N-&O9-(U0Z=8QVL=[<PQ0[;DA78R2/ UMYDCD,T@?@*%S]>
MKG=[5O;0^DZ)D-K T&X%LC)/7J2<D\YQ^?X"L[QE?:II?A/6+W0](_M_6;:T
MEFLM*^T+;_;)U0F.'S7^5-S +N;@9R:V:*"CXK^*GQ"_:5^)WPQ\7^$F_9:_
MLUO$&C7FD?;?^$_TN<VXN(7B+[2%W;=X.W< <=:3X5?$7]ICX7_#'P?X07]E
MG^TQX?T:RTG[8/B#ID'VCR($B,FS!V;BN<9..1DU]JT4#N8W@^^U74_"^D7N
MM:0- UBZM(KB]TD3K<?8IV0-)"95^63:Q*[EX.W(XK9HHH$%%%% $<V\J @R
M20#\V.._Z5YW\</@7X5_:$^'NH>#_%^FM>:;=XD2:)Q'<6LZY$<\3X.V1,\-
M@@@E6#(S*?2*X#XT?'CP+^SSX7M?$?Q!UW_A']&NKQ=/AN?LD]SNG9))%3;"
MCL,K%(<D8^7KDB@#\Q?C5^R;\9/V?-0\)V2>,/"_BS2/$_B*P\):1JFIQ7,%
M[]JN4)C>XC0.$C1HG7<))6Z-M^8A?KG]D_\ 8%M_@3XM7Q_XM\2-XQ^(+V;6
MR316L<-EIPD6/>8$*EO-&V5!,"F^.9U,2Y;/C?[7'[>'P+^)_P#PI?\ X1GQ
MR-2_X1WXEZ+X@U/_ (E5]%]GL8/.\Z;]Y N[;O7Y5RQSP#7TCX1_X*+?L\^.
M/%&D>'=$^(/V[6-6NH;&SMO[%U!/,FD8(BEFMPJ@LP&YB ,\D"NF>(JU(J$Y
M72.&C@<-AY<]*"3]#Z'2WVX*PK$%QM5<<8&/PXP*DDCD;Y1PAY8@\YXZ \8J
M99%9BN?F]",4ZN8[BE)#<-#A0BR]BS%@N0 3VZ<]",XZC.1^9_\ P46^#^I_
M#/XR'XSVFA2S^"-=T^UT[Q%>6TTDK6NH1MY<5U/%SL1H1!"K)\N]6#!6D4R?
MIX3BLW6K#3_$6DW>F:A9P:EI]Y"UO=65U")(IH9%*NDB,,,I4L"K @\C%:TJ
MLJ,U4ANCEQ6'IXNC*A5^&2LS\5%\2Z&UN+T:KILEIYH@CNWN$\G<1D@N6"AM
MIS@FO<O^">?PKU?XN?M!'XKW%AJ6F>#?"=A)'H<UU%+##JMS<>? [1%H]CQH
MGG!]IW*WD ]"*].C_9?^$Z_\%(AHG_"O- ;0C\-SK[:(MFG]GK??;_LGF_9<
M"+_5 C&S;N^?:'^:ONKP_HMEX=TVVT[3;&UTS3K6%8+>SLXA%%%&HVJJHH"J
M H4  8 &.@%>EC,QGB8J-K>A\[E?#M#*ZOMHR;[79:DMY/,0[B\:C.T]2<Y!
MSG^E>#_$K]A+X)_&7QOJ/C#QEX&75/$FI-$UW>KJU["9#'#'$F!%,B@!8T'
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MN>>N*^6OV]MG_&.N\$C_ (7'X=(QZ_Z17T_;VYA;*C8I'*_EC'/8<5\O_M[
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MM1NKC4;V]DTR>XNKR4S3SN_]C%V+G+,S%B6)Y)&<C.:W_P!KS3_'NL?\%'/
MFF_"SQ1X>\)^.KSP&J:;J&OV:W:28N;YY8XV:VN!%(81*1)M3*"1-YW[& .R
MTS_@IIJ7A6_L;GXN?L^^,OA3X6N)ULX_$%U#/-!#<,02'62VAR!&)V^3>_[H
MA4;<Q7Z%_:B_:>T?]F?PGIMW?:/?>)_$6OWK:9HOAO1W47>H7/EL4VJ3YGE[
MO*1GB20J\\8VG(KY*^*/[.O[9OC3X?>(M,\;_&7X;7'A">R?^T/[3A@2"&!1
MO\QI#I:^5LVA_,!1D**X*E1AD'A_5_A[_P %"OV2O 6JZA',_ACX;"S:&RED
M>S2Y6PU&&>6$.  &\A 7*AF$:9' P =]X)_X*636?Q T+P]\7O@YKGP.TS6T
MDCL-;\02RK:^>I3B02V\&V/<X5I02(R\9;".SIW_ .T5^W$WP=^(0^'O@OX;
M>(/BWXXM[&/5+[3/#[,R6%JY=5,QCCFE67_4'8T07;.C;L[0WKGQSU+X7:'X
M.L)_B^/#<GAT:I!%;2>*K:":V%XY:.)@LBL%?:SDN -B>8Y*HKD?,?Q,^-_C
M#4_C]X^TO]F[X+>$_&/CWPXUG9>*?&^H3V,,DAE1C]C5A-#+($-L@8F8E'@D
MC,8VHX -?X*_\%%!XS^+FD_#GXC?"[Q!\)?$FO!#I/\ ;<^89QME/[SSHH"F
M]XQ%&8TD\QY ."!FY\2/^"A4/PY_:$\<?"5?AYJOBG6='TV.;1X]$EDN[K7+
MQH+>;[,MLD)\E5269WD+, EM(=I;"'YF_:0T[XXVO[6O[,VJ_&77_"-[8ZAX
MMM3HFF>$DE-K9[;RP%QDSQ+*1)NA;+22;2IP$&T5[/\ !R/R_P#@K_\ '$?-
MEO"%N",X)'DZ,-WIZGCU/TH [[]G7]OJ;XI?%Z#X9>/_ (8:]\)/%FH67VS1
M[36!,_VY55VD#>9;PM'\L;E6VE&,<B[E8()/KB8>?"53[S#/S#I]0?ZC\*^!
M?^"A*;OVG/V-F=MY7Q@^-R[5!^VZ9\HP1C!7OGCU/!^]89([=9#D0PJ3N+8"
MY.#G/XY^K>M 'RA\3OV,="^('[3&M_&#XM7^D:_X"TG0;6'2-$OHOL\.E20/
MYLTMQ(K*LT*;9'_>[E87,B.JI"I?PCP)I?P?T?\ X*0>!8?V>GGELVTS5[KQ
MD?"]P9] "2VTCPA"C,H7S7MPR+F!6^RJBB0,H^V'^*7PS^.6L?$#X1#51?ZY
MI]G+9:_X=N[>ZL;G[-,K1.R%UC9XF5P/.@+ ++&P8>8A/R-\7/@+X<_8T^-G
MP.UKX-^(;[P'%XN\9:?X>UKP9'J,L\&L6K2E7NC%-(Y;REE:-CAE3[1"R>4_
MS, 5/A=X"\/_ +;'[=7QH\2_$/2;;7-&^&;V_AS1= O 9(%=+J?$[R(4\U#)
M:W+F&5)%(O-A.(AE?BEX%\/_ +$_[='P8\1_#_2[?2=$^)DUQX9U?P[;@K"3
M+=6X:=&=G$0WW-L_E1*B_P"AA0565L;_ .P#(?#W[6W[76CZP\>GZS>>(H]0
MMM-N%\JYEM3<WT@G6,_,T96X@8.,@^<A!(=2TG[?DDVM_M=?LC:/I ?4-6M?
M$+ZC=V%F&DN(;,7E@[3O&GS",+;SL6(VXAD/\)P :-Q_P4RN7\8_$[P9H'P=
MU_Q3XN\)ZO)IVG:/H$DUZ^I6T-S+!/=R&*U(MHDV1#_EH2]Q&OW0SK:\&_\
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M:!4<RLR?+U^@-244 ?,_BGX$_M":EXFU2]T+]I5M!T>>[FFL]+_X0/3KC['
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M?CP:/%P\0"\7:-8-D+86YAQD>3*#N\[CI]PU]7-G;D<D=O6HD@*R;BQ/&,<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>-IS&<X+%"=JYV@ ]UHHI"P7J<4 +13!,IXS@^A!!_SS2-,BXRP&<?KP/SH
MDHIGG)O";@&89 ]11YR8)W _3DT /HJ);B-TWHX=<9!3YLC /&.O4?G3O.3.
M-P]_;Z^E #Z*8LJLP7.&*[@""#C_ #_.GT >6?M6?\FO?&#_ +$[6/\ TBFK
MX$_X(=_>^-/^YH?\K^OOO]JS_DU[XP?]B=K'_I%-7P)_P0[^]\:?]S0_Y7]
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M)?\ A(AI/DF[+:?<VQB\[>4P9HDW9\MA\N<;1G&1D ]:HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFNZQJ68A5 R2>@H
M =13!(K=#GZ"AI57JV/;OUQ0 ^BFJP;@'FG4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 17 S$<_=_B'J.XKY#_X*(?L;ZE^U9X!TB\\-WQM_%_A7[3+
MINFS.JP:C'.(_/A9B1LE_<H48MLR"KD!]\?U[-)Y>TXSDXQNP3P>!ZFO@O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU8Z;9SWBZ?I</G7=R8XF?RH(\C?*P4A5R,D@9'6MNH;E0T8SC .>?7MW]<4
M?D)X#C_:M_;ZU#Q3X]\)_$N7X?>%;'47TVSM#XBN=/AC4EIU@V6<7[YXHYXE
M,TJJ9,QC+X(3W7_@FW^U!\1/%GC?QU\%OBM>SZEXM\)P,\%[<1PM) MK,MI=
M03W"-^_VNT)23#,W[\M(?DKZ(_:@\)?'SQ3)X:7X%^./#WA3[(+D:S_PD%NL
MOVIG$7V<)_HLQ4H%EW ;>'7@CI\?_P#!-CQEX>^%_P <O%GPQ^(?A#5M%_:
MU6:XDN_$FM77VZ:_*[IY8,A<PJ8U^T>86D6Y(\PR8\A* +'[5G[1'QM^.7[4
MVH?L^_ R_31[73=D6I:QH]WL+2 023SW-TBEK:*!\6Y2,ARZNC>895A'+>!_
MC9^T)^PS^T1X1\!_&7Q0/%?@/Q+=Q0MKFL:@US:1I,\4<MW!J$ZB2,6[!2\,
MI" ;R4'F)+6O^PF-O_!3[]H<B16Q_P )$3M7.&_MJW!P ?89SW&?I'_P6VQ;
MK\&4V?(#K96,848 L  ,C&!CIC!% 'N/_!1[]K3QG\#;7P=X(^&4<0\=>*YY
M&2:VB%Y>VD:R(D*QV91@[7$KLBLP(_=2! SD-'\J>,M/_;._8FT/0_B9KOCF
M^\4Z//Y4.IZ7?:M/KL&G[WC*V]Y'*"$+OF+SK=^H95F4R)O[G]O!?^-GG[/4
M62&?_A'OE5F&,:U.!MX^7IG'0=?K]3?\%--W_##OQ&2)&0Q_V8H5>0,:G:\#
M\NI[8- 'N?P5^)UE\8OA7X4\;6'DQ6VNZ9!?-:P7*W/V:5T4RV[2*!N>)]T3
M< AD8$ C%=PKALXS^((KXA_8MO==T/\ X)>66I>%3(WBVUT'Q!-IGD0B:47J
M75\\*B,J=["3'RD'))'-?'D7[27_  4!$8QIGCH,<'_DGL.2, ]/L/O^HH _
M5#]JPX_9=^,&>!_PAVL?^D4U? O_  0\4C_A=!QP4T/'Y7]>'>/_ -H#]N+6
MO ?B33O%VG>-%\*7FFW-OJQN_ D5O%]D>)EFWRBS78-A;YMPQZU[G_P0_C\M
M_C0"$W*-%7Y'W]#?C.<G'0<9[4 ?J71110 4444 %%%% $<V=F0I8CD '&>.
ME>4_'!?C1"NBGX/KX#&!*NIMXX:]XSY8A,'V8'/_ "TW;SV3'>O62=H)KQW]
MIC]I;PY^SGX+MK[4(9M>\2:Q/_9_A_PKI_S7NLWC858HU"L0H9TWOM.T,H =
MV2-P#YX\7?&K]KCP;\5O '@"[B^"YUGQL=1_LUX8=6-O$+.W6>4W!9@PW*P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\(^*;CXH_&KQ+!\1?C%-!]ACU6)=MEH]DH*K#9Q^7&JLW+O)Y:?ZQPHRTKS
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MK*^=A4$$<D>O7KWR:GKU3N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAAKU2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO&@EBTFU@\J5M-B'#7DD39W'_6;"X6(>5,SMMA=6C\+_ +-_Q%_9W\+:=8?
MZX\':WX@U6YFO_&WB;XD&]DOM7O&*%9E> L0,O.=C$XRK9=GD=]O]CS]F[4/
MAKH-Q\0OB$C:K\;_ !:6N_$&K7EREU+!&6S%90LJJD4:1B)62+Y-RX!>..(+
M]+1JRN2Q)Z\MCOZ8[4 ?#?BSX)_M=^-OBGX \>ZC+\%8M5\%_P!HG3[6WFU=
M;:9KR%893,I1F;"@%<,,'->T_#.']I[_ (3?2C\1#\*'\( 2_;QX:&I#4/\
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M+EL"OK;_ (*(_L8^./VOO^%>GP=J>@Z8/#W]I?:O[<N)X?,\\VNPQ^5#*#S
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIM^S=O4?\+(58SM9R^@ZH"=Q !&;? 'OGM7J?P+_ &G/AG^T:VL_\*[\1_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI@9[<=>1G\:^(OV$_P!K7POH?P>B^'WQ3\9:!X5\8>!9#H:C6;^*Q%[8H/\
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M?I7R=K'_  4*L=!TNZU'4_@1\;M*TZUB>>YOK[P@(8+>-%+-)(YG 5% ))]
M:F_X>=?LV.JG_A8I&0"I;0M2"DE<X!^SG& 1GTS2&>L?M6R"3]EWXQ(N2W_"
M&ZR!P>?]!FK-_8Q\5:5XN_92^$UWI-VMY;V_AJQT^1U5EVSVT2VTZ88 _++#
M(N>AVY!(()^*/VO/VOO"G[65OH'P<^%MY?ZEH6K7,-YXGUQK&2WC2S@D\Q;9
M5GBW%_,6-RY"J&6)0S"23;4_8/\ CEHG[+OQ@\9_"KQEK^GZ#X%UQ1K^A:CJ
M%RD%K9W)"K+ SD':'C"@--(H4VJ@+NGY7,KV.-XRBL1]5YO?M?Y'ZE;A2,P4
M9)P*\K7]JSX)R*2GQA\!-@$G'B:RZ $D_P"M] ?RKM]!\7Z!XVT&WUCP_J^G
M^(M'G9Q#>:7=1W$$Q1BK!9%)4X92#@\$$'H:9V;['SI^WE(L@_9U*G('QB\.
MO^ %P<CU_P BOJ6-PS,!G( Z@CU_PK\RO^"EGC_Q)\2OB]X0^$G@G4OLLOAF
MQ_X3&^NM,OXS/'J(5DLT+?))!(@*D.) 2MZKLH$:D_:G[)WQWL/VC/@CX=\;
MP-;Q:A-&;35;*UVJEK?IM6>,1AW**6_>('8MY<D;'[U)23T1FJM.4W3B]5O\
M]CV:BF+,C/L!^?&XKW ]:?3- HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M".;.T8&>?4#'OS7QK_P40_;:N?V6?!]IH/A40S?$'Q#;S/922&.1=*@5@INY
M(B2SNS%A$&'EDI(6W"(QO]DS$+L)/1N/>ORS_P""I=AK7PK_ &H/@Q\<!I;:
MQX=T?['$849T/VJQOI+LPO+L*Q>:DORGYB?*E.W"<@',_LI>,/VA=!_;H^&&
M@_&#Q1XMMQXGL;W7O[!U#5W-M/;2V5Z\9>T23RX-LD9Q 43RS& $7BO:] _;
M"\>_#K_@H1XB^&GQ"T>YTGP;XOU.&#0H[V>67[*PB2VM;FU>-3N@NWA3?'MV
MQRRMN93'/N\;\:?ME?"GQ?\ \%#?A%\8+;79+;P7IGA1[;5;FYTVX\S3[J2#
M4/\ 1Y51&9V4W,*EH@Z<_>(!-8DGQ4A_;X_X*-?"WQ%X%\/W^F:/X:;3Y99M
M74E_L]C<O>333" NL6YI?)3+L&?RMS+OV@ _82W;=P%QMR&)X^;C/'Y_Y-3U
M4LV;<0Q&"-R@9Z9."<]3C;GT.:MT %%%% !1110 4444 %%%% "-]T_2ORR_
MX+??ZSX*_P#<:_\ ;&OU-;[I^E?EE_P6^_UGP5_[C7_MC0!]]?LH_P#)KOP>
M_P"Q.T?_ -(8:]4KRO\ 91_Y-=^#W_8G:/\ ^D,->J4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '(?%\>&V^%/C%?&1*^#VT>\76C^\ %B8'$Y)B_>
M >7NY3YO2OQO_90_X*0:A^R7X0UGP2OABX\?^&%U.:YT6>_OVTR[MX6/S*T8
M6Y148CS/+4X6228[Y-V1^O?[16@GQ5\!/B-HO]IV&B?VEX<U*S_M/59O(M+3
MS+25/-FEP?+C7.6?!PH)K\_OV!-1_9:M_@Y<>'?B39?#RV^(NC:E<KK5YXW>
MPN!?,\SB&2SNIW>.:$11QIB%MH9"V/W@>0 K?\/OV;_FB_ Y.?%>/U^Q#%?I
M!\)?&Q^)7PQ\)>+C8_V9_P )!H]GJ_V/?YGD?:(4E\LO@;B-^,X'2O O^,*7
MZ#X OMY/.B$#W/'3_&OH_P &G1/^$9TG_A&5L5\-M9Q/IG]E^7]D:V*CRFA,
M9VF,IM*[>,$8H W*:S+&I9B%4=23@4ZH+K[JL,;E.0=I;'!]/\GIWH Y?XL?
M$S0_@_\ #K7_ !GXCG,&CZ+;-=3;3&KR$#Y(H_,95,CN51 6&7=1GFN&_9I_
M:<\,?M3> [_Q;X4T_6K'3[+4GTJ2/6+:.*<R+'%(658Y) 5Q.G4]0V1C&?@_
M]K'X*_M%_M*7'Q0\3>,=1@\)_"+P-+K&H:+I[D1F^CLTND26.",[Y#(MN@:6
MX9<"Y9X 48QGUK_@C:JM^S!XE*[S&OC&YY9L'BRL@.G;''0YX% 'MO[3G[<W
MP^_9,U;0]/\ %<6K:M>:O%//'9Z MM/-;QQN$$DZR3(RAV\P*1P3%*.J&O%6
M_P""S7P7:18AX8\=JS8Y:PL]HSC!)%WP.1Z\5\I?MR?&CPOJ7_!0YM4\5Z?'
MXK\)>!XH--33M(>.3^T);>)[I;:Y,AD38;^8PRC9\L:,NTNISZ7\#?VT?V7_
M (C>,(/#OC7]GGP;\.VOIHH(-2DTC3[W3X'8,&^TL;>)K=-P4!RDB@R%G**F
M: /T>^+7QI\&_ WP7<>*O'>LPZ#H<,B6_G2QM*T\K\+%%%'N>1\!LA0<!68_
M*K$?-OPV_P""LGP*\>>*H=$O[K7/!C38CCU#Q%:1QV?F&145'EBED\O.XMOD
M"(JHQ9EX!^?_ /@IQ(GQ4_;*^ ?PGU/_ $?P]="V5[BQ8)>(=2O_ +-.-Q#H
M,):ILRG#,Y)88QZ!_P %&?V/?A-X,_9+O_$GA;P;8>%-6\(/8K976C1);M<I
M+<06K+=L%+7'RR%A))ND#C(8!Y X!^ARRK)C!YQGH>/KZ4^OE[]B/XM0?\,(
M>!?''BJ2#3=+T+P_/!=W%K#*Z16FG236XD* N[-Y5N&;:#DYVJ,A:B/_  4_
M_9F7:/\ A9?+#(_XD.I^I'_/MZB@#U/]JS_DU[XP?]B=K'_I%-7P)_P0[^]\
M:?\ <T/^5_7M7[0'_!1C]GCQO\!_B1X<T7XA?;-9UCPUJ6GV-L=%U&/S9Y;6
M1(TW/;A5RS 98@#/)%>*_P#!#WY?^%TL>FW0QP,]K\_UH _4TG'6OD/_ (*I
M^*M*T7]B_P 6V%[>"VO-8OM.L+!#$S>9<+=QW!7."$_=6\S;F*CY<9R0#]5Z
M]K&GZ'I5WJ6IWEMIVGV,;W-S?7DJPQ6T2*6>5G;Y555R23@ 9R:_,#Q]\=T\
M>>-K[]HF_P!,T[Q#!IMY+X4^#'@FZM[Z237-1%S&KZTL)5=VW<HPJ [TAA9X
MYH8I'0F?.&N_ _3?A?\ #KX'>+/AOXT\17'Q.\:L\RZEH]VMK9Z9$81]IC5X
M,S121>>L3G<XVQ3[@N @T;KX(_";7/V5M?\ C/XF\0>-(_B)%<W&F:AIM]?P
M2>?KQ?B-_/@22;=O2XD7>76/S!N=HV-5/V5? ][J5[J_Q%U:"U2>[E>.RCCM
M4MXT+/F:2!4C$<*_*8T\L%%'F(% &!UZ_!7PAJ'[6G@=_$6H:[X;T?Q5.EM9
M:QX5O1:W.GZLI4VLP86[J6FEC0'!4B25I"ZA>>6,[RL?+4\ZI2S267+HM^C?
M;<^Z_@/_ ,$\/@YX1\&>!=9\3_#+3Y/'EGHUH-7_ +6NYK^W-Z;14N-\,DKV
M\@#%L87:I4,F,#'8>'?C)^RY\&=+U74?#/BSX5^%K-HO/N_^$;NM.CENEC#R
M*GDV_P \I3>2J(&8F3@$MSRNE_\ !,/X!?8Y)/$'AS6O'&MW$LMS>:]KVO7G
M]H:A+)*[L\S12Q(6^?&X(I./FW$DGU72_P!C_P""NCZ3::?;_"'P+)#:P+;Q
MR7F@VUU*RJ %,DDJ,\C'&2SN6)R2Q))KK/JCRV\_X*7?!J]NK+3?!EYXD^)W
MB*^G,<&A^%/#MVUYM$;R-*L<ZPJ\:B/+;79L'.-N2OSW^W)^T OQ9^$LEY%^
MS]\2M!E\+G^T[7QMXD@'AZ?P_<M/!% ]JY64W >66-9( R'$:L,%!)'^F"6L
MBKMWAAG<2V<YZXZ] ??IQ[U\6_\ !0[X0_&/XRZE\-]+\&^"K7QEX*TF\FU?
M5;+^U[.WDN+M!MMTD%RB[8PCR#]VS;Q+(KJFR-V")W46TKL^.?"_POG\6?##
M7?\ A)MDOB;Q@\NK:I<&#]XEY*[2 [$6,KM;#>3T#B3 P &QOV(_ ?Q_^(G[
M3'B/4?#/C:^\-ZQ81-I/BOQA?K:ZQ-:1L)#%&8;ELSAI+&.,%,E!&.0H /N,
MGPA_:7.P_P#"AQ(N 0C>+=,(09R4QY@!!.XG((Y&.E;W[+G[._QY\%_MBZ1X
M[U;X=?\ "$>$;[3;G2O$#_VW87_VB+R7:'A)"ZYFBM5^1,_)D\,]<])-2=SX
MO(Z69T\34EC86C/7=:/MN>U#_@GV=8\,KI7B/]H3XV:S]JL_LVJ1CQ6!:76Z
M,K*IMY8WVQR9/[MF< ':2W4_%'[5OPE^!'P]_:JT+P#X.TG3_!UIX=L3JGB2
MYU#5[EX[R:3RVM[,"Z8H"$*2,5?#K<.N0T>#^R,H?"N5^<=%W84^N>>>.?PK
M@/%/P'^&7C36KG5?$7P[\*Z[JEQL\Z^U;1+:>9R%V+ND="2<  >G'K6[5U8^
MPKTW6I2IIVNK7/S$\2>*_ 'B[1]1TC4?%6A/8W,?D,BWUN#&O7(\PLJD-N<<
M'!P01C-?7?\ P3-^. ^)_P $;KP9?7L&I>(_AW<#1)+JU.^*\L@"+*=&$<:E
M2L31+]YB+?>YS)7-_!#X"_#/5/VP/VG-'NOAWX4NM'T=/#1TW3KC0[:2WL?-
MTZ1YEABV$1[VY;8 6..#7UQ\/_A-X+^%\]^?"'@[0?"AOEC^U-HNFPVAN FX
MIYGEHN[;O?&<]34PCRGAY/DRRE35.;:>NO\ 74Z:6W/D[6CR"VT@'<,-P>"#
MQSTZ<5^9OA;]@?\ :6\/:MXDUAM>^&=]KGB+4IM6U'4+B>^1Y;B5B[#]W;(
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MO!7BY+(7GDRZAJ-QI6J3W6HR)'M#S2-;<\;F\M L:L\FU$+,*S?"_P#P1?\
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M$C>"M)U)?.UF&VFF;PU<3SB%X;J%O]3 TBR.%4"02>;A)#)^[^BOCY_P4_\
M"L/@/5+/X+6^J>/O%LFG75Q+?66FW-O#X?A6+ OY_M-N?,5)'4A2FPA3O9,H
M'";GAGP7_:*^/'[/O@SPI\)/#'AKP7+IND^.)_ARFLZU'?W45YK,E_/+(_F0
M^6L$*)/!Q(OF2?-(BR8E$/;?'SPQ\9/B%?/\#_'GQTM+KQWXPT2\U^S^'>@^
M#X&TR7[-+)-;6B:G*8Y$WFW;:TGW1;-YCY*&7T[_ ((_^&M4T/\ 91O;V\LA
M#9:YXDO;_3W\Q'\ZW6*WMF8[3P1+;RKS@DKG&#FOMZXC&W;Y:A<Y& .OK_\
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MD+EF.T'&23BOS!_;$_9I\#_LS_'SX>S^%-*MM!\.ZUI,]O:6SZE<W30:E;R
MO,YG9MJO%-#&O/+(QPN,MO0IJK4C!NR9S8JL\/0G5BKN*;'S?M1?M*WDUS<?
M\+7MM)$DLL@T_3O#EC-#:H'8B*%YHM\@5  #(<G'+'[Q^D?V(?VWO$GQ8\=7
MOPJ^)MKIMMXVLK,7&EZQ98A@U=(HT60%2W^O;+2XB4+L\SY(_+^;X]6*21HR
MC,NYSABAQ'\O1N..K+SU)]JS/#?QRT#]G_\ :7^&?C/Q#!?7VFZ&FH2SVFDP
M(]XZ7-M)#$5$C(I^9Q_$/EW?0_1YA@*-*@IQT:_$_.\AS_&XS&^QQ#O&2?3X
M3]-/!O[:7P]\??!/Q[\5=!LM:OO!_A&\N[6[:/32]Q>^1%%+YL,*;CY;"9"&
ME\O8 S2>6JL1<\4_MA_#OP/\#O!_Q8U]M4T;PKXEFLX+!;O2Y%O(OM'S;Y(@
M#M5(TFD++N5UC!B,A>,/J_";]K#X0?'.X6T\%>/]'U+4Y9Y(TTR<M:7TI6/S
M'*6TX25E$9SO"%?E;GA@.3_:L_;'\.?LSV^G6 TUO%GCC5I%?3_"]K.L$CQ;
ML-<3RE6$,0*[0Q5BSJ57(21H_EDG)V2/TR4HP5YNR.U\1?M%>%_"GQ[\&_""
MY^V3^,O$UI<ZA MI!NMX+>))F#32,P/S?9Y% C#G=&=ZH&4E? O[2'ACQ]\7
M/'OPXT^PUZUU[P=Y(OKJ^TV2WM)?,7(\J1^G;:) OF*=\7F1AG'Q%8_\%+/C
M%HVK7^I:U\+O#^LZ&ZS-!H^DZI/#J%GA\QB2=S*DY\L/D11#<=K?+C;7WA\$
M?C9X5^/W@&Q\9>#;[[9I5PQCFA=!%/:SC)>WF3)"RJ6&<,0<AE9E92U5*<Z=
MN:+1S4,51Q"<J4E+T.#TO]MGX7ZS\ ?%WQ?LM4U&X\)^';N>PNVBL'2Z>=9%
M2(1QN!GSO-@*%L!1*HD*%9 G0>,?VHO"/@W3?A;?LFK:O8_$;4K#3=$O=,L'
M,/\ I>TP33M)L$*L&4["?-(+[4;RW*^JR1JJA67A2,;#M//!(';]>O'-?$O[
M27_!1"\\%>.M=^'7PN\,VWBCQ-HTZP:GKNJS*-(L9"8VV!89/,G8 S1NN^)H
MWBZ2;66B,)5)\L%<UJ5(THN<VE'NSZ7UC]H;PAX<^.'AOX37]Y./&?B#39=5
MLX(;>1X3%&';:TN#AG$5TRCIBW<,5+1AZO@#]I3P5\2M:^)FDZ'=ZC?ZC\/[
MTVFLPQZ9/(0X5\_9T1"\X$D-Q%M0%F>%\*5>-G^(=)_X*9?%;P3K,5[\0/!'
MAW7O"KD_:V\%BZBO;10P+3?Z0[JZK&LC",A QV@R("0?T0\ ^-M!^*'A#3/$
MWAC6(=>T/5(3-:W]FV%>,M@CGYD8,K*5.UE965@I4@.I3G3=IQ:(P^)HXJ/M
M*$N:)YAI?[7O@;4/V6Y?CP]MK&F^#!!,ZV_V5'OMR73V@C6-'9-SS* IW;?G
M4L5 8C3\4?M6?#_PI-\*(KS5)Y3\3I8X_#<T-E*T<XD1'BEE4J&B5VFMHP&P
MP:X7("H[)Z_Y!,95E#K@ 1L 5X[^_;KZ=J01,T>)8MQ QP0<Y&#^O^>U9G2>
M;Z?\>M#OOV@+SX/QV6KCQ)9Z"/$3W4UJT5BUL9UB"I+(0TK_ +Q22BL@*NI<
M,CJ,GPK^U3\._%TGQ82UUJ;9\,YWC\1S2V<GDPJD;M(8MJEI54PW$> "Q:%B
M%*M&S^N_8\^8#NP[$]00.G0$?4XYY-*87\L-C,F-IS@$]NHX]3T[T > :]^V
MI\/]#_9FT[XVO;ZYJWA*\,2)!9Z=YEW%(TWD,DH)"1!)%=3([B-F7",YDB#]
MK\4/V@/!GP?\7> /#7BB\FM-5\<Z@VFZ7'';/(K2A5RTC '8N^6&,=PTJG&Q
M9'3TORG3"JN4R1@' ZY!QW]^1T/%"QLL@.QV!))W$'&#]>A[#M[8Q0!YCH'[
M07A#Q'\</$/PEM+UI?&WA_3(=4NU:VD6WVR%0424C!91-;%AG&+A0I8K($S_
M (<_M.>"_B-X#\>^,K:#5-!\.^#=2U#3M5FUK3GMYB;.-))I!;@&7:%D(".J
MRA@5,8;BO73;O.I6559#U1A]X$8(../7CF@QR&/.#N8#Y"V<<8Z\_I^7- '@
M&J_MQ?"WP_\  /PG\7=4U.^M_"GB*]@T^U>2R9[B&9Y&257C4$CR1#<,[#(8
M0/Y9DW1A^T\5?'70?!OQD\#_  SU&PU63Q!XOAO)[*Y@LF^PHEO$9'$D[D N
M57 6/>P8J7"!T+>E/;/MVH63;G:5(&#V/.?4]?R-(8'\Q7$?W1QD@^PZ_AG^
MM 'FF@_M$>#==^.'B3X26][-)XU\/Z7#J=ZHMV2!4DV[D21Q@LHEMF*YQ_I"
M@%BD@3FO#/[8?P\\9? KQ?\ %?1)=4UKPOX9FO(;^&WTR8W3M!\VY8BH^1T:
M*0.VU8T?,K1[) GN8A:/&P83/*+@'@8 'Y#_ ![4B0-'\NT;1CE#CZX].G3/
M0_A0!XMXV_:T\ _#GX*^#OBIXB>_TSPOXG.G+IX-BTMS&+R)9E9TCW ;(1+(
M^TMQ$0N]BJMN:O\ M!>#- ^.'AKX27]^?^$R\0Z?/J=G;QV[O \4>XA&DQ@.
MR13%><?N'W;2T2R>F+!*D<@!!8]-S$C]<XY)]>,?@YD>0@X96R1N4@<<X[].
M: /*_"/[1'AGQCX\^*/A:ST_7(-1^'8MSJLUQI4O[X2QRR+]GC4&>7 A?'[O
M][E3%YBN&/+:!^VC\/\ 7/V8=2^.?V77M(\'60EC>"ZTTQWGF+,(%2-<F-R\
MKHH=7* MAV4QR;???(SC;&(QGT'&./Y?I2M"_+'YFQ]Y0!C\_P * /(?&G[4
M'A#P;IOPNOY8]7U:Q^(NIV.E:+=:;ISF'==A3#)<&78(%*R(VQCYI!;;&VQB
MMAOVC/#7_#0@^#HL-=3Q0NC?VZ+R72)!IPAR1@W ''3!DV^5G]UYGF_NZ]46
M$^7M:/<O( XR!C&#DG)ZT+;LADVCER2"WS*IQUQZ9YQGJ30!XSX'_:P\ >-C
M\6O(DOM&/PPO;BV\1_VA9D&-(?,_TB,1;_-C;R)]H!\PB/E!O7.!<?MO> ['
M]F"S^.<FC^(O^$5O)OL\.FV]DCWZ-]K>VS(J2&*)2Z%M[2*I!0 EV1&^A!$X
M0X1LGLS#OU]<=??I0]H9%\DC$)R& ;;D=>W/MU% 'D/Q"_:D\'_#/Q?\+/#^
MM#5+>?XC/+#HT\FGO&D,JB QI=1R%9H69KB),&/*LQ\SRPI(MZ-^T=X5\0?M
M"ZU\&=.^V7/BO1-(_MF\N##BSA4M$%A\UCN:4I<PN=JL@5B-VX%:]66,KC,8
M/);CC'.?7DG^=,:.62-MP7G'!4$\@ ^WKZ_CTH \/\&?M<>#?'?@?XJ>*-+T
M3Q'#IWP\N+^#5[?4=(:TFN6M86E<0*X"LQ",/*=DE3Y?,1-Z;H_%'[9/PX\#
M_ WPA\6M?EU+1_"GB2>SMK!;K3)%O(S<$G>\0!PJI'/*67<KI%F(R;D#^[>1
M(W4A05P57@Y[_,.W ]Z8UJ7WNH,4A)(*-@EN@8]CP!U!XXH \V\4?';1/!?Q
MH\!_#&^LM6;Q#XPBO9[&ZM[%OL*);0M*XDG<J"VU -L>]@<%U0.A9?"OQ_\
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M6WD+,<[26R<H<@C/!SV.,5/4,4;*P+87@@JIX))SFIJ "BBB@ HHHH ****
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MX)R87_AL7P"N#@,(K')R3U_XF/?@BNJ^%/[$/P<^&_Q>\!>(;3]J[PIXEO\
M3_$>ES6VB:7:V\EQ?S?;8A% @BO9'^:3:I8(0@)9L!20$W/UMM<JS(S[FSGH
M1@# [D^G7O5FJ\);S,;MR8/WLDGIR#TQ_GUJQ0417#;8PQR<'H 3GZ@#-? O
M[4'[6O[3?PO^-GB3PW\.O@TWBWPK9"W-CK/_  CFI70G)MXWD4R0R!7VNSC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5'<;_)8QKO< E5/0G''ZXJ2B@".-=K
M9VD=<GCGGC-2444 %%%% !1110 4444 %%%% !1110 4444 >6?M6?\ )KWQ
M@_[$[6/_ $BFKX$_X(=_>^-/^YH?\K^OOO\ :L_Y->^,'_8G:Q_Z135\"?\
M!#O[WQI_W-#_ )7] 'ZG4444 %%%% !1110 4444 %(>:6B@!NTTC+NZC-/H
MH 8,^F*,<]*?10(C93V%&T],<5)10,CVEC@CBDD5]JA!DY /.,#N?RJ6B@7D
M5?L[;]R@HW=L]?3('7''I_,5\S_%+_@G]\./&-U!KG@JUF^#OCBQ@,6F^)/
MA73WM\QRIAX8]J.I,QWE=DCJH3S0ORU]14UCTIH'L?GY\8_VFOVC?V*?"=V?
MB)H/AOXI:3=S&RT/QO9W TTFX?[3(B7MDN2[^7&K;(1'&%7!F=VW+\@>(+SQ
MQ\:+$W7Q9\9:SXIDG9)UT5KTPZ7;S1QJD<D=O#MA5PI()1!_K'R,G>_Z#?\
M!3WP7K7B;]G.QUS1[(ZD/!OB.R\2WUG'YGG2VL2RQR>7L1N5\\2,S85421B?
MEP?@C3=6M=:TZVU"TN[>ZM)8]XN(S@-ECDG.-IXY7L<YYR![^44:4Y-U=SX;
MBK&XS"TX+"Z7ZK<Z[X%?M2^/OV5O%WAW3-8\27WB;X*--#8WUOK#M/-HL#"*
M,30RJC2JD*H-L*@H5WHJJ[+)7Z^6K.S9<J3MP2HQ@^G4X.<\9/\ C^&_C/P[
M?_$K5-%^&>A1+=>*/$U]!:0P%9&-L@<.\\@C1V5$527.TE4#M@A&K]"]1^,'
M[6/PQ;5YO%'P=\(_$W2HK5;M;WP'KLMDMLJF0S1M!=B2:XDVK&P2*/H<*7+X
M7CS*G2H5W&F>KP_BL5BL#&>+7O'V']HC+;0X+<<#KST/T_PKSG5/VF_@_H>H
M7=AJ7Q5\%:=?V<KV]S9WGB&TBF@E1BKQNC2!E=6!!4C((((K\_\ ]M#]LSQ/
M\8ET'X2^&?#'C3X86VM1RS>)8O%FDC3;RXT_(1(X"'<B&0B=78KARB)NVF5#
M\\6?PQ\*Z=I<5C)HMM<JORF>>$-,<J S%\!NI)&",'.% "@F$R^KBU>(\USW
M#92XPJZR?1'[G?:$R1GD'!X[TGVF/<5S\P&XK@YQ]*_,'_@GW\7-<^%?QHM/
M@U+=7UYX%\1174VA6ESMF.DW\2-//&C[@?LSHLK8VYWE"%4M*S?IEYVY4V+N
M8CY58@8/]W/MS[CFN&I1E1FX3Z'MX7$4\92C6HNZ9<^T)\W)X]%)_P#UTHF1
MG*9^;&>G8_\ ZC7PS^V+^V_XA\!^,KSX8_"G3K5_%]G9AM<UK7+=VMM,6:#S
M+>.)>DLY$BOEPT:\ J^9/+^<K?\ :D_:4TV_M;M/BY9ZWY$R2'3]2\.6-M;W
M(#JQC>2*,2!& 8-L*MTVGG<NU'!UZT'4BM#BQ6:X/"551JU$I/H?KG',DF I
MYQGH1^?I3\U\_?L:_M/1?M,?#N\OM0L(-#\9Z'=G3O$&D0S(XCN !B>-0[.(
M),,$W]XI5#.$WM[V;J)2,N!E@@]R<8 ]>HKD:<79GJJ2DE*.Q/36D"<FA9%;
MH<\9ILS!5!+;>0,GU/ I QX8&C<,XJLLBJ"P;?@[3CL?\FI%FC#-DX*]<CIQ
MFC;J/2]D34A;;UIJR*_ /.,X(P?RHD=4 W'&3@<4 *9 O4TH.:Y'QQ\6O _P
MS6Q?Q?XQ\/\ A5;X,;1M<U."S%QMV[O+,K+OV[ESMSC<N>HK?T?7+#7M+L]3
MTV\@U#3;V%;BUO+202Q7$3*&22-ER'5E((9<@@@BC4-30HIJNKYVD'!P<>M.
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2O /VO/VQ/!O[)?A33+[Q!
M97NN:OK'VA-)TFP0?OWCBRS2RM\L<0,D2L?F;$F5C?:V/?95+*-IY!]<"OS'
M_P""G/P)N;CX]_"[XI^)=-^W?!^T&F:%XGN+=7=[*W6_D>0RI"HD2.2.?8DD
M9SNRGRLT8< Q_P#A]I&\9Q\&2H8;5_XJ@;$48P /L)_'CK^&.G^$?_!7[_A9
M7Q,\(>$#\)%TL>(-8M-+-X/$7F"V-Q.D1D*?9%# &3IGIWK['T?]FGX$:]I]
MGJ>G?"WX=ZK8WUNES;7UOX?T^6*YA90R2QNL15E92&RO!R".#6KI_P"S5\(=
M U&TU'3_ (5>"=/U"UF2:VN[/P]9Q30RJP*.CB(%6! ((.1B@#T>SC5 WEKA
M-QYX&2,#.!]*LU7@C16&3OD (W.06QQG\.A_$58H **** "BBB@ HHHH ***
M* $;[I^E?EE_P6^_UGP5_P"XU_[8U^IK?=/TK\LO^"WW^L^"O_<:_P#;&@#[
MZ_91_P"37?@]_P!B=H__ *0PUZI7E?[*/_)KOP>_[$[1_P#TAAKU2@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M45N##'!+E@\$H2*..($H_F0M$0&(D /UFA7]\3M;Y<KN8@GM^G0U8JO;R*^
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MC0!]]?LH_P#)KOP>_P"Q.T?_ -(8:]4KRO\ 91_Y-=^#W_8G:/\ ^D,->J4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT'QK_P"A8\ _^ -[_P#)M?L]M^O_ 'T:-OU_[Z- 'XP_\/H/C7_T+'@'_P
M;W_Y-H_X?0?&O_H6/ /_ ( WO_R;7[/;?K_WT:-OU_[Z- 'XP_\ #Z#XU_\
M0L> ?_ &]_\ DVC_ (?0?&O('_",> >>/^/&]_\ DVOV>V_7_OHTC*5P>V>1
MDG/^30!^,:_\%GOC:P!7PKX$;) &-/OB<GH/^/SJ<4?\/GOC;MW?\(KX#VYQ
MN_L^^QGT_P"/SK2_M('=_P %@-(C9E)_X3#PJI9@3PT%AN7'3!^G\1K]F%5F
MD)Z*./<YP<Y!Z=1TH _&7_A]!\:_^A8\ _\ @#>__)M'_#Z#XU_]"QX!_P#
M&]_^3:_9[;]?^^C1M^O_ 'T: /QA_P"'T'QK_P"A8\ _^ -[_P#)M'_#Z#XU
M_P#0L> ?_ &]_P#DVOV>V_7_ +Z-&WZ_]]&@#\8?^'T'QK_Z%CP#_P" -[_\
MFT?\/H/C7_T+'@'_ , ;W_Y-K]GMOU_[Z-&WZ_\ ?1H _&'_ (?0?&O_ *%C
MP#_X WO_ ,FTJ_\ !9[XV,&(\+^ L*-Q/V&]X'_@;_G-?L[M^O\ WT:^6?\
M@I\JK^PW\268$[3II&"3S_:=J/7WH ^"#_P6>^-BJI/A?P#AAD?Z#>__ ";2
M?\/H/C7_ -"QX!_\ ;W_ .3:^I_^",BLW[,?B@EB^/&%T"2>_P!CLLXXZ=_?
M-?>^WZ_]]&@#\8?^'T'QK_Z%CP#_ . -[_\ )M'_  ^@^-?_ $+'@'_P!O?_
M )-K]GMOU_[Z-&WZ_P#?1H _&'_A]!\:_P#H6/ /_@#>_P#R;2?\/H/C4?\
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M#='_ &X/BQ\4_&WQH>X\9364-H);>ZFGMWFN+AI DBRP2QF-8DM6C6)1LVR
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M/?\ JM1_\)0?_)E 'WM_PUA\$/\ HLGP_P#_  J+'_X[1_PUA\$/^BR?#_\
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M,4 ?LW_PUA\$/^BR?#__ ,*BQ_\ CM'_  UA\$/^BR?#_P#\*BQ_^.U\$_\
M#CW_ *K4?_"4'_R91_PX]_ZK4?\ PE!_\F4 ?>W_  UA\$/^BR?#_P#\*BQ_
M^.T?\-8?!#_HLGP__P#"HL?_ ([7P3_PX]_ZK4?_  E!_P#)E'_#CW_JM1_\
M)0?_ "90!][?\-8?!#_HLGP__P#"HL?_ ([1_P -8?!#_HLGP_\ _"HL?_CM
M?!/_  X]_P"JU'_PE!_\F4?\./?^JU'_ ,)0?_)E 'WM_P -8?!#_HLGP_\
M_"HL?_CM'_#6'P1P3_PN/P"<#)QXGLC_ .U:^"?^''O_ %6H_P#A*#_Y,I#_
M ,$03'A_^%S>9MYVGPJ/3T^V<_\ UZ /OEOVK?@FN<_&'P",#//B>R''K_K?
M>F_\-8?!'O\ &+P"![^)[(9^G[WFOQA_;=_8?'[&J^"U;QD?%Y\1->%"NE_8
M3;BW\GC_ %\@.?M&<\?=]Z]^^%/_  1W/Q0^&/A+QE_PMYM.'B/2+36/L?\
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M<''B>R//I_K:&_:N^"2DAOC%X!4@X.?$]D.?^_M?AS\./V61\0/VPKSX%?\
M"3M8O;ZMJFC)K[6)DS]B6=O,\@2C ;[-]W>?O^V:^S$_X(@[E5?^%R[=H^\/
M"BC/0]/MG^<4 ??/_#6'P0_Z+)\/_P#PJ+'_ ..T?\-8?!#_ *+)\/\ _P *
MBQ_^.U\$_P##CW_JM1_\)0?_ "91_P ./?\ JM1_\)0?_)E 'WM_PUA\$/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'-O*@(,DD _-CCO\
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M(_S_ )ZBGK=1R+N5MR\\J">E $M%-5@Q('\J=0 4444 %%%->01KD_H,G\J
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M4OB=^S-J4*Q:G),/['@FM+::R\\R22P^5,J6LUHK!-BM\R%H\(WDB2OU$HH
M^#/V#?V _$7P5\8:M\4_BIJ$6L_$#5HG,5MYXO7LC.!)/--.X):[+$QDH2@'
MFGS)?-&S[NCWY4E54$'([@YX_K4M% #7.$8^W89K\LO^"X!VR?!3ZZT..?\
MGQK]2YHS*H V]?XAGCN/RKXO_P""B7[%_CG]K@^ /^$1U#P]8'P\NHBY.O7$
MT0?[1]FV",10R<+Y+9S@]* /H#]E$Y_9=^#_ /V)VC_^D,->J5P_P1\$W_PW
M^$/@;PKJ<D,VH:%H-CI5Q):R,T+200)&S1Y525)4XR >G%=Q0 4444 %%%%
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M%HVW,58XP2%P2>Y_' X]J )Z*** "BBB@ HHHH *^6/^"H W?L,_$H#UTO\
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M0K21X,AWH/,O^"6_AC4OBK\<OC1^T'<6QTC2M8OK[3[?3XY%F#3W5U'>S*)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX!^#NLZ?\:[C5KKQ7-K\]Q;R:SJZZI-]D-O;*@\Y99<*)%FPI;/!.,')^H*
M"BBB@ HHHH 9)(L>"[!02%!/J>@I//C# %MI/0-QZ_X&DN&V1YP<9[=?P]37
MP;^W%_P4FT#X,Z?K7@?X<7]MX@^)/FRZ?<2*@DM=$<(,R.64I<3Y;:L2Y565
MQ+@H8V /O/SD.[GE1DC!R!]*<TBKG<P7Z\5^;O\ P1]^+'C;XE2?%M/%_BS7
MO%0T_P#LHVT>N:G->/;&3[;Y@0RL2-Q1,CCH,]*VO^"IW[8/B+X&6?ASX?\
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M=@8 /0/A!X*;X:_"_P '^$C>_P!HKH6BV>EK>>3Y'G""".+S/+R=N[:3C/'
M[9/95!!"T+GYF<$<LY!.?\Y^G:IZ "BBB@ IDC +SW.!3ZCF5F4 ''//'/\
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M,W@74?!_B[31K'AW43$;NQ:>6 2^7*DJ?/$RNN'C1N#_  X.02*\ A_X)?\
M[-6T!_AL#QVUW4Q]!_Q\D\#WY)- &O\ LL_M!? +QE:VWPS^"FL6LJZ%I;7$
M&F6VE7ELL%JLBAF+SQIYA,LREB6WN9"S%CN:OAFS^(.F?L+_ /!33XC:IXSM
MKZ[\,^+C<O\ VDMJT/E0W\\=W]H2(!C<10RQ20.4Y.R1E#,OEG]#?@[^QK\(
M/V??$UUXA^'OA$^']9NK1M/FNAJ=W<DP-)'(5"3RNGWXHSG&?EZ\D'I?BY^S
M_P" ?COH8TGX@>$K#Q39P'%K)<;EN8 7C9_+G1EDBW&*,,4<%E4!MP)! /RX
M_;0^.'AO]O?]H3X3_#7X7M?7>EVMV;:3Q NG3/Y_VIK<S2QVC!9#%;Q0%V9P
MN<2<!%WM^PUO(KN!&/D0%<;1QTP ?3'Z8/U\J^"_[*_PP_9YCG?P!X+L-"O)
MF)EOMTES=NI"!HQ/,[R+&?+4^6&"9&=N<Y]9C5E<EB3UY;'?TQVH EHHHH *
M9*Q4 A2WL#[&GU%<*6484. 22I&<\'@<T ? ?_!4+]LK6O@1HVG?#SP1>'3/
M%/B&Q>XN]5A:59].L"QC0V_RA!+*RRJL@8M&(F.%8QNODW['/C;]C3]F/2M+
MUJ_^($'B+XI""19]?70]6,5F9@H>&TC-N-JJH*^<5$K!Y.41_*7[9^)7[!OP
M/^,GCK5/&/C3P2=:\1ZEY7VJ^_M>^@\WRHUBC.R*94&(T5> ,[<]2:Y>3_@E
M_P#LT!#L^&OS=,'7]4 ([C_CYH Q/VS_ -JOQW\&O@CX-^+/PGT[0?$OA#5?
M*DOKG6+&[D:.&XC22RN0$:/RHV7<C&3!W30(!DD#F8_^"MGP='P;D\4LVICQ
MI)9B3_A!Q;3"07>X)Y:W?E>3Y>[+^9G)C!81[P8J^P=/^'>AZ/X M?!-KI=O
M-X6M=,71XM+O%\^ VB1")8)!)N\Q/+&T[]V0>0:\4_X=T_L\-XG/B%OA=IHU
M,W9O#']LNS:&0R&3!M?.$/EDD@P[/+VG9C;\M 'S=_P13^&NM>'_ (=_$+QK
M>VXMM%\1W=G9:=OC=))OL8G\V497:T9:Y"!E8_/%,I *<_I+6?HFC6F@Z=:Z
M?86=O86-G$MO;6MK"D44,2@!8XU7 5% P% X %:% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'E7[5S%/V7_ (NL.6'A#5\ G@_Z
M%-[CM7RA_P $8=)@M/V>?&=Z+2WCNYO%4MM)<1H!+(L=I:E48XSM4RN5!/!D
M?.#FON'XC>"[+XC^ ?$7A+4I+B'3=>TZXTJZDM&59DBGB:)V0LK+N <D94C(
MY!'%?BU\"?CQXU_X)H?%'Q]X9\5_#\:[_:YBA:*22?3A<?99YHX;VUE>$[[9
MR9]K>5\YVL'7:P8 ZC]G'/\ P^%U1AD)_P )EXL!?;D<1:AD9[=OS]Z_9>VC
M56RJ@#&T';V&._US]:_*_P#X)D_!SQ1\7/C]XG_:.\4Z'#8Z9=MJ-QILXEEB
M$NJW,I$\EK'GYX(UDNHB78@-)M!D='9/U4C5M^XKL7& O&?QX[<]Z ):***
M"BBB@ IDA(P0N[VSCL?SI]1S*6VX!^]V.,4 ?$/_  5-^%/Q$^,WP>\/>'_
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M%&YB3R2:]O\ ^"<&GV^I?L"^ [&[L[6\@N+?5;::UN(=\4T;:E=JR..=P(+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 44A;'6FI(LB@@\$9Y&* 'T4UI JDGMSP,G\J&D5>IQ[XXH =13
M%D5C@'GZ8STZ>O44^@ HHHH **** "BBB@ HIK.$&3G'L":19D9]JMEL;N/3
MU_S[T /HIK,%&3GJ!P,]3BA6#9QV]J '4444 %%%% !1110 44C,%ZG IIE4
M=\\9XYH ?135D63E6##V-.H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2DCALPUJ+CS%FG=@$9EFW*6PAVLN[>45@#R']OS]F=/V5?B-HGA/0]2US4O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@;Q6]F+ZRTCQEI)T^:_AW2;O(3>VXJ(WR."VUF4,$;;F^-/VS? O@?XF>)?
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M3[?4?A+\'];\*_M"77B3QG\9[/Q]XQF\*MIT6CG28-,NDLFNUD%P(HY3F,2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9>-_#,&NV^GR-+:L97MY8F<%'"2Q.KJC *63.&PI()48@^$O[.?@#X(_:?\
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ME#?>Y'HWPY^&NA_"OPC8>%O#&F)I7A[3PQM+'SGE"%Y&E<%Y"S']X['KWP
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img192321128_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_20.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &> Z@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:['P]-JUQH-I+KMO#;ZFR$W$4)RBMD].3VQWH TZ*** "BBB@ HHHH ****
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M8^%NGZQ\1K+QA)>.DMN8V:V$0*R,GW23GCMV[5V6JV U31[[3VD,:W5O) 7
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M>VU*)I88+A+A$#E077IG'4>U:E% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-EY:0_*L?G;1(% Z9'I6QJ2KX1\<ZU;:!"ME WA&2Y:. ;5$L>0DF!_$.F:
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MZGX;\4+I/F6EFERK:>KX.Y@!RQ]#Z5Z'0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% ')>*_ 5KXLU;3=1N-3OK
M673LFW6 IM5R<[L,IYX'Y5)=>"(-2T'^S-5U;4;YTN%N8+R1T6:WD7[K(54
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MWQ#_ -@B#_T(5Z-7G.D?\E]\0_\ 8(@_]"%>C4 %%%% !1110 4444 %%%%
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M%L8/%MUJ6C<B>UU)!)*!@X*2#G.<=>U=K45O=6]Y");:>*>(G&^)PPS]14M
M!1110 4444 %%%% !1110!YUX<_Y+CXT_P"O2R_] %>BUYUX<_Y+CXT_Z]++
M_P! %>BT %%%% !1110 4444 %%%% !1110 4444 %%%% !17+^*=(M'@%Y_
MI*SR7,",T=W*@P752,*P'3BMZPT^VTV PVPD"%MQ\R5I#GZL2: +5%%% !11
M10 4444 %%%% !1110!YKXS\>>&;N/4O#MQ?ZS;R12"-Y--A;=,X(+0QN.K<
M\CTSS2^$_ _PWUO0TOM-T**XC9FCD-ZK-,KJ<,KACD,#7767A73+"_U"[AC?
M?>W'VIE=MRQ3;2IDC!^XQ!Y(ZUR%CXW^'?P^CE\/C76\Z&9WN'=))W>4GYB[
MA2"V>OTH U[+X8^']'UNVU71!=:5+$X:2*UG813K@C:Z$D$<UV=9'ASQ/I'B
MS3FO]%N_M-LLAB+^6R88 $C# 'N*UZ "BBB@ HHHH **** "BBB@#SG2/^2^
M^(?^P1!_Z$*]&KSG2/\ DOOB'_L$0?\ H0KT:@ HHHH **** "BBB@ HHHH
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M([4L$4<,0<#;E022:JRM<5W>Q.3@9-<%XSLKN"SU34;2W%Q;7:Q"5=X5U92
M&&>"I&!Z]Z[8 W'+ B+L#_%]?:L2ZM$\0ZM?Z=?-+]AM5C'V>.0H)2PW;F*X
M) Z 9QD&A/E$U<99+<:4]S>W4*MJ.H,J06<;[L! < M^)+-T'\ZOB'1DCT5[
MZYD=]3::!7N89&C8*TJ*44J00F"1CWSUK0T6 6VN:I;O++<M"L6R>9MSHC G
MR\^Q&?4[AG-'BUW_ +"D41,P\^W^8$8_UR4M6[CV1LVMI;V-LEO;1+%$G15'
M^>:FID;LX):-DYZ'%/I#"BBB@ HHHH **** "L^;6K"#7+?1Y)@+ZXB::./'
M55Z\^O7 [X/I56;09'DDD_MS5T!);8DJ8'L!LKQR\MO$MQJ<VIKI^O?:Q+O@
MEDMF,B*O"+D+CIUX_B/6L:U5TTFDW=]#GQ%=TDFHMW?3\SWVBN<LM%FN[&WN
M6UG78&EC5S%+*@9"1G:1LZCI71*,*!DG ZGO6QT&)XM\0?\ "->'Y;]+?[3<
MLZ06UOG'FS.P5%SV&3S[ UAW-M\0M.M/[335-.U.=/GDTE+/RD<=UCE+;MPY
MP6X/>M'Q[HUYK'AQ3IJ+)J%C=0WUM$QP)'B<-MS[C(^N*S+KXBBYL&M]&T75
M9=>D79%8W%E)&(G/>1B H4=2<T ;6K>--$T)X8=3N'BNY8A+]ECB>:15[DA
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ML<BM,[[CM8-@@#':M:Q-\83]O6W67=QY#,5Q^('-:&I9HHHH **** "BBB@
MHHHH **** "O$I->UK4-?UN+5/B3:^&IK2]>"/3S!$<1#!1@S'YL@U[;7A=I
MH6LZ5JNM>=\+;?68KG4);B&YN;B$R;6/0E@<CN.G6@#T[P/(\FAR,_BF/Q(?
M/;_3(U10O ^3Y...OXURWQ/\':=XT\0Z'IUQXA.G7WERM;VWV<R";&"QZX&
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M_/3Y58$^^#@X],]ZUG1Y::GW.6GBZ=2M*BMT=C1116!U!1110 4444 %%%%
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ME>JG<""1]:]+4DJ"1@D<CTH 6BBB@ HHHH **** /.O#G_)<?&G_ %Z67_H
MKT6O.O#G_)<?&G_7I9?^@"O1: "BBB@ HHHH *IW^EV>IB,7<;.(R2NV1DQG
M_=(JY7DWQX\5:UX;\-V,.D226PO9F2:ZCX9 !D*#V)R>?8T =1X>ALM)\-:=
MJ(BFFOYX0B*T[LTKMVPQ([9)[ $US?B(WR^(?]"U26*[M;29]3N(;(SHS.HV
M0>P &<'H,'J:\O\ A%XZUNVUE]*8RZF\ELT>G1S,7\F8D8P3]U3U;V6O=G\$
MSG2(;*+6[JWD(D:[FCSFYE?[[MAA^ [# [4 9WP[CO+D6NIWNJ7%R\FFQ(MO
M)8&%(1P<(_?W]>#V%>@5SOAKPS<>'@L;ZQ=7L"0+#'%+G" 8P1\Q'05MW-Y#
M:@>827;[D:C+-]!32;=D!P?Q)\0W^G1MIEE<6S&\MF5K=H2753D%B^X #L."
M<BKO@SQ=+JMG.VI74!N(RJBUAMV$B^_!;<#V(QWK&\=>&]6U'5$U:RL'FE:%
M8GMD/.T$D'<?ESR<C]:U?AUX<NM(%[>ZA#)#=W 1/*(X1%R1SW.2<XZ<5U.%
M-4KO<XE4Q#Q+BX^YW.1^(4EW)XI\^^AEBM&A46?G#"X_CQV#9Z]\8KH/AEI\
MUSI=ZUT)CIAF4VD98A&./G('<9Q[9S7<:AH>F:KG[?9QW(.,K)DKQTXZ58M+
M&VL(S';1>6A_A!) _/I2E77LU&.C7]=PAA.7$2K\V_0YG7_A_I^O7BW)N)K.
M15"9M55,J.QXP>_O6YH6BV^@:8EA:G,2DL"1R2>I)[D^M:5%8.I*2Y6=2IP4
MG)+5A1114%A1110 4444 %%%% !1110 5X3:P>"M4U[Q0_Q&NHQK,=[)'''>
M3M&(K88\OR@".WIS7KWBC3]6U/0I;;0]4&FZAN1H[@IN P02"/0CBO,=2U7Q
M)HC+<>/_  -IVN6MN/\ D*6,:.R*.Y5A_P#$B@#J?A#/=7'@EC++/-8I>3)I
MTMQG>]J#A"<_B!["N]K"\)>*-'\6Z(NH:([&T1O)V-'L,; #Y<>P(Z<4SQ'I
M/B"_E@GT+Q#_ &8\2D-%):K-'-DC&[/(Q[>M %)_&$Z?%*/PA]DC\E].^V?:
M-YW9W$;<=,<5UM>;0:CXTM=1FN3HWAKQ%<VW[F6;3KD0W*#KL8.#CZ9KT.TF
MDN+*"::!K>62-6>%B"8R1DJ2.N.E $U%%% !1110 4444 ><Z1_R7WQ#_P!@
MB#_T(5Z-7G.D?\E]\0_]@B#_ -"%>C4 %%%% !1110 4444 %%%,DB25<2+D
M#F@!]0RL7;R4."1EF'\(_P 356V$*0"2-5>4LRKALY.35V*/RUP3EB<LWJ:M
MI1)3N4-3NH[.."%(YI;B0E8+>!]K/@<\Y   ZD_UKG=)M[U+:Q\.W<,UD5@)
MF;S]ZS(#@K&0?<9Z$#IUS6KJTLJZ_8RV$!N[JVCD\Z$,% B?'.X\!LJ,#N,]
M,4W399O$%Y8ZRUJ]I:0QN8$E93)(7 !)"D@  =,Y.>V*F['9%W4K?4S;I;Z5
M]ACA\LQL)U;@8P-NTCC%1Z%::O8VL-I?R6+PP0K&C6ZN&)  R<D^E;%%(845
MC^(#JL%C<7FGWT$"V\#R&.6V\S>5!/7<,5)HRZFUND]_?0W EC5E6.V\K:2,
M]=QS0!J445S/C'3+1]'N[]_-2X5% D2X=,?,!T# =Z .FKS_ .)^NR6ME;:1
M9R^7=7#"=W'\"(P*_FX'X UTVVUT0FSTR!I;RX^98FF9@ .-[%B=JC]>@S7,
M^*/!-C+:RZM>75Y+J,DD"22I,47!D5<*HX PQQ^?6LJRG*#5-V9CB(U)4W&D
M[2[G6>'=9CU_0K748P%:1<2)_<<<,OX$&M2LG0/#EAX;MIK>P,_ES2>:PFE+
M_-@#C/3H*UJTC>RYMS2/-RKFW"BBBF4%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!@^+HO$LVBB+PK/:P:@\RAIKD95(^=Q P<GIVKC+;X.
MC5)EN_&GB/4==G'/D^88H ?91S^6*]1KR#PO\88;:RN+7Q.FI2WL5S($N(=/
M;9)'N^7  R./44 >I:3H^G:%I\=AI=G%:6D>2L40P 3U/UJGXFL]>O=-2+P]
MJL&FW8D!::: 2@I@Y&#[XY]JE\/^(++Q+I2ZC8"<0,[(!/$8VR.O!YK4H \4
M^"NG>*38FZ37+==&349Q<61M1OE?NP?J,G!Q[5[72!0HPH 'M2T %%%% !11
M10 4444 >=>'/^2X^-/^O2R_] %>BUYUX<_Y+CXT_P"O2R_] %>BT %%%% !
M1156^N+JWB5K6R:[8G!59%3 ]<M0!:KB?'6E67BC5-%\-7L"2P7#27,[%B&6
M.,#(7!X+%@,]AG%;>DZ[=:F@FDTJ2UM0TBM-).A"E&*G(!SU4UY-XRU&_P!>
MN_[5L-0N-/1+C99R0G#W&T?+@_PH 6<D]=X&*:3D[(F<U"+E+9'0^!/!>A>&
MM3T34].LF%QJ%E(KEG+>61@EAGIGH?P]ZVOB%XCETC[+9V3.M[.C.)-[!8T!
M S@$;B2>/QK@?A-)J?\ ;D,]WJ]Y=3FS:.&RE.8V3(.0W\.T]1C)SWKT7Q7X
M1N?$,<,ID'VZ(,(Y58*D8.,J5(^8''7(/'X5O2ARS3GH85)RJT6Z#UZ&1X&\
M2ZEJMY)I5Q+F[$)E%TS,04! (V$D;LD<]/:O0;:SBMBS+EY6^]*YRS?C_3I7
M*^"O"$GAV::XO LMY+'L,X?Y57.=JKC@9Y))YP*[*E7G[S4=BL-&HJ255WD%
M%%%8&X4444 %%%% !1110 4444 %%%% !1110 4444 8OBI=?DT"9/#$EM'J
MK,HCDN?N(,_,3P>V>QKAH?A!<:S*+CQOXHU#67Z_9HG,4 _ ?TQ7J=>2Z+\8
M[&PO]9T_Q/-<--;W\J6T\%DY1H0<*O SD8/4<^IH ])T70M+\.Z>+#2+**TM
M0Q;RXQU)ZD^II->76&TB8:"]HFH\>4UV"8^HSG'/3-0^&_$VF>*]-:_TJ25[
M=9#$3)$T9W  GA@#W%;% 'AWPXC\;_\ "8>)_)N-%"+JP_M7<CY9N=WE>@QG
MK7N-10VMO;O*\,$4;RMND9$ +GU..IJ6@ HHHH **** "BBB@#SG2/\ DOOB
M'_L$0?\ H0KT:O.=(_Y+[XA_[!$'_H0KT:@ HHHH **** "BBFR,RKE$+GTS
MB@!U<]XK=MFGP2,4L9[C9<L&V@C:2JD]@6P/?IWK82Z=@6:$HBDAF+#C%4]4
M,SVA8Z?'>1MPT$LBHH7');<"#]*M*SNR6[K0P+&VM]-\1Z='ID$4!F+BXAA4
M*IB"$[BHX!#;0#[XKI=1OWMS':VJK)?3Y\I#T4=W;T4?KP.]<IX<UFVAL_-T
M[0;>%9Y7B7R+I)'DD4D!3CG'&<] .:ZS3K!K7S+BY<2WL^#-(!P/15]%';\^
MIHF[NX15D5O(NM)M52QL_M\TK%KB6281LS?WCD'Z8[  57\-+JUG86MA?:;'
M D,6TS+<A\D>V!6_14%%#4M5330I>TO)U())MX2X4#UQTJ/2M:BU=0\-I>Q1
MM&)%DG@**P/3!-1>*-6BT7PW>WDG)$92-/[[MPH_,UA>$];U#6O#5G;Z? D$
MEM&MM=7,O*(Z@ [%SELC!YP.>]3SQYN6^I//'FY+Z[ESQ_K2Z3X7GA1A]JO@
M;:$>FX?,V/15R?R]:K>%?%TFI:#;A-)OKBYMP()_)5 F]0.A9AU&#^-5?%'@
M*RO+6XU:;4-1:]MK20B0R*=Y +<@K@<@<# Q6KX/\*VWAZ![FWO+R9KR*-I$
MF92H('4  <\XK.U7VM].6WSN8VK>WOIR6^=R\=3UI_\ 5>'V'_7>[C7_ -!W
M5Y_\1=?U"Y\OP_=PVL$<BB>X6&X,C;0?D4\#&2,_\!%>LUQ?C>/P_)9W:76G
MP3ZD43#FQ,CD9'\04]L]Z=:$IP<8NS?4JO3E4IN$96;ZDOP[U*'4_#[.S^9J
M,3^5>2,VYY& ^5B?0KC [<UKZGX<MM6E9KB[U!58J?+BNW1 5((( /J :=H7
M]B>5-_8MK!;IN'F"&V\G)QQD;1FM:KBFHI-W9I!244I.[*FGZ>NGQ/&MS=3A
MFW9N9C(1]">@JW115%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7DNCMXR^(-M=^(+#Q7_8ELES+#9V,=JK@!#C,I/.3W%>M5\_Z
MU=> +S7=0FTY_&$<,T[?;%T56%K<OT;CW[XQ0!ZO\//$MSXJ\'VVHWL<:7:N
M\$QB^X[HQ4LOL<9KJ:YSP-<Z3<>$[1=$L+JPT^#,,4%U$8W&#R2"3G).<]ZZ
M.@ HHHH *BN;JWL[=I[J>*"%/O22N%4?4GBI:X[XE>%]1\7^%TTC3IK6(O=1
MR3&YW;2BG.,#KSCB@#I;/5=.U%)'LM0M;E(_OM#,KA?K@\4^SU&RU&-I+&\M
M[I%.UF@E5P#Z$@UXAXGUR[M/!WC;P[+8:;8ZAI[VJS3Z5 88YX9F7&1U! .#
MSWJQKZ)X5\9:];Z! EC"_@^29DMU"J'0X5\#^(#C- 'LUKJ5A>RRQ6E[;3R1
M'$B12JQ0^X!XJU7B6C6-MH?B7X7RZ5:QP27^G2I=M$H4S*8@Q+X^\0Q)R:[K
M7_&^JZ-K,]C;>"M:U*&,+MNK9 8WRH/'TSCZB@#-\.?\EQ\:?]>EE_Z *]%K
MR?X>ZI<:S\6?%]]<Z9=:9+):V@-K=#$B87'/UQG\:]8H **** "L_7-6AT/1
M;K4IAE8$R%[NW15'U) _&K%[>P6%N9[A]JY"J ,LS'HJCJ2?2O(OC-K%QIVA
M:;?:G:K+%+<,(=-:0A =AVO+M.7(Z[0<#CKUI.]M!.]M!FCZO?\ B+1'\+FY
MC:[N)VVB,<,DC%Y9'[;4RP"]RRYKHO&?@R+5-+T[3](M7FN--W8'F[%(8#(9
MLCYF(!SSCOUKQ_X1^(IK_P"(5A ;>..^E$B)<1DJ!'M=F5EZ-VQZ;17U#;P)
M;1"-,XZDGDL>Y/O54+TXIR=VC)4FZ7LZCOW>QYI\._ =UH>L_P!I:CI[V<D<
M31P1).)57.,DG=UXP !ZUZA1153GSRNRJ5.-./+'8****@T"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *\MMKWQIXXO]6N]!UJST73;"\DLX(G
MM%F>9X_O,Y/0'/05ZE7AGBB[\!6GBG5/L?C+6M'NIY"-1@TI9&B>3HQX4@-Z
MD&@#TCX?>([OQ'X?F?4888]0L;N6RNC!_JWDC(!9?8Y%=77)_#J;PV_A2.+P
MLTKZ?!*R,\R,KO)P69MP!).>M=90 4444 %(S*BEG8*HY))P!2URWQ%TG5M>
M\#:CI6BB(WET%C_>OM 3<-W/T!H Z2*Y@G)$4T<A'4(X.*>DD<A8(ZL5.& .
M<'T->,)J)\):7XKT5-%T_2M=L=&^TQ7=@Q831XVY)(!# G\ZKZ7!%X4\1^!)
MM)B,3ZKH<[WWS$_:'6$2AF]3NR<T >WB1&D:,.I=>2H/(_"G5\^Z1&-.T/X>
M>*8/,.M:GJYCO;DN2]PLC.&5O48 QZ5ZCXA\:ZIHFKO96O@W6=4B5587-JH*
M-D9P/I0!E:1_R7WQ#_V"(/\ T(5Z-7DG@?5[C6_C-KU[=:3=Z7*VE0J;:[&'
M ##GZ&O6Z "BBB@ HHJ.>3R87D+(H49+2-M4#N2: )*Q/$UU/;V5M%!*T(N;
ME())D.&C4YZ'L3@#/O26'B:RU&X:&"YMV9>0H+ NOJN0-P^E,\2Q0W6D&.]^
MT[)G6.."V8!Y&/09/'O[8SVJ^6SU)O?8R(H!HVI:>;(S[;FZ6*6W>9Y%D!!)
M?#$X*XSD>^:UO$LEJ+G28;]XA8RW)$RR'AB$)7=_L[L9[=,\5R^DZ+?>'=0B
MFNHM0EO)YFBM'EU#SH54Y*I(6&5P!U&=Q%=)J&GWEI;>?$9[R_F.V>6.".3Y
M,'Y0KNH5/8$GUSUHG*[N@BK+46X@T\>)M*DTV*V^U@N)VA4<0%#]['3YMF/\
M,UT=</X+CN;<I'!!>)8O)*7:2R@B!;<V<E)"W!R!Q^E=7?:M9:<56XF_>O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS?7(-5-'T,Z.D<2:G>SP1IL2*8H0/?A0:UZ*U-@HHHH **** "BBB@ HHHH
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M\E]\0_\ 8(@_]"%>C5YSI'_)??$/_8(@_P#0A7<1ZSIDNHOI\=_;->(,M")
M6'X4 76944LQ 4#))/ %9,'BC1[FX$$-X&=CA"48+(?1&(PWX$UF^.=3T^#P
M[>V<]S&)I(P1#]YG ()&!SR 1^-8?B$ZI-X>G1]"DACF") \DR?NG+#8SK_
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M#L:TJG8I--704444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<1S@#%>HUXIHOAC7[F#P;X:O-%N;5?#M^US=7SE?(E168IY9!RQ;([#%>UT
M%%%% &=K^JIH?A[4=5DQMM+:2;![E5) _$\5QOPZ\7:KXL6&XN]9T.4&W$LU
MA:1L)X2>F26/'KQ79ZX+@Z'>?9-/@U"X\LE+2=@J3'^Z2017 Z18:GKOQ&TC
M7AX=N-!M--T]X+A9U1#,[<!$"D[E7KDXH ].HHHH *\[F^(US/\ $C2_#MAI
MTBZ=--/!/>7$17S)(U)(B]0#C)[YKT2N&\4Z5?W?Q*\&7UO:2RVEHUS]HF4?
M+%N0!<_4T 4/$/CK78M8\0PZ%:V+6OARW2:\-UNW3LR[BB8/RX4=3GFNZT;4
MX=:T2QU2 $17<"3*#U 8 X/YUYCXCT?7=,USQFECHEUJ4/B:UC2VFM]NV&0(
M4829(VCG.:]&\,:2V@^%M+TEF#/:6L<+,.A8* <?CF@#6I&8*I8] ,FEHH \
M[\-?$:Y\3?$&328-.DM=)^P&Y@EN8RDL^'"[P#T0\XR,\9K/_P"%AZEJ/CS5
MM#M-8T'3K>RN4MH!>HS27#$?,%(8#(((_$5M?V5J'_"[CJWV27^S_P"Q!!]I
MQ\GF>;G;GUQS7/>-+/6?$.F:MX7M_!1M;JZO4:#4X/+,!0.&\YWX8/@$$8SS
MUH ];'3GK14=O&T-M%$SEV1 I8]6('6I* *6KSW]MI-S-I=FEY?*G[F!Y!&K
MM[L>@[_A7%Z;XRUO3O& \/>)DTZ2233FU 2V&X>2%SN1@Q.>AP1U]*ZOQ-J&
MH:7X<O;S2K![_4$C_P!'MT&2[DX&?89R?85YQ\/M%N#-J$^N:5KA\2:O ZW6
MHWEN%AA!'^K0[N!T[<X'04 7='^(NMW$_AW4M1L["/1/$-T]M:QQEO/@()"%
MR>&W8[8Q7J%>+:+X:UZ[B\&>&[[1+FU7PY?-<W5\Y7R)50DIY9!RQ;([#%>T
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<YXU\8VG@O1DOKB
MWEN99IE@M[:(@-+(W09/3IUH Z.BN$T7Q]J=QXAM=&\0>$[[1YKQ6:WF\P31
ML0,X8J/E-7-#^)'A_7M8U>PM[N*/^S3@R22J!, "7=1G[JXZT =?16=)K^D1
M:?!J$FI6JV=PP6&<R@)(3T /0]*6^UW2M-N8[6\U*TM[F49BAEF5&?Z F@#0
MHKC_  5X_LO%FG1S2B*QNYIY8H;5Y@SR"/JPZ9KIDU.QDU*334NX6OHT$CVX
M<%U4]R.H'(H M45Q/C7QU>>%]9T?2=/T1M4N]3W^5&)Q%RN.,D8Z']*@T#XC
MS7GBB/PWXAT"YT/4YXS);"642),!G(5AWX/Y4 =[166WB70TU/\ LUM8L!?;
MMOV<W"[]WIC.<^U6K74[&]GN8+6[AFEM7V3HC@F)O1AV- %JBJMAJ5CJMN;C
M3[N&ZA#E#)"X9=PZC(JU0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%1W$\-K;RW%Q(L4,2EY'<X"J!DD
MGTH DHK@8/C+X,GNXX1?7$<4LGE1W4MJZPLW^^1C\3762:_ID6O6^AM=*=1N
M(FG2  D^6/XCZ"@#2HHHH **QM/\4:;J?B+4]"MFE-]IH0W 9,*-PR,'O6S0
M 45C^)O$VG>$M%?5M5:1;5'5"8TW'+' XKGM-^+?A34=4M].-Q=6=Q<D+"+R
MV>)7)Z $\4 =S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUH>BRM+IFD6-G*W#/! J,1Z9 S4PT/2EU9M573;0:@R[3<B)?,(QC[V,].*
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M7M7T_5+J*:*[L%"0O;3&+Y0<A2!VH \TT'4)O^$'^*,DMY)NBOKH(S2G*<'
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M5O%5Y)*SZU?/+ CL2(X%)5 !V[_I7H=4M(TV#1M'L],MEQ!:PI"GT48S5V@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img192321128_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_21.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X22(17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(R.C R.C Q(#$S.C,T.C0Q   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,X-P  DI(  @    ,X-P  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,CHP,CHP,2 Q,SHS-#HQ,  R,#(R.C R.C Q(#$S.C,T.C$P      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  $MP         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ 40$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M!5W!"[#D;53.2,&0+U!JHOC;438QRGPS=K<-:?:FB+-M&750@;9R^UBQ7 /
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MM]'TRTECEM].M(9(P0CQPJI4$ $ @<<*H^@%0^'/^18TG_KRA_\ 0!0!IT4
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MB5IH?M.AQ)$R%I#YA41_NU;ECG^+<.!T(YX:K&D:M:6'AS38;J0)<PVT<<T
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M)9X<_P"A@TK_ ,#(_P#&@ _X2SPY_P!#!I7_ (&1_P"-'_"5^&S_ ,Q_2O\
MP,C_ ,: #_A+/#G_ $,&E?\ @9'_ (U+;^(]"NYT@MM:TZ:9SA(X[I&9CZ
MY- &G10 44 %% !3)88KB%X9HTDB<;61U!##T(/6@#/ACF3Q%<.+-$MVM8T^
MT \DJS$+C/0;V[#'J<C#I(96\1VTYM4,4=I*@N,G<I9T)7&<8.P'H3P,8YR
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%"Z^R^'_ !SIDEW))'%;6VH>98273R.R(L2SHAE8NNS;'N(8J" 2!7L7V@9
M8;-W"[B!N/H*&K:L%)2V)J*XSXF?%SPM\'O"LGB/Q?JT&BZ0LZVRS2;I'DD8
MX5$C0,SMPS%5!(568C"MCDOA+^UE\+_CEXDN- \$>)?[<U:WM6O9;<6-U;[8
M RJ7S+$H/S.@QG^*BSM<.9)V/8**\@^*G[6?PM^"?B6V\/\ C3Q*VBZS<VBW
MT5K_ &==W!: LRA]T,3J!F-QU_AKC&_X**?L_P ;!6\>JN5# G2+\#D$]?L^
M,<<>N::BWL)SBMSZ2HKS/X0?M'_#[X\-JR^!M>_MMM),0O5-I/;F'S0YC/[Z
M--P/EORN?NUE_%#]K;X3_!K68](\7>,[#3-3?[UI$LMU+!E49?/2%':'<)$*
M^8%# D@D X7*[V'S)*[9[!17BWPQ_;&^$GQB\31>'_"?BV/4-8E@EGBLY[.Y
MM9)1'C>(Q-$@=@"6VJ2V%9@"H)KU\7R[MN-TF =B,"1GU_4_0&AIQW'%J6Q:
MHKR'XJ?M9_"CX+:XFC>+_&=AIFJL<-9PK)=2P95&7STA1VAW"1"OF!0P)()
M..9\._M]? GQ1J]OIEIX_LK>ZG!*G4K:XL84P&/[R:>-(X\[3C<P)RH&2P!K
MEDU>Q+G%.S9]"5"UR%+;E8!<Y.#VY^G3WIJW6Z41[<MGD+DXZX)XXZ'K^&:^
M.?CM^W9J7P#_ &G++P7XE\,6<7@:ZM;.5-8^T,UR(II2DEWM0/F-&62,6^SS
M',>\. 0*F*<G9#E)1U9]FCH*6HT;Y5')X'4YJ2D4%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M="-E4@#<2!N8#/L,]32 GHJLMYN; 3&<$ Y!P> 2"..<^_'X4JW)903'S_$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC!X#M/B+X^GGUG3]0DF33M#MIY+8- ADA8W4@ E.77**C*H5%)+A]J^Y3_\
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M.I>&9I+*_L%?>Y:1Y)4N@ID=P)1(27;"F1)@JJJ@#6I'D7-$BE+G:C(^1?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=X"F49V7DQH$WH,MG-8__!6;Q%JES\9?"6A22L^EVOA[[3! J@;99[F1)R6
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M7#9YW YYS7IH.0#7/U.F.PM%%% PHHHH **** "BBB@ HHHH **** "BBB@
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M%:[-87FJ:3]L\^;3Y'>)O,NII4 9E4GY9,$%>#^OR]\5/V!_B'/^TYJ'Q-\
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MB6-69@H!8A>2 ,D]!TKH*YGNS=;(6BBB@84444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;2OP+_X*@?\ )\?Q0_[AO_IKM* /WS V@"EHHH **** "BBB@ HHHH ****
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MYKVS_A@W;(K+^T/\>1M/?QKGCCCF#U'ZF@#ZD5@ZA@<@C((I:15VJ!Z#%+0
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M LT4@Y XQ2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M((I:15"J !@#@ 4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'RM_P %0O\ DQGXF_[NF?\ ISM:^J:^5O\
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M?_X(N_\ )SWB;_L3KK_TNL:_:"@ HHHH **** "BBB@ HHHH **** "BBB@
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MM=?'J]_9Z^$-QKVDZ6VN>+M2O(=%\.:(D<LQOM0N&_=KLC1F+(B2R;<J'V;
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M^%?@IX!T[PEX2TNTT[2[6WCBDDCM8HY;Z184B-Q<^6JK+,XC0M(5RQ%?,?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %<YX\^'V@_$[PCJGA;Q1IL&LZ!JD9BN[&X!VNN05*D$,CJP5E=2&5E#
M*0P!'1T4 ?(<_P#P3#^%A:]TZR\1>/M)\#W]Y#>WO@2Q\22_V)=O&82?-C</
M(^\P(2QDWCC:R[4V_1OPY^$OA+X1^%[;P[X+\/Z?X;TF#8PM[& +YLBQK&)9
M6^]+(51 9'8NVT;F-=?10 U%$:JJC"J,"G444 %%%% !7E'[2WP?@^.?P/\
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M0PB*J G:J+DLQ=W]B5=JA0  !C &!2J-J@=:6@ HHHH **** "BBB@ HHHH
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MD8Z]?KSZ8>\S* 50/EL?*W^T!^@R?PJ53N4&@ 4;5 ZXI:** "BBB@ HHHH
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M 5^!?_!4#_D^/XH?]PW_ --=I7[Z5^!?_!4#_D^/XH?]PW_TUVE '[Z4444
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MAF?X96OBI8O#<D%S)/I[%);I2;><Y65C MGN<%F91$6)RI(!^A(^F*YKQ_\
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M16IBCOK.X4Q75C,\>_RI8R.WW0ZEHV*N%9MIH^/_ .TYX!_9E\*PZWX\U;[
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MAXOO6M--M#Y4<$2AKB]G()2"W0D>9(^#@ X&&9BJJS+XS_PWQZ?LY_'X^_\
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MRYX8$=JUJR/"/B?3O&WA/1?$6CW2WVD:O90ZA9W2HZ":&6-9(W"N PRK X8
MC/(!K7H _._]M3]N#7-<_P"$P^%WP!@OM0\4Z19ZC<^+?$MO#);MH=M9&072
M0NX7$H\ME\X$!1+$(2\CJ8_:/^"9(=OV)?ARTC,9"VIA\YR3_:=T,G/.>GY=
M!7<_M(>#M"\+_LO_ !T.BZ+I^CG4?#>N:E>G3[5+?[5=O93%[B78!YDC$#+M
MEC@9)Q7"?\$P3G]AOX:GISJ7_ISNJ //O^"KWB75+WX1>$?A?X?NU?Q+\0?$
M=KIUOI2JO^GQ1L"4,CKMAQ<M9'.]22 .5#UE/_P1G^"D9&?%7Q!P3@!=4LL]
M0"<?8^@]NU=O^V?^R#\0OVH_B]\.[_1_%^E>#/"GA2*>:/5K7[0^MV]_*0V^
M%%*Q[5\BUVMYD;*6D;YB$%<!X]_X)6Z5X?TWQ%XU^&OQ$^(:?%E(+F^T[5+C
M5[=9;J\8,6C>98X9 9MSH9#+D&3<V0-K 'U[\!_@YH?[/7PKT3P%X?N]0O-&
MT4SF*XU.6.2<^;-)/)O>-$4@/(P'RKPO.:T+'XY_#J^\'WWBBT\=^&;GPOI[
MK!=ZY%K-LUA;RDHOER3[]BMF6(;6(/[U./F%>0?L%_M%:I^TG^SUI?B+Q'YD
MGB;3;R;1]5N4MUACN+B)583(JL1\T4L6[:%42LX5 H%?"_\ P3;_ &1= _:7
M^'FI:C\1[F;6_!OA_7KA=,\-V-WY"S7<UI#]MEN72-92I4:?Y>R9<- ^1C.X
M _5WP?\ $CPO\1-,GU+PGXCT?Q1IL$WV>6[T:_CNXTD"JQC+1%@'VNAVYSAA
MZBLNQ^./P^U;QE)X2T[QOX<U'Q3'-+;/H=IJ]O+?+-$"9(S 'WAD"MN!'R[3
MGH<?F1\6OV;8OAO^VUH?P)^%&NZIX&\!_$_0;>3Q'8PZI(T<MK'+=M/#'*ZR
M-N,5I+M,F\EYI(R1#(R#TK]N+]AOX0? +]G/7_B5\-]!OO!7C#PQ>Z=>V&HZ
M9K-VSB0WD,(!\Z1P IE$@*!7#Q(=V,@@'Z/?:MRAHU5P<X.[ ].OU_SVKC]3
M^.'P_P!&\61>%[[QOX;L_$TEQ':IHMSK-M%>M+)M\J-86<.7?>FU<9.X8ZC/
MRS^TA^T]KOPW_P"">/A7QQ+=W$OCOQIH.E6$>J0+Y)@NKNR$MQ=+Y;Q^4XC$
MYC:/I)Y(VD9%9OPC_P""1_PGT?X2QZ7\0+>?Q-XXO8&:\U^ROYX192.HPEJF
MX(RQ$#:TT;;R"64*WEJ ?9EG\1O#.H^,+[PE:>(-)N_%=A"+F[T.WU"%[VWB
M(0AY(0V]%Q+$<LH'[Q,9R*^._P#@JUXJU2_^$?A#X6^&[O'BCQ_XFM;.WTMD
M"_;[>)D.P2N-L1%U)8')9#R<$J'SXS^P+\*=9^"/_!1#XE^!]>\0GQ1J.A>$
MOL@UAI)/WUOYFF&T3#DE2(#&IC!94V!58A0:],\9M_PNK_@K+X7TB,FYT;X6
M^&VU"^T[6"'M6O)$W1S6D0W)YHDO].8LWEMNMLYS'&6 */[='AG3?!'QW_8<
M\-:);FST/2?$L>GV5HTCR>5;PW.E)$FYB6;:JJ,L2>.2><_?VK:_8>'])N]2
MU&YCLM-L89)[F\N7"0P11J6>1W/"JH5B6/3%?G__ ,%.O%&G^#?CO^R?XEUJ
M<66B:-XEN+^^NMK.8H8[G39)&V*"Q(12<!23T Z5RUOXL^(/_!57Q%J>@V^J
MV/P]^ >C:Q%]OT^"Z4ZYJL)0O"TB*S*>82RAL1([D@736WR@'Z+>#?B1X6^(
MNERZGX4\1Z1XFTV*=K5[W1[Z.[@255#%#)&64,%921GC<*S-4^-WP_T7Q9'X
M6OO&_ANS\3R7$=JNBW.LVT5ZTTFWRHUA9PY=]Z;5QD[ACJ,_.O[:7CK2_P!C
M']C.?2/A[IK>&#<JOAC0TT\NHL#,LCRW/F"17$HC6=UE#,S3,A?<237)?"7_
M ()'_"71_A.FE^/K6;Q)XVO8':ZUZQOIX18NZC;':H"(V6(A=K2QMO()90K>
M6H!]EV?Q&\,ZCXPOO"5IX@TF[\5V$(N;O0[?4(7O;>(A"'DA#;T7$L1RR@?O
M$QG(KHU.X ^OJ,5^67[ OPIUGX(_\%$/B7X'U[Q"?%&HZ%X2^R#6&DD_?6_F
M:8;1,.25(@,:F,%E38%5B%!K]35SM&>M "T444 %%%% !7QW_P %3/#OBOQ'
M^R+XE7PV6:*QO+>_UNT6(RO<Z;&VYM@".0(Y1;SN?EPD$I)QU^Q*\#_;:\#^
M,_B5^S'X^\+?#]+F[\5:G':VUO:VU_':M)&;J(W$9=W10CP>:K*S8925P<X(
M!\=?LY?\$K_A'\6/@7X*\8ZIXP\4:I?:WIT=[<'0[RS2UBE?F2 !H92'A.8'
M+/G?&YPGW$]#7_@C3\%)E$@\6_$%PWS!O[2L.<]_^/.OC_P5^Q?^VY\.])?3
MO"=EXF\,:=-*;F2TT;QM:VD+S%0IDV1W@7=L55W=<*.>!C?_ .&;?^"@O_08
M\>C_ +J)'_\ )U 'Z_\ P]\&67PX\ ^&O"6FRW$^G:#IEMI5M+=LK3/%!$L2
M,Y4*I8J@)( &<X Z5T%<7\$]-\0Z+\&? 6G^+7N)/%=IH%A!J[W5P+B9KQ;>
M-9R\H9O,;S V7W'<<G)SFNTH **Q/%GC+2O _A?6O$6M7/V+1M&LYK^^NF1F
M\F")&=WVJ"S85&.%!)[ YKQG]EW]M7P3^UH/$Y\):9KFFCP\;9;L:U!#&SF?
MS-NQ8Y9"0/*;.<4 ?0-%>3?M ?M/> ?V9?#$&L>/-4-B]WYR6&FVR&:[OY(X
M][)"@Z\;5WL50-)&&9=PKR;X(?\ !37X,_'+QA;^%K*YU/PQK=Y+';Z?#XB@
MCABOY7#D)%+%)(@.4VXD*,S.BH&8D  ^LJ*X7XM_&SP;\"/!\GBGQ[KMKX=T
M%)DMOM4P>5I)G)"QQ1QJSR/PQ*JI(578_*K$?-/PY_X*S? WX@>*(-%NFU[P
M<9L+'J'B.SCBLRY=%"-)%))Y7WB2\H2-0C;G'&0#[0HJO]JVD!TQD=5.>><C
MI]/?GI7QQ\1/^"LWP*\ ^*)=$M9=>\9/#N6:_P##-E'-:+(KNC(LDLL?F?<!
M#QAHV$B%78$X /L^BN&^$_QL\&?'+P='XI\#:[!X@T1I7@:X@5T,4JXS&Z.J
MNCX*D*R@E71@"K*3V\;B2-74Y5AD$'- #J_ O_@J!_R?'\4/^X;_ .FNTK]]
M*_ O_@J!_P GQ_%#_N&_^FNTH _?2BBB@ HHHH **** "BBB@ HHHH ****
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MP5!H%WJZ:3<J AG*7S,3C#R*[65J#&VY&$6,$.X+?VLOV>_'/P9^/FD?M'?
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M;,KL1E8U& <<"@#Y\_X*$?LN7'QH^'MOXT\%(UA\4_!C_P!I:5>P1R_;KZ"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -C?$CPM:&W2PN7$4=W#%Y\B+"Q7;YCM-+$R3'RI$FPSQJ")/M6H&M(VD9B
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&T.5KW\#: **6@ K\"_^"H'_ "?'\4/^X;_Z:[2OWTK\"_\ @J!_R?'\4/\
MN&_^FNTH _?2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS75OV9
M?A!KVJ7FIZG\*O!.HZE>S/<W5Y=^'+.6:>5V+/([M$2S,Q)+$DDDDUZ510!\
M+?L7_L__  P\73?'9]:^'7A/5UTKXK:]IMBE_H=K.+6UB$ C@BWQGRT4L<*N
M .@%?8'@[X?>%?AII,^F>%?#VD>%]+>4W;V^DV45I"TF%5I'"*%+X1!N/)"+
MSQ7S]^P;_P W%_\ 99/$?_MM7<_M4_M4>%/V5?A^VN^))9+O5;MW@T;0[-E%
MSJ$X[ L-J1J'0O(P(4'H[,BL <'^U]\>]:TW6]'^!_PQ@^U_%WQ]9NEG?3W4
MEI;Z+9,LXEO?.3#>:J0SF,1DL#"6;)$<<WJO[-G[/.C?LU?!_1O NC7/]H?9
M-TUYJDUK'%+?73MN>9POOM10Q9ECCC3<VW<?,/V+?V=-?^&FE:UX]^)\]IK_
M ,:?%TQNM7UAF\V6RA81^7IZ2ABF$V9;R@J9$:#>D$1KZEC_ -6O7IW.30 1
MKL15R3M&.22?UKY9'_*49O\ LC8_]/9KOOC/\5OB_P"!_%5O8> ?@?\ \+)T
M5[-9Y=7_ .$LM-*\J<LX,/E3(2P"JC;P?X\8XY^;O[6_:77]J0_&+_AF@-_Q
M1W_")?V,/'VF8_X_OM7VCSC_ -\;-GON[4 ??2_=%+7S]\,?C1\<_%'CC2]*
M\8?L[-X(\.7!D%WKX\;6&H_9<1,R?N(U#ON<(G!&-^><8KW]&#JK#D$9% #J
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBHVD*@EMHQR?F[>OY9_*@#\M/^"IWP97Q!^U%\'/$OB2Y?2_A[KPL_"^J:
MNLOE"P5;UWF9YI$,,.8+EY$+,>+>8LF%)/U0O_!+_P#9EVC/PS!/OKFI_P#R
M37CW_!0#]@+XA_M4?&32/&/A'5/"^GZ7:Z##I,T>M7$\<[2+<7#LX$<,B[=D
MJ?-N#<-QP*^9C_P1D^-4AWGQ1X#);G+7UXI_+[)Q]* /T<^&W["OP/\ @SXX
MTSQ=X1\$MH_B+3&F-C=+K-]-L\R)HW 26=D;,;N.0:^A%^Z,'(Q7YA?L?_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH Y+XC^&[WQ;X%\2:'IFL3^'-1
MU+3KJSMM8M2SSV$LL;+'<IM96_=N=P 9>G45^7_BKXN?MJ?L,VZ_\)4T7Q'\
M$P0LJ:QJ"OJMDGF2Q.))+Q#'=HX>;R4%RP5]S*BN$4C]9_);+'S.221Q]WC'
M'_UZ;]F9'9DDP&()#+GO\W/7)&![8% 'Y::3_P %M+VTTJQAU+X007>H)%'#
M<3V_B)K:*6<* Y2-[9S&I;)"F1RHP"Q/-8WC/_@M9XFO-*B_X17X7Z5HE[YZ
MO+)K&IR:E"T.U\J(HTMV5BPSN+G '0YR/TK\4?L^_#'QOKD^M>(OAWX3UW6+
MDH;G4-2T*UN)Y]BA4#O)&6;:H &3D!0*TO!GPC\%_#=;T>$?">A^%1?;/M1T
M/3(+(SE PC+^4B[MN]\;LXW'&* /SY\*_#?]KC]M:[!^*FKR?"/X6WDVS4M!
MTN$:=?W=OY<D,T,41#7&UROSK=OL/GK(D<JA4K]-%.Y0>O%1+;E68E@0?NKM
M'R^H^AXJ2-2J*"<D#!- #J*** "BBB@ HHHH **** "BBB@ K\"_^"H'_)\?
MQ0_[AO\ Z:[2OWTK\"_^"H'_ "?'\4/^X;_Z:[2@#]]**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O*?C/\ M2?"[]GSR5\?>,;#0KB;8T5B!)<7
M;H^\+)]GB1Y/++12+YFW8"N"P)Q7J$DS+G$>5R #N]\'_/YXKXD_89\!Z7\9
M/&'CO]I[6]*FO-=\3>(;V'PO=:B;?_0M&BV6\;+%$2([C9&]N[DEF6#@E9&>
M4 \[_92_;:^&GP:3XK-\1#X@\"?\)IXQOO'F@?VUH5S_ ,3#2M0V^1+'Y229
M \ALL<1DLNQWPVWT3]G/P+KW[5'Q8O/C_P#%32+E_#%I<-)\+?#E\!"+2T#$
MC49;7)'G.HMRDC2,2VYU 1;9E^M_'?@'0/B=X3U/PSXIT:WUC1M00P7%I<#B
M0?*RE67YE965&#@AE9%92"JD?.'["6J:MX/N_BU\#];O=6U&7X:ZXMIH\VLS
MPW#KHES$7TV/S8R-S>7'(Q4J-BR1H,!-D8!]9F%I%/[P@D$!@.1D=NWZ5*HV
MJ >3CTI(^8U/M3J (S%G)XR3UQ_GG%.5-BA06P!@9.3^9IU% $30DYP5SU7<
M,X/KU]<?E4@& !2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7S9^V!\+?BYXRTW2/%'P:\?3^%O%7AV&^*Z)E3::
MZTPB18I&D;R5=%23R_-C9?,E',7S2#Z3J%[?=T<@9SB@#\HE_P""HWQT^ OB
M@>&?C)\,-/OM1M;3R0N)M*NKR1'\LW7FKYT$L;F.7!AC$;$;E8*N#KG_ (+>
M/&=O_"EU.WC/_"5,<_\ DC7Z9>*O!FA>.M"N=$\1Z18Z_HMT%%SINIVR7-O/
MM8.N^-P0=K ,/0J#V%<)_P ,H_!,\M\'_ );N?\ A%['_P"-4 ?GY>?\%?OB
M-\3+K3]"^&/P;M3XIFG\R.VEN[C6FGC179XT@@BAD5L+NW;B J/E<'*_3G[*
M7@7]HNY^(^J_$?X[>*[>TM=0TV33M+\ :5,#;V;-=-*)&6-C"'1(]J,'FE:.
M8!Y%V;3]+>#OAKX6^'>GRZ=X5\/:3X:TN2;[2VGZ/80VD!F*JIDV1JHW$(G/
M7Y!6^UJ&_B(&,# '']/3KZ4 2JH50   !C &!3J0 *  , =*6@ HHHH ****
M "BBB@ KRC]J[_DU[XQ_]B=K'_I#-7J]>4?M7?\ )KWQC_[$[6/_ $AFH _+
M;_@B[_R<]XF_[$ZZ_P#2ZQK]H*_%_P#X(N_\G/>)O^Q.NO\ TNL:_:"@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH @>[19"G0CJ6X'4?GU^E?%F
MCV__  U9^W-J?B*^MFN?AS\$?,TG3C/:_N[OQ#*1]ID#/;Y_T8(HPKY22"UF
M1L2FO2_VVOVDKC]G?X7 :##+?^/O%$S:)X6TRQ\E[EKV0$"Y$3AS(L1*':$8
M%Y(D;'F[DZK]E']GNQ_9N^!/A;P7;"U?4K>$76K7EO&N+J_D^:>0,$C9U!(C
M1G7?Y442MG;0!YW^WE_J_P!G7K_R63PWUZ];BOJBOEC]O3[O[.W_ &63PY_.
MXKZGH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEW_@I[\#_!O@XW\]C+X:O]1N+S5)Q+=W%Q)#JJM(Y"HG$<<2 1JO$>2"Q9F
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M5]3U\L?MZ?=_9V_[+)X<_G<5]3T +1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:&,?[,/BA6W,S^,[K!8Y+?Z%99Y[G@U\:Z;^RW^T9\7?VK?%GB#P_P"$]?\
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M3G_!*]?VD_C?XB^(I^)_]@+K'V=AIZZ +DQ^5;PPC,OVE-X/E;A\HQNQSC)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXH?]PW_TUVE?OI7X%_\ !4#_ )/C^*'_ '#?_37:4 ?OI1110 4444 %%%%
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M#W[:7QP\6>.O%O@[2?V8A<^(O"K68U>S;Q]9Q_91=1&6!M[0!'#("?D+$?Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN(=/US3+74[>.Z55F6.:)9$#A&90P##(5B,YP2.:Z&@ HHHH **** "BBB@
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M3:)JMUIFI?M<^"].U"SE:WNK6[MK6.6WE5RC1R(VI!D8,""" 000<'BO=_\
M@J?\=O&:Z]X4^ ?P^,UMJ_C:-#J30M%&U]%<3FUM[1)F<;%D>.03!PH*K&H<
MH917GWAC_@BCKEUHL%QXB^*MEI>MG>L]KIFAO>VZ+O;;LF::!GRNUB3&N"2H
MR!D@'L'[,/\ P2W_ .&=_CEX=^(7_"R5\2IHOVC;IW_"/_9O,:6WEAXE^U/L
MP9-Q.UL[2.,YK[_5@R@@Y!&017Y.?L;^(OB3^QI^U_9?L_?$'6DN/"^L67V>
MPCN+]QI5O<RJUS;S69GC4N7E:6V,<0C#RRG.YHES^L2$%%(Y&..<T .HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!\8B;P9/J4<%E>V7B:Q6?3+DSC9-"9T#QF)1\K/<+"A5U) ^8+VJ_P#!._\
M9>\<R?\ "06GPZTV]MM8']HPW6E:S>QV<R2CS%>%89Q$L;;@4$8";?NC  H
M^-/AKXMU/_@H=_P4,\+>/;3PSJ.E>!/!'D2"[CV>;;06LDUS9&Y=]R>=-=$
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M--L[?3].LH4MK:TM8A%#!$BA41$7A550  .  !5N@ HHHH _$36O ]C\;O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MANVU?Q+KSC?)<W;X+1B9AYDD:'=AI#EGDFDPADVK]!*H50HX &!38U"QHH&
M  !3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L7Q3X,T3Q
MQI,^E>(-*LM;TJX*&>QU&V2X@FV.'3>C@@[6 (]#6U7A/[4?[9'@7]DG3_#]
MQXQM]6OI]=GEALK'1[999W$04R2'S'1%52\8Y?<3(N 0'*@'A?QP_P""3/PE
M^(5QJ>K>$9]2^'FMW"X2'3\76G"1I&+O]F9E9=R/Y:I'-'&H$9V85@WR#XZ_
M8Y_:-_8>AU3QKX(\;P'PI92-?7FI:'K(L!(EM(3;&^MKAD2<MO"B!3/DL\8W
M%\2;7CK_ (*I_&WXX>(M,T/X.^#T\*ZA/\Z6NFVXUW5;YT25F5=T&SR0C*Y4
M0[E\HGS,$@5O ?\ P35^/_[2EQI?BCXL^+;G0K>2W$*S^*KV?5-:AM3'YT6V
MV9CM4RR$&.2>-T/FY0, & /6OV"O^"CWC[XR?%;P]\+O']AI_B"[U)KAK?Q-
M"%L[N$Q074[&6"-#%*2$2-=BP[0/F\PM7Z>*2R@D8..E?*_[,_\ P3I^&'[-
M]]HGB*T2]U_QUI@=H]?OIWC\MI+<0RK';QN(@AW2X#!W E(+L0&KZH'% '+^
M/OB)X<^%_A76/%'BK6(-$T+2X6EO+VXSLC48QP/F9B655502S.BJ"S 5X'K7
M@SX _P#!1GP#_; GN_%FG:')=Z79:I;O>:=/I\\T4+2,JR! [ >0P:5'3*#(
M.&S[O\4OACHOQ@^'_B+P;XBA$^C:Y:/:7 6-#)'N'RRH75E$L;!71BIVLBD<
M@&OREF_87_:R_9[_ .$W\%?#.6Q\3>#?&%H]EJ=[IS:? M[:D7$:Q21WA#PR
MF.5R?*)5?- $C;. #T/_ ()+_M,>.?'GC_Q?\/O&7B/5_%<']E_VW:7NKW\E
MS<6K121021YD!D(D%Q&0I<*A@8JA,K-7D?\ P1I9;?\ :?\ %0QRO@Z\)4$<
M8O;'C)./QZ?KC[<_8#_8A/[)^@ZYJ7B"_P!,UOQWK6V">\TZ/-O9P1NQCA@F
M=%D;>2'DX53LB79^[W/X3^T5^PG\9/ _[3U]\:OV>S8SW>HW;7WV%[B%;JRN
M[B&:.\DQ=EH)(G9G<_-N5KC:D8"!J!,\E^/FEW6L_P#!8;3;:RL;J^NU\5>&
MYW2UC>4I%':V<LKX49"I&C.S'@*KDX XJ?M'2?\ &W[3"8RJCQAX5P%_B?R=
M..WT!) S[ ]^OT7^PY^PSX^\"_&S4?C9\9'L(O%5_P#;)[/2X9%>\CO[EY1<
M7,Q@86R%HS)MB3S%VW&3Y;1@'K/^"C/["NM_M-?V'XO\#R6/_"7Z)9S6=Q8Z
MA))&=2M5W2Q11/G8DBRF15!"*WVC<\B^6N05CQC_ (+=_,_P:3&0/[:(7=PP
MQ8YZ]_0#U_+[+\,_#G7/$?["&C^ 4M6TOQ%J/PWAT40ZDCP"UNGTQ(=DJE=Z
M,KGD%<@J<C/%?$'AW]AW]HC]IKXS:'XG_:-GL;32=%>UM;W[1/:>=?6:/+,;
M>)-.957[V#([QLHGW*7(V5^L'EELL&P2,=/RH&C\81_P1?\ C2H _P"$G\!<
M<?\ (0O/_D2L/Q]_P28^+7PW\"^(O%>J>(_!DNG:%IESJ=U':W]TT[0P1/*Z
MHK6H!X!ZL.HK]NU38H4$X P-Q)/YGK7E/[5D8'[+_P 8MS,W_%':SU/8V4I(
M_2@9^7/_  1?(/[4'B<@DC_A#KODC!_X_K&OV?K\8/\ @B^Q;]J#Q.QQD^#[
MLG: !_Q_6/8=*_9^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVNBD5@R@CH1GIBEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6T+3?@#HFKW^JZ*-6T#Q+8>(M.\,Z^BS1>(/)E\B6V\DR*98@MR))-@;"+C
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M<CY@/T&2?I4RG<H- "U!)9QR2>854,1@L!R?3GZ9'XGUJ>B@"%X6?=^\()!
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M!4&(XY&Y(SM(]*]]1MZ*V,9&<4 .HHHH **** "BBB@ HHHH **** "BBB@
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M7:K(YN $=?KS2?#]AHFEV6G:;9VVFZ=:11PP6=I"L,4$2*%2.-4P%50J@ <
M #I5TVYVE1(PX*ANK+QZGO[FD:5X8^8BYZ!5(!8\].PZ>O>@".2W==X64J"H
M7@<@#T]._;N/2OEO_@F+;(_[#_PS;HRC4TW8 ;']IW1P".0,X/X"I6_:&_:7
M;/\ QB;GC&?^%D:8/YQ@_G7EG[,.K?M+_LW_  -\-?#K_AF?_A(O[&-R?[2_
MX3[2[7SO.N99_P#5_/MQYNW[QSMSQG  /OQ5"J !@#@"EKD/A?XG\3^+/!.F
MZEXO\'_\(-XCG\S[5H1U*+4!;!965<3Q *^Y K\ 8W8YQFNN4EE!(VG'0]J
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MGB[_ (1.Q\<^&[[Q6)IK8Z':ZO!)>":+=YL9B#;@R%6# @$8.<8H [FBHFF
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEO(V^46X56%NP9A('"[@V=Q=2ZO^R/A/QAI?C;POI/B+2+D7&CZI9Q:A9W#
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MOVSM+\/>"-/\!6^A6']J07MMI]I++J5_<WP66%%1O+1&5UN% C$18,N=YW;
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M]0RJ/NCC/V//VHOAE^QOX"\:^"_BKX>U/P-\5=-NYI]6,MM-=77B!P)'A4.
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MF4KY;1D_92\*!C''2H7M5DD=F^?<  KC*KCT'Y?D*F4;5 R3@=3WH 6BBB@
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M@F^"OBKQ)J(GF^)VN>*=2D\;-=VJ07$.I+*"+?[B?NTBE279DA)+B8#:244
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M_C5??MAZ1\'_ !Y>ZK<_!RPTRTT&_N+NXT&36([^"%;>1Y);=LC$H .PDXW
M9%>PZ3\>?BA/\!_%7C.\^!U_8>+]%NYK>T\$G7%FN=1@A=$DF2982>OG%%",
M9%C1DR)4)U_BE\4/B!X-^%/AGQ%H/PGN/%WBW49[.+4/"<>M112:<TZGS/\
M2-C)(D4Q1&8 +L+2$A$8A/87F?DK\+=/L=+\"Z']@>US-$DDTA02.[MG>'*@
M@X8E<==JJ/F(Q72ZC;VVK6-U'<)(UK=0F*=@Q0!74CD[EP,9Y)(!8\X.*].^
M,G[$WQ(^$/QD71?@QX1OO&7P^U*VDU6&WN[J.$:0Z2%)+43RR@G!:-X]^6D5
MFV;S%(]8%E^Q7\?_ (N>*G\*ZSX7M_A;I0@CFU37+_4H[T36\LA0P6_V<E9)
MMD;NT64&$3>T0="_V$,SP\<)[)K6Q^45^&\?4S'VBE[C=[WV\K;GK?[#?Q@^
M-OA3]EWP9IG@_P#9^_X37PY;KJ#6NN?\)I9:?]K'VVX9QY,B%T*NQCY/(3(P
M#@>^_P##0_[3"\']DT$C@D?$C3,?^@5M_LPS^*_#/[-,MG'\'IO!&K^&(KK3
M='\(W6M02RZNUM&0LSW*11QQO<W/F[IBF'SYV66135G5?C[\4+'X"^$?&6F_
M N^U#QGK%W!!<^!6UR."XTZWF>1(YGF:'G %NSIL!B$S&3:(G-?(R=VV?J\;
MV2?0YO\ X:(_:7_Z-,_\R3I?_P 17P)\8O$7BGXB_M6?$+6O'WA5O"GB6QMM
M/M8-!NM475%TV%K56\N.:/\ =D.2TF$ YFD4\LQK]5?BE\2_&'@OQAX"TSPW
M\/+CQEH^O:BUGK&M1ZDEK'H42A7\^13&WF*8UN#U0;HD3=NF0'X6_:\_9I^*
M'Q _:N\3>+/AM\,9/]$TZRDOM4U#6(A;>)O,$,2+;K(%$$T2Q2JZF0+MMXW(
M5I4$_5A:D:=52FM#RLUPU3%X.I1I.TFCPN2W$=NX-ND>XE=D;-RO8]>,=O2N
MP_9+^,U]^S[^T;XNCL/"/BSQEI?B7P]%?7N@^"]&COKG[3%<JD=PRC:4C5)9
MP2&^9YQNR2NWB;/PY\5M02VM-/\ @C\18M6O&C@B.HZ#+:VL<CLH)DGD54C0
M98F1PJ@*"=HR5^L_V4_@WXP_9I^ _C'XT7G@._\ &'Q@\0VD%S_PB#+%97=M
M8QR8%O$XC=_-,/[]X]N]S'%$8_,7+>[F>-P]:FE25V?%\,Y5C,'B75Q,>56M
MOO\ B>HK^WIM4!?V<_CX@ P%_P"$'Z?^1ZD7]O?@?\8Y_'X_]R/_ /;Z]#\1
M?%KXAZ&_PGCM/A//J@\4/'%XDECUN+R_"S&-))#)($9;A547(WJ45F@1<AIH
MP=C7/B5XRTWXZ>'/!EA\.Y]5\&:AI\UY?>-8]15(]-ECW#R'M]A+,S-;!?G!
M83.P4K#(1\OU/TGL>.'_ (*2_#KP_K5M8^/_  ?\1?A-#=P/+9WWC7PQ+;17
M;HT:M%$(3*[,/-!)VA1C!8%E!G_X>@?LT%?^2D_EH.I__(U>A>'/BQ\1-?N/
MBM#=_".;3F\+W$L'APMK4++XI*QRO$R.45;=67[.-[%U5I70_-#(!BZ1\>OB
MA=? ?Q5XTOO@;?:?XQT:[E@M?! UQ)KC488G1))HYDA]?.**J,9%B1DRLL9*
MZW"]F? 7[6W[1.C?M<?&S3+3PIK>H:U\+?"EA#<O:2VS06U[J<K/F;RG D=5
MB=4S*A"[)E50LI:3CC:(EC]AV0_9EC:$PQH#$5*A=NTY!3C[I^4\9!KV/]OS
MX>>)/ GBKPW\?X_#.H:98>(].M+;QOIMC="Y_LB_1(UAD:<.58CY80R(L6;?
M&[=<X/SNWQ/\*0Z0-076;$6H Q#'+F4+N"\18#8!)XQG R 0<U];E=?#QHN-
M1:GY7Q/A\PKXJ,Z*?+TMW/3/V6_V@O\ AD;XS:I97ECXAUOP+XPM?]!\,^&+
M2*YE;6?.A1#%"TBD,8V9/W>"WFQ*581J4^WX_P!O<>6NW]G7X^R+CAE\$9!'
MJ/W]?*O_  3S^%/B7QI^TI<_%'Q!X"U?2/#.D^'7D\/:MJ5O-;QS33[4AFB!
M*B<M;R76=FY%#H<[BCM]M^$_C;\6?$?P7\0>*+CX'3:5XXL=1>RT_P %W7B:
MW5M1C26..2<731JD:C,[+N7#K"K(S+*C5\[BI0E6E[/8_1,N5982"KOWK'"I
M^V-\5_&.J7$7@#]EOQK>V%K#$TTWCC4+?PO,TKF3Y(8YE<3 *@)9'R"V&5?E
M+?-/[??Q.^*WCGX>^"['XE?!!/AMX<B\7V=RVJW'BRRU:)W$%RHA>*)/E4J[
ML7/&(R#UK[!USXY?$ZU^!OA7QKI_P/U#5/&FLWD,%QX(.NK;SZ=!-)*L=PTC
MP]AY#.AB5HEG8R[5B<C+_:>M_$7Q2\0VGP9E^$FH^,?AWXJLX9-6\76?B**Q
M.CE+Q [A'C8M)"#!<(A8><%951PDHK"$N22D=M6+G3E!==#\\O-'F"$RYD!#
M-_O Y(( W9[<UP/QLU(:'X/%\ES-8ZU9WD%SI5Y"7AFANPX;S(Y 592H1SNS
M@$#OLKU^^_9+_:4\$^.-=\+67A)OB7H]C&C6/B)+VUL/M43[Q$S/-(K;P8V$
MD1R4;'S,K1R/V7[,7[&/Q,O?&FL?%'XH^#[J#5/!2M=^$/!T-];V<6J:I TF
MW,A=O*1)K>+$CC;+OBD#O$N)/JL5FE&IAW&*U:M8_,,KX8Q6$QRJU)>[%[KJ
M?JBARN<D\=32"%N3YG))(X^[QCC_ .O7@>J?'_XH6OP'\*^-M/\ @7J&H>+M
M7NX8;OP.VM)!=:?!-)(D,SRM#CM"TB,B&%96,FT1.:Z'Q1\7/B'H-Q\*H;;X
M23ZD?%$L</B62/6XA'X58QI))YCB-EN%11<C>"BEH$7(::,'Y(_4^IZVUOPP
M4[-W4@8/?G([Y-.,9W,P;!(Q_A7D'_"W?B*W[0USX&'PBN?^$"@@CN#X_;6H
MA$R/;NX"6ICW.PGC:%D5RRY1V"K(FY?#OQ<^(6M3?%:.Z^$TVE_\(O-)!X;:
M?6XMGBEA&\D9C;RPMNCCR/G)=4,K*Q#1.  >P(HC55&2%&!N))_,]:=7BC?&
MSQ^/V:V^(H^$&H_\)O\ 8Q?K\/6U("\,7G8V^9Y6?-$&9O)$9DR/*V[R*L>)
M/B]\0M%D^%"6GPEGU,>*9(XO$DD6N1>7X58QI)(9'6-EN%51<C>I16:!%R&F
MC! /7O)X(W'&[=@DGW[^]*8R<\\^OIQ]:\VUWXE>,=-^.GASP;8?#JXU7P9J
M.GS7E]XUCU%4CTV6/</(>W\LEF9FM@OS@L)G8*5AD(;\+_B=XQ\:>+?B#IGB
M/X<W'@[2O#^IBPT;5I-32Z77HSN;SXT5%\M0A@8\N TKH6#PR  'IU+7@.E_
M'SXH77P)\6>-;WX&WVG^,=&O)H+7P1_;:2W&HPQ.B231RK!Z^<40(QD6)&3(
ME0GVGPIJ6HZQX7T>_P!8TDZ#J]U9PSWFE&X6X-E,R!I(/-3Y9-C$KO7AMN1P
M: -6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH Y3XK^.O^%8_"_QCXQ^P_VE_P ([HUYJWV+S?*^
MT>1 \OE[]K;=VS&[:<9S@]*\1_9;^/6A?MY?!/7M7\1?#^QL-)766TFXT/4+
ME-5AN?*A@N%=BT2#K*/E*\%>O8>A?M7?\FO?&/\ [$[6/_2&:OQ:_9B_;^^(
M'[*O@&[\)>$M%\-W^GWFIR:I))K5K/-+YSQ11$*T<\8 VQ+V. ?S /VDC_91
M^"7EK_Q9SP&.!P_AFR+?B?*ZUU'@?X1^"_AC]N_X0[PCH/A,WQ0W/]AZ9#9"
M?83L#^4J[MNYL9Z;V]37Y'?\/GOC3_T+'@3_ (%I]YG\?]+H_P"'SWQI_P"A
M8\!?^"^\_P#DN@#]H% 50 , = *6N+^"?C2]^)'P9\!>+=2BMX-1U[0+#5;F
M*U5EA26>VCE=4#$D*&<X!).,<FNTH **** "BBB@ HHHH **** "BBB@ K\"
M_P#@J!_R?'\4/^X;_P"FNTK]]*_ O_@J!_R?'\4/^X;_ .FNTH _?2BBB@ H
MHJO)=>7DL%VAMI^< Y)XZ^Q!Z]Z +%>*_M4?M(^'_P!EWX5WWC+7H)]1+3BR
MT_3[8%6O;IE=DA,@!$:?(S-(0<*C !W*H_K.K:]8Z#I=WJ.HWEK86%G&T]S=
M7DZQ101("SR.['"JJJ[$DX 4U^>/[3>N_"']M/\ :^^ /PYT_P 1P^+],L9]
M9N-<CT.X8Q,HLX+F&-+M 497^S,C^3)E<,-R-@@$SP^3]M;]LOXMZ;!XE\(>
M&M>TS2&A\FT3P?X':_TV[9))$DE\^9)B&!^4A&*YCP54[B?7_P#@EK^T-J'Q
MI^.'QSU?Q??P/XS\2VVFZI%9V]NR6RVUH98&$6,JJ0B>U0!G+L#N)=MY'Z.:
M1X=T[0]'L],TRSM]/TVTMX[:UM;6)4BMX8U"QQQJ  %4  #&, #I7P5_P4:^
M <%Y\5/@]\0?!NL7?@/QQK_BFU\&7GB#0TDCN\72,D=PSQ2HV8XXY%P,-)')
MM,BJBJ02/OUE#,54AGQMR#\X'?G(..1TZ<5\:?#V'P]\2O\ @I;X\\5:#HUC
M=6G@CP?#H>J:Q#' RC6I;@8:/:V]I1:I):O(5!3[.\3855#:LWPA_:T\5:+?
M>#]?^,OA'1-(62=8_&>@Z \FOW\;.ZQQSP'R[>VS&ZGS(#OC:%,.WS.WM'[.
M7[-7A#]F7X=KX1\(2:A<V$M[)J=S>:I<":YNKAP@WN5"J,)%$N$51B,$@DL6
M"CU$6HDCPLA\MA]U<$8]N/\ .?IB=5VJ%ZX&.3FE'  I: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#Q7XS_M.?\*:\56VB?\*I^)OC@362WIU'P;X<.H6D>YY$\II/
M,7$H,>2N.%=#GFOEI?VB]:;]LH?%T? 7XS+X;/@$>%3:OX0<7JW7]I&Y,FS>
M4\H)@%M^03]VOT*$&V1V!P6.3M&.<8R?4X_D/2D6WVX.[)Z$<[<>@&<4 >"_
M##]KH_$SQUIGAC_A3'Q:\)_;=_\ Q-_%'AG[%80!87D_>R^:VTMY911@Y9E'
M&:]_J%;7"A=V5SG!R><]>O7^O-3*NU0/08XH 6N7\=> ?#_Q1\+ZKX;\4:5;
M:SH.H1>3=6-U'N20 Y!SU5E;:RLI#*RAE((S745'Y9SUX^E,-;[GY&?M%?L9
M>/OV2_!?B/Q?X:\9:5XJ^'FE>0OV?7TGBU&V$UTL$4"*F8Y BRPDR[H\Y;$8
MP ?I3]E__@G[+\/_ !I9>/OBIK6G^,?%>G;CI>DV$++IFE3>:Q656?!N)0!&
M59D7RV!)#NL<B=Q_P4\3R_V'_B6^=P TTD$#G.IVOX=.^*^I'MRV0)"O! 8#
ME>.U;NO4E'D;T.*G@L-3JNM&"4NXZ)=L*CN /3^E<)\:M!\;>)OAMK]A\.O$
M=OX1\:/$KZ7K-Y EQ;PRHZMMDC='&UU#(6*-LWAPK%<5WBQD8R>WI36M]V><
M'& W.X GD9SG\NE<_D=M[GQ#XYL_VG_VHOA6_P --:^&VF?!ZVUJ*WAU_P 8
M2^)$NVDM_,07,5K9VS%U:0;ODFE9&B#QNY9PPZ'QQ\+_ (I_ WX_2_$#X'^
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M/YGUQ3A V\.TFY@,'Y>O^?\ /O/10!!]F.$'F%MISEAG/7&<8IK6K.P;SF#
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MC\*LT4 5FM-S19**B'<56,?,1C'7.!QVYX'/'-CZTM% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 >3_M5L7_9@^,2@<GPAK"_G92CCWYZ5\K_ /!&+'_#+?B@X^0^+KKJ/FQ]
MCM,]^G7'OFOOLVZMNSSD_CC.<'/;.?PXH\G.XG!8X/3C(Z''^>E #X_N+G .
M.W2G4BJ%4*,X QR<FEH **** "BBB@ HHHH **** "BBB@ HHHH YOQ]\1/#
MWPO\)ZIXG\4:K;:-H6EP-<W=[<L0L: @<  LQ+,JA5!9F95 )(%?AA^V=;WW
M[2?[07Q+^*OPUT37O%OP[8VH;Q)8Z)>?8H?L^FVZW'FR&(>7Y90D[L<$'H0:
M_1/]J_PW-^TM^UU\*_@/J6GW$_@#3;";QWXC^SWB0/.JO/;6XW%1*JK*/+81
M-EEO20$\H2+]G:1H-CH.DVFFZ99V^F:=:PI;V]G:0K%%!$@VI&BI@*JJ J@<
M  8H \X^ 7[4'P__ &E_#+ZSX$U@:A]F,":AI]PIAN["25-ZQRQGC/WAN0LC
M&-]KMM->CZEKUGHVFWNHZA=6UCIUG"]Q->7,P2&*) 6>1W/"(H&2Q.  2>!D
M_ '[:'P=\2_ GXX>"OBC\!M6L? WB[XB:O'X*UEI88IH9KB\E26*<0R02K&&
M:!FFD49)5&"EGE+\MIO_  3[^*?Q@\*^.O%'Q]\0ZUXV\>:1<W\GA'PRFKQM
MH^H/Y8D63=N'D6]U*L<?EQ_9'C2/)*%E,8!]$?%K_@I]\!OA7//:P^(;KQQ?
MP31Q2V_A&W%XBJ\1D$@N69+=U^ZI"2LP9L;?E;;\Z2?MK?M5_M.61'P3^$#>
M%]"NK/SX_$4Y6Y!DCN"LAMKVZ6&T?G]V8S'(XQ,<C;F/V?PO^SSX@^ ?[.^E
M^)/A9\!O UM\=6\JYNK.YU&2[>UEE41W*P7=P_F ;  85N5C4/*5DD(!F]_^
M(FK?$C1?B;\.++P=X:T;5/!%]/=)XIU#4;PVTNG(J1_9C P<L2Q\P;%B<$H%
M8Q!_,4 ^!Y/^":/QU_:*']M?&[XSQVE^S?:K.SB\[5_LDLY!N8"ADAM[;:5B
M79;[D8K@'"*6]'\2?\$Q[+X+V.C>,/@'K6I)\3_"VJ?VM:Q:_? V^L($C!T^
M4PB'RU=5D ;*AA/-'(VR16B^LHM>^)S_ +0%[HU]X=T.'X2+H(GMM=6\\R\G
MU+S8PT,D;,"BB+SFP(W7"HWFY8QK!\._$7Q8U23XD)XQ\+:'IT%GJUW!X1$&
MH8_M2R5B('N@HF,.[*9<;F.YOW";%\T \B\+_P#!3;X2K:&P^(4'B'X4>,[4
M1K?>%_$6AWC7,+-%'(64PPOF,^9A"XC=@ ?+4,N>#^'_ /PGW[=GQT\)_$OQ
M!X<U3P+\#O!4ZZGH.@:P_P"_\1:@/,DM=014";56*6!\[Y8\H8XS*))BOL-]
MX[_:)3]EFQ\01> /#$WQLEES<^'I[U([")/M4B*\;"=DD)@\D[3<)@.[;R4\
MMNY^(GB3XK:?-\/4\(>%-!U);[6+2#Q?)<:DS?V99-@3O:LPA\\J=X#'#@JG
M[AA(3& >I-\Q94!0M]X[2..>0P[\YZ_E3DNBRL3&1CD+D9QCJ<XQ_GITKRI=
M>^+I_:&_L>3PIH?_  IW^QQ-_P )$M\W]H&_+\Q>3C@?PE-I78!)Y^X^33/"
MWBGXM3>-_B;;^(O"FBV7AG3_ +-_PA-S!J39U0F*0R?:Y1N>+Y_)4_N!LW.!
MYP3S& /6O/VL%*C?U*[AP/6C[1\H8JVT^BMG.?3%>!Z9XB^/%Q^RX=6N/#'A
MG3?CDJR2#P[?2NVF%TNF"0[X[AP&DM1'MS-M\UQN9?FVZ&M>*OC7!X?^$<ND
M>$-!N-7U&]TU/'L=U>@+I$+JOVPVB^9MD*L94!\V1EV1@1RARZ 'MGGDXPF!
MG'+#^GO_ %I!<_?)3H3@!ADC'7VKR;7-6^+,?[06@:7IFAZ&?A!_9!N=8UJX
MD;^U/MNZ9$MH%27@$BV<EHMFP39<'"F]\//$7Q-U3XG?$.S\9>']'T?P393V
M:^$=1TV]\^74HVC=IVF.X,'!"?(8D"[BJM,%\P@'IC3%<#9EO[NX9/TSU[?G
M1]H( +*0.GRAB<Y^GZUX)X,\6?'B]_9MU'5]?\$>'+/XQQPW"V?AN#5<6$S*
MSB+S'W2*K;1GRQ*P8HNZ6'>XAN^+_%GQLT_X;?#.]\,^$O#^K>.M0O-,7Q;I
M6H7PM[6PA>$M?/%()&*[)"B!E^T,%;(CEQR >W_:!QD;>N[/\.!GGL*3[0O.
M0PYP/E.3^G\J\R\5:Y\3;/XV> M(T'P_I5[\-KJ"[?Q)K,EX/MUDZPL;8)"2
MFU6E"+N42[MSAEB"!GK> ?$'Q;U/XP^/[#Q7X4T+2OAU9^2OAK6+#4VFNK[(
M'F>8N/4,6W"+RR%1?M )D4 ]8\W/\/I[]Z;]H&#P<@9Q@G/TQU_"O!]#\8?'
MF7X3_$>_U;P+X7M?B#9:E?1>%-(74G-C?VBI']FDDN,Y9F;SAAUM]^Q%9;</
MO5WC+Q5\?;/]F_3=9\.^!/#=]\89(;9[SP_-J;-9Q2%L3;"Q0.0,'89E5<N1
M-,47S@#W?[0O'8<Y)!&,#//''XTV2Y*!<1DY90<D *">IS_+Z5YIXMU[XFVG
MQN\":3H'A_2KSX;7<-X_B36)+W-]9.L3&V5(2R85I=B[E$V[<X81! ST]+UK
MXN+^T/KFF:KHNB?\*<71UO-*UNS=VO\ [=OA1[:=3+SP+IP5CVA3%\V[*4 >
MM>;GHI[=CZ_2F-<$*Q"C</NY88)[#/OGTKQ7PAXF^-][\,/B5?>)?!?A_2_'
MEC>:FGA+2;&[-S::A D"FQ:68RJ3YDVY6+^0=H!,<59.N>)OVB])_9FT_6-,
M\%^%-5^-4GEO=:"E[)'80*\[%D7?+B21(RBMF=4SYK)(P5$D /H%;@$*2"O7
M=N_AP,\D<#\Z43[F ",#WW @8^N,5YE\2-?^)NE?$[X<V?A#P_I6J^"K^>[3
MQ7J&I7HMY-/14C-L82&)9F8R_*(I Q559HE;S!'!KWQ._P"&@+W1KSP]HUO\
M)%T+[1:Z^EZ'OI=2\]=T#H2IC7RC(<"-U(16\[<YC0 ]/%P>-R;01QD\GZ#K
MTS^5*UP55_D 8<#+#!/89_'TKR;X<Z_\6-0D^(J^,/#&BZ:MCK%W#X1:VU)D
M.JV*MB![H()C"2 @,@RQWOF!=B^9RL?C3X_K^RDNOKX*T _'<@N/"XN4.GD?
M;]I(;[7M(^RD29\_J<#GY* /H-;CY0Q1@#VP20?0@"E$Q9@-C*W?<#@#ZCC]
M:\F^(GB3XLZ?<?#H>#_"^@ZB+W6;.'Q@USJ32+IEDQ'VA[0L(?/*YD4.<.-L
M?[AA(3&J:Y\6U_:$&C-X4T3_ (4V-&$P\1?;R=1-]OYB\D* !_"4V;-@$GG[
MCY( /54NBRL3&1CD+D9QCJ<XQ_GITIWG[6"E1OZE=PX'K7DOA;Q3\6IO&_Q-
MM_$7A31;+PSI_P!F_P"$)N8-2;.J$Q2&3[7*-SQ?/Y*G]P-FYP/.">8W)^'O
M%'[0M_\ LRWVJ7W@_P )Z7\:X9)'M= FO7FTZ94F("L5G(CD:%6"J)W3?L9W
M3<ZQ 'T-]H^4,5;:?16SG/IBCSR<83 SCEA_3W_K7B>M>+/C5#X?^$<VC>$=
M!N=5U*]TU?'B75YA=)A=5^V-:+YFV0JQE4'S79=D8$<H<NFEKFK?%F/]H+0-
M+TS0]#/P@_L@W.L:U<2-_:GVW=,B6T"I+P"1;.2T6S8)LN#A2 >LBY^^2G0G
M ##)&.OM3_,/]WGCID]_I7F/P\\1?$W5/B=\0[/QEX?T?1_!-E/9KX1U'3;W
MSY=2C:-VG:8[@P<$)\AB0+N*JTP7S#Q'@#Q7^T)<?LZZ]K'B?P9X1A^+JFX_
MLCPU:WKQV>U5"QK/*9I5,A9)7VI(%93$C/"=[( ?0?VCH2I*]/E!)Z^F*7[0
M.,C;UW9_AP,\]A7B/C#Q9\:]/^&_PTO?#'A+P_JOCC4+S3%\6:3J%^(+6P@>
M%FOGBE\QBOER%$#+]H8*V1'+CGH/%6N?$VS^-G@+2-!\/Z5>_#:Z@NW\2:S)
M>#[=9.L+&V"0DIM5I0B[E$N[<X98@@9P#TW[0O.0PYP/E.3^G\J=YN?X?3W[
MUYAX5UKXHWGQJ\>:;KGAG2;/X:6D-F?#FMQ7A%Y>.\2&Y5XPSY59#* S"(KM
M0!90[.G*:)XP^/$WPH^(^H:KX%\,6OQ LM2OHO">DC4F-E?VBHGV:22?=DNS
M><,.MOOV(K+;AMZ@'O'V@8/!R!G&"<_3'7\*7[0O'8<Y)!&,#//''XUX1XR\
M5?'VS_9OTW6?#O@3PW??&&2&V>\\/S:FS6<4A;$VPL4#D#!V&957+D33%%\[
MH?'WB#XMZ?\ &+P#I_A'PIHVJ_#B[,X\3ZQ?:DT-W8X'[ORH\<^HPLOF$E&\
MA0)" >K"?<P 1@>^X$#'UQBA9MP!"GG'8_X5Y?:Z]\3F^/E]I5YX;TN'X11Z
M MU;:]#<>9?RZEYZ[H'0E?+3R_,.T1OD(A\P,YC7,^'.N?&C7O GC]_%GAGP
MSX9\9VVIW]MX7@6[DN]/GM5B3['/<RJ_F,K2EPYV1.44?NHR0* /86N"%8A1
MN'W<L,$]AGWSZ4OGDX(C)XSMW#.?3KC]:^=;KQK^T7#^R[9:Y9> /#LOQN:X
M=;OPW-?!;&*'[6ZAD(N&61S$(R5:X3&Z0[LH(F[+XL:Q\6;'XB?#:S\!:+H%
M]X3U"[F7Q;J>N3M_Q+X$,)C^SA948RR*;E5Q'(-_E[]B_-0!ZRMQN("J?7)!
MQCUSC%-%P>-R;01QD\GZ#KTS^5>8P:_\3O\ AH"]T>\\/:-;_"5="^T6NOI>
MA[Z;4O/7= Z$J8U\HR' C=2$5O.RYC2K\.=?^+&H2?$5?&'AC1=-6QUB[A\(
MM;:DR'5;%6Q ]T$$QA) 0&098[WS NQ?, /66N"JO\@##@988)[#/X^E97B7
MQIHG@G0;G6_$FJV/A[2+8KY]_JEU';V\.Y@J[Y7(5<LRKR?O,!W%>(Q^-/C^
MO[*2Z^O@K0#\=R"X\+BY0Z>1]OVDAOM>TC[*1)GS^IP.?DK6^-UOX^\5:3X$
MT.S^'WA'QCHNKZS8P^-]/URX6]M+&RWJTSVZ3)$MR4=6VNP#AHXB+=MY,8!X
M7_P46^/WPQ\;_L;_ !#T30?B/X1UO5[HZ='#I^EZY;75Q*R:A:NX2-'+-M4%
MC@< $G%?1Z_M9?!5E'_%W? 2M_$K>*+'Y?KB4_I7DT?[-]@O[0@T8_LY_"4?
M!P:.)QXB.D6CZB=0+\Q^48?PV;2NP"3[1N/D@\+?L_Z=)XW^)D.O_LZ?"BP\
M.Z>+7_A";J#2K/\ XFA\MS)]JD6%GB_>>2#^X 0L^WS@F]@#ZK:9EW?NR2 2
M%SR<#MVS^-2J=R@G@X^M>4?L]ZQ\3M>^&MK??%7PMH_A/Q<T\R3:;I-UYT2(
MLA$;LNYUC;'\*2R KM?<I/EKZLGW%^E #J*** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIF,)RF76,$5]EM;EMP:1BI).,#CT _\ KU^"O_!3J=X_VXOB46.^2,::H;
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M03_H,>/O_#BP_P#R?0!^SWG?[)_,?XT>=_LG\Q_C7XP_\,X_\%!/^@QX^_\
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MOB>YOK.?F.X6*98[ADD1XW7>H8 J2,\U_0''Q&O!''1CD_G0 ZBBB@ HHHH
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M_P#*#I?_ ,BT?\///VEO^BE_^4'2_P#Y%H _?3/M1GVK\"_^'GG[2W_12_\
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MH=2?^)9@D\C&F6AX_$U^^E?B7_P46_9[^*/CK]L7XC:WX<^&_B[7]&NO[/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP3\-5O!X0\(Z#X6^V[/MG]CZ9#:_:MF[9YOEJN_;N;&<XW'&,FNN4!0 .@H
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M8?M%^'/B#^SGIOQ@8-IGAQM&EU6_C DF>R^SJPNX\>6K2^4\4R;E7Y]F5!W
M5^9\G[=7[5W[1%WXW\6_"];'PWX1\(V37VH6-@FGS"TMML\B2N]V&>:3RXV5
MO* 4F(?NE+8(!^P;S,F[]V20"0H/+8':I5.Y03P<?6OE']@+]KRX_:S^'>M7
M6M6.GZ5XPT.[2*_LM+BF%LT,P+VUPBR9"9VS(4\QV_<[SM#JH^K8V#1J5;<I
M (;U]Z '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUJ%Y8!>0F&6)D<Q212+R Z2JZ':64E25++@D [NBD7D#/6EH **** "BBB@
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MUS!<!_&.IB*W6:XC>![.T#QK,B+\R-YTEY&P;D^7'@!?F;]"$.Y%.=W'7UH
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MBB@H*\W^-?P)\"_M >&8_#_Q T?^WM%M[M=2BMY+VXMT2=$>,.6AD0X"R/\
M*6P=Q)&0"/2*\K_:.^-]G^SW\&?%?Q U"PNM5M]#CC*6=JRI+-++*L,2[F!"
MKOECW-M8JH9@KG 8 ^8/VU_BI\/?V-?V5[OX.>"%M]/U77-.N+'2/#ZRS71M
MK.ZDD^UW,S-)O12);CRW9SF7& 5CDV)_P20^ ]Y\,O@7JGC76(;BVOO'4T=U
M;64RE!'I\ =;=]K1JP>4R3R J61HS"R[26S^=_P3^-'PSU;XM:U\1_VC++Q9
MX_\ $,E['>P6=G#;2V=XX#*ZWBS2(=B;(1'$C+&!&$*LGR5^OO[+?[9G@O\
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M[1%M\-=6\ ZD^E.;*XO_ !-=74D4:0S,"]Q;6ZPR-<11JI!92O[R.2, %<D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0N9)%CD4QKB10'4#"L,G/N[0LRD>8<X(#8Y'';MG\*FHH 11M4 \G'I2T44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;QRQ",GR%D<O(%,RY9RFV7'E[E5Q]I44 (J[5 '0<4M%% !1110 5X'^V?\
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M* )J*1264$C!(Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWX;_ /!:?PEXA\506'C'X=ZAX2T:8!3JUEJ:ZE]G<L,M-%Y,3"-4\QB4+O\
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MAWX:KC./[2)]O^)E='_#\Z^0/VV/V9?B'^S?^T<?VA?A7I4VIZ')J9\07:6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"-H>N-H!Z@K
MUIBV^&SNP,8V@<?E4]% "*-J@>G')S2T44 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img192321128_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img192321128_22.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (C!(0# 2(  A$! Q$!_\0
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M&V__ *+6IE&Q497-JBBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.\,?]"YI'_@#%_\ $T ;5%8O_"'>&/\ H7-(_P# &+_XFC_A#O#'_0N:1_X
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M.3GDXQBES#Y3Q>KRZ-JKPVTR:9>-%=/LMW$#%9F]$./F/!X%>D_\(YX6\-^
M#JVL:.=3OH=1ELOENY(1,5=U[$@#"D\#/'UK2L;.T&B^ -0MDN(1<:OD0-=R
MR1QKO?"JK,5&!@9 !/XT<P<IXY=6MQ97+VUW;RV\\9P\4J%&4^X/(JS#H6KW
M&GMJ$.E7TEDJLS7*6[F,!>I+ 8P,'-;WQ-_Y*/K7_75?_0%KOO ^N^(=6NX/
M$6I7,.D^%]'MC"T4.Z.";"D !23N(R.?8 <FAO2X):V/(+#2=2U5W33M/NKQ
MD&76WA:0J/4[0<5'%I][/??88;2>2\W%/LZ1DR;AU&T#.1@\>U>IWVL2:/\
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MJ,)FL;N"ZB5BA>"0.H8=1D'K[58KP#P/XJOU-MX3TJZ73I[O4I9)K^2,/M7
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M7QQN+-O%,%NECLO%@5I+OSB=Z'.%V=!@Y.>^:\MIIW0FK,^GOA+_ ,DQT?\
M[;?^CGKM:XKX2_\ ),='_P"VW_HYZ[6L7N;+8****0PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH Q;K_ )'?2O\ L&WG_HRVK8D3S(G3.-RD9K'NO^1W
MTK_L&WG_ *,MJVJ!'/>"_"__  A_AY=)^V?:]LK2>;Y7E_>[8R?YTWQ!X5_M
MWQ!H&J_;?(_LB9Y?*\K=YN[;QG(V_=]#UKHZ*=^H6.-U+X?P:KKNN:A<7[B+
M5;);4PI'@Q[=N&#9YY4<8K/LOAMJ$-_H5W>^*9KQM&=1;QM:*B"( #8 &SN.
M/O$GH..*]"HHNPLC@M6^'VJZFMY8CQA>C1;R42265Q MPX&02JRL=R@8&!V]
M^<VM1\!RC4;34O#VMS:/>P6BV32&!;@2Q*!M!5B!G@<^U=G11=A9&;H.DOHN
MCPV4NH7>H3(,R7-W*7>1CU/).!Z#L/4Y)H>,_"__  EVAKIOVS[)B=)O,\KS
M/NYXQD>OK70T47ZCL%%%%(#Y&\8_\COK_P#V$KC_ -&-6K\.2!XBG][5O_0D
MK*\8_P#([Z__ -A*X_\ 1C5FV5[<Z==+<VDS13+T8?YYK?H8=3W>BO(/^$V\
M1?\ 00_\@Q__ !-'_";>(?\ H(?^08__ (FIY65S(/&Y!\77N#_SS_\ 0%J]
M_P )[>6O@W3_  _I"W&FM;RM--=P715YV.>#M P.>F3T'I7*SSRW,[SSNTDL
MAW,S=2:CJK$W/0-*\=W6JZ=I?A[5H9;ZX35(9X+^:X+/'\XX(();@L.HZCTK
MJ/&GCFR\-_$/4I$\-VMQK%M&D=MJ#3,NU6B4_-'T8@LPW @[<#MSXO12Y4/F
M9U&I>,Y=3\$P>'Y[4F:.^:]>[,O^L9M^1LV\<OUSVZ5?MOB']GT;PUI_]E[O
M[$NQ<^9]HQYW+';C;\OWNO/2N(HIV0KLUO$^M_\ "1^([W5_L_V?[2X;RM^_
M;@ =<#/3TKMK_P")VA:IHUGI-[X,,EC: "*%=5DC48& 2%09/USU/K7F=%%D
M%V=KH_CNRL-.O-(OO#L6H:-)=F[MK22Z93;G/"A\'< ,#H,\YZFM'3/BL]KX
MNU#Q%?:+'=W-Q&L-NJS^6+:,9^4':<YXR>._KBO.:*.5!S,Z7Q-X@T/7$,EA
MX<?3[YYO-FNGU&2X:0$'((<=R0<^U)>^*_M?@+3O#'V+9]CN6G^T^;G?G?QM
MQQ]_KD]*YNBBP7-GPOXEO?">N1:I8B-W52CQR#Y70]0>_H?J!7:7'Q9M(;2Z
M_L'PAIVD7\\9B^V1%"RJ>O C7/0'DXR!D&O,J*&DP3:.TTSQ]%9>$+70[K18
M[N6QN#<V5S]H9/*DR2I9 /GP2W&0""!CC-;R?%VQCU>YU5/","WUY!Y-W.+Q
MMT@  &W*X4<#(P<X&>E>6T4<J#F9TVM>+O[7\(Z+H/V'RO[,W?O_ #=WF9_V
M=HQ^9J?5?&=MK/@W3M%N]%4WNG1^5;7ZW+#8N1G]WC!)50.3[C'2N2HHL@NP
MKZY\'?\ (D:!_P!@VW_]%K7R-7USX._Y$C0/^P;;_P#HM:BH5#<VJ***S-0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K%T/_ )"_B3_L))_Z26];58NA_P#(7\2?]A)/_22WI@/\4:'_ ,))
MX;O='^T?9OM*A?-V;]N&!Z9&>GK5O2;'^S-'L=/\SS?LMO'#YFW;NVJ%SCG&
M<5<HI <Y;>%?L_C^\\4_;=WVBS%K]F\K&W!0[MV>?N=,=ZYV3X5(^C75HNM2
M1W3ZH=3M[E+<?N7X&TJ6^88[Y'./<'T6BG=BLCB-+\ 75IK]YJ]]XCNKRXOK
M(VMPZQ"%P21AXV0_)@*,#![G-0)\.]1N=0TU]:\5W.IV.G3B>W@>V5)-P/R[
MI02S=LYZ^U=]11=A9'"W7P^ODU/4)M$\47>DV6I2B>[MH8%9B^<L4DR"F?;]
M1P.SBMS;V*6T4KDQQB-9)6,C' P"Q/+'N<]:GHHN%CS32?AGX@T2\N[S3_&P
MCNKMBT\SZ3'([DG)^9F)Z\XKT"[LWN](GL9)OGF@:%I=G<K@MC]<5;HH;N"5
MCRBV^$.N6=D+*U\?ZA!:J"!!%$ZH 22?E$N.23^=;-Q\,(8M+T.#1]7GT^]T
M=W>&Z:)9=Y<Y8E"0.N,=@,C!KOJ*.9ARHX?2_AY+ISZZS^([^235Q&TEQ%^Y
MFCE7)+!U/0EF^7& ,#G&:73? >H+XBL-8U[Q)+J\NGHRVJ_9%@VDC&6*DEOQ
M[]^H/;T47861Y_%\+H(_",NBG4S]I^W&^M[Y+?:T,G'\.[G@8ZCMZ5;U/P/J
M,^L-K&D^))-+U&YME@OY$M%D2XV@ ,JEOD/'J>V".<]K11=A9'&ZWX";5O#F
MF::FMWB7>GW"W$=]<_Z0[.,\L&//7@9XP*Z,6-Q)H1L+N\^T7+VYAEN?*";V
M*X+;1P/7 J_11<+'G[_"Z"3P?I.CC5YXK_2GDDM=1@38RL[EC\N[IR.C Y4'
M/:G>'OAK+INO0:QK7B.^UNYM0?LHN-P$1(()^9F)Z\=/Q[=]11S,+(Y[Q+X7
M_P"$BOM$N?MGV?\ LN]2[V^5O\W:0=N<C'3KS]*Z&BBD,\P^,G_((?\ [!LW
M_I795\]U]"?&3_D$/_V#9O\ TKLJ^>ZUAL8SW/;]!(/AW3,?\^L7_H(K0KQB
MR\4ZUIUJMM:WS)"GW5**V/S!JQ_PFWB+_H(?^08__B:.4?,CT#QJ0/"-]D]=
MG_H:UY3IES;V>J6MS=6HNX(95D>W+;1* <[2<'@]#Q5K4?$6K:M (+V\:6('
M=M"*HS[X S675)6);N>D>(?B3H7B=TEU3P<\TL49CA/]K2*L>>X55 ].W.!Z
M56T7XEI8:;I<.HZ##J5[I 8:?=M<-&8@1@!E (;&!Z< =^:X"BCE0<S/0_#G
MQ/CT2UU47>B&]O-4G>:ZNDO# Q#?PJ54E0,G&#QDU2L/'6GZ#XAMM3\.^&X]
M/C$;0W=O)>/.+B-B"1EA\I^7@C//4'I7$T46079U_B'QM#J7A^+0-'T6+2-+
M68SR1+.TS2/SR6(''M[#L,57\&^,Y_"-Q=J;&"_L+U!'=6DW20#..<''WCU!
M!!/'IS%%%EL%WN>@:_\ $R/4/#\^C:+X<LM$MKH_Z28""9!Q@#:J@=,'.>/2
MI8OBDD8T"X.@1OJ>CQK"ETUTV'CV%'&P# + ]><'\J\ZHHY4',ST&_\ B187
M&B:UI5GX8CLH-5/FR,MXSN)B<ER2O(X7"C &#Z\87C3Q7_PE^K6]]]B^R>3:
MI;[/-\S.TL<YP/[W3VKFZ*+(&VSKO&WC.U\9/;W3:*+/444)+<K=,XD4 \!,
M +R2>YKD:**:5A-W/I[X2_\ ),='_P"VW_HYZ[6N*^$O_),='_[;?^CGKM:P
M>YNM@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E_%&B6&M:MIJ
M7T4CB."<KLF>,C+19Y0@FLO_ (07P_\ \^UU_P"!]Q_\772:I_R&;+_KWG_]
M"BI*T3:2):.<_P"$%\/_ //M=?\ @?<?_%T?\(+X?_Y]KK_P/N/_ (NNCHI\
MS"QSG_""^'_^?:Z_\#[C_P"+H_X07P__ ,^UU_X'W'_Q=='11S,+'.?\(+X?
M_P"?:Z_\#[C_ .+H_P"$%\/_ //M=?\ @?<?_%UT=%',PL<Y_P (+X?_ .?:
MZ_\  ^X_^+H_X07P_P#\^UU_X'W'_P 771T4<S"QSG_""^'_ /GVNO\ P/N/
M_BZ/^$%\/_\ /M=?^!]Q_P#%UT=%',PL<D_PR\(2.SOI)9F.2QNIB2?7[])_
MPK#P=_T!_P#R9F_^+KKJ*5V*R.1_X5AX._Z _P#Y,S?_ !='_"L/!W_0'_\
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MLB,I5T)Z9!]?7I6W7D7P1T&ST:#4)QKFG7MY=; 8+2</Y:+GDC@Y.3VKUVA
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MR<'IVKZ%BECGB26)U>-U#*RG(8'D$&J0#Z***8@HHHH **** "BBB@ HHHH
M**** "FVAV:['Z26SC\59<?S-.J+.S5=/?L9&C/T*,?Y@4 1^-!Y>APW8ZVE
M]:S9]%\Y5?\ \<9JTZK>*[1K_P (:Q:Q_P"LDLI5C([-L.T_GBEL+I;[3K:\
M3[L\22CZ, ?ZUDPD6****1(4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &;X'.WPC:6W_/F\MGCT$,K1
MC]$%:.L+_HL4G_/.9#^9V_\ LU9?A4^3>>(+(_\ +'4C(H_V9(HY,_\ ?3/^
M5;&K+NTJYQU5"X_X#S_2K6YHBE10#D9%%62%%%% !1110!AC2=-U3Q?J']H:
M?:7?EV%KL^T0K)MS)<9QD'&<#\JT/^$3\-_]"_I7_@%'_A4>G_\ (WZI_P!>
M%I_Z,N*W*)R:>C)C%-:HQ_\ A$_#?_0OZ5_X!1_X4?\ ")^&_P#H7]*_\ H_
M\*V**GGEW*Y(]C'_ .$3\-_]"_I7_@%'_A1_PB?AO_H7]*_\ H_\*V**.>7<
M.2/8Q_\ A$_#?_0OZ5_X!1_X4?\ ")^&_P#H7]*_\ H_\*V**.>7<.2/8Q_^
M$3\-_P#0OZ5_X!1_X4?\(GX;_P"A?TK_ , H_P#"MBBCGEW#DCV,?_A$_#?_
M $+^E?\ @%'_ (4?\(GX;_Z%_2O_  "C_P *V**.>7<.2/8Q_P#A$_#?_0OZ
M5_X!1_X4?\(GX;_Z%_2O_ */_"MBBCGEW#DCV,?_ (1/PW_T+^E?^ 4?^%'_
M  B?AO\ Z%_2O_ */_"MBBCGEW#DCV,?_A$_#?\ T+^E?^ 4?^%'_")^&_\
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MUI:G9KJ.E7ED^-MQ \)SZ,I']:RG.S4=/D["<J?HR,/YXK?J9#1S?AF[:_\
M"VDW;YWS6<3N#U#%!D?GFM6L/PH/*TF>S[VE]=0 >BB9]G_CA6MRLR0HHHH$
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !63H)\CQ5XBM>GF&VO0/]^,Q9_\@5K5CQG[/\0+<]!>:9(I/O%(
MA _*9OR--%+<V=7&=,E;^X5?_OE@?Z54K3O(O.LKB+^_&R_F*R('\VWBD_O(
M&_,5:V&R2BBBJ$%%%% &?I__ "-^J?\ 7A:?^C+BMRL/3_\ D;]4_P"O"T_]
M&7%;E*>X0V"BBBH*"BBL33K[Q!J>F6E_#I6F+%=0I,@?49 P5E!&<0=>::1+
MDEHS;HK-SXD_Z!FE?^#*3_XQ1GQ)_P! S2O_  92?_&*+!SK^DS2HK-SXD_Z
M!FE?^#*3_P",49\2?] S2O\ P92?_&*+!SK^DS2HK-SXD_Z!FE?^#*3_ .,4
M9\2?] S2O_!E)_\ &*+!SK^DS2HK-SXD_P"@9I7_ (,I/_C%&?$G_0,TK_P9
M2?\ QBBP<Z_I,TJ*S<^)/^@9I7_@RD_^,49\2?\ 0,TK_P &4G_QBBP<Z_I,
MTJ*S<^)/^@9I7_@RD_\ C%&?$G_0,TK_ ,&4G_QBBP<Z_I,TJ*S<^)/^@9I7
M_@RD_P#C%&?$G_0,TK_P92?_ !BBP<Z_I,TJ*S<^)/\ H&:5_P"#*3_XQ1GQ
M)_T#-*_\&4G_ ,8HL'.OZ3-*BLW/B3_H&:5_X,I/_C%&?$G_ $#-*_\ !E)_
M\8HL'.OZ3-*BLW/B3_H&:5_X,I/_ (Q1GQ)_T#-*_P#!E)_\8HL'.OZ3-*BL
MW/B3_H&:5_X,I/\ XQ1GQ)_T#-*_\&4G_P 8HL'.OZ3-*BLW/B3_ *!FE?\
M@RD_^,49\2?] S2O_!E)_P#&*+!SK^DS2HK-SXD_Z!FE?^#*3_XQ1GQ)_P!
MS2O_  92?_&*+!SK^DS2HK-SXD_Z!FE?^#*3_P",49\2?] S2O\ P92?_&*+
M!SK^DS2HK-SXD_Z!FE?^#*3_ .,49\2?] S2O_!E)_\ &*+!SK^DS2HK-SXD
M_P"@9I7_ (,I/_C%&?$G_0,TK_P92?\ QBBP<Z_I,TJ*S<^)/^@9I7_@RD_^
M,49\2?\ 0,TK_P &4G_QBBP<Z_I,TJ*S;&^OI-3NK"_M+>"6&&*8&"X:565V
MD'=%P1Y9]>M:5)JPTTU=!1110,*Y[P]_R#[C_L(7O_I3+70USWA[_D'W'_80
MO?\ TIEJX[,A_$C5HHHIC"EM/^0O%_UPD_\ 0DI*6T_Y"\7_ %PD_P#0DI#1
ML4445 S'U3_D,V7_ %[S_P#H45)2ZI_R&;+_ *]Y_P#T**DJULA!5'6KV33M
M"U&^A5&EMK:29 XRI*J2,X[<5>K)\5?\BAK7_7A/_P"BVJHZM$RTBR;^S_$7
M_06TO_P6R?\ Q^C^S_$7_06TO_P6R?\ Q^MRBIYV/D1A_P!G^(O^@MI?_@MD
M_P#C]']G^(O^@MI?_@MD_P#C];E%'.PY$8?]G^(O^@MI?_@MD_\ C]']G^(O
M^@MI?_@MD_\ C];E%'.PY$8?]G^(O^@MI?\ X+9/_C]']G^(O^@MI?\ X+9/
M_C];E%'.PY$8?]G^(O\ H+:7_P""V3_X_1_9_B+_ *"VE_\ @MD_^/UN44<[
M#D1A_P!G^(O^@MI?_@MD_P#C]']G^(O^@MI?_@MD_P#C];E%'.PY$8?]G^(O
M^@MI?_@MD_\ C]']G^(O^@MI?_@MD_\ C];E%'.PY$8?]G^(O^@MI?\ X+9/
M_C]']G^(O^@MI?\ X+9/_C];E%'.PY$8?]G^(O\ H+:7_P""V3_X_1_9_B+_
M *"VE_\ @MD_^/UN44<[#D1A_P!G^(O^@MI?_@MD_P#C]']G^(O^@MI?_@MD
M_P#C];E%'.PY$8?]G^(O^@MI?_@MD_\ C]']G^(O^@MI?_@MD_\ C];E%'.P
MY$8?]G^(O^@MI?\ X+9/_C]']G^(O^@MI?\ X+9/_C];E%'.PY$8?]G^(O\
MH+:7_P""V3_X_1_9_B+_ *"VE_\ @MD_^/UN44<[#D1A_P!G^(O^@MI?_@MD
M_P#C]']G^(O^@MI?_@MD_P#C];E%'.PY$8?]G^(O^@MI?_@MD_\ C]']G^(O
M^@MI?_@MD_\ C];E%'.PY$8?]G^(O^@MI?\ X+9/_C]']G^(O^@MI?\ X+9/
M_C];E%'.PY$8?]G^(O\ H+:7_P""V3_X_1_9_B+_ *"VE_\ @MD_^/UN44<[
M#D1A_P!G^(O^@MI?_@MD_P#C]']G^(O^@MI?_@MD_P#C];E%'.PY$8?]G^(O
M^@MI?_@MD_\ C]']G^(O^@MI?_@MD_\ C];E%'.PY$8?]G^(O^@MI?\ X+9/
M_C]']G^(O^@MI?\ X+9/_C];E%'.PY$8?]G^(O\ H+:7_P""V3_X_1_9_B+_
M *"VE_\ @MD_^/UN44<[#D1A_P!G^(O^@MI?_@MD_P#C]']G^(O^@MI?_@MD
M_P#C];E%'.PY$8NBWLFHZ%IU],J++<VT<SA!A064$XSVYJ]63X5_Y%#1?^O"
M#_T6M:U5+=BCK%!1112&%%%% %:^.R*.7_GG/$_X!QG],UT5<YJ*&33+I5^\
M8FQ]<<5T$4@EA21>CJ&'XTI;#1S.E#R/$OB2U[-=172CT5X44_\ CT;G\:VJ
MQYA]G^(+]A>Z6I^IAE.?_1X_2MBLV2]PHHHI",VZ\0Z)8W+VUWK&GV\Z8W13
M7*(RY&1D$Y'!!JW:7EK?VZW%G<PW$#9VR0N'4XX.".*\5\41PR?%+7!-X9N=
M> CAQ#!)(AC_ '4?S'8"?;FK>GKKGA+P+XAUFVM9-&%Q=1-9VTO[QH5W[3D.
M#V(&2,G&?2NMX=<J:>KM^/XG.J[YG=:*_P"![-17G.HZUXFT#0+2:?5(K[4]
M9DBBM8VM5CBM&<9/(Y?&0 3Z9([58BUO7?"_BJSTK7M1CU6UOX'DCG2W6%XG
M0$D87@C ^O/;&#E[%VT9I[5=4=]17DR^(?&5YX,O_%T6K6\$&YA%8BU1MB!@
MNX.1G<#G@@@_B,6O[<\4:IXET;2+'6%LUO-'BNIIC:QR%7*DLP! Y) &,X&3
MQ5?5Y=T3[==F>GT5Y)KOC;4;77+S26\3QZ9_9T*H)VT\2M>S;022 I"#/IZ]
M^UC4O'6MWGA30]5M"=/M[AW74;V&U\\6Q5@H^5N-I)SSST .>I]7GIYA[>.O
MD>IT5Y]:>(/$$G@;4[S3]0LM>O8GQ:S6L1$NPMC,D.!M8#) Q^?=G@7Q'J&K
M:F$E\3V>IPO &EMYK86US#)R<*H&' [G)_#O+HR2;[#55-I=ST"XN(;6!Y[B
M:.&%!EY)&"JH]23P*DKSKXRQ3MX1AD2XV0)<J)(=@/F$@[3GJ,8/US4U_J?B
M-M?T_P (V6KQK>BW:YO-4>T7++DX"Q_='H?PZ<Y%2O%23[_@#JVDU;L=_17(
M>$==U.XUC5_#^L21W%YIKKMNXT"><C<@LHX!QCIZ^V3U]9SBXNS-(R4E=!11
M14C"BBB@ HHHH **** "BBB@ HHHH *Q=8/D:_X<N^@%Z]NY_P!F2&3'_CZI
M6U6%XN/E:$+OO9W5M=9]%29&;_QT,/QIC1UE<_:#9;"/_GF6C_[Y)']*Z"L-
M5V75W'_=F)_[Z ;^M7$MCZ***HD**** ,_3_ /D;]4_Z\+3_ -&7%;E8>G_\
MC?JG_7A:?^C+BMRE/<(;!1114%!53PE_R)NA_P#8/M__ $6M6ZJ>$O\ D3=#
M_P"P?;_^BUI]"7\2^?Z&Q17D7Q8_X2S^W_#7V3^Q?L']M6W]G^;YOF_:-K8\
MW''EYS]WGI79>)!XB;X8ZH&, UXZ?)N_L_?MW[3GR\_-G'3OFD4;$'B30KG5
M&TRWUK3I=05F1K6.Z1I0RYW H#G(P<C'&#6G7SMJFI^!;#PYX8?1/#NF:D\/
MV>=Y[74HK6^2=6 ",H4S/DDYQ]>, A_BOQ3XK'Q%UC[#J$D$UA=QQ6=M)KEO
M:6^P!3A[>0@R[P3\P(^\/0"@#Z&HKP'Q3>:_%)XRUZV\3ZQ;/HVK6\=I9QW!
M\@;S&&#IR&7D87[O7@[C5_4M5\0^$8OB%86FO:EJ#6-O9SV\]ZXEDA,I E9>
M,  $D # P/J0#VB\O;73[22[O;F&VMHQEYII B*.G+'@4Y;F!YO)2:-I=@DV
M!@6VG(#8]#@\^QKQ34]2AT?P3XLBT#XAZEKCQ6<%PK/,TLEJQD"DK<KP-W]S
MJ,'WJ)I;#0?B+XNU74O$6KVQ33(9TBM[I/-GWQ$,%1AABF<KGA>IH ]PN;F"
MSMI+FZGC@@B4O)+*X544=22> *%N8'M1=+-&UN4\P2A@4*XSNSTQCG-?/EKJ
MMRUEXXTN+Q!=ZMIA\/-<QFZU,7S(V2 "X50C;6^9%R ?XFK1\+ZL]AJNF6FC
M>+[W6K>\\/RS7L,EP)%LI$C&THHQY7/&WJ.^>* /<;6[MKZUCNK2XBN+>4;H
MY87#HX]01P14U>%Z.=9\4W7@[2Y/%&M64=WH$D]S+:W;"25UDX)8YYSC)ZX!
M&<&L6]\9>([WP)X&234;U4O(KIKFXBU6.PEF:*0QJ#<2 C@8)!Y8^_- 'T=1
M7*?#>^U34/ FG3ZQ+%/>#>AFBN8YQ(JN54^9&2K'  )!Z@YYKJZ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@# '_(Y:C_V#[3_T
M9<5I5FC_ )'+4?\ L'VG_HRXK2ILF&WW_F%%%%(H*Y[P]_R#[C_L(7O_ *4R
MUT-<]X>_Y!]Q_P!A"]_]*9:N.S(?Q(U:***8PI;3_D+Q?]<)/_0DI*6T_P"0
MO%_UPD_]"2D-&Q1114#,?5/^0S9?]>\__H45)2ZI_P AFR_Z]Y__ $**DJUL
MA!63XJ_Y%#6O^O"?_P!%M6M63XJ_Y%#6O^O"?_T6U5'XD1/X6=%7"_$7QEJG
MA-M,73+>UF-T)FD$Z,V @4\88=B<_2NZKSWQ_;QW?C+P;;2C,<LMQ&X]01&#
M112<U?;7\A5VU!\N^GYAXS^(ESHFDZ/=:1!;S2ZA$;@K.&8)'M!_A(YY_0UT
M#^,-+TWP]IFI:W>PVKWEO')L568EF4$[5&6P,]>W'->-065Y-H?B$7X).@V8
ML(\]F:X)S]<;A],>U=7'/'X?\1>&M?UF*0Z2VBPP17(C+K;R[!U !()&>G7=
M[''1*C"UEY_,YHUIWN_+Y=#T-/%FAR:!)KL>H1OIL1 DF16.PY P5 W \CC&
M>0:K6'COPSJ>IQZ=9ZM%+=2?<38X#<9P&(QGVSGMUKS2[B:[\+>.M=MH)(-*
MOY8?LJNFWS<2#<X'H2>ON?0UMZU#'#'\-1'&J;9X0-HQ@$1Y_.H]C#;^MKFG
MMI[_ -;V.RU7QOX;T2_^PZAJL45SQF,(S[<]-Q4$+^...:RO%7Q"LO#VI:/:
MI)#+%>;9II_F=8[<G ==H^;.&Q@GIT.17*V6J6/A.7Q7IWB.UE-_?S2/"3"7
M^V1L"%56QTSGKQSZ@U3FL[GPUH7@&ZUD2P16MY))-O1CY*LP=5('.=H)QC/4
M=JJ-&":O_P /IT)E6FT[?\-KU.O;XCVEEXNU2QU2XM;?2[>"&2WE$;F20NB-
MR!G/WCT7CO72'Q5H8T$:V=2A&G'I-SR?3;C.[VQGVKD?#QM[WXQ>(KI LB/8
MP-&Y7^%HXO7ID5P\-I='P+87D#/%:V.MR/-*D(E$"X3#E#P0.>.G-+V,)6Z;
M?B@]M.-^N_X,]BLO&&@:CI-WJEIJ*2VEH,SL$8-&.N2I&[].<&H;/QWX9U#[
M2;;54=;:'SYG,;JJ)QR25 SR!CKGC'%><0(=0LO%^MIK%SJJ-II@DNFTY;6*
M5L*1M.[)90,'Y1UZ],[5Y+/I_P #K%[*RAN#]GC9UE@654!.YG*D$'!YY''6
MDZ,5IYV_K0I5IO7RO_6IV&C^-?#NO7$D&FZDDTT:;V0QNAV]R P&?PJFOQ*\
M'NT*C6H\RG"YBD './F)7Y?QQZ]*X+0KJ"Z^(^G7,.J7NI)+I\J_:;F'RD9P
MC%EB7 "J/0=#FLS1M<TJ+X5W>@O;2MJE[*1;Q+;LWVABP"LI P2",>O'%5]7
MC?KT_7R(^L2MTZ_IYGM=MKFFWFK7&EP7(>]MT622/8PPK8(()&".1T)ZU1?Q
MGX?CTZZU!K__ $2UG^S32B&0A9/[H^7GJ.1D<UP/B2*_\%VOAWQ"J$W4>F_V
M;=@?W_+^0D]\-GG_ &16[:0Z7X,^&%H=>L/MD1*RW$1B60F20YY#D#(R!^%9
MNE&R:UO_ $S1597:>EOZ1WRL'4,IR",BO*=)\:?$77K5[O2M"TJXMED:/?G;
M\PZC#2@]Q7JL;*T2,HPI4$#T%>!:#\/D\1^#;S6+264ZE#<.$MV(\N55 .W@
M9#'/7/Y=0Z"C9N7D%=SNE'S.UN_B3?M\/;+7[&SMA>R7@M)8I0S1[L,25P0>
M<#J>,D<]:=;>,_&&FZ]I=GXHT2RMK;49A;QM;N"P<D 'AVX&1G@=>M<WKU]I
M6J?"73(M-M5LECU*.*>V4DF.3:^>3DG.<@G/Z5VNA_"OP]H6JQ:C$UY<S0_-
M$+F12J-GA@%4<CWR/;.*TDJ<8OF7<SBZDY+E?8Z^^O(=.T^XO;@D0V\;2N1U
MPHR:X;P]XSU_6M3LV^RZ-)971+-:P78^UVL>>'D5FY&"#\HY![=*75M \=:C
M-J\$^KV,ND7$=PL%JJ@/@JWE*3Y8Z';D[O7K7%:+'97,GA+3M(L7A\0V-X6U
M']P4>- _S&1L<CM@YQTXS@Q3IQY7U_0JI5ES+HOS.RU_QIXETN?4[Z'1K:+1
MM-F2)C>"2.6ZRVTF(_=Q[X/KST&CK'BO4I-:TW1?#MM:-?7=M]L>2_W!(HL'
M (7G<2/P].<CE_'&OZ?J\=_I&JZ7<VNO64NW25B:1S.68 .FT <X'!S[<U8N
M;JX\-^--$\1>)-T4-SI2VUU<+$66.XP25(4<$X[>_852IJR=M=?G_F)U'=J^
MFGRU_ TE^([CP2=3DL4&K"Z^P?90_P AN/7/9<<_IGO6MX3US6M5N;N+45TB
MXMX@/+O=*N1)$6XRA4L6!YSD@#BO,[GP[>W7PZDUAK.<P2ZLVH&#'S_9BN-V
M/U^G/3FNJ\&FQO\ XBZCJ?AR 1:$;)8I&CA,4;394X"X'(&>@]?7DG3@HNPH
M5)N2N>F4445QG:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SOA
M7_D4-%_Z\(/_ $6M:U9/A7_D4-%_Z\(/_1:UK5K+XF9P^%!1112*"BBB@!&
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M9S@YZ8]<8ZUU%%%-R;23Z"44FVNH4445)04444 %%%% !1110 4444 %%%%
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M[N"W-Q*(81+($\R0]%7/5CZ#FDU"_M=*TVYU"]E\JUMHFEFDVEMJ*,DX )/
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MAS6)])U;6?L]]!M\R+[+,^W<H8<JA!X(/!HN'(OZ;-/^S_$7_07TO_P62?\
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MB+_H+Z7_ ."R3_X_1_9_B+_H+Z7_ ."R3_X_6[11<.1?TV87]G^(O^@OI?\
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MP[_T =+_ / ./_"C_A%?#O\ T =+_P# ./\ PK6HHYI=PY(]C)_X17P[_P!
M'2__  #C_P */^$5\._] '2__ ./_"M:BCFEW#DCV,G_ (17P[_T =+_ / .
M/_"C_A%?#O\ T =+_P# ./\ PK6HHYI=PY(]C)_X17P[_P! '2__  #C_P *
M/^$5\._] '2__ ./_"M:BCFEW#DCV,G_ (17P[_T =+_ / ./_"C_A%?#O\
MT =+_P# ./\ PK6HHYI=PY(]C)_X17P[_P! '2__  #C_P */^$5\._] '2_
M_ ./_"M:BCFEW#DCV,G_ (17P[_T =+_ / ./_"C_A%?#O\ T =+_P# ./\
MPK6HHYI=PY(]C)_X17P[_P! '2__  #C_P */^$5\._] '2__ ./_"M:BCFE
MW#DCV,G_ (17P[_T =+_ / ./_"C_A%?#O\ T =+_P# ./\ PK6HHYI=PY(]
MC)_X17P[_P! '2__  #C_P */^$5\._] '2__ ./_"M:BCFEW#DCV,G_ (17
MP[_T =+_ / ./_"C_A%?#O\ T =+_P# ./\ PK6HHYI=PY(]C)_X17P[_P!
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M3+K_ (2;[,;3^R!9.9#<]?,SC;U_>9SFO?:* /%[?Q+I?@/XDE?%.H_9Y/\
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M>)/^@9I7_@RD_P#C%%@YD:5%9N[Q)_T#-*_\&4G_ ,8HW>)/^@9I7_@RD_\
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M^@]I?_@9'_C72T460^67?\/^"<U_PE/A[_H/:7_X&1_XT?\ "4^'O^@]I?\
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M )ZZI_X-;K_XY1=!RO\ ILA_LW4?^AEU3_OU:_\ QFC^S=1_Z&75/^_5K_\
M&:F_X1;3O^>NJ?\ @UNO_CE'_"+:=_SUU3_P:W7_ ,<HN@Y7_39#_9NH_P#0
MRZI_WZM?_C-']FZC_P!#+JG_ 'ZM?_C-3?\ "+:=_P ]=4_\&MU_\<H_X1;3
MO^>NJ?\ @UNO_CE%T'*_Z;(?[-U'_H9=4_[]6O\ \9H_LW4?^AEU3_OU:_\
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M3_OU:_\ QFIO^$6T[_GKJG_@UNO_ (Y1_P (MIW_ #UU3_P:W7_QRBZ#E?\
M39#_ &;J/_0RZI_WZM?_ (S1_9NH_P#0RZI_WZM?_C-3?\(MIW_/75/_  :W
M7_QRC_A%M._YZZI_X-;K_P".470<K_ILA_LW4?\ H9=4_P"_5K_\9H_LW4?^
MAEU3_OU:_P#QFIO^$6T[_GKJG_@UNO\ XY1_PBVG?\]=4_\ !K=?_'*+H.5_
MTV0_V;J/_0RZI_WZM?\ XS1_9NH_]#+JG_?JU_\ C-3?\(MIW_/75/\ P:W7
M_P <H_X1;3O^>NJ?^#6Z_P#CE%T'*_Z;(?[-U'_H9=4_[]6O_P 9H_LW4?\
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MZ=1\-Z7?$\W%I%*<^K("?YUI5! 56\)?\B;H?_8/M_\ T6M6:K>$O^1-T/\
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MF-V>=V.N><UYDVGZ)HFF>,(;>VDCU#3O$B22*JRL8]/653&>>" =W/WO7C%
M'TS17S?XKUNQ\1:=\4]4TUWDLYXM)\J1XV3>!(HR P!QQW%6O$/@K1K/4?'E
MA$MW]DT[3(M1MX6NY&4711LS'+?,W7K_ 'C^ !]#45X'XCFT*YU339_B-)J$
MFD2:!;OISJ93&UP0#*<I_P M>GWN,=>U/L/#LOB;7/ FF^-(;B>8Z-<27$,T
MC([X?,8D((;.-I()SD<]Z />:*^?+4Z3H_QK06ACUS4KG4V# K>VU]:;R<]?
MW+Q(@_%3_=&:]!^+$DNC:9I/BZVB+SZ'>B1@.IAE4QN/_'E_*@#T%B%4L<X
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M[2T##HTD4/SCZC<!0!WE%%% & /^1RU'_L'VG_HRXK2K-'_(Y:C_ -@^T_\
M1EQ6E39,-OO_ #"BBBD4%<]X>_Y!]Q_V$+W_ -*9:Z&N>\/?\@^X_P"PA>_^
ME,M7'9D/XD:M%%%,84MI_P A>+_KA)_Z$E)2VG_(7B_ZX2?^A)2&C8HHHJ!F
M/JG_ "&;+_KWG_\ 0HJ2EU3_ )#-E_U[S_\ H45)5K9""BBBF(**** "BBB@
M#-;_ )'+3O\ L'W?_HRWK>K!;_D<M._[!]W_ .C+>MZE/H$=V><7/@?Q3H]_
M>GP?KL%II]Y(9GMKA?\ 5L>NT[&_,8.  <XS5I?APQ\#KHLVJS/?K<?;%NF)
M94FYZ*3]WD^Y))]J[6]U"RTZ$37UW;VL3-M#SR!%)ZXR3UX/Y51_X2KP[_T'
MM+_\#(_\:OVTV9>SI)Z_F<_9>&/$&I>(M/U;Q1>:>XTU3]F@L5?:[D<NY;&#
MPIXXX[=\V/X?:LGP\U/P^;BR^UW5[]H1][^6%RAP3MSGY3VKLO\ A*O#O_0>
MTO\ \#(_\:/^$J\._P#0>TO_ ,#(_P#&CVL^@N2EU?XF)<>$[^7Q5X:U19;8
M0:7;&&92S;F.TCY>,$<]R*P;+P5XSTW1=2TFTU'1Q::C+(TOF"0O$K  E#MZ
MD<$$<8&#S7<_\)5X=_Z#VE_^!D?^-'_"5>'?^@]I?_@9'_C0JLUI8'"D];_B
M<X/ L]KK?A::SGA-GH\31R>82)')!Y  (ZGUINE>"M2L?#7B;399[0S:I)*\
M#*[;5#K@;OER/P!KI?\ A*O#O_0>TO\ \#(_\:/^$J\._P#0>TO_ ,#(_P#&
MCVD_Z^\?+2[_ -;'&'P%KMG/X?O["?2I;S3;,6SQ7BNT0(+$.F!G/S>V,"B+
MX=:H/!NNZ)/?6LL][=BY@N,$ D%3\ZX^7.WMG&>]=G_PE7AW_H/:7_X&1_XT
M?\)5X=_Z#VE_^!D?^-/VU0GV=+O^)S2>%-?NM=\-ZGJ,NF!M+5TF6W:3#+C"
M[=PY.,9R157_ (0KQ-IEKJ.C:)J>GIHM^[,S7*/Y\"OPX3 P>/7].M=?_P )
M5X=_Z#VE_P#@9'_C1_PE7AW_ *#VE_\ @9'_ (TO:S[#Y*7?\3G?^$%FM=;\
M+SV,T/V+1XFCD\PD2.3GD  CDDGJ*E3PIK$7B7Q%JMIJ4-FVHQQBVE1?,>,J
M!G<K+C!QC@GK6[_PE7AW_H/:7_X&1_XT?\)5X=_Z#VE_^!D?^-+VD_Z];CY:
M7?\ 'RL<GHW@C6$\4V.L:D-$LQ9HV1I$3(UPS#'[S( [DY'TQZ=7H]OK<-[J
M;:M>03VTDY:Q2, &*+)^5OE'/3N?K2_\)5X=_P"@]I?_ (&1_P"-'_"5>'?^
M@]I?_@9'_C1*<I;H<53CL_Q,S5_#5Y?^.]$UR*6 6MBCK*C,=Y+!@-HQCOW(
MJO#X3O=(\<'6-#DMH=-O% U"T=F7<W/SH ",\YYQW]>-O_A*O#O_ $'M+_\
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ME_\ @''_ (4?\(KX=_Z .E_^ <?^%/0J\NWX_P# .CHKG/\ A%?#O_0!TO\
M\ X_\*/^$5\._P#0!TO_ , X_P#"C0+R[?C_ , Z.BN<_P"$5\._] '2_P#P
M#C_PH_X17P[_ - '2_\ P#C_ ,*- O+M^/\ P#HZ*YS_ (17P[_T =+_ / .
M/_"C_A%?#O\ T =+_P# ./\ PHT"\NWX_P# .CHKG/\ A%?#O_0!TO\ \ X_
M\*/^$5\._P#0!TO_ , X_P#"C0+R[?C_ , Z.H9K2VN)H)IK>*26W8O"[H"T
M;$$$J3T."1QV-87_  BOAW_H Z7_ . <?^%'_"*^'?\ H Z7_P" <?\ A1H%
MY=OQ_P" ='17.?\ "*^'?^@#I?\ X!Q_X4?\(KX=_P"@#I?_ (!Q_P"%&@7E
MV_'_ (!T=%<Y_P (KX=_Z .E_P#@''_A1_PBOAW_ * .E_\ @''_ (4:!>7;
M\?\ @'1T5SG_  BOAW_H Z7_ . <?^%'_"*^'?\ H Z7_P" <?\ A1H%Y=OQ
M_P" ='17.?\ "*^'?^@#I?\ X!Q_X4?\(KX=_P"@#I?_ (!Q_P"%&@7EV_'_
M (!T=%<Y_P (KX=_Z .E_P#@''_A1_PBOAW_ * .E_\ @''_ (4:!>7;\?\
M@'1T5SG_  BOAW_H Z7_ . <?^%'_"*^'?\ H Z7_P" <?\ A1H%Y=OQ_P"
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M@TK_ ,#8_P#&C_A+?#?_ $,&E?\ @;'_ (T68<\>YL5SVG?\AGQ#_P!?Z?\
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MZA;+<V5S#<P-G;+#('4X.#@CBGSW$-K"TUQ-'#$N,O(P51DX')]S0!)1110
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M720W*6*N9/.;/*LQ''0CG/M79_\ "4Z=_P \M4_\%5U_\;H_X2G3O^>6J?\
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MW069RWAOXA7K^(M(M;CQ##K$>HGRYX%L3 ;.0] K;1O&3C/M77?$K6]1\/\
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M_P#@INO_ (W1_P )!:?\^VJ_^"FZ_P#C==%11H%I=_P_X)SO_"06G_/MJO\
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M33W>?42RO(/T85NUF2PJMX2_Y$W0_P#L'V__ *+6K-5O"7_(FZ'_ -@^W_\
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MID^RXW>1@;O.QSNVYSNY^]FL34[?1],EUNY$^A:U8M>,\]I?![;4$??\R1G
M; R,GH<-QUR<H<Q[??:II^EQI)J%];6B.=JM<3+&&/H"2*LQR1S1)+$ZO&ZA
ME=3D,#T(/<5XSXAGGNOB!;W$J:-';RZ5&]JGB+?Y*@X)'^_G/7W[XKLOA7#)
M!X-"F\@NK<W,AMG@$H18^/E'F*K<-O\ \<YI-65P3U.VHHHJ2@HHHH ****
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MZO>?8KJUU6X\\C*DJ\9P"N#U]>,UM_"Z^N]0\+W4U[=3W,JZG=('FD+L%$A
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M.02.G:LU_A;:Z=I6NO8WE]JNIZCIS6;'6;HRK)U*[F4!AC@<$8 '?F@ \/\
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M"-WJ'^TM1_Z%K5/^_MK_ /'J1+LF]7_7R)?[?N_^A:U7_OY:_P#QZC^W[O\
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M_P#QZC^TM1_Z%K5/^_MK_P#'J OYO[O^ 2_V_=_]"UJO_?RU_P#CU']OW?\
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M_P#QZC^TM1_Z%K5/^_MK_P#'J OYO[O^ 2_V_=_]"UJO_?RU_P#CU']OW?\
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M]>?]"UJO_?RU_P#CU7Z*-.P6?<H?V]>?]"UJO_?RU_\ CU']O7G_ $+6J_\
M?RU_^/5?HHT[!9]RA_;UY_T+6J_]_+7_ ./4?V]>?]"UJO\ W\M?_CU7Z*-.
MP6?<H?V]>?\ 0M:K_P!_+7_X]1_;UY_T+6J_]_+7_P"/5?HHT[!9]RA_;UY_
MT+6J_P#?RU_^/4?V]>?]"UJO_?RU_P#CU7Z*-.P6?<H?V]>?]"UJO_?RU_\
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M#<V\@S'-"X=''J".#4U<9\+].M--\'A+2^L+KSKF6>06$RRP0.YSY2%3C"C
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M_'Z>O<7+_=_(B_L"T_Y^M5_\&UU_\<H_L"T_Y^M5_P#!M=?_ !RI?[.\0_\
M07TO_P %DG_Q^C^SO$/_ $%]+_\ !9)_\?HU[AR_W?R(O[ M/^?K5?\ P;77
M_P <H_L"T_Y^M5_\&UU_\<J7^SO$/_07TO\ \%DG_P ?H_L[Q#_T%]+_ /!9
M)_\ 'Z->X<O]W\B+^P+3_GZU7_P;77_QRC^P+3_GZU7_ ,&UU_\ '*E_L[Q#
M_P!!?2__  62?_'Z/[.\0_\ 07TO_P %DG_Q^C7N'+_=_(B_L"T_Y^M5_P#!
MM=?_ !RC^P+3_GZU7_P;77_QRI?[.\0_]!?2_P#P62?_ !^C^SO$/_07TO\
M\%DG_P ?HU[AR_W?R(O[ M/^?K5?_!M=?_'*/[ M/^?K5?\ P;77_P <J7^S
MO$/_ $%]+_\ !9)_\?H_L[Q#_P!!?2__  62?_'Z->X<O]W\B+^P+3_GZU7_
M ,&UU_\ '*/[ M/^?K5?_!M=?_'*E_L[Q#_T%]+_ /!9)_\ 'Z/[.\0_]!?2
M_P#P62?_ !^C7N'+_=_(B_L"T_Y^M5_\&UU_\<H_L"T_Y^M5_P#!M=?_ !RI
M?[.\0_\ 07TO_P %DG_Q^C^SO$/_ $%]+_\ !9)_\?HU[AR_W?R(O[ M/^?K
M5?\ P;77_P <H_L"T_Y^M5_\&UU_\<J7^SO$/_07TO\ \%DG_P ?H_L[Q#_T
M%]+_ /!9)_\ 'Z->X<O]W\B+^P+3_GZU7_P;77_QRC^P+3_GZU7_ ,&UU_\
M'*E_L[Q#_P!!?2__  62?_'Z/[.\0_\ 07TO_P %DG_Q^C7N'+_=_(B_L"T_
MY^M5_P#!M=?_ !RK-AIUMIJ2K;^:3-)YDC33O*S-M"Y+.2>BJ.O:H_[.\0_]
M!?2__!9)_P#'Z9I5Q>23ZE;7TD$LMG<B$201&-6!BCD^Z6;GYR.O:D[VW!))
M[6^XTJ***DL**** ,/Q&/.;1K+_GYU2#CU\HF?\ ]HUU=<O=#[1XVT*WZB"&
MZO#[$!(A_P"CF_6NAO)?)L;B7^Y&S?D*I%HQK0[[99/^>A:3_OHD_P!:GJ.!
M/+MXX_[J@?D*DK0 HHHH$*"0<CK7,^)[?78HWOM)U"X**,RVP.2O^TOJ/4?Y
M'2T=*SJ0YU8SJTU4CRWL>+W^M:EJ<2Q7MV\Z*VY0V.#5"O1?%'@T7ADOM+0+
M<?>D@' D]U]&]N_UZ^>;'\SR]K;\XVXYSZ8KR:M.<)6D?.XBC4ISM/7S+MAK
M6I:9$T5E=O C-N8+CDUZ'X8M]=EC2^U;4+@(PS%;$X+?[3>@]!_DY>A>#+^Q
MCAU"6SM;BZSE;>YG:)8AV)PC9;V[?7IT^[Q(?^89I7_@RD_^,5VX:A*W-)_*
MYZ6#P\XI2J-^2U-(DDY)S16;N\2?] S2O_!E)_\ &*-WB3_H&:5_X,I/_C%=
MUCT^9&E16;N\2?\ 0,TK_P &4G_QBC=XD_Z!FE?^#*3_ .,46#F1I45F[O$G
M_0,TK_P92?\ QBC=XD_Z!FE?^#*3_P",46#F1I45F[O$G_0,TK_P92?_ !BC
M=XD_Z!FE?^#*3_XQ18.9&E16;N\2?] S2O\ P92?_&*-WB3_ *!FE?\ @RD_
M^,46#F1I45F[O$G_ $#-*_\ !E)_\8HW>)/^@9I7_@RD_P#C%%@YD:5%9N[Q
M)_T#-*_\&4G_ ,8HW>)/^@9I7_@RD_\ C%%@YD:5%9N[Q)_T#-*_\&4G_P 8
MHW>)/^@9I7_@RD_^,46#F1I45F[O$G_0,TK_ ,&4G_QBC=XD_P"@9I7_ (,I
M/_C%%@YD:5%9N[Q)_P! S2O_  92?_&*-WB3_H&:5_X,I/\ XQ18.9&E16;N
M\2?] S2O_!E)_P#&*-WB3_H&:5_X,I/_ (Q18.9&E16;N\2?] S2O_!E)_\
M&*-WB3_H&:5_X,I/_C%%@YD:5%9N[Q)_T#-*_P#!E)_\8HW>)/\ H&:5_P"#
M*3_XQ18.9&E16;N\2?\ 0,TK_P &4G_QBC=XD_Z!FE?^#*3_ .,46#F1I45F
M[O$G_0,TK_P92?\ QBC=XD_Z!FE?^#*3_P",46#F1I45F[O$G_0,TK_P92?_
M !BC=XD_Z!FE?^#*3_XQ18.9&E16;N\2?] S2O\ P92?_&*-WB3_ *!FE?\
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M]- "BS:!3#@'(&S&W (!Z=16=CQ)_P!!/2O_  6R?_'Z,>)/^@GI7_@MD_\
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M3D\FD_X1S0C<R7/]BZ=]HEF6>27[*FYY%)*N3C)8$D@]1FJ>/$G_ $$]*_\
M!;)_\?HQXD_Z">E?^"V3_P"/T6\PYGV_+_,O_P!A:/Y0C_LJQ\L7/VL+]G3
MGZ^;C'W_ /:Z^]2?V1II2\0Z?:;+W/VI?)7%QD8._CYN..<\5F8\2?\ 03TK
M_P %LG_Q^C'B3_H)Z5_X+9/_ (_1;S#F?;\O\R[%X>T6#2Y-+BT?3X]/E.Z2
MT2V01.>.2F,'H.W858_LRP^UM=_8;;[2T/V<S>4N\Q9SLW8SMSVZ5E8\2?\
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M@GI7_@MD_P#C]%O,.9]OR_S+G_".:$;F2Y_L73OM$LRSR2_94W/(I)5R<9+
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M :]<]IW_ "&?$/\ U_I_Z305T-<]IW_(9\0_]?Z?^DT%'1F<^G]=&:5%%%2
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MS]YV.%4#J23Z5;HN'(OZ;,+^S_$7_07TO_P62?\ Q^C^S_$7_07TO_P62?\
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M1?\ 07TO_P %DG_Q^C^S_$7_ $%]+_\ !9)_\?K3TW4K/6--M]1T^X2XM+A
M\4J=&!_D?4'D'@U:HN'(OZ;,+^S_ !%_T%]+_P#!9)_\?H_L_P 1?]!?2_\
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M@$UR2$B<H\DC/R/E6-5.,C);J*$JFEF#=/6Z.BLK*VTVRAL[.%(;>%=J1H.
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M"BI*M;(04444Q!1110 4444 9K?\CEIW_8/N_P#T9;UO5@M_R.6G?]@^[_\
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MZS\&M2OM/\/.BZ+?7NGZ8NGW$%_+<+ =K%@Z-$58G+,,'C!]:U?%'PSU*_\
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M*#4BCS&Z1C)"X&"4P"#W/S?3'>GS^"M0N=1U^:>]AD74M-2T24@AS(J %V4
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M]\"6R\-ZA9:K;7@:UD"7]Y.ZF1A^[G;((^4Y8#MP/>NLHH=23!4HH****S-
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M7_XS1_9NH_\ 0RZI_P!^K7_XS5/^S=1_Z&75/^_5K_\ &:/[-U'_ *&75/\
MOU:__&:.7S7]?(+>3^__ ()<_LW4?^AEU3_OU:__ !FC^S=1_P"AEU3_ +]6
MO_QFJ?\ 9NH_]#+JG_?JU_\ C-']FZC_ -#+JG_?JU_^,T<OFOZ^06\G]_\
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M7_XS1_9NH_\ 0RZI_P!^K7_XS5/^S=1_Z&75/^_5K_\ &:/[-U'_ *&75/\
MOU:__&:.7S7]?(+>3^__ ()<_LW4?^AEU3_OU:__ !FC^S=1_P"AEU3_ +]6
MO_QFJ?\ 9NH_]#+JG_?JU_\ C-']FZC_ -#+JG_?JU_^,T<OFOZ^06\G]_\
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MU-CRH)KA$=\G VJ3DY/'% %^BL^\UW2-.FDAO=5L;:6.,2ND]PB%4+!0Q!/
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M'K/_ )^=5_\ !M=?_'*U:*.9]PY8]C*_X1ZS_P"?G5?_  ;77_QRC_A'K/\
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M4L ,Q2&0R*PP!GC.3T[]78?$?PCJ6A7^MVNM1/I^GD"ZE:-T,>>GRLH8YZ#
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MLMO]G3RY'R#N9<8)R!R?04K >$P7MO)X-M-.M8988K+Q5; (+P74"[@Q(A<
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M.PANWK1X;\$>(]-L_!4%W8*'TK5+N:[99T951]VUP2V6!R/?U%>P44 %%%%
M!7/:=_R&?$/_ %_I_P"DT%=#7/:=_P AGQ#_ -?Z?^DT%'1F<^G]=&:5%%%2
M!BWP^T>,?#UMU\G[3>X_W8Q%G_R/74US-D/M'C^[?J+/3(D!]Y9')'Y0K^8K
MI68(I8] ,FJ1:V,*$[WGD_OS.?P#$#]!4M060/V*$GJRAC]3S4]: PKGO#WC
MCPYXKN9K?1=1^U2PIOD7R)$PN<9^9170UQW@WX:Z-X'O;F[TRYOY9+B,1N+F
M1&  .>-JBD([&BBLCQ0NIR>&K^'1XO,U":(Q0_.%V%OE+Y)'W02WX=Z .;T#
MQ/J5YXG2:[F#:)J[W$>F+L4>682 .0,GS )'&2>@QQ3_ !AXUDT_P]K<VE6M
M\SV2O#_:,<4;0PS@?=(9MS8) )"%03R>#ANK^ XK+P_;'P_]M?4=+>*>QBFU
M&9HRT9&5V.Y1=R[EZ#&[TJAJNC^(H_"6O^'K+19+HZA+/-;W!N(D1%E8R%'!
M;<'!+*, J>/F S@&=2/%MC'HVK:A-'<*-*=HKB,JN]F"AAM .#N#+MR1UYQ4
M-YXUM+-;R;^S=1FM+ @7MU$L92V; +*P+AF*@@G8&QG')R*R-8\*ZG=^+[-[
M>-3HUZ;>75,N.'MMS(-N<G<2@.,_ZOGM6;XD\,:QJT'B"VN=%GU2\N))3IUU
M->K]E@C9!MVQL_R2#!7(CY/)8 D@ ZF\\:6MO>:C;6^F:E?-I\23W#6J1E5C
M9-X8%G7=P#P,MQP#4T_BVU\Y8M-L;W5Y/LR7;BR5/W<3YV$F1E&6P<*,MQTZ
M9S=+T74HI_$<LUJ8Q?6=M' "Z$LRP%6'!.,,<>GI5/P[IFN>%4BF;2)]0^U:
M79Q2Q6\\0>WGACV,K;W52IR,%2>0W'0T ;L_BZW68PV>F:G?R1VZW-PD$*JU
MNC9VAUD93N.&^0 MP>.F72^+;-C NF6MWJSS6PO-MDJ?)"WW6.]E'/.%&6.#
MQQ7.W.A:G%KVH:I<:3J-V=2CBD\K2]9> 6\J($*/^\B#*< A@"?O<=,S:-HF
MK>$;M)K;2TOHKC3H;>:&RF"B":(N1@S/DQGS&YR6^7[O/ !)X=\1ZAJOASP_
M<-<^9<7MS.\TGEJI-O&TG\.!CI&O3/S>M3VWQ$L;JWTZYCT?6/L^I?+92&&/
M]_)C/E@;\J>"-S )P3NV\U6\$Z!JUA91?VO:+!/;6DL,8617!:6=Y),8/3"P
M]?Z5'IGAS5;?1/ EO+:[9=+E#7B^8I\H>3(OKSRP'&>M &ROC2R-HSM9WRWJ
MWOV#^SRB>>9L!MHPVS&T[MV[;CJ:S=>\:W%OI:/8:==I?1ZE;VEU:S"+S(@[
MK_M[3O4X5@2.>2,'&;J'A'5)=?O=6%K/+''JWVA(+>\-O+/"ULD3%'5U*L".
MC,H(!&>:=<>&-0DL+V\M](N(Y7O[*>.VN+]I[J2."0,V]Y)60'!;: P&.IR<
M  Z*^\96UD;XKINH7,.GH&OYX!$4MCMWE6RX+%5()V!L9]>*=-XOMQ=3Q66F
MZEJ,5LL;7$]G&C+%YBAE&TL'<[2K816X([\5RNO^'=7UF/7H;S0[G4;B[WG3
M99[U/LUHK1!0#$9,+(IW_,J-DG[P!R)+[0-0DLT-MX<OK76AI\,$&IV.I)%M
M8(.)P'7<%8<@+("!P>P -B+QA)!XB\21ZE;RP:7I<4+)-A".03_"Q9B^1M '
M0 '!/*ZGXUDM+#4D_L:_M-3AT^2]MX+KR2)57@ME)",*2"P)#8Z UGW^C^)8
MY?$9LHY6NK^UM6CO(9DC#O$,21@[@R,PR%;&!G.1BL]_"-Y<:U/<67AV;3[>
MXTJ\LY);NZCEN))I I5I&WN67J =S$8.0HQD Z"Q\7010VD^L2WEFXT8W]PD
MR1&,*K*"YV9;<<Y"@XP>F[BM*W\3*PF:^TC4]-CCMS<^9=QIL9 ,GYD=@K <
M[6VGVX..3O/"NLZW#&AM&L&_X1_[$#<2(0LZ2HRAMC-\IV9R,\'UXK>OI];U
MZS&G2>'9K*WG,:7<EQ=0DA"X\P($9MPVAAD[3R.#S@$.TSQ-<"YL=&N["]NM
M8:SANKIH5C6.(2$@DDLO"D$8 R1@@'G$UIXRLKR2V=;.]2PNYO(M=0=4\B9\
MD ##%P&((!90#Q@\C*#2+M_&^J7SQE+*YTN&V28,,[P\A88SG@,#G&.:YC2O
M"-_;V6DZ3/I5XTEC/%YMY/J\SV;)$<AXX1-G>=JX4H%4YZ@ $&=7;^+(;NY7
M[-I>I3V#7!MQJ,<2M!N!()P&\S:&!4OLVY&<XYH3Q?I[Z#::P(;G[/=7:VB*
M57>':7R@2-V,;AGKT[=JH>'8];\/Z=;:!_8LERMO*R+J'VF-8&B+%@Q&3)OP
M<;=F-PZXYK$&B>((_#VG>'TT9V^QZNES)>&XB$<D(N3)N0;MV[!&05'0X).
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MN6!'KVK4TWQ/#?W=M;3:=?V#W<1FM#=H@$Z@ G&UF*D @[6"MCMP<<9-\/\
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M,N/O6T";V7Z':BGV)%=5J7_(*O/^N#_^@F@0W2=2AUG1[/4[=9%ANX4FC60
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M^@1I?_@SD_\ C%7Z*=_(+2[_ )?Y%#^T?$/_ $"-+_\ !G)_\8H_M'Q#_P!
MC2__  9R?_&*OT47\@M+O^7^10_M'Q#_ - C2_\ P9R?_&*/[1\0_P#0(TO_
M ,&<G_QBK]%%_(+2[_E_D4/[1\0_] C2_P#P9R?_ !BC^T?$/_0(TO\ \&<G
M_P 8J_11?R"TN_Y?Y%#^T?$/_0(TO_P9R?\ QBC^T?$/_0(TO_P9R?\ QBK]
M%%_(+2[_ )?Y%#^T?$/_ $"-+_\ !G)_\8H_M'Q#_P! C2__  9R?_&*OT47
M\@M+O^7^10_M'Q#_ - C2_\ P9R?_&*/[1\0_P#0(TO_ ,&<G_QBK]%%_(+2
M[_E_D4/[1\0_] C2_P#P9R?_ !BC^T?$/_0(TO\ \&<G_P 8J_11?R"TN_Y?
MY%#^T?$/_0(TO_P9R?\ QBC^T?$/_0(TO_P9R?\ QBK]%%_(+2[_ )?Y%#^T
M?$/_ $"-+_\ !G)_\8H_M'Q#_P! C2__  9R?_&*OT47\@M+O^7^10_M'Q#_
M - C2_\ P9R?_&*9I5O>1SZE<WT<$4MY<B81P2F15 BCC^\57GY">G>M*BBX
M6?5A1114C,KPR/.UCQ'>=C>I;H?58X8__9V>MK4W\O2[IAU\I@/J1@5C^"1O
M\."Z/6\N[FYSZJ\SE?\ QW:/PK3U@_Z"$_YZ2HO_ (\"?T!JUN:(J*H1 HZ
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M7=[;>'O!^N3ZMJ$]W>7JVUR9KEC&\1608,?W,C8IW8W$@DDYJNNJ:L@\/:S
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M?^@A:?\ ?Y?\:+,"Y15/^UM-_P"@A:?]_E_QH_M;3?\ H(6G_?Y?\:+,")-
MT:/4_P"TTTBP74"Q;[4+9!+DC!._&<X/K4NHZ1IFKQI'J>G6EZB'<BW,"R!3
MZ@,#BC^UM-_Z"%I_W^7_ !H_M;3?^@A:?]_E_P :+,!PTVQ6"V@6RMA#:L&M
MXQ$NV$@8!08PI ) QZT^6SM;BX@N)K:&2>W),,CQ@M&2,$J3R,CCBHO[6TW_
M *"%I_W^7_&C^UM-_P"@A:?]_E_QHLP,]O!GA9V+-X:T8L3DDV$62?\ OFM1
M]/LI+..S>T@:UCV;(3&"B[2"N%Q@8(&/3 J/^UM-_P"@A:?]_E_QH_M;3?\
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M6+BTMKP1"YMX9Q%(LL?FH&V.OW6&>A'8]14/]K:;_P!!"T_[_+_C1_:VF_\
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M^B/_ (DU:W+&44459(4444 %0W=I!?V4]G<IO@GC:*1,D;E88(R.1P>U344
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M5::C:12+J.J?;W8Y5OLZQ;1Z87K7/67C;&FZK)?);2W&G $FSDS%,&.%VGG
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M_"%:1_S\:W_X/+W_ ..UT5% '._\(5I'_/QK?_@\O?\ X[1_PA6D?\_&M_\
M@\O?_CM=%10!SO\ PA6D?\_&M_\ @\O?_CM'_"%:1_S\:W_X/+W_ ..UT5%
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M,<I#Y1?8/3<6R:ZNBAJZM?\ %@Z::Y=?O9BZ;H!M;01WU]/>S;B?.WO'QV&
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ME8>&8/%+:I!J>D%7C$<5HAC 1\KAEP>O!Z#O6:A)<M^AA&E47)S65GMVU?\
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M4VD7,EYHMA=3$&6:WCD<@8&2H)_G6MUS6ZG3>/M+=;%RBBBJ- HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L#[+/\
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MH^G_ /@,G^%%%#2>X.,7NB_%%'#$L44:1QH-JHHP /0"J'_"/:)_T!]/_P#
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MP:KP:+I5M,LT&F644J\J\<"JP^A HHHLMP<8MW:+%U9VM]$(KNVAN(P=P25
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M ?3_ /P&3_"BBAI/<'&+W1?CBCAA6**-$B5=JHHP /0#TJA_PCVB?] ?3_\
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$F4?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>32
<FILENAME>rptx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T16:10:22.9304+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="rptx-20221231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails2" xlink:href="rptx-20221231.xsd#DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="rptx-20221231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="rptx-20221231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="rptx-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureLeasesSummaryOfLeaseCostsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:href="rptx-20221231.xsd#DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="rptx_ResearchAndDevelopmentTaxCreditsReceivable" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_IncomeTaxReceivable" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivables" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchAndDevelopmentTaxCreditsReceivable" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="rptx_RevenueFromCollaborationAgreements" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RevenueFromCollaborationAgreements" xlink:label="rptx_RevenueFromCollaborationAgreements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rptx_ChangeInFairValueOfPreferredStockTrancheObligation" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForLoanAndLeaseLosses" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rptx_ForeignCurrencyTransactionGainLoss" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable" order="11" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rptx_IncreaseDecreaseInCollaborationRevenueReceivable" order="12" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="13" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="14" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="15" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="16" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent" order="17" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxes" order="18" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet" order="19" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="20" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan" xlink:label="rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ChangeInFairValueOfPreferredStockTrancheObligation" xlink:label="rptx_ChangeInFairValueOfPreferredStockTrancheObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLoanAndLeaseLosses" xlink:label="us-gaap_ProvisionForLoanAndLeaseLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyTransactionGainLoss" xlink:label="rptx_ForeignCurrencyTransactionGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable" xlink:label="rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInCollaborationRevenueReceivable" xlink:label="rptx_IncreaseDecreaseInCollaborationRevenueReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent" xlink:label="rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet" xlink:label="rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="rptx_AccruedResearchAndDevelopmentExpenseCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="rptx_AccruedPropertyAndEquipmentPurchases" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="rptx_AccruedExpensesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="rptx_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccruedPropertyAndEquipmentPurchases" xlink:label="rptx_AccruedPropertyAndEquipmentPurchases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="rptx_IncomeTaxReconciliationStateTaxes" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges" xlink:label="rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation" xlink:label="rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxReconciliationStateTaxes" xlink:label="rptx_IncomeTaxReconciliationStateTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_IncomeTaxLosses" xlink:to="rptx_IncomeTaxLossesExpireOne" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_IncomeTaxLosses" xlink:to="rptx_IncomeTaxLossesExpireTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_IncomeTaxLosses" xlink:to="rptx_IncomeTaxLossesExpireThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_IncomeTaxLosses" xlink:to="rptx_IncomeTaxLossesExpireFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_IncomeTaxLosses" xlink:to="rptx_IncomeTaxLossesExpireFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_IncomeTaxLosses" xlink:to="rptx_IncomeTaxLossesExpireSix" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLosses" xlink:label="rptx_IncomeTaxLosses"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireOne" xlink:label="rptx_IncomeTaxLossesExpireOne"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireTwo" xlink:label="rptx_IncomeTaxLossesExpireTwo"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireThree" xlink:label="rptx_IncomeTaxLossesExpireThree"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireFour" xlink:label="rptx_IncomeTaxLossesExpireFour"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireFive" xlink:label="rptx_IncomeTaxLossesExpireFive"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireSix" xlink:label="rptx_IncomeTaxLossesExpireSix"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_InvestmentTaxCredits" xlink:to="rptx_InvestmentTaxCreditsExpireOne" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_InvestmentTaxCredits" xlink:to="rptx_InvestmentTaxCreditsExpireTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_InvestmentTaxCredits" xlink:to="rptx_InvestmentTaxCreditsExpireThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_InvestmentTaxCredits" xlink:to="rptx_InvestmentTaxCreditsExpireFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_InvestmentTaxCredits" xlink:to="rptx_InvestmentTaxCreditsExpireFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_InvestmentTaxCredits" xlink:to="rptx_InvestmentTaxCreditsExpireSix" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rptx_InvestmentTaxCredits" xlink:to="rptx_InvestmentTaxCreditsExpireSeven" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCredits" xlink:label="rptx_InvestmentTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireOne" xlink:label="rptx_InvestmentTaxCreditsExpireOne"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireTwo" xlink:label="rptx_InvestmentTaxCreditsExpireTwo"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireThree" xlink:label="rptx_InvestmentTaxCreditsExpireThree"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireFour" xlink:label="rptx_InvestmentTaxCreditsExpireFour"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireFive" xlink:label="rptx_InvestmentTaxCreditsExpireFive"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireSix" xlink:label="rptx_InvestmentTaxCreditsExpireSix"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireSeven" xlink:label="rptx_InvestmentTaxCreditsExpireSeven"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rptx_DeferredTaxLiabilitiesOperatingLeaseLiability" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rptx_DeferredTaxAssetsShareBasedCompensationCost" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="11" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits" xlink:label="rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets" xlink:label="rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:label="rptx_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities" xlink:label="rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxAssetsShareBasedCompensationCost" xlink:label="rptx_DeferredTaxAssetsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInSecondYear" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInThirdYear" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInFourthYear" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInFifthYear" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>33
<FILENAME>rptx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T16:10:22.6887+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationReceivable" xlink:label="rptx_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OfficeAndLaboratorySpaceMember" xlink:label="rptx_OfficeAndLaboratorySpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CombinedLicensesMember" xlink:label="rptx_CombinedLicensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent" xlink:label="rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AffiliateOfBristolMyersSquibbCompanyMember" xlink:label="rptx_AffiliateOfBristolMyersSquibbCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInvestmentIncomeReceivable" xlink:label="us-gaap_AccruedInvestmentIncomeReceivable"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SpecialtyScreeningServicesMember" xlink:label="rptx_SpecialtyScreeningServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_LicenseAgreementsAbstract" xlink:label="rptx_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireOne" xlink:label="rptx_IncomeTaxLossesExpireOne"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate" xlink:label="rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireTwo" xlink:label="rptx_IncomeTaxLossesExpireTwo"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationTermExpirationPeriod" xlink:label="rptx_CollaborationTermExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="rptx_AccruedExpensesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet" xlink:label="rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_MilestonesPayments" xlink:label="rptx_MilestonesPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="us-gaap_StandbyLettersOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationAndLicenseAgreementMember" xlink:label="rptx_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_EstimatedSharesIssuableUnderTheEsppMember" xlink:label="rptx_EstimatedSharesIssuableUnderTheEsppMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PreferredStockNoncumulativeDividendRatePercentage" xlink:label="rptx_PreferredStockNoncumulativeDividendRatePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyRiskTable" xlink:label="rptx_ForeignCurrencyRiskTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" xlink:label="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FairValueAssetsTransfersBetweenAllLevels" xlink:label="rptx_FairValueAssetsTransfersBetweenAllLevels"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OrganizationAndNatureOfBusinessLineItems" xlink:label="rptx_OrganizationAndNatureOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireFive" xlink:label="rptx_IncomeTaxLossesExpireFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember" xlink:label="rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ShareIssuanceCostsPolicyTextBlock" xlink:label="rptx_ShareIssuanceCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CommercialMilestonesMember" xlink:label="rptx_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="rptx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireThree" xlink:label="rptx_IncomeTaxLossesExpireThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchServicesAndRentPaidMember" xlink:label="rptx_ResearchServicesAndRentPaidMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLosses" xlink:label="rptx_IncomeTaxLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember" xlink:label="rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquitySharesAuthorizedUnlimited" xlink:label="rptx_TemporaryEquitySharesAuthorizedUnlimited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits" xlink:label="rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxAssetsShareBasedCompensationCost" xlink:label="rptx_DeferredTaxAssetsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting" xlink:label="rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_COVID19PandemicPolicyTextBlock" xlink:label="rptx_COVID19PandemicPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationRevenueReceived" xlink:label="rptx_CollaborationRevenueReceived"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ContractualObligationsPaid" xlink:label="rptx_ContractualObligationsPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares" xlink:label="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RevenueRemainingPerformanceObligationNetAmount" xlink:label="rptx_RevenueRemainingPerformanceObligationNetAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SalesAgreementMember" xlink:label="rptx_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SeriesAConvertiblePreferredSharesMember" xlink:label="rptx_SeriesAConvertiblePreferredSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireFour" xlink:label="rptx_IncomeTaxLossesExpireFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OptionsToLicenseDruggableTargetsMember" xlink:label="rptx_OptionsToLicenseDruggableTargetsMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase" xlink:label="rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare" xlink:label="rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SeriesBConvertiblePreferredSharesMember" xlink:label="rptx_SeriesBConvertiblePreferredSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TransferOfClinicalTrialMaterialsMember" xlink:label="rptx_TransferOfClinicalTrialMaterialsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_LesseeOperatingLeaseExpirationMonthAndYear" xlink:label="rptx_LesseeOperatingLeaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireThree" xlink:label="rptx_InvestmentTaxCreditsExpireThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FairValueOfVestedOptions" xlink:label="rptx_FairValueOfVestedOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FollowOnOfferingMember" xlink:label="rptx_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepurchaseOfEquity" xlink:label="us-gaap_ProceedsFromRepurchaseOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC" xlink:label="stpr_CA-QC"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RevenueFromCollaborationAgreements" xlink:label="rptx_RevenueFromCollaborationAgreements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RestrictedCashMember" xlink:label="rptx_RestrictedCashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance" xlink:label="rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InitialUpfrontFeePayment" xlink:label="rptx_InitialUpfrontFeePayment"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_StateAndUsFederalMember" xlink:label="rptx_StateAndUsFederalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan" xlink:label="rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RepareTherapeuticsIncorporationOptionPlanMember" xlink:label="rptx_RepareTherapeuticsIncorporationOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FirstTrancheMember" xlink:label="rptx_FirstTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities" xlink:label="rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireOne" xlink:label="rptx_InvestmentTaxCreditsExpireOne"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCredits" xlink:label="rptx_InvestmentTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorizedUnlimited" xlink:label="us-gaap_PreferredStockSharesAuthorizedUnlimited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SecondTrancheMember" xlink:label="rptx_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OptionsToPurchaseCommonSharesMember" xlink:label="rptx_OptionsToPurchaseCommonSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TheUniversityOfTexasMDAndersonCancerCenterMember" xlink:label="rptx_TheUniversityOfTexasMDAndersonCancerCenterMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxExaminationYearSubjectToExamination" xlink:label="rptx_IncomeTaxExaminationYearSubjectToExamination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RestrictedCashPolicyTextBlock" xlink:label="rptx_RestrictedCashPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OnoPharmaceuticalCompanyLimitedMember" xlink:label="rptx_OnoPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:label="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchDevelopmentAndRegulatoryMilestonesMember" xlink:label="rptx_ResearchDevelopmentAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SecondAmendmentAgreement" xlink:label="rptx_SecondAmendmentAgreement"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ScientificResearchAndExperimentalDevelopmentExpenditures" xlink:label="rptx_ScientificResearchAndExperimentalDevelopmentExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchAndDevelopmentTaxCreditsReceivable" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CommitmentsAndContingenciesDisclosureTable" xlink:label="rptx_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireSeven" xlink:label="rptx_InvestmentTaxCreditsExpireSeven"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_NewYorkUniversityAgreementMember" xlink:label="rptx_NewYorkUniversityAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="country_CA"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OtherReceivablesMember" xlink:label="rptx_OtherReceivablesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation" xlink:label="rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyRiskLineItems" xlink:label="rptx_ForeignCurrencyRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_NetIncomeLossAndComprehensiveIncomeLoss" xlink:label="rptx_NetIncomeLossAndComprehensiveIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering" xlink:label="rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_NumberOfTranches" xlink:label="rptx_NumberOfTranches"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock" xlink:label="rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_NumberOfOperatingLeases" xlink:label="rptx_NumberOfOperatingLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="country_CH"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:label="rptx_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_LicenseAgreementsDisclosureTextBlock" xlink:label="rptx_LicenseAgreementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxReconciliationStateTaxes" xlink:label="rptx_IncomeTaxReconciliationStateTaxes"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="rptx_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TaxCreditCarryForwardExpirationYear" xlink:label="rptx_TaxCreditCarryForwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable" xlink:label="rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses" xlink:label="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_GrantOfLicenseMember" xlink:label="rptx_GrantOfLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OrganizationAndNatureOfBusinessTable" xlink:label="rptx_OrganizationAndNatureOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_BroadInstituteIncMember" xlink:label="rptx_BroadInstituteIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ScheduleOfFinancialPositionExposureTableTextBlock" xlink:label="rptx_ScheduleOfFinancialPositionExposureTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares" xlink:label="rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock" xlink:label="rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationRevenuePaymentReceivable" xlink:label="rptx_CollaborationRevenuePaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear" xlink:label="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges" xlink:label="rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireSix" xlink:label="rptx_InvestmentTaxCreditsExpireSix"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyRiskAbstract" xlink:label="rptx_ForeignCurrencyRiskAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccrualPotentialMilestoneAndRoyaltyPayments" xlink:label="rptx_AccrualPotentialMilestoneAndRoyaltyPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ConvertiblePreferredSharesDisclosureTextBlock" xlink:label="rptx_ConvertiblePreferredSharesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchAndDevelopmentServicesMember" xlink:label="rptx_ResearchAndDevelopmentServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireFive" xlink:label="rptx_InvestmentTaxCreditsExpireFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchAndDevelopmentTaxCreditsReceivableMember" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ChangeInFairValueOfPreferredStockTrancheObligation" xlink:label="rptx_ChangeInFairValueOfPreferredStockTrancheObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue" xlink:label="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationTermExtendedPeriod" xlink:label="rptx_CollaborationTermExtendedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="rptx_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PreclinicalStudiesAndClinicalTrialsMember" xlink:label="rptx_PreclinicalStudiesAndClinicalTrialsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxesTable" xlink:label="rptx_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OptionsToLicenseUndruggableTargetMember" xlink:label="rptx_OptionsToLicenseUndruggableTargetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses" xlink:label="rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ProductResearchActivityMember" xlink:label="rptx_ProductResearchActivityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" xlink:label="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ImplicitInterestRate" xlink:label="rptx_ImplicitInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ScheduleOfDepreciationExpenseTableTextBlock" xlink:label="rptx_ScheduleOfDepreciationExpenseTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ContractualObligationPeriod" xlink:label="rptx_ContractualObligationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares" xlink:label="rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxesLineItems" xlink:label="rptx_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_GrossProceedsFromInitialPublicOffering" xlink:label="rptx_GrossProceedsFromInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLoanAndLeaseLosses" xlink:label="us-gaap_ProvisionForLoanAndLeaseLosses"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInCollaborationRevenueReceivable" xlink:label="rptx_IncreaseDecreaseInCollaborationRevenueReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireTwo" xlink:label="rptx_InvestmentTaxCreditsExpireTwo"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA" xlink:label="stpr_MA"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_BristolMyersSquibbCompanyMember" xlink:label="rptx_BristolMyersSquibbCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering" xlink:label="rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent" xlink:label="rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones" xlink:label="rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:label="us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_LeaseLiabilitiesMember" xlink:label="rptx_LeaseLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ContractualObligationAmountPerYear" xlink:label="rptx_ContractualObligationAmountPerYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyTransactionGainLoss" xlink:label="rptx_ForeignCurrencyTransactionGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares" xlink:label="rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets" xlink:label="rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ClinicalTrialMaterialsMember" xlink:label="rptx_ClinicalTrialMaterialsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember" xlink:label="rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue" xlink:label="rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AdditionalClinicalDevelopmentPlanMember" xlink:label="rptx_AdditionalClinicalDevelopmentPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SmallerReportingCompanyPolicyTextBlock" xlink:label="rptx_SmallerReportingCompanyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccruedPropertyAndEquipmentPurchases" xlink:label="rptx_AccruedPropertyAndEquipmentPurchases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PercentageOfDepreciationUSDAgainstCanadianDollar" xlink:label="rptx_PercentageOfDepreciationUSDAgainstCanadianDollar"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination" xlink:label="rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CompletionOfContinuingTrialsMember" xlink:label="rptx_CompletionOfContinuingTrialsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireFour" xlink:label="rptx_InvestmentTaxCreditsExpireFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchActivitiesMember" xlink:label="rptx_ResearchActivitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireSix" xlink:label="rptx_IncomeTaxLossesExpireSix"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock" xlink:label="rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_MarketableSecuritiesMember" xlink:label="rptx_MarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ProductRptxOptionsToLicenseDruggableTargetMember" xlink:label="rptx_ProductRptxOptionsToLicenseDruggableTargetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Provision for Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office And Laboratory Space [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory space.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CombinedLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined Licenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CombinedLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Combined Licenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CombinedLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined Licenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liability current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax examination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Year under Examination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum aggregate amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows From Financing Activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AffiliateOfBristolMyersSquibbCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Affiliate of Bristol Myers Squibb Company [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AffiliateOfBristolMyersSquibbCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Affiliate of Bristol Myers Squibb</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AffiliateOfBristolMyersSquibbCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Affiliate of Bristol Myers Squibb Company.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedInvestmentIncomeReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedInvestmentIncomeReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Investment Income Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SpecialtyScreeningServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specialty Screening Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SpecialtyScreeningServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specialty Screening Services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SpecialtyScreeningServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specialty screening services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases incurred but not yet paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized to be issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_LicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_LicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Assets, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2042</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Losses Expire One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax losses expire one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly vesting rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Monthly Vesting Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment monthly vesting rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2041</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Losses Expire Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax losses expire two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationTermExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration term expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationTermExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Term Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationTermExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration term expiration period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other liabilities current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liability net.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_MilestonesPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestones payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_MilestonesPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestones Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_MilestonesPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestones payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, No Par Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StandbyLettersOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Standby Letters of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StandbyLettersOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Standby Letters of Credit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows for operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares under the 2020 Employee Share Purchase Plan, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_EstimatedSharesIssuableUnderTheEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated shares issuable under the ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_EstimatedSharesIssuableUnderTheEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Shares Issuable Under the ESPP [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_EstimatedSharesIssuableUnderTheEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated shares issuable under the ESPP.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, No Par Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred shares, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PreferredStockNoncumulativeDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares, noncumulative dividends</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PreferredStockNoncumulativeDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Noncumulative Dividend Rate Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PreferredStockNoncumulativeDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock noncumulative dividend rate percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Notes Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ForeignCurrencyRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Risk [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ForeignCurrencyRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Risk [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ForeignCurrencyRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency risk.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Roche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hoffmann La Roche Inc And F Hoffmann La Roche Ltd</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hoffmann La Roche Inc and F Hoffmann La Roche Ltd [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hoffmann La Roche Inc and F Hoffmann La Roche Ltd</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_FairValueAssetsTransfersBetweenAllLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, transfers between levels</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_FairValueAssetsTransfersBetweenAllLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Transfers Between All Levels</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_FairValueAssetsTransfersBetweenAllLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, assets, transfers between all levels.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OrganizationAndNatureOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Nature of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OrganizationAndNatureOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OrganizationAndNatureOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and nature of business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OfficeBuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Building [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OfficeBuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax benefit - foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split of share capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Nature of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2038</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Losses Expire Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax losses expire five.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares under the 2020 Employee Share Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements, Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting on Monthly Basis at Rate of 1/36th</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds Included In Cash And Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds Included in Cash and Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Money Market Funds Included in Cash and Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ShareIssuanceCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ShareIssuanceCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Issuance Costs Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ShareIssuanceCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2040</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Losses Expire Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax losses expire three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of common shares outstanding-basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding-basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Intrinsic value, Outstanding at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Intrinsic value, Outstanding at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchServicesAndRentPaidMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Services and Rent Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchServicesAndRentPaidMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Services And Rent Paid [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchServicesAndRentPaidMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research services and rent paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beneficial conversion feature</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Beneficial Conversion Feature</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax losses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts payable and accrued expense and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Expense and Other Current Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable and Accrued Expense and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquitySharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquitySharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized Unlimited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquitySharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity shares authorized unlimited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net federal investment tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net Federal Investment Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets net federal investment tax credits.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting on First Anniversary Date of Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxAssetsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxAssetsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxAssetsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets share based compensation cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares ceased granting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Payment Award Number Of Shares Ceased Granting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by payment award number of shares ceased granting.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred shares into an equivalent number of common shares, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_COVID19PandemicPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Pandemic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_COVID19PandemicPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Pandemic Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_COVID19PandemicPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID19 pandemic.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationRevenueReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationRevenueReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationRevenueReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Revenue received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ContractualObligationsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligations Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ContractualObligationsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual obligations paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common shareholders--diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Diluted Net Loss Per Share in Attributable to Common Shareholders Indicate to Anti Diluted Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of convertible preferred shares, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gain (Loss) On Derivatives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred shares converted into common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred shares converted into common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares, no par value per share; unlimited shares authorized as of December 31, 2022 and December 31, 2021, respectively; 0 shares issued and outstanding as of December 31, 2022, and December 31, 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Liability exposure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrant and conversion into common shares, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Warrants And Conversion Into Common Stock During Period Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of warrants and conversion into common stock during period, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RevenueRemainingPerformanceObligationNetAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research service payments entitled to be received, total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RevenueRemainingPerformanceObligationNetAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Net Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RevenueRemainingPerformanceObligationNetAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue remaining performance obligation net amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SeriesAConvertiblePreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SeriesAConvertiblePreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SeriesAConvertiblePreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A Convertible Preferred Shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in net loss currency risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInFourthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInFourthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued upon exercise of warrants outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments at Fair Value, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net financial position exposure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments at Fair Value, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2039</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Losses Expire Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax losses expire four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OptionsToLicenseDruggableTargetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to License Druggable Targets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OptionsToLicenseDruggableTargetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To License Druggable Targets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OptionsToLicenseDruggableTargetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to license druggable targets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Expenses And Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price of shares as percentage of fair market value of common stock on date of purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Price Of Shares As Percentage Of Fair Market Value Of Common Stock On Date Of Purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price of shares as percentage of fair market value of common stock on date of purchase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Options Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate proceeds from exercise of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of common shares in follow-on offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred shares, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price per share as minimum percentage of fair value of common share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Per Share As Minimum Percentage Of Fair Value Of Common Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price per share as minimum percentage of fair value of common share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SeriesBConvertiblePreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SeriesBConvertiblePreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SeriesBConvertiblePreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B Convertible Preferred Shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TransferOfClinicalTrialMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer of Clinical Trial Materials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TransferOfClinicalTrialMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transfer of Clinical Trial Materials [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TransferOfClinicalTrialMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transfer of Clinical Trial Materials [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and Off-Balance Sheet Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Transaction Price Performance Obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses from transactions with related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration revenue receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_LesseeOperatingLeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_LesseeOperatingLeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Expiration Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_LesseeOperatingLeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease expiration month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2040</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Tax Credits Expire Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment tax credits expire three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_FairValueOfVestedOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of options vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_FairValueOfVestedOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Vested Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_FairValueOfVestedOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of vested options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of common shares outstanding-diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding-diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow On Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRepurchaseOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from (Repurchase of) Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRepurchaseOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from (Repurchase of) Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRepurchaseOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received from purchases under ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Shares Issuable Upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA-QC_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Montreal, Quebec</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA-QC_lbl" xlink:role="http://www.xbrl.org/2003/role/label">QUEBEC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense related to unvested stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RevenueFromCollaborationAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RevenueFromCollaborationAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Collaboration Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RevenueFromCollaborationAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue from collaboration agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents cash at beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions used to Determine Grant Date Fair Value under ESPP Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents and Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock initially reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Initially Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock capital shares initially reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InitialUpfrontFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial upfront fee payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InitialUpfrontFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Upfront Fee Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InitialUpfrontFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial upfront fee payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_StateAndUsFederalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal and state research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_StateAndUsFederalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State And US Federal [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_StateAndUsFederalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">State and us federal.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure Of Cash Flow Information:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common shares under the 2020 Employee Share Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock under Two Thousand Twenty Employee Share Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock under two thousand twenty employee share purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RepareTherapeuticsIncorporationOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RepareTherapeuticsIncorporationOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repare Therapeutics Incorporation Option Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RepareTherapeuticsIncorporationOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repare Therapeutics Incorporation option plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_FirstTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Tranche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_FirstTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_FirstTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First tranche.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax (expense) benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Tax (benefit) expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expense and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Accrued Expense And Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities accrued expense and other liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2042</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Tax Credits Expire One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment tax credits expire one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment tax credits.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments entitled to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research service payments entitled to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred stock shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury bills</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Bill Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SecondTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Tranche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SecondTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SecondTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second tranche.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Assistance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to extend, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OptionsToPurchaseCommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OptionsToPurchaseCommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OptionsToPurchaseCommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity balance, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity balance, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TheUniversityOfTexasMDAndersonCancerCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MDACC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TheUniversityOfTexasMDAndersonCancerCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The University of Texas M.D. Anderson Cancer Center [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TheUniversityOfTexasMDAndersonCancerCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The University of Texas M. D. Anderson Cancer Center.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxExaminationYearSubjectToExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax examination, year subject to examination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxExaminationYearSubjectToExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Year Subject to Examination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxExaminationYearSubjectToExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax examination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities and Other Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RestrictedCashPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RestrictedCashPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_RestrictedCashPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted Cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OnoPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ono Pharmaceutical Company Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OnoPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ono pharmaceutical company limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OnoPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ono Pharmaceutical Co., Ltd.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual increase in number of shares available for issuance maximum number of common stock issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Increase In Number Of Shares Available For Issuance Maximum Number Of Common Stock Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase in number of shares available for issuance maximum number of common stock issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchDevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research, Development and Regulatory Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchDevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Development And Regulatory Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchDevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research development and regulatory milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Intrinsic value, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL SHAREHOLDERS' EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities, Accumulated unrealized loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Cash and Cash Equivalents and Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, no par value per share; unlimited shares authorized as of December 31, 2022 and December 31, 2021; 42,036,193 and 41,850,162 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on available-for-sale marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SecondAmendmentAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second amendment agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SecondAmendmentAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Amendment Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SecondAmendmentAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second amendment agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScientificResearchAndExperimentalDevelopmentExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scientific research and experimental development expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScientificResearchAndExperimentalDevelopmentExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scientific Research And Experimental Development Expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScientificResearchAndExperimentalDevelopmentExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scientific Research and experimental development expenditures.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D costs capitalized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets exposure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credits Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credits receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront payment received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireSeven_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2036</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireSeven_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Tax Credits Expire Seven</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireSeven_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment tax credits expire seven.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_NewYorkUniversityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NYU Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_NewYorkUniversityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New York University Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_NewYorkUniversityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New York university agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canada</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CANADA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OtherReceivablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OtherReceivablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OtherReceivablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other receivables.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Long-Term Contracts or Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital gain income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Capital Gain Income Equity Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation capital gain income
Equity compensation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ForeignCurrencyRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Risk [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ForeignCurrencyRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Risk [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ForeignCurrencyRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency risk.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financial assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total financial assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Loss Before Provision for Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Segment Reporting Information By Segment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_NetIncomeLossAndComprehensiveIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_NetIncomeLossAndComprehensiveIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss and comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_NetIncomeLossAndComprehensiveIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss And Comprehensive Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_NetIncomeLossAndComprehensiveIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net income loss and comprehensive income loss.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credits Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credits.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercised options, weighted-average exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate fluctuations on cash held</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold gross proceeds of initial public offering that triggers automatic conversion of preferred convertible shares into common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Terms Of Conversion Trigger Minimum Gross Proceeds From Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, terms of conversion, trigger, minimum gross proceeds from initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax basis of property and equipment in excess of carrying values</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_NumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of tranches</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_NumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Tranches</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_NumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of tranches.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net research and development expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Losses Expire</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Recognized Tax Benefit Of Losses Expire Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of recognized tax benefit of losses expire.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_NumberOfOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_NumberOfOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_NumberOfOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of operating leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents cash at beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CH_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Switzerland</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CH_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SWITZERLAND</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Stock Options Determined on Grant Date Using Black Scholes Option-Pricing Model</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Options Unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net and Right-of-Use Assets by Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Options Unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AffiliatedEntityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Affiliated Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AffiliatedEntityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Affiliated Entity [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows From Operating Activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued and prepaid research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued and Prepaid Research and Development Expenses [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and Prepaid Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities operating lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_LicenseAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_LicenseAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_LicenseAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (Decrease) Increase In Cash And Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash interest received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash interest received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial nonrefundable upfront fee payment received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Collaborators</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxReconciliationStateTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxReconciliationStateTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation State Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxReconciliationStateTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation state taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expense current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forward expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carry Forward Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carry forward expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development tax credits receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction of research and development expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Research And Development Tax Credits Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">increase decrease in research and development tax credits receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Commissions And Estimated Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting commissions and estimated offering expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting Commissions And Estimated Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_GrantOfLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant of License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_GrantOfLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant of License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_GrantOfLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant of license member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OrganizationAndNatureOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Nature Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OrganizationAndNatureOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OrganizationAndNatureOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and nature of business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense related to unvested stock options, weighted-average remaining vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years) , Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_BroadInstituteIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Broad Institute, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_BroadInstituteIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Broad Institute, Inc. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_BroadInstituteIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Broad institute, inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Commitments to Settle Contractual Obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScheduleOfFinancialPositionExposureTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Position Exposure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScheduleOfFinancialPositionExposureTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Financial Position Exposure Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScheduleOfFinancialPositionExposureTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of financial position exposure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in additional paid-in capital as exercised options credited to common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Share Based Payment Arrangement Exercised Options Credited To Common Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional paid in capital share-based payment arrangement exercised options credited to common shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments under Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal investment tax credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net (accretion)/amortization of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premiums on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of Underwriters Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Other Operating Lease Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Other Operating Lease Information Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of other operating lease information.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows From Investing Activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation, to be Paid, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Following years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationRevenuePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue payment receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationRevenuePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue Payment Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationRevenuePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Revenue Payment Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual increase in number of shares available for issuance as percentage of outstanding shares common stock on final day of preceding calendar year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Increase In Number Of Shares Available For Issuance As Percentage On Outstanding Shares Of Common Stock On Final Day Of Preceding Calendar Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase in number of shares available for issuance as percentage on outstanding shares of common stock on final day of preceding calendar year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting charges not deductible for tax purposes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Rate Reconciliation Nondeductible Expense Accounting Charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax rate reconciliation, nondeductible expense, accounting charges.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due to Related Parties, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due to Related Parties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Due to related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SHAREHOLDERS' EQUITY:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized and unrealized gain (loss) on foreign exchange</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Transaction Gain (Loss), before Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Preferred Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current income tax provision - foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireSix_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2037</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireSix_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment tax credits expire six.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireSix_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Tax Credits Expire Six</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ForeignCurrencyRiskAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Risk [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ForeignCurrencyRiskAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency risk.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccrualPotentialMilestoneAndRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrual of potential future milestone or royalty payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccrualPotentialMilestoneAndRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrual Potential Milestone And Royalty Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccrualPotentialMilestoneAndRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrual potential milestone and royalty payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ConvertiblePreferredSharesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ConvertiblePreferredSharesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Shares Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ConvertiblePreferredSharesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred shares disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development, net of tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, expected dividend yield assumed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, existence of option to terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Terminate [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchAndDevelopmentServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchAndDevelopmentServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchAndDevelopmentServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Development Services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2038</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Tax Credits Expire Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment tax credits expire five.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Tax Credits Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credits Receivable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credits receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ChangeInFairValueOfPreferredStockTrancheObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of Series A Preferred Shares tranche obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ChangeInFairValueOfPreferredStockTrancheObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Preferred Stock Tranche Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ChangeInFairValueOfPreferredStockTrancheObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of preferred stock tranche obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of warrant into common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrant and conversion into common shares,Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Warrants And Conversion Into Common Stock During Period Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of warrants and conversion into common stock during period, value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Intrinsic value, Options unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Outstanding at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Outstanding at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationTermExtendedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Term Extended Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationTermExtendedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration term extended period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CollaborationTermExtendedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration term extended period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for new operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, conversion basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Conversion Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Property Plant Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Options Unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PreclinicalStudiesAndClinicalTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preclinical Studies and Clinical Trials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PreclinicalStudiesAndClinicalTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preclinical Studies And Clinical Trials [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PreclinicalStudiesAndClinicalTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preclinical studies and clinical trials.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of common shares in initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax at statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OptionsToLicenseUndruggableTargetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to License Undruggable Targets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OptionsToLicenseUndruggableTargetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To License Undruggable Target [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_OptionsToLicenseUndruggableTargetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to license undruggable target.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Options Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Preferred Shares, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) In Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction of research and development expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidation Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Issuance of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options granted to employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ProductResearchActivityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Research Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ProductResearchActivityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Research Activity [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ProductResearchActivityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product research activity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Aggregate Fair Value of Series A Preferred Share Tranche Obligation using Level 3 Inputs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Employee Share Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Employee Share Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty employee share purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ImplicitInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Implicit interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ImplicitInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Implicit Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ImplicitInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Implicit interest rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, Date of Incorporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity incorporation, date of incorporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Outstanding at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Outstanding at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScheduleOfDepreciationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of depreciation expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScheduleOfDepreciationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Depreciation Expense [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScheduleOfDepreciationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Depreciation Expense Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest or penalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common shareholders--basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash taxes paid, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ContractualObligationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual obligation period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ContractualObligationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ContractualObligationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual obligation period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Savings Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash dividends declared or paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of holder of preferred shares election to convert the preferred shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Holders Of Preferred Shares Election To Convert Preferred Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of holders of preferred shares election to convert preferred shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_GrossProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_GrossProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_GrossProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForLoanAndLeaseLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for Loan and Lease Losses, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForLoanAndLeaseLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForLoanAndLeaseLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Provision for Loan and Lease Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInCollaborationRevenueReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Collaboration revenue receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInCollaborationRevenueReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease in Collaboration Revenue Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncreaseDecreaseInCollaborationRevenueReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in collaboration revenue receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2041</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Tax Credits Expire Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment tax credits expire two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Lives of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Estimated Useful Lives Of Property And Equipment Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of estimated useful lives of property and equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss for the year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cambridge, Massachusetts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_BristolMyersSquibbCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bristol-Myers Squibb Company.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_BristolMyersSquibbCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bristol Myers Squibb Company [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_BristolMyersSquibbCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bristol-Myers Squibb Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_BristolMyersSquibbCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Affiliate of Bristol Myers Squibb</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographic Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold price per share in initial public offering that triggers automatic conversion of preferred convertible shares into common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Terms Of Conversion Trigger Minimum Price Per Share In Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, terms of conversion, trigger, minimum price per share in initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses or other impairment charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan employer non matching contribution percent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Non Matching Contribution Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of non-matching employer contributions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Matching contribution expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement milestone and royalty payments upon achievement of certain clinical and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Milestone And Royalty Payments Upon Achievement Of Certain Clinical And Commercial Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement milestone and royalty payments upon achievement of certain clinical and commercial milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canada</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_LeaseLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_LeaseLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_LeaseLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ContractualObligationAmountPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual obligation per year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ContractualObligationAmountPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation Amount Per Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ContractualObligationAmountPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual obligation amount per year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of vested stock options, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ForeignCurrencyTransactionGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ForeignCurrencyTransactionGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency transaction gain (loss).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ForeignCurrencyTransactionGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign exchange loss (gain)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of liquidation rights waived by holder of preferred shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Liquidation Rights Waived By Holder Of Preferred Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of liquidation rights waived by holder of preferred shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of vested stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease right-of-use assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ClinicalTrialMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Trial Materials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ClinicalTrialMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial Materials [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ClinicalTrialMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Trial Materials [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible preferred shares term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expense And Other Current Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expense and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated period of completion of trials to get revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Period of Completion of Trials To Get Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated period of completion of trials to get revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AdditionalClinicalDevelopmentPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Clinical Development Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AdditionalClinicalDevelopmentPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Clinical Development Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AdditionalClinicalDevelopmentPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Clinical Development Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SmallerReportingCompanyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Smaller Reporting Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SmallerReportingCompanyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Smaller Reporting Company Policy Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SmallerReportingCompanyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Smaller reporting company policy text block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds on disposal of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedPropertyAndEquipmentPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued property and equipment purchases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedPropertyAndEquipmentPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Property and Equipment Purchases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_AccruedPropertyAndEquipmentPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued property and equipment purchases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Available-for-sale marketable securities unrealized losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PercentageOfDepreciationUSDAgainstCanadianDollar_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of depreciation USD against Canadian dollar</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PercentageOfDepreciationUSDAgainstCanadianDollar_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Depreciation U S D Against Canadian Dollar</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_PercentageOfDepreciationUSDAgainstCanadianDollar_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of depreciation USD against Canadian dollar.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity adjustments to additional paid in capital termination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Adjustments To Additional Paid In Capital Termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Tranche 3 termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CompletionOfContinuingTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Completion of Continuing Trials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CompletionOfContinuingTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Completion of Continuing Trials [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_CompletionOfContinuingTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Completion of Continuing Trials [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized, Unlimited [Fixed List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computed income tax recovery</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2039</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Tax Credits Expire Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_InvestmentTaxCreditsExpireFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment tax credits expire four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Activities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ResearchActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research activities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireSix_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2037</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireSix_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Losses Expire Six</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_IncomeTaxLossesExpireSix_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax losses expire six.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Investment Tax Credits Expire</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Investment Tax Credits Expire Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of investment tax credits expire.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred shares into an equivalent number of common shares, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ProductRptxOptionsToLicenseDruggableTargetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product RPTX Options to License Druggable Target</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ProductRptxOptionsToLicenseDruggableTargetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product RPTX Options To License Druggable Target [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rptx_ProductRptxOptionsToLicenseDruggableTargetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product RPTX options to license druggable target.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant off-balance sheet risk, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Financial Instruments, off-Balance-Sheet Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted share units to employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of assets, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average exercise price of stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_CollaborationReceivable" xlink:to="rptx_CollaborationReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_OfficeAndLaboratorySpaceMember" xlink:to="rptx_OfficeAndLaboratorySpaceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_CombinedLicensesMember" xlink:to="rptx_CombinedLicensesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent" xlink:to="rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:to="us-gaap_IncomeTaxExaminationYearUnderExamination_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_AffiliateOfBristolMyersSquibbCompanyMember" xlink:to="rptx_AffiliateOfBristolMyersSquibbCompanyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedInvestmentIncomeReceivable" xlink:to="us-gaap_AccruedInvestmentIncomeReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_SpecialtyScreeningServicesMember" xlink:to="rptx_SpecialtyScreeningServicesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_LicenseAgreementsAbstract" xlink:to="rptx_LicenseAgreementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncomeTaxLossesExpireOne" xlink:to="rptx_IncomeTaxLossesExpireOne_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate" xlink:to="rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncomeTaxLossesExpireTwo" xlink:to="rptx_IncomeTaxLossesExpireTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_CollaborationTermExpirationPeriod" xlink:to="rptx_CollaborationTermExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="rptx_AccruedExpensesAndOtherLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet" xlink:to="rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_MilestonesPayments" xlink:to="rptx_MilestonesPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StandbyLettersOfCreditMember" xlink:to="us-gaap_StandbyLettersOfCreditMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_CollaborationAndLicenseAgreementMember" xlink:to="rptx_CollaborationAndLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_EstimatedSharesIssuableUnderTheEsppMember" xlink:to="rptx_EstimatedSharesIssuableUnderTheEsppMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_PreferredStockNoncumulativeDividendRatePercentage" xlink:to="rptx_PreferredStockNoncumulativeDividendRatePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAdditions" xlink:to="us-gaap_DeferredRevenueAdditions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ForeignCurrencyRiskTable" xlink:to="rptx_ForeignCurrencyRiskTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" xlink:to="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_FairValueAssetsTransfersBetweenAllLevels" xlink:to="rptx_FairValueAssetsTransfersBetweenAllLevels_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="rptx_OrganizationAndNatureOfBusinessLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficeBuildingMember" xlink:to="srt_OfficeBuildingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncomeTaxLossesExpireFive" xlink:to="rptx_IncomeTaxLossesExpireFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember" xlink:to="rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ShareIssuanceCostsPolicyTextBlock" xlink:to="rptx_ShareIssuanceCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_CommercialMilestonesMember" xlink:to="rptx_CommercialMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="rptx_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncomeTaxLossesExpireThree" xlink:to="rptx_IncomeTaxLossesExpireThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ResearchServicesAndRentPaidMember" xlink:to="rptx_ResearchServicesAndRentPaidMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncomeTaxLosses" xlink:to="rptx_IncomeTaxLosses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember" xlink:to="rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_TemporaryEquitySharesAuthorizedUnlimited" xlink:to="rptx_TemporaryEquitySharesAuthorizedUnlimited_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits" xlink:to="rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_DeferredTaxAssetsShareBasedCompensationCost" xlink:to="rptx_DeferredTaxAssetsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting" xlink:to="rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_COVID19PandemicPolicyTextBlock" xlink:to="rptx_COVID19PandemicPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_CollaborationRevenueReceived" xlink:to="rptx_CollaborationRevenueReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ContractualObligationsPaid" xlink:to="rptx_ContractualObligationsPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares" xlink:to="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_RevenueRemainingPerformanceObligationNetAmount" xlink:to="rptx_RevenueRemainingPerformanceObligationNetAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_SalesAgreementMember" xlink:to="rptx_SalesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_SeriesAConvertiblePreferredSharesMember" xlink:to="rptx_SeriesAConvertiblePreferredSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFourthYear" xlink:to="us-gaap_ContractualObligationDueInFourthYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" xlink:to="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncomeTaxLossesExpireFour" xlink:to="rptx_IncomeTaxLossesExpireFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReceivable" xlink:to="us-gaap_IncomeTaxReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_OptionsToLicenseDruggableTargetsMember" xlink:to="rptx_OptionsToLicenseDruggableTargetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase" xlink:to="rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare" xlink:to="rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_SeriesBConvertiblePreferredSharesMember" xlink:to="rptx_SeriesBConvertiblePreferredSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_TransferOfClinicalTrialMaterialsMember" xlink:to="rptx_TransferOfClinicalTrialMaterialsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_LesseeOperatingLeaseExpirationMonthAndYear" xlink:to="rptx_LesseeOperatingLeaseExpirationMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_InvestmentTaxCreditsExpireThree" xlink:to="rptx_InvestmentTaxCreditsExpireThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_FairValueOfVestedOptions" xlink:to="rptx_FairValueOfVestedOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_FollowOnOfferingMember" xlink:to="rptx_FollowOnOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepurchaseOfEquity" xlink:to="us-gaap_ProceedsFromRepurchaseOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA-QC" xlink:to="stpr_CA-QC_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_RevenueFromCollaborationAgreements" xlink:to="rptx_RevenueFromCollaborationAgreements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_RestrictedCashMember" xlink:to="rptx_RestrictedCashMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance" xlink:to="rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_InitialUpfrontFeePayment" xlink:to="rptx_InitialUpfrontFeePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_StateAndUsFederalMember" xlink:to="rptx_StateAndUsFederalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan" xlink:to="rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_RepareTherapeuticsIncorporationOptionPlanMember" xlink:to="rptx_RepareTherapeuticsIncorporationOptionPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_FirstTrancheMember" xlink:to="rptx_FirstTrancheMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities" xlink:to="rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_InvestmentTaxCreditsExpireOne" xlink:to="rptx_InvestmentTaxCreditsExpireOne_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_InvestmentTaxCredits" xlink:to="rptx_InvestmentTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorizedUnlimited" xlink:to="us-gaap_PreferredStockSharesAuthorizedUnlimited_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryBillSecuritiesMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_SecondTrancheMember" xlink:to="rptx_SecondTrancheMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_OptionsToPurchaseCommonSharesMember" xlink:to="rptx_OptionsToPurchaseCommonSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_TheUniversityOfTexasMDAndersonCancerCenterMember" xlink:to="rptx_TheUniversityOfTexasMDAndersonCancerCenterMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncomeTaxExaminationYearSubjectToExamination" xlink:to="rptx_IncomeTaxExaminationYearSubjectToExamination_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_RestrictedCashPolicyTextBlock" xlink:to="rptx_RestrictedCashPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_OnoPharmaceuticalCompanyLimitedMember" xlink:to="rptx_OnoPharmaceuticalCompanyLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:to="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ResearchDevelopmentAndRegulatoryMilestonesMember" xlink:to="rptx_ResearchDevelopmentAndRegulatoryMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_SecondAmendmentAgreement" xlink:to="rptx_SecondAmendmentAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ScientificResearchAndExperimentalDevelopmentExpenditures" xlink:to="rptx_ScientificResearchAndExperimentalDevelopmentExpenditures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:to="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ResearchAndDevelopmentTaxCreditsReceivable" xlink:to="rptx_ResearchAndDevelopmentTaxCreditsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_CommitmentsAndContingenciesDisclosureTable" xlink:to="rptx_CommitmentsAndContingenciesDisclosureTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_InvestmentTaxCreditsExpireSeven" xlink:to="rptx_InvestmentTaxCreditsExpireSeven_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_NewYorkUniversityAgreementMember" xlink:to="rptx_NewYorkUniversityAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_OtherReceivablesMember" xlink:to="rptx_OtherReceivablesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation" xlink:to="rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ForeignCurrencyRiskLineItems" xlink:to="rptx_ForeignCurrencyRiskLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_NetIncomeLossAndComprehensiveIncomeLoss" xlink:to="rptx_NetIncomeLossAndComprehensiveIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock" xlink:to="rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering" xlink:to="rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_NumberOfTranches" xlink:to="rptx_NumberOfTranches_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock" xlink:to="rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_NumberOfOperatingLeases" xlink:to="rptx_NumberOfOperatingLeases_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CH" xlink:to="country_CH_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFifthYear" xlink:to="us-gaap_ContractualObligationDueInFifthYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliatedEntityMember" xlink:to="srt_AffiliatedEntityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock" xlink:to="rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:to="rptx_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_LicenseAgreementsDisclosureTextBlock" xlink:to="rptx_LicenseAgreementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncomeTaxReconciliationStateTaxes" xlink:to="rptx_IncomeTaxReconciliationStateTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="rptx_AccruedResearchAndDevelopmentExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_TaxCreditCarryForwardExpirationYear" xlink:to="rptx_TaxCreditCarryForwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable" xlink:to="rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses" xlink:to="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_GrantOfLicenseMember" xlink:to="rptx_GrantOfLicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_OrganizationAndNatureOfBusinessTable" xlink:to="rptx_OrganizationAndNatureOfBusinessTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_BroadInstituteIncMember" xlink:to="rptx_BroadInstituteIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ScheduleOfFinancialPositionExposureTableTextBlock" xlink:to="rptx_ScheduleOfFinancialPositionExposureTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares" xlink:to="rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock" xlink:to="rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueAfterFifthYear" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_CollaborationRevenuePaymentReceivable" xlink:to="rptx_CollaborationRevenuePaymentReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear" xlink:to="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges" xlink:to="rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_InvestmentTaxCreditsExpireSix" xlink:to="rptx_InvestmentTaxCreditsExpireSix_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ForeignCurrencyRiskAbstract" xlink:to="rptx_ForeignCurrencyRiskAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_AccrualPotentialMilestoneAndRoyaltyPayments" xlink:to="rptx_AccrualPotentialMilestoneAndRoyaltyPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ConvertiblePreferredSharesDisclosureTextBlock" xlink:to="rptx_ConvertiblePreferredSharesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ResearchAndDevelopmentServicesMember" xlink:to="rptx_ResearchAndDevelopmentServicesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_InvestmentTaxCreditsExpireFive" xlink:to="rptx_InvestmentTaxCreditsExpireFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ResearchAndDevelopmentTaxCreditsReceivableMember" xlink:to="rptx_ResearchAndDevelopmentTaxCreditsReceivableMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ChangeInFairValueOfPreferredStockTrancheObligation" xlink:to="rptx_ChangeInFairValueOfPreferredStockTrancheObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue" xlink:to="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_CollaborationTermExtendedPeriod" xlink:to="rptx_CollaborationTermExtendedPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rptx_CommitmentsAndContingenciesDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_PreclinicalStudiesAndClinicalTrialsMember" xlink:to="rptx_PreclinicalStudiesAndClinicalTrialsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncomeTaxesTable" xlink:to="rptx_IncomeTaxesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_OptionsToLicenseUndruggableTargetMember" xlink:to="rptx_OptionsToLicenseUndruggableTargetMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses" xlink:to="rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ProductResearchActivityMember" xlink:to="rptx_ProductResearchActivityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" xlink:to="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ImplicitInterestRate" xlink:to="rptx_ImplicitInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ScheduleOfDepreciationExpenseTableTextBlock" xlink:to="rptx_ScheduleOfDepreciationExpenseTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ContractualObligationPeriod" xlink:to="rptx_ContractualObligationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockCash" xlink:to="us-gaap_DividendsCommonStockCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares" xlink:to="rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="rptx_IncomeTaxesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_GrossProceedsFromInitialPublicOffering" xlink:to="rptx_GrossProceedsFromInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForLoanAndLeaseLosses" xlink:to="us-gaap_ProvisionForLoanAndLeaseLosses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncreaseDecreaseInCollaborationRevenueReceivable" xlink:to="rptx_IncreaseDecreaseInCollaborationRevenueReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_InvestmentTaxCreditsExpireTwo" xlink:to="rptx_InvestmentTaxCreditsExpireTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_BristolMyersSquibbCompanyMember" xlink:to="rptx_BristolMyersSquibbCompanyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering" xlink:to="rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent" xlink:to="rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones" xlink:to="rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:to="us-gaap_ForeignCurrencyDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_LeaseLiabilitiesMember" xlink:to="rptx_LeaseLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ContractualObligationAmountPerYear" xlink:to="rptx_ContractualObligationAmountPerYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ForeignCurrencyTransactionGainLoss" xlink:to="rptx_ForeignCurrencyTransactionGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares" xlink:to="rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets" xlink:to="rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ClinicalTrialMaterialsMember" xlink:to="rptx_ClinicalTrialMaterialsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember" xlink:to="rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue" xlink:to="rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_AdditionalClinicalDevelopmentPlanMember" xlink:to="rptx_AdditionalClinicalDevelopmentPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_SmallerReportingCompanyPolicyTextBlock" xlink:to="rptx_SmallerReportingCompanyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_AccruedPropertyAndEquipmentPurchases" xlink:to="rptx_AccruedPropertyAndEquipmentPurchases_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_PercentageOfDepreciationUSDAgainstCanadianDollar" xlink:to="rptx_PercentageOfDepreciationUSDAgainstCanadianDollar_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination" xlink:to="rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_CompletionOfContinuingTrialsMember" xlink:to="rptx_CompletionOfContinuingTrialsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_InvestmentTaxCreditsExpireFour" xlink:to="rptx_InvestmentTaxCreditsExpireFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ResearchActivitiesMember" xlink:to="rptx_ResearchActivitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_IncomeTaxLossesExpireSix" xlink:to="rptx_IncomeTaxLossesExpireSix_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock" xlink:to="rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_MarketableSecuritiesMember" xlink:to="rptx_MarketableSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rptx_ProductRptxOptionsToLicenseDruggableTargetMember" xlink:to="rptx_ProductRptxOptionsToLicenseDruggableTargetMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>34
<FILENAME>rptx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T16:10:20.0434+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.reparerx.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:rptx="http://www.reparerx.com/20221231" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" namespace="http://fasb.org/us-types/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rptx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rptx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rptx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rptx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails2" id="DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails2">
        <link:definition>100020 - Disclosure - Leases - Summary of Future Minimum Lease Payments under Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" id="StatementConsolidatedStatementsOfShareholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical" id="StatementConsolidatedStatementsOfShareholdersEquityParenthetical">
        <link:definition>100060 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness" id="Role_DisclosureOrganizationAndNatureOfBusiness">
        <link:definition>100080 - Disclosure - Organization and Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecurities" id="Role_DisclosureCashAndCashEquivalentsAndMarketableSecurities">
        <link:definition>100110 - Disclosure - Cash and Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100120 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100130 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreements" id="Role_DisclosureLicenseAgreements">
        <link:definition>100140 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100150 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredShares" id="Role_DisclosureConvertiblePreferredShares">
        <link:definition>100160 - Disclosure - Convertible Preferred Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquity1" id="DisclosureShareholdersEquity1">
        <link:definition>100170 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensation" id="DisclosureSharebasedCompensation">
        <link:definition>100180 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureEmployeeSavingsPlan" id="DisclosureEmployeeSavingsPlan">
        <link:definition>100190 - Disclosure - Employee Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborations" id="Role_DisclosureCollaborations">
        <link:definition>100200 - Disclosure - Collaborations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100210 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100220 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGovernmentAssistance" id="Role_DisclosureGovernmentAssistance">
        <link:definition>100230 - Disclosure - Government Assistance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100240 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRisk" id="Role_DisclosureCurrencyRisk">
        <link:definition>100250 - Disclosure - Currency Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedParties" id="Role_DisclosureRelatedParties">
        <link:definition>100260 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformation" id="Role_DisclosureGeographicInformation">
        <link:definition>100270 - Disclosure - Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100280 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100290 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100300 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100310 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesTables" id="Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesTables">
        <link:definition>100320 - Disclosure - Cash and Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100330 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100340 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100350 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesTables" id="Role_DisclosureConvertiblePreferredSharesTables">
        <link:definition>100360 - Disclosure - Convertible Preferred Shares (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationTables" id="DisclosureSharebasedCompensationTables">
        <link:definition>100370 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsTables" id="Role_DisclosureCollaborationsTables">
        <link:definition>100380 - Disclosure -  Collaborations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100390 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100400 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100410 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskTables" id="Role_DisclosureCurrencyRiskTables">
        <link:definition>100420 - Disclosure - Currency Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationTables" id="Role_DisclosureGeographicInformationTables">
        <link:definition>100430 - Disclosure - Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" id="Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Organization and Nature of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
        <link:definition>100460 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100470 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails" id="Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails">
        <link:definition>100490 - Disclosure - Cash and Cash Equivalents and Marketable Securities - Summary of Cash and Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails" id="Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Cash and Cash Equivalents and Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100510 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails" id="DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails">
        <link:definition>100520 - Disclosure - Property and Equipment, Net - Schedule of Depreciation Expense Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100530 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail" id="Role_DisclosureLicenseAgreementsAdditionalInformationDetail">
        <link:definition>100540 - Disclosure - License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails" id="Role_DisclosureLeasesSummaryOfLeaseCostsDetails">
        <link:definition>100560 - Disclosure - Leases - Summary of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherOperatingLeaseInformationDetails" id="Role_DisclosureLeasesSummaryOfOtherOperatingLeaseInformationDetails">
        <link:definition>100570 - Disclosure - Leases - Summary of Other Operating Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails" id="Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails">
        <link:definition>100580 - Disclosure - Leases - Summary of Future Minimum Lease Payments under Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Convertible Preferred Shares - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails" id="Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails">
        <link:definition>100600 - Disclosure - Convertible Preferred Shares - Summary of Preferred Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" id="DisclosureShareholdersEquityAdditionalInformationDetails">
        <link:definition>100610 - Disclosure - Shareholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" id="DisclosureSharebasedCompensationAdditionalInformationDetails">
        <link:definition>100620 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails" id="DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails">
        <link:definition>100630 - Disclosure - Share-Based Compensation - Schedule of Assumptions used to Determine Grant Date Fair Value under ESPP Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails" id="DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails">
        <link:definition>100640 - Disclosure - Share-Based Compensation - Schedule of Fair Value of Stock Options Determined on Grant Date Using Black Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails" id="DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails">
        <link:definition>100650 - Disclosure - Share-Based Compensation - Schedule of Share Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails" id="DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails">
        <link:definition>100660 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense for All Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails" id="DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails">
        <link:definition>100670 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Type of Award (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureEmployeeSavingsPlanAdditionalInformationDetails" id="DisclosureEmployeeSavingsPlanAdditionalInformationDetails">
        <link:definition>100680 - Disclosure - Employee Savings Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails" id="Role_DisclosureCollaborationsAdditionalInformationDetails">
        <link:definition>100690 - Disclosure - Collaborations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails" id="DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails">
        <link:definition>100700 - Disclosure - Collaborations - Schedule of Transaction Price Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails">
        <link:definition>100710 - Disclosure - Income Taxes - Summary of Loss Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails">
        <link:definition>100720 - Disclosure - Income Taxes - Summary of provision for income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails">
        <link:definition>100730 - Disclosure - Income Taxes - Summary of Reconciliation of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100740 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails" id="Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails">
        <link:definition>100750 - Disclosure - Income Taxes - Summary of Losses Expire (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails" id="Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails">
        <link:definition>100760 - Disclosure - Income Taxes - Summary of Investment Tax Credits Expire (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails">
        <link:definition>100770 - Disclosure - Income Taxes - Summary of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100780 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails" id="Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails">
        <link:definition>100790 - Disclosure - Net Loss per Share - Computation of Diluted Net Loss Per Share in Attributable to Common Shareholders Indicate to Anti Diluted Effect (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGovernmentAssistanceAdditionalInformationDetails" id="Role_DisclosureGovernmentAssistanceAdditionalInformationDetails">
        <link:definition>100800 - Disclosure - Government Assistance - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails">
        <link:definition>100810 - Disclosure - Commitments and Contingencies - Schedule of Commitments to Settle Contractual Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100820 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails" id="Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails">
        <link:definition>100830 - Disclosure - Currency Risk - Schedule of Financial Position Exposure (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskAdditionalInformationDetails" id="Role_DisclosureCurrencyRiskAdditionalInformationDetails">
        <link:definition>100840 - Disclosure - Currency Risk - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails" id="Role_DisclosureRelatedPartiesAdditionalInformationDetails">
        <link:definition>100850 - Disclosure - Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails" id="Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails">
        <link:definition>100860 - Disclosure - Geographic Information - Schedule of Property and Equipment, Net by Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails" id="Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails">
        <link:definition>100870 - Disclosure - Geographic Information - Schedule of Right-of-Use Assets by Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails" id="DisclosureGeographicInformationAdditionalInformationDetails">
        <link:definition>100880 - Disclosure - Geographic Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100890 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="rptx_ForeignCurrencyRiskAbstract" name="ForeignCurrencyRiskAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_LicenseAgreementsAbstract" name="LicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_AccrualPotentialMilestoneAndRoyaltyPayments" name="AccrualPotentialMilestoneAndRoyaltyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_AccruedExpensesAndOtherLiabilitiesCurrent" name="AccruedExpensesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_AccruedPropertyAndEquipmentPurchases" name="AccruedPropertyAndEquipmentPurchases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares" name="AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear" name="AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" name="AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_ChangeInFairValueOfPreferredStockTrancheObligation" name="ChangeInFairValueOfPreferredStockTrancheObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_CollaborationReceivable" name="CollaborationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_CollaborationRevenuePaymentReceivable" name="CollaborationRevenuePaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_CollaborationRevenueReceived" name="CollaborationRevenueReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_CollaborationTermExpirationPeriod" name="CollaborationTermExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_CollaborationTermExtendedPeriod" name="CollaborationTermExtendedPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance" name="CommonStockCapitalSharesInitiallyReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rptx_ContractualObligationAmountPerYear" name="ContractualObligationAmountPerYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_ContractualObligationPeriod" name="ContractualObligationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_ContractualObligationsPaid" name="ContractualObligationsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits" name="DeferredTaxAssetsNetFederalInvestmentTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets" name="DeferredTaxAssetsOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_DeferredTaxAssetsShareBasedCompensationCost" name="DeferredTaxAssetsShareBasedCompensationCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities" name="DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_DeferredTaxLiabilitiesOperatingLeaseLiability" name="DeferredTaxLiabilitiesOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent" name="DefinedContributionPlanEmployerNonMatchingContributionPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue" name="EstimatedPeriodOfCompletionOfTrialsToGetRevenue" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare" name="ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_FairValueAssetsTransfersBetweenAllLevels" name="FairValueAssetsTransfersBetweenAllLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_FairValueOfVestedOptions" name="FairValueOfVestedOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_ForeignCurrencyTransactionGainLoss" name="ForeignCurrencyTransactionGainLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_GrossProceedsFromInitialPublicOffering" name="GrossProceedsFromInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_ImplicitInterestRate" name="ImplicitInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_IncomeTaxExaminationYearSubjectToExamination" name="IncomeTaxExaminationYearSubjectToExamination" type="dtr-types:gYearListItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_IncomeTaxLosses" name="IncomeTaxLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_IncomeTaxLossesExpireFive" name="IncomeTaxLossesExpireFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_IncomeTaxLossesExpireFour" name="IncomeTaxLossesExpireFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_IncomeTaxLossesExpireOne" name="IncomeTaxLossesExpireOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_IncomeTaxLossesExpireSix" name="IncomeTaxLossesExpireSix" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_IncomeTaxLossesExpireThree" name="IncomeTaxLossesExpireThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_IncomeTaxLossesExpireTwo" name="IncomeTaxLossesExpireTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges" name="IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation" name="IncomeTaxReconciliationCapitalGainIncomeEquityCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_IncomeTaxReconciliationStateTaxes" name="IncomeTaxReconciliationStateTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" name="IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_IncreaseDecreaseInCollaborationRevenueReceivable" name="IncreaseDecreaseInCollaborationRevenueReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent" name="IncreaseDecreaseInOperatingLeaseLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet" name="IncreaseDecreaseInOperatingLeaseLiabilityNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses" name="IncreaseDecreaseInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable" name="IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_InitialUpfrontFeePayment" name="InitialUpfrontFeePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_InvestmentTaxCredits" name="InvestmentTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_InvestmentTaxCreditsExpireFive" name="InvestmentTaxCreditsExpireFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_InvestmentTaxCreditsExpireFour" name="InvestmentTaxCreditsExpireFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_InvestmentTaxCreditsExpireOne" name="InvestmentTaxCreditsExpireOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_InvestmentTaxCreditsExpireSeven" name="InvestmentTaxCreditsExpireSeven" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_InvestmentTaxCreditsExpireSix" name="InvestmentTaxCreditsExpireSix" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_InvestmentTaxCreditsExpireThree" name="InvestmentTaxCreditsExpireThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_InvestmentTaxCreditsExpireTwo" name="InvestmentTaxCreditsExpireTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares" name="IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue" name="IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_LesseeOperatingLeaseExpirationMonthAndYear" name="LesseeOperatingLeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones" name="LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_MilestonesPayments" name="MilestonesPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_NetIncomeLossAndComprehensiveIncomeLoss" name="NetIncomeLossAndComprehensiveIncomeLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_NumberOfOperatingLeases" name="NumberOfOperatingLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_NumberOfTranches" name="NumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_PercentageOfDepreciationUSDAgainstCanadianDollar" name="PercentageOfDepreciationUSDAgainstCanadianDollar" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares" name="PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares" name="PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_PreferredStockNoncumulativeDividendRatePercentage" name="PreferredStockNoncumulativeDividendRatePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan" name="ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase" name="PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_ResearchAndDevelopmentTaxCreditsReceivable" name="ResearchAndDevelopmentTaxCreditsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_RevenueFromCollaborationAgreements" name="RevenueFromCollaborationAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_RevenueRemainingPerformanceObligationNetAmount" name="RevenueRemainingPerformanceObligationNetAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_ScientificResearchAndExperimentalDevelopmentExpenditures" name="ScientificResearchAndExperimentalDevelopmentExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_SecondAmendmentAgreement" name="SecondAmendmentAgreement" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting" name="ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate" name="ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_TaxCreditCarryForwardExpirationYear" name="TaxCreditCarryForwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination" name="TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_TemporaryEquitySharesAuthorizedUnlimited" name="TemporaryEquitySharesAuthorizedUnlimited" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering" name="TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering" name="TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses" name="UnderwritingCommissionsAndEstimatedOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rptx_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_ForeignCurrencyRiskLineItems" name="ForeignCurrencyRiskLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_OrganizationAndNatureOfBusinessLineItems" name="OrganizationAndNatureOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember" name="AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember" name="AccruedExpenseAndOtherCurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_AdditionalClinicalDevelopmentPlanMember" name="AdditionalClinicalDevelopmentPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_AffiliateOfBristolMyersSquibbCompanyMember" name="AffiliateOfBristolMyersSquibbCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_BristolMyersSquibbCompanyMember" name="BristolMyersSquibbCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_BroadInstituteIncMember" name="BroadInstituteIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_ClinicalTrialMaterialsMember" name="ClinicalTrialMaterialsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_CombinedLicensesMember" name="CombinedLicensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_CommercialMilestonesMember" name="CommercialMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_CompletionOfContinuingTrialsMember" name="CompletionOfContinuingTrialsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_EstimatedSharesIssuableUnderTheEsppMember" name="EstimatedSharesIssuableUnderTheEsppMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_FirstTrancheMember" name="FirstTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_FollowOnOfferingMember" name="FollowOnOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_GrantOfLicenseMember" name="GrantOfLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" name="HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_LeaseLiabilitiesMember" name="LeaseLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_MarketableSecuritiesMember" name="MarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember" name="MoneyMarketFundsIncludedInCashAndCashEquivalentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_NewYorkUniversityAgreementMember" name="NewYorkUniversityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_OfficeAndLaboratorySpaceMember" name="OfficeAndLaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_OnoPharmaceuticalCompanyLimitedMember" name="OnoPharmaceuticalCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_OptionsToLicenseDruggableTargetsMember" name="OptionsToLicenseDruggableTargetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_OptionsToLicenseUndruggableTargetMember" name="OptionsToLicenseUndruggableTargetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_OptionsToPurchaseCommonSharesMember" name="OptionsToPurchaseCommonSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_OtherReceivablesMember" name="OtherReceivablesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_PreclinicalStudiesAndClinicalTrialsMember" name="PreclinicalStudiesAndClinicalTrialsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_ProductResearchActivityMember" name="ProductResearchActivityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_ProductRptxOptionsToLicenseDruggableTargetMember" name="ProductRptxOptionsToLicenseDruggableTargetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_RepareTherapeuticsIncorporationOptionPlanMember" name="RepareTherapeuticsIncorporationOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_ResearchActivitiesMember" name="ResearchActivitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_ResearchAndDevelopmentServicesMember" name="ResearchAndDevelopmentServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_ResearchAndDevelopmentTaxCreditsReceivableMember" name="ResearchAndDevelopmentTaxCreditsReceivableMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_ResearchDevelopmentAndRegulatoryMilestonesMember" name="ResearchDevelopmentAndRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_ResearchServicesAndRentPaidMember" name="ResearchServicesAndRentPaidMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_RestrictedCashMember" name="RestrictedCashMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_SalesAgreementMember" name="SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_SecondTrancheMember" name="SecondTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_SeriesAConvertiblePreferredSharesMember" name="SeriesAConvertiblePreferredSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_SeriesBConvertiblePreferredSharesMember" name="SeriesBConvertiblePreferredSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_SpecialtyScreeningServicesMember" name="SpecialtyScreeningServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_StateAndUsFederalMember" name="StateAndUsFederalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_TheUniversityOfTexasMDAndersonCancerCenterMember" name="TheUniversityOfTexasMDAndersonCancerCenterMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_TransferOfClinicalTrialMaterialsMember" name="TransferOfClinicalTrialMaterialsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" name="TwoThousandTwentyEmployeeSharePurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_COVID19PandemicPolicyTextBlock" name="COVID19PandemicPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock" name="ResearchAndDevelopmentTaxCreditsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_RestrictedCashPolicyTextBlock" name="RestrictedCashPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_ShareIssuanceCostsPolicyTextBlock" name="ShareIssuanceCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_ForeignCurrencyRiskTable" name="ForeignCurrencyRiskTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_OrganizationAndNatureOfBusinessTable" name="OrganizationAndNatureOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_ScheduleOfFinancialPositionExposureTableTextBlock" name="ScheduleOfFinancialPositionExposureTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock" name="SummaryOfInvestmentTaxCreditsExpireTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock" name="SummaryOfOtherOperatingLeaseInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock" name="SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock" name="AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_ConvertiblePreferredSharesDisclosureTextBlock" name="ConvertiblePreferredSharesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_LicenseAgreementsDisclosureTextBlock" name="LicenseAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_ScheduleOfDepreciationExpenseTableTextBlock" name="ScheduleOfDepreciationExpenseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rptx_SmallerReportingCompanyPolicyTextBlock" name="SmallerReportingCompanyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>35
<FILENAME>rptx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T16:10:19.4170+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="rptx-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="rptx-20221231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="rptx-20221231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="rptx-20221231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:href="rptx-20221231.xsd#StatementConsolidatedStatementsOfShareholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical" xlink:href="rptx-20221231.xsd#StatementConsolidatedStatementsOfShareholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="rptx-20221231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness" xlink:href="rptx-20221231.xsd#Role_DisclosureOrganizationAndNatureOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="rptx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="rptx-20221231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecurities" xlink:href="rptx-20221231.xsd#Role_DisclosureCashAndCashEquivalentsAndMarketableSecurities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="rptx-20221231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="rptx-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreements" xlink:href="rptx-20221231.xsd#Role_DisclosureLicenseAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:href="rptx-20221231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredShares" xlink:href="rptx-20221231.xsd#Role_DisclosureConvertiblePreferredShares" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquity1" xlink:href="rptx-20221231.xsd#DisclosureShareholdersEquity1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensation" xlink:href="rptx-20221231.xsd#DisclosureSharebasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureEmployeeSavingsPlan" xlink:href="rptx-20221231.xsd#DisclosureEmployeeSavingsPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborations" xlink:href="rptx-20221231.xsd#Role_DisclosureCollaborations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="rptx-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="rptx-20221231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGovernmentAssistance" xlink:href="rptx-20221231.xsd#Role_DisclosureGovernmentAssistance" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="rptx-20221231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRisk" xlink:href="rptx-20221231.xsd#Role_DisclosureCurrencyRisk" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedParties" xlink:href="rptx-20221231.xsd#Role_DisclosureRelatedParties" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformation" xlink:href="rptx-20221231.xsd#Role_DisclosureGeographicInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="rptx-20221231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="rptx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="rptx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="rptx-20221231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesTables" xlink:href="rptx-20221231.xsd#Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="rptx-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="rptx-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="rptx-20221231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesTables" xlink:href="rptx-20221231.xsd#Role_DisclosureConvertiblePreferredSharesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationTables" xlink:href="rptx-20221231.xsd#DisclosureSharebasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsTables" xlink:href="rptx-20221231.xsd#Role_DisclosureCollaborationsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="rptx-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="rptx-20221231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="rptx-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskTables" xlink:href="rptx-20221231.xsd#Role_DisclosureCurrencyRiskTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationTables" xlink:href="rptx-20221231.xsd#Role_DisclosureGeographicInformationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="rptx-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails" xlink:href="rptx-20221231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail" xlink:href="rptx-20221231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureLeasesSummaryOfLeaseCostsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherOperatingLeaseInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureLeasesSummaryOfOtherOperatingLeaseInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#DisclosureShareholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#DisclosureSharebasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails" xlink:href="rptx-20221231.xsd#DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails" xlink:href="rptx-20221231.xsd#DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails" xlink:href="rptx-20221231.xsd#DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails" xlink:href="rptx-20221231.xsd#DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails" xlink:href="rptx-20221231.xsd#DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureEmployeeSavingsPlanAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#DisclosureEmployeeSavingsPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureCollaborationsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails" xlink:href="rptx-20221231.xsd#DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:href="rptx-20221231.xsd#DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGovernmentAssistanceAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureGovernmentAssistanceAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureCurrencyRiskAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureRelatedPartiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#DisclosureGeographicInformationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchAndDevelopmentTaxCreditsReceivable" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="rptx_ResearchAndDevelopmentTaxCreditsReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IncomeTaxReceivable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivables" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorizedUnlimited" xlink:label="us-gaap_PreferredStockSharesAuthorizedUnlimited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockNoParValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorizedUnlimited" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RevenueFromCollaborationAgreements" xlink:label="rptx_RevenueFromCollaborationAgreements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="rptx_RevenueFromCollaborationAgreements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" xlink:label="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SeriesAConvertiblePreferredSharesMember" xlink:label="rptx_SeriesAConvertiblePreferredSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FollowOnOfferingMember" xlink:label="rptx_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SeriesBConvertiblePreferredSharesMember" xlink:label="rptx_SeriesBConvertiblePreferredSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination" xlink:label="rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue" xlink:label="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares" xlink:label="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_NetIncomeLossAndComprehensiveIncomeLoss" xlink:label="rptx_NetIncomeLossAndComprehensiveIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_21"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_22"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_23"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_24"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rptx_SeriesAConvertiblePreferredSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rptx_FollowOnOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rptx_SeriesBConvertiblePreferredSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rptx_NetIncomeLossAndComprehensiveIncomeLoss" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SeriesAConvertiblePreferredSharesMember" xlink:label="rptx_SeriesAConvertiblePreferredSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FollowOnOfferingMember" xlink:label="rptx_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SeriesBConvertiblePreferredSharesMember" xlink:label="rptx_SeriesBConvertiblePreferredSharesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rptx_SeriesAConvertiblePreferredSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rptx_FollowOnOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rptx_SeriesBConvertiblePreferredSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan" xlink:label="rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ChangeInFairValueOfPreferredStockTrancheObligation" xlink:label="rptx_ChangeInFairValueOfPreferredStockTrancheObligation"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable" xlink:label="rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLoanAndLeaseLosses" xlink:label="us-gaap_ProvisionForLoanAndLeaseLosses"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInCollaborationRevenueReceivable" xlink:label="rptx_IncreaseDecreaseInCollaborationRevenueReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyTransactionGainLoss" xlink:label="rptx_ForeignCurrencyTransactionGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent" xlink:label="rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet" xlink:label="rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rptx_ChangeInFairValueOfPreferredStockTrancheObligation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForLoanAndLeaseLosses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rptx_IncreaseDecreaseInCollaborationRevenueReceivable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rptx_ForeignCurrencyTransactionGainLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxes" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_LicenseAgreementsAbstract" xlink:label="rptx_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_LicenseAgreementsDisclosureTextBlock" xlink:label="rptx_LicenseAgreementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_LicenseAgreementsAbstract" xlink:to="rptx_LicenseAgreementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredShares" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ConvertiblePreferredSharesDisclosureTextBlock" xlink:label="rptx_ConvertiblePreferredSharesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="rptx_ConvertiblePreferredSharesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureEmployeeSavingsPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGovernmentAssistance" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRisk" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyRiskAbstract" xlink:label="rptx_ForeignCurrencyRiskAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:label="us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_ForeignCurrencyRiskAbstract" xlink:to="us-gaap_ForeignCurrencyDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedParties" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SmallerReportingCompanyPolicyTextBlock" xlink:label="rptx_SmallerReportingCompanyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_COVID19PandemicPolicyTextBlock" xlink:label="rptx_COVID19PandemicPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RestrictedCashPolicyTextBlock" xlink:label="rptx_RestrictedCashPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ShareIssuanceCostsPolicyTextBlock" xlink:label="rptx_ShareIssuanceCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rptx_SmallerReportingCompanyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rptx_COVID19PandemicPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rptx_RestrictedCashPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rptx_ShareIssuanceCostsPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ScheduleOfDepreciationExpenseTableTextBlock" xlink:label="rptx_ScheduleOfDepreciationExpenseTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="rptx_ScheduleOfDepreciationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock" xlink:label="rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" xlink:label="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_BristolMyersSquibbCompanyMember" xlink:label="rptx_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rptx_BristolMyersSquibbCompanyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock" xlink:label="rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock" xlink:label="rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyRiskAbstract" xlink:label="rptx_ForeignCurrencyRiskAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ScheduleOfFinancialPositionExposureTableTextBlock" xlink:label="rptx_ScheduleOfFinancialPositionExposureTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_ForeignCurrencyRiskAbstract" xlink:to="rptx_ScheduleOfFinancialPositionExposureTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OrganizationAndNatureOfBusinessLineItems" xlink:label="rptx_OrganizationAndNatureOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OrganizationAndNatureOfBusinessTable" xlink:label="rptx_OrganizationAndNatureOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FollowOnOfferingMember" xlink:label="rptx_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_GrossProceedsFromInitialPublicOffering" xlink:label="rptx_GrossProceedsFromInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses" xlink:label="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="rptx_OrganizationAndNatureOfBusinessTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rptx_FollowOnOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessTable" xlink:to="rptx_OrganizationAndNatureOfBusinessLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="rptx_GrossProceedsFromInitialPublicOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember" xlink:label="rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_MarketableSecuritiesMember" xlink:label="rptx_MarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="rptx_MarketableSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FairValueAssetsTransfersBetweenAllLevels" xlink:label="rptx_FairValueAssetsTransfersBetweenAllLevels"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="rptx_FairValueAssetsTransfersBetweenAllLevels" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_MarketableSecuritiesMember" xlink:label="rptx_MarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="rptx_MarketableSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInvestmentIncomeReceivable" xlink:label="us-gaap_AccruedInvestmentIncomeReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AccruedInvestmentIncomeReceivable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="rptx_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccruedPropertyAndEquipmentPurchases" xlink:label="rptx_AccruedPropertyAndEquipmentPurchases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="rptx_AccruedExpensesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="rptx_AccruedResearchAndDevelopmentExpenseCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="rptx_AccruedPropertyAndEquipmentPurchases" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="rptx_AccruedExpensesAndOtherLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_LicenseAgreementsAbstract" xlink:label="rptx_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones" xlink:label="rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_NewYorkUniversityAgreementMember" xlink:label="rptx_NewYorkUniversityAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccrualPotentialMilestoneAndRoyaltyPayments" xlink:label="rptx_AccrualPotentialMilestoneAndRoyaltyPayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_LicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rptx_NewYorkUniversityAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_AccrualPotentialMilestoneAndRoyaltyPayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC" xlink:label="stpr_CA-QC"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_NumberOfOperatingLeases" xlink:label="rptx_NumberOfOperatingLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="us-gaap_StandbyLettersOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OfficeAndLaboratorySpaceMember" xlink:label="rptx_OfficeAndLaboratorySpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA" xlink:label="stpr_MA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_LesseeOperatingLeaseExpirationMonthAndYear" xlink:label="rptx_LesseeOperatingLeaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ImplicitInterestRate" xlink:label="rptx_ImplicitInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA-QC" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rptx_NumberOfOperatingLeases" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_StandbyLettersOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rptx_OfficeAndLaboratorySpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="srt_OfficeBuildingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rptx_LesseeOperatingLeaseExpirationMonthAndYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PrepaidRent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rptx_ImplicitInterestRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherOperatingLeaseInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquitySharesAuthorizedUnlimited" xlink:label="rptx_TemporaryEquitySharesAuthorizedUnlimited"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FirstTrancheMember" xlink:label="rptx_FirstTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SecondTrancheMember" xlink:label="rptx_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_NumberOfTranches" xlink:label="rptx_NumberOfTranches"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PreferredStockNoncumulativeDividendRatePercentage" xlink:label="rptx_PreferredStockNoncumulativeDividendRatePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering" xlink:label="rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering" xlink:label="rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares" xlink:label="rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares" xlink:label="rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_TemporaryEquitySharesAuthorizedUnlimited" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rptx_FirstTrancheMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rptx_SecondTrancheMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_NumberOfTranches" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_PreferredStockNoncumulativeDividendRatePercentage" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FollowOnOfferingMember" xlink:label="rptx_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SalesAgreementMember" xlink:label="rptx_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses" xlink:label="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rptx_FollowOnOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rptx_SalesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" xlink:label="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RepareTherapeuticsIncorporationOptionPlanMember" xlink:label="rptx_RepareTherapeuticsIncorporationOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting" xlink:label="rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="rptx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance" xlink:label="rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear" xlink:label="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:label="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase" xlink:label="rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare" xlink:label="rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate" xlink:label="rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FairValueOfVestedOptions" xlink:label="rptx_FairValueOfVestedOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares" xlink:label="rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepurchaseOfEquity" xlink:label="us-gaap_ProceedsFromRepurchaseOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rptx_RepareTherapeuticsIncorporationOptionPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rptx_TwoThousandTwentyEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_FairValueOfVestedOptions" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromRepurchaseOfEquity" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" xlink:label="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="rptx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rptx_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" xlink:label="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureEmployeeSavingsPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent" xlink:label="rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationTermExtendedPeriod" xlink:label="rptx_CollaborationTermExtendedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationAndLicenseAgreementMember" xlink:label="rptx_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OnoPharmaceuticalCompanyLimitedMember" xlink:label="rptx_OnoPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchDevelopmentAndRegulatoryMilestonesMember" xlink:label="rptx_ResearchDevelopmentAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SecondAmendmentAgreement" xlink:label="rptx_SecondAmendmentAgreement"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AffiliateOfBristolMyersSquibbCompanyMember" xlink:label="rptx_AffiliateOfBristolMyersSquibbCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CommercialMilestonesMember" xlink:label="rptx_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_BristolMyersSquibbCompanyMember" xlink:label="rptx_BristolMyersSquibbCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AdditionalClinicalDevelopmentPlanMember" xlink:label="rptx_AdditionalClinicalDevelopmentPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" xlink:label="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ClinicalTrialMaterialsMember" xlink:label="rptx_ClinicalTrialMaterialsMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InitialUpfrontFeePayment" xlink:label="rptx_InitialUpfrontFeePayment"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchAndDevelopmentServicesMember" xlink:label="rptx_ResearchAndDevelopmentServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationReceivable" xlink:label="rptx_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CombinedLicensesMember" xlink:label="rptx_CombinedLicensesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationRevenueReceived" xlink:label="rptx_CollaborationRevenueReceived"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_GrantOfLicenseMember" xlink:label="rptx_GrantOfLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_MilestonesPayments" xlink:label="rptx_MilestonesPayments"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ProductResearchActivityMember" xlink:label="rptx_ProductResearchActivityMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationRevenuePaymentReceivable" xlink:label="rptx_CollaborationRevenuePaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ProductRptxOptionsToLicenseDruggableTargetMember" xlink:label="rptx_ProductRptxOptionsToLicenseDruggableTargetMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue" xlink:label="rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RevenueRemainingPerformanceObligationNetAmount" xlink:label="rptx_RevenueRemainingPerformanceObligationNetAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationTermExpirationPeriod" xlink:label="rptx_CollaborationTermExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_CollaborationTermExtendedPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rptx_CollaborationAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rptx_OnoPharmaceuticalCompanyLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_ResearchDevelopmentAndRegulatoryMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_SecondAmendmentAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rptx_AffiliateOfBristolMyersSquibbCompanyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_CommercialMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rptx_BristolMyersSquibbCompanyMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_AdditionalClinicalDevelopmentPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_ClinicalTrialMaterialsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_InitialUpfrontFeePayment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_ResearchAndDevelopmentServicesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_CollaborationReceivable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_CombinedLicensesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_CollaborationRevenueReceived" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_GrantOfLicenseMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_MilestonesPayments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_ProductResearchActivityMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_CollaborationRevenuePaymentReceivable" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_ProductRptxOptionsToLicenseDruggableTargetMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_RevenueRemainingPerformanceObligationNetAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_CollaborationTermExpirationPeriod" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_BristolMyersSquibbCompanyMember" xlink:label="rptx_BristolMyersSquibbCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchActivitiesMember" xlink:label="rptx_ResearchActivitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" xlink:label="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OptionsToLicenseDruggableTargetsMember" xlink:label="rptx_OptionsToLicenseDruggableTargetsMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OptionsToLicenseUndruggableTargetMember" xlink:label="rptx_OptionsToLicenseUndruggableTargetMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CombinedLicensesMember" xlink:label="rptx_CombinedLicensesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CompletionOfContinuingTrialsMember" xlink:label="rptx_CompletionOfContinuingTrialsMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TransferOfClinicalTrialMaterialsMember" xlink:label="rptx_TransferOfClinicalTrialMaterialsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rptx_BristolMyersSquibbCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_ResearchActivitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_OptionsToLicenseDruggableTargetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_OptionsToLicenseUndruggableTargetMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_CombinedLicensesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_CompletionOfContinuingTrialsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_TransferOfClinicalTrialMaterialsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges" xlink:label="rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation" xlink:label="rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxReconciliationStateTaxes" xlink:label="rptx_IncomeTaxReconciliationStateTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_IncomeTaxReconciliationStateTaxes" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_StateAndUsFederalMember" xlink:label="rptx_StateAndUsFederalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxesTable" xlink:label="rptx_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxesLineItems" xlink:label="rptx_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLosses" xlink:label="rptx_IncomeTaxLosses"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ScientificResearchAndExperimentalDevelopmentExpenditures" xlink:label="rptx_ScientificResearchAndExperimentalDevelopmentExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCredits" xlink:label="rptx_InvestmentTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TaxCreditCarryForwardExpirationYear" xlink:label="rptx_TaxCreditCarryForwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxExaminationYearSubjectToExamination" xlink:label="rptx_IncomeTaxExaminationYearSubjectToExamination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="rptx_StateAndUsFederalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="rptx_IncomeTaxLosses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_IncomeTaxesTable" xlink:to="rptx_IncomeTaxesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="rptx_ScientificResearchAndExperimentalDevelopmentExpenditures" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="rptx_InvestmentTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="rptx_TaxCreditCarryForwardExpirationYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationYearUnderExamination" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="rptx_IncomeTaxExaminationYearSubjectToExamination" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireOne" xlink:label="rptx_IncomeTaxLossesExpireOne"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireTwo" xlink:label="rptx_IncomeTaxLossesExpireTwo"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireThree" xlink:label="rptx_IncomeTaxLossesExpireThree"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireFour" xlink:label="rptx_IncomeTaxLossesExpireFour"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireFive" xlink:label="rptx_IncomeTaxLossesExpireFive"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLossesExpireSix" xlink:label="rptx_IncomeTaxLossesExpireSix"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLosses" xlink:label="rptx_IncomeTaxLosses"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_IncomeTaxLossesExpireOne" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_IncomeTaxLossesExpireTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_IncomeTaxLossesExpireThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_IncomeTaxLossesExpireFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_IncomeTaxLossesExpireFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_IncomeTaxLossesExpireSix" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_IncomeTaxLosses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireOne" xlink:label="rptx_InvestmentTaxCreditsExpireOne"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireTwo" xlink:label="rptx_InvestmentTaxCreditsExpireTwo"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireThree" xlink:label="rptx_InvestmentTaxCreditsExpireThree"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireFour" xlink:label="rptx_InvestmentTaxCreditsExpireFour"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireFive" xlink:label="rptx_InvestmentTaxCreditsExpireFive"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireSix" xlink:label="rptx_InvestmentTaxCreditsExpireSix"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCreditsExpireSeven" xlink:label="rptx_InvestmentTaxCreditsExpireSeven"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCredits" xlink:label="rptx_InvestmentTaxCredits"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_InvestmentTaxCreditsExpireOne" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_InvestmentTaxCreditsExpireTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_InvestmentTaxCreditsExpireThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_InvestmentTaxCreditsExpireFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_InvestmentTaxCreditsExpireFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_InvestmentTaxCreditsExpireSix" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_InvestmentTaxCreditsExpireSeven" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_InvestmentTaxCredits" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits" xlink:label="rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets" xlink:label="rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:label="rptx_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities" xlink:label="rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_DeferredTaxAssetsShareBasedCompensationCost" xlink:label="rptx_DeferredTaxAssetsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_DeferredTaxLiabilitiesOperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rptx_DeferredTaxAssetsShareBasedCompensationCost" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OptionsToPurchaseCommonSharesMember" xlink:label="rptx_OptionsToPurchaseCommonSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_EstimatedSharesIssuableUnderTheEsppMember" xlink:label="rptx_EstimatedSharesIssuableUnderTheEsppMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rptx_OptionsToPurchaseCommonSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rptx_EstimatedSharesIssuableUnderTheEsppMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGovernmentAssistanceAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses" xlink:label="rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationDueInSecondYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationDueInThirdYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationDueInFourthYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationDueInFifthYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PreclinicalStudiesAndClinicalTrialsMember" xlink:label="rptx_PreclinicalStudiesAndClinicalTrialsMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CommitmentsAndContingenciesDisclosureTable" xlink:label="rptx_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="rptx_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TheUniversityOfTexasMDAndersonCancerCenterMember" xlink:label="rptx_TheUniversityOfTexasMDAndersonCancerCenterMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SpecialtyScreeningServicesMember" xlink:label="rptx_SpecialtyScreeningServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ContractualObligationPeriod" xlink:label="rptx_ContractualObligationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_BroadInstituteIncMember" xlink:label="rptx_BroadInstituteIncMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ContractualObligationsPaid" xlink:label="rptx_ContractualObligationsPaid"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ContractualObligationAmountPerYear" xlink:label="rptx_ContractualObligationAmountPerYear"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rptx_PreclinicalStudiesAndClinicalTrialsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="rptx_CommitmentsAndContingenciesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rptx_TheUniversityOfTexasMDAndersonCancerCenterMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rptx_SpecialtyScreeningServicesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rptx_ContractualObligationPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rptx_BroadInstituteIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_CommitmentsAndContingenciesDisclosureTable" xlink:to="rptx_CommitmentsAndContingenciesDisclosureLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rptx_ContractualObligationsPaid" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rptx_ContractualObligationAmountPerYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyRiskTable" xlink:label="rptx_ForeignCurrencyRiskTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyRiskLineItems" xlink:label="rptx_ForeignCurrencyRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyRiskAbstract" xlink:label="rptx_ForeignCurrencyRiskAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RestrictedCashMember" xlink:label="rptx_RestrictedCashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchAndDevelopmentTaxCreditsReceivableMember" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OtherReceivablesMember" xlink:label="rptx_OtherReceivablesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember" xlink:label="rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_LeaseLiabilitiesMember" xlink:label="rptx_LeaseLiabilitiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_ForeignCurrencyRiskTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_CashMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_ForeignCurrencyRiskLineItems" xlink:to="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_ForeignCurrencyRiskAbstract" xlink:to="rptx_ForeignCurrencyRiskTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_ForeignCurrencyRiskTable" xlink:to="rptx_ForeignCurrencyRiskLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="rptx_RestrictedCashMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_ForeignCurrencyRiskLineItems" xlink:to="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="rptx_ResearchAndDevelopmentTaxCreditsReceivableMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_ForeignCurrencyRiskLineItems" xlink:to="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="rptx_OtherReceivablesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="rptx_LeaseLiabilitiesMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyRiskAbstract" xlink:label="rptx_ForeignCurrencyRiskAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PercentageOfDepreciationUSDAgainstCanadianDollar" xlink:label="rptx_PercentageOfDepreciationUSDAgainstCanadianDollar"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_ForeignCurrencyRiskAbstract" xlink:to="rptx_PercentageOfDepreciationUSDAgainstCanadianDollar" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rptx_ForeignCurrencyRiskAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember" xlink:label="rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchServicesAndRentPaidMember" xlink:label="rptx_ResearchServicesAndRentPaidMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rptx_ResearchServicesAndRentPaidMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="country_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="country_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_BristolMyersSquibbCompanyMember" xlink:label="rptx_BristolMyersSquibbCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="country_CH"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" xlink:label="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rptx_BristolMyersSquibbCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CH" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="rptx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rptx_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>36
<FILENAME>rptx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T16:10:19.4656+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:href="rptx-20221231.xsd#StatementConsolidatedStatementsOfShareholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical" xlink:href="rptx-20221231.xsd#StatementConsolidatedStatementsOfShareholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="rptx-20221231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsTables" xlink:href="rptx-20221231.xsd#Role_DisclosureCollaborationsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="rptx-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails" xlink:href="rptx-20221231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail" xlink:href="rptx-20221231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#DisclosureShareholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#DisclosureSharebasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails" xlink:href="rptx-20221231.xsd#DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails" xlink:href="rptx-20221231.xsd#DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails" xlink:href="rptx-20221231.xsd#DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails" xlink:href="rptx-20221231.xsd#DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureCollaborationsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails" xlink:href="rptx-20221231.xsd#DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureRelatedPartiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#DisclosureGeographicInformationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="rptx-20221231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" xlink:label="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SeriesAConvertiblePreferredSharesMember" xlink:label="rptx_SeriesAConvertiblePreferredSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FollowOnOfferingMember" xlink:label="rptx_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SeriesBConvertiblePreferredSharesMember" xlink:label="rptx_SeriesBConvertiblePreferredSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination" xlink:label="rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue" xlink:label="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares" xlink:label="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_NetIncomeLossAndComprehensiveIncomeLoss" xlink:label="rptx_NetIncomeLossAndComprehensiveIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rptx_SeriesAConvertiblePreferredSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rptx_FollowOnOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rptx_SeriesBConvertiblePreferredSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rptx_NetIncomeLossAndComprehensiveIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SeriesAConvertiblePreferredSharesMember" xlink:label="rptx_SeriesAConvertiblePreferredSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FollowOnOfferingMember" xlink:label="rptx_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SeriesBConvertiblePreferredSharesMember" xlink:label="rptx_SeriesBConvertiblePreferredSharesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rptx_SeriesAConvertiblePreferredSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rptx_FollowOnOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rptx_SeriesBConvertiblePreferredSharesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan" xlink:label="rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ChangeInFairValueOfPreferredStockTrancheObligation" xlink:label="rptx_ChangeInFairValueOfPreferredStockTrancheObligation"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable" xlink:label="rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLoanAndLeaseLosses" xlink:label="us-gaap_ProvisionForLoanAndLeaseLosses"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInCollaborationRevenueReceivable" xlink:label="rptx_IncreaseDecreaseInCollaborationRevenueReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyTransactionGainLoss" xlink:label="rptx_ForeignCurrencyTransactionGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent" xlink:label="rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet" xlink:label="rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rptx_ChangeInFairValueOfPreferredStockTrancheObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForLoanAndLeaseLosses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rptx_IncreaseDecreaseInCollaborationRevenueReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rptx_ForeignCurrencyTransactionGainLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" xlink:label="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_BristolMyersSquibbCompanyMember" xlink:label="rptx_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rptx_BristolMyersSquibbCompanyMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OrganizationAndNatureOfBusinessLineItems" xlink:label="rptx_OrganizationAndNatureOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OrganizationAndNatureOfBusinessTable" xlink:label="rptx_OrganizationAndNatureOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FollowOnOfferingMember" xlink:label="rptx_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_GrossProceedsFromInitialPublicOffering" xlink:label="rptx_GrossProceedsFromInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses" xlink:label="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="rptx_OrganizationAndNatureOfBusinessTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rptx_OrganizationAndNatureOfBusinessTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rptx_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rptx_FollowOnOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rptx_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="rptx_GrossProceedsFromInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_OrganizationAndNatureOfBusinessLineItems" xlink:to="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember" xlink:label="rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_MarketableSecuritiesMember" xlink:label="rptx_MarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="rptx_MarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_MarketableSecuritiesMember" xlink:label="rptx_MarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="rptx_MarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones" xlink:label="rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_NewYorkUniversityAgreementMember" xlink:label="rptx_NewYorkUniversityAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccrualPotentialMilestoneAndRoyaltyPayments" xlink:label="rptx_AccrualPotentialMilestoneAndRoyaltyPayments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rptx_NewYorkUniversityAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_AccrualPotentialMilestoneAndRoyaltyPayments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC" xlink:label="stpr_CA-QC"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_NumberOfOperatingLeases" xlink:label="rptx_NumberOfOperatingLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="us-gaap_StandbyLettersOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OfficeAndLaboratorySpaceMember" xlink:label="rptx_OfficeAndLaboratorySpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA" xlink:label="stpr_MA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_LesseeOperatingLeaseExpirationMonthAndYear" xlink:label="rptx_LesseeOperatingLeaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ImplicitInterestRate" xlink:label="rptx_ImplicitInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA-QC" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rptx_NumberOfOperatingLeases" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_StandbyLettersOfCreditMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rptx_OfficeAndLaboratorySpaceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="srt_OfficeBuildingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rptx_LesseeOperatingLeaseExpirationMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PrepaidRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rptx_ImplicitInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquitySharesAuthorizedUnlimited" xlink:label="rptx_TemporaryEquitySharesAuthorizedUnlimited"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FirstTrancheMember" xlink:label="rptx_FirstTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SecondTrancheMember" xlink:label="rptx_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_NumberOfTranches" xlink:label="rptx_NumberOfTranches"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PreferredStockNoncumulativeDividendRatePercentage" xlink:label="rptx_PreferredStockNoncumulativeDividendRatePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering" xlink:label="rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering" xlink:label="rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares" xlink:label="rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares" xlink:label="rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_TemporaryEquitySharesAuthorizedUnlimited" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rptx_FirstTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rptx_SecondTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_NumberOfTranches" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_PreferredStockNoncumulativeDividendRatePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FollowOnOfferingMember" xlink:label="rptx_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SalesAgreementMember" xlink:label="rptx_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses" xlink:label="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rptx_FollowOnOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rptx_SalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" xlink:label="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RepareTherapeuticsIncorporationOptionPlanMember" xlink:label="rptx_RepareTherapeuticsIncorporationOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting" xlink:label="rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="rptx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance" xlink:label="rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear" xlink:label="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:label="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase" xlink:label="rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare" xlink:label="rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate" xlink:label="rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_FairValueOfVestedOptions" xlink:label="rptx_FairValueOfVestedOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares" xlink:label="rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepurchaseOfEquity" xlink:label="us-gaap_ProceedsFromRepurchaseOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rptx_RepareTherapeuticsIncorporationOptionPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rptx_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_FairValueOfVestedOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromRepurchaseOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" xlink:label="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="rptx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rptx_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" xlink:label="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationTermExtendedPeriod" xlink:label="rptx_CollaborationTermExtendedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationAndLicenseAgreementMember" xlink:label="rptx_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OnoPharmaceuticalCompanyLimitedMember" xlink:label="rptx_OnoPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchDevelopmentAndRegulatoryMilestonesMember" xlink:label="rptx_ResearchDevelopmentAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SecondAmendmentAgreement" xlink:label="rptx_SecondAmendmentAgreement"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AffiliateOfBristolMyersSquibbCompanyMember" xlink:label="rptx_AffiliateOfBristolMyersSquibbCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CommercialMilestonesMember" xlink:label="rptx_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_BristolMyersSquibbCompanyMember" xlink:label="rptx_BristolMyersSquibbCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AdditionalClinicalDevelopmentPlanMember" xlink:label="rptx_AdditionalClinicalDevelopmentPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" xlink:label="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ClinicalTrialMaterialsMember" xlink:label="rptx_ClinicalTrialMaterialsMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InitialUpfrontFeePayment" xlink:label="rptx_InitialUpfrontFeePayment"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchAndDevelopmentServicesMember" xlink:label="rptx_ResearchAndDevelopmentServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationReceivable" xlink:label="rptx_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CombinedLicensesMember" xlink:label="rptx_CombinedLicensesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationRevenueReceived" xlink:label="rptx_CollaborationRevenueReceived"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_GrantOfLicenseMember" xlink:label="rptx_GrantOfLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_MilestonesPayments" xlink:label="rptx_MilestonesPayments"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ProductResearchActivityMember" xlink:label="rptx_ProductResearchActivityMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationRevenuePaymentReceivable" xlink:label="rptx_CollaborationRevenuePaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ProductRptxOptionsToLicenseDruggableTargetMember" xlink:label="rptx_ProductRptxOptionsToLicenseDruggableTargetMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue" xlink:label="rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RevenueRemainingPerformanceObligationNetAmount" xlink:label="rptx_RevenueRemainingPerformanceObligationNetAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CollaborationTermExpirationPeriod" xlink:label="rptx_CollaborationTermExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_CollaborationTermExtendedPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rptx_CollaborationAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rptx_OnoPharmaceuticalCompanyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_ResearchDevelopmentAndRegulatoryMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_SecondAmendmentAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rptx_AffiliateOfBristolMyersSquibbCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_CommercialMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rptx_BristolMyersSquibbCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_AdditionalClinicalDevelopmentPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_ClinicalTrialMaterialsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_InitialUpfrontFeePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_ResearchAndDevelopmentServicesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_CollaborationReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_CombinedLicensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_CollaborationRevenueReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_GrantOfLicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_MilestonesPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_ProductResearchActivityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_CollaborationRevenuePaymentReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_ProductRptxOptionsToLicenseDruggableTargetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_RevenueRemainingPerformanceObligationNetAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rptx_CollaborationTermExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_BristolMyersSquibbCompanyMember" xlink:label="rptx_BristolMyersSquibbCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchActivitiesMember" xlink:label="rptx_ResearchActivitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" xlink:label="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OptionsToLicenseDruggableTargetsMember" xlink:label="rptx_OptionsToLicenseDruggableTargetsMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OptionsToLicenseUndruggableTargetMember" xlink:label="rptx_OptionsToLicenseUndruggableTargetMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CombinedLicensesMember" xlink:label="rptx_CombinedLicensesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CompletionOfContinuingTrialsMember" xlink:label="rptx_CompletionOfContinuingTrialsMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TransferOfClinicalTrialMaterialsMember" xlink:label="rptx_TransferOfClinicalTrialMaterialsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rptx_BristolMyersSquibbCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_ResearchActivitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_OptionsToLicenseDruggableTargetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_OptionsToLicenseUndruggableTargetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_CombinedLicensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_CompletionOfContinuingTrialsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rptx_TransferOfClinicalTrialMaterialsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxesLineItems" xlink:label="rptx_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxesTable" xlink:label="rptx_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_StateAndUsFederalMember" xlink:label="rptx_StateAndUsFederalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxLosses" xlink:label="rptx_IncomeTaxLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ScientificResearchAndExperimentalDevelopmentExpenditures" xlink:label="rptx_ScientificResearchAndExperimentalDevelopmentExpenditures"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_InvestmentTaxCredits" xlink:label="rptx_InvestmentTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TaxCreditCarryForwardExpirationYear" xlink:label="rptx_TaxCreditCarryForwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_IncomeTaxExaminationYearSubjectToExamination" xlink:label="rptx_IncomeTaxExaminationYearSubjectToExamination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="rptx_IncomeTaxesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="rptx_StateAndUsFederalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rptx_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="rptx_IncomeTaxLosses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="rptx_ScientificResearchAndExperimentalDevelopmentExpenditures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="rptx_InvestmentTaxCredits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="rptx_TaxCreditCarryForwardExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationYearUnderExamination" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="rptx_IncomeTaxExaminationYearSubjectToExamination" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OptionsToPurchaseCommonSharesMember" xlink:label="rptx_OptionsToPurchaseCommonSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_EstimatedSharesIssuableUnderTheEsppMember" xlink:label="rptx_EstimatedSharesIssuableUnderTheEsppMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rptx_OptionsToPurchaseCommonSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rptx_EstimatedSharesIssuableUnderTheEsppMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="rptx_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_CommitmentsAndContingenciesDisclosureTable" xlink:label="rptx_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_PreclinicalStudiesAndClinicalTrialsMember" xlink:label="rptx_PreclinicalStudiesAndClinicalTrialsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TheUniversityOfTexasMDAndersonCancerCenterMember" xlink:label="rptx_TheUniversityOfTexasMDAndersonCancerCenterMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_SpecialtyScreeningServicesMember" xlink:label="rptx_SpecialtyScreeningServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ContractualObligationPeriod" xlink:label="rptx_ContractualObligationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_BroadInstituteIncMember" xlink:label="rptx_BroadInstituteIncMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ContractualObligationsPaid" xlink:label="rptx_ContractualObligationsPaid"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ContractualObligationAmountPerYear" xlink:label="rptx_ContractualObligationAmountPerYear"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rptx_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rptx_CommitmentsAndContingenciesDisclosureTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rptx_PreclinicalStudiesAndClinicalTrialsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rptx_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rptx_TheUniversityOfTexasMDAndersonCancerCenterMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rptx_SpecialtyScreeningServicesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rptx_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rptx_ContractualObligationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rptx_BroadInstituteIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rptx_ContractualObligationsPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rptx_ContractualObligationAmountPerYear" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails">
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyRiskLineItems" xlink:label="rptx_ForeignCurrencyRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ForeignCurrencyRiskTable" xlink:label="rptx_ForeignCurrencyRiskTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_RestrictedCashMember" xlink:label="rptx_RestrictedCashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchAndDevelopmentTaxCreditsReceivableMember" xlink:label="rptx_ResearchAndDevelopmentTaxCreditsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" xlink:label="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_OtherReceivablesMember" xlink:label="rptx_OtherReceivablesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember" xlink:label="rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_LeaseLiabilitiesMember" xlink:label="rptx_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rptx_ForeignCurrencyRiskLineItems" xlink:to="rptx_ForeignCurrencyRiskTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rptx_ForeignCurrencyRiskTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_CashMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_ForeignCurrencyRiskLineItems" xlink:to="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="rptx_RestrictedCashMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_ForeignCurrencyRiskLineItems" xlink:to="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="rptx_ResearchAndDevelopmentTaxCreditsReceivableMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rptx_ForeignCurrencyRiskLineItems" xlink:to="us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="rptx_OtherReceivablesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="rptx_LeaseLiabilitiesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember" xlink:label="rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_ResearchServicesAndRentPaidMember" xlink:label="rptx_ResearchServicesAndRentPaidMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rptx_ResearchServicesAndRentPaidMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="country_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="country_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_BristolMyersSquibbCompanyMember" xlink:label="rptx_BristolMyersSquibbCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="country_CH"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" xlink:label="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rptx_BristolMyersSquibbCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CH" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="rptx-20221231.xsd#rptx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="rptx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rptx_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564398029584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 24, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RPTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Repare Therapeutics Inc. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001808158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454,878,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,077,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7210 Frederick-Banting<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">St-Laurent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H4S 2A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">412-7018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the definitive proxy statement for the registrant&#8217;s 2023 annual meeting of shareholders, which is to be filed within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2022, are incorporated by reference into Part III of this Form 10-K, to the extent described in Part III.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Montr&#233;al, Canada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564403541696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 159,521<span></span>
</td>
<td class="nump">$ 334,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">184,420<span></span>
</td>
<td class="nump">7,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ResearchAndDevelopmentTaxCreditsReceivable', window );">Research and development tax credits receivable</a></td>
<td class="nump">1,280<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesLongTermContractsOrPrograms', window );">Collaboration revenue receivable</a></td>
<td class="nump">1,525<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">1,518<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">5,715<span></span>
</td>
<td class="nump">6,314<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">353,979<span></span>
</td>
<td class="nump">351,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,228<span></span>
</td>
<td class="nump">5,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">5,371<span></span>
</td>
<td class="nump">7,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">497<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,620<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">364,075<span></span>
</td>
<td class="nump">368,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">461<span></span>
</td>
<td class="nump">2,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">21,645<span></span>
</td>
<td class="nump">18,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">2,171<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">53,102<span></span>
</td>
<td class="nump">11,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">1,240<span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">78,619<span></span>
</td>
<td class="nump">35,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">3,257<span></span>
</td>
<td class="nump">5,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">2,682<span></span>
</td>
<td class="nump">39,613<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">84,558<span></span>
</td>
<td class="nump">80,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred shares, no par value per share; unlimited shares authorized as of December 31, 2022 and December 31, 2021, respectively; 0 shares issued and outstanding as of December 31, 2022, and December 31, 2021, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value per share; unlimited shares authorized as of December 31, 2022 and December 31, 2021; 42,036,193 and 41,850,162 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">482,032<span></span>
</td>
<td class="nump">480,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">37,226<span></span>
</td>
<td class="nump">17,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(428)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(239,313)<span></span>
</td>
<td class="num">(210,266)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">279,517<span></span>
</td>
<td class="nump">288,421<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 364,075<span></span>
</td>
<td class="nump">$ 368,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ResearchAndDevelopmentTaxCreditsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credits receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ResearchAndDevelopmentTaxCreditsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesLongTermContractsOrPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesLongTermContractsOrPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397807504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorizedUnlimited', window );">Preferred stock shares authorized</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common stock shares authorized</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">42,036,193<span></span>
</td>
<td class="nump">41,850,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">42,036,193<span></span>
</td>
<td class="nump">41,850,162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the number of nonredeemable preferred shares, or preferred stock redeemable solely at the option of the issuer, permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564403189136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_RevenueFromCollaborationAgreements', window );">Collaboration agreements</a></td>
<td class="nump">$ 131,830<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of tax credits</a></td>
<td class="nump">119,066<span></span>
</td>
<td class="nump">90,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">32,560<span></span>
</td>
<td class="nump">26,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">151,626<span></span>
</td>
<td class="nump">116,260<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(19,796)<span></span>
</td>
<td class="num">(108,660)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Realized and unrealized gain (loss) on foreign exchange</a></td>
<td class="nump">308<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">5,631<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense, net</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">5,896<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(13,900)<span></span>
</td>
<td class="num">(108,586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(15,147)<span></span>
</td>
<td class="nump">1,678<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,047)<span></span>
</td>
<td class="num">(106,908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on available-for-sale marketable securities</a></td>
<td class="num">(428)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive loss</a></td>
<td class="num">(428)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (29,475)<span></span>
</td>
<td class="num">$ (106,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common shareholders--basic</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (2.83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common shareholders--diluted</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (2.83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding-basic</a></td>
<td class="nump">41,922,042<span></span>
</td>
<td class="nump">37,818,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding-diluted</a></td>
<td class="nump">41,922,042<span></span>
</td>
<td class="nump">37,818,115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_RevenueFromCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_RevenueFromCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397615600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>2020 Employee Share Purchase Plan</div></th>
<th class="th"><div>Follow On Offering</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th">
<div>Common Shares </div>
<div>2020 Employee Share Purchase Plan</div>
</th>
<th class="th">
<div>Common Shares </div>
<div>Follow On Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>2020 Employee Share Purchase Plan</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 286,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (103,358)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,902,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of vested stock options</a></td>
<td class="nump">986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of vested stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">12,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,288<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common shares under the 2020 Employee Share Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common shares under the 2020 Employee Share Purchase Plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_NetIncomeLossAndComprehensiveIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(106,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106,908)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">288,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(210,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,850,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of vested stock options</a></td>
<td class="nump">$ 447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of vested stock options, Shares</a></td>
<td class="nump">148,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">$ 19,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common shares under the 2020 Employee Share Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common shares under the 2020 Employee Share Purchase Plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss</a></td>
<td class="num">(29,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,047)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 279,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (428)<span></span>
</td>
<td class="num">$ (239,313)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,036,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_NetIncomeLossAndComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net income loss and comprehensive income loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_NetIncomeLossAndComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564402189328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rptx_FollowOnOfferingMember', window );">Follow On Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rptx_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rptx_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564398087872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (29,047)<span></span>
</td>
<td class="num">$ (106,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">19,691<span></span>
</td>
<td class="nump">12,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,978<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForLoanAndLeaseLosses', window );">Non-cash lease expense</a></td>
<td class="nump">2,206<span></span>
</td>
<td class="nump">1,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ForeignCurrencyTransactionGainLoss', window );">Foreign exchange loss (gain)</a></td>
<td class="num">(298)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net (accretion)/amortization of marketable securities</a></td>
<td class="num">(2,233)<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred tax asset</a></td>
<td class="nump">3,620<span></span>
</td>
<td class="num">(2,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">593<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable', window );">Research and development tax credits receivable</a></td>
<td class="nump">1,287<span></span>
</td>
<td class="num">(556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncreaseDecreaseInCollaborationRevenueReceivable', window );">Collaboration revenue receivable</a></td>
<td class="num">(1,525)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(1,147)<span></span>
</td>
<td class="nump">3,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other non-current assets</a></td>
<td class="nump">89<span></span>
</td>
<td class="num">(298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,348)<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,020<span></span>
</td>
<td class="nump">11,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxes', window );">Income tax payable</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet', window );">Operating lease liabilities, net of current portion</a></td>
<td class="num">(2,146)<span></span>
</td>
<td class="num">(1,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">4,250<span></span>
</td>
<td class="num">(6,473)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">322<span></span>
</td>
<td class="num">(85,796)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(602)<span></span>
</td>
<td class="num">(1,690)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds on disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">81,400<span></span>
</td>
<td class="nump">7,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(256,576)<span></span>
</td>
<td class="num">(7,476)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(175,778)<span></span>
</td>
<td class="num">(1,676)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan', window );">Proceeds from issuance of common shares under the 2020 Employee Share Purchase Plan</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common shares in follow-on offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">94,288<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">880<span></span>
</td>
<td class="nump">95,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate fluctuations on cash held</a></td>
<td class="num">(330)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (Decrease) Increase In Cash And Cash Equivalents</a></td>
<td class="num">(174,906)<span></span>
</td>
<td class="nump">8,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents cash at beginning of year</a></td>
<td class="nump">334,427<span></span>
</td>
<td class="nump">326,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">159,521<span></span>
</td>
<td class="nump">334,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure Of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash interest received</a></td>
<td class="nump">1,966<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash taxes paid, net</a></td>
<td class="nump">10,810<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases incurred but not yet paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liability</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 4,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ForeignCurrencyTransactionGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency transaction gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ForeignCurrencyTransactionGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncreaseDecreaseInCollaborationRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in collaboration revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncreaseDecreaseInCollaborationRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liability net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>increase decrease in research and development tax credits receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock under two thousand twenty employee share purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLoanAndLeaseLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to estimated loss from loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.11)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLoanAndLeaseLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564404429248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Nature of Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Organization and Nature of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repare Therapeutics Inc. (&#8220;Repare&#8221; or the &#8220;Company&#8221;) is a precision medicine oncology company focused on the development of synthetic lethality-based therapies to patients with cancer. The Company was incorporated under the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Canada Business Corporations Act</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 6, 2016</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. On June 23, 2020, immediately prior to the completion of its initial public offering (the &#8220;IPO&#8221;), the Company was continued as a corporation under the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business Corporations Act (Qu&#233;bec)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 12, 2020, the Company effected a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1-for-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_e1a9b1e0-b4b1-4ba7-bb67-f01adfdb1126;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.062</span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reverse stock split of the Company&#8217;s share capital. Accordingly, all common shares, Series A and B convertible preferred shares, stock options and per share amounts in these consolidated financial statements have been retroactively adjusted to reflect the reverse stock split on a retroactive basis for all periods presented.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 23, 2020, the Company completed its IPO of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,650,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of its common shares, including the exercise in full by the underwriters of their option to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,650,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional common shares, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">253.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company&#8217;s shares began trading on the Nasdaq Global Select Market under the ticker symbol &#8220;RPTX&#8221; on June 19, 2020. The Company received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by the Company. Upon closing of the IPO, all outstanding convertible preferred shares converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,558,393</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares and the outstanding warrant was automatically exercised into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">750,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the Company completed a follow-on offering of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,600,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of its common shares, including the exercise in full by the underwriters of their option to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">600,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional common shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, for net proceeds of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, after deducting underwriting commissions as well as offering expenses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payable by the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception, the Company has incurred operating losses. As of December 31, 2022, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">239.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company does not have any products approved for sale and has financed its operations primarily through equity financings and funding from its collaboration and license agreements. Based on its current operating plan, the Company expects that its existing cash and cash equivalents and marketable securities on hand will be sufficient to fund its operating and capital expenditures into 2026.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There can be no assurance that the Company will be able to obtain additional debt or equity financing, or generate product revenue or revenue from collaboration agreements, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#8217;s business, results of operations and financial condition.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564404346800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and as amended by Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accompanying consolidated financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Repare Therapeutics USA Inc. (&#8220;Repare USA&#8221;), which was incorporated under the laws of Delaware on June 1, 2017. The financial statements of Repare USA are prepared for the same reporting period as the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">parent </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">company, using consistent accounting policies. All intra-group transactions, balances, income, and expenses are eliminated in full upon consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller Reporting Company</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company qualifies as a &#8220;smaller reporting company&#8221; under the Exchange Act as of December 31, 2022 because the market value of its common shares held by non-affiliates was less than $560 million as of June 30, 2022 and its revenue for the year ended December 31, 2021 was less than $100 million. As a smaller reporting company, the Company may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. For so long as the Company remains a smaller reporting company, it is permitted and the Company intends to rely on such exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign Currencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The functional currency for the Company and Repare USA is the U.S. dollar (&#8220;USD&#8221;). Accordingly, transactions denominated in currencies other than the functional currency are measured and recorded in the functional currency at the exchange rate in effect on the date of the transactions. At each consolidated balance sheet date, monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using the exchange rate in effect at that date. Non-monetary assets and liabilities and revenue and expense items denominated in foreign currencies are translated into the functional currency using the exchange rate prevailing at the dates of the respective transactions. Any gains or losses arising on remeasurement are included in the consolidated statement of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Segment Information</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s singular focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, right-of-use assets and lease liabilities and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company classifies marketable debt securities with a remaining maturity of greater than three months when purchased as available-for-sale. Marketable debt securities with a remaining maturity date greater than one year are classified as non-current where the Company has the intent and ability to hold these securities for at least the next 12 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s marketable securities consist of U.S. treasury bills and U.S. treasury notes with original maturities greater than 90 days. All of the Company&#8217;s marketable securities have a contractual maturity of one year or less. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company considers its investment portfolio of U.S. treasury bills and U.S. treasury notes to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on observable inputs, other than quoted market prices. Unrealized gains and losses are reported in accumulated other comprehensive items in shareholders&#8217; equity. Amortization and accretion of premiums and discounts are recorded in interest income (expense). Realized gains or losses on debt securities are included in other income (expense).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#8217;s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss on the consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive loss. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in other (expense) income, net within the consolidated statement of operations. Losses are charged against the allowance when the Company believes the uncollectibility of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Our investment portfolio comprises money market funds, U.S. treasury bills and U.S. treasury notes. Our investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company maintains deposits in accredited financial institutions which exceed insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s exposure to foreign exchange risk is primarily related to fluctuations between the Canadian dollar and the U.S. dollar. There are balances in Canadian dollars which are subject to foreign currency fluctuations relating to the impact of translating to U.S. dollars for financial statement presentation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in shareholders&#8217; equity that result from transactions and economic events other than those with shareholders. Other comprehensive loss consists of unrealized losses on available-for-sale marketable securities. Total comprehensive loss for all periods presented has been disclosed in the consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	Level 2 &#8211; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	Level 3 &#8211; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An entity may choose to measure financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair values of the Company&#8217;s cash and cash equivalents, collaboration revenue receivable, other receivables, other assets and accounts payable and accrued expenses approximate their carrying values.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s marketable securities are carried at fair value, determined according to Level 2 inputs in the fair value hierarchy described above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and Equipment, Net</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment is stated at historical cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.498%;"/>
          <td style="width:1.004%;"/>
          <td style="width:49.498%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset Category</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful Lives</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the shorter of the lease term and the useful life</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. Expenditures for maintenance and repairs are recorded to expense as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of assets may not be recoverable. Recoverability of these assets is measured by comparing their carrying value to the future net undiscounted cash flows the assets are expected to generate over their remaining economic life. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying value of the assets exceeds their fair value. Indefinite-lived intangible assets are tested for impairment annually, or more frequently if indicators of impairment are present. To date, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such impairment losses have been recorded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the consolidated balance sheet as a right-of-use asset and current and non-current lease liabilities, as applicable.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company enters into collaboration and license agreements, which are within the scope of ASC 606, to discover, develop, manufacture, and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (i) licenses to compounds directed to specific targets (referred to as &#8220;exclusive licenses&#8221;) and (ii) research and development activities to be performed on behalf of the collaboration partner related to the licensed targets. Payments to the Company under these agreements may include non-refundable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">license fees, customer option exercise fees, payments for research activities, reimbursement of certain costs, payments based upon the achievement of certain milestones and royalties on any resulting net product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company first evaluates license and/or collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC 808, Collaborative Arrangements (&#8220;ASC 808&#8221;), based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for collaborative arrangements (or elements within the contract that are deemed part of a collaborative arrangement), which represent a collaborative relationship and not a customer relationship, outside the scope of ASC 606.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s collaborations primarily represent revenue arrangements. For the arrangements or arrangement components that are subject to revenue accounting guidance, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company applies the five-step model. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration, except for sales-based royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In determining the stand-alone selling price of a license to the Company&#8217;s proprietary technology or a material right provided by a customer option, the Company considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating its estimated stand-alone selling price, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling price will have a significant effect on the allocation of arrangement consideration between performance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within one year following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within one year following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive Licenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the license is the predominant promise, and it is determined that the license represents functional intellectual property (&#8220;IP&#8221;), revenue is recognized at the point in time when control of the license is transferred. If it is determined that the license does not represent functional IP, revenue is recognized over time using an appropriate method of measuring progress.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Services</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; The obligations under the Company&#8217;s collaboration and license agreements generally include research and development services to be performed by the Company to benefit the collaboration partner. For performance obligations that include research and development services, the Company generally</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods of which revenue should be recognized, are subject to estimates by management and may change over the course of the contract. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Options</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; The Company&#8217;s arrangements may provide a collaborator with the right to acquire additional goods or services in the future. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment or (ii) upon the exercise of the customer option. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Milestone Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalties</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a complete discussion of accounting for collaboration revenues, s</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ee Note 12.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. The Company&#8217;s research and development expenses consist primarily of costs incurred in performing research and development activities, including salaries and other compensation, share-based compensation, fees paid to external service providers, laboratory supplies and costs for facilities and equipment, partially offset by fully refundable research and development tax credits. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are expensed as the goods are delivered or the services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and Prepaid Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into various research and development contracts. The payments to these agreements are recorded as research and development expenses as incurred. The Company records accrued liabilities and prepaid expenses for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgements and estimates are made in determining the accrued and prepaid balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for all share-based awards granted to employees and non-employees as share-based compensation expense at fair value.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized over the employees&#8217; requisite service period, which is the vesting period, on a straight-line basis. Forfeitures are accounted for as they occur.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each restricted share unit is estimated on the date of grant based on the fair value of our common share on that same date. The fair value of each stock option grant or purchases under our 2020 Employee Share Purchase Plan (&#8220;ESPP&#8221;) is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected share price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option and the Company&#8217;s expected dividend yield. As there was no public market for its common shares prior to its IPO in June 2020, the Company determined the volatility for stock option awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies blended with the historical volatility of the Company's common shares. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price. For purchases under our ESPP, only the historical volatility of the Company's common shares is used when developing an estimate of expected volatility. The expected term of the Company&#8217;s stock options granted to employees and non-employees has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. In connection with the adoption of ASU No. 2018-07, Compensation&#8212;Stock Compensation (&#8220;ASU No. 2018-07&#8221;), the Company calculated the expected term of non-employee awards using the midpoint between the vesting date and the contractual term, which is consistent with the method used for employee awards. For purchases under our ESPP, the expected term is based on the length of the offering period. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award, for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common shares; therefore, the expected dividend yield is assumed to be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. Any consideration paid by employees on exercising stock options or the purchases under our ESPP and the corresponding portion previously credited to additional paid-in capital are credited to share capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share Issuance Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share issuance costs applicable to the issuance of equity instruments are recorded as a reduction of the financing equity proceeds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted-average number of common shares outstanding during the reporting period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of common shares and potentially dilutive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">securities </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, shares issuable under the ESPP and options to purchase common shares considered to be potentially dilutive securities were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all reporting periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on differences between the consolidated financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and Development Tax Credits</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes the benefit of refundable Canadian research and development tax credits as a reduction of research and development costs when there is reasonable assurance that the amount claimed will be recovered.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13). Certain amendments thereto were also issued by the FASB. ASU 2016-13 and the related amendments implement an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. The Company adopted ASU 2016-13 and the related amendments thereto on January 1, 2022. The adoption of ASU 2016-13 and the related amendments thereto did not have a material impact on the Company&#8217;s consolidated financial statements or disclosures as of and for the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no new accounting pronouncements issued which could have a significant effect on the Company's consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564401490032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.844%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.256%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.256%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.256%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.278%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Money market funds included in cash and cash <br/>&#160;&#160;&#160;equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,995</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,995</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,362</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,362</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,058</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,058</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184,420</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184,420</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">227,415</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,995</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184,420</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Money market funds included in cash and cash <br/>&#160;&#160;&#160;equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,974</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,974</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure the fair value. In determining the fair values at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transfers between fair value measure levels.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564403157376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash and Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Cash and Cash Equivalents and Marketable Securities</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, cash and cash equivalents and marketable securities were comprised of the following:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.588%;"/>
        <td style="width:0.288%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.814%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.264%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.814%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.288%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.56%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.072%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.31%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Cash</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116,526</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116,526</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,995</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,995</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159,521</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159,521</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,641</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">280</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,362</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,207</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,058</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184,848</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">433</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184,420</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">331,892</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">331,892</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,535</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,535</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">334,427</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">334,427</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,439</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,439</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest receivable was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nil</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively, and is included in other receivables.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nil</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> available-for-sale marketable securities with an aggregate fair value of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nil</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that were in an unrealized loss position as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. These marketable securities have been in an unrealized loss position for less than twelve months. The unrealized losses as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. The Company does not intend to sell these securities and it is more likely than not that it will hold these investments for a period of time sufficient to recover the amortized cost. As a result, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">record</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">allowance for credit losses or other impairment charges for its marketable securities for the year ended December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nil</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in net unrealized losses in other comprehensive loss for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The maturities of the Company&#8217;s marketable securities as of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> are less than one year.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564492675888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.61%;"/>
        <td style="width:1.604%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.615%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.128%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">473</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">469</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">514</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">509</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,075</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,536</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,519</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,465</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,581</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,979</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,353</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,375</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,604</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense recognized was allocated as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,837</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,325</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administration</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">146</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,978</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,471</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564401369984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Accrued Expenses and Other Current Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation and benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,616</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,867</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,078</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,272</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">680</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">387</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued property and equipment purchases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,719</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">377</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,645</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,622</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397892608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_LicenseAgreementsDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. License Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2016, as further amended in February 2017 and amended and restated in July 2018, the Company entered into a license agreement (the &#8220;NYU Agreement&#8221;) with New York University, pursuant to which the Company obtained a worldwide, royalty-bearing, exclusive license under certain patents and know-how of New York University to research, develop and commercialize products covered by such licensed patents. The Company is required to pay New York University an annual non-refundable license fee, which is creditable against future milestone and royalty payments. The Company is required to pay amounts up to approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the aggregate upon</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">achievement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of certain clinical and commercial milestones and pay a low single digit royalty on future net sales of any product covered by a licensed product and a lower-single digit royalty on future net sales of any product not covered by a licensed product. The NYU Agreement expires on the date of expiration of all royalty obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any potential future milestone or royalty payment amounts have </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t been accrued at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> due to the uncertainty related to the successful achievement of these milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_LicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_LicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564484104672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has historically entered into lease arrangements for its facilities and certain equipment. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating leases with required future minimum payments. The Company&#8217;s leases generally do not include </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">termination</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or purchase options.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2017, and as further amended in 2021, the Company entered into a lease agreement for office and laboratory space in Montr&#233;al, Qu&#233;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">bec, for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term, ending in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In August 2021, the lease was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extended</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through July 2025</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2017, and as further amended throughout 2018, 2019, 2020, 2021 and 2022, the Company entered into a lease agreement for office and laboratory space located in Montr&#233;al, Qu&#233;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">bec, for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term ending in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extended</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through December 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company entered into a new lease agreement, effective January 2023, which will result in $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of minimum lease payments over the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_5c64d736-3755-4363-b2f0-d376d83f9242;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">thirty-two</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> month lease term.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, the Company entered into a lease agreement for office space in Cambridge, Massachusetts, for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term ending in</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> December 2024</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which commenced in December 2021. The Company has an option for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewal, which has not been recognized in the Company&#8217;s right-of-use asset or lease liability.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2019, and as further amended in July 2021, the Company entered into a lease agreement for office and laboratory space for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term located in Montr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#233;al, Qu&#233;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">bec which commenced in September 2020. The Company has an option for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewal, which has not been recognized in the Company&#8217;s right-of-use asset or lease liability. As required under the terms of the lease agreement, the Company incurred prepaid rent of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million prior to commencement of the lease term, with the current portion previously accounted for within prepaid expenses and other current assets and the long-term portion accounted for within other assets. As well, as required under the terms of the amended lease agreement, the Company incurred prepaid rent of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million prior to commencement of the lease term which was accounted for within prepaid expenses. As of the commencement of the lease term, this prepaid rent has been reclassified to the right-of-use asset.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating leases for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,456</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,101</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">278</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,767</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,289</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.818%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.501%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.48%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except as specified otherwise)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Operating Lease Information</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows for operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,948</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,240</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets obtained in exchange for lease obligations</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,690</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.43</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.35</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease costs for the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> include contingent rental usage, common area maintenance and other operating charges. As the Company&#8217;s leases do </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments under the Company&#8217;s operating leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.883%;"/>
        <td style="width:1.93%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.187%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity of Lease Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,342</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">957</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,694</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">266</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,428</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564402254192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. Shareholders&#8217; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Shares</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective upon the closing of the IPO, the Company authorized for issue an unlimited number of preferred shares, issuable in series, having such designations, rights, privileges, restrictions and conditions, including dividend and voting rights as the board of directors of the Company may determine, and such rights and privileges, including dividend and voting rights, may be superior to those of the common shares. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> preferred shares were issued and outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Shares</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The articles of continuance of the Company authorize an unlimited number of common shares, voting and participating, without par value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each common share entitles the holder to one vote on all matters submitted to the shareholders for a vote.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The holders of common shares are entitled to receive dividends, as may be declared by the board of directors, if any. Through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cash dividends have been declared or paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 1, 2021, the Company completed a follow-on offering of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,600,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of its common shares, including the exercise in full by the underwriters of their option to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">600,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional common shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, for net proceeds of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, after deducting underwriting commissions as well as offering expenses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payable by the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 2022, the Company entered into a common shares sale agreement (&#8220;the Sales Agreement&#8221;), with Cowen and Company, LLC (&#8220;Cowen&#8221;) as sales agent, pursuant to which we may issue and sell common shares from time to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">time, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or the ATM Shares. The ATM Shares to be sold under the Sales Agreement, if any, will be issued and sold pursuant to our shelf registration statement on Form S-3 (File No. 333-257668), up to a maximum aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares have been issued under the Sales Agreement as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564398000128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Share-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Employee Share Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, the Company&#8217;s board of directors adopted, and the Company&#8217;s shareholders approved the 2020 Employee Share Purchase Plan (&#8220;ESPP&#8221;). The maximum number of common shares that may be issued under the ESPP was initially </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">327,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Additionally, the number of shares reserved and available for issuance under the ESPP will automatically increase each January 1, beginning on January 1, 2021 and each January 1 thereafter through January 31, 2030, by the lesser of (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of common shares outstanding on December 31 of the preceding calendar year, (2) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,300,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares, or (3) such smaller number of common shares as the Company&#8217;s board of directors may designate. As of January 1, 2023, the number of common shares that may be issued under the ESPP is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,487,035</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ESPP enables eligible employees to purchase common shares of the Company at the end of each offering period at a price equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Participation in the ESPP is voluntary. Eligible employees become participants in the ESPP by enrolling in the plan and authorizing payroll deductions. At the end of each offering period, accumulated payroll deductions are used to purchase the Company&#8217;s shares at the discounted price. The Company makes </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> contributions to the ESPP. A participant may withdraw from the ESPP or suspend contributions to the ESPP. If the participant elects to withdraw during an offering, all contributions are refunded as soon as administratively practicable. If a participant elects to withdraw or suspend contributions, they will not be able to re-enroll in the current offering but may elect to participate in future offerings. The ESPP purchases only whole shares of the Company&#8217;s shares. The Company&#8217;s first ESPP offering period began February 16, 2021 and ended on August 15, 2021, with a second offering period commencing on August 16, 2021. Subsequent offering periods will be on a rolling six-month basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021 the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,915</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,943</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares under the ESPP, respectively, at an average price per share of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.43</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.46</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. Cash received from purchases under the ESPP for the years ended December 31, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. In February 2023, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,703</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares under the ESPP at an average price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions that the Company used in the Black Scholes option-pricing model to determine the grant date fair value under the ESPP offering were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.663%;"/>
        <td style="width:1.159%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.51%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.159%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.51%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.36</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.05</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85.37</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61.91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average grant date fair value under the ESPP offering during the years ended December 31, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.91</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.94</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option Plan and 2020 Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2016, as further amended in December 2017 and September 2019, the Company adopted the Repare Therapeutics Inc. Option Plan (the &#8220;Option Plan&#8221;) for the issuance of stock options and other share-based awards to directors, officers, employees or consultants. The Option Plan authorized up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,074,135</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common shares to be issued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, the Company&#8217;s board of directors adopted, and the Company&#8217;s shareholders approved the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;). The 2020 Plan became effective on the effective date of the IPO, at which time the Company ceased making awards under the Option Plan. The 2020 Plan allows the Company&#8217;s compensation committee to make equity-based and cash-based incentive awards to the Company&#8217;s officers, employees, directors and consultants including but not limited to stock options and restricted share units. A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,600,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares were initially reserved for issuance under the 2020 Plan, plus the number of shares (not to exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,807,448</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares) consisting of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">298,605</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares that were available for issuance of awards under the Option Plan at the time the 2020 Plan became effective, which ceased to be available for future issuance under the Option Plan at such time and (ii) any shares subject to outstanding options or other share awards that were granted under the Option Plan that terminate or expire prior to exercise or settlement; are forfeited because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares reserved and available for issuance under the 2020 Plan will automatically increase each January 1, beginning on January 1, 2021 and each January 1 thereafter through January 1, 2030, by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding number of common shares on the immediately preceding December 31, or such lesser number of shares as determined by the Company&#8217;s board of directors. As of January 1, 2023, the number of common shares reserved for issuance under the 2020 Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,025,525</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Plan is administered by the board of directors. The exercise prices, vesting and other restrictions are determined by the board of directors, except that the exercise price per share of stock option may not be less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair value of the common share on the date of grant, determined based on the average of the daily volume-weighted average trading price of shares on each of the five trading days immediately preceding the date of grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options awarded under the 2020 Plan expire </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> after the grant and generally have vesting conditions of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on the first anniversary of the date of grant and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on a monthly basis at a rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless otherwise decided by the Company&#8217;s board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option Activity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions that the Company used in the Black Scholes option-pricing model to determine the grant date fair value of stock options granted to employees and non-employees were as follows, presented on a weighted-average basis:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.663%;"/>
        <td style="width:1.159%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.51%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.159%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.51%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.99</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75.99</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average grant date fair value of stock options granted during the years ended December 31, 2022, 2021 and 2020 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.54</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#8217;s share option activity:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.132%;"/>
        <td style="width:0.402%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.456999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.182%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.290000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.298%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.134%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.805%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.303%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>average<br/>exercise<br/>price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>average<br/>remaining<br/>contractual<br/>term<br/>(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intrinsic value (in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,322,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.15</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,722</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,346,567</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.41</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">148,116</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.02</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">488,140</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,032,902</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.38</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.90</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,592,087</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.41</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.94</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,538</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options unvested, December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,440,815</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.65</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,712</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common shares for those stock options that had an exercise price lower than the fair value of the Company&#8217;s common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value of options exercised during the years ended December 31, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total fair value of options vested during the years ended December 31, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">148,116</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options were exercised at a weighted-average exercise price of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.02</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, for aggregate proceeds of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As a result, an amount of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> previously included in additional paid-in-capital related to the exercised options has been credited to common shares and deducted from additional paid-in-capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January and February 2023, the Company granted an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,495,240</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options at a weighted average exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.42</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">626,260</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted share units to employees under the 2020 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense for all awards was allocated as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,671</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,148</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,691</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,829</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense by type of award was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,400</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,632</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">291</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,691</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,829</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of unrecognized share-based compensation expense related to unvested stock options. The unrecognized share-based compensation expense is expected to be recognized over a weighted-average remaining vesting period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564398000128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Savings Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Employee Savings Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has offered its employees in the United States the ability to participate in a 401(k). The Company has also offered its employees in Canada the ability to participate in a registered retirement savings plan. As of January 1, 2021, the Company started making non-matching employer contributions into both of these plans on behalf of participants equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their base salary. The Company has recorded an expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in matching contributions for the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564404569504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Collaborations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Roche Collaboration and License Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, the Company entered into a collaboration and license agreement (the &#8220;Roche Agreement&#8221;) with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd (collectively, &#8220;Roche&#8221;) regarding the development and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commercialization of the Company&#8217;s product candidate camonsertib (also known as RP-3500 or RG6526) and specified other Ataxia-Telangiectasia and Rad3-related protein kinase (&#8220;ATR&#8221;) inhibitors (the &#8220;Licensed Products&#8221;). The transaction was subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions, which were met on July 13, 2022 (&#8220;Effective Date&#8221;). Pursuant to the Roche Agreement, the Company granted Roche a worldwide, perpetual, exclusive, sublicensable license to develop, manufacture, and commercialize the Licensed Products, as well as a non-exclusive, sublicensable license to certain related companion diagnostics. The Company has agreed to complete specified ongoing clinical trials in accordance with the development plan in the Roche Agreement, as well as ongoing investigator sponsored trials (together, the &#8220;Continuing Trials&#8221;) at the Company&#8217;s expense. Roche assumes all subsequent development of camonsertib with the potential to expand development into additional tumors and multiple combination studies. The Company retained the right to conduct specified clinical trials (the &#8220;Repare Trials&#8221;) of camonsertib in combination with the Company&#8217;s PKMYT1 compound (also known as RP-6306). The Roche Agreement also provides the Company, at its sole discretion, with the ability to opt-in to a 50/50 U.S. co-development and profit share arrangement, including participation in U.S. co-promotion if U.S. regulatory approval is received. If the Company chooses to exercise its co-development and profit share option, it will continue to be eligible to receive certain clinical, regulatory, commercial and sales milestone payments, in addition to full ex-U.S. royalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Roche Agreement was subsequently amended in October 2022 to extend the timeline to negotiate in good faith the parties&#8217; rights and obligations with respect to the Repare Trials, as defined in the Roche Agreement, and to clarify indications included in the development plan that are subject to milestones.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Roche Agreement, the Company received an upfront, nonrefundable payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in July 2022. The Company also received an additional payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million negotiated with Roche for revisions to the clinical development plan under the Roche Agreement as agreed to by the parties at the time of the Effective Date. The Company further received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the transfer of clinical trial material on hand to Roche, as agreed to pursuant to the Roche Agreement. The Company is eligible to receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.172</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion in potential clinical, regulatory, commercial and sales milestones, as well as royalties on global net sales ranging from high-single-digits to high-teens, subject to certain specified reductions. Royalties are payable by Roche on a product by product and country by country basis until the later of 12 years following the first commercial sale of a licensed product in such country or the expiration of certain exclusivity rights.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Roche Agreement will expire upon the last to expire royalty term or, as applicable, the end of the U.S. co-development and profit share arrangement. Additionally, Roche may terminate the agreement for convenience in its entirety or on a product by product or country by country basis subject to certain notice periods. Either party may terminate earlier upon the other party&#8217;s uncured material breach of the agreement or insolvency. Subject to the terms of the Roche Agreement, effective upon termination of the Roche Agreement, the Company is entitled to retain specified licenses to be able to continue to exploit the Licensed Products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed the Roche Agreement in accordance with ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and concluded that Roche is a customer within the context of the agreement. At inception, the Company identified several performance obligations under the agreement, being (i) the combination of the exclusive perpetual license to the Licensed Products and the non-exclusive license to certain companion diagnostics, (ii) the research and development activities related to the completion of the Continuing Trials, as well as (iii) the transfer of clinical trial materials on hand. The Company determined that the exclusive license to the Licensed Products and the non-exclusive license to certain companion diagnostics should be combined into one distinct performance obligation as they were not capable of being distinct from each other within the context of the agreement given both are highly interdependent of each other. The Company determined that the combined licenses, the completion of the Continuing Trials and the transfer of clinical trial materials were all capable of being distinct and were distinct within the context of the Roche Agreement given such activities are independent of each other and Roche could benefit from either separately.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the transaction price at the onset of the agreement is $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, being the total non-refundable upfront payment received of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, the additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million payment received and the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million received for the transfer of clinical trial materials. Additional consideration is to be paid to the Company upon the achievement of multiple clinical, regulatory and sales milestones. The Company utilized the most likely method approach and concluded that these amounts were constrained based on the probability of achievement. As such, the Company excluded this additional consideration from the transaction price.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has allocated the transaction price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to each performance obligation based on the relative stand-alone selling price of each performance obligation at inception. The Company has determined the estimated stand-alone selling price at contract inception of the combined licenses by applying a probability adjusted discounted cashflow model which forecasts future cash flows related to the licenses. The Company considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success, discount rate and the time needed to commercialize a product pursuant to the license. The Company has determined the estimated stand-alone selling price at contract inception of the research and development activities required to complete the Continuing Trials based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to complete the Continuing Trials included the length of time required, the internal hours as well as external costs expected to be incurred, the number of patients and the number of clinical and investigator sponsored trials. The Company has determined the stand-alone selling price of the clinical trial materials transferred based on the purchase price from external vendors, without applying a markup as the materials have a built-in margin from the external vendors. </span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the relative stand-alone selling price, the allocation of the transaction price to the separate performance obligations was as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.153%;"/>
        <td style="width:9.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.845000000000002%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transaction price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Combined licenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105,327</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Completion of Continuing Trials</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,585</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transfer of clinical trial materials</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,714</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total transaction price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,626</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue associated with the combined licenses was recognized at a point in time upon the transfer of the licenses to Roche on the effective date of the Roche Agreement as the Company concluded that the combined licenses were a functional intellectual property license that Roche could benefit from as of the time of grant. Revenue associated with the completion of the Continuing Trials has been deferred and will be recognized on a proportional performance basis over the period of time to complete the Continuing Trials, being estimated at within </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months of the effective date, using input-based measurements of total costs of research and development incurred to estimate the proportion performed. Progress towards completion is remeasured at the end of each reporting period. Revenue associated with the transfer of clinical trial materials was recognized at a point in time upon delivery of the clinical trial materials to Roche in the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the year ended December 31, 2022 as revenue associated with the Roche Agreement, of which </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> related to the grant of the combined licenses, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> related to the clinical trial materials transferred, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> related to the partial recognition of deferred revenue for research and development services performed towards the completion of the Continuing Trials during the period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (December 31, 2021 - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nil</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) of deferred revenue related to the Roche Agreement, of which </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (December 31, 2021 - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nil</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) was classified as current and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (December 31, 2021 - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nil</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) was classified as non-current in the consolidated balance sheet based on the period the services to complete the Continuing Trials are expected to be performed.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bristol Myers Squibb</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2020, the Company entered into a collaboration and license agreement (the "BMS Agreement") with Bristol-Myers Squibb Company (&#8220;Bristol-Myers Squibb&#8221;), pursuant to which the Company and Bristol Myers Squibb have agreed to collaborate in the research and development of potential new product candidates for the treatment of cancer. The Company is providing Bristol Myers Squibb access to a selected number of its existing screening campaigns and novel campaigns. The Company is responsible for carrying out early-stage research activities directed to identifying potential targets for potential licensing by Bristol Myers Squibb, in accordance with a mutually agreed upon research plan and will be solely responsible for such costs. The collaboration consists of programs directed to both druggable targets and to targets commonly considered undruggable to traditional small molecule approaches. Upon Bristol Myers Squibb&#8217;s election to exercise its option to obtain exclusive worldwide licenses for the subsequent development, manufacturing and commercialization of a program, Bristol Myers Squibb will then be solely responsible for all such worldwide activities and costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The BMS Agreement was subsequently amended in July, September and November 2020 to include additional campaigns to the list of existing campaigns from which Bristol Myers Squibb may select campaigns under the agreement and to enable unblinding of a Bristol Myers Squibb alliance manager in order to streamline the collaboration and selection process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the BMS Agreement, Bristol Myers Squibb paid the Company an initial nonrefundable upfront fee payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in June 2020. The Company is entitled to receive, on a program-by-program basis, option exercise fees ranging in the low six figures depending on the nature of the applicable program. Bristol Myers Squibb also has the right to retain rights to certain back-up programs in exchange for a one-time payment in the low eight figures per program. The Company is also entitled to receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">301.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in total milestones on a program-by-program basis, consisting of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">176.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate for certain specified research, development and regulatory milestones and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate for certain specified commercial milestones. The Company is further entitled to a tiered percentage royalty on annual net sales ranging from high-single digits to low-double digits, subject to certain specified reductions. Royalties are payable by Bristol Myers Squibb on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On a program-by-program basis, prior to the earlier of such program ceasing to be included under the BMS Agreement and expiration of the last to expire royalty term for such program, the Company, alone and with third parties, is prohibited from researching, developing, manufacturing and commercializing products that are directed to the applicable target for such program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has provided Bristol Myers Squibb with certain, limited rights to first negotiation if the Company determines to divest, license or collaborate with others regarding certain existing programs, including in the event that the Company receives an unsolicited offer to do so. The right of first negotiation expressly excludes any potential change of control transaction, as defined in the agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The collaboration term will expire </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months after the effective date of the agreement. The BMS Agreement will expire, assuming that Bristol Myers Squibb has exercised at least one option for a program, on a licensed product-by-licensed product and country-by-country basis on expiration of the applicable royalty term and in its entirety upon expiration of the last royalty term. Either party may terminate earlier upon an uncured material breach of the BMS agreement by the other party, or the insolvency of the other party. Additionally, Bristol Myers Squibb may terminate the BMS Agreement for any or no reason on a program-by-program basis upon specified written notice.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed the BMS Agreement in accordance with ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and concluded that Bristol Myers Squibb is a customer based on the agreement structure. At inception, the Company identified several performance obligations under the BMS Agreement, being (i) research activities for each campaign over the collaboration term, as well as (ii) a selected number of material rights associated with options to obtain exclusive development, manufacturing, and commercial licenses to targets identified. The Company determined that the options to obtain the exclusive development, manufacturing and commercialization licenses were material rights under ASC 606 because there are minimal amounts to be paid to the Company upon exercise of such options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the transaction price at the onset of the BMS Agreement is the total non-refundable upfront payment received of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Additional consideration is to be paid to the Company upon the exercise of options to license targets and future milestone payments. The Company utilized the most likely method approach and concluded that these amounts were constrained as they represent option fees and milestone payments that can only be achieved subsequent to option exercises. As such, the Company excluded this additional consideration from the transaction price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has allocated the transaction price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to each performance obligation based on the relative stand-alone selling price of each performance obligation at inception, which was determined based on each performance obligation&#8217;s estimated stand-alone selling price. The Company has determined the estimated stand-alone selling price at contract inception of the research activities based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to perform the research activities included the length of time required, the internal hours expected to be incurred on the services and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">number and costs of various studies that will be performed to complete the research plan. The Company determined the estimated stand-alone selling price at contract inception of the material rights associated with options to obtain exclusive licenses to druggable targets and undruggable targets based on the fees Bristol Myers Squibb would pay to exercise these options, the probability-weighted value of expected future cash flows associated with each license related to each target and the probability that these options would be exercised by Bristol Myers Squibb. In developing such estimates, the Company also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a product candidate pursuant to the associated license. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the relative stand-alone selling price, the allocation of the transaction price to the separate performance obligations was as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.122%;"/>
        <td style="width:8.978%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.899%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transaction price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Research activities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,405</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Options to license druggable targets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,148</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Options to license undruggable targets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,447</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total transaction price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue associated with the options has been deferred and will be recognized at the point in time when options to license are exercised by Bristol Myers Squibb or upon expiry of such options. Revenue associated with the research activities has been deferred and will be recognized on a proportional performance basis over the period of service for research activities, being the collaboration term, using input-based measurements of total costs of research incurred to estimated proportion performed. Progress towards completion is remeasured at the end of each reporting period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021, the Company recognized from deferred revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, as revenue associated with the BMS Agreement in relation to research activities performed during the period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the fourth quarter of fiscal 2022, Bristol Myers Squibb waived its rights to exercise options for druggable targets directed at two separate lesions. As a result, the Company recognized from deferred revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as revenue for the year ended December 31, 2022 with regards to the amount allocated to the performance obligation from Bristol Meyers Squibb. In October 2021, the Company received notification from Bristol Myers Squibb of their option exercise for two druggable targets directed at a single synthetic lethal lesion, pursuant to the terms of the BMS Agreement. As a result, the Company recognized from deferred revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as revenue for the year ended December 31, 2021 with regards to the achievement of the performance obligation from Bristol Meyers Squibb and the option fees received.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (December 31, 2021 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) of deferred revenue related to the BMS Agreement, of which </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (December 31, 2021 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) was classified as current and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nil</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (December 31, 2021 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) as non-current in the consolidated balance sheet based on the period the services are expected to be performed and the expected timing of potential option exercises.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ono</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2019, the Company entered into a research services, license and collaboration agreement (the &#8220;Ono Agreement&#8221;) with Ono Pharmaceutical Co., Ltd. (&#8220;Ono&#8221;), a Japanese pharmaceutical company, pursuant to which the Company and Ono have agreed to collaborate in the research of potential product candidates targeting Pol&#952; and the development of the Company&#8217;s small molecule Pol&#952; inhibitor program. The Company is primarily responsible for carrying out research activities to identify a product candidate, to be licensed to Ono, in accordance with a mutually agreed upon research plan during a research term that will end upon the earlier of the date of the first submission of an Investigational New Drug application (&#8220;IND&#8221;) in the United States or Japan, or the end of the research term. In the event that Ono elects to collaborate on the subsequent development and commercialization of the proposed product candidate, Ono will be then responsible for such activities in Japan, South Korea, Taiwan, Hong-Kong, Macau and the Association of Southeast Asian Nations (collectively, the &#8220;Ono territory&#8221;), and the Company will be responsible for all such activities in the rest of the world outside the Ono territory, including the United States, Canada and European Union.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, the Company and Ono entered into an amendment to the Ono Agreement whereby the research term, as defined in the Ono Agreement, was extended by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2023, the Company and Ono entered into a second amendment to the Ono Agreement whereby the Research Term, as defined in the Ono Agreement, was extended until July 31, 2023.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Ono Agreement, the Company received non-refundable upfront payments of &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">900</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million), consisting of an initial upfront fee payment of &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) and an initial upfront research service payment of &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">790</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million). Additionally, in connection with the research activities to be conducted pursuant to the Ono Agreement, the Company is eligible to receive additional research service payments of up to an aggregate of &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">750</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) upon the occurrence of certain specified research triggers. The Company is also entitled to receive clinical, regulatory and commercial milestone payments of up to &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) in the aggregate, plus a tiered percentage royalty on annual net sales in Ono&#8217;s Territory ranging from high-single digits to low teens, subject to certain specified reductions. All future milestone payments and royalties are payable in U.S. dollars after conversion from Japanese yen at the then applicable rate. Additionally, upon election by Ono to collaborate on the proposed product candidate, Ono shall be responsible for a specified percentage of research and development costs for the IND-enabling studies of the selected product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assessed the arrangement in accordance with ASC 606 and concluded that Ono is a customer based on the arrangement structure. The Company identified a single performance obligation under the arrangement consisting of the combination of the license to develop and commercialize a selected product candidate targeting Pol&#952; and associated research services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the license and research services are not distinct within the context of the contract, and the license is the predominant good or service. Accordingly, revenue is recognized in accordance with guidance for licenses, and because the license represents functional IP, it is recognized at the point in time control of the license is transferred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the transaction price at the onset of the arrangement is the total upfront payments received in the aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which is recorded as deferred revenue. The future milestone payments represent variable consideration that is fully constrained at inception of the arrangement as the achievement of the milestone events are highly uncertain. The Company will reevaluate the likelihood of achievement of the milestones at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price. In October 2021 and December 2022, the Company achieved specified research triggers amounting to &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) and &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">200</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million), respectively, as research service payments provided for in the Ono Agreement. The &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">200</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) is included in the collaboration revenue receivable at December 31, 2022 and was subsequently received in January 2023. These amounts have been added to the transaction price as the consideration was no longer constrained. Should a product candidate be presented for selection in 2023 and Ono exercises its selection option, the Company would be entitled to receive &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">450</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) as well as &#165;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) upon corresponding grant of license, for a total of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the Company classified $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million) as current deferred revenue related to the Ono Agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564402227568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. Income Taxes</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before the provision for income taxes consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.61%;"/>
        <td style="width:1.604%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.615%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.128%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Canada</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,550</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110,433</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,650</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,847</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,586</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the provision for income taxes are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current income tax provision - foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,527</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">530</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income tax benefit - foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,620</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,208</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,147</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,678</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation between tax expense and the product of accounting income multiplied by the statutory income tax rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.818%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.501%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.48%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,586</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax at statutory rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computed income tax recovery</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,684</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,775</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect on income tax resulting from:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal investment tax credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,899</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,093</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting charges not deductible for tax purposes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">679</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,078</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capital gain income</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,956</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,492</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,220</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">777</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">142</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">644</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,434</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,285</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,147</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,678</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's applicable statutory tax rate is the Canadian combined rate applicable in the jurisdictions in which the Company operates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had tax losses of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which are available to offset future taxable income in Canada. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not recognized the tax benefit of these losses. These losses expire as follows: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.968%;"/>
        <td style="width:1.938%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.093%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2042</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,279</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93,834</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2040</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2039</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,394</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2038</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,111</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">883</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158,501</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had Scientific Research and Experimental Development (&#8220;SR&amp;ED&#8221;) expenditures of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for Canadian federal and Qu&#233;bec purposes, which have not been deducted. These expenditures are available to reduce future taxable income and have an unlimited carryforward period. SR&amp;ED expenditures are subject to verification by the tax authorities and, accordingly, the amounts may vary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had non-refundable Canadian federal investment tax credits of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which may be utilized to reduce Canadian federal income taxes payable. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company has not </span></span><span style=""/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the tax benefits related to the non-refundable investment tax credits. The investment tax credits </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expire as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.919%;"/>
        <td style="width:1.919%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.162%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2042</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,392</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,253</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2040</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,702</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2039</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,362</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2038</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">776</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">455</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2036</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,964</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s deferred tax assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.539%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.117%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.117%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,003</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,093</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net research and development expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,468</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,656</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share issuance costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,369</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,538</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net federal investment tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,589</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,805</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,775</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax basis of property and equipment in excess of carrying values</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">376</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,429</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,995</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,445</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,950</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expense and other liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">785</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">760</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,783</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,656</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,492</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">988</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R&amp;D costs capitalized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,911</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,040</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,226</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,040</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,606</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,620</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and has determined that it is more likely than not that the Company will not recognize the benefit of its net deferred tax assets, and as a result, a valuation allowance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million has been established at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and December 31, 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has incurred net operating losses in Canada since inception and the Company's U.S. subsidiary operated profitably in the United States since its inception. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had U.S. federal and state research and development tax credit carry forwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which were utilized in the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company files income tax returns in Canada and in the United States. In the normal course of business, the Company could be subject to examination by federal and provincial or state jurisdictions, where applicable. There are currently no pending tax examinations. The Company may be subject to tax examination for fiscal years </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_1d4885b4-4eda-475c-a5da-596a44a20fc7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2017 to 2022</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> due to unexpired statute of limitation periods.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the provinces and states in which the Company operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when the Company&#8217;s judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> uncertain tax positions have been recorded in the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and comprehensive loss. As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564404376720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. Net Loss per Share</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.61%;"/>
        <td style="width:1.604%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.615%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.128%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,047</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,908</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average number of common shares outstanding&#8212;basic and <br/>&#160;&#160;&#160;diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,922,042</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,818,115</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share&#8212;basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.69</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.83</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s potentially dilutive securities, which include stock options and shares issued under the ESPP, have been excluded from the computation of diluted net loss per share attributable to common shareholders as the effect would be to reduce the net loss per share attributable to common shareholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common shareholders is the same.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.573%;"/>
        <td style="width:1.175%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.882%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.175%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.195%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,032,902</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,322,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated shares issuable under the ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,216</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,654</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564405874496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Government Assistance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Government Assistance</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. Government Assistance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company incurred research and development expenditures which are eligible for refundable investment tax credits. The refundable investment tax credits recorded are based on management&#8217;s estimates of amounts expected to be recovered and are subject to audit by the taxation authorities. These amounts have been recorded as a reduction of research and development expenditures in the amounts of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564404543568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#8217;s commitments to settle contractual obligations at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, other than leases which are recognized as operating lease liabilities in the consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.919%;"/>
        <td style="width:1.919%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.162%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,090</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,106</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,379</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and Research Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and research agreement obligations primarily relate to a strategic collaboration agreement that was entered into with the University of Texas M. D. Anderson Cancer Center (&#8220;MDACC&#8221;) in March 2020. The collaboration consists of preclinical studies and clinical trials designed by the Company and MDACC with the research to be completed by MDACC. The Company has agreed to commit $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in funding for various studies over a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was paid as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company entered into an agreement with the Broad Institute, Inc. (&#8220;Broad&#8221;), in July 2022, under which Broad will perform specialty screening services at the Company&#8217;s request over the course of a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term in exchange for payments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per year, beginning in July 2022, totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Purchase and Other Obligations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the normal course of business, the Company enters into contracts with Contract Research Organizations (&#8220;CROs&#8221;) and other third parties for preclinical studies and clinical trials, research and development supplies and other testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and provide for termination on 30 to 90 days&#8217; prior written notice, and therefore are cancellable contracts. These payments are not included in the table above as the amount and timing of such payments are not known as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has further entered into license agreements under which it is obligated to make milestone and royalty payments and incur annual maintenance fees. The future milestone or royalty payments under these agreements have not been included in the table above since the payment obligations are contingent upon future events, such as achieving certain clinical and commercial milestones or generating product sales. As of December 31, 2022, the Company is unable to estimate the timing or likelihood of achieving these clinical and commercial milestones or generating future product sales (see Note 7).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indemnification Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in these consolidated financial statements as at December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564403271952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Currency Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ForeignCurrencyRiskAbstract', window );"><strong>Foreign Currency Risk [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDisclosureTextBlock', window );">Currency Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17. Currency Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is exposed to the financial risk related to the fluctuation of foreign exchange rates and the degree of volatility of those rates. The foreign currency risk is limited to the portion of the Company&#8217;s business transactions denominated in currency other than U.S. dollars.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company incurs a portion of its expenses in Canadian dollars, as well as other currencies to a lesser extent. A change in the currency exchange rates between the U.S. dollars relative to the Canadian dollar could have a significant effect on the Company&#8217;s consolidated results of operations, financial position, or cash flows. The Company does not enter into arrangements to hedge its currency risk exposure, although it maintains expected Canadian dollar cash requirements in Canadian dollars to form a natural hedge.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is exposed to currency risk through its cash, other receivables, accounts payable, accrued expenses and other current liabilities, as well as right-of-use lease liabilities denominated in Canadian dollars as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.61%;"/>
        <td style="width:1.604%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.615%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.128%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,904</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,583</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credits receivable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,261</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other receivables</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">851</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">745</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">324</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">665</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,289</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,116</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,392</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,564</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net financial position exposure</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">756</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the above net exposure at December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and assuming that all other variables remain constant, a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% depreciation of the U.S. dollar against the Canadian dollar would result in an increase of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the Company&#8217;s net loss for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is also exposed to currency risk through the Ono Agreement as the Company has a collaboration revenue receivable balance as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and any future payments receivable under the Ono Agreement, if any, are denominated in Japanese yen.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ForeignCurrencyRiskAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ForeignCurrencyRiskAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30885-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564402896160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Geographic Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18. Geographic Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s property and equipment, net by location was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Canada</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,888</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,675</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,340</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,929</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,604</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s right-of-use assets by location were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Canada</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,578</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,939</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,793</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,552</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total right-of-use assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,491</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022 the Canadian parent company recognized revenue under its collaboration agreements of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (2021 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) with Bristol Myers Squibb, whose headquarters are located in the United States, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (2021 - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nil</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) with Roche, whose headquarters are located in Switzerland.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564403606704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and as amended by Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accompanying consolidated financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Repare Therapeutics USA Inc. (&#8220;Repare USA&#8221;), which was incorporated under the laws of Delaware on June 1, 2017. The financial statements of Repare USA are prepared for the same reporting period as the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">parent </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">company, using consistent accounting policies. All intra-group transactions, balances, income, and expenses are eliminated in full upon consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_SmallerReportingCompanyPolicyTextBlock', window );">Smaller Reporting Company</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller Reporting Company</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company qualifies as a &#8220;smaller reporting company&#8221; under the Exchange Act as of December 31, 2022 because the market value of its common shares held by non-affiliates was less than $560 million as of June 30, 2022 and its revenue for the year ended December 31, 2021 was less than $100 million. As a smaller reporting company, the Company may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. For so long as the Company remains a smaller reporting company, it is permitted and the Company intends to rely on such exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign Currencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The functional currency for the Company and Repare USA is the U.S. dollar (&#8220;USD&#8221;). Accordingly, transactions denominated in currencies other than the functional currency are measured and recorded in the functional currency at the exchange rate in effect on the date of the transactions. At each consolidated balance sheet date, monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using the exchange rate in effect at that date. Non-monetary assets and liabilities and revenue and expense items denominated in foreign currencies are translated into the functional currency using the exchange rate prevailing at the dates of the respective transactions. Any gains or losses arising on remeasurement are included in the consolidated statement of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Segment Information</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s singular focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, right-of-use assets and lease liabilities and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company classifies marketable debt securities with a remaining maturity of greater than three months when purchased as available-for-sale. Marketable debt securities with a remaining maturity date greater than one year are classified as non-current where the Company has the intent and ability to hold these securities for at least the next 12 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s marketable securities consist of U.S. treasury bills and U.S. treasury notes with original maturities greater than 90 days. All of the Company&#8217;s marketable securities have a contractual maturity of one year or less. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company considers its investment portfolio of U.S. treasury bills and U.S. treasury notes to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on observable inputs, other than quoted market prices. Unrealized gains and losses are reported in accumulated other comprehensive items in shareholders&#8217; equity. Amortization and accretion of premiums and discounts are recorded in interest income (expense). Realized gains or losses on debt securities are included in other income (expense).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#8217;s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss on the consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive loss. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in other (expense) income, net within the consolidated statement of operations. Losses are charged against the allowance when the Company believes the uncollectibility of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Our investment portfolio comprises money market funds, U.S. treasury bills and U.S. treasury notes. Our investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company maintains deposits in accredited financial institutions which exceed insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s exposure to foreign exchange risk is primarily related to fluctuations between the Canadian dollar and the U.S. dollar. There are balances in Canadian dollars which are subject to foreign currency fluctuations relating to the impact of translating to U.S. dollars for financial statement presentation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in shareholders&#8217; equity that result from transactions and economic events other than those with shareholders. Other comprehensive loss consists of unrealized losses on available-for-sale marketable securities. Total comprehensive loss for all periods presented has been disclosed in the consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	Level 2 &#8211; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	Level 3 &#8211; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An entity may choose to measure financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair values of the Company&#8217;s cash and cash equivalents, collaboration revenue receivable, other receivables, other assets and accounts payable and accrued expenses approximate their carrying values.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s marketable securities are carried at fair value, determined according to Level 2 inputs in the fair value hierarchy described above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and Equipment, Net</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment is stated at historical cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.498%;"/>
          <td style="width:1.004%;"/>
          <td style="width:49.498%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset Category</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful Lives</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the shorter of the lease term and the useful life</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. Expenditures for maintenance and repairs are recorded to expense as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of assets may not be recoverable. Recoverability of these assets is measured by comparing their carrying value to the future net undiscounted cash flows the assets are expected to generate over their remaining economic life. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying value of the assets exceeds their fair value. Indefinite-lived intangible assets are tested for impairment annually, or more frequently if indicators of impairment are present. To date, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such impairment losses have been recorded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the consolidated balance sheet as a right-of-use asset and current and non-current lease liabilities, as applicable.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company enters into collaboration and license agreements, which are within the scope of ASC 606, to discover, develop, manufacture, and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (i) licenses to compounds directed to specific targets (referred to as &#8220;exclusive licenses&#8221;) and (ii) research and development activities to be performed on behalf of the collaboration partner related to the licensed targets. Payments to the Company under these agreements may include non-refundable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">license fees, customer option exercise fees, payments for research activities, reimbursement of certain costs, payments based upon the achievement of certain milestones and royalties on any resulting net product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company first evaluates license and/or collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC 808, Collaborative Arrangements (&#8220;ASC 808&#8221;), based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for collaborative arrangements (or elements within the contract that are deemed part of a collaborative arrangement), which represent a collaborative relationship and not a customer relationship, outside the scope of ASC 606.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s collaborations primarily represent revenue arrangements. For the arrangements or arrangement components that are subject to revenue accounting guidance, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company applies the five-step model. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration, except for sales-based royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In determining the stand-alone selling price of a license to the Company&#8217;s proprietary technology or a material right provided by a customer option, the Company considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating its estimated stand-alone selling price, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling price will have a significant effect on the allocation of arrangement consideration between performance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within one year following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within one year following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive Licenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the license is the predominant promise, and it is determined that the license represents functional intellectual property (&#8220;IP&#8221;), revenue is recognized at the point in time when control of the license is transferred. If it is determined that the license does not represent functional IP, revenue is recognized over time using an appropriate method of measuring progress.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Services</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; The obligations under the Company&#8217;s collaboration and license agreements generally include research and development services to be performed by the Company to benefit the collaboration partner. For performance obligations that include research and development services, the Company generally</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods of which revenue should be recognized, are subject to estimates by management and may change over the course of the contract. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Options</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; The Company&#8217;s arrangements may provide a collaborator with the right to acquire additional goods or services in the future. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment or (ii) upon the exercise of the customer option. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Milestone Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalties</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a complete discussion of accounting for collaboration revenues, s</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ee Note 12.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. The Company&#8217;s research and development expenses consist primarily of costs incurred in performing research and development activities, including salaries and other compensation, share-based compensation, fees paid to external service providers, laboratory supplies and costs for facilities and equipment, partially offset by fully refundable research and development tax credits. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are expensed as the goods are delivered or the services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock', window );">Accrued and Prepaid Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and Prepaid Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into various research and development contracts. The payments to these agreements are recorded as research and development expenses as incurred. The Company records accrued liabilities and prepaid expenses for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgements and estimates are made in determining the accrued and prepaid balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for all share-based awards granted to employees and non-employees as share-based compensation expense at fair value.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized over the employees&#8217; requisite service period, which is the vesting period, on a straight-line basis. Forfeitures are accounted for as they occur.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each restricted share unit is estimated on the date of grant based on the fair value of our common share on that same date. The fair value of each stock option grant or purchases under our 2020 Employee Share Purchase Plan (&#8220;ESPP&#8221;) is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected share price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option and the Company&#8217;s expected dividend yield. As there was no public market for its common shares prior to its IPO in June 2020, the Company determined the volatility for stock option awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies blended with the historical volatility of the Company's common shares. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price. For purchases under our ESPP, only the historical volatility of the Company's common shares is used when developing an estimate of expected volatility. The expected term of the Company&#8217;s stock options granted to employees and non-employees has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. In connection with the adoption of ASU No. 2018-07, Compensation&#8212;Stock Compensation (&#8220;ASU No. 2018-07&#8221;), the Company calculated the expected term of non-employee awards using the midpoint between the vesting date and the contractual term, which is consistent with the method used for employee awards. For purchases under our ESPP, the expected term is based on the length of the offering period. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award, for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common shares; therefore, the expected dividend yield is assumed to be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. Any consideration paid by employees on exercising stock options or the purchases under our ESPP and the corresponding portion previously credited to additional paid-in capital are credited to share capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ShareIssuanceCostsPolicyTextBlock', window );">Share Issuance Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share Issuance Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share issuance costs applicable to the issuance of equity instruments are recorded as a reduction of the financing equity proceeds.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Loss per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted-average number of common shares outstanding during the reporting period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of common shares and potentially dilutive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">securities </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, shares issuable under the ESPP and options to purchase common shares considered to be potentially dilutive securities were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all reporting periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on differences between the consolidated financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock', window );">Research and Development Tax Credits</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and Development Tax Credits</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes the benefit of refundable Canadian research and development tax credits as a reduction of research and development costs when there is reasonable assurance that the amount claimed will be recovered.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13). Certain amendments thereto were also issued by the FASB. ASU 2016-13 and the related amendments implement an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. The Company adopted ASU 2016-13 and the related amendments thereto on January 1, 2022. The adoption of ASU 2016-13 and the related amendments thereto did not have a material impact on the Company&#8217;s consolidated financial statements or disclosures as of and for the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no new accounting pronouncements issued which could have a significant effect on the Company's consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued and prepaid research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ShareIssuanceCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ShareIssuanceCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_SmallerReportingCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Smaller reporting company policy text block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_SmallerReportingCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564404376432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">Schedule of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment is stated at historical cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.498%;"/>
          <td style="width:1.004%;"/>
          <td style="width:49.498%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset Category</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Useful Lives</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the shorter of the lease term and the useful life</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564484195648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.844%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.256%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.256%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.256%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.278%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Money market funds included in cash and cash <br/>&#160;&#160;&#160;equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,995</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,995</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,362</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,362</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,058</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,058</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184,420</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184,420</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">227,415</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,995</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184,420</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Money market funds included in cash and cash <br/>&#160;&#160;&#160;equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,974</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,974</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564404522976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Cash and Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, cash and cash equivalents and marketable securities were comprised of the following:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.588%;"/>
        <td style="width:0.288%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.814%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.264%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.814%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.288%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.56%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.072%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.31%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Cash</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116,526</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116,526</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,995</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,995</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159,521</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159,521</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,641</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">280</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,362</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,207</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,058</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184,848</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">433</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184,420</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">331,892</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">331,892</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,535</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,535</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">334,427</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">334,427</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;U.S. Treasury notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Total marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,439</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,439</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564403273360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.61%;"/>
        <td style="width:1.604%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.615%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.128%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">473</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">469</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">514</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">509</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,075</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,536</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,519</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,465</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,581</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,979</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,353</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,375</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,604</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ScheduleOfDepreciationExpenseTableTextBlock', window );">Schedule of Depreciation Expense Recognized</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense recognized was allocated as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,837</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,325</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administration</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">146</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,978</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,471</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ScheduleOfDepreciationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of depreciation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ScheduleOfDepreciationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564404572208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation and benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,616</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,867</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,078</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,272</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">680</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">387</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued property and equipment purchases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,719</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">377</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,645</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,622</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564487923152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating leases for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,456</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,101</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">278</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,767</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,289</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock', window );">Summary of Other Operating Lease Information</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.818%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.501%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.48%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except as specified otherwise)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Operating Lease Information</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows for operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,948</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,240</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets obtained in exchange for lease obligations</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,690</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.43</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.35</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments under Operating Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments under the Company&#8217;s operating leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.883%;"/>
        <td style="width:1.93%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.187%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturity of Lease Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,342</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">957</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,694</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">266</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,428</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of other operating lease information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564403774848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions used to Determine Grant Date Fair Value under ESPP Offering</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions that the Company used in the Black Scholes option-pricing model to determine the grant date fair value under the ESPP offering were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.663%;"/>
        <td style="width:1.159%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.51%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.159%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.51%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.36</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.05</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.50</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85.37</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61.91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Stock Options Determined on Grant Date Using Black Scholes Option-Pricing Model</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions that the Company used in the Black Scholes option-pricing model to determine the grant date fair value of stock options granted to employees and non-employees were as follows, presented on a weighted-average basis:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.663%;"/>
        <td style="width:1.159%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.51%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.159%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.51%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.99</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.00</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75.99</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share Option Activity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#8217;s share option activity:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.132%;"/>
        <td style="width:0.402%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.456999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.182%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.290000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.298%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.134%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.805%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.303%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>average<br/>exercise<br/>price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>average<br/>remaining<br/>contractual<br/>term<br/>(in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intrinsic value (in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,322,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.15</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,722</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,346,567</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.41</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">148,116</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.02</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">488,140</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,032,902</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.38</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.90</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable, December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,592,087</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.41</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.94</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,538</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options unvested, December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,440,815</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.65</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,712</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense for all awards was allocated as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,671</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,148</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,691</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,829</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation expense by type of award was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,400</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,632</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">291</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,691</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,829</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397876896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Transaction Price Performance Obligations</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the relative stand-alone selling price, the allocation of the transaction price to the separate performance obligations was as follows:</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.153%;"/>
        <td style="width:9.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.845000000000002%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transaction price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Combined licenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105,327</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Completion of Continuing Trials</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,585</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transfer of clinical trial materials</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,714</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total transaction price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,626</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Transaction Price Performance Obligations</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the relative stand-alone selling price, the allocation of the transaction price to the separate performance obligations was as follows:</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.122%;"/>
        <td style="width:8.978%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.899%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transaction price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Research activities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,405</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Options to license druggable targets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,148</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Options to license undruggable targets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,447</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total transaction price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397818688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Loss Before Provision for Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before the provision for income taxes consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.61%;"/>
        <td style="width:1.604%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.615%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.128%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Canada</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,550</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110,433</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,650</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,847</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,586</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of provision for income taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the provision for income taxes are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current income tax provision - foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,527</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">530</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income tax benefit - foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,620</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,208</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,147</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,678</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of Provision for Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation between tax expense and the product of accounting income multiplied by the statutory income tax rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.818%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.501%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.48%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,586</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax at statutory rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computed income tax recovery</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,684</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,775</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect on income tax resulting from:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal investment tax credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,899</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,093</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting charges not deductible for tax purposes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">679</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,078</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capital gain income</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,956</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,492</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,220</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">777</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">142</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">644</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,434</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,285</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,147</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,678</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock', window );">Summary of Losses Expire</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has not recognized the tax benefit of these losses. These losses expire as follows: </span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.968%;"/>
        <td style="width:1.938%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.093%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2042</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,279</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93,834</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2040</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2039</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,394</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2038</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,111</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">883</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158,501</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock', window );">Summary of Investment Tax Credits Expire</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company has not </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the tax benefits related to the non-refundable investment tax credits. The investment tax credits </span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.919%;"/>
        <td style="width:1.919%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.162%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2042</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,392</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,253</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2040</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,702</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2039</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,362</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2038</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">776</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">455</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2036</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,964</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Deferred Tax Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s deferred tax assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.539%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.117%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.117%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,003</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,093</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net research and development expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,468</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,656</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share issuance costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,369</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,538</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net federal investment tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,589</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,805</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,775</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax basis of property and equipment in excess of carrying values</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">376</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,429</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,995</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,445</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,950</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expense and other liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">785</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">760</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,783</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,656</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,492</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">988</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R&amp;D costs capitalized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,911</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,040</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,226</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,040</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,606</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,620</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of investment tax credits expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of recognized tax benefit of losses expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564404370416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.61%;"/>
        <td style="width:1.604%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.615%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.128%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,047</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106,908</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average number of common shares outstanding&#8212;basic and <br/>&#160;&#160;&#160;diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,922,042</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,818,115</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share&#8212;basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.69</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.83</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Computation of Diluted Net Loss Per Share in Attributable to Common Shareholders Indicate to Anti Diluted Effect</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.573%;"/>
        <td style="width:1.175%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.882%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.175%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.195%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,032,902</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,322,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated shares issuable under the ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,216</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,654</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564484204944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Commitments to Settle Contractual Obligations</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company&#8217;s commitments to settle contractual obligations at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, other than leases which are recognized as operating lease liabilities in the consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.919%;"/>
        <td style="width:1.919%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.162%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,090</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,106</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,379</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564404562128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Currency Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ForeignCurrencyRiskAbstract', window );"><strong>Foreign Currency Risk [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ScheduleOfFinancialPositionExposureTableTextBlock', window );">Schedule of Financial Position Exposure</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is exposed to currency risk through its cash, other receivables, accounts payable, accrued expenses and other current liabilities, as well as right-of-use lease liabilities denominated in Canadian dollars as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.61%;"/>
        <td style="width:1.604%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.615%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.128%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,904</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,583</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credits receivable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,261</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other receivables</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">851</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">745</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">324</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">665</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,289</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,116</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,392</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,564</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net financial position exposure</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">756</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ForeignCurrencyRiskAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ForeignCurrencyRiskAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ScheduleOfFinancialPositionExposureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of financial position exposure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ScheduleOfFinancialPositionExposureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564484211024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of Property and Equipment, Net and Right-of-Use Assets by Location</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s property and equipment, net by location was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Canada</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,888</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,675</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,340</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,929</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,604</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s right-of-use assets by location were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.766%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.844000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.163%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Canada</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,578</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,939</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,793</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,552</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total right-of-use assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,491</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397426128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Business - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 23, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 12, 2020</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_OrganizationAndNatureOfBusinessLineItems', window );"><strong>Organization and Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity incorporation, date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  06,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-6.062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.16496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (239,313)<span></span>
</td>
<td class="num">$ (210,266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 94,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rptx_FollowOnOfferingMember', window );">Follow On Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_OrganizationAndNatureOfBusinessLineItems', window );"><strong>Organization and Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses', window );">Underwriting Commissions And Estimated Offering Expenses | $</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_OrganizationAndNatureOfBusinessLineItems', window );"><strong>Organization and Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_GrossProceedsFromInitialPublicOffering', window );">Gross proceeds from IPO | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from IPO | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Convertible preferred shares converted into common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,558,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares issued upon exercise of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_OrganizationAndNatureOfBusinessLineItems', window );"><strong>Organization and Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Exercise of Underwriters Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_OrganizationAndNatureOfBusinessLineItems', window );"><strong>Organization and Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Follow On Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_OrganizationAndNatureOfBusinessLineItems', window );"><strong>Organization and Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common shares | $</a></td>
<td class="nump">$ 94,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Common Shares | Exercise of Underwriters Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_OrganizationAndNatureOfBusinessLineItems', window );"><strong>Organization and Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_GrossProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_GrossProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_OrganizationAndNatureOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and nature of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_OrganizationAndNatureOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting commissions and estimated offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rptx_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rptx_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564403285040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk', window );">Significant off-balance sheet risk, description</a></td>
<td class="text">As of December 31, 2022 and 2021, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.<span></span>
</td>
<td class="text">As of December 31, 2022 and 2021, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Share based compensation, expected dividend yield assumed</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of financial instruments, excluding certain derivatives, with off-balance sheet credit risk (for example, standby letters of credit or financial guarantees), including (1) information about the (shared) activity, region or economic characteristic that identifies the concentration, (2) the face or contract amount of the instrument, (3) the nature and terms of the instrument, including the market risk, cash requirements and accounting policies for it, (4) the maximum amount of loss due to credit risk that would be incurred if the counterparties failed completely to perform according to the terms of the contracts, and any security or collateral that proved to be of no value, (5) the entity's policy of requiring collateral or other security to support financial instruments subject to credit risk, information about access to collateral or other security, and a brief description of the security supporting those financial instruments, and (6) the policy of entering into and a brief description of master netting arrangements to mitigate the credit risk, and the extent to which such arrangements would reduce the maximum amount of loss due to credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397681792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives of assets, description</a></td>
<td class="text">the shorter of the lease term and the useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397427152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 227,415<span></span>
</td>
<td class="nump">$ 9,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">58,362<span></span>
</td>
<td class="nump">7,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">126,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">42,995<span></span>
</td>
<td class="nump">9,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. Treasury Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">184,420<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. Treasury Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">58,362<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">126,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds Included In Cash And Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">42,995<span></span>
</td>
<td class="nump">2,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds Included In Cash And Cash Equivalents [Member] | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">42,995<span></span>
</td>
<td class="nump">$ 2,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">184,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Marketable Securities [Member] | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Marketable Securities [Member] | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 184,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=rptx_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=rptx_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397323696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_FairValueAssetsTransfersBetweenAllLevels', window );">Fair value, assets, transfers between levels</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_FairValueAssetsTransfersBetweenAllLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, assets, transfers between all levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_FairValueAssetsTransfersBetweenAllLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397385536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Marketable Securities - Summary of Cash and Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 159,521<span></span>
</td>
<td class="nump">$ 334,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">159,521<span></span>
</td>
<td class="nump">334,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">42,995<span></span>
</td>
<td class="nump">2,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">42,995<span></span>
</td>
<td class="nump">2,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=rptx_MarketableSecuritiesMember', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">184,848<span></span>
</td>
<td class="nump">7,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(433)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">184,420<span></span>
</td>
<td class="nump">7,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=rptx_MarketableSecuritiesMember', window );">Marketable securities | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">58,641<span></span>
</td>
<td class="nump">7,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(280)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">58,362<span></span>
</td>
<td class="nump">7,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=rptx_MarketableSecuritiesMember', window );">Marketable securities | U.S. Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">126,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(153)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">126,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember', window );">Cash | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">116,526<span></span>
</td>
<td class="nump">331,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 116,526<span></span>
</td>
<td class="nump">$ 331,892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=rptx_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=rptx_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397104736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Marketable Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Positions</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Positions</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities | Positions</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInvestmentIncomeReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Accumulated unrealized loss</a></td>
<td class="nump">157,900,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized Gain (Loss) On Derivatives</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded', window );">Allowance for credit losses or other impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInvestmentIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInvestmentIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564403252352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 9,581<span></span>
</td>
<td class="nump">$ 8,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(5,353)<span></span>
</td>
<td class="num">(3,375)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,228<span></span>
</td>
<td class="nump">5,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,075<span></span>
</td>
<td class="nump">5,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,519<span></span>
</td>
<td class="nump">$ 2,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397823840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Depreciation Expense Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,978<span></span>
</td>
<td class="nump">$ 1,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,837<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564402650032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">$ 5,616<span></span>
</td>
<td class="nump">$ 4,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expense</a></td>
<td class="nump">15,078<span></span>
</td>
<td class="nump">11,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_AccruedPropertyAndEquipmentPurchases', window );">Accrued property and equipment purchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 21,645<span></span>
</td>
<td class="nump">$ 18,622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other liabilities current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_AccruedPropertyAndEquipmentPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued property and equipment purchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_AccruedPropertyAndEquipmentPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397201536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Detail) - NYU Agreement - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones', window );">License agreement milestone and royalty payments upon achievement of certain clinical and commercial milestones</a></td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_AccrualPotentialMilestoneAndRoyaltyPayments', window );">Accrual of potential future milestone or royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_AccrualPotentialMilestoneAndRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrual potential milestone and royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_AccrualPotentialMilestoneAndRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement milestone and royalty payments upon achievement of certain clinical and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rptx_NewYorkUniversityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rptx_NewYorkUniversityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564399457920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_NumberOfOperatingLeases', window );">Number of operating leases | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Lessee, operating lease, existence of option to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ImplicitInterestRate', window );">Implicit interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA-QC', window );">Montreal, Quebec</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Minimum lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">32 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rptx_OfficeAndLaboratorySpaceMember', window );">Office and Laboratory Space | Montreal, Quebec</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Minimum lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_LesseeOperatingLeaseExpirationMonthAndYear', window );">Operating lease, expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020-10<span></span>
</td>
<td class="text">2021-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, existence of option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend, description</a></td>
<td class="text">extended through July 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">extended through December 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating Lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember', window );">Office Space | Cambridge, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Minimum lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_LesseeOperatingLeaseExpirationMonthAndYear', window );">Operating lease, expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating Lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ImplicitInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Implicit interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ImplicitInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_LesseeOperatingLeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_LesseeOperatingLeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_NumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_NumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-QC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-QC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rptx_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rptx_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564395540288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,456<span></span>
</td>
<td class="nump">$ 2,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 2,767<span></span>
</td>
<td class="nump">$ 2,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564403488768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Other Operating Lease Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows for operating leases</a></td>
<td class="nump">$ 1,948<span></span>
</td>
<td class="nump">$ 1,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 4,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">2 years 5 months 4 days<span></span>
</td>
<td class="text">3 years 4 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564399446128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments under Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 2,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">2,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">5,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 5,428<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564402708768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Shares - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 23, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Convertible preferred shares converted into common shares</a></td>
<td class="nump">21,558,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564396796080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2021</div></th>
<th class="th"><div>Jun. 23, 2020</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each common share entitles the holder to one vote on all matters submitted to the shareholders for a vote.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared or paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 94,288,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Maximum aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rptx_FollowOnOfferingMember', window );">Follow On Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses', window );">Underwriting Commissions And Estimated Offering Expenses</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Maximum aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,288,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Maximum aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Exercise of Underwriters Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Exercise of Underwriters Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Follow On Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common shares</a></td>
<td class="nump">$ 94,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Maximum aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,288,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Sales Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Maximum aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting commissions and estimated offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rptx_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rptx_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rptx_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rptx_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564395290192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,036,193<span></span>
</td>
<td class="nump">41,850,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.54<span></span>
</td>
<td class="nump">$ 22.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_FairValueOfVestedOptions', window );">Fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,100<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised options, weighted-average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Aggregate proceeds from exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 447<span></span>
</td>
<td class="nump">$ 986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares', window );">Decrease in additional paid-in capital as exercised options credited to common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation expense related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense related to unvested stock options, weighted-average remaining vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,346,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,116<span></span>
</td>
<td class="nump">333,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember', window );">2020 Employee Share Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,487,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear', window );">Annual increase in number of shares available for issuance as percentage of outstanding shares common stock on final day of preceding calendar year</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued', window );">Annual increase in number of shares available for issuance maximum number of common stock issued</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase', window );">Purchase price of shares as percentage of fair market value of common stock on date of purchase</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,915<span></span>
</td>
<td class="nump">9,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.43<span></span>
</td>
<td class="nump">$ 28.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.91<span></span>
</td>
<td class="nump">$ 10.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepurchaseOfEquity', window );">Cash received from purchases under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember', window );">2020 Employee Share Purchase Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember', window );">2020 Employee Share Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance', window );">Shares of common stock initially reserved for future issuance</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rptx_RepareTherapeuticsIncorporationOptionPlanMember', window );">Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">298,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rptx_RepareTherapeuticsIncorporationOptionPlanMember', window );">Option Plan | Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting', window );">Number of shares ceased granting</a></td>
<td class="nump">4,074,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,025,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear', window );">Annual increase in number of shares available for issuance as percentage of outstanding shares common stock on final day of preceding calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare', window );">Exercise price per share as minimum percentage of fair value of common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate', window );">Monthly vesting rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1/36th<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Vesting on First Anniversary Date of Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Vesting on Monthly Basis at Rate of 1/36th</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Subsequent Event | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted share units to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance', window );">Shares of common stock initially reserved for future issuance</a></td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">3,807,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional paid in capital share-based payment arrangement exercised options credited to common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual increase in number of shares available for issuance as percentage on outstanding shares of common stock on final day of preceding calendar year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual increase in number of shares available for issuance maximum number of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock capital shares initially reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share as minimum percentage of fair value of common share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_FairValueOfVestedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of vested options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_FairValueOfVestedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of shares as percentage of fair market value of common stock on date of purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by payment award number of shares ceased granting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment monthly vesting rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow resulting from the entity's share transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rptx_RepareTherapeuticsIncorporationOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rptx_RepareTherapeuticsIncorporationOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564402598480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Assumptions used to Determine Grant Date Fair Value under ESPP Offering (Details) - 2020 Employee Share Purchase Plan<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.36%<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">85.37%<span></span>
</td>
<td class="nump">61.91%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564402598640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Fair Value of Stock Options Determined on Grant Date Using Black Scholes Option-Pricing Model (Details) - 2020 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.17%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">78.95%<span></span>
</td>
<td class="nump">75.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rptx_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397293600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at beginning of period</a></td>
<td class="nump">5,322,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">3,346,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(148,116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Forfeited</a></td>
<td class="num">(488,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at end of period</a></td>
<td class="nump">8,032,902<span></span>
</td>
<td class="nump">5,322,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Options Exercisable</a></td>
<td class="nump">3,592,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Options Unvested</a></td>
<td class="nump">4,440,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at beginning of period</a></td>
<td class="nump">$ 14.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">14.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">3.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">22.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at end of period</a></td>
<td class="nump">14.38<span></span>
</td>
<td class="nump">$ 14.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">11.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Options Unvested</a></td>
<td class="nump">$ 16.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years) , Outstanding</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Options Exercisable</a></td>
<td class="text">6 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Options Unvested</a></td>
<td class="text">8 years 7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value, Outstanding at beginning of period</a></td>
<td class="nump">$ 55,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value, Outstanding at end of period</a></td>
<td class="nump">37,250<span></span>
</td>
<td class="nump">$ 55,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value, Options exercisable</a></td>
<td class="nump">28,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Intrinsic value, Options unvested</a></td>
<td class="nump">$ 8,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397719792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-based Compensation Expense for All Awards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 19,691<span></span>
</td>
<td class="nump">$ 12,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">10,020<span></span>
</td>
<td class="nump">5,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 9,671<span></span>
</td>
<td class="nump">$ 7,148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397588272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-based Compensation Expense by Type of Award (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 19,691<span></span>
</td>
<td class="nump">$ 12,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">19,400<span></span>
</td>
<td class="nump">12,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564403530784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Savings Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent', window );">Percentage of non-matching employer contributions</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Matching contribution expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan employer non matching contribution percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564388661488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Additional Information (Details)<br> $ in Thousands, &#165; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 23, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares issued upon exercise of warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_OnoPharmaceuticalCompanyLimitedMember', window );">Ono Pharmaceutical Co., Ltd. | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_CollaborationTermExtendedPeriod', window );">Collaboration term extended period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_SecondAmendmentAgreement', window );">Second amendment agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In January 2023, the Company and Ono entered into a second amendment to the Ono Agreement whereby the Research Term, as defined in the Ono Agreement, was extended until July 31, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Initial nonrefundable upfront fee payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="nump">&#165; 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_InitialUpfrontFeePayment', window );">Initial upfront fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_CollaborationReceivable', window );">Collaboration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred revenue, additions</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">&#165; 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">&#165; 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Milestone payments entitled to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">&#165; 450<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_OnoPharmaceuticalCompanyLimitedMember', window );">Ono Pharmaceutical Co., Ltd. | Research, Development and Regulatory Milestones | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Initial nonrefundable upfront fee payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100<span></span>
</td>
<td class="nump">&#165; 790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_OnoPharmaceuticalCompanyLimitedMember', window );">Ono Pharmaceutical Co., Ltd. | Commercial Milestones | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Milestone payments entitled to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 17,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_OnoPharmaceuticalCompanyLimitedMember', window );">Ono Pharmaceutical Co., Ltd. | Grant of License [Member] | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Milestone payments entitled to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">&#165; 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_RevenueRemainingPerformanceObligationNetAmount', window );">Research service payments entitled to be received, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Initial nonrefundable upfront fee payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_CollaborationTermExpirationPeriod', window );">Collaboration term expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,400<span></span>
</td>
<td class="nump">42,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,400<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Collaboration and License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Milestone payments entitled to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Research, Development and Regulatory Milestones | Collaboration and License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Milestone payments entitled to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Commercial Milestones | Collaboration and License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Milestone payments entitled to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Product Research Activity | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Product RPTX Options to License Druggable Target | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember', window );">Hoffmann La Roche Inc And F Hoffmann La Roche Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember', window );">Hoffmann La Roche Inc And F Hoffmann La Roche Ltd | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Initial nonrefundable upfront fee payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_CollaborationRevenueReceived', window );">Collaboration Revenue Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue', window );">Estimated period of completion of trials to get revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember', window );">Hoffmann La Roche Inc And F Hoffmann La Roche Ltd | Commercial Milestones | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_MilestonesPayments', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember', window );">Hoffmann La Roche Inc And F Hoffmann La Roche Ltd | Additional Clinical Development Plan | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_CollaborationRevenueReceived', window );">Collaboration Revenue Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember', window );">Hoffmann La Roche Inc And F Hoffmann La Roche Ltd | Clinical Trial Materials | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_CollaborationRevenueReceived', window );">Collaboration Revenue Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember', window );">Hoffmann La Roche Inc And F Hoffmann La Roche Ltd | Research and Development Services | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember', window );">Hoffmann La Roche Inc And F Hoffmann La Roche Ltd | Combined Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember', window );">Hoffmann La Roche Inc And F Hoffmann La Roche Ltd | Combined Licenses | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_CollaborationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_CollaborationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_CollaborationRevenueReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Revenue received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_CollaborationRevenueReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_CollaborationTermExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration term expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_CollaborationTermExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_CollaborationTermExtendedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration term extended period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_CollaborationTermExtendedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period of completion of trials to get revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_InitialUpfrontFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial upfront fee payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_InitialUpfrontFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_MilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_MilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_RevenueRemainingPerformanceObligationNetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue remaining performance obligation net amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_RevenueRemainingPerformanceObligationNetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_SecondAmendmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Second amendment agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_SecondAmendmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rptx_OnoPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rptx_OnoPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rptx_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rptx_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_ResearchDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_ResearchDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_GrantOfLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_GrantOfLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_ProductResearchActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_ProductResearchActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_ProductRptxOptionsToLicenseDruggableTargetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_ProductRptxOptionsToLicenseDruggableTargetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_AdditionalClinicalDevelopmentPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_AdditionalClinicalDevelopmentPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_ClinicalTrialMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_ClinicalTrialMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_CombinedLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_CombinedLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397086720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborations - Schedule of Transaction Price Performance Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Transaction price</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember', window );">Hoffmann La Roche Inc And F Hoffmann La Roche Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Transaction price</a></td>
<td class="nump">134,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rptx_ResearchActivitiesMember', window );">Research Activities | Bristol-Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Transaction price</a></td>
<td class="nump">6,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rptx_OptionsToLicenseDruggableTargetsMember', window );">Options to License Druggable Targets | Bristol-Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Transaction price</a></td>
<td class="nump">31,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rptx_OptionsToLicenseUndruggableTargetMember', window );">Options to License Undruggable Targets | Bristol-Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Transaction price</a></td>
<td class="nump">12,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rptx_CombinedLicensesMember', window );">Combined Licenses | Hoffmann La Roche Inc And F Hoffmann La Roche Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Transaction price</a></td>
<td class="nump">105,327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rptx_CompletionOfContinuingTrialsMember', window );">Completion of Continuing Trials | Hoffmann La Roche Inc And F Hoffmann La Roche Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Transaction price</a></td>
<td class="nump">26,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rptx_TransferOfClinicalTrialMaterialsMember', window );">Transfer of Clinical Trial Materials | Hoffmann La Roche Inc And F Hoffmann La Roche Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Transaction price</a></td>
<td class="nump">$ 2,714<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_ResearchActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_ResearchActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_OptionsToLicenseDruggableTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_OptionsToLicenseDruggableTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_OptionsToLicenseUndruggableTargetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_OptionsToLicenseUndruggableTargetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_CombinedLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_CombinedLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_CompletionOfContinuingTrialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_CompletionOfContinuingTrialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rptx_TransferOfClinicalTrialMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rptx_TransferOfClinicalTrialMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564398110160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Loss Before Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Canada</a></td>
<td class="num">$ (17,550)<span></span>
</td>
<td class="num">$ (110,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">3,650<span></span>
</td>
<td class="nump">1,847<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (13,900)<span></span>
</td>
<td class="num">$ (108,586)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564487918784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of provision for income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current income tax provision - foreign</a></td>
<td class="nump">$ 11,527<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred income tax benefit - foreign</a></td>
<td class="nump">3,620<span></span>
</td>
<td class="num">(2,208)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax (benefit) expense</a></td>
<td class="nump">$ 15,147<span></span>
</td>
<td class="num">$ (1,678)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564395256624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (13,900)<span></span>
</td>
<td class="num">$ (108,586)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax at statutory rate</a></td>
<td class="nump">26.50%<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Computed income tax recovery</a></td>
<td class="num">$ (3,684)<span></span>
</td>
<td class="num">$ (28,775)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Federal investment tax credit</a></td>
<td class="num">(4,899)<span></span>
</td>
<td class="num">(4,093)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges', window );">Accounting charges not deductible for tax purposes</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation', window );">Capital gain income</a></td>
<td class="num">(13,956)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity compensation</a></td>
<td class="nump">3,492<span></span>
</td>
<td class="nump">2,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncomeTaxReconciliationStateTaxes', window );">State Taxes</a></td>
<td class="num">(777)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(142)<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">34,434<span></span>
</td>
<td class="nump">27,285<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax (benefit) expense</a></td>
<td class="nump">$ 15,147<span></span>
</td>
<td class="num">$ (1,678)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax rate reconciliation, nondeductible expense, accounting charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation capital gain income
Equity compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncomeTaxReconciliationStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation state taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncomeTaxReconciliationStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564398035216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncomeTaxLosses', window );">Income tax losses</a></td>
<td class="nump">$ 158,501,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ScientificResearchAndExperimentalDevelopmentExpenditures', window );">Scientific research and experimental development expenditures</a></td>
<td class="nump">54,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_InvestmentTaxCredits', window );">Investment tax credits</a></td>
<td class="nump">8,964,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">97,040,000<span></span>
</td>
<td class="nump">$ 62,606,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,775,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncomeTaxExaminationYearSubjectToExamination', window );">Tax examination</a></td>
<td class="text">2017 2018 2019 2020 2021 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=rptx_StateAndUsFederalMember', window );">U.S. federal and state research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncomeTaxExaminationYearSubjectToExamination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax examination, year subject to examination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncomeTaxExaminationYearSubjectToExamination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncomeTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncomeTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_InvestmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_InvestmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ScientificResearchAndExperimentalDevelopmentExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Scientific Research and experimental development expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ScientificResearchAndExperimentalDevelopmentExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=rptx_StateAndUsFederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=rptx_StateAndUsFederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564395540288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Losses Expire (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncomeTaxLossesExpireOne', window );">2042</a></td>
<td class="nump">$ 45,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncomeTaxLossesExpireTwo', window );">2041</a></td>
<td class="nump">93,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncomeTaxLossesExpireThree', window );">2040</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncomeTaxLossesExpireFour', window );">2039</a></td>
<td class="nump">11,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncomeTaxLossesExpireFive', window );">2038</a></td>
<td class="nump">7,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncomeTaxLossesExpireSix', window );">2037</a></td>
<td class="nump">883<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncomeTaxLosses', window );">Total</a></td>
<td class="nump">$ 158,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncomeTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncomeTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncomeTaxLossesExpireFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax losses expire five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncomeTaxLossesExpireFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncomeTaxLossesExpireFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax losses expire four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncomeTaxLossesExpireFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncomeTaxLossesExpireOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax losses expire one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncomeTaxLossesExpireOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncomeTaxLossesExpireSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax losses expire six.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncomeTaxLossesExpireSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncomeTaxLossesExpireThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax losses expire three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncomeTaxLossesExpireThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncomeTaxLossesExpireTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax losses expire two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncomeTaxLossesExpireTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397173488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Investment Tax Credits Expire (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_InvestmentTaxCreditsExpireOne', window );">2042</a></td>
<td class="nump">$ 2,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_InvestmentTaxCreditsExpireTwo', window );">2041</a></td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_InvestmentTaxCreditsExpireThree', window );">2040</a></td>
<td class="nump">1,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_InvestmentTaxCreditsExpireFour', window );">2039</a></td>
<td class="nump">1,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_InvestmentTaxCreditsExpireFive', window );">2038</a></td>
<td class="nump">776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_InvestmentTaxCreditsExpireSix', window );">2037</a></td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_InvestmentTaxCreditsExpireSeven', window );">2036</a></td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_InvestmentTaxCredits', window );">Total</a></td>
<td class="nump">$ 8,964<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_InvestmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_InvestmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_InvestmentTaxCreditsExpireFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment tax credits expire five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_InvestmentTaxCreditsExpireFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_InvestmentTaxCreditsExpireFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment tax credits expire four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_InvestmentTaxCreditsExpireFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_InvestmentTaxCreditsExpireOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment tax credits expire one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_InvestmentTaxCreditsExpireOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_InvestmentTaxCreditsExpireSeven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment tax credits expire seven.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_InvestmentTaxCreditsExpireSeven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_InvestmentTaxCreditsExpireSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment tax credits expire six.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_InvestmentTaxCreditsExpireSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_InvestmentTaxCreditsExpireThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment tax credits expire three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_InvestmentTaxCreditsExpireThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_InvestmentTaxCreditsExpireTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment tax credits expire two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_InvestmentTaxCreditsExpireTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564403178448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 42,003<span></span>
</td>
<td class="nump">$ 30,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Net research and development expenditures</a></td>
<td class="nump">14,468<span></span>
</td>
<td class="nump">10,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share issuance costs</a></td>
<td class="nump">2,369<span></span>
</td>
<td class="nump">3,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits', window );">Net federal investment tax credits</a></td>
<td class="nump">6,589<span></span>
</td>
<td class="nump">4,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">U.S. research and development tax credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Tax basis of property and equipment in excess of carrying values</a></td>
<td class="num">(376)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(1,429)<span></span>
</td>
<td class="num">(1,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_DeferredTaxLiabilitiesOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">1,445<span></span>
</td>
<td class="nump">1,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities', window );">Accrued expense and other liabilities</a></td>
<td class="nump">785<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">14,783<span></span>
</td>
<td class="nump">13,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_DeferredTaxAssetsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">2,492<span></span>
</td>
<td class="nump">988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">R&amp;D costs capitalized</a></td>
<td class="nump">13,911<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">97,040<span></span>
</td>
<td class="nump">66,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(97,040)<span></span>
</td>
<td class="num">(62,606)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets net federal investment tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_DeferredTaxAssetsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets share based compensation cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_DeferredTaxAssetsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities accrued expense and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_DeferredTaxLiabilitiesOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_DeferredTaxLiabilitiesOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564403540304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,047)<span></span>
</td>
<td class="num">$ (106,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares outstanding-basic</a></td>
<td class="nump">41,922,042<span></span>
</td>
<td class="nump">37,818,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares outstanding-diluted</a></td>
<td class="nump">41,922,042<span></span>
</td>
<td class="nump">37,818,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share basic</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (2.83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share diluted</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (2.83)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564396958464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Computation of Diluted Net Loss Per Share in Attributable to Common Shareholders Indicate to Anti Diluted Effect (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rptx_OptionsToPurchaseCommonSharesMember', window );">Options to Purchase Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">8,032,902<span></span>
</td>
<td class="nump">5,322,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rptx_EstimatedSharesIssuableUnderTheEsppMember', window );">Estimated shares issuable under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">47,216<span></span>
</td>
<td class="nump">9,654<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rptx_OptionsToPurchaseCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rptx_OptionsToPurchaseCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rptx_EstimatedSharesIssuableUnderTheEsppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rptx_EstimatedSharesIssuableUnderTheEsppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564483946384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Government Assistance - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses', window );">Reduction of research and development expenditures</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564402720864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Commitments to Settle Contractual Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 3,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2024</a></td>
<td class="nump">3,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2025</a></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2026</a></td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2027</a></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Following years</a></td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">$ 6,379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564402727664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rptx_PreclinicalStudiesAndClinicalTrialsMember', window );">Preclinical Studies and Clinical Trials | MDACC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ContractualObligationPeriod', window );">Contractual obligation period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ContractualObligationsPaid', window );">Contractual Obligations Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rptx_SpecialtyScreeningServicesMember', window );">Specialty Screening Services | Broad Institute, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Contractual obligation</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ContractualObligationPeriod', window );">Contractual obligation period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ContractualObligationAmountPerYear', window );">Contractual obligation per year</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ContractualObligationAmountPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligation amount per year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ContractualObligationAmountPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ContractualObligationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligation period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ContractualObligationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ContractualObligationsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligations paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ContractualObligationsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rptx_PreclinicalStudiesAndClinicalTrialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rptx_PreclinicalStudiesAndClinicalTrialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rptx_TheUniversityOfTexasMDAndersonCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rptx_TheUniversityOfTexasMDAndersonCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rptx_SpecialtyScreeningServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rptx_SpecialtyScreeningServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rptx_BroadInstituteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rptx_BroadInstituteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564403553904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Currency Risk - Schedule of Financial Position Exposure (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ForeignCurrencyRiskLineItems', window );"><strong>Foreign Currency Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet', window );">Net financial position exposure</a></td>
<td class="num">$ (4,250)<span></span>
</td>
<td class="num">$ (756)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ForeignCurrencyRiskLineItems', window );"><strong>Foreign Currency Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Assets exposure</a></td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">3,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=rptx_ResearchAndDevelopmentTaxCreditsReceivableMember', window );">Research and Development Tax Credits Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ForeignCurrencyRiskLineItems', window );"><strong>Foreign Currency Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Assets exposure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=rptx_OtherReceivablesMember', window );">Other Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ForeignCurrencyRiskLineItems', window );"><strong>Foreign Currency Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Assets exposure</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ForeignCurrencyRiskLineItems', window );"><strong>Foreign Currency Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Liability exposure</a></td>
<td class="num">(324)<span></span>
</td>
<td class="num">(665)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ForeignCurrencyRiskLineItems', window );"><strong>Foreign Currency Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Liability exposure</a></td>
<td class="num">(2,289)<span></span>
</td>
<td class="num">(2,116)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=rptx_LeaseLiabilitiesMember', window );">Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ForeignCurrencyRiskLineItems', window );"><strong>Foreign Currency Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Liability exposure</a></td>
<td class="num">$ (4,392)<span></span>
</td>
<td class="num">$ (5,564)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ForeignCurrencyRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ForeignCurrencyRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126966630&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rptx_ResearchAndDevelopmentTaxCreditsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rptx_ResearchAndDevelopmentTaxCreditsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rptx_OtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rptx_OtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rptx_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rptx_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564483946384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Currency Risk - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_ForeignCurrencyRiskAbstract', window );"><strong>Foreign Currency Risk [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rptx_PercentageOfDepreciationUSDAgainstCanadianDollar', window );">Percentage of depreciation USD against Canadian dollar</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Increase in net loss currency risk</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_ForeignCurrencyRiskAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_ForeignCurrencyRiskAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rptx_PercentageOfDepreciationUSDAgainstCanadianDollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of depreciation USD against Canadian dollar.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rptx_PercentageOfDepreciationUSDAgainstCanadianDollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rptx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564396612704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geographic Information - Schedule of Property and Equipment, Net by Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 4,228<span></span>
</td>
<td class="nump">$ 5,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,888<span></span>
</td>
<td class="nump">3,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 1,340<span></span>
</td>
<td class="nump">$ 1,929<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564399339840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geographic Information - Schedule of Right-of-Use Assets by Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="nump">$ 7,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,578<span></span>
</td>
<td class="nump">4,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,793<span></span>
</td>
<td class="nump">$ 2,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140564397901984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember', window );">Roche | Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 116.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>rptx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rptx="http://www.reparerx.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rptx-20221231.xsd" xlink:type="simple"/>
    <context id="C_440d565d-c87e-4c67-922b-8dd7ab19917a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rptx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="C_39535649-8458-447e-b3bd-2d67c59d8b5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bda62528-1f40-4600-97f1-d787732fa2f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rptx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_baf42153-e67f-4dc2-ba51-e440db83cb6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_17e3367f-80ab-4165-a57b-7a3da73e2379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rptx:EstimatedSharesIssuableUnderTheEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cb5cf079-696f-4343-a699-77c7dc62a392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f8706cb3-36b5-4d0e-af7f-dd5993e51a36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_86d0da1c-aaaa-4a1a-982b-05aa91d37fd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ff1c845e-bbd0-4d13-bdde-c076815d4982">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a3402cc5-4f44-4db4-b2f1-72ae898426a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ResearchDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="C_98bf928f-8526-4b16-9053-723fa23a52a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a9d543b1-b2e8-4033-a16b-a49687bf6b19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rptx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_69c1b260-1116-4599-800d-1afb2f09f79f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ff4a68ee-b5b1-4384-8e04-39e5e83483d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MoneyMarketFundsIncludedInCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bcf5a011-b156-43a6-a346-9debd16c577f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4fa8599e-cef5-4581-9bfc-a45811c2a414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_6fe10c4b-5340-414c-899a-6ed2280ce2c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ac38558a-83a0-47fb-bd07-2be4ac80a958">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7f118fdb-411f-477e-a3a2-4b54c2f8d660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">rptx:StateAndUsFederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_42ff0858-ec4a-443e-a421-33c199818df7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rptx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="C_48281951-8326-4dc8-8373-9afcbedac008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_94ac4eab-f661-466e-ad3c-d52a1dad0918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_404f23f3-7385-4056-868c-5316d49ea62c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ProductResearchActivityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6c9ad6f4-0f96-4cc2-a1f8-7552b59f9ad8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:RepareTherapeuticsIncorporationOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_84f40979-c89b-461b-ba1d-ce4f4b049543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="C_df372273-07d1-45f3-97f2-72265a4457ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_82791e69-edf1-4fd6-8015-240f7998a7d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_edf78ca6-0a38-4dce-a237-43ab79035e63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_2c1f1f11-816f-44a0-818c-677c87d99b95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_12d929c7-4102-4a0a-82ac-5737d31dbf45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5b7ac425-2255-44fd-ada4-9a500ac1d1b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:NewYorkUniversityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3b9dcbf4-525f-41db-93e3-091d15eb10d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MoneyMarketFundsIncludedInCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d32f5d4c-c383-401d-8204-bd0f61937dfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_4a5e155a-5edb-4aab-8fba-3f55b166f8d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rptx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="C_a780ab50-a50d-41cf-bc67-6e53d80a9287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_9cf3be3d-b394-4173-992a-035a20692942">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_36e12a3b-5472-493d-b0e7-efefbdab666c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
        </entity>
        <period>
            <instant>2023-02-24</instant>
        </period>
    </context>
    <context id="C_a8717ee6-9026-4027-9c4d-810f9e98e2d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:AccruedExpenseAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_79831ab9-e01f-4b6c-ac9f-05479c973e07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d537aff3-5446-4d5f-b08a-5674e6242a97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fad67f8b-88f3-490b-bbfe-cdc36bfeb2fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_df52d1fe-29fc-4d0d-8f6f-fd0bf0ff0418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rptx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="C_ef8a6a09-6b50-4f94-bb7e-8070837f1e1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0bcff83b-674d-4098-82be-f88a301739b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rptx:PreclinicalStudiesAndClinicalTrialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:TheUniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_48b390fd-4b46-46d7-aee6-263c90700965">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_51f4647b-4513-4f59-b327-5fe1b4b8ec0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8f5ce4e2-c290-41fd-9af5-5d0fb88c397e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ResearchActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_44a2af96-1633-4609-b79e-fb906b4b9e17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e1f902aa-4006-405b-b0bd-e5a178b2bfaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-23</startDate>
            <endDate>2020-06-23</endDate>
        </period>
    </context>
    <context id="C_10a635cc-4c15-4e96-be01-4a9e22f1dbef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6a124d3c-84d9-4aa0-bd9c-49a33f8564bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ProductResearchActivityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ea477cfd-4c08-4194-a45f-5b0534acacdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9e6d1afd-0b5e-467c-9164-fafb352d5632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:OptionsToLicenseUndruggableTargetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1eeb9ab9-2a11-42de-9a18-4d0e8bc99e37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e4e66d4b-8df8-4150-855e-17cb5ce1bcb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="C_fc490bf6-e1b0-491f-b8e0-2dc975bea1ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MoneyMarketFundsIncludedInCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20ff1fa1-ce48-4c09-9244-1fba1284c839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2a16f0b2-09c2-4e09-be6e-37e84f297dcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_4ea84029-b253-493e-8495-d6a1f2b4c88a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ClinicalTrialMaterialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4e010701-b9b6-4606-92d0-3a2915bef141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_17dcc120-3760-4de9-9e06-6064cef30d4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_678241cd-18bd-45e5-b0fa-05a4f27297f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rptx:OptionsToPurchaseCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_edec0475-471a-4ae7-bedf-0d8f8f6903fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_725a0d91-5730-423e-a433-8f6615c75200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2885b753-de7f-4392-894e-f84483b20968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:NewYorkUniversityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_93008ec0-d0c8-4150-bb27-d96cc8c66909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5ef6ce9a-5c8e-4c42-b1be-099fd91b49b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fcd2c4f4-1550-4748-b6e8-c629770be22e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_db2b4777-c5cc-4811-a937-f402d6499701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_63512c11-8031-488d-bf0e-063cdf64bffb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d7dc9fc2-b468-4689-8b15-f9d0f5c26ff5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rptx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b1cc4d13-0ecb-41c8-b252-fe8d061ccd9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bfafee29-fc89-418f-885a-bdf98c97ba34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-10</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_b3c5d94f-28fa-4de1-b6e2-f03d2f331b1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4efbd3ec-210d-4b1b-84fc-55cd67ef578f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_421e346c-f45c-4450-9712-2cde91dba0a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c9e1d8a8-8da6-496e-93e9-56257c4a31b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rptx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ba8a8b55-bc32-45e4-ac52-b062d5026bf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-23</instant>
        </period>
    </context>
    <context id="C_434cd7cc-5862-46ac-a5bc-39dc683d789f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="C_209bac12-6e02-4442-87b0-25af22df7850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_aecc3de1-8a93-42ff-8549-71726fd80b22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3cfc3e53-1c58-46fd-a5b8-3badfcad9efb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="C_ad4b56bf-9860-4d20-8314-347221a8f5e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rptx:SpecialtyScreeningServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BroadInstituteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-31</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_c204b568-e22d-442d-991f-8208f6b49c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ceb724a0-d094-4e75-ad7c-5458548dadc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_21132067-3295-4e05-aca1-b407f86fc88d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_51a377d0-935c-4a85-8c6a-d896a70f1212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f2334817-ca3c-48d5-8771-4bdef45705e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ResearchDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_e75a721e-63db-4a19-a404-91703f5b0417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_df9028e4-3b11-4078-8748-bb04b49d52e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3dbc6dec-8dff-4b9e-b1b2-8ee0fd0bfed6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_b5d1add8-29f2-4667-a5b8-f33390d83a70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5d5cfdbd-0c58-4551-828e-64319099c53b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_2aca0240-4cad-4cad-b715-46c7dbbe4758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_04d861cf-f6d2-4f55-acdf-2117513160d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_06d3eba4-beff-4c6e-9e0d-74f30c8e9c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_570d5b98-d1b3-467c-8957-e622df2b9b75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="C_acf39634-d069-4302-ab50-45e5dd9d130f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_28941f5b-2a91-41bc-8b35-389f61385829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_25443f6f-14cc-4288-8365-8cdd9a2d1076">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rptx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="C_1a6bffab-7ac1-4529-af70-4292b5a90b4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0059be0f-88d6-4e76-a6ad-ac729b891744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-31</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_7a43defd-03d5-46c3-9322-0c22c5e6e0fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_03151e6d-e0d6-4a61-8ae6-3e23b66eafd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:CombinedLicensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8c1fa03b-d7de-4cdb-bb33-3af841c54489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d02b1f3e-16d6-4441-958a-8ba01e196c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_67d17037-8967-4b35-afc2-31124ceecc4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rptx:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7fd1537b-f85a-4ef2-915d-82497b788de9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-23</startDate>
            <endDate>2020-06-23</endDate>
        </period>
    </context>
    <context id="C_22564969-d47a-4706-ae91-ce5a0d5d6dce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_455d4f5d-1b00-4d1c-8c1b-ced04b5ee882">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:CombinedLicensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_882c43fd-0865-4bcc-8ec1-4fcf0c9a4cb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0b3e7aa4-3459-470d-87c2-e0d9a02fb4d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4a0b6ce9-b609-4951-87ef-6b33661b30ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0a2ab1c6-eeb2-450a-825c-b2e0500e4ba4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_19ce3969-55ed-4e30-9462-0263222e2f93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ae5f3fdb-a581-43e3-bfb4-15c88e51dc08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_27f1745b-0673-4b14-ba25-3054bf45721c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:ResearchAndDevelopmentTaxCreditsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9422e8ce-7702-44be-86dc-e5ed61056018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_78e0ac1e-933a-4450-9b1d-ff16a6fd8f1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_094da959-0fa8-48bc-82fd-7da9a531e3da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_43d1551f-e850-4ce0-95fc-dffbed44030c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_378a21ae-1938-4ec4-a0a9-d3c1716ef61a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_eaa1c4ec-6b84-4c2f-bfb1-0f3c64fa8a22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:NewYorkUniversityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_483e024c-e743-4735-98ec-df737668fd18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_218b32a4-44d8-4f35-a8e8-8985b015f2a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:TransferOfClinicalTrialMaterialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0d97e526-4833-4dc6-8113-19ae64b7fa24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fb05acb5-808b-494c-bd17-c15d87dfa489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rptx:OptionsToPurchaseCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9271e61c-f687-4b91-af75-f7655d9f62a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9a420b6a-118c-4efc-bb28-d98095401947">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_09a80f4e-72ef-4a70-a01e-600cbb7a0251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_30716fb3-44b9-47e8-800d-7c2d957e670b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c7524e4f-ecae-4724-8931-850f78dc9340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MoneyMarketFundsIncludedInCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6fb87044-e5c7-417d-afb8-2aee7d0f78a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8d0b1ad6-feb9-4c5d-a621-f47ee6f509c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:NewYorkUniversityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_04b847fd-b66f-4a41-bc49-b1bd4e09b5ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_956a103e-2e33-436f-86ac-ceaeba13380a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c095c251-0ca6-45ab-ae2c-2aec9d4fb280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rptx:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="C_afaac43e-017a-44ba-b75d-7ea6a3b4e368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_47bbe3ab-c619-4531-a810-632c68de1388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-23</startDate>
            <endDate>2020-06-23</endDate>
        </period>
    </context>
    <context id="C_b9ebcd23-ea43-4fa8-a367-3a44c77fbe15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:RepareTherapeuticsIncorporationOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_96aa4796-a454-4289-a8e9-eb0a4d889465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_80ef95e4-5908-4482-8697-3e73902fd846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ba56d68a-153c-41be-98bc-d302dc2e8772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_301dd1df-f42b-4bd5-982c-d7e2d3733b57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e2261616-9a81-42da-b0cb-ad4847fe864b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5bca2e86-6a57-4346-8aee-8fb3b26b2aca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_847f53e5-4018-4e25-b322-9a0918e5fc97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ProductRptxOptionsToLicenseDruggableTargetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2d3ca020-4e0b-4919-95d8-caf1bce5c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_28dfec78-046b-45a4-9c58-7424c3330c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e91f697c-b5f2-425a-b238-1ed83d875ffd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3f5323db-0b40-4adb-a988-178988f085e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:CompletionOfContinuingTrialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_29efdcd1-f366-4daf-8b98-5eaef0a24f0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rptx:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_dcd5c372-fa91-4030-89f6-8275c0abec98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ProductRptxOptionsToLicenseDruggableTargetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d3cd720c-8de2-4d2b-865b-f5dd9deaa416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_75c9b122-048e-43f5-a14f-971257b2c683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rptx:PreclinicalStudiesAndClinicalTrialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:TheUniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_9f257956-22fd-4563-8031-ee9a1b01466b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:GrantOfLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_df85d4b4-de4b-4eb8-a1de-ef8901ea52bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cad33b29-12d6-4338-9a56-8e6337e0ac19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3b217459-d769-49eb-838f-22205ffafcb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:ResearchAndDevelopmentTaxCreditsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5c19b01e-f2cc-438a-99aa-b2fa48bdc135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_11682b1d-2900-4c40-ba7d-c2e787aa1c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bcb6ad6a-f6c4-44a8-aa2f-56e18ff3d4ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_35a0d25d-897e-41e7-bd44-d80a88e5d9aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_60665830-af4d-49c6-8e90-64c9fd7235be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_633aa886-db18-4e4b-ac98-428a52434cba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_609633f0-8edb-44b4-852b-0714140adf5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:OptionsToLicenseDruggableTargetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2359962d-31e5-43dc-80af-bffa2bb8add9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_def3be0b-e33c-41d8-b724-4a3e58ec67c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fc472ea4-5bfc-43cf-afcc-45da63beb221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a5be591d-88a6-4798-a866-48f091aca5bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="C_a573d49c-e7e4-4254-b7c3-222222b5c736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_805bc016-191e-4564-9965-a49c941c6abe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_c2f83839-f843-4da9-8ac0-9aab66ecad59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:AdditionalClinicalDevelopmentPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1b80891b-1319-4360-8f15-2497ed8ea0b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rptx:TwoThousandTwentyEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_179763b9-efbc-464b-afa5-88c1837ed3e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1c19b0ef-d0c5-4bcc-8394-10c1c635f4f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
        </entity>
        <period>
            <startDate>2020-06-12</startDate>
            <endDate>2020-06-12</endDate>
        </period>
    </context>
    <context id="C_26af78f0-c117-4481-914d-922b16ea388a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rptx:EstimatedSharesIssuableUnderTheEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3c1983cf-a5f8-4eb4-9f92-f0536a7871bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7e79f2bb-36b7-445f-a31b-fe962378bd7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_17d80998-566f-4f86-8cc7-530d916cebec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0af7e506-9a9a-47a8-b222-a900c293b675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b8b79edc-32ab-46da-b385-c6a9975de00c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2e186f36-a60e-4c0e-bd2b-4f70ac8527fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c2cfdb5b-e3da-4229-a14c-8c3fc5b962d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7ba4f675-ecb3-4e4b-9b5d-3da50cb072d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ad1fe6be-ea8a-4207-b357-2558aad861b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:AccruedExpenseAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8de25cbb-79b8-4c61-83cd-426c93b13621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rptx:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="C_404b861d-d003-4142-9ce1-6483dccfba5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rptx:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="C_4de6f4d2-6787-40e5-b77a-57e8962ad678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rptx:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f916e232-9243-456b-b6ab-fa90b5090b81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7bcf5428-90b7-43b9-ad8f-851d706606db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ed70d3e9-a443-422c-a3ca-f76fb5ddd9dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rptx:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0432e0bc-120b-4705-8281-2d047c8d1406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rptx:ClinicalTrialMaterialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rptx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rptx:HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_JPY">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Positions">
        <measure>rptx:Positions</measure>
    </unit>
    <unit id="U_CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Lease">
        <measure>rptx:Lease</measure>
    </unit>
    <us-gaap:CommonStockSharesAuthorizedUnlimited
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      id="F_9e5deaed-1136-4770-a34f-3ccb49c019e1">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_9b4187e6-d52e-4cb1-9870-e5cca921222a">FY</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_c6dce487-0fd9-46be-b529-50ace5b91fb6">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_a034e603-6bb2-4ed0-a821-c4d7b64aa710">00-0000000</dei:EntityTaxIdentificationNumber>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      id="F_0e6da3f2-5c56-440d-847a-a498c1b804ad"
      unitRef="U_USD"
      xsi:nil="true"/>
    <rptx:IncomeTaxExaminationYearSubjectToExamination
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_1d4885b4-4eda-475c-a5da-596a44a20fc7">2017 2018 2019 2020 2021 2022</rptx:IncomeTaxExaminationYearSubjectToExamination>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_60c9489a-ae3e-4feb-bbbb-83c570d2da18">A8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityCentralIndexKey
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_01886432-1548-4ed7-8790-7adb335816ca">0001808158</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_2b8d184b-6872-45a6-912c-81feb34b4318">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesAuthorizedUnlimited
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_90ad6daa-50a2-42fb-9ca1-285b49414761">Unlimited</us-gaap:PreferredStockSharesAuthorizedUnlimited>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      id="F_219f75ab-b85e-4e79-9264-ee3449aabe80"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesAuthorizedUnlimited
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_7996140e-14fd-40cf-a2b8-d50b8f060a13">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:PreferredStockSharesAuthorizedUnlimited
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      id="F_cafa14d4-bdbd-4f40-86d7-72f79346b421">Unlimited</us-gaap:PreferredStockSharesAuthorizedUnlimited>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_4fa8599e-cef5-4581-9bfc-a45811c2a414"
      id="F_5c64d736-3755-4363-b2f0-d376d83f9242">P32M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_1c19b0ef-d0c5-4bcc-8394-10c1c635f4f6"
      decimals="5"
      id="F_e1a9b1e0-b4b1-4ba7-bb67-f01adfdb1126"
      unitRef="U_pure">0.16496</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_b25607a0-2ab7-4cad-be80-c8f88a5534e1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_b507af14-bdad-4169-90fa-eb118b8af29e">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_54019296-e3f2-4f58-a108-53d82ef57796">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_aa6027a9-1f58-46ea-8ed0-53cac794aa64">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_844dec4b-ed66-4bdd-974e-54e4a7d7fb99">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_8f3132f4-6248-472f-ac96-f4e322e8ab1d">001-39335</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_a6cea6ec-0ae8-4245-b027-dd23de8598b6">Repare Therapeutics Inc. </dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_38bca19e-2ef4-4756-97a3-9f1a2a01bff0">7210 Frederick-Banting</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_53659468-e5c4-46b3-a991-5f62dbc3f971">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_c8cf3ee0-4c02-4906-a0de-3ea9e20d64c0">St-Laurent</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_76abd2ae-c47a-4c27-8158-40f661a73e57">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_5f64f7b9-db49-433d-92c1-20f1e57616df">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_dbeb8a41-0341-4bbd-bc65-b57d83d646f2">H4S 2A1</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_d8e7cbde-01a9-4549-bafd-a2a5587e9b9d">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_47b5c3a9-4592-4a5a-aea3-d7a1e4e699f7">412-7018</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_48a96e99-25ab-4ded-abfb-eb67f1dbb3fe">Common Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_8a2fdf16-3aef-47f4-85a1-4bef87d64b7e">RPTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_3e7f178a-8839-494b-81a5-32e3cb7607d2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_0c3377d2-5554-44fa-814d-acf65fbc96af">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_c8c389c6-03dd-4cc6-b9b8-6f21409cdf7e">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_4b287648-d7d8-484a-a768-7419ade5a4b6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_b8804e04-03cb-4628-9f72-4b58bd4e51ce">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_987b70bd-2e58-4ce9-a7bb-c3457e91b407">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_ef454ed0-12ac-414b-8d62-0123c928c133">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_8b088dc5-5196-4b93-bd59-17e85b02c6ed">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_5a5f645a-6657-4318-8ee9-8f7ebef64f04">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_d984c708-53ab-4a4a-8901-dadee64f97f9">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_2359962d-31e5-43dc-80af-bffa2bb8add9"
      decimals="0"
      id="F_1f4427a8-2774-4996-9397-433755c3ca25"
      unitRef="U_USD">454878023</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_36e12a3b-5472-493d-b0e7-efefbdab666c"
      decimals="0"
      id="F_0fef3485-773c-4153-ba89-60a10d7305bc"
      unitRef="U_shares">42077896</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_e42f184e-61c7-4520-a0b5-6fa81a84a285">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Portions of the definitive proxy statement for the registrant&#x2019;s 2023 annual meeting of shareholders, which is to be filed within 120 days after the end of the registrant&#x2019;s fiscal year ended December 31, 2022, are incorporated by reference into Part III of this Form 10-K, to the extent described in Part III.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_a14e52bc-28e0-4d3d-b7aa-f85ec3b68012">1263</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_76731d4f-5e46-4f4d-9e96-5f6385eaf30d">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_cc2af8f9-da5f-4006-8266-be1e415abbcf">Montr&#xe9;al, Canada</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_e0de40c7-0f1e-4619-9024-a469497b2af2"
      unitRef="U_USD">159521000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_9b63e317-3acb-456b-8c46-e485f262f501"
      unitRef="U_USD">334427000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_72b3094e-323e-4146-a8a9-6db220ec6b0c"
      unitRef="U_USD">184420000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_1df37d46-c2bc-44a2-bf72-08c80a731aef"
      unitRef="U_USD">7439000</us-gaap:MarketableSecuritiesCurrent>
    <rptx:ResearchAndDevelopmentTaxCreditsReceivable
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_df62af64-3faf-4dc6-b236-88640397bbf0"
      unitRef="U_USD">1280000</rptx:ResearchAndDevelopmentTaxCreditsReceivable>
    <rptx:ResearchAndDevelopmentTaxCreditsReceivable
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_9d13f017-80e2-4dfb-a323-eec75e728360"
      unitRef="U_USD">2580000</rptx:ResearchAndDevelopmentTaxCreditsReceivable>
    <us-gaap:ReceivablesLongTermContractsOrPrograms
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_b794dd1a-7ee9-47b3-8a50-cf54a4bc44c2"
      unitRef="U_USD">1525000</us-gaap:ReceivablesLongTermContractsOrPrograms>
    <us-gaap:ReceivablesLongTermContractsOrPrograms
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_05c1f336-8f2d-40ab-b027-77314b1a9970"
      unitRef="U_USD">0</us-gaap:ReceivablesLongTermContractsOrPrograms>
    <us-gaap:OtherReceivables
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_83c2b54e-3507-4c8a-9ab0-9a402480584c"
      unitRef="U_USD">1518000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_1dbc0bda-a0d3-4924-95a0-7fb581ea432a"
      unitRef="U_USD">654000</us-gaap:OtherReceivables>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_23481c33-1368-4da6-b419-7552ff699977"
      unitRef="U_USD">5715000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_e3ae9703-4c73-4ae6-9832-396779250cbc"
      unitRef="U_USD">6314000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_eff6fc6c-f9cc-42d7-8fb5-a0dbba12ab4c"
      unitRef="U_USD">353979000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_54d3834d-c31c-43eb-87dd-0d1fc9a5f5f9"
      unitRef="U_USD">351414000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_40d3bf1e-52b0-487b-94a6-1b5a0155462a"
      unitRef="U_USD">4228000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_57c827d4-b11d-4614-b62f-8ada745e9d79"
      unitRef="U_USD">5604000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_89564830-d0a2-4701-a898-67d8dcdf1f3f"
      unitRef="U_USD">5371000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_105eb0b0-0cc5-4004-a6f4-ef9602768326"
      unitRef="U_USD">7491000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_15b65668-a697-4310-b56e-1fae5c4a092c"
      unitRef="U_USD">497000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_ad489842-b3b7-46cd-ab1e-78cd94f966bd"
      unitRef="U_USD">586000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_b3b5c357-226f-4eb3-9ceb-8c67203e4782"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_a10d97f7-3de6-416f-9f42-fb7e7fe1bfe9"
      unitRef="U_USD">3620000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Assets
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_a588ce74-dd72-49be-9286-5668bd2ed5b9"
      unitRef="U_USD">364075000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_0633582b-eefc-4c97-a074-4fd9c9776c08"
      unitRef="U_USD">368715000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_3d8ee6a5-db3a-4823-bd46-94ea91d10164"
      unitRef="U_USD">461000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_98f6f8c7-ccb9-48ad-b73d-c362d533f6b9"
      unitRef="U_USD">2302000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_460681da-66a6-4df1-aa8a-e78d460584fa"
      unitRef="U_USD">21645000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_aefac0a4-0f0e-4ca7-b1df-9934a545eb2c"
      unitRef="U_USD">18622000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_88647044-2037-4c9c-96ff-7e4451ea351a"
      unitRef="U_USD">2171000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_c40079c8-5278-4634-ad04-ffa253424b97"
      unitRef="U_USD">1721000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_8cd1468c-8583-4504-8393-2af7934a941f"
      unitRef="U_USD">53102000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_6bb7f9b4-c28a-40cb-8572-7c0d0963095d"
      unitRef="U_USD">11921000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_04d69c69-b4ef-41bc-a78e-9037b95440da"
      unitRef="U_USD">1240000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_af804d48-b990-4233-8be7-08985d3e39e7"
      unitRef="U_USD">523000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_c1ebaacd-e561-4bcc-92fa-b4d69fdba100"
      unitRef="U_USD">78619000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_65fc4493-757e-4114-8844-86ea341efe7f"
      unitRef="U_USD">35089000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_31848297-1712-4d29-a842-ee45f5665aa5"
      unitRef="U_USD">3257000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_1442be17-977c-41a8-9c16-fa02b0348158"
      unitRef="U_USD">5592000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_6f0dc5c8-2c94-4f50-8a5a-7a7736610045"
      unitRef="U_USD">2682000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_ee17284d-ea5f-4ad9-aaad-fb22a0118888"
      unitRef="U_USD">39613000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_93a3d81c-bdee-4134-abcf-9b520c10fdd9"
      unitRef="U_USD">84558000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_1f1d4bdb-ec31-478f-9460-d1a791350a0a"
      unitRef="U_USD">80294000</us-gaap:Liabilities>
    <us-gaap:PreferredStockNoParValue
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="0"
      id="F_3c881e2c-139d-4ed1-92fc-eccf1f1171dd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockNoParValue
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="0"
      id="F_d89f0cdc-130d-4a58-a3dc-6d4a00078958"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="0"
      id="F_247bc6e0-fb71-4e09-870c-26e012b720ae"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="0"
      id="F_84264e65-beb4-4e9c-b3f3-ce1b11cacdc7"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="0"
      id="F_7a7c7de4-f72a-4aad-96b4-d87e694c53c0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="0"
      id="F_7dc49a28-7aff-4ba4-8e39-84dbd8cc1ec0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_5dbc4233-d9bf-416f-a046-d999d9fa26c6"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_639dfb29-a548-4206-ae77-cd4dc6b4f653"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockNoParValue
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="0"
      id="F_3c834d01-1f07-467a-a12d-bea8010c70e1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="0"
      id="F_2955696c-1735-4119-be06-2505ba7fca6b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="0"
      id="F_0d00a1f1-34b7-4ba0-b907-c213d801a9ba"
      unitRef="U_shares">42036193</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="0"
      id="F_9660d7c5-2295-4526-a39d-bd49ac07e8fb"
      unitRef="U_shares">42036193</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="0"
      id="F_c60ca675-7a4d-49a1-aeff-2a522e44b1e0"
      unitRef="U_shares">41850162</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="0"
      id="F_8ba6f1aa-9ece-44ca-aa53-fe99cc4d0d82"
      unitRef="U_shares">41850162</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_9c8d3be0-3c35-41e3-b1dd-3717e1308fc4"
      unitRef="U_USD">482032000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_e7fbc695-0fe9-4a62-a647-857cbec81d6d"
      unitRef="U_USD">480699000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_578984f1-d19c-4dc9-81ef-506ca258b322"
      unitRef="U_USD">37226000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_fa6b6285-18c4-4e93-b115-e2acf6943a67"
      unitRef="U_USD">17988000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_51ea4728-dc46-4fe9-ae68-cb4ec30b96f4"
      unitRef="U_USD">-428000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_3549b956-d677-4b1c-8c2f-3dad01ebd4cc"
      unitRef="U_USD">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_7b789594-d1a7-4660-8049-3a4abf9c76ea"
      unitRef="U_USD">-239313000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_bbf1ea5b-562c-4a75-8196-5548876643c6"
      unitRef="U_USD">-210266000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_37024716-79b4-4ddd-acf3-cb93dcf3d6a9"
      unitRef="U_USD">279517000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_1f373b91-ce81-4384-9031-8cc60a08c37c"
      unitRef="U_USD">288421000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_00fee654-7bff-4d56-b576-c1cb522ad205"
      unitRef="U_USD">364075000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_6dd972c7-ab86-47d5-a3a7-6e05352655ff"
      unitRef="U_USD">368715000</us-gaap:LiabilitiesAndStockholdersEquity>
    <rptx:RevenueFromCollaborationAgreements
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_28efb5a6-79d8-487a-be68-17db9f53225e"
      unitRef="U_USD">131830000</rptx:RevenueFromCollaborationAgreements>
    <rptx:RevenueFromCollaborationAgreements
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_0d23bb8d-fa67-4801-bef7-0ad038e8dbea"
      unitRef="U_USD">7600000</rptx:RevenueFromCollaborationAgreements>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_4aada8ef-ec15-4d22-9b28-c343d042e41b"
      unitRef="U_USD">119066000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_ed6ab41a-f53f-4bd3-85d8-6c56302a7790"
      unitRef="U_USD">90047000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_79f3b090-04d7-41c7-af60-403d6f1f6ef3"
      unitRef="U_USD">32560000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_d401f4b2-b5d1-4b54-bf79-3127716e572e"
      unitRef="U_USD">26213000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_e11e8323-2d6b-4564-9e1d-2fc1df701e1b"
      unitRef="U_USD">151626000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_af356dd3-8209-4655-b31d-50dda72e6ce4"
      unitRef="U_USD">116260000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_9275fe46-baa6-41c4-b8da-19ca7f51d78f"
      unitRef="U_USD">-19796000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_af6a6b38-37ad-4542-a12e-666415323d1e"
      unitRef="U_USD">-108660000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_29568da7-ab27-4fbf-a858-827d06fb9e83"
      unitRef="U_USD">308000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_19560f43-2838-404c-aa56-c15740a08aef"
      unitRef="U_USD">-144000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_ca8f2730-eaea-4456-a342-b0dd5432d00a"
      unitRef="U_USD">5631000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_8e05a97a-5380-4470-b4ca-f3db3b593739"
      unitRef="U_USD">259000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingExpense
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_e2c27148-d2e1-4f94-8fa1-acd665c5addc"
      unitRef="U_USD">43000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_1ad5db8e-f64e-4e3c-9f86-4d800bb36c23"
      unitRef="U_USD">41000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_99acda49-4410-4ebf-a69d-2b8f1138ec7f"
      unitRef="U_USD">5896000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_f0c7359b-6b33-4f3b-adab-7bc6c4f67e09"
      unitRef="U_USD">74000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_cb2e201f-b2cc-42f5-9701-b79f7aa6a372"
      unitRef="U_USD">-13900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_2ca4c068-dece-4a07-b815-2bc17e14e671"
      unitRef="U_USD">-108586000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_30cd8e8a-04ef-40e1-a9a5-97f1302e3ff1"
      unitRef="U_USD">15147000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_54a5dc9b-96bd-44b0-a561-2544e3a89b41"
      unitRef="U_USD">-1678000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_a0defccc-06eb-443d-9b32-b5a1dffa8de0"
      unitRef="U_USD">-29047000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_388d91e7-da0a-4fc2-8852-e0a88ca9b260"
      unitRef="U_USD">-106908000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_a50e9b8a-35c2-4a02-81de-eb4ac586191b"
      unitRef="U_USD">-428000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_744f36ac-e18c-40c0-8037-b937d1f7cc4a"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_cca7e00d-44a1-4836-bad1-b1524ccc4d18"
      unitRef="U_USD">-428000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_c5f79fa9-4075-47b3-bb5e-b8870edf8fd3"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_e78a9c26-c2de-423a-98e5-c6d4c95fd0d1"
      unitRef="U_USD">-29475000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_5490188c-517d-498c-a85e-79ba284d1d71"
      unitRef="U_USD">-106908000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="2"
      id="F_b565843c-7023-4b9b-a47d-50f7d8e41d6f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="2"
      id="F_6209e164-b42e-4945-b321-f46d34a50b0b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="2"
      id="F_1d4b85a9-29e9-4dc4-9c4a-9fc3796d8830"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="2"
      id="F_d9bbac0d-8e9f-4860-8827-592c3f0e38d5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="0"
      id="F_15cf1b86-5302-4e7a-9d22-60ea6047a5be"
      unitRef="U_shares">41922042</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="0"
      id="F_0040d686-6394-4f75-a98a-d2a812b7a5a1"
      unitRef="U_shares">41922042</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="0"
      id="F_bc00c1bb-555d-49cb-a58c-6d11a245d409"
      unitRef="U_shares">37818115</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="0"
      id="F_daabc04f-a5c3-4b25-9287-9002e95c1879"
      unitRef="U_shares">37818115</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_3c1983cf-a5f8-4eb4-9f92-f0536a7871bc"
      decimals="INF"
      id="F_680e8300-82ed-48de-9da2-7a6362ae3bf0"
      unitRef="U_shares">36902924</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3c1983cf-a5f8-4eb4-9f92-f0536a7871bc"
      decimals="-3"
      id="F_4dec7916-92af-4f75-af62-986a8dceae01"
      unitRef="U_USD">384313000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0a2ab1c6-eeb2-450a-825c-b2e0500e4ba4"
      decimals="-3"
      id="F_2ece9126-a297-4d81-8713-f42ed3bc15ef"
      unitRef="U_USD">5875000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4a0b6ce9-b609-4951-87ef-6b33661b30ce"
      decimals="-3"
      id="F_0be4a614-c6b0-4d6d-a319-85f5c7e1d85b"
      unitRef="U_USD">-103358000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_179763b9-efbc-464b-afa5-88c1837ed3e7"
      decimals="-3"
      id="F_569bd4f0-eb6a-4029-95e4-5ead1f68e21d"
      unitRef="U_USD">286830000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_956a103e-2e33-436f-86ac-ceaeba13380a"
      decimals="INF"
      id="F_5af53bad-1965-4a91-b231-0df88b35fed2"
      unitRef="U_shares">333996</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_956a103e-2e33-436f-86ac-ceaeba13380a"
      decimals="-3"
      id="F_8e19b099-109b-4f20-9d60-b975858e9bc5"
      unitRef="U_USD">1578000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_df372273-07d1-45f3-97f2-72265a4457ed"
      decimals="-3"
      id="F_84e3df28-a464-4a7c-9665-eaed7467c1cc"
      unitRef="U_USD">-592000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_7064e2e4-b50f-4c20-a84d-b8ed015ca295"
      unitRef="U_USD">986000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_df372273-07d1-45f3-97f2-72265a4457ed"
      decimals="-3"
      id="F_c8f1b550-a7ad-4690-9f23-22e14337a731"
      unitRef="U_USD">12829000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_c62c49ec-524b-4aee-84bf-3d31ad1ed179"
      unitRef="U_USD">12829000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_29efdcd1-f366-4daf-8b98-5eaef0a24f0d"
      decimals="-3"
      id="F_76862b28-3f59-4019-af85-e278de0f2820"
      unitRef="U_USD">840000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_67d17037-8967-4b35-afc2-31124ceecc4c"
      decimals="INF"
      id="F_5f318df8-1ff7-4c85-bc35-ca7b32efa7f9"
      unitRef="U_shares">4600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_67d17037-8967-4b35-afc2-31124ceecc4c"
      decimals="-3"
      id="F_e70b9b4a-4f9e-40fd-bee1-adcd5c01d66c"
      unitRef="U_USD">94288000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_29efdcd1-f366-4daf-8b98-5eaef0a24f0d"
      decimals="-3"
      id="F_94f2a2b2-1bbe-4650-8f7d-f1035840a98f"
      unitRef="U_USD">94288000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_956a103e-2e33-436f-86ac-ceaeba13380a"
      decimals="INF"
      id="F_37eb26ce-00cf-4af6-9572-5cda8b007021"
      unitRef="U_shares">3299</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_956a103e-2e33-436f-86ac-ceaeba13380a"
      decimals="-3"
      id="F_d06b7073-3107-4a8a-9e85-549c8b61af24"
      unitRef="U_USD">113000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_8c58a37a-f82a-448b-895f-70193db22f69"
      unitRef="U_USD">113000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_df85d4b4-de4b-4eb8-a1de-ef8901ea52bf"
      decimals="INF"
      id="F_e9dd142b-98fd-4d40-a7bf-09c1c418bcef"
      unitRef="U_shares">9943</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_df85d4b4-de4b-4eb8-a1de-ef8901ea52bf"
      decimals="-3"
      id="F_09bfb667-366b-4020-bdf8-5c6ae0d7a920"
      unitRef="U_USD">407000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_483e024c-e743-4735-98ec-df737668fd18"
      decimals="-3"
      id="F_bc6b5d0d-504a-4497-a547-9f65e859ca9b"
      unitRef="U_USD">-124000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735"
      decimals="-3"
      id="F_471e6cce-8868-4009-892e-64a83345fd99"
      unitRef="U_USD">283000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <rptx:NetIncomeLossAndComprehensiveIncomeLoss
      contextRef="C_79831ab9-e01f-4b6c-ac9f-05479c973e07"
      decimals="-3"
      id="F_531ea8e0-fe81-4197-97ac-8300c3ce983a"
      unitRef="U_USD">-106908000</rptx:NetIncomeLossAndComprehensiveIncomeLoss>
    <rptx:NetIncomeLossAndComprehensiveIncomeLoss
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_bfbf66c9-e00d-4889-a8d1-c888aae13676"
      unitRef="U_USD">-106908000</rptx:NetIncomeLossAndComprehensiveIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_28dfec78-046b-45a4-9c58-7424c3330c88"
      decimals="INF"
      id="F_c35c489d-c2c3-476a-b2c1-376aa868088b"
      unitRef="U_shares">41850162</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_28dfec78-046b-45a4-9c58-7424c3330c88"
      decimals="-3"
      id="F_fc47ebc8-070d-47d4-a6a7-9a9ce5f27927"
      unitRef="U_USD">480699000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_43d1551f-e850-4ce0-95fc-dffbed44030c"
      decimals="-3"
      id="F_fd0bb5f8-df53-4d2f-99fb-ab886d77ff54"
      unitRef="U_USD">17988000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ac38558a-83a0-47fb-bd07-2be4ac80a958"
      decimals="-3"
      id="F_e02d88e6-2c7a-4dbc-8123-163848174537"
      unitRef="U_USD">-210266000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_4b57b830-7a72-4edf-8049-33a4faf98532"
      unitRef="U_USD">288421000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_7a43defd-03d5-46c3-9322-0c22c5e6e0fc"
      decimals="INF"
      id="F_6f21b4c8-3a77-407f-bbfd-279994ed1288"
      unitRef="U_shares">148116</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7a43defd-03d5-46c3-9322-0c22c5e6e0fc"
      decimals="-3"
      id="F_45d3a258-ac48-499a-ace8-0065e71ec6f1"
      unitRef="U_USD">708000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_4e010701-b9b6-4606-92d0-3a2915bef141"
      decimals="-3"
      id="F_33fa51fc-b396-4d66-87e2-0711266f7040"
      unitRef="U_USD">-261000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_6e5cb57d-c649-4f7f-aceb-72fd1739e2bb"
      unitRef="U_USD">447000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_4e010701-b9b6-4606-92d0-3a2915bef141"
      decimals="-3"
      id="F_938b2d6b-0fff-4a01-809f-9f8432c87e2c"
      unitRef="U_USD">19691000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_3feae2e4-e63d-442d-8fe9-5e8cb7ba77ea"
      unitRef="U_USD">19691000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_1a6bffab-7ac1-4529-af70-4292b5a90b4d"
      decimals="INF"
      id="F_0deece05-2a45-4a85-ac81-a114ed745ab2"
      unitRef="U_shares">37915</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_1a6bffab-7ac1-4529-af70-4292b5a90b4d"
      decimals="-3"
      id="F_db54954c-f253-4a9a-8ee2-af3e445cd7c1"
      unitRef="U_USD">625000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_9a420b6a-118c-4efc-bb28-d98095401947"
      decimals="-3"
      id="F_c6a6d695-0905-4345-9a5a-668ee304e019"
      unitRef="U_USD">-192000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0"
      decimals="-3"
      id="F_e734b927-c6fa-496b-909b-9dc4479c020a"
      unitRef="U_USD">433000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_82791e69-edf1-4fd6-8015-240f7998a7d0"
      decimals="-3"
      id="F_42969dcf-f6ec-471d-be32-80a9bfc97de7"
      unitRef="U_USD">-428000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_20fb8e07-729d-4d35-ade3-40a51e4effe7"
      unitRef="U_USD">-428000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b8b79edc-32ab-46da-b385-c6a9975de00c"
      decimals="-3"
      id="F_2b26ef36-73f7-4dab-a770-37d1f1540334"
      unitRef="U_USD">-29047000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_e858b1fb-4dcb-489b-862e-611c0dc358a5"
      unitRef="U_USD">-29047000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="C_def3be0b-e33c-41d8-b724-4a3e58ec67c7"
      decimals="INF"
      id="F_851165db-49bb-4dce-98df-a67f6e3ebd6e"
      unitRef="U_shares">42036193</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_def3be0b-e33c-41d8-b724-4a3e58ec67c7"
      decimals="-3"
      id="F_21100982-8d98-49ce-9cab-9479f4e80742"
      unitRef="U_USD">482032000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c2cfdb5b-e3da-4229-a14c-8c3fc5b962d8"
      decimals="-3"
      id="F_050d60e0-dc16-4ed1-81e8-1a35365c4f74"
      unitRef="U_USD">37226000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_51f4647b-4513-4f59-b327-5fe1b4b8ec0e"
      decimals="-3"
      id="F_7dd9aad6-b165-4bbb-9e81-0f9c7fc1e26b"
      unitRef="U_USD">-428000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_63512c11-8031-488d-bf0e-063cdf64bffb"
      decimals="-3"
      id="F_11c804ca-59aa-4f16-a01d-4d40edec72e5"
      unitRef="U_USD">-239313000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_f4c581fd-233e-4129-96ef-7ee935d20300"
      unitRef="U_USD">279517000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_bd59ea78-0f52-4e51-8e08-bb1aa5ccb4fd"
      unitRef="U_USD">-29047000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_d412620e-e6fb-447a-91f6-6752c5112214"
      unitRef="U_USD">-106908000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_ecc1f7b4-c760-499b-83c4-3305dcf0bd3d"
      unitRef="U_USD">19691000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_290ee402-4cd6-435e-9c66-7fce1b53f7e4"
      unitRef="U_USD">12829000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_5d3b6c65-7350-48cd-84b5-0c3f5bd23657"
      unitRef="U_USD">1978000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_a6a1ec44-8916-4caf-9c72-bebdf4223f4e"
      unitRef="U_USD">1471000</us-gaap:Depreciation>
    <us-gaap:ProvisionForLoanAndLeaseLosses
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_0a260d32-4733-4bee-b8df-ea203df5a241"
      unitRef="U_USD">2206000</us-gaap:ProvisionForLoanAndLeaseLosses>
    <us-gaap:ProvisionForLoanAndLeaseLosses
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_2f1d7219-395f-42ba-89fd-e4c5f9bbbbc3"
      unitRef="U_USD">1873000</us-gaap:ProvisionForLoanAndLeaseLosses>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_7c3c2e7d-df44-4572-856e-774b576adc98"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_de325a78-cc2b-4de2-a088-60a5c19e24e7"
      unitRef="U_USD">-24000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <rptx:ForeignCurrencyTransactionGainLoss
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_4d9606b1-415d-417f-8285-74786432102b"
      unitRef="U_USD">298000</rptx:ForeignCurrencyTransactionGainLoss>
    <rptx:ForeignCurrencyTransactionGainLoss
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_45826a29-b046-4637-9540-6c154ffbae54"
      unitRef="U_USD">-12000</rptx:ForeignCurrencyTransactionGainLoss>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_7758ec16-2328-45ec-96b8-19f668ff47c2"
      unitRef="U_USD">2233000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_91479586-fe73-4544-b3f6-3e2708ef8802"
      unitRef="U_USD">-113000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_ee2e0a16-ab69-4d11-8755-1f4fc04d1154"
      unitRef="U_USD">-3620000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_72421a48-a920-48c7-a942-7c00c2d2a893"
      unitRef="U_USD">2208000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_f0e54639-1522-49fa-8ea0-d8a98b3c8718"
      unitRef="U_USD">-593000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_40d46361-7b16-4610-9ea5-3254e8476461"
      unitRef="U_USD">32000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <rptx:IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_ca7a2bfd-3afe-43b0-9ee6-a99c15e1fcbf"
      unitRef="U_USD">-1287000</rptx:IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable>
    <rptx:IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_b11b4768-de5a-416d-bac6-758752b8c235"
      unitRef="U_USD">556000</rptx:IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable>
    <rptx:IncreaseDecreaseInCollaborationRevenueReceivable
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_8324fd93-03b3-4a03-b0b3-93026a5dd7f5"
      unitRef="U_USD">1525000</rptx:IncreaseDecreaseInCollaborationRevenueReceivable>
    <rptx:IncreaseDecreaseInCollaborationRevenueReceivable
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_70dbe2d3-ac20-408e-86ce-fb7d0569acff"
      unitRef="U_USD">0</rptx:IncreaseDecreaseInCollaborationRevenueReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_fe9921d4-5e6e-4143-988d-8c990d58d10b"
      unitRef="U_USD">1147000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_d4a5ff77-1eb2-419f-a7e6-99601443c805"
      unitRef="U_USD">-3554000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_8e315a9d-24a2-45ad-8d78-a70e8b8d4682"
      unitRef="U_USD">-89000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_e1863d6b-369d-423e-8215-ec0e93a3d542"
      unitRef="U_USD">298000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_eafe4f0c-54af-44f2-8389-6206fa9ee504"
      unitRef="U_USD">-1348000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_6c1afb41-2743-4cdf-8a4d-ee61738768c7"
      unitRef="U_USD">152000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <rptx:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_a3532898-a26f-4e6f-8a37-176fcedf1ad1"
      unitRef="U_USD">3020000</rptx:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <rptx:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_bf7be4b1-dc74-42b5-bc71-708f40965f0e"
      unitRef="U_USD">11166000</rptx:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <rptx:IncreaseDecreaseInOperatingLeaseLiabilityCurrent
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_0df88618-8d64-43ac-bd75-0b0ef2444467"
      unitRef="U_USD">615000</rptx:IncreaseDecreaseInOperatingLeaseLiabilityCurrent>
    <rptx:IncreaseDecreaseInOperatingLeaseLiabilityCurrent
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_cb98bda8-7f7c-4ced-893b-157bdbeeb85f"
      unitRef="U_USD">98000</rptx:IncreaseDecreaseInOperatingLeaseLiabilityCurrent>
    <us-gaap:IncreaseDecreaseInIncomeTaxes
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_ed1b1b6e-e7f9-4537-8aae-233b3722076f"
      unitRef="U_USD">717000</us-gaap:IncreaseDecreaseInIncomeTaxes>
    <us-gaap:IncreaseDecreaseInIncomeTaxes
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_3095fa78-8109-45de-a618-bae528d4c08d"
      unitRef="U_USD">505000</us-gaap:IncreaseDecreaseInIncomeTaxes>
    <rptx:IncreaseDecreaseInOperatingLeaseLiabilityNet
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_dd0642a4-134a-4643-ac55-80d59fc42238"
      unitRef="U_USD">-2146000</rptx:IncreaseDecreaseInOperatingLeaseLiabilityNet>
    <rptx:IncreaseDecreaseInOperatingLeaseLiabilityNet
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_629945ff-764f-42eb-be3b-e0da19efe707"
      unitRef="U_USD">-1118000</rptx:IncreaseDecreaseInOperatingLeaseLiabilityNet>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_75afe671-67db-4da2-8e89-9ff744adb1b1"
      unitRef="U_USD">4250000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_b9068de1-6c53-4a8c-bc8f-2743a9b28d25"
      unitRef="U_USD">-6473000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_83cff550-c3d8-4de4-8932-2946aa551311"
      unitRef="U_USD">322000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_7a223a11-fe41-4f28-a8ae-3f56104d8e7b"
      unitRef="U_USD">-85796000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_7f7d63e4-3bb2-4c0f-8fc9-f2bff3dde5f4"
      unitRef="U_USD">602000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_e4ac418c-9fe1-406d-8185-2e47ea9967cb"
      unitRef="U_USD">1690000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_a25d6a3e-09bd-4dc1-9772-7699144bc771"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_9ad34990-72e6-444d-9304-ecdc6d4d561c"
      unitRef="U_USD">40000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_772d3876-1d7e-46bb-a5a6-4bb2183cbf91"
      unitRef="U_USD">81400000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_9a7d2112-dfc0-4990-9f7f-76969b3984eb"
      unitRef="U_USD">7450000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_8b726749-f419-466c-a1fe-128a35e90580"
      unitRef="U_USD">256576000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_84f2ff9b-0840-416b-9573-92cfb178efcc"
      unitRef="U_USD">7476000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_9f56d254-2f06-4326-8946-bf767a50273b"
      unitRef="U_USD">-175778000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_8e305361-79ab-420e-b26c-18d6e181a877"
      unitRef="U_USD">-1676000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_c51c4d87-4d53-4212-bd48-557abb13a640"
      unitRef="U_USD">447000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_e97d4c49-69ce-47c6-a3fc-ce986f460d3c"
      unitRef="U_USD">986000</us-gaap:ProceedsFromStockOptionsExercised>
    <rptx:ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_24c0a31e-67ef-4a38-a89a-4db00fc3e17c"
      unitRef="U_USD">433000</rptx:ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan>
    <rptx:ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_22d206ca-f2d2-4780-a0c6-00a67ca329df"
      unitRef="U_USD">283000</rptx:ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_d8bd2f13-63b6-4fff-8726-daaa83f7de37"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_f489d960-4205-4995-9295-d1f1f9ac665e"
      unitRef="U_USD">94288000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_f5762335-3871-43b3-8724-c6058abe153f"
      unitRef="U_USD">880000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_78fb91b3-635a-4029-b1a0-aaf6be175dc7"
      unitRef="U_USD">95557000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_af81be2d-68c1-4a2e-bb71-5786443143fc"
      unitRef="U_USD">-330000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_1156713c-2c77-413d-997e-dce4c0bd7f93"
      unitRef="U_USD">-54000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_b9f46a74-414b-46e9-8781-a2b78937789b"
      unitRef="U_USD">-174906000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_d859dd98-884e-4e7a-8643-aaebaf10c127"
      unitRef="U_USD">8031000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_9d444525-f2cb-425c-bb34-3888c5bf77d8"
      unitRef="U_USD">334427000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_179763b9-efbc-464b-afa5-88c1837ed3e7"
      decimals="-3"
      id="F_66d541fe-01fb-48d4-8263-2a3381e718bf"
      unitRef="U_USD">326396000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_2b7091ea-9877-42ed-830f-a7a8de900265"
      unitRef="U_USD">159521000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_555f5430-7b3e-44b4-9a9f-27a2f9768988"
      unitRef="U_USD">334427000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_1339c83d-38e5-46d4-819f-c40a10517fe8"
      unitRef="U_USD">1966000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_75764ec5-e3e5-4b92-b3b6-838a04c74f90"
      unitRef="U_USD">240000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_bb496e0a-57dc-40f0-ba07-994609aa9b2a"
      unitRef="U_USD">10810000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_50054d93-0efa-484c-bdb9-13b2c1901ae8"
      unitRef="U_USD">25000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_d6243ad6-890a-4df3-a6dc-32c668026f3e"
      unitRef="U_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_fd1d71d7-702a-48a0-8c43-a939bf44a232"
      unitRef="U_USD">1719000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_18e74b9b-ef06-44ff-b60b-7fe936afb54c"
      unitRef="U_USD">86000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_2a63c9f2-21a8-461d-801a-525987b7b050"
      unitRef="U_USD">4690000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_3c633de7-e6dc-4603-8472-91c628ddba9d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1. Organization and Nature of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Repare Therapeutics Inc. (&#x201c;Repare&#x201d; or the &#x201c;Company&#x201d;) is a precision medicine oncology company focused on the development of synthetic lethality-based therapies to patients with cancer. The Company was incorporated under the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Canada Business Corporations Act&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 6, 2016&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. On June 23, 2020, immediately prior to the completion of its initial public offering (the &#x201c;IPO&#x201d;), the Company was continued as a corporation under the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Business Corporations Act (Qu&#xe9;bec)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On June 12, 2020, the Company effected a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1-for-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_e1a9b1e0-b4b1-4ba7-bb67-f01adfdb1126;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.062&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; reverse stock split of the Company&#x2019;s share capital. Accordingly, all common shares, Series A and B convertible preferred shares, stock options and per share amounts in these consolidated financial statements have been retroactively adjusted to reflect the reverse stock split on a retroactive basis for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On June 23, 2020, the Company completed its IPO of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,650,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of its common shares, including the exercise in full by the underwriters of their option to purchase up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,650,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional common shares, for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;253.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company&#x2019;s shares began trading on the Nasdaq Global Select Market under the ticker symbol &#x201c;RPTX&#x201d; on June 19, 2020. The Company received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;232.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by the Company. Upon closing of the IPO, all outstanding convertible preferred shares converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,558,393&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; common shares and the outstanding warrant was automatically exercised into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;750,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2021, the Company completed a follow-on offering of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,600,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of its common shares, including the exercise in full by the underwriters of their option to purchase up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;600,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional common shares, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, for net proceeds of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, after deducting underwriting commissions as well as offering expenses of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; payable by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Since inception, the Company has incurred operating losses. As of December 31, 2022, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;239.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company does not have any products approved for sale and has financed its operations primarily through equity financings and funding from its collaboration and license agreements. Based on its current operating plan, the Company expects that its existing cash and cash equivalents and marketable securities on hand will be sufficient to fund its operating and capital expenditures into 2026.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There can be no assurance that the Company will be able to obtain additional debt or equity financing, or generate product revenue or revenue from collaboration agreements, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#x2019;s business, results of operations and financial condition.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_2e2acdee-a7ad-4e70-82a0-301587318e19">2016-09-06</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_1c19b0ef-d0c5-4bcc-8394-10c1c635f4f6"
      id="F_14d31809-db5d-4b73-ac28-dd84a504a2ef">1-for-6.062</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e1f902aa-4006-405b-b0bd-e5a178b2bfaa"
      decimals="INF"
      id="F_b566739e-82de-43f5-a99a-b1ea14264af9"
      unitRef="U_shares">12650000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_7fd1537b-f85a-4ef2-915d-82497b788de9"
      decimals="INF"
      id="F_2cfff554-3005-4b1e-8e17-b82984d892b3"
      unitRef="U_shares">1650000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <rptx:GrossProceedsFromInitialPublicOffering
      contextRef="C_47bbe3ab-c619-4531-a810-632c68de1388"
      decimals="-5"
      id="F_475db824-9d6b-4db7-89ab-247dec172c0e"
      unitRef="U_USD">253000000.0</rptx:GrossProceedsFromInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_47bbe3ab-c619-4531-a810-632c68de1388"
      decimals="-5"
      id="F_fdc534aa-b2fc-43a1-92b7-5f18d7d2e471"
      unitRef="U_USD">232000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_47bbe3ab-c619-4531-a810-632c68de1388"
      decimals="INF"
      id="F_10e9e5e9-04c4-40c4-bb18-f099663f2fd0"
      unitRef="U_shares">21558393</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_ba8a8b55-bc32-45e4-ac52-b062d5026bf6"
      decimals="INF"
      id="F_22fcaab2-df12-4d03-b21c-c5891031b7dc"
      unitRef="U_shares">750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8de25cbb-79b8-4c61-83cd-426c93b13621"
      decimals="INF"
      id="F_818b5f21-3aaf-4b1c-987a-ea2c5c6ec8cf"
      unitRef="U_shares">4600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e4e66d4b-8df8-4150-855e-17cb5ce1bcb9"
      decimals="INF"
      id="F_97e097bd-f237-4eaa-8b75-472c4249408a"
      unitRef="U_shares">600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_c095c251-0ca6-45ab-ae2c-2aec9d4fb280"
      decimals="INF"
      id="F_38bdd1e8-9b76-40b4-a057-b6c01b58868a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_8de25cbb-79b8-4c61-83cd-426c93b13621"
      decimals="-5"
      id="F_053d2195-a6f3-4622-9b6b-02ec4070f2ce"
      unitRef="U_USD">94300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <rptx:UnderwritingCommissionsAndEstimatedOfferingExpenses
      contextRef="C_404b861d-d003-4142-9ce1-6483dccfba5d"
      decimals="-5"
      id="F_fe469a77-f5ed-4432-90c8-8bac5d7cab9a"
      unitRef="U_USD">800000</rptx:UnderwritingCommissionsAndEstimatedOfferingExpenses>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-5"
      id="F_1f6416e6-b748-41ad-9cf7-7a61bb72ad1c"
      unitRef="U_USD">-239300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_ba389a2e-2047-432d-8b0e-c0bde3dcc39f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and as amended by Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;accompanying consolidated financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Repare Therapeutics USA Inc. (&#x201c;Repare USA&#x201d;), which was incorporated under the laws of Delaware on June 1, 2017. The financial statements of Repare USA are prepared for the same reporting period as the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;parent &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;company, using consistent accounting policies. All intra-group transactions, balances, income, and expenses are eliminated in full upon consolidation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Smaller Reporting Company&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company qualifies as a &#x201c;smaller reporting company&#x201d; under the Exchange Act as of December 31, 2022 because the market value of its common shares held by non-affiliates was less than $560 million as of June 30, 2022 and its revenue for the year ended December 31, 2021 was less than $100 million. As a smaller reporting company, the Company may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. For so long as the Company remains a smaller reporting company, it is permitted and the Company intends to rely on such exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign Currencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The functional currency for the Company and Repare USA is the U.S. dollar (&#x201c;USD&#x201d;). Accordingly, transactions denominated in currencies other than the functional currency are measured and recorded in the functional currency at the exchange rate in effect on the date of the transactions. At each consolidated balance sheet date, monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using the exchange rate in effect at that date. Non-monetary assets and liabilities and revenue and expense items denominated in foreign currencies are translated into the functional currency using the exchange rate prevailing at the dates of the respective transactions. Any gains or losses arising on remeasurement are included in the consolidated statement of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#x2019;s singular focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, right-of-use assets and lease liabilities and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company classifies marketable debt securities with a remaining maturity of greater than three months when purchased as available-for-sale. Marketable debt securities with a remaining maturity date greater than one year are classified as non-current where the Company has the intent and ability to hold these securities for at least the next 12 months.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s marketable securities consist of U.S. treasury bills and U.S. treasury notes with original maturities greater than 90 days. All of the Company&#x2019;s marketable securities have a contractual maturity of one year or less. The&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company considers its investment portfolio of U.S. treasury bills and U.S. treasury notes to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on observable inputs, other than quoted market prices. Unrealized gains and losses are reported in accumulated other comprehensive items in shareholders&#x2019; equity. Amortization and accretion of premiums and discounts are recorded in interest income (expense). Realized gains or losses on debt securities are included in other income (expense).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#x2019;s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss on the consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive loss. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in other (expense) income, net within the consolidated statement of operations. Losses are charged against the allowance when the Company believes the uncollectibility of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Our investment portfolio comprises money market funds, U.S. treasury bills and U.S. treasury notes. Our investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company maintains deposits in accredited financial institutions which exceed insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s exposure to foreign exchange risk is primarily related to fluctuations between the Canadian dollar and the U.S. dollar. There are balances in Canadian dollars which are subject to foreign currency fluctuations relating to the impact of translating to U.S. dollars for financial statement presentation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss includes net loss as well as other changes in shareholders&#x2019; equity that result from transactions and economic events other than those with shareholders. Other comprehensive loss consists of unrealized losses on available-for-sale marketable securities. Total comprehensive loss for all periods presented has been disclosed in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x95;	Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x95;	Level 2 &#x2013; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x95;	Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;An entity may choose to measure financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The estimated fair values of the Company&#x2019;s cash and cash equivalents, collaboration revenue receivable, other receivables, other assets and accounts payable and accrued expenses approximate their carrying values.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s marketable securities are carried at fair value, determined according to Level 2 inputs in the fair value hierarchy described above.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment is stated at historical cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.498%;"/&gt;
          &lt;td style="width:1.004%;"/&gt;
          &lt;td style="width:49.498%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Useful Lives&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the shorter of the lease term and the useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. Expenditures for maintenance and repairs are recorded to expense as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of assets may not be recoverable. Recoverability of these assets is measured by comparing their carrying value to the future net undiscounted cash flows the assets are expected to generate over their remaining economic life. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying value of the assets exceeds their fair value. Indefinite-lived intangible assets are tested for impairment annually, or more frequently if indicators of impairment are present. To date, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; such impairment losses have been recorded.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the consolidated balance sheet as a right-of-use asset and current and non-current lease liabilities, as applicable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company enters into collaboration and license agreements, which are within the scope of ASC 606, to discover, develop, manufacture, and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (i) licenses to compounds directed to specific targets (referred to as &#x201c;exclusive licenses&#x201d;) and (ii) research and development activities to be performed on behalf of the collaboration partner related to the licensed targets. Payments to the Company under these agreements may include non-refundable&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;license fees, customer option exercise fees, payments for research activities, reimbursement of certain costs, payments based upon the achievement of certain milestones and royalties on any resulting net product sales.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company first evaluates license and/or collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;), based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for collaborative arrangements (or elements within the contract that are deemed part of a collaborative arrangement), which represent a collaborative relationship and not a customer relationship, outside the scope of ASC 606.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s collaborations primarily represent revenue arrangements. For the arrangements or arrangement components that are subject to revenue accounting guidance, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company applies the five-step model. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration, except for sales-based royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In determining the stand-alone selling price of a license to the Company&#x2019;s proprietary technology or a material right provided by a customer option, the Company considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating its estimated stand-alone selling price, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling price will have a significant effect on the allocation of arrangement consideration between performance obligations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within one year following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within one year following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Exclusive Licenses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the license is the predominant promise, and it is determined that the license represents functional intellectual property (&#x201c;IP&#x201d;), revenue is recognized at the point in time when control of the license is transferred. If it is determined that the license does not represent functional IP, revenue is recognized over time using an appropriate method of measuring progress.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Services&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; The obligations under the Company&#x2019;s collaboration and license agreements generally include research and development services to be performed by the Company to benefit the collaboration partner. For performance obligations that include research and development services, the Company generally&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods of which revenue should be recognized, are subject to estimates by management and may change over the course of the contract. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Customer Options&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; The Company&#x2019;s arrangements may provide a collaborator with the right to acquire additional goods or services in the future. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment or (ii) upon the exercise of the customer option. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Milestone Payments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For a complete discussion of accounting for collaboration revenues, s&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ee Note 12.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. The Company&#x2019;s research and development expenses consist primarily of costs incurred in performing research and development activities, including salaries and other compensation, share-based compensation, fees paid to external service providers, laboratory supplies and costs for facilities and equipment, partially offset by fully refundable research and development tax credits. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are expensed as the goods are delivered or the services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued and Prepaid Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has entered into various research and development contracts. The payments to these agreements are recorded as research and development expenses as incurred. The Company records accrued liabilities and prepaid expenses for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgements and estimates are made in determining the accrued and prepaid balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for all share-based awards granted to employees and non-employees as share-based compensation expense at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized over the employees&#x2019; requisite service period, which is the vesting period, on a straight-line basis. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each restricted share unit is estimated on the date of grant based on the fair value of our common share on that same date. The fair value of each stock option grant or purchases under our 2020 Employee Share Purchase Plan (&#x201c;ESPP&#x201d;) is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected share price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option and the Company&#x2019;s expected dividend yield. As there was no public market for its common shares prior to its IPO in June 2020, the Company determined the volatility for stock option awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies blended with the historical volatility of the Company's common shares. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price. For purchases under our ESPP, only the historical volatility of the Company's common shares is used when developing an estimate of expected volatility. The expected term of the Company&#x2019;s stock options granted to employees and non-employees has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. In connection with the adoption of ASU No. 2018-07, Compensation&#x2014;Stock Compensation (&#x201c;ASU No. 2018-07&#x201d;), the Company calculated the expected term of non-employee awards using the midpoint between the vesting date and the contractual term, which is consistent with the method used for employee awards. For purchases under our ESPP, the expected term is based on the length of the offering period. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award, for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common shares; therefore, the expected dividend yield is assumed to be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. Any consideration paid by employees on exercising stock options or the purchases under our ESPP and the corresponding portion previously credited to additional paid-in capital are credited to share capital.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share Issuance Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share issuance costs applicable to the issuance of equity instruments are recorded as a reduction of the financing equity proceeds.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted-average number of common shares outstanding during the reporting period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of common shares and potentially dilutive&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;securities &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, shares issuable under the ESPP and options to purchase common shares considered to be potentially dilutive securities were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all reporting periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#x2019;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on differences between the consolidated financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and Development Tax Credits&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes the benefit of refundable Canadian research and development tax credits as a reduction of research and development costs when there is reasonable assurance that the amount claimed will be recovered.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13). Certain amendments thereto were also issued by the FASB. ASU 2016-13 and the related amendments implement an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. The Company adopted ASU 2016-13 and the related amendments thereto on January 1, 2022. The adoption of ASU 2016-13 and the related amendments thereto did not have a material impact on the Company&#x2019;s consolidated financial statements or disclosures as of and for the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were no new accounting pronouncements issued which could have a significant effect on the Company's consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_fee877e3-5968-424e-b959-40567b5a2d86">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and as amended by Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_c35a59cd-a5ab-4eab-81c9-62ad1fccdd68">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;accompanying consolidated financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Repare Therapeutics USA Inc. (&#x201c;Repare USA&#x201d;), which was incorporated under the laws of Delaware on June 1, 2017. The financial statements of Repare USA are prepared for the same reporting period as the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;parent &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;company, using consistent accounting policies. All intra-group transactions, balances, income, and expenses are eliminated in full upon consolidation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <rptx:SmallerReportingCompanyPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_4399e4a5-7464-4a5f-b1bd-fb169755b054">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Smaller Reporting Company&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company qualifies as a &#x201c;smaller reporting company&#x201d; under the Exchange Act as of December 31, 2022 because the market value of its common shares held by non-affiliates was less than $560 million as of June 30, 2022 and its revenue for the year ended December 31, 2021 was less than $100 million. As a smaller reporting company, the Company may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. For so long as the Company remains a smaller reporting company, it is permitted and the Company intends to rely on such exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies.&lt;/span&gt;&lt;/p&gt;</rptx:SmallerReportingCompanyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_5fe81733-1ffd-4a06-8cea-4268b8d69215">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign Currencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The functional currency for the Company and Repare USA is the U.S. dollar (&#x201c;USD&#x201d;). Accordingly, transactions denominated in currencies other than the functional currency are measured and recorded in the functional currency at the exchange rate in effect on the date of the transactions. At each consolidated balance sheet date, monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using the exchange rate in effect at that date. Non-monetary assets and liabilities and revenue and expense items denominated in foreign currencies are translated into the functional currency using the exchange rate prevailing at the dates of the respective transactions. Any gains or losses arising on remeasurement are included in the consolidated statement of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_ffdb7106-2bdf-4ad5-93a3-533d618397a8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#x2019;s singular focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_d466ed84-5d08-48fd-b32e-25c622304296">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, right-of-use assets and lease liabilities and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_eca0d058-2702-4cf5-87ab-78f93681b760">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_0033c5f1-fff7-44c3-8cd2-153a5ff96177">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company classifies marketable debt securities with a remaining maturity of greater than three months when purchased as available-for-sale. Marketable debt securities with a remaining maturity date greater than one year are classified as non-current where the Company has the intent and ability to hold these securities for at least the next 12 months.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s marketable securities consist of U.S. treasury bills and U.S. treasury notes with original maturities greater than 90 days. All of the Company&#x2019;s marketable securities have a contractual maturity of one year or less. The&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company considers its investment portfolio of U.S. treasury bills and U.S. treasury notes to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on observable inputs, other than quoted market prices. Unrealized gains and losses are reported in accumulated other comprehensive items in shareholders&#x2019; equity. Amortization and accretion of premiums and discounts are recorded in interest income (expense). Realized gains or losses on debt securities are included in other income (expense).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#x2019;s carrying amount is not recoverable within a reasonable period of time. In connection therewith, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss on the consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive loss. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in other (expense) income, net within the consolidated statement of operations. Losses are charged against the allowance when the Company believes the uncollectibility of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_db9fa0e2-2ec7-4e25-b34d-dc141547bc84">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Our investment portfolio comprises money market funds, U.S. treasury bills and U.S. treasury notes. Our investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company maintains deposits in accredited financial institutions which exceed insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s exposure to foreign exchange risk is primarily related to fluctuations between the Canadian dollar and the U.S. dollar. There are balances in Canadian dollars which are subject to foreign currency fluctuations relating to the impact of translating to U.S. dollars for financial statement presentation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/span&gt;&lt;/span&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_dc58231c-2712-4ff8-a057-7b98ca524ecd">As of December 31, 2022 and 2021, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      id="F_2ffe40b6-d86a-4ba5-a525-067387abf024">As of December 31, 2022 and 2021, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_e3934388-4323-412c-b012-61dcd45365ab">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss includes net loss as well as other changes in shareholders&#x2019; equity that result from transactions and economic events other than those with shareholders. Other comprehensive loss consists of unrealized losses on available-for-sale marketable securities. Total comprehensive loss for all periods presented has been disclosed in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_913aab03-1110-4216-8fe1-d500bc7fe77a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x95;	Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x95;	Level 2 &#x2013; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:5.653%;text-indent:-5.047%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x95;	Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;An entity may choose to measure financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The estimated fair values of the Company&#x2019;s cash and cash equivalents, collaboration revenue receivable, other receivables, other assets and accounts payable and accrued expenses approximate their carrying values.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s marketable securities are carried at fair value, determined according to Level 2 inputs in the fair value hierarchy described above.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_18967427-34d9-47de-87d2-94b7bc230949">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment is stated at historical cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.498%;"/&gt;
          &lt;td style="width:1.004%;"/&gt;
          &lt;td style="width:49.498%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Useful Lives&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the shorter of the lease term and the useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. Expenditures for maintenance and repairs are recorded to expense as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <rptx:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_72b0a24e-09b1-437c-a3a9-364abb9fd773">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment is stated at historical cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.498%;"/&gt;
          &lt;td style="width:1.004%;"/&gt;
          &lt;td style="width:49.498%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Useful Lives&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the shorter of the lease term and the useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</rptx:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_d02b1f3e-16d6-4441-958a-8ba01e196c61"
      id="F_11e02b5f-b68a-4975-b6a0-5ad5be566092">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_b1cc4d13-0ecb-41c8-b252-fe8d061ccd9a"
      id="F_c8b6ebb0-9de1-44a6-96fc-6c7dbc579ec7">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_80ef95e4-5908-4482-8697-3e73902fd846"
      id="F_662c7343-0baa-4bb7-9515-fb95f3b1d503">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_5ef6ce9a-5c8e-4c42-b1be-099fd91b49b2"
      id="F_04d4909d-87a1-4497-9a67-dffa30adbb59">the shorter of the lease term and the useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_db088e45-d88b-4613-b0b6-f64e49280618">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of assets may not be recoverable. Recoverability of these assets is measured by comparing their carrying value to the future net undiscounted cash flows the assets are expected to generate over their remaining economic life. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying value of the assets exceeds their fair value. Indefinite-lived intangible assets are tested for impairment annually, or more frequently if indicators of impairment are present. To date, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; such impairment losses have been recorded.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="INF"
      id="F_d6707f54-89c6-4c60-8668-3f5cefc39378"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_e9cb4726-9509-4706-bd66-df558bd76f6f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the consolidated balance sheet as a right-of-use asset and current and non-current lease liabilities, as applicable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_9fa2c9f2-0bad-47ef-b53f-33eb5c6ce6f1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company enters into collaboration and license agreements, which are within the scope of ASC 606, to discover, develop, manufacture, and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (i) licenses to compounds directed to specific targets (referred to as &#x201c;exclusive licenses&#x201d;) and (ii) research and development activities to be performed on behalf of the collaboration partner related to the licensed targets. Payments to the Company under these agreements may include non-refundable&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;license fees, customer option exercise fees, payments for research activities, reimbursement of certain costs, payments based upon the achievement of certain milestones and royalties on any resulting net product sales.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company first evaluates license and/or collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;), based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for collaborative arrangements (or elements within the contract that are deemed part of a collaborative arrangement), which represent a collaborative relationship and not a customer relationship, outside the scope of ASC 606.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s collaborations primarily represent revenue arrangements. For the arrangements or arrangement components that are subject to revenue accounting guidance, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company applies the five-step model. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration, except for sales-based royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In determining the stand-alone selling price of a license to the Company&#x2019;s proprietary technology or a material right provided by a customer option, the Company considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating its estimated stand-alone selling price, the Company evaluates whether changes in the key assumptions used to determine its estimated stand-alone selling price will have a significant effect on the allocation of arrangement consideration between performance obligations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within one year following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within one year following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Exclusive Licenses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the license is the predominant promise, and it is determined that the license represents functional intellectual property (&#x201c;IP&#x201d;), revenue is recognized at the point in time when control of the license is transferred. If it is determined that the license does not represent functional IP, revenue is recognized over time using an appropriate method of measuring progress.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Services&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; The obligations under the Company&#x2019;s collaboration and license agreements generally include research and development services to be performed by the Company to benefit the collaboration partner. For performance obligations that include research and development services, the Company generally&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods of which revenue should be recognized, are subject to estimates by management and may change over the course of the contract. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Customer Options&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; The Company&#x2019;s arrangements may provide a collaborator with the right to acquire additional goods or services in the future. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement as an upfront fee or payment or (ii) upon the exercise of the customer option. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Milestone Payments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For a complete discussion of accounting for collaboration revenues, s&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ee Note 12.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_175756c1-f13c-41cc-972a-6344860480cb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. The Company&#x2019;s research and development expenses consist primarily of costs incurred in performing research and development activities, including salaries and other compensation, share-based compensation, fees paid to external service providers, laboratory supplies and costs for facilities and equipment, partially offset by fully refundable research and development tax credits. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are expensed as the goods are delivered or the services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <rptx:AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_364849a0-d94c-4df7-ab76-bf3365460da2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued and Prepaid Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has entered into various research and development contracts. The payments to these agreements are recorded as research and development expenses as incurred. The Company records accrued liabilities and prepaid expenses for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgements and estimates are made in determining the accrued and prepaid balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</rptx:AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_8d9d6d73-1b34-4a98-8db1-cec89b42ee87">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for all share-based awards granted to employees and non-employees as share-based compensation expense at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The measurement date for employee and non-employee awards is the date of grant, and share-based compensation costs are recognized over the employees&#x2019; requisite service period, which is the vesting period, on a straight-line basis. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each restricted share unit is estimated on the date of grant based on the fair value of our common share on that same date. The fair value of each stock option grant or purchases under our 2020 Employee Share Purchase Plan (&#x201c;ESPP&#x201d;) is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected share price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option and the Company&#x2019;s expected dividend yield. As there was no public market for its common shares prior to its IPO in June 2020, the Company determined the volatility for stock option awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies blended with the historical volatility of the Company's common shares. The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price. For purchases under our ESPP, only the historical volatility of the Company's common shares is used when developing an estimate of expected volatility. The expected term of the Company&#x2019;s stock options granted to employees and non-employees has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. In connection with the adoption of ASU No. 2018-07, Compensation&#x2014;Stock Compensation (&#x201c;ASU No. 2018-07&#x201d;), the Company calculated the expected term of non-employee awards using the midpoint between the vesting date and the contractual term, which is consistent with the method used for employee awards. For purchases under our ESPP, the expected term is based on the length of the offering period. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award, for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common shares; therefore, the expected dividend yield is assumed to be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. Any consideration paid by employees on exercising stock options or the purchases under our ESPP and the corresponding portion previously credited to additional paid-in capital are credited to share capital.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="INF"
      id="F_8d5a4cd8-ee31-46af-a963-d10ce1772cea"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <rptx:ShareIssuanceCostsPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_c8af7464-363e-47de-9120-6bf4e71d2c78">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share Issuance Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share issuance costs applicable to the issuance of equity instruments are recorded as a reduction of the financing equity proceeds.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</rptx:ShareIssuanceCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_501fa323-b9ec-44d9-bd28-7ea345a36977">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted-average number of common shares outstanding during the reporting period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of common shares and potentially dilutive&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;securities &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, shares issuable under the ESPP and options to purchase common shares considered to be potentially dilutive securities were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all reporting periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_5fa69eac-72df-475c-bccc-fd3fca656c11">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#x2019;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on differences between the consolidated financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <rptx:ResearchAndDevelopmentTaxCreditsPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_24484398-75f2-4c51-a582-ccdc47f8e84a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and Development Tax Credits&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes the benefit of refundable Canadian research and development tax credits as a reduction of research and development costs when there is reasonable assurance that the amount claimed will be recovered.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</rptx:ResearchAndDevelopmentTaxCreditsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_d4f0687a-bf12-4e08-a0b2-18ef2a0c6515">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13). Certain amendments thereto were also issued by the FASB. ASU 2016-13 and the related amendments implement an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. The Company adopted ASU 2016-13 and the related amendments thereto on January 1, 2022. The adoption of ASU 2016-13 and the related amendments thereto did not have a material impact on the Company&#x2019;s consolidated financial statements or disclosures as of and for the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <rptx:RecentlyIssuedAccountingPronouncementsPolicyTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_500be597-f031-4549-9d93-10e7d767b71b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were no new accounting pronouncements issued which could have a significant effect on the Company's consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</rptx:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_6155466b-3762-4487-8855-36124c0df958">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.844%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.256%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.256%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.256%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.278%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Money market funds included in cash and cash &lt;br/&gt;&#160;&#160;&#160;equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;U.S. Treasury notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;184,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;184,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;227,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;184,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Money market funds included in cash and cash &lt;br/&gt;&#160;&#160;&#160;equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;U.S. Treasury notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure the fair value. In determining the fair values at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; transfers between fair value measure levels.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_a7cbf7d5-222c-4c16-8241-207ddbc3b832">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.844%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.256%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.256%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.256%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.278%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Money market funds included in cash and cash &lt;br/&gt;&#160;&#160;&#160;equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;U.S. Treasury notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;184,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;184,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;227,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;184,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Money market funds included in cash and cash &lt;br/&gt;&#160;&#160;&#160;equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;U.S. Treasury notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ff4a68ee-b5b1-4384-8e04-39e5e83483d2"
      decimals="-3"
      id="F_deda845f-7443-4578-8ab7-1605f759a9e8"
      unitRef="U_USD">42995000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fc490bf6-e1b0-491f-b8e0-2dc975bea1ea"
      decimals="-3"
      id="F_ab4dad1b-cf11-4660-88f9-435b0c60daf5"
      unitRef="U_USD">42995000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_094da959-0fa8-48bc-82fd-7da9a531e3da"
      decimals="-3"
      id="F_f8db5da9-5c8e-4692-be4f-681ad33decb1"
      unitRef="U_USD">58362000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2e186f36-a60e-4c0e-bd2b-4f70ac8527fa"
      decimals="-3"
      id="F_ce7d3179-c07e-46dc-b0fd-7c13257975f9"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_06d3eba4-beff-4c6e-9e0d-74f30c8e9c98"
      decimals="-3"
      id="F_e7a1590d-dc2e-4a9f-a8c6-f70478c2c014"
      unitRef="U_USD">58362000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_17d80998-566f-4f86-8cc7-530d916cebec"
      decimals="-3"
      id="F_b16732e0-6262-4aba-af79-5707cdbb637f"
      unitRef="U_USD">126058000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b5d1add8-29f2-4667-a5b8-f33390d83a70"
      decimals="-3"
      id="F_f5947c8d-7fd4-4e8b-bff9-58ab777df16f"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_df9028e4-3b11-4078-8748-bb04b49d52e5"
      decimals="-3"
      id="F_9a14d2c6-8d8c-4d50-a8ba-1f74be4821e3"
      unitRef="U_USD">126058000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_28941f5b-2a91-41bc-8b35-389f61385829"
      decimals="-3"
      id="F_36344168-ac79-46a8-aeca-fd68a42bca79"
      unitRef="U_USD">184420000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ba56d68a-153c-41be-98bc-d302dc2e8772"
      decimals="-3"
      id="F_7f36a447-9ac1-4d70-a8b7-0a7fd3c9ae67"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0af7e506-9a9a-47a8-b222-a900c293b675"
      decimals="-3"
      id="F_715c9956-0beb-48c0-901f-52e47c8d2ea6"
      unitRef="U_USD">184420000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_baf42153-e67f-4dc2-ba51-e440db83cb6e"
      decimals="-3"
      id="F_04e08bf9-9831-4b95-a3a8-5322090b2292"
      unitRef="U_USD">227415000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_aecc3de1-8a93-42ff-8549-71726fd80b22"
      decimals="-3"
      id="F_00c37e62-294d-4c33-9764-055d8f50473b"
      unitRef="U_USD">42995000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2d3ca020-4e0b-4919-95d8-caf1bce5c167"
      decimals="-3"
      id="F_d96afcdd-8b2e-4d07-8b4a-2347893493fa"
      unitRef="U_USD">184420000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c7524e4f-ecae-4724-8931-850f78dc9340"
      decimals="-3"
      id="F_751efc18-a744-4bed-89f8-c6ae235cc8f5"
      unitRef="U_USD">2535000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3b9dcbf4-525f-41db-93e3-091d15eb10d2"
      decimals="-3"
      id="F_98ed075a-98a9-4a43-ac58-f2e8b4d8e9c6"
      unitRef="U_USD">2535000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b3c5d94f-28fa-4de1-b6e2-f03d2f331b1c"
      decimals="-3"
      id="F_4fd29ada-f275-441e-b794-a3bb42f48dab"
      unitRef="U_USD">7439000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_12d929c7-4102-4a0a-82ac-5737d31dbf45"
      decimals="-3"
      id="F_b1bc83dd-df90-494a-9ab9-cdb7252085de"
      unitRef="U_USD">7439000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0d97e526-4833-4dc6-8113-19ae64b7fa24"
      decimals="-3"
      id="F_d7db79a2-b38d-49d9-b3b0-397649439805"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_44a2af96-1633-4609-b79e-fb906b4b9e17"
      decimals="-3"
      id="F_0c55d1f7-1e26-4fe9-b50b-67ee61be7ee9"
      unitRef="U_USD">9974000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_20ff1fa1-ce48-4c09-9244-1fba1284c839"
      decimals="-3"
      id="F_5454ce8d-897d-4278-b382-778d0ddc718c"
      unitRef="U_USD">9974000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f8706cb3-36b5-4d0e-af7f-dd5993e51a36"
      decimals="-3"
      id="F_5675b08d-50b6-4ca3-8196-98eccc7cb072"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <rptx:FairValueAssetsTransfersBetweenAllLevels
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="INF"
      id="F_15e0d143-4fcb-42a1-b524-67cd640cca91"
      unitRef="U_USD">0</rptx:FairValueAssetsTransfersBetweenAllLevels>
    <rptx:FairValueAssetsTransfersBetweenAllLevels
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="INF"
      id="F_4817b4bd-36cb-48b3-95de-a1bbaf3682e9"
      unitRef="U_USD">0</rptx:FairValueAssetsTransfersBetweenAllLevels>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_d942644b-65db-4da6-ad9f-ad7f18afe0d7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4. Cash and Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, cash and cash equivalents and marketable securities were comprised of the following:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.588%;"/&gt;
        &lt;td style="width:0.288%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.814%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.264%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.814%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.288%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.56%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.072%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.31%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;159,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;159,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;U.S. Treasury notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;184,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;184,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;331,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;331,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;334,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;334,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;U.S. Treasury notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest receivable was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively, and is included in other receivables.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company held &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; available-for-sale marketable securities with an aggregate fair value of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;157.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; that were in an unrealized loss position as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively. These marketable securities have been in an unrealized loss position for less than twelve months. The unrealized losses as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. The Company does not intend to sell these securities and it is more likely than not that it will hold these investments for a period of time sufficient to recover the amortized cost. As a result, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;record&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;an &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;allowance for credit losses or other impairment charges for its marketable securities for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognized &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in net unrealized losses in other comprehensive loss for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The maturities of the Company&#x2019;s marketable securities as of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; are less than one year.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_32774934-5a90-4cbf-9d65-e7dec4b0fa33">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, cash and cash equivalents and marketable securities were comprised of the following:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.588%;"/&gt;
        &lt;td style="width:0.288%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.814%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.264%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.814%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.288%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.56%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.072%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.31%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;159,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;159,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;U.S. Treasury notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;184,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;184,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;331,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;331,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;334,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;334,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;U.S. Treasury notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d537aff3-5446-4d5f-b08a-5674e6242a97"
      decimals="-3"
      id="F_792631e9-6e73-4e3f-a2a4-7764d9d35e29"
      unitRef="U_USD">116526000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d537aff3-5446-4d5f-b08a-5674e6242a97"
      decimals="-3"
      id="F_bca0e672-0fe4-42c7-885d-60dd73b229c6"
      unitRef="U_USD">116526000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ff1c845e-bbd0-4d13-bdde-c076815d4982"
      decimals="-3"
      id="F_48121dea-944e-4d5d-a3de-ee8a354c8400"
      unitRef="U_USD">42995000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ff1c845e-bbd0-4d13-bdde-c076815d4982"
      decimals="-3"
      id="F_5650fbeb-da3c-4515-bc17-33ac8442a93e"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ff1c845e-bbd0-4d13-bdde-c076815d4982"
      decimals="-3"
      id="F_dc2232b5-6e10-4c20-b7c6-078e6894c867"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ff1c845e-bbd0-4d13-bdde-c076815d4982"
      decimals="-3"
      id="F_d3dd945d-4cdc-4c7c-b3a3-c1991f14b0d1"
      unitRef="U_USD">42995000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_51a377d0-935c-4a85-8c6a-d896a70f1212"
      decimals="-3"
      id="F_20a3549c-fbe0-45a3-8663-7e0460aab520"
      unitRef="U_USD">159521000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_51a377d0-935c-4a85-8c6a-d896a70f1212"
      decimals="-3"
      id="F_b2471d1b-7d88-4971-934c-9ff275d75414"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_51a377d0-935c-4a85-8c6a-d896a70f1212"
      decimals="-3"
      id="F_ee5ae3ba-34ce-4f62-8c6f-f9264acac843"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_51a377d0-935c-4a85-8c6a-d896a70f1212"
      decimals="-3"
      id="F_9bbb47b5-4de7-4490-83cf-07c27b247584"
      unitRef="U_USD">159521000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_fad67f8b-88f3-490b-bbfe-cdc36bfeb2fc"
      decimals="-3"
      id="F_ce0e3b5d-71ad-423e-853c-af968339a325"
      unitRef="U_USD">58641000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_fad67f8b-88f3-490b-bbfe-cdc36bfeb2fc"
      decimals="-3"
      id="F_f0086962-a934-44b0-b3f9-12ea0be72674"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_fad67f8b-88f3-490b-bbfe-cdc36bfeb2fc"
      decimals="-3"
      id="F_88d998ef-f631-4694-8e17-5442d1aa58f1"
      unitRef="U_USD">280000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fad67f8b-88f3-490b-bbfe-cdc36bfeb2fc"
      decimals="-3"
      id="F_897971a9-ce69-4512-b4c7-7ecddc75890f"
      unitRef="U_USD">58362000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_bcb6ad6a-f6c4-44a8-aa2f-56e18ff3d4ea"
      decimals="-3"
      id="F_3b186167-b3c2-4531-9473-9787468902b2"
      unitRef="U_USD">126207000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_bcb6ad6a-f6c4-44a8-aa2f-56e18ff3d4ea"
      decimals="-3"
      id="F_0cd63be6-ae09-478a-a133-d4b66cf74f1a"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_bcb6ad6a-f6c4-44a8-aa2f-56e18ff3d4ea"
      decimals="-3"
      id="F_4af84f6b-5213-438c-8f8d-2915364994c9"
      unitRef="U_USD">153000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_bcb6ad6a-f6c4-44a8-aa2f-56e18ff3d4ea"
      decimals="-3"
      id="F_4100937c-90f1-46d3-a4d2-937045ea9380"
      unitRef="U_USD">126058000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2c1f1f11-816f-44a0-818c-677c87d99b95"
      decimals="-3"
      id="F_9eb931a5-02e0-47a8-9f51-4641f9a44d30"
      unitRef="U_USD">184848000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_2c1f1f11-816f-44a0-818c-677c87d99b95"
      decimals="-3"
      id="F_dc95c371-71a3-4972-bb2f-9a6d5809fba1"
      unitRef="U_USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2c1f1f11-816f-44a0-818c-677c87d99b95"
      decimals="-3"
      id="F_f2ee18fd-fefd-4551-aedd-983073b54b4f"
      unitRef="U_USD">433000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2c1f1f11-816f-44a0-818c-677c87d99b95"
      decimals="-3"
      id="F_7dfb5288-8e34-40b4-bf5b-1fc5e1d27469"
      unitRef="U_USD">184420000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_09a80f4e-72ef-4a70-a01e-600cbb7a0251"
      decimals="-3"
      id="F_f2466dca-e8a6-465f-ba17-8df85d2f403a"
      unitRef="U_USD">331892000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_09a80f4e-72ef-4a70-a01e-600cbb7a0251"
      decimals="-3"
      id="F_79354b55-c8d2-4fae-9bdc-21157eee2f8c"
      unitRef="U_USD">331892000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_725a0d91-5730-423e-a433-8f6615c75200"
      decimals="-3"
      id="F_8e92f792-1462-4f70-ae27-09d469b58d48"
      unitRef="U_USD">2535000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_725a0d91-5730-423e-a433-8f6615c75200"
      decimals="-3"
      id="F_49262e02-30bf-4944-abce-33072d0a8b0f"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_725a0d91-5730-423e-a433-8f6615c75200"
      decimals="-3"
      id="F_25727c41-c4a7-476e-81e9-286889527184"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_725a0d91-5730-423e-a433-8f6615c75200"
      decimals="-3"
      id="F_83704238-554e-4fcf-8617-8bcb944c7408"
      unitRef="U_USD">2535000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7e79f2bb-36b7-445f-a31b-fe962378bd7e"
      decimals="-3"
      id="F_a6c5416a-0893-4b77-8589-0839df79ea50"
      unitRef="U_USD">334427000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_7e79f2bb-36b7-445f-a31b-fe962378bd7e"
      decimals="-3"
      id="F_74bf028b-a486-4a46-a1a9-ec9055301ec7"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_7e79f2bb-36b7-445f-a31b-fe962378bd7e"
      decimals="-3"
      id="F_b0327574-ff3e-4991-9d71-ad063e955efb"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7e79f2bb-36b7-445f-a31b-fe962378bd7e"
      decimals="-3"
      id="F_d6d3d097-6b87-42bc-87fe-52e8223b82ba"
      unitRef="U_USD">334427000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_cb5cf079-696f-4343-a699-77c7dc62a392"
      decimals="-3"
      id="F_e70d4201-54b9-4058-ac62-4a931541afc6"
      unitRef="U_USD">7439000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_cb5cf079-696f-4343-a699-77c7dc62a392"
      decimals="-3"
      id="F_4b4bb48e-f619-4dbd-9765-fddf121943c7"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_cb5cf079-696f-4343-a699-77c7dc62a392"
      decimals="-3"
      id="F_53c8255b-c9e5-4a2c-93c2-2750db089855"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_cb5cf079-696f-4343-a699-77c7dc62a392"
      decimals="-3"
      id="F_a71738e0-6f29-417c-9917-0bb7943174cd"
      unitRef="U_USD">7439000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4de6f4d2-6787-40e5-b77a-57e8962ad678"
      decimals="-3"
      id="F_1bcd7666-fcb5-4ada-9da5-dbb75b88e9cd"
      unitRef="U_USD">7439000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_4de6f4d2-6787-40e5-b77a-57e8962ad678"
      decimals="-3"
      id="F_387cc116-9c2b-4191-8556-f60d5d392fae"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_4de6f4d2-6787-40e5-b77a-57e8962ad678"
      decimals="-3"
      id="F_8ae028b7-4f9f-4b83-a1e0-1281fb25a1b8"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4de6f4d2-6787-40e5-b77a-57e8962ad678"
      decimals="-3"
      id="F_9dcd62db-f919-4860-9551-b16df86ec7ab"
      unitRef="U_USD">7439000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AccruedInvestmentIncomeReceivable
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-5"
      id="F_c4a3be18-b986-49a5-b0e1-2a5ef79189cd"
      unitRef="U_USD">400000</us-gaap:AccruedInvestmentIncomeReceivable>
    <us-gaap:AccruedInvestmentIncomeReceivable
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-6"
      id="F_70ce94c6-6422-4243-99b2-455351d0c731"
      unitRef="U_USD">0</us-gaap:AccruedInvestmentIncomeReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="INF"
      id="F_47a8f803-1c3e-480b-a988-49da206b7267"
      unitRef="U_Positions">28</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="INF"
      id="F_7065fd8f-6976-4ae7-8ca8-d6474aa67aad"
      unitRef="U_Positions">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-5"
      id="F_be73f293-8091-4be3-9fb1-ef8754aa7159"
      unitRef="U_USD">157900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="INF"
      id="F_d523e318-599d-46fb-8ccf-1d107fb642e0"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="INF"
      id="F_a9862e7e-2ef1-429b-8516-275a1af49628"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="INF"
      id="F_f67c83fe-d740-4806-af86-ca5ff33b6289"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-5"
      id="F_4b218752-df1c-46a4-987f-c066418ef2bf"
      unitRef="U_USD">400000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="INF"
      id="F_f17ac80f-f357-4905-873f-97060d057ebf"
      unitRef="U_USD">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_83ffc622-77e4-4693-91d5-5555324fc3f0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5. Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.61%;"/&gt;
        &lt;td style="width:1.604%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.615%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense recognized was allocated as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_b0d78a34-a0ae-4b12-8b61-5e23df876a06">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.61%;"/&gt;
        &lt;td style="width:1.604%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.615%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_22564969-d47a-4706-ae91-ce5a0d5d6dce"
      decimals="-3"
      id="F_0e8566f7-b3ad-4154-86d1-f12c889e8f5d"
      unitRef="U_USD">473000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8c1fa03b-d7de-4cdb-bb33-3af841c54489"
      decimals="-3"
      id="F_50cf299c-74ec-4f40-a73c-5fb0bf3f7c7f"
      unitRef="U_USD">469000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_48b390fd-4b46-46d7-aee6-263c90700965"
      decimals="-3"
      id="F_36d3a60c-2be4-484f-b641-9f6ea20da775"
      unitRef="U_USD">514000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e75a721e-63db-4a19-a404-91703f5b0417"
      decimals="-3"
      id="F_64f83168-ab3d-4d11-ae6b-091b6e069a8a"
      unitRef="U_USD">509000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5c19b01e-f2cc-438a-99aa-b2fa48bdc135"
      decimals="-3"
      id="F_58eb5e1d-a515-494d-a2cf-225831d3ef79"
      unitRef="U_USD">6075000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c204b568-e22d-442d-991f-8208f6b49c11"
      decimals="-3"
      id="F_757dabff-328d-453e-bedb-0c2b70a61706"
      unitRef="U_USD">5536000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4efbd3ec-210d-4b1b-84fc-55cd67ef578f"
      decimals="-3"
      id="F_ced9a2fe-4fbb-40c7-8e8e-cb571073d56c"
      unitRef="U_USD">2519000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0b3e7aa4-3459-470d-87c2-e0d9a02fb4d5"
      decimals="-3"
      id="F_b4d340a0-e476-4d55-9507-22b561cfcc66"
      unitRef="U_USD">2465000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_c0dd68ef-2a2f-4560-b6e7-e987b212054a"
      unitRef="U_USD">9581000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_c336e51c-ddbc-4134-ae5c-b78757a4eb3b"
      unitRef="U_USD">8979000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_0cf87a77-36c1-4e0a-b675-13405891d69f"
      unitRef="U_USD">5353000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_c33c33c0-c369-4141-add0-d168ed226f61"
      unitRef="U_USD">3375000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_665be909-f1a2-4630-9b96-bdc77668ba37"
      unitRef="U_USD">4228000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_822e1fa3-fa4f-4d21-937b-ec67efa5268a"
      unitRef="U_USD">5604000</us-gaap:PropertyPlantAndEquipmentNet>
    <rptx:ScheduleOfDepreciationExpenseTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_e01830ae-88b1-44a5-9318-34531a2a40c4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense recognized was allocated as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</rptx:ScheduleOfDepreciationExpenseTableTextBlock>
    <us-gaap:Depreciation
      contextRef="C_afaac43e-017a-44ba-b75d-7ea6a3b4e368"
      decimals="-3"
      id="F_b92bc943-7f65-4fff-893b-6b5070006a16"
      unitRef="U_USD">1837000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_30716fb3-44b9-47e8-800d-7c2d957e670b"
      decimals="-3"
      id="F_dab248e7-9aa2-49e1-854d-2793650c0d43"
      unitRef="U_USD">1325000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_301dd1df-f42b-4bd5-982c-d7e2d3733b57"
      decimals="-3"
      id="F_0b372b05-7fed-4de7-ace2-07c3653d3359"
      unitRef="U_USD">141000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_48281951-8326-4dc8-8373-9afcbedac008"
      decimals="-3"
      id="F_3f8b0d76-8698-418a-bf09-034e49c6c537"
      unitRef="U_USD">146000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_b8c55cac-5efa-4e5b-98ee-1fe19493ca43"
      unitRef="U_USD">1978000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_4a96163f-c1d7-42db-94c4-504a33724189"
      unitRef="U_USD">1471000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_c6170a9f-41d3-4a3e-a305-103df1366739">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses and other current liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <rptx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_76a008d8-ca78-465d-bec8-59899a1fcfd5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses and other current liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</rptx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_6ce12c6b-947d-40e6-a3ea-34e47d480102"
      unitRef="U_USD">5616000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_39e05642-505e-44f5-8e14-b121f59cac05"
      unitRef="U_USD">4867000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <rptx:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_037a7399-2b6c-4aaf-b9d7-58ebc8928ef5"
      unitRef="U_USD">15078000</rptx:AccruedResearchAndDevelopmentExpenseCurrent>
    <rptx:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_2e4d5b93-85aa-404c-85a8-d8bbd0785741"
      unitRef="U_USD">11272000</rptx:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_b3fbb868-f438-4200-8bc4-70455a764752"
      unitRef="U_USD">680000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_b87e9d86-f13c-4c25-b7bf-20d082100b83"
      unitRef="U_USD">387000</us-gaap:AccruedProfessionalFeesCurrent>
    <rptx:AccruedPropertyAndEquipmentPurchases
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_ff8563f4-7b8c-4f8a-8246-e412ac5830a8"
      unitRef="U_USD">0</rptx:AccruedPropertyAndEquipmentPurchases>
    <rptx:AccruedPropertyAndEquipmentPurchases
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_ba3ffd9e-68b4-4347-882d-8ffc29741a33"
      unitRef="U_USD">1719000</rptx:AccruedPropertyAndEquipmentPurchases>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_f2de2660-c2fc-402e-8e65-a3dd2a994614"
      unitRef="U_USD">271000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_8cf761b6-d179-4c2b-b596-5850aec01695"
      unitRef="U_USD">377000</us-gaap:OtherLiabilitiesCurrent>
    <rptx:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_21ff22cc-531c-4655-bb7a-1ba9e5e4b9a5"
      unitRef="U_USD">21645000</rptx:AccruedExpensesAndOtherLiabilitiesCurrent>
    <rptx:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_5de99437-6329-4959-b4d1-792fb3b7ec5b"
      unitRef="U_USD">18622000</rptx:AccruedExpensesAndOtherLiabilitiesCurrent>
    <rptx:LicenseAgreementsDisclosureTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_685e782b-5215-4853-813a-a04b42e0839e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7. License Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2016, as further amended in February 2017 and amended and restated in July 2018, the Company entered into a license agreement (the &#x201c;NYU Agreement&#x201d;) with New York University, pursuant to which the Company obtained a worldwide, royalty-bearing, exclusive license under certain patents and know-how of New York University to research, develop and commercialize products covered by such licensed patents. The Company is required to pay New York University an annual non-refundable license fee, which is creditable against future milestone and royalty payments. The Company is required to pay amounts up to approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in the aggregate upon&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;achievement &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of certain clinical and commercial milestones and pay a low single digit royalty on future net sales of any product covered by a licensed product and a lower-single digit royalty on future net sales of any product not covered by a licensed product. The NYU Agreement expires on the date of expiration of all royalty obligations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Any potential future milestone or royalty payment amounts have &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t been accrued at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; due to the uncertainty related to the successful achievement of these milestones.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</rptx:LicenseAgreementsDisclosureTextBlock>
    <rptx:LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones
      contextRef="C_2885b753-de7f-4392-894e-f84483b20968"
      decimals="-5"
      id="F_da945872-f009-4a45-b18f-940a5bc6ca61"
      unitRef="U_USD">6700000</rptx:LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones>
    <rptx:LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones
      contextRef="C_eaa1c4ec-6b84-4c2f-bfb1-0f3c64fa8a22"
      decimals="-5"
      id="F_c5bbc78e-443b-4d85-8470-417db148e1a1"
      unitRef="U_USD">6700000</rptx:LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones>
    <rptx:AccrualPotentialMilestoneAndRoyaltyPayments
      contextRef="C_8d0b1ad6-feb9-4c5d-a621-f47ee6f509c7"
      decimals="INF"
      id="F_9f6a7c46-a2c4-4356-bfcd-c8b071b706f0"
      unitRef="U_USD">0</rptx:AccrualPotentialMilestoneAndRoyaltyPayments>
    <rptx:AccrualPotentialMilestoneAndRoyaltyPayments
      contextRef="C_5b7ac425-2255-44fd-ada4-9a500ac1d1b0"
      decimals="INF"
      id="F_2ef713e9-e7c2-4880-895b-b2d300049e2f"
      unitRef="U_USD">0</rptx:AccrualPotentialMilestoneAndRoyaltyPayments>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_3958ba3d-8c91-412d-9a56-9b276e8bd3ac">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8. Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has historically entered into lease arrangements for its facilities and certain equipment. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating leases with required future minimum payments. The Company&#x2019;s leases generally do not include &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;termination&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; or purchase options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2017, and as further amended in 2021, the Company entered into a lease agreement for office and laboratory space in Montr&#xe9;al, Qu&#xe9;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;bec, for a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; term, ending in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In August 2021, the lease was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;extended&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; through July 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2017, and as further amended throughout 2018, 2019, 2020, 2021 and 2022, the Company entered into a lease agreement for office and laboratory space located in Montr&#xe9;al, Qu&#xe9;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;bec, for a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; term ending in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;October 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;extended&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; through December 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company entered into a new lease agreement, effective January 2023, which will result in $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of minimum lease payments over the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_5c64d736-3755-4363-b2f0-d376d83f9242;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;thirty-two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; month lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2021, the Company entered into a lease agreement for office space in Cambridge, Massachusetts, for a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; term ending in&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; December 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which commenced in December 2021. The Company has an option for a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; renewal, which has not been recognized in the Company&#x2019;s right-of-use asset or lease liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2019, and as further amended in July 2021, the Company entered into a lease agreement for office and laboratory space for a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; term located in Montr&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xe9;al, Qu&#xe9;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;bec which commenced in September 2020. The Company has an option for a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; renewal, which has not been recognized in the Company&#x2019;s right-of-use asset or lease liability. As required under the terms of the lease agreement, the Company incurred prepaid rent of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million prior to commencement of the lease term, with the current portion previously accounted for within prepaid expenses and other current assets and the long-term portion accounted for within other assets. As well, as required under the terms of the amended lease agreement, the Company incurred prepaid rent of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million prior to commencement of the lease term which was accounted for within prepaid expenses. As of the commencement of the lease term, this prepaid rent has been reclassified to the right-of-use asset.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating leases for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.818%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.501%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands, except as specified otherwise)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other Operating Lease Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.43&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.35&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease costs for the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; include contingent rental usage, common area maintenance and other operating charges. As the Company&#x2019;s leases do &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future minimum lease payments under the Company&#x2019;s operating leases as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.883%;"/&gt;
        &lt;td style="width:1.93%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.187%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturity of Lease Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <rptx:NumberOfOperatingLeases
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="INF"
      id="F_c87c1c6d-006f-44b8-aa92-7ed51109d254"
      unitRef="U_Lease">4</rptx:NumberOfOperatingLeases>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_1a894885-00d0-4aca-9a12-3811d417d077">false</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_4a5e155a-5edb-4aab-8fba-3f55b166f8d0"
      id="F_19caa646-f87a-4a57-84ba-dfc7b73166ed">P4Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <rptx:LesseeOperatingLeaseExpirationMonthAndYear
      contextRef="C_df52d1fe-29fc-4d0d-8f6f-fd0bf0ff0418"
      id="F_66b44b3b-b1ff-4bd0-9c2a-581d06b714b3">2021-07</rptx:LesseeOperatingLeaseExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_42ff0858-ec4a-443e-a421-33c199818df7"
      id="F_fee16209-de14-41b5-b344-5ddb59abb950">extended through July 2025</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_42ff0858-ec4a-443e-a421-33c199818df7"
      id="F_a1db1fec-e1d8-443c-a5a1-05b20922cc8e">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_25443f6f-14cc-4288-8365-8cdd9a2d1076"
      id="F_4ccb494e-c9fe-42c1-a9ce-be5917789e72">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <rptx:LesseeOperatingLeaseExpirationMonthAndYear
      contextRef="C_440d565d-c87e-4c67-922b-8dd7ab19917a"
      id="F_21bdc6ce-7870-4d95-987e-01fedb8fd130">2020-10</rptx:LesseeOperatingLeaseExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_440d565d-c87e-4c67-922b-8dd7ab19917a"
      id="F_ebf818ad-31d2-4f2f-afe2-9e1138456ed6">extended through December 2022</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_440d565d-c87e-4c67-922b-8dd7ab19917a"
      id="F_74aa88db-e93b-4f3d-bac2-02357c493744">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_4fa8599e-cef5-4581-9bfc-a45811c2a414"
      decimals="-5"
      id="F_c43c8cf2-ec97-45d4-9e83-a58dd0ca6b20"
      unitRef="U_USD">200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_a780ab50-a50d-41cf-bc67-6e53d80a9287"
      id="F_cc3deb85-4222-4422-9268-f902df5d9c1b">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <rptx:LesseeOperatingLeaseExpirationMonthAndYear
      contextRef="C_3dbc6dec-8dff-4b9e-b1b2-8ee0fd0bfed6"
      id="F_6b113d51-aa16-4dcf-bf20-5dd60b01dbf2">2024-12</rptx:LesseeOperatingLeaseExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_a780ab50-a50d-41cf-bc67-6e53d80a9287"
      id="F_09f5621e-f9a0-4d8c-b1c7-c51d673881e5">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_c9e1d8a8-8da6-496e-93e9-56257c4a31b4"
      id="F_85cb8c3c-a3be-4ae1-b504-65e0cdd0a6b9">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_c9e1d8a8-8da6-496e-93e9-56257c4a31b4"
      id="F_c2915a26-db49-43a7-a257-0bb1a26d5dc8">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PrepaidRent
      contextRef="C_c9e1d8a8-8da6-496e-93e9-56257c4a31b4"
      decimals="-5"
      id="F_22f9b9e9-0af1-4098-9416-d3d2365797ff"
      unitRef="U_USD">1000000.0</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent
      contextRef="C_bda62528-1f40-4600-97f1-d787732fa2f1"
      decimals="-5"
      id="F_4b53d18c-f1e8-48a7-96c0-8393799e3c86"
      unitRef="U_USD">400000</us-gaap:PrepaidRent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_c38dea62-a1c5-4166-9761-601e0cfc1479">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating leases for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_ced4dfe6-ac07-4701-9892-2fb45ef71092"
      unitRef="U_USD">2456000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_34136395-8992-4054-ae1c-905446d5ca6b"
      unitRef="U_USD">2101000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_fef83314-0856-4d9d-bfef-7d84d2c13bdf"
      unitRef="U_USD">33000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_91f00097-e198-4cbb-9b17-511a82affda8"
      unitRef="U_USD">25000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_42fc6b92-b301-4df7-a04f-a9e46d792c83"
      unitRef="U_USD">278000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_48dad2b4-2fb6-433d-bfdd-e69b0d86fe55"
      unitRef="U_USD">163000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_ec72bba5-e3b3-48cb-b9f4-09a1a9b8cb67"
      unitRef="U_USD">2767000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_9cacbe76-10f0-4831-b710-619c4b8ed3f9"
      unitRef="U_USD">2289000</us-gaap:LeaseCost>
    <rptx:SummaryOfOtherOperatingLeaseInformationTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_fa8afbef-993a-4b2f-b6c6-781371e9a065">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.818%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.501%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands, except as specified otherwise)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other Operating Lease Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.43&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.35&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</rptx:SummaryOfOtherOperatingLeaseInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_8d88a417-9a66-47ff-aedf-9edfba6e3446"
      unitRef="U_USD">1948000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_cf3a44eb-6790-416f-888b-fa432e3c8bac"
      unitRef="U_USD">1240000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_2783493c-2bd6-4e8c-8a96-cc30b91dc848"
      unitRef="U_USD">86000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_67b6451c-e085-4c84-aefa-d229593928ea"
      unitRef="U_USD">4690000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      id="F_358d98cf-1db6-4cea-aa4a-5cfc0d1e286c">P2Y5M4D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      id="F_aef00da5-4e8e-4ef6-92a4-614520558323">P3Y4M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="3"
      id="F_95c697c0-297c-40e6-923c-367907296e56"
      unitRef="U_pure">0.040</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="3"
      id="F_f9667be7-2623-48c4-abd5-6f6edb2fe7bd"
      unitRef="U_pure">0.040</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <rptx:ImplicitInterestRate
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="INF"
      id="F_8b158aa4-4bb5-4dcc-bd7d-6fc0560d1493"
      unitRef="U_pure">0</rptx:ImplicitInterestRate>
    <rptx:ImplicitInterestRate
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="INF"
      id="F_02e3c648-50bf-4da4-b212-23b54f05b72e"
      unitRef="U_pure">0</rptx:ImplicitInterestRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_d3989b4f-7a43-4484-9e7b-d4dfcd086521">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future minimum lease payments under the Company&#x2019;s operating leases as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.883%;"/&gt;
        &lt;td style="width:1.93%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.187%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturity of Lease Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_3850c38e-5549-42db-a2f5-f100e3399578"
      unitRef="U_USD">2342000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_de59f857-1d16-4df9-9f8d-2fad770ee795"
      unitRef="U_USD">2395000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_a34392f0-fe1e-4f25-8c6d-c3a2993bd3b8"
      unitRef="U_USD">957000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_ac12cc35-96e0-45fe-8fbb-5de3c082e0ad"
      unitRef="U_USD">5694000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_14c21209-7a4b-4c19-aa2e-b048b7ff5332"
      unitRef="U_USD">266000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_14444dc1-d102-4fb1-a898-a61820f9dbae"
      unitRef="U_USD">5428000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_3490e5c2-c0ce-4d1e-b45b-38152d320eba">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9. Shareholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Preferred Shares&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective upon the closing of the IPO, the Company authorized for issue an unlimited number of preferred shares, issuable in series, having such designations, rights, privileges, restrictions and conditions, including dividend and voting rights as the board of directors of the Company may determine, and such rights and privileges, including dividend and voting rights, may be superior to those of the common shares. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; preferred shares were issued and outstanding as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common Shares&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The articles of continuance of the Company authorize an unlimited number of common shares, voting and participating, without par value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Each common share entitles the holder to one vote on all matters submitted to the shareholders for a vote.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The holders of common shares are entitled to receive dividends, as may be declared by the board of directors, if any. Through &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; cash dividends have been declared or paid.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 1, 2021, the Company completed a follow-on offering of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,600,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of its common shares, including the exercise in full by the underwriters of their option to purchase up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;600,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional common shares, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, for net proceeds of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, after deducting underwriting commissions as well as offering expenses of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; payable by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 2022, the Company entered into a common shares sale agreement (&#x201c;the Sales Agreement&#x201d;), with Cowen and Company, LLC (&#x201c;Cowen&#x201d;) as sales agent, pursuant to which we may issue and sell common shares from time to&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;time, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;or the ATM Shares. The ATM Shares to be sold under the Sales Agreement, if any, will be issued and sold pursuant to our shelf registration statement on Form S-3 (File No. 333-257668), up to a maximum aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares have been issued under the Sales Agreement as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="INF"
      id="F_ad4091c4-0097-41af-9bdf-e3e02ff27d7d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="INF"
      id="F_4e888e13-6bff-4e71-bb1d-1bd3ec7abee0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="INF"
      id="F_9c1e91cd-0862-44fe-8237-4526aad014d2"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="INF"
      id="F_b3d03ac3-18f8-4372-b8ac-bb896a41438e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_cc003efb-daf8-4111-8d5a-570078a1efb1">Each common share entitles the holder to one vote on all matters submitted to the shareholders for a vote.</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsCommonStockCash
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="INF"
      id="F_8668c655-6604-411b-b118-9a7a31e151f9"
      unitRef="U_USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8de25cbb-79b8-4c61-83cd-426c93b13621"
      decimals="INF"
      id="F_02813acb-aa5c-41fb-af4b-79127abf1853"
      unitRef="U_shares">4600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e4e66d4b-8df8-4150-855e-17cb5ce1bcb9"
      decimals="INF"
      id="F_cc4d7590-882b-4502-8f9c-cc57a42b59a8"
      unitRef="U_shares">600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_c095c251-0ca6-45ab-ae2c-2aec9d4fb280"
      decimals="2"
      id="F_9dc88657-ddbd-46df-83f1-75c5f7dfc012"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_8de25cbb-79b8-4c61-83cd-426c93b13621"
      decimals="-5"
      id="F_82484bca-acdc-4767-a920-b9180ebd5424"
      unitRef="U_USD">94300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <rptx:UnderwritingCommissionsAndEstimatedOfferingExpenses
      contextRef="C_404b861d-d003-4142-9ce1-6483dccfba5d"
      decimals="-5"
      id="F_4d049447-dfb8-41c1-b6c6-9e3fb5148508"
      unitRef="U_USD">800000</rptx:UnderwritingCommissionsAndEstimatedOfferingExpenses>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a9d543b1-b2e8-4033-a16b-a49687bf6b19"
      decimals="-5"
      id="F_36655176-ec8a-4e22-a49e-83195f9b365a"
      unitRef="U_USD">125000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d7dc9fc2-b468-4689-8b15-f9d0f5c26ff5"
      decimals="INF"
      id="F_a24a6e01-22c7-4dc3-8c9e-7a5d7b373e0d"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_1f3a37b0-bebb-4e2b-93e3-836190a4ecc4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10. Share-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020 Employee Share Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2020, the Company&#x2019;s board of directors adopted, and the Company&#x2019;s shareholders approved the 2020 Employee Share Purchase Plan (&#x201c;ESPP&#x201d;). The maximum number of common shares that may be issued under the ESPP was initially &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;327,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Additionally, the number of shares reserved and available for issuance under the ESPP will automatically increase each January 1, beginning on January 1, 2021 and each January 1 thereafter through January 31, 2030, by the lesser of (1) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the total number of common shares outstanding on December 31 of the preceding calendar year, (2) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,300,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; common shares, or (3) such smaller number of common shares as the Company&#x2019;s board of directors may designate. As of January 1, 2023, the number of common shares that may be issued under the ESPP is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,487,035&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The ESPP enables eligible employees to purchase common shares of the Company at the end of each offering period at a price equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Participation in the ESPP is voluntary. Eligible employees become participants in the ESPP by enrolling in the plan and authorizing payroll deductions. At the end of each offering period, accumulated payroll deductions are used to purchase the Company&#x2019;s shares at the discounted price. The Company makes &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; contributions to the ESPP. A participant may withdraw from the ESPP or suspend contributions to the ESPP. If the participant elects to withdraw during an offering, all contributions are refunded as soon as administratively practicable. If a participant elects to withdraw or suspend contributions, they will not be able to re-enroll in the current offering but may elect to participate in future offerings. The ESPP purchases only whole shares of the Company&#x2019;s shares. The Company&#x2019;s first ESPP offering period began February 16, 2021 and ended on August 15, 2021, with a second offering period commencing on August 16, 2021. Subsequent offering periods will be on a rolling six-month basis.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the years ended December 31, 2022 and 2021 the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,915&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,943&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; common shares under the ESPP, respectively, at an average price per share of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.43&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.46&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. Cash received from purchases under the ESPP for the years ended December 31, 2022 and 2021 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. In February 2023, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,703&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; common shares under the ESPP at an average price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The assumptions that the Company used in the Black Scholes option-pricing model to determine the grant date fair value under the ESPP offering were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.663%;"/&gt;
        &lt;td style="width:1.159%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.51%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.159%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.51%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted average grant date fair value under the ESPP offering during the years ended December 31, 2022 and 2021 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.91&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.94&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Option Plan and 2020 Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2016, as further amended in December 2017 and September 2019, the Company adopted the Repare Therapeutics Inc. Option Plan (the &#x201c;Option Plan&#x201d;) for the issuance of stock options and other share-based awards to directors, officers, employees or consultants. The Option Plan authorized up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,074,135&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common shares to be issued.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2020, the Company&#x2019;s board of directors adopted, and the Company&#x2019;s shareholders approved the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;). The 2020 Plan became effective on the effective date of the IPO, at which time the Company ceased making awards under the Option Plan. The 2020 Plan allows the Company&#x2019;s compensation committee to make equity-based and cash-based incentive awards to the Company&#x2019;s officers, employees, directors and consultants including but not limited to stock options and restricted share units. A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,600,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; common shares were initially reserved for issuance under the 2020 Plan, plus the number of shares (not to exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,807,448&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares) consisting of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;298,605&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; common shares that were available for issuance of awards under the Option Plan at the time the 2020 Plan became effective, which ceased to be available for future issuance under the Option Plan at such time and (ii) any shares subject to outstanding options or other share awards that were granted under the Option Plan that terminate or expire prior to exercise or settlement; are forfeited because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares reserved and available for issuance under the 2020 Plan will automatically increase each January 1, beginning on January 1, 2021 and each January 1 thereafter through January 1, 2030, by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the outstanding number of common shares on the immediately preceding December 31, or such lesser number of shares as determined by the Company&#x2019;s board of directors. As of January 1, 2023, the number of common shares reserved for issuance under the 2020 Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,025,525&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2020 Plan is administered by the board of directors. The exercise prices, vesting and other restrictions are determined by the board of directors, except that the exercise price per share of stock option may not be less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the fair value of the common share on the date of grant, determined based on the average of the daily volume-weighted average trading price of shares on each of the five trading days immediately preceding the date of grant.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options awarded under the 2020 Plan expire &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; after the grant and generally have vesting conditions of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% on the first anniversary of the date of grant and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% on a monthly basis at a rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1/36&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;th&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; unless otherwise decided by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Option Activity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The assumptions that the Company used in the Black Scholes option-pricing model to determine the grant date fair value of stock options granted to employees and non-employees were as follows, presented on a weighted-average basis:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.663%;"/&gt;
        &lt;td style="width:1.159%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.51%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.159%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.51%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.99&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted average grant date fair value of stock options granted during the years ended December 31, 2022, 2021 and 2020 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.54&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.49&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s share option activity:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.132%;"/&gt;
        &lt;td style="width:0.402%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.456999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.182%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.290000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.298%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.134%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.805%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.303%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intrinsic value (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,322,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.15&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,346,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;148,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;488,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,032,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,592,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.94&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options unvested, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,440,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.65&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common shares for those stock options that had an exercise price lower than the fair value of the Company&#x2019;s common shares.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate intrinsic value of options exercised during the years ended December 31, 2022 and 2021 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The total fair value of options vested during the years ended December 31, 2022 and 2021 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;148,116&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; options were exercised at a weighted-average exercise price of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.02&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, for aggregate proceeds of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As a result, an amount of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; previously included in additional paid-in-capital related to the exercised options has been credited to common shares and deducted from additional paid-in-capital.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January and February 2023, the Company granted an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,495,240&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; stock options at a weighted average exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.42&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;626,260&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; restricted share units to employees under the 2020 Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation expense for all awards was allocated as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation expense by type of award was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, there was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of unrecognized share-based compensation expense related to unvested stock options. The unrecognized share-based compensation expense is expected to be recognized over a weighted-average remaining vesting period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <rptx:CommonStockCapitalSharesInitiallyReservedForFutureIssuance
      contextRef="C_db2b4777-c5cc-4811-a937-f402d6499701"
      decimals="INF"
      id="F_e2732bfd-c767-4598-b85e-9b6397b3266f"
      unitRef="U_shares">327000</rptx:CommonStockCapitalSharesInitiallyReservedForFutureIssuance>
    <rptx:AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear
      contextRef="C_9cf3be3d-b394-4173-992a-035a20692942"
      decimals="3"
      id="F_669efacf-95a9-488d-b4d6-575506610091"
      unitRef="U_pure">0.010</rptx:AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear>
    <rptx:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued
      contextRef="C_9cf3be3d-b394-4173-992a-035a20692942"
      decimals="INF"
      id="F_82b3a2ae-d139-42e6-8a9e-fe353a9caa76"
      unitRef="U_shares">3300000</rptx:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1b80891b-1319-4360-8f15-2497ed8ea0b5"
      decimals="INF"
      id="F_4578cc6f-8c44-4f40-83ef-d1352c753ca8"
      unitRef="U_shares">1487035</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <rptx:PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase
      contextRef="C_9cf3be3d-b394-4173-992a-035a20692942"
      decimals="2"
      id="F_c1b99a36-df4a-4fa6-b7a6-1f4bb6ceb016"
      unitRef="U_pure">0.85</rptx:PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_acf39634-d069-4302-ab50-45e5dd9d130f"
      decimals="INF"
      id="F_4edaf743-981e-47b4-8059-db98fd133ebd"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_421e346c-f45c-4450-9712-2cde91dba0a4"
      decimals="INF"
      id="F_9b780417-245f-4f18-9656-00e7ae982482"
      unitRef="U_shares">37915</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_633aa886-db18-4e4b-ac98-428a52434cba"
      decimals="INF"
      id="F_93f00897-d4a6-43e1-8d60-a6052d5c2f31"
      unitRef="U_shares">9943</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_421e346c-f45c-4450-9712-2cde91dba0a4"
      decimals="INF"
      id="F_23b3326d-931a-46f6-8242-b762ab5316d7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.43</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_633aa886-db18-4e4b-ac98-428a52434cba"
      decimals="INF"
      id="F_8a506f37-875c-4d7b-ba11-86b0ea1b4fa6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">28.46</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromRepurchaseOfEquity
      contextRef="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0"
      decimals="-5"
      id="F_b77c2925-7504-4150-a29d-c17d486c59c0"
      unitRef="U_USD">400000</us-gaap:ProceedsFromRepurchaseOfEquity>
    <us-gaap:ProceedsFromRepurchaseOfEquity
      contextRef="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735"
      decimals="-5"
      id="F_9a2e7dd1-29d7-4c8b-800f-4187e524512a"
      unitRef="U_USD">300000</us-gaap:ProceedsFromRepurchaseOfEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a5be591d-88a6-4798-a866-48f091aca5bb"
      decimals="INF"
      id="F_27618ee6-907e-45ed-965a-fe123dd4fc58"
      unitRef="U_shares">41703</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_a5be591d-88a6-4798-a866-48f091aca5bb"
      decimals="2"
      id="F_9198747c-a40d-4e44-8622-099b5d223576"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.80</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_716cfb44-5114-4f42-8adf-a8a9bf93ec04">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The assumptions that the Company used in the Black Scholes option-pricing model to determine the grant date fair value under the ESPP offering were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.663%;"/&gt;
        &lt;td style="width:1.159%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.51%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.159%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.51%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0"
      decimals="4"
      id="F_4fb9e6c4-dc8b-4bb8-a8c1-0ce77fde9ed8"
      unitRef="U_pure">0.0236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735"
      decimals="4"
      id="F_d16cca0c-80ce-48a7-adfb-6512dbdafe83"
      unitRef="U_pure">0.0005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0"
      id="F_de38f535-1955-424d-a616-98f382c949ae">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735"
      id="F_61f9f831-6aa1-41bc-9b0c-05f0469172c8">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0"
      decimals="4"
      id="F_c85d1af0-d6c8-427d-924d-3a6aec98f2b0"
      unitRef="U_pure">0.8537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735"
      decimals="4"
      id="F_3fe11fda-8f75-4fcd-bc75-3228057fa873"
      unitRef="U_pure">0.6191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0"
      decimals="4"
      id="F_8a7149b5-8464-4570-9217-83d76558692c"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735"
      decimals="4"
      id="F_ed4f9b4b-a383-4e5b-bcd5-46acff1b41ea"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0"
      decimals="2"
      id="F_8956377b-ea51-4384-b080-a7410dce2120"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_240fd7d8-96cb-4b43-bc62-a49b2bb24735"
      decimals="2"
      id="F_48e6abf6-012c-4ab5-930e-1a04e7c0381f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <rptx:ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting
      contextRef="C_b9ebcd23-ea43-4fa8-a367-3a44c77fbe15"
      decimals="INF"
      id="F_ffc568e1-77a5-4b36-ae05-850bc8b04658"
      unitRef="U_shares">4074135</rptx:ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting>
    <rptx:CommonStockCapitalSharesInitiallyReservedForFutureIssuance
      contextRef="C_96aa4796-a454-4289-a8e9-eb0a4d889465"
      decimals="INF"
      id="F_3783e132-1e92-4307-bb7c-fc1aaf842c42"
      unitRef="U_shares">3600000</rptx:CommonStockCapitalSharesInitiallyReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_96aa4796-a454-4289-a8e9-eb0a4d889465"
      decimals="INF"
      id="F_47e21fe8-ac27-482e-84c7-680d0f012744"
      unitRef="U_shares">3807448</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6c9ad6f4-0f96-4cc2-a1f8-7552b59f9ad8"
      decimals="INF"
      id="F_f5a0997d-1fe3-47ff-b9af-bb5e0b6a6731"
      unitRef="U_shares">298605</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <rptx:AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear
      contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a"
      decimals="2"
      id="F_ed33f74b-a687-4520-8750-cc829f242605"
      unitRef="U_pure">0.05</rptx:AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a573d49c-e7e4-4254-b7c3-222222b5c736"
      decimals="INF"
      id="F_3360ddee-3866-450f-9ddd-dd5699378d09"
      unitRef="U_shares">10025525</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <rptx:ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare
      contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a"
      decimals="INF"
      id="F_54f2b426-098c-4506-bdcf-db25d6051d8e"
      unitRef="U_pure">1</rptx:ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a"
      id="F_154e9f42-7a34-406a-a954-c70254d0ec8d">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_ea477cfd-4c08-4194-a45f-5b0534acacdc"
      decimals="2"
      id="F_2ac4bb2c-44f6-4e14-bee9-97af5df9275a"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_ae5f3fdb-a581-43e3-bfb4-15c88e51dc08"
      decimals="2"
      id="F_22132e17-e1e9-43f5-93fa-e25f21731df4"
      unitRef="U_pure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <rptx:ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate
      contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a"
      id="F_8d71bc01-dd9b-4b99-b8cd-bd6103de3a8b">1/36th</rptx:ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_a322185c-5655-4b15-acc8-0445fd111a25">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The assumptions that the Company used in the Black Scholes option-pricing model to determine the grant date fair value of stock options granted to employees and non-employees were as follows, presented on a weighted-average basis:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.663%;"/&gt;
        &lt;td style="width:1.159%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.51%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.159%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.51%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.99&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a"
      decimals="4"
      id="F_962f85dc-e6d6-4a5a-83f7-f101b88cad02"
      unitRef="U_pure">0.0217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_93008ec0-d0c8-4150-bb27-d96cc8c66909"
      decimals="4"
      id="F_e0ccc714-9a8e-4cc6-a0ee-8b161dd2e59f"
      unitRef="U_pure">0.0080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a"
      id="F_cd3f8662-e96c-440f-aa8d-22fcb83eb716">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_93008ec0-d0c8-4150-bb27-d96cc8c66909"
      id="F_7c62d082-031d-4143-aa19-e8d80a6c9350">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a"
      decimals="4"
      id="F_d317206a-a9bb-4602-9137-004dd61368cd"
      unitRef="U_pure">0.7895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_93008ec0-d0c8-4150-bb27-d96cc8c66909"
      decimals="4"
      id="F_e1eb04d2-2373-4956-9943-53ded99464c1"
      unitRef="U_pure">0.7599</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a"
      decimals="4"
      id="F_8c5afacd-2970-4371-a877-2baeb7fa4eba"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_93008ec0-d0c8-4150-bb27-d96cc8c66909"
      decimals="4"
      id="F_36f38555-e25a-4b3e-9c4f-21776aa7b1d3"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="2"
      id="F_7f8ba0ac-1aa5-4a82-9da1-6a5c0800b064"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="2"
      id="F_ea95cb83-b23d-4324-8bc8-c4b61c36239a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_6418eb3a-4bb4-4786-96b1-a67349bd81a9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s share option activity:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.132%;"/&gt;
        &lt;td style="width:0.402%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.456999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.182%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.290000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.298%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.134%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.805%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.303%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intrinsic value (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,322,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.15&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,346,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;148,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;488,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,032,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,592,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.94&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options unvested, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,440,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.65&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="0"
      id="F_1e71705a-15a3-4ac1-a824-dac2b596ac64"
      unitRef="U_shares">5322591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="2"
      id="F_bcf97ca3-accd-4945-a4fc-fe0108a7f130"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      id="F_0c4b8cd3-a080-4fa2-a666-902831d3196e">P8Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_97afd906-5235-4b24-801f-fa9c8893309d"
      unitRef="U_USD">55722000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="0"
      id="F_c157ac71-89d7-4ff2-874d-0e3adbeefd1a"
      unitRef="U_shares">3346567</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="2"
      id="F_f8d494c0-9f1e-4a78-adf0-f007990d855c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="0"
      id="F_ff3eaae8-9a96-449b-bd51-e55e0798da59"
      unitRef="U_shares">148116</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="2"
      id="F_b3d66aa3-2f63-46a7-b446-91b06d1d30fb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="0"
      id="F_4203aca6-b54a-4cb2-ba23-884d0c13f9ff"
      unitRef="U_shares">488140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="2"
      id="F_a049e1c9-5352-4a26-9a32-0672d7ad3748"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="0"
      id="F_f163cefd-ddf3-4161-a1bb-1928280875ff"
      unitRef="U_shares">8032902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="2"
      id="F_7501f2c1-5fcd-4383-b2d0-ebfa0db335b9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_b9e0729b-6eeb-41d9-a8da-248ca9367425">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_3bec71ee-78a9-4fe2-9cea-067f21fde02b"
      unitRef="U_USD">37250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="0"
      id="F_f726448a-e639-47fb-bd24-d50e4b8bbb6d"
      unitRef="U_shares">3592087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="2"
      id="F_2776ace7-1ecb-4fa5-bc73-820dbf92d1ce"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_c9697ffa-5892-4d31-bb48-428ffdbe9a95">P6Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_8ff40e93-76f2-4859-a97a-3d26cf53c873"
      unitRef="U_USD">28538000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="0"
      id="F_57c2ce23-59e4-497a-9cc9-659f7edc76d7"
      unitRef="U_shares">4440815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="2"
      id="F_74942d9f-6ad8-46c7-93d6-d4238f928459"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_f673a122-4230-4e89-b3eb-79b568aa9cf4">P8Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_21e8b927-a3cc-44c0-b141-5b624b320cc4"
      unitRef="U_USD">8712000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-5"
      id="F_033a084d-5949-43f7-994a-fab8bde83c4a"
      unitRef="U_USD">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-5"
      id="F_89a01753-2181-4e69-876c-54b1d746ebe7"
      unitRef="U_USD">8500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <rptx:FairValueOfVestedOptions
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-5"
      id="F_78112d9c-7d6b-4624-90df-e9ff272225ea"
      unitRef="U_USD">20100000</rptx:FairValueOfVestedOptions>
    <rptx:FairValueOfVestedOptions
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-5"
      id="F_a3e59ee7-7000-479e-b7cd-563e62978f7c"
      unitRef="U_USD">7400000</rptx:FairValueOfVestedOptions>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="INF"
      id="F_2efe3ac8-65c8-4fe7-bbe2-8f834b48aa72"
      unitRef="U_shares">148116</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="2"
      id="F_8d73f962-6579-41fe-8eee-e949198164e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-5"
      id="F_b4460ae5-9403-46cb-8298-813e9c1e73e4"
      unitRef="U_USD">400000</us-gaap:ProceedsFromStockOptionsExercised>
    <rptx:AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-5"
      id="F_a331945a-8862-447f-b72c-f935f7fa7dac"
      unitRef="U_USD">300000</rptx:AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_434cd7cc-5862-46ac-a5bc-39dc683d789f"
      decimals="0"
      id="F_1e1295c7-b8d9-41d1-8a56-415630ddf493"
      unitRef="U_shares">1495240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_434cd7cc-5862-46ac-a5bc-39dc683d789f"
      decimals="2"
      id="F_cb0fdae1-94a2-49d8-853d-6d4cacca0236"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_3cfc3e53-1c58-46fd-a5b8-3badfcad9efb"
      decimals="0"
      id="F_23a94621-e43f-4775-b8e2-351ed9a65fa1"
      unitRef="U_shares">626260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_7f38f313-0b9c-4eb2-b771-ce34adc85422">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation expense for all awards was allocated as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation expense by type of award was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_afaac43e-017a-44ba-b75d-7ea6a3b4e368"
      decimals="-3"
      id="F_9a1fed79-8753-460e-83df-9869de3bee35"
      unitRef="U_USD">10020000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_30716fb3-44b9-47e8-800d-7c2d957e670b"
      decimals="-3"
      id="F_ed15206d-7acc-4672-b182-a9aee98db635"
      unitRef="U_USD">5681000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_301dd1df-f42b-4bd5-982c-d7e2d3733b57"
      decimals="-3"
      id="F_64eb4361-e416-49e2-a943-be5a9c1c7164"
      unitRef="U_USD">9671000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_48281951-8326-4dc8-8373-9afcbedac008"
      decimals="-3"
      id="F_918c4f7a-a494-49ce-abe9-5d963d756831"
      unitRef="U_USD">7148000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_14824014-61fa-4998-b6c6-58f0ba6d0e46"
      unitRef="U_USD">19691000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_d344d51c-22c6-4e85-bd87-266e2ceb6be1"
      unitRef="U_USD">12829000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_19ce3969-55ed-4e30-9462-0263222e2f93"
      decimals="-3"
      id="F_0462ff58-9d88-4636-ba65-d0fa2317a667"
      unitRef="U_USD">19400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_35a0d25d-897e-41e7-bd44-d80a88e5d9aa"
      decimals="-3"
      id="F_ab766815-0487-40ad-8086-684a63ac5736"
      unitRef="U_USD">12632000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_10a635cc-4c15-4e96-be01-4a9e22f1dbef"
      decimals="-3"
      id="F_f8e4cdc7-85fa-4bce-8fdb-0c99bc98926f"
      unitRef="U_USD">291000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_17dcc120-3760-4de9-9e06-6064cef30d4d"
      decimals="-3"
      id="F_7d0beca8-a55b-4b1d-977a-99ee464aa619"
      unitRef="U_USD">197000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_ac79e78c-1be8-4eb8-8d55-ae2ed76d2851"
      unitRef="U_USD">19691000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_a5480416-2ad5-45b2-9b56-219d5e496582"
      unitRef="U_USD">12829000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-5"
      id="F_cfd35817-2ef9-4671-8e60-09055825fb7c"
      unitRef="U_USD">42900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_54ed3dc7-1d1a-4f1a-9e3d-a8d6c57ebe70">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_bdd1d3d4-6247-4a54-a1b8-c6b047044083">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11. Employee Savings Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has offered its employees in the United States the ability to participate in a 401(k). The Company has also offered its employees in Canada the ability to participate in a registered retirement savings plan. As of January 1, 2021, the Company started making non-matching employer contributions into both of these plans on behalf of participants equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of their base salary. The Company has recorded an expense of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in matching contributions for the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <rptx:DefinedContributionPlanEmployerNonMatchingContributionPercent
      contextRef="C_570d5b98-d1b3-467c-8957-e622df2b9b75"
      decimals="2"
      id="F_34c972a1-eef7-4096-bc1a-d9641ada0bb0"
      unitRef="U_pure">0.03</rptx:DefinedContributionPlanEmployerNonMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-5"
      id="F_99956717-4abd-4c5e-b911-326912a9c1dc"
      unitRef="U_USD">800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-5"
      id="F_d38743b3-0f8c-45af-87b9-b46ce0bc7f6b"
      unitRef="U_USD">500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_2ebf2a68-c770-477b-b64b-89df3750a4aa">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12. Collaborations&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Roche Collaboration and License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2022, the Company entered into a collaboration and license agreement (the &#x201c;Roche Agreement&#x201d;) with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd (collectively, &#x201c;Roche&#x201d;) regarding the development and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;commercialization of the Company&#x2019;s product candidate camonsertib (also known as RP-3500 or RG6526) and specified other Ataxia-Telangiectasia and Rad3-related protein kinase (&#x201c;ATR&#x201d;) inhibitors (the &#x201c;Licensed Products&#x201d;). The transaction was subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions, which were met on July 13, 2022 (&#x201c;Effective Date&#x201d;). Pursuant to the Roche Agreement, the Company granted Roche a worldwide, perpetual, exclusive, sublicensable license to develop, manufacture, and commercialize the Licensed Products, as well as a non-exclusive, sublicensable license to certain related companion diagnostics. The Company has agreed to complete specified ongoing clinical trials in accordance with the development plan in the Roche Agreement, as well as ongoing investigator sponsored trials (together, the &#x201c;Continuing Trials&#x201d;) at the Company&#x2019;s expense. Roche assumes all subsequent development of camonsertib with the potential to expand development into additional tumors and multiple combination studies. The Company retained the right to conduct specified clinical trials (the &#x201c;Repare Trials&#x201d;) of camonsertib in combination with the Company&#x2019;s PKMYT1 compound (also known as RP-6306). The Roche Agreement also provides the Company, at its sole discretion, with the ability to opt-in to a 50/50 U.S. co-development and profit share arrangement, including participation in U.S. co-promotion if U.S. regulatory approval is received. If the Company chooses to exercise its co-development and profit share option, it will continue to be eligible to receive certain clinical, regulatory, commercial and sales milestone payments, in addition to full ex-U.S. royalties.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Roche Agreement was subsequently amended in October 2022 to extend the timeline to negotiate in good faith the parties&#x2019; rights and obligations with respect to the Repare Trials, as defined in the Roche Agreement, and to clarify indications included in the development plan that are subject to milestones.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the Roche Agreement, the Company received an upfront, nonrefundable payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in July 2022. The Company also received an additional payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million negotiated with Roche for revisions to the clinical development plan under the Roche Agreement as agreed to by the parties at the time of the Effective Date. The Company further received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the transfer of clinical trial material on hand to Roche, as agreed to pursuant to the Roche Agreement. The Company is eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.172&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion in potential clinical, regulatory, commercial and sales milestones, as well as royalties on global net sales ranging from high-single-digits to high-teens, subject to certain specified reductions. Royalties are payable by Roche on a product by product and country by country basis until the later of 12 years following the first commercial sale of a licensed product in such country or the expiration of certain exclusivity rights.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Roche Agreement will expire upon the last to expire royalty term or, as applicable, the end of the U.S. co-development and profit share arrangement. Additionally, Roche may terminate the agreement for convenience in its entirety or on a product by product or country by country basis subject to certain notice periods. Either party may terminate earlier upon the other party&#x2019;s uncured material breach of the agreement or insolvency. Subject to the terms of the Roche Agreement, effective upon termination of the Roche Agreement, the Company is entitled to retain specified licenses to be able to continue to exploit the Licensed Products.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assessed the Roche Agreement in accordance with ASC 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and concluded that Roche is a customer within the context of the agreement. At inception, the Company identified several performance obligations under the agreement, being (i) the combination of the exclusive perpetual license to the Licensed Products and the non-exclusive license to certain companion diagnostics, (ii) the research and development activities related to the completion of the Continuing Trials, as well as (iii) the transfer of clinical trial materials on hand. The Company determined that the exclusive license to the Licensed Products and the non-exclusive license to certain companion diagnostics should be combined into one distinct performance obligation as they were not capable of being distinct from each other within the context of the agreement given both are highly interdependent of each other. The Company determined that the combined licenses, the completion of the Continuing Trials and the transfer of clinical trial materials were all capable of being distinct and were distinct within the context of the Roche Agreement given such activities are independent of each other and Roche could benefit from either separately.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that the transaction price at the onset of the agreement is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, being the total non-refundable upfront payment received of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, the additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million payment received and the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million received for the transfer of clinical trial materials. Additional consideration is to be paid to the Company upon the achievement of multiple clinical, regulatory and sales milestones. The Company utilized the most likely method approach and concluded that these amounts were constrained based on the probability of achievement. As such, the Company excluded this additional consideration from the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has allocated the transaction price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to each performance obligation based on the relative stand-alone selling price of each performance obligation at inception. The Company has determined the estimated stand-alone selling price at contract inception of the combined licenses by applying a probability adjusted discounted cashflow model which forecasts future cash flows related to the licenses. The Company considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success, discount rate and the time needed to commercialize a product pursuant to the license. The Company has determined the estimated stand-alone selling price at contract inception of the research and development activities required to complete the Continuing Trials based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to complete the Continuing Trials included the length of time required, the internal hours as well as external costs expected to be incurred, the number of patients and the number of clinical and investigator sponsored trials. The Company has determined the stand-alone selling price of the clinical trial materials transferred based on the purchase price from external vendors, without applying a markup as the materials have a built-in margin from the external vendors. &lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on the relative stand-alone selling price, the allocation of the transaction price to the separate performance obligations was as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.153%;"/&gt;
        &lt;td style="width:9.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.845000000000002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Performance obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Transaction price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Combined licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Completion of Continuing Trials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Transfer of clinical trial materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total transaction price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue associated with the combined licenses was recognized at a point in time upon the transfer of the licenses to Roche on the effective date of the Roche Agreement as the Company concluded that the combined licenses were a functional intellectual property license that Roche could benefit from as of the time of grant. Revenue associated with the completion of the Continuing Trials has been deferred and will be recognized on a proportional performance basis over the period of time to complete the Continuing Trials, being estimated at within &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; months of the effective date, using input-based measurements of total costs of research and development incurred to estimate the proportion performed. Progress towards completion is remeasured at the end of each reporting period. Revenue associated with the transfer of clinical trial materials was recognized at a point in time upon delivery of the clinical trial materials to Roche in the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognized &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the year ended December 31, 2022 as revenue associated with the Roche Agreement, of which &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; related to the grant of the combined licenses, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; related to the clinical trial materials transferred, and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; related to the partial recognition of deferred revenue for research and development services performed towards the completion of the Continuing Trials during the period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, there was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (December 31, 2021 - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) of deferred revenue related to the Roche Agreement, of which &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (December 31, 2021 - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) was classified as current and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (December 31, 2021 - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) was classified as non-current in the consolidated balance sheet based on the period the services to complete the Continuing Trials are expected to be performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Bristol Myers Squibb&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2020, the Company entered into a collaboration and license agreement (the "BMS Agreement") with Bristol-Myers Squibb Company (&#x201c;Bristol-Myers Squibb&#x201d;), pursuant to which the Company and Bristol Myers Squibb have agreed to collaborate in the research and development of potential new product candidates for the treatment of cancer. The Company is providing Bristol Myers Squibb access to a selected number of its existing screening campaigns and novel campaigns. The Company is responsible for carrying out early-stage research activities directed to identifying potential targets for potential licensing by Bristol Myers Squibb, in accordance with a mutually agreed upon research plan and will be solely responsible for such costs. The collaboration consists of programs directed to both druggable targets and to targets commonly considered undruggable to traditional small molecule approaches. Upon Bristol Myers Squibb&#x2019;s election to exercise its option to obtain exclusive worldwide licenses for the subsequent development, manufacturing and commercialization of a program, Bristol Myers Squibb will then be solely responsible for all such worldwide activities and costs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The BMS Agreement was subsequently amended in July, September and November 2020 to include additional campaigns to the list of existing campaigns from which Bristol Myers Squibb may select campaigns under the agreement and to enable unblinding of a Bristol Myers Squibb alliance manager in order to streamline the collaboration and selection process.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the BMS Agreement, Bristol Myers Squibb paid the Company an initial nonrefundable upfront fee payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in June 2020. The Company is entitled to receive, on a program-by-program basis, option exercise fees ranging in the low six figures depending on the nature of the applicable program. Bristol Myers Squibb also has the right to retain rights to certain back-up programs in exchange for a one-time payment in the low eight figures per program. The Company is also entitled to receive up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;301.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in total milestones on a program-by-program basis, consisting of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;176.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the aggregate for certain specified research, development and regulatory milestones and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the aggregate for certain specified commercial milestones. The Company is further entitled to a tiered percentage royalty on annual net sales ranging from high-single digits to low-double digits, subject to certain specified reductions. Royalties are payable by Bristol Myers Squibb on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On a program-by-program basis, prior to the earlier of such program ceasing to be included under the BMS Agreement and expiration of the last to expire royalty term for such program, the Company, alone and with third parties, is prohibited from researching, developing, manufacturing and commercializing products that are directed to the applicable target for such program.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has provided Bristol Myers Squibb with certain, limited rights to first negotiation if the Company determines to divest, license or collaborate with others regarding certain existing programs, including in the event that the Company receives an unsolicited offer to do so. The right of first negotiation expressly excludes any potential change of control transaction, as defined in the agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The collaboration term will expire &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; months after the effective date of the agreement. The BMS Agreement will expire, assuming that Bristol Myers Squibb has exercised at least one option for a program, on a licensed product-by-licensed product and country-by-country basis on expiration of the applicable royalty term and in its entirety upon expiration of the last royalty term. Either party may terminate earlier upon an uncured material breach of the BMS agreement by the other party, or the insolvency of the other party. Additionally, Bristol Myers Squibb may terminate the BMS Agreement for any or no reason on a program-by-program basis upon specified written notice.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assessed the BMS Agreement in accordance with ASC 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and concluded that Bristol Myers Squibb is a customer based on the agreement structure. At inception, the Company identified several performance obligations under the BMS Agreement, being (i) research activities for each campaign over the collaboration term, as well as (ii) a selected number of material rights associated with options to obtain exclusive development, manufacturing, and commercial licenses to targets identified. The Company determined that the options to obtain the exclusive development, manufacturing and commercialization licenses were material rights under ASC 606 because there are minimal amounts to be paid to the Company upon exercise of such options.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that the transaction price at the onset of the BMS Agreement is the total non-refundable upfront payment received of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Additional consideration is to be paid to the Company upon the exercise of options to license targets and future milestone payments. The Company utilized the most likely method approach and concluded that these amounts were constrained as they represent option fees and milestone payments that can only be achieved subsequent to option exercises. As such, the Company excluded this additional consideration from the transaction price.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has allocated the transaction price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to each performance obligation based on the relative stand-alone selling price of each performance obligation at inception, which was determined based on each performance obligation&#x2019;s estimated stand-alone selling price. The Company has determined the estimated stand-alone selling price at contract inception of the research activities based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to perform the research activities included the length of time required, the internal hours expected to be incurred on the services and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;number and costs of various studies that will be performed to complete the research plan. The Company determined the estimated stand-alone selling price at contract inception of the material rights associated with options to obtain exclusive licenses to druggable targets and undruggable targets based on the fees Bristol Myers Squibb would pay to exercise these options, the probability-weighted value of expected future cash flows associated with each license related to each target and the probability that these options would be exercised by Bristol Myers Squibb. In developing such estimates, the Company also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a product candidate pursuant to the associated license. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on the relative stand-alone selling price, the allocation of the transaction price to the separate performance obligations was as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.122%;"/&gt;
        &lt;td style="width:8.978%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.899%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Performance obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Transaction price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Research activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Options to license druggable targets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Options to license undruggable targets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total transaction price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue associated with the options has been deferred and will be recognized at the point in time when options to license are exercised by Bristol Myers Squibb or upon expiry of such options. Revenue associated with the research activities has been deferred and will be recognized on a proportional performance basis over the period of service for research activities, being the collaboration term, using input-based measurements of total costs of research incurred to estimated proportion performed. Progress towards completion is remeasured at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the years ended December 31, 2022 and 2021, the Company recognized from deferred revenue &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively, as revenue associated with the BMS Agreement in relation to research activities performed during the period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the fourth quarter of fiscal 2022, Bristol Myers Squibb waived its rights to exercise options for druggable targets directed at two separate lesions. As a result, the Company recognized from deferred revenue &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as revenue for the year ended December 31, 2022 with regards to the amount allocated to the performance obligation from Bristol Meyers Squibb. In October 2021, the Company received notification from Bristol Myers Squibb of their option exercise for two druggable targets directed at a single synthetic lethal lesion, pursuant to the terms of the BMS Agreement. As a result, the Company recognized from deferred revenue &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as revenue for the year ended December 31, 2021 with regards to the achievement of the performance obligation from Bristol Meyers Squibb and the option fees received.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, there was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (December 31, 2021 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) of deferred revenue related to the BMS Agreement, of which &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (December 31, 2021 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) was classified as current and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (December 31, 2021 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) as non-current in the consolidated balance sheet based on the period the services are expected to be performed and the expected timing of potential option exercises.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Ono&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2019, the Company entered into a research services, license and collaboration agreement (the &#x201c;Ono Agreement&#x201d;) with Ono Pharmaceutical Co., Ltd. (&#x201c;Ono&#x201d;), a Japanese pharmaceutical company, pursuant to which the Company and Ono have agreed to collaborate in the research of potential product candidates targeting Pol&#x3b8; and the development of the Company&#x2019;s small molecule Pol&#x3b8; inhibitor program. The Company is primarily responsible for carrying out research activities to identify a product candidate, to be licensed to Ono, in accordance with a mutually agreed upon research plan during a research term that will end upon the earlier of the date of the first submission of an Investigational New Drug application (&#x201c;IND&#x201d;) in the United States or Japan, or the end of the research term. In the event that Ono elects to collaborate on the subsequent development and commercialization of the proposed product candidate, Ono will be then responsible for such activities in Japan, South Korea, Taiwan, Hong-Kong, Macau and the Association of Southeast Asian Nations (collectively, the &#x201c;Ono territory&#x201d;), and the Company will be responsible for all such activities in the rest of the world outside the Ono territory, including the United States, Canada and European Union.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2021, the Company and Ono entered into an amendment to the Ono Agreement whereby the research term, as defined in the Ono Agreement, was extended by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2023, the Company and Ono entered into a second amendment to the Ono Agreement whereby the Research Term, as defined in the Ono Agreement, was extended until July 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the Ono Agreement, the Company received non-refundable upfront payments of &#xa5;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;900&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million), consisting of an initial upfront fee payment of &#xa5;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million) and an initial upfront research service payment of &#xa5;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;790&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million). Additionally, in connection with the research activities to be conducted pursuant to the Ono Agreement, the Company is eligible to receive additional research service payments of up to an aggregate of &#xa5;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;750&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million) upon the occurrence of certain specified research triggers. The Company is also entitled to receive clinical, regulatory and commercial milestone payments of up to &#xa5;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.21&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;149.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million) in the aggregate, plus a tiered percentage royalty on annual net sales in Ono&#x2019;s Territory ranging from high-single digits to low teens, subject to certain specified reductions. All future milestone payments and royalties are payable in U.S. dollars after conversion from Japanese yen at the then applicable rate. Additionally, upon election by Ono to collaborate on the proposed product candidate, Ono shall be responsible for a specified percentage of research and development costs for the IND-enabling studies of the selected product candidate.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assessed the arrangement in accordance with ASC 606 and concluded that Ono is a customer based on the arrangement structure. The Company identified a single performance obligation under the arrangement consisting of the combination of the license to develop and commercialize a selected product candidate targeting Pol&#x3b8; and associated research services.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that the license and research services are not distinct within the context of the contract, and the license is the predominant good or service. Accordingly, revenue is recognized in accordance with guidance for licenses, and because the license represents functional IP, it is recognized at the point in time control of the license is transferred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that the transaction price at the onset of the arrangement is the total upfront payments received in the aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million which is recorded as deferred revenue. The future milestone payments represent variable consideration that is fully constrained at inception of the arrangement as the achievement of the milestone events are highly uncertain. The Company will reevaluate the likelihood of achievement of the milestones at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price. In October 2021 and December 2022, the Company achieved specified research triggers amounting to &#xa5;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million) and &#xa5;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million), respectively, as research service payments provided for in the Ono Agreement. The &#xa5;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million) is included in the collaboration revenue receivable at December 31, 2022 and was subsequently received in January 2023. These amounts have been added to the transaction price as the consideration was no longer constrained. Should a product candidate be presented for selection in 2023 and Ono exercises its selection option, the Company would be entitled to receive &#xa5;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;450&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million (approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million) as well as &#xa5;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million (approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million) upon corresponding grant of license, for a total of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; the Company classified $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million (&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; - $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million) as current deferred revenue related to the Ono Agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_21132067-3295-4e05-aca1-b407f86fc88d"
      decimals="-5"
      id="F_c9d6e089-b8b7-400d-8722-a3db2b3044ce"
      unitRef="U_USD">125000000.0</us-gaap:ProceedsFromCollaborators>
    <rptx:CollaborationRevenueReceived
      contextRef="C_c2f83839-f843-4da9-8ac0-9aab66ecad59"
      decimals="-5"
      id="F_541a579e-f2a5-40c0-9be5-0f91843cc375"
      unitRef="U_USD">4000000.0</rptx:CollaborationRevenueReceived>
    <rptx:CollaborationRevenueReceived
      contextRef="C_0432e0bc-120b-4705-8281-2d047c8d1406"
      decimals="-5"
      id="F_e5f15c9e-978b-49e9-9f02-e8d3b9d1ffec"
      unitRef="U_USD">5600000</rptx:CollaborationRevenueReceived>
    <rptx:MilestonesPayments
      contextRef="C_fc472ea4-5bfc-43cf-afcc-45da63beb221"
      decimals="-6"
      id="F_927d6f56-99ad-49c1-86d8-ddacaac25291"
      unitRef="U_USD">1172000000</rptx:MilestonesPayments>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_39535649-8458-447e-b3bd-2d67c59d8b5a"
      decimals="-5"
      id="F_86eade20-f6e3-488b-8799-f7280981a6a7"
      unitRef="U_USD">134600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_21132067-3295-4e05-aca1-b407f86fc88d"
      decimals="-5"
      id="F_c59da578-adec-4e4f-81af-40968f82ef0e"
      unitRef="U_USD">125000000.0</us-gaap:ProceedsFromCollaborators>
    <rptx:CollaborationRevenueReceived
      contextRef="C_39535649-8458-447e-b3bd-2d67c59d8b5a"
      decimals="-5"
      id="F_b921cb96-c8ff-4b77-b36a-e780054b65c2"
      unitRef="U_USD">4000000.0</rptx:CollaborationRevenueReceived>
    <rptx:CollaborationRevenueReceived
      contextRef="C_0432e0bc-120b-4705-8281-2d047c8d1406"
      decimals="-5"
      id="F_946e24b6-7963-42ec-ad45-214a242f2765"
      unitRef="U_USD">5600000</rptx:CollaborationRevenueReceived>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_39535649-8458-447e-b3bd-2d67c59d8b5a"
      decimals="-5"
      id="F_a4b98b1d-4bee-4a93-a1ff-ccd722d7b992"
      unitRef="U_USD">134600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="C_ceb724a0-d094-4e75-ad7c-5458548dadc5"
      id="F_1df85dc8-30fd-43dc-a4ff-9fe29708e9b1">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on the relative stand-alone selling price, the allocation of the transaction price to the separate performance obligations was as follows:&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.153%;"/&gt;
        &lt;td style="width:9.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.845000000000002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Performance obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Transaction price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Combined licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Completion of Continuing Trials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Transfer of clinical trial materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total transaction price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_03151e6d-e0d6-4a61-8ae6-3e23b66eafd4"
      decimals="-3"
      id="F_36a58c1c-888b-4f75-978c-509f4664a093"
      unitRef="U_USD">105327000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_3f5323db-0b40-4adb-a988-178988f085e5"
      decimals="-3"
      id="F_e1aba1e6-42f6-4a29-9fb3-e2f7dab87927"
      unitRef="U_USD">26585000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_218b32a4-44d8-4f35-a8e8-8985b015f2a3"
      decimals="-3"
      id="F_a2e8996b-7377-4645-9dc9-7242745ea20b"
      unitRef="U_USD">2714000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_94ac4eab-f661-466e-ad3c-d52a1dad0918"
      decimals="-3"
      id="F_ac89b97a-e7a3-465d-a6c3-78c2300b30dd"
      unitRef="U_USD">134626000</us-gaap:ContractWithCustomerLiability>
    <rptx:EstimatedPeriodOfCompletionOfTrialsToGetRevenue
      contextRef="C_60665830-af4d-49c6-8e90-64c9fd7235be"
      id="F_175938c0-ef22-4a5b-8b64-cde920401af9">P24M</rptx:EstimatedPeriodOfCompletionOfTrialsToGetRevenue>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_21132067-3295-4e05-aca1-b407f86fc88d"
      decimals="-5"
      id="F_ecdf1736-a513-4026-b7f3-501d82ad7cb0"
      unitRef="U_USD">116600000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_455d4f5d-1b00-4d1c-8c1b-ced04b5ee882"
      decimals="-5"
      id="F_1ce18d2f-6b3a-4c6e-bbb8-7e776f586b8a"
      unitRef="U_USD">105300000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_4ea84029-b253-493e-8495-d6a1f2b4c88a"
      decimals="-5"
      id="F_7f5724a8-f370-4028-9ae8-0645f2c23c62"
      unitRef="U_USD">2700000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_d3cd720c-8de2-4d2b-865b-f5dd9deaa416"
      decimals="-5"
      id="F_b7b56fad-0c90-461c-aca7-914c68b76c29"
      unitRef="U_USD">8600000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenue
      contextRef="C_39535649-8458-447e-b3bd-2d67c59d8b5a"
      decimals="-5"
      id="F_6916cb26-67bc-4ec4-a026-a6412199f2ad"
      unitRef="U_USD">18000000.0</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_882c43fd-0865-4bcc-8ec1-4fcf0c9a4cb3"
      decimals="-6"
      id="F_fbc2660b-19c3-4f93-94e7-e2db4418cba5"
      unitRef="U_USD">0</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_39535649-8458-447e-b3bd-2d67c59d8b5a"
      decimals="-5"
      id="F_69acf790-605e-4658-82c7-e2863453aab7"
      unitRef="U_USD">15300000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_882c43fd-0865-4bcc-8ec1-4fcf0c9a4cb3"
      decimals="-6"
      id="F_52ddf445-e2ae-494b-989b-fa153b3355b5"
      unitRef="U_USD">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_39535649-8458-447e-b3bd-2d67c59d8b5a"
      decimals="-5"
      id="F_962968cd-e63b-47de-a0dd-9c8e941d6c1e"
      unitRef="U_USD">2700000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_882c43fd-0865-4bcc-8ec1-4fcf0c9a4cb3"
      decimals="-6"
      id="F_75d84c27-5be8-4322-a1f3-0993cb8dcee4"
      unitRef="U_USD">0</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_2aca0240-4cad-4cad-b715-46c7dbbe4758"
      decimals="-5"
      id="F_da34742b-9626-4df5-b226-50a23a776f6b"
      unitRef="U_USD">50000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_2a16f0b2-09c2-4e09-be6e-37e84f297dcd"
      decimals="-5"
      id="F_36429b38-97c2-440b-a486-6a9d069adcc1"
      unitRef="U_USD">301000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_f2334817-ca3c-48d5-8771-4bdef45705e6"
      decimals="-5"
      id="F_8a84d3b2-8aac-4be0-ae7f-968355597e45"
      unitRef="U_USD">176000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_ef8a6a09-6b50-4f94-bb7e-8070837f1e1b"
      decimals="-5"
      id="F_b6425d77-9243-4c79-bce6-6dc768d8d5e9"
      unitRef="U_USD">125000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <rptx:CollaborationTermExpirationPeriod
      contextRef="C_805bc016-191e-4564-9965-a49c941c6abe"
      id="F_4d35b2de-6e03-41ac-9082-abda559f19c4">P42M</rptx:CollaborationTermExpirationPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_5d5cfdbd-0c58-4551-828e-64319099c53b"
      decimals="-5"
      id="F_c3e8b722-4175-474d-8cfc-6ba9d98adeb5"
      unitRef="U_USD">50000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_5d5cfdbd-0c58-4551-828e-64319099c53b"
      decimals="-5"
      id="F_0d979240-e402-46f3-90a9-d60dfb41b746"
      unitRef="U_USD">50000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="C_78e0ac1e-933a-4450-9b1d-ff16a6fd8f1c"
      id="F_0cf56f0a-25f4-4823-b2d5-e8472ebeb3d1">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on the relative stand-alone selling price, the allocation of the transaction price to the separate performance obligations was as follows:&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.122%;"/&gt;
        &lt;td style="width:8.978%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.899%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Performance obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Transaction price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Research activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Options to license druggable targets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Options to license undruggable targets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total transaction price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_8f5ce4e2-c290-41fd-9af5-5d0fb88c397e"
      decimals="-3"
      id="F_c00a4de4-33da-48bf-aaa1-501d743ed5dd"
      unitRef="U_USD">6405000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_609633f0-8edb-44b4-852b-0714140adf5c"
      decimals="-3"
      id="F_41daf8d5-b035-4e36-aeb6-27b170d4fe73"
      unitRef="U_USD">31148000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_9e6d1afd-0b5e-467c-9164-fafb352d5632"
      decimals="-3"
      id="F_c20b8f3e-e114-4b59-b0a7-1cac297d40c3"
      unitRef="U_USD">12447000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_86d0da1c-aaaa-4a1a-982b-05aa91d37fd6"
      decimals="-3"
      id="F_ed9c4837-d886-45ab-9f88-32c7d230209a"
      unitRef="U_USD">50000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_6a124d3c-84d9-4aa0-bd9c-49a33f8564bb"
      decimals="-5"
      id="F_c74b1e91-abab-454c-9375-055e9833d805"
      unitRef="U_USD">2700000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_404f23f3-7385-4056-868c-5316d49ea62c"
      decimals="-5"
      id="F_976348fb-e2ea-4a66-a343-ead498b206be"
      unitRef="U_USD">1100000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_dcd5c372-fa91-4030-89f6-8275c0abec98"
      decimals="-5"
      id="F_e934b717-4850-478c-ade5-3caabc8dec3a"
      unitRef="U_USD">12500000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_847f53e5-4018-4e25-b322-9a0918e5fc97"
      decimals="-5"
      id="F_1a144ac8-44a3-4615-831c-643e0c10db33"
      unitRef="U_USD">6500000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenue
      contextRef="C_11682b1d-2900-4c40-ba7d-c2e787aa1c94"
      decimals="-5"
      id="F_08c58008-f030-4ff5-8a14-2e35aa8b9f69"
      unitRef="U_USD">27400000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_6fb87044-e5c7-417d-afb8-2aee7d0f78a4"
      decimals="-5"
      id="F_350fc9ba-0e36-487d-8269-e84556332d57"
      unitRef="U_USD">42500000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_11682b1d-2900-4c40-ba7d-c2e787aa1c94"
      decimals="-5"
      id="F_04f661ba-a9b7-4757-8ac7-b693f37ae395"
      unitRef="U_USD">27400000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_6fb87044-e5c7-417d-afb8-2aee7d0f78a4"
      decimals="-5"
      id="F_052b5c60-8e02-4577-8ebc-cfebb3eaf3b4"
      unitRef="U_USD">2900000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_11682b1d-2900-4c40-ba7d-c2e787aa1c94"
      decimals="-6"
      id="F_3d747680-851c-44f9-a7b5-bb53fc5f9d2c"
      unitRef="U_USD">0</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_6fb87044-e5c7-417d-afb8-2aee7d0f78a4"
      decimals="-5"
      id="F_922e7413-5a34-4500-8110-32879d853e0f"
      unitRef="U_USD">39600000</us-gaap:DeferredRevenueNoncurrent>
    <rptx:CollaborationTermExtendedPeriod
      contextRef="C_bfafee29-fc89-418f-885a-bdf98c97ba34"
      id="F_749ac560-66d1-4b10-b427-d30dde09e9dd">P1Y</rptx:CollaborationTermExtendedPeriod>
    <rptx:SecondAmendmentAgreement
      contextRef="C_edf78ca6-0a38-4dce-a237-43ab79035e63"
      id="F_c475b2b1-f720-4023-b318-47d955d99e21">In January 2023, the Company and Ono entered into a second amendment to the Ono Agreement whereby the Research Term, as defined in the Ono Agreement, was extended until July 31, 2023.</rptx:SecondAmendmentAgreement>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_84f40979-c89b-461b-ba1d-ce4f4b049543"
      decimals="-6"
      id="F_5b6216e7-076a-4f71-80a6-e06c62cfbd3e"
      unitRef="U_JPY">900000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_84f40979-c89b-461b-ba1d-ce4f4b049543"
      decimals="-5"
      id="F_b9ca6bd6-178b-4603-a647-fd4f127edae7"
      unitRef="U_USD">8100000</us-gaap:ProceedsFromCollaborators>
    <rptx:InitialUpfrontFeePayment
      contextRef="C_84f40979-c89b-461b-ba1d-ce4f4b049543"
      decimals="-6"
      id="F_d0cb386d-3fe9-4c27-8a84-5f6dbb04487f"
      unitRef="U_JPY">110000000</rptx:InitialUpfrontFeePayment>
    <rptx:InitialUpfrontFeePayment
      contextRef="C_84f40979-c89b-461b-ba1d-ce4f4b049543"
      decimals="-5"
      id="F_016e36a1-8a8e-4d03-bb53-a9141e13fff0"
      unitRef="U_USD">1000000.0</rptx:InitialUpfrontFeePayment>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_a3402cc5-4f44-4db4-b2f1-72ae898426a4"
      decimals="-6"
      id="F_fba85479-cf9d-47a3-bb1e-fc6445ccbbf1"
      unitRef="U_JPY">790000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_a3402cc5-4f44-4db4-b2f1-72ae898426a4"
      decimals="-5"
      id="F_2cc38b89-00d3-4a9e-bb67-1a51e9235485"
      unitRef="U_USD">7100000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_378a21ae-1938-4ec4-a0a9-d3c1716ef61a"
      decimals="-6"
      id="F_d83bb115-5725-4880-8357-97b5219ab780"
      unitRef="U_JPY">750000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_378a21ae-1938-4ec4-a0a9-d3c1716ef61a"
      decimals="-5"
      id="F_85965057-60b9-427f-98f9-fe95c917dc6f"
      unitRef="U_USD">6500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_04b847fd-b66f-4a41-bc49-b1bd4e09b5ba"
      decimals="-7"
      id="F_d648d45d-8c81-42e9-a42f-bef2d14d6519"
      unitRef="U_JPY">17210000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_04b847fd-b66f-4a41-bc49-b1bd4e09b5ba"
      decimals="-5"
      id="F_858d9139-7bf6-4db4-95bf-5a8e8164b228"
      unitRef="U_USD">149500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_378a21ae-1938-4ec4-a0a9-d3c1716ef61a"
      decimals="-5"
      id="F_677f2d62-05bf-4cd3-ab9a-083c48ebc40a"
      unitRef="U_USD">8100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DeferredRevenueAdditions
      contextRef="C_0059be0f-88d6-4e76-a6ad-ac729b891744"
      decimals="-6"
      id="F_4f3185f2-db08-491a-a996-d8f578b598f6"
      unitRef="U_JPY">100000000</us-gaap:DeferredRevenueAdditions>
    <us-gaap:DeferredRevenueAdditions
      contextRef="C_0059be0f-88d6-4e76-a6ad-ac729b891744"
      decimals="-5"
      id="F_d91f0f6b-e0c7-4b57-a615-49916e71f17f"
      unitRef="U_USD">900000</us-gaap:DeferredRevenueAdditions>
    <us-gaap:DeferredRevenueAdditions
      contextRef="C_7ba4f675-ecb3-4e4b-9b5d-3da50cb072d2"
      decimals="-6"
      id="F_08706b6a-7693-4cec-8424-1911c54dd182"
      unitRef="U_JPY">200000000</us-gaap:DeferredRevenueAdditions>
    <us-gaap:DeferredRevenueAdditions
      contextRef="C_7ba4f675-ecb3-4e4b-9b5d-3da50cb072d2"
      decimals="-5"
      id="F_c59c4e71-9642-45e0-a599-d0ed8948c644"
      unitRef="U_USD">1500000</us-gaap:DeferredRevenueAdditions>
    <rptx:CollaborationReceivable
      contextRef="C_378a21ae-1938-4ec4-a0a9-d3c1716ef61a"
      decimals="-6"
      id="F_e2560a45-6f3d-411a-8055-9b4aa0e191e7"
      unitRef="U_JPY">200000000</rptx:CollaborationReceivable>
    <rptx:CollaborationReceivable
      contextRef="C_378a21ae-1938-4ec4-a0a9-d3c1716ef61a"
      decimals="-5"
      id="F_d89645d8-49d7-4553-878b-d0261ed4fca6"
      unitRef="U_USD">1500000</rptx:CollaborationReceivable>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_d32f5d4c-c383-401d-8204-bd0f61937dfb"
      decimals="-6"
      id="F_9a3fdd33-9427-4dcd-91ae-8c00ed5e6179"
      unitRef="U_JPY">450000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_d32f5d4c-c383-401d-8204-bd0f61937dfb"
      decimals="-5"
      id="F_0ff3f018-a36f-4a90-825f-67a8b95c8bbd"
      unitRef="U_USD">3400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_9f257956-22fd-4563-8031-ee9a1b01466b"
      decimals="-6"
      id="F_b2a2d231-d3cc-4889-9033-0bf042e2d317"
      unitRef="U_JPY">110000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_9f257956-22fd-4563-8031-ee9a1b01466b"
      decimals="-5"
      id="F_4f590742-a625-4f6f-9d7c-dddcf1a28caf"
      unitRef="U_USD">900000</us-gaap:RevenueRemainingPerformanceObligation>
    <rptx:RevenueRemainingPerformanceObligationNetAmount
      contextRef="C_9f257956-22fd-4563-8031-ee9a1b01466b"
      decimals="-5"
      id="F_667b03ef-5693-491a-8ad8-1da9bd8b5ed9"
      unitRef="U_USD">4300000</rptx:RevenueRemainingPerformanceObligationNetAmount>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_378a21ae-1938-4ec4-a0a9-d3c1716ef61a"
      decimals="-5"
      id="F_620562a3-4206-4ddc-88ec-e84ad6be6f4a"
      unitRef="U_USD">10500000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_69c1b260-1116-4599-800d-1afb2f09f79f"
      decimals="-5"
      id="F_c2df493a-3f62-457f-a2b1-b5b6e5c13ed3"
      unitRef="U_USD">9000000.0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_575ff9ee-1c50-42b7-9386-777f1af85738">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss before the provision for income taxes consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.61%;"/&gt;
        &lt;td style="width:1.604%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.615%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Canada&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of the provision for income taxes are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current income tax provision - foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred income tax benefit - foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,208&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation between tax expense and the product of accounting income multiplied by the statutory income tax rate is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.818%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.501%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computed income tax recovery&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effect on income tax resulting from:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal investment tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounting charges not deductible for tax purposes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capital gain income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company's applicable statutory tax rate is the Canadian combined rate applicable in the jurisdictions in which the Company operates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had tax losses of approximately &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;158.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which are available to offset future taxable income in Canada. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has not recognized the tax benefit of these losses. These losses expire as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.968%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.093%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;158,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had Scientific Research and Experimental Development (&#x201c;SR&amp;amp;ED&#x201d;) expenditures of approximately &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for Canadian federal and Qu&#xe9;bec purposes, which have not been deducted. These expenditures are available to reduce future taxable income and have an unlimited carryforward period. SR&amp;amp;ED expenditures are subject to verification by the tax authorities and, accordingly, the amounts may vary.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had non-refundable Canadian federal investment tax credits of approximately &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which may be utilized to reduce Canadian federal income taxes payable. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company has not &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;recognized &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the tax benefits related to the non-refundable investment tax credits. The investment tax credits &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;expire as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.919%;"/&gt;
        &lt;td style="width:1.919%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.162%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s deferred tax assets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.539%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.117%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.117%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net research and development expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,656&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net federal investment tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax basis of property and equipment in excess of carrying values&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expense and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,656&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;R&amp;amp;D costs capitalized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and has determined that it is more likely than not that the Company will not recognize the benefit of its net deferred tax assets, and as a result, a valuation allowance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million has been established at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has incurred net operating losses in Canada since inception and the Company's U.S. subsidiary operated profitably in the United States since its inception. As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had U.S. federal and state research and development tax credit carry forwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million which were utilized in the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company files income tax returns in Canada and in the United States. In the normal course of business, the Company could be subject to examination by federal and provincial or state jurisdictions, where applicable. There are currently no pending tax examinations. The Company may be subject to tax examination for fiscal years &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_1d4885b4-4eda-475c-a5da-596a44a20fc7;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2017 to 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; due to unexpired statute of limitation periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the provinces and states in which the Company operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when the Company&#x2019;s judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; uncertain tax positions have been recorded in the consolidated financial statements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and comprehensive loss. As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_11dff0f8-84a2-485a-bc4f-6eb983c42c75">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss before the provision for income taxes consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.61%;"/&gt;
        &lt;td style="width:1.604%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.615%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Canada&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_fb72ebf6-ab3b-412c-9082-4cc5267234b6"
      unitRef="U_USD">-17550000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_ecf1dd42-1f1a-437a-87f3-e473c4d1bcf0"
      unitRef="U_USD">-110433000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_b03053c8-9fb3-4304-ad60-f2a596131bca"
      unitRef="U_USD">3650000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_6dd47305-ceb9-4961-890a-08c2a4435d76"
      unitRef="U_USD">1847000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_ac971dea-308c-4f60-a8be-609068ff6e2f"
      unitRef="U_USD">-13900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_5e0ace4b-05f5-4b75-8f8a-3d74f51b000f"
      unitRef="U_USD">-108586000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_df27257c-06c5-44dd-ba45-c8f7d7f3fa62">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of the provision for income taxes are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current income tax provision - foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred income tax benefit - foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,208&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_39ca7506-2083-464f-8f71-896515a31c63"
      unitRef="U_USD">11527000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_8ab58bfa-9834-4725-8a2f-9c9ea47cc89b"
      unitRef="U_USD">530000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_2a77a19b-196b-40c1-9eb5-d784eaac83f0"
      unitRef="U_USD">3620000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_eac2fa1a-9858-4281-a057-637d6fc7ccbd"
      unitRef="U_USD">-2208000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_3b97de9c-0594-4c4d-8503-fd462590a718"
      unitRef="U_USD">15147000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_719ba709-43b7-44a2-996c-6bf6eaa46d2c"
      unitRef="U_USD">-1678000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_e25d0588-126e-4dc3-b622-0fa5d03f031c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation between tax expense and the product of accounting income multiplied by the statutory income tax rate is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.818%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.501%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computed income tax recovery&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effect on income tax resulting from:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal investment tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounting charges not deductible for tax purposes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capital gain income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_7efd9dbc-eed9-42ea-87d3-c60194dfcf4f"
      unitRef="U_USD">-13900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_9476d429-bfb5-4483-9dfa-fe0832c61fe8"
      unitRef="U_USD">-108586000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="3"
      id="F_6d1129ae-3fe0-4519-a7df-1abbf7bdb0b5"
      unitRef="U_pure">0.265</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="3"
      id="F_8090adce-bdbb-48a2-8692-da2459acf98f"
      unitRef="U_pure">0.265</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_b04bb110-1315-44ba-8306-054b676416b0"
      unitRef="U_USD">-3684000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_60847106-feb0-4d08-8d4c-55a8345be624"
      unitRef="U_USD">-28775000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_5e81730d-0121-4cbe-8f9e-38d62b0f261f"
      unitRef="U_USD">4899000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_b5ac372d-a5c0-4c87-b384-0df1bf547bd1"
      unitRef="U_USD">4093000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <rptx:IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_3b292296-7625-4f1d-bb12-381b18c337aa"
      unitRef="U_USD">679000</rptx:IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges>
    <rptx:IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_2a126834-b48d-4b48-9b53-b03cbf7fa6d6"
      unitRef="U_USD">1078000</rptx:IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges>
    <rptx:IncomeTaxReconciliationCapitalGainIncomeEquityCompensation
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_498e2627-12d5-4cd7-a94c-0ad2f308d0a7"
      unitRef="U_USD">-13956000</rptx:IncomeTaxReconciliationCapitalGainIncomeEquityCompensation>
    <rptx:IncomeTaxReconciliationCapitalGainIncomeEquityCompensation
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_aa30dad6-2da2-4943-bc64-8aa0d6c581db"
      unitRef="U_USD">0</rptx:IncomeTaxReconciliationCapitalGainIncomeEquityCompensation>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_6692a99b-9bbb-453d-b542-e0b538f83053"
      unitRef="U_USD">3492000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_322b77f0-e498-4a51-922a-f1b1d7c95654"
      unitRef="U_USD">2220000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <rptx:IncomeTaxReconciliationStateTaxes
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_7ba12067-1e6b-4eb6-af6b-b38b99303647"
      unitRef="U_USD">-777000</rptx:IncomeTaxReconciliationStateTaxes>
    <rptx:IncomeTaxReconciliationStateTaxes
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_4c2f6825-b5cd-4f55-a376-bd735e232f33"
      unitRef="U_USD">-37000</rptx:IncomeTaxReconciliationStateTaxes>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_feab9bb7-3a4e-4b42-8980-57608d4466c7"
      unitRef="U_USD">-142000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_376895eb-8fe4-4ebd-9e62-51a5fb57c928"
      unitRef="U_USD">644000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_804612b7-a186-439c-9911-a159e9a8404a"
      unitRef="U_USD">34434000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_a59e5bcd-3f02-4dfc-868c-d20a5f4567d7"
      unitRef="U_USD">27285000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_71c102d7-3503-4d65-af4f-2fcc484f6b97"
      unitRef="U_USD">15147000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_60fe9412-a074-4cb6-945e-eef9e0a6c2b1"
      unitRef="U_USD">-1678000</us-gaap:IncomeTaxExpenseBenefit>
    <rptx:IncomeTaxLosses
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-5"
      id="F_f902c92f-47d5-46a2-b4e6-6dd03d833cb3"
      unitRef="U_USD">158500000</rptx:IncomeTaxLosses>
    <rptx:SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_6b5c35ae-7953-4af0-a629-c56001987bcc">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has not recognized the tax benefit of these losses. These losses expire as follows: &lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.968%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.093%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;158,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</rptx:SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock>
    <rptx:IncomeTaxLossesExpireOne
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_5de9dfbd-8250-480c-bc3d-a226f3148bc4"
      unitRef="U_USD">45279000</rptx:IncomeTaxLossesExpireOne>
    <rptx:IncomeTaxLossesExpireTwo
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_543ebe95-147c-4780-81c6-2b4001b2f825"
      unitRef="U_USD">93834000</rptx:IncomeTaxLossesExpireTwo>
    <rptx:IncomeTaxLossesExpireThree
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_d8a8a312-edd4-4668-b4e8-35bffee3e5a0"
      unitRef="U_USD">0</rptx:IncomeTaxLossesExpireThree>
    <rptx:IncomeTaxLossesExpireFour
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_77756e40-050b-4473-9dd0-dbaa6e9e3192"
      unitRef="U_USD">11394000</rptx:IncomeTaxLossesExpireFour>
    <rptx:IncomeTaxLossesExpireFive
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_210dcbf1-f525-4eaf-806b-79ed172c6fd4"
      unitRef="U_USD">7111000</rptx:IncomeTaxLossesExpireFive>
    <rptx:IncomeTaxLossesExpireSix
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_329f7204-18a0-4f79-83e0-7ff50cf82e72"
      unitRef="U_USD">883000</rptx:IncomeTaxLossesExpireSix>
    <rptx:IncomeTaxLosses
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_052de913-b7d6-42ca-ae7f-21d3aa576cdb"
      unitRef="U_USD">158501000</rptx:IncomeTaxLosses>
    <rptx:ScientificResearchAndExperimentalDevelopmentExpenditures
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-5"
      id="F_939ed3dd-c8b3-46eb-bae4-af40ec6b6744"
      unitRef="U_USD">54600000</rptx:ScientificResearchAndExperimentalDevelopmentExpenditures>
    <rptx:InvestmentTaxCredits
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-5"
      id="F_42788497-2ada-4037-8fa6-b80761c100cc"
      unitRef="U_USD">9000000.0</rptx:InvestmentTaxCredits>
    <rptx:SummaryOfInvestmentTaxCreditsExpireTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_2d3a9de2-5537-4605-8efc-86ca0bc4addc">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company has not &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;recognized &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the tax benefits related to the non-refundable investment tax credits. The investment tax credits &lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.919%;"/&gt;
        &lt;td style="width:1.919%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.162%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</rptx:SummaryOfInvestmentTaxCreditsExpireTableTextBlock>
    <rptx:InvestmentTaxCreditsExpireOne
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_63a9b84f-6312-4847-a18f-242c8424b42d"
      unitRef="U_USD">2392000</rptx:InvestmentTaxCreditsExpireOne>
    <rptx:InvestmentTaxCreditsExpireTwo
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_46253b8f-5b82-40c7-99b9-73e3d4f344d5"
      unitRef="U_USD">2253000</rptx:InvestmentTaxCreditsExpireTwo>
    <rptx:InvestmentTaxCreditsExpireThree
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_a3d54c0c-d084-462e-b951-5d8c6245e4ee"
      unitRef="U_USD">1702000</rptx:InvestmentTaxCreditsExpireThree>
    <rptx:InvestmentTaxCreditsExpireFour
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_1dc0977f-ad2d-4a18-bd83-d1bc5305e0f6"
      unitRef="U_USD">1362000</rptx:InvestmentTaxCreditsExpireFour>
    <rptx:InvestmentTaxCreditsExpireFive
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_e7e1bbec-d733-4224-a5a2-12fbdf45107a"
      unitRef="U_USD">776000</rptx:InvestmentTaxCreditsExpireFive>
    <rptx:InvestmentTaxCreditsExpireSix
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_13cf81bd-c88d-4bb3-ad27-717914ebfe55"
      unitRef="U_USD">455000</rptx:InvestmentTaxCreditsExpireSix>
    <rptx:InvestmentTaxCreditsExpireSeven
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_793c1865-85c9-43c9-a2ee-f44205c00250"
      unitRef="U_USD">24000</rptx:InvestmentTaxCreditsExpireSeven>
    <rptx:InvestmentTaxCredits
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_cd7f2b00-cd98-4fef-bcfb-32a4e6d3f162"
      unitRef="U_USD">8964000</rptx:InvestmentTaxCredits>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_701f2598-0d02-45ac-9896-3b5bb72aea22">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s deferred tax assets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.539%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.117%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.117%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net research and development expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,656&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net federal investment tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax basis of property and equipment in excess of carrying values&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expense and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,656&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;R&amp;amp;D costs capitalized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_4fc2dd07-afff-4d24-9343-a6e7e80d2410"
      unitRef="U_USD">42003000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_0601b1a5-cc43-40a4-968b-c8baddb2ad93"
      unitRef="U_USD">30093000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_723a799f-5b1c-4d53-af98-49728cc7d9cc"
      unitRef="U_USD">14468000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_842ef5c2-1d63-49c8-9897-5a925a421936"
      unitRef="U_USD">10656000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_7a4d86d2-37b3-4e03-961f-8ced01e9910d"
      unitRef="U_USD">2369000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_d6099783-5df1-43a2-8398-87c1d66c05cb"
      unitRef="U_USD">3538000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <rptx:DeferredTaxAssetsNetFederalInvestmentTaxCredits
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_91e3a16c-c085-4f81-a01a-9cbaeb2d7844"
      unitRef="U_USD">6589000</rptx:DeferredTaxAssetsNetFederalInvestmentTaxCredits>
    <rptx:DeferredTaxAssetsNetFederalInvestmentTaxCredits
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_a1255a91-b628-4dc2-acd4-987a67aa2f67"
      unitRef="U_USD">4805000</rptx:DeferredTaxAssetsNetFederalInvestmentTaxCredits>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_5d0ba5de-f0a9-4743-bec0-05f454b2d519"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_713cd1b0-9c00-4393-ade5-e5a62f2cf527"
      unitRef="U_USD">1775000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_5db4e780-9f1a-4966-94ca-1a9b1525568f"
      unitRef="U_USD">376000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_b7fda231-1cfd-40de-9751-6e0be3e04ec5"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <rptx:DeferredTaxAssetsOperatingLeaseRightOfUseAssets
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_0b890586-59b4-4f58-a997-dac2aa4ce031"
      unitRef="U_USD">1429000</rptx:DeferredTaxAssetsOperatingLeaseRightOfUseAssets>
    <rptx:DeferredTaxAssetsOperatingLeaseRightOfUseAssets
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_d89a9d02-13ea-46aa-92cd-5446168f721b"
      unitRef="U_USD">1995000</rptx:DeferredTaxAssetsOperatingLeaseRightOfUseAssets>
    <rptx:DeferredTaxLiabilitiesOperatingLeaseLiability
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_7356c289-bdc4-4538-bf23-d834747932fd"
      unitRef="U_USD">1445000</rptx:DeferredTaxLiabilitiesOperatingLeaseLiability>
    <rptx:DeferredTaxLiabilitiesOperatingLeaseLiability
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_99e13d9a-a5c1-4223-8b9b-4ae971e277d1"
      unitRef="U_USD">1950000</rptx:DeferredTaxLiabilitiesOperatingLeaseLiability>
    <rptx:DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_2fe0e314-2970-4c3c-9f8f-db4da28ec3f3"
      unitRef="U_USD">785000</rptx:DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities>
    <rptx:DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_a5cab24c-86c5-4328-9681-e0731edd1bae"
      unitRef="U_USD">760000</rptx:DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_20578975-e4ca-43a8-93d2-0e47e37ce5d1"
      unitRef="U_USD">14783000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_9e78d32d-8feb-4a4e-a1f0-f17e640bae35"
      unitRef="U_USD">13656000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <rptx:DeferredTaxAssetsShareBasedCompensationCost
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_8e4f5caf-acf2-492e-88fd-29cc5f0e04b5"
      unitRef="U_USD">2492000</rptx:DeferredTaxAssetsShareBasedCompensationCost>
    <rptx:DeferredTaxAssetsShareBasedCompensationCost
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_efdcf0b5-5e3a-4fa9-90f3-96ecc191553a"
      unitRef="U_USD">988000</rptx:DeferredTaxAssetsShareBasedCompensationCost>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_f307eb9e-9cdc-483c-8c0d-54298748b37e"
      unitRef="U_USD">13911000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_f7842e3e-1870-4b0a-919b-9b416b6a887e"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_ca9a57fa-277e-4ff6-ad0c-0026d578328f"
      unitRef="U_USD">97040000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_9bf3ea53-08ef-4c45-b2af-abf501bdc20c"
      unitRef="U_USD">66226000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_c6882c01-c9cc-41f9-bcb5-2be296a0a2b5"
      unitRef="U_USD">97040000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_a9e8b675-e3ed-4f0b-bb29-b215f5303bcb"
      unitRef="U_USD">62606000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_c88d62cc-7b1f-4183-a8de-27cbe6c3a912"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_571f3a20-632f-4606-8fe0-ce7e22c8f693"
      unitRef="U_USD">3620000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-5"
      id="F_0b4f3619-d94b-4167-b4ea-1124a496ed50"
      unitRef="U_USD">97000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-5"
      id="F_3044163c-8452-4a3e-a9ab-c88dc934cfe9"
      unitRef="U_USD">62600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_7f118fdb-411f-477e-a3a2-4b54c2f8d660"
      decimals="-5"
      id="F_8ce97b7a-c9bb-4abf-aeb0-5682e325ef9b"
      unitRef="U_USD">1800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="INF"
      id="F_38c6322a-601b-4526-9033-511f619dac2c"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="INF"
      id="F_f3f646d1-039c-4bdd-a665-984003c85ecb"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="INF"
      id="F_5c5ac785-44d4-4393-97df-e301b3187026"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="INF"
      id="F_565d1350-9dd5-4047-bd88-e97e875ae46b"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_0f4e5e36-e3b4-4ca0-afa2-05d225293258">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14. Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.61%;"/&gt;
        &lt;td style="width:1.604%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.615%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average number of common shares outstanding&#x2014;basic and &lt;br/&gt;&#160;&#160;&#160;diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,922,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,818,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s potentially dilutive securities, which include stock options and shares issued under the ESPP, have been excluded from the computation of diluted net loss per share attributable to common shareholders as the effect would be to reduce the net loss per share attributable to common shareholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common shareholders is the same.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.573%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.882%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.195%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,032,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,322,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated shares issuable under the ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_cda8e853-aaa4-4ba1-b7a7-d31bdd813c8e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.61%;"/&gt;
        &lt;td style="width:1.604%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.615%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average number of common shares outstanding&#x2014;basic and &lt;br/&gt;&#160;&#160;&#160;diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,922,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,818,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-3"
      id="F_fcd8e087-6dfb-43d1-ae48-9d974d1b02f7"
      unitRef="U_USD">-29047000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-3"
      id="F_c28c30ad-8351-4163-822c-5f2049716fdb"
      unitRef="U_USD">-106908000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="0"
      id="F_8d740e79-e42c-4675-913a-082108a242fb"
      unitRef="U_shares">41922042</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="0"
      id="F_1ff0b100-70fe-4689-83d6-94090610da14"
      unitRef="U_shares">41922042</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="0"
      id="F_8e1b2534-97af-4336-921a-db0de5bfc0cd"
      unitRef="U_shares">37818115</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="0"
      id="F_692abfe6-9271-48c9-9611-5a730051a00c"
      unitRef="U_shares">37818115</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="2"
      id="F_f4d309c4-bb63-46a5-aaed-2c0c32b249e3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="2"
      id="F_649f97e1-fbba-43bc-8d77-214b4ebf127a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="2"
      id="F_09be5b79-b9e2-4b7a-bb74-f7c5442f8ba3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="2"
      id="F_4b82bc3b-2d1c-49c7-8f72-128792b9a7c3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_0f3526fb-bf45-48d9-987d-0ae9dd4685e8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.573%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.882%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.175%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.195%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,032,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,322,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated shares issuable under the ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_678241cd-18bd-45e5-b0fa-05a4f27297f3"
      decimals="0"
      id="F_7d1a732e-2a8f-4455-8979-aa0283864402"
      unitRef="U_shares">8032902</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fb05acb5-808b-494c-bd17-c15d87dfa489"
      decimals="0"
      id="F_eed3c471-1c26-474d-b24f-a72307501374"
      unitRef="U_shares">5322591</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_17e3367f-80ab-4165-a57b-7a3da73e2379"
      decimals="0"
      id="F_de7d9e78-cf80-44c3-900e-ed870627a482"
      unitRef="U_shares">47216</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_26af78f0-c117-4481-914d-922b16ea388a"
      decimals="0"
      id="F_ac584caf-d7e0-487a-899d-6cde9b19ba43"
      unitRef="U_shares">9654</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_8062bb85-8ffc-48c5-b976-f25386823e98">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15. Government Assistance&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company incurred research and development expenditures which are eligible for refundable investment tax credits. The refundable investment tax credits recorded are based on management&#x2019;s estimates of amounts expected to be recovered and are subject to audit by the taxation authorities. These amounts have been recorded as a reduction of research and development expenditures in the amounts of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <rptx:IncreaseDecreaseInResearchAndDevelopmentExpenses
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-5"
      id="F_00e8b263-c33f-4a6f-bde3-503b976caea1"
      unitRef="U_USD">1400000</rptx:IncreaseDecreaseInResearchAndDevelopmentExpenses>
    <rptx:IncreaseDecreaseInResearchAndDevelopmentExpenses
      contextRef="C_fcd2c4f4-1550-4748-b6e8-c629770be22e"
      decimals="-5"
      id="F_a291e4d1-8034-43d3-8242-44c18cbf83fb"
      unitRef="U_USD">1100000</rptx:IncreaseDecreaseInResearchAndDevelopmentExpenses>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_0629dfdc-01fd-479d-9584-2925258c81d6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s commitments to settle contractual obligations at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, other than leases which are recognized as operating lease liabilities in the consolidated balance sheet.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.919%;"/&gt;
        &lt;td style="width:1.919%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.162%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Following years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration and Research Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration and research agreement obligations primarily relate to a strategic collaboration agreement that was entered into with the University of Texas M. D. Anderson Cancer Center (&#x201c;MDACC&#x201d;) in March 2020. The collaboration consists of preclinical studies and clinical trials designed by the Company and MDACC with the research to be completed by MDACC. The Company has agreed to commit $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in funding for various studies over a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was paid as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company entered into an agreement with the Broad Institute, Inc. (&#x201c;Broad&#x201d;), in July 2022, under which Broad will perform specialty screening services at the Company&#x2019;s request over the course of a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; term in exchange for payments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million per year, beginning in July 2022, totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the aggregate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Purchase and Other Obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the normal course of business, the Company enters into contracts with Contract Research Organizations (&#x201c;CROs&#x201d;) and other third parties for preclinical studies and clinical trials, research and development supplies and other testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and provide for termination on 30 to 90 days&#x2019; prior written notice, and therefore are cancellable contracts. These payments are not included in the table above as the amount and timing of such payments are not known as of December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has further entered into license agreements under which it is obligated to make milestone and royalty payments and incur annual maintenance fees. The future milestone or royalty payments under these agreements have not been included in the table above since the payment obligations are contingent upon future events, such as achieving certain clinical and commercial milestones or generating product sales. As of December 31, 2022, the Company is unable to estimate the timing or likelihood of achieving these clinical and commercial milestones or generating future product sales (see Note 7).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Indemnification Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in these consolidated financial statements as at December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_5a61653c-b3a8-492d-b207-5d4258aefa63">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s commitments to settle contractual obligations at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, other than leases which are recognized as operating lease liabilities in the consolidated balance sheet.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.919%;"/&gt;
        &lt;td style="width:1.919%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.162%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Following years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_89072264-a8d3-42ae-901c-bb5f6de5530f"
      unitRef="U_USD">3090000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_dac54abf-9976-453d-856a-7f60481b8b71"
      unitRef="U_USD">3106000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_16f6e17c-7cf4-4026-8be9-78ead029e103"
      unitRef="U_USD">32000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_35ec2130-a8a2-431b-aab5-3f8c17fdccd8"
      unitRef="U_USD">56000</us-gaap:ContractualObligationDueInFourthYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_b1ad51d8-f68c-4abb-9b41-740c88b7c5d4"
      unitRef="U_USD">32000</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligationDueAfterFifthYear
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_a31a3f99-0b60-46f4-86a5-75aff0e9e8bb"
      unitRef="U_USD">63000</us-gaap:ContractualObligationDueAfterFifthYear>
    <us-gaap:ContractualObligation
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_a6c7984e-6a55-4bc0-8600-7b4ef9280b12"
      unitRef="U_USD">6379000</us-gaap:ContractualObligation>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="C_75c9b122-048e-43f5-a14f-971257b2c683"
      decimals="INF"
      id="F_668678e9-4335-4e2e-915f-3fec1bdf5f2a"
      unitRef="U_USD">10000000.0</us-gaap:LongTermPurchaseCommitmentAmount>
    <rptx:ContractualObligationPeriod
      contextRef="C_75c9b122-048e-43f5-a14f-971257b2c683"
      id="F_a73400ce-dcdb-4d1c-aabc-68fac5d0e374">P5Y</rptx:ContractualObligationPeriod>
    <rptx:ContractualObligationsPaid
      contextRef="C_0bcff83b-674d-4098-82be-f88a301739b5"
      decimals="-5"
      id="F_74fbefde-4aab-4e3c-8cb4-76ff381061eb"
      unitRef="U_USD">5400000</rptx:ContractualObligationsPaid>
    <rptx:ContractualObligationPeriod
      contextRef="C_ad4b56bf-9860-4d20-8314-347221a8f5e0"
      id="F_f2a03a11-a564-47ee-95e1-ab0f8e22b3b8">P3Y</rptx:ContractualObligationPeriod>
    <rptx:ContractualObligationAmountPerYear
      contextRef="C_ad4b56bf-9860-4d20-8314-347221a8f5e0"
      decimals="-5"
      id="F_e87b91db-57d8-4f8d-ba36-57de3d8d69b9"
      unitRef="U_USD">800000</rptx:ContractualObligationAmountPerYear>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="C_ad4b56bf-9860-4d20-8314-347221a8f5e0"
      decimals="-5"
      id="F_75d98dfe-3444-4d11-bd5a-89c99c4cd62f"
      unitRef="U_USD">2300000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:ForeignCurrencyDisclosureTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_bfee6f6c-0514-4ce6-a0a2-885b06df9e54">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17. Currency Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is exposed to the financial risk related to the fluctuation of foreign exchange rates and the degree of volatility of those rates. The foreign currency risk is limited to the portion of the Company&#x2019;s business transactions denominated in currency other than U.S. dollars.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company incurs a portion of its expenses in Canadian dollars, as well as other currencies to a lesser extent. A change in the currency exchange rates between the U.S. dollars relative to the Canadian dollar could have a significant effect on the Company&#x2019;s consolidated results of operations, financial position, or cash flows. The Company does not enter into arrangements to hedge its currency risk exposure, although it maintains expected Canadian dollar cash requirements in Canadian dollars to form a natural hedge.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is exposed to currency risk through its cash, other receivables, accounts payable, accrued expenses and other current liabilities, as well as right-of-use lease liabilities denominated in Canadian dollars as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.61%;"/&gt;
        &lt;td style="width:1.604%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.615%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credits receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net financial position exposure&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on the above net exposure at December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and assuming that all other variables remain constant, a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% depreciation of the U.S. dollar against the Canadian dollar would result in an increase of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in the Company&#x2019;s net loss for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is also exposed to currency risk through the Ono Agreement as the Company has a collaboration revenue receivable balance as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and any future payments receivable under the Ono Agreement, if any, are denominated in Japanese yen.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyDisclosureTextBlock>
    <rptx:ScheduleOfFinancialPositionExposureTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_2ce13d03-0604-41e6-a53e-459bd2556008">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is exposed to currency risk through its cash, other receivables, accounts payable, accrued expenses and other current liabilities, as well as right-of-use lease liabilities denominated in Canadian dollars as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.61%;"/&gt;
        &lt;td style="width:1.604%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.615%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.128%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credits receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net financial position exposure&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</rptx:ScheduleOfFinancialPositionExposureTableTextBlock>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="C_04d861cf-f6d2-4f55-acdf-2117513160d7"
      decimals="-3"
      id="F_6c96ad9a-f92f-46e3-8e6d-4f2fa2fdaf8e"
      unitRef="U_CAD">1904000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="C_9271e61c-f687-4b91-af75-f7655d9f62a4"
      decimals="-3"
      id="F_a13c4f5f-5c60-4efa-8438-f5ced7367cec"
      unitRef="U_CAD">3583000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="C_27f1745b-0673-4b14-ba25-3054bf45721c"
      decimals="-3"
      id="F_6584a3f9-b443-4dcf-b9b9-b767ce268b14"
      unitRef="U_CAD">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="C_3b217459-d769-49eb-838f-22205ffafcb9"
      decimals="-3"
      id="F_0f685fd9-3d28-447d-b250-d58b06fdb0ca"
      unitRef="U_CAD">3261000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="C_edec0475-471a-4ae7-bedf-0d8f8f6903fd"
      decimals="-3"
      id="F_b3365f05-3809-417c-b66a-b6f5065c8d4f"
      unitRef="U_CAD">851000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="C_7bcf5428-90b7-43b9-ad8f-851d706606db"
      decimals="-3"
      id="F_acf6a7d6-10a9-4515-8156-0967ec7d6832"
      unitRef="U_CAD">745000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="C_cad33b29-12d6-4338-9a56-8e6337e0ac19"
      decimals="-3"
      id="F_1d99496c-eb5d-4cb2-85d0-4535c06e6b69"
      unitRef="U_CAD">324000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="C_f916e232-9243-456b-b6ab-fa90b5090b81"
      decimals="-3"
      id="F_a404b8df-6f8d-4050-8961-3d84039a192c"
      unitRef="U_CAD">665000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="C_a8717ee6-9026-4027-9c4d-810f9e98e2d0"
      decimals="-3"
      id="F_6915171f-794d-41dd-81b8-42db276e2017"
      unitRef="U_CAD">2289000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="C_ad1fe6be-ea8a-4207-b357-2558aad861b2"
      decimals="-3"
      id="F_7c217e8d-68c5-4950-93b7-144445b7dc72"
      unitRef="U_CAD">2116000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="C_e91f697c-b5f2-425a-b238-1ed83d875ffd"
      decimals="-3"
      id="F_d3645cc7-2fa4-49ac-a420-4b2b33c402d4"
      unitRef="U_CAD">4392000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="C_ed70d3e9-a443-422c-a3ca-f76fb5ddd9dd"
      decimals="-3"
      id="F_0d7efea9-d107-40c0-ba6f-7c59ef4fab1d"
      unitRef="U_CAD">5564000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_8485ada4-700c-4f9f-88ea-ed01f5a3b5fd"
      unitRef="U_CAD">-4250000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_5572919a-03bc-41f8-aa71-8c0fb49eddb7"
      unitRef="U_CAD">-756000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet>
    <rptx:PercentageOfDepreciationUSDAgainstCanadianDollar
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="2"
      id="F_6caf81aa-be52-43ac-9e07-17f42d900129"
      unitRef="U_pure">0.10</rptx:PercentageOfDepreciationUSDAgainstCanadianDollar>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      decimals="-5"
      id="F_1d319c11-0f52-4cc4-b643-689d8d2af40a"
      unitRef="U_USD">300000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_aa1fa3a8-af9b-4e69-b79a-e69d3b0f44b3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18. Geographic Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s property and equipment, net by location was as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Canada&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s right-of-use assets by location were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Canada&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total right-of-use assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31, 2022 the Canadian parent company recognized revenue under its collaboration agreements of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (2021 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) with Bristol Myers Squibb, whose headquarters are located in the United States, and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (2021 - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;) with Roche, whose headquarters are located in Switzerland.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="C_007402c7-e8a5-42b8-ac4a-63efb2891fe0"
      id="F_8b81ce67-ed02-42bd-b113-24fd8953b130">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s property and equipment, net by location was as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Canada&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s right-of-use assets by location were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.766%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.844000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.163%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Canada&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total right-of-use assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_9422e8ce-7702-44be-86dc-e5ed61056018"
      decimals="-3"
      id="F_01f23e67-76e9-4b59-9151-f76552bd2b33"
      unitRef="U_USD">2888000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_209bac12-6e02-4442-87b0-25af22df7850"
      decimals="-3"
      id="F_77571108-3de8-4522-8a24-134bb83f5918"
      unitRef="U_USD">3675000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_98bf928f-8526-4b16-9053-723fa23a52a2"
      decimals="-3"
      id="F_1103ba9f-be99-4253-a491-20a67e48aba4"
      unitRef="U_USD">1340000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1eeb9ab9-2a11-42de-9a18-4d0e8bc99e37"
      decimals="-3"
      id="F_14a487ff-a3c6-4477-a012-568120395709"
      unitRef="U_USD">1929000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_4e92d5ef-1478-43c7-a3f1-e9f4c1382689"
      unitRef="U_USD">4228000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_3b61ea5d-1214-41cd-ab5d-9a65dc59857b"
      unitRef="U_USD">5604000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_9422e8ce-7702-44be-86dc-e5ed61056018"
      decimals="-3"
      id="F_e7c0e52d-21ac-4399-840a-129f9d035ab9"
      unitRef="U_USD">3578000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_209bac12-6e02-4442-87b0-25af22df7850"
      decimals="-3"
      id="F_e9571bf2-36d0-40cd-a16b-d775ff5b2cf6"
      unitRef="U_USD">4939000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_98bf928f-8526-4b16-9053-723fa23a52a2"
      decimals="-3"
      id="F_e29b242e-5eeb-4a53-b835-b941e609529a"
      unitRef="U_USD">1793000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_1eeb9ab9-2a11-42de-9a18-4d0e8bc99e37"
      decimals="-3"
      id="F_de2cb9f9-a4a3-4559-8590-c3a81c729749"
      unitRef="U_USD">2552000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6"
      decimals="-3"
      id="F_721d6695-06c0-489e-b098-fd3aa4d75d4c"
      unitRef="U_USD">5371000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10"
      decimals="-3"
      id="F_c946c2cc-c386-4ede-9737-def122126068"
      unitRef="U_USD">7491000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Revenues
      contextRef="C_5bca2e86-6a57-4346-8aee-8fb3b26b2aca"
      decimals="-5"
      id="F_f4d20f49-480d-4694-80a4-8877e5e97df5"
      unitRef="U_USD">15200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_e2261616-9a81-42da-b0cb-ad4847fe864b"
      decimals="-5"
      id="F_a013fc6d-0057-463e-86f4-be8052b639b6"
      unitRef="U_USD">7600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_bcf5a011-b156-43a6-a346-9debd16c577f"
      decimals="-5"
      id="F_ee11f445-cc6d-42c3-9725-740f9f569ec5"
      unitRef="U_USD">116600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_6fe10c4b-5340-414c-899a-6ed2280ce2c6"
      decimals="-6"
      id="F_8e8e4618-c729-4f4e-9934-6915dfc7bd02"
      unitRef="U_USD">0</us-gaap:Revenues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>120
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M"'SW(6AW(MBF_I;RP(1@>7VXIB2A7!G(^RO&Q.N)^CS3?HZ;_PM02P,$%
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M'::ZM01A O3[%>=J-S$;U,UJ] ]02P,$%     @ >()<5KJQI-,^!0  :Q0
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M;>W>%S0^P)U71+PQ?(+AQ<K_ E!+ P04    " !X@EQ6C>(^LVD(  #$)
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MDE^E+^!<KRVMP:I86^,8J\F(\N#B.Y$>SB<)&J/6,+!W5O<EXY )U"Z!>AV
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M+$BB1O$"?%\9X[L'=M#_I\7IOU!+ P04    " !X@EQ6_DP.$#LH   WA@
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M6-4C+L4#6<)8GL13MJ9$>ERDQY Z_2JX<_0%(6U8\J9H/\G1DR.NWZ A/:D
M@76K8/"?Z"^2A%M7*K$)#QH0*'8K#O'ARFU ".,;M.Y"$"HJ!EDZQ3UV(&]#
M1 J]<T@+1K#N]QBC"-Q#@Z- ^1S4W[F'E29$/GU>0D;)S+!\]AA09L*R:%9T
M3]C(#TA3[Q(TN1<<3M"9S0V?\A-N&OC)E6@S0QA:1]A@U JL<%OW><BNKF7E
MRT;/,-@,)5XH<I*LP- 3* "1!G>&MSK]G*,KJZ*8,$6$DGW9-!3P"%D49"J0
M.HKKC7$2VO3 ;1'WBY6359,@ZUG*T!IMP2)TOW>Y?'R6Q"=%];11]O F&@2V
M;%O4/;NT&K( \,&6 .WW!N./Q(NZ/8X#:"L#@W\=.S1 <L:.H,=1,7YL@53
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M1I\ .?>HS@M-%IB8S[H#PT>*D:T@+9N+(0 /2^@.=9EAG&^8I")0HY- VRE
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MT(E[X !0ZFJI'\-/80TY5M2%Y_*9QZV%PELI%Y0M >PH5^ELTSG5B'Q?53#
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MC.Y'\*!]9?<@E:O6?#&<GD0=Q.'RF0=MCC 01B?#R7S1N3Q;#QZ4I0H5QQA
MN)@-9]'DR?=PW?B^.!SO(8I.A[/P(.O6]RGKXW4._V.=H^%\.N^-_Z?*1'YZ
MUCQ;G)_F?#8\.YWUQA<$X%N.DDXO'3I5.CGT3CH:RPNGAV%??^[7P LZ][5,
M*H-.)"IVFO=Y<%E6C1I)$"]-*_G">%338%O&A7M]&)#\#'ROJ II6_I2\\2A
MJE;DSU0Z@D^RTZ2_80X^^TU&1D)-*;_VXG$W1:RVSZ)K%)R^D'8;"DULNJ+
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MF?,6J?3W,2^4,N+C,KB\+MQ*)G351OTXLFMJ3Y\_&XS[KTY8$-<6Q*?0_Z]
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MDE80#U6/8_K0O:S1,@]&'*]>Q"Q'=!ZG3%V6X:VEE"=RY%E(Q4,]7),BIXH
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M4#L /2^5LON)VV#X6ZU^ U!+ P04    " !X@EQ6S@G)L H$  !U"0  &0
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M!1? ^U1KU_Q! ^VWN8M_ %!+ P04    " !X@EQ6D-82<E %   ^#   &0
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MBW!"NA#0W$A;,LM2623!6#?$/(1:RPT(>;+0'24!*9 <<+#>9_8SSI, .B<
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MYD\#U\PD"*\WKFZL7!&KN7+]<]GU)I7Q9W$74R8@!WC+%5&G %GGB>+>E"@
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MW=>?@655B 50<0KBJ@$WTB:<'9<NR%BANJ0+.I+B5MCRP'<S$O T"4EC974
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MH73'V;J?OX*PM0Y'R>WCF:1VYN"FQ(F3-2BAFPE=!4591;&"9)P.&)"3R%]
M5>"S>$+)P(5PZ!J*2XA(V])V&8;QV_/?08$8>4;Y)I'$1]2LF\!10(;E2!TZ
M(_:);7RO1(^)<CGK$U$T?W@VI$1$QZ'4ULY<>8&V.%GN)^9'75ADUCF<P\#T
MGL1@,@%V!Y7\Q%9R#: ;>Q-XW$!*T!=4G)J$MO_O&WYFLI$D2]R9C:D!'3//
M'.0:=E)PFK7D^<=)M_/Q2+OR!@_HM;_@$=:$\+B58+ #>MS [6&'9]YV=3TY
MTKH2PG3\DO/9/-:)KH-\=_Z8U$UX-78,F.SZJC<@.<$:"=:M24D)>H@.^=F
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M0,-I/X-P%HDT02[3D06%_[8N__;-D\O%4Z>>'E$M6(EK*/181GX,]Z:O468
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M%&A_:+.=B/=,&\,@Y2(5G"S?RIS50:$ACU"V[) Z]QH-A"H.;.("@5;JHB"
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M"&+4GC!*:2&'>-YP(]A4O@_(VX&'(>&6SPOQC5Y[-D1E3>$?M#7W827GZ63
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M<5FBY*$[#&L3RJ1#UPJ28-7R3A')D3YG$Y>]VW.Q'CRT9+YH(5+6TD!#KT
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MP&GH8:'O"A)*B%<V'\-+[@_GP*8+)672]I9:.'2?!=#.2T7JJIYV.!JD)%3
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MPV.858AVS=_ &F9EGSM><";?Z!U<J@)^OM_5P+YG]7T%C;?]IBWR L3G*OE
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M PL!:=67!-1[P.9YL46?!$&^;@?R* S^W# ]V7=DO\ENAN4HW#TO?(D$I'U
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M\L:3)S]S0%PV*U(9&NYN /9L/R&/HL\^]6,])D]3%!.%>%:>>;\Y)[<AV&X
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M/)' WK4T8*$!VQCQC\XIZJ'C?,IL5Y.Q;H3^I)5/F$-TM.PT\O(/Q+*/GL/
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M>Q9_C!1_E%?":BA,6N79K'T<W+<G=!>--;975V RPL\8Q7!NPN.B!/,*3W_
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M/TO1173K/4:F(*%I202@*%\J:KHP"P#5E WE(WC3C<:NTG\=K-S =1F.4'-
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M.'1R]>M-!J'?;[U ODT[9>N)-U0ZUOQ)P" .;*^\IX,@"<:/S/)_4$L#!!0
M   ( 'B"7%;).Q&L? ,  (8(   9    >&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;*5646_;-A!^]Z\XJ$71 H9ET79B)[8!)UG0 0T0)&GW,.R!ELX6$8KT
M2"JN]^MWI&19:3QWV%Y$GG3?Q_N./)ZF6VV>;8[HX'LAE9U%N7.;BSBV:8X%
MMSV]045?5MH4W)%IUK'=&.19 !4R9OW^65QPH:+Y-+R[-_.I+IT4"N\-V+(H
MN-E=H=3;691$^Q</8IT[_R*>3S=\C8_HOF[N#5EQPY*) I456H'!U2Q:)!=7
M0^\?'+X)W-K6'+R2I=;/WO@UFT5]'Q!*3)UGX#2\X#5*Z8DHC#]KSJA9T@/;
M\SW[;=!.6I;<XK66OXG,Y;-H'$&&*UY*]Z"WG['6,_)\J98V/&%;^_8C2$OK
M=%&#*8)"J&KDW^L\_!L JP$LQ%TM%**\X8[/IT9OP7AO8O.3(#6@*3BA_*8\
M.D-?!>'<_)8+ ]^X+!'ND-O2(&7<6?CXQ)<2[:=I[&@5[QNG->-5Q<C^@3%A
M<*>5RRW\HC+,7A/$%%X3(]O'>,5.,MY@VH-!T@769^P$WZ#1/ A\@Y]KOA$V
ME=K+MO#[8FF=H6/RQS'1%>7P.*4OG0N[X2G.(JH-B^8%H_F'=\E9__)$P,,F
MX.$I]ODCE6)62@2]@ENAN$H%E["P%FFGN,K@B^!+(843)*/>Q@RX@Y927P'P
M@&EIC%!KN.)6V&,Z3T9R7.=3CK#2DNK;,SM_<"!\]0=)J.KF""6XI&L!'+E?
MZV+#U>[#NS%+SB\MK!I5_*!*ME05+54KK^KEH,HTJI9>5< *E8F4.T+ZY22^
MH/39\T8+G@LTW*3Y#DI'*_U%_$Y343LT5&M(5U6:M_SM1><&;6K$)LAYLQ5?
MPC))/;)Z''0^"D4KZ])29/939V&]"CK56"S1-">[4[%TJ'IP1S5NGNE.7I4$
M(36I+*F8: (IMWF0&";O8<BZD\FH/0E999>'6><ND(6-L3Y9(:>=K[W''CR9
MD-D=*.VS-1IW!V>LH7AM_H"@S9$6$G;6[8_&#>0'N_.D'66H.!8!).-A=\CZ
M!^QKN\:^.1SO@;'S[C!YI7J//:@^GN?D/^:9=4>#46O\/UFFX >3^KGG^:GF
M27=R/FR-;P* 8U=-W.H-!9IUZ( 64ETJ5[6)YFW39!=5;SFX5QV:]*V%LE1-
M*X+V>^>C"$S5]2K#Z4WH-$OMJ&^%:4X_"FB\ WU?:5)?&WZ!YM=C_C=02P,$
M%     @ >()<5MK\-R]F P  R0@  !D   !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&ULG59;C]HX%'[G5UAI5<U($4F<P 0*2 S3=BOM2*,RTWU8]<$D![#&
MB:GM#)W]]7OLA QM">WN ^3X7+[O7' .D[U4CWH+8,BW0I1ZZFV-V8V#0&=;
M*)CNRQV4:%E+53"#1[4)]$X!RUU0(0(:AL.@8+ST9A.GNU.SB:R,X"7<*:*K
MHF#J^1J$W$^]R#LH/O'-UEA%,)OLV :68!YV=PI/08N2\P)*S65)%*RGWCP:
M7R?6WSE\YK#71S*QE:RD?+2'C_G4"VU"(" S%H'AXPD6((0%PC2^-IA>2VD#
MC^4#^GM7.]:R8AH64OS%<[.=>JE'<EBS2IA/<O\'-/4,+%XFA7;?9%_[#F./
M9)4VLFB",8."E_63?6OZ<!20AAT!M F@+N^:R&5YPPR;393<$V6]$<T*KE07
MC<GQT@YE:11:.<:9V8+I+6%E3ISP[FO%GYB TFBGO&7J$0Q;"2!+R"K%#0=-
M+NZM1E]. H,96)P@:]BN:S;:P191<BM+L]7D79E#_CU @*FW^=-#_M?T+.(-
M9'T21SZA(:5G\.*V'['#BSOP/I9/H$UA.^"3&U@9UP?;%_-\W(._YRMM%/ZF
MOISJ0LV1G.:P]VRL=RR#J8<728-Z F_VYE4T#-^>J2!I*TC.H<^6]?4B<DW^
MQW!/57.6[W0U<VWY<3A0K$"U W*\*. Q.^3F!/@AM^(E-_W2]#TH()DL=HIK
MR"V#V0)92X&O%EYNQKUY(97A_Z!M(;4A#R6^IX0[?\#WDSY6_"FU1LCWC"OR
MF8D*>A>\1#Q9:4Q 7_:P!&9^+J&WZ$I\7)M>DR@:^@,Z1.G-JY1&].UW4F/M
MX46 YZ90LJZ0DR34'XT&K>_A6:M[]](P<:9O"#T8(73415Q;>[>G>CON/?27
M?7*/_=$5_GI*:<!"#E)_F%A$^[D@- W)9:V.A_2'F!470I.(#GT:7I$$W:-!
MC.Y6$P[2IH#3HT6"-/'3)+7@CBJ)8T=E]0D-.^81_<8\8O1-1[2C+8WUU#RH
M/XA_'H?3_L8TXM@F?M5)ZZS_;1I7?A*/.@"=[1<]_F4\.?4""H[62P%JXY:H
MQHM8E:;>-*VVW=/S>CV]N-=+'JO=V(LH8(VA8?]JX!%5+\[Z8.3.+:N5-+CZ
MG+C%_QJ@K /:UQ);T1PL0?OO9?8O4$L#!!0    ( 'B"7%8.J!C(5@,  -0'
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;(U568_C-@Q^]Z\0W**8
M 8SQG:M)@+EZ +MM,+,'BJ(/BDW'PLJ25Y(G,_WUI>3$FRFRWGVP=9$?/XH4
MN=Q+]4G7 (8\-USHE5\;TR["4!<U-%1?R18$GE12-=3@4NU"W2J@I5-J>)A$
MT21L*!/^>NGV-FJ]E)WA3,!&$=TU#54O-\#E?N7'_G'C@>UJ8S?"];*E.W@$
M\[[=*%R% TK)&A":24$45"O_.E[<Y%;>"7Q@L-<G<V(]V4KYR2Y^+U=^9 D!
MA\)8!(K#$]P"YQ8(:7P^8/J#2:MX.C^B_^)\1U^V5,.MY!]9:>J5/_-)"17M
MN'F0^]_@X(\C6$BNW9_L>]DL\TG1:2.;@S(R:)CH1_I\N(<3A5GT%87DH) X
MWKTAQ_*.&KI>*KDGRDHCFITX5YTVDF/"!N71*#QEJ&?6&X7Q5>:%4%&2^\\=
M:_'&34#^P'RX>$>W'/3E,C1HR<J'Q0'UID=-OH(:)^2M%*;6Y%Z44+X&")'B
MP#,Y\KQ)1A'OH+@B:1R0)$J2$;QT\#MU>.DW_ [(AE-A7KM/_K[>:J,P8_XY
MYWN/G)U'MJ]HH5M:P,K'9Z)!/8&__NF'>!+]/,([&WAG8^CK1WR59<>!R(J,
MQ.X<[5'@\[1?68 O%@1F!]66 \8%FBVH(39.%"<Q*20^76V@M'*F!E))CC6
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MT)^,/-#M^&H-JZIF9"3*T@!JE@5-?-3.@<Z72MF-X1)T_R'Q/U!+ P04
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M[SOYLN$&UZK^3Q2V6@;S  HL>5?;:[7[ P=_,L>7J]KX+^QZVS0.(.^,5<T
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MRFY,CP5*8T#K*R'T;F V:)Z?R1]02P,$%     @ >()<5F3=NT8F!P  U#P
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M<O=['JC7!$H+0&D4BF;NJFB])M=J:,P_A$]Q6J1:+H!EK+VLWCLL0$TG4%H
M2J-0-/,9:$TG%[_Y7,D%]:5 :3XH+0"E42B:*7WK7;EV[^K%N5(3OSTQZ)PJ
MV<OIK1BHYP1*HU"T6K'1UF;,E(F':MML^?_8(E/U3L7-V<W6W(MJ0^K.^0"?
MTGJ#;8NI]_M^",5#G$F4L*5&.L,3/?B*>@MM?:!X7FWYO.=*\;3ZNF*ASOCE
M!?KW)>?J^: L8+.1>?X_4$L#!!0    ( 'B"7%91>-Y#%0,  !X)   9
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MG#5"W\ON!@8]EY8OE0+=EW1][OR;1](&M2P'L*F@Y%4_LN?!AR- </$*(!P
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M5"D/E/Y6@YM@HAF*$43@"P5!Y-\*IA!%"DGR>"Q M?*>*K%^_(+^(2]>%O-
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M6IN#/O;T1P4"*\)6B%K#V0G#-<O0LIBNLDF#P3!*W,V^D8X@W_/;H%<"AZW
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M!YCO;XM"/V[8 K8_IS#[%U!+ P04    " !X@EQ6<^[7A(8,  !.?0  &0
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M77\ITFWULNGKM"C23?7QEK,ES\H5Q-]OTK1X^E)6L'^%^MG_ %!+ P04
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M4PXV2._+PNT>CNU6;.^7YSNF"_C[3Y>Q+Q9K\\]0@+OS+X;/=S7ETC0LQUE
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MR"AY723;][%MM9"T3GLB^162_[HE!DF@7UQ^A]*WAF1DD19EMUU[$38 1A7
MZ*4 >5GBN^E&9Q$<BGO474/.B%A^>PUIW?<<'6S5]=CJB?>8;( ?F7FET7TX
MV[8M'SLM.+WWOG1[:@-KZ;[GLDH6.;H!)F4B@O(3@=8LG$/?[WWIU=O#Q_;
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M80N,_OT=(<FUA$3\J3,X/[]9?[YZ,RY$1GWH&_@H".!+,+S/GVS7^E)GSH'
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M:@&JA:@6H5I,:=W8;5N%TU^_'Y[T+RDL\HO=LKP_FT1Z7QTM?UV53[@0O7A
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M,L_+NR_J#7S+BW_LWY9W_P]02P,$%     @ >()<5JR!9]+U P  Q!0  !D
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MAE[?0PG,Z#+5#V+]$:J"B@1CD:KB/UI78P,/Q4NE1589FPPRQLM?^JUJ1,N
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M5(W0# OUJP*N ]3W)6-R-]$;=#^_]#=02P,$%     @ >()<5ABU7["W @
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ML)7=H^:M!'6RZ)Y6('/<M*U-/]KWS7>F6SP;O]?]M&D*#S)M,_Y)'5BT$JB
MC9+T;F+%Q-O^MKV1K#8MXII)U7":RUQ]$P#7!NKYAC'Y=J-?T']E+/X%4$L#
M!!0    ( 'B"7%;+B88UR0,  #(.   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8Y+GAM;*U7;8_B-A#^*U9ZJNZD._("!-@"$@L]=:6>M%JZUP]5/WB3 :Q+
M[-0V+]=?W[$30CBR[NZ*+V#',\\\S]@>V^.]D-_4!D"30YYQ-?$V6A<WOJ^2
M#>14=40!'$=60N948U>N?55(H*EURC,_"H+8SRGCWG1LO]W+Z5AL=<8XW$NB
MMGE.Y?=;R,1^XH7>\<,#6V^T^>!/QP5=PQ+T8W$OL>?7*"G+@2LF.)&PFGBS
M\&8>]HR#M?C*8*\:;6*D/ GQS73NTHD7&$:00:(-!,6_'<PARPP2\OBG O7J
MF,:QV3ZB?[;B4<P353 7V9\LU9N)-_1("BNZS?2#V/\&E:"^P4M$INPOV9>V
M<>219*NTR"MG9) S7O[30Y6(AD,W>,8AJARB'QPP,^T.W<JA:X66S*RL!=5T
M.I9B3Z2Q1C33L+FQWJB&<3.-2RUQE*&?GM[Q1.1 _J '4.03F:4I,^FE&;GC
MY2(QR7Z_ $U9ICZ@R>-R0=Z_^S#V-88W('Y2A;HM0T7/A HC\D5PO5'D5YY"
M>@[@(^^:?'0D?QLY$1>0=$@W_$BB((I:",U?[AXZZ'3K7'8M7O<EN?SK=QPE
M=QIR]7=;KDJH7CN4V;PWJJ )3#S<G0KD#KSISS^%<?!+F\XK@9VI[M6J>R[T
MHVI-#R032H%J4UM"]"V$J2R[:=@?]H,P"(*QOVM*<09[HY1^+:7OE+),&'#-
M5@R-$9S*9$,H3PD<"I"F>&G<%RGLL/@5IF<'..Z8K6R778:+&[+[O3@(+E4[
M>;U1=5RKCO]G G>@M-5C)C&1@(I:Y<07<H:CN'>IQAGOC6H&M9J!4\T"5B!1
M@MF&9(;K4:N/Y"O-MF4EFV5X<%&>0)N^P86^T2#HM4S7X&(YQU$<Q$W#,_+#
MFOSP]>1->VXGA<RIE-^Q+.^I3''DH5JD;5J&%Q1_%#&\4!L.!OUG-8QJ#2.G
M!D,7#A3/*IOQ-FYN@"@(!UB2PZ'Y&9GB'-@*_6R5=\*]<;F%P>D #9QT'[F$
M1*PY^Q?GS6R@0BA[AK9NH0K,-2^52=QJ<DZR<<J'3I*S))%;Y,>X!DR")D(2
M+%TTTZR]<E5X3I[ABWE&)YZ1.YF=98>L( 6)E=:47J6IAO-JW"C K<R=$5Y[
MLEX+[3P?IQM%>,4K17C5.\6UT,Z5GVX5H?M:<<52Z([TZKRTW&6&YV=Z*=EO
MW,ISD&O[6%$D$5NNRPMZ_;5^$,WL,\ _F9>OJ2]4KAE7)(,5N@:= 4:7Y0.E
M[&A1V#O^D]#X8K#-#3[J0!H#'%\)H8\=$Z!^)D[_ U!+ P04    " !X@EQ6
MD[AU(J("   \!P  &0   'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6R%E5UO
MFS 4AO^*Q:JIE;8")GQU!*EI-JW2*D5-NUU,NW#@)%@%F]DFR?[];$AHMM#D
M!OSUOL\Y!A\G&RY>9 &@T+8JF1Q;A5+UC6W+K("*R&M> ],S2RXJHG17K&Q9
M"R!Y*ZI*&SM.8%>$,BM-VK&92!/>J)(RF DDFZHBXL\$2KX96ZZU'WBDJT*9
M 3M-:K*".:CG>B9TS^Y=<EH!DY0S)& YMF[=FXGK&$&[XCN%C3QH(Y/*@O,7
MT[G/QY9C(H(2,F4LB'ZMX0[*TCCI.'[O3*V>:82'[;W[ES9YG<R"2+CCY0^:
MJV)L11;*84F:4CWRS5?8)>0;OXR7LGVB3;<V\"V4-5+Q:B?6$524=6^RW6W$
M@0#C-P1X)\!MW!VHC7)*%$D3P3=(F-7:S33:5%NU#HXR\U7F2NA9JG4JO6<9
MKP ]D2U(]!'-NX^#^!)]XU+JL<_;F@I EU-0A);R"ET@RM!3P1M)6"X36^DH
MC)>=[8B3CHC?(+H8/7"F"FW-<LC_-;!U^'T.>)_#!)]TG$)VC3SW \(.QNAY
M/D67%U<G?+U^;[S6USN[-VA*959RV>B=^'F[D$KHO^G74.Z=XVC8T1RQ&UF3
M#,:6/D,2Q!JL]/T[-W ^G8AWU,<[.N6>8F>$AV+J5'ZK,J=TG8Y\',:)O1Z
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M(9V+/E:KJ'J?:J!X8=J')5?8C)C/!-M%$-H UV/.U7:@-V@:T. W4$L#!!0
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M(X@%93'BL)YJ]_AN9N8)><0_%+9B[QIE5%:,/6<WG_VI9F0500B>S""(^MK
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M+E#W-XS)AXV>/9I1,_@'4$L#!!0    ( 'B"7%9$VYC6TP(  (8*   9
M>&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;+56T6Z;,!3]%8M54RNMA4 (H4N0
MVD3K*G5:U2S;P[0'!VZ"5;"9[23MW\\VA(6&1JV4O"0VW',XY_B"[F#-^*-(
M 21ZRC,JAE8J97%IVR).(<?B@A5 U9TYXSF6:LL7MB@XX,2 \LQV':=GYYA0
M*QJ8:_<\&K"ES B%>X[$,L\Q?[Z&C*V'5L?:7'@@BU3J"W8T*/ ")B"GQ3U7
M.[MF24@.5!!&$8?YT+KJ7(Y"76\*?A)8BZTUTDYFC#WJS6TRM!PM"#*(I6;
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M4$L! A0#%     @ >()<5A4K<$0/ P  N H  !@              ("!AQ<
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( 'B"7%:ZL:33
M/@4  &L4   8              " @<P:  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " !X@EQ6-/1FM8<'  "!2   &
M@(% (   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ >()<
M5AI% Q4] @  O00  !@              ("!_2<  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( 'B"7%:-XCZS:0@  ,0D   8
M      " @7 J  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" !X@EQ68%PQ@/T&  # $   &               @($/,P  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ >()<5OY,#A [*   -X8  !@
M             ("!0CH  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( 'B"7%;B)96:0P0  (0*   9              " @;-B  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ >()<5IX7\B(C!0
MJ@T  !D              ("!+6<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " !X@EQ6X[DZ;B\#   I!P  &0              @(&'
M;   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( 'B"7%8*
M9U=VX@(  +D&   9              " @>UO  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ >()<5LX)R; *!   =0D  !D
M     ("!!G,  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'B"7%;!#-%=/AL  .=E   9              "
M@>:4  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ >()<
M5B,[X7P'"P  IAP  !D              ("!6[   'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " !X@EQ6E#3DTA8$   1"@  &0
M        @(&9NP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( 'B"7%8ER,X)[0(  +\&   9              " @>:_  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ >()<5ATF)+%W"   FQ0
M !D              ("!"L,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " !X@EQ67X8!Q3$%   L#   &0              @(&XRP
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( 'B"7%9_1QN+
M8P,  )\'   9              " @2#1  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ >()<5CY6(?3.+0  W*(  !D
M ("!NM0  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !X
M@EQ6^PM[%NX"  !P!@  &0              @(&_ @$ >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( 'B"7%;).Q&L? ,  (8(   9
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M970S,BYX;6Q02P$"% ,4    " !X@EQ6I8.L9CH%  #9#0  &0
M    @($B& $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M 'B"7%;;UMSM; ,  *,*   9              " @9,= 0!X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ >()<5OWDZM>*!@  F1$  !D
M             ("!-B$! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " !X@EQ6MC"S8>,#  !,"0  &0              @('W)P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( 'B"7%8:'+@2Z0(
M $\&   9              " @1$L 0!X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ >()<5FVL3-9$ P  XP8  !D              ("!
M,2\! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !X@EQ6
MT](](.L"  "*!@  &0              @(&L,@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( 'B"7%9DW;M&)@<  -0\   9
M      " @<XU 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ >()<5E%XWD,5 P  '@D  !D              ("!*ST! 'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !X@EQ6<?>U%!,#  #D"P
M&0              @(%W0 $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( 'B"7%8( #9=804  (TG   9              " @<%# 0!X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ >()<5M!NDRDP
M @  (@4  !D              ("!64D! 'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " !X@EQ6W5*6UP\%  "!'@  &0
M@(' 2P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( 'B"
M7%;KA+A&,0,  ,P(   9              " @091 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ >()<5ITSANB, P  -Q$  !D
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M=#4Q+GAM;%!+ 0(4 Q0    ( 'B"7%:DC3>ZH (  '4'   9
M  " @?-H 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
M>()<5@["UV'^ @  / @  !D              ("!RFL! 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " !X@EQ6G[BO1X,"  ![!@  &0
M            @('_;@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( 'B"7%;/Y;(O,@(  /($   9              " @;EQ 0!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ >()<5K3]<3D-!P
M6D$  !D              ("!(G0! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    " !X@EQ6<^[7A(8,  !.?0  &0              @(%F
M>P$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( 'B"7%;^
M(<9.%P,  %8(   9              " @2.( 0!X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ >()<5DWZO#0D P  = @  !D
M     ("!<8L! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'B"7%9Z]2CKY!@  $?2 0 9              "
M@;:= 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ >()<
M5JR!9]+U P  Q!0  !D              ("!T;8! 'AL+W=O<FMS:&5E=',O
M<VAE970V-2YX;6Q02P$"% ,4    " !X@EQ6,J;'1:L"   (!P  &0
M        @(']N@$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0
M   ( 'B"7%88M5^PMP(  # '   9              " @=^] 0!X;"]W;W)K
M<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ >()<5KD;WP#V P  <0P
M !D              ("!S< ! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q0
M2P$"% ,4    " !X@EQ6RXF&-<D#   R#@  &0              @('ZQ $
M>&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( 'B"7%:3N'4B
MH@(  #P'   9              " @?K( 0!X;"]W;W)K<VAE971S+W-H965T
M-S N>&UL4$L! A0#%     @ >()<5M\9S$^+ @  )@<  !D
M ("!T\L! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " !X
M@EQ69_ZN;$H$  "K#@  &0              @(&5S@$ >&PO=V]R:W-H965T
M<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( 'B"7%8S50I:+ ,  .@)   9
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M970W-RYX;6Q02P$"% ,4    " !X@EQ6%7O:A_P#  #/%   &0
M    @($2XP$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    (
M 'B"7%:L@< .<@(  &<%   9              " @47G 0!X;"]W;W)K<VAE
M971S+W-H965T-SDN>&UL4$L! A0#%     @ >()<5G>*X\3. @  =@H  !D
M             ("![ND! 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"
M% ,4    " !X@EQ61-N8UM,"  "&"@  &0              @('S[ $ >&PO
M=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( 'B"7%9,<)/IW0(
M %()   9              " @?WO 0!X;"]W;W)K<VAE971S+W-H965T.#(N
M>&UL4$L! A0#%     @ >()<5M*-E913 P  S!0   T              ( !
M$?,! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !X@EQ6EXJ[',     3 @
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8;6Q02P4&     %H 6@"M&   H0("

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>199</ContextCount>
  <ElementCount>394</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>76</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Organization and Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness</Role>
      <ShortName>Organization and Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Cash and Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecurities</Role>
      <ShortName>Cash and Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquity1</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Employee Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureEmployeeSavingsPlan</Role>
      <ShortName>Employee Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborations</Role>
      <ShortName>Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Government Assistance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGovernmentAssistance</Role>
      <ShortName>Government Assistance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Currency Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRisk</Role>
      <ShortName>Currency Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformation</Role>
      <ShortName>Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Cash and Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash and Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecurities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100380 - Disclosure -  Collaborations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsTables</Role>
      <ShortName>Collaborations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Currency Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskTables</Role>
      <ShortName>Currency Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRisk</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationTables</Role>
      <ShortName>Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Organization and Nature of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Nature of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Cash and Cash Equivalents and Marketable Securities - Summary of Cash and Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails</Role>
      <ShortName>Cash and Cash Equivalents and Marketable Securities - Summary of Cash and Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Cash and Cash Equivalents and Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Cash and Cash Equivalents and Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Property and Equipment, Net - Schedule of Depreciation Expense Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Depreciation Expense Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100540 - Disclosure - License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Leases - Summary of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails</Role>
      <ShortName>Leases - Summary of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Leases - Summary of Other Operating Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherOperatingLeaseInformationDetails</Role>
      <ShortName>Leases - Summary of Other Operating Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Leases - Summary of Future Minimum Lease Payments under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Convertible Preferred Shares - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Shares - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Shareholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Shareholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Share-Based Compensation - Schedule of Assumptions used to Determine Grant Date Fair Value under ESPP Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Assumptions used to Determine Grant Date Fair Value under ESPP Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Share-Based Compensation - Schedule of Fair Value of Stock Options Determined on Grant Date Using Black Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Fair Value of Stock Options Determined on Grant Date Using Black Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Share-Based Compensation - Schedule of Share Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense for All Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-based Compensation Expense for All Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Type of Award (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-based Compensation Expense by Type of Award (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Employee Savings Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureEmployeeSavingsPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Savings Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Collaborations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails</Role>
      <ShortName>Collaborations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Collaborations - Schedule of Transaction Price Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails</Role>
      <ShortName>Collaborations - Schedule of Transaction Price Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Income Taxes - Summary of Loss Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Loss Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Income Taxes - Summary of provision for income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of provision for income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Income Taxes - Summary of Reconciliation of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Income Taxes - Summary of Losses Expire (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails</Role>
      <ShortName>Income Taxes - Summary of Losses Expire (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Income Taxes - Summary of Investment Tax Credits Expire (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails</Role>
      <ShortName>Income Taxes - Summary of Investment Tax Credits Expire (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Income Taxes - Summary of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100790 - Disclosure - Net Loss per Share - Computation of Diluted Net Loss Per Share in Attributable to Common Shareholders Indicate to Anti Diluted Effect (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails</Role>
      <ShortName>Net Loss per Share - Computation of Diluted Net Loss Per Share in Attributable to Common Shareholders Indicate to Anti Diluted Effect (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100800 - Disclosure - Government Assistance - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGovernmentAssistanceAdditionalInformationDetails</Role>
      <ShortName>Government Assistance - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>100810 - Disclosure - Commitments and Contingencies - Schedule of Commitments to Settle Contractual Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Commitments to Settle Contractual Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>100820 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>100830 - Disclosure - Currency Risk - Schedule of Financial Position Exposure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails</Role>
      <ShortName>Currency Risk - Schedule of Financial Position Exposure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>100840 - Disclosure - Currency Risk - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskAdditionalInformationDetails</Role>
      <ShortName>Currency Risk - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>100860 - Disclosure - Geographic Information - Schedule of Property and Equipment, Net by Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails</Role>
      <ShortName>Geographic Information - Schedule of Property and Equipment, Net by Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>100870 - Disclosure - Geographic Information - Schedule of Right-of-Use Assets by Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails</Role>
      <ShortName>Geographic Information - Schedule of Right-of-Use Assets by Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="rptx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>100880 - Disclosure - Geographic Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails</Role>
      <ShortName>Geographic Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityIncorporationStateCountryCode, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  rptx-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="rptx-20221231.htm">rptx-20221231.htm</File>
    <File>rptx-20221231.xsd</File>
    <File>rptx-20221231_cal.xml</File>
    <File>rptx-20221231_def.xml</File>
    <File>rptx-20221231_lab.xml</File>
    <File>rptx-20221231_pre.xml</File>
    <File>rptx-ex10_31.htm</File>
    <File>rptx-ex10_32.htm</File>
    <File>rptx-ex10_33.htm</File>
    <File>rptx-ex23_1.htm</File>
    <File>rptx-ex31_1.htm</File>
    <File>rptx-ex31_2.htm</File>
    <File>rptx-ex32_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img192321128_0.jpg</File>
    <File>img192321128_1.jpg</File>
    <File>img192321128_10.jpg</File>
    <File>img192321128_11.jpg</File>
    <File>img192321128_12.jpg</File>
    <File>img192321128_13.jpg</File>
    <File>img192321128_14.jpg</File>
    <File>img192321128_15.jpg</File>
    <File>img192321128_16.jpg</File>
    <File>img192321128_17.jpg</File>
    <File>img192321128_18.jpg</File>
    <File>img192321128_19.jpg</File>
    <File>img192321128_2.jpg</File>
    <File>img192321128_20.jpg</File>
    <File>img192321128_21.jpg</File>
    <File>img192321128_22.jpg</File>
    <File>img192321128_3.jpg</File>
    <File>img192321128_4.jpg</File>
    <File>img192321128_5.jpg</File>
    <File>img192321128_6.jpg</File>
    <File>img192321128_7.jpg</File>
    <File>img192321128_8.jpg</File>
    <File>img192321128_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="684">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>126
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rptx-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 684,
    "http://xbrl.sec.gov/dei/2022": 40
   },
   "contextCount": 199,
   "dts": {
    "calculationLink": {
     "local": [
      "rptx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rptx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "rptx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rptx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rptx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rptx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 667,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 8,
    "http://www.reparerx.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 15
   },
   "keyCustom": 83,
   "keyStandard": 311,
   "memberCustom": 38,
   "memberStandard": 35,
   "nsprefix": "rptx",
   "nsuri": "http://www.reparerx.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Cash and Cash Equivalents and Marketable Securities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecurities",
     "shortName": "Cash and Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rptx:LicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - License Agreements",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rptx:LicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Shareholders' Equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquity1",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Share-Based Compensation",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Employee Savings Plan",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureEmployeeSavingsPlan",
     "shortName": "Employee Savings Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Collaborations",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborations",
     "shortName": "Collaborations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Net Loss per Share",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Government Assistance",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGovernmentAssistance",
     "shortName": "Government Assistance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Currency Risk",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRisk",
     "shortName": "Currency Risk",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Geographic Information",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformation",
     "shortName": "Geographic Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "26",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rptx:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rptx:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Cash and Cash Equivalents and Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesTables",
     "shortName": "Cash and Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rptx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rptx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Share-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_ceb724a0-d094-4e75-ad7c-5458548dadc5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure -  Collaborations (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsTables",
     "shortName": "Collaborations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_ceb724a0-d094-4e75-ad7c-5458548dadc5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Net Loss per Share (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ForeignCurrencyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rptx:ScheduleOfFinancialPositionExposureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Currency Risk (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskTables",
     "shortName": "Currency Risk (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ForeignCurrencyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rptx:ScheduleOfFinancialPositionExposureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Geographic Information (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationTables",
     "shortName": "Geographic Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rptx:RevenueFromCollaborationAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rptx:RevenueFromCollaborationAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Organization and Nature of Business - Additional Information (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
     "shortName": "Organization and Nature of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rptx:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_d02b1f3e-16d6-4441-958a-8ba01e196c61",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rptx:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_d02b1f3e-16d6-4441-958a-8ba01e196c61",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_baf42153-e67f-4dc2-ba51-e440db83cb6e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_baf42153-e67f-4dc2-ba51-e440db83cb6e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "rptx:FairValueAssetsTransfersBetweenAllLevels",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "rptx:FairValueAssetsTransfersBetweenAllLevels",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_51a377d0-935c-4a85-8c6a-d896a70f1212",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Cash and Cash Equivalents and Marketable Securities - Summary of Cash and Cash Equivalents and Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails",
     "shortName": "Cash and Cash Equivalents and Marketable Securities - Summary of Cash and Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_51a377d0-935c-4a85-8c6a-d896a70f1212",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Positions",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Cash and Cash Equivalents and Marketable Securities - Additional Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Cash and Cash Equivalents and Marketable Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Positions",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Property and Equipment, Net - Schedule of Depreciation Expense Recognized (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails",
     "shortName": "Property and Equipment, Net - Schedule of Depreciation Expense Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rptx:ScheduleOfDepreciationExpenseTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_afaac43e-017a-44ba-b75d-7ea6a3b4e368",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rptx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rptx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_179763b9-efbc-464b-afa5-88c1837ed3e7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Shareholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_179763b9-efbc-464b-afa5-88c1837ed3e7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "rptx:LicenseAgreementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_2885b753-de7f-4392-894e-f84483b20968",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "rptx:LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - License Agreements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail",
     "shortName": "License Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "rptx:LicenseAgreementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_2885b753-de7f-4392-894e-f84483b20968",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "rptx:LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "rptx:NumberOfOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Lease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "rptx:NumberOfOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Lease",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Leases - Summary of Lease Costs (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails",
     "shortName": "Leases - Summary of Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rptx:SummaryOfOtherOperatingLeaseInformationTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Leases - Summary of Other Operating Lease Information (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherOperatingLeaseInformationDetails",
     "shortName": "Leases - Summary of Other Operating Lease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rptx:SummaryOfOtherOperatingLeaseInformationTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Leases - Summary of Future Minimum Lease Payments under Operating Leases (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails",
     "shortName": "Leases - Summary of Future Minimum Lease Payments under Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_47bbe3ab-c619-4531-a810-632c68de1388",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Convertible Preferred Shares - Additional Information (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
     "shortName": "Convertible Preferred Shares - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Shareholders' Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
     "shortName": "Shareholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Share-Based Compensation - Schedule of Assumptions used to Determine Grant Date Fair Value under ESPP Offering (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails",
     "shortName": "Share-Based Compensation - Schedule of Assumptions used to Determine Grant Date Fair Value under ESPP Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_fd5b4481-aa50-4b83-9f43-0d4f67b640f0",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Share-Based Compensation - Schedule of Fair Value of Stock Options Determined on Grant Date Using Black Scholes Option-Pricing Model (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails",
     "shortName": "Share-Based Compensation - Schedule of Fair Value of Stock Options Determined on Grant Date Using Black Scholes Option-Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_a7cd030b-efbe-4cd0-a62b-2f8cc6a4315a",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_29efdcd1-f366-4daf-8b98-5eaef0a24f0d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_29efdcd1-f366-4daf-8b98-5eaef0a24f0d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_fc09d0a9-5789-4d3e-b55d-437b9fe4fe10",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Share-Based Compensation - Schedule of Share Option Activity (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails",
     "shortName": "Share-Based Compensation - Schedule of Share Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense for All Awards (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails",
     "shortName": "Share-Based Compensation - Schedule of Share-based Compensation Expense for All Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_afaac43e-017a-44ba-b75d-7ea6a3b4e368",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Type of Award (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails",
     "shortName": "Share-Based Compensation - Schedule of Share-based Compensation Expense by Type of Award (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_19ce3969-55ed-4e30-9462-0263222e2f93",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_570d5b98-d1b3-467c-8957-e622df2b9b75",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "rptx:DefinedContributionPlanEmployerNonMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Employee Savings Plan - Additional Information (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureEmployeeSavingsPlanAdditionalInformationDetails",
     "shortName": "Employee Savings Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_570d5b98-d1b3-467c-8957-e622df2b9b75",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "rptx:DefinedContributionPlanEmployerNonMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_ba8a8b55-bc32-45e4-ac52-b062d5026bf6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Collaborations - Additional Information (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
     "shortName": "Collaborations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_bfafee29-fc89-418f-885a-bdf98c97ba34",
      "decimals": null,
      "lang": "en-US",
      "name": "rptx:CollaborationTermExtendedPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_86d0da1c-aaaa-4a1a-982b-05aa91d37fd6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Collaborations - Schedule of Transaction Price Performance Obligations (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails",
     "shortName": "Collaborations - Schedule of Transaction Price Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_8f5ce4e2-c290-41fd-9af5-5d0fb88c397e",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Income Taxes - Summary of Loss Before Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Summary of Loss Before Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Income Taxes - Summary of provision for income taxes (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Summary of provision for income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Income Taxes - Summary of Reconciliation of Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Summary of Reconciliation of Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rptx:IncomeTaxLosses",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-5",
      "lang": null,
      "name": "rptx:ScientificResearchAndExperimentalDevelopmentExpenditures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rptx:IncomeTaxLossesExpireOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Income Taxes - Summary of Losses Expire (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails",
     "shortName": "Income Taxes - Summary of Losses Expire (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rptx:IncomeTaxLossesExpireOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rptx:InvestmentTaxCreditsExpireOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Income Taxes - Summary of Investment Tax Credits Expire (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails",
     "shortName": "Income Taxes - Summary of Investment Tax Credits Expire (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rptx:InvestmentTaxCreditsExpireOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100770 - Disclosure - Income Taxes - Summary of Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Summary of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100780 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_678241cd-18bd-45e5-b0fa-05a4f27297f3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100790 - Disclosure - Net Loss per Share - Computation of Diluted Net Loss Per Share in Attributable to Common Shareholders Indicate to Anti Diluted Effect (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails",
     "shortName": "Net Loss per Share - Computation of Diluted Net Loss Per Share in Attributable to Common Shareholders Indicate to Anti Diluted Effect (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_678241cd-18bd-45e5-b0fa-05a4f27297f3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "rptx:IncreaseDecreaseInResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100800 - Disclosure - Government Assistance - Additional Information (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGovernmentAssistanceAdditionalInformationDetails",
     "shortName": "Government Assistance - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "rptx:IncreaseDecreaseInResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100810 - Disclosure - Commitments and Contingencies - Schedule of Commitments to Settle Contractual Obligations (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails",
     "shortName": "Commitments and Contingencies - Schedule of Commitments to Settle Contractual Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_75c9b122-048e-43f5-a14f-971257b2c683",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermPurchaseCommitmentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100820 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_75c9b122-048e-43f5-a14f-971257b2c683",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermPurchaseCommitmentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rptx:ScheduleOfFinancialPositionExposureTableTextBlock",
       "div",
       "us-gaap:ForeignCurrencyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_CAD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100830 - Disclosure - Currency Risk - Schedule of Financial Position Exposure (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails",
     "shortName": "Currency Risk - Schedule of Financial Position Exposure (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rptx:ScheduleOfFinancialPositionExposureTableTextBlock",
       "div",
       "us-gaap:ForeignCurrencyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_CAD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ForeignCurrencyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "rptx:PercentageOfDepreciationUSDAgainstCanadianDollar",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100840 - Disclosure - Currency Risk - Additional Information (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskAdditionalInformationDetails",
     "shortName": "Currency Risk - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ForeignCurrencyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "rptx:PercentageOfDepreciationUSDAgainstCanadianDollar",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Organization and Nature of Business",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness",
     "shortName": "Organization and Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100860 - Disclosure - Geographic Information - Schedule of Property and Equipment, Net by Location (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails",
     "shortName": "Geographic Information - Schedule of Property and Equipment, Net by Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_9422e8ce-7702-44be-86dc-e5ed61056018",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_b7faa4ad-4e00-4b68-bcb9-79815e1dcac6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100870 - Disclosure - Geographic Information - Schedule of Right-of-Use Assets by Location (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails",
     "shortName": "Geographic Information - Schedule of Right-of-Use Assets by Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_9422e8ce-7702-44be-86dc-e5ed61056018",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_5bca2e86-6a57-4346-8aee-8fb3b26b2aca",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100880 - Disclosure - Geographic Information - Additional Information (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails",
     "shortName": "Geographic Information - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_5bca2e86-6a57-4346-8aee-8fb3b26b2aca",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "rptx-20221231.htm",
      "contextRef": "C_007402c7-e8a5-42b8-ac4a-63efb2891fe0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 76,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SWITZERLAND",
        "terseLabel": "Switzerland"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsTables",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Entity incorporation, date of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsTables",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "rptx_AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts payable and accrued expense and other current liabilities.",
        "label": "Accounts Payable And Accrued Expense and Other Current Liabilities [Member]",
        "terseLabel": "Accounts Payable and Accrued Expense and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpenseAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_AccrualPotentialMilestoneAndRoyaltyPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrual potential milestone and royalty payments.",
        "label": "Accrual Potential Milestone And Royalty Payments",
        "verboseLabel": "Accrual of potential future milestone or royalty payment"
       }
      }
     },
     "localname": "AccrualPotentialMilestoneAndRoyaltyPayments",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued and prepaid research and development expenses.",
        "label": "Accrued and Prepaid Research and Development Expenses [Policy Text Block]",
        "terseLabel": "Accrued and Prepaid Research and Development Expenses"
       }
      }
     },
     "localname": "AccruedAndPrepaidResearchAndDevelopmentExpensesPolicyTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_AccruedExpenseAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expense and other current liabilities.",
        "label": "Accrued Expense And Other Current Liabilities [Member]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedExpenseAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_AccruedExpensesAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other liabilities current",
        "label": "Accrued Expenses And Other Liabilities Current",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherLiabilitiesCurrent",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_AccruedPropertyAndEquipmentPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "rptx_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued property and equipment purchases.",
        "label": "Accrued Property and Equipment Purchases",
        "terseLabel": "Accrued property and equipment purchases"
       }
      }
     },
     "localname": "AccruedPropertyAndEquipmentPurchases",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "rptx_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Accrued research and development expense"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_AdditionalClinicalDevelopmentPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Clinical Development Plan [Member]",
        "label": "Additional Clinical Development Plan [Member]",
        "terseLabel": "Additional Clinical Development Plan"
       }
      }
     },
     "localname": "AdditionalClinicalDevelopmentPlanMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional paid in capital share-based payment arrangement exercised options credited to common shares.",
        "label": "Additional Paid In Capital Share Based Payment Arrangement Exercised Options Credited To Common Shares",
        "terseLabel": "Decrease in additional paid-in capital as exercised options credited to common shares"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_AffiliateOfBristolMyersSquibbCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliate of Bristol Myers Squibb Company.",
        "label": "Affiliate of Bristol Myers Squibb Company [Member]",
        "terseLabel": "Affiliate of Bristol Myers Squibb"
       }
      }
     },
     "localname": "AffiliateOfBristolMyersSquibbCompanyMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in number of shares available for issuance as percentage on outstanding shares of common stock on final day of preceding calendar year.",
        "label": "Annual Increase In Number Of Shares Available For Issuance As Percentage On Outstanding Shares Of Common Stock On Final Day Of Preceding Calendar Year",
        "terseLabel": "Annual increase in number of shares available for issuance as percentage of outstanding shares common stock on final day of preceding calendar year"
       }
      }
     },
     "localname": "AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfPrecedingCalendarYear",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rptx_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in number of shares available for issuance maximum number of common stock issued.",
        "label": "Annual Increase In Number Of Shares Available For Issuance Maximum Number Of Common Stock Issued",
        "terseLabel": "Annual increase in number of shares available for issuance maximum number of common stock issued"
       }
      }
     },
     "localname": "AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rptx_BristolMyersSquibbCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb Company.",
        "label": "Bristol Myers Squibb Company [Member]",
        "terseLabel": "Bristol-Myers Squibb Company",
        "verboseLabel": "Affiliate of Bristol Myers Squibb"
       }
      }
     },
     "localname": "BristolMyersSquibbCompanyMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_BroadInstituteIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Broad institute, inc.",
        "label": "Broad Institute, Inc. [Member]",
        "terseLabel": "Broad Institute, Inc."
       }
      }
     },
     "localname": "BroadInstituteIncMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_COVID19PandemicPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID19 pandemic.",
        "label": "C O V I D19 Pandemic Policy [Text Block]",
        "terseLabel": "COVID-19 Pandemic"
       }
      }
     },
     "localname": "COVID19PandemicPolicyTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_ChangeInFairValueOfPreferredStockTrancheObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of preferred stock tranche obligation.",
        "label": "Change In Fair Value Of Preferred Stock Tranche Obligation",
        "terseLabel": "Change in fair value of Series A Preferred Shares tranche obligation"
       }
      }
     },
     "localname": "ChangeInFairValueOfPreferredStockTrancheObligation",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_ClinicalTrialMaterialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Trial Materials [Member]",
        "label": "Clinical Trial Materials [Member]",
        "terseLabel": "Clinical Trial Materials"
       }
      }
     },
     "localname": "ClinicalTrialMaterialsMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_CollaborationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration receivable.",
        "label": "Collaboration Receivable",
        "terseLabel": "Collaboration receivable"
       }
      }
     },
     "localname": "CollaborationReceivable",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_CollaborationRevenuePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Revenue Payment Receivable",
        "label": "Collaboration Revenue Payment Receivable",
        "terseLabel": "Collaboration revenue payment receivable"
       }
      }
     },
     "localname": "CollaborationRevenuePaymentReceivable",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_CollaborationRevenueReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Revenue received.",
        "label": "Collaboration Revenue Received",
        "terseLabel": "Collaboration Revenue Received"
       }
      }
     },
     "localname": "CollaborationRevenueReceived",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_CollaborationTermExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration term expiration period.",
        "label": "Collaboration Term Expiration Period",
        "terseLabel": "Collaboration term expiration period"
       }
      }
     },
     "localname": "CollaborationTermExpirationPeriod",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rptx_CollaborationTermExtendedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration term extended period.",
        "label": "Collaboration Term Extended Period",
        "terseLabel": "Collaboration term extended period"
       }
      }
     },
     "localname": "CollaborationTermExtendedPeriod",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rptx_CombinedLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined Licenses [Member]",
        "label": "Combined Licenses [Member]",
        "terseLabel": "Combined Licenses"
       }
      }
     },
     "localname": "CombinedLicensesMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_CommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestones.",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones"
       }
      }
     },
     "localname": "CommercialMilestonesMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_CommitmentsAndContingenciesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments And Contingencies Disclosure [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rptx_CommitmentsAndContingenciesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rptx_CommonStockCapitalSharesInitiallyReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock capital shares initially reserved for future issuance.",
        "label": "Common Stock Capital Shares Initially Reserved For Future Issuance",
        "terseLabel": "Shares of common stock initially reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesInitiallyReservedForFutureIssuance",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rptx_CompletionOfContinuingTrialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Completion of Continuing Trials [Member]",
        "label": "Completion of Continuing Trials [Member]",
        "terseLabel": "Completion of Continuing Trials"
       }
      }
     },
     "localname": "CompletionOfContinuingTrialsMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_ContractualObligationAmountPerYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation amount per year.",
        "label": "Contractual Obligation Amount Per Year",
        "terseLabel": "Contractual obligation per year"
       }
      }
     },
     "localname": "ContractualObligationAmountPerYear",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_ContractualObligationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation period.",
        "label": "Contractual Obligation Period",
        "terseLabel": "Contractual obligation period"
       }
      }
     },
     "localname": "ContractualObligationPeriod",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rptx_ContractualObligationsPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligations paid.",
        "label": "Contractual Obligations Paid"
       }
      }
     },
     "localname": "ContractualObligationsPaid",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_ConvertiblePreferredSharesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred shares disclosure.",
        "label": "Convertible Preferred Shares Disclosure [Text Block]",
        "terseLabel": "Convertible Preferred Shares"
       }
      }
     },
     "localname": "ConvertiblePreferredSharesDisclosureTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredShares"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_DeferredTaxAssetsNetFederalInvestmentTaxCredits": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets net federal investment tax credits.",
        "label": "Deferred Tax Assets Net Federal Investment Tax Credits",
        "terseLabel": "Net federal investment tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetFederalInvestmentTaxCredits",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_DeferredTaxAssetsOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease right-of-use assets.",
        "label": "Deferred Tax Assets Operating Lease Right Of Use Assets",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_DeferredTaxAssetsShareBasedCompensationCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets share based compensation cost.",
        "label": "Deferred Tax Assets Share Based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsShareBasedCompensationCost",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities accrued expense and other liabilities.",
        "label": "Deferred Tax Liabilities Accrued Expense And Other Liabilities",
        "terseLabel": "Accrued expense and other liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAccruedExpenseAndOtherLiabilities",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_DeferredTaxLiabilitiesOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities operating lease liability.",
        "label": "Deferred Tax Liabilities Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseLiability",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_DefinedContributionPlanEmployerNonMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan employer non matching contribution percent.",
        "label": "Defined Contribution Plan Employer Non Matching Contribution Percent",
        "terseLabel": "Percentage of non-matching employer contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerNonMatchingContributionPercent",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureEmployeeSavingsPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period of completion of trials to get revenue.",
        "label": "Estimated Period of Completion of Trials To Get Revenue",
        "terseLabel": "Estimated period of completion of trials to get revenue"
       }
      }
     },
     "localname": "EstimatedPeriodOfCompletionOfTrialsToGetRevenue",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rptx_EstimatedSharesIssuableUnderTheEsppMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated shares issuable under the ESPP.",
        "label": "Estimated Shares Issuable Under the ESPP [Member]",
        "terseLabel": "Estimated shares issuable under the ESPP"
       }
      }
     },
     "localname": "EstimatedSharesIssuableUnderTheEsppMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share as minimum percentage of fair value of common share.",
        "label": "Exercise Price Per Share As Minimum Percentage Of Fair Value Of Common Share",
        "terseLabel": "Exercise price per share as minimum percentage of fair value of common share"
       }
      }
     },
     "localname": "ExercisePricePerShareAsMinimumPercentageOfFairValueOfCommonShare",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rptx_FairValueAssetsTransfersBetweenAllLevels": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, assets, transfers between all levels.",
        "label": "Fair Value Assets Transfers Between All Levels",
        "terseLabel": "Fair value, assets, transfers between levels"
       }
      }
     },
     "localname": "FairValueAssetsTransfersBetweenAllLevels",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_FairValueOfVestedOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of vested options",
        "label": "Fair Value Of Vested Options",
        "terseLabel": "Fair value of options vested"
       }
      }
     },
     "localname": "FairValueOfVestedOptions",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_FirstTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First tranche.",
        "label": "First Tranche [Member]",
        "terseLabel": "First Tranche"
       }
      }
     },
     "localname": "FirstTrancheMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_FollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-on offering.",
        "label": "Follow On Offering [Member]",
        "terseLabel": "Follow On Offering"
       }
      }
     },
     "localname": "FollowOnOfferingMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_ForeignCurrencyRiskAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency risk.",
        "label": "Foreign Currency Risk [Abstract]"
       }
      }
     },
     "localname": "ForeignCurrencyRiskAbstract",
     "nsuri": "http://www.reparerx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "rptx_ForeignCurrencyRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency risk.",
        "label": "Foreign Currency Risk [Line Items]",
        "terseLabel": "Foreign Currency Risk [Line Items]"
       }
      }
     },
     "localname": "ForeignCurrencyRiskLineItems",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rptx_ForeignCurrencyRiskTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency risk.",
        "label": "Foreign Currency Risk [Table]",
        "terseLabel": "Foreign Currency Risk [Table]"
       }
      }
     },
     "localname": "ForeignCurrencyRiskTable",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rptx_ForeignCurrencyTransactionGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency transaction gain (loss).",
        "label": "Foreign Currency Transaction Gain Loss",
        "negatedLabel": "Foreign exchange loss (gain)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLoss",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_GrantOfLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant of license member.",
        "label": "Grant of License [Member]",
        "terseLabel": "Grant of License"
       }
      }
     },
     "localname": "GrantOfLicenseMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_GrossProceedsFromInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from initial public offering.",
        "label": "Gross Proceeds From Initial Public Offering",
        "terseLabel": "Gross proceeds from IPO"
       }
      }
     },
     "localname": "GrossProceedsFromInitialPublicOffering",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hoffmann La Roche Inc and F Hoffmann La Roche Ltd",
        "label": "Hoffmann La Roche Inc and F Hoffmann La Roche Ltd [Member]",
        "terseLabel": "Hoffmann La Roche Inc And F Hoffmann La Roche Ltd",
        "verboseLabel": "Roche"
       }
      }
     },
     "localname": "HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_ImplicitInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Implicit interest rate.",
        "label": "Implicit Interest Rate",
        "terseLabel": "Implicit interest rate"
       }
      }
     },
     "localname": "ImplicitInterestRate",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rptx_IncomeTaxExaminationYearSubjectToExamination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax examination, year subject to examination.",
        "label": "Income Tax Examination, Year Subject to Examination",
        "terseLabel": "Tax examination"
       }
      }
     },
     "localname": "IncomeTaxExaminationYearSubjectToExamination",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "rptx_IncomeTaxLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax losses.",
        "label": "Income Tax Losses",
        "terseLabel": "Income tax losses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "IncomeTaxLosses",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncomeTaxLossesExpireFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails": {
       "order": 4.0,
       "parentTag": "rptx_IncomeTaxLosses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax losses expire five.",
        "label": "Income Tax Losses Expire Five",
        "terseLabel": "2038"
       }
      }
     },
     "localname": "IncomeTaxLossesExpireFive",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncomeTaxLossesExpireFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails": {
       "order": 3.0,
       "parentTag": "rptx_IncomeTaxLosses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax losses expire four.",
        "label": "Income Tax Losses Expire Four",
        "terseLabel": "2039"
       }
      }
     },
     "localname": "IncomeTaxLossesExpireFour",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncomeTaxLossesExpireOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails": {
       "order": 0.0,
       "parentTag": "rptx_IncomeTaxLosses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax losses expire one.",
        "label": "Income Tax Losses Expire One",
        "terseLabel": "2042"
       }
      }
     },
     "localname": "IncomeTaxLossesExpireOne",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncomeTaxLossesExpireSix": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails": {
       "order": 5.0,
       "parentTag": "rptx_IncomeTaxLosses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax losses expire six.",
        "label": "Income Tax Losses Expire Six",
        "terseLabel": "2037"
       }
      }
     },
     "localname": "IncomeTaxLossesExpireSix",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncomeTaxLossesExpireThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails": {
       "order": 2.0,
       "parentTag": "rptx_IncomeTaxLosses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax losses expire three.",
        "label": "Income Tax Losses Expire Three",
        "terseLabel": "2040"
       }
      }
     },
     "localname": "IncomeTaxLossesExpireThree",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncomeTaxLossesExpireTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails": {
       "order": 1.0,
       "parentTag": "rptx_IncomeTaxLosses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax losses expire two.",
        "label": "Income Tax Losses Expire Two",
        "terseLabel": "2041"
       }
      }
     },
     "localname": "IncomeTaxLossesExpireTwo",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossesExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax rate reconciliation, nondeductible expense, accounting charges.",
        "label": "Income Tax Rate Reconciliation Nondeductible Expense Accounting Charges",
        "terseLabel": "Accounting charges not deductible for tax purposes"
       }
      }
     },
     "localname": "IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncomeTaxReconciliationCapitalGainIncomeEquityCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation capital gain income\nEquity compensation.",
        "label": "Income Tax Reconciliation Capital Gain Income Equity Compensation",
        "terseLabel": "Capital gain income"
       }
      }
     },
     "localname": "IncomeTaxReconciliationCapitalGainIncomeEquityCompensation",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncomeTaxReconciliationStateTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation state taxes.",
        "label": "Income Tax Reconciliation State Taxes",
        "terseLabel": "State Taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateTaxes",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rptx_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rptx_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued expenses and other current liabilities.",
        "label": "Increase Decrease In Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncreaseDecreaseInCollaborationRevenueReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in collaboration revenue receivable.",
        "label": "Increase Decrease in Collaboration Revenue Receivable",
        "negatedLabel": "Collaboration revenue receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInCollaborationRevenueReceivable",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncreaseDecreaseInOperatingLeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liability current.",
        "label": "Increase Decrease In Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilityCurrent",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncreaseDecreaseInOperatingLeaseLiabilityNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liability net.",
        "label": "Increase Decrease In Operating Lease Liability Net",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilityNet",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncreaseDecreaseInResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in research and development expenses.",
        "label": "Increase (Decrease) In Research And Development Expenses",
        "terseLabel": "Reduction of research and development expenditures"
       }
      }
     },
     "localname": "IncreaseDecreaseInResearchAndDevelopmentExpenses",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGovernmentAssistanceAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "increase decrease in research and development tax credits receivable.",
        "label": "Increase Decrease In Research And Development Tax Credits Receivable",
        "negatedLabel": "Research and development tax credits receivable",
        "terseLabel": "Reduction of research and development expenditures"
       }
      }
     },
     "localname": "IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_InitialUpfrontFeePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial upfront fee payment.",
        "label": "Initial Upfront Fee Payment",
        "terseLabel": "Initial upfront fee payment"
       }
      }
     },
     "localname": "InitialUpfrontFeePayment",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_InvestmentTaxCredits": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment tax credits.",
        "label": "Investment Tax Credits",
        "terseLabel": "Investment tax credits",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InvestmentTaxCredits",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_InvestmentTaxCreditsExpireFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails": {
       "order": 4.0,
       "parentTag": "rptx_InvestmentTaxCredits",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment tax credits expire five.",
        "label": "Investment Tax Credits Expire Five",
        "terseLabel": "2038"
       }
      }
     },
     "localname": "InvestmentTaxCreditsExpireFive",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_InvestmentTaxCreditsExpireFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails": {
       "order": 3.0,
       "parentTag": "rptx_InvestmentTaxCredits",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment tax credits expire four.",
        "label": "Investment Tax Credits Expire Four",
        "terseLabel": "2039"
       }
      }
     },
     "localname": "InvestmentTaxCreditsExpireFour",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_InvestmentTaxCreditsExpireOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails": {
       "order": 0.0,
       "parentTag": "rptx_InvestmentTaxCredits",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment tax credits expire one.",
        "label": "Investment Tax Credits Expire One",
        "terseLabel": "2042"
       }
      }
     },
     "localname": "InvestmentTaxCreditsExpireOne",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_InvestmentTaxCreditsExpireSeven": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails": {
       "order": 6.0,
       "parentTag": "rptx_InvestmentTaxCredits",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment tax credits expire seven.",
        "label": "Investment Tax Credits Expire Seven",
        "terseLabel": "2036"
       }
      }
     },
     "localname": "InvestmentTaxCreditsExpireSeven",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_InvestmentTaxCreditsExpireSix": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails": {
       "order": 5.0,
       "parentTag": "rptx_InvestmentTaxCredits",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment tax credits expire six.",
        "label": "Investment Tax Credits Expire Six",
        "terseLabel": "2037"
       }
      }
     },
     "localname": "InvestmentTaxCreditsExpireSix",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_InvestmentTaxCreditsExpireThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails": {
       "order": 2.0,
       "parentTag": "rptx_InvestmentTaxCredits",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment tax credits expire three.",
        "label": "Investment Tax Credits Expire Three",
        "terseLabel": "2040"
       }
      }
     },
     "localname": "InvestmentTaxCreditsExpireThree",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_InvestmentTaxCreditsExpireTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails": {
       "order": 1.0,
       "parentTag": "rptx_InvestmentTaxCredits",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment tax credits expire two.",
        "label": "Investment Tax Credits Expire Two",
        "terseLabel": "2041"
       }
      }
     },
     "localname": "InvestmentTaxCreditsExpireTwo",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfInvestmentTaxCreditsExpireDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of warrants and conversion into common stock during period, shares",
        "label": "Issuance Of Warrants And Conversion Into Common Stock During Period Shares",
        "terseLabel": "Issuance of warrant and conversion into common shares, Shares"
       }
      }
     },
     "localname": "IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodShares",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "rptx_IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of warrants and conversion into common stock during period, value.",
        "label": "Issuance Of Warrants And Conversion Into Common Stock During Period Value",
        "terseLabel": "Issuance of warrant and conversion into common shares,Value",
        "verboseLabel": "Conversion of warrant into common shares"
       }
      }
     },
     "localname": "IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_LeaseLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liabilities.",
        "label": "Lease Liabilities [Member]",
        "terseLabel": "Lease Liabilities"
       }
      }
     },
     "localname": "LeaseLiabilitiesMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_LesseeOperatingLeaseExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease expiration month and year.",
        "label": "Lessee Operating Lease Expiration Month And Year",
        "terseLabel": "Operating lease, expiration month and year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExpirationMonthAndYear",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "rptx_LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement milestone and royalty payments upon achievement of certain clinical and commercial milestones.",
        "label": "License Agreement Milestone And Royalty Payments Upon Achievement Of Certain Clinical And Commercial Milestones",
        "terseLabel": "License agreement milestone and royalty payments upon achievement of certain clinical and commercial milestones"
       }
      }
     },
     "localname": "LicenseAgreementMilestoneAndRoyaltyPaymentsUponAchievementOfCertainClinicalAndCommercialMilestones",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_LicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementsAbstract",
     "nsuri": "http://www.reparerx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "rptx_LicenseAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements Disclosure [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicenseAgreementsDisclosureTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities.",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_MilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones payments.",
        "label": "Milestones Payments",
        "terseLabel": "Milestones payments"
       }
      }
     },
     "localname": "MilestonesPayments",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_MoneyMarketFundsIncludedInCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money Market Funds Included in Cash and Cash Equivalents [Member]",
        "label": "Money Market Funds Included in Cash and Cash Equivalents [Member]",
        "terseLabel": "Money Market Funds Included In Cash And Cash Equivalents [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsIncludedInCashAndCashEquivalentsMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_NetIncomeLossAndComprehensiveIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net income loss and comprehensive income loss.",
        "label": "Net Income Loss And Comprehensive Income Loss",
        "terseLabel": "Net loss and comprehensive loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLossAndComprehensiveIncomeLoss",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_NewYorkUniversityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York university agreement.",
        "label": "New York University Agreement [Member]",
        "terseLabel": "NYU Agreement"
       }
      }
     },
     "localname": "NewYorkUniversityAgreementMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_NumberOfOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating leases.",
        "label": "Number Of Operating Leases",
        "terseLabel": "Number of operating leases"
       }
      }
     },
     "localname": "NumberOfOperatingLeases",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rptx_NumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of tranches.",
        "label": "Number Of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "NumberOfTranches",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rptx_OfficeAndLaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and laboratory space.",
        "label": "Office And Laboratory Space [Member]",
        "terseLabel": "Office and Laboratory Space"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_OnoPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ono pharmaceutical company limited.",
        "label": "Ono Pharmaceutical Company Limited [Member]",
        "terseLabel": "Ono Pharmaceutical Co., Ltd."
       }
      }
     },
     "localname": "OnoPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_OptionsToLicenseDruggableTargetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to license druggable targets.",
        "label": "Options To License Druggable Targets [Member]",
        "terseLabel": "Options to License Druggable Targets"
       }
      }
     },
     "localname": "OptionsToLicenseDruggableTargetsMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_OptionsToLicenseUndruggableTargetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to license undruggable target.",
        "label": "Options To License Undruggable Target [Member]",
        "terseLabel": "Options to License Undruggable Targets"
       }
      }
     },
     "localname": "OptionsToLicenseUndruggableTargetMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_OptionsToPurchaseCommonSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common shares.",
        "label": "Options To Purchase Common Shares [Member]",
        "terseLabel": "Options to Purchase Common Shares"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonSharesMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_OrganizationAndNatureOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and nature of business.",
        "label": "Organization And Nature Of Business [Line Items]",
        "terseLabel": "Organization and Nature of Business [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndNatureOfBusinessLineItems",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rptx_OrganizationAndNatureOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and nature of business.",
        "label": "Organization And Nature Of Business [Table]",
        "terseLabel": "Organization And Nature Of Business [Table]"
       }
      }
     },
     "localname": "OrganizationAndNatureOfBusinessTable",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rptx_OtherReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other receivables.",
        "label": "Other Receivables [Member]",
        "terseLabel": "Other Receivables"
       }
      }
     },
     "localname": "OtherReceivablesMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_PercentageOfDepreciationUSDAgainstCanadianDollar": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of depreciation USD against Canadian dollar.",
        "label": "Percentage Of Depreciation U S D Against Canadian Dollar",
        "terseLabel": "Percentage of depreciation USD against Canadian dollar"
       }
      }
     },
     "localname": "PercentageOfDepreciationUSDAgainstCanadianDollar",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rptx_PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of holders of preferred shares election to convert preferred shares.",
        "label": "Percentage Of Holders Of Preferred Shares Election To Convert Preferred Shares",
        "terseLabel": "Percentage of holder of preferred shares election to convert the preferred shares"
       }
      }
     },
     "localname": "PercentageOfHoldersOfPreferredSharesElectionToConvertPreferredShares",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rptx_PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of liquidation rights waived by holder of preferred shares.",
        "label": "Percentage Of Liquidation Rights Waived By Holder Of Preferred Shares",
        "terseLabel": "Percentage of liquidation rights waived by holder of preferred shares"
       }
      }
     },
     "localname": "PercentageOfLiquidationRightsWaivedByHolderOfPreferredShares",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rptx_PreclinicalStudiesAndClinicalTrialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preclinical studies and clinical trials.",
        "label": "Preclinical Studies And Clinical Trials [Member]",
        "terseLabel": "Preclinical Studies and Clinical Trials"
       }
      }
     },
     "localname": "PreclinicalStudiesAndClinicalTrialsMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_PreferredStockNoncumulativeDividendRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock noncumulative dividend rate percentage.",
        "label": "Preferred Stock Noncumulative Dividend Rate Percentage",
        "terseLabel": "Preferred shares, noncumulative dividends"
       }
      }
     },
     "localname": "PreferredStockNoncumulativeDividendRatePercentage",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rptx_ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock under two thousand twenty employee share purchase plan.",
        "label": "Proceeds from Issuance of Common Stock under Two Thousand Twenty Employee Share Purchase Plan",
        "terseLabel": "Proceeds from issuance of common shares under the 2020 Employee Share Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_ProductResearchActivityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product research activity.",
        "label": "Product Research Activity [Member]",
        "terseLabel": "Product Research Activity"
       }
      }
     },
     "localname": "ProductResearchActivityMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_ProductRptxOptionsToLicenseDruggableTargetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product RPTX options to license druggable target.",
        "label": "Product RPTX Options To License Druggable Target [Member]",
        "terseLabel": "Product RPTX Options to License Druggable Target"
       }
      }
     },
     "localname": "ProductRptxOptionsToLicenseDruggableTargetMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of shares as percentage of fair market value of common stock on date of purchase.",
        "label": "Purchase Price Of Shares As Percentage Of Fair Market Value Of Common Stock On Date Of Purchase",
        "terseLabel": "Purchase price of shares as percentage of fair market value of common stock on date of purchase"
       }
      }
     },
     "localname": "PurchasePriceOfSharesAsPercentageOfFairMarketValueOfCommonStockOnDateOfPurchase",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rptx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently issued accounting pronouncements.",
        "label": "Recently Issued Accounting Pronouncements Policy [Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_RepareTherapeuticsIncorporationOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repare Therapeutics Incorporation option plan.",
        "label": "Repare Therapeutics Incorporation Option Plan [Member]",
        "terseLabel": "Option Plan"
       }
      }
     },
     "localname": "RepareTherapeuticsIncorporationOptionPlanMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_ResearchActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research activities.",
        "label": "Research Activities [Member]",
        "terseLabel": "Research Activities"
       }
      }
     },
     "localname": "ResearchActivitiesMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_ResearchAndDevelopmentServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Services.",
        "label": "Research and Development Services [Member]",
        "terseLabel": "Research and Development Services"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServicesMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_ResearchAndDevelopmentTaxCreditsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credits.",
        "label": "Research And Development Tax Credits Policy [Text Block]",
        "terseLabel": "Research and Development Tax Credits"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditsPolicyTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_ResearchAndDevelopmentTaxCreditsReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credits receivable.",
        "label": "Research And Development Tax Credits Receivable",
        "terseLabel": "Research and development tax credits receivable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditsReceivable",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_ResearchAndDevelopmentTaxCreditsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credits receivable.",
        "label": "Research And Development Tax Credits Receivable [Member]",
        "terseLabel": "Research and Development Tax Credits Receivable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditsReceivableMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_ResearchDevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research development and regulatory milestones.",
        "label": "Research Development And Regulatory Milestones [Member]",
        "terseLabel": "Research, Development and Regulatory Milestones"
       }
      }
     },
     "localname": "ResearchDevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_ResearchServicesAndRentPaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research services and rent paid.",
        "label": "Research Services And Rent Paid [Member]",
        "terseLabel": "Research Services and Rent Paid"
       }
      }
     },
     "localname": "ResearchServicesAndRentPaidMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_RestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash.",
        "label": "Restricted Cash [Member]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_RestrictedCashPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash.",
        "label": "Restricted Cash Policy [Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashPolicyTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_RevenueFromCollaborationAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from collaboration agreements.",
        "label": "Revenue From Collaboration Agreements",
        "terseLabel": "Collaboration agreements"
       }
      }
     },
     "localname": "RevenueFromCollaborationAgreements",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_RevenueRemainingPerformanceObligationNetAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue remaining performance obligation net amount.",
        "label": "Revenue, Remaining Performance Obligation, Net Amount",
        "terseLabel": "Research service payments entitled to be received, total"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationNetAmount",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreement [Member]",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued expenses and other current liabilities.",
        "label": "Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_ScheduleOfDepreciationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of depreciation expense.",
        "label": "Schedule of Depreciation Expense [Table Text Block]",
        "terseLabel": "Schedule of Depreciation Expense Recognized"
       }
      }
     },
     "localname": "ScheduleOfDepreciationExpenseTableTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of estimated useful lives of property and equipment.",
        "label": "Schedule Of Estimated Useful Lives Of Property And Equipment Table [Text Block]",
        "terseLabel": "Schedule of Estimated Useful Lives of Property and Equipment"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_ScheduleOfFinancialPositionExposureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of financial position exposure.",
        "label": "Schedule Of Financial Position Exposure Table [Text Block]",
        "terseLabel": "Schedule of Financial Position Exposure"
       }
      }
     },
     "localname": "ScheduleOfFinancialPositionExposureTableTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_ScientificResearchAndExperimentalDevelopmentExpenditures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scientific Research and experimental development expenditures.",
        "label": "Scientific Research And Experimental Development Expenditures",
        "terseLabel": "Scientific research and experimental development expenditures"
       }
      }
     },
     "localname": "ScientificResearchAndExperimentalDevelopmentExpenditures",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_SecondAmendmentAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second amendment agreement.",
        "label": "Second Amendment Agreement",
        "terseLabel": "Second amendment agreement"
       }
      }
     },
     "localname": "SecondAmendmentAgreement",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rptx_SecondTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second tranche.",
        "label": "Second Tranche [Member]",
        "terseLabel": "Second Tranche"
       }
      }
     },
     "localname": "SecondTrancheMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_SeriesAConvertiblePreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Convertible Preferred Shares.",
        "label": "Series A Convertible Preferred Shares [Member]",
        "terseLabel": "Series A Convertible Preferred Shares"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredSharesMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_SeriesBConvertiblePreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Convertible Preferred Shares.",
        "label": "Series B Convertible Preferred Shares [Member]",
        "terseLabel": "Series B Convertible Preferred Shares"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredSharesMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by payment award number of shares ceased granting.",
        "label": "Share Based Compensation Arrangement By Payment Award Number Of Shares Ceased Granting",
        "terseLabel": "Number of shares ceased granting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByPaymentAwardNumberOfSharesCeasedGranting",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rptx_ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment monthly vesting rate",
        "label": "Share Based Compensation Arrangement By Share Based Payment Monthly Vesting Rate",
        "terseLabel": "Monthly vesting rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentMonthlyVestingRate",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rptx_ShareIssuanceCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share issuance costs.",
        "label": "Share Issuance Costs Policy [Text Block]",
        "terseLabel": "Share Issuance Costs"
       }
      }
     },
     "localname": "ShareIssuanceCostsPolicyTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_SmallerReportingCompanyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Smaller reporting company policy text block",
        "label": "Smaller Reporting Company Policy Text Block",
        "terseLabel": "Smaller Reporting Company"
       }
      }
     },
     "localname": "SmallerReportingCompanyPolicyTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_SpecialtyScreeningServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specialty screening services.",
        "label": "Specialty Screening Services [Member]",
        "terseLabel": "Specialty Screening Services"
       }
      }
     },
     "localname": "SpecialtyScreeningServicesMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_StateAndUsFederalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State and us federal.",
        "label": "State And US Federal [Member]",
        "terseLabel": "U.S. federal and state research and development"
       }
      }
     },
     "localname": "StateAndUsFederalMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_SummaryOfInvestmentTaxCreditsExpireTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of investment tax credits expire.",
        "label": "Summary Of Investment Tax Credits Expire Table [Text Block]",
        "terseLabel": "Summary of Investment Tax Credits Expire"
       }
      }
     },
     "localname": "SummaryOfInvestmentTaxCreditsExpireTableTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_SummaryOfOtherOperatingLeaseInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of other operating lease information.",
        "label": "Summary Of Other Operating Lease Information Table [Text Block]",
        "terseLabel": "Summary of Other Operating Lease Information"
       }
      }
     },
     "localname": "SummaryOfOtherOperatingLeaseInformationTableTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of recognized tax benefit of losses expire.",
        "label": "Summary Of Recognized Tax Benefit Of Losses Expire Table [Text Block]",
        "terseLabel": "Summary of Losses Expire"
       }
      }
     },
     "localname": "SummaryOfRecognizedTaxBenefitOfLossesExpireTableTextBlock",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rptx_TaxCreditCarryForwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carry forward expiration year.",
        "label": "Tax Credit Carry Forward Expiration Year",
        "terseLabel": "Tax credit carry forward expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryForwardExpirationYear",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "rptx_TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity adjustments to additional paid in capital termination.",
        "label": "Temporary Equity Adjustments To Additional Paid In Capital Termination",
        "terseLabel": "Series A Tranche 3 termination"
       }
      }
     },
     "localname": "TemporaryEquityAdjustmentsToAdditionalPaidInCapitalTermination",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_TemporaryEquitySharesAuthorizedUnlimited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity shares authorized unlimited.",
        "label": "Temporary Equity Shares Authorized Unlimited",
        "terseLabel": "Convertible preferred shares authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorizedUnlimited",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rptx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of convertible preferred shares",
        "verboseLabel": "Issuance of convertible preferred shares, net of issuance costs, Shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "rptx_TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, terms of conversion, trigger, minimum gross proceeds from initial public offering.",
        "label": "Temporary Equity Terms Of Conversion Trigger Minimum Gross Proceeds From Initial Public Offering",
        "terseLabel": "Threshold gross proceeds of initial public offering that triggers automatic conversion of preferred convertible shares into common shares"
       }
      }
     },
     "localname": "TemporaryEquityTermsOfConversionTriggerMinimumGrossProceedsFromInitialPublicOffering",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rptx_TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, terms of conversion, trigger, minimum price per share in initial public offering.",
        "label": "Temporary Equity Terms Of Conversion Trigger Minimum Price Per Share In Initial Public Offering",
        "terseLabel": "Threshold price per share in initial public offering that triggers automatic conversion of preferred convertible shares into common shares"
       }
      }
     },
     "localname": "TemporaryEquityTermsOfConversionTriggerMinimumPricePerShareInInitialPublicOffering",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "rptx_TheUniversityOfTexasMDAndersonCancerCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The University of Texas M. D. Anderson Cancer Center.",
        "label": "The University of Texas M.D. Anderson Cancer Center [Member]",
        "terseLabel": "MDACC"
       }
      }
     },
     "localname": "TheUniversityOfTexasMDAndersonCancerCenterMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_TransferOfClinicalTrialMaterialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer of Clinical Trial Materials [Member]",
        "label": "Transfer of Clinical Trial Materials [Member]",
        "terseLabel": "Transfer of Clinical Trial Materials"
       }
      }
     },
     "localname": "TransferOfClinicalTrialMaterialsMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_TwoThousandTwentyEmployeeSharePurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty employee share purchase plan.",
        "label": "Two Thousand Twenty Employee Share Purchase Plan [Member]",
        "terseLabel": "2020 Employee Share Purchase Plan",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "TwoThousandTwentyEmployeeSharePurchasePlanMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rptx_UnderwritingCommissionsAndEstimatedOfferingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting commissions and estimated offering expenses.",
        "label": "Underwriting Commissions And Estimated Offering Expenses",
        "terseLabel": "Underwriting Commissions And Estimated Offering Expenses"
       }
      }
     },
     "localname": "UnderwritingCommissionsAndEstimatedOfferingExpenses",
     "nsuri": "http://www.reparerx.com/20221231",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r610",
      "r615",
      "r714",
      "r753",
      "r754",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An affiliate is a party that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with the entity.",
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Commitments to Settle Contractual Obligations"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r380",
      "r548",
      "r573",
      "r611",
      "r612",
      "r643",
      "r649",
      "r659",
      "r709",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r380",
      "r548",
      "r573",
      "r611",
      "r612",
      "r643",
      "r649",
      "r659",
      "r709",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficeBuildingMember": {
     "auth_ref": [
      "r767",
      "r768",
      "r778",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Building designed primarily for the conduct of business, for example, but not limited to, administration, clerical services, and consultation.",
        "label": "Office Building [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "localname": "OfficeBuildingMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r282",
      "r549",
      "r644",
      "r657",
      "r704",
      "r705",
      "r712",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r282",
      "r549",
      "r644",
      "r657",
      "r704",
      "r705",
      "r712",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r372",
      "r380",
      "r411",
      "r412",
      "r413",
      "r524",
      "r548",
      "r573",
      "r611",
      "r612",
      "r643",
      "r649",
      "r659",
      "r703",
      "r709",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r372",
      "r380",
      "r411",
      "r412",
      "r413",
      "r524",
      "r548",
      "r573",
      "r611",
      "r612",
      "r643",
      "r649",
      "r659",
      "r703",
      "r709",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r381",
      "r695",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
        "label": "Forecast [Member]",
        "terseLabel": "Scenario Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r235",
      "r381",
      "r672",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r283",
      "r284",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r614",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r645",
      "r658",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r283",
      "r284",
      "r595",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r614",
      "r616",
      "r645",
      "r658",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r235",
      "r381",
      "r672",
      "r674",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA-QC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "QUEBEC",
        "terseLabel": "Montreal, Quebec"
       }
      }
     },
     "localname": "CA-QC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Cambridge, Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15",
      "r656"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net (accretion)/amortization of marketable securities",
        "terseLabel": "Amortization of premiums on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r4",
      "r153",
      "r166"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInvestmentIncomeReceivable": {
     "auth_ref": [
      "r150",
      "r169",
      "r680"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.",
        "label": "Accrued Investment Income Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "AccruedInvestmentIncomeReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued Liabilities and Other Liabilities, Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "rptx_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r80",
      "r184"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r191",
      "r568",
      "r578",
      "r579"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "negatedLabel": "Accumulated other comprehensive loss",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r25",
      "r28",
      "r132",
      "r508",
      "r574",
      "r575",
      "r682",
      "r683",
      "r684",
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r692",
      "r693",
      "r694",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r114",
      "r115",
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r151",
      "r165",
      "r186",
      "r217",
      "r263",
      "r273",
      "r278",
      "r295",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r457",
      "r461",
      "r475",
      "r656",
      "r707",
      "r708",
      "r756"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r180",
      "r193",
      "r217",
      "r295",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r457",
      "r461",
      "r475",
      "r656",
      "r707",
      "r708",
      "r756"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total financial assets",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "verboseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains",
        "verboseLabel": "Unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses",
        "verboseLabel": "Available-for-sale marketable securities unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r289",
      "r302"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r70",
      "r288",
      "r302",
      "r562"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Debt Securities, Available-for-sale, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r135",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r53",
      "r54",
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases incurred but not yet paid"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r50",
      "r182",
      "r625"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents cash at beginning of year",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r43",
      "r50",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents cash at beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r43",
      "r145"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (Decrease) Increase In Cash And Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r217",
      "r238",
      "r239",
      "r241",
      "r243",
      "r250",
      "r251",
      "r295",
      "r320",
      "r323",
      "r324",
      "r325",
      "r329",
      "r330",
      "r348",
      "r349",
      "r352",
      "r356",
      "r364",
      "r475",
      "r613",
      "r671",
      "r687",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Shares issued upon exercise of warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsTables",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r156",
      "r171"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r313",
      "r314",
      "r597",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares of common stock reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r692",
      "r693",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "terseLabel": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorizedUnlimited": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\".",
        "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]",
        "terseLabel": "Common stock shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorizedUnlimited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "authorizedUnlimitedItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r9",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r9",
      "r656"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common shares, no par value per share; unlimited shares authorized as of December 31, 2022 and December 31, 2021; 42,036,193 and 41,850,162 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common stock voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Savings Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureEmployeeSavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r29",
      "r199",
      "r201",
      "r208",
      "r564",
      "r570"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r162",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk": {
     "auth_ref": [
      "r144",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of financial instruments, excluding certain derivatives, with off-balance sheet credit risk (for example, standby letters of credit or financial guarantees), including (1) information about the (shared) activity, region or economic characteristic that identifies the concentration, (2) the face or contract amount of the instrument, (3) the nature and terms of the instrument, including the market risk, cash requirements and accounting policies for it, (4) the maximum amount of loss due to credit risk that would be incurred if the counterparties failed completely to perform according to the terms of the contracts, and any security or collateral that proved to be of no value, (5) the entity's policy of requiring collateral or other security to support financial instruments subject to credit risk, information about access to collateral or other security, and a brief description of the security supporting those financial instruments, and (6) the policy of entering into and a brief description of master netting arrangements to mitigate the credit risk, and the extent to which such arrangements would reduce the maximum amount of loss due to credit risk.",
        "label": "Concentration Risk, Credit Risk, Financial Instruments, off-Balance-Sheet Risk",
        "terseLabel": "Significant off-balance sheet risk, description"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r130",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r367",
      "r368",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Non-refundable upfront payment received",
        "totalLabel": "Contract with Customer, Liability, Total",
        "verboseLabel": "Transaction price"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r367",
      "r368",
      "r370"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r367",
      "r368",
      "r370"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueAfterFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, after Year Five",
        "terseLabel": "Following years"
       }
      }
     },
     "localname": "ContractualObligationDueAfterFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "ContractualObligationDueInFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "ContractualObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "ContractualObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "ContractualObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfCommitmentsToSettleContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r53",
      "r54",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Convertible preferred shares converted into common shares",
        "verboseLabel": "Convertible preferred shares converted into common shares"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r7",
      "r8",
      "r91",
      "r94",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Common Shares Issuable Upon Conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "auth_ref": [
      "r7",
      "r8",
      "r91",
      "r95",
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of conversion terms for preferred stock.",
        "label": "Convertible preferred shares term"
       }
      }
     },
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r690",
      "r745"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Current income tax provision - foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r152",
      "r154",
      "r164",
      "r221",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r491",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.",
        "label": "Debt Instrument, Convertible, Beneficial Conversion Feature",
        "terseLabel": "Beneficial conversion feature"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r19",
      "r221",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r491",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded",
        "terseLabel": "Allowance for credit losses or other impairment charges"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r292",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "terseLabel": "Debt Securities, Accumulated unrealized loss",
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r293",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r126",
      "r690",
      "r746"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax benefit - foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r428",
      "r429"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets",
        "totalLabel": "Deferred Income Tax Assets, Net, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r677"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Deferred Revenue, Total"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.",
        "label": "Deferred Revenue, Additions",
        "terseLabel": "Deferred revenue, additions"
       }
      }
     },
     "localname": "DeferredRevenueAdditions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r676"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue, current",
        "totalLabel": "Deferred Revenue, Current, Total"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r677"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, noncurrent",
        "totalLabel": "Deferred Revenue, Noncurrent, Total"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.",
        "label": "Deferred Revenue, Revenue Recognized",
        "terseLabel": "Deferred revenue recognized",
        "verboseLabel": "Collaboration revenue receivable"
       }
      }
     },
     "localname": "DeferredRevenueRevenueRecognized1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r124",
      "r744"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r124",
      "r744"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Net research and development expenditures"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r743"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r124",
      "r744"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "negatedLabel": "Tax basis of property and equipment in excess of carrying values"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r123",
      "r124",
      "r744"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "U.S. research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r124",
      "r744"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Share issuance costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [
      "r124",
      "r744"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "terseLabel": "R&amp;D costs capitalized"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Matching contribution expense"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureEmployeeSavingsPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r48",
      "r78"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r385",
      "r416",
      "r417",
      "r419",
      "r424",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Cash dividends declared or paid"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r15",
      "r322",
      "r323",
      "r324",
      "r328",
      "r329",
      "r330",
      "r512",
      "r691"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related parties, current",
        "totalLabel": "Due to Related Parties, Current, Total",
        "verboseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r209",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r236",
      "r238",
      "r241",
      "r242",
      "r243",
      "r247",
      "r466",
      "r467",
      "r565",
      "r571",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common shareholders--basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "verboseLabel": "Net loss per share basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r209",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r238",
      "r241",
      "r242",
      "r243",
      "r247",
      "r466",
      "r467",
      "r565",
      "r571",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common shareholders--diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Net loss per share diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r480"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate fluctuations on cash held"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r219",
      "r431",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "rptx_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized share-based compensation expense related to unvested stock options, weighted-average remaining vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r741"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation expense related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r90",
      "r178",
      "r203",
      "r204",
      "r205",
      "r222",
      "r223",
      "r224",
      "r226",
      "r232",
      "r234",
      "r249",
      "r296",
      "r366",
      "r420",
      "r421",
      "r422",
      "r442",
      "r443",
      "r465",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r508",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r468",
      "r469",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r140",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r339",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r469",
      "r521",
      "r522",
      "r523",
      "r639",
      "r640",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r468",
      "r469",
      "r470",
      "r471",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r339",
      "r373",
      "r378",
      "r469",
      "r521",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r339",
      "r373",
      "r378",
      "r469",
      "r522",
      "r639",
      "r640",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Aggregate Fair Value of Series A Preferred Share Tranche Obligation using Level 3 Inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r339",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r521",
      "r522",
      "r523",
      "r639",
      "r640",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r290",
      "r291",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r305",
      "r306",
      "r308",
      "r347",
      "r362",
      "r463",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r636",
      "r698",
      "r699",
      "r700",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value",
        "terseLabel": "Assets exposure"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet": {
     "auth_ref": [
      "r134"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivatives not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments at Fair Value, Net",
        "terseLabel": "Net financial position exposure",
        "totalLabel": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments at Fair Value, Net, Total"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value",
        "negatedLabel": "Liability exposure"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskScheduleOfFinancialPositionExposureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDisclosureTextBlock": {
     "auth_ref": [
      "r489",
      "r490",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.",
        "label": "Foreign Currency Disclosure [Text Block]",
        "terseLabel": "Currency Risk"
       }
      }
     },
     "localname": "ForeignCurrencyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRisk"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r479"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Realized and unrealized gain (loss) on foreign exchange",
        "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currencies"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r136",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "terseLabel": "Increase in net loss currency risk"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCurrencyRiskAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment",
        "terseLabel": "Loss on disposal of property and equipment",
        "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense",
        "verboseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r48",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r218",
      "r446"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r31",
      "r149",
      "r158",
      "r173",
      "r263",
      "r272",
      "r277",
      "r280",
      "r566",
      "r635"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income taxes",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r218",
      "r446"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r128",
      "r217",
      "r225",
      "r263",
      "r272",
      "r277",
      "r280",
      "r295",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r467",
      "r475",
      "r635",
      "r707"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r219",
      "r432",
      "r435",
      "r440",
      "r444",
      "r448",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationYearUnderExamination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year being audited in the income tax examination, in YYYY format.",
        "label": "Income Tax Examination, Year under Examination",
        "terseLabel": "Tax examination"
       }
      }
     },
     "localname": "IncomeTaxExaminationYearUnderExamination",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r220",
      "r233",
      "r234",
      "r262",
      "r430",
      "r445",
      "r449",
      "r572"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit",
        "terseLabel": "Income Tax Expense Benefit",
        "totalLabel": "Tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfProvisionForIncomeTaxesDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r202",
      "r426",
      "r427",
      "r435",
      "r436",
      "r439",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReceivable": {
     "auth_ref": [
      "r163",
      "r680"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.",
        "label": "Income Taxes Receivable",
        "terseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "IncomeTaxReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r742"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Computed income tax recovery"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r742"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Equity compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r742"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r742"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "Federal investment tax credit",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r45",
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash taxes paid, net"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r628"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxes": {
     "auth_ref": [
      "r685"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.",
        "label": "Increase (Decrease) in Income Taxes",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other non-current assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r210",
      "r213",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedLabel": "Cash interest received",
        "terseLabel": "Cash interest received"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r35",
      "r37"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest income",
        "totalLabel": "Investment Income, Net, Total"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r505",
      "r655"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement.",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Operating lease, existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]",
        "terseLabel": "Lessee, operating lease, existence of option to terminate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments under Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Operating lease, option to extend, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating Lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Minimum lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r217",
      "r295",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r458",
      "r461",
      "r462",
      "r475",
      "r634",
      "r707",
      "r756",
      "r757"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r14",
      "r155",
      "r168",
      "r656",
      "r689",
      "r701",
      "r749"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r181",
      "r217",
      "r295",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r458",
      "r461",
      "r462",
      "r475",
      "r656",
      "r707",
      "r756",
      "r757"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net and Right-of-Use Assets by Location"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Long-Term Purchase Commitment, Amount",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities",
        "totalLabel": "Marketable Securities, Total"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities",
        "totalLabel": "Marketable Securities, Current, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r212"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r212"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r43",
      "r46",
      "r49"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r32",
      "r49",
      "r159",
      "r172",
      "r179",
      "r197",
      "r200",
      "r205",
      "r217",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r240",
      "r263",
      "r272",
      "r277",
      "r280",
      "r295",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r467",
      "r475",
      "r635",
      "r707"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss)",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r263",
      "r272",
      "r277",
      "r280",
      "r635"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r498",
      "r655"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r494",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r504",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r503",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Nature of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r194",
      "r195",
      "r196"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on available-for-sale marketable securities",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r90",
      "r198",
      "r201",
      "r207",
      "r481",
      "r486",
      "r487",
      "r563",
      "r569",
      "r682",
      "r683"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r128",
      "r129",
      "r131",
      "r198",
      "r201"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r656"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "rptx_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other",
        "totalLabel": "Other Liabilities, Current, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Other expense, net",
        "totalLabel": "Other Nonoperating Expense, Total"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other Receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Exercise of Underwriters Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConversionBasis": {
     "auth_ref": [
      "r8",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.",
        "label": "Preferred Stock, Conversion Basis",
        "terseLabel": "Preferred stock, conversion basis"
       }
      }
     },
     "localname": "PreferredStockConversionBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockNoParValue": {
     "auth_ref": [
      "r8",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, No Par Value",
        "terseLabel": "Preferred stock par value"
       }
      }
     },
     "localname": "PreferredStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorizedUnlimited": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the number of nonredeemable preferred shares, or preferred stock redeemable solely at the option of the issuer, permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\".",
        "label": "Preferred stock shares authorized",
        "terseLabel": "Preferred stock shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorizedUnlimited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "authorizedUnlimitedItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r8",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r8",
      "r656"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred shares, no par value per share; unlimited shares authorized as of December 31, 2022 and December 31, 2021, respectively; 0 shares issued and outstanding as of December 31, 2022, and December 31, 2021, respectively",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r192",
      "r309",
      "r310",
      "r626"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "totalLabel": "Prepaid Expense, Current, Total"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRent": {
     "auth_ref": [
      "r627",
      "r637",
      "r702"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Rent",
        "terseLabel": "Prepaid rent"
       }
      }
     },
     "localname": "PrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Initial nonrefundable upfront fee payment received"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds from issuance of common shares in initial public offering",
        "verboseLabel": "Net proceeds from IPO"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from issuance of common shares",
        "verboseLabel": "Net proceeds from issuance of common shares in follow-on offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from Issuance of convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Proceeds from issuance of Preferred Shares, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of warrant"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepurchaseOfEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow resulting from the entity's share transaction.",
        "label": "Proceeds from (Repurchase of) Equity",
        "terseLabel": "Cash received from purchases under ESPP",
        "totalLabel": "Proceeds from (Repurchase of) Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromRepurchaseOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities",
        "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds on disposal of property and equipment",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r112"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "verboseLabel": "Aggregate proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r179",
      "r197",
      "r200",
      "r211",
      "r217",
      "r225",
      "r233",
      "r234",
      "r263",
      "r272",
      "r277",
      "r280",
      "r295",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r456",
      "r459",
      "r460",
      "r467",
      "r475",
      "r566",
      "r635",
      "r653",
      "r654",
      "r684",
      "r707"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss for the year",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Estimated useful lives of assets, description"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r79",
      "r183"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r81",
      "r170",
      "r567",
      "r656"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r81",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForLoanAndLeaseLosses": {
     "auth_ref": [
      "r47",
      "r67",
      "r160"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to estimated loss from loan and lease transactions.",
        "label": "Provision for Loan and Lease Losses",
        "terseLabel": "Non-cash lease expense",
        "totalLabel": "Provision for Loan and Lease Losses, Total"
       }
      }
     },
     "localname": "ProvisionForLoanAndLeaseLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesLongTermContractsOrPrograms": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date.",
        "label": "Receivables, Long-Term Contracts or Programs",
        "terseLabel": "Collaboration revenue receivable"
       }
      }
     },
     "localname": "ReceivablesLongTermContractsOrPrograms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r379",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r177",
      "r511",
      "r512",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r379",
      "r511",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r509",
      "r510",
      "r512",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r117",
      "r175",
      "r764"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, net of tax credits",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Government Assistance"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGovernmentAssistance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r596",
      "r675",
      "r686"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r11",
      "r98",
      "r167",
      "r577",
      "r579",
      "r656"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r178",
      "r222",
      "r223",
      "r224",
      "r226",
      "r232",
      "r234",
      "r296",
      "r420",
      "r421",
      "r422",
      "r442",
      "r443",
      "r465",
      "r574",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Milestone payments entitled to be received",
        "verboseLabel": "Research service payments entitled to be received"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r206",
      "r217",
      "r260",
      "r261",
      "r271",
      "r275",
      "r276",
      "r282",
      "r283",
      "r286",
      "r295",
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r475",
      "r566",
      "r707"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "totalLabel": "Revenues, Total"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r502",
      "r655"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liability",
        "verboseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherOperatingLeaseInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedNetLossPerShareInAttributableToCommonShareholdersIndicateToAntiDilutedEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Computation of Diluted Net Loss Per Share in Attributable to Common Shareholders Indicate to Anti Diluted Effect"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Cash and Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureCollaborationsScheduleOfTransactionPricePerformanceObligationsDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsTables",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Transaction Price Performance Obligations"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r110",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseForAllAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Summary of Loss Before Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseRecognizedDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r382",
      "r384",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r105",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions used to Determine Grant Date Fair Value under ESPP Offering"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Stock Options Determined on Grant Date Using Black Scholes Option-Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r86",
      "r88",
      "r89",
      "r91",
      "r92",
      "r93",
      "r95",
      "r96",
      "r97",
      "r98",
      "r187",
      "r188",
      "r189",
      "r250",
      "r348",
      "r349",
      "r350",
      "r352",
      "r356",
      "r362",
      "r364",
      "r643",
      "r671",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r87",
      "r88",
      "r89",
      "r91",
      "r92",
      "r93",
      "r95",
      "r96",
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Summary of Preferred Shares"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r263",
      "r264",
      "r274",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Geographic Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureGeographicInformationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfPropertyAndEquipmentNetByLocationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureGeographicInformationScheduleOfRightOfUseAssetsByLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r678",
      "r679",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Shares"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r678",
      "r679",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Shares"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted share units to employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments",
        "terseLabel": "Share based compensation, expected dividend yield assumed"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized to be issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of shares, Options Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of shares, Granted",
        "verboseLabel": "Stock options granted to employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Intrinsic value, Outstanding at end of period",
        "periodStartLabel": "Intrinsic value, Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares, Outstanding at end of period",
        "periodStartLabel": "Number of shares, Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Outstanding at end of period",
        "periodStartLabel": "Weighted average exercise price, Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "periodEndLabel": "Intrinsic value, Options unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of shares, Options Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Options Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseByTypeOfAwardDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised",
        "verboseLabel": "Exercised options, weighted-average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted",
        "verboseLabel": "Weighted average exercise price of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting on First Anniversary Date of Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting on Monthly Basis at Rate of 1/36th"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r389",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantDateFairValueUnderEsppOfferingDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfFairValueOfStockOptionsDeterminedOnGrantDateUsingBlackScholesOptionpricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "periodEndLabel": "Intrinsic value, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (in years), Options Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (in years) , Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (in years), Options Unvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r499",
      "r655"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r57",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "auth_ref": [
      "r85",
      "r127",
      "r174",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.",
        "label": "Standby Letters of Credit [Member]",
        "terseLabel": "Standby Letters of Credit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r217",
      "r238",
      "r239",
      "r241",
      "r243",
      "r250",
      "r251",
      "r295",
      "r320",
      "r323",
      "r324",
      "r325",
      "r329",
      "r330",
      "r348",
      "r349",
      "r352",
      "r356",
      "r364",
      "r475",
      "r613",
      "r671",
      "r687",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r24",
      "r90",
      "r178",
      "r203",
      "r204",
      "r205",
      "r222",
      "r223",
      "r224",
      "r226",
      "r232",
      "r234",
      "r249",
      "r296",
      "r366",
      "r420",
      "r421",
      "r422",
      "r442",
      "r443",
      "r465",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r508",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r249",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r23",
      "r90",
      "r91",
      "r98",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred shares into an equivalent number of common shares, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r8",
      "r9",
      "r90",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common shares under the 2020 Employee Share Purchase Plan, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r8",
      "r9",
      "r90",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common shares, Shares",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r9",
      "r90",
      "r98",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of shares, Exercised",
        "terseLabel": "Exercise of vested stock options, Shares",
        "verboseLabel": "Number of options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareOptionActivityDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r24",
      "r90",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred shares into an equivalent number of common shares, Value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r8",
      "r9",
      "r90",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common shares under the 2020 Employee Share Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r8",
      "r9",
      "r90",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common shares",
        "verboseLabel": "Maximum aggregate amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r90",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of vested stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r9",
      "r12",
      "r13",
      "r68",
      "r656",
      "r689",
      "r701",
      "r749"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "SHAREHOLDERS' EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r216",
      "r349",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r363",
      "r366",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquity1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split of share capital"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r488",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r488",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r488",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r488",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r515",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosure Of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r2",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r320",
      "r323",
      "r324",
      "r325",
      "r329",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Temporary equity balance, Value",
        "periodStartLabel": "Temporary equity balance, Value",
        "terseLabel": "Carrying Value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Liquidation Value"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred shares, par value"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Preferred Shares Issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary equity balance, Shares",
        "periodStartLabel": "Temporary equity balance, Shares",
        "terseLabel": "Preferred Shares Outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredSharesSummaryOfPreferredSharesDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of convertible preferred shares, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r290",
      "r291",
      "r347",
      "r362",
      "r463",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r698",
      "r699",
      "r700",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. Treasury bills"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "auth_ref": [
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Notes Securities [Member]",
        "terseLabel": "U.S. Treasury Notes"
       }
      }
     },
     "localname": "USTreasuryNotesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r632",
      "r646",
      "r648",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury notes"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "terseLabel": "Unrealized Gain (Loss) On Derivatives"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureCashAndCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r425",
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "terseLabel": "Unrecognized tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r252",
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r500",
      "r655"
     ],
     "calculation": {
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r237",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding-diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Weighted-average number of common shares outstanding-diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r236",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding-basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted-average number of common shares outstanding-basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.reparerx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.reparerx.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126966630&loc=d3e41228-113958",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.11)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org/subtopic&trid=2197926",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(3)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r661": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r662": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r663": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r664": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r665": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r666": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r667": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r668": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r669": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30885-110895",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907907&loc=d3e12803-110250",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>127
<FILENAME>0000950170-23-005113-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-005113-xbrl.zip
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M&%! K*,5"C![A2[8!RP1'DG+/ORY#R/T%]2&%E*G"=P#+]$5-0H((EN&7*"
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MDXMO1T1K?+R% C"+TH(DS2-+YG;/95FKJQO&&X]>JI71%"0G/"-M=O9^9E
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ME#U=O1*?7N'N%B:IVO!K4.3WNH>2 1ROTZXVW6SMZN/ <_#$#FQ"!<O,V;9
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MH>TB$4U%))WBC.P+\X>4YEBPU0=E9_N'685)2^=1IQ2FDLCLMNHUWJVGRO@
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MC;>JV9L*@&#NEM'(/=I?/N*AFHK7 (:1&]P&27[^I[+=@$%@"'O6W_W.HR,
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MQ/?<(]IW-<IIZQX+F4Q$W;]R>XC>,,RAKNH.]Q(5)K>=LS^0#C_) S\PFMI
M0+7SB5=P#Z/JWS[U>'AVNXY7-4$UG+7; ^0<+1.Q$V86BX,(F04]W4^N0]?V
MN'DQD6X"L,_CBBR&(,O8, @B'W)Q!W9[RHT7[[5C#H_%VEG,[ Q+>'C;=&J8
M_8OA8J,,]JZ.!G*@'(*[5A:6V*.TJM0:**$"$ 4PM%X@6):(42^EAG*N8C R
M4.49#&S7PQ1BG'@YBXD=0.EB2(FW%ZYN^"^#E,/-W_8<4AH&7FHZC8\+0'DT
M\GJZ=S;./1B:Y,FTDYO^40& #8L0-6%,]31D1^P(><P;?"4P=['E<#-*6RDC
M$HP.V>M=N>6P+#W]VBP6X1@!L^*=,Z4K&_R00PFZ#RP2+[_I@KOH=L@'-XWN
MUQ8/S[T./ ..<C]^&]UE*OUC)6;$#9L\)7^]0HR^]ZE!K?IA8TS.E^A;%3*.
M>(*$ HXJWY:J^;-ACR6BN1SR^$NPM!64V8K)TPO6=>L9JSXAT8_[N.Y)M8FR
MTTHPB.U;LLB7]0WVII7G2W#G6+]ZH_KAL7E]G-)"6#GM'2P+B;?L P9KR/P9
M=[%=0JG5PZE7(RXX9;0PU2<]<)M-6>Q(!_7>,H5T7:4U]CP*BA2[NI"):="4
M1Q"#;<M.N/NNO8.AF+=4I=<37M)6&FS]]B8&$^<I\D@9]5[SSXD3CU2<=$-$
M\3EAY?O:;3-]R_;6%\_;K$CZN)O[VQ_>E6ZES.X06/<F='*K$[@R5:BOU.;B
MWME5CCI8QP_#.#N6Y$LJ_A*UYO22W\\<+S-Q\>3]\&&^S$79Z% A[):GL^9Q
M#J\$>WF<XS2D6?[GP$H.F(/V5S^F6^C0LI0D7<K(QM()KOL<YBYW>/DR4B/A
M##BR\_Y=B>0QQC@QHD:!R)I0M_GLXL6I%?]4'^&J1.AWYCG2HPC: S(]_W0-
MQ00D%5Q7UVU>C\L..K[7*D; GXJ5'KW29!!V=.@U+E7Q<]:2DJ_%;46LCRJ.
M.M7GH!M6#3T6&%0)FR]B-M>0=XZ3(JBL&[(MTQ,TY.B>7?AA>FFP0\VBC(=2
MVME2YHS!=TR$:_0-@9!%G_><ZP2LG[B80MXW]%AM9QV1TPY5W@!-J;3$5!3P
M]0%N^,Y,?#3)J"/S.X(@G!UU(G4\;Q>R[;UW=>'J=B!KDR%=N ^/#UBG8J0
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MC?#")<4U1[G 1=SHJ5 \W@_M"EA42VR6(FQ^HS3>R-#XYWUEC'BH70@.,9&
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MO@-4MY4;WA7EUA7/N$QUZ.KW=-C2NW +=R;4?44A%+\ >R=W6^'5-4!.@7-
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M^C"71<)=@4MF/W0@Q\M"X:Y/HJ)<> LZJ>5 7$OAHFRZ+;',/)"\.?%3N6N
MQ]Q@$@$QN/#9<0.9XOO%#;2L!RRTB]DMZK&5Z[:K*)Z(:&,G'80C1?. PB_G
M7@ZHY77HY%B)XT52A';GPA?.?B*14YA+E;7]N+7^L?H%;XU37.$?=XZB50L@
MB&/C2VX'ES+;HJN49MUJRLD*GRR7Q/XCO@JJ)3O1C2U-2E/\9QIV5RG+8-1M
M$98A;TWZWM4[-'W/NTD]9(^<*L*N.-:"G/L8GX> R:PN OI_(7V=P.25G]M5
MHJK.^,3M/3]"GAMDA19= \RL$NI2)FOG=JAPQ-%]]<9&#O[0^M$Y0M0G")%U
MG@?)W;3W? /8=%S9GCGS8T^XB4)<<MID!<M.$&K.AQ8:"Y/;A=[W%D'A;PT2
M/>P6/7R[X%*J%N'3+E><R:/ S_5-O*?OMMX=1?+N<#^(S.YW#3L>6 JIRD+!
M7I:4C F<.[-6%M?_>'^?MCGK*>R1&V[7VL8K@RT&ZKAQRQTT^^#+SAZZ!J3Z
M%%4$+:Y'TQJ94/Z3?I)/!CWR8^*[Z/ '>5:Z"4(_LMQAP%';6>2C4]6:#[<.
M^.9C[? /1BU$LN8V'H\C5&I'!',$Z0F+7EC1[AH_-EC^%/11J:L?;TN[ *UG
M)11C ]M*8-9/0/+T>'S>(?B2_"T6[Z$637P(Q28GISB]&">AT+")V!13/,\U
M8-9"(B9"FH8G<%/3H<9MR*UA('4,E2([> )AG'DN_25A^-#C@7=@*3-VB0SM
M&=8 8[*)>X?6H:"A\$M52B5GK3=QXF,$[Q]^4L45X9"APQ[9>N/[>!Q24799
M\$KVU$E4<V5OI@(?SX 8J-*0YP[E=A"H$J07[ZN!(V/Z6:=.LYLN\P&=4O-G
M$IZ$,/L<?9*UE>$]'Q==S(]@'Y?3J<E"[R_<Z/:9%9E$)N![^@ W\X&7M2B+
MGSRP/'I1"H_NI^56%<EK-Q/>@.6X_&BVCSNS:-)VLI2.P<3'?\1A>3Q\M>ZT
MX=Y&->]DN4^(,F/_$7^# QNM0SO_IK5F6:^55IC!>5GU$4++9F[3DS5V@3;Y
MGE)MXJNX0[-HKZ#/K2&4.(",-5'LD\)?'0H(9UNF%KX-5SD@#[C"V%QI*/1I
M^S0_D1P%8ZR']K?!J3E9@7V/_8['I2TU=OM$*FMXU!?: _=MGJ'\#:I&LX!<
MO7-<7J4E,HW4%_C6"L6M\FRL94/,\%]SO3L/AQ0"#N*&9P5OS>J]W#?-:M>9
M]\*.0FGQH71EQFN!7F2>Z.'I\^'.<2N+DCD"Y1>NME7Y/4#:<VR9:%OQ_LJA
M,XY.MJG5=EDL):1#A.A:ZDFAIYHZ9"='4-7<DHW_QV!.EQR("7J\&Q)K_42/
M,V\6N>$<*;^/^>6R%YP0T/NU+M_&E)F3-C*9W%[*9 L1V5SLG"WQ*,W:WAJ\
MR!FZ6N;  6I[.T3I(LK()](N_QBU278@D+!HN< &'?N93+&$ORM#V]'3H9YT
MY>/>31>@^8#<1E]]9\Z85VX<YNE"KW.(RFIQ$N_5%9VJ"N[8,DR=S+3Q)1Q&
M3DLH?9WN#&MS$NCKH6-005=> ]SH.?T**S3KGNFAP*U"\^)Z&:XQCS#4CT0-
MK@&UE=)^&3]BJ;U?>VV<;QI[@21U6R\V@EJ<Y@S:Q#E:R J+_>LJE)EV.]F*
MJ>AMU$=>E _7&BY<?N$*#YU!SE#;>N\)*/301M"RB5X@)'E#C\\71VTSAYB%
MW$9"8>%@E>+XI.0I#\VHPZAV:99KP.=9EKIAMB"E-Z8CCZ%DP6PB[Z-4(I38
MF$39DBZU#>GY<N3%RXN<3X^.=]8.60<%O&P*6,<MT;Q..7;FEVJC9[=QZ([#
M @'S;I)'ZF*"R45A>]Z2X#3Y["CIW66H!VGWRUMN9&^?\H\>:5&VN3I.;)3,
M63:OKJE']OAA1GNH <MVD72G_7?Z.38.QKZ5;I&JI2FO6G_ B5;T*(E[FBN$
M7;ROQ'S<[X",KY:+)=(JK'8^/-[;FHX&$1,,9-O0A!?\L&53]J/LCK!H&^V=
M>F[''&L [?B)5Y5=X%Q J^>O.&J[39BFG"=OXF+-ZJ:HTS1]5SR(FMY&;*35
MTS?%X1G2<N<JQ>5NX.:P31K&0I2 BATI>RKHI8I(K1X7(.0$CK2%AWEF\/^B
M?EG$G/AQ^HW?H,-']FI<,4<?J=V*C:QQEK@.F5$8 G[)S9V?-9*:X&Z'VU+U
M]84'0<92U,;(;)&E+WU)O:&@] )%=72_BWS\J\JJIU7FFYTUQ5H6$7<?_SI)
M>:"'-+)Y98640\[,U,:=4;(ZSJ>"OW-$'>YVY)S"B.GTA?*L\@92[[IP.H=+
MM+C.&G?S??T^OR39B;-V.S1O\W4L.:]'4<W R/%Y\"DAH]+^RMC*> +O+M-8
MYB^Y(PG3=VE)7V%%Q@/(\GQ3>&G-C[4(JWDIT@@]4ZOO<?W-6B3J0U/8?A.Z
M]-DVBY<JT%;]\W>&*JKSJR^7'/U*J:C;Q3"QZ;9+5&DU),#,NXMB<E;@!TF%
M\T(KA[<57(]WH'#6X !]:WW0+LFZ7OAM1&NU8*E5O,[9G(7EL$Z44X5G)7>T
MV'U%E<S%*4XO-2MS>/B[\KJ*B$/VT;</HYS@7MA)7N]2W'+;\D!ZZYZV&6*V
M7U)ZI7S:=X8?A.\] @#P*M9>N:=K!&D@F&WDU)+NQ(U/7@.@EJFR:'O@DC*R
M79N%$@_,VY!3=D 64#N4ZA=<HO:,">P?^W M:M=>^M&;:B=K1+7CAH9 NFK"
MCD3[8<5CI59VEI*FC79Y$/Q K6:#XL*\+",+AEOHVXMQDF=^>V+82!<)QI3Q
M:QXH(@4ZX74<30(U.#']3^@R9Y7%^46;1)889=?9;8V6DE*?B"5-'8]CD@N.
MQ B?:PP?@\EY@Q;W3Q.Y/S]CJ8T4$(?%B$Q/7?@/4.7<_@%S_^#>6IYBZW-Z
MU[:^F^?54[65$BB*FIK^]$C/HKV<DK)X,[Z>[M.2;MB32Z5*,T67]3XJ*C:8
M[UC<+!O4B]"5-KMV\L3J<=3*7"17.D4CU;)31#H5S-EZ2U.M!E8'GU)\7^%%
MSXU)?6^[P,UFK(:M)'P&9N8AK-B52V=XX=&^U"&MCX27%P_7VK@Y$28HV@H'
M(7=![@J427;XXA;T>0.\@GME*&.U(=^^TNW72ABW'\F7P2)3$7PIFB#EI=-0
M?4-EYU:NZK<CK6 AK:].M>C:R%.(OK52]KLG1ZQS=LFVV9?BH;SDELA132L*
M"ETAG:S=61MVB5I<B3RG?D>QRU'D6%^\?V;)<,&QH=!!0+6:D^0R@ZE*7Q<^
M<(91I;/J0#[)4VTF(C2=)_&TE[NWP<I*[YL3W(PP+=.8XLWL#;&I^)F5[F3Y
MB7T7M^>%'I[,/'8-6>&7T^*RJGAA+X\+7^@+!N%A6X%D;^X0JIW"MQ$KC]FD
MC!;.($\A8FN<B@;C=BY7^H9RZQPU"]JDNVE^'].1I;D,%W2Q!N^%EHIO<#AU
MP+\C=N=Z/+'* P+(I,3QT1DD;W+.[7@OH7=(0+7/ZQ5(]<69!_%,N(^:EV]
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MH_$L &-]#< G:H1E@)[,JA#C .%^3)G;TF=YUDXF[D-=IW4UY9<"T-+1?A'
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MB+ZJJPRSA\DEKM^6D/&TA+-L!'R:>5T[P6]D+< &O1_V51!)\,,.IY65Z1H
MDP>2?%"?.M^#G=F!R=2TN4KLG&?RX/51O6DO7P3X 6-B4IV%)41'>2O@O<=:
M:5*J=1-<V>7E80,U<6*/' P723V8B3]/V-P:_'-RX'>'[-_K,LR?XBIKP]Y_
MX3/1& '=+;.MKEM8;5ITLQ6VXXOYLJ-H9@8N-.ZVM&9($D^Z7_]Y\*XJJU\+
M/TG\_"1P1%8/.U2'[<>.'C:/B.\S]<]*8N=^=X''FGA>QOXM->Z/_@ J81]>
M:6!](&M#R&O #N65_-D%-LVGX+EL8TR*K"1;LG4L<]?9^^($@/EE.MZ*:CT\
MO6O/P.![\O-ET\B(\8<O2Y!.-$"(TL%PW6B*]CAL9<QY#JO_!I5H;3+RP,EK
M]1IP@F(Y"V2DX:\KC2AZE@NR:[7#BS6-?7',HBA"?PVX\A;C4S43,UZ8RML0
MN;&3O/?9H*K$-V'8S,55:>+&.;W'A_5/<]7W#?+D/#V'X>P\3C9 5XOQ4[=$
M&I]9-^WR2K"<4\GS:NZK]&U=-[O#V3S'\,7EK!_Z>5Y!7S%Z]LM 95B5V&;W
M/M/)&?W$J,Z@MD[U7P8"$0W/E^LA#_5M/\E[45VM&C>M(.H*Q]=']KS0+VR*
M:EE1OI;RLF3:W3E_3^W[OU8R'WTO(TNF\9]B,?^C=KF6YU^+FBO1\%O!N-#M
MRTAPV\+OA=]3"Q:7JAGKV"T&UP4N!@\52=36CGX&?H-L$3JEK5JGKG,*84=Z
MLJQS.,&=^< O .!B=CZZ-KJ\KE,VKPD>(H<V)#[J*6LG370S^UPDPCP>G[3,
MP7KIU5X7&+]^+K=-$2YUIKCIFY2CUJF*:FYS-*)2$Z".IO,8::F7;/AI/UJ?
M1JOW<^JX!_Y8<,FR*C&;^!Y3 >/AO6,877E<-SWNR-J(O3C0MFCKML/'0-Z9
M\5@5/9%N"3TGH/WKB6,AM.HR0=3]&4-K7AFZJ!=25J[NN;^Y>SOB>F[CFN6_
MJ28?#F =/_$$]E<::;Q+7*2K"T\\4_7FX-0UK.RWZ(EI$:M(_8SG.]&SX_MD
M,@O-LY2"/HF0YGI6GV118Y!(*DS">5O02?XV[$=NKZ39_"8,#\4Q%=% "<X&
M\;DG&VS!2940W$_)[+\A9])RO.=>4G6:U,5U-A&AORS]AF&4)?.2*[?H1@1?
M*]5.Z-YA]HN8QL4YSOYFV%TY8LSB)A1R @N[&/3+0T?NM<TEKDN:B7;XO4L+
M2;T[*$(EGNXA8-(.73$R,9X4IVAB3^8O=[/FF@'W!=C6J*LLQ4KO=(E>I&;V
M>T')5WP)4>EEN6C++@9$HGV!4A9OL'E2&(4KYW?F0QVG+T.%I6)8TBNMX\G)
MH0[:^$DA>QI=?Q,NV-N5OJU!GBA/[W"1D6.HK(OCX[2<*3XZV?O\D3X :H%E
M8T%49#7DASNKQNA^?GEMTR./0GN>UQ[DV2;?;_L+67Y)SZL6E\G?;B)$VY8^
M5NW0\6R<_T$Z+\5?Q<35SKX6]<Y@[,>B^AH#3ZT72N?U&$8B#Z0Q;6,ZHV:-
MR\X4Y?[;09'V  <Y\%$6-=1.VAL#C2PE^*GVW6S_QE4&IJ%33!%X0=XD'V.H
MF2O$WH(F9N\=2N9L')56***#ECGD=2HK:@[N%EH2'A9)] <JE]WR,/O^N>4B
MU%6[5LBM;-.%?*)-7U\9S&@:PZ30ZAE]UQTFCLH9(WF$4XS^Q2]!]*3?0=>(
MUZ@'X_12HPN\,^SXJ\0DR)=E7,!6JC/993!?,-?2^G:*0<BAN<63+D7Q0X"P
MQ'.G+:=:>-GT#$9^9,^;W&4YIZJ)0G T.)TW9#U63\>OGJHO$@L?L:9)%9V,
ML2Z<>1%"-*[$_N+S7<#%8DQ&5X/8FVM ''A*:N<$<OQ)8"<=YQH0<_O5C5YG
MNP;$DVJ3&7P,.*T&F17^WBIE2=@[SN!D2W348O"8&9&3ETH I:.D;GQ$8K3.
M.T%*6["CZP_JI_!PGBCQ\-B7@V(?H3OTC^K&,1]R=R8O^JM YOXB'"OAV"NW
M/79=[D54*ZZC'B(P92D*,&^3SM608%G;,'N_MW<M*42,B0K7,M_8/^!#?8HH
M902_U(/-*1IHVN2,UWOEEN^V5B^I^TC>WAY2 :96H\>6@!&*MD+S'>$SLOW1
M?I13^W:WMX' )4A Q&D:S,83'A1C ?UU6<\43Z^];O=;^/RGJ(/$#M.R79);
MWHS>EF(.@>I=O2%:VC!SG6]\)"G[DI#@\&B1/?>\V,8 -U#Z[+WW]QB_]#PM
M:"_R0$P,IIS2_L9\U;G4C%[&YYMF$(^9-<T978=G*%8D=YXAQ-F&JSSS[DJ]
M6>*$BYV@8!$_#'9BB*HBRZ6IXJLZL,9N;(-D&S6%"GE#<D64B/S?]I]LF]J]
M'$^KGZ_/M#<^Z?8@]E4;TC^RY5*<A',%;BW39E" \'T35,6!1%U,.#@MCA._
M9GZQ-NK%=7@F9/D^-H*/EPE@(DYS0GJ9<]@N>X691(3/\GLYS1KA4Y]@]B=B
M0#/FN*WZUXNL*.X7@!-A!JA2CHT4 F$HM&#:4'[DYKM\R,6IV?[PB%.%+SS*
M%#CH#<SR2>GRY4IS459+[I)%T&_&"&X:).&A'J9+<+/;$\^!]!/;B)XMN1R7
M)RN:(#WC=SOJ7CUS<*VP7.\"_$)&BOK]>'N,Z"E'D>=> T($)(C9-BCUG;K&
MQ-A^MXYS(\!QK1N,.DG&.Y,TQ/5937XK1O(Z'K!L_[W1]=U9IM?==_RZR*XD
MY'.=L737@-CF%=6+-<MK0%8 !;%98U8H^YO_SH+!]Z=$72)V)X^,]&:&."KL
M_=9"]++L1-3E>]WIHJ2U07W[DHSH%"PID8SRF',]"%:A^I2]VYZIJ=.G5LQ@
M:U!L7!7%U('X-%(%S90G?.')3_I:UZW5%!+O6G+'$MYTY+>N27%V&:6556XG
M+IMOX.[A\HOYZ<"*'F544L7(RQ-DZ&+SDCDZ3"U!;N28.8%<ZJA+,9A^3>%6
M>6Y L3J2HSYYHDL]UX*U&%FX[:Q#L*0:#)D1C1X3 ,K"ZS]]M6 &/L0PTTOO
M:#>8K3@N36>5550;0%^]H[4>',==-"=6E/PFSJ&E,3WS3K>7,Q'>%/1!UN,L
M2!P"<8,]BRG=VK$4S_]DH18=N$NM&S<$U4/EA[LHX^E6C%76*W!:I'-<T@NZ
M,I<! #F>-!#-8J1$AE'G"4)R8+PI3%4LK9.\%>W6@>48=]D!&:F^NN1(36GX
MU?2+W;8M5L3,K^<VJD#@&A#L=@ JWQ(E3JX&O^JD*^=+^##.7H@7I0_1*-CH
M@<+/**<*V<#U4-NJ_,P10_DO&+=G];X7'W.MJJ9:*(P^!WQRH1+W%STIJKL&
M=(CUN!3R0V^K4%:T=9J;AI_?/*F4A+XV]^1- R9A'&*4O3NAM'E\5+O)K\.P
MN$#=MVQ?.3T[DUN5>6NO!;>0NLM!18Z8ET\-3=#E9LQLJZHR\<-_06<LGV>
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MP")G9 _8&JNGIK0:TY%9@6N[-(R #XVN?N$%XH^FYNN)++PED]<C) L*!/B
M\OE-M*[+DA\.3[MAY&O<UX!?#VJN 3]O?B-]KQ1H+4NDPHZI*ME<"N%D8:I)
MH=TO"GH,_:5Q%.92O\S ^>10^4$-TNZ3GG8YY;-%>]P-]K0QV[<_JR[I27*-
MVW)@Y#-GVC/33(RO5JMX*K'JKWF.1%@CYX/RS4(W!*A/IM#9BUOP%&7146U0
M0 3',VOFZ8JTU<\\0U37 )M8&=MD&JX. R7@PH/.964CG=V+RM/3F&"G/E)Z
MX0BPWS9$=!,^Y]MK<L<01 ,)9OI9]>2^C=K,58Y\HAH65BLR$SD]9-.!M@=9
M7A6O *.#[6D-:R)FZ,X_E&=OQ2[$.R*6._&^8ED,]!9UNPMFOH_X;M?&"/EM
M#0KG6S@:_3X16Z#<U!?O Q7:Q'0Z<%!L[LO1KG!4<J]0<V"8,FQ29% J8<NJ
M_-9"6PXW*JCD57ADL]8?T3*TG\ZL08]D58X OWM+ELO76((\(G'H,<FN)>95
MZ&[^A"_FH^ZVO[_1U>/3XEYDQ$.>O.EQLY0O\'YY4)7H>RKDV:'D2-WA]W#V
MR?''=Z^PS^IHO8+MD"LUU?$L@;*$L7*M\7Z;TH]!O[ ,!NA"S,-/SL40(E5+
M\#H_U/6(VMRTVRTI@#%]X:V.T<&"<H;"06%Y,K8+I;XN0UWVO8_,1L7UUDMQ
M4O>SS!P_P0&DB<$8/P&31]%\)^BN XW,6=2/V[$^ 5HCXGJ9[I&*9J-PW'3=
M0..G4-J"$T0+G?/&XYV4*5*QC'#)Q_X'=_W%J'.KY=>\=U-3/1=OH^^7K;B-
M<DA..-(4H9..ZS/*RO'FS319ZAR[F>WV1\/N])U)/11GL?8]U0"]"XFI$M%T
ME;5_M4C.$ *54.KPE(M.B() R'CF8AFC5[,7[087N>^*_%HNPY!_R&4(3#:J
M";U;GMZIO\A-JY<$\:A'#:T96^1W7F4N1>$8&'.E6;D4,@4K\-(S8FYOBT:-
MACTQ2L^W1A&T)<Y#XJ OQ8/[8>O%\H<7$2UV&#X=?E5**V.F="M^J+1E\L/:
M%;:>%L^ES\Q.(O19M<V4_X.]]XZ*\ED610=!41$0)&<%!"5)D@RBD@4D9Q")
M0\X91D! R4% XI!S9F#(.><\Y)SS2!K2\,;S._MLW??L_=OOA/7NO>_\\:W5
MWYKI[JKJJOJJNJNKU#7GKMX=<O3?YWUZ&*Y,L1NB :+M9T'<@S=*/[\5Q_45
M/5SX\,'D8"'1F]IG+O++QLGQ#ZT?F4N=GE9] SRF*] OR?@"NR\TP)0%9RVW
MIO9/';/T>!UO@=]+'>M."9U6:19Q8!/R=%?%;1$08$.\L:*33 >:U'W7QD=C
M\?V4/6/%>W96]'SGHP?;N#[THX4^G%/"9//);(;!#-UH6571KMM$Y@H;[N99
MU+096:2H[:W\.HM@.?+]%?1UAB'#\9!';?$B7Y9B=)Z>L[Z5K12[W]/E.?Z)
M]D>1],#$/22_F9(,?ETXT!9BY.^$KVSHOD(+SQ&<D<$-;'@6O^8T%8)G7'WW
MA?H#*T'[1./H\/W^2_!7*CQ(M;NK8\Y9NH6Q9(8#YE!-KMY$KLMHI]/T+5/Q
MD7T.*"R<J^@)$ U"=V!$@Y><G(WI/5]*4S]A58?%[,;@!^GG:>T'TM+JZ1(_
M?7*/645T-=15),1$BU.D%11 _Y7ATFW,"VWM5E)X==S\C'G,14"0Q0A,]RE6
M",\>WE96E\]B-97S]U>TH_K'_0**\#._XZ"STOKQ99DO W3*$N'BGB0YCT'X
M3.!Q34/$4(@5)S_"ML^ M->U.&RB\(H16FX=X&3W)"-2!R4<_=T19R4"]2Y-
M&Q5,+)W.[I0L&U^.W2E?PA2J&H,UYB0C6OF-QJ<:#I[C4CAN*3-[N"]YRBC)
M\H^J!<K$X4S"#)YW>1)^N;_@S;T*LZ5%$%UTO""7#FO/(A=-%BQ(QH2*Y!8=
M+2?BB2[MD:9^I7UA5KG,DG>G>1!]-"6[QZ]O\%61NP(<YN^0)+D%JX&PS['R
MI*A^ !\08K MBSEP-WDP^C^[HG<5:C,]@_*,7C?:=)O,G6G!?$<7YC.?)&SJ
M'5I_I6\8JO"44&L,;C7/F14O+U%6_BHYTP5PWIDHT/00/TS:VU6U,<>+R[(L
M/0A\JR;T@O3;LZL=_Y'L(8?& ,TQM4J6'&"G;CR6N?ID<;PS+K,A%2;IU;-&
M_*(K>1Z?N!,6\G>CS,OQM&1!X)=&'[S>?T>3H$[A5E5CB._:YF[\0E0CT88E
M1&0>01G?TK%#-,+I^OG6IX<XXG<%O1@JK':$N0Y/O9U/9644)8N<]MGIK&F]
MMU_?DEA1OP!?Q5!B(9NAU .YFF8P?)<P':J'AWV/WD%U99&ISLYK =$NSXDQ
M%MT_N"N644Y-;5ZLQRUC45=NJ47,:>U/ZW V']/\P*4M-%5+N&+GH=6#!SN;
MFT45_B#%'P(_T_:?@PJ>$&X1Q)>3.8O^_7HTX;U_R4"),HV);P"K,3LBIZA_
M2G3J.BZ)W-H2?HS@<_>P^+8-/]_#;HDD?]93K/W0-JRCOE%]>)?[^KDEIY+O
M8'F"=1S5J<[DA]9HFA/T>HDT4WZ3 *[A;*#J@@GD@;9$/3@*%D,WA)EPA0DS
M:CA<.XT2;)]N43'UI5+EP?3>)=4ZRJB$-[;F%_*[5UW1I3%"K51'"W_8<( "
M:^O1FZDH#^MGH9HODRV-XP2K[R9+/*@>%/_('R;=J>>+Q'A]?U.]>?#*<_ &
MT#[6S5/*L7Z)T\YVUV6F>;HCW\0H;9/-2+#V*ON2@OUS2ZE@/CX'VM:.KNMR
MR%.8SG6J\2A;=/STLKKJJT)(Q*F#$.C^R1[#4N-GB) QI9;<B$?0IK.KW76:
M:H=R[M+WT,^AT7;RMQ%>>H_"\(7!2>HOK"&N(X[W"3QJ*Z^',*5M5>]*Q""-
M0+@>(H>#?OO"HUG /"AO4[($D,*)EPZ.^%BGI5E>A_"#9UV,RM=?LGO'T5:1
M"BNV574U#S(+@-P:PHI ;P\E CP$<F5SMC1!$<X<!)&JR5)8MT1%7,,4T;(4
MCFX ;;AWS'4?5(TZ8NWIGQ!'?PFUK_H^=9?&H^TB4MB_'GV%-9.H]+!<;"R%
MMK>FSM^HTW*HRQ;A4"P#N^++0"2W,U<DB-I;1=Y3$>QX]P(#/9KF^&GNG MY
M:VP#9<40*]?1TSASAK@'=UR%Q<^KYVIM+_>:A:[]T 7#% ]9HVP/7X_J0LK4
M3R0_2*U&W^L+JL6N,J'$ =W?O*(OZBV\PIQ0739@:8\.F2LOIY+$PT<Y2Y]*
MJ/W<WO'C)%BG@/0E+.XDK'(WANN$[7?1!$<E?SY*G/"*703A;-88IV8#+US]
M!]^_H>S3,XWPS;TM/_]1 B,XF+KK/>9G#]8)#^),T=PP(E$3IJ[A:_ >D:X7
M +N6^EFG@N[<8KUU"UF9;O;GY<JOCQFMB.;[FCBFIN5[.,]D%5#^A.BB_ 4:
M:'46Y<SH6+DX-U\0^PF/7G\U.-6#[!V!/ YJK9RNUWDO.[,+ 59_6U;CJ#$H
MLOLZ(FOZ/(N7H::M<,:[P[.:X;#(;F$)&<;SE9N2LN)9K&6>]M1@_?V:B",B
MDE7T30G"+>$7D.&B*P'^G3)75=,W7]%::1UN>\K3&<Q7+SQTX7P[7L>F[Q$;
M.2-J\/&^7 Y)W6/G!SX20O*Z&1.*(7.#;(\"UO.?30E!&GN1=Q<^-QKIX%\P
MIK>W.9,;1ZA'AQNLT8[6NQ':(6^-0H)PL<6GA;IK IW8Z/I>M-=\")T\1OE]
MV\\7"PF<]#^NB#_S(U!0=OA[H39W9WR24H@Z 8FWO"HZ$(^:H;H4L2IC%< 4
ML.I8-H?T(;Z"&MTB/MJVE*";FYJ)F$!@\Z^Y</\DY\<_D1;WW\]CX?=OU[?_
M06Z@OY\6HF_T6!Y7;!'!W:]?P3$RQUTE\S(8S3O<IG7RK,"X^*F+>H^52USF
MR$(DWWVF0K#H4 4;KMZV&\:%3W?V+G"QX:XS+861-'SG7%GS[#.KQ0%-F%19
M8YU?X9-X"?7@! U_R9[B6^G1B8.X7$45NGJPB-YAM>,DLDO-,;&0;P+KJY4K
MGP+YRQ\-W1^&6_E:+NV]'IF87ITMJ+0=&%DE-/[HJ@W"1:<$:DRO/K>SL:\,
M$!%SU 3Y.YSO0ERM3W!+N8]DF2.EMW/"LP$ MW**%7!+<CQ; '<0MAA$ZH1Q
M?]=R>C-SOZ6LH]&=7 )S1SXZ)D>V>*=B0#JP5/^4K;+].H45.POD>FHGV&=0
MZ;*CDT%&[<LJR.=8F MKKX?T8CUV<8ZT[3JW#?4TE5[.EAJKC^?E9X*,.(@\
MV&Y5JPNI<"P9W8NQ+(!_55_=1^*S-[4_C4A'R+3Q^VS%<.R\A$4QN7)HDR0+
M-3WR(4"?#E6,H9*;,->I&^ (W''0P]EB>#-^0FE;W'GJL75/YN4K*09K./K"
M?)XN]9WK4+U2UOK3PNR>HWC*A%JKI@'A;W:1FQ4$,](; F*.I9O\1-&IZF94
M-.#W0,?;'&^PO\A'8SJQ=-HVG>35)(>EHV?-;I%%R9L[TX1*/C4B?DBQLHY>
MNFL;R*?.CR]]@+PWH*!35)WIPO-ZHHBK&Z8;*7GW ;P7!T>9BJ/A)&%9'KL]
MJSM+/K-;J#\K^V'DE*'>O&]GSZMM5THA$'M[ZL#G=*_*V0W&7 8?<^ \UI?D
M9^^7TB.DR\"O<:4WN<"X&I1X%7-VV^:>(GT_4D,Q[F@L4.P- G"5-H'T]KQ*
MWY(B^H=U+/BIO(NF=;#OK+P/1$[3BD1XEGP-=[S?<P<7AN)1OEXACAN  C.S
MA955H.<2QCO$Q:)2J6(FO15T5R6M  NKH_X2?UK.ZH=$.*W A<G^BA!?;L9P
MA7IJ*)!KIBU0D8C'E(0I:@@]U%ZZS:ZW5#RPPC5K =A^^R2Z/]?VVZ.V[MJM
MB'Z12VKE2^(94+FU<#?4&;SZLL]MOX-=S#=&K2)0674OU+_F^W!*1>78V[/(
MFD'.-S4LJ9_FJ/@$1 7*1P,#U(>LC@_PM(&VFCJ<]Y(LQ],$UH+9[S<9A+_:
MYDWKRY:6LM=Z\R00ZIIIQF^CY*GO:$:^?WY89K(5H85D.'3LB"V0L<[4V"9V
MBF@+'CD7E\THDJ17ON_T(5<V:Z^T9UAMCR4E5FK,)!(+%H]''4W'^.!93/.1
MO$4H,>66_E!%D!\V3K3GDV_XMV+VQ4<X<-%3*;&9L"+E)C@W<S]65B6O:HEA
ME,G)#>,_9I;/XA^#QEN>)O9 )]1>%IQ/,WP-!V>)W5ISJE8-K,X$0LDZ<JVS
MIQDY!R[5& !N4;MWY)=T'DQ0/2BI-\=*F--U-0"Q:N40<7]YL1B>041#C:P$
M9MHM277K&:W;*:MV-"Z='\M:;.6AO.MYPD47?X]QJ\]H"].Y\T#-T,0\6(WG
M>%EU2]R2(>96A'1?G-(W+5D+I33(XZ$*=S_L.]&>C(QTMUGFRK+3;?BI-4,<
M0F3WJ/8<=BHKW^U_?]5.3&DWV=1.I-_-VL[/]#-46WG6A4=^W.)Q775#=97+
M/$FLR_WJ54;270&8@!#DM!Q"_%#J06]SZ-OGK8>"0^,!_'9^Q6.!@;7VZ68Q
M3LO+.[)U/H]&I#X8Z?4%JSR_"RS\]1@+4VD19<KU+^U$8*QEC*Y:)_%_'SR+
MO0@\-3?__B_.<H2AO]AL439-X'E+#1@3T6*-J_V%@>5I$JW'UE@'J*YQ3'5L
M6TO<S87"N?QZ3C[@AU!18.#\,GFMRS[+JL;C"&?:W*XGF451"W(7*6F!S_X7
M5?_?5+%Y."WPN3AA[#(/.\+INN.[XZLG @7-S7&@+SBXO(,DZQ6HSP+FV/+A
M0.I2:Y9IO']CCAD^HXPLD5I$Y'@W:<\>X/9&+NTY+'?>A5-^'$+)VJJ CQ4B
MS#A!GN!Z7^I1WB?ID@O0\RW3/#OZM^L0,,;6A6X!MT8Q-Z7<]<,,I>U'YX4/
MA9P^ :ACBPMU#V\  9:"?-B[JG9R.Z[.]*O)]K?>-'#< :RL4:]H'BM6[0;K
MT+:^U&0+R!BVS*PR!PKV08*QKE:C4![)2F#N#> N:_ \0<7A;IJKI27.)CV0
MG=DZ\LV=]R_$Y<VV3--VF4/-I0YE_>/RG^8*G6;F+KSU>YR@4'7TCN9D^@5@
ML%@S5 1@NK7$%(8-B574D'_VO592L/UC<]E=@(U$IB.7@A.1Q#/717+R2TLA
M*VY9G6(++!)N/+O;70_L1"VK:*&TF2\7EM:C[Q0:Y%7L9]OF3$NM8^4'A;&O
MDG1,='7,US%2FA>F!964\4X@++-8YD[6LK(+-'1T9[MM!2=B7[^TW*#GU;;$
MI#,T-#Q2HS]\&HS$ ;?BW5LL3?+M@5=QU-Y1G=7P[J87=]G:TN$FT/&+"&P@
M*9-_I+73HA56(6K(K,*#[<=#U$TRL O6=E=::*T,6^ZZ$C<$[T5,>P;3Z*_M
MSFKQ=MA'[2!4ZPFTF6U'/7A'^L[8]'.V+[1YWNFZFV,ULCZ[M^T4;@NV4)/*
M !+Q4\7A)&6_*M%Z_2)/1%'>SM-L[^>L8<NX#[:0=/ZWZX[2X^?.9F9GN@QB
MB/95_%2&Z\BS-\]&]>K;]]-!S%Y*.F:/7(MHD9N+ )'[FSD_J<^")-TBB<'R
ME%"O&,WZ. *<./.SG!$2GS5$W\0VUT%(R-0@VY4U6-*&UQ]IMJ.AV?'?Z>*C
MCC@KW&:LQ:)EO12M&./>8U"/D8I9>7=4%_WZ%L_W5"V;#GGT8#S$Z-/#O0SD
MLTHXEA1O+11J[O"JM?>Y%%U$\ 98$Y86W=*)B]FR]W1@+J5LW+%6[!L4?.I>
MDNQ"E\B+Y1L<$8[625JH=8!A>I9, CW\05=9^5 RDL;[DT7N(+WW@+SFYF:V
M$Y'X6V%*B&\[C_!C#08>9Z(=JTUU5WU1C(?LB? =!1$_ARW'RVM= ^:R!4W/
M4!>=@!B#@P[.J)/"'L8J]>4]%.(OFBK#<LTYM_+L:CR@GYLPM2T!^$)?\V47
ML5FN&(R61AT]3]V??3Z%W1+32+=1]R%AY9UU5U,1(]8W_*#I(C<!TZV8B#^]
M6#^=[]Q]O!&AY6;%4EV2$M.]<Z'J.=A:R"&3'U=P0JGW+G"K=U9+7>?<5E)>
M40V3]+3=\?@GX_(X+WJ2;;2>:M))L11&)VX)FJ,#9%CE4>C9V2_,%R$"6BN3
MZ<M\)GY(K822?ZY2PD+]:H,CNA(/^\FR]U</&JB!L6XA_7L5I[G9Y.4).06L
M=3D;0KT/J.0]#'*+R@+52J:K>R0.#T3#6M7X[W3W!\.>;HE&K7\=8"_Q;B)I
M&O \4MY'$F]I1@?-F+D507.,7G?2CZ^?!F!0I,Q '@4;^MC(.ATKU1)&#)KK
M/H1,'#!;)]\ WD,:RE]'S&E*XTW)OY]2Q%V;SYV]$AY=&V<]V.,6,I UARW8
M$X8LQ%(4SGUIYN,3NKNC8_F32;V7%C"WDHEK&A/><:;IGALM.3_(4\:+Z-A-
MC+23YVX4(_ GE)"X 81KBQRR7=\=W_XE08+IK;_4D7VH.S6S,"UEZ6Q-V(8C
M;)KU:GN2CQ0S-(5LC4601PC< H1(,C\)4$R0<LGP%PIJ6$J=MFOUD6J:E5_1
MB29 ZS<E$\_,1O@J5C<D%1G$#XSPKAN)K9%][/4[GJ]+KC[-T\4;9H74VZLE
M[[Q[4=$^-Y9KO]8<(/&]+&2[XTVX:"O@CI"?D_)[3'+,@.)EA*]M(;G#)1?T
M+:9.ZJEG#/<#.3LEMQ=38?7^6_TB[36Z%3EF,<2:%G@UP!3M%!- +]OW:K%N
M$@%"&$.P) BG(1"P?J67IKU3NO7R4 (]0VW>HF/Y\?,GKAQ%TO@\'GUU;N'N
MBBZ^;^/E,=HSM"3HCUHLB?$M3*(-8CC: AZK[RG:R&$[0-YCBA1LQ?(TX/F/
MC,S2P;D+\JUFE*Z52[N4UNA%6_":.]R7P6G 4<*)C#&+":ZQ@P>-QM_R(ZBC
M*-SU,'('6L/OD7#7B@'LYQ\.&0Q!+B'(02@DWGPF0%B1AH4TKD^#:9+V 4[3
M2J"6$ =2!,O,B7'!J#[9_=3G5=/ND4ETND>8L=*V<,60PBM2*O**T$%)=8/A
MT,@W'H>/2&<G23W2*:=.!!/MF$1:R(PF8F!PJ0\3IWW;PU*\87OXX 3G[\/E
MF)V]_B+LW?T.QW]SZ$1(<41?45?>G121ZM2IC1;UB@H$=^ ;AHQ<(KM8;P">
MT.O1L%%'RQN E0NWH-"I_!Z+X%8+)=CDR-LR.<&^]F)<5JG#B[CQ<%H^1XQK
MVG$VY*YX4&2OCSM\)O[H!L"T! 6ONUY,S&[TM.Q=. SN:/"8.+BJF.6HV/L&
MK<LX7YLZ4=_UO0$8;%MXMZ?67G=9GXF#9"LVHP<0(FI#)RSL*4/Z+I:6DK+!
M"3;RPMDBFIMYRP6AL\S*INT,-J@O=^BG/\LA]9?GMUS[Q;^XF:\(<M("H_Z9
M,6ZY-*Y,_,NYWO-_:S&2_Y&0[!]?/Z'2@XMD)=P =*Q$3I/HD];!)H=E [(2
M,F3!$HHVI:33+(60H^C5,Y*SS%\\T*K8<6L]R3!I8+D11991D-GAJ@%?AQNU
M9H?5B,G7P-Q=.*<G;#,D_P9 V'3!/"T7EMZ:.3W[@N>V$5#W'<4GC>K."@>J
M9Q,53"*/3!]JZ0X2/#.W:.&RRY,27,6IWNIW[=>MFV [P:IB+<H^>NJ-SSOS
M,22OT>'# PKE(XI>/%8UYZ($5W(J7B<(O*,L9G^8.2S@KN0LR2W1SO?RW&S!
M3R+=P3AO\&,C9<F&5204)6GN;SABO]Y1;HPY/=5[N:P4ZYEJ9QOZ"6TZV]/Z
M?>2/CKT-;*%@VTZK#NYS0N'-CA>V!_%JLXKYI'RGUB<\@E(F+_-7[CJPL L>
MF1 X/?SDMJOW/6JWO5QQ6VV"BGBDR('EB5%-0[5.O-_A92IHXYO7?/95,*5(
M&UE6;)YLKL:<JW.4U1$]>[[5K)T+3:BLJ3;BJ"TVIEQS,(?I#0>7'=M4&JGB
M"_'7JS; .:*\T;/,O*@?6V>):T[QUE>1.N;(QK0;P)1Y4'ZI&6QHBW-+83#H
MV2J^%%'[^7<#3-Y!_?E()_9,[CLSV_&7 ^5-'*TX0<MQK"SM;4S&F4O,RKSG
M55VKJF'^1<>7.TSG'ISI,T DC0\'G#E2<%T2[KL6(\)TM G2Y65BT;R4JZR%
M5H![ W^(L#I.9KM=&(;RG^;LLNU#:C>++;)>S+8XTW["P94+\)65GN#)_JJ@
MH#I]-GUY; )<"CH=15(C_/<*"_?CK/3[G&W/O[254/C"BKPJO',0*=LO\:<I
M'[VM/&*_G#%GIPCRP<5.YC?8E*6/#:[8$S:OMK16?5H;U0\F@H?O[?A44?O)
MVJ\,XNMJ]IL+IQ0^Z!KN:C3^8B393(H5T9RV/8&IR7I?L%]#RVAC'1@BHW4X
M$)#5[@G,WHX7&I,1JID56Z=S+Y/V;VIUM[LMH% ZR@HII&U[R6^_%2GO1>-N
MN1;1J;.5/&NP<[&XI<L"<]!2LM3/$7QO(JSUI,9WEX3"BU!/$7XG/W]>S!GD
M3G?TIL_H$YK 8<H'!\J<=55,78K*\8L9^>0-YV5+^58%%^3V@MH0D<(Z3<RN
M=A<N8]7'3ROHH4+YF)W%>9HN_G/&+NE0'WI^]^EGDFV>RMD,F/!=H?SX,4?R
M>DVDULZ6QTR<).OEZPT 6A/ X58ASY<*U<K11?/"X:U]*IB#V3M#BF *P]#$
M1Z&8F3AJ5<IMSXX8,N?&(Z] A7WG&_'KSLG+:C%J?$"ZCWV=8U$3-7/B][AQ
M_34I)A(R9/G-O^Q'H E@5:X9[(4B3WKU=&?->,IU=;K7?^;\]4PQO,8D?!E;
ML,W/O/<RR9F^MJ35<K-UE@IW18J31([=3MXD._GL&J>QV:GF3J,]58+M4ETW
MQ8.1>:QJUP_\T1AH46J*&[*C7I2;QC*%NM/D =%K4;(JY&O8P7QT5)BBL[CZ
MVDD;(8)BGA83HV96)8WSZ@:24$\GM/CB3)<$]>''D93")VG^;ZK3#=44/6V:
M/IE]BQBF$./-IQ]UIY])\]*Y2 ZRYN+1Y3[T;)G1+0BSIN$A;M"+L_'&Z7BL
M?I$LQZDA3 BKD.FG;H?:+\@=L13'?ZY^\E*@6F]_I9+_@QJ5ATP!I25W3(/3
M&.T2O9$2Y$/P;5K AV3V^?PI,]BT8\5<?0%26RWBW+ZH70 V2F<+JZ!8N9A>
MKVG4:Z<+'91+.M'#V&)03MI_[Q+)JY']<3*XXQZI4#47]*(S\-&RRES%=]>L
M1X+OIR0[NTU+G-:<T4*JA*J+&"ZE#RYI+YD&;@"OCY"C:Y;4.R_W!FR3$PUX
M"_40LE=2IR)E*"];JMPDMO;C>8(GSXKSC@0[$QY1I&6^EC7;#A)MJ&-42\,%
M3_F[MMXL[=V93X+'&(94$F;E0)8I.'6PM=&85Z^Y)5VXC(-"9CP=4/UYN\_+
M8\'3E<#%T&(/RP)+Y-!;)YQ!BUN?#(P??QW@< 4<:>H=)K@$7(H6=Z2)M;Y]
MXO2P SV'[E,O%#/2E59PN"^ XAUKL1?X0K:V>*=TPHQC:NZ*;8RNHGJL:#GP
MY*5LSH>D*<#NZN('9%941WQ#O?G*)2_S1A*A*F[YZ]#74HDF-#9V4YB3:I2>
MR_WVBI#DB1_7F= $*T2?*?$:'PG H^["0&A[X8JA@6%V[SIG!MP83:7V25@O
M=FT1Y_O)C@3'<_7OW.85E?-J1T?\EDY,+DK+^%JW\<YC K"&V,.)4"YTN<8\
M(\Q1B >)EU%>'T^R/&)IA)<>K3BY&LY_C!Z_FC;.]A%27R$U&.6F/'L'$'>_
M<BG2=6>08&9._$#AY?J^'N?N(4N='B.Y@5X-+\7*V)%4UX#+M]$UE'?>;'TB
MI.-7D?VUSMY)K,VNG8#$G5N)@Y;M@)3CU3$=3,C=T\AS$?N=%LA2[PT%G&3?
M$9?Q"]TL!\'!7$_R)PJ32O-O5/03Q-J>1M9)CO=X7:.5K4C0;[]J)D$/=LH<
M1W&?N4TG3JJ;42!GM8&RLO;%TBN,43OQJ';1K%CP\@)X$W@E4.L_V'&*S:>B
MP=-6!/*+D\3PXJ4.^;  A#F194Q[P$6F#<([U("]%/ P[=.3?F5,3-I"!UN7
MH[:AMHBBG,X/TP5P\7W,RW:I:S.K0F-[<1N;]TG'SJ.#^[O6".O7=8>GV?ET
MR4KF>$!L6[,(C[U'/)7"",KJG05NM58>V$6R][)+!=/7H@+%YLPYV\>>4>@_
M/D0U,XB$%\FQ:+T/4"9+=(["&IJYNI[ZZ#GH5IN+*-:>8/'J]?0:1+/LX!(+
M9C]Y_&IP13Z.K*,.?V0;-EI_>0-HI=3-S->;T7-YWC._K_[ADK @.*+Z?7L"
M)N].2V@#LJ+P3J8G0T<NUVGM]ZE2E_Z&HW+K2"UR-\>-'5V3EZ4@6Z%O/P9K
M9$A&F.Q+Q=O?1%/R-0L=*3%\J5"&W0"@1#MD,5)'=17;:L!SV]!$A^P!S?:,
M49@#4G+;N&&,V0M_R[@#F"I1%V$4^?2Y;4P3G=/@#\+J##20^V)^O8*JK-A>
M42"D#I+ ][G2#1Z)NZ)]![P\9R]3'C@P<-D+#;-5[Y-L7>?CZ^+;@&4JUT]4
ML$@HD86,KY;ILK[L3<JT';7B-Y@.-<0B))G:/I:>XX*>4P;X5 BA/A0JXUGY
MMK9"&27OV%:J#"J(@=W/7;1?8EH85]V?KX>#OSB2\[%8.3*8&I&$TYGZ=:83
M L!M$]@R)D*:@0H*LK5Z:AMG?@0*DDU_/8"I9VA"8@[&YIL-NW$1[8L\U;_R
M4_ZXNANR^3X)^*-M F&?:1;O%?-COJ?;6IB,W)BB^%)WZKAH(I"IC'U-53@Y
MA%[Z/E:*@ABAN/??1F\IH;PJJM%_J:;^YI?V4PPN!;$7?UJ^X=<,IVI_37VJ
M7)HN'LB8^Y^N%O@?K"#X3S]3!E)I+AGON[95O/=Q-1T)T'K,:ZP_.["@B4!V
M];5(,IXR?J*+U;^B%9(3D5[6:@-C1Y<(\CFTCKUMG)!>0%0\D$^;E&7.P> 1
M"*8_C2,F$?"47#G*A$XTD :YP._$I)N>&Y;VXGZ43@:1=1]8XK)"X=K$S(J5
M6V0-M\<\1'(T=7D"CK<LTB44GG>E6/$N'G;4]+0=KFT$6-,DU0E6YN.7X%\G
MXS*:4)AXQ\\4TI8NB&K&CXO(^@0R9IG]LR@22JC_])H7#JFO[ZIL_S6?&^.M
M: (%Q0__S!#RQ%=N@S< -*3C[5^:Z/HH[J'Y$^\#?<#K"1 V_:GDDC"I?:#;
M9&&U;1 JP)Z(PT_=4Z7W6W"J[HGYB/7%]OC' "FIV=7BV [(["Q4V/-/HD4O
M[@?J-CNS([L#CC@W%OY!M&M*3OHDZ])U%.ZZR>#O]Q3"?NNE)ZH@4:+3>OF4
MNF\0#/HM')/ZMVX-/FEA?S<X\W^)XZ1J=L;=_0[B_&<0$O+9IYYZ@33VN/RS
M./)CPI_AGB)E^E=]YV>_1ITJ_&V$[N9SQE.L*I!AZWG<T<'?#U8=4E;8);;Y
M@YHK2_4. +F@G,5C$2,OD+3\[V1Z*X52%4.@IL:D-S*3K"O_S )D[Q+;_K^"
MX'_6\[]X/1WER,7&1(]?HL $_X[\E]H;0%CLE4CT_^>K&8]@:"HHBD\N15/,
M?C$C645S W#UOK[MID*@6AH86"9TG^"Q.,7/^I\YD_]>[<__UBK!_\E:1_^9
M^D?_S).>;%@)C7'E+.-BG=SYQ&$F[7.R'-JRM/'ZL."=H<)8$8[$VJODSGO+
M+.XM9$@_(U >_<HT:=+CR4PM&W0^ (QM_>K%#0#L*7-D#<\_6!$!2!E01ID2
M9TTSL$:<2_D9C-T "D[S;@"'D5<\-X!4LP/D-=L-@** O-&@/5>1,Y;S&W6>
M@ @ &D V@&+>MBK)NO8CC]T-)]X.62?";@2QPB$R%>@R3SV:619"^3;_B7?5
MBF\KV0Z3^J[;=W-W>G./ROO]$\=A>_GTE<CA,>:77=3]I> >^T_B]YI7DI-;
M(#EYDU,9XW&=*'Y%NP$H.0>B0#&Z 4RBB'87\UIV'B6:S;$W  ,=/T+MW<')
MUM)_XI\$]B6G+W91ZWSX"30VM]QX10HZY0+]W@NF+T:Q*Q0L0 &ZHJ$^X7$I
MO@'<T;L.H?ZE"_>D@H0 K@%.)_7?S"#Q6Q<G H6!UO\+ >-64CQDB-)G!A]&
M(U+A8=$G%+Y=>Y6U-;^8&QOZN_J3RZ"E>S> 7'!;(X+Z7P>7OWZ'I$?IRAL
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M1[CXOAUC6W$1G&$:*Q-(LS"D;'J02A$U2& 74**'Y39]"3Q#>0&\_,\'DFX
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MR+L=?8;.UC< #>9V![?U[]!GF1J%6W,.-*+L)Y[ISCOQ/]S[Y5O<3-K!!-#
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M#)GX:@WIS9TFYFB0TS"D@7=MT%XD+[0DDXS0#!>S?*BKF. BS_<5*BQ/ZZ5
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MS1Z/KLE%\8DN2&2']W+&\P:@.0<">(C"D_/-YEFK'TZWN!I'/E&1XRRE76%
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M'[/] 2>8%6[R[=3G3Z=AU_;RUR05N"WRYT_)1*XK;P##(TH-L25:6MJY*S>
MKS%4)!55):7?Y0L)GY?F='V*. -#20?XSI8+KIA@)R+X+F('%>9@B'90=K!(
M3.Z/3U4D[S'M5:Z,EBBI!M_ Q1LJYXTS[8&/.26=+<[9/U-679D5-]T SA^B
M3(/B*9%C@LQLQI/UL>-XQK24DG_&(F9 ?QK8#G?LBTE^-);U)1K$9$I;N4Q\
M,08UB+=;"XHUP%)#Q&9/Z@C5)^7/?^,%8G@_!!OX@GL*$*#.4[*YY:E>]&EM
M$3Q_SY[.45X*)*'\4G*"60WM]AUZ\[BG1D<DAGG!-D("$WLW@,\.26]4@A1B
M&*16FJ]'+1Z(=C%0;,RGV@O)/;=^Q)7WC,7-U2V&>^&A.L*M3UN7CSZ4]BN?
MB7#K!8RJD7")4Q_R%4/CLL5&Z\?,M1DX\*'9PB/FX\M(V9KOZ3/;N'T@05C:
M[-9+'DU[=2E+XJG Z+L$@(:5H6&GF9+S?)7$^L2"F 0KE3 ]2/7A[D4_^" M
MD#A67T!.&5_YI'FYW(-E1?+_8>^]PYKLED7Q* @B(!9Z54% BDCO("!=0'H'
ME=ZE=R(@O4F7EM"+-"FA%Z7W7B34T(NA$P()R<5]SK?/]^U][]GW]]QS[S^_
M\T?RK&<E[RHSLV;-S#M%3)EO!NZ , SOV9!AOMI;" Z<O)PL'.-HD5RYLB3D
M$K2##@R9^W>!.:(O[QS#>6C@/!TD#^:JNB@L*>C!;/%@LX9K#<J8A3G]2=V3
M\F=R5Q!Q>9,C)P1]O47A5=@(2D%ST[O98Z/N%.IZ,27Q[*@2S2AX",4"K*Z*
MAJ*&%K?L>YG,:-0*7$"L4]G3:$78WI[9EPV%6-&2D[M2YWB%R'C).3_M0B.'
MQ0WIRGJA$=K,-^MGS(7,?C7.*<.&FWI80$C5?_B*U1[N0Z[:\WJ+_<%]2T-M
M)E<_?_0:W5G][14'_,,/;I=%D)[C\*V=#KFKR9//RHG?\*G6;X!NH'>Z+Q8F
M0JR8X9KI@W9ZI?YK&89.#PRV$6.<XRE:D8HI1K?G,BBW7:,OXY1V]_J<3MF!
M=Y%K+ZOK/1(Y<6/ATU\&Y)SGLU=;?3(-/1L+J0L4&Y^=OI,EU:9[]^\B!NX1
ML+?LW^03K?]HOA&XOCYN_JN8)V&X:<>,Q%,"Q)PC(TJLVOY87\[38<2%Y%S6
MXIJ[EXUA 5M[;[" ]@@LH$O'LTM%#J5&SO"^I:%NF0.%3M,7-+/D#1[5O)@E
M_%V!I_%W!1X9+. F&&W[E)7EJ]B"MI^8;<,(!?"01/D:GOHY6,#HS/47\!IB
MX7D8,LLP+$#2(.P*K89YTC*)><#IB@D6"</<DD2._\-X-JZ=5:-GF5QHE#C7
M7Y^+0VJG,Z"O;!G.CR21D2=J2 7(Z"71+@.2% OX6\62K2L\=Q+T'>!1'H@N
M>$_(] +A8XIF&R;!!$!(4$@P6I;AL)1/\N)R2O)@%7A$M@D^C+<#GU)-21X^
MPP)^UP/Z\WABHO@S']I/?IVV_V5:29B.-?#DK!BXW(4%K+(/2\*>S$IN\Q8#
M5S2Q@!B&OXP8Z^5!4@8#;LWM /\\,2GP'\"MFP[LD*T CEG]#E\L^K?"*7\:
ME/;P%X-^QS5 :R:NJ?#/T[/^$Z@K^7[7@/D=W3ARW16H]K?Z,G\>6ACV4Z(F
M! L 6Q7\$]K5L8 [-==8 )?+8# L6,!]$YM_0([U/X[NVOG-W^J:)"1&_P_1
M;KT5]O9RA +C#TK]QU7(_P6'WD5_P?1?QAR]^^/?*$<80[JM3.3X_(RVSA75
M!?\W__A_!#KX@5T^P+U<'B<;I7ET.?$/@#+ZKX2ZWW^C\/\K"O_[\/_?//Q%
M:H=%TK&6LLU3'\3-K\&;]D]T8^NG6%$U:&<0(5&X<[V=Q#]C:>*_ -.3_TTM
M_Q744E_DU6XX>9#7*!(SW%%RD0NR='^W$P0T$-Y!4'?!N,IYQR3_!=54)$K/
MVI]="3O":: *HTLQK<0V,P/W?/)]G#M@^8UY9&;A_XHM-/L\0PDAV'?=))-I
M_XH[=Q'5>*O<G^4%2;YFM G>EA+YY_P^D;;W#9_LP'8T/3_9=T2R?A6XDRZ)
M1/RM'";U'ZV=%X__9YE]_RDKR=\]O-E:]:[YT901<-8#(UT00^O434*W"R+
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MXG0]P<:14R;!^0?]!5/BU-&./*N8()O#H-H.;2?2<7=9NV9R?]\>SM048OE
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MXJVTL8!*X?93'(T1&U'9&D',PP,BX)@:%O!($0OHFEX4[*86J&2J^KGD7?Z
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M7'0A;*0WK7DEK;#%8D/'NTQY97W8'L'9(KRBSYSXP$A\,/S=*(=')<M/]9%
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M*<2"!5382:O1Z%>4^Y;.68.MIO;?L]9 9HX>UNMJL\\RI*X9.9"Z<E^]+S@
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MI%55IWZKM;0[//7<7FN]DO;AGC%Y%JSR%Q9 :7>MAD'1HW"^$+\X+GK3E)P
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ME A3!YUB_B>IQX\<G&J*7.'I6A7)Y>]?P(_G4V8F&T8IMY4/BWK2M9>"_3_
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M./@UV)P15^<=8 4:F/=P[!$(O%HS(3D\A_6B6>)M'P!MK\)^Q5#VSJ$74?7
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M76O^W,GJT>98@.=9J=U2XZP(YRJC!I3)83;3IOU8CRO@6OS)OG/JLPEO>88
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M]C&E^D\SNLA,]WQT@9PJEFGR *D7!ZPD6A$]F(,;V+LF^70"#;H#,&*^NP/
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MU%I9,>]1TB7\"<= ZS %_XGJ3M9N^>X\P"_._Q7N&^X5R^T\3IM)Y8>553
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M&-P BA7;R52_?(K2D+,^,A:_HJ>,C6,//8WA)4KP2[9J@B2:6'&%P!9JS!C
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MUDEX_B9D.Y7@'O5]^\4AC7F7HMA\\R9X(KB,==^* [.RHMCRTR$WO8WT$)D
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M*G@SC-]<['>88G2*/=RR >LL&]<5(+-ZU#*W,15T$IPBXN_?FWN+]UF!5DF
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MS<9WB9XA$T9O;3189V%VZ8U9REDB1<_3&+2--))BY77G*T-&COYT+"QI78&
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MU;.E*#D[:S#WQ!H0YE6\(PWZM%0#"5C85RPW/%_# .<\>0E()@-+0XJ^DL'
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M+8?K\VH$'R(#^OG>>YC5:WO.:.\QE7E^T=Q\R4G/>8=HT?FN1R3'!Z1 0%&
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MH$.RIW3TIBPH*4?*65\4SZ3QW)=QQQ98 3$XWQ3@)C<_QZE\M13A,C0O3PV
M[X-2S&T<SX_CLZ01CBT'3SRM'J13]/3PL_'&OXR7T*!'EO(8E!GEWW)<E.Z#
MBT2:5Y%TQ?0?AD7&',U VVN\71=-8[)/'=#[W1A )>YX?B[SF<O3\&Z^4!S<
M9(]QY1;%MPJ(EO9:CJH^G,\G//Z7XP&Q)8?LX+WOP#J:'B43]".N]K.#Q;"!
MP @3U]13G&FZ(MSQ6DB A_Y$B)>WY[)55578W82%SK#]>>-<P'J3_)J[A-RR
M^-+$#P4%JSF.5I*Y)^1(OM;\Z#NOGQ!'^5_MR(CT3A66!=8"M[L(BP2^X K?
M81B"=IAW7(QB^3ZH\88OA)SW9V=-<\Z-ZH0M:K]ZY=M3+<XM<<LCV]>'R2VF
MM>%!Q!62%][A3&1Q9&^[%_EXT22<H[< )6L-5PZCK2QQ)2R3(OKFAB\=UN$H
M&I[A,5%P:KR$CEJ"DNILC-=Z'ZKK[4WO;T\+?C-.IC_4 0Z?LZ;YXGAYFV4;
M6C*:3>87<GF5U*"^)!Q'J/NV>?L;V"*ZI4?$2>%-UU5WQ[BS%0*9H+&F=R(@
MLSGKE59I84IR59?./'E$IE&+E7%"K@=G@BYELSVA9W;M^B5;OHH*"@E<#=UQ
M^Q5-U@W/OW%#7SCW>=/8TC/2VE)OQFD.70VC:=(5TJ8;K-KAX.G8@64=00_%
M9 CID?X3HR<.3A?&C=@B9@GRJ+0GIYI[M\?;#3IZD8:!<5J:(/+R+]R<655?
M;GX*-^]^=-ES+#XQ+-"QJZACBVTU(D4[_V+J/BX@;\%1&G[:';S-D5A^-FUZ
MF-Z=?X6%WYC_VAO?O7--'B#*F(A67E2^;6@5GY@*+=)^&/V\H]?OY]B/ 2#6
MH#IO@:I"+.?;2'F=.PU3S?Q^@/#"U9B9B3G7XH-D&*"$D9*Q_%3SKLG8DF/3
MU&]QG_)U8@")/+:Z.A?Q?!/M;J_2$$O!NOHJ43P4Z?)1+ U,-9;P)FCZ]CYX
M+_'H.6N>JMQ>^E/^HAYOSRNHJ_'NC<4\U^"1M<.>3$G#@3.!(MI+4KVP+Y2B
MAAVKA418H,K <+&1% .8H]211/&78>G3ETD[X)\NXW4L\>\V&\76U_H=W%;>
M6PF].,U=JC?4&"U/$7M<WM 8_)03!4N[QT'2=_=J(V9'I)5[_'V5Y<LQ>VLI
MTB4HQ^J$EJ'@)"%7=_? :#_9>MK.YTV=,DM)H<*/!=(*"<?6> .&B</)_"/J
MEQ\?^=W0V,\@\W1,7@Y>W'96E'I^.E#4E6E1D&/8P]FJ\H/.O.NU0T<Q0$O^
M;'7RG*P$#.<:Q !P%@SPP79G 2F$ : 0-@Q0T[AG/7/BOG4^00./^$0[B^9C
MI$+*1.'$KB3@#;[%$7,%''KQ[CC?2,( -T$H0]MM\+8U"-V([D''8@#&F2M0
M9(;&'ME%RK*>A8]S4YD[ND6A)!B.G37Z-\2SEPFJ43,NAR<%M6<GJF,VAY#P
M\X"Q /^%>2J>%IMLNH0TP&S2C&7294O?.:AU@,3"AZUR"&:2ICM)D'9=[8<2
M%0L04^-/B)!C(I_UO*E<,SM[6B=5CB37N7XR(R!2N>W?[9B\+_FZ#J)3YYC_
MLS(QH!(JL<WF[F!/2%>ZU^[AW,'@H95J9<!T(=2N#Y9%MPVM'A :_BR=WJW1
M\S\Q%#>NHFBRK$IEO]H#=7/=2+)T'HO$XZPBYOQ\%U]^84[DH@7:'4#G'QN1
MGE,D@A1J#5D@[LBT4/VIX+ID5<WD7F#,G,'[:-6-N:HO&?!PA.J-(/G:).D:
M*R+:4QD"QX=7B\NF8_8/NRYZB21X;W%I2K[U:*-8!Y.@[\V[R1S(")),ZTW-
MWXV6<39]\[YH]N[[E=L3$GG&3=-5H0(6V=!648FLE#=#095X4U&?)*AMA'\<
MX;MGFEE%)!ATZ/^6U/?WJFN]2KU;WS!R2)=7P#NS(Q25PR.U6K8K]EZ<F\7/
M0X5-(5;P_"9D28+EQ:]2)CV-7/L;.8%@SOZ=OG*'&[B2614</P3F/%NUYEF'
M]RINL6R?!]3)6!>@!^ZY?Y#46F5AX>R@V$PEF!!_4N!==^'Z_((X=O4,O+$O
MW2A6Y;WO&$J46D&:,A?.3CVFF1Y0SX_J+PSN0"H5GE,%VE:P_N!]ZF\J([-V
M5P9"QM$/$UHT0X:'"\P9:\&L0@)MF?.PJPAEE+R;%M\DQ:9$%>CL\FG Z>H,
M*X,*)U@6%VA 5'J;GIPX]?5%L:NKI7UU+O([**;@52_F"8_RV@7?BKS<K$ *
M,5.MLU'F8+SK_DV+H8=KI9*4;BXCVJ.[W+O,*28C&8%RS]Y=*[D?T1?I>"+[
M0N.@<BS<+"1Y4WU%1VS. Q*_Y-) AHQ++W++5A_A^E8AQRGUV3S6GUY8-;F$
M02*ONN@6HC\0?0=96/'&UJRBDI-#>86>/V3->_;<#-I< 6,C1%.=9@H%&<&B
M%1X0"M; &UW7V#H46[)\RM.%1I,EN2QYUK44IS$ @E@O#2;U<OPA3'&98,-+
M.F]6^Z=@_\_KJDR".P6^/ZY?<V>.].:0:J*=U3$,"PS)WHQ>V)AX_#'QY6O5
MRA6[QTV='=BX14,7TH[:RTMKZ=9TE>>7<Q&&:3"PXN# )TFFK6GC.46<;S75
M<<O==_B^=S^FOR@^RFN0*+.^ID@E0[; $A3-G9)^IZSAH$X"ZS7/>[>U<&]N
M(V\7O?#L!R&*&&"1L4/:G3C@H3CG9;VU9,A2R-8K;.)#W0#\89#B)+[C"/6#
M>H_O7.N*^/WY-A.SNU<3N>JOC+!8,K^)PAW[[8]1K"8O1<1:P1(U_]CPCN2@
MD06A?^^S]J?+>Z0;5E45,N']>+-&<0+7/4C8+=GNFSFR#H5:/D^;FT'PB3])
MEUJZ1;3^(J'R9ORJU]MT[$@(C]ZMP!0D7<NYI_DQB8Z>CM\SK0?2O:^A\![L
M,W^#=&D6NDU%/7%+A=0=B7+A" (W=EOB#=%XZ+U92]>A1P[9ODW-?MX#+"CV
M>%\O$,0$OF/\8GQ'L78>_IB,@]Z:"<PFP3'$FAY%5OQY)*S6$"D>#;IU>B [
M7(B2,+J5/^W=\NA"+NK)2R/_T&(FIB+<Z;H]O%,G-^,6I,6:=/2;=OD4#SZH
M\FL %& S]#3XB0(!OMJ:8D/PY;5_ZZ,6,<XI% ,P66" 0L,+U:W0HB>G0>F6
MB1'!M%8,@OMK=P(4FK"%<3V3WQ+!(OIKE$^E44]^D;^4,0 6,P; 7TOTZCT+
M-1&IW;=PYC4OL/W]?3"<"HE["52 4==C4.P/^VW-)'N[TBH:?WOY3^2U5M#A
MM5\%X,B4$6F]$LD7? ^"QW]W_1=YC00R2/"K,)P\N#GDT;'C=F\BA^[?7H[X
MO0@/6Z8&ROZA;*QEQ/^\:/5\< S0<N!F/';D]K$*Q$_R" .\0@\=9Y\2PT?+
M7M2FUKU#R@3QZ'1GOHK(PQ[TU"I\3PX @!VPH],,U?2HIK_:2+B_]+@#L%Y=
M7<2:C@OF<)SYO\Y_^X<<.% ;+3_Z+F)G/M;6YYW.ZE/^)8D5+AEX:'@Z4Y''
M9-I[\=0>^(VJK)D03V+0)F7Q-;EP/'TJEMP?\13#5HW$=Y!4@8=SDAA O=I;
M5EF%:;0D@::85XXY)AE[0H3!JCP-RL<22R_TH8&N#3YGJFBE,E8HX*T8F:8L
M&E5,ZC_V)2:<+S5V(+MIQX#A^;JJ?X>0RTG\0QV+KY7F4_L.#L_J^0S*I"5-
MZ7-6G(BOT]'=W/&2S@61!7V6)QTU.A#/)_3Z-H4!7FCZU""*Y,>\GF1N"N::
M&%F;;HZ\:GN3Q/78KE40C]XW_,F6_A%Y84=WH!2AYJ#L==(,E?9O9/PJW[_?
M   GP*702A=AWCBNI3M<(1;&I(7'Y/E10_2Y_U<G<:$G9YZ$SN1JU=OV0VZ,
MFQ<:%0U(P7JNDF-9,MV9$&<_"ONA8#]74&Y>M)M"+U(F]VKI MF.H-M6S@P=
M+PNFUG_Z'A7&!;N^*15.@@3-RR3 /<$[$@N36@^\,8!9!_3@=JC-F<?16J7X
M$WC1SISLL[H+PZC+!!<N%W=/V"R$R('G:*TJ)VW[8;C.3)-@'OB3XC8&L*R<
MT..///,4+\:BQF5A25X/?5-&!S].=S2BC( LU=6EX/.F;T--I:.&E)[R?UT)
MQ[7<8_W5A>1)DY;%DLA1 ;:^]0.KG&B.CWW?^\-)</2NR<P".-+9;M<4;MFJ
MC#&/K]<EJ11;Z096?Z0T8]GSP[L:S03A<U85:2'%I;SBW-\P0+, O(X3M .R
MN."-/7!Y-Q?'DJ4D>CY&3.(F>Z&E63GNM//<FENK2HILMMU/VHE%3)^8D&_O
MDF=$5;IYCLA0&O'YV&-Y*[&]A*L@]\S@A1KU!Y[FE.:T:%YORP%_+P$,@!<?
MN#@L.7'<R#8'6^#NZ5]CR5(N*K =DIY\12_1V/)EZ=3%B^5!UO:S5$O]#+'G
ME9?+J[,^*9;;/F0-\8:#SBD*.KIU!6QF6ASF3 >H'X\7!:F <_KE"F>G7Y_=
MJ)!"*L.WFZ;#D[P=J>NJ@P0KNUOZHE^@ K1RS]ZO:'9\X#?^ZJ;9W*QD0REQ
M4.42&[[.,A$-81^&*A;7U@7N+G5/ZWX!C_8Q/Q\ 7>3+R,(U<QKB"*SL?D\$
M^]?9Q?]]8ECST"(B)2O;WC9-.JT%0AN;*G;_DXD*WO5'!H]Q&3S'=\Q>_=R?
MV=))62ZEWH45O+\=56'GV 8\@62Z.;ZLUQI]QY_74V%D<ZN5IQ/NER#H]2-Y
MYW[)AJ.*9:+LA[>CRS%:(^6RC3 Q8ZOJ-[S],E1 <0]I+"CV:M;$Z^M W3><
M 5E:0Z=!%OM>XU.KES%=%]7MEW,8H&ZA0G?,J6<+2FI!&Y"K_&#J?KB)T*W;
M1M-,D=<>V7\<Z'Z^'FZ.S:<Y(GXS'4:R27LCKH"WKCTWXY./1ON:&,D.MEV7
M,/UX>[89_%*M66Q'9T*QMCR8CUW9G594)A3K(4T@<(?(.\#DM*JYBI$)5A%-
MEVX3.:7?5'/_K?7^QV,G^J).!^*J&P6;H@*[Z? Z!F[OBC)LW&E8\7/V+.KO
MUT3H/A.22.I=LF+K>-8I@E_$'<N3B7&XO<C?Y,VC+90'7'[LO'*)\Z&=V%4J
M8$PPMG>E_\I_,(63*D)^C:]>*A?;@F8GPM+_@D %$N3*"(IS,T"6G[V+?M-A
MY17ZL=<^-4E^\2"U(B_CI^"Y1%D;5E2JUH%I]"N"\HAR+GG);MQ!?""Q1Z5D
MC+/WF"KNQ&[=(OJFIO1 UA.F:M06M_*P.!N(UB4EK6BF( DML?C1.PT[;,')
MJZM[/6=%'78_R] <S5 QLM=-4S!D3!A_BS?R>_J=4C;52!\]>H\Q8B(W&PSP
MO&:D88*S3"K+8L\(ZV.)A12_F>>U&R,?W_]@R5VO ,PM6EI$9=(?Q&;=NM=]
M_H*JO')_.;:XAD:Z29S^\*=:5]H&%6V/OGR61?1FU'9"ECF3Q42.+ M=T.P=
MT+&2J 9T:O_J)5:XS*P1AY:<T3FXVBS42?"$>@X101_Z,#>,*K#$2*3 \+^F
M-*6[?XEIY_FD17\,_GB#[R<:OV%BK=2;ZD7-Z*L>I86IM,?T81U>2?B!$G9*
M2I9M<5"XV"UOZWQ^;\D%]4^N-SD/$5GBN<N]+YNC,Y#)D=YL3M;<&D-'"I.Q
M[]:&=PM7ZPY>A)9]@WPIG,MX-#>X2^^R%'6HNW>JR#1FW4HY7O=\MMR52&?C
M77->6]5K]HZ[^THW1&F!C3^M6GWBUS-AMQ<=L.XZ$T3;SYRX0I8XAK<&O.C@
M>[1N"O+>_!C@C8'N+C?E5H)*N[*!5WI4JOVN>\%=1,6E\SW=M/FRJY<Q@@8R
M^11T26JM.[ZP+[H)/2:ZNCH4+]!V91P^Y/7)S;@(1W@7E6J-$&\=_T5L\5><
MYD6 5/;.I>4AK7(K.?+Q^%I,2[YBZ72/+7W,/=$;IKCWY0D)&"'/*V,+(%M/
MU5TGZ[)R%8GAYX_8?[3BB9.B_05<7G8R<+3I!(4ZI2BHB.K1FOC&-@S8BD>+
M\<ET13]GE?"N'M#9VA*))TD+9L?_M7:+-RY5)N0:6HIJ5-)ZCPU^ MD'4MIE
M,]'\*#1L=3QM:3W1K*)JH*\-V_'%NUOR!3N:6&0@T[.-(BE@?AU'C[C\,Y1/
MZY*8(Z(=#;90U6T^5?MQ^Q(*QD:?%VFD!6<D;CH-9;*[KL7$YZA*4\AT!*-$
M,$#TPM+ A1<&&/Z<A:+# %'+K0M2&"#]ED=X"IR!6'Z"ZRB)#L2A4K>PWK=6
M9SO?E.372EB,ZRL3=G6WY61"JU8_8FJ7JW$"G+A7EWQH>L?QI^;*1U6S^)]O
M(Z:?(JX]EGQ]A19JR%,)K_[JK.C2!G(H4*0:TBQ*+\D,(>DP#GMY4 L1..O>
M 7/MU$ODE"+"@[*W3FA7"R+B<_5L#DP/]'9G'7S49F29BM,3<#G$&UL?:AT'
M#0<G@V8C^N0R,4!2"@8 'ZP:0!WA#$1[K:I6!Y-[H_"94HA .\^/,RGKRU_P
M3_9*I0]0-)ER,09H74#[B$^@UP;JZFSGEK.W9'F)--T)K#1%B7>P/=US.N]5
M<AE;:-O3F+^_?F$6T9YYFIVG[9;7YD,_PB\";Z@.F^2/VV:0=WEQJZ50,-J;
MSR#;?M'PEOYFO$=L?RS]A%9(J6O4G'\X^$-*^F[XXQV%-#>F%A_Z6JL"CN?!
M!'YX!PI\Q;B%!+<CFL--JAWJ(_B0(%2R8,Q1T-7^1H"RT=DV&SUX7*45(VMK
MT_#*PN3U=]R8T&@W;('-"4G2P5V4-&6C1/BE$D,=RX&>,3WQ9\&%X83"4^Z6
MAOO5X<M:(TS5B0+3I;9OWWF09;QU\!CJ]8]-?5FX25G+TB$!;G6-P1WF9I(W
MJE9.$*3V@OF)OI]%3H[MA4JR#3FG7.N0&RZZ,\I]O_854&GT8) B2'4V#IO!
M8R);W\WP6?T0?-C&:?)^B>_3MMNA9Z\);V7GG*_E;LQ?0S3X.G&5SS%2%U+%
M1DUEF)Q3L8 "Z'OL5CT999%/NW4);+&U9['6=:<>\A(??Y8AWN18V+JM=^7F
M)840BR,K4'F7-90--J%8<P=:VR*!JS.3,3<X7';U+F1\30MF!7ZUOXE++OK-
MD<7_@;2K%0NX$&NW=(7QAH65RX!T2>68.I^)A9,J0K-L*7U%<C7Y>TQ*/-:9
M#6NV'_EC)YP(^GB^<$,9*2(0Q2+J9[X&SFF6/H\0+JG3'*>6GJMA29UQ=WKS
M8E*_XS$QIW8D'GFP"<_-=A<0N;.U3>WL"W,#;H9JQ8V-$Q5?F1KJ9Z^_6I42
M7&,98282>U.# ;";EHAO6DV(.B7BC X9*)+;.E#XR7QOM>V\3AK(DO/3H$Z:
M2S'?M-A>#U:038<62S5>O,6A6HKLK[)W-G*^3O8PB3F.\N6[;KPF)MQ@UV.#
M*_!%T'(AM4UE^ 8#0*'W88VGQS,G)>$P;ZL1UO08A5M&][Y1+Y@Y=E: B#8E
M:9#.N]^H@I@FG&8JS;030?Q9R\E.]^5$:)HZ+X50]ZKB:VNJJQ%**1DSLG'A
MMF4?5]7#@<XNR5.*!=6G 5^^?5!)63JLW_FVYD,T?$1@^.G\<JXM8%1P^#*]
M)U'NE>H!;U0@$RY3X@+2)[MHLHM6V\V'0:VI8^_)#1G)]-<_C]9JI]ERIK2K
MX6<6U3*:X^N?9C=HXX,KZJ2,X4*#]V1ZAR,[1?U37\I2+V(M[!]WLZ;Q%&\8
MC='5S35N?;V:CF0?__VM_S]3+![KK[L=K>^_+>_RKR/?_SLVC=\$WOXU9)3U
MVM%_65#$W_M ]A^6_DC7:J9>4)O_ @,4ZPL*ZIW=T_]R!_H9X< +IJV1OF:Y
MV0&ZPJ![H5=O\=5ZT_T,O"R+8FK@N_JW PS 1H(!PES(7SJ"?])<4)] KNSP
MB]_SP;4=<B@)6;T'0J:C21=H,,#@&0;X_!'2_HLD!!DF-F;<VX/\(@HAPD\'
MT$$#J PI-#^D66P9? X"[T<1GTX82=,/G#_9-IZ[W$/U@_^VDXA3V5\135+K
M:+6[&(!VFS4] 0/(281Z-M9C@%]<GM]T-/0[X7\1@L _<4LB7$\:_T0*^INN
MP' &)/22&'HF%X2R*DX+-[N\<\RSBSY!F_UC(ZCV8H ,QG:)A7D,\(NJ])NN
MS/_&)+^X3M!#_\F.NHN%LV3([SH"_<8D I.JLGSH2,__!RR;F^L&:?MIQ*&P
M',%S@Q<ZQ4.X+[965_N;@,@UHS_+Y/J'M_^G>7L$7D1=Q@%BN-9S(C\$[SQW
M5/K?9X/_6:,K)*(9S1T$B5_.MWVS@P'(/KJS('-_+[+I'P/\?Z1S_[#L'Y;]
MP[)_6/8/R_XG6%86%( R)+I,%6T_YEI L@9%0VAWKA0,^N\K\1]CX0_+_F'9
M_X!EOULT@)">D\^&W)9[I))9CE_(TJ>>%>[^S=&*R)>_R)/RAZ?_QWKZ[ULV
M*>V5I8N@,F5>'L12Z>W#,N^$U]/5U/IY32NWH1#+WR1Z,76ISU;(VW!U(1E8
M4>"U?B5RIN28*AF[GH<!".B:DU];45K-)"B!9=%OZ@D,ZF E@T5<3J?/)NRS
MWH3FODL^QS\8@AO2G6;L33C;%D]7:9,<8P![.S!?8K_GAMV;&$>]8+UY7:]S
M6@_EMI1[/UM%,V'37C_@G^@&03DTH%A7P?BXB>.2V6EE>H0<;ZG,U(T:.NZ
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M7</R4J6FA!F+XJFS\J5>=)5-]7 ^]?X$/^O-I6S0]9J?/</![9ZG"64]-)L
MM8Q3E0IOGJ3SKN.+GD2<B3"--^EE(0)Z=B\_M)P>'/A"Q+[OU4:<F:#!=_3U
MCL7NQ$49KAGO LZ\J!YR2YINFK?W@%_#SYB553VH6I&LK:CW@+$'Y7O)> ^
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M[^_G<P_(/SLCRELF&=?IS.[<[!#;+T\5'8V/,!-Q3-M*VQ+(DJ.UMTZ<V/H
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MI.V&(T\,$9_DO?GXB[L;QB\<JL#SUZ09."E;W?JBS7"QN93E ::F@M.1-3_
MJ&-$?%2:1KX& 32:4$\>!I;I3+J0LUI/])12P_K6#K7C%WXN<0VQ4:0@^2H_
MURC4V'C]9ZB#\S_"+J*N>:3$C5)7:!/=;5+MX-)=PD7$%F;KH0U2$&*C4(PI
M%$2HP0H]HK)89H"C9^7N' ^I]W.>]O$&V\RV4=D?VI_E&B[NFI<)PG&[#?9;
M"09_6HC2-$P?0F$26#&.$3$_F0G\(?D>AV<+]>QGC?+U-AGS<E M<@PQ;N.(
M U%8J@(F]^"G_RP<_<^KZ;9\H>H(KCN_E2L>OGL B0SR]0JZ[QC%/8 A[QX
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M8+AA/ <&NL=1=:Q;4]8'IAS+.GZBSG1ONGU4.3O14"8J[P&F-ZFR+.<WF%3
M*>%UE] [#284*EQARJU)T3.4;7T41'(N LZ6%;RL0R4)208STL;4]ZQZ1AR[
MH5$O,:=.W?&WS3?W9$)!.);4+ZP<O.9L0C']ITJG'*0]8QX[:0A"0IR]:;JN
M-8+862AT;EC'S,'?Z8-M<HAW3KW6O3J%4V"M9EA+ E[LQ5I7Y:4Y[!]^T]$*
MA']Y++KZ_![PX68,PV*U+/0:% EKJJVL3H1H5DN.YB^6J]KWXNRDH?9(>Z@\
MB,CM(Q*M*L<]F;<\^QY?WC1SB%]@2TBC[K.TD"<D;0=_8=>W6OA2^Y46ZPLY
MG*F8M&P\4$4T)<TR$8V^96UH-:8H@9?1U+FF<CB5:8]%K.2&UT2.__GI)[,Q
M$8"':2"<\0Z?_=M\?E!)5?K,O)TOG_*-$IDJ862J;Y/LS1(*3VBQETVD<S%8
MJ%.4=$I8DO49&V,-_8NU0@J54"IW?@Q*^V%5!#-T,%PIA+RT"KJ@,M/4*WWW
MHHA, \ZB>_>BZ0C*DQ]E6^),*DP'$V'^\(K)*MRSZB,SI=UBUQ9(!1*8P82Z
MXH6U=L#<F^($(6:F)^'=Q]^<L09]2UN%3U%2TACI>^?=C7%9'G-[@ +*RIQI
MN\+EM>8-EOPX-[ZZ4Z898>SR#[<&46-!G Q(+:_O'H+3AN\:QW69-[S>5VE]
MX#J_L&S$M<=9J>^%J12G6X9DMD>X&L88#9]8G\\GE&6$+\SK.K.+3)BF:!OC
M?=-S]XJ*QE-7JB*H??GG _HT@H'84>W,[GL OB^4'!X5"4T58;R1OE%ESCS+
M9'I'=E$HQFR633 )T*" UTP8/'/+[Q05KGS;,.\<L 6" UR9D!I#'Q&?:'"?
MP+=ZFCU[&-D-\Z-?#W^CI8S\)NT[JT'OPL*$NE0\(FP$MUWI;'EQ#_CJ*3?.
MSK.D]XD[\:(K,IFL]VE7FF/;T4PS=9/^7G?#:%@+FP'"2K)NTHFW/.J=X/>9
M<)[!@]=D&JZ4\9/C<A<_GX6TW0.(#YITR@9_&IA#M$5+PH9HDVM1:XM."(-[
M^8%YEHF5\-*%M_":7&ACY---TVJ4SYX67OUL]'2R$M3+HO M^YVC,*@7Y2^Q
M>?4'@JI>T3"6PSLRL#6Q1Z<XA+</K'JH'7 0W0,L;R8&*&Q/.+D"+PR' <XM
M9(AQXC+8+)*O!.%R^K8YN4:2T4$1QHGZ2HTY8Y%:%LQ.XZ51?JR8!<I]FS]:
MM'OJ-VB%93./V;%1KBBW#6#<Z7%C#]TWO/TE3 J':@7%?,'076S(G R+DC.<
M;+6L355SBA*P7Y?CZ-@ =^1A7E[)- ,<5LB$+;WTB(.(1B*]LW?5]=WK*ILD
MGX:<7)33/Y*87PIY?UW:XGB;R[9O,EU%86X<66889L3_,?'3EU04Y%O(^'>4
M]F6DW-T0(M=F=?" L3_L0 U\=#<9<_,]]L1FC>6I]V'5 X/#9(_5<W,L$N?E
MIMG/&5_'A$<S@^@TTL%I\=%M$"[XC52:^;5!.(NH_##UABL_Y5=3"J55J.]1
MMJ8H5H,8P1W?(,SU[6UFSGQ6$*GWS$*0P<U^WST@"."!&^7S2MM-2+5Z_."L
M,5U'NTY\S\S:WL_#>#5.\1D #;X0L>7V<8U>>RO,Z'BY KJWA*N:^H)_Z\L*
M+Q]@3NVU[$ZW*:*LASPC&^ZQT)[">&&:ZOPT&I&RM, RD5VE R<5QDVHB%K/
MF.X9Q$Y<J5(/ MF7]8.7WHV77"H6-1I@NSS6!P"B1.1^XO@2W@/ZQ[9]#SOO
M 3^K09;DM2'Q%X%5DSG'O<DEY7H-M0OK%+X.LK<CO!G\MU88W6(G3H(T-^4/
M&32K7-'#I1#-6X)[@-PPP"6#&]%N <U\7A9R-DR]I3.-6$'#J7H%I)-XVE4C
MT$83Z2X3@=2A"?=A<GN_N@/QL%FJ&GOK;.82I,]X>AHEWM=.%3)1B\1DT?8]
M ,+<SN7P!;;XY&TVT_"UU8Q119!-:_/%7MJ-%?6(#>CW:K=E-^H9H;@0(9U1
M^E>7@.@A98P\Q!XL(3.P6MZ&&O*A?OH\/.A98N(6*4:>(F9_>QL@0S1Y^#B_
M1[9ZE+ 7VFS4"6F@SN5]9S_2W6)MB_*[Z%/L9-@PW"""1T0&=EX;R*VT/\R[
M2T0#YVFLT<J5,:^%O7&C83:BZA<ICDPD8VTU!S]=7C.(UVD(S=8Z3%=S:2'=
M?]H$0*'TB!<G\O*&#1O>\6DNUH1XZ;ROQYO7)/%:^AI;06\$HCCF\/-PYH%X
M2<.E(UE\\)KA? $OZYJ;(I=H4Y43E_9'U@=B"&U%<&F=BJC%Z'PMV+$2:;&U
M3WSWLL=OWKX!/4?(%J*9ZLO<P,<P"MR.8&S1JQ3\^DAY>U?[S!<SE+9>SO09
M@*VR=1P'XE8J]?F[91H"A/S',7"ITF&IR6);])%AK*)(CU4Z(@J^<P^H8@P^
MJDY4F^055Y635A$WW9LU'%'*DRC-7+N]2Q2EPK+(#3IBK(O<A]#68K"L+=A*
M>S@>B3\DVW@^P'R_JD@QY7!%/46AN:=L"YDL*+5VGUUJ''5K\N$G0F1?&L([
M!'-2*'];1ZM^_Y%HX/38SH.:#_6LE OF1$*\\E@8 V>B8:B(LVP*EYV61I&C
MV[65^$6D#^J+$DMB_I(+ +^^LOU.+R'*3H-BH15XAS@E-SRINB'4)"(V,("K
M;]_;,C_42S[/3?YMJL9T'L>"E-^CB,J*[2*A^#NW$IJO#MR93YM$1QS>8;?Z
MN:">$77Y3"@OB05S6V1CVP ;#=D$,5Z=$" PD-N/5. G)M\L.1$TZ@HXJ:C*
MR[+":S?^C@<M57= Q-&!P=,%E>.-])XLLZ).>D[=SGJ?OKK_H[WS#HKJ^1;\
MX$A.BN0T1$').3,8 !&5S)!1D9R#DAF"Y)PE9\E)D@3),.0L&088,@)#'F08
M%M_;K7K?WU:]]_[8VMJJ]8_[QZVZW?TY]YYS^IQ3?;N[J+#>2!7W@_3@4V=9
M)*#/-4LI^_J*WOR]8?G8]DLK"K@7-7Y1V3/Q;K2$7]K,^:B4'C=U<<?52C7Q
M$_C&[L<HKEA@^6!9GD-HRZ@$46_V]OFY)^0K:4R/0]M5.'E%S8D6MT1.*4N]
MKU/RX%:,QFGG^NX/YYKM]DOT:;9H>MRWVL&7[-,W@+,S,4R@85O8#6!=Y?9V
MKQ-Z33F%M7$.!NEK3J0:BG7,1Y[GT)BESO^<?QXD,#[_!$2S%?FC:<84>;*F
MD'6$T[FK[VG)?5!.$+J_[C!+G"[80$//V%4X\;UMKH[<#0QQR'-LZ[!QDHMT
M &M<S@@A<QY*MG5;ZXLPST^_(V."#='*97M\S":944.MTNW.:/M0(^OSUO!X
M2#@:Z[GOD?P2S3/U.'9,]W#6_P2FX!;) NQFLH__RO_^??*!]T@6=Z;^5PDP
M/W'O4C>]<VV4!"P"_;#N:&,S$DKU6?IUOF4US$%O;7Y?<^#-^,G)@XSOU'M3
MC#+>I*L0/Y'7?-HS=0P:NN-URC)&E+HW@)K"$V#?D!*;C180&\7X@Q-8.-GZ
M4,\8S?/]J/K;<6"34NOHR B;]GQQF_T160L"U:3N!4:E62.\<35^LE?3NIX[
M9TF"P<.7H@?PC-*HR%XIR"@59#XH.,^ZC3C12,ET.@\?!B=XF76U7<;F(U*\
M1@D-G(='2 O94"]8I7JIR<V-N%+TRRZ\ZMH+ UQD!6' R6LD:9X^+LZ%"PM#
MS)&1L+1-44%XY_=VKKWI;ZU2AE9);<0<M@+Y\IXAB&:+_KMRS\QC9^O;O4/+
M*P-32=&L;23"GHI/:P:IYLV(). <PP&G=TD[<U 9"#.D; #V>BK9[G2R8)I[
M[.;Q3Z?\B,C(& ?%&T"%K[10EQ$1RKS2S0-++**"^^-,B'W4>KZ:XB,&_L$3
M3IFNDWVC!>1M;,*,S I:GQ3YH3#P>U'<\V%=XCK>9Z=&4WKSV(@SD8XEE.MM
M*%KK5R)?HK?];1#TY:C+C35.%,:U(>K!R%\Z:N7ZZZAH200>XO*E8K-I?#_%
M:"[_+C;[EP_ "U>L.)G66BS]<],;0$HA9@E\7N>-92SN,TI[$)W[9\/<\I+9
M67>XV3%FQB'6'I;VO^J82V5HP]5RA0,I9="]'3&((#T;OU'OP:)Y('%\>S9Q
MZE$:.+H3M:0WCWIYOJ<9I1ZC.__25+!H1"<F195?$F?/:-A8VF=T)NF>6UMW
M_62+I;>X<<T!$Z66ZS)NI>:?XP@4D* >3U):*PBM?&^6;'S94T(ZI85/*[+G
M)%A]!WB@:/&NJ5;Q<%)RJV50>!>56')]O#!E]<(;PXIT>N^Q%#5?%;KH!L>1
M09ZZVU1.P_IAG/83LK7-%RITGXGHV#S?J;219P+EH?.0[J$!?)4ZP?C90S5T
M:#:IW!3FD3[*LT-;;RO$)3Q#$G-:%:#$T_3^"4P""*3F8(V($NHQL<RB&[.:
M3C)ZB&S-6T4=XE%>B+$EV)QR./'BLL;&<"6@SAM"CX"=-5V.#$6SN81I4>_#
MGO JB^'Z)7($P$R4UK* :(4CF?*,X!"TY6HHPO6DW,3][JMU(M.7G81$8I.%
M=0"/AFA9YAVC.S5^AR9)F\?KL?:6)&*R G$J[_K0*)Q&0E!4*$FYK?E:-,$N
M(RAL/?KQVFJH 6B-.?;-LCNK>(4*[&@XS^L=4OCW:9_M2GV-+B_UILP.\_(<
MDPL;F3=>I<41:8@T1[Z!Y6'ETLZ1\B,3BPL"ZJB4QPZ?HM*1DJJXV$=\$.1^
M<G<ED;Z5#S5FLC6M_TKF<&$]N&]H%L02(4HJ?;:CWRJ**K5?-71BP.E2:)ZN
M2U$%S]E&B0:D$_EVIQ.M 'L<P-09'U =*X4*1.7G3M3T_K+CAF+=?,'69:A>
MN,$86HLR<DWL">WS$QNA>W@#,:[ !G\ 4S2,B5:6#%4NV[;&/G9FC&_5)(*H
MV#BYOZYU"D]0SUXY5N#B,O[9(D,%RWC<B>AB]*E8X^/3O/(*W]C0!S4!+6'@
MC'>6K1)'%_XMG@4HXQY7T=0RR(0\M<5Y36ZS[5T*P);T:C!+VEK6I20#Z?4L
M])0RF^0*!J*H'<6U$K"\-V=@U32435%3C[#SP!&7SFR_ WVUB?)$R)=?A#"/
MH>6SC=T^_5X)_&Q(IA4J#MC0C#C%I;ZH #]-91 ZSY@F:61S[!?[PL-HAZ/#
ME^SOP9 "/"YNLVC\5?D0B4FSKK<U'_8NOC\45EX+<-R=A8V-X3HB*L.FE^\>
MB:85+.^4B]1-/;6T2[*A3G;$Q:\]N#4R+(Q,052E+4[-*H.&\N3!F_=-W]EU
MX\'0=VHQ0B/4&)$1]-N(K'!&_# '^H0&7: 3W05Z:[H.;"FOL;I//!#9N=\N
MOGXG_0; ?*F*VU"*HSKP1%T0;]OZRU%;M# 4:\=QV<J6+6ZHYVW]YSO'L3,T
M*UBQ<=Z*3MBVVP<3%DDD6]S3XW'>2FI&=$>EE&V47@S>Q8@K"J^,JUZ-C2S!
M=6B3AC!6,RDLP%JF)9,):5>:OS-S%\^>NB8(MY6 5T%B):NW"<Z(?A[0D?F@
M^@B[/-6J_B(9G_P=KW255FRZN&UY5O,DPQX'PJPP']I9\D-WRQ_2). =PN5O
MV%"\^'WWSOKZI]\S*:@FPC3H7'*GP%(068:<./&,"6&0"MJE'/#)(QC64^_/
M=:6"9^4J*74OLDB*.A>^^&CVF7-L/^XL)!N&R"!&$V7R>09%O[3P6AJ2?>O<
M8(9[9'?IN&>@&,H2C:&)PSZ>L3\7B3>A-[]0!!N<&'D6\RS> +XM1[WC?A^@
M82(JI;CY4N(&X/=M#-<,#C*_=QO6^=4]RSE<N,[^P.R!N$J[C3A^$&(H<8.#
M_:EZ>G]%\L0S)5YO_D*8P0_-(WPD8"+)JS(F7=5HAO&#,\)PH8*.PF<,,U^
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MFFK+@P]**GR"17825'&Y$%# CI%,=6WM3XZ6("E+HA!;0\TX!8G%\AZ](ZJ
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MI(5TH&Q<GB6N'G8S]S\ 4$L#!!0    ( 'B"7%9_I1W,&JL! +87 @ 2
M:6UG,3DR,S(Q,3(X7S$N:G!G[+P'7%/=LC<<>N^@@)30FW1"";U)D1J:("@E
MH9- "%T4$!"0WJ2)]-X[@H" -!'I54100)H("")8WH"//LUS[KGWW/=^]_U]
M+$RR9V;-_&?-FC5[[>RXOTU_>P4@U[RD<0F @8&)X8/A P!\VZ(7T[-'H!#N
M]@A7H*B $$!224,;&QN ;O2T;;8!OY. :PP89@"L"QQJ#)@  ";@&P.F'@ ?
MB00)20D)23)@X@!DM1ULD AWA"T*:() 0H'\0 C,U0H)0Q]HZ.FBWPWXA:\K
M(Q#.,!^@"M(*W4U,0$1 1.BZ !1AXWV*Q'&*1/[AR ''X[.]C_NK=&-%+H+F
M4QGX5+9\(D>_,$XI(E>D QREZX%R]4"A29P3GIX[RL :C7+:0P..@L'@'BX_
MCD\^E9V1)S39J:Z!@_=)#R4'U(G.[S9A2!TK%YBAZA7#GV#?%?20"(2M 0SE
MX:IK[6B#9A,#] !(  +]9PL  @P ,  *X %P/54A=/W9^X<9)6<4_#>/B*T]
M')Q1#O!3DVB:X+2WLK;IY>_3('W2'Y/_3R.F_,.(=5U1#@BX.YI[_G1<KBCX
MCT&@!VF-_$E [-RU?Y<@X<J_$W#4[X26M;/[3T+'#N7YDU!U<5;Y2:#C^+MI
M)1LGN]\"\=U! $1-21G]@75Z# 4"H0@/:P7$*\"/IH:$_XVGY/SW?DI(J*$1
M''6)#>*, ORA*3E#@;_B0]R=4:=\/6]G!8> 'VQ"3Y@-"H%4L4)9_<P*/3L]
M]Q]9<7+\VZ?R:1!@MJA?F3=$+Y!?\0ULG+_S]9 V"J8_V>3HI>!J8@]#3RYZ
MOAS@=C\B1GHB@*!]4D*@4 @79P3<[C<5XA^2$Q?^P"?YP8<XV-G_44#T0X#V
M[2?[)'.PMK[[@-7^%81>JI@_/D^SBO-41OK[".0#OFMADYR2)ZO]^VJD^TDS
MG5K=.Z4)?NAAG&IQD7\/\X_I_XZ"M7]ZK X0M+5%2YS1[[B_*7WG9*>F_>2(
MG+Z;H=]_<$"G[_R_<TYM'IX>HU?2MU\VK+<GXO]^V6DL\+]']-0O *;"]]=O
M,J:?<?I.TY\<88%^>O\]+.C9QV[[&;J_MS_P3OIA.O^3#C_;[X4! /=P/E'!
M/(&U1GC H>Y_69<V*.$?;IXD\Q\2"?"7C ,H_<S,[VY ?B;>Z1!PW9T=;&#N
MQLY:)TL'XT\X.*<R] $E^H5W2FBH_,$VGAT2X>'Z)Q8N NE@Y_"S*JH:G"CI
MGO+0-(F5!PJA!H/#D%8H&/34>Q_7'T6=\'OG$\Z)1,/%#O@_,'XL#Z3SGTX-
MI\'_,T?;W>[/IP]<*V>4H97=GWBD-C"T'LP;I>&N;JBM]:- X?]@_ZDS@3T"
MZ:OH[&#W(U)DWP>O_H-]$ETHS-;*X[1"$7C"D*A?=#?^P?YS=R)K.V6$,P+Y
MA^!2?%=04OLI.'%#!P$_^21 (5S1IR%WV!\#1^B,#N3?N,36IZ7N;WPBY$E!
M^PO[= 5Q?]<[26?Y]X#?^12GAQC?*P\V]2EU,J'8I_1)?P!9^F\!RSJ9-_3A
M*P @M0/-OP6@!6!\F_ZV!2!6A"*L8=>5M0&8W]X!2$\I #3@1._;'" 80(R/
MCT^ 3TQ 0$Q!1$A$04-&3$Q&0TM%14-%14M!?-I^^_AUPR A(B(A)2$G)26G
M)B4EI3YY(Z7^KD+QKQCXU@&@P$<[GX6%P0K I,# HL#X-H\>*.&W;@QYM)<X
M&*?MMS!B 3 PL7%P\? )"(DP_BK$0%?_'T)R  8V!A8F-B8.'BX^#A:Q*%I(
M@87-0BF,HZAO1<7J%BB"2QV77:W$QDX#>6PM*H8,&E'&XX@W>+^X8^,..I=3
M<YM3)<$0JMJ9BQ(_/VJT!-NM#>X:\WB]=XDK,2^D+JE[_,V'_/HG$\O[QK:>
MH<D%#3V3*P<2:B9V7G?N%3;V3JU^I !@8J*]Q3[U"0\7!W3J HLP)3;: S=6
M*AR1P#CJ$P\>0T;>B[);+R*#XI4-:&S<Q78X<$\<P.,$=8ZBG<@]#U4U$D?!
MEGZZ\(\]X/K=A6^S &*L4TP*@#S@PX=XI7;6,M]GR5246&;8S4/RJI&(5=G^
MN_%9*Q+\T]NT.C8B_@6-5SC2I%H^?@.8/>K#XY.:C7 L8[I@T^]V>.0RO?"9
M0N.14L,]B8O^25LXH[M$^,P:$W-;\XU[J9^7Q/1""C>H">"TP'7.+N M[G-?
M!-=OO:'2G636:'MQW6B(8\FB/BIMMN-Y;O.<K%W+K=529?$:!= U4)3CC5OW
M\=?,XJPE.)HF&OF?W51 K)D_S]'=13GR5GI:N11$\.U7(,:FG.C C>.U\]M>
M1^(2OLRS>Q?>>8!F1SZ$"$KW/FX@J?P&D*LK*IDK9AGS\)J<<Y1.>4?&8+^2
M_,#=?&'(D97 *2]G::5ZR,FKB8 8ET#^8:E1JHU3\Z>D"']I<>$RZ1=K\CF5
MEA_]LP?G-K\N[&D<])I1S33$C=,*J0O=((LN::Q,VU(%&9.1-'1:['V8JVX_
M9$TRE2[[ +<J>,M1SN5^#6\49'H2BE*O-<JJT-I;JUA7L*UEZK.DA@1>?%1K
M_@;(_;!1N? IG;I,%C4Y<M5--1K/+__]F$!4>EORI._U0\%=V<M]=(W0,>7[
M47H/^[A>;I4Y7VI@SJ]=\Z>.QXF5?AL?9U]0[8;[:O(HO_5\;VMC#'P99#$3
M5QU9-A-[<.<(&.:D2]JPG35Y<V5A55Y8HCP#)#8&1?9<46Y3W9KY!M +"1:'
M*!<<;=L>O5&</6A23EM\>A&QS<I:^&WXP_)E]H1T=MV9MPM7=2]D7@.<M;-V
MUL[:63MK9^VLG;6S=M;.VO\/V[=%!3I[%,H5+"@(=Q>P.OGZ1, &X2+H;>4J
M*"P@) B0D?=VM;)Q@J& UC [![@LZW9+.RO0 2K+:@+2%M)V58;9.ZC[(F$&
MOCJ&-KY.-E)05GDY0AEOL+>+JPL,907T=G&&NX.]95E/C8/1QR=L05;@:1>4
MDRSKZ9<VP"O:>D!E!!(&! F(\ML("0L#Q<4%A,5 XN+"%X$B0L(B@D+H?^+\
MPF)@D#A81 +X6V.5(T2_RR"AMF"(RJ7?X-"4+.MOX_+R\A+P$A5 (.T$A:6D
MI$[,B(CPHWOPN_O 45;>_'!WMN]&?MA1@;G;(!U.[\@ 3V@K:X0'2I:5E1#X
MA_;;N%Q<?P+],H _+9\81_<&*R-A5BB8"OHE)R(D(L0O),8O)&HH) D6!8&%
MQ?B$0&!1(1G!O_3\E0T$TA"!<);3,SCU%20 =78&&L.0[B=>@T[NQOW!RF]]
M_V)&&P%UL/7YA2L@*;"PY!]=^4//O]I 3R;4"F7U+UGY8]\? 1?\2\3_JS/A
M^H<I_]-,H 7HF1#]\TR@F6 ]) +J80-#RBG:(!'65BB@BH,[RL'9&88$"@L)
M" L( [E-'.!0A)<[CXS@GQ3^NWV'VOQTW=4#Z7R:JU ;09@SS 4&1[FCW1?^
ML_M0&[#-]WF5^Y.Y4V #F-N?N3\$S@YR/V[R?G<=S?BSNN#?]64$?PEVX@+*
M >4,^X4#BLZH?^3 R8#!SE9P.UE6;_[?OK%FE?NW[C;_LZ'\V9/3H?S5Z9.!
MV"*0+E8H.0<7*SN8(,S5W?:TYV_<_^[)1J\$;>U_7C1<7 1_I>F.4O5$_7--
M]Y.O]@4A,'>$!](&INJ)3A^V7YN"P/[!>OFU*71WMK_6,FUML ;<'64%/[DO
M)(=F"#@X0,$@13$)"6$Q%9"2!$A545A845110EE83%)$7$Q%24E4ZK06_%GU
M;V95$#8>)ZG_FUDHVJRRF)2HA!A($23YS\W^0?5O9K_?B+)R_C?,_\+$WV#4
MT74$@?3YSRW-T[1!9[W[Z1TP6=8?@6?]F\*)SFDJ@*UL3A/1W<H3!I41_!/O
M'RLY_'W*_N/!_TWU']OWLH?!?W$F /TX$_RAUS\V<E(,O- E0-$.'6.Y[SN$
MWW_=HFP@_L?:_"N5?VS:QAY=?F!0.<$?BC\8?YN87Q:6_QTS!I+ZCQ;9OS]C
MDF<S]OOLV"#@)S=A_Q.SAL:Q0F]UT3LR.5LDP@5HY>KJ[&!C=:(EZ F'_E9Q
M77^&"(4 _O$$]#<C_X.#A<*0#O^9!/V#ES_C!/Q_;=#__IK\#T]\9VORS]R_
M[C3_T>GSQZ[@>UI>.DFL?VV>94[W.?_5 OH7U5]9AOY7=A)_4_V59<2_LU?Y
MAR;^'NT_!/6__YKL1Z[]@RNS'^*_7RG_%(%/?[""OOZ$R8G)"/Z*_4^=_LZ%
MJ%R2(T0/^,>7$K_*Z__^=@9R!G(&<@9R!G(&<@9R!G(&<@9R!G(&<@9R!G(&
M<@9R!G(&<@9R!G(&<@9R!G(&<@9R!G(&<@9R!G(&<@9R!G(&<@9R!G(&<@9R
M!G(&<@9R!G(&<@9R!G(&<@;RWPQ"^/M_\X?!H;*L7JSR<M_F ,H C'^SG1CY
M=VU@G#Y#$8,=4QH+@^+',Q2[ 4PG#T3$Q/K]^8@  !X^#BX&-@$F%B%:[D)^
M\M!6+"P\7#P"(FQ2] ?&Z?,3 7@4E"SZ^%3"5G$CH]0TK(KQV><@UFXY8^]I
M10Q, JMK'D^>9V-70B8DW\L=7Q0%!;TFX. 2$Y=0-KYBDY37.<7)+:GBU;"C
M>DG=T*-QR3TX]$Y7#QJ.$>.W!S;^_G %3(S?GM>(%EM3 $Z?UXB+BX./BX^-
MB4&#]H8"@(U#R2*LJ(]+9>46-X+'*A*8_9X:4OUX5%3)&AF?D+.(3\,FMK1S
M[KR125+-^ 2[<E RAWLGIX2* 1=(#>:1J&IL8^=U.S>_H'OWSX]#_+HU_C(G
ML"CT#E.4FE=I;FZEUW)/B-VD\=<1X6UY^B&%829YVN7W%2 F>87YP[Q,N^XQ
M5I\;NO>_TQHK-[1%N.YU?QK3?_V!9"'X?Z-XJN^!3MS8Q$CAJCA=C.A3]W9>
MF*Y@^%Z%PE%T6FAN1?I#U-CUU_[M G31GR+=T[[+/!O7BIRZH+-?;X@RE]UP
M2))IXQI*BV'.@7\V$#[J[4FE>KIT8ZU^DJF_9<>\=X.9'J9F%[Y7&2>>'NS?
MB76D((F96\TI$80J,(QF8O\T!91[I%;5]0T0IDP]Z%/ZFN'C; DD4WFSX.%:
M>V'NB)#3M*2M] IXJWBJY<'#8C36T2<JW/>SY&.KKPL5'L08-Q7I<V*PIXYJ
MK;6EKQFQL+G&-;R7F.L-\0?@(V8IIL+POUI]7.1*W1$;2.CP?P!S+]HYPMWN
MU!5=<OSNYT_:(>ZW<63!/[/OR7'^KQ!S;G<)GTQ5X;TYLZU8M6>O &Q?#]6B
MVWO>8C#ZJ>6:6U@^#4B=WF8+>^GM5XI'@?6V=W_8Q_VX5&E8C&)60MWI[8/"
M6P,+>Q]?^R0.^-^'J ^[\"QH;SRH$".+1$"_RESF;5?KN$EOH'#8<Z#[NNM_
M'V6"E86W<&&J(%_(J?#(6_%"XB'&080) "A=O[!.<A3S9FY<SFT^ FY)_=$W
M+X;DPY35@G:=]&YE.5;XHX2;N8MX:7),A@6!.U&;#WJ#F>S?_TY0-"M,2B*>
MNJQI8[V^,",?@R\]P)9!QFN@L(2P_"K#]B'NLYQA!9["?LPR%MZ;,<3>VEA$
M8,?C=T^WA\/':A(Q,*9&&>?!&,'*JR3MSRJP72@JJ9+)4 0+VL7F;YEI7_9_
M]H:9O#T\L?>_)Y;_@&I:?L\<FG3/H:@1&!:C\46-^9.R*X.J$@&SM&$'-EEG
M[@%M,?>1>XDCD.E>I4X;4')U:JMT/^D@;7UL,R83M)?M?6?D7;>CX7"K\MN/
M5IKVUU@^^%7EBPF2'\E.0]+.A_DS;?)H$W7+Q7A2%X0L,:NU$!HH[9#ESH?P
MG&IV)OY2L37D&P :=#D18"?(*1FM*W'L;SW':/0\8]A!/[#J<L^4N[@)3QIL
MJ_H^[VL\IIW:"V(>0<(\#X\OB3CP!C(\L\?5ILG8LIO&?=A2+SD-P=R"4.?B
M$+E!:0@^CV2SVXMQ5@MH=L;FQ:U'05BUL+K\_7(\BJ[SWYHA2HDW291SAKU]
M-,AFVX-$*@S<N)MESA\?;F#_L?7ETT2ZR\KJSG=K3*P7+PX6/'=2(D@P@A:P
M&<Y23[H*QC]LH2;+%3$D#TUK<GN"13<\PP)>X] C)DB-JU<43)B$Q9?UC4
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MO=+CCK1>%C9L&F-;5*<C,AT\FK1<WN1T4C"Q,?9+H?'V,7^4&C^H.>]FDGR
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M_ R?:8NAC7K\G<BANY]M'4QCR* 9T?XD-X,]5Y1(GZK=G!DQ-[C>U??(>S]
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MMNWB,=N]&PD%<QH"DBG8SSLE-^7FQ5(9EGUU^:=1]]G(,D%XII;[2K$/B.C
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MZI!DE()^B9KM<HQE#1@BP2:RXQ"Z+,EYN?Q]/'E5*;5G@/D3H[D@3QZQ,)=
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MUQ2&+/=\61/L;"K#XBWG.$WDJYP@/7 W8/9)M_7YR6^ 1 *_;P!%Y[UY$3'
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M(S(^=/89LSZ:#ZQ<P7_1[?3^/I>%X_6)P]P./+?+PXJQ!43.6@YT5YTYE&1
MH]HD> ,Y>%;J@WM-3:R75F_$6]/'B<_[2^PY%;,8&JNL7= F)9!7GY?FY([.
MVA 6(Q%@1^  5MX0 +<9ONPK6X57!83N2'?::F9R-XLV##6HX0/L0</]99\1
MO!=W<P0,:Y4%6>##_2F$94^P*_@\S[W!(<25[-#IU^B^S!"VE;&4N$E.NXP9
MUQ9$^W"2=\\1<ZNB"BMG+A8B-L55HTZ?,B"I?D%?,A2]QYHWJ[TQX(F<X6MX
M2'#AJ9-9^4M3I@',:8WIQ+Z[X<ETO?>:VVE;D^A]>'!H&<4*K"QR6CTB< ;R
M9[7KQME&LUF8/)3MKU[,P1Q94_=(D4(%8.:V6>_<#::IJZG^-&REL:G'B;&Y
M8"%1_B29S>YF$L\=1;<<RCT^0I<#8T464I$B/5ZJ. 4>4@QNLV#Z1.R."]V/
MF.49Y226OP$8H$$$6,>*K-!N[R G.3)RA7#LG<T5,EH@1:\%W^KWZJ+[KU>=
MZ*W[H/F-+Y>^5YY[]OJ[2$<P:>'\VDWR;P!N89=K(Q_]@RJXK#8P9K@>;)#5
MY(6HJ9*-?.Q:Q_A\^/L/"*O>??JT6'_3-\;$TLL:9.8H:Q$X?W(%[8GGB;YT
MGIAFG(:TGR>E< P:,B^YZ[DUJN\Q=64M)X([1YF[9* D*TYL5$,D99UAA0=?
M*:6''$#123",J;'\2"\6.Y-F.=EN92LW<7-LP(-B[E K!EZ=VAIK"S/56"GV
M$.$K6NZTT^YRQ%R>Y5//(=2<O8#?E#I)-Z /ES@W&=:H9&ZFE%A%J#B*5Z>1
M*;L G20JO7IG LAUCYFBT>$0O_B>X*XC9M7C'%7K>4K6>!5M]E&M$!8#@<?J
M2N2 ?!9" "01"PH0XTZ4P+6^]V VY0( @)5Q0Y*D:=MX-)Y3*V'OY:WG-9RA
M.X-IB81!V (!&!7]'O,C68!;84<[SL'OL:.G0>#-0,A"MD:7 K<C>!^ 6/OX
M^; @5%Q&+>40TLZ1"G+5QZ'05DJ1A9(L?E(NO74%\<1S.FZ^<#=?]9Y,Z>UJ
ML2MMZF$IW9+.X42C+%D.+=YA89_G)5/<U+%#^.H8<TU?5Y*1<I87<ZBI8[+%
M[>P<YY3*:C[S?I,J8]/#QF+=/Q5#?:U?45T5EM6\'UW:PD@@FD%E!30HR6TV
M6_>C2&99-5*/Y#02716OX$]KT4S,Z/=@5=<)M)5<DT9FSD0TC4!(\\C)",89
MWSA4HK1]<:0&F+FS7O&)KC:"4HGJ%(8@6:4DS*;\#=,YK$1E1Z3%Q#,OCI,O
MJEL'=\</7NA1H%W8.IZN25SAO%>,XF.Y!"'0R>Q@NT>[#-1M-;:_PD,XI=_K
M+R:;OELD(@#Y."!R@?N3@I&#*$I\B]XVPYE&9T[*P D!J45=$A"H3'?5,:MM
M&TW3O1^)&5.J/ZJ:;+_TP,,[M[>X9-G^'I7.I?$"]%\]-YV>*8#+;;VXAA4
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MAQ6,)D^K%<TBT3ME&LFB1/5TS^+SEF(O4[%5% #8'H#Y87J'L?9H<1XEBLW
MF4%2IKUBV58OFM'LY'1L[( ** GJ)25;!T",X8DS3(/2$5*@,-\*R![9<RC:
M?[=8(9!'TID,FE/_>%2H[9V6HGDIVY'5 ^">>6-_*SL6CE#IS[,\GL?.;M>)
M'5/X_*@IFXH];/-V99O<-!/[A"&D:!0T'E=QO/;ZXV2]J%Y8BJK*I&-R(<97
M%J]U1DRPTYY314K#51>%$'9%;$;LX_:A<O!3.-<5XUU\;+H5,JR&UH^SQ:&V
M;Z#UCK!'QP+L"X;O]#IA;';9D022V)&H*3-Q50P,%T'\3RKZ!+2F[!EJ;2P$
MSUEA$%7#^FVSBGFK.0^/2^[40<@*"2),?XC86!@]1J-HV"*AYHB[\_K6NZO8
MM:@7'L_ZA4;S ,LU!8R-D)K6^RR\ W4S<)V9HTR7JOCR6=.Z2MM\;?;09]=4
MM-] (G6 $>(#SY/PR\HN3 &X)>U+2EL#;K(P?#(:O29^Z;+[G>N<RSCUG1;.
MOGW2]\7 C)=&NC5&^=B(NZ.F+)R0T97DC5\G7 H@\UV7]PV\G).8C?*+H!#J
M?-YYR%P:>:VM&,F"3_L;CCT;:#R!7AB/<"73L&9 3$.C;"MI;\CWJL-Q6G4,
M%%[I6ET$GNY5[!D(-CF"29]3'*YIOR#89&=Z_[83#^C'[O39;E-VO&Q,7U!(
M6P&L.U)]J.S**$P#]_JXW<B<NEJN3MV3]?RYBP9A6-"=8=2'.[GT.,>.7V#^
M!0^[C]E6H] 7T11;#">_!0D[B$9OP[O]U-#[K"79W!#> .3@(-Y>C*6/C#'C
M?1"_-H'EX,1LB:4IO6E&T:1 34%OGDH%DN3Z.;U0QJ2-]Z/"T1!ITV%Q<4F/
M)C?55>QL7)&AU4"J@K@!#VR=VLBCPG%<TE#_7O6/0=)/7'RL5&%F88Z0+"7:
M</)\[O-VVH_;L["5=<!DQCL]_4]H*(D1A=8V*AN=;*]G:/O5=1U69_;:%TS+
M.@?M&5HC=YM!LW?KQ_0O13$\<F%X0:ZBKKK0KPX6DH@,MX7%XR&29V=$PO\/
M'V\9% ?3]'LO! ]NP;/ XA+<(;@L[DYP=Y>0 ,&=97&'75A@<9<0W"&X2]"@
M(7B D)S[NN[GK3KGK3KG4\]TU\Q\Z?]O9JIFNLWYTT@"<%%9KPHEOJ,F)RDC
MF]JE4GDZT#0C*LA8F?W*'FW<!Z:>PAPJ%C=KS,?9G3#2\"/F?OALS=E65?GI
MP>O^_?U<!Y6?JLQ2"X#!BT@TA82&F2?VA,$FI[6<)Q80E\S 0(_(,Y=W <\G
MY;8\5B\K+W'>^?Z>+$F%@CB9,O?4$\48+/6A3?YJ[P9&7OCD.5UIX^_"J;'Q
M#O!-H;@OE!\.-ML\W+OB];:IQ\FSH:Z!1H5D; _V,#_3&&1K6LOGSRUBMJ+O
MM'=+J'JR<Z2+2Q73U)ECL/AJ(5?N*E2^L"6W+^X]?P$%(:!%J?>_/A:X"%5-
M.]G_-AE_:Z^6@^2$E!I8':IRNZB /*Z8?1&9[E'*;,T\M:N@:U25>?UQ[)[J
ML6)+T%PI/?" -M>)_S\S!?@WQZ9WO/6<T7<;:Z?(?K^=O]^*;ZQP\,-)56'B
M75$!TY;)F0TZ-B/74Y**V;N,?>0 YU!XDL)F&O:#"N8D:]JU5NP+.Q\A<H5H
MP2M9TU/M[+23.ET^83Y,8ALWX8(J-W;]#$6<"M9M#;KK[9$4 A==>B)Z8N5(
M=5 \-BS7$HW!*14 H\?1 M"#M5##P?_S@Y]B[N)4.AWD-*W\Y'>_Y$D(V&<<
M #\+T@;W>!T_872>SD>ZU">?.V@6><(%B>8],?(%?^]*9B-1!0&%'R<>%@&?
M>O(3BYJ7Q>5.:*4VE+3OOPFL$*!<7U0M4_V3]6S_3?I::?E0F[6WU69LVAK^
MAPDT!1.J@L>[3,%7DE6<I[,86F.Y_HO<!Q3C&VQJ6GR1&K+F\WJ%HNJ"[[=I
M"&P7@*5CVB^3!,R]L&CV"P&N_NNA?P&CZWY!A)JT,45=YU5XJ:L!#,\.]^(A
M<&:NS"#T[\@F;AQ/ UGSH]33_"@M/7Y_]5ALO@1K'%J1E5:DS0RA3"G3&UFP
MB:R).Q\,H$1S2=E^))CJO^57$V);I:=8D5@@?UQR?[J^YKPK'D"+3G'P]!VK
M(2G9-0 _'VG)H%P<Y\<[+?49(( *11OF"<?2I1EB7=L;U@Q:JPU8M @IQ/NQ
M]$K0\26#5I3\27BV?';R^<NTUKGXA\U+XL#AVI?%NJ^G+&U=L<M!6E]M"N)6
MB:Z_3PP72;;\JC,,#ZYXRT03.9#&BE(XG:,R\IT5XYOV3<=6EPC '2 V4.S.
M/1T>KT3Y)/#T1Z#&P-H_3SYP]9.P=SU_(S;END@GM7&4/0U,033U0S>M6U.$
MA.WF.Z7"7,M=3@U=$((5:/N3\9M#S/:?T.;*M]S74_D-Z-@5^Q_I$N:&:J0"
MEWD@GHW,[++I',@7S51UI%7?JNPU],E=]Y)Q,A2,E9H!WC4??!]VP/5\7C4'
M5 5DHQ@O"*5+Z;\$>J!LB-UZ['Q9C(\B M'^)F![^ '7[G*>VRAL$F(4J1ZM
MA?F@8XC=$RZ0\;KJ&;J3Z%A]22\'&O+-]$H7U%*LLP>MQMGT]>/"X:*W T[M
MMDQR3S*G L)L/'X@M:0.1U$\QY63Q6RZ.8RP\[=6.R-)P4.4H&EK,2D+WMTW
M97;&@FDIP:L:?EW#;[09,Y-3M819$R+)U&V3S:7'\LOQ^JFNAV6 /X2I71!/
M,C5A?"@T\LL!_X+7(/=_2\[_$MD 8_CMN:?'7\ 6T7+@I; A4CCX,BAEG"#T
MG\=H*:<5%P^_%MXSN#UBW407IM[>_+@-_AQJ+N91H7?\4%%8MK@L?^^S'?R]
M^KOC7X -@3]3]M5?0-[/N3RE)XJ0^LF@CU._G,Q.K!;0E&2^69WNOD9XN0UF
MH;D*?"M#\&&)*G6[!DXO?%-Z2\<3,CAZCG@I>J5U_YVG;8US1<NG-ED) [ZM
M)3T!/,^M8(SQ3>A"Z_@2Z8M],"?/9*VO54N)1,^(]AR6H=<V)W\367L\7.=:
M))1=@S"IN>"+;(6E,B_= %[>U:42P[(YA_T7HB*7*VY>S!$>K0=L4A_3AA^_
MD6ZXPG@[NYQ9W%KX@E'DQPM/Y%A_IXHU_(7=^\A;]PID:[?S[J)[J\19W6'S
M"(?:@7;4YSSVO8U"^1EX<7.Z -1S^E.4C>O]KX!H!J:BZ.Q41Z2"NQFB\O#(
MOEPIW_6'O3Z+V4$K-])B?]6L[.C> ,1PLDC72?I-CWUWT[.P<W:(D/!&F8%F
MO,'L"^RU8O*W^\  -4]<E<*,8.$1VJ#:V)O<Q9=<0D],<H3]7G?A.IZUD!6B
M!7.C3EDSIY;_F.>FJ,%'/Y,P%W2:!%\=>EP=0DS9,/>-%S,ONM0??Q(8=.Z5
MR\I9LJBHL<@ LV=0&6U@X3]315MUHDO8@(@P30KMY3 BEE6JWB1UA:"L@AG2
M91FLR$%^2D9VKJRT#"T#F6H(JKUVHJVJ_DMZRVQU?NB$@%W]ED@Y.LBLO!BV
M^'XIFYU=]U-TA/#,"0%7^#>''GYJ)Q=M4*]8',Z"&V$QK@<54?-2W>$-)]Y\
M@"@]BQ-C/_,W5+_^^)$"P7@<F&WUMW1'16N]!=2LW'B%7A)I<[GJ9JMQL%8J
MJE:!:-S#_=@Y<K Y'//#NX,#LN2T3Z72#5Z\C)0647;D<9MO6.T3&<%]H!L2
MD:M=HA>MQ.[$K I@2ZFPHG(F0FC%"4MO4.CV^&<3OUO=NJ,BL8'E:WCS>ZB/
MD=/8/?(@BR,0<7JF7I*HM]:/(0Q9JB6Y'&T')4"._-TL>J#N/R-74JQSY*=)
MFEOS#,:2)?#+ _T]BY),S!OU>:R5<X@%'A[B6P372>UJ!2P:T56G$/9U>YOE
MV%+)P3E8?L92<HZ]N4/LD:+X<HA/D:0J\W99KHW@(HO6"><(_Y7A/.6'98NU
M02T=6TX\E)DD\3A"^61QI23#[K^ <<=JOP\*@E1$.IR;UMF=%*5,HKC4B>KX
MNH#D8FML#9F9(5XU=,+E;5,F1WQ0\+X+46WZ-0V':KQ1B_= K*X-XQB;)P@
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M'"VS)O:5+]7>WB9V*Y32)DZ0T,B3J0@CR.1:O,UWTUM5<9+H&$))%>;82TO
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M2QH< @ANLL5$&EZOK,2'X46:8RV\ J$E#VPZN;PE@V.HDBP&#Z\YF;-O?H[
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M84C$SH(4)@(BB[.L ?28LB38LB2 $@" 35H 1Y_%'4"D1 =(9.>#08+*'V8
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MZV.S*T'(0S/Y@0"Q2(#K4ABV;((,!.J!,\HHS\(>/#,2QJ0@DWOUF6/<0-_
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MV?.S2O)X%:RBP&C@(J%48B08PGL'%0Q\%?[6.57V#AX15(MRW8/2KYQU#(L
MM<_[A*= 5#C3^8[\3"PZ4PR01+7YW5FU$YQ[,U/H2<E^M$Q8WFXC]\SKS._$
M[(Q[N");099IW,XD#^>'4F/>-H$RB!',5C0$8++/D#E(2+7%<^&1U0GW+V*A
M$>[,YI]<\0*%3@5Q02AE:H%+KGB\GWQQRZ "%'AN% ^7ZP<*3)-C9,K-J"7
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MD_ C""RG>IW^9M5GGUEZ9[-+(;<+EC7XEL@Z](NNPLQ5#BSO$XNTYYH3FJY
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MR.V.6=X_8'"$Y7_Q.=D0WVAF^E+F?>)MMY3MQ15;_X7;R6'8SF7HH-7PH5W
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M&>7)T"*3_>%DQ!J$&&B"(;\ F513C9-TQ/#E:V\W4DT"&/#RL\#MEZ_576
M6.#@IWKX,TURXF.%$"7U5&C;7V8O]G\;]:9<1SU5-Y@J!R1U73/Z?JT;2ZJG
MX'8 )&RQ*E$F=2L,NI\;>?VS=TIIUG_3]I:"MHG2X,]T1B=)=@]*ZE#\G3#&
MXP>M_QE3^?_?]'SA3,O3/4==)2A%ED]66:_VB_W'ICUL!X)5/',E@@0B!$8P
M2>_A5)"7&DY@,+<<V9 Y[4/_F !+OL]M5B8*W;D4^=?JUC\P'%:'O_?*"X0>
M'1T#4AGD(1^/M9"O<O%A;E"\\Q^M6%ZO-FM4':D8Q2S0KU>)&@@6#]4&WEIQ
MH5B+AD;&!":<J.NSB<.WYZ!4AB11F0?E5A.%ZE\8WHCY>DA1E,?DL/!\O5UK
M:7D/_V<HLS^+7O&7>[!HS;;_<07^*VE<R=9!*==\;%V[FN @C)E#*4CZUW>W
M9$W54^M")Z0:F=N)OUT&)M4:-U7!^ZV#I2M+Z6XGLZK:IB7#?*LWWVKCU?=>
M?Z-(E9!*_6U;?/^I]]NTF+LU?6!3_YW_M>1/]F_E]^[C;^7G4/N@:X.OUOU;
M^2TA['X!YH@=+B8#.MY^4969MC9[:/X6AQ*/=_?;AES];4-BJ+[=5F>_$_RM
M[#Z:[<S<7@V:/%3F/PQ>W@WG-3E<V#Z"?P'&<%7S\L=NMC?4FL07?@&B3D96
M5W\! H6?Q_X"".??_;"(?"A\'?[0'R8S/5I[]:SL9S[%;Q/RU'_,.$M@=>X&
M=8Q+8/7@!QK*\+/\A\;\FMH6Q/1NXMW[[K>W[K-5BF47[W\TZ[$=/M0&D)3]
M\P#]9[ M9;^W')MA_XGL=EQ%5<]#O%R_JWO8UGBWZDW(%VW>X<2\,T'UBQ>V
MHEKNBX=+TP9H,W-E9Y+3[WY^(OO0?B?8] MP[\Q_NQ,O43;&OBK1^GKN&WKU
M+\ _'?Y6=G]Z1\R6T#Z=_:W@\0W4DA34=)7A51.\AA51J0N&VAF"5NMG. 41
M)U:9A*)\F< Y5.56/O^B=%MG+F566?=B("Z),+/:%Q-P!G6"_>Q+T'O/3T*?
MQ15OY],/W]0&<"VL_K\35X66 &8,\3G>PSQ J>FX,Q.&N%*96EZ$U)'_^!^T
MO75<',^S*+JX!+?@KHL$=P@N&W1W<7?7H"$0W-T]0%C<70/!69S%)<$=@H0D
M$$A>DN\YYYU[/[][SGGW\WGS3]=T=<],5U?75$U53_D^1G7]N[A[>'"20;A?
MW$95/ 9*O=E-V(L??X0,RY]\==@0K'O5@:B0P(^QI0.:97"4:_G0X0SNO[B&
M"9[@#6YGOZX,@I85R*Z\%L#/> 9/_],RTN(:=@?.]<:PN)R4AO8!H;[9?%?U
M!?OC>[;C./8/@W%OR%-RJ[9L]R'AC47Q#&HZQ.@#V\U9FI(P&6U&TN!DU;9B
M!6Y[4+=F?\CHJXKLE>_$I>P![=*_ /&Q++.O4*Y#?FY^S\7$TG1_V,</)H36
M_7F0'8,H>-8^J.IU5;"/OZCK!G5UDYLOK/O;^$_QR.WMD^WHMD"[W\*.+3X!
MTC=YLPW6)*QKG'&W"RZTTU#>=/I_KZ#]WXP%HE%T)DWQ]UX."S11@[QWX(=*
M=?&PAN__U^3Y3Y=,,E]1>I?C'T*_YDP#[PLN$DD+0:]FM=>=.^B(MT*(\X?F
M)>=>MZ]S$/+3-(S@B]H@63KK+R_L/?V\,8IRX/6Q3+,JY?#B[B(!*+?Z9T0_
M_]P)RH[4(X)A<:5(F&%X^3S_W6 *(2AIAWPD38#'DWV*=*BZ*Y#TW<EW82@^
MV7!\Z[G^JKS$(9K0"Y[N8U:83&7ZD7_^J-8(VAAJF]?X $D!ZG&Y^VPADRLU
M:QG_^=WNVV[(6&& >R7*GS'P'/PAP?\]L>A_ 7X!?I_8KAU/$IO4>C\??6!H
M1',-\G,_VQ-U@5#0:SSX_JA2AGI!'^E>2]&CW%T5F;75+^FM.55K-DG[S/_[
M3R(R_I>?1$"T3\[PSCC4_^ :8/^@,DS\]0[4.;GXB?G+W)HG3[400E12JJ4M
M,3K,#FPU.IT^6O$?>U1)"9*8\WZZ2E6WC[I.7O,8" B$UIRC+O2Z1G3\<) !
MTD<D,ZW*I4*]8X)MT4LU(H&(4M1JOF"MQATTBT[R \5G_)U"^RAPP5,C*NP1
MD]G*U&LNL+$5HFGY6&B/C8FRUX!D786#Z$HV*:CG5:)A,>/F.DH=WFJ7+.D
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M5M%BWJ>7W2)1S4XT=IJ?^LUCO2N#-4EOL9V*,*,!P8#H8!)499EE&<!'1BD
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M!ZAHQ'JJM[9&(?.DHPAAGW^UWSVXIWU))#/*LX7EJ>[C!S7Y'T[5*&V8:<[
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M* @NR^#K:5PBRC4HCT]Q/5"+Y;W98_A.46G'X?A]D,VBVK2LNOP/J*_Z2S-
M&74G6*#48,]^-'IVA0AD%0K+%C6  C$[P/6( %?$RW7S8G@R!AU Y_I@R_P+
MP,U)5:MKP&+25=WE]\TO=FN*Z'F))?I% L!KUOOHUB?R\<<5^&,DF*D%J<==
M%ZS,!_<2(CCY<*O4Y=#)]RT@R6.M$6]KO0YB+Q?])3*8-JD&P_V($M,)48^+
M(?O$T<T<4R-,)MPF9;4FH0Q3JD3=5NCU#A*:#,QT'AI>+1:>9. X68$A=@]'
M90'!O4[U:KZJ-?H^!R)F,I?XN<%&6]5W^XF;(BE'[+E,)F#]Z;P/[+<\-MV9
M,128-I.I/!JK&'9>CP$U)AL&E<-HHM?8.&U-)& B@3=6+ RTX\@Z &)))]7$
M+R^PCE\(5S@;;*V$X=F0%_2FN621F\)Z9*NMZ6#"<V+S5RYZF$3A[$4LQ:Y.
M9,+"8YC5.*]<"=RXAKOG6U_EVK^WM4EC6+"AW^2#1C^W?WG#,XN6-%D'(<'Q
M/++R)DLJ.VXS567BEUV(N4U6LUD(S8[0"-.P?/]JN*&[AXJP>] -67&XN8YA
MN*FHC8=*[KKMYH5:L4L7R7IM)78$@RJ?N.[+OU%^=K('0;0Z=?\$;/V!H?\'
ML$_$W-=<*5(U4?RWCN1=%)66-H_P?[1Y8+CO#11MJIT9$;NJCEEYM>4C<P@6
MS[VILJ>\EQ^]Q?R/Z'#=M]:^>M-E6\]?]!%6(2#N=+!/$1R5'?CSGP?2%S8P
MCGVW?\JW7))4-<*KQ?>:NM[1&955O;W(R9Z0C*ABMR1U"SNC*LT:H,I-R 16
M/KOT[VX;'R[:9C$2:U099+Q"LQK^!1#)LAV=IZ:/<1$7>Y\;EOZU8.BXN !-
MW]^=/ZQR=T7YD^2/Q"NS)@&V;#W&.?=.J/N^#:G?^>XPU.M>]@:6>'QZ>+&!
MM2$5=#=?+>YW[@UU/X=7\W1%Z<A3^_(D\[>E8,G HV?#3SL25,5/O^E20E!3
MK0NEQ17>=M4,A<>K^PCY8[&I[UH9I)<T1TQCE:F_0W9(EG($5D4RLC-F4]@L
MB=N7Y"R(@81/O G[)G^@IDR21OMHQ\>^D0--IV7AF;"BE*V1?N7977).'5Z
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M?KU;BRS#G*BL^?H7 )CMN;80;YD,I'])EO=*-JUC(9$>JW]JHIUS24$&%7;
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M366G_LN[?_'FJ5-FOAO7$<%)W+='1Y9]5 /-S'%_.14<.T%A$!T#.WY9^1=
M%_SC_RWZI_;*Q?KYMZ_V$L#_1#O0_X2/DYILY+1<P,\Z)/MT\G#?EDI4CN.6
M!O B=LS-RY/#([9GNKRG$1.<.H+^\6%C9W^BLI3 X)'Z=6QOS4'HN(;XF(Q)
M#,9;X(?6VLB\A.3:Z!*U5X\.=!LS 85"S1-T03G'(G'!^V667 2*:SR\RY)8
M!IUBJ.#/,LMU?>#FH.D*NL^J7Q]^:B[7!3H_-XNA&'1Z4.PY8%#F]F,R,J T
M19L-8"&1O,AAXX;\WF(.0'AD%9E*,,">@$ L9YB N3PP1T1>7/;4B)O#4Y,A
M!\ \?L'D/@JAO[5);ZVP;H:*7SE888;T$HK<$02*?&V2%/%+ M0MNSU;[XY+
M<B5[?"G6GN&3Z\CY&^YHW2,*0MN'Q>*=@'[0G&Q5:-6'JMC%K6VN/J,TI';W
MN<]I4;:$=>ZA]!%9%D!]$"?_$H8&Z%=/F<V\',')CLZS>X:/ZK[R1A1-?<Y$
M1%YGZUL]R4H_Z%U[ KOG )W[E[@32 SL3"I\B<X7A\PX4EYUA^?W6+\;"N)Z
M))*3FQJS&C39P.]$)P?_ HCM,R BUV1/>LN"QZ,W^H&D]MN\AZ61U:@@+1/:
M&XZP.)C;.7JYCZUI6-#S(I9]PW/=4KPFR3!:YHS/389)L$'2N(CJG;$=)Y!M
M;N>4(\:A0+CEQ.&1=D2X%W3U:TK&[<W9THV%9;N5GHEL$47KL:L6D:N;\L)Y
M>UD)E1.1I"U-T1V[K5A\1\+"FONWE[QM8R>TY UV1V46JKWJSW'I>\MB:E&J
M5K^FDRJR:+4%>MB;A9EI[1>W&8JQ"7(94RJ2G[(R$V"]F78_-9"-9(W/3?E,
M6;2J,XP(OH,\B(GX920%2;T INK-SVH>6PU6)*?W=JEJ./:>S1!P6-43A<_&
MMWBLCPA]/N/.(U*7Y]-*--1@EOL3O)P$4=Y5ALKDUMN8<@);C+1>%-9;J$EE
M!:_[0SSLS39B_@*$DPX<<SH\T)O#6#,!5#436& R9[&GQ=; MK#FA.6M0'7Q
M:G)5M@L*P9R<2$S H!IW%NXP7[B&*^>KZ\"3-"4#-5$J0!FOW;6KP5\ [QB,
M$XC@-!.6 3MUZ1CPXC-5Z&PHVI*1B:AVAX??Q'ZQ?IBFE'%0:6!V#OE&%NS:
M6./U@/?KI0)/C]5- 7#6SS7;5V[\@?O *OR7Z>&T%JJ4;M"!]TB4K=;^G,7G
MWATX=98OA3LWC!48D1KZV;'S]0OC+?'/I2\(%@HS"R=:)%->B!,4JJ@PGAN]
MB=G_PH(K:+S^OP_L_PX'@!)9]R\LI$R*1P['!03A+]DDCKA]ZB6%3.9UC1?'
MEOSNTT@W([DIJ$W2/+[/9/*I!H("C+)=U(@-D1\Y8( -964'WS@XRE@ @]^/
M8$61&S?]R[=:O(1GGD6@.*_<-PMW2ZUIFI4M7LHWF-#+A9=+R0FY\K?;8:5;
MX :.7QK.YA(>T^GJ.WA.A>$%0:QHKE **]"F_'K FH;$.*TD <+M3*G7W  >
MYVZN.C"NQOU.(4/I [6+82A/Z8Y&=L&+[N'<]O<.3[R)[>)L HZROIG7:X]#
M\54<F;6)IIKMA-,IBC20H<8W=;'WP,9!;U]BV7-*Z;[]]EH1CW,=9!),O"/?
M</N6C2"$< (;B4?["UYG&J*I: 2<39L<GZ8#]BTE%[.MN(N9*_4N\-YJ,_,B
MJL3C\5C!J0>4,IP4FC-&IC0:A6J*TO?4'44F7M[/OCZ\R;:[LMJM[M ]YR#M
M(70X%<QF '+9DK5_)RN?B-3!^0"7SSN_-S(S,S7="[+"&T$U#J]WA3WIEJYG
MH.]1*XU P=?HD7$,,"3?$ZXVWD@C#B..^3J?#+,02,;SX :=&IDT$;O/J1(T
M*YH'ZYUF><*&_H9J>>*#/L=N3IYZHQ0R%U&!)[R_AOI]O<)&NK4C-F'>S,.-
M<A46KR\D=R%G(54DW0 BY7D$AIZC("=Z'%<U![<_]21;2U#6:FZ* YVE*SM2
M_\QI:T-0OGQQCZ)9W3AK7(E/GT\XB)&$_U7I]O<GPFYS*C:.(UD37O233M0I
MB9?[[YB35G2HTNN6T@TRJM2LI3Q0WP5.I\3Y-834L'5^,]8N=H/1Y+WNY='G
M71M6[:FR:MZ+E7R:'**IX>=G$56S\;?QE)686F3<;1")'HGZ(VUF,9%:,15-
M.]%<CW;P7N'B!62<4M0KF&ZL<FQL.4%)Q'[\7.N4CLWC$B\MAWM&;:%SC8(Y
M4Q8!,D+S(K_)4J1734DR<9AC-A-@B42=15?2 X#BTVQLBI7ACI[4+G[JVY1W
MN WQJPX05$1N4M.(P!O?*<]"E, 2I3JS+N#)@0J/0LEG0^I]![% Y4AU34Q.
M)7:E* 9Z!E]<-''XFY.?S&ZO>\3Y.WEB1!37V2LT0]OQ7J(:5HI2"30-2YN=
M];##?GZ?C3"NK(!_7UJ?/#[4U&J>?[YOTMKV-&*]>> 9Z4&XOE"XOH*$!);N
M7D J1R4^P/T;.+PG0%5';Z" M #M+?L;>%E[OZ\K?3[P[4?&L<F#\K<?:5$,
M9Y/E_SG*5/\[U.)DP'Q<9-.07!4O)\B>]*U8%X9OR\OZAJ1-D"JZ;['_GU%=
MR=#0T#>0/P5_ 2%WEZ,_=4J5+H 2CWH3QS4I\,_/_P)P>?XK'_#?Y']$ TBQ
MOGS]K^0^^"'K=V2E8XLF)RGLD]>41W^T3"([H^[^A6#=%P/AB]@J&:B)WYHA
MZ7ZZ >N5<*QXSEZ6P#+&)+\=9P(WS2ZVAQ3F$PS9KP6TFIC9CI,$G(Q)#U1
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MY=2!DM(_A#.>[5H.:TSK\0LW+[5:-UFZN_Y*:/UE._6A9V6OV1WPXZ?5[+!
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MZ7'JE-/@9M!D.$H_>?\AM?1?U#*)6_A/%IW>^^31YG_U6KKP\Q\_A5?@W_Z
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MN+3Q.]B=]^3)G+'AGN<0:Z$)T:0R6JLRRW_&X/^^P_QZPD;D\Z Y#3M?TU]
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M1$CG4-&4*-NX-],2"#$N4G8 0G2*J2_.RHXO!MNFX ,(2L'JX#%QWX%!3MG
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ML#0Y[/ZZII/VV?!I<29!?=$1[B"(+,<(0]J(T"BG=OK'DDO$9F;9M&1\A=G
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M -E@QLR=PVOT:=7%ID]8\&E.GCMA4UDE <]H9YTAH^.* -EIZELEK-,+S2O
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M<?'^T[^<[5I 8D/*\M)\YC;W<'_MJ!]1P26*@]0/ZW&(NB&J.%-LJ5S(QRU
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MV<V",]I*#HC5U$; TDW"I=Q\O,$6-E9,R4[I$;SQ(1H5Q%E_ T .)7,@(A6
M2'@E*;K!?S/G" .>S]268ZOO1$6LUX:>E"C;R':O*$3VRTP6<SEYBE**4J=<
M#E"DS-I9F6S"FFU!&"+JN.#<!E>-[!@U#+/J*("8EX=T#)OMW/AUXUZV;U)L
M<+QW1^=;5WBB2<#=7JGJ[_MDJS4J%<T6>9L)$2@<F7YNCG!EJQ1V9*>!;U.Z
MON+J"MG:&N\S$!9T.U0YIQ5 Z+">?*+6F"\J\?]NNSG=OPPN_[]F\ .$74_E
M'?DV;('^]W8^XK\%+&H>D >I!+SD_Y_2([^']@IX;OX'**COOTP,WZ)0_0.C
M%G"Q8'O_+J,2QSK2/"@"@1T82\$=?, 6;]$AD[_H4L)K$WZJ!!+]56,K",V4
M@YNC#-6\CUO%432OD/N.=VZ;@9';-YI0WKF&^[%E?BL4?!!$_\X0V= 73I8O
MEYA0=N9%@.,3\[W0V?(_KVJ:N7T%9$JL"'6YVJ M_&0ZS>KR\>;LK"@6]%*F
MGEN%7$:O7=_]W]2 ]/MYBM>^3]V",PV.3RE-=1E#I.+%DK!$S0&W=L70L')I
MV5E?$A$3>/';G!@"Q;5VM8[,PDI=L0LV<\GF8K2?**ZW= -4U+*LZL*H3MH*
M8#)A^Y8MZXB@A*?'Z&3HM=F(-P1<',\TX)OLS!$))1"?NYQN?<()5UX!-:1=
MYG9RI3[J=Z^ \,(K"6\Q@?\HLCU,OHZ)N2O]ET#W?R!0\_!F>UY8\Z9Q^/;2
M[?]<V%NF.\\OL%G\4_L^S?OHM N+N_D5H"?D/;TQ]^F(A.1<>3_Z*?R_$[S9
M_M\D52>]20UO6E[^30O1/=9_-4_XV^4N=WPB&PR+VO4* +GS_P@/SL 06K3S
MYP?&!,[L1WL&:&KC/_3<S!OW2J8.4?ZFFJL>$5],93<F7Q:CN3M@ILE;VIH-
MHFB F.69ONL3E='#\,6"G0;!B"%\J>$ZRB5%[H-2U;)JTIL_^Q?'$O=?-&U.
M-O\':5MU#D9,!2\BU"$ZU)33QA%@]HMKPP:A #<W.*,;&#:& LY6WP6@\!^4
M.1_1XOE%02V#9B07F*PE\?%+F=PT!]U.YU!AXN[/;84+K6MG2"95Z9P&8^6*
M+*:K] M'"0_F6A."5@J>R_K(PQL%!P#(!2/64H0_#NCIG ^:;(\USO+65I=:
MBBI7:(Y.M)5181.UV/2X@M!I>4C,CK]L9 NJ;_Y9Q43O/ @1^EQHN(B#.4VO
MR2"-U2EVY.K-:S)/:= >?/(G.=W<1G.5S+BSUD+.C-KWGEB5*> 5T,M):W=?
MJB+T"GC9PW@%2(80DA"\ BZ=X5X!I_@E5\C>;&]-)G'4\V(3]>WO>BVO>;FN
M_?$1PP=L\'-K[S.Y_",)P7,OR76B[C6ZS\N?+X0^_;4"CY3\1]2Z5R8[S,^(
M9=ZK&R]QU,\Q42\;,0\C/B41KX!;O_VMET]A/DNTMQH\KX!\3MJ8?17EFSW4
MJS"!8ZMOKX#QQ5= >?%#Z)NY78FCKEX!YTV4Q:^ _W1_SV^W2#[SRL^BNC&O
M 'CBJ('L$T_I;W=4LX\5F3X_TR&#5W2ECPXA#Z+9-_R<C\$"1W39A\2/S[_=
M.6=> 0.+27'5CYCK\FW#"\]XK3(^PF79S5P^!2"2EY"!5X#MX+.QVK/(^BN@
M U6"Y-Q*^F7XW_9\!1AN^;08OM2]+?L*^';MM[_>_K#R]E?6*9_6.;T"Q&V4
M2:;*BD\F2 XP?!;OUD]Q7P$5?UU;]DL+<33U*V!D$3+XA)'ME%#]P&J?\A*D
M(F!C^V:(A)?!?YV!P*S8*^"Q^\KN%8#3]PHXAOQ75T;[DO?I%? ++C_FKNEM
M8:,JD<2$RE? 0_U%*O(:F53IT31!U\8$C;LHA0P)@5^9GWX*15*RT:G0*:R5
M+&J.Q^4K8 /FY\#O@&?KL!%)TC$?I;"4$:?%M#66<@@?O[F6Z;ZAX%AD5]U"
MN9WS @,K(@HYZ>GO7:-M SQ>_=VE)5_U(B^L>XK+C@'_T%!K1T/6#P,I71TM
M=1S-.,U(FLWV155XTGHL1Q'6L P\F^"*(=(H^-6S8M89']'%2:$_#*P%S;@+
MXN=C%-C]U;:J-NX"/@XN<P:JJDD+MTB=<^.99>G0OTZ""@VY%%6U$27+W_W+
M5;O^ID/3T1!D=D*5Y(4G?G;1IWW([Z<X*S3%#W/S=R=[\M& N]L]ZJ]OC3;Y
M[UG/WDJ^NZD.KZW??19@Y$P1H?7#7_Q(M"JJ:Z^ AA*?/]S)WWJ7OG@)W=<V
MU[Z<[KT"WCQC:'T2L<]G1=YE\_X^H<.0JE(9$2R0XE9T46A6HE!V#=></CX>
M%&T=*<Q2H4=A2.\D%"9NXVQO(QA!-5[W;2]G<[')8OQQ[VP[ 78E+M]T8H7T
MQV=)PDX]I19^UZG<=55ZEU+56>FUQ Y03_+GD_J]<Z;=]7)TC.FO2E@7GV6$
M+?2Q#8XFB$'LXCUW_A- K>\P3<"IC!G2&_3:V\'>C#-P+.=,9^-JS:2A"=\L
MDJ"*/VY]8L= S8>XM,N0^" 8-N2D%] XK#2_RT0[&?MD>)@;2C[)6,?,J&B!
M<13VH-WH6O-:)9 HE/]A9-GAU ]9VLXRN':!4E6'Y^80JB*C?%_]@%/#ICW)
M!:=Z.S8PS0TIRENHK/82)3'8T1GE!@VGG*D.OAQ7C>*W.:E<ONS1>?-%\&CX
M)EX0"1%7C_.14-&:=1E82"VN.(F=F!)$&UJD+"WQ";^]"?$#1SUH$%]V&[Y3
M2(,*X5!T-EX3*..'V?FR,6!!:>N*)I[V=,%>"D=7!MMH4\\I[8)G[<7H-,+C
MN,UJ+H&45/V1PQ1/9% 6^I1<AN7<#/HL.<ISN$5,'1SAN)21[P#<$+]20I01
M4B/GNK6]FQ,.!)%Z=#^^+"?1<_](<J'GJV2IM0M+J1=.$IS,6T[URL<AN[!S
M$(]V+$.H2V7 RAOJGXCD3=Y  -8Q4(JE-RJ+SHY4EU6[4IR6#?%(EE)CE<T@
M@IW(7@'$W-AO4=2!]140/XA[F[V6?/;X3C%[%.7R9J[Y;XP-9#6Q_3WH@?SS
ME;C@#+4=W4#T(M=5X0-K[1-.7-5!%V*XZMU[>:,B.-1UES)R\O *V&?4K7Z+
M+9K7<+N#4K=-'F_N35-IMO3E#8^%2E6,X'U>7PE?^ VI:LCJE8NK]XL.?@"Y
M3%%TS<J1Y6["([93Q.>OT0U]3OZ>]*?:U)1_Q!#NN.%A3;@WW.L+AEX!8_U!
MS-OQ\0HJ8Q[%&1?+O!:!?JTPG6UG]S+&ER4/VT$H0HD'W!6C!3O;X=:9[<$Z
M6,V&K;A'4.E#8G@SBWO(FD17/*4YD4Y^)8CG=<6"P6H?840SOB<TB+J>"2!*
M[O*)V6!E_/:MFV(I.N&#!\^/0W(U!46Y7 O\Q+UMB*Y6S+"VAX;+I+EXN8:A
M;-J#QS =R][9Q/&5.I_,^?O% H"BR+R37=&_T"N!#L3L41P^QCU,#%7)=;U1
M-FT9#B(C+$HZXBIS81YBOXHIX']U3J-+H,I,J\:1CX?_F2A<@'C.&[>J-XI3
M<MJCCY0NWN%CO-]V??)HMU2,WS&&*,POMJ1J\A%(1=YH#I@P(.\#M;ACXLP>
MAFEUG>,C-<497.^&]*(IALMA YK._[PH(>]^(!I'')&E@;6DR.J-^;:DH.0;
M2C%/;KI6;!3%CJ_JF9%[P%RV2W8JCS]'8:X!B=;L;_O(M)NYDE4I5O$+<9..
MG(Y= UN-'N]6L,(#EA(ITI.U-$@K,:5"-7&H%$"$O2SCD#(3DBDG."V>]NWR
M?"%3]G."(HZDZR@L; 2W*RA)=CNOD&)!=@;O/<HT^4EF@WU89/P04]Q(G@5:
M#[3B-<JQ)CD"81@Q]M?A34@1MIB51\R2;@A5E(#=G;7$6S9+?<O"I^SU)>YO
M!<!"Z?>7B]NCXA?Y3-1O=*.F2R0/G;.SE[FNCX,_(K]^E_TP^%<85/] M?][
MRHF$1EHN&T)*XE'U_0M4AZOC7S=A$_HNM(GI&>BNQ1SEG[#G6%U=73U5/O.^
M7)ZL1/WA*5ZZP;Y?*UF7135VF/N'_ 5C_*&K\:U=S\Y>_]U=?NUCX=GY4V3G
MYND63)&@N_M![16 [?"VR2JJM7JD>07,W<P?KE](\O7--H?.'>I+^:WL,<SN
M[(ZJ%QI7C-=]EZCO5SY5P]K3TU]ASO2<H)-2;" $EQWPUE"J1*;JW?2TXNB]
MXXF0Z,4P42P[CF K!(*8?W.[S0&1AX@?^I>YY7;R$?M'+)(Y,3V2"^]+SG(T
M!'0X1Y:'EE/ "['1"3KLO>9<0_?4X<T.E"@9&6Y  GQ&4]DU@I^EUEKLA-R9
M?MNT%"GGV UJK%GOA5M3.-IY)&?UZAZ9*R%X"!\_0;R7P.7*9L*47+_W!_-,
MX(>8-BBQ;0Q:I;B9F1>\\X"*]M)ERR;RJ)>$-P39")*[](W4F=BX1V?=>JE5
M#G%H-ZF::1.[1/6Q%4'.Y*5\PC DK)^(GS%[EE-'1JLJMBUJ*M0BU/$E88O_
M@$3-1V4]_CJ5DM.YD5YZO53%HGPJ/%FUBOL*F;+L./!%[:<RC/*=G8&7?@GV
M/=O@C'@?JB@+]D!1%IDT[A2Y41(RK/KI .?J8V.U.;7CS-:39IO9N#'7\ FO
M:3QGMR;HR%FZ5.]'^AT'UEM1/%\Y9BP*QI_8,*)X?DO8N@RJP@I#N"'V$'\6
MZQY<@XE[1=BJ:ZUZ5Q\Z$WGF33JUPE]EJ4'P./A&HVY#<8Z'7XRG03,J2T/,
MRFD>1.0_+I"-*( :):1J,D#\)F??E(Q#2AB(."PM"[D0_KZ')S(4G &J7=KR
M.6+EYT*Q)3G\\3WYMT((>^L5\+FD ^##08?$Q?&4NCKX"K \JQ2;.'@6]2HO
M_8>!(Z*U2^VF*]%0^>]?P=_FGJMWI,S;95]>L@UUAR/D4F/F= 9<D6]>O ]S
M%V_"BS0 )"?>-A8"+Q3U3YQ'AV-+SP]6I]=.,5V$..AY=N:O@.L08E*9-_68
MGB1^_*=VQ<M>;#&Y#U^.KZ3WNP:?D7HX;MT&\;-Z37TF^&M1GR@>.JVL+S+)
M**R-,I_$;)\:Y#O>SE+Z%'OB;U(W//DY8NISY=7LY3? 6W >%7!HS3 TER-&
M8&!4HMP8B PG[&6618@&_I[+@Z:%/B,JH6TT"\WHN$Q4DC;+L1;N'^]U3KK]
M^*F<@H&E.0F-TO+PQAK_<'-66+QM'TATTX*#[!:SQ66"'!)(L"I^7FX"4T:K
MWW$?GNW45]A/F826V'DO!1)A;*N#Q\YK&-\AVR24VZW4UZJ.4IBB[:5[<>88
MJ)BYG_(8[V8U!JBQ2&FDP@#[9T4XY,-+>,FV="2Q/V8,\+J4BWRQOJ3JIP-R
MIIJU*$THY4""A2&%L0F'.QJJRN]$,3B_.8+:V^<_OT08#!TP3FC^=)O3X [B
M-(M@\6U/KOKT2[;YVN'02:A]X5>S)$/IIUS_HOHCU2Q%M',YTKE*9F,;_RQ#
M,1\BKA$K!9LV%ZW)X-$ !"4&ATQQ&F-P@D*((GNB[=A/Z8*A7=Z""M[(NN78
M)"4FM$/&511@9!#GQ]!ZP?=L"G;&8OS37O%0L%%5!/MGZ*W-G=J/9;V?&&S.
M(S33>=-!=K4!5_9'!4&2:NKOI8LJVR"E%.4CFS9HS01D=,OU$;PE]ZPZB9 Z
MJ5K@"'8Y431.1]F$DAW+UT?R"GN:C7(\0%BTQL48^23+/?1@LP?I'#I/- [H
MG?TGNP]67][95"(X4$13UA'2N2'[9>HN!5U+"BE!9R@@"'V%(BTE/6BCGQIS
M*6Q&9@]:XKFNLSFV8JI6GLLM(OSN9"Z,D;QF>:!F8=RL*UO8K.E8A.<TM:ZZ
M/)NU:N.TL]7Z]=KX)(F)?X._!V_:%D[%&,OBP098S_QG= A&:9""X<1/Q7&
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M6H)5W<OG2\(1.&TBW0&K*EJ- 3QC0^O?FGNM#S<!_U][7QD49["U.6@($#Q
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M"+Q(5U/4NQ7:=J"CF];6T=PS4!J8XO.X0%?V.!^/KP?/+3RS8.N=!"#<EK1
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M8.X6"&'WO4-P29=4U6ZR;[O8U^^X?3P,<\^4)KSHEU&/Z SO/+=>7 Z^D1Y
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M\1ST*HG.G?TR0DF4T@\R!8Y'P[HQWY6(M_:461U\MQ36BG$'4 4*?&LU??#
M86]&D6U@HLMJMY3:P2<8.^6"PX??(7+68]UQ+>R ORW:K(WGB6M^7)'BHCO/
M?JYOD4H\X4!M76'HK T33B>H5-5)>==TT<!F,6MH189':W7 ""E/O:91]3?)
M'7+&(:8QIB<TC7= ->WT;"'4YE8^D/?V4^JEEAPT[A??RI$GM@&GQ>1_8K].
M)Q_WJR/W#P^C]./"-@&_;]Z1Q1%ZEK8O&)J U0;-!SJW1=MV"'7=:B* B\]8
ME;7#FF*D\T. =$1*NB'"M_.WH>W_Q="+<$/;C'O'=6Y,R<-'6^CV8<'L>"+&
MM@"EOW_Q"4OL<,O7&>L!)K);^L3IT[+&]23I4NWC<WS45V:J_8O^A^XS"7Y9
M7Z A=P"#6M$=\ )N+/-9*56Q. AM5T9!KP_-NJ$Q4M^OKOV4P1=Q<9_DS"")
M?C/'R%?[?A\H&E(#L\[9?X18/O=6JFZ+II;]<5:YPVKI\CQ-$4VH&498/%XM
M).;Y/NK0LM5V7='PW1N6_M=IH*C:K]]?;4DOGTU^VZJ(_\L3^$,_>%Y6KK4T
M_7+DKK8.6&-VB6^P2%*GWBD0L,?RQ5\'<SG2LM+R-A.UF2^I$7KYKMH(1KA_
MO -@X7FWW2+@*RK/(1_6VX>ZP6?[9Q.X:W4TF\XH_10^=:1:3T?;F'#:GWFL
M7%*MPP>H_@XHH)@_O$&7-\5_MY_+W-&<L(Y0&KO"79!JEVSRPFIC>WZCG GK
MF'..-W@:M\IM^(7FKD]-/^\EKL$=,(N[ZS 1(  ?K(Z,.\!D&/:>+!@_UXOR
MYK @$H*KW3+I$5428U>DL]S9$EC5Z3SDOHVKD>M3A8MN7Z1;UY)+^3[VO7S&
M"X*EPLI7SVV\QE%-[1?V+%JUC&"ERO_!3>QC#.J463+$^R;>.P[S(^H"OW+X
M<W//WJ[)L9X;1LM@,4D&P%S [?O!!L9(Y?Y:4\6=?&2'6"PL7Q4"6ZG.-CH4
MA9(KMM^C1FS]LLX(4&E!8_9)_; I9Q9)C>,WX6*[WFYZ!S :S\X$)[T/ M\!
MR:^"9XFKAXYH'XKC0#)@?K:=9S\[AS2J[X"AC/P;BA()Q6F)M^HAP3]T$F\_
M@G]5!O]'YKO/+"OX)*Z.C*^V4PFL)1)?&[#3#.*J0CT]781NU,YW=;*L:M-5
M]U5HVW,;Q]1TE&G4*-['E*+,PKY&]AH,5$HJT'6VU?O6O+7RM]4"G7R1%'5Q
M 7U ;#D4JY&K?NTO>.3H+7C0N?%=.DW(>O1AJS,A<\^N3DIYXLBES*7E$I^:
MFHX\V0\O&-Q)RF@] CFQ&\BSSGY>&^S;!8Q6%N<67QTKN(#F-!$C:I"3]@3J
MOX^*!O+\J!C"0[OU@5)J406Z3[8&(\/U?'QT^RGW(SU,6&4ILKOS1'#Q#NCJ
M3),O@7^U17H3F'>#]FW,>ULI:\DVP%GBM6;/MEGMF(9)C?]M?J #1MNC=]/_
M:2HP=G@OG+9FC(GKB)?+)"<U@D_E\^17HI%Y:P%,P;<E^*(B0C=>2#^OUX^F
MALJ.:MVC1<MSN77 %[4,]EYQ[<N)L:V(B  Q_Z@W4V*C5URN#W6XKDCGYQ<5
MG57^8,ZW.>"]C3O )UC\6T7R$MQ/^JZ,>[Z&C%?S#;<CS6UTX IEKW$ZU]O5
MH[P8F*I73,H_.'B;CP%WDW?E]JYVR7TG[T4R.080$S+I;,XJ'2WTKM4C;3CM
MQ AX)H>0.#S$F+Q^QB+9$,)Y<DEQV/$>%FX(@5,LCO&VI<I+T><*_S_-,_'>
MMX\^H6[/@!:D"Y9V S#AK&@(/INX ]Y:P&3@?L6J<0<T!5^!''*K3P3Z@A^8
M1**NKER22.K"F0.?R?*'5:&N=P#]6\7;[LG@;66CVFO62!4_4W[<2 S4N'PZ
MX(EF\#;+IXJFPB/"J9%LC^S T3\G"]7<*%W.]6PE)^>JAVR&^5J1)].'E!\M
MP[9]: JS",63+Q0GZY@A6/B[!/-1;[.$M;F3$+XJDN^%LB'QZK5%;.F]97 ;
M)<EPJSE)#NL &VS"".&]X.R\.O=;INVU_#040 GGAVHG#/-2R\ 9EN :/#L/
M/R.+?W$1]"JV*GAH!]YI4[G+F#/#E3.D/3WM!6;&_B#VX"&_V=N6X&<ZDG+5
MZH4^%KT"B]W.G,4(H4LLIV+&[=4*?E>S3,8E\S\42NO[M%-../=F'VRM5<?L
M YST:E)UG"50"_CX]<*G&*_;U^M'FK?R&AG2W"KM:LNT9W ;M(/?.NC427DH
M"C[T,6"QT38+U8C)ZTJ0YY_\O#S 2-T@2_1V=)@YL9PU)7!4:3A3.X)<MGN,
MH>[LAQ),PJ^L0$O!!XD(88L&'H*3J_=V.X>T.VGASMT#WHN9?>&=6) GNPRZ
M Q)526_;9R\QA%8N"4YIB[0&;:_"=CVE4> [&8"OMN^ K[6W=,%#J65WP"+X
MAJQQ3->7?!T<QBL7=NP,BZ7AA+L%W#7&+4M@HG= TE=X O!\!WS*5*UTD]K[
M[A-O)FYOWB55U1VPEY-WA>VOZJRX)L75#.6=GFJ"8WM<:4W/[Z!H?9RJJK%6
MYM$N1K^PL)$0V-4M !L S4_X!D9;BS1[6ZG&425JX%W7OP/V"=WA<_F@461H
M\ ]F;[A3C1GCW5+2'\K!O8S"\0Y8-?U<.!7\PSWVMF/L]I6#3=LID['#K:)*
MXM45[1?=BN4[H(S6H*=Z@MU34G<] Q99%;P7>29XA#=B\R!Q3=\3D[;9@+MF
MS/GGFXN (JI$.2/OQYHO(#E%%&=6W V<]GDG*J=.H.N+#;%!UDZ_O2 R>*<^
MW %GWSO?:05'G_"$J1-EW3YKCKP)"#["W3*8J4PT0R%F9-M]:K2DB+$H/*"O
MG7F!IX64^_:&SY]0+ZLZ0]S'S4+J>X^@2INE>TK55,08DR7MUS>9 SZ=MPKO
M:RK@/JH#"X9[)AI\EN$T3EZ6?N5!O4$+/9T(WAL-3BHRAEN)5_8."/EMMDCW
M\F->6 R<B[.*MYZ)$*3;1W":P=UXN[_:KVUH#!]&[D=%&Q;\0P]B>N/'>QO&
M++(V"(OPQ+U&58:/*;.;XGXN-?=.P% 0%5RM3><[P.@'W+(.XXX$QSZU,^^2
M7ENGZXH\&CCN6*/@TN^BJU8>="H5^D3[ZM1M90W\K.UO@X83 3I,5X&PCW$I
ME=D,_.Q/69S"H+5[PV0[<7[/'EI[U5#W.!!F5B-7+!@/RS N-C@G)K3/\J[F
M7:+#%9JM_W9\2\G\OV=1(=PX\ ^]X]D;O\0?G!&&0\<.,,\.6?AX#H/@X[/7
M%BQ@;--+>TE">]O6?/H^<N 3]O'*$9P-&!(^?R7PADKG3S4T0>1I^&\3B!64
M3XG']L3??!S?2L"4:+5,>QRN5">[^FNGNX3%)8@QX?RZ+T4%)R- QSD3(1(Y
M'*#]R3$6A[U<5"4OU)$9H"./7[+MVOJ2E3:)];CZG>AW_#*?=]7558*=O$\Z
M$,DT2;EQI-T>AD!34'@:G+)[_%[0SF=\_F8_"N);93LK?Q:?9.]!0SI-^WB<
M9/E(=9I WMHB"KV+I5Y2VU6Z>4WEO0.V\*TR*WY#<&L7HU_S"7&\JF$M<>&F
M:K^7&!C3[N.[FLBS[>))9Q63Q:C511(Y/"K:Z1CGD(8#=;5IY]*\QY].%A94
M BI];WYN;IP*A8:-GZR]*GLK454MOUK%J3T5H+JU9.==D<2I2*]WHI')+WJ%
M%TR1][AQAFZ6YL%Q;_ZOM5R5 G*[9.W$+U(BCF*T!I-9FSHV:B0Y.W)IU:4-
M=E.^YZ#A3642-^'/;7KN.SIE-L5$3Q&TJX\LZD'12-1;M&Q?I48!=_'# ON%
M]A!+IGCA=<97%K]($Y%*:ZMUNR] B[NDJGS)I$.6P_$=%Z5JC1.X(84T/Z2)
MWG*WJQ"E<D5%O^TO<N(7/=#8^<7A\U%,WQ*-1R7%PKDM=4PMK2CEM[N8>*3V
M_U**960T0M5D=%)0E.*<Y!7Z+O)9_OKITF!(8UWPX\\E%<R,P]),A/Z5BRJ.
M5'6#F\A+M<("N6_%IX,X<<&1@F@;$=8^CCU#R*HG5#BXQ(-LPZTTW/;/W"LF
ME[LK4)TC#8P_1#B+L^L7J[/7%>6J$TMGE^WZ*?9>D*"[4J^U4:8]9U%G.^-
M&PC<+2 IR=YW4,C9,%:N$E/+ZZ:ARSV_/;!QF'C.+&MS/LUB1-/Z7(S\T&%R
M3Y^F@7JF)R;EY0F?/:>_CZ,YOBS!(-EV!1\;DECUIC1=PO># GI93+;4G]K/
ME3>6RDI,35_/5.4+[ZY9/4QP/TF_5!Z3<1D,FQ7LXZD-8LBBM'!*"?U\!T@
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M/+7<UPCEMGCZ,HP898S&!7X("2!EK\KSE(K0_@PR)#$8/_@M?=II"S47EL#
MM2P'<J5>VL6P\]8S10<'"ZP\ZU!*JP'#D3BVJR0V),I>-9:LRYXN[2:S]1<1
MM"(:+1NG>^H3]*'4ID_1'8G4/[VTE#<>:3D=- T.:NASGO@'OY#=#X5/4,B9
MU1X(7&E3,RPK.5J&ZBTI4-JCZZ7H(M5:;T#R,;W.=9I".D8=L2@[+M+(C&ZU
M%54FGJFVYFX$N*GPZN@]Q!/(<1T XU;;(E:])H'X%.Y752IMI25;:.14_+#$
M4?.5V@O*)N!O?,.:2;B_?<"!^,R.\Y?_A^<RL-V;_K>-"Q5+B_U\SY*89.;
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M6]C"'%34+'?Y%+'X>)BS+Z5(F4:D[/GCK1)%>_4&&?0'MB=4])216'ZX-8V
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MI9(:QQF]07S''=EK(R/*E0U2TH:^596G#HOQ(#-;X 21THZ1HS9-0?OK#*@
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M%E>U?2)-'=&:,#"Z1UY()[:',[*MKNYLEDXZ"]Y8N5*BQ&6J9%5+(4->EL(
MD6MBE=>T=4QV0L^$/!$66QG+1[PFC%IRS*3B$R6D_)VAFT!L9:S<%_9W /N2
MP$E.8M<4\2"\9<3?V9)RKBV";5EQ]DA@RY;3_OEJW!T@;O_=29<C.R8%[6@@
M4/%R%)&U0CP]U;E2?T7?5 Y[,_X'-_*W67RNY*&X=_KDZEC%!!C)7Y7$4(E=
M35U&R:5?(_RB*;\#D&^.20I>>-C"5#:R39%\DX<DL3H8LE1)-Y.MK$#26QPG
M/.<W/U>_;NJ[@8XZ,(]9HH^/>JZ"(P-$2GN+MIOP+W7.O?9>R:;TMP[;6#-G
MSJ5;,Z4HLWS$NM;(LZ^VJ96LN)!\+WN3 Y-:6TE<9H&V.939QZ^#\>QV2KXO
MJ'!9CS+*A\C&/WR@P_!=F7F,Z8:S 5(3Q@WS7/WNW^M]02AG56EW0?'BQ+")
M2>]=?)%Y6YW(R\&?=+-R>?8BFFW4R2='$9W/C1F[/U)7Q^?#+*"?BNR$\Z.X
M7D@^39*CT:MW?/02(9TI!T>9M;SF$81U?[;8IW?U"3R!$5HA\BG5G^(!"!TR
MKF)&WRO'%KBUE=I^3JDL*V+O83/U.]N?D)]S*\+MNL5K.$8-;<#%LCM1%<XK
MW#F_<FS(X*+0B2'[)L@C S3!)Q$<?YU-H>)>% SU*OPA)N.N4'Y%FD&B2 =<
M.(?(-+1_MN$--]108<]O2.>]W(+EJ%*2QNO%$0C$_7Q3#3\I_E]=A?QOE)3X
M::#AF;?FX7G^(P%#W[8.-W[9*_S$8VJ'+76"H.Y;M!FF&;IQ28V-1,!6O/9/
MOAI,/6E/?Q)MZ4-.A;VMPQ_=**P00X0P-BEV7B0]_2"2_'AP]0X(E\:!&@>
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MO=8FRT_>B[3QE$NGFQ/MHA=)>(D=&6N6UA#TRZ->?=QC]'$<$2(W86UL3_;
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MB_:'"?$-Q6LH F"O?%7OK7SE0=2-%HQ>XHO:5'2 MT9,#DHU[+^#Y7+H* '
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M.6[R@!-4PPWSLW<';E0-7$OK"01 ,/ST5ZE 2JD1X%/6D4<\I [<O3)_X5.
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MA(C\6($W?TOIUFQ^J[4J3/?TR;_(S*A\P+827;49>?3*^QO3_:A3BVM5]\W
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M*\0KB^S?<)3$@=FV#.!4*598^A4U$O"A&C%HN5:=$T>G8..QPAFQJ$:IR;E
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M3!"/2@(G^<N"6[GN+%Q[I]/.JM/N/S3;=CJ L2*P'\<2XI1 7L-ICGG8LG,
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M7=LJW+_T#$.8MZWQ9*H(6GF6+UC@4F5(H UE%>FWFK%#-4Z)QKT-H?KK*FL
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M -83?<E-MN2J0A>N1QJ..W J>,;L)J/4V,<%9XEM&8^OMEQN?D&EAGUZ>C.
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M='SVFYE=VJ'D[;2VZV8H_Q>C\;G5 GV([W8>CR [,@:J?+66;.&^BU0S&4O
M:-A)X%$D%\JVQGHM#Y^"'&5^EAS'VFB6T]766I^E) A3G1LLV&XTJH'?]K)#
MJ#@/[?:&1K_+ G0"7&-GO;N//G-J"4M:]C2=Z!,&M(A7+_SMRU8F7N*+KH/G
M@*PQ>:<:(H^!QQ7TMZO__R<H_M_DZ/[)64C%B=B_1V4%)LHBI*L*K:L*W4ZG
M.\TNZ._5\&*R<T!PGB-S4=JIS/240UGM_:^;E94,)5_MVQ>O:RK,QB?UOGG@
MELOZB81?M=CS+!6Q$N'SI\*Y]ZQ0@=H>P=A(A*U3'C>ZR,(GLNU,K-.%.;I6
MG!I;-U:Y_E2Y@U2-]9ES%W9#S@B2KY_H,:U"8.QFZ0"N[!\+953AAW/2FF%L
MUI;):YIZ>M?QF*7LVJPK(6*+H0^;'E[0+V.U287+$(ZOR >HDKCD_1IG>3M"
M*_+I!.?(A#;@:[0M:E9]2,:2U3<BSYOH6Q?VAMS.\?TE\#8?VAHC;:&E.%(H
M:*:8OJ86DU5H93FT^I0L,B=!2DWZ6/O+D\8FM6,W<7N<.I; P)AAM'*<="1G
M\(Q:N4E6OYS&A4N%7ZIC;HJ5>/F2,U[+W'GI;6TOPW:]5=]3V%W=H5FY?7=J
M5V6PPH6D8M.^4ORYEW>IDHM-I&V"^=5-3@FB\JM-%V*G%K- !B!;^P278'86
MWDN@87>F;HN6-?/X!"V=#K7.33"\EBK\:X#D1Q4[Z^LP_DMV+RZ[T0HC2=P8
M#HL'7:;B@*A<^3OZ3^AK94[FU!WKF&M>H@TW3ZBH<DI^@@JY?C=Y^I"X]OR+
ME;$9^[]I_)QX),6I:"EW"H9VUV [\;.(@U)^#/]_*\_J6X%"1>[W]")F"Z!A
MX/CC,F'YSI,1F?R>.#%\>;_ 2BW7\?Z'8XCBOQ1>$9+8XN&X*1*\YDP+%'-$
MV)>[T><4*-,)T+7Y'+"[[0OYU'"JYYB>$JYP$9NC.^RR4]ZG-+/U42!#-IV/
MP7-4'6+3?(C;W$<WBN+NF5]&KT?.E?1(E;DFG@/B)N81%>< 4%D<3*4"CD]J
M!V>XV3P;,&?^&JBFY"QFIT5K):#3T:YL:%X7N*X@[XBDPXX&*-5B/DH>;GP)
M+-4JAQ\XO>O.["03%?=A9"L802RY!MR3(>G,XO7:Z?LZ^^P<L'RX_#@'3Z\'
M^'ZA67#V0FKE.<!TF\@I\>8'^>75-S3*PGD:]Q-+5FT]2Z[KYY."@L 3GT_L
M3@4W[X1'*!!A"7."?F/MZ.['4Z,T3U\)30'D3QN6S$A>P(6!)Y?\&GQVM\+R
MH'90TI"),Y'?V/YT8!?0)5"1NMV_%"RS<F%PO=#O(#%)INO,3#C1YXZN\W:[
M^7$QINFL^/U9YH3ZD(?CK4,M%C#GG%)M:'V"B8GIKN<^]U28U4Z>4@[1Z_C4
M3V3 U1^_)+W3#0AD>=R#\8'P)".#MGDJ,0<GQ^JN"ZGWF HQK,=9+SD@@6L5
M1>5GP'8"C'[>@G#:8Z28 VI3JS(T1T7H57GW#E"5-I/;AC2B%2Z\:Q0FVN'K
MWC^C52JE+7KAHCU\'9=%67;V1V;]T*8U>YD!C<,GD\<D&*VS;^6(:7ZS :IY
M!SW[+*$1IP2DF?% !@4J.+Y;T [P7HTQ.":!-IN"D-9IY="%?"E=N7BAU9IK
M<C'+<;^U!0]$3;R&+GX*UT2%%E; P[>+A3G#!C3C31G7G#@-TR]I3CYZO/\Y
MQBOTQGLRVJ@S*D,36O%K.F'*\ZD8)AGVN5J#?8^20ED%#;%?JY'^=D+[;<JM
M\WM1B:PF[Z$_'R_P$Z:0L?SA7,NDCN="_\[7^J&@E1+I:<^1&2#IB$Z(QS>W
M0]]>,7XJS$_@SAE2]+$,TT_%<X!\3:Z]]JN<H"9 _,A,E?/;%):,WIEN2R(Q
M $>'?^P[$?E#3'&"QT+$0@5)L\G6!_1Z\.V%*#Q#V*V^_JI%#.GG'+671AG0
MM_T_4L]F7WYY8^11+T=>YJ@DG#@&-*]7L+XL_#LRRX><@>"%=Q@I_+O?E+@G
M-C$N4HK-Q!XK'"ZR \YJ&J]CJP?R%WQB09<=DQ6>@S<@0HH?U>S1/:NU\K!'
M<MTKG%UM,7-DC0N!IQJ^_O7U?PNMHS7/JBYQ8WABY*O'_$(7 _E&)V?\PCHD
M#O-U_^9@SR>7;OIX[16(<-7611?6\:%H< YUX,0)5!VW_D^3(YC:$7CC3. #
MU&YP+1_3H-4/CC(F$%CF,M4IQ3STQU&1==0&GL\:3^\- VU)$")2SGQ-K,"F
MPSF C#U<#AL2=1*"X=TD_+?[OQ;WT L[^[?ST4#MOM\P8;1&'#N9Q!2D"[$4
M-<(Y'N!=#IT.0-\1HMP=F),)>B/,[HK%4YA%MECYU]9OUDUY7?MTP9\86V\!
M_=&;A+AGB<^D= 1JX=N>?SX'D/H8Z(,/E.A4V&R+_XL!8P*:3VD"=QD(<9;P
MZ8WPC#.S0*H]R3W&A:/$TG]%F+'B4-:(_RN$P>]R&0>H#+*#4'F(6!Q3,=;V
M<(>ZTZP$KEF3,*[(.M1ZVU;:?@8H<,E*4;9YG801E B^BG-%2^!))]!R)A5H
MDM ,_2%/EP/_"*UNIR\15?+2]%6V$@G!RB\ $+4T"[I17^@WZ6N7*::.P_E=
MCU1)X.,(8<DZ-JE-M7KFO,RO)W9"WFRC5L;J_#L\]WFV*$DO19["W%0YZV%L
MP!<?LZ:9#5.$TGH@0PLHG3CJ #>4 %;OWB!BB;P$(<2>+]3XP<6VX?6K2]^L
M6<VXK%0#J#*5PCCO+N'KSMX<G ,NXWM I8&Q54@H@_UXLE]%VTGA]LGS-W.F
MT9EUD#XBE;92;J_L1ZY,5*F)Q(* XMZX:$L>U$"DL! 2M98\[D*C23>*;OE&
M&O^--B8N04T7\L*SXT*WN _1TL1K>>^O,R;MR(P"7QQA)#^M&4F86['H,HEO
M+7U9]ZJ#)?2F*I%<#UDYS*3CB]3.0![4JD%J=UEZ>Z8XX.&@8%Y<JY1I6$'A
MX^FWE.RW=NF1,C1<;I&I_5KSS:IYTX\O0;[.?+,/ =R3E?^L-S$XT0E&:2$N
M;"A0C>"<7#XV8?I>.K&;[,E/,49V8&0V]VE"+RCRDDF K6;:WK112UX)>0],
M*P;1D#PN"/GA/62YW?WO78:^<M7D_K^':5*=A\7E+9 9H,L^6A83Q1]\!0_J
M_@_VWCNNJ:[=%HUBI0I2I40%!*D"T@2)BH"(@$@3$")-I(8B/22*4J4(""@(
MH1<1$.E%0N^]2^]-2D(-D(0;0-_7MM^S][?O=^ZYYYP_\@>_A#77FFNM^3QC
MCO&,1Y[?2C__VJ,(>I7$5YQLQ]@UB8*"3^"IS%>56I3]$:B[_/1. 0.W2BQ/
ME[]G#=B4MU1=B%"*.K3*,G3!!^8<%4W+6&5EYP[-'0@DQ&7+J\=V =7 ;(J
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M/YP*'8NBNJ ;PWEOX-TI>0.;_ V;;Z?KUQ^=?BSP44>1<T=6_T=W48%14J(
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M!=8$7I'&BA+@.&A;E==9/!P5GMJN8->5FMX3I6B5NYJL\K\L49T<7JP.\QI
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M8(S'1@[WE4\,@?"G*:CK:LP'^C+Y+-/;\D VU#97B,Y,+%\BH)L (@N6T[N
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ML<5O?*+NI3Z?HT[+BVZ[@ LS$\ =6\(MKTOK2_L%#*EXXZD_4_ 3IL V'<\
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M%'S: I"LG1:%/8DZQ2><<B7$N[-1>#WA@MKC\?S!M//8U-4L<58V)L)+65I
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M5//L)E_02MYB._*K&PT4\'PS*+]MA9(;@AWD]S#+CW=!EO6,%5>-OT,0WM!
MM77;[ZMP=),)RR0;MY&A_)*DSLLT4&=C9[2@Q5+D1OL;OQJ6*U]9Y80%+\<"
M^22V3LI%RT5#GN](KO>=D-6-CUL1QJNF$M<8!8U./37Z-R)EF?]I*?J?EJ)T
MW)C\C"JTIH1]B<!.4L%]S']!>[5=0_T^K+69>TJA<:MO"E)O^KP!N_R9!MJ]
M_7,$8A)\&/Z6^B]ROSJ_KQ:$_!Z2WJ*!1N%J2XA58>CZ/ UD_PL 5B?ZI_Y@
M_0HU\E7:)@'0(;(_\J\3P)LWE5817R )\"P*?2$/EQ_7)H,&Z9N%RP;9T;";
MVQPO$6.B6P)15]U4Y)R91#W'W81Z=_G:KDZ09H'("7 @BF=!::^G$F;+K2._
MP]S>(1 3TAL6TS/M7G?UJ"?L39*A^G*M$'I&KNV!S,"5_?OK@K\?1IQWF3LD
MMFK>F'@JB.1! _F&JN&S[>8,OIPFO2H+7[UK:7EDH[_R9L3U-C:)H_M&N0Z#
MH_8%"]2\VMJ_;CD;*:.^0 /ANF)C9YB?T%VK'18:/BC9$QI% UGXO'FY^1"7
M.I*[=);%]VCD=%MGBPZ\IHI/X2H._-IXHP9[=.Y+<+%[MZ9M&F;$5+QU4-N*
M3SY(K]%#XFT)CW,&"?$65H^LE$8')^XF+#][3_3;"+IH52YRW@K7^Z&7W=#!
MZ(BR>?$9[8332R@FP7L+#Q@,N#9K"*Q-!E4%'A3."XA7QGIO)8>:2&T;@:J&
MWXOS3+CSGG_776!YY^/FINJ8T,)S^\;D+=UP6/-KXX2W1EO*K7J!\5&,>Q.G
M2RED]Y0=FC'R_,V]@=>8&+;K*KTZYW]$)6/Z*M/_A)33?/\)4KZ#"$S0P%Y\
MUPD!0@@NU54<A=N,NL2  #N*FM<'\2:2J^QF%"?'7O:E9ZAS5V ?B5-B]H]U
M2Q0&.JE"!,M_9^D[.FUGN%:%Z20%%VPG4)AL/?85IB7A0QS671<%OZZ0^ WU
M=5\6MB\+ART4OX:3?24K=CTZ6.&)_&G5>_W[54\;;<.4@VDA9>:22^P7<?H\
MZO7^EZJOJ-N9&3RRSKI3V'Y2W"X0RE#)!UA.;#1JAP@J$-.0C_%N/93K8RP]
M%RN<CS\]&&P,LQ*.DD:,HA.$-N/TSYN?NB>Y"I7Y[UML9X&:=:ZCY(LX7?WN
MBC:L6L)8@(0/L'T_<MJHP^M/9>O8;79RVJ$1G^8\=G+:)J;V[4[ES8'& KE"
M9J\M+WS*.6XA#V&$Z:3#?EX.K_R9,_5UP*7@SN%DUY/*7+=Q8=U7QB_MV_*]
MK[,F&P3SPG4&?($9))X:<.T\-*AYOBAP6J],TS!1.:N-+_]-:F#RF_?3S/?*
M$071M?KWBNMI((8<KSI;TC/JL98&*Y@^((4#AYJ""[O*+5,3S#6+2[C#3)ZF
M6>UNYWJC]-#U](&E\Y[3J5[*.X>^(RR[:@!X !4_,$$#V?;FF-C<+44GK7('
MP#12@"KJ@5''3"OCU*C"U'L.*XX%Y)>)3.XS\B:V2:)/6JO'"5<%,M>2*B=V
MMBX/*?* !V[Y)0U$T+L/J:WDZJ&!\@H$(.UDZ?>Q&K"*+7YU&NAB<+OS4E.X
M]Y;![/"/C'9W&G%-ZC\9[?\+,MKTUS(*<NR"X^81G;5M'6!Z4*=!P.^H09OB
M$'"SV*SAZ?(?FJ_4T$$#'5O\KM+0VPA!KE4J]D-\?PQ6VP3?:-GH[$7,N '?
M2QK@C;^^J1!+/@^8K2I62M) T1#(;YC0; N='?]/G %R>]?]Z #Z^LGF2%_$
M=^)73H5#G@CJU2-TZY?8WM^O)R,J'WM11\4EZD_<J-]<7&U &R[:3^F$=!)1
MV[\ P<Y\H</N2\5+ ^7=U0ZBPGMWN^>HKW'UZEP1=$NG?L4RKSU5[KS=4RG@
M>:ON=EZ81<&7XF_9NII>G+ZAP4+[C&[X[I?CR49RP<0)J-"4/$<.P%&-*)*'
M)9EG67\;Y=%\R7*[.=W:_B=.S+RUI%Y[RZ0J_%=FIN/!4)3M 9/AH>'KN=?V
MVLA\.G$&=.;HOAD03\/]4$GNUHH+VOA;VG/6:ZB&VZW7'I.K",<I\WC4H#;U
MECR)KO#<;,A:O@ZZ,/5O/LGFKFVW_**4^6\4H VU4GEY^X&7/Y\ %#IUFHY\
M_Q4$G:KZESEK8CY5:EW>H!;N*K,3A>7,_E&Z]=1WZ.C^2^B=A#?DMZ?EL?PI
M/KOB\N.X/"A;SU_Q+=%=R+]"WU%&A&8WCY^CR>[_;T:3?W^V'R#QY\CLCV#R
MK4"3Q%0MAX(Y6S=TPN50DS^'7 >):I27 =L^2+HERY$[Z [CBUDN^X$_P&F#
MW#^R,9/9*"+>@J:/J9,FE L4Y$_TQ)@&I9WD;9H3]&07N#.!NVWET)]YEIOH
M/X'NBJ.,1' 2B2)$I8$D"-2/T+_JK@%-H8'^*EN-EJ2>6#MTC@9Z&@!PS\G^
M-/AG@!=KZ23ZJA?A\<N->W_?I1#Y+Z*T6Q[4^16("PT4<X*^]X"2K7_:/W2K
M!4N?_3DDV[=ZG[66VCER\2G=E[LB+F\; 1)T8_>H1I%VT:V^VQ7=:O;70=H*
MNS*\Y0R,_LL84;10'EH6F"5# #62/Z$O!XDOHVOO6QI9)7(][L0]3*D0O/&Q
M66'OOL="C <&1UZUC<UA&A/>6Z]@Y[Z$I$6FU^Z*72$]#N3)<\^9LML5\1P8
MN "7HBCJG2SWPL7O5C4P+!9Z@5P>*&U'FZ]A\M.U5CKFX+96X-S+0#+I'1%:
M:SZQR_%40&K3QQ"[V> I9_JT>) FI&1@7<+S8//X>9<R9!?4%[H+=I*PI\YY
M5I"K($+VPN: QT 6VL5UZ*3F%[_&:O4KSY6C+&HLG;&2 #<^P'?-$3@#J:]B
MGS,]U^6Z?' $\.9YT+>TOO]A84S?Q15=.:/:,OC2U6?>26#M#(.)Y3HF874.
MO/9+05SRZEYS:,',Y0AR^S.YED8&,2/K#X,Z3XHOQHP]BG>0N]3H]:/51^@8
MGK_-TT$\+70*8]5OF.Y7UW3B/$M.UB71JWO9>ODB=K[3Y.;J>BI6?W Y^6?N
MZEVGGY/\8F^^&?^VQOSO+M74E$;K73LN&T5WV?S:P V8=#+PQBC*]G%?UHDO
MAZ/V..D<.\91Z*SV/DM1GN0!0)/GCGC[)Q#F:]WY_-X&2:>.5OK9A)LTIW"Z
MFO&(MMX]?+6YP?NDN('48**>3SPJ$'[$4[M)UTCV-44V&7@[Y$B6[+\XXQ!\
MLI;AS*,[!44-+0)/%!EDUCH8.E5Z%K,N L=S>Q;--'U\Y*VBSCP(4>V[K@+:
MM^=9!6@/3S;?F9*%-\T3;.?Z9L-W"/5W;BU96\O'7OO_U7GO_P%E_P%E_RM0
MIODK*.MQ&:7/T7?_HX*I?[5MUJ**WC3_>ZR3\N.3AO\Z#!G[SP]#1OS^+&0C
M:(V0Z*]QQ2!5L]S_ODH=M5,=_YN 7=P?J]1=?U2I3_ZQ2MW<LA6I=/R?59Z$
M_41C^ULFW@<:Z/=4O*0?5+Q<GSP!^_J?@-N(L=1!Y'_')VS?(07^!A5A?\\G
M3*=8SGE(_)%/R*]TUXOX;]3;S_Y2;Y]8N!KP;\06C_O]5<\QB.T2Q%*"!V6[
M<\[/+]@G[4 Q /T.M]?\N>[$W&?;.FMWO!LZK+*9^C1_\-8_ S\*N^%=6V"G
M6DF$:01U^>^J[;7(4">RG&?3CD];RQ&E#.W$':VGP/6:S8EG-W(_%Z^@?^+D
ME=PO[52*G *S6>S<Z5^%&8_]IBERCHTVAHP<:FL\C>FDCRL>G1Y. SW>!)?2
M0.TAB(&J[0(*YI?P8M1-1T0V#]MT_%2EZ98AY8*QF.2+OZM!0;#]#3R"2HRB
MD@@!Q+FVYE7P<'Y#%)QS.W9]N>"S2<B-N>[&[L,O-U=BPK6RG/SJG=IKWOEM
MRGQGE]I<)]#=KPD01G3!05_#A88*"Y$!!7$:Z#TV$2V<7P)K_:;(HL+V%0;6
M5YILHC==(I]6W=\Y<J]@41GZ$LY1Z@\TI>949BBAOC-RC$B7C]VL-)NZ$'1T
M%OF%^N0LPEVL6^&T>1J\%TRX5:9]:,992[P7?O2%UI&PCJ-W3J4^"'OW_DWI
M,%_Y9V7G88U /<>()T+8\,D;ZML,GL8<G^9N7"Z *9(%X$W<J )2:N:8Z5QG
M$J!](^ID:9G_2)OT0HKO@U=O.!\J1+V)$IFZMG+>#IU%[4,1;LE#7X[MZ879
MCVO9WNYW'97BYO,/R?3S2I0Y=S)1Y,%UL&C>$=5;;/<I[3EU8 I' "F7D%Y[
M7^(>X71((4\Y)!4*;7!+Q;;P;\)=DQYXID<XK43;7)]K__B)77?AQ4.#"O@0
MM,B@;EML?/E5^7$<E'VV\@S1\E46O#9JR\%1?,+W*5%;./SZL.SFPP>')>VG
M%-(.V3P6:77/+1?I"3D]DD_>3;E1"422E:QS;4YWE!*VAV=.S(N19_#7K4+[
M])B+Y-B5-E<VV#4-NBP!!)9K!47AL+W:=Q$R-+:L4UEHF%TH[K"TU:@2:601
M(A1ZY+2#.W6%VS0A<ZYQ_/D;N%-":=/</G;]+@'.@2]9OW(Q1<)^_*'@FJ.4
MAO]G!(&?2 +O]WUX$Z^COB_E!P1Z\)_68_]7M1X3.XV%Z-"=^<[9&W_S21_]
MU6,37/X(NW(V>78KF=CY.3E0_L E=)1//B'&H2Z0C/U#=MOW$IKNNG\/6-;R
M:*"-ET\=#]! S:U*R!6E7U$6L<7IMX7C+=X&JC]2[+!_FF+/"M1[%!EX]H93
M:5Q&Y^B>,M>)C,4_I]SM@>2),D>_*E:8!GXX@C,HQ:C#ZZASJY#$A1RAUQKZ
MH+*W6H/"7N7.SDIH5LH95/GW/)TVJ^*A!(8D+X8(<S>?IT[[4A.R',4;ZKOW
MA>Y5.;NT )_[J*LIR"#7 ,O%LP(BEK6*X+NQ_:W#]=Z+>9&&A<S\/.&\]]_*
M?#L5);=K[V+-S>DT51ZJ.\40:,%7A0B>C#,D*GTLEN)^9S1;JTH^^>$MN+38
M[_6!0'9!9V9.7:/ <,AM*C>BYB*5PVJ,J7N<F!@A&TA1)32=2W8[E?[D\^84
MIU'RR^L/1YF>?.?E+#WH;V>FYEIJC?9<%]+5@W-Z:]>Q!E>R %WF3SW&*]P%
M',1$=/G]V,K9Z[]>2$T.TZL]3T876V,&(2)-ED+[7K:6O[\D3(Q?.^;6U'N
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MX!Q.1-MR/LR)860Y$"^X_]AXL'Y>L[ %Z*@$T1UR8_/._ZA[%C=03,>W;(\
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M4%!R.T#!6<HT!3(>5U5 WY;$AM!M$ $D8.E.1=H["+R_$)XF&;PE1 ?-P4A
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MU&G\)+;%'<ZS)_?!/E--$#G14;IPFY+61F>D=&C'5<R% ZB;/20DW>9%S?=
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M.=]TBB0!43>DQ%OE!Q-) JS1B )JKVN(##,48CDDXSCXPEU61BK^T<#<(0P
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M O BG !P"ZT->!+AK''MFW2Y[OXME@1:M43V\JUJY#0+6ZN+_S+Y6I%B/6_
M\-JO3['A-_[/%ZU+QG@'F.YU2<4':,.L:RV\SAEM)"4&/A&]\DWR39"H:Q%T
M6 S\QJ^=,-;74EA/.>S&\8RB-4Y K)B>!:5:2EKV<7XCDP7.7399MBV!;^3\
MZW?+C[M??W\[=R^*+GBL6T)0H LF"E5;,H4;'\IB26*R/[=-)[-^->7LS+].
M)?P54<D]WYWC^Z;H^;VK/6A?,I*9I@O(GX81" U#1EFOQJ#EETY T9/'YX?K
M\:R=R)76T;P<=X+0"+/R'+AN4\@B ?^.5_(&?O.89Y3F2OV]'TDQZPXV[,S
M@FG@I5FMWE%/]$V0J:-%<VO$QW<#9[XMNL2H<^!<AW8^GWW=%!?D=\4L=T\;
M=\M1DO'[#R8AO&Q^L>>Y/J]8 ^TJ1NVF$Q#,.JM*'<I#=NVI%"/0S"FG\6T6
M\4CX[$'<MNK?^J&[O[N'KL^L$7RNQ*IWHY1V!GL8.WO\5U+9!9]*A)X"'U;(
MT.%MI1^,&")]E?L9T65&)1_ONC^:/1YHE_^C<YAG K13MF_64=,_<T;)1:G!
M.1<]''I-XAY<-V6S-OJ]DA]WR25U\&E9+.^9Z1\O, WF@^V0CO8$NN1$]APN
M4/P)Z/G?)FWOJ5<L4-8Q&S?7@CU% $QJ3&KCH9IT+;(?RW__N("OM(8_<1.7
M'UY&&11[,M@3<\8C=UQV!IYH294]*;GX[=D1%R<4!Q+]$"'J"CVNWSD!A?W!
MB].> W^)R.B<RY1;)R!PFQS15F?'##P+M^N2+<!X^Y=R(9H<.99+OJ8,?X#Z
M?!!X?KMR_$KV2!CGDD_0R_&:$?;W-'(=YT=QXV_DAFOK02>@O3;$5YPBT*>4
M2[4\YDXZZPYS'%.203):SRQ<,"GK+%=.</55R'E0]5C ]T+$@@T#NV6]L9"7
MGGW4_(_G,) !XC4P4[0VA66D!3F7>!CJC<H,(\FMXP3&-,\+B$"-?BE=H?U+
MBJ^_:CWG=+-YG3:RPD&MW0]%MAZJ7A-3P6F/]6*H_1LX/K0!D$>6X#%S),-?
M1Q&/,\3>#[:\HJHU%#J]@]K;[WRZ4^SL+N(-#43UJ1$E0!CDXNL<?N ^$<N.
M*NV6ST<(GZUQ>S9LM6!W$YW^K5IQF;-J2]FH1(+[\O64AY][S=K0E_Y# +3G
M5(4LB7#H+4)OKECJ8IMBD2V!Q.LV\DZU6K+CJN%<:AM%?:+N4*A4O%TX[?49
MGZ =,^U_8^V=F5YZ-H6,C-=6584X;5;^6L:'IXX-@PL<QZ>7<!JT>V,Z'&@5
MJD2\G]]5:W?U\HL-5D(<W>71Q-<JI7SNTB],ISNWYHS.M 69 7Z')D"C6<V4
M&BR^Q2Q436O96)J"2R7:V.I.#BXYJ.58F32?#X -WG!Y'F_Q$*MW5*HCL X3
MQK@N"J/TC%(')BHVS1$W6D."HF422=="'4I:"3*FR[36VO!X2^Q:>^-V9X*&
M27T]=:*W8 G,QTQ&G( X$,)JU*::-W]$</@H\RO]'6>^6<1^EC$H]63/?G_]
M!#2#)_UL)?^E.1.1XC/NZ1+GT!+%,H4%_ G2*=9XY/,<YX)QF]Z')N(AMMVT
MS/-LS^">K_CBG:U>4E;E*L>G?F!KCA,J$3AUH)SZP)KRLXC(3$-@G#D20\MF
M_P:$3?:#SRM)Z\[FN9LH*ZLDO/=MN?&U]%?3#:Z$)LEEBE9JZ@-YNY7>_6H9
MWOOF]_X7MZ_IXDA)W)A.9>(1PN*ZW];GH_?N,M,U8_97GSS92,#VQ\!B#69?
M-2_7[ ZA;4_-$%IJ?&@I4DLY((W^@E,BZV"4J(;$181-Q!?\; \VN\[@P8%=
MH*8<*X@A_3 [;^[O?%\AT]_3X+#$MPOC((:40]+/N%S@*C&#I@"+O9Z>_;,I
M)K=:G6#][?D8W%B(12CS>77J0&)WKW3QUJU-S[LB)-BF&0DIA&*SH:R&A7#0
MK,?:+"H(N.Q"NW5A'O?G!--K7.5=3_Y&]5\<W9Y_I8)5OIDA<8?VWQMT]$1\
MQ)\OOO>$&YH="VVLUP5(CS(V-91[/RN\GV-T^"&X\DH.^@JQW(J?'2-QOC_-
MP7S I^TEHW!="JY(-J9LT9ATZ,^?$4WM'7DW"5:N&I.UXJW4]D[1Z:;DY!:O
M+PB,0OR"E>M,K4FCEY"JO=FNZJDU]-(Z'J]JGCE8OHQ75[FF9OXE)MQR>+)"
MB@R+54*#*=C>!>GJ6+8$$^,12&6Y0[/IFE2/UPZ#Y+G;*>&27%CKS=_10 \Q
MD!9 :>U=$&Q,7R"0K4<J_DP[-_D;=0W1][+5A%GX="G02?I#7;CRH(?=V#H!
MFF1[C6=2SQ'R]F%P=XYXU83LF(+9VYHGMM*2MPIFVIK:OK_ER3A_4U(+!*9W
M)6((A5-=$-(,[@+*8[N'@Z'1E=A&4+C0Y;O,=A^=HO ^C_U,]JS)IU*CAW5I
M/4#K_LNC_#9W"B>>*+:RW=F*Y+29GG$G;?VP-=":B!TULE/0--!W>&K;YWIG
MR35YWZ ]&%,(N#YL&540L)E0W%A.&;AK/#IG^X1!]MJMA+2DP,ZM9Q%SX-NS
MN?CQ?N 2U= ,&*-4=N6HC?%\;YPH;_NN>)!Q"%WOU20JW/BO>Y3T7%!+Y=J%
MUI=4_/0)B%A82XG:]Z8@(]!ZHE=^JR<_,?5E5PD,D\WY:=7)O]4OP]KMY,41
M9L"R?[W[UTT['BIBOXK2UV46S04HS>I1#1-IYNF+7JVC:*&";%T$LT\K1P=G
MJP:2@?.Y>CH;3OMX$ZZ-8NIZV1=^ GIF%M=H2;"8:X'%JR9(651-;&X^(?3M
M7R,03*Q<"+QFS:_C!!7N.'U(:"I)7#9SC*T[+2AQJ+N'1J/U)F91&.ZB,3]$
M?M78MN6-F-POS2Y^CW/3O%C[5R8BQ^=\$I7?W/@W.1W9J$L'BB>V)#GBK6F]
M[[N_YX<,^K?7JA5FE,)I+T^+</103J:G_=-^ZMVL<#O]S[.V1GP.T;.U)!]'
M[Z:&CBB_D&R;;[(1HDZ10G\CP<.)XT87C.V"J:T/J3]B* =6., O?QJ!4XJ0
M4A?V+[P1YJ+26X-T29<$1?=C)I6,:4>,)4\NI9CFFCWA_]9[[=N>J&NAUD-A
M<4U2I3C:_O3KK]$L 7DT^49J4HP:!Q06[6E/91=VLK;%IXJHR+W_&?BQ?_2B
M9,-P]H%+LU"(&AJCK)(T\S'MJ8G! G1LVLE1DA8%._)!#.B<#YD6+NCK2PH_
M2,^A VH_K0U7E!W@A+"&*0OD)QP>)3D6E=B&U>^*/Z]H3@MJV#$5K&,;_"8:
M,M#/< QH>ZRYT?N-X2> <Z[5,F'6<HASY>%;4,WGI\Q/RZW+XT7&#TY1N7!O
M.PG,. T'\KHPE.C?M4(Z(WD8MU.\/D.5NAQR!+*<"X6']F[X5Z2WU>[;4_#Q
M;6(4N<XL>+?(7S6(8!][K0>/Z<NIQ'*%T=O5=8-W=X6O&SR_G?#._"&]78&5
MR/\ER/-0Y<[(EHP!DZ[-VF;'\NH8GYKA<M)5%+WF]V_X9]YKA%<Z<D<E[1Z>
M-L94B7#5+Q)?3T#<;3K_X$EE2ZWMIJJSA-_I5&C)?L./FJ1ZEJJR9%$F^I2B
MV#_&F&<%\BN8SD1@<*6)=8&;-?\?MXO0KY#[J:&_ C?:W9$QXB+ @Z4!4U\[
M2B--]F6*QQ5]XJ:X%JP.[U?:L.OQQEEBX(T]_IVFQ8_AH7KP6\-#*[0=)GJ1
M$J9_J/.,"MDWVY^:9DIX=L"F+'5#%KP2Z!3X_H&[0Q#92[@AMN5*JO'Z2XT-
M+#C)F6+77DZ[%;O3]X *B5;:*^40N8]#9/X)UGD:*:+1GP1Q&8NF,+/3L=ZT
M.+BF$7BI==LQB]H^DT3VV][DH.1,]3:&")RZC4O_%LFHS--I/.)O4XR@Y+NJ
M!"O,2YD[5[[M-/H("N\[_UAX.>EI]=Y@<CB6=&%I]]7MQ ]DZ*X=C,)$2B^G
MW@^1,BR;71LNBFSS_ QXC"A\<N*>O;DB2+@QN-@F,RL-NG)JM.!(0ZV&37(%
MYO)?N2X,*\8M*>+X G47)8N).+C.%$VS+$:%8HB2P?H5#C89#ZII=1:"#^\R
M!N('#0W%OF=OYL)/H7>TSM7CR7.+J-^="]J-P'W*>E!DPW#=FJJ6K=W6L: 3
M:KGY0W^W[LIPQ81C0OL+Q\'W$^VNV#@[2>I*7SQ:BOR;0^X.]2 <2:J?4%1]
ME+Q1V)C-T)"A'#4@^>+;M-6[P,"G$0V*V)D HMUG"FS)+**-JW(($53FCO%P
M7QE="91$JOQTKRH;$#E'_\HG+T=YH?J8!>#IR3+K@R2*JT_]B0L6N4M5VTMH
MR'!!.C9EH13L43K#LSH/C1_F7>9I-G[:\92_4+=Z^W9/WMFTM__4K_Y[D%&@
MCQQ\^I0^M57L:BIV2NUBV<OW.=K4QOT,"OZKIZO!L)>B&H875?M88=).F#)4
M,K_.P9U7G?EICCGIHH'!8V)L*8,/SMCO!'26GQ*<F%SFH8)6![*11>X:V)F#
M _Q'W3=6=Z4?TS+SW3OU90\LF)=%:ZC?F)JHAE%^"0+[! H^MKU&:4^,R9KB
MO!B%FW7T&%/"^G)\:U7TGZ:[D*QC]$TFZX8EO6;EAS8_,A),DQH^ ;GAPT,N
MCVW70P2!L2>X*33$T;/ )("_X"B_N ')QMN7R? K(G&8;^R9BZ5@>7HOV'<;
MS_(;2TE%P8TF=;J""Q-T1^5S74MTS[>$OV2<40W\*RW4!7%@+O=8#CDW_=L:
MWHEEG$&]F=.(+O^#N%8OVX+%OYM78):!R/Y<F.UR;A3-\4%4E"6820/?*] /
M1MN<EP2A],0A.1O*_$+>"JKPX-X;Z7_!V$R0B@WV.K0Q?2PGT4<@\<ISG!3Z
M/M!.W!:R(P"62RAJ9!3S \\*,#_!2NAK@E"[]V7^)$2Z7;M&1D[D%PT2+#[C
MU-LB_#B"#GFLJ5(V@7J'D*[)R/5]SQV%0*-PI8W T$2CSE+Q">IV5SMA]V$2
M>;7G^[:.!-IZ4G4 NX&M1GDH\FW)CK2//+XMVW"5RTL6N: $6J#SHLT%R-J(
M%VGT)A'  ]X"&Y-,DL:M??OTFO:M@G?"!*#+CHE-/<$09GGA2$W8;6"6--6'
M%*-Y4T(I<EU)D5A>J A)VVMGX2HIP:735'CJ3J0F?Z#SU?R(YL?]G@Q>CYS/
MOE- [FLW_DL3\^Z3TP:/CYR_E?[_JS49:9REW5W<\<LD6+M)],,_A\)B6O)/
M),A54U-H,U%;ZQ[3?UJ>EINFI>XZ4A27C#P 1K*,6C2A[GT0"%@K?!]DZ[,@
MEV8W.3-Y?S]7G2]%ZM62ST.J70QD\VT!NA*XORCTH9'.IO/F0ZSNG2YM<+_*
M<VVP=L:F(E7J-$6@A=PK$ O\I^D);VYJP-RFG=?GNI^Y5>^_X&G.GO?7AUUS
ME^ER,T&H(7<G^@2$@,3AJ2+'YXS:78=R9(Z_'Q,.0=3R'**+M!O#5UJE0M)5
M#T\%,[1GUZ,12P-N=VTS@Z-4(G4#QS:UUQZ=;/=X/42&>G:AWC[/0V/(5R>I
M:/!<E\O?^RL;!&]Q.KI7YXTNXU8XMV4"@C?8IQ)#!C$BE1@WY.M]G%HKI9TF
MI6X9P*WOB)#-APQU&WUEZ'GM,7 X<MD^TC"M]4W'5$V%=_AD34IUG:<G<[[I
M*&1>_@.?_8>#O;TS;> E3-_O2J&0_N=H.ZIS6AN/GG/Q>E9$13+;9=5'J3_:
M6RU],V9 T*JSU?V59L'N?(]?!?!!(Y;#XX]%7TYU';,=8=O=84PTNB;@IG,0
MI;Q-2RDSN/![P/-_<78,K>[Q/4\D[[*7\;XE)_1[1Q8G:_^H[: <C\ %59EQ
M4@3:C1$:&%&*Z1[3HR@0%(0CFFNG*SW%ADB;F0Q?]70Z?M"GM(*W\O9A,P-D
MF:E><%3M D+XQ4O#.%5;@U4]*F<F0Z31IA^SQ+.21&/V?%[O2,_<SBUIIRV:
M%&5H*O28#Y#ORMB9Q>7EN>V_].N:2;%WOQ#*U1T426HV-W@^32]5'HC?R%@R
MXP<TNG346ZF):0CBD4V/#F0<>DOU'=*<6I:+'1!_4B.Y,]/N'VB7&WK-LT/S
M&9?VD6#-9_FZY/Y_00\^OUD=8'C%LGH&:Y4E;DOM(_=%'I]=^V?[HPV)1.XA
MZJM&ZVS%N;R+/7B4[YDSUZC<@"XG6O%R#Y:@8V' 1=E04<)>&Y8U1$&Q-RQ.
MJ5PT1S1&Q"SAS;>:N^SD?CWA6D8T1^F'J?O4PZZL&EH( ":;F&K=GZA+ #\<
M?S&D.V4<NI(#V62[SQY@3K<3AYJ!!9Z7<GF8,$<>:'.GPCHQM;!-,#7)''B/
MA.*$@(B\M<:73]Y,#WA[HAHFA]S5PE?\_Y;]*+(_FC:VR$]FB[A>'F^W.B'!
M$B)MC;8#_#ZA>KM,)E018G92WDC7<ILR 5WMC9*-V$'0<_K/[#YE15_\]DCP
M:M<HFBD1/H/IL(;';5:6[<T&6>D1UKVL2<QW=M3:O%AD6#L=X I+'^F8S5L-
M&R9=BG?,"%?M@()<E*59!E$N\D\2+Y!0SYNX/F"=ZL3FY/"F+?RJ?@:WPK6O
M4&[E'_K(."Q7R$646?>YQX &D0=U KJ=,B*3\> T*+/&[CQ\^XVX2?O\L)I0
MDM">R_U4-!QK2#6+9HI\H>CZZ'KP_G^D5'%QNNY;_)2&C!1DY5:X2+[G.[:Y
M_TBII<0FLN0$U/4X;NR47'X;AA%9U$] E$CUV$7$H?DBMY]$]=]9= VV9;>V
MZ0-$BI?<K#*]YPQ,4(^DS1=K7R?1%,R27LP=DEGF-O_T:ED.+_#AQNO-V-T%
M6GK37VA;_QR]5*E:^[R1\8?+#3PX"ZOP7C!MH4U]+K%^I[(;2<CK7E"E<#82
M\4QH8:#6F?3%9Z3N2.70?/C]G;!1TG,I 0X?)^1% R=.3M!932<AOW\V1)>$
M$A22B(U030BX?SP]I7IT>1)_;QPZ]7;^21]W_F@&)C/N>BWWHK)<CJ^%8DS<
M^+K;I]C!_R%")#^HHX(:ZUL I]XYM9T$$4M34&OA"6[T;_4LB-,N:>5T-G^"
M6Q4-7I3'MLF/K9?UXWS2+>9'P'H?G':W0_L:EX<S*1H;2*H\F2GR!.1R F)>
MPPD"0B<@%J\HEB_G?M/W3#ZZL.JWV75MQS9 :2K@3L[=CGFJ736QG8UF"?0<
MW@($^G*T*!9)7:;@CH: 18>JXXDXB^;Q"HCCE8'=SJ_FJOH)-0-?R:N+[]H.
MNQ?K#WI+3^=Y_: 7PP($?+4.Z)Q%=#%F(RJ#"X,=?M)=MPGL>?KN%DLF=EFA
M0#?GL6? -AI,=2578 ]OH3 =,&Y%'3&KM7\YJ;ZEAL$?CYHYMM/2^"='[RY!
MUWNDDUF?ZL[@H<]\]W1*PZ,[NL NTMC!\3115GX9M@]^(BTGH#U<FLS3%SE:
M<MU'C\P( \=\3?6UQUVG\[GX>]-O!4:(Z)M]34>_-5M5:&R;G\)T;>GO03=$
M#'T;J*6V/@(<*7T6=129C->>FULT/=+L[$7(2F!11'Y]0V/#\X<5&E<U)2,-
M?O$J'.A T+) O=PF'[@;&_D I:%(?$&9']112*=X[Q=EYZ@UWKUV\6JKYOP;
M$,/"44X(+W "ZH3SZLB>UF6^OLBB2:C#BXE$&/O \^$;#<G&_*.R]Y;2G*2W
MGKV9(:C'SCRS5^P_I@>BJ#S$HEX.*6)4]R;"B*K=T%XTX$?$\LU8!4>N_T,I
MRTS4#]6D&\W?WXG//9?_I-9H66ZDX02T_G!/?'$UJ<B#8A8M3D<UBSL!>51&
MB,O4CXQ"&%$:9N-;6WY1;;I>2DI$==*,9X>2[9G2[<-\HRY-V_+M-]5NX\GA
M>T.W$B[H5-&L2(I:G=:,I17KJ6S!5TWJ4[;^^27,?PI3=0V@HW/I#/,OEMZ-
MSY'W:0;'BG.81>?04>&1CX!IDS)WR^M6K0^MA&?Q$7F<Q48,8?W3WWXPFMU.
M:S9S_,E6.>M+8A>&1>T!.O2+6'94[:.X.Y25O1-0C*)GT;BXO[WG.VBA&[K'
MM"M0/HPY.90]6& )N<E!EHA9Y*79+FWSHJ_ S\RC7$:%*K<2OW#\C33>AW*A
MD\_*D#D/T]Z!(>X_F\P$:%#J6,CW=E:9)LKK9&"1F+V?6FY"U&*+=O74?_'3
M35@U_6K-56E8.VON-UBKA4LY)OPJ"DM:W;Q93K-JH>C4+\&8K5#W4(]^3/4H
MJQ46!2@WFQ2]L]FM4?NN:R)*TBZ2O65:Y[8Z_:\$^A?](<? .[92?757?<?R
MU> -9N\<<A$;7CNX!.6[\B'>J7IMRUU8;+,5NBF?.)>#2?/-RZ? Z ',?_+Z
MK*C8L>X<*4IE#$[Z>W#[[;8OL;?&\FKEF2^I?&6_\^/,G/J91H57U:*/M#0V
MGXWD/@*4A/I8%PD=JRG^8=<D7_[SKX2>@,(B3Q-$%Q'<#>:$=:FG=L3^\X8+
M:43;ZVM5;.;#?C7M&D@//N&&Q6UEYPUGD*,V&2E)0&\F[Q6A76A@D7S0'SN6
M\LE3P#V".]=%=?6OTKE<%&XG.8)Q@;PF;)"W8^[TKLY\ZAT;UUQ'C#LXC'R6
MXDA$26%[<8%'62%B -F4&M#=?HJCSCU3I&E7 J2M84C4LR(!^4("0>HFLWM:
MK&IB>?JT\DZI*/\T5D\/J^ $,H.RAZBEJNG]^A2K_[]T"/)_/PAI%A,B\7L?
M5G\"BFS#V!=5E'Z$H\Q7NZ[GXY[=%Y,N[[?55Q)J-%VMWFFX^->?4?I/I7_E
MAQ!EQ,NI;GR2/_SL,[4CRZ_7M5#.;18EB"QVW*/<%Z5^^ZCR"^_"%,=UI/WI
MLFZ<09>V^QGZ:A((.5ID-HP0^GP#L$GI,@5L24DBX&A"_<_/>:@HX\:9IR(/
M8AS2M3(#-&9H48_^3A-QNX$7]::F)9C04H&4$Q 1$D93+C8]VYO[Z5?#2\_!
MR69E:%5'<JOL#2V32U*2$O:C. ? D)PD@I"@W%6C^F%C*Z+BRE]\>? @Z?%$
MTFQ!ZL9!AHI@_M5J]DI1.R,%(WVM]M>L__*(V'@8T1ZM26F,U7\W=@)J5&WU
M--LHA61=V/UDI1Y%:'TUGS!K\'+I14G:QAWNYM$I'FI<C^5I3H&3X;SNU3>]
MB]U:Q#:/\A_<&I4WY05?D+_\IH?M\O(9ECTQ1$.)<&\<HM)]JB5X[\N7E8@-
M1:0OPH]U@+>ZZO*O;S./'IG?-&=>?1/(E_F9>C?Y]!_[%D0 ^8_H@#C2"2BV
M_BADT2RN5Q@77K(NHFISJ!$_AW<6:S)X+/(]N/C0B+W$XD)_]$\*TX;]*4^*
MA[&\:(\.D:3RE_M1,3V/)H_EHGIQZ*JAPGD349]9A4=K%V_R/DXXLWJ-R?&6
M.O/Q6XKAQJE-L70TY7$=\1GMS<7PK81E[[7&6B;^_2F%(<42H]PG?1FI[!NC
M'*L'V<H>DV.&M11<P1*8 3'9HO.9N*FDJ,[0F :I>!'FV4F 5EWE?Z;4>P;>
M)@ -SYHPZDN;ZSUZJW,13G,^RFD3(FU://;(:!C5"Y#G&]R]J?H&"EA8P)4_
MJ7A:T 5L"H&$]TJ(QRQH2#4 H11UY;"-+>+#C1MV<LCN9G6#@WC50Y.&117#
M0/7(\P%+3T%,2"N1./@5FA'UU WC),34,)%P=C\4C:D(N"L?A.4":O[]$)D1
M-GD70)BUGC5BK=)<<()UQ[=FN%F%Y%0FZT@2:'  >6@*I/8L<AQS5S03YWTF
M%\3\W6FFSEY9W<,V%QN:$V0NF+B^3J43>I%F>+&(VZ+/1Z8*=YUJV)LT\\"P
MD1H5AW9'4*,Z!J"/_BV;?.K*7_=GWE[ID_D<L]\O;&QA]=BKOYNW.% :7D[&
MI[?B]C7)HE-=</'M4^Y>F;@@7D7I6>T05,4SL_U20M\L,B;]9EE\7!_KMGQX
M\1W?E<\$DW,%B0+L39=/0+?0%X#W5,.>A0LY?;TG(*;3-8.O51.,5=8E**DV
M'LZKG*'V.\0GK_I'U7<P*SG*>$X;'J;@I*?%=@N:;-LBC?Z.R;,?:9<MM-[R
M?-TV( R.4_ $.5)%,@7[F'*OCJ**/1<BO3[E0P <3<-D>.)+XIK/CAF<@%P3
M'"\^26SS8@V=1\>2]X>! G<,.4X#H&LX_,K_9AX5IDPV,?>T3V%JLOP6== <
M(_WTPESP0PWZJ6---(S*64J-6VI/;(,55=2@(:7SUO#'=2-=*S.+-M$RK;MB
MD7>T+-H*V$>].GJOVB'(GLA3_EJ;L4E'!?>JPSBAIE0I?>I"AJ/?LP61VEWK
M@7NU\;-'Z<ZF@U)^SLF%O0:WRWP\T9YB\3*.O^!AQ]KM0 &EMBM$:?R%!&!0
M-%D>,B^>Y37Y*Y^SN_.GO@5#FX&F\BO+D+%O:K.0V]3V&29B8B,%N>]-<7T-
M->8]A\A"6X+]..IP'K=&YP:NW)COCSGS@5N%DT44Z\27JF[#]G\_2TF$U6-/
M$1 7:K4SA'^\[5*14F,%2J/'&ADK.>*4+"F<\6:CDCG'P")Z(^U](/Y?V]-5
MIA1@3+R64KJ?<AK=/:U@%B"N[[I2+K&Y[5(Q >4Q_>3)VHK7V3F!,]I_DYUT
M'"2:B@6T=KZ5SQZ/PWC5L%$Z8I0O45$RD7UP:E+,,^@E]Q(\ZZ!JK>]/ETV'
M9PI#PGF>NC?F^HV>LFKD' ^T^%<OG8"28&)MX,#3_,&#PAL/9]RTN41[4&H2
MY"V0[:Y:D[ ,8G&1\+LI><:X@Z_.7W.YX@6F&A\!M<@%(#TO5^-4DP"#>H@P
MJN2@QR3WN_=/,WN._MY'EZ+9&F[6%C$Q>%EX]NM$A4=;QGN/C1':KNY; A$D
M"5'4U5,3Q$$L;2=I4J1RDR[+ZU_#M.P_'^7<ZUSNC.7F:="W+;$YLO--EPPJ
M<_4YE@ZI_U#A*?(XS&'@O.3*#>E7(5X?G@9  _8JX_Y(T 'X_4(JO&?(99>T
M'4<3A,)()HNLOZXC7R-E:JH:;*X>XXAZ]-Y2F6^;%#()#]7/!,(]ZF2PSY]Y
MXS&Y8E$K=A@B//18G +K7N0!IFX&92MM=X\8J"6H@R$; 0_RE&T^/%NHH6UQ
M3C$'*%]^G)Z?W<A8@6ZE%"WUATQ9'\2IG8 2&A^@TN&,ZQQ+I<&L/S;+-QQ:
M&V+G[!9+=<^[N*\,@"S\+\WNO@J#W3U*=1I'LY"28C",6WY!^'-K</"6*C5_
M_67JY2&QA/GV;(X\4/@%4#X37JN*7U5??P_.^4N'%7A08?LKRX3PZU]17'W0
MD/O&ZI>C_5S4>J6O@O*WP_?,GY//$9I_7$U]>,Q'.V46K\&]<"ZT5;''0 7B
M6&4B90=14,]_K/^!6:JNKK/9<L<2M7NEX, YTL>T,9=5:;5 ]VN&E)C1M3T\
MK-SHRZ7J7'U0L^_1SU[,;3_G\>F_?>034#=>'"'!IVH6CF5O2^"!XZJ3NH6+
MXOR8\](5Y<ULPH6N="_%. ?8OI.B?YE$4M$; F;O H<4@:Z7V(1E("J?9C/R
MXO6A71%Q_D'7&[?-_6L_#F,^-H4"F5)WZ<,B HA689_K#V^YM?/4P0G@3IPF
M *<L'G/;#)C*'UZU')>=4O0LK]R0SLPQ80I[IF)4\:8_@ZN1FN:49D @XS2
M]_O9P&?*H@4E/8FBLMBE@CA77_\S5R-.]? O1UGR]2'N2\H1+N"J9NF++M-T
ME]=.77BE>6_Q%=H*05X\A8'=#?=-S^94VS/FLFM(LC@:.UJR+O%$T549W&66
MDFW\O8H/"U$'\NQ/H3_3.AQTFDOI*;81Q6-CYCK*=>,Z/>Q7^")N&;%]ST[N
M2YD1J?%-# DSM_(QD%=_%FE\+E6K62P2AF]?A:NA=LF>4Y''UU#AG7 VG7.-
M26A;L?(O4['UU[R>CEZ(NOAI4E,I/_[HTWTV_H=XEC<%T6\,_PRAX*^/17\O
M<!T5X^10"7^6<92D^+HO*LOK^J0'KH%ND>#:P)MQW[\(FOP4^^C)3'=--J^9
M9YIJJK5/!2+*4;!.';EZ@#/5+41^0L!P9"N/&M'^SW0MF63T2OWP+7^LQ4(_
M#\MWD8C@E@_%9&1UY0_;!U]/<60>0.]WJ/"8ID85ZRUN&9C1(R/>W^>,4OH
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M+>9T._OQ;EO@;\AY)(&$,%5 @TU!501,]*U16Z/Z;XZ/GULWU;2X#WZJBZQ
MM,:NN81Y471D_<IP:8P7H4>VJ9YUHVUB6FW1YT\Y*= ?VA]BG K+E]S>6":[
M)9NV9P92#/]:W5QGWC3TX'K4>6"6%5[L5>G\!#N/4[/X<U9M11@W/EY]?U?/
MUQ-E00FQZGQ^\%7UPS-M"JM!P$WMH0IC^#]TUUFG[FQ37-=[NZ16-RMZ.O;X
M8OM4R<9\)JN^_U/(/7VA/>8\KX4BXHQ.MNPEH1!Y^N]?A9O"1M[@YDG0F?T%
M8IC J"^MF,:W$SW[1J*L]%/CU51?K#G>&WO+T-0Y+F:Z;MTJP%:>6BPQY'9<
MX]0[W^4@$ DQ9D2&*0_%U_C4[T P!1/8KT<$!<]P_<!HQDL!J6R&F-.%_3V?
M49JQRKQ^CW!PY):\^3%1@GS/_7O.?4DQ[G1B<2,HW?Z)'/LK*OEQ76@(CA'/
M@L[L2XI 0U]@5K.=41.LV/X=Y*'^3*NFMW=P[5!3ZJK<Q\>1]^.Y=8[N,6_G
M?V,MBFTO'C9>.#53YG1?0\-U446E_.@R"(F?/<SID>[6673^1E!P([L&I=?B
M&ENTRH&/#S,1'_MK*LC%_"BX)B.%K"<TIH--F=;EM>7 ^A7@UMKV>8Y4H&_K
ME%GE)S?G##B?W:,P#A5URF2S$<E:.AO= 8GW76R/;P.T.[L&&MMN/]!5EY&E
M%='\!GPO)[63.D%^67P-N&F=S0/A>)9U78H1<\Q:W$$EDUZ:^:L<SP\R(^R9
MDA-1M'*&R;;V6R2#(P)%V)E0CBN :TL5/5073<@MQDO,^%,#S.$K-A;F<+?4
M(4CMDE*O#UQ@*-N!/_=Q\L\ (^*DG#9[U%RFJP_N,92LI6;.8Z_5T?N;&]!V
MVI]\2\QF>\R#21\^J=:I1^_(*BH^^7K_O-E$$D/9 Z8GT$(],)D)!":LR-I
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M'2FCJ7L@J57Q<(F9^BP?.H8A0]GTA(87LK5J.A=!7O192V*3D&R*P6.PZ:Z
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M-*W9WV*3+'BE^&>AQ@'U[8_O:LW<YO#<_:8[4;<*I?*^[*6O)$HFKIG_E1P
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M,<HA4TMOP_S1LA7GXQ2G$7NU?&R 0Y+O/NW22?O9]SP5,SCC6GFK#&5Z7W2
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M,G5 C>2:%O17#(L_/27U^$S:+DT(U=[6QZG-<SEI4>Y!D).AL'NG\&0F[!6
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MY+@RVX X#\30Q^(-R["USS"-B0&58\,5UOR6*$'_=/V?6_ <D8'P?&V[IU,
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M@CQ3U74U&ZX( PGD7R_7K,XXQUF^9S@;.I$ 77]>/H,9WG&TI">%/3.^\Y.
M=9Z*2#3Z'5XY8@F^6UOH6>=ITID4SK"4%"/%>)VU),"JN%Q3019Y-E$ST;]
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MLK0ACI!5@E.S+L2YN3HN5WP1H4:=A A'9QYRW;[PTP#L9WR?#)GHUE2.'>Y
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MEU]0M7!C@:]Q&'IH6[+%&;LO+OD"KZ/YQPHRJ06P0(A@ZZ$T*AD+X*N@=+
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M35905PJ;?:)*61VXU*&9YLS#X7S:^WF=*W3T-(8QWC^_O[-TGP^M;+]+62O
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MEU3;=?7><\]VAT%3;4JV' Y.5+@;3[+C4YA43I=[=T$CFQ]0^/PGYL9,Q\A
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M!3[9!2.*&L)>5\^):M:UU*'"2D]O<\8==S+?X0AFF,#)D[MR0>CFB*9*0$-
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MJ>N_ QS%*CDP"^TE:AI9<FT.^2@?05S7RI7C4M"7TE7.LEH<V=9MV?H"93*
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M1>HS#:3T<_Z3">BX)5,+%EE<R&N >51A,&7,>W\R3&8!#B*IVC[O2F[_-W;
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MU4*]*1GB@C-MRP&#Q=>JSU:LG*V]RYQ.[!,=#ZY%SM]XYRK'H.NWGW/7,-7
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MWLA,H*32)0ODH$\/^UZ)M ^&D>@I/QC4K4@]AS1=>4;L1]\2!+R=O+9D?/;
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M= E<446I"][I:#D@2<2VV$&/G">:G$4)$L"J7S'U://=94<'C\Y^/>BO#FR
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MH1D/9T8XIV^+WQP*NV?JJ<F]+=8).\"8F' 1AZA,X@'?"[]V5!HC9,GX*_/
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M;MNH'9QC575*:D1DCR,T!GP__>1&(G*\Q9PUW,^7.(044O=4WWNT'\]$43?
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M$.'5!A"6DK]D3+,I=ZX];0WR87(*Q?)\P;S>XE,?P*'Y179BRM/7;KEG+86
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MYLH)'E4[/%TQ-L?Q@]3:FJ#))=])KNM770,@;3TQIYIH' Q"M!F^!M!= Z@
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MFX*.]GZKU5I])3<T5X7ALVU8IP9=],2(MLEJ ]_B'&<F2A,/>9S73K8C?YL
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M=$9/9LA (O&6D6=TYX<4!)('87I0Q<O3.524G:S"5AVDV.E*1=--E_>T$68
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M5'D4C=.3@?05+\.\:;Y_#4@W++LDBOO3R4SM;YW1X,Z)&_(?.@B&>;/XOTM
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M<2J\?ZDV^8*TI&U%[6LC]^=K0'YQQZ Y@\4]9ZXEF2\XFR(0AVI-WM7NLX>
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M)J]$IW>5:$QU"?0CJEW*F[^^_TZA$AW0#'*@8UZ=T,VSKH<'!>?W^7Q;4(*
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MT(%F3[[PZ'\3G-X3"6]0%]3P[S9FW:%RCTA3KTZONL=CQEH-)0#T"8]/\=[
M_FV#G'K;HDSC-IMB<*Q@JRUYE0//$X1B#PM+$\ M%(678[[P.\S^.?Z4W6F#
MU=&0K.IQ&:XU8GS.:'-IVNQY\WA8Z"[YDU9JS]*(1H$41G>T7D>7+%GBO9I
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M]GX=ES9TTLID%H7SORLU GN_:%<AX@\Z2KP(EK[#%UPF)>Y*M-'Q'3Q,6_[
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MHEPMSV;K:5K]\_#NG&Q@L"NVW]G-[R2A0O+3H1F'\VIN," EOUO.]%<3?]\
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MMKM+^8]:LSSC3!N$K"?9!=PO9/K((.?MPL\U^DNLV2W?R8Z6S8S59X*1!$P
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M$:N2B0<.:Q:6W.%-+]2O@<(FBVM@^OGL3L-F>%T-*K[S]C50VV3^Q[7?.Z\
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M631?X:QCMB3_JPJ'5"S"0+HWZ]J5DF^LN@_(Q 0<RDAAIJ!QF*'G#" (HMT
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M!B!D3\O1O$2;'GY(1'63D_G@QG-"+T6,8% TG6\80ZN<5#J WGH3^-Y&P'?
M;Y=4H@T34)N8V#1(68C<*K_XV]>C8I[N/2YJG_O8EFR" !(=*0%(>CB]T62V
M$$G+/OU[>J6"^_J)<=EHE%2>)Q^;^$@F^V,ZNTQ3,R)M-Y!1_3ZQ!,<6A?8O
M<#K-<4'3+)&,^J3%DSK&C/=<#Y=53&]XQ7()VKF^<K\("$SYLY[JE^^N:^MS
M\:_;K^&F^]=<*V]U7K]&:"/H/#,I64"1Q#+=9#<72CZ+-$73XF=>]-0=DS6A
M<JZBHDFO:,(EZC5@F^;_Z5^QN77B/_[I$\U>>/.YCA()[3FA)DW>BZ_SP&W
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M3W; PBXWZ\K]8,(TVZGV9/I^WXPM?A%V<^]%2N)J ]=;T\\(Q=.O: $B[$4
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MYP1S$="3&KWS(H[+]G-R&^""N_T%1/1=R94!V<-YDETI@K.%E.>@]$,V7/K
M>[CL6_ROFMFO/@W&(K4?!!L"VHH68E>N*L2071$JX,NVQ'[Q)F!*:0*K<H2
MOEMIED'+5F[-(&(4]%H^EG;0GG95_W]F=$8A>$DCN-9X*AM(A#!FV4MG:O1R
M9LK19,O%Q];C2M=' T[W^/QXC6Y?AO]A^P@ XQC_W?=Q\+^4.AD1^GN/M '2
M7!EA-%6:M)Z*NPE;NF1-BC.)_B0A4B&'C@0V(8CZU'HKI?GXE:[Y[3X=Z5+N
MX;2_8"KRXUA3\<!-Q"GP&;+=J-69*0/)/8O@(6RG.!Z>:$_$'1866]';*<M5
MONIF?L)(H[-])#?HKMES5Q.L365:;^4\,+AQ2KVY:@4<5A3+E,ZW$FY.6K]U
M WOIW=V;U^OL@K'- JZH?W6XGP%(-R%=<UA(NUSG/#ADJQ3>,X'.,C6J'T\:
MTZJQ.0+Z<TJ^O8#X>5>N721Q+8?P#Y*7>@>HO,#;H]8,UONX1+E%6);_;NZT
M4;&=(?^K.5+E\$:0!A@_MV5+*)S/S+$EZL2^?S/Q9RM&NT)\FVJBP76?W:Y/
M_8(FWXZ5[1F :6^AKN?1+I4'\:]-&90??<2I/R/>?0Y+D8B([[AAJRH8TD6;
MV.V'Z8!,I>$2VOZT$Z"A"C,W"+&@?)L]U-N%I",.GL0HU:&!>-@8P9YV*1+Y
M1NT,$,4IO=(+C!86(:7J_L5>S"S4'6%0G3Z$,SH UE(#=9Y!08%S<S_3.BR!
M!B1_%-Q%"\1^S@*0 OB;]3EM26YTZMZOWZ-<MW72<UT74$1ZU&@C2>3PX%RO
M2A2_@D/;O5-GKS5@U&47FD5>C*?.:37"DV899"5%@Y5:N",N/_4W9,! Z:B7
M2:;S;)TS:NW9+!4P:?Y_JI9-]\2R351]WR(0@S-#^@!ZP(6F]7DJ*^7=>9"#
MF?KQ;,Q(>R&09&JURY;DI?>+>]S&\1S&S(\$/6(#C6?_VSUW%_CQ5!F$6BB^
MKK/9IF-OPP\5OM#\HJ?LZ]_3]-V)O,2W.O$07/O]["[.#<L"MW/.#N19S>$'
M 1UGF8DW9D 1Q;?%_GK[L-#%E]QH&5YWI[E-TVOX>$<3F /2./VN;DN^36J%
MC.62\G!LV >/;2W@"JJE4VA=@,1V07?EK["@];=J"06!410UHL90')H-M\,^
MNXH!"3>-;UY'9^@VGP&@[[:#8R%MQY]JV6A7):-(# 04CB&8 AJCW!Y&:\!>
M5^G!Q*A))5)Q4LXVB:*92U,I*9_"G>6B#[PLT>XZ#;D,H\*?J@T9/B)<3U,"
M!0*'$W658]'R#C]@3-9B8=]+<6BR]NMILSN:8F;]S/$U*P9D&I*%'@E).'I
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M8K2Q>&+Y\'ZDM6GJVGCBU5=/II.C:4X ,Z,_8$*:_VA#U@EPG_2&L'178M*
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M -!9"P6PG=%1//,],WRVV@:%>._/,:AR!R?%9FJ;8EA1M\ZJRQN]S_7XX,6
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M&KX]S25J-;$9SN]G6?DM_:V;"/B.O&.W>:/15*W"%3U;]%'N5A%E8,6Z66@
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M'NL<A=X;^+:(1BD]O*2L>CNAKN(PY9 ^L>7I6EP, <-)CB=O_)$J>Z!^UN
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M]QZ/6WN(D65LD YM/=<NPE".:@%<C?Y 9L&!WC?T(CJB[-<T"/>KM'R_ZCE
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M"!N%?FD(R4F9M4LRFGQ\V4I[?Y;]#IUH,GSDY[[3SUR *4"7]'MI. XS&E_
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M#N$UD4LG650H'E++LFA)ELPJEQ/PWG_UI]%!+NMY\'N%-A-&?MD1)G6WAK\
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M*4)KD\!+U#_%A"*U9>L=:F31M:S6-^U9*L]/,CVS PQ8;IT=_]C[ZLR!VI*
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ME&$3*^=<$IQL7>,\;ZCS8'&VS_H"U=T'H''JLZFK)*NX5#@X&/^=/]U40-A
MLM7:(M,Q\J,M>_64:YJ.\#SW2O8B49%4@ F9.C*H)?-B[-VJ&=<F2QO;IO")
M#UJZM.VL'^EB@-]L2FH2E[@?=25' 9DBA/]OW'AE&7ALN5;(Y VN]7?FT!:
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M\'#Q*/'Q*06?TCP5_-^^D#\ Q-AH=QCAZ&B,@ ?$:.C$:,AN #TJ3DRT?UR
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M!-F:H^Q(;FGS A1YCN9[\-R_/IKG+'5Z5#Z;Q=\)+?TIBX$$],?[(P%F;$C
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M!D,=%[:V+K.<$*E[$]!"V?/M"S_63+- ;W]'YYK5_4WOQ3[?83_2X)FZ5TC
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M$L+?#%^AWI=>@K]ROQG2WI0P\;/]-!;#;W.&\8I13!9JJA.:4Z"_-&(1<(.
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M_E_,_%9MF7=U-!.5YQ?T]$><\-[61OH@AF=N:_.":Q.$<!C ^42-C4'\ZR\
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M1Y$U!\@B*? )4NK,4Z^G2"P,VK. / *J^AI=0W'MWI!'%TG^.@B*N\/1;>9
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M!OQ8:=A)&__>K6LRBZZ:=ML6G7".I"=\+TW B20)$&Z,E"LWEMD,^:A%_OQ
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M%1!$?S4_6U$6569EX+,?>'U0.D('F-<59:/.N!/,#-G.<#CP3CQ?$0J#+K_
M0LXD.O;<+,5 >&<@B"&L!\KI8,_DO^^YT1<]=DG/^KI%SO0V @![&=N!UOT*
M6." Q3>+R$T:FPJICJT*J6[UQ,XF]7AK#DCV[V*R!?]]X<XH[Y/> J;W$<!
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M.M""V;@9\_C\DP.S^]AC.,"5F]-84^!9B%-T@D[),=!8JU]12=XJL*!$ HI
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M%*JB_4&A$*W'>P2RV!ZBSR8PGM>AF/E^9L+.NVKR/.75,-/N@:,W-$P!LW#
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M^&O=%5(D81BDC9<227<_.DS%KY46II4A3#]0-\=@KM6X+,9IWMO+(DFVY$+
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MQ7#VIE.?)16D;M*7<1?9J^/:Q[_5E<1*'Z]\R<Y[_YDLLY6I^03VW>^Q/AZ
MHC5 ;\CM6:D"-@E.@@=-L_E9?@9ZKF=.C?(&Y/)#,/)FL:W@ ,7O.N7YLZS$
MV)0X+'R_,=KHW'B-^ #T,DX4D;#OK;(F:=<^C$/+&"^*G.JF\(XD6P)B. 4H
M'K"L;VIZQ$Z%]N# )4X#'!B+-M2=F^NT<B!OK>7H1+>!T$1+EL2*(P-:_1\X
MX$#\DB$<J$SJA459%]F_N11R0-V)]5H1HIZY>D[,^D:2_YL$#H[H*>ZD187N
M?*)<LJ9,HD:+N=07%C+$XA[^AZ7OU T8R+U8.3NJLQ#_#!,ZD^?NCO+\VSZ)
MNG_.$7B_)LH*K*&D4N(MT@S1_N(UEW\:(D8-!UR?W&KY613M)C=9=/H8B*ZN
MF#1:X?AXSNY_$UY&<=ONM+)O%:C@FKJ@F[K0.<H3CV:@I!?X 3RY14W&PMZK
MJ[.Q< !;LT.+&%_&[$P!(C*C3C&*:I)MA06[;9C'92\4_4,/;$#<'B]>=25(
M;PQ((LI-]FX4$=G-GTUJL:V)4"J-;;6/[PN+">CAU3D<J"=+9>P^YT3XTHD;
M$-W -'E>KL2B]SY(.5$Y4J4Y9D!288[V%XW)86/'MACCHSQ"I41E]CRDC64K
M'1&+\K]SWZ%CE"@A/:&)U95GMZ,(79Y+ S-U$*:6UWOB=JXR'("Y'[+]JBW(
M$H";DYA"_HX>@*>Q@KF@5[^F4I59DV,'*_>GNB!MU.PS_.KGMG6@UB6>]<M%
MFAGFLNGA"9U)(XB*9"?^1 D@3X>**4 +<R.:<7/"J*71:,/6K?1QO9,Z" Z5
M#!)C(!:.$)#<*KP.U:P?=Z/$VO%>[5C%<%^4IVU*-G]%Y:6-KWP9N"7D28;Y
M[<=:V^NG2SAN22KR7/2 QPU!Y9';@X4J=N2!+FS[S=P:[GSSOH-J8L=528J6
M%F$]FXN'$TO7*5E+=:.[R:'RZ\]E&/.7@R-T!@:\FR]I-=V;@K^0A(:Z*=BR
M5-E5%:;$H489'2"C8\KM%K2V?S[WL^CR<-[U5I>ZDU5OC: +D?_6[M',TODL
M=E,_P>.0Q;]$T(OY]K+&#0];WWKF3-9^X#@OA?4G+SEJH"=-':/;B6'86$:*
MX91$?% C88+O+X!8^-01N'_&JDG6=YZ%J6V9ZA#I2VJ#%&D[0]BDTI:ZJ?/*
M'(<HCZKD""J@?)AN$86=>LJ089HJCT,;KA.._?V5"NZH:6+ H?Q5*5.IM;R+
MG7-J,'3$CBCB^9M?)+3$/XN'U9T]*0I*%;GK<?N%3X5KY+H793_^^J4D3WM!
M>U4BIY@E>TTV(%8CFT)F-*N]<9K]&(/XB6#'MF<S1/N,!F]O#SL_S-#6I/4G
M*)021=IAG%:_\*0NNN8]'9C=*67I7[ADDCW-?(?25SW(3]3QOEFV7%;81,0T
MM3YX/;H\OV$BPS3./CXP8S@W*OV/24GS!O*,B[JRK>HONILUBK#2"X'?AT='
M;&79::KI-R1S<TBH_M4E@7G^#;06$Q23LRT*Y?(%K5=IM0H.CG>&_4]?OSLX
MG20_B#(Z1&JR<O#EHE&T8]H9UHCNJJIFN*D:C(]I.'HG&!NL0;$^6!#@KD.A
M6'JW&!Q$YC)I(5K;"&IA,S]<JKT'5>RD3Y>66&M2FC<2?E0H'(_N33^6;B1*
M6I'3#UX_&6FS]@&;Z$(,E%1+A"*Q+5=(B$[H4F66'5N>#'.,B-CDI-YUOI<7
M5FO+/+ ACM%P5=O(-LI7)D-?_I@*30DQ5:&P$T@^L[Q) OG4KKCT\HMPC<<8
M'GVB<5U8*/DDJGF_KW'"_&+!,ZBS<EZ:K(I[_% >CS,KL8$GIBFX._CB\EO!
MK^.?#J8$NQ$!A+;&>2J_4*3?N_@7CIH(E,<<J1]/W<I?]I>Q$LS>+SJ7WIBF
M>Y"Y=--!6]B$W=W?[%209?'4OL(K'L1.(NJEH]G3H"\X_*86^"4]E[9BZ[1J
M4,]&*T%?;[=>ZXSF=<1I7'PIZQ$[W?Q:,9 I2U-$IB6Q8J<$.[U[7]>6-G1*
M@/SN"W/S9,)S#=5,9+*UR8OB3PLK#"SW"U 3*8>[2E](E\_9:0S_,.E%,9CM
MGL=,L-N"-<N!N8^(F;'(P"E^U$^1OI3[)EB)E5-QY&1)@>QB^0XY<NA\M*-H
M3M&+S(J;<]5&WJGV9<>PX'TK%DAR\H2UR-;UDB]H^(NA5Q:UZ8UE-W\O$96?
MSV;]</&*1<J=8L%$JH9CNQ5C?I!)0#/Q-L.GB15073\<H%J"<'*7^T+F!U1J
M./BW&.5%N\8&H9+K-;XU;X_:,^" 5'J:]O0:9)''"@UDTEL$*HH\2HQN]SA<
M.QEQ&@\Y0:H1R^"T1GIYN<TRSA.,6M+7*"*C).1R,>1J5^)IN#_(I5CHA9YE
MAJ[AJ.'HVY:!)-&K9-5SU<E .YHR$=3UIOKUU,W;<Y->U3UH"A/,H>O#$!P8
M&>G:4@[C"6D6=)Y_U\UZF'LG24LMH_V#$?.>CK3:<QB9J)3$O;%$WV!AR,N]
M&",C4+^%W<LV9I;V_@=94-0QB&0F3?6XK&YP2[Z@!7=@'-C._Z 4W$A6+^)]
M]KXM=Z4[X417#^.$7B%.PQGO138?^1,J-?FE59(@)=C$R:E -)>\V'&\LMWK
M-#/OD]_BIH2AI-I1590TSO*B26Z0O8V35RTJ2HJ1AI"T-WT1N98=J !++[*3
M<?J:/9,;3\8S>Y,,UOVN*R/$."/N; X5KJ4X:<T[4##ZZ:)7JG$J'0;M'*%S
MO;A\C\N1+*."/(::JF;4^/26R'+LS7,KT"5R(AQXR_BPKGGUB3.0A17K/,UJ
M>DNEE5FIN^,I2]<5\8TL97Q/=]WWE5E[EH1I/93-!)$XE"GU+RQCCH($(Q00
MPX-%' \[6?=D@U<&,Q2Z]IC.$@M16QMTHI/T^7CE@=QK1/0N+)3KZN/9E54G
MWJR9^ >'93KQRWZ#G:?#S@H)\IT6,5^/--W$X<#Q%ZD-N?*>199C_N4 %\IA
M(1RD(T>GJ*U(36AH*/-AA.Z@,>)9=GP+1-WB/=]31X'ES6H''C1RY0^!EN1T
M]=JKAK42@1JP"6P4OW"HUSZFT(2[*J3GQ@13??H!\V<$/7AX]#_X" F!LFMZ
M;&$[&KWYDJ>[G7X_"N4;RLLO@9BR*C9,=T@SL$\7H'O2!=#)P-Q,^SJ!V-XJ
MU@-9DJ95;GV@_*9CO$S^0JPXT,]C\U$GXR'(!@Z(>;?#, [;KS<H9WG;SZ[^
M6$NW^)@)Q6A19W*>R%1M+EB2H#MKT[R@\#WT]?;MS#).W?%E6B4X(4B=&+1X
M578BVH\= %4N281):WQ#=;+OJ_E/J6J$0?QX?;)JI(J@\F+*#*_?+\4)Y*>I
M3QQL>=*U0R+4#0Y(?Y4,M.7A_KC*TQC3^TM_Q"KM0%M'6G"@HW4&#I 5Q]3D
M@XN:!).^UM-9?AEN?GX^[*2]R'7"?8L4Y%"T\Q/JPKQ'Q&D65ZPI0"H'V\[Y
MZ2RO/P'K@,"!K-;'# [IRO#>.7:?U/#F[H]E@@YN<*"7<5(WZ?.,H@W^06W*
M\ZOO\NH-MU&;1=!=/I;R);T1K[PT.37G7KS" ^SS37$E8.]612A'^:\4Z/^&
M01YL<>R2!@Y8S^['K9 >/ \1#<JTGNI>@.11^ UUJ73" 1%:Q]*;U*?;N?^I
MWM0'RW8<K%B@UKRQ#H2<;Q.9&!_D>&+-5N_L;.3:&B?L65BV_.,";U5R+7N'
ME_\'95\9%^?VI-D))#B$!'<G08.[A>#NP:5Q=Y<$#6X!@KN[N[LTUKB[NS;6
M++G_G9E[9W9F=S^\W_JMKJI?53U5YSWG/ 0!7+U8'V)$6\NBK8S@8FTH#\0:
MTXFM?V\GAC)1M%/$2/!?<\S%0KT9?<[8;: TF16M]-G=+EX.AA(RDS(VU"?N
MUZI\118RHGV/3-4M]8U(4]TT;0+D(G,G?D<2+RIBMT/P.?YLR_R;C"PO"\G(
MT=7"><:81<J1 ]ZZW<!=O\ZU>[S$TZ/-J@>+Y8ZZWW!CS(#?U# [H]SG(G/:
M"#<4+XX*77U$2?ZSE_,?DI5ZZ1R^QO0<4EAG1D]M?>:#Y^NU]R8[=UJ.+TMB
M"-:_.18ONT5)K8S(YN/1NX:)EI/_%:-F(O4_"-3*B]P 65I,F!&13/2V5"/W
M4S90BLW&X]S"A1PP.'DQ#^FCK&2;P>9G23$7>W^=*/@5JT;\/XC[NA 0UQZ]
MJZ/9OYLBW*9"I+]YLG4YY7A=L#G#.ABO&JI0X^1O_*6Z$.%Z-[(O;E[M:[J!
MW!WDSZ[G^79($7]/^N6YQS/@1[7/N?*AYK#F7LNBU&]K\E&.7A*[](*"]MJK
ML5JOA =1\#%N?]QNV>,32Q)#UY[/W]P=64G]^*CS$AR6JX\J'PZP5*MSL+'C
MST D0V(4127=<Q] 6$GAX=!G0.6*YI+E>DNBRLV3K6O6$<-/:T</GKD>%]$=
M0SA2PZ:X0%LQYRL*;S9IB)@P4XXQ*(244FTL%I#6<-<:H&UE(B657LV>:UR]
M2Z20*FP"Q@5]:VRNK_8'.=EAH*,B#:VK7;(QH,?OC2KO#ZM3C'2O6Q&FF;"7
M:>A]S1^+W=TB\K9V T QT!!-LX=ZLZ&[3[JG6W=<8\0<!)<:3*OS(--9.^V.
MFR$$LWA!^5>#E-41-#EMY!.D02 OC7Y]Q0.1+L(. KLQ7E_.4ZGY_HI4&MVA
MMBVA9P!\6G"=R .^@:R6VX7GTFYZTB]7-5%U,COS]?7^^"XWYM]<.'<-+VD+
M:4(Q$6YN 3/0E>X&5Q3[?%11&<!/@8F#X_78*%J%%$'[%<^N"[D]APN QQ^$
M&V,+<,-V\_DNY>;%*GE_N6SKVI7P4F;!IY$:=W&0)GK>?18?1>5P'GP$"4#1
MK0@DJ[SB;HO\52^W!K2 Q!YYG/<J#]JB?9"&FI;ZAD_=/XW4%J\[-THF;VR/
M%+.E<M26#'RZR#/O^-7FDH>7FVW2J5C  N[I?\[C1NXD>@]!];4#6NZ8U?#M
M;IN (7-9D2:H ]Y]Z1?E#3W\Z.,CM C50+Q*O33/W[!K'VY;@[;5-L!Z/]A%
M*!<8I/1M*&$HMM);EV+,MS$V,0GC@O!L(RHE,-O^'F:W8>;\: UU38PT=_;"
MG S"XD7B>N)<VV+E[DD)$OW)!1KU-%H2D3?J=H_316E]/_7.VE($R7;52)X!
M4P:G+_5G\AG019__TG;TE3\#_$+;H3P:> Y8X'5D^X$V36*G.[D#FFG1[,K0
M/P:]6"6 UPY%97@&0(Z)ST)?!O/+\S^5;../I)EI?=?JGALHY@1TD<[83+O'
MMBO_S=PS@+1?]SQ3.WB>MO*EEOZG=R;^BU@[!]?5OGM#!7.\\H!U;:ZYU^0#
MT4*<NSL4Q$4A5Y33]&\3L3)YARUL:&@#&\GX,L*^.XR#S;* 'P>R_XLHU>0.
M;_RFE#&W_-JCQ2\(C-9&#7H9,0!FIHY!7C2-A>HINEJ<D7B.^%LF/]]Q20*T
M'KSB/]NV H$2 G6.I_2+YO4+L<A>K\:HXG--C5_<U'H6^81T(W![$@E1:WL9
MYS.]^Z%/,\/F]^8KE-GF[+[;YW4?F$\MK[IVJ1JS-Q'6(4$NF=KXG(Y[]/Y]
M+D,5G$K#6'W,*[_ 42DQ##[_C;3&*;W&R?QF<#G=MDIXB+01RCL]EDOF-+_V
M6OG)ZQX91-IE"Y4)Y98 W@>I,,W*70 +D>RKS;D)9YZL]D?:5?AGP'@[\!G@
MO?<,"/!8)[['/O(Y7;;L+38#K["E< >4)$BDCE,,:0'+E G -FREM'*_1#P*
MYQ?%1;_(<&<*_& MZ]H;^/NKQ&?EGB\@]^4I\NFA\%%DXXFVV]U@14NZ&E=4
M+X3Z3>XMP=.JDH+6X84<52A#0J&IP<*)3#52<EA+2@$M*CA0/^:S1US^*<*@
M)0<4\]3?9T_W)0;:'?]F?%VYDXR #*)->:F5L!>8=RCQWA"\  59AA]J=] #
MEDR847Y?+X,QROHS YX!B+== E>,+R&UVB2PK@,1@P8\$#_<:A27FQY3*)25
M&NCH__ZEE:?E4\4RMJX$*IC77!:QX-MN46/Q*0K85G%Y!CA^B(4H.&.+$O^W
MOG(,&_HY>H2I;!AC"RAG?P;XG_;B'??VI&&,DS54!(3<W7+AG^]??AR3Y6*=
M93GX)"'FD"_W"J)#Z10DYOMNT^).>K#!D,A6U V3!L(BJ$X2I?[9E6F;8X%B
M:&T+N'/-IMFY0I/<XZQ&==\EA=\L-L]<%154_L7KLSV/:F]=8XZ.EE?:K$IE
MFL_=-F87B[?@3I:\S'*I^%:N@%N."1JLJZL(A; <&1<."V,Z%0)NY\/*[F5^
MY-L],L.$(YD=LK]JECQ39"N8P(OFJFDGUH9B E2D+GH&!*DU" +'9#K2!/ H
M9AU_9H2XL6EB!.I>V[-UO?')'&-M3?& J\II&WJ(?H%$>($@3S^T&[>+4)O%
MW<&P3=R':>I'TB:TU%VOX):N9"2W"\.RY8:'E135X25AS,:&&-/)=\UA81T?
MB1KW0WR'5<"U9%U]T)F]\I4+*K7^V;>1)D2=1V:,56U;ANFPKHX=%82\O^-"
M RZW.B@ <BLWQ''B*RCC&F9&%E3,TO#181>>'==C(#5=G8G-RT>01J=GT,7.
MLKW?L+6WZK\:CRI&*XVQXU 'A-K%YM'W_XH/#\X;-".I.[6E,.!:.AK.IK">
M<Y^$T$TPOZ+[YLY-/O%;4^3+QDJ>_+$DSSM^;X<QT,&K4GP^H/24=DR_0DV3
MT5;)A^+H.SR&6B_F/J/ 2X6:^CCH@0QW-G$&U5_J%_K0/$2G\.)F?/H>2O5V
M]4D!^[UGRLGFSC7%C+^&3 D3A0*^?S@&3='2P.L?'3 [A0Q.M/CD\$VM==]'
M[-[%J^A^OF>0XQ.3T^B:;?'(-$VRT*8_PJZRGHO2&"D;F3OUZ[CF*\K&]_QH
MII1?)(&?/C_N,R95_HCXUUF8!VZTN_V7#O2'XC/@7"76KG28H3R/(;G(5$[?
M(;5+RM<X =9OVXK3^O>]GWH21[C.;D_24T0A97AN?"IC L;(BHZW ;\!*.Q\
M$5,C;K0<6 @=]8.Z:_NL*;<_JA#__9\*UQH"#V#35DQW@OM4Q>>8Z\=#8EY:
M'!H?DQ=HYF-H/Z/Y<^#F:$]@-W<6^N;/(1J5IH_-K_-O'(DO)U]:V==_#OD4
MLRA42BWC*U0DYCD%BL3!)W8_YAIJ<?+\0.;D.M:<EGO%9JS(K[ZV?Y*?/M&_
M_47/H3A3@SD0.ZD1UM"GYZ^&^,5,O847/%KY@T<>Y5 NM5+E?K0866FZEV1M
MDX7;#TDJ2<;U^6<7K?#/'MM<0?#_\@MC2'ZO7.:P%1!H:L/&4V;@;P(PP>4\
M7+U@B[79> :\_V8>7[=",A[_T5K3G*^"3FP+E&[7F6\LG*)4.>7S3_W$;E#*
M'Y_^G&GB:'H&;,99G\I75:A8# ][&%D'FJF\>@1]:J_69'&U7L/*,!PQQ.?C
MO[$3+T7\G_7[)J,K'>^Z%JE0XY;S*H8M5>HSK^];-Q#WJF)%<^IZ76M=DO+#
M($'12+L\&L:;";7_:9PJT45S[3Z^/.A631J:I.6)I*&FWP[$M<Y-CNW8U^0>
MS61KBV*H>0 Q,X\T&[?]^BG.OW9]E=6E**.-]$^5E%ZJ(7GWUVJ)'"'6B-X5
MB4O:Y@\QZK]C9.44+:3-G:-*6UQ<9H+MF-^J7 JN]E,*<9'EU$Q9VMP^15RL
M;)J@; V5UQ_Z]<(T,?NLPYVU/P%*?$['LZ'O?)!>"C'B"_8A3GB92$;L'HT5
MSI=V\'CF_:LO-3DDH@>S6HG.=+E%+<F1J.)WO"OL']FZPN&ZS2_@HJ!^)(%B
M/P,R,".?[C%\NM#6?>Y??7L!B$PEL4*MX0W*NHA;"0]L?^Z>JEA[>V9XW+Y5
M'\EFNV*SNMB?#$Y(XL9\Y#%&JB_ 9XXM:O+?B=*XY;AQ%H]T<8&%WX6?',!@
MNL+E!>M/'3$P:"P@'9J9R+6^ERP9O@;LQ,V=A)5#A!X9GP&"M,0/5Q]?/$;<
M]0RX>OT']K[4O;^?E.JOEBK .V!;.D-XY41@KU9 $#FB[)Z6;9.S7X]]*_WU
M,]5.O](>7",G<3BVOJ/12]?Q'WJ(_4U!3! :#J3M8**61P!-^"GIE9XNY=!]
MY.\/UTC:SN'E0D6F"@>QI-5?!%RI>;X0%_:)9>87HB<9V?SWRM5:L?&@"%94
MM=4UTM[Z,Q=O'OK)I[J(H0>C%@,K*F563:6M"44=9J/[6VFKRD*(S_P@NM#O
MJ@*W>PI_$.,%G/?>_ '3 '/^POQ^V_A3'_/J0=_HQ%\L)GEO[<TUDX<M/K8L
M%O_4B\R[T_KX",(&-GWB"+K*C_BX )+\"@B78G\' '2,$=!$9A#]RA<"(XWL
M3&&E\YO1S<=24[OP7K",N=>^N<X%-3;4-_E^PZ88)/CQRYL\I/RI-?M(##I=
M.4_:Q;'P =D+CG=R^VLM85\XC!21+#WVK<!!F_'3*M>=VV:::\Z+Q1Z2BS1/
MX>Q##B1+MKM<NVENQ0D<,_&VP65EF;[D$]M1'P6"LV9N9NX9V2=W\']>AD^(
M$W@;1*C,<0'GBECIF0P#16I?BPNB?W8> MBSIYP/\GWRZT[ZTC4>BH'.A#R
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MQ:+!SCFR0_OO5>X4N[ U1\)/6MZ@E=U$,PW^=(ZN5E&HU+>%8^V0$5%U6U$
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MI* -M !JB66V B; \(FJ4MCF=S$0Q+BFQ@?=C/NI)@%/^T!+!+TGZ(WDDS!
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MC[76>V",G0W$76U^*OM]+,/#XZ?&&[/: X8$]7K#^SYI.\EP'RTL!Q'$HS8
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MG$DCY9&OH360[K3S0ZM\/+I7"_ 1  "LO5H(["1]R4SA_Q\>748SW0OXJF=
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MWRB5G@)K%FWFBNNK[P_ +=<-Q58U"WJ*A2(Q!8E++-&]L04#(W.B6;ZU+G9
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M[N30,]T^G9 GZZ/NV^Z] -ZSF9V]C4TJM50L:MM]FK6#RGU<PVGG0*27.)D
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MQ-D:S?8:$4Q:X+U.8WROS8/49ECN86R"?8G!MO.;SZG7D[M1'W:%*Y,=VON
M3!N\35)/0)'EE^ZY6HN?YUK."UQB%1H1"_L;'LH1OPN70"0DF3?+"U!/3UN!
M>O@7WVUQMN%H8G*:%)]^UOI1T2YWHT8LL"I6B>J-4K@Q_K2KE^$7OI2=>E":
M4HY>)K*2,ZJ3Z.4EA-**FUGI17ZU;+0/GC@LS!08+N6Z+"14]DJBK&3^K&;5
M(A^Y "[@*AB9).G'0*&EY2_99J*$B-R3;XZ;T4J['FA/[K6!&8?TNL_W9E/:
MG#%V#C1.O5&W9J3+[@K.BVYVJJ$#_@>F)Q[1&VN*Z!ATSG<*#M4J-N5J1+%.
MM7C/6/<RZG[@>]2#GC6(**(I20% ._<454?XTR5S4>G5]3I!M[$HK$(4?MWZ
M\.)/GV#LWXQCM2*1W.3"DNB , I\7&N+1Z9D:CY#'YN0(97UP7]W):B[5B)R
M:4.@1T! X!I! <2MKG?8X^K=BSO 27(\+_(<9W VILQ;NVG8J%@]T0,3H(6)
MV/]"".Z=^9]6SNDL:+5>FM:::)QU] E0.%Q?)T8I'JZE)I1::%=S*4Z2^7QB
M;GI:!$D2([WM+PEA0N'H$GQ1%LSCRC/8SP A)=6JID-?6G5$]8K)0)5':[8I
MH <IIZ?6HQ#2_^]GH2?:727"1V=("#$FIJ(> .EL!K![AU3KJQUNZG;*K%,5
M-8=^5#Y!_Z--$R=JR2>V5P6W.XHCK]"B7U+E?Z<N%2B(D#>RZ#VB#G!8)##?
M,<_/NM]K[OL:7-N/]0!P50)=A4P5"K96F&1J)0UN?92I?U-8\#5B5$J=(M(3
M3994$-?781Y]??^(G:.L!BOG>*VE-6TX/A<PG?P$&NTTVH9"+,R]W 3$-"O(
MT>H7_DE;%9#B\RTJJ@_@%:,*))EE&WII0?:U()>^,PB9>DZH-0V58BV>E=LE
M)QR#.>-7#+GXM3=:!_'2P;5WE&$'/Z2)TY32!LQ!P%]S%-"3*76!>Y)++P5&
MA?):RUDB6'(_VD3QC>G<U)P\GBL="BS,UJ?;R4'%B4B&F+B3D@B+S6A<J$12
MJHC.TK[19O<SCK/O@"+23M'^ @)8(<._9%%(W.F\>"$RY8G#25F.4V_S%)JV
MMK$/B2^-+-R:;)LADK<_UTD"#^VLZ?96]"!8(D5PN$3$T4/+*SGWFHFS9[?)
MUF:#2X&UY>P9\;[QI,MB $AK;I7#08 V0UJ^]EP-(L^5,(FXNKJI81&MZ=5/
M%1O.,&?&1<;$/:;,7=8P-N"O6$&KAB*+PT&[2;+<11&]Z,(E[V<HM&5VEO2B
MI&81FT1N:LYDON1O$RTMI]:Q;+$XT6K+E07:]ZY/]%((]/PC!K>\ &,..WH?
M28<1N=>)/YKJX0PG]!& =KU.DM[\C3QA;(F,6^'Q:H6/"[<+%FX_:B.N-'SO
M5X9T3'HX20 @"$MIYC_'TOQ^N0B(I35J#F(]EA'IG.-,\7D=#Q!KI[!A2:'&
M=% ?Y^#)@3O:&MK31.T^ ,Q4?_Z<;1731($E)V/N;SY& A%2O;3-V1:$/1+O
M&<&:G"/_UW)@=DGI=^G8!5C)/]_91_0C:SW>+Y<(_9HQG7(X^UDD$"EG A[_
MN'$9?Q2E0_#XO%@6M&8L\%R):\MUN^O?Q_$83M)F=!QH,&7^'-(QP/ZL[5)Y
MTV4[:&/-8:AE+&UR_"M?^1UG\FU60S;BEL.D;)M,;WZWC@26>X+T)Y6TNOU2
M3Q,5Y@8YJY,2\@]3>G6IW=NMH:RCWV_[O"[%-,32"7.S4^0Y!L13A*GRL"4&
M&N*(B]?+VZEO(!GQL72P' WS"0 @?B7C-IL9Z@_1$\;(Z<C?T70Z61!K'&(C
MG&^VRJ2MQ]-]VO!BD&*CB(K%0'P,W"R4J;W%!V7I^):CDD-3T<\8":"\8Y$.
M82?BM&KF-'%&#E*_[&=K;Z[TSP@GC!MD[O#IZ[$_H4+6YO_]OQ#_70C9@:[Y
MVE+3S@/>3ZJ]-PURU.#D0_!,:+5*'%"#GSK=>J2D^V98<>U&.ICD^KCWJL04
M_<1J/W=WG, @\[9MB"P;VY- 14W.I]1%NE>OU?>NU/J;=89JJ"/H?<QKI?TH
MOUZ&_/>=*5@W1#"%'_.S=['6HBSQ)K/OHL)J=T&,%N<K*"0E8!T]/N)R<X23
MM6?^2*Z4CRZ-&@;:/'2>=*6!L48"C"0/.I/EV3-5N$&]$+CA">9/?"M+RM($
M".CEITWD)?)_)DIESK=5P#R_C>U(;HLV*/?.R1[>^G'#%A@HPCQ[R:T828E)
MRXN8)XS9.QR,HZ7V_F_O7LE[Q&E\KI;Q!&NDAEU(N(U/*(HO8%19G.2LP)J7
MA5) I:P,7*(^ N<>R">YQDXU@_-P9QR6IA#5%%J$F<0J*+XF[.(BY(P!8#\)
M.\:PLV2'+;>&6CJC!GA^<-<Q_Z/V_-5<;)U_\.A _:B!JOTB+^R%='>)<2-Q
M[?K"&PTYR:**9_PTR4LOU5<1; 8R37">JSUKU6<IO7%V/B2%4;Y7OTZWW1RS
M5#8E+)=GA8"O#';&^@4:6\)!$:0![01,)"2CAY#URJCE_;!$)IADG9_)6%/
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M+$$JY'CWO1F\KW]42P^I4YG]58L8$_L1$_[TJ=L2MEI,$LK#]#\!4$L#!!0
M   ( 'B"7%;W4<V[H1L  *0?   3    :6UG,3DR,S(Q,3(X7S$T+FIP9\5W
M951<R[KM:AJ'T,'=(3@)!$V0 $$:@@:'( &"NQ/8C9-T< (D!&C<+7B0X$&"
MN[L3W"7T[>R]W[EGGWO&V.>^,=YXM<;\46O5^%;-JJ]F?1,YB5P$[BK*0>4
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ME<7I>':!8$='.909;XJ$C)G-WXE+YY9P4G(#"6@A@>9+V#=_P<TBV(6\"1)
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MSZ-<G] ERKHN'(1L&7G%]8YZ!,^L(0$KU?"-TH5^*T>,+3FW:&A>B!;#[TM
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M([8W&8LCHC/?\?TNC?V>SVP'C5 *0+( 6#)9++5J.!(CF4(VTLE2,H5-)M,
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M ;:,$$*(X$K](^B+%NV5^!? 40V0*$1DP95H &&H*-H#R"BR!6D?(AM7%(X
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M/WF2R>N30(8_YO16G*D!WAZI@<D[?EH0/>#[.X+H <CAZ_CQ\2@^/XGM\/I
MAPYBTU+@AD2S69^$QN)0* R6@B<1<'0R"D6FH#!$/ V%9N!0)!*.4CG!'[+^
M3BSMS7FX-V+U?T/L>ZR_$RN$M[9F!VA[C\;OAV7C:#"@D6 4P5 8- H*14)A
MR40<"4G#H'!((I7X5O8G^'^G0P(Y].8*/Z#:0*\WY<U!U;<2/NK]O>&0QQR
M] R/T_X7STDE5WI%DOD3"X'YLQG['>NG).L_L19_4;+^4_/T3K+S'R_'9_D_
MI<;SF17Y9.]'0/#ADOQ^O5AFK\_I"7_B!)P4<O\[)^ J@S4)U%5BCA>$AU(Q
M]/?:/L_T":? 8FD,%(I.H&((V(JEHU"H\!PCJ10"'8-'X4AO97_.*3Z0'S1!
MCG>'$=$R%"X)0TQ"H=\>1GR/ZO-"O$Z#+PAZ(+(17L(_/Y7X*:;/"]>90(<1
MTJ< ;QG?-ORU!/'?8\W^'/K^\9K]_A#J__@UB[9^&'YO8_FC</W7<KKYG>V?
M3JOO$40/*K\_N/<ZD^"=I\?G=XD\3H/9!J6(/&8'#%5_0/%?4)[(1']R6MH'
MN(R?J5!H9OM?*2Q@,LA1\0:!]S,%"L/QEPH4AK.B+OG,J>\_._+]<3T#VYW$
M KT*L]>LM4'" .1Q54Q_BLSCARH]Z',$?R1&Y@$=7A@X((<NG,( ;=Y/B?J
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M++-50=W^;G R]C="A<2U?!9&<G3[B-%9,;YS-A9^@]H@A6O@QZ0%F<5\[>@
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M!:"CM9;?**<+IE7D$"5YUIE&V./ \5V8B+^$1&W,Y:>_EN.PT6W[9U2RT^E
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M399NNXLYD<Q97(P</FJD3 37S7;O=&[LA$:))>4*2/G(]UN5SWSL&\0#A(%
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MNNK4^=<YU5WG5/=,8\>Q<\#Y&^I:Z@ >'A[0C4L =IZS4@WJY   .CJ (
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M\,^=^_G!$0'N0TCR\]T!A&3$Q$0D%&04%.1DY.245+3G*:EHJ,C)SS.<I[E
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MP9Y@JA<8T;4XW2[^.W3+_&.0 GV[(?\=3Z[_YM?6F?K_]ZO_J5$%)ADCT;7
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M;/<IQS]"XI;1Y)8MD#V9>W"4.&Z@(DOZ)5E+9F+=OU[):MF#]"3_['W0SR[
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M>S.S1<I$SJL8O$][Z4KW1R*1B?PC ?^U&6.0Q*G3'U_.\TBNI+6C,<R=2UA
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M[*(BYT%D.8)FH!=A@6G0C="-=:OD-O:K!V VE)'6B?'@\)A5:2W#.W4:A@L
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M.7!XDR.8:@J:W!XD,;*E0HY6:>2X^ 5-3I5Z7L8_]&8G9=7="(?3T[9\]1^
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MCQ N3O^L^.G M-ON7E1L?71P?$1"V+FRS-,X-#>X+0.EYNUJU#YYVG60?+"
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ML!HWN;K#4.W2?<JT:!6DU[B563OK%>[7 3O)1HIGU Y@=N.K4;2%[;P%H3O
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M1N88OEM_>?%F1]*F*,907,EU"KGJB;-)*7^N<1J C+Y5CD[7%:EIWE03#R
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MV?HO(4@/LYR2=D;@T:<SPGB#7IN,U>BLBG)<];"^YB&(D#,<Z7F)$G"(VR4
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MZ>65G&JS@./"'6E)LTD>&;SI>1U"?4$.NEEW4/99BU"B&Z2>PKXB %<11SO
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M_;>Y+?\O90)^:/ %1P#0/-,(K =Y$W*?ZNB0!ZDH;(\3_G-#[0 !"$["RA,
M99.C$L]&!.!'O6LE:@+0H_^CK#0,]QB^BH7QX)3Q>3;F?[FL\1  O8U:XK(>
M.ZJV&/((JD$ 4KJ"8&B)!0(0O?AKT\J:,]:^*Q"YI8?[4>6:F*ZPI^%97:?6
M#QEA/TI7VQV5KL9WP3? 3>!^:"$1K#IX& PU!J(C (N2* B.ZN@DH3?XEY8#
MDU_I_ ,?R#_Q*9XA+A_--D1H]0?,P<1DXQ%.8P0V[?H/4C,U+@3@>!&V<-I)
MEV6-F#B?:#E+!J<W'P]\8;A3"IY@W*?](<5/"$"GP1\XQ^)9G7\;?@'?<@21
MV6MCMXMNBJ4R!Q,A^B"N=G2I[%(6[,ZF 9Z#$1.+#P8?'==R(Z+"?:2585AB
MVG,==+1S4&Z3B)3C5N[1?'8/&9V/P_Y9T3OI1T5ODWK0;Q6]=PA J<LX<N/.
MM_TH9EP_$7!EJ#4!> <_.K7$X474P1)88VJM!*R[=0J&HZXASL[X4/!7.D=2
M0P,C"HWJ[[7(UTP]G'$OE=*"P5(P5 ^$!;QHA0;CR<UA&R(@]&)A!&)+' LB
MRF$A>.\L\B;RY^Y'BSRYI5=#^T<I\[0# XZCLZ0TV2AX)P3[Q*!%>Y\91T,4
MN4$$+EP5)R<TPW](Y7=TS&RE"Z]<V%OX*XE?\,#WM[H3@,_7EV6L_E)4P3\P
MO?W_=4CY_P'I01?^QK\-Z<Z_0 K_CY :Y.(HB?KB#-7 6KOUY3CZ,2#6)NTV
M\)\]'@\-\7Y=&U@YQ$38??+-^J$>/N7-L#\(7V#;2<;*L\8[A^%/$H%\_\,7
MZ";;12460Y[J-*"6:JT]:7#BB$CP(O_1+L,;! !G"\=:@5EAW=I7B5,():+?
MZ>N,0IR]/W&I9VW;E_1N\<#6FX &MD.E)\D4[D7Z(XMJ,C8\A3K&R#@7V'U+
M_5?R7MQ0HAF@LIO1WJ=8!&-IP02 )0W/W-6"V*+OAJ&Y87A)B"W^KB5\C5W5
MY>#2CP_;_\</%]X\)%HHN_4S.$%,W$!^KOG2J[.]0^H.N3;"$0>):J_I6*68
MF^R0+I K:QEY#E9"_5J2WL<"C,.5&0Q8_OYF^?_4HVE[4L+W"FX97"HJP?AF
MJ4NV!:S=^$G<-#'L:4$/">\9<A#<8EOQ_<K%![@"\>0<Y7,Q.CJ^[R1.>/$^
M;5L&LT)D8&Y(X7VB#@#JRLH[S[Y$;*@#UNXX^ULI%\E,R+%%S<3VJSMM.T)V
MP>>\HRA:2&1;O5TJE5?J6URV97Y4C%4Y?_I\77IT1%*49'+-@5\)KIODQ]9)
M+[1*X&C"?[:9<G3XRR%<4M*@;@ R#HO>F^/^V-)L0F[/3N. +F34) ",Y_.J
M/9ZZ<<=@P2T^EI_Z7WH]\)DB ()H.*._@GH>T0_!/X.W>,Q;*5;T7=;&<(B0
M_,Y+'9]6"(!"VF_5NS_!%E["=HGZ=<J9P062;3^)5AK 6Y47XC;@>"P(I;)-
M )*) =@D*>Y"C4XSJP?NV-_O_L_>G0-O? 5#*L -T08N=9^G$'6/'<NQLFA(
M,YBCQLT"I7W*?MTM>\QO0QTA1/;R9IU"GQK)R= 6;=Z8G'?C<;>T'F4Q79#G
MF[UK(/FQLOFB4&1WSIS'Z1XKN+DJSY):'O.4*HL,GKCTI[;A(Y)3I_!=>%[T
M0 14U6+:2 I&8XQ]6E#2X1MWJTOB09AFDR;S1JB1G]F7/<&2]4 $R12&Z++<
M8,S8M):S8!H<6?IX<]:8HT=\W[BZFZN@FOY$+[.*W8L'=[C)]=5F:0)("ISS
M=7;\^C6TKVO;B3XTT^9O_?XL^9:-NM +_RG_K"2:G9!9^^J6J;,,MKS ,>H%
MSK@U&"O8=OPR:MU_2_NYTBE,,Z+)^9B#AW.&4K[S_1U)(TBVQ\&ELJ\=RZSB
MGXRJ1;5(52!-_3653!)>UV7$GM8I<"*_EJ4]SS 6R<+2"Z2OMJJ>2PA(%R]V
M$BD1^ H<3[)2(.WJ[GUG_Y(AC#LK8/0*9;T,[]82Y-82K-B@06#;$7+:,W?G
M9;<P5%VXJ%$Q,SIM;-G8N"3B%-DW#]Y;;U@\BN^I#'^5'F *(@ V'"J#,P:1
M4+:9T;+>/"AE^A@VO.F./=]#SN\MXW37A)\V4-A&W9?V2G>B:@Z^8S$7;W'5
M#.)4<NDN:".9I#)>8N-:-,F@-U44#3EIE(KL>K-B7!J+YVW11Q1PEAG%UKUF
M'Z8U<G168RTEFNAT<2Y3X8>ZN_6<XL'K!](TM'G7]4I\U*'AT6(Q5#8:J.YW
MP'L;K@>ZVWA1'']/+2T6U##@73(8BKFCMUEZVD3%3EF3KE50A"OAAMUEN@N;
M:A-!3"33Q]]+%SV93W.:?)%Q4\<XK6WW/Y%.]Z5)]$7DZ[7_S!2HO"4 P-_O
M_X7OZTH*47FYS"#;Y#S6U)M)V0\%3#_!N) )![[$S&$R@G_5=8KJ= YUZK4H
M_[<W%S%[B?O6G-N;VCCZ"+L=632UHAOH4-;,H#?FX?#&]AHD9KJTZ:Y&-:[K
M0_K8N[,'U)) DT74"<_CW;QDUY^0#X;MO9HF7\M (2EQYCVUG)XPE4\8$=P(
M_FVJ@W%D2;#BY5OQRZJ0"UFW1PN8K,3A)&K4I-]5==8(P!D%EPRH"%JT>KKS
ML3./9N]:\K2[RE7A)A=VEQ#!?*&RH1YUMK??J%,_S-DFM5?VMPI$W_4?LHB.
M7M-:@@@O(TH)0#B.;L3C.<X+?<<4#6\,SVU#P6@UWS>ZN5I1Y4#??W]@=5T8
M+![)H6%#R;B'<+C<%VO^,%B'5?SM[8\M6I1GY*A IL=4V7OM\UN??$ZK4&=4
M6X2QNR317>CD+I3E<!FH"9DN;T*$F=-B^$JS OR(L6M#?:]U&9UF#JQ!TS%S
MC_ZAQ>S>XPNV4Z05+IV/.*D.<VL\\J$>O4IG/=.FFB;.?ML^+>>DJ_$:=YTS
MO:PL)V;/5:WH&J/>7(3RIMP+L\>R+'3.]YQ$6+9ZQT[@3ZP$=A, 'FVZ8^\J
M@?VP/9H61.FKB"<L4/N92,DK/=^5SF!!YDIL U/5B4\&"\^K6X29A%^C><%C
M\/982^<KVDKAH(#"(J@/MM(+7=AX<<3S8<-IV+3H)[&A&JF4:MQ^9!=;^CWQ
MY^_@$FH=/2FW&=J"OO78BEI[UWAH\#[W9_^XOM:WN8#NU#0R!HVT(.S.9BC0
M+^NDF(0*3]\_YW7,O]G*[G&.AO6QSA8)38=> 8'4,.#OYZ][K.M*K*E+-SR:
MG$]?/3#PZZ[:;1PWN/LM#T<RI:C4N?WV?,-WDSMYD^8O*X(O!'RG&Q4^NS=C
ME1YULTS%<84R9&/FJTL;**$9&CL-IQO#=\!*52-PSM,F0JU8BYE(B:^.DW0C
M2S%CF=&^]W.=&6M:Z#IREG&RU\SFPZ28HU1RP[DU[B1BE] &*H=14/Y,J#Y6
M20PG1?TT9[C\^27#TC<)(E(K+'P;M^AX,_4V&><;Q &N1'T6%Q9(BIM8Y!FL
MS\ZS;C\6!U;-SH^.(\*#5>;(6M6PY?GSECOWO$P\A,5+YB:T7WF+*5DN-"@)
M0!^B=]?>GWB##D=5+2=^C\Q=/NL\[<QX/4O[=&:<%=MGA>B\=4[+*JO[J>*\
M*M(3)[XW%A]6UDB]7U(ZC48T^U)_<>ST0-46<19)&)EV414OY5V;J),^0<)[
MC.><15 H+^^+4\7&WS6@U1R'DZVR;-.P2)RX!>K-^..N^EJ0IK9>;9_UI&SM
M(YL0[>#^%RS6GG?;.)@C7EX/EBD04S_,5K!(P?8ULH*;0<]&0AK;:>C-I!.R
M',_N-[$V:4#5:$T^SY[GIK.:XXVM+FMVUP9C_2;/Y!&]."P4<1;'D:XAUDS#
MZ<"D=*XH^/N8J=FH4<(-_6Z5C3,/]85LO%+,WFDGYA1=Y ,UB$G!3RR;2V!Y
MDVFQGS'\TV49SC.1=(KZ"TVZ9DJQQY/OM7Z?OR&N>=XLC21=R=0U,+;=_DO$
MWO".6#-\!-*D= K;:8\>;2"F@NLXWVDA)$VD TW1<O1P"[.IA,2MWH*V-$IZ
MQ*6BL7F9NO99L8@:G:S/F/8=7PB=)W/C3*1ENV',",;-Z]CBG?QGNJ:C'YNJ
M10,#SDB2P,4>S4X7&PW#IMX]?5GXBNA72E!WK:Q@CC0ODJ*TODMJ8V?*\6R4
M.XZW2$NP+RS*%LBUM$YXS9*V;7$7SZG4= QC\S%]TQZ!T*MYHUB-*??\&4UZ
M]4"WE@(W3^$1=867"3$#8[F?'Q]KRXTCE1!*^=IK#S4[T+\_8K?:1 !8%2YG
M:A0N^=T2._'V4O#7.SSC?&G7>1A\,_CL262$7F-EY'/GUT/-)0]4F]<Y#7%&
MV#0,6UWBB'GIJV<*M.BML:M\^$2* V$,<Z_A?.+<J,-<W, -:\LTVL:W<PFP
MJ1<K%.,+\L(V5OICDM/'),AY/79F!M[&12M\7=U=/XD?')G$G??C*,.T-CB?
M@2J@7X6NI_<]$?'1@=:\.J$9CQX?.4[S8,/_V&R9X>G*:Z:^LNSM7'<"\CP%
MO0,CIJ9K'0Z+/F)PIVR$(?BS\<%+I7Y.&79C6N2D5(\;2WWY6%^^$%5?&9IZ
M,G7P[69SR\ZWY'^G?GMR.7IN\9$MY+O>;_7;FY']B'=X/922, &(CC4@ (4_
M$JWO0QM=BO"-0@J,.1C%U[]' %[]:)\\!6/-_>ZGT3BBE='A?6%4<7%X'9)E
M>'"UY$Z93T_Q1#@P\ENCLK\3PUKRUH/=U#KI,/<N;VF?GGMLRO)VG]@4%S^<
M3GU;/!&9O&5XHD=K>%VERUN8]'[6@]TTNT]G2?Y30IFD+->%2.OJU]:V&8O3
ML;'&Z-F1K!WS(J\,C6SCSQ:>#^RL#Y337]MSN^FS3<>"+EF?<8DUNGEJ-O#K
M25"<^R2% :K)>WL,3#?:#$%'L:ENT#Q3ZGBELM !$:[J>BE #Y-M<ZK@6&%M
M'_<V': K'MON&M4YZX8]0ZHN3_3-[[M-U^0_IJVQ:7,ES2+>R*PT2TZM1^#9
ML.T['@-X.IPJ1FK7?_# %VJ0ADUEHY"B-.*C%:F)[S-IN5QTLJ.^G.H5B\U&
M/R@;B\$X[CS$5J(.F4>-H+=+!VLD46HULN_RWF?FIR/M# XDQZ'?6X6Q[G#[
M$2U :A9Q<IOFZ0;6?;YK.CYZQL17GVTPN4\';=.<>YA*'B5U9DS9=6->.MR[
M:J-%?WQ7!>KP9+0A^XN$IORJ6^7UY&63Y-TL[!T4_!G,"C+"W85:AXO5\IA6
M>SYV7+NIR;=U8*A72C][G4XC@?5J@M'0V]<Q%RO.!4%UOW2OCXVR4$":W-MV
MUM=;I=:0;+52GB;&Z.0$]#K*/<@7M1["ZCO5G^08>YBFTR\E^?"<3^6HCS!$
M=(Y6^1GO*YZX&PT8FN=*C!H'8$\/M1ZH5*X)SC@ K]+OMA(Z9*QM]P8A<D9X
M:()TU'6V4& LZ?0HZE,^9>=[)7NWTIW2S[D"=V/4AT7?H9E0BN7-- SF7=-.
MN@N-"&H%,--HC<:T]2FRH(_OQ;-E&C4D21CN'X\PVCTY.Z3LCN<^S/^^+39B
MTH*D72MY[5Q"0]\J&IF]>/G!0*=/6HD]\+RJTM/V?NKS!&[7,M/D.P+C!"!,
M2=2O7>D\FB8$1U<&8RJ!4=T?S=00N6@???@1LSD/&8M9M:G@6CV.*TH996U)
M?[^W,"T$E7C3DFCL2;?9HH\_<W\*W_.J*7I4TR^&(NF+E1KGI2>T<8(1[:_$
MXH$ ";BB0TS<_9L#[GW[_>&)XC=[E5*P'M-%,RO@TY[+K0T74.NDGI=O$X!G
M'JBL@'/?K*L<)\^.RVF%>SR:X_6\D=49/1O#,%+$':)T_U6[DH)?ET1])G:E
ME=6CB9+F>3)WMQ1<;)I!>M^ZRJNWE"UTG"75X]0KG3?1EV#5>J-Q3J]M+WR%
MWCI,8],C"IRO3[W<S?OXTVCE_FJL=J-<%"?EW0#E6&@N"UMZLI[$30\FWB")
MLGZ'E5IAOQZ_8]^@E!A232PL%1LS:HA]FVVR["?H3-?E+/(I_/JC78W3(3&,
MKUDR[EF_MK.D>F\GG/1MT5) +V))5149@X2LN!KI/4O=5K+Z3<^WM\H4>O[/
M&P@B(3@DXXB"]^;(:U %&*T%VI-$  1@3)4 :!GH;26U5RG8D?.0L[1*;4)P
M])%E^%8E$J5].#ZI('=)G;XCHG"3<>^\D/&V(F3>]RT(U=J]Y[R3AYZ(1$UB
M[]BI]ZY>(@#EN'L]I9299<$R-0<)"C.\'5?89A]0%;73-GO#U\31F>LSA76(
MLU@VC6_W^J0X= 6:F)AT6+CI5.5NY7*QYQ3!+>Y1W!XF>7X*"IN!UT^."$UW
M/2^!G]]%O2T+0A6>59[6I&H;\:]R>;C!]J1RCT5]B !<O$6U<.*3R:T>_&4'
M&*7;Z]+.._5R!DTW:HRV$K8<?1*VBJELF<Y\+?;#0'MC559#!#Z>N/5Q^N-:
M=FEU-WHR',P(OJ_H/&40^23?>2H^#E71%;P.+I4Z0#*,FH[R6O9,+#CEF:1/
M+'-8Z:YF?PT*%RSS>WKX)H%IQP=[CWR=Q_G4TD/I C_(1^6G\"RE!9FM0M%^
M)7*</1;E0A."%U_QHRS#.I^C=S 6"Z1;Z?HVS!NFEA)C$B3"2OY<W#/LQU7-
M3[:Z1NB)WH81JCEU( ][-G&^%RHTS;Q]<C9Q\^XS=;81KX<<)RQ?/IS0"6GO
M\0[CLY7)A%_YMJVA"-*HK/VV;O'Q0TEH@6C!]W3#F8!+9E]7%TCT'JE;15![
M+BO9',*=^+#AT\CG2,YM2D^1<YB,]:$G>A5ED:*6?4[D,06FZN?T7<_RPH/$
MG&N@U0#1.L!1A1%^(E#&@1J.J94#1?F[_2/,YVL^U2;V6)93%TJS"KQ-JGH?
MD<EX\\MP&YM)CX(D2AYT$NMX"XV/>UAFK/7*D3'RY<E5_"W:E!NW*OD^Y)R8
M?NR=['5!7H@[L;I:R0D;?2"\N(/!3J_?QO3/AZ.M[E:]:<*+HQ^P.HPISHV0
M552^-,\^N*73=B\TD9?L.16/-?4[&0@E5 LCM="L#O7*]#P!8<-I893"!A.I
M \_F.V=>S_"4[!JWYVOJ8)6NJ$!0?^'43:NQ$B_O 3/4GG&$G%7P13DZF:]H
M@ZDNH42^YZ<6R[?GFP4H=5)]+J$I;FK\*AL=KW(R_RR#E 7T+E9\)ALO: C5
MQ%K 4%W8FZ]N*+%4%6$<3'V?#>W-HZPC1E$#.OQ?KA_+T%)I2%?,?/[2K$L9
MJXJY? W[&4T KF+@(=85OCQW(VHN/ ZXP&TCPAXM1QK9MKC\R$A=]VY<(^=$
MS<H4?WT[["F8 B<UY6.FXF0NPLFO7UM!PNEE'3V7\"4*D%";%=7J*;&.CETL
MC1WKE2=CT%%+20T3 /Y^_I*'Y*-8 IN #.\C!^100]OJ>V;A:HV9>!9^>XX6
M[3N'\TN)I>I7SEQ_8/6BB.?A1<;'Y*9;2\G>N^^MX=ZTW3M*(449]=L9\W%#
MAD'Y5^]-K3V2AE^13(*)M>F*O*?-B8TW]Q ?<]UNUNYD[_NF?X-[+%0#J/CJ
M-9LLL^\Q0P#Z-<\NW+_&D U0N41X^\4IT>0+= H5#>65%9:<QBXKF9/?HO*&
MB9:HVL]EUOGI7FRNY(^P6YE,+%9FLMY(K39IJPNR,;_*3D?.-<-QL#F 8$3&
MURVDC)";GW#I@A  /4UEB6=6I:[_^'ZA>A,,VAD8J?V (<.-Z =FFX^.2.%V
MNA4^.V2=%A*,/T5-P\_,N;W9-#*&9%82Q%[6P-CY/RSIE):$^K7GM_2-CK_W
MESZEP7P\-^=#BXN_O51'WE=3/:;G[^0NC"9([2(2KMY"<&=2/J*YB79F@$YP
M]8/8H.V?+\IO\Y?"KN2CR5$(YY!:QJ[#IT>7SJ:)K;:CPSQ$^!LFR=34/XN@
M5J['KG2X#<8.&.FI:_L@..+1:[<H8]WHD>]Q^S]5MF$\/$X &L5P[#_NY8'C
M^!_\=LM@.P$@!R^^].0A !2C8+P41 __H1'OF[RP R4 K_&^OY:^P ? 4*_P
MU+ > ;0JGKX,AG. 'UT[&XC8NJE 2XPSUA#$G"CMT"($=T"S2@SKQ7$'_T->
M5/<;:?9V0,.;>*N]G9_J<@CM4Q" 8 A6E@#<2*L'8;6&"0 F!_PS9]O!H,U5
M</$"KG5S[><"0 9;],1$%(EVQ8>J!H#1;W^_N^@7OE:HP M#,+NN/?C"Z"_E
M/0H7^?$LL*F%0SKX<1A*WHX M&3_&6,#S+"N#_@NQ":HJ_RG4D*0;NVC*TCK
MN_;Y.$\2,P'WH_N/=/Z$M;R+! !A<8@ SX,1SC\5'T&F(/YD%?Z$-4,+ J#4
M>* $ZX I_5+I"'85_,LJJ$T6T]3WF\*?X2F<+5"C8D?K4O^/==G]95W(B-.W
MP4JKJ#; CB=/;H@>[0S)>73X&D]]6?O9C[U*[L0A(G6)K+QS/+AXA G/'O87
M,D0D@N\=[2^Y@?B!(NQH=5__V'[#_V-Y(;\O[QK\0"Z+""OR%UA_OU6*%W_R
MCT%U_KA%"GR$ZL=_HOH 7)P#(TKJWB^2^L=E5MH_! +YCYLY8[$_ !+[0TP;
M_^;B;R[^YN)?N?#D_[>YH/E7+G1AC>(X=I$@K/94_#9/8YDI;%80=F2)1YEV
MW+2)!A#^BP'\S0TAM]1KZ/\P@.G.P^%3TZ+:1%/TE !8SOW3-5GA.]\3G0+F
M5Z= C23:NWE+,$H7RTNS#FN0MPDD "^6)G\81M@O[DEL=1GQYZ84@FZ?_-<.
M.(G='[?<_=/*_W"V(;_-"/+[C"ZXTR93S&3V=97?_.%K:X]LWC]<VAO^U6JT
MURM2%/AIER).WFZ% )C^TZS+P3J\"G'TH8U^K4H S[RN&_L9%? LGQL>QKIO
MH]XE%8N"4RQQ4O2LE<!IEO3E..$/V;[T;8U:EP>(=!B5J?@+SB6$UBT[FI _
MVBJ$YX,==>^,K.Z>XS3,WN%09M"W"6+0N4+V]T-\="6=6%:N4"JK% L!5]L4
M3XLERKM>J3+U9>B2(@HWS[4V-BXW#E67*ZT].GGUHP#(M"^A83;Y); L""H5
M$HS3?]0:0063TRX5BX<XDHSRL"SMN;7*I"B$+F;7=M>@QV ?55W[!M]E=VY9
M6G"RN=QNA-^!=^$BIGIFR1(%R:K,TC]6T39>,)W)RN)HW6/(?1(9\7 I=B-9
M[I$OC:( K10C:P=S=CU;U1/<DO&5W"3ZT:>)"L%*8?=>G&T%PXDQF4R&[5"E
MH@#)M[LZ8\*OZ\!PY\VN60?-AO@#H.0.;YR%66>2-34)?VQ40+2MOF5EHS?G
M)P)0UW?LYK]=I2<]A2PU5;TIQ'_4BZ2HY6H]0_ZCYU=D/Y^[4J^0",2$1<G&
M:\E==IN*VY')ZC[6HUX5^0THT5$&B(E:9ZDK$=>+ZI7^P,S!M]7N8Q+?37WF
M:XT/*Q1L\G%R?0HBA8M,R.']YG=5%TV]U"_JSH^SS44;^@ZX]'WRU?QY8]"R
M=,J(PFK+XZS ?!EY*:8]D!@Q]+3%V1* =Y]A:(.CH.@^,=+HQ'82@.LQ!&"J
M@*B7$8//UQB<&%$^WF^[&@A :1$!V-Q7+8?]FQT9B/T:#TQ ! "<[N.!DW9N
M<=YG?T4 R-QA1_ON'DQ&3&[)BN%/K1YMN_.,ZKF9PSP-=[Y3 7.T0BYLP9U^
M)=M# $Z_P;S!A_ 1XT0SQ-'N.3H]?84D7:6VM\34^SKC5X]C=4_]#61E97"R
M:]HC_=]U.S9/K.:J[:S_-!P(/8QD02X^AN 8CP+31 P+8^H!1H[=.C BZM'5
MA0!J5<5FI?NW%#Y6P&'Q'Q_(F_0EN42WD9.39X@YWW$,V<FT\!'L52S$LUV>
MN7Q(K4$  JK!>$G5GR99HYDJN)H75<%K_6[MJ_>CDY\7^I+823.<46:6!XWE
MK(?)T3"?=Z/(5])9S@_6G-CH4H0T(E/F^@)<-_,-2G/'*N997HZGZ=_:+ORO
MN,_ED'.Z<SO@RU<6T8*'O(9.,Z$LB>Z\P!F2F,=?Q/'=:;?[['K7[8JK DQ\
MJMVM$RG2K&,DLAQ/Z$I<G+RPQ<.H-)'U&%RR2<F_9O-^%?D3<3"JV$\2UCV+
MQ H=Q=]2T_+*;,J<Q!ZPOU0@XF#$-",BYS'4,JN<U8;H/:S,SY7<?B0.U\$M
M&H:%FX3LE('Q,,DJ;-"!%]0=7>-.F85=_R)Y5NPM=],6Z0#](<K4 Z?@NO/<
M'(RZ!YMCTS[:9;TI%D&,NT,AAZ5XG<$D<93C=D0X94BA?Y9N'OW#A44C<\$2
M],N%"V;+OA<(  W'82IL,84 S(&T?]O_/8,LT3YD .'2E@@ #@Z1>ICFYC.I
MTP#K*MWE1 P($I.ZK4*<@L=.*-'I$[WC2U_P[UO2H_ ]X*W;L UXUM'F?&@_
M4:]]58DQO]+@&,@P%]?:BT1C)D?X\6$T>)TM H!73<-SRA_<(#JXJP3@BQ+B
MZ&##IO[R99UM=G[< >21KV7A)N@F467_'_+>.RJJ+]D?;05%@H#DW"@(2)0@
M&5I!DJCD'%H)DK/DAB8(2$Z2E19)DI6<I,DY""(YYTPW(#1TT_W:[\R=.]^9
MN]Z=>>^/>]_[K;,.:V_6VG6J:E?5_M3NL^OT0&UA%SR@<Y4?.,#OU_5]#O?Q
MJ[P2$0[ <P']?=!BR.3SO,JX*^QX/Z#M5Q1\,(#O7Q0,J/F'7$3_AE@3#8Y7
MQD\8=HW]*,(]XVD"ZM#,ZM]^8COLSR85VF?4!NEZW3@/**F^5C"Z Q@)I-CU
MW=N6BLKM=-3\:)E^YE?9? ?]"UIPX. M<=5+Y_TB-:S&>+J]R*KDF6G3A@.P
M[9HS9G4:0T-DE?R744EVY&4N>7-R&889J<K4A--A/.CT6GI+JQ@M6:[K6=5+
M":OZS;4V5=!_08$.#6E>8S0Q11R,K''2,7'*;HE#C#WF1![;AWJ_6-@6AKRG
M8"Y&,E+ )_\"L= %%+#3S^7-/D3'\^../I:QJ=[?Q,Q>74KIPV"_*<-*EG./
M8_<JB0;/XKRC9Z;$WB:2NQ-,X@F,E+9Y4U$!H7VYP5@C>1I3ZDBG1G6G78U#
M(=#NUA/!R;F.@61G#8JT+K,NK^V&P!^WYK,S_OMI-K^UM$C@L$B),<I'V71D
M.L[4-A3UWZZN?O.B=^Y@_0M L]0HLKVXBHI6C3$S.TL^,<#;QO4[X_XK!]^;
MS=NRUN,)LU8QE9*KX=JZ(3<X]4JYK@VD/#)-,ZZ<K]JJ^"?11_^9G_,23^82
MC<_+H,T9=.1%%WA#/N6?; KX#Q91D5FGU1C_ES&AN[30] N#?[*1DW^<B!;[
M>>4=^=PW>+#N<$!1JH>UW ;_JPQ^OHBCQ@94U,M_-3B/SX?^@PI5,++^IY'
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M.I_LKNI]#RU4Y,>LL"1^L2.^N<=U ,=G1=)"F;FV@*< 3@]C]W3[ ,NED>A
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M:4YL/V1';!LF4%TGIU <9_+4J[/D#$:+NWV/(2/_UNU;HI?XY7^\U,S_@ML
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MFXAYM; QW6R9FFHO[G69/.ME/)-(#_4CEC?7U?N\8W-/WHP<G\]3=#D(Q>(
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ME]W+OY>'SAAW>E0-$05BZ%3WP:AJ?V6B_I:[2ZZ2P*W?E;80YQH7>39X1]?
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M""5R&)4KC(80\&[5320_WKZC4*Q/V:]YS>H>YS61P9L- B&_RE3+8G*X2Z3
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M?3P[95OZA:4;M!<[*L*AD[^'6U^C$XB1(K5I-2[5FS_<U0M_#R*MYF&MS(=
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MI5E7>,\S.-5F)T+CZ*;S1/%;$GM&<.9+M'@3-*B:M'M,\+_;,$$[:[#.(&?
MX5'/T;V]*I#G9% PI+@04^98!=]0EC=](5/W.%G]WM>:^,/5FWMZ53,_[A(!
M;1RS%(TK*-VAXTR<P[KW'/S41C91V>B?#VHC1P7>+:<V[PV>C!1.K3?#HXD
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MCJ :Z.%^^X1>(J"&+:I%8D[CR)T<-\1EB&5()+>-[(/(Q^E0,W]]67:+9MQ
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MJ_3D)?AB?_4/NSK+J)1!'SN:_7!=JJI+5S5IR SO_DCOEGRCEXG ,XWIX&6
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M77I?UD-NI>= 6W5LP'CSQ/]$NJ6;K_#RK*#,*ZD.93-(-66'"GVD HS1#6_
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MQ"[!,Z2%VONAEYRM/5L^.K0D"S ,(G?25H9KP]I*Z<F#;A<"[K=DM-TOH)\
M?F"9$I#(S!6J="J*S3/D$OWZ[(-IW:W._4M4_D' ,_QTK5OCQ"P,FG2E*D8"
M6$D!>$XLM5RX);KY2O?LG$G1UM.GK=$$._@:_?<"5WMVXCM,$=@$KCV:Y+S-
M&_2&L\K:N-R'ZQU/B]\7YA#.0<3[!&4/%SD-$,&M"?%3S0X9V7A^26TJ)W>\
MZ(/EF$6N5_;&&T%S4W%TM:&$TN8 G],<+OJL#S:LW:8O(G6X'IEKM5C+'#H[
M4 _ZG-GNE-L!]J*/_&3(]NI[.>?#7W[YHPIF4CX&EEE,$I\_IPV,6+@U3)L.
M:T@0:,R)_6=SJ7I-IS$"LW%BL23&J7W4^BYB5\P7;74B4CW"_)T]UM%IK"Z.
M\]TL]V.=KXBV:>9M"B!JZ@I^-ZW03:T1@9OF7'*RP/=PXFT^\MXJI1\8__5-
M*>+L-XQX3V1![6U,N!!1)$+KBE8)G@)H%3A;4FPGH]]/&D_IZFPT//QE,.US
MZ80>8$VG63SGI1,=QT@ ;#<Z^<:/[8CQ5HLJ>_4?A:#29V .WAK35;^7_.>M
M?T#7+<V3[EV(W^OPUI;RRB]RD<^_<,#!:CZM%+FV$PP[O;: -$5_BOO.%"!9
MV%]@P/W;JD^WM-I9/5<.I6)<@Y95ZK6,8G4CIB]LFCYQF@:3JRY1>\DKMIV'
MB_N!BKT32DY_=[!=N+JKD^.@B#<Z\.?DD!R\3/(LM+KR\'5FI/C75\TZ[,;/
M.!G,.S68*(#T\K?/G>)'(Z5KW\!A1U'D\RZH\XWB!E@0>R:LI0:O69XN2&#&
M7?>X*&N#3(WCN#_+RO6D^Z:NO<H"8Y*MY0>2&S'G"\25F(4UXG.-$ZX8J0BJ
MOYZM_ MC?K[9P\I8^3TNYEX=4^7$#-\\^@U9'DPTQ(!B-$ZX9"[)_0PH6H.5
M*ZH..#QWJ$QY\DKQLO$%AI8;B=P.\W%W.0 S@@_R[PXS=;XZ?S)#9;PE^D03
MWP<*@*LH\$>.HOW]"$T__95YN'BD \Z*4U:)7=?[4[>$M-_IYHL?GFIW+JJN
M@?78/8G^](R'[; H)H[']Z 6_6DT*MLJW_H\]#F^01X=?:G7(W1CT:$D&#:&
MI;5L64U(J5@Z-<EC1-G%TTMHA8_0*5B65?ZUD 9@&7TVMQ$\/FH&9D:&T353
ME:8$9J/RJ'K)$*-W*/Z]RBF]^"C7*6TNH:[XK$HG1ZSX_=1\UME?T]XS&,;L
M/A;B0X)3.X(>8L05075ROV>X=C(5HWU."A;&E^Q_"IBUU+L^+1?*>^.4Q_V3
M6M^)_IA@/5M"TCNJP'78"S; L0L=7L+HZ!TN,Y[DL.V"@,9!_E<.$GQ5<6W*
M@I4_,?>-B_#LB%@-38(UC(7T* RK8'TZUA,S/'X_1.?^'/QNY?NN)]H\>I>+
M]2=";TY&9ZY_ZWHO"94**#,D?A1ID^#WPZ([V%Q-7!-=+9:_?%>(_GY)7$M7
M=\+GO#$W4Y=97KND!3<6K/',CQ3$QA I)5!""&F&TA(\FS1!V-%7&A)>^&5U
M&"NL1=@74S6,L(CU.[Q8:UA1'4=WF[E_'R87=S[Y(1/O@NL.*&JZ7*F*X&,X
M^ RVZLD2H-YJ(:?8$N#?8NVY"TW?DSR9EANMSI7VX/SZHVO&FV^$HP)=VI_-
M?%)3J''U<+"X95++&BGZ]3"+EVK,Z_RX+V:YP?*%_.QMP5[8$$Q-^0>+\]%;
MU&R6*V*7P?.(FSG8JMRR"U::3'IK9TINOD,!9%U"%BA%$DHB\JLT"[6*M<N-
M(Y4B96T9?4I6@W&',A1 )S-^]*@!MG2[8FE+>O'609P:VS22CZQ9.YI,[J8
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M6'7_^N6:08@B1DK[ZUQ]#3U6<U/T!KMSBXAD%VX6+?0&NFQ0X;/J/98P"Z^
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MM9=NZ,6B\ YNU(KE"/PB_#5H6R%@A0(XK80B1=FC=W>YZJG"R5%;MIF%&7?
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MG7HDK7L40+\@B&@"VQ.&NJYKE7MH4=>(&=2[HU6MAG"RPW8!&2@*6XQ'D,1
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MK(GFY4NQ)5@#CU>TU96LO'ZQIR4'ZF1]XP!?2FJ+'S7!N8B:^*H;)4=Y4/:
M$ RZ:8.'I(%O_S(<6I 7D"J1DV1PYW44CX:I@<@OW&F=,Y<$OP?R,;U_C\@D
MGR."S0>.4SV-L5E7#WA*/2LR"X"M*N]Q)@AQ0<W?1LB\N]24Z.9N6J4BPK]<
MSEJ]$0[CKG=#0LR'H+RDRX,*Z@A69S_"LAJY"/OE:_+M,JOK]%(AU^O2L3=A
M"DK7\]NZM_C' Y'GH/U@=BU^HD"K-D&Y=9RW+YI\<<2C''76A8>_NSO7]7P'
M^T>=B$<_;#I*I6?]SXX;GF>MNX E"*,C04ZH,4,T5!W>;$T!P.M9<'7\JHX4
MP&N+9NF-0E\)YS%ZC&P@)OJ*\+M4DY<W- S3L^<@ND,:7@1!"Z(3(;<5=7;G
MD!T/+0MF)U\8EKI\Q_I0O[HR5KV[Y$R*7U>Z;4G[:;OL*R+<)NS?XW-^#8R3
MO(D%^"HL74@Y,%K-Z/79*)S$QFH!?U +ZS1]H<<KA+18_6+O_,=?'( G8[31
M_N*R7\@*$ ]B61;D>171'8]NU>(;GJ_!;UMW3ZQX:QCDLD$>)6#M2F72.'M"
M^!QZ.J<8<0X^M8T-.-#8--:IM=L.U-1XB1@X8T2W/ *5&*J <[N$CFSNSG-Z
M7AD8XV^WTG>:OB@$Z?)FR+^S2--:VPV=E,*>R)EL#$<Q?T]8/ME/[AT%CP7U
M )W'RZ_:\B."^+9S<Q])"8;\@&J0?S3*C2C"PFJ57VH(.N"FF5QUF6&VJ/JX
M12_KSA-)O?J7K;1^](DCZKZ!)>8EYL]S94/.$U>PP$@P/<2PL!-S"0B'R'L%
M?5K6$HA=5PP-MIY2=&"2+RO-5/^6ER2DV_9UP>SL-I0EP-)D$.2*&..R;.C?
MD%)POU.O,0;]I,%:2!6?UQ$2NAN;C2/J]S^MRZ_8!V&,PB@ -D&BR*'N$O1L
M51T>';UC)+#"5<LT&J^9-F%39S,W$S\*5U)\Q^K5,<_<X%5CCC7/C@V=QH$Z
M$*^A:GA-5+LF5[-U[FL-N_P;&"*RGD6J*:GU'N)(.][#1D[WY\5WBQE57>8F
MX'R.$&]-MRTV(Z(>IIR0V\*+" ,"&@6)CX)%.GANK$"%"$_J"=_P0B^C K7<
MLD(J/L[JW(0_N"#P*/)(,1*,\!C<@U,='_)TD9CPC^K*/9$_F&M@+\M6%-Y\
M>O_R+@@/.A(K__H!>/@=9+Z?,DIF;V#Y]EPT$V6II?*W2 S19?I>%<TO.1=F
M$U^<=M%\L<<22@%P:;$0P<VU4 06]O([E@(X-Y["LV +YIRZ'SA35QK/Y&KN
MIVNB)1]_8:?]N<R:U0Q5Z-.YB"SX;C/\=.L<'MC&PH'<'72)=RMU?32H?_)F
M>(W+T\;  "&3RW1[W@7GOFD3-G[ES@0OH#=B[('X1]H7BVM\M/*>9L#+K$3D
M#3[&<E3&?;'SVT^X6:B[W']4T"AC1?(@ML/RG>_=<,=H7A'=!I^U^J7+*KK]
MT^"^UX48!@_O3=HGIV7ET!_SY;%WHY_$1.:(/"D8/D)[^X6X>P3TSMH_5@'O
M51ZI'E  !VCK0\_=J/JC= K :3HZ=>&EWBI^;/''V!G3>P**J*JS F-3X!TG
M*&!+:=-K4R8/W2[%>T-63SPZNR Z[.+)&T]9C$-7.O0T+(<$J([^JY<0Z$B%
MFYU2\*UN++MUZ"$OG&'9^E1VB:N]=Z"]02Q]9GR'[4..TO:W_%UW/:^^L3(S
MOW@T5#$R';?8):$;#?Z%:H&>)XRV@2/2A9-;J1;@(R*XE:<J:AO,["IGX._(
M,]WM9FB3<"UAGKXM@V.JT2DI8_W4RW[BT@RO3$0Z,Y$+Y\D48&/T0\.4(+NQ
MZ@$!889L[,1MHH*JUQZ<N[EJ<8:?_T9",Z/T6KYA8O+AG;'.0T7R3ZA8#=''
M2R;LRD"%J&?Y=$GF]<HBS7*?;WD\&=H,^UA9;ELU2*'0J8(1R!FL$:>]J[T
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M]TDT1'DLD*NKOQ/&C$K.&=<WBZKKU+KO0/,\B7M_0L+C?'9TS3@XK:CO<Y"
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M;(-4#>\0T,% FS>D]2Z&(E!QX:9"ZYV%Z*=OKD38FO.7,MKTU=%N5VL0W^N
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M1L^NGCMMYLX%4P,A*C:):[._/'N+N^OZR("+(1H?5I37'LQ!H4P>_&K<7.O
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M_B:3['0^NA4=N@0KF$8+GCH(Z\UPQSJ1=JI38$L5;25;NJ>B\W5"[W="7]T
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M5 %.<2DI"8#A9SL2]@[_L[H""L%W.YE0A0E[CGK'SA6E\HW>=2[\^S3PPF>
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M2/['9R1DB PX,D8<5'V#'V@'*]3&5P>[,1/W]^UP;(CW)]DD_I\$"J]%@LB
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M6BZU$P(SUW$T0CKNM6>G?TS[R[+_.<-"_A]9]B_#_FW7/( !_W 3XL#C &+
M[ZOG0-FAN6[]^-.&U&/G:'"/4/#HA(2 Z.)KC.[W_<X&NV-%$@5+<G;XS\\:
M+1!)9EP+4#?2B\944OS6#V?"\ZKC<AHG*K1,K7[KXR3^=G#.E\8V3J',P)[.
M"-]Z$?0UH#!CC799C2"N?H"CJ>,M93J6W '7CG,U[*+O.7=X^]@+)5D!-9)
MI>@/<P)=F_< -?CL/2?W^TAN23J7VR_'L8GBIBZ-(1+]PWLHE'GD&FQ0$7Q]
M!6[U08%HWMA^<E:==V:%4;XA+W1C/I'M=7UG'T49&.BZ*09C/,^&BP"8$E7(
M]2(CI1JK&T/0QU)1ESX6*ZWQD5-]=+38OUW; >>[\)G9^!LDZ"XN5V3QUS9
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MSDU(D'="J>7-5&A"-+LDELO E07H;*^<L#$U*!Y"\G;H##708C^J@A^9&%F
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MH1IJ+&VL0NI3<1*M0/B3P]2/^MB"M-CQXP9"\E$M-4-5U''!7#M :3M)F%
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M@FQ5PE9(ZG9K@]#W!_V*OY:M+\N2,GA0Z'+]"+C2_O+BT@9;8DK-D8)KA 7
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MCW4P"M9) 7"H"6%O7=>XZE[4(RS.R_E=)F/Y)[M8!&-KPB>!:T0:(O1H$P:
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M'WPY,1FZM<$_]:FU:/,T.CO><^^I0=SL;:C916"&#YB>O "N96M%>W,,H2D
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MX41*?TD!)%^P4\6R]XX >RL6+"PV%7VU/ (^(8(E;?IJM5(8 4DT2T+;/12
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M"$OC1 )1F]2HI@B*@;D;"7O=0/B7:Q2=#P_D$;W/Q_X@30[<Y"OIU*?H1_)
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M*IW:HJ6.ZXLKXGEZ[XL><<.12;[!QV>2!:TDQ7GASZEC;992C(8*[RCU+LR
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M>I<]95E>U5<F-2T*YZ 53GX1U"R[/2@ ^H#)Y\N1JE*A88%6,8R73XQY>&<
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M.(E3'3K(WH[$R*QKGO_W@/+_K$1N/DY[H6X(D+YLK_):\M,6EVK7V@M]HL<
MU>I'$K-B.T%1*LC$E[E,8"[W1O*#@);GC+9E&99%\4J"KUDBOOPI#5=7?33I
M*3_O=L/[QM.&1GAFAMN9:P<I^DJ",Z^#*G%=>*EEPEZ=._5:'THI]Y^]W78=
M)G:VG:Z=E(FD'IR7=?A(O#N3V2DLG 56897==39-]&L:Q/FOV7,F+_:UVLJ0
M&4M69&K%<64]AEX>4_U9GI<2!P>VP[\9 L*^+N>CK%>,>O1-R)Q[<?QLY6LK
M9@(]@NBRH2B[O,\BU[[X2W1?CEA.\A^".@9EDQF+BL0^@Z+;1=TSCNV=03L&
M$G.*ZTGOOM< HY]M++*2$+"G[U!;4R,]>S3S5)"M2W%NO:;")>AX440P979'
M$UB1>*5IP3Y8)&IS.M>FK!O(HX^&T[K:74[KV$RNM.B$3/N>$8U82[9$VP?3
M6[R^LRZ2M;7Q[_?=!LC5[3&Y_UKH/X9U>B/7;F'@Y.8M\"G/5V@JD9X"2 -B
MCLF].ZH4@+X#8F@$+WU,C-'@I !FU TH@+M-B'%0.')?BRQ,+2:^EL$VK[^D
M6?QG68D90PIR[<$,%4R[T!2 =H/W]-\= $!^45V5BF[IBA@P809\^E@LS!(L
M20%TWJ0 UH:(%\A',^0W^F"S?\BT_RHZX_/-(,4I':-?8&'B,[PBEGT9V9>L
MA09UAMU0]_1W8EZ%,0Q)WBE_2W<=*SSR#8UJ[R^?%7ZA=WPF7$/A"ZF!?&5K
M6J8,[X(+QH;B/SS0N3*I:1!Z=\%RK7^X*#WZ\-,!SH241[R#.3;#RO2PQS75
M; .YVLQ6&I@33:\LCG-^M^YBOZS9%^IH/O:X )PKTNEW<+X V%=F]P8@<]_J
M7TJDL]]*,@'+IS,\V.R53]E8:LJ+;Q.I^.2I$*82>CN=')QQEX=<,>O=U1J2
MXB1[KT/N,GG_J("]AP)@W-*XAC]QP:SCC*>R3IGS6?$I_C-E3/..M0GF+OWE
MIH2RL@7$W%>0=L-X??DA08(\])3N#*-#<E#R$T\^VEF9;4LS) M1YNGJ %'7
M;>6KRKQ=]HM,$X-[7.T81: <0JGS=,:8,T.](B GQ2>/.,JP9I=:;4N]!FKM
M*D';1OADS G$"$/HR4I<G'4'.Z;XQ\C^BI)\VA1PT=S+[ZW&VPVR!A454B$7
MIPX=GF(0*Z%!E7T7-'M=/()79L_+OTZ2[%K+ 3[L0NKX[[%MDJ_&6!LZ&#9.
M5EG0_+*]FX:P.;PTS1#3SH;GZ@R,V;Z#<8[^L,B[@$L&&:1<6-AN-I>GP>;O
MW/%83:4:RNJ,%\3E@YLP$"LTF_#[=_?=)NL@SKG(E3?^D&M1*2$AYA,40)W4
M6=)[C0OEEU(+4&<TXL+).E^Y>C78Q]6>%AN5;F?9YGTN-?PQ;=[XP3$U@D$)
M=.?$]*O,O=K1PWE/T,//<,.:ICA=^J_%=^630SR9SM(#H)X0"WO0<ET[3;K(
MX.V;Y5YSO)D7+Q[Q?%UY=(',?'%5P:^& K#7"T:3+>[J;HZ,M^^UX%U65$>X
MK?&EZ"[4$[)8H["-57V&J]<C#ATSP]98NA15X'UILI K[^(U\/G>E1U9&<X3
M.ZWM*]-RO@/UD@(8@0_HC3 )VH/T55S9*GC6 #<^TW[M:H1/)4056_\<%?'Y
M5<8K99:EVS<97\=T;D?9&O6RXZ7$8]J,5I3KC5Z%"",K@U:)85D#Q0W,:XK.
M'<-[]TDL4_*)ML]FK1=1U;^RD^&>:GH;'=AO5YKA3$1!##ABS[E]5$WD@^M,
MF@8+"IHMR!(V $BGFMX0$$4-(OBH4N)94@Y[S\XS3^L^<ZA(VA;V4R-0_ ?3
M()\4:<K^B_KD3!FL\T[[17QV-XR#+ @)P31&JAGG 2.>3EU'+0U)7Q#Q>>#+
M5/O(R/<6JOT &Q@.44#_J@=S;O!:39KYQGOV'I6_Z;T$"O8;;R0/OR;OJCK.
M<NM&)UVCWX27 * ^&Q0 AEKWS]7C82-3&H*&+M4?Y/2?LD6X77E_;GA\C=B&
MQ<^4DWM 7&T.V,$^U%Z".-ZE ,^^0OHPP)LRMIFG32R)4UX\RX2>2$%:G1H?
M+,MT)QN8D<>:\6$KS?[<GJN;]>4LK_+*?LQ] ?:U)FL,"R@Y1#+#/FMQ]/A<
MJ_C ]H[&]0R*FLO_]W9&C/_/Y+?.-H[16V&5OV'4,K)F+Q;*3(3.:(@&A9JW
M&Q@^%97;\.3;SW [)];M F\+-9^8?,20"WF)][[0.Q*]>!GC-EDVJE/I)9UI
MW'#7[N=GF1\%G!F'Z]4O8)\1';!89.U(.*S.TU]"^NJDTX&,?[+9;XFAM947
M>L]T^4SVUY.RCBMCY@0T1N>ASV]UH/.^5F*+5ON[X8+D17#C,5SM @5P3LXU
MRRMRA_O6$F^:0-!K2$5M):#WW='(5P"T"9AD=R:1ANB]TJ/</U1I#2?E-=0#
M^?&AO><-A!,1;EEMJ8!QZ>@UOS<,A9<MELU_.2&)G"(]&]]WL& #VRK9_#E9
M1=CI-O@QM M6D_&1<,DC3ZQM4LW4:55^JB!>A*!>7,.-TE=F68-9 0@W$MQ)
M*/]_Z:J86&DG.;V3.!+GCG&=,KCPB*93>2/D63A06\%1M]/,C"$U2O===L*N
M[7=9<[4(3;8/6;:FOA8T2>OR<'F?=4@"<H]#'=0#?0DXE6R=4?HI-U$MD!GP
M,WEV6&X(H/(OS;3-PP&-C5/XNB8P&4@'^G539824%-)/CLM#.L4N@?$7#A!]
M^9' _7="+N0^=0<*X)X1N*Y[#T%D/AFE^V<UDKC?U,_X\/]*.:M)'*8'W%AI
MO7CQL.23W*IX+YP1(CH^\0@+CZO?8W/;;^]IG?3B%94FC:7)AD4'8TB-Y#,[
M(&Q FTPX#6ASN[\L!'!\V[Y(=#ET7*IROTI@PZ-?#42P@_!BS1K<BEV7N""*
M%>Z9*2)-GZ,>:8E6Z=PM%T\+92-5SCI<>\)C6X#KDSAS__]I >KS)--SM*(!
MPY*3,\,345&S:'D::I(&0M6"''#!^$"_523WP/7;W6L)TS^]LH*-F.+GU<GA
M>7WMUN.PY2H@BW\R@PUR\M#0^N[4\VJ']HG#!2WE23Y,Y%73Y72BIGW2=":1
MQV,%'D?TP;ATHZ9CRQ8\;N*]312/IV_'_=C7ZA?3%&>B]4LY*BR!"&$4=X8P
M2RN!/5^(&HL,7\:\AO[PUFBFGD1*WG[GQ$?(;S%6?Y<%V!\"DID\L;1=&E=&
M/T&E(")?,/E1_L$^WN6_,"413L]Z 'JTKU]H#JA+'8)UIZ0;DF\/DZ>U,U X
MT2\Q]Y3-S1]]]U52$YQ9CR5R;Z\&5*.'#.Z1\MK$E[._.EA/.34A+SAS_>I1
ME*TH'9OXZ$ 4^22UFQ^5Q]6,D>FB^E=0")8X."3SH.GS^R:ODW$QEH)C0"0-
MKH -5;EP]\;EH#DM$=9BV5VZ,-7)P[]>D!0NA>K*P/:DWOCV-N#:-4]:X846
MTZQ_T%+-%C]M/.7WOVUTY'DH3W.B32URVRF U_U=H-/UC[ -LZ-37<P%LAZL
M>XEPH7Z/)):"5 0M-RWM\^%U*0";(QD2TR)2CWR& AA@QX=2 ,]PN11 <>TH
M0_!_P%+_KV4AK$(!I,J!*0 $,YS$.X7\NP.3- >91"YV\H.E3MB>+6SSWMLC
M)TC9_TZ _V=N]U[>-- &:(DO;*?H0@(1_6#4-BZEEI0+\F)UZ*4 F)P#L, T
M::*A6S#3@)M\&5VT\O#=MW^]#B!]\XO+A,*)^?(2:Q#7\AZ1N[*O%J*K\B#+
MK-I;]%1ZN$36Y@YS7:']EM& . L@!+#.3N0=[+L64-9M2/M+36;>A4^CC<T/
M; ;M C;I-!%L\%$]C2']T<\A*BV>+08"EC;OM6J?<P3ZY9B/EI%Y;+NB\L^V
M/>?NNX]RF#2_LP+"WVL?4R2*@&;S FB:R0.<M"F]C:&C#,9?)2>G_J6\9\B
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MA'_',*S1A6!=X&">H#P8J*9=*THUJ+6WF.YJ?_!3'$9 =:"Y*0^IM=#G_:(
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MWS)%1;(/^Y2[!+;>,[W\M=FGIQ*WO[*[1T;_/@;%PKE*KYE,6;>90YGVUK9
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MOZ_7&Q&X#'P;6/\\:'J/<G(Z8WK]("*!"N6]2;E.S!N3+UTA=4<\?+'V>9R
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MOEHDFLS/6,^BZ];D+GY"%_DZA ,HRPWQ .RR@"G=4+)&I8Y'H3Y348?7C(4
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MGF=<FVST^D'-0RH@A[&)N2&,Q"$@H&6]ES]#AW3MY^VSD+G*V*(,-9T#]#^
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M01*WOO#>(8"[M<-)1G]M_687OSD>]U+=TBM!R(QET!&@/?=0R>E%!J+"OQ0
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MHT$]Q*DZYIUN%7O]TN71?L!"HL 9%Z3+B/<AKZ@/ 7F\*?].DT>"R>S51:"
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M_R_BC/YX@G-1ABYCAG')0KF \]]0 S#>$9%G&?[\$(<1C2+=RKV!7=116]?
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MZ";"W2'0?A'$W.0_.T$>GX1X0Q)(=A3]3HU29%>^SF]!_^!9B@K++^1!"5!
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M/:Z\CUN]7GN>\-YJ=C&)1CZL07MO&>)/[G=F3\)/A\UVRI6$56$LHGU4:HX
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M:9@5;NZ]OW;I)-,<M.WV/F<86 8B7R_R41W93.N13>L2:W[C>I?ZL7(Q#JI
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M^G%:F(XB?_'V;2(:0]+FZN1:08%K,KM\_^^GW5@4]1<NLQQK;N>(4!S!/IR
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M/VN1,T@>U1P94SP^DV9S$/*#>=ST^97*\O9/;,F]X._@OC1'<V&.$]O'L?9
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M(71<\-K/X.&M8P)J$[O8#>$ [FSLNW*YU :[J_">Z;AXQUSN3B9)R$WU?HO
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MY+44^)#^&Z^*(LDH$L98 ,C@=G*POXWYZG/4+X[_D#+5%7-X%@_.DYA"JY^
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M]KL^N',GXGYG/D<F!/L)S($2A1D!7)17A+&>X[MF+1,%^IOF3/%2[>616(A
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MO0G?V'X&$K^?0/_Q'(O00[/3F+^HI=J@N*LV)*6QJ<M^@IAGN;L.M!E!WK9
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M9?X7K+&/F@4-EVTSNW,=FIS5\7#MH".)L":KR@;Z7UFPAR3E>GQ*+DZT5U"
MB$!W$D)T>HZO-]2\=]HV$%+]"(\25G?;/:;BD+BL:V8-N-2M?HQ-?B9[I\]W
M^_R2N\)JRY!F+,^&>!1'5 JG;:6Z;9T,W"$RWE?0)FONU #ZBQ>TM8I#F>"A
MA5QS^?,2WU^;MRG*9C?PPH_5EOS.$Y #N]%@5@UQZ&_6;E\LBLMVO?;J$.'4
MD-Z(0:@JX>+=NJ9SNO7=0>#M&<QN?.M='-50\L;1"W15./_P[X<(Q;Y(LBA,
M^=>V5/B1F:/CD?S?@85 +9X![(KY=I\0U'8*^>G9^HMT7]9]-<.T%UZVGWXT
M@FVR:G! PBPQ&J?;;6T4CQ=_XLD;('GBC*;,-(H3XM6C9R_U/NBGE>B5/TE^
MZ>_FRW35>J#RP>:G9SX?V^[VHD=&40R4NP9,E(OCUSZ*5!F%,0;8W,C_](.A
MA/Y&51C@ (E2XSD%DAPF(-?0RPWDO&8[1\Z!!?W7V#IMSJ6>O <-R]O\CE/,
M#E&1@E41Z@B;*._#*B9@=7F92$COQ^:D=YOW^Q)OBVVT^0K];54$3[-T335^
MFE))W:;!;G[R;;LR_^$#"<&>\&_SZ0%CI$\QR8J8#74\7<1K3+.@J\\ *GN(
M NO2K/53(P@8>(YRF8CH<:.?S1_;/@/X,N.:\E]PT&M$A#O47T!=AN@C Y 8
MQ[2>&BRC@%N7X/4)U@75XGQ/,8$S@ (GR+ !<)( SOG7M"6Q:77,PMJ1['8!
M8"M\01.&3]5R7.+%1$U!O95(O$_=J_;ZCRPMD(BE,P!')R:><_C1(WGNC]J!
M+GN18=J/\QS*E9!NDIV=K*J&,T"I+&S)TNU@:^^_:G4=0;O1%,[!PH#8]DG>
MWBB(5N'%F9T[3@D6YN#FRO*[[9&6\"_]Z^!\Z"6JW;^Z0,5P&K$:F;BY'D$I
MO%K%>50%CO!YM)V_,SQ:;U87F0_1QDJQW4/_$5RZ]:JI,;YL>WLF.<V%_S5#
MB;)#BH#X(1=!B*@;C(LBN.%>A9?.:G'^^"$_-%HB^23O1IO#^,>+[/LJ[&N#
M1QY_ YEE6E62BJWY&[-H\ B,\;8\?@X-CJE6YUMZ+\B*VUYY'V:G93+AP/7J
M;M.'IY^6*V@]Z(]*,<B(HVC?I;F+?I4C#L"$.SS'Z 2CR84675N?^:EM2E.@
M0FK.HGVG\Q';;,>^-M,=VD<#EUCCCEXH4.2/+Y_>#Z#M 5UMMO+&(.A(Y_&H
MSL4KMC__XMV;&[[O/%T^CM#L<R O20_YK!#S(XJ+IS)?F@[]V)#V>\4Q67$A
MV<W;UU=,ZW(ESRM)S0ZXWNJXE_I02-T9X'PIKB#W&V5XZB1SB\U:JVQ3D8M@
M,1H&^CTM9 D@*"FIX\$7(.K$V_A[-:<&J&C4!9(OUD!<=Y$SR4G,IH-([^Q'
M*^+1+OS+<DNJ+9O5CIB+AD<'!B]M(@!&%<>ZG4?"J[7F:$LA9FGX1#F([[#!
M&6Z+N%'Z271;8$Z=QD=?IDD'K112Z'+4R[[BF9:'%#KY@X@"N2'/$5'WR+D0
M5KSU6$==EC(N)<'UZJY^I47BTQL6#BW"@.5:S?6%>@2G2ZLHN;Q5%:(Z25+'
MS5GA;F:C-_/J6R8.3YTJL@=E+OC&/RS?NW*W5]WMP,)YO/@.8S!-FE/B$TV[
MMJ!;YVK,F034C8<6YWRZ6F6)7_#4=.U^]%[-*A"'U$V^T63'9IBB._YYN>F2
MPK92!]IG$ZQ/&08!OZN9%ZUG,8Y2. ,&VZVU,],9@S/=##@)&U?XS[6%8+Z>
M+D_]IMB47OA3SX)^!OI<B-%^7F/IZ9U-J7F4_U.I8WAUX QPM5FU'#J:S54&
M$5"'E^9!I'#SZX&E!B)2](3N@=J#F)M"EZXIT=0F*E^OEXKCA45#&2BCC8BX
M*?1D(5:*T17*QROQ2>5R<;V-OL9:/);![]I\PVN:=F1];BQ=[8,?RWN:R[\F
MUZ5_?N!)_?8\P3AS2W#(?C4,VDG%F_=P(TN2205$./#'!MO\_$)-V)[$^T1.
MLY$?V^![X](Y7.>%;]MG:I)*7,.UOS[19H_\+R^?^]\8''Q.7KVV9P![UX=Q
MY W _FV0,RSJ(\D2'+6-L0$2']EN&8H'[->=OZ,CF[%MX@WW!K-"7E #6V>!
M])28C0%QZF+G[#0D+);G;U14^COOCXCZ!CK%DZSRB,(4ADW.JO(-A1.=)+<@
M0<S>>FWO57+*O13U2#W2YH$K<!:[=/1%Z P0\07=[*5[\OA \( &]P"$>]!T
MD Q9_(#39U5ZEO+HX@C/2I-O+\3R#["R;JL4G3UCV>[C# 5FV=W?V7BN\:WX
M3U>IQ%A$CP[+0.YH#1^AGJB2*X&7[0P.QJPY'4\94ZL/%A2F<=O63@L-8G.9
M/:@MX77>*G\?SYM%\Y)>"!@$V+'\'TWX_T1+EX9INOW/*.I?6_3";$ Z89_X
MQ=N?U]#=A7!3NC\S+_VBPBJ>AW09.OG3+PR6"16'3ARE]:2?>D&LQ@_(DB'&
M!C4V^C77F"2$VWFJ8U]'L#N*/5O. @R[(2_=TJE<5?LYP!V-%A-C^:KMYBF1
MYT<Q\^D4VOMY[DH%ZQCC!C1YV=HX_I!E)ACK6Q?;+"Z1F=QI4ZTOOWS3>9O4
MYO^27C14\^AZDS'1>H$#/C649%WK4*VQ L[L-5&@4DJ>O\4012(8 X,#JYTB
MW@Z&^RY-CI=E!?/%#AHK:-=JSDER*G(++2UE,3.+K\L&?1*])V:3G8DKYY(N
MC/U44I#[UX]U UA#O^W.\&?N3T"5R=C<3ZM7];Z_WX)O+1<_>I;T:R^P7&.0
M\.!WJ^""_"J\53& OC,MHLFSX4?DRJ'+E-KSG \_?))^85"ZKV%+Z1KLD[6*
M")([%LC_LQS(MG%A^*IFV_5;/]B#+7\$L!"TB.JX2?0KJK$ZR==GUUB(I,2Y
MH?1"4^'EC/WCJ;ZWNANK?R=C7=# *^W,V>A^BCSD>4W<:SM0QZ1XCHN=<I=S
MPQ/X&V,EY$.<U-8@GIOZ_\]#AZ"7<"%5&>F[ JXRKI91ZE8)<$:8-5F."L;+
M'.ZY>PJ4P$:4'%B1F+MB>^6_8P#$5 -R'%2.F+:@ZLD%\8*QK-_2,%1L:X0$
M!2#(F:<^B'4[Q:@SP%(:B+[,R8"*46<V%M0FS);_$,/-TDQZ&\3R6$9;:W)"
MU8XZ0.=)C#CR<T%NG#WB&[>2?MD=!_B3'AF^\TEA02=3JX4=X(AL-NAYZ*\S
M %NSCSL.:#.Y=6C0D/,[UV#Z\]R#,5G9"Z!%?OPO?G_D^.QSVYH'N4/?,M9[
M<ESMC&/_$C?QB<%6[CN@5T-!&\J?OL4CT;,# 6(+75YN"&ID!I NX?T[%N-0
M5P]15P)H'^-2TLMR] O)Q;]3.&14Y:P$O/3:!.*AH5OL[MT/;NLPKPUD"6:*
MO_EJ[?OORJ%>O?],4/K_KV$*5H4^OC02Y"O76))R!V"O/_(0<)Q.V,;[=^_2
M0H3'D!2FF44[8L+ATQ?U-I=5MZMN-.G*2D^;1_YJIQ%YYB'0APSC(D234=::
MQ=^(Q=,'].UX[$$DRKY9&U/&U^&7LVD]\?UMNI\W[R#,E__BT\AK6LJT(N+\
ML,H0\0S/>'N:I(MJ[NCOB;+_A.(=>@(IH$>_Z+'(:)#'R!Q+N\K?[,( Q)/Q
MMP+WCT-KZE X<K.$@M%\3C/X[LA7^9/?IV*;"])XEC9/>E?0E6>-U?CXB6*5
M]XJU'0O/;_D!U9Y;NLQ^78)C6C6I1BF'Z!'=D!"FRHJ*R>H0RVZ)8FW)=(4D
M'_:Q^URJE7WZ9G,I(X_>@2TIW12YB58AZ$\82\T?+XYQI-Q6'[= KUMEV,R.
M)OV:,^V<\[_^3=*YWS_XK]Z]N)UU<'*+=@5(O%47K2'RE,18_ZN5)\#?8DH^
M) A<:=>?-S.H5EL[??PYT&%%E'ND!?J2Q#8*<V.9V9FDL-"05/$*R1H%&QZB
MV1VQ:G!--1['N$HX.6C)<F=?AWN5!O$M;^\,L)[XF'YU<4L+#R;DX'=[W$J!
M<;RO&IZCW^4;5AIJ=>*GM5=W:+S0[$D'ZBWB0V< ]^SI;$QA!$5E'N)$O)N:
M6F>9>IT0+'$7EC=GZ\[0S054^3&L:V0(+1![=@8H?;)SV\I?\A8M?J0-5+FX
M??G4 ?+J%T0;7]!K,G9P60)KTR]?*OQBET$!D] !6'@:"N(]/27\(B?/$9*(
MW M<H[-\$IX&"9)OPZ]U:7ZE'?#4]N4F*!T@<W/CM$)SPR?SOK)T3D,%*#,J
MGF'@I3J2L+WH&>#]0[^[@8:.+VL<[S#>;J1=00C#@X(MUQ6WV$XEYBF#*'I3
M_8DNF8!TBZ3MM+R/'P?B+HQ_8!T7RZHYZ-0=WCDX7->\6%H;#9JH^S56_!_[
M1+^R#$@1)8Y(D1JL9X I=6INN%^'' 6%HO:T*()G@.F60MCZ'=_CAC, 7>L9
MX&-O!^ADM1BV9G%XHHOCHNC!.A=/N:IWR3?@H:H#6J,I,0"GH+]082+6F.B_
MU +N2LN9UR]<_W&\+_']Y7*;D%=N4C\PTBWOX_;&_=,TJH5F33$KJ+;%<(U;
M>,CDNO^-^+J=YV\ B4[/$I#JT%?T FURD^4=[MIV6Y S@/=_7#XNY<!K$'(&
MN'0CO/IYG(^+S+9M%LF?W89*4"PU&%U9*^HTKC<QR$#B!1T06AE>XOOX:L:1
MF",6+!"X8%@>$&4J&!PF??X62>S\DP@&EJ"L7KU)Z)6-R59I8K"P,_3:Z%SP
M7"=O>O!GLS=Y2D([ML6]94%G@)FJMRTE0< [Q-C+AZB2F873.2W"2#M4O!9?
M%UG=$M157S$N,1F0XGA;J&_XHKI2V>2S7)%0]4W,(B.LW4CC"IC(<K^QOJ4I
MM8OKL;B=LXI?^ITQK5OH\6?NHO[WUM.X""=X4$Q>BE348M41O*:EP2S)I-90
M@X=9MM^[EW_JXX&?TP30^3@ZP\.6[,)XP<0\:DK^> [O3VBE8EKZG,XB(N(!
M,007IIR<QN?N]D1QBJ47V/0A*6N>Q:?'#=L <P?.NF%[8X1'U40Q=L:/QT5>
M&0MW6IQC%SJG?SG\76C@:Q-:@AL&T3-R'L+S*W\" L9(@'2KS><UQKS>+2\#
M6"_1#>LM6?[MW5:G&N UHJO1J!"-BDQC%W<*]+R1-[M0'H>L&2]V?K'1S'94
MXAF!PAF@>$@/TBEL+ BH0FO-O-I(1>"F&MH8+./T3'B3)%P3S-7E&0&N-&Y#
M1:C\B<@AZK@_/YC[4.8AN6NR<8)Y%?WI<GOTL/%]C8S1FX2FK5@0S@ TR]<)
MO444S2<I-;1&#G9;,^IQ#J^'Z?NR*>!%GGTTEF&-\Y,G6,*;0[Y"%'#_5##4
M]$MMUGD-$[G2,!AS36F2L#>/PYA (+('&0FZ"%''@"):@:V)?=:NQ7R?QN6.
M'>NR0)^7=D9^NI6"WTVF'7RLBR;=*P_(X;Y_;#&;/]<LWK=<I#8IF0M2*^M5
MMA?,6QOW3).<8R)*(0-2"=G$17QZ%Y2;J(5F^6!8:J?MM8A+G.=S<&'&)+ .
MWWL9!PS:JO$DWNSM@O&$E)!)7%2LT%9%Y\289V]7I:/9!_!H%RW$FIT!'-U]
M,%&AE-L0PR@TL/./:-=M]8E&>_U@Y1H#\W.&L?#Z-9CU"73?A%Q54V1[$X$[
MZL0?1PV[I4>_U+#B5NHUA6<1RR9+5A?0F[IL]SD<<A)_D2;(213 (#X7*QB%
M3JFO3QQ8^&LPPOH*=N#-9,):S9R_R$\[HHP<SYZ=6I)']AJ'\B(CM^6(DY2!
M"8_J$)1XYQWI'V;T/]Q+TT@+Y%0G8AWUU0WQS U+(4XZHROCY;,+ZSN_,SN%
M(>UOE.A:W.;. &A?Z)A;N"@<HF&N]T9CJ$E)N9VV"--\,D_J[R+.6P2F+N&O
M%MI<S<$V4A+V=K?0V,V1R%;EB=WO&N)VI+OUE)\&@4C1T3- ]<T4[>1[M4^#
MDY\O9O">)*%WNZ7FG# I#3)$L9._JYTQTPA[/$M4V6NA=+7 Q6:$_Y**=Y;8
M"(EMJMWR"%B;C2C$?^+5J"B>#P@Y5$A;^//@2=^1-&W%Q6-]IF#+C;>N%25?
M#8M08M\U0VFP!=)VOYMB&@A/@Q*0#^77#;X8F)$0/:APQG*;C46VYWCUGUP:
M0N%=8UK%0U?,=#/U+7T9 .UOH>$M08_\KPR]C_DK+$H?Q<^TE)W_%EAC3&*C
M[5J\HG$SH+#7G@XO49#1F!2ON5X''QC]^3CPO=*QI43S\AD@>*%5ECJ96Y;X
MP2X@ER\HXH?-YT/RS075P6YWK==7YOKC-+#C_!1Y_JB5XRG:7KGN$:[M8]M&
MZU44T;\#*HE/W?9%AP#;[.\(7IP"ZC=^<DWHD63RCMLQ+$1\=D*6NVU&HUZ@
M8@6%M56.MB4P?^\L-Z[[X=NDX3^5.8:@7=DX8_&1F3G,-7Q=#$37$[EYO6UN
M]D9E/?Q/'OU/0)T)EQ#9;8<XY8HI%^LCT]X>M+ ,+XPP^;MBD\VK]6^;9%UC
M*K0"WX0IJ"Z,@F_:=-3]HFG;M9RB7$+@K+#"UC5XKNC,H$P#VWK5_5ZEYV#P
MV(V1%.^INN-N2YNLGL+EJ.WN4[[L&939;Y(3+JO'CJ_#1[/6.J?+L?&NP+P>
MNE)O.^TX\E1[O&;HH4  Y,&8O5Z.H"'V 4"8_^9"+TF<($M((^<>9+\[XK5(
M+R4R=@O*Q9K4)0P$^.O;K#G,:LY(/@4\Y6R[CE(F>7OCLL%$/-J8=1U4-86H
MWCT_VRVVJ2*V)G&Q-2-R^J'P1S-.>F4!\5:XZ(SXTSUI)2[KDE(>JQ/1X^0S
M@ ,5_E!ND7-:U=:.&FM. Y+:-+@2/'=VT\;YK%88_#H:Z&Q3YY*7WR7-HJR>
M$:66;IF/D(1:^7O^^H%F'K/U#]/WKX-!E"$J%0DCZ6/<@6AJ 6]E(HZA5Y+;
M?"/==3O7G5X"4YD2KUAQ)WS\S$1^^FY\:LIEKW>$8] $LK/JQXN86/I:"Q9&
M2U$#B_#$'=RA(A5'X0^P[I%PZO3AD93;ENP7#FXR[02PWKLC8Z1>BIX#QZ3=
MZ'(<#!%,]65=. E98AVD#0^+X_L8(KO(<>J$,>9:$V2#TT_5#"D^B$3'>6OD
M^O,S"M,DEMB&&JDRD$CD>@DHJQN8C<)H[^)O?[DY$*(7_7W0S9OQ?=T9("LI
MT+UCE9@><W#W\S':/"=@ID W<DC9SJ:@29 %!T0;(4\M(&:_7U>K*N?@F%-#
M+E-*R_HO.?_)\7K@/#W[<[I']A=UIARNQ5LH/;PY?J^&S<66:<G1KXVC@RC:
ML\CT]C38$-@I>!W7TJAZ[#=I[?'-_0M<C\^<[XYA$"<ZS)^):9FL,B5XO;GB
MZM^$M6=>[)4G#!$2"=TD"Z+--Q(8IU&,!K(^C6WA,XG+BV'9%7X=I_<]B'4*
MAQR$S8H3C(FQIQ)KTJY^K<)C)(.E&:FET:W(;X*2PBX9%P>QY1=I-;X@)UM\
MNM)T([:T_U:5S+@HO QCC-U\'R;3Y:4H3:LQ@4>0V),P4>$0*O+1_S$*L?GF
MFKJ."1'SJZD<_Y9F'O]*-:.D0E5'Q_A>6HQOR1.B0#R>^R%WJ=CO1AVIK=U_
MT@43KR%.!40LIJ?4K71A'>TA-\+R]-NIR-5M)1<6O"^I.V37(]],<BC4#UA4
M+F5(',)1G-WO!ZQV&KW2&[W;V-*PT!O*M;J\.MKTL;WQ2L#0@\+;34/SC>S7
MHF(BY!W%QM9SRU2^KHG/K](SHFH7K8EN!#0Y%LK_!Z**S^[:EIG$=@K>&'OM
MV)QH>#O.V[81NZL[IH%I79J0YS.\/AP\MUGT^ON2R=Z\K9XP7%[ 0%J)=GYJ
M&%ASU#UR;A-8Q=)E8 #D)?H1-G;U$L4#) Z?B@1F8!EB@'>,GXDEK4RP*MW/
M6<GP")S:,CYE)RG\(@'1+-&IL[:4:_A7Q?F=$-%)\(B!/H_^3[<CGZ&0"H:!
M*YY"*<I*W&V]QBO4(!F$<373%4!'8"S;DB1/]*!-DQWS@O+VWXFR4;TOIG\M
M38Y-5,-'6\.J6FO'RYXW5M?';,R^M;J>QL6<> T0:<%_Y=YYUDVMI.#W+W*^
M?\0FP!<CY'0,G-1.1>75.50X+0.(JD<J1W9?QQ.*&#NV!3]WZVO3%/VBSU>)
MN45S^3_TZ'.I'_^?"GC\GT8N*"@KR,RT^&Y=?_.[CRVR,0"2!36OL,Z0J/ R
M+-W5G@[5FFI8,RDE'&;PV4SVZY64): O+1X)0U NUJ#%DXV)R)K'TI'F=?>#
MLKI.&8[<D-/F!>3*%\2U5F'A_OK]R*05W&+3[:.6JNR.UMIX,UE OE<0%@G;
MU 2F7Z*ZGC'.;T<-]EW4?=$ACI)>NH:8H27P_48YAAC8-H[6; ZYU^A-<KD5
M=5QA#__E/=N:FQ/*&F3R^S_ONVG)[%J84I/K#9!K=+,G;I$P.D7RQ4UU9@G5
MI_>]DQ<X@=0IJ#2772WMK<XLN NP70KU60>7(9L2<T5K@\PN7V2JE('\U'0O
M:899GQLTW;.?(JP0'4J(G^9FH#_]1DD&^]:<8Y.SU]4.3)Y^)K4,<$R).'HQ
M!T^BME[Z8,$"T!E\P"8&'.D[%V*R;Y H;L7W*.#.:X6P\T(ISW(':;E[14ZG
MZ'"&+"1UK&6L?YIIE\IDMPSKY.Q2,,LDRKXF$V26A;;NP=EHUS&EFU<=]_Q9
M5VV9'EN9GD:(=:7V.20<FQU&?YW;^'6!-Z+#E@G7K@GZ2'ML>MBD_G ]5R6D
MKU9\O,YX&98LS7N<4_'Z]>'G%>.:15TYAUVQ(A[2)[.3H1IRGY:#TKNI)B;$
M(/WQXPN9$CZ3M;P; UDAI#?:V5_,-:DL3@ X7.VKY.D4H9W1<4D7?Q=[2/TF
M'0EA+0MOMI1K]&@=1:;#^'JSS,00Y,0:J6N-SH Z;_Y.8M]YV!H[3:X.>N1Z
M0^0H25MDP,8$,;#SS8SM# "W&/<:(;PHZE#&QV_E(LE[M\X="M]]DB+$8FI;
M1)W55L/9.)E<0?8B8+$%Q;SEI:?:71JY],+>)P.44)@8H)Y;\%[?UQ]/$KW4
MW;[4CT%T'#_UAC"6 E,4'N<B__VBPD%@WN*;!\,7U'0[\*LUH/FB&ES[YB$3
ME]=\$-.^+>7;R[)Y6X^Z>C@[208DYXK*F=VP^"VSP:7_9@;K^@[1Q[*BR6L3
MZ9WE/*_H(*R1'%YLL_G&%I9KR.Y%C0"NC3)2B?O-,=-(1=[XV>$\G+ 13!LX
M$*K@HLCT+LM-V"+<K#Y-N/!G[1I-O_>(\7V6O:+J8 '7!2W"Z=K.E0RT&<MR
M3JBB\_>R%XN/,S]._Q1ZN?%3!I1 ,3<9&+&U*1J:.'C33GI81*,&JU<]_76!
MS"-8DUEJO6C[VHVGB[EEVIN$V/N^]I8<8'LMBZ)\?>1GR==_,XI8U100X-!Z
M'+GG;&;]2.@3C(WYWS,_-T*;1VDDO_'USM,].0-4/J;7RO#-+[DI'E'C:'D.
MXGV3AI9JXN]/#U!7=I)&QAU2;BI?Y+AW!OCM=/R8_M%PZ43H29I=V\'UXCEM
M.;^F2UW3Z+[ST!A0\HO6; R;2/CV;Y6*XWN/ :OCI52[K'\)*W\:JFX(6$WH
M*_&SV.\$L.DWPJA&>P=+?C'ODG7=)3.%(GH?:M:!(!? ,@%ON\,.A4PNL<)I
M;VM\*5&0MNN\R'6#RNH#[QHOLUN$D,N;Y*;KFMYK!LO0@;Y84,QH4/6.3/MZ
M/#9*0A3YU-Q95P7"3FIE7IR1UK7U8[J2V<SR*OD.<LK3Y^'$.@?O@XWXA5!%
M2/>P(A/992(V9\ZU=DN;/&![3<U=4YH8"DI6M:D:+T^3+9R/?=%B\):B2PV
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M9_*5YZ 7"^F#1JD)#& $6!1ZN*=]]-^[!,ZX";Y?4ZY)Z/:\VZLG%;WYFN"
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M9LW?,6/#_X,FCF+DX],XY?"96V']!0/?]QR(%?Z0?.H\P=Z&_%F+;4)QB:5
M'C\#74AO>\Q[U9-5V/33CYI. B9,JV?ATDT]!EOG!87X^&75RN[YI#FJ7XKG
M$4[",??ZN1T*\S8Z?^.Q;#"I,1;P%7V0?^B0J/=$:_]XC* %>S!.5H.=_T)T
M*PH7M'H)=_A8_F::29\UO!F%V\P$]IH<<OU#]7?S/VM[V^@<'P<4#4AY$-8G
M P_S0+V5$>"=5T).Y%Y->PIPS>2?\ADOFW2 ,\C,-!4<5+/Q-./>?<(1CV!H
M$"0-/KA%$W53+HO@I\T^=F/W-F']:.QG\>',;A[#__S\>_]<.:O*6D!RIMDS
M\^3K?5+X=_F\1%_5F;.DDTE<I>*RMZMM5&#&T"G+%B3=I1:%#$43HEJ?U!+T
M<]TNO!],J#U#:\^KZ>NV9QGU0R2>8'XQL2.K5%KVF^<R+@_T2HL;OI1[BOCH
M70?H>=TLD0-C/B_\-M_MEJ&7_(V>JT"! ZS;-X3_J.Q@C50!0;_38 [!;J,^
M/"L/6AM<C5CG;\MPTTC'*#Z O90JD+O N;]ZOYC(76Q8-4[4P?9:NZD'R7J9
MD2VWWH:S_9"TH_5S< CK$]X_EB&H!2%NC&LQ!IU3)%V<N<FC)O1T5Y].JD3T
MC;_Z&UJZG.)U;592IO]0-A@%[IIG+CM?.Q]GPSY]7D;"K/K*W7-F\2 IG0VW
MB37)R7A:WOO^\^-_GUW];]E>_+[F+VJWDZ.YOF-"/I5& 3A,YM91![F^0SZN
M[(LR!=^YW%XN2.]_FJQ&"0I&'L_\6")RTZ(_--MC(#2PF^,55I@A_;B-&7$N
ML<YUR93+O.$['U!EJ9-9 7F@=Q0 E9]YYPV\!RY>GTDG=^^JU_?C?'% :^D;
MT>WU[\CY-0X;\H!R^HXR?*C4]H_S[L(.(]+?H7/YY%.ZH$T6@L8L3'-,D7G(
M)L3TDM!U2\8'!.A6GF"5(W,?;.879(,6"R>@^C8ZT#;,MV/R)SWCFPK'JSD#
M7!PNOM?AZQ<(R@.E09RA>&F&!*U31'=<=*0_!:!WSLQ.3PWV0#<UY9A^;M89
MY67(W/U=FG$6=B6Y/BF:+$!U+E]G[,M RVN"(->:6U+60NE[K4NL8:F&'AP*
M6?;IHN(Q&CQY\IL>M$; "U9WC"8%^)8'6IGI1-:)UZ'!<SF[RP^=[P9:[1UG
M3^'&?[I<\QE0,Q0HZ04)^Q!]H+>11.[FOJ%/,V@*$'WDSC)A$H]8NC-*Y)KP
M$*/.HL$UW7&1O@K*MC8F4Y L+7+K=-_6,N"320JMQX*C9;#YVA-\+[WA?> 2
M"N"T& :1H #H ^@9Q"]M[!*) KRA ''Y9/ C' /Y*8B% BP=(?%-)&>J>E;1
MH0!O$3>HB[M' ?"9$#3+%\0OZ 0$RPTABX=!SOW/.'\UCAM>X8IDNS._L]@#
M-A<P&+\)P(U5B-Q=&'[[P*YMUHO!CBXD']*Q)015M\0FZFB!#T%//E(]6Y3%
M1@&2IL#X"_1O7-Z2QVP!(V:C$.?O7Y;3#=XE/-3S";PD%@_XJE9.;;/@);HH
MP&RP&PBT.@@?>0VMNG99BDGBQS  OTL!NC;:1"C EW TDD !5"@ CSY1:P@#
M(C$*4_D3N8O !1R/40!&ST@*<(5,%:6P*@J 4T1T"N11>R&+$*@+"*(Q #?Z
M_^M('!3@_T3>JZA6FD8M\'C_86T2!8C) PWDXD.3NF6/)<C_, /JZ_Q_4L5Q
M&G;MSL(22$.-1W4@$^8TL3WS#=P0_6PO5/;@*OYMX*-\E_0,TU7KY4SU>U,O
M8FZ_>+Q?F05!)6B!)Y2\(FQ55)H\L@FZ&)FR<SW5<O,'SHFLJ)OR7XF2M/W_
MR):Y>"\R!1BF #W4!8.J\;]7S!!% ;:)2T0;>'5E!$SKLK#PN,Y!33QBHY8Z
M]:O^X&.>O5'BR3_/&X$/S>@&'Y_1H"X>09TRYA=5KWR%_5XN;1?BD.Q%OHBT
M^FNI2/K_W""*PL?TKY..]_X\2#@%.%F-C^BF^7V'QH$"S#RALD$@4:L!<W8I
M*;I-Z(C^)VF/ DCV\T$@)>!L>.4PJN*$[LY\5Y.E7KO'=')R_.Z8VPXMF:G9
MR:N4O"1\L;HM5H!@7CWU/ )-E_S(T_Y.9W(B=Y@*XG]H^!\]R)_E$8'SW_\'
M<=1.9O2*)@N=TCF9CO'61YX.#I7>3VX1R M#8'(G6(-$-ZKV(%A^XN^*,^,N
MRE8J\7"^<PG9=3&97:;R<<Y/'YHLZC>(T&0AK #2/>S%!MF8EO/YZPK:+PS?
MS\Y_4]/[/%BX?%K[ LVRTA<+4>Q3*DE+L#X;_B%7J$;>MV[F7ZZ,^7_;C!>;
M([;X-,(SQ1Z^[S[]0B'VR(U\BH5PV_9W/3$&\M>WI.R6V^5#!\;JHW:$JIVC
M%'M(9P%JC^Z#,^W:W62N0&Y33<,"#E'E+VO65*3?5P$7O*^RF91'O%R'_PIY
MKG&M22/F(/+)0:'\$[H3-1I!%,!,A^'Q)9UU:%'NQ^)-)8E-3>S=&>LI80Z,
MIARYKZ2 [N0B3\SU?;-V81!:&VSTYP3?A@)E#O1TB?F:JH6_*W[*_1L2?A=2
M*3U/ 9X3U_>B4=*TV*OH T8(SL2%:N_._9''>O ?CFO/\T7$IX9O:S/KGI/Y
M+_N2H:Q[NH!K05-:W?K+!LS07BN[[)[U&K__4!6J,=Z@'/1>J5@7".I[1@$<
M()%MS#B>@Y\)V/6K'R<',/YAGT;\LE1.M$9QI2B=ZC$9)DJ'\0C2')M/FM+<
M2-T*7Q(]FEAK[8RR*2]O?\%HVXK(J*QWIL75H)*9J)HO;-HR<8IJ\I+N7=:$
M+"^B9C::=@;U17,0_+O& JC?UP!ZHWOOYC",N1-OB>W<-RRSGOWC_E:*LL70
MRN6SLX+!F7MQY@XWK:6)BC2:?WMV<?9!7HHWPVTCXQ?A?&(OU%$.7QB6^XC<
M(8>(6I6NGUYI"+2PK0DM&?*H<B:!)GS,G?$R/2.. L!.83006 DJY.W>O#Y_
M&^?TM+;RS*(.3RK+%"DO&6/VH[YD1%_&YD?LTP31.XS)N(_Q]B)G>+X /MH\
M_WO$14J8UN\8Q[ (A#TB%G4Z=X.J;_/9VWZ7O+L@"./ X36X<<+ZC03%JY!7
ME6TM4+2F1!]<N.U+P+ 6B[5!ZRVNJ;3!K43S!59>.!]1F@.]W3G*0!2K_C1!
M/(O^IM*EK'!SPMBK:/XY6U9XU(,6CO#X3&#S7[P6:R;\LO:U<"V-0):LAL6R
M+)'C I68$9%!2 GPK^"FW?6#E\M[2@0%<=[0)3GK>)_1%5L_U%(8 M3"C(DA
MFE W@]8Y\V+S8[%=V8T-=O6D1:'Q1[LY!BO"2"M@KX!0NQ:K?*J4"6@P"8;O
M_XZ/<J:9_"L.,\P$W./??WK(Z>![4WWF>RZ1>R,)?[.-\_2.XCQ&GU07362!
MUQO ;T=&?O')LL@A7L.+_KX S-+S;#M>XVP!/B>$SAF5859C^97MTR/;H %.
MFA)L:!C>"/7 @.Y7NBKX8"MM=AJ>84^?:N_AY'9JSM+ZCQY.]1/ESO1<%D(
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M.Q[UW\Y!7K7M0(&?YPCBWZ+7(6>"G.[53-?&91VIW/7;UNN[U<<'+H1?A_=
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MGBP?.;#0&R]7,E\+>(:ULI;]GY-%_RV*C9H@9X91#(4RHX:=I-?_PO38,WL
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M"RNF?4^^X\U6?G+50&,!@,E(X.-];[%[;#<[63:!5[I5<NW+'F#?ANUDL@5
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M(VTK*P!.9?_>?*7_ZK_ZK_[OXMK#_0M02P,$%     @ >()<5M-6SLTY=0(
MO.D" !,   !I;6<Q.3(S,C$Q,CA?,3@N:G!G[+QU5!S/M^C;!'=WEP#!W25
M\.#!W8(SN+L'EP#!2;#@$MP=$MQ=!PD0 @.!#,'>?+_G)V_==_XX]]V[SEKO
M7?9T%[N;ZOK4WEU5O:L'ZG'Y<1O 49)3E /@X." 4=@'>-QAKI+UL7L+ "HJ
M  L  "@ $H ./(-IC+ #"S@\ !ZFP\$^ !SWO\['P/'\K1/ ])IH.P#A[SP
M2O\Q!8 ,^XD!.]8! %PYBN._RWR2)WF2)WF2)WF2_T-%U\[9"N3M3J-N"_(
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M+C>U)#+.DY]2&6]\ZD=-]K6>SAC>;!M6F+HU:>I1J7]N5K%($R>5>W]PC/)
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M8M^)D:M_UM9!IWJ63JB:D\7/XD8]3<%+2IX%)S0\$^\Z'_KUV,7W5(?UX!&
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MT$.TDR(ZQ2M.LINFFV8]QO0YG7]J*]]HR)7L"0%ID5K3^*<GASUHDO9GD8\
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M?/?(7Y4_9PP[^*[:=0Y@=CJ(R+?K7!2#/T6P[1,0H6<81T]0'4YG$5CI1C[
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MMH=CO9Q[0#O=99>FQ@K@F29RO4\)] _V=76>H<7F0W_V:BUF7:!Z<  (\;[
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MH"J"?6J&>@V6C'*X=EUX^[*A(B4\G 8YUU+H:/WWF;:H@0AIGXGFO&>GTR/
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MGL5# KZ,#.F:YA>U7E)"KP&+8%0?(C'!N<@!C$C[VQ;TPXY.&AS_K;%1^<-
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MX5%^#;!BT3F$-M(UG&*;(F%2<0Q]CT"7+X,1!WESN^#:X\-HL*T8TC)I('S
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M$5N%T$&YH]TQTGO&D1#$:>\\GK5YEIN>_DW]N(=H)0UO./_$<0-!K]L2F1"
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MILZF]KB!A>*30",7Z.FG6M6(/O&-H@\$!#&4/4E3F^@@&"7:Q5_6 Y>5=..
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MLD!=FVNVA:-T86P:GZ9<>%W!FS<]S:V\%*CEG:XL"]T'[;'VJ5DD)*&AIZS
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M9DXNW/A5))X;VUV.$_NI[%UN!K[4ERQA4Z#<=$C52A+\*/ZAX2&1N_L>LAM
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MBJ9/5>(&^*FX^T,4T!JX>_F\,^_G&]PFR$># 6U9!S.:MR:S,5!^!8%8K_-
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M==D5XMRP])>/(0HHZ'N\S![7?1BVWN:+Q9Y)OF*S?.:%[%REZ,#"A3MYKXT
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M??'_U+?^I_'X+9$Z4? J;OTCX!/7XL-AU>;S@LM'.#[4#E+GTA,,WZP;F.3
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M:_/M<Z\![[C'J!MX.TI@AOBA:P"'[%$2G,I/J8#U#V99/@DB6[..=;-J:33
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M"[Q2,?.D69;EJET7_-\\MGYUC[PSLQJC *F(,/,?Q:]"\<QDUH .ME43F]2
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MD(?DW4^1MC3U2] %#=ZX%6B]$(4KX>X6;BKDW?WXHCR_L=$SLS!]VEW<^K4
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M6QC^9@5%MC"-X,@ZF2OO%&24]*.I=C[HNSE:,I"OUT@+Q((_:&\L7]1?QX-
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MOJ7=5QUDN:RE4)A?-M0<.*%<@J\2HTQ4H$BH,:*JZDDXX([^<J$'NWT:1VB
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M-8))0(Z) 6R/1.6!H/L$%$F-L(BN%G9'*OYL=\ OQHE=&!U 3$_9JQ-YFDY
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M^8<(ZSA8[1@4E79ZQ_F%_"[N;5_3FY?LOF3E>XTN?+*VW9>0<8K$N9_5P04
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M)R".X+^[AKE&M43?\<\M;34&OT;Q+P;2,)>MH>F=3/<0-D"6/>!#UH/>&@E
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MK,79'/5?[(99*3@5FAJB,!ZSI4]6=PND:@%%V!-0U,)Y(,CY%:O0+QA#^G&
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M_X[,Z6=IH06#HLQO3&U@MKJ)3@Z .%D>6.W1Y0L);K_NS-;.]_)7YVJAE\Z
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M?WGM!"3R>NJM(4'UTG%9%EYP,AQ"B$8P*R21'(Y"^>%NNTWDS9DZ9%"@;F6
M5!;3\RC:<B6LH1]@E0$-.2Y&@JD#,)$46^)D^_/NJ5S1Z%Q/SOR->YDJ+FY+
M22&1#28U#RW]V3=:3$'FQZ4HES:'618T52@'\_@$]$:]QYYGLG)_D*%K9&W4
MWMA9\YI<L3I8VR?*2<"9E=AE^\*T:$$!X"\-GL.M=B)BA1"Q2T)984X3F>L+
M4W?2GDX4?ZLW"?*G?SJY7F02=N<]*T]3?TO[J<*@,FLMG8"8!YW44Y B4$O
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MXEC CPYU0'+?))(5^I929N,F%]$T;N%?2$Z-WHF^(U!_,*KPGYQW:4&*C(]
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M:)+R/IER8*SVPBB?A2+5^F3FB^H3MJ)^_I^$=RDTL21@>PA\^[''=&+*981
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M%2WN'L*6TJE3?"2KZ*34F%^(WM<& JS=AT.'I\B)78G3 \3:>$TNH)C$U'4
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M8&Y$Z&AGPV2DNI_T[(8[RY9\)]K%3['*SK!;,F0827J2^3Y/,<D9>?';X36
MNLM]! K_6HCTHB@E%@!Z=\=^8]BF5FK/->"#TU8#EMP?#!K:5<6?#>?0-#7N
MB3SGF00>U^2@*&]P4]RP=@+N_FT9Z'89II5)T7EKX:[G#3W9);<>HR7F9K$>
ME';(&V$%.7%Q/?A5G2MN;P!ALEC/(<<Q)?18A3)78\#!L=C[@)/=Z/Q(_'B]
M/,Q'>M[F8]*#KL:7PSY-[E=]:AF^,24CS2<UKSFW5J)BJ>:V--.LR6[S))?
M)CO&D9MEX9"[#<Z?#*W<%[Q$4E0:MNW\O0?J>MYLS2>A;WV\7_74N[_UJJP_
MB.V4"G2]5KA0<WP+UH-[H:E*B:1Q/,<2/=*S%3<31COM(.7I=Y1?@?$S?8Y[
MS$MJ42WPJ_<;46RSXJI<OT>1PY5J4>5'(&DVE;W=OZV5H&VS410_:N"0@](:
M8QV$9EKF;GB/C:Y>*VXLS(G?%),026<9O-DB;!8AJZPTKM/7#OB0]D*0-PN
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MW4QHU0Z:AVE]:(@I[ A$Y+1E;0K.8U<(K(6[<)R=_.0^M6SH%4JWAB'#X">
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M4I1?IONEG[SKU:<]/H^0=MFW,C,';%SF[J@7O6PJ^"#[Y($>O-RK%[D1OB?
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M0T\X?>QST%_N&/P_4P*44W?MIB-Q+AN1)0?[4UAX978L$,1[6@6B"A@Z _"
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M\9I']X,Z4E8(#C)5X72Z=OUW-F.-^5T[H5LJ[,#)W'WE[;8S (Q%;168ELT
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M>X=C)[YI?Q--UA[):939)3)!9+31SE#)\N&<;,;QB7]_K?,LM:./R@)OU#K
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M^XFF^Z_K7MRF2]M"I[D#QP<G#R^G_W,\_>Z(O[,SXZ.#;,:.^,D"\F/@MS/
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MPUOXLI]@%ABZ$\Q0Y0=AADO^J&T:WWW9_MMY#^8VZM-?] Z <^..M37^Q20
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M)E8,E&(#;SZGXXG](?U4953V!A,ZO],JKS)%MTV*&&?"0BR9H(.5;7$3Q3>
M5>,M")H^O'2GZ9PH01/3$[T\2+J0;\7%0WLLDMKOIHDQ\1)?X;9[)%1O^>%:
MY[O<4^7%W>EX#&<PB',&]J6M<THY0IK_=U^!TYCRNUFK^X-5WUOQVJ6'&]-W
M6&\&<=N4#/R: N,,I1EGI@)Z:ZPE1[R VY((M$7?^;$],$_!SNEF[?C6/%=/
M8)$SOM*#SLR+%4S(>VGX0%%O%%5E6MX16F)<!5&,6\2*;H%QTMC9SD_@R #>
M=>.9"<N2*GGG9H>/G2)1MW)UE.+Y_^AB8YDA NRO@C15=IJ929<(?CC.VZFZ
M.,;0E^KRSC*T'B)?'>KK+BS9[[OSI=E/V2>['ZK=??[J5EEPTW/B&[@58;)T
MGC$T517:-G!Q<JZ;OC9R1U+KE%S)9Z!*_3P.*_(D$OW>F^LH%[\"3*,J#>A&
MU,1'PQ\O%D-"(9P2DI:=G-XK5HSM%L)TDHI!;+PK<5KK?(0X<UKZQ,P$=IDL
M1T>Y-7NZ'JK'+#B/KY^T&C;\B_!EC]$J"^FZF-C7S-YT(7ND'R#D_0Z\6705
MZM*:\MLQ5+'S%'^R2W:??_$LVM6-VH$F6.]IZ&WS#[[]>I<*5[M(K$1W.!LA
M=/$++B 4+_V@83S=ISI*)7$A#*MY(T*D:>]FAUIEP[NGDSTQ<F'<BF8:.EZ-
M&NNV3_>K[/ *6R8<^^I)77QN+:TG,@./YG.XC]:-NS\U>?S9)!A?F,AI> *I
MOI7X^IW\=3RWD,]51,&#/;]'JP9QX7Q,][UWKO1[QC\?\<JFWC/"/Z[UWK56
M)#X,&$H';C7B2O<[54>4>6+;[M>H.J2ZU[GVC.O L,XR]^Z;*CLXK'WU#G,K
MFN>W#IA'5AED6+GNP6A_SD\H'4FK9P'-I>:-.:+%>N\LOY"I:A6Q^_$P9+QG
M8&?-C>]6IC>0<I'/0(MWK?0(K.O>-*:Y?%_HN-E!Z)8UZ>T9X.1X+<"#<$R$
M$6@7&.,EFIC][$L)M1W#4]7M)V:ADG8-*5UN#,%N>]>,-^M;@WN9[\K0=%GR
MMH)QQHS!;\=;(?2P^?8YJ6&XB$<11QB"T4!Y^H!7K"612X^^HBF:6[;>W)S]
MOL*+4+G+P*PS0 5I[ 0=N-ND*?GG!!GA):EM66)!7FLT$AE,J!V0/9Y@MT\H
M%U[1V4'+BWX)3T8Z[(JTJ%N$RQN.'6P,#*&"P+5F;=!X?JF,5E-6EV8N?-(N
MC*2&C69V]%)PYND:X&; HWYUU%#-5U\]W#(>_7.Y:>!ZR_4G^!3M3I.LP(7]
M]40T)8HGX 8LDLQ#ND>P7W2C,JH;@;OFPU(F+,R=:Z&7=W*A]4V;UQ[*LZ>^
MB@ZUN;?\:GK2:)8GG,0&OH/[\=XB/JJ9B?0<YQB>XF3;-'ZP>^58R91F+Z*]
M4N9C0KT-Z(F4X<5BE@O7)DNUTA$O;9P7V?B@"%09Z=(F-X/)5^*LSEC3^,^_
M@@NJQ8$(B]U@N$9I-)+5:<\0ND7N4/!33S,5:_;1TF[[8$VMOO1VO!_%#5XH
MG*?Z PQ[.WO4-L R14!UZKM3IN7-.:<>_NX14BT]MEIX5,U6E2^7W^[WY/UW
M11PD"(%1PNO$D31]O1;I75M!LNES*XO&(PIJR$H#C1Y]XBBB<MLLHO?UH$Z+
M@ ZOY[/J(C^5.S)FC2-$/@UU81FN&0<I[T,98]/:?9&2 [\_X->+";7XBU3<
M!QI]^LD0+G(+N.HHFBSN8JU(\,>S/BH?58=@S 7JJD:Q23>NCVY=ES+5KKG-
MYNL;+17HH7!SX=9UP\;#A-.&)C!.J$.H154JZ.OYTD?\EAQV4E4KTK%G?G%<
M)CK5R=>YM7!E!F/R72OQV:&5Q6I4\= ']@CC(XL?)\"'GG%5TBA%O%'K/$%,
MI/D'7NTV3KH=$OZVH*W/J%V9:7+M*&$>731MI)#_P=0A[E;O"U12B$M=;SU"
M4GN#*$5MA=7Q50JS^IE-81.7MZ>Q/Q3]Y<G-D<T6DP+Q@HE&+1/BO:)!1LD(
M:%HMD](J'^,SQV'\P.7#??E*(?%256X9ZA:T)@%(8,J>*/]_0$SE/T:W,'-0
MT@712Z+<H/> Z9AC"4[>+C5-M^S,M^/+X209Z':9D#W"J4PR[[@+RK-YW_=2
MG("0T/!UE"Y<#V_7TLR!UPH/JX[G@B'T\ S9G%OI4CE%FE _KQ]1.DOM_=RU
M=3>O4 DSJ93U=:%);*VZ9K^X5&:4XND%5E=4*%ZPUKWR&,X'>%J8M8&G7!<@
MVW:XNZTH9K+B!B>/3J375W<6K!'W?$^!M<BW;I&.#(D.\[Q$>-T@CT:%QH@3
M=<_+TS<U=M=FE(J62,4C0,3=<4&4.)F/_.L,4%W;639EA$''!&@\BU6[@WNR
MW5Q(WS[.\R:2&!VQLG>MIN)5L<2WKSRFM'O:<OUV<4JG!K6S*Q=N:%[3_)69
MQ"#?3^6QOOX'P/'U<Q2@$Y^T68+1L('9.*^V(U^D$N6)3^LJB:9MR]Q-WR$]
MC%4U\QF Q712)^$Q\0)Y''@9;E1"0+:< 5CA5,^QDGY@]S%%(9&#[=;*XQ@>
MRT\@'>-^'Q##U0^T+SXO'F@FZ 4&_/ P>/KH[F6KQH8/"^0W%_93VY#!\RSJ
M;CBJS@# :2Y<)Q?6\VA\1S184N=NF(BEY?4P:7'W3=T/CE%/DDR\8Z-JVI#O
M[59FQ0^OGA:%A_!BE'+PF[H5!"T^>>=-Q9+"E#/ UK5*'>['%V]I'PO!8L=&
M8RHN"=ZX>W)WN?0UI<H %=O@17%9WB!;ZN-XZ#[A-Y4 +A73'(Y#8(["FS@Q
MQ9"*M0;))(M[WR(J5 #N*5911?8)*SHVN9Z-RMRKY5[T@=J:&V(LBO%JVF >
MC__H[* H"R5(>)<GZ?++XQTT4)[_X\*.O^.!0TH4P.Y>:9Y,EX9.B:_.MAU-
MV58M/K9^@"30,&",6.UT.?"EO;E\6W1FP>P7@OV<T$#BYME0&.DA%":?\M/"
M #/M-)2@@PZ2<-B3$)U!.; >1PMA12=77BAS]_MFZQ0'_*K!]Q&EX$"SVS\)
M\CK/@$;?VSK>(B<7(0UUZTAK\65$**02C(:&HG#ASF[$^V< )X)RVQG KIKG
M D[D'=BI/%#P-'5@WT)KEN7E? ]#_8#B@<)K[JN!;BV&C%<9@4:(_J#=7/7&
MPSR"' @,OX O"$S9W%*V^)&MY)FF)#C;(6@$7;D:!Z]4>!1.DQ^5,AT2#!;R
M<@-C4]NNVHZWS"D3'+$J<%=8V>$5A6EP%;I0XJ%OW/,DH*SP1'Q]NPKS?E:&
MV1&'_0R5\&M5%HWB9>@4H]#A\FE2:N49H-5"=^"9L\>X*9#=C&Y>]'%?Y_($
MO/,F5\1:_ <0]4;ZZA8GWA82 >1O!FY86(7'ODS5&?8JX<"YR,(0;CT*8[7,
MVLNR-P6MW&,:;:_O_4Y)$R+RHB'EX)_ *<[VUZ2[XR0Q*#;ZU)O7+Z3$8E.Y
MF'[I#IMN7LQ=5?3WSG+,^^>! RHS_JB.+.;?)-=LJ[4L@2$)KQ*>M;)/!2X/
M=3R@LG3</CK7;K3+%=/%<6MN]@5HPEV&FHS.4?A >UF@-2M^#)5-XOV]8]L8
MW?9]@_N]Y';2K\-H>4;9$GF%P-:MKDFZ7T.R;R,*L463[GWB3]H69';RJMX]
MVD%^+]@2PDDO4FT5+T"Y8>@6R%26T C]>N,(N!JZL*_>2(S(/;;]].A58M'2
MA6'1+!0<_A!'3?BT8*7?!L0E;,ZQZ+<P\:##W,D=7RVYEO6HH]R^<7K_+%A>
MUF>@[B)9#<$?+2(GO4J:#' ][5,IJ07KRO/01MRW\<=Z^=;NL7:>(C4DI25>
M\X\[-!>TC:/CAX$QX%I$*^H*G'I<W0[#R ^SZU"=<K:U$KT;\BA*OU[T_4W-
M%0O?0M6BRK /('-FCKMM4C?+;[W]:)&99)D8U"MS' O\]AS9 (-V "?G+7&0
M;=YS8F/A@YZ/C?\,6]LL*>P!1R\Y8Y12G-5M.9ZVQC0R37^HX[/9AT#@E 0F
M%,6TA3B>$9VE;F5@\^@,0%U3HPBLN.(3M&2K. 'L[?'J'UT/0?XR8B?=)J#P
MTNAT<#N"F72[85@=DE-?_WM<)^S&5I5"8F\\2SM7Y-W.'EZHA)6)<.S-*.+T
MX873HH/=6!RAN 7!Y#!,U0ZF;;)<^OXDTHM7GL_Y,##+SMWC9OG[SL3.YC>
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M5>T^KMH'NGX!8,=]_R[Q:L?MI+*65R,XU>G%2VFMB0[_OLTLVV>#20UO4KN
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M)*&AGF"-G"+2W/RU++=2-RRT?CFWU/)1TW13L':U.JOTYV\%MU FCQ(!=P$
ML^_PIIA,C(XEKAEMIH\[9>P):<S3M<)+J][Q"<\2HO76:K'ZY'U%_\:MQ!BA
M7\D,D$2"-&X+-9:P0ATX%F=)8:>#VMU5DA* [;'H@/,,G;)!M^Z.B<?=D@M[
MR?@U\[<D)_=9,]F'KJM=(ZO,N),/E]D]5(JKU_B"'CV)*<261S?F]AH-"C-U
M4 FF\YRZ*=]+H>G-,FRG<GZZT\^9K?>5:R*QU3K-S*KR1,VV ^>QFJOPPVH8
M00^&_)B_DZ U8VH $_?+<&@ 7.=;:%EU(:;-0P:1%&IRX>[$C)J&48YUWCP
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MCSKL2V0Z8Z-ZK!_SW\Q7[ASM[IM?4GN&KXM'T/<5^_;%:'_[0L'9=0\[-H-
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MS62N(+KR:[.H1Q> A%J#D=H!@6BO(N 0Z KA)0[F@C&SQL!B"#I>JR!.C]$
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M  U<%RWHZ3)E+48X&E,5K;4G9,X+I%A1TW&9N./G>U 7@.C.&=1N,?I'%MM
MK#U83BDZ\>'?00O*9QDCU <FA2:/RIM%\[6Z !"+[0M <^D^!SI#I5JGEV,>
MV+LOPDW=V=0^6=B0MWS#H@0OES',.;\]>RRH?765+YXBZCP7?3B@8,=$8$0A
MV=UJK2W_G).R?"H6'K^JJ!<W>I+Z.8C^P8LZ@*\6M>IT^AT=QJ)?-:%G(5,1
MT75_TU7VTJM^Y-V;$/IVQW!/Y,2FR.<#+1O$GG!?\[GRN=':RZ4>@'1*LGZ
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M?_D:QNFP1Y]U)[EN!_FR+GE7OS.B1C"K6N?V[91L!8D.29-/Y<%2-F9[ W@
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M/Y&^[L[?JB'T#TZ*:09)EP3KOD];35ELPB*>"(F790#>A7VF.[8@P$YCC+N
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MBW#&MGB7%$@0MF?M7U4I*<M'9>7?2X4"X[^V[7A]XFVONNL0$6O*&\"L]Q,
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MDYG[NT\LDE3OD#2#_:V;XDG:L^6'W]5/5A0#9!<?9&W=S-0JETFV>+F:N.[
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M ")D9A4V>P33C6&OO36X??R%N>84\W/\461K]I\"<X=]IHR4CQ%L08/<?\\
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MS[M&(CG>U>I6UH$-[SX*NN*<; L^C)T!_,X 4<9K3N?ME*3>Q$3^7<-.S_?
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M<[I6!9J1PQZO8I^QTG-=2?256W'Z+62K7US/B53W_'%X# '/\#C7W"KF>&
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M/M ];R"_=DM-2,UZJ$3![OH6M*X*4U]1%]NB435$%ZW_'N[U7)U=_!'[;]T
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M5FEZ4CHR@BWP9G227RXPV'%V_OT'- X60<((Z+8,F/$@!9&SNN/B.?URWCE
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M#>2"S)'Q0PH!SEX!DC^-36M5!=:0TN;+1WNU;I3J *?O?PR#6R?KXYF>=)F
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MYPI:-2 79<8$[V#7H%BPFYX$E<F%V].8TNW#7ZYZ Z # EL0DG32>^R]2J\
MB(TE*<&G0',Z51ZDW^^QRAJRM*:<7X3D&XOB]RSR_=*:C%NU%%=T=:=E*'34
M'AIBIU0NSP,^F7FF(5T"+(@C?S]S]&G70!,,TW6-^VOMA":+K=6J;+A,0]G^
M<>_=3GPV3T)=[9!*<H:6M^UL,L''<NK=J7UNN<4#(% CZ',E.XPT,LN[=MX*
M&/0(BHBDT_H<FYVB!&Z7&;CC/W7TXV/V,V6O\>FIVB/Q>4[Y J>_Q:""[.EX
MA@DJN +H'U('MD(3+B2V?D=_/Y!0#8(X^T#<9W[>I;J6^I0XI>O@+>:GN[OR
MUFY4*F;6Q>V,>%\[GWL)>P6A4%NHD3R><!XG:M9O'HXZP>'3L6"E5*$>?6EU
M[ ;I"R1_?'16()2&[.CAQJ9*7V+0#>B7;'S0[$[RR-5&>[>?T_N$DU6@SAJ7
M>-<H[L3N2:;G##KC+O'06X)G+*Z&/L3<H^B+@3]&T48\EZF^NWB.R!MF[AEN
MDNICP*(Q]@'N(T %2>+%/8!15$#!M">0E=Z&\PH0 Z32Y U3G\4^?7L:19=Y
MQ*7UR G17;KP9;**T54&^]R"&]"8V[W?W-Q/-.:DT#\7_0+=+ M"_KMS!U81
M-/"-DS&"R*^*:2^:P5I1/+D?#;HA#J*BNA.(J)\<C9=@YISZPG2S-?KE(BJX
MG\IRZQ C!03:E'14L1F'KS^TG_?T[P$'*[YF.4.>62>:SGHQQ*!7;C-@<A)A
M/8YX:.9T$='WX6U34IRAW:;@472)@.^I-Q()"EY)T :E[/YJ'T3]QW%OLG:6
MY4IV.Q?=1D5OL &GP99AYW#=(^]T<N!ZAG--I?ST@%2SN26Y_".I]6;*-F.#
M[#%X%:D6)_@>J$7;8T$*Y#16R_EAK%!L-.AJ^NUQ#:OS8'PW^:BBHI+3=-"K
MH$V$>P"2$72EQ038F3GH33\9.,?G[)*S?-6XO/,>X65VCLBG!6>IL\ORPTJN
M7$_(.04WM[NU,3*[JP^+Z. /<1)D)+N%+S.8KM_Z;+3JK-B$$7[@&J4$X[]A
M2[<,1V+,F9RUB5DGSB0G45ZT-E67I>D+IOW#>1!,A(,YG0^\-/"96NTI;HN#
M2S 5WZ/;]"W>;NWQWZYV'X:_Q\G0'#^LA!Q4,$SF-R0@)5-PZZQ(K,(FP.M5
M#)&Z$=W/[KY*.TW239XS+*:9KK0\/9PG<L^O!+S&')!_.6.7"&!2EAP<5EHZ
M9A4S$O1S),@JDOU Z*3"$;.R31VQ5\/2QW^S'<TH/V4J2YO\WIL*'M;Q@&15
M9?"'D?F)^'JI(H06PR>IBR9?4J3\(02%;[Z_X:=/IT:GB@&BYHP:C.TTGE<E
M7(Z=2+\M(*GO%"&! 9>+B+A9DAZ7N:/!2(XN6A,#L8YQ(K-2D'+^:['AH5#N
M:MFM3GFY=H,>*T^P=Q\+PKEK0.FH8\"6Q.R<<+@>>W+<6@CHARS-U CT.3:W
M]E';R+M\89[.\5J/_!J&=]?/4H122HL2 *T5%UPPZ3VP1CB./:S!R,UK:VN=
M-LQ.@NR.:X+J%-0:4$4:-DUIAH6BF2Q//#*+]/%C;+0T& 50X=!6+7Y4)>!6
M\ G#B*<GF@<):S5!V&4W^ZAI)\9JF8%WQ"("E'A \-H:.L; QM<2DSJ,$YS3
MZCGDI$_R2Z]%S9PN9LA"(O)%.7W%31"MR0O/G=PLD<YB<.LTU\'I+H.=^J6!
M1#X5#ZA$-@[+DYQ99(P\3W,R8*3\)K-\^F>!VG0CP<+'O) Q#+(4G*"H)#$<
MWLSQ;Q^AGJH&F\ABA1B'V VIG> <D.S84TW4>*(^^  QH*%0P:\\GULP+LDX
MM\!4"F--7W@WT"32YY;C(8,N55.F%$!EGS?PK67U!4&/.93YL&0K085AL\]=
M0;J;4,VU^5,#2:4CNUG]#].TF)OH)15X+V//_V&%&/\QJ^#^PF=B"#5^ED)I
MDWY%OI1);HE/XD:!U\'E9TGEV=E)]A[S.S15Q_F)JLVWBAS!'(.I/.V6-%FZ
M$']N$:04A*4N$<%>^5(5'ZDP9R*\4JX"T8P#69P9OW=[>)OQ:Z[N+1%4'B=8
MZ1 +:RY=C\J.;S?R7NM^JK63[\5,[*\7?-U[WX"Z, "=09T4I8T0K84+'Q-E
MS_!$'6.ONG?YC8_#&7!PWVLJNAIX](ONH2#69BUV>.4_'UP7@>AI,:K8,QKG
MQ_!U1>]FX^!2MP4XQ!=%UD4=G!*3:BJ<L5)7X/7D@3<1/\B2=TE"!\><-$G2
MS@6V:Z9T]#.WQ2^EOG)BE))-1J0RAKKR]W\^=!B+3%^7QC50\LF5I'OF_T&G
MGRH4)/%24^#=B!C+GS"S<0Q]>7EX7<T"5:6PCF#@Z;$9QY='!'C%1("B+'-)
MW[<VO6 QUM\'?/,PSD<MNN\6^TCMK[M\:-R"@<V<-/WN!KPEH7+!UN\CA&;U
M,_%AK+?SGO3!0C_^%;[^,Z++?%=[GJF[55XW;+2HAME/]7/Z$3BX^X=OL8 I
MG:>Q"MCPZ[)5H=PVVD=1,$YR:=A$"?GYK@P%QX?),JQ0'L>,H]%D<[^\V-@%
M90BS<<EK50^*@54E=L7LY#DMI;6<_$SD<;\,+G^F0HVR[E+%>)1)? &M-\%H
M_#E/-E+X[US9I7#1'3[W%X6M&VXZ&JH.-B]Y?Q5GW1'I4V+\O4&ER^JCZ)+5
M-M%P&INZMSZLJ\H^0F&::VN_?(@6E_R(CP<ZZBKF/?!S.J\.%AEQR+G/=)*.
MX/\UB>-SVB#('GD#*8<_6VO@P%/:(;7FKJ,L,V7YQ_>O1\,>%M7YBCZ*GD-]
M8DVT2^<EGS8_=]2J9FD\LF-"+GN/3--_:7E48&/&UQ8;(*:E;*X $/= 496W
M.V:V0]=5RC>;.<F\%)"XZ1A1+%S=Q59SVGX@%:7*3UBGLU)\]R!$5=#6A9*1
M:[HJ(87R)N%JLC5$KB>@"T+7XRWC(0L8L<'2/K0.P-Q_FA)_,B1*S6\D]X!1
MF)9PS1>+J!X2AK#1P_A9ZCF&IL>[#=F)V'8\4C&5J"W%:I1C_&7=KKK*]H:1
MR"_QQP+SPF0(U<RQ L&U$XE17KR,]<<J9T&2L4(8:]6D .X;=T45FC2NDKR
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M%A2'&F<HI2@P5EF]&/(=DP-1LPN91=)00#?QYUK=Q9P(?(]Y96O!;.11R"P
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M44Z"^S\9_/<5N _AVK\\#G<_^'] 'D >0!Y 'D >0!Y 'D >0!Y 'D >0!Y
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M]6.UOP*\PA<QM;ZR"H?ZET(9S@UC[9/,RN!(1N"Y$MTS AER265J-:AWP3V
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MKE(6[FXY[777>K?LE[<7TI70E2_W 'YMO/[:D&E''&>Z3?4U=N1"(=#SD\Y
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MGI%#/(D7?':6]/%M)O,BN8V459 (R($<1S>TSO_7-3.\CDBY%)>_Y(2$XT:
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M;$;(I$#?.J^;F<_G+_?(CMDK)6^3@^",UY&C0XJ)F-_X^BT)?P:/&XA%6=T
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M6QZSS7BF'.5E-SFB.P9!WZ\8%*\L5]E?[;KZ[F5 R_SM,]],YCMJ(F,]U:(
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M+SA>\^"B<)\; .E,\VSQ'-/Z$=!SZO]>^EH%X<ZFPF;VW;$T;VQ>*1=\Z@9
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M,<P/T.<W.VH]?8OF'D7?:TU40^@&%P3 &G/$[9&VPH]=>@[<=!'"7/V1WV\
M<6-7:2@!7-8.+/DE#^)#?)>;."Z[]I@UM4@PP^=+"+V5RH^/1:E[SU_/Z(AH
M4_>1Q=]ZH"?\(DZY=*R Q4]3^ JV6KTK]^X2MJ(T].E4E;MIL7G2XRE$>^Y<
M.JG"V6HMZ5U8P*]X3]7%S0F&?'ZC?(XOW9+_*'44Z*]^\J;,$E\"_K?ABF+>
M7W.7;H4<QFK/"ROT6H7D147*OHU6JU[ZYWFW#Y?63D51$P(:YPQ?R93^A-3^
MRMOY2\=85 P@^8$DD""/JE? /^I/W"D,#72S;?+I#_,A<UV2<A>:D M:S1[?
M_GK^4624.RT[0;98I#@KQC!SLGV5H814?KC2.JM  P\A(C> K:)VGS6*'>H%
M%RIL7JR)0$C]-\-,>?;4&X E6A='_EU$!ZV("A>MO $D-BZ$(K)<@J*>8XN@
M6_E\NTM#XF'#>KO04\-JYE8+#NZI&<]OB;#]#V<4R?%O(S8IS%I "["F9%CS
M#: _ MA7O0-$::PN&2<9W84XREG<HYPY_370< .8]CST17]7&/GJNDE3_SVO
M><E_$+B5Y3*.+0A_,CF#,?,;A[UU<TDKMT0UI\/@A@(*NSBFKR&[:6?V.%[H
M\QO JQO 2@O4F2;N;URL9I>RMD^ 6X!6!_I.TQ#*/LWN$5^J<L94V%(B#4H0
M X7_B-M)PXC1MG<9XT6A_&QJO*HZLM?/_K?&D"_D@U+8FS+6C(.L<[FGU@UI
M]C"X*0D56@'E[S.AGU@+9W@%N=3MGSNR ,*?W@ 87#NT3@]WLR*JS2WOY^ZP
M%6A>?[UOR+2*EQ:\(9(@\^ELB8G7Y>,@D'%:!=!5(JK#]HP 7F<.]RZ16%[=
M(_.\HN%Q"=-];S<S4C3-IZ!I,&8I]X:RLQ&H?#F-XK\89)$X_0Q%"+WSJF%Z
MHB,A?GY^V!9#_>.72#,YOQT!CYPFV7%_=/'^FW4KM@,3ADS5/FQW-T/KH,\*
MU,95T/RB2Y(FOG:A[-?.^UZ&0H?N>>?>A(/5=I: 9P6=*2!35-!N3DDQ;GKS
M'LK+*R)8>M+?O&%^L#6;@H#AL;X,IV=(U.J3N9$>NR<T?]0?^&R,[HH21$!4
MS6,<\P\5=I7S Z<]7XO"\\Q13G?3@*ZU5KU ZM7-W[K="*JA@N*\H,SS#:^<
M_1P6Y7E)I<<9*6<24X&$\_26!AX?LB\E:T$@IWGL/PW!!7,/2 -V$;5Q.%_9
M7N@R]/N;E5>M3M5G1:GEPQ(H4)I&_IMGZJ'?:P5^K/OGQ"%X7)QG.,<V5DIM
MCAM]_T/9ZJ"3F_<K-TJ#H2@^O0D=3Y&H3/\YU7*/[[Z3O_5&3LLYS4O%&0R-
M7/^]"WW_$X/$B#, WH-%+(4)@.3/C"L^WQ[DF51,!/A(E[FY?B;^K;N9DPAX
M[GJ0\\]')2I'KF7V\?ZK69\"&,P?.Z3JB3/T/'MA/#0KS$Q2N*O2@ 6+S<\;
MD$SC[F)3NP2V8:FK'X986KCH3D 2'3D[P;L+,@*9;.J2#&ND&NHMO([DHDU$
MC]5^UG1?L7LWWGI^ET1$T3\-!STT-M3K]AK(?*2CJ\&3\"W+ITPQ\3';I,1B
M3J+80V',/=<OM_PU\&YONN%=?&R OS@&SOSC]%-+X<^W2W[>^\?QIU*Z^.+E
M(\N*(^D_60J7V9$+%W_\9QTFF=8V_AL!AF:#6R &HYG_AG6@T^[X:"L,"LX]
M+XYD2Y2=J\"[^_B@0 ,@M/VO8KGB7_.D'"2S!C ,2/E(G_N?X>- =? AWVCF
M&?&9-"7^!H=_N4YUD).3>%N N:PXZJ.J8M-2  W12<XF<]?;YPCV1:DO>4%O
MBHIC]X8VC=M$8,(1I9C:'N"](UMFT! 4KA\!WM(?.$! 4JXX[AJWU[>X-G^\
MS#T(TMFSR7Q^/J/Q=M]9V;Y1('"$[P#]+;%B=-#BSD[IW"O:(70_<$)3C9\@
MM; @5<HXJ*SX<WUQXKU(0PT&P/^Q_V/_SXS'TR&2*5&OYW UNN>6SLX_K_L+
M0P-*7<A+LWI8=C\! A@6,UY$^A=^I[F^T&[BDR+R&O1-5QAR);@T-NE_HU!N
M0*#!\/]U&^4W=W3QCS'0D9^^%<FE(35A'37-GQK7PN_/W_DM_TQ>F7:9:T\#
MH/,_[Y#Y>%^J\+G\[27@KD3\)B/*_TM_17#=0*AMK*=@MM=.^Z($7TNJCOE#
M\X52;JGTY,!4D/$@X,V+%R"_UX]&^!0(^7[72+"$/X'7]=?>%]<?! G.8!Y^
MF51<TPJI@0VZ48R9?-3DU"0W?^='[/\+HJ[&0<6HJ[/8C 7K-"U(CY]$:.E]
MC_$6]Q$7L'!H2XC=RY0S4J^^16J?_NBV24]O F'%UH];,__MF?/_KID)(/R'
M2;8_]$&9@[O,"Y[]9-58K!![5VB1WT^OS4?U-GK--Y^S97'>7]AU+"/;Y_W>
M*[N_-P")H4B@^!*.PG-6<@QR>R4_V9M3:/N14#3,8??S;OD_N_LT 3&,#W S
M,+8N*3A2/Y8+GO:E"=GE;@M/IRBBC9UU&_F%&^?TXUW[,R1'>!J1A<1@BZ_T
M5^J0(7BN%:>C3^<>E.':83*W6H.PFA;.F)ABB4YOT)"=B"76%_5K9)HFPJOZ
M*6Q.<UWT#8#X#91]0[U\$]4_E//Z.-/=@&3#HWRBDI_IZ=YN5%Q$%:$"((=V
MZ)*@'.V*E^F/I6$K-(.%[/!3$#WG_:4 41V)K[5K1AX$;@1VZ=V_?7A'^%]]
MM+OSHG_D^OW2E/X-@*CKMQG)UN(ZS0,NE*Z*PD^Q6%#N85GPTID;XM?Q;QSY
M(]7O7]RXX(VOX $;W2G;6%J^3P38(N]DWC1/[<9G#O-EF7HEN8&>E+0Q8;#^
M&P!*I#4MG 9!/=X/:Y;HYT*I2Z.W&3(V5H^6/H4C#;)X9?K7K.^&E$B*1,YD
MBU0+WOYZRX!D%=+L<J:QY;,2U"<;"DNN<R[4/4EK6CY2?*,COG]"3+XCXZQ!
MP>S9V21LF^UG,6.U"XGC@EO2D'MT\W]K1M3U=UZ0']$T/JQ:=B<T0BLG'Y>5
MQO>SB=S^S;:W>6U]VVN%?0G#\!'<UX?M!+K@]1B(.^NLFS+_J#"P "(V(B$C
M&[UWG:B.0:P-*&**_+JR7O[!1T4>9;O- G7 .F-<95]OH-1/"?O_W-&H/ZKX
M8[HXD7[&YZE'[_7PUSLQ%[9L;0":7F.QIJ56<<VPOJL%VM 5XUU[7K-/-ZA\
M7XH]?C?65(V4C_LPVD-]PF9-+GQY:A-U59<)=8 D9N%K#*X/)$.=#/C+G)7'
M-8L_#LE9X--AG>JS>I? <']AO7ZM.'RX /I02+#K (@2.^PU*HJ+P00D@Z=C
M<C35Y&\ :5\+P#PG:EP1341&SU\3A[+2:60I/3_U'0PGA\$MZJ(S7X<_W.VB
M#IG[U]0.KHB_()D+8"/XK&!K>O4$1^>[325G,S<<%U.W>@/X=K:5) B6LTO6
M$,NEV&M3&/9N)KCD^._>9>,_,=+GHH,@2=P*%W'W[1-"#41=JMBI3#[=7YMF
M>EMKC5\E!&*O^3ZVBL6;3:RUL7]5DY_ -G<1(EQV@OK.1/O!)%=SVP7>ORT3
M6L0- P@=[!M2R?;D<QE+;>;*&G%G.DKUL,[[6J,P2KQV3>)D;FE(](GO5EEH
MT3VBNRL+XHA6TN9^[^V6-?'^J?-C;=+ )Z^9L\?MU93T4>'#O09F07'A 6UT
M<N(Q)<+#?AHP;N1N*JK.$(57@T3W400(A1KQM2$N>(+[G]A'6,A.F$O3@S-*
M?_$AJL98$S:=#YDF( 2%^28O7K\$XT9Q)+,7 1#:8-/^Q[/B3QP.?ILB5*Y:
MFGE*36Q^Z?@Q^/B54((0UG;Y$&4N^'/;%=W=E*O!X:AP!X3ET>*/M8WE8(F!
MQ;_O'WQP(]?AR?7FE/6!,#L9U\-?#T1&($I//H&^EUFZASJ==9=\V7S\078I
MIY&,MU#(X(C?NYVZIO3.>+K6TV^98OFBKU)+VOZF+L"%3J?15!@K;!9((=CM
M$AA?/@@FER%XT\TS"T?:"WA8!#[SX@_A W;%CBHOPR:OOV4+LU1?E%*:2U&R
MT_;NUBT=J='AH9G@$-Q,,I1"CPQ%Z==@U! <M=CSE%(9*,2GK%AE_+II^-:I
MV1OCV&R=<6H"%;6Z?M@:WV[Y@,^J$;H/2J=L]AG<)[XUGA'AN.VAY(;_TQPR
MDR_IQ.#"1X>/Z*?B$P\8;3X/](*#<=S!)&JHO.V0+I6=%$&8]8_#PLV02W2]
M)<LGELS@_J]J;^@TWY4XF=^J8::C.1#",)7HMORXA$3]#80X$N>66_36//)P
M\F(M-7A2W&M(:T9>5<7X.!(PS/*99N&>H?C:Q!"#W_GP9T(6_L)^8"WH(88$
M95,+[L7#JKL$&ZI_./1KTY=@,]VXL&$/90GQ9*.G.\-Z407$"P:-G4]Y^S^6
MKC,>_!:]"D*^G_6^NE@YW,G)LW?RK[3=0)D91Z].30GFA.QYZ&0[IMP]"')0
M(U?@WX&J0K?BW9] 6<:)Q&\ =$;,U.UR$Z!\1DQ<&< >U*?8FGP#< *O)0W8
M-G57AOE7_OP4,SG_F.S^$]^0#"NV:AL-1WTI#UV/.U3,X1G2]K_L :#&M9$:
MXG7:Y$P:H]?^42?3P%W;-#!;EV@E"HJCN.?D5&:!;70-U]W&/GYUOX)I<[5O
M:B=(()[9O"BC8>';UBUMDI]0E(C9:2\"B$P'4@[WUU% [H =9:M\DEZNKH6H
M!BUCH%>S6IU!V4)ZRRNC>Z\(+PF!APS>C"B6&P!U+_;+#>#GIS0,QQ$8D_72
M"@%%VJ'RT'A<<Z@;\*&Z ?0IRM0IG7+;6JY?XW32)FX AJ*[G)[@X.3#Y*T?
M))?QC6+YE;?#C*O'@$Z,]N@'&&Z!5O @5RG'P%[^BOKT[A+4\BKTWS;J\>\V
M$86LB66IU+ (&A L1L=PFB5'I2A7X?@[F!R :<:VC8%F8'"#&\ [6]+/F@CB
MN.(DXYJ?>Q3^Y&/X])PG6:5>]%S1\!Y^E>_H'G[:!]7?BYM,#VDS-XGJ)XSE
MAE/K,P__R/H$'P4Z7)"VGIG< "C^H,TL5<4,U.:29R@(<7'(YV;CL#\*Z(V0
MNI#,34TGEM]\0[,U(2>C0JJYNPP$\&C0NBT-B .WRBD$-QO@BF75[]\(FHBX
MU\VC<O9]XL/KQCXDQ#/#WBR1S/Z7[4'VP)/B-@*+K!'@5BVXF:LO+8&3&!X4
M$R[QU4U5 J'WK0Q;CJTNT2<ZE96-5>#+(6FWZ:6<LE>US,*52L40R&%[T=J@
M(2 5V-WU+&\H]-F/8V0ZMG#IY:P@T](BXKI:Z$-;M5A2AN#MQ-[;C5[D4Y/6
M0CU0E*!++R2*\T$+0B\FIW;'QGLJ^*N8,X)CWK\V.0%*P^ZKQ<HT+DK(V[V8
MPB(K>?Z9)@'HD4;ISM4$&X NHX<*[[=D,L!O +'2'*HW +VYO53=$>=9P52/
M 7)?MO!6\HJ^QQ1\;YOM(.%X'$\"+0/)PCW0_)O!'OV%#^<P9C7!_:?B3AXE
M$XVCMWUMK-:[/AAFLBZ?&A0K -*;=KUIQR(J$6%;=>]4E8-E;2E0%VIQ+V<X
M3=J8ZOCX^!.?<_!KFJ7 M<<>R+L8/6T@.8#&PN Z=5$P:HPA=5, <>>N.BD5
M8UR"3TG.Q%/V!QD[L<+O($%$_# 6RNWW>W<(EG #$-),&)(>KA4=;I1^'/JR
M\[.^S$(SW5BW4^'G7^NDN=U&M7OK5;+K]MGU^I;1$BA!DM.95H]P:7D.J3IW
M,";[*&VLNS2&O%Y)7S1S(F2ZZ.KB\LS8@*3?MID$0U^"#(7+]8 3./E^='-%
M)%G.*LM4VBYO<'@8IFLHFS8J^[2<D^=+OHTFK6/&QX8S']_2#P[E]>CY7/'O
MTWZOP8 %$;_1IN#1NG"[&T"#DOD-8/9>]98^B@>VB9K#'<1AZGX27BG^ETWS
MO_=U1T8L-(SR'Z':R_O-=XJ:AC@VEU&7Z5K+]%28X-*(F"B>,_=H^%#WOXR\
ML-L.2B1W4Z"$2H\LRU,#T&!JMT^%9=097B&!:7O8+P:G27Q5&70[<H(ZY,4Q
MXP^^)@Y;-BTUAW'H/_W>VCU7YY@8%C8>0C@H_9R0KX0RUO0V;>IGA/7TD,1;
M52H48JM=672WCF8-E?0D9+?MSO-I-@T1%\\$7LDNK^CQ]W9/.^_).]I2KN,&
M@>S 5]\M]?R1KJBWOCLVMZRBQ ^CPG4E:9IET;[<-H->>V[*WV 2?Y4KV<.8
M-!U<"<?![E1R?5 N\%9)*"Q253)<OP,.[L>2/$UH!DONB+H6?=(5#?G$6*@V
MHS8KG<:GQ^V >_J$YJ'C!-BM+A9("GR5-TV(6D."4##_VN!-#KW1Q&GCIOG"
M3:+XG+R)EA2^>/"X;*Q!7T!NK&QI))9CUR<1UA1WEENEOJV?MLFRH$J">3''
M<X=_=>!@2-=55Z9OH-5(,^/T(>\="1XUJID[YRX2+R_@<C@R"-QC2RY9O,NP
M?,5]4VC)TUDWB2V-SGI8T7PL"CG.;C!()^4=8/?*5&2&C\?4.IVF1GREZ\!Z
M7^TP8TFH%5AY>2GC7&UU9I'[^&Q7Y2&DG_/C'OAIT[\JCC*C3T*H[A94%KK5
MP$41[H+0Q3&*H)3Z% \34SXN,OW\N>JY]!@6TK1VP&!TAR,M>IGKWF7=K$YK
M-@&Q#C=7'GL05H0XYBVQ>:O4'98DNUWY*87;47\-;ND)?=3L;^@VHHSO_QKJ
M.WK%]3+[6A!V&Z0"[E4$*;C_ 9-T204AY'HW>5N"SQ+FO"\<35(U7DMP-[^A
M\*5=3[A'Q.+L%Z4KJ?5W:V1+V+SG)\UD,P"$?(CSU_ZV.S&:7+"APP=YEHHE
M40%; C"+V'=@9]L$'!!;T@);E=K!IM9NUQI,R@Q]*-LLT4"V"UELO7$]R#B,
M90MN8-7B3:[6:JF/"SIRT#QYH/2;<_:!?_[A5_^TV?B@<Z^CUOK1VQF1(1B=
MR@H"MG-(&<@"W.L#70QGO &T+>&6EXX](N8NZ\8E4.)__DY'0_^PW@#66 'H
M$Z3A#2#+!J6"[^P#TVX I0^6JLRR<6/ 7QY0$NCI\YD;P&4LZ]73?U^76NJ\
M*NF_Q$XY]R1QHH<]^R1U'G!@5\*_96QJXM,1%$'"R-$?\VMTY'I(B7(K*NNO
M[S%1>,"._NKNCL0@5QHG+\H83M&[:EH=MAT6FS:@^@#Q5I\ZVX67C$XW(%6
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M8Y58*@V.=?^/0PJ_IE>;<'IANR38A-5A7(:>[2UP+S7NSQ#DCS1P'VP;@5N
M_/* ,0-/GR\"+Q/=4?0XTJ _W7C:WEYT Q#]"\ ^_]\]!*P&S&Q[_,GLW57>
M!HTV#K986ROP:5P'_7@-VQCP>*;_ #J6]Y%H?9UR#V'%8$ RPBF&K82Z @E1
MCN8(U5:T:$32TYG3<NCWCAM 3$RYSM[:0 I_;4Q"07UU016U[]!S(HD8L'O=
M*M<0[NX,1J,8-P;SGFD)DP^@$$U#F7]ZX^PJH!$,\WA2TVYJ' M(WHKT6 5[
MT%S+U"6#D8(GP+_J,A*GY3< 02@\##>PP74#T"[Z3'W1^V?U2_EV!"_::I8X
MJL;&4L,WK#1A<??4C#*J]-T85"S//'N]BZ.=W:%E4R/9*6VN'?AHL^"%S(;I
M\*.9"QF5Y\>;_7J-"5^]?>Z7FN^T)A"X9&_$FY@8F#?( ^C5N"1QFY[\P*9Z
M(^:Z(7UJ^K<W %N2:[/YF8RVY%^ 29 GY@VVO$5B=:6+0Z@7& ,21FPFP"\&
MX<&--P"S'.'3,PDS_</3;S%)RHU/F_8$9X0!#G='"8]N )%<WSY$XR2#LW!W
M)I_VFZ)"$)+,SSZH4B T2G.6W)\\?(HS?K#&&Y,EHJK#P@@9,V'Y3%-<\45L
MG$_R[5@^;;0*<,#XYW_5V6^$XT!7O)B8[H.UD/0O8_AV1F4H/+1]BN:]ZJ2K
MHZ@FFQ&Q-C\M+)X;Z=R)-7JPE_S ""BI;'(#N+V+_0)UL0$%H1[N;*C;S/J0
M=[6".!9BDY1"U"1K)[NR*NQ8=6X19;YD'%WI$@<-Y*QA.EZ8T3$FC './Z>7
M?U$;&3U;C00REV"+H3[H\)$W,$Z]-CLY#+>O9(,MVN]R^IE+W63B*KPN\E];
M@ZZZ6+9V=R!($L-I;]LWK_A<*2'A>P^DW5]M+IKV*=@J+3R)9E%U('X<;8PD
M:!4%5(3(^X4E;_DI0HX6/_@-/[BO!GS-N='VMU )R4" T#\-P!=@$L_DG6\
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M1.^ML!$0Q"#(8O=IAQY6>I65S AQM12::8DEW1%YY$&6_I$0DG[Y>\S=*RA
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M*B@8N[,X]?L"8-POW*R7]^^DMM(;S=P722M3>S\?0)M_#I(["\7C+P YKR\
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M3$ %)C=J6>5YK^59K0C;V?3Z+79G<GV6-$3*?2YD:=('*@F@^2X SA]85QN
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MZ#SW:3@SE%*@>2Q:NO62_DV>2C#C[+IJ]#-<3!\D.5>=$(<1I-0=AP&]7@2
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M[EE#QE*7?MRJ]VW2ZE67!ZR,SZ2+.3,OA8,RSKZ /1G. 5&G+.$5(('?W.<
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MFU4.ULWJ!B/?FM;1<8-P_(FQ?-!0S1NW_A7^#DWX)) ')$)@. K%2[QNXRN
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M9>EF[25UL$S\>_,8R?OR)9EKJ^.Q0-QO#1R\[>7D?<S&TWL3359(DCNA^1Q
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M"RS[/4\3<QBW,]?%BA11,4TO^!F5>^=!&V.&9-*A&XE#LZ<A<Z4VG) "M7N
MA_0*NIG-D&X7FS :'BR>55H'5664Q<:\FZ0=U:F;Y)IGGCATK"ZR_?/28?=#
MB<W"%K_W+QGJZ?HMNL=9*M0NR7<>6Z3F"9=\$TY].4ZS(=&-BCD'<(,AWCR6
M$S 7O*K%1>!:;RG49\;)!&B&,9CA'U67>R9<$=88\*"::(UV$:OU?K;<U'#&
M1$#\URP/!\5N,N]DQ5\GYDTSAE I@<>^"1^K7<5J%55L<N)<75V??C>J^HA
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M16FHAL-N^8>%%GI<0]O9;Z49B'>QCXGM-'T6.3NQHW@$^T29IN!,>(C3O4L
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ML@7-Z7I-0$4EFJ *K7A1:O),@9'0O2<?KEX'RKWN284BYA<LIU%NR'D[3/#
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MEG5!E8 "T$:L6^^2[.F*V7@O>,'R>K$G2ZG]LC$DZ)E:HY@1;U)OAZ\!^TW
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MX_L_%RF+[^H$F9.PXGECUL9AGMB!1I.GMTBW:NI<A.V*LVXZ1*6S1UZ[.=X
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M'5NZ](>"NY)"9MXVQ1IF=2[A0IY/'D)TO)Q97$Z^/7Q!\[/#N"\03*J\_JF
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MY90&M:.91-6R[$<>"H14,"]@B' 5ID#3Y ^?'K*JF*R6TXTE,O^5Q4J\Q0R
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M56UCYN57U .H<2M"A7;P:YKB#UZG$Y<F_X?U@?\_'2K>GY<.[^?\]!K@<\W
ME_3*,,"4IU$SL)=H:V#W!Y]D25KORG4=%];AE^EVIBE!4HV\6-[$0H+2E'%;
M"MRZE[^=P6M^%\)(643@P&Y^A"8BMAA:0&&E!]-"W4=Z//]TZS6Z[A:\;WX^
M%,SX>_:Y?>=ICOM>]6HA;Q 3![E6ZRZ\ER+8/"?$SW0."%WO9R(7%[S 6=$8
M]>=WO1A7FA1-4_]U*]4ZS?"P#?NJYR=Q>>.D9SW&1A&/72LXTR &]/\S"MU9
M@LZ\59*/H;]6D&'F-#.G[GQ/.D9 ]]K=6%')%[ES"2% G-%X,(C&]$D+@F$
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M!Y*)^Y?GE]1T$ZZ&%5JX+#ED*;,K>U;]*$KY?BVO.>J%N&YY81B=[-6K "N
MA!%_Z;&ZXC&(XQ;Q.=ZR&]&P'=?^' .D@ND3X\H7=TQ-YCJ$:W%5(WJ!3;IA
MTL]IG%(V!9C[VQ(E2B]+OF&R<\.SG$!FE1(8+6% 8ES9NLNWOJNUQ27AUB5-
M\<X+_=*"#!8"^%1Q3E&O06$Z,@TQ&^>$R8W1\"W;Z6 A?QW_J*$IF[!GP4&Z
ME:IR#K#K?5-S=LJKGN;KI![!,QQ_52_-&50+&6"B)Z[WV\A,@US"FN=)5E*Z
MC3X=5+4>C3'.&1*>0B[# @_=D*)61VTBEU]O9+:B[>3?*JO?J%6RW+(T;^C
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M"(Z,V%@+-%A64#&:Y]?]W78]WC?&)D&:<*5/\"V/-(_55PHY/[1/!E#/)G4
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M^OW618-(!Q'I-0H(2I6.M*!(ER(H58@4I4D3$)! *-*;@(""-*5(#;T;.D%
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M?KE>OII-1MA][#' *IJ[FU(HG)K*>[#$9)DA8K%,W==L@N+I5C^4V3ZHHUM
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MU)''_/Z:=:3XAY'!4:7H ,^V,2X>E#4['AVQ)$L#,:7,_5=9W+G?'O_!VS8
M<0?_Z,(D=@3U?V3)4\\!Q7?F*BPSR?_N9=NQP?^2ML+_+]>6AE#03P0:$0[1
M7OMA?'=SRI]?!?.X+67F48EK87R)3\2"I2^MY@A%NJPF3/PLZR*^2E.09SDT
MKK=B$]QGE6S8)OM"GE?;%,M6#'$A!-^G/W!V3(<QMW(M^@"*O&#XG/88!#Z
M4!3@Y^11OG@/[6EA_1(F\" !S3'L.%D7GZ5916'V*#/<\4G$0!@[>138S)P*
M<LXSZ>>TIVOZ>5 =D!@DV%$[6VWC.C\XYI@MH_:*VNXP(@;YH#A3^#8 .+']
MD0:7.A;][NYU+\R,WD'J-CC)B<QP%U=;'X6&Q>+2H1LER?LTRA<DY"$&!YOU
MCM20[R0D8V.[5\1FA%H2G\SY,_#;K*DZW^91PPI7552-]MQSI#9Q!^R[_@>/
MZG#\/^O* (>29PH./5!<H%WC6=!1@CN!E4P;> *7/P>T%9T#Q/\"SHS_KS+
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M/.1\/;-2T;>YM*E@YG%T:>[@&H-#_:)=O'CZE2OZ!_G*"$WQ/XMD>E_B'9(
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MRIT;F* 4K=M\GNM\:> \5*/2[@PLK ]$2PK&,:^.#_!;]L$Y$D)L*V$TO]]
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MPK,V)LRM#K7)TC4U$,R5<X#XF7\-IVLF^6!E>=S@N.(0''X.$$@=')Q]3-+
MH2) #6;+YX"UYDEH WQJ,_:Z+6FO4S0[YFBI:><QX+$EX"5CT'R@,R:%&;9!
MF&Y*Q3#)F<]VBE?.N[;#\!P-?F[R%C:PA?2M74O&M]J@]^< B5R^REVO*TL\
M@&];;S^(_Q_4O5=84^VZ+ARD=U"JE- $%1"D2"<JTD2,=)$2$>G208($(B"]
M1$! I(F B)3044%"KT*D0ZBAB"@E 8R!%':^N:]K'ZRY#O[KW_-@[8-WG(XQ
MWJ?=]QC/>S\JSV_H9@IES-)_ F+O9CU)B0NF[+_:TB]";=CUH_@[A*D3M"I
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M^**_4.EIIM#5YX(:=Q4QSL# N!%PUD#.,_6W_\PUJOV!:M5X/VZY#E.Y33@
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M1N#6P76S-:'[S.%2)[](YIG+$Y"K0;J5P K?=]<['A7BPS/B _'\"#)?X[I
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MU4I;CO-%VAI2GG4G6(IZM@7U,.AJA0(;*BJ61T.UP&W(NIYP6, "(B9;<O3
MY$Q' 4SK,RK<O&'\661MYFK9$U?KJ^6T-:?CM H<4G4@\N>>>R5V@>I-.A+I
M2.S8J*XRN(V1/K8@6J*FOM*J3.%F4]S<V8"FJX)2GWS[+0.D/UF^ZFND(S8D
MB_J)Z%ISV7($DSH:Z.;?_L@[_!+.^3*%1879ZT6B?:N0[G(,8!_*"?,?T>+!
MY;8BV*"E=4XX8-R%YNSNK?FNEO9H3]9;2X9SA;)U@%EA/"/#!-T'1VS%GQ:\
MA(IEU40=WIGI+6Q@5-OWZ4%$D&RYC(W7D[-ZHF\5I>IYX3O&<6CYJULI7 >)
MXJ1Q32;>-H\P_0)(SO DZNZJN<UG?8"DA-S^,V+!Z]>[R;]S@.S884P4=K\;
M0ML$P4%NI#_XT22WF%$A@HI$WW[[4U-WW\LB)C%YY&.2IJ?%R+ZT?O75UX0>
M?"DV/:R%FZ1$>!'\R3U=0S4!^FQ Z.+\P!T>GLJZ@U,N&8MZ,G=:6TMU[+FE
MN*R4,:[_Z![NP_LI]XMD#'O[>UL/U@5Q?=ID]87'M%9!K/)#HU82DCY,PXS:
M"?+WQ^7U^EOK><)8BA92?#,S_U.%<T3?[412-H=OX_^T3))RCDA\B7#=#3L!
M<&O=S%5IQF[).Q>X/2QRQX=UC^*-,G*>/:T":? E=#H+.Z=*BEQ;H>3-X7C5
M6^G/=0?N]HPI8]&812+K!J*6,:Z,(D:(7>J*ZK 1-1H5&5U_=V]L9)&M0:%:
M<^A0_J-\\,NXIX;G 4%=@!#FCY1)!+VRL<+H'BBVA;FA-IL^4_S+),8SCV79
M)RIZVE9E-C$U5%3L-%.9)QC_EJ!=X>:OX92!LVK3R,X-\A:J*TM%OBJ3R S*
M"NM^%2OB9-?U%# (-Z\@G4,MO'\+(7A  .4<=$RE/CXF$,+;PX68K19.2B>8
M44> 9(OE>>4)=MME"4P[ 9C@A-.5ZZ/S9F;[O!&JLW9GKH9)3X/67KNE,5VC
MM:SD3#KG^[M^4NI;'/&=^H8>H'7'I,#VMU-)N]6W;DQ?^&&UX6:OMCPEQ*V+
MX8RURE2'X'OAT'/(0CIEK!Q&E_B(,H9@I:@$ONY <+2PJ\;"I!UD!Q-J3@!,
M:WG/)"[.JR;?3NKEPG]5:UV/(>Y=?<K$=WY<0,S2_Y/DA1X)?R <0#?EIT2S
M/[F=C@,N\6!HL!6FXRWR!/[9#O[?"2TCCS8#^&]V?>1=L'+-:3QM_;5E\9)=
M1=)U/98]!EC GW[-IE4D 7IGRG4/OD31BSTO$CL*#U;V(44E?/NL9U[7%FH%
MP[5. +<($A26/*(<S)C\B6<129*N8/O3ZYR<H*P;0D&ZNZ\<H1WV3@"3_>]J
M5@T/?>.;ED7/@YX&=MSGEXOTB[^Q5:\!FI85?^OV/.>GJVL=[]%818;PQMCN
ME?US4@5KMKG[B@M0TMGTA=U.=E6;)C"_,A T/36O7U#_89$U.%C:(M]BU/5T
M_]JB!(UX^"D%VBM)\D[]!9N4AEQ+0OBMYC%E:4EE614\=_V7ZB_Q#I%+$@RV
MZER?'1S%3NO2G[WRW'P5=@*H'*;R6HQT8V(7Y6P<Y(< NFLN>\Q9ZFNTQXF]
MLNGPUTI/XGEF:$>_:)U\.JD(L"='3_#?Q5^BYM09+A1F;%J9;^$TPLO")5%\
MTX5$UKQG ?:[$I_^39[Y>^1YN0Q:P\JGN3L0@J3SMOTR=.88%-73]J@^O$ B
MBC)_&=%P>3W.0(*[Q3*NBRUCB7O(>\([VWL=76V^S8J[ $V(Q0W@P\?+?H.X
M2LN"/#_U8FT'\&TMRID^Q4_B[>\FLER]T[%ZVFZOJ>98G+:7-X-Q<$P4A=AR
MH<-EH!;B( )O?)<0-(\/;6X=BJ)(1R> ]Y-A5 1;A8Q'.01@"W$)11^V(+,G
M #=NY%2#XK=SO?*[[&L=PB/$@YE3NTM#TL=\_U'O[JN@D/__E;,6V=*IK>VS
MUHL8NE78-\.LK4G31Y*D.^HAOR5!<;&M.EKCRL"PNVZ3PE*O[Z2PIH[4.DY<
M)/*EG/*Q<_G$TF+7L8_A5>,[JH2_.P%$OJ9J3ACBNV(/D@ ]?P)8X<> %U(0
M]"TB)-4_;3N+ VM:L\6P0QG@B/*RC\T3M1F8)T'&/Y.9A,9I.T63%%,XDUN5
MCR<2*]:O@N) V%$(]N[%5D^YGDY$#7:'UG=2C<@.KX&QC=>1G1=V7R@#N?6]
M03'EM:S,O_V^A&_OQ?8TQ T)RQ:?:1J<OGM*WJ:V*H,'4+G[(T4-WS]8>3%$
MXW6VX>\%%D#F/UY??VPT=T'YT\#BG(\H0@B."5E.FCT)3"I1T<(P-[!F.2K<
MCWQ]\;!SF,/%%]U2]BGU]-;(HXBLQ\U1O!DJNI5T;?U'L5+=KW2NDN-@TDL@
M@N1\45EBO+#*A!^*C<"U79Z#I61 H8_3QZR/IO:S.6\7?SK;TSI/CZDV.!K>
M!&,L3P 7FW'AE$Z,_0G (+_B!7@A"A&\;$+,!.VA<AZ"30X\A<<Z\-Q?_+-<
MH06;:4_SFLNR/DESWM4KYKIWYFGQAZLT5UOI$M1X+)RR;M*).H(?F9D6E.G$
MT-W]TXBQ+*M1,'GV1U,N/H[\CB1'O ,#0Y@#:]'B[\V](;-SKI.TS#E9=)>>
MB=O<64EY(#(1*9A$Q^#W.U.2^UAQGP5*N CM$0"=O9SAB)/NX*%PF4>*E,W/
M]''G)X6VN+,ZQN<Z]SVF?ZV"R4F[%GC<@#<DQY+ 1)G-YZF3LRLXYP1EG_NF
M..T#6G5^0&M>DZ3-MWL SN3&V,H!01D7I(&ILKMIW:T^/1]/T;2TLQ',ZO?#
MC'?MNUIDX+THIA950^6>!!A#[M9DBK'@Z%:EZ#1ZR#ZV7U?VFTS-K0^!,T/F
M+Y<E\U&R3;[8M)X%-$8;)]&N\JB\J.SFAT<;>/\O:<W@&:\TQJKHES=3S6Z5
MGSG-<&1Z);< 7#=Z*47K4ALEZ]>RW,P^GFT"KD0X'EXR[R CC+$]\7;5"?WX
MCGNUL_8EQ;TJM7OM;#&_SDA:1 <P+=Y;W9[S;W_PP%W/=%KQM7+[L%!$%I.F
M2JV.1)1/Y?WF1WI3R05R(NOB5[7>T_6LVQQN*RX#7R$YX&(PI]C%@G9=G/IE
MY*W@U1/ RY396RKJ5FFW0W)4WXK)73IZRN,ZY)/S<!1ACY[Q[7Q],>$$ #RH
M8(YM'="I*W;''W+[$^*0:9+"AD\M3TM*2\CN>Z>@@BF]R.KL#.(E@NJ#4;L)
M@<X9?!7L\+C@E42-49"7R<^$\W2*3".ZYS51PV)Q++LS+=W.\7G1,7' ],72
M=UQI$T4:N_IC']I=*>?)53#+RQ^"GBQ (Y <!VAUT\E;.*>"@$)(DJCQF*%R
M;-!E5F@/4X<7DQH'.A-,_VBZ16"SC+?!,,W0U/_A47BZV"E[M-=(;39MT?!@
MSPYI8!WVR<$YV^ $ %Z97)_$*)X Z(]P99.=G@$]J%-^5O11EL'QYA;8^BJ?
MQ7R46&.P>H:%]!W#_J]ZA5-'^--51]/PB[QN\Z/!PFM!H45O%\CQ/,4D6.);
MIYJ$'47V;V=,V JOZRM$ZIER^' $=@<+-ZM7U" 64K*ETA^1,_V"@77&.J\_
M$#*/!VY'+MX=8"C19^^]7Z6WY/ Y(UKL?0I-*TL+0\X)H$U'1YUDW7 E$$GD
M6=2)56SB\1X(5#;6,SNS8WZSX<+%^$\B!JZIW8+OXTX=.__YV;</P;P#,LT_
MW&["\PO%1 K(?S1K*?>JMJQ&OT@,X@3:K ]W\/7B7LVXWV\HEM14<E'>QC+_
M,F_1S;&I_4#HI4['9ZL8RN3-:IWFX,+<Z<;V=,T'PF5C!17W3"RYO@A/5[P2
M(Y?K7($//+=.@G^GXGBQR8- 43/(*Q"P-7LT@-4K''-7W40D+N6S*V]G::O,
MW=2CDDU4. K41(/[==/3JM7V4B6.J_0)[* ^I&8VS?G!N:M3:6=A#3UO2SY?
M<NQ=:U+$ &_,2<YI/'!RZ?$>TSGH_FR&_HQA'D].F/[@7@FMLE=Z<&9.;S!T
M-L% ZYEH59%HAH.$Z_!B#)U9H_C_@_'HS+=6R16';,[W7OB*?B1!JKMH*3$:
M70MIAX9EVGQ3>>Z?Q][THW_L5E5?<%"0[,?F;H4\>X.]E_J-6IOU:< 8LGD2
M]_V$YIOP$$2;(=@1\BK["N[P!5R9)%7;.-%DM,B;ZE05L1CDF?+CX9>Z[)F?
MD^>N)/7S:WV5OU*LAU8!Z%R#$"1@F0@,#$E+TL71:O-5U$(QGG2/^"6RE4W/
M!27V&J)\.#O\50T6&J8U8+@?PVT5TY!;!$8JD&# IH?J2+J;=M+7STR^]"N[
M;"$21EF2?B'^(<OQ\A-+_AF71UQ'I%W9N]6G!P\F,?N+)M%_[G2 X8A:_<AG
M(3K$)8GP[94JG*9+_:%J?9A<C5*UZIN%(W\#J[MZ;]XD/UR2>WO%%"D'._>C
M11:.1M<WO" %AWR:Z0*]W*G]^O/.TM#/LEJR2O_,1G]A7-?/3ZF=1+.,K QT
MLJ!#-TL/QJ8XCKU0U/9I2;?BEK9;UW7^K'Z#;AI>DIO;J7^LC2'Z'[2,)1O_
M'\#TUZ'OC>JSY]]]RFRFS=P#*I>Z)4FK-NGN["KD$[B>K6CZ/RDZ$N3\/P_V
M%536_L^;70#@!?]8[L54V-4EYQ1&*>[KE[BQC9Q3;,=V<;ZCR)NTHH[:$0(F
MM[U-[UWMQ:>IB<88<N$+=5\G =5:=Q!2:3$,*V9$3>A<3FZ Q^^#7B'OGH)]
MKGUPEQQ!XK CD?>G;GF@U ]H>(M:56A7/N%U:\2SPX9O/OG"O/C<(D6A57^#
MK0]:WU&R(3>-[4<S&:N.CG")^$QR+L(.R?P3^2H3&$FYY*KJ*R +[,8'T!E?
M7*2,71#'I*Q\/?(N\7BISVO6EO&S0:Y7^'P3KJ<[]IP?SKG[T7",0U:*W\BC
M@XZ\V4%!M^0^H2;-)^8L!N*G$:6PN*S=8W:J^FEC;>N6H--#/=8CVPF?M 26
M-.7.HBU[UH)&9SJK>R32JP12]SOC!B,>&/(BTQD7XE4?UOVH_>5Y;71G?FO4
MXC#VU1"=8X+AD$JVNFV/^OKYX*.;_/=?^P7H",14??XFJR9S.7VK06/W!:1.
M+A'E".4)#+C]0\LP9 D:%J^DHOKCN*-VWZ7R2HR\DD*Q4G%2,7MEH:3Y<ZF2
MZCY(15KI]K3/)TR;E'SXYOC"NI;#"2!Q$15'TD3@I!^,P/DV[LE.QF@9AS!\
MNL*5'%_-R+'?*ZKO>,-,?&C4C*Z>2:_B>[/^,B/&'MM5%]1T#QO0#C[WK+#L
M(08*8RP?<*COS[^NY,DPE>(>K5+J<5;R6/"2#\%6JS]+BFO.-;L"N%1E4<KF
M'&N+PX-F1&5KU61[Z"JT@6,DZ2$_DQGH B6JT&;*#<(%XRJ 3/?C#U4"LD5J
M8US$]:1P7Y1>I$Z\8##H/1\FO7\"P'\GUVB9X**?@5ZV\%$!D0ZOE?N] =5H
M.YQ3BM+L0#Q8Y*P:4\ %/J8LFYC%_@M>,X[7][N0'2"6S1GKAPHN]9-2J$O9
M@==O^^0H\K1Z?4H.N^(; 9"\>$ZN)-;\U;[U(?N;S^WEU2%GB%GXEWU\*X+"
MFJ,A^=I=OOLTG\LYO \JOH$($NBN0=]%2'>L2;CI3XAM($_G/1OC#X^L,6\W
M57&B)EHNQ!=$Q8_]4[-9JTQFLM*JF^E9C??M=NQTS.Q. 0]],<.?USZ[W4OE
M^VSR ;/HS8E[D_LH]HOC<*W$8-_RB.$)X/=H=/+[?+B'<P'5"K>4L<.86"*4
M$-4*5V@BV&,+[M0A>*:G(R>5RWQ^SLS>MLS9EUV.?FZD?E9ZM4.OB;8B0POU
MOHQJJB8S]XU1=5]-8M.>HY,5#)Z1C3K25'X<GM>HBE^)D3^O1Q/N(?53)3O@
M\OA3OU^ZXS'?E[J</FN)F^F5W?AT#"KW_I;R^-(ZWX;^^J;)((Q,Y*>,C<#'
M0!R[<G6L3$I@OHT YSNX4\ELO4N:H:<DXJ_7O!+KH$?/7WJ@^')^'N_UT51A
MP3$,Z.,=JOT\9L6U:SJ[."7%-*'SX$>2Q,6(9*L/PWSYW]H>G)T-HI,8QUZB
M$^;E5V5;*I&)R:GT)&C>T03MN=W,O#+X.JS91\,[4V5+6\[!V, *^LBMMZ)5
M:UE-E''OH_X#.N_N.XR<@/RKS<:2ZN7Z/2#N)B!VT /219''G@ B'A+D:SU]
M[X=]L_:<_3J@4+T[V^C;H#;7N"6-T)^44<9<'KX_!CT_KC0[]7#IQ]ZHKHSY
M&85(0U''7C_'\Y'684P7XJ_?OQ;C]J7%/^GI4^]?_[DGE'\[Z"L Y JPA\DI
M2A^<<TRN2=<QN-SMN&?FG.&HQVDX>3E69K0?+>--)W:K9\W#,#4>7Z^--Y/)
M=5T!6;.0>JAH[SV)N?$SX1#[=0D9_0S=  /5\CM%+ 7'^@4$2_NADE<4/DF)
M&:PDA$2+.6M6(Z65GK3*GP 6\<E-SJ!3MR(%S"E2+ZHX[0' 2F1/ BI2 _$2
M@37?)5A"SFF)+-)ADY]5+;';C1FIAG?:/JY7/?=)[QK2X6XKGX9SP7,B2)^<
M":=WGPG)+BB R1("BJ?05GF#=;]140='=HT1;Q2,!$IO6EH:>%0PGD]@=]L\
M =28MPO1W:O]4\XZPI9Y[#>K98J[^U<PT+)+2:&$-B'A H/%::;S*W:AVL)#
MRE?G'RVJ"@?RB=*I@6[5F"W$<T7>.0*(^B99"3IC-Q!G'OY3#R8:@?_36?Y_
M>5SB"RN2..#+*RQ7$.VU&9S=TR;>I6N:Z.-K$WR63_YXI;2KOC@NS>N43AVV
M@L1)AU_"!;1"N%P@;"U\@4$5L( *B](PO#NBKLE0L8_ARZ/63QE>L$ZGSI@'
M3ZY::G4TM'N< #S1,P%X0T)$KBNZ]F'D%W24\D=Q/W<C\<\69AD.*J\MD>*K
M]V5\M!3./BVD>64@& JOVA6H7W_OS+E5Y-3/9>4K].LK1\ 9=/CW!'W1<LV)
M1'5M[QT]!D 0XO\*IH#=^I+@ VA>'>\3P 7_*C3EO9,R5I]TFGP;@6V<[IYP
M_-YJ_SU);D]Q2_$JJ*CVOM8XY9CR+*B(_)NT07/P_]:?<8K&^_>)OXY&U@H.
M)_=SF-8>.ISO:1+.C4O>4(0(!990F%VQ);:X_(J*C>/A6-)I9772D=(P^]9I
M74?FGF\7]"(R.*OLSGF;#7%*1=S#FV0BT9"A1&5P"RKK@:/D]K?5.UQ<^>6!
MC-L_B3P$(/[QYXG=)E7N#Z7N,^_"=;Y6&'%U;42%XY\],VCOMN!6NVN1.F=Q
M08K8F=Q'.01W;;Y?>)Q8H S^RZ+)^;;?4%D7Y]Z]J9-.O1G\!90-QCZ 1AW"
M^1NQX&Y6;16C=T8,"&!@FKOYFSZ\I=C9&956-N_.UT&MC5)=!=$^1P+PAZ,D
MD_Q?F3>>QV>1>+BE6CS&^,Q/8_GBHL BLZ\CVXZ,X6._OMA$O5)ZUZQZKZY^
M_-FOWLSYK:$=I32^I:=FR\\>FZ6^23T?=SJHXKTRF" !W%XO<YOD.82PYUCN
MK+I'1[24!$-9:E26SDKNT%Y8P1:KA%ZY N#Z]7B?>=%N')@Y6,VOGG739@/_
MG1"%MR)G>X+=*^*!?A6N/ELH%IB$IS?7Q,Q1<EL1Q$ EK\GGTZO.\EVU:JBU
M7G$K\QMDU39B(?LY, )C'!71(@>SPP9$/705J_FN!.()XO:_8&CS[6E11,9=
M'FC3M\'W->=2X.^PR(AG)O0;^&/]J-H2('#CQ^)+?J]WM%:S78VQ];UC+(U.
M3FJ"*2;/Q[_,:GD*;],R]2<GMVUF*]J&N V5SLUOXRL#;P6RG.ZX[@"7#1QH
M#T"S(UR@,?/G)NM*T.=^^?-4&@LW%D,,@X.#'__8PG^T%'I0F]R*+4GZ/$?4
M9\G+2U$V@ZCN*-(DP6VMH!)CA<=DZ8,H_"=R/$F$>-=R\W F8F(X4LL^;[:/
M/2I:*23,3T]/^$:QWL7PX+0I2PM8FR5]XM?U$C!!'!7M,"[+48;;6EN^LY^K
MZII/<),6R'CR4"!5PBK2P:=).JG-QZ=4Y_[.XWV+)QM$==&E&CA/66)7B-V;
M41MS2/(:J/($$-<B09#N@?#\AD2!&?,)R7FVPP66UG,]Y==S=5V]/=F*O^=:
M7Y3PZ&=NT^1Q!_TN0>;/XBGC31(?YX>7AZ?7EQHBY91JO,EY*LC<^.NW&@QB
MO=Y O*)MKQ1]_FSS>6BTX_4NB![.2#!:8.SX"6YK.3WV8^!6W=&G%'^@]O9@
M1,K28C=]BMJ](0! JM#,S&RWT>X6ZHV%_2XP/2$W3$$=7X%\3ZXS?*#S"V@X
MFLN/Z"^%819!!,F>;<PRN\^L40TAW=%=N[W*L,Y(H$QG<M5X16F_,_DBI_V:
M=TK_*2- R#5P(HJ]#LU$2.]\I)K0!%X2$NCPAQ:Z'?*+DYY'36$FQ/Q=N6FW
M:2SR6F>,/![G9,[B&CIVV6 &8R)C6C:+9%"7!LPG>G3R857D&OV;4V9)8A\B
M%\I_)4]//5/>-\?($9E)_),4?L) IX9$>[,*B'=S7JB)7T9'H"%EUF_<VUB\
M9<#(R6(UJ;]C5\_HB5DU@)8C? 42C:B'=E7,:-I.2&!1,14Z_"2YSWZ1[<-&
M-XP?+?&NL:\K]U/V^*P3'JK32IK=5IO;<R3(X>L)TT2UG?&H&#FX5*!-_K[<
M 913T\2/,R@N+6R[\8U05?5JK-[7@;>0->56DMH/S[IA6I=K[8N7SS?4QDRG
MB*:D?&1?B&,31IP9SK/">35"%U'L6SR'3UG?BKY$UO1^ZM$)/%.O/M/#FCRF
MOL$>\E*!I%39,E:6V">.=(+,P(?X+[O[U'W9@8\&@CLSH;%-FI]^S6COXB/C
M2RR["BU_/NEYQU8LK$H3>I[K\=.KHBW!@5#,;Z*N&ZJF89L84$9P%2)9ED Z
M/FZ,RE9;BZF>C?(5U?NFZAESZ5;<%06FCDLV$TO@ZA/ ME4IH00?1 @J^W4"
M$(++NJ1_28N%!@DE1C0]_G$<TEP;V_)#,M?ESF#]&I<C?:&CB"'@7"P1 N\X
M;HB$,[OIR']OD8$9X2AYB\S+.-H-N KN]+C'IP2VHVKZ"[(I^@):+\+/F@G1
MIBR#Q 5\@V=!I<9UIY8;<2M@CL6)RXX_M.S]_)8A7&B]L_OF$\XIF_F>Q5S<
MYG:Z%NT?&^GC<T-/25<3@#C-N^2D%ED7C9:LTBU7;/7N7966B]]G@H1'U=8?
MQ*&#GHBUZ5D@5^^)!KES8ZKMJF&*2T;46"WO=GQ[0+R*!N)VQ666A<U1O0WR
MQJ^/7EAWT-DX!]P#!1&@BW)1X@WI]W#LI+L_T9<,X1VTY\3VDH:*;97BWW9_
MXPN5.K7VZ/B;,9O,E?=]);-&H!3'P&\_++.*Y^=FT Z)<YHJYDY)HB)V'=[J
M<XIM?>LH@L/CB::$U$<J B]\(]OHGDKW,!; <S/?&KR+GD=EP<+!-AO1DOG_
M$O'^$NR^R_]35#2;^,P&_#Y6^(\P[W]ET*W)$215MP>6D#,U"T/QBW),Z(UC
M_SSGBK9BP\MU6M_;[8R"W\:$<_JH8,8NTO"V:ATP[N]2!+MP=;&7<*JAAK-M
M&O%'=%J(X6S%N,E-9TP>T? F489T:J+)4?#T_*^40>%WN99ST5I%%6)L>GNA
M647\QI?H\Q?/7-WZEM_RI[R>&:)]$Y=?M"P7HZ/]E;_A91/$F7]Z*S-U*F7'
M%;.S(R_4)#DK6S:RUO23[P9?BIRDY\^K(#7C$P"]$^$'SS?H.0*#(4/&NWO-
MUL]7R$FONS7QX/O3?[!MV!T8A.",2V_-EAXGZ2_TE2II/^^Y_SFFYUZSZ[RD
MEWW*U1A\<:E_47L:X'AR$]4]".H2OD P6AH4;3._:Q%883JV5C5642Z75V-E
MZ'2?]_/9+L&$,E[?"QCKM)M\MW<AWQ*G&/%QA'2L/CZL@9Q-N?CNU3-BR>N"
M-O<EUKWJC89[5N%L3XW2@/0?+B2HO9"D.,B>H7F51/<[DXN,T[1:[=^Q8\8<
M/U.V*YGMK0A]9\ W]R"Q.3M0F!@USE_UUSNJ'T]CTQ9"I->!YQ!M>BAG(/.O
M27[MW2Y9C:4]]A=(H]HOX[)#JVPJ)M!SG:0S6:5/?3B8+H3J)'^L(LDO"[%V
MS\C65RW^M.NQ'=D)5^)/R'B:KC+&X*1W2>IL6>3#^^%MO,JK:!Z$QW#8"8"V
MKO< PA^([[C]0T#S@&CAW/(YG%4 J*'Y+/G#7'7WP!K#O(!T$@= .S]F"7Z6
MY(HU[X$PZB\A:=VQ@>'77;/GYJX+)C?Y%,S'+R>;C52:A56'F8U$FKW)'A2S
M5'O8)Z3O_5NHD&;P_Q0T_E\?7((#7Y_,E%YW\!+2=(#3GP N_Q;7EZ?1,[1^
MS_;\.^-J:6_)G[M<XXW;<4B9=\QTPH):<>L!3Y(3=)?+0Q0IK++[\ $*C\P"
MW3*KAQ!*<C!^<^5P2YU1D&B> O\Y0HC%&Y,_D^2(-UTUV+[L1 6Q&4K;-AR+
M?+40K\F<L+RS\7[FU>JUUK#5*4:FA:>(>CE,T@F@H:LG7.<L21S[L,J;\\O'
M+0&_F]=#O/U%4VDOZ$M_O)IL)!:WFB#_]="=SQE 9L6"8BM:^"BM+<(XVRR/
MLJ(-,+NGG]KC1KU9L>^;MS;*/X0+5A<G?]6RU_(]FD%C+2OB8]-UN+'2M*<$
M+2#T@@YA.M.36G[;@163)E$ZK#4$Q (8&*AOTOBYN?+[P8#G1;[RRB%<Q]G.
M/$*;72'S,J%:K5OCB4#0RP-K>Z%A]2'=S3[,5="K>1VJ2ZB#61-2%\!G"=<?
M8-?#<L;\R KKMQHSAT8Q%Q,N+;ED)=6-23XN->@555Y!5^]B/BQ#IH6:3"G
MT6=")L2@LI3-NBFGMSTK?#$1>WFQ]$>8]^N:>AKF.SP8BR@*7_C2)GU<X'5S
ML?!>D%VZF%,+$W7'\U*]:+X^L2_EKV@V]Y)#$K'=FGY*-*L([#$P'G$@$\AX
M @! $4<JB800QF[4,;<6W0D@5!5%>@>IF86C#D=RH9.48R4:0L<) )A#F#P!
M7.L)16!/'5)3<ZH%1'V'46WH@WTKF$ 73+67.J)V S4XA_"KD!&[N5=!<>#_
MNGUZ0=BX0,9L\'+WGP_=\<%_F1&7]S38.3G%EV(,@,M7D+B#E]T!YNTM]!Y)
MIY2(2S[/@032EK<^22=XV>LG&AM# 'IY?R7J$/D.3@")0[6HVA=_6E>%CHHZ
MF2(6KV"+TQZ;L#-$KO;<!A7@^,EOS9R2LF/4#M7;J%(<?Y8#[(;\(_G4I<.7
M(61689H30*L FF)<,8U!08@;(__"!P#IR3]SJ1;1L:&C? +X7K4 (M$TGP!6
M9LC9L[]/ "WQ G]X0=T']%^RSQ_#S"9,M;W"HD(K<[W!3YH7$ O0HT'X$.;X
M!(#6:Z%FYV%(J8IM59SXVW.UFY\>OQ[&9Q7^/LP!A@'_\-*N^/4B K 8J7_,
MODM-Y$?_F?!C)(6IMQ1= XIAMB/@(KZ+99\ [*N'U#;1:.7#%G0%^<"%#A=%
M >GB*B@1B8 3P,)?5AKY9S'_JT0]_T):*)@7L7@ XC\!;%A@@13 _ E@SU/B
M#Q/NG0 R(/]ZQ%0B^.\5#O0/"J>02( ==E<<<Y'^RLD,2 WQWQ6NLQ;,"U[<
M/P'P8[T7$32"'-Y/8 C\WGOP0@U$(*,^D9EPNIYY1NG7-FXRL=Z?$HER^@FD
M9TO^_GHLH8[01U3UH'*]U6VC;[);6!)@_^+5;S8VY_?>1QR:(T\K54G<OLN/
M[R(6>; <VC?C-X5,R#I$_L=4E@^1W/XJ)YI_.80Z"[>9/QM(<)W/-H./Z^(?
MMKFZ-H?U+#.2=!!_*_;;N7]86?*WK#3?IOR%S?^B0"J*_P&W1T$$F?7NHD =
M 2R;,WT).>Q@8>$$,+98,4W^&QVZ]APYN)Z@ _XE?(607$08[1Z^@XTL*C$1
M7\OECO0R;EX=Z]U3VA/_MO\D.CG43(23ILY<[(=M!B[L&,RW01'Y<4"6Z_+>
MW#OJT/OQ0?:)O%!>#'=LX)  7X<G"W$\&3+:\C=D>I0\B*E^+KC+KF>F71.V
MONMITGV1RIAO, <S<9CBPL7DP#D9.<!LPENB[?-UU,(E*OQO<]11JKV=$FC5
MRL![IJY4CLE[#M&S+MJP#KE/_:<+)Z)#EN!P.@@74?GS_3+Y%%%B;_!Y%.G<
M*3"A'12Y&D /G@DTO2KH%F"ATZSV:Z;JMX9LKO[R[JL3@,LPD(#L--?H6F_=
MC7QJ;>UI'GO+V+8= &!]$\:NIS86!TK5L_#:,JRX0:#J/@,G[D]CXKPM%1T:
M@CUVO0/G=JZL:R[6O7!8:U77C%UI<ECD;EY]^?:E %&!!$10_1_%U/N+1.?4
M[;*VX5?D_NC%;5&[0.=6!LX%KLH60>_$(UCN7Z6&^#>I3?Z=8$60_R7.U-6<
MPJJ-J]9C:>'&GI/?^-A^*+%)H<[[^F=>OC&?(\!+5*OP_ [OAN_4=\96,-:D
M@B#)TPF>:5A6J5N4X]Z@\(X=_)*E]315?V85_&I-(:^K]O$Y\<[0\NE9-;Y>
MP=^,!V=1O."%V*D30.1'G,E#B;;)&U7:E.DGR.'P'RCGC?]4KK $)$@?1OSV
M1.#O5[6,R7QJ"K^.4\[^ !^IWHD\%;,TI<80KKKK]<3ZHM7:,$ 1:$5^"9=P
M09X%.X(B#[\8CZ:./K/RY,"?>B8']7,]VW&AEVO6Z9I,].=(EQ6]\\YT,S#W
M11O5'MLS/V":I=-9UPTG2M>JFNK.UMH^4^CNNP UY0N05E@U$ V@]ZOHKXA&
M8F^!8U%,)#/5& HCH7<+;2^#OQ>O>]#LJ?I5?[7T0PK/+&O\*-^3.;K"Q)RG
MP!_1EA)QG(Z]3R)%U;3!UA0]%!5ANH+.6/UQ!F'E).G1)K&!HKE TT.CZO&5
M?=EO<,>\N?1)78>?<3?/O9&:M39DS3%=<(Z"3A7@YPBE@XN)/.X:OU%1T*//
MU"1DP79SH.8P1CQ&?<V)8?DVS;G0+@Y.V@[,\%0 A9E8 ._S@1"B[OU 0G#=
M>2YIKZVMZ(2RWK!="/)<>"C6EV'/ES%AF7J?%33<1/<K^&[Q8/<D>)Y7AA'Q
M;1WWNT19T&V@;4&.3CBK^!; (T7&S3)A0FB3K?A4$%4Q[[@VL-=?Z9%@S*%?
MWP(,PEB)=^$_4+7H]A- ?+88%MU1$6Z\A&:99O6U+ST!M*L7V3#W-<2OW!=3
M8 @I'[JBOA2J$TVN:>&%725,8^7N8_4[LN[KC=0).?G5CT/]WL6^HK7 ^$IU
M8DN$AMK5IBUO*9DH) _"C/,1;2HDD07T%+1K7HP0L3AXW8C0_"1W:Z;M,W]O
M<NG,[#?WP ?7,%ZXIJ==395.IX*N]/K34R,+WH2PB*-;TF\[ 9P.+%G6"_?$
MHN^-_M9\:ZM9PG?PV;XZDLF1:)0W%V>FZVKH?YZ&KR*^189DC5LG<4XN=:*9
M*9S*/5$4]HVQ+K]20L(:LYE7\IW5;$<&HTN.@\U5(I\<]@7+YUII&JGYH1M.
M)>\C29[P5:4A@)RU8'/Y>/9>V!Z!U8KW,IL"N3%N&]#>Q?[NBI,(S?6(?6;H
M'__WG,1.C8Q>P%@0)\D3]V%'RU'YC4J857!104-0^67^JRDRE49\\79&#^/M
M[M5XA (^< )'>A&./QD7#[>;EW9?@CG*[$;3'WZ'UF[L*C/?(9;,QCI'8<SO
M7^!VLC.7X5EE*2[F,F/L!&-O9-WI'WY(Z,@;]!-\E#K^R/@;MZE&:4J78'JL
M3')/5M?IP=-V"IR]H>3%) YSO/=(.=C^3QN'YLEV;<7N=+HVC9=K_1@_'H.'
M.*>Q^,$WBG3$&H4!F2NY.0P9KVZ:J.=63 #Y2#98<,?#*AT%7'H4Z>+D1UUW
M<D.QKH/$7G^T2E#YU_H=Z^7\H&[WO?2EA^$G -;[U%3!W7V1K'_GBPKEXBA4
M&%J[$X=PFIH=]N.V9X_FV7Y]LS9!3,#*BQGD29E!5A+(5>@V;*(0DAG$'EM3
M0Y3#H%W.'0$$@W O9QYKTPPMOK=/ EI!9SH6$JA .*)G 4B2DD$0,' H-5S8
MZ4@%RBTY()E0BT"<?\02JO($X!Y20@2:1N[WSLOT0_<RZG>8IH9M"H2DJ2@J
MZGRM3#F*GY7K,6+E(1VJL&D0UD"$PCO1V.Z]0(EO..KYV)=,ZIUNCNET?V?U
M!O0H&C6ALK*?GIKCJ*4Y+B JPT=13#!-HCI,=DP9$M/"/.8G#61U?9CN'Y!]
MH2;&*BAE2"SP)_]5L]34%XQ)NA74A#.RDB!R KCY>O$$0.'B!I/\4:HMG(@V
M(?W.W0@*$)=$J/UB3A+3T,XNPXMA)]^M!&'%6FSW_549T W^$T,*-_T0V&7T
M<1EU)69=*L9X0W/80%*.:@,>RR"!)P!L8=4)8)D*1"U@IT\ '_NP)]2PPQ(+
MHFA"J!E>1R)BJPY$$J?&F8M4N,6A?0(H'D=@WX!(&5=!P?_!)/U_6KH.:T)2
M.Z244*>WWT7L.8+^.ZDY@\'%MDJT\'3B;U!L/>5(R@%MEQ%+N$#ZA87E3KP^
MTN1W'583T0:\,Y88[P B<M& 7A$=8?;89;PEZ#380WKX!03[NBYV=FLF/RZ3
M:)&AB!?/:AH^?^N*P#8Z((A(F<X!SCF12UJ8+XFTR <R&*BIX[23UBF4T?^(
M8CH)TAE&GV+JN5=G:T,6%V_R;3P/J2$M(?\_P,C_/#5?*!-H^JRPBFXY0(WP
M"YB)@^$)H+=6%6.#-?1_3972>=5K,!-'JKTGN^]-XJG)0IAYXG3#@G,T_ (H
MFKI+,KO@3.+V6$Y(^N!^^6*XCDMCR%?83[1W30/ONN@ P@XX%0+VR,=5]RR#
M"=?3.\(ZJ<M+8_(1M2$%<4$C+V=7$'599#WYJZ :!/8'B!Z\40T#4VG]V',"
M2*"Z5O8GV.N46 DJ,/H79P []_=\T/^[TP%",/\\!?1/ZTZV@?^>#8B_Y?1=
MQGGT?R<I3TU(E\& ]VSO [-[3P"81P0)BB UJS K/ $L2H*/%)*H[N[T[4 $
MP7K>:=X?R9)H8E+O>P*8S &V6.'+"!<;A[M!@#BV_:5@D9Z*8_1SZ!^A"Y\
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MJOESMKU3"FWE\D*M2O;N A-8@*^/, >6XFO80_X",4-[%"\ 3@@VUQ.7^0L
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M'?GM3>D)Z.Z#]$6C:P^_MIZ][^%J2#& 3D#R/P7]2X6"M'NTDSYAH/)=$P<
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M\N4"P",!?3D9<<.T7_F(81EK,6^4AMS'2/ZD#QCE>MJA=ZP8=Z_*/NG)9U*
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MT5V2:QJO4D5$U,H?-_ZT/,WN5IAD6;A\80V@[3HG<1Z,JM5ZZVO-H ]FD+T
M+,U;M!9(WFR1*_0+]%;=I[*?\"/LD*E\I1Q"H RKY0X0]HC%Z\;Z2M]_? W0
M$-OI2.0<C=*JFQD3/KY*=D_'3.)*N*J2;-!>-S#Z M 4'4NDQ@H]15$.3@*6
ML.+6/"O.<I<0&J[5%,9']5F9_K*_0-89SNTT#C,F;<&N6K3G?JHS6AWS$'7:
M,\EBW<-:5OI=R3W-U22%?]VA"QZN@,=&E-N6N5;T:+TL3I47Q"?''$ W,B\
MC<T1OPFN?:K,V+[BA0"Y\UVHU)=UJ]FJPH[([F3IQ6(Q5@L!PV'S*-6'8Y_H
M 6\8\->11.H+P*7^7 0A55NW)EE<UF[,RN#&*4+N\$W5>#BD.KCF.C.'B3(F
MYKYX#K'U::Y5()"T[-Y3"AX=41B2/3[:%\&QKA!'5#EFV8S1ER(V!IYHR)_^
M ],P>C79=E<!ORZXTB60TNB">)FJ_BZ16?1Y"[1<?&'HQN?U_+X=-:FUE0M
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MO\\8->]+HB6X$0T,.Q5+-XZ/L'PT&81L%2.J'A[I]HT+P'Q&*E$SE(U(JS(
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M5GD>ZDP<O5S$GLE$GBMM:,00;S*KDE:,[.BBH_Y=B>OFB^M"1]P%KI@V$__
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MH++BJWX/6X@Q;!*Z.N;N9<!U*TRZK89U:+XDRD0N%M\=TWN;8H&01MCQ+DZ
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M^BGNLG-,# 2I(W-!;,FJ*BU4HRN&Z9> Y#Z.N#^C'!A=S>1%/E_\$-*SI$_
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M?V)F?D';\I1IFJ@$H! 3?<R5*)<K_&SO=\ST=WGC(FRE>JC1K!3XN:-F*\$
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M:\TK<*]!14*-T?Z@?VJ%'L4EUVD_S];E-)UBGYBDO#=LEJMG/ R7R'HHHU>
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M'K2Y3CW<NKTM^Q;P)JOZ3QY0-_RXUEL@^,SOM4I0 [76$UYBIEG-^T$*=+>
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M)%!PW6DA_R'Z,E[J=^5$2<./P*&BO]&%)SD3,>9_WW8VQH>,7GWQ[1^^^C9
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M*A"@A068/=E7M=(I5,M'_&%D9GK?]>XJM),U-GWS0.%=\F]VZ>OZ3LI-Q>A
M3C1KNW%TDQLCZ(GK=Z=_PFD7;><\*3Q9-Q-U;53#RF.[GQF)7 \?RG13!,ZS
M,V)GJ\ (\NJ(%N0)G9,Y^64D5-/V@N46P-.?_#2LX[U$J^_J?P'P,<MF>@:(
M]ZCB2N- R(7&:@@8R:E=NK);)!4L&..1%+\S/.A(4+X5G""PM9#HAQ)!V*.D
ML\K,I-:N%WL#U!#K"XSR>VGY%^]45/ %39)/$_3&B<QHWQX*^YF<E%YW=K.:
M'2 *=!0'%_/)YX[C2TX2&Z^9CJ&*M /X3OF<DX.CLP6(,!K.AUK?G/6PO,Y
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MSMPY=^:NKWKMO[I6K=K/?IY=NVK_GF:??@->RDK*2 +@X $ N.<?X&D>( Y
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M.#D?MW$%AM5N[9L=U"4,UB4-S8P98+DR3#83FIOR>?O,QZ5E>OE]T1BM/3!
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M3KS39OMM*$G<KOZ+:G:REE:[_E&SG5L< ^&96I^W5K;WU*G9KW0%@]Q\X9\
M^S6%/I)\.M;5^E*9XW\!DFO"W!?IOQW*_S\C;2T-3-.*)P)B9V1U-CB%,:5<
MJ4AQO [^=8$7T/ 7%R:J\?_;73T^^GH;MRO,V8SA)V>KDS'ZOL5?Q>;5>^A/
MG9F2FBE:M(T77:[H4U]O =8S$:\]? R*0A$)ZZWXSDV:;J>60YUH]86@,#$
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MO..&T1+U!QBFCCKD' '(OL4O6&4?S[OS\K(Y97S+EL1FT!E&*GJT FG(#D8
M1#NP^, M3T]/AWR8C*L[4S>B"<O!F'/4IK77V3*A%;K5RK#V[%ZB.TY!H.4!
M78-YPMMT*[HZ>U.^[07X9I>R3=Y$Q8E+&GFFCB]!+,&+E:,L3HIK[W6KM?+U
M)^"K2=,(CC7C-NIN3]^C3TR"O;QGV+)AB]84%)4G^#/?@*7V6V:I<WE/ $FU
MMX_E@[1 MM.M,N_+HD*04&UM?Z#5Z[>K4Y$#;'H#IN\_K170%#RK8-M5<WD>
M4]YE[>VMCI@%SH%@!K7,"-LDF'^&("$Q.>-$8C)Y)!=[MFP#/$5=;ZHYT%,:
MB[)$3!/42\Z7#]NK6[:>.,J)7V=="6GQ<'\9Q<B6<K"3)CV:F6O8L*BL:Q^?
M/_J0F&.C(4S7"-[T9[**F#!'<P_PJ143B]@"@/UJ@TJM)3A;%)4KIVKW!OO(
M%X$'4]G5'WD6V@6(I<0\:2>>0P+RMW7EGOC2MF.#FM);<_PE'H6W5\EC3R'A
M= F]V-N*3BWY=\4W; T8.^@<?U2KS^PZF#8R8#3K?2_%:;^21Y0">*^7@M0\
M;0<=_?/7,G( [&<(0-""5S@;\)Q;=P^!KVL@":MN\WC2IF[MO$KL"BBU!%<X
M>O,2( 3[L$^X-(81A<0H*+!Z;\;#/.B]7-%@X2XF5^WPO=LV4)/6.C<PLJ&=
MIO+@<X3QMR.3-'(*YE)%C03)"9.8DIIQAN2A]T/EK\G6*A#!3I[/4,\M&<QK
M>E):)5K Z#5?W\@L'(PY\NY,GJC;#-LYV#MPIO(!S>JCYSV2#",67YJAYOSF
M0]P(<927*1DNW+FZ#>XIY*ZS#G2F*\LT[=&Q-.Z#T7ZE^$6V3O)\ZF!9J:":
M)DO.DUEK@9\)*L\.W27=XP4>I/N\ZJGJN:9QJNCC%01CBOISNP@4KL2E5POD
M? 7=TP8R1]3:+*IL=;A562>.2SAGW<S0OYE[3FHX_?8-_7>+7F?]N8:VYR^8
M?QZGU+T!E5J=Z<D[D\<?)6+$-;BC*NL@13$0"Z;9Y&28U_S9E<C[>Y-B*../
MGAMIV_6E?^?-M)G5XA.@M_J1<J2:*8L>7U5Y@J76F[NF#0)>1:;:!XV!OU!D
MW(7522A%V'%T- )C7"^+!83JX-R^F<5OF%$$-/#>OZGSPQDK+UMOJ*_ I"TA
M4:KBS\EQ=T%D]J.:7L3390E+GTLPL+]SB&[UC[FT75\;''$[V)F!%6A[R(E5
M-H5M+OUBB:ZT_!PS]YJAD9I.XQ@>4I#!8K+LH2$QZ4"QN]LG6&4R/$]3- C^
M.?F2\A$14T"I>MS.P7#:88E4JW1F0"XTI2O3LR--+&8&L%E-LJ?V?(DHTM+<
MM5" 3$2 #L&(,;DQB:"18\=L*D/#-,\RBT_UDUQ/@&LIB:FYNH90C=@!(PS+
M/K,HCS. H3=6*%@1K]NY9<JN)E559K&@1M&XR>(5<1C36O1*.]%MD)*NA\&'
MMGJ=AE+$6*(I=#1=-"4LA #'-<JE8:G5?I*)=J_LC,AD9LG>))*J%*Q=416A
MRK"1V#7-UA-!+[6\_$M2Y5P)IZ%H&LCI81MP)0 5H7+G%W$.\B0_,":?/K4*
M/]B6@SQO1V=]^32F?STM93./1"BP]/8K[R0:CXB WW$\S/OD5R]1&:%RP^2%
M'8H"(?]G\.9,%YKY:2>NL:168,D/JM\1%N38(%CIDLWM=]CB93K^82ZBM@>8
MDGM4[DY.GOJ]5DHP4W;,:80?WCZAE*+[2NKK6U+-_!K>&E$RK-A&?B!;P*ZX
M"<)TCCR"++AG:4" 4\[;,V&55DR25GV!*-I)P7.+[TBW]W*IK4#'PPES-$_?
M0)Z31^"@PC&LUZDX(B*X;[3<"WRF.X7<X)Y3^ICS+;\7MZ4[+^DR-$U2KPOR
MLB@"YQ<@S3-K" B^K+(8J_D$I:NJAWS5K"GE* $[DO^D"WH5[>1-P='MK'H=
M:N" ;37#,;^D9>[YNK4^K*OF:QC6C.8/,N0U/A1\<8V6^FD?3$]:KWN-BFY?
M^)RQKF*:P@1!M$_E []2CI$=A;H)T%-SRT-<O'GML\+ZM>P333<MK+0ESEG6
M8X6J9?(]3*2A90F;T*DO [DXZTGKL_D%>NL'E!_5XVN<Q.W(G$8F^HH09'?A
MG'?? [!_?:H)-7FMB&%YNA-M-6J*6=M$^ 6-B--6AK8XJ)Y"T>O3\0@X66WD
M!^2]MNX3H%QO7UM\=S2UZV2&JU0"SKCFDF"&)R'16:+16]+\<QU.156\($)0
M.TUR]=^;J_^%!D<1?UF,2>F<;YS2ET'DX[L/$5_>;3OED+1(  QUKM^*U3:$
MK9)ZQ[ HD*.UI 90K3L:H&Q;+]_3),M4M%3:<-EX;UD!U5)_] U/)C#P[8 ]
MGMDDKGA"GP=+K>$/*;]D%3UTD\M;@J&NFBY(TD0#Y4R(!!J$BE6(FT7+Y8H6
M-*V_&9'G3B9 QHCPIR4C?B<1!3KJT&STH)0*2;C8+EW;R$P*AC1 W&)1NY0'
MJOMB$1]W7 V[?&7R14)=0J$FT.$(L8'7)+PSS)6A)_!8XDZ>(YXE(.$&W]6=
M\_'"<%Z[_=]I$B%X/GURR("*D8FH<@2B+5Z:;J^-A_B>?//;Z&C!$-@ *UWN
MYRG-@%(JW5C0Y#M NC5+Q_:!T?%2#'*JLR%$=OJ*@:,D8@1*J6Y.%R4*]LC3
MO-:1G"@W;H;4&#GC5M&6<X+;%=C1S/G(0&FIE<E;M6]?&2SLB74@%,Q*X.>H
M#MBYG#D#;]C%*F#M[Q'J^_G."T;:5M%J(MG8+]UC]RB-K,I8AOQ<),B^"4+6
MW03=5?B5S0FE/J81CJOTK'9I%M;6^[.MN)LKS8U\>G5Z-CH8EOAQC'.80LNL
M"L+,F<$\2!M%4T&.O$6[-L_U,T=WUZV5L7F\_*AUD:@&O/LFC4Y*M_J-:@W
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M4/Z<J-7[J=U2W32=47V*N[FF&3* AL$$[Q I8_X+J0]P,6H$#7^QN79MTFD
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M'L3EVT912&73NFREGISH4H=)#$]'N<R 9$ULA'YU;'.<%9I$>ZZ;Y!KNQ!D
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M^G&*/C5K^PZPX6&'#5T>#2_)Z _VABS\<"W7C>O8XO0NJ,;(-I[H0+RI N%
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MCJ&^NY/OKOHX=ZG,E-ZW1\TPK>:31/19YB?H#J>#U =CI?;Y++!BX0%$PAW
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M>KD<RZF><8]>Y:C+UZIH>P20QDO2Y>E&4TB%L9=I0-HL$^5\=]+!P0<?FL8
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MEYGKS(\,3+PG-N01T/*<S>?@2UBE&UW(H;X0"]& _"*-FF"5P(H70OKZI4!
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M/T]HCP=U2G:?SLGKX2%>?2WY*,^9EDV70C548_W.M;N.P.'>'?ZWA\9+O>\
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M6ML0+H6N^+@&!GLR+#&$?H6806QM'_5)T/@R/IBC(")!>?VWV:Z40,X+/?C
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M\+CLD'(J/F[5L&]4!'X"3$/E-.>> .6&[WC'Y4@9_WTP^?T,[P/77=_3&$0
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M.R?[KCA..4AS@I9J943/3%Y\TVST=_M*MDC:%*<0B_3H?- 0)4RMIO93,TH
MNFR]" PUW[/7.+OX#RP=:.KXE[G&_+?LLN6NZ*)T;BZWLBIY5UKY?> ?FI.Y
M$RCG:%.&8><)B;I0\!$I"A>!)*9C[IL'=",=)%X!5X\*=5,;E)$FATOGA1W:
M<3&&FM2#:R;2&'J907U<MITG/=BH^$<2%JU4L*A6=QPJG!U5296T9*VQ=P2L
M'@JE8$),;*K_B6=KY2Y?>? 9&L4S_9!(!'+G&:UT[]AW=HO CEVB('\"[&E[
M/:S7NZ\I!PYT%5,Z%Z#_VF[_X.SKS,'-^L#8^VK,IZ)G?PLNC'I_I\73/MZB
MX\:T-CS+$#L/1KWY+I<H //E>3N *PJ<=9D9],U'Q]G9>/U1>'NF<U>4TJ)'
MR]K=%%S]A_'!W"PW=-LOZ\"8-56UFCPDZ5E:5B3%07+'%"]-S>F5$]?;;^X,
M=2NPK&SQ42=E#4UESMO')AK<RR*:LC!DF)G7[ZELS.M0,^O[/V4R/:_?W>9#
M.9OY !//9T?4I0%H_@= ROC2BFL6I)!6V\(K3\Q,\M&-C(F""7N"C@:)(FZ&
M&^5Q"3=VH^TQ=9LJA@T#679&VK4=O1:10M77R5T[@\/VJ(SUNK(PR5S:Q]7<
MIC:7QE/)@4VB1KY#*IESF&'6RK'E"?ID_Q7C=S,ZMT_23P"8JF &3ZZ\4EW4
ML,VFL9:VKPAYJ/YS(C:I/;IRR6[&2*-)0Q]1U_UIP82-, 3,+K-G &6GDQ&S
MP(;A"2!W@GOO[-CGO";1[8R_!U3Q>@+8GU(NM,32;J12EWE_WY%5ER-LE /Q
M)EX\ 7 ^Q;(&E\M-,MV@/3Z^&D]LA!7N970U&5MI/([ *3WJ:LK>R:8'1LJ>
MH[(>EWGW\)5(;^= 7B,SW5F_<5S]7/9P 3Z;#P69$=%=8QD]FG]U$7!+H7R3
M!N9B "ZH&5!L^>:K<^=:FNW54/MQC+6-,[XYU @0T:4F\)4Y,#2TV_Y$+E$4
M:RK2T!B@B,W 9KTQHM.Y=TY_F25B'*(9HM)^<45T[:V1<(K4YP&Z]E:C6SW>
M9C3!E@+P)^K_9>HZMY%K,3_F.+;O'D=O304I/3R_WRO^)^12FR9GV6>:'<+Y
M*O"?JB-/A8A#>P'UEY(I3&'<W#J"??CH(4%<"I _=(%>K9X%X><2[W ]:U-4
M/'G FW)$/^.JY0?>C$$" %M[6IQSLK&4N3N@)5-93C6XO4MS;BO<\I056X_>
MG,";<.D) -4^=$&?.?WP(4:$ZW ^@;5(P(9;]X0$M<#$;UGL"1 H!RDT'6DF
M5FWE\@  VZ7RK*QL:6T_;E1.WPM.\EA5M%8T1.<"A4S9?Z\'?OIJFHGT$SWD
MC#[&"_3,W9D6$MK^TM#BN*BQ&X+2YWLCE><Z5=Q:*V'W-B:/E'O@JJYO=R8[
MBII@0/U#R*!.4^2&+<A9 L,OWE[#L"\GI%(K-_>FW(RD%G9_-_@$\*'4YV9M
M2*/41PK'?R=:4!,!8,]F9]3N_[JDW.VJ.#PZM&ST.%A_HT!%.O!-A;!S+YT/
M&#_\?</$B/&X2U=8\D>,E*R1_B_^^'!S==*-B[9CI0S'&_=EL(/)FV@-SZMM
M(=^R=[Y33C=?2K%B:>3D^ ?T0CK[YU99^J"!LRUUBP.DD_&.HN9>7X-/2G12
MLE$O19A@@TQY<;=A*!ECB'@W+7"GH)&KC!R)3MC_A9B/N>*J<-IL0'& "NTW
M+T3KU;WW5X&8@;) &EE.' )Y&5*NQ8PN1X0H(M]U3I]I,OPA\)R/WQY1]/Q&
M.[40T_VCPA#F&J*R1L.ON9M6[JZ7+%H\E#SL-;K!H.NNOE/ZU(+!M;IL18/2
M@1V:<]:74B:?T]?>YS#[N+45,$5F]8_99PD?#%$V)3_&-IREIOM"#)RK1V_3
MW*U8B\]\5Z^6<N[QS+K;F*9K<341!EG-"0,[OT4?0NU>AZ7EF5/7?Z"^>P A
M+0M*YSU\75^T$SPWW#6MGLN>*0UO=^H@[]-?CO! /:,1* CB!]*\WWV)((0Y
M*XEU,CWS6E'JN$?GO+95C%4RYM[O-BBY":5P6ZE2DQGQ3G_8F8W'$7REL!B_
MV&J:>$^G%HSO5V2KA\2=)!,ZK#+<94>MCPL9P9?N5#+!_Z1F@RCPE<AMHZ]O
M4!%K_#@KNZ5NYZ]2!6'$@?QE>?YS$9PEM*3CNGW>S!4:8!'=F-?[*)QC$1[B
M;GN+>9'=3=H?Y[OJ;#?F8=2:)7RO+>20WV/[,)U&O]8T&DAIE2-,0WV9VK6=
M8TQMOE(%ZTS$'")U X:,N_D%^\D25 (Y/N*V/0'"#2LG?61H\YCCIJ--5)WR
M4II=3Q/>4"=UF(A&0@XFZKE;N+.1^O,&,E^*T$>)PO=5\%5[MNC"#<#$:@E.
MG,B2AOH[WJ&>2,Z[AA'\::@8G^**+4OK'C!OR?UJ9[[KN*V@L+]PV*S49&3Z
MBT37XFK_EVU'9=%4T:V(U&,%KSU.7N7CQ=CL02:D[^\@!>/2N]D(T;5-5KH'
MF\G\EI%4?E9LGUJ:I1*_4&RV'(RDL7]K:_E_1X;R4%E)XBU'>-\:I0?\3JEJ
M_(KDY2"$L<9J:<@9#"S\*[5((>U>ZP0/FB/S&2^-<TY!Q(QI9YJ1_*.WZ[!9
MYQHO04:0UA*96Z-*I7V]A>>,O(JOS)KD1;?M(NN4N R$*[%>DY_K+F9>Z$_Z
M;]KN5BG-J=H7WJ[C62U)7 SA,H%&@<X=?,1[,>JD0ULE5B.3?2+:J:L+4'.W
M=+R3R)^6XP*(Z-PV6Q4'40HFJI#V#\3S9JRT4V3=2V2VM\&AC-7-S0FGBZYF
M]%]]6I[)XJMYP%J==DJ6=BCE6J&!\X@]EWS/,'OMRGEM_,P7MP^<DMU:;1-;
M?#/&PV#VY1HU>86LBYRT[7>] SQDL7#(KB@G59=7[NUH8,W#NW7>#'X_R?%O
MBDQ6)WVVEDW$;07C77]UMO&[$+9\C8[M)4(!7/O'0S$_7-+*RD:/<E[#FW==
MH?>?E3<B4&ER"JC/NKF_LBJQU[0W'!\,UP>7\TB.8N3#BYA_T;_\B5/X1WSK
MK$B<= 7\#O;^A#NH!'.VO<;!ROJ/J[.9*T!H0+T=,WF-OSQ(Z$0=5&#BH:#N
MP '9VB/:):I2(6#:^*Q$$M0'&*5VQC1L=PG]LW^!_S.Q:!5777G<1T"PV*47
M8R/AP,S/-WJYVA^FME7 *"AP1#>8N[CM5H?$79A'MEAD!R[U)PAU=+VM6(L-
M4 ( U(5+\2D]S/0G+U)F$SLO*>,BDBHG2X^^]O/CAJ&R<=_U:9+15$@<\[7(
M@,MWOC(=X^!S&4;4.^#,A5415+\&Q"]Z]IL(T=XG$\FXN1DJ1$YXUGJK>G^(
ME6^;6+E[/];29?'FD\] !TYJZB>\-;13#!\IXDU%J("$2K>>KB1=2^+@=PW/
MJ0BL5P9KJ!QX6"/J=1[%=8]XB'O5(H](W6EHSH3%I-W73K!=+%8(?GQ]-2^:
MO<Y:T58!18%0L ^HS,-=]=@M)\_0$'09$3U:E#?1D, V0F9NMHEI3>,5/3(_
M;DYF)5OH<?4QM(_LD7+B7H ES]V62+FTWI:HXI72O/YGZ85=9Z>]GA<GRD/7
M[ )'^[./T\SC5:H20![X!1)/U*Q-HC*Y.O?:3Z/F&@K=>VNX#[?G6@W":ND5
M2WK_*<S*\:Z@\, H3@K_7EZ<4E?,8V5JO[9^$IR5(&>1Y-A @0F($8N&IUKQ
M&Z#/9K:Q( XE.;;=FO+2-D/):Y*VJH6^Z)NC4 </I$'#W*D)#0E]-*ST!43$
M)2!D006-=Z(V4-$M$<Z&WK# ^><C?B8<67^9Z2K=3TK[RI)MIYTZ0J2ZW6[B
M+SZ%1FKSZ+#UBCX4F-?F^5^%C_Q!)),W?ZVBWL I<B905(LE7A\:^YC'I(L[
MAC</>=CU>F$2#/%=6U 5-ROTL%4Z'MS5T[6E#NS=[<FCT/DEEAA&ADHA4IRS
M:GR!R"ID25P!ILD/JC7H\^37-VJ]%JN+J5B#X 3!/OB/+#KYR8T)O.#]]<@P
MM5$[6[  [*1I:9X\Y/CYO,\=3_N"IB3N1.A'BZQ?R:(*YH]]M>R)[Z RT/0F
M?)"JBF:-.^&K&K \WY&=$W?^8F9>A4@1E<T"-XB<43+SG'\76B +<<A#RG@*
MI^\*:[#$X5]$D& X]*Q/)0?\9Z_=LRH?]7R5TFM3+7BF;[41L$E>J6,A N62
M-011:'_PN;4Z?6)%J%,<3!V::J]+SGC*G]Q4Z;+1+\ \=O:@99A\(<YI>2N9
M!6(R3*M(*WO%%ET5(%A"2R>^7":/KBLJ3FF94\92E&WK'C-O,NAJRY(AT!%A
M$76([5./_8,6RT[/V&+EA:UML]+6I"OGBJ6[8:_[VZKWCM+TZ&A16(!*@3&$
M<HI7=9-^0_="07V)L<.#WX<U?C"'"AW)#CI_?55ML*Q'V&>D=N!090;OD(2Z
MZ1^$8%'FTJ*!30RNY*;%]Y[LZX[ ;,\50H98JF=XGDP$7E O"U*U9)L^C3ZU
MMYMU[<?VCDWR*9^=2I4$,S)M*F[<8MA:)\M8-2D:3A$B2B->"<LX[L5>JJWK
MR7H!G\"BM^S\>^4<.Q;U%C.Z+ZD:Z=R9  NX7@(DWJ\]8&49W@XYID4=.T)-
M[<$^XDCTME (3PG:!'-+FRR5 6DN%Q,($_"Y2H9^77<I ESF((Y5 NQ\,>K$
MW/92^&/UFS_;F +CX^JQ*D;!/UOE-!2 2U/IGD4[!$@/N%[;Y/FPX>[$PRMO
MSYKIC USZ;"(RM<2_FAASI[YJKFSL"R0K=.*JAH2(QE4;["@)#"5(B0O/$BT
M5HBVMMA*&6(R3,EE5]H"G3K7?6Q?&>6W-7;>ZM:2X[!QUQTL,:Q-G#-C6>^B
M><'WC>^;L[.\$Z+6CN>PA=L;BAS-M1'RLVF+N40 ]7%^L47AQU6L/&>D$\1X
M8UQ+PN$V]4:%;"C5@H;N'O_T7EWJ>#&P$"1:'L306/<)?#X8S=>7"R-N^=DI
MY#+*Y+V,. HZ**/_BTI,8RJ4JE_+B44):'QR*32]P@*$S\LB0FRP"+5(.1*;
M%K[68[-EEV[^=^')_UF(\LM>][1N;$V3%N-[F)25VUSU QQ."RN RCQDE!M_
MW>^(XG6/^2A]3\:$Z,M9?:&"%=Y@P,.#N1C!Y=-^1-QQZUH,6JW5I0/!MWY)
MM871T6ETWE<#6<7L,-)C\^3R@/S6?4I&APFZU(V/W]Q(ADT5(K7#G_MQ;'+=
M./NG6A4R-@AX+:Y2%1)Y>[Y43+4P4,=(<7='#V]6A[!%".RJ0[8Q(0<&"XL/
M\LY/@,_3RP\S=4H*5A$6G??'-E/!P8?,C2II.F,_Q&(6\%;2>R/],O,<2(.^
M?();>3P!6@Y),KJ3Q^"N<ZK*ZLRRW8X8/DGR6+29$;C6\P<57I0?BG<'=BGT
M/P6\?5YFZ(>_-*,,_.":/)_.X([<V<=:CBS#1S05P]I.:*"Y!PXXSL9J!3B5
M9C89[V#M%</OJ9N>#U#^-1C>B3O-L;K'2,_<HK-*_2X+585GP;G1"#:JW,7J
M%]TN!&+I0E;QT!?"CE\] 1)"9/TO8%)1 JTDE<-$*L0E?6O.5:D!$D7#@X44
MR7TA3=%**U&R[N1=C10X4DV+BP\EC/M>]W[-=PSM=TIO#QX4I?)<$J<OD:[M
M::[T<B. /A4Z:;'D7DE.IDV)MQ"Z$L7,1Z,G@*B3<]U/"86=KW3Q/#%7FM&T
MVB(13"+:DKE74IE7T-FLB%7,('-\ZA"=N'/Z*6XA@YHI(2:YG"1Y0PH,<GS3
M=Q*]UMK]S;M\<8FRD^=74I]=F[Y?RPKK:6Q#.F]/%)O4:GTZ6;% 9"=\PF[W
M@+4S@2SW56]]2VMP5LS!Y$J8.1HFW&GOVC(GN-?M\1-PT "J_008?">;>;L6
M?:.SZ#:C*\AEEP4_($(N*,H=JJD03\;NVARTWUX4ZL1/OHT:D)?!I ])7GKP
M0GQX<:XA)_U?H/:OX P#]57Y<T%T*6)A@2, VMRI%Z:$0_:$]@<3PL" ;?7!
M0]_B_'K83RS[(";8IHUBCYR\D[%-*@DI8HNI6'5X=E^)]Q>/S_1KPZP?='&-
M]-%[!X9(DR+:@A>O9:D+'4]B4[T(O$.Z$P>>.X7$=AOMZEEX/9^62GH"[$VD
M,OY! M$XU--8CB %Q5<O!:<_4%K[?WI-3E1 FT0]%<(9G7MN!=1C>P*8&_B-
MBD@=G?WEY72S+T4V63YO3[S!/&8IU]#:7YE]$>]& ,@$ %"_8=H8LI60_Y\N
MCS'\=^25": DC!IC^^\X[-:%ZA-@5BC=Q/V&.\R7PV1SS.V[%;-OJ>E>O;/,
M9\ZY64;2^53^])OSXH/L)62DZ(NYN"A(QNMD^U^7[?O7>*G@^[%NK]'4MU>
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M7[CY=7!&63=/7T'1@)>1VR2!CNIS"=P]\'S"O^Q$<M?03D.1%,8I,G=F2V6
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MZ7ZLJMK,3M;@(K:984M@6'2=A,?D#PI0K9LRM^F3DF'S6GU!X\MS_SO@.V*
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MO"0@*[_^^:O"%FT2SYQD"W;<#Y81LB@NHP#4Z?3G.4?)N+ZKYA[R9- )#7F
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MG.6HGAF77P8Q=,?<I+>+:F*-7N70UJ,#]98#P0.=Q0@"?PTL@:#\1B&=,;_
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M0B_8.XNLF*Q<<]T1NGBU",[);MA3S*T]V6;24H//U'[:A1FR[.]RG3BHUHF
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MG[OZQ;[%M]A\Q[^&*LG;[E60^!<BL1*BC$S V3$O"P+UG@+#*8HD=K2H]MY
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MIDL9 L%KK?6>6210Z42%7N[4JC%RES'KQ3U"D4<9O]Z8\V&JZP_Y3X#,^"?
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M.=BV];%:7M%W$5)4RWK_-'9:W4O 6HUJ@[AQ43%3?AV?"6N1QDWL]D^8(T\
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MB'WI*$B>/%G:CM5#WQ[,ZVD1M0X5(?XT,1T"1$="H0RI8R')_G]6QUA%#)\
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MV*C#S&Q*,WIFFH,"TZ.:1\5+ZP=UA$9"9>B'B5]U*WQ^_8PTFSR,A)SW.NM
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M<PYS2<ORO+?S<?EL?TCGE605M;(1Z<U4HN5'%"Z?;,,:4F<A9-:K(:$\@V5
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M0WUW7VWF 3"W SR[#SBWFSP"WH9R!>SV >]26AU.:7_$JJ:QTQHVYKVY/3_
M][<:Z,'_NGFEHZ>7P!'5^BGH#K?I)^+CU4>S.,G#&#:'W7LI?Y)KX'VPSF\9
MC'^T>=^5^/L5Y:<%1P@:^8UW-K^35K0'^C&/?-!5M[/T 2%VN&&&U0'U>!..
M5UZ;55WH3?PYEU='7'<^2K<[!/@/@('AO-]3X[KGC+$IQR%[54-68#AW.'"O
MG7M/!@"<;/E,PZ(_-9;-SI&",FB)IBE#](31:(P;"&:!ORV8@+N4^EO=!P =
MPN9NOBM]JK,4)<;-MS"[FWF^Z$HW3[266PW=CVVNWD_(UDBU(\SO7FNYJ929
M^4S@*R)@0*$[YZR;ZPZ[@[=E=[ ^(N+WTK<,_VN)>?^SZ)\F^-5EC8NBDNE1
M$>@QGA\[MS5&CD/7+79COMP!64LZR:>+1!T<5Q1OKI0-8Z>$4,_*]>^9?CJ=
MP]P>K<J*FLK;T^=(Q1C<RRR6586Y&ZCM1HIZ6QPPP*,O+>-!G+X$:L52%F:.
MQ4:5';4021<E87;?!-_?O^^BA9V4>]7NG*0#!>T0F1T\CN"[SD([YB9S?2$K
MLQ"9+85*/JWI_=,V9W9DVN?]&'YDYC7!4<59UV<[LZ90 <71><=EKQNR9TGW
M,@*^KW_M>:3BN'ORM+28:B-A87Z29Q<"DI=!^DF'(:,P_KVJEK$-S'M=7]4C
M8KAQ9>$>T+K9]1-=;8P?RIY?[*:1A"^.6@C2=<Z?[.Y$M0B.X]?_XKEQD5_-
MP+4+6R[4Y;!W](3?R*IU].GR&!T=U@/ $E]]+B+,]8TD@SK>TNA7TS=]\1>$
M+]D#GDP="XS#8-^L[%/.CSZ%BQ#LJ+L>&J]ZQ6HUO778RTV1N%=B[=G"HKU/
MGC!<E JP2R4Y[!3<<@XD<%*P4'N/D!FO*MT6O*Y0KCU0>O(9J=Z>LRI>3GCI
MJBM3PU69!FP?^GIO_-M<ALT(>/&73 ^0*Q4\ /2Q_38NSJG/(MSOK$9/ZQMD
M[[?A_2<#]SIK(Q#4Z<G)4TRWJ\XI_J*-75)B[J_J)OE-<Y7@.#+E:C2B0 *?
M_LFSR\-BDB;"#'">A"XB.>!"O:KF#FR6IJG"@UWVI]:GSM#%M(VP\XIGA/2U
MU7@PP6U-$G'Y*4.<>$N1W(IO*=RO\^H]=!L@['A)M'VE77PD-C6@_[I!/\HM
MW7ZEHSO&^4!]Y75L;]/L'MY=DN-SCR"ZT%NTQ)S1^HL]<BI&0CG((QE<,*6B
M8%F5).O(;XNZ;/:"R 14\$N1,;Q/-]2G[L]Y.PG]W1]OQ+\U@]N_AZ#8OAEA
M8N*K-Y^MXCG[\H:.^YRV28_[I"BC7BB>0L]+9(KN<D MT_1)K,9]Y?RB_B=5
MV%=C-%Q#\L)?MV.T]7G*,41!8T<*+U<K^:2FWO.\=]O:AT"9&C1JOJZ\W^JI
M^J%#DT%V,S\F[EUQI_:T>5: U!*M_T67910* VT?"MDSA$RN+<F1RE,1W2CG
M'X!D8@3 29CB ^6]@/#47KI\?,7^<'WD2POB]=:[V5&1F/Z24F>>%++!);D[
MX(G8 \ D!$_L,E&]/IBV832'MX<0%K'QEC28\I$TU'G;J!62G5SRHB:@,DQO
M!T]:#AQ> #L?JA"KKHK3L$![&[6YV-KB=O,2)I\^NBB?Q!+7KJRR+VR\[AHT
M<%HT4F@[]SS<6R"X(E4I,+&=U<1Y"E=>G@5)WM/ MNVP].K>)L/K8U0K9UV%
MS+,*#KRU,A/$JS0/)J6GK H?.C5(A<@L8N"))J&A >L61\ [O_X_<;P-EA/\
M:5#&YE256N]U-+%HA^!,HD"L/G5*W<\0CLHT&(Y7GBTFIX5D6S4W7TPS /NI
M>_-*:)+-CZ6SJJO,PL*4U%($^(+\6'H*9)I$K'9CM/A,ER?9 ??M>J,\KY(P
MU-,4R[U@M[7BM]9<7%D#[;:(+61MZ;#V?,CCR9:"*XTZC_C(C287FQKWN[J;
M@<6.EAEKNRN&@^(#Y17$II@FZEL.LG<@@J,JX4_+?_QZZ?'8(TZ)C,&11HW%
M^867#<N"3!1$9$J[[<ADY*Q5G=VCNMY^30)$X>3)=:$FN>[Z7:FPLJB!HV?W
MQNK8K=SVB^W8=3.,US*9;Z()W]A%, ;<H((C-*L;,XE&7*+TJ _]#/4=QC1*
M_V1^AM*4 PG"9FK?"F06AMI=0;]]X2)A&E3\)3\I0-]V2:U+_ 'PX_B&[ !2
MK^)=22Z;)B:T+A;@K9#]BFA+<G#,#C;S=J(^@-!6G]P2C!TMLF--\AEW@&&H
M><_@)$1X5'B4K35(O;;!$NRKXF4D=%O T_?<SD94'@-5;#6W<:*^[:4>R$1P
M%.MI C7+,\4QC#C1B2'E[D'&J@6DXXD0)H<<M&XEY48BPR%U(:F?B'?$^8E<
M"I^B].&@N.":V$;^U'[@UOWSNIBA217?4JB1EW4 ZTNDEJS9@!YB"1"4E3_9
M@8U'H-A N["MQQVW2WN\/^$TG/D*M63PVX5$_5J^K376%Q%(6HC-"5/L@$GM
MJW+<MSFN"K0ISZ!=LSG(R\Q,9\S;5ZO#2M%Y1K():(U-\04Q/Z,,+7$'\DOQ
M@F\*UB)VW5+35<F_'V#Q";1;2R,\(61C:[J']:*^E9P<O(\C9GL5BPSHPQY[
M?8-KH'QH$1H\'8."M=+U7A6J?M]=N+X)C& I>_7/-2/MWX#<0GV'!\#T/7V)
M$OWW)P.;F!&&L=5ETB_M?"#!IV:'NOHV2DWV;)>S8N2"0?S?@/7I_@$S:5\Q
M;NWBGER&K,.-$]<W+S0> -A5#J+IV:K8,$6UK]'UR_O]&%/SL]L@^>Y-75P>
M4&]U#WD_>11KR=>G5>3*T91A5*1ORW$#V3+'N38#?VU[JDV^U!H7I8R/*5,_
M+GTO5S):VU\$$U9B-)D<Z-#UPV@I67\_2_9L-C)7AD?;'T+@->N L0*K/^W@
M4JU[(S%F#^U!-[]9.-DWP"HP7.BM=#J2-UXF,\#KW_%)CP%YGRK=SU@JKQTJ
MW'**8Y8WG+[F]&A(*]LVLIH_.>3!B1%;OB'87"R&*#^>!-:W'+^OXOYM)ZF/
M12!SZW.,/B/>\'@XMH8>?#E]E,?CN\<1C:/Z7#K[[>.C-H8"R"N,7X<F]/1]
M$6&YNO*//GYX[.)IA"8M5@90D!9B."I?I)HN2D9.0>'MU="M=7%#<8+F8B9W
MW^ #R B:/G<]7U^M/$(W1 KJ J&1BC#/@4$(@#N]RVNW+]UWKPX<NVHKLQ($
M *-#3@;9D3GJ1H%+,@U6EIH4O'Z_N!6OIR)J9Z*6IMP6<# C#>FS[JP0S4UK
M^N61Z $$)EC+S'M7=WO [N$=<4QHCN:T5K^*[PS%<?XPS2)SX>N\PQV*9 $3
M!J6T^PFWU5F96=U$,\>J2KWJ"7YA*]S4-Q"K=;;A^ ? ^XL*)0CG <=Z5\JB
MJO1N51+I([]4,>PZSJA*"%5W[_EQ,EY,3.@40X?>XG[_U.>]KP  .F 9Y>\Z
MDL$K=VJ@><:F5N&6)EJ^ #]UF;/*^3]Y;&L3&J,2I?^43=87+[WT]SU\LGV=
M]_O3=D _LS\08CRZFI.1$QJL_+#"U8[GYRZPP#33; AM1R+:1+U'O79'0+/O
MZ3Q+[/2?$\*E2YG*>E'7"7NH@XJ?S6OJ[UMRZKCP72H?J'"0/&L.=8^1+=A$
M>Y*3&KL94443>*C=/;4=LK&T3^#$I#T*1XEZ$G6?O*"IT!#GDA]?\RMZIOZZ
M;M 5"S1@)'2^29OM7>*6@V%JL /S6Y\C?-H855Y&K 04Y(F?2M]GR8<-"&M^
M>_61*[+J6K=SPL/JGGU/Z'RW7WVV<M>4H'VZ@4-Z@R+L&2>1( 8CH125DXCS
M;!LKRWDM7%AS<&Q%-(WS5$EOE:,1LY13:OCM)O(!L#MG*/>,-S%E.?FWH):2
M_I=YMJO/%E+K)S@WPI(3K6?,YFMP<F:;N/X$P;)IUI&'9#F_ ]DF8^)M^01=
MK4)%RT.UTVJF-B#<A5'Q,LX?&+RU?:JF+6TBQFO9O(OC&=C&<$BMWV:@N.](
M#GZM0'!I@/7!X&2>,2+8[_OOJ<_RG<NDXP41^6*9G@)U1O 09-[VY1U2E31#
MG;B>)<#3^8D#]>X ,$5A[747$'(DNW(%<JJA/5WFN1V\>ZR^TN;->88EH/!G
M-]NM?I3@;RX>PG.9;MV&LPWK/_^ L7>!(M-T08GK>@;PI\^!L>4Z4(#*P>7A
M!]#*KKI *P:B9VY]O(9U@2+G%0@]47 ;GT!]V9;_7I@/T?8!GNWWLM[Q8RG2
M+3#U-;*J2(7B*;JAVC.=MUSE-)(BZ1IZ3S,+F6HJ2^V(1Y:W;$9_.B3PFPOU
M[3G<\5W-OO<X]DMG,Y'8P/&=HX@;(8KWB&E_)*[@@^B:E%VDN1_]$#TA'T@?
MT/ZYS[_Y#HSSNBO8$H_?S,$<G:_=+'%:*SK3B#)#5>ABQW[D'5X),<0&^Q4A
M-]:!9,4AOBAH]Y7'A_L#Q5NX#S>MS1&:OZ[ 015QM[_9U&QB#TFM$N-U09FN
ME28E[1E;9LKUDR@_%ACG<M-+FM,' -'B,+,H(P^M>++7O3<P^MW" APF +\.
M1M09QJ;3QB7S5-TH,(M9-&A,KT$8C+T'@-9MD)V[H < <8[_VNZ^$5M9K_EZ
MT'<\TQ^4Z:TFK_W>RL[N>MNPUFAO*-!3'HO0_-"K"N=,-\&?T4<^C_GX $#
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MB_CO$3X*_ =QNS0//_\;4$L#!!0    ( 'B"7%9ASRJC@WX  (F0   3
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M7"Q_&D0*3$R-7!]A-D!!)>HW>OK@;6A0KS%NXD6W!>]:WV1H$.?:I);51T3
MXI[ML+G53D5CD!-%?'X">.ZBGT-88$8%5C"U*"CJ-#^H$7("AORJH73'9=2$
M9R9)/..YTUY#-5Y<\+6!7Q@!N^PK)L/X%%](O4\'G#YX50(]S;HHBFO,$R5&
M*VP'JX.UDH9%NFCJ=B8\#V'3UMR>0;Y\14";ZC><4JZJ%^3D8ZNW^T?^*;,/
M6C-'7(_$B+#/IV (N<F;;G+M01K3JZ["LYQH?@[&#<%$CFNP%7Z(<H(W>9J[
MN^MRYFX]*W+>F6Z,G3AH(\;/<I*"8ZOP9]50O,RLRUH5^D1T<I\_YU0K=1'6
ML:8NTK(Y=W]1MM51F01H4)+T"=!M7.++F733?>?6-ML'+3NJ F:5T6,&]R3F
M?$-"4%RI87=5@"@,28WXI]CI9^T@>N Y;FHS,H#PUD;S32YV3EBVR(RX6XEM
M@W=8A6#_TED/E5/P<PA2C_D5^378(3*;L?4L)YCK*@-CPR?#+T/'Y%UF([HP
M8Q6$;UWWP=NS_+&',.#U,F+^"<!4\/$)4&]\QV.-G%T-I^T'ONF'GJ_U+#'*
M.%&,4)+SI'SZXK3C35&WB4?M.:X&AV9L!.#9W+GUS<X&KWQM'+Q]].ND[C1!
M*9,D1GPH'2K::\Z%C]56U7(;^GT5^XR,5.]WDE7.!E/]UMPQX$<S5/>=W_'.
MR'^9*H-"G#R>+W&>[! :*+B.B-K,P4.D*?V$YT0<?:J9V<&7$RC83HE"OA_-
M-#=WTK\;Z,51[@X@Y*A-P)<#T4;4H4J9MZMK]4/CE0;00Z9+)>MVO!]S: -]
M=3=63?&(6:)+A"0_UK4$"&RBT_(^[*)/7 L? JWZ1TX12@[\E4@V@HFK(%)"
M< ]?P$CU^F;V(CG+@D\T8'*JG1Z1W,<%BU.6K:D!OE .E[%BGZSR^:YECEL0
M^\RONN[3(ZMJ!VI:/P.;2^E/ @Q'WPXQ_Q4SD7Z1?EO:X/356BA%XUG*;+Z^
M;;ILJZ[@O=/.*[,TR1)QVIZYUA:U\ /C%_J^/*XNJ!V1T.UX3^[2,:G3+Z.(
M"?1RA!K,;Z[R;,0 3E*$PF-+H9=B'D94=O+\.?:+;*4!_1\@6$!T>GU0H6VZ
M?%RA:EHJU#7\S0<;S@4 *6TWT:/ KI%XTF8/E WN$7J<&.K/V%B73ET0E+82
MP*OXP#;_R' 0T?D$P-P*[_R:*4.38ZON-R6_DI ?K-#.^BRMAY8<T="77E].
M4V-1,O#)]/U+'\.-$A0+F159 %^21/F4_4MED(W5%YCPEQ9::305YW;J"8@O
M\]D8CIA\0S3P'24C U,F>P.J!_5*/!:5V[ZA5*2X,OS9=!<-?0#1O@X)C[+5
MM8]N73+GM&(7STW"60UM=Z#8:024;D;\PP:E'T@CFBS[0 E;B? +RJ=HB+.:
MN*Z&D4< >IPOST8.GHT_[E1%I0YT0L[MNF1).QC"<X%;X@ZJ.KM<JNL/L>%L
M<<!I+QY4Z57/S*]74U7[[)&+(_I_+7VO4?AR2G+ )=I;T",=^,N_<?0^MTO.
MM(CWL$>Q<F>;*,W%$SR[Z3JD9NO%!WFWUY6"TNI7EC/ZA_M]J B5&!N$KXL1
M:1M,Z3<QD%99&UC,;T[8!HF@@597)\#,T41Q4V#?51T]PR;@^>EGL!L(M$9N
MFQXK&A9:;\'IW"VQ2=G)[D4[5Y6+>.&$D[2 1PUB,T'Z8$?V.D.-":F%^C?;
M0FDNMC&6I\'[,_\(DN2BMR//"'^=.)_S'/SR TF.=&GH/;R=$3?BRBILK2?9
M6>A_5DKIM9KM?UKB?5":^ZQ1A7$C/*?05[X='NJ1)-X@^<G C R+4E((WV7<
M?_6P)3]0F,-LPSZGPE>^&AZ:%I^T_&T1'"I=$9OCFIPMYGX,3"TW$5"AN5>S
MP0:Y.3"A=@ZI#^L*/]BN$B&-(1B[$Q%LW6?6B<"VJ;<GCR Z30\>"5X_4'Y^
M-(#U/P&V6#AM]_ASS_*/R=JS%3NIQ[,:WZTLR#2".@46)Z6I!L(E:3W-N@E;
M[R2_)1J*'O.UD/IZ/U-#WM?S'NC&0P<MM8W]"##C3_/@:M<QB%!7FZ XV<O%
MI>G98 GE7Q73_%E7]=WNBFR.+=">*E7;K@==W/GU5RGD5E3L$99KK6H[D:4;
M7F(IC?1+?=9GE ;*/I2*8#OZ>"S/KTQ._2W:TGN 'Z7Y@3R^8ALJ+-U#GNE:
M7(105?N7J_2?FPZ\]C\<WN%$1-7:7&:I"B9-^3IH.Q>N!XO0P&KW<C'8/V],
M'W$<@;]6D, K-'Z(=)=V[NZQ?8,K]*AA>_9HJ2CHU::"OD:^J4CFQ<E-0D.Z
M,@.Z$2'U6N=@/)#FVFK8DGCK''[+<'7@!]/)7P$R+>MJ*U'VO*4B*^ON01YV
MFC>2=KU3I,(L3-B75+C9P<T4K,C93X!0%ED:KC]?Q6)>#+/1QUZF*2GF9 ._
M"D+ZI>C?2F).Y,)#VU_'3\3I:RU,G0KOD8IY6R&30\*C ;MN#LA[HFN11P+W
M][(O\\P:AKXH2E-^_#E(1?4"6H%([E[2C3ZFJYO-]_H4_$GTM:+N+C5??!O(
M\L_R<0'/KK-@8B ?NW<O4\DX"3?P1=2!WE;4"G6V&M*H1/^-_\9_XU\!_LKJ
MLMX;R^;&:(R@+B_#UX^67U>D.1XG+&-E&CR^?;0;@'B;-N%%LFU(2$ZM]4J^
M"K*7"]^N:TB,88?TG$2.#_]RFHD7G4_O*CG0@:*?I7XOZ[RN]^Z(TI'_:>J8
M^DN9G8DF)C'39P*]M<L%]1>61.OD"!9V%*/CL,+,![M*#@<S+I +]EZ)C74F
M-_IT])D:_HI*WH*OQE1MW3USJ(>@D;[L>86_^R2=NJBYMTY_8?D&+=6ASA(*
MFP6RI[QR:CQ2W=NJ+:9OM+VBEH$2\93+!E%%X5C?+%(9HPB8L ?].O<_S(=;
MI[K?O2PX@]RH-'R$N+%Y:5Z_)0,%3I83[B)^*HG/!U0B1HRFW+X?5;02_#AP
MAX<M>Z"4$;XO90'$]R8BU-%MY)RR\>$KCR_GKC@8+F2:I[C8&>.5&!N_\-#?
M.:)3N0"S $0:<O^?8 42?4S9.)1KGCW-JPW+,*V-.!7*I5:ZTW+/9I[DJE42
MR+!375(1Y>Y7#D1H#0 7]Q3R*L:I0**D$?R- EF6DYPE]6F_GW$$%=E$KBOL
MJ57:GK>9R<U>GH8U]Y=7ODUMH(#6H*Z.YL>R$Y 3V3D<(O[,588<7#(*QN8%
MX<]ZAU6Z+OPUKW^,;U"8SJQ-KL"SHP=*WY(^KS0+ANR&6DP)[I+W*Y2..R4:
M&6\B\_OSP\<7Y&<DB=#4V"!'ZZZG#5)ASRDD C82IP&XOE).'<,G'58H5K3'
MKC>Y>&HU\+0( 1R;2Q\5TSD[&?*OG95#;#>!$IC4G>#AV_OWZNW(B(_7T3FV
MHFO,_G#F-?^ ]_,EB%A?^<>% (3\<D^!RE*+Y.K.;4O5F#L\=@+=0LYK-Z15
M&;:<0W7@3PE_LR]I491N6&YS@!#[AC1"*[MO%/%__43]>U"E13^@@F"C!BHS
M]@)BAWJN1QEN@<6SSBXMV"79Z-N:0$\&'&69QU^S;G;RMU,;]B:MB9.6#8G^
MA_3: +,][_0#ZUQ<S>F-ZSC<L+)]#SN7T@ 0C\]AQ@\^]M&%+0#:"K:)DW*>
M)Y[J9$E+4_;!C59S<P-)@L1#T(*TU/:W3F2:]KK9/R_A'W*V^V["3=E@JW6&
M\[&'LN\3SDS79JW. 3X 3Y57"=;RG#473_1L]R&-EB)@OBCM,9!M$C36*O($
M8![HS[G:MW@"Y#Z_U/]/":S_C1I(W6^*?H>7ISH_&[X&H#1@Q-V^D*;@UQ*<
MU[GY$@6V9\AFG(0Y#@<0?%!'DB-21R.-;*7/1_P &^C6>8T6D 16C(5A#C#:
M4)V]8G^@S->S:6AV7E:2*-I[Y@DI27+L>413E7H._2.7^-4PK?UIPG<X1+OP
M@0 6&_)"&VDRI!A"1>18U]):*12$1T]:I5?1_@_4'OI8$7?3J,QC8.^QX450
M$!"5"&E<SY.RQ]N]WBT&R,EZZL%7;F]:5>,'BU:=96D"Z,K*$2'MBBH\I*WA
M/P$6&/!^8^@6Z&;NTYX;^\H^ 4PBI2[IC>+^ZSO%3"@2=EL4WW\-8F(2V+(N
MYHDOQ%G^AJ=>J"$50=?(FSHC('?!]R4- AC/'2?6'SYY BA/YTYU5'.^;&J(
M^A2O>'W+BTJ&;2#%VHD2S"MF&2B*L:5DIL=H,KC.^U,$A28\R_ D:X.UHO80
M9#E3QS I7_;.2!0BO8LLCB<#Q"!3YU65L$9.@U\]EA0@'$&BYA4=B],#3F[X
MZKZ'C@&>K9>W2B)_[,:\45/MV>S/26;:)?W:2?T%18 PK[,Q371&QADD&P9E
M:[&QVY6&OPNC5GM3:!)]H8:R)]H)IVZKKT(I-]OP-*^=WO[BY R,7T2'+ 17
M5K%  T5]G@"4-J+,TS8U E=7HQ6V]NE3DSOG\I*78?)$V8V'QWH4.?$F-?#L
M>-/6I$W%]FFF;#+P)][:<P=@T9O8R_$&L(F1C9 ^;;3 +9<)W* OP-7^F'F2
MZ:6(C+J@,*U;%]G0>JQ.6MB#E%.19TE/AFMYAK(UOT_@"'^V4QC4Y)Y"-:R)
M'ZD=RC/E!A12:ZN=L3^>4E%A_XY"ECPVA$9.'*Y%LY-3^B![]O@]P 7$GZ;)
M41#:TA@\NQ6^F&#ER(U76>*KRRR9^", 9"2Z?X-*V2\X+QTYABU#RO5XXIU>
M5[)VT$Y0,W>I<S:65PH=]W.2R*R2;8?NO5O^VK*+%;M1L_#'?P*%^O9!98CN
M3=T9(IMTOU]8]@MCQ!OR2(Z\O:GKSJH@*WFX_W?PFD"LL@?(D_%"!WJ]N.ZA
MFO&5>\MU?UI\/O,@FWS>82!RA\(79EWG0WGZ>K*UAG?@601^U0FNHY^6SGRX
M*Z+RX9-% '5$=-;GO"^_*_4SRWK'N#74SWMO)-#$)M"+)N6( !K_.I &/#MZ
MN;,DSP>4X99IA<;ZS7[57HM \*:#G%2O9S^(9'PCI;C2.CVT701.DV^EON^"
MEE?-=Y(G\PS2=5:C1!%>X..#4W19;:3L97FQ'&QJ0W2B)[6;'RZ"U&RBDQ!:
M43N.:DU@W2 ZF[Q2T%IC,45'O5#U_/NM;C8J0'?B@1DFA0<BZ<<C6;75%V+P
M 2JA) 6%!"?ANF2Z'0/!<@YN#EX8J4N>)9&9#E$]V+_EE/_AK-&X;8S?<DKR
M/P$JE;E^ W3SY[,\71Z5$^*D#J=&G@#2Q'NU_^<I,.R(=HU1"#0***PX-^R,
MG5P=#D&=5>S^22T,/L217%8)[/G,A&'@=,%L@^M?H92+I?5/$KY79>R#UT9&
MXQ47[HKQH>"Y'%W<UO0GNVEANEJ>QH.5<PF^4:[0![RS-8.)J7N5B?S&N.\%
M7Z#E_,,'CL,;\;+(0+>T,-<1K-]O3LC6_(X'EKX#&]@_V+TVCZ5M[*51/#0,
M2XA[I'Z0C#?&BW-KW;/T:/108O'XFO.M)8RNWOLW*[+1R$9"Q*6?_;+V).I<
M"KLJA2+8ZA/18;!@,Z$,U;R5'@T57#(1-BI2>6G04;O,'L[P:/"2#*#8 _")
MGL]]%LWZ=\ 3F9+::D=$/';A!^R]::-HW55\ B3=PVCO462> 'G/+VW_A221
MG[2#\;$BZ77BH<K+:[0CY8]+.='\HS16T6<K>< FB[K$^1TZO.]:\87/Y^(_
M;J/T=U7-$R? QF])"_\L9$S ;ZJO!D"Y/>/I.C$_39;4A??$E#87GZS'_&-1
M#?.C9?^^_%(AXJM7(B<&&2D)(BM?96+.TQ1]6.T\D:;SGDCIWMDFBAX^(/_(
M^W.0;HO@S_XA'O&5G1/ P>I*T[TS',*!C6#;,/93<=YJ8W8=]E!TP8G:><[L
M8P1;I**/KEC![])J<E05Q=<_/BL[6,09I[E$VKO41?UAA$C6@2];WZDVIJO4
M>IM[1+A%J_[ZM>WH01 ?#+$6A=19;)(_<(&-97YT+,A="B5*TYNT7!.YHL0W
MTB5X XZL(;K]V0Q-DVFJ53_3YZ 7&BDS0&#.JH%\3+,2QN 8&H#\0,X2X6 \
M#_E\989ZD@.+_!3RJZJMQGKCPF*7>S O\D,F_BJW-7)K?NN%VMR#<C&B1G&J
M#FB@-OMR1C:CG,W ,>%3Z&H+??P'8<-ZOL1H\^;=&+=(MS87N=;J$+6IDG0R
M=N9ZJ(-O3KO^^^#O=&&==Q/H!1I&H#+/:Z"\LF+M;\L>Z1H[2<I[\!NXSIMP
MPZ,HHB^8&]4J;OYX,VX2:K(7=;(@]A@V)EWW>##QBNS)<.Z+!HGGV:$4@+7\
MUOE>Z*MF-0J@C1.B1^WL."NK503TC3&E.%UE -F)#.G-H]N:S2O'=.V?S1TJ
M;^R^@PIC&4:R99YC LRH<0"&^4V@CD@H4553*G13&Y.)+\,K(IF>@%M8;-"0
M=>A^ !E:L?\H=';R QQ@OFAKP[&!K?&&6^_-[^-X^?D!O\()=!DYYS0IPE9&
M&Q=QPD,,"O3SU=17Y%B[J+)A2Z/9G<D*T0++]Q+R6"J";]^DDNK>H'X1&HP*
MI;H<^2EU]D*:&D@\@G#IT[E)%PJ'=33A5=BF^^J^9-UDRLQEWV+MYE3[$+3T
MW0/.TJVCJTMR<;!'L1JM>$@4F]'5);WAGOH$,*>:0->58_AI@2U*D/B/L>I_
MP7<U5W_O@YS_A:_D[(.FY*KDJ!%_P&48U"DQ&V/?6'$^,NZ5N(B;AP5MOX\/
M&E]K]3(9/25UO$'P@[,WMCIZH2<NFZ(O=Y3%QG+6,UJ!\04($BZN_PU+F^OL
MN.>K7]G4\I+,:@2T/$^ Z4EM69<;Q\)XMKS_>;S[X4+1_)68UN<'^G7#?83(
M5;Q"PVNK&BMS]GF;JV*J9\0-,18-C8(-/+WPSEROT*%8+D.K''W P1[$QM>H
MOIDFK_PP7>4D 62>MWPL1M8HM8HQD+EN-C.CSQ)_) #*:#$H5VY[?3*W8"0N
M-$ST#>^A%H60YW!?FEJ;>,#:F*!VU4.KMII$]SJF5/Y\_V*EGYAS5A)N2"@S
M($SG!(P#>,U'2&TU(J8?V]@[+I&,8HS^&MPG_J8H_SE,04O9Y44R'+-U*877
MDV%/ #W'P:TD=.E"CRLP%OH,->W]&RS/3-JO,J\<%=JUU%%I7SP!!E]SW=TW
M/ $FRPT$8,8DCZ_4-MJLK5,Y<'Y5M7X83L!\QH[?Y6%_&]4I@894*8OP@S4^
M6&R$SB:YN?,2):(8Z44%DG^XH+H:\\/(Q2W[2QC]-[0J]RAO,L^TOA/GRM\S
M4Z5HO8W1LKQ(4A7R6]N0D/?SK+2K1)X#2[Z0A>'(6?@YPXX,A9:R1XM=":T2
M$P?0 B4BNM>6GP"+#D\ 3.+B##NOG:P?):D\7SN[Q%IVI8KLYBG/9GW%VRF_
M>=HYS(T<<S0:.ZQUV.Y2-O7SW,U;_#][C3@.YD!DX_]BRD!]EF7A^S*1+>^%
MI+ <]5"%M7@ =@<V97^U'MDF/O^:Y06O$K86YY&'\#$T4.PU6^*4.#! ,,H%
M?*C_GL+].T[EDN_"Z=LC>2'BUT0FFVM@K0E)!L&2L@4]6V_^9OT#]SBODA&F
M ]C'&?,3Y)/ZM0PJ^)_'I+.-7W9$[9<:VR1PQDFTQY6OM$%R2OG+?.<UI5>R
MM'C0J=(OGP,NLA@?E4\C XX(T!]#V2;+QUQS;KG:Z9\ /]_2WN%7RO_CQ/X5
MN:U/@ 0E*;S=#_,$FWZ:CV-B*5.G]BJ]3@6MK%48,-2?6'S/G'V0KLKB]S07
MC@]3X>V5-E:%E+J\$CW*R+?J_6-=;X>&.M>=@K)+@G0NJ66VHV$B)YR[+7&=
M29B)0F^=!E@!K[U#].::B8O!, ZG*^O6S9V^[64QZK+LCSTF;KON>)^=Y,"-
M1O?4$BE7]06?.3G,U\B9:#!>*ZC+;!'LV?:Y&%%4&>" C*,QS9/FQV)&H,OU
M0JE"G-Z93O/9TL= #L7N?T?G^=3B;>GA==2\)^/KWWS[AF&5RZ[+PJ[U4Y#M
MYG">YV2PE^3<W)2_[LOP/F0K%'D0:?<7O&U\:;%/H;R_))#R->T#7]=S^3Z#
M8.D!FMD?<L0<]?P53L8D'-FG&\?;S6\N'+(7B.38W]T.9:-+\!G>1#T@%7EJ
M^D@1[U&\-L01Z0'N'S=KL.OMO,5693+*G2_74+1*-]R;>V1#?)N7]]/$$IJD
M3WH%9DE:=C>WQS2T"IFXA*1/=]4O"<2=34#,ZV8YN\-G[&. PXZ>8]=;9HSD
MU*"B_$#QECY)ZED.B*\$^/"B(8INZI3))S2XDUXQ"X"S_4/LNCKDM_ /U^4?
ME:T&8,^2[COQ<<MT]4"F*H'2&4[9$S)LI%M=ML8$6)^W!1'2=K*MH.0K.$F(
M4ZYU6FKZBNX/P2+':SM[DU#D'06V+\B[@8#Q]]?%/>5#&RI\O4:4.>]G7LZ<
M<)X43FM26KFVZ$6QR@;5.1K@)/'$7QW4JJ-_6=@G>42"TV25'B[Y-I!$O&VH
M)G4R$.BLSY9J+61E0D/Y%'@DYV:,^[FXH6:.LR^S7I#T[FN:H&!U<;]BI$96
M3E=CL/O]_;R-',"QN3+2-8NT5S]3="T\"V4OQZJMH4J(UH'242/Z1P]R/]DF
MV4ZM)-5^0[-:\.?CREP?+ZP1!@.1H6!!=_/8^[(O/$O-9:S(0PS5:8_XE=&
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MWY,/9>_^#S&@W?NLKJVKNLV.;\.M,K("Y_)1/L^/Z15?W&X$+B83C=3SZR<
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M:.]3,>;0:PBI/7:7X/VCQ)3*QC!Z[TC*.;I?9$MJ>L,/C34&$C@<,<C(T.L
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MW>NUL4:SY*S(UIK$/:E*&6B@>/*F0^]()2[!1A8O6>R\>Q_$,L6E6F@X3./
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MQ++8?,$EDC #G_5^Z5(X-WCC,;_.C&.L+>N'G&8F6%>UXLBG[_34.(LDSKG
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M L,X\E0$ T)8J,+"O<0;A(B%P2SP8\6IWZR)@W*2J:.4V!"*HU9"B,<F6*T
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M0Y]542EXRMO>F*'K'GR]Y&![K=H_-9'4FDF#.GOOXI[W7$^0YN43(-Q\BD1
M<JF3]]I9Z+=HTUP0+]#?LRJ/^:PL>Z-:J,3-J3PG&0OO#5,#)'4:*:]Y"L-G
M<6(HR$.KCPFT3,?;]Q*-U6>YQ).\=(+-W5CFH4;X-U>=Y8=;4RW&>A(]Z"S#
M]^>_4F3*A.!N[Q+47?M*[?BY:QE5G)T\FIP,=WAH^50Z(S"!CB,!"Y*;7-32
M&_*ABZ+FX#75TD'C:U9FU_8$W* PJG5(#\X9Z%O<RUSL=G!W:U\*P=WG=S-?
MUJU<_%T5&-M]007=8(E@FV#_AE8;YK*;A4-?9V?J*I$XP0292?KCWW% %_=]
M78O\0;2!5#7^M)3#EU;G(*CUFQ2,7^G#OF23G_1?P^IH[!Y)VA)FUK-.SA9\
M(PF*/]PVL" +K7N6%&T=Q>9L/I]DL?ID.EE3FA9G9+2HY#8[S#FKI&@P_02H
M874=H^ZV-RR!##<Y4 E<'Y<U.SDQV:$GT\87ZI/17615;GPC^(DH5A/T,IXN
M_I1.#L"EM!02>D _U!'3V)QDZ[]Y[2"BX>XUT37@A/2J.XY BOQ(9$[+<7$Q
M!A*:*.KG+1++)BBS\$E,K@STF/_2-H9U?!,+*%*-,]Q<Y?6:;WY:2XX(ZW\Z
M>6'#'&XAI2@/Y9^@?,OE*OZED@*G9D@=;=.X61,MQI;4U2=U\ F 4SAGI)\J
M5Y\,QJ]/;,IG9QZ9DC' CST!/P&0[46@3>+W-'P+'C]+,..,E62&OVH*T2"F
M( L?*J(-JBK8W12IU41"Q!CDX1*%KF<J@XOVB"G32 <'?VO_P2\8-ECM2%,N
M(B^.OFT8VC\!+K6ZM)X GY]U^.-B2EML4IL/VKFS35;*$3EC(-NC+R!3_P8=
M ,XT*'V,!R7(YBX/XS2H$>G;M6 R1VHC-Z_B78X1U]C]?[Q5-TDLX*(.H6?T
M[8'(F2AX7:K6O)>&8J'+?,-JOC8@$";$:+<=9^5-96$0XEOG6$.+AC#"1=O#
M+%E:GG"E&#__G1*"8["5\ KYZQ,@XF/U$V!&_DSA$>7%#O\4)B)*Y:P\LEDQ
MP!MFR''USG57U48X;D)J N@Z)K33W?B7Y]9\(_"A-)H1XZXZ: B0.6-/,5Q4
M$2DV<1G22<)M)3[DES6>W81>LCVP&E*\.N581?4@9R579+0YE**QV\A'/O0[
MC6@&&9E'FS$EJ$P8[%JI)! UADI=[X"#_V&YG::82HDRT^Q\7TOL+)M:%8F7
MW]=K 7,"V61"Q+1Q,7TBS6,$)2@D1,]>-<>I&?>Y[N9D<)(ZE[UQ-Q6\9^,P
M?XP5C)6$T^D7S4C1,)TA#QC=A-VS"#0X;I[B3[&[#9$I<4J\:^_/RS<ZD/S'
M#Q9,YF.&2X;P,Z79V3'VV4IFY'F+]%XW#.>;\FH!KLA?WET [T8PWJ'?30P[
MIY@WS.##[ D4W43=G35)73THMWIQ[Y]^L7VONP'REX)V"5KB)G8IL-HOK%DG
MYVU^(?LA+[K0 L6-%N- B^97([AUR/P0R'QXS%T%>!M%UC=E#]CYQ__9[,'U
M[$!$HLDY6#+>\UA>J-4)W/&5S^VCXI:_C:26:>F_W^+4=91F3%7M4/S,P\=)
M2.T>%MLD!PBX*QW-H'F!,+6THZ=$@.ORF.[V&Y;;&2IZ&?@/)%ZV("(X:X\W
MCF6EH]07.PG.7V-];OBA_">V[7;>6"&9T\O0;9FM@4&8IC+=DBJ2FQ98R'>:
M]Y#[+N^<HZ-@T 8JD<@0_N3RMS;)1:ECW%:.+[AS5\&_'N)@-P_/N]B> $'6
M?V+$Q0;XT';=X.2[P2D^U-F385$K(.$.JC8&"] RT>A@#WGT7J/R7A=>%\7%
MWSFI,*"]M%C55**IU+8="K1!KJ0^5%ZDC<O0JU]FKMYXWUC4ADKN'LJ[;Q;/
MAV_2/SU%H$(8N.6)A0NA\$'280T!D &\"G!%[TB'3F\Q??0?[R<?B:,*#LV)
M[F7]:XR6[&DHXR^KAYN_CJ%\]:)>(-\\C+VFV!9[N1$WA6N?Q]31D85!J O)
M.\''%]81SZ9SOYP$?/C+:OK/.%O/5/H/R_A7"S?:@YNYBAL2QT,UTM:$6(0V
M$^:/=(F@<)-/%QL)ID!JP0K'&A'\O*C5$+$3#C;8(%*X2&*X)9:;E_$X3Z /
ML;$N_ DPA&VNGCZEV0/_<GW$HUN8'2J,0N6B /)+XU_P^%1<B:*)^ZZWAWQO
M5:1KVO(,-<9]X^<CQ!1Y58%-N="@DNH98/1X ;C@><T5MW9) J][^)U]S^:\
ML1#I=$^[7BU.<FO+W/9YR]H'XY6WZ)MA*7%L3YTEQY58;BV]V$8QRJ'K8#Q^
M#<(]&HIYYP"Q&_T\#^B<+%4L'OW', +>4'$T"WV/M<@@L=G3O /*NA?CD[3I
M!#NO/^JBA"H^]\O!<5BD6$7+$UXE6[3MPWBI:>B^@ 96TLA3%FN=CI+'"9H!
M^>?1UB+0AA/JJM;^9*X"8W9.=T5SQ;:&&9'B^BA [R%->&N8F 9H_SJ/?E:R
M'@H](,$?JL2@;NBL)7I/FP'MGM,!^Q\S7\\*Z/JN^WQIE3)4)+\_9.N]Q9Z*
M#" MLUUPDV,:*I&CAC%6BL9LTM$\IIE!37)RT7WLG>I:6KM\<]<&:"E65S&K
M8\3X.C^<WW=RLQO7*U'K7(S5F+(,F+%&C70DA-GVT#BTL1=G3AZ(5>$GRM$A
MYR3GB>I/SY.U?G:BV+  JD^ 2UX(XN]IF&A?IVQO]83==DLZ'#N>TF@\ = 5
M!I%N-,(T;TL($[=-1F+%J&'.N ;F/HE&(CK0/<))"G>1+[0>U+7"6PF1/6&U
M[B-YM.UG&J&>X@0_#(K:.N1T?&/0WQPLKQ-.^VF'+]/R4-N_ :%A'/F6):[C
MTDCC=\\Y-SO8UN'33F39W2 E\#8AB]W-FVILW,07YADO[1V#E6PL4BUYN56Q
M  &S.!+AL.[^?E3P' BT''KV-GK0@Q' .J1C/Z:17TG8/Y?+]>%::"W*C+0+
MOIKLMK#%,;]5I!=A[ )\#L"Z$7,W32/24597/UK$TXP%>DG_9ZO[_[?].\L0
M1=^?31 !5C.U)!#/;?I>X<>+U"OQ"V3__0PG(8\.OE-<HO0RWIECE7H3H42&
M!N=#VEVE.:.-;OZ3,/KH+1G.#Q<[PU1(VUY-,P9;?WGE@E=!;D+=)GQ5IU/'
M![\)%Y/EBNX2]:T;^(A"0]WH;X#=-2SKL2WC/(PZT^QQF'79\7<ZXD?&0Z/(
MS^MJ\C=*AL::_0K.VPK=8;Q(.>\OR?D5-AY!#X7B6Z0T=)#3NO5XL3MQ^4G'
M/ )Y[^<O,-#.:C,&V6H%DG8'9@UK"VIJJKU*A@]7W(11;B],3B,#Q&LDX\%<
M)(=)QK^FW.W377[U<6?8OQZS_@10$@<<2U%W$VE)H8_8IX:Z\'XVL]N8(D;D
MZR JF7.KC:AY-0+Y:SF.R*J%GDD5+B< ?3?KA_P^NJ$-=$3=<Q3".!J> #;!
M5@^I7D^ [.\7@AZ7(WZ C;HN5YC.'#\7N5QEE1U49.$GJ?(Y47$_U>L/B)6N
M7>$?S_U%ZCVPRNF 869*OO!#\Q3HGYUYQI$YS04./B;IL5-,%YI M;VV3!_M
M%1YF@_:^*)3J109H/IM74S\QQN;9.:%4<MJ.Y=EW)EW[DA K/FG\MU'_C9N8
M+MFJ0S.VQ$'[I#%+1CEVV "FIQ5'\QM:[F&>0'<#&N0SZ])J^Q:UNL/;[K3)
M[>]EB\/^SQ-6K5!@W"]54Q-E33.B D0K]_/8SR)+N=*HC$H:Q(MWO5<2G0R#
MNJOIG7$0 X.+/2$]C%%JK:TSI]A+*T:J@RMO[CYK @NNQ@IPE?[&H\(PZ-6Q
MLO.5XY(2P<Z9)X?KRAYDH?@$B+/=[YP3T\\:.4/3FVD^I2J_CG5PW5/! W]+
M8=*>E1S7:K$P=O#SHS@.HC?RR=:"=Z73D+S*\.8D,#32(E>L]W:4*/^,R-HY
M$L-T=X7?O(,'7V.),!)*87E+?B+%9O^%YKXA?8"VT5N :48-]3SF&M'[<^4/
M/C8 4W,=C['U)S=KAT5J-0/TJ8 79O$F:%$!@G7+B/&E0;.7K<W-#MA\!M)_
M=-*<.V9"41T5Z4CDPO3A/SQ4CYAZ<-_!D6.P''\PXN<M@,=>.?1VZ3B=5*"T
MY?<,GW\W#_K4G[#,H?A>'GK"#+\NK_CUDSD&1ED.!B?0KP:VCZ&;Y%&Z4JUC
MZ5<LQ-KVD"V<O(<[1];Q&6?KPH_O3%;,A<WI=?0^Y!FBL1LSU _YF_[OD_QN
MJVR#:"">AMPMLXM*]?YIVE+W&L3#]R)G7M6PH4C8J>'T-NJR"G]$R2>6\+Q,
MID2:+GV;6LRPPM7 U#]&LNU\3$7I)ZMJ<(<2BCYRB8&]W^F@(X,9#77;M"/?
MBOAZF^$\WO?CWK<OU+?-VH4*<-7_A5A%-!O&__T)0,#W#>>GW2QG+M]<G_CV
MH%S &(.V8AP$&9CWN^YM+>60B.[#VF =JKGQH@I':;')0]%'6G;CI.=3D.GG
MN'B(0],X@S,L$6)0G!'";86Y2]"X5?U[9RPS[D0$M;IO[:$\9 /:K$*M#7BK
M[\(XCJM)AASV>^$K(E%AP6/2?=C.LLC47A.1!>5KR5IS^FF%KA6>R6"[*UPG
M#Q].6<2-:.YF^LJ[:#2"^6;/X!4:;8(MLE'R5]9T<<#8W[C^3P?,\6L#U,Y0
MU9BQ151,68Y0=S"<+%^S(UPZ>\7Q+H# LZRI/_8OJM)>0FR^653-4GH.=%2K
MO8CD!YPUX:9]HTV&%8I^+^<8_-&>%MZ9 +I6"FYZ C2@T-J-C.WXMB_EF[B;
MW,2S7^7C[6>U1AS?$SDZU=9I%4#6S[\_1XZ\R$6\1Z#@ R^@(>*?/'9!Q-1=
MCMC-6KP95E*EB7ITGI6OGJ77B3^TI+H+9%AG9(SGMW_>PJ]N[:0)^[9A8I:]
MR>&L?A8"OXE)54]1XMN!H+101J60BB:'$>9%H7A>UM8-+D86EB+<KB^4Z_T?
MI!F>  JMTBDGZJB!D6Z!$;XC \<DZY,5&K5V1AMGS'7((&BQKQ,)F33MP?3)
MNL?Q#S1I*5*/X.B.E<%':@B84A3]4@-O11Q<XYI^L4Z7%#&VT6K9PFU6:,91
MA' PZXSKRZ/LF>%TU!_(F'3W#-@.B-'%>+V=Y#;4*(JEW_SO'(?R/UX7_>&S
M,"R0ASF3<@M;-<ZTSGS?VA(=,CNZ@JJAGFN+7%S4ID8ZLI@[$NWHX8SGHWZG
MD'5F"-JY0)EI0!;Z4+S-[RZ+2-YX\#>8/^(X@27>\:V/,5:A]#XSA=B<U(I,
MHYG+V2C5[>/;P>T)[/6J;5SZ+'+&GREJ2.'*SJ;?F<XV+WT]=N9G4_'/E/\0
M:9A&_AB2!9@N:GL"//=YG!C*\G!7IF_HS/+]$#F_@W6.?EN_G[6?^JXA53M5
M3:7-Z):/0+S-Q53GAJ&"*A8 EG.5X#^;WXVXRJ55FKN4G^>\$G_4^>!*RI;
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M61?>YVT7@S&UKB1^'<="V)*NF.!PL+!O,X$#M#2ZWH7:1^=EDR?\::TIVC>
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MY-%/-*S>Y3@_R?ZE;7(CZS<CU\YYJYCS #LCW^X U19;.-\<':N4>;PH'KT
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M7>3S^;PXNL&2D8=$*-1LF<$K]R8S'T\0-M(S&6 .$8D53?/C?E1%L_4B5!/
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MD)'W=[>P<K+Q9K*TL7-PE64_^=+)SN1@+<MN)*HEH.6N9&/OH!;H::,?^-C
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M*_6NX>W"XDL=\QQ/30V;Q:L^X3ED$"N8:JSJ/F ?M@H5VP9O2=:PWP)1L<'
MTT45R"I(-Z='=9KH[-5RJ/<[$R.UX(FOU2'LR@%1W9V+)AO-_9T--:]DGEE5
M:KO2C=AKFBP7YBN.O4C3T^8)B(%_*Q&:'W.2WIP#6YR.K(?%5"'DM_COY3 ^
M::DW^5GHA)>95F#G;;A"]@CK.RV^ST^/5UG!U5!"^\5+V8C8@=/Q6&<9BXUK
M;M-):Z<J;H.&V-^36U;LF?C1U?&-X2"NG@B4P^=NFT2+XQM^;VXXNDX/=2'\
M:5O4U565^H^0(TE[;1E[D4RH4H6YU39ZNP,3DF481'@PAZP:<@L0A\[FX05S
M0Q3YHXP38]H3J37]G&P8LD3@S02\W46*'8[=5K3IRI(K#6'$IG2!4Z8O2.XE
MR4HBL#KL\:J&RFO(IVX!Y\374F6] >T86'',M\#K.NXK[Z:IW8:6F- 9V@87
MH@^0Z&9JLD($S([KD_H+HMK&KJ<+$:Z@?/T/-_+&P54XZK*ZLN3;YCBW@.-X
MI#DM0MFKP%^X5]5HQJ6*X?=3N2X?S/DG6XI+)3%&E;60#X@5"8D]A#+<+YCP
M-"]:5);($%+;,.,]\M&Y&GP+U+D5GY7&#TL=J^$V4:L-IQ!*L.B.<"]VC58%
MY<*5@U?EUPL9 1,/!DG/6.$O<$H=X&),V&U<>_9KZL9X'Q$1POC4+"H6P1YP
M755@GHE1]2-^XURFE49,VAKWFYL*7:RD\0KJN^>CAQSES]?[QW#OD5G372"D
M?D/!YI+\"#)S:,@+',BIZ7K8X'W$F8I',@I]HM)BBM;!RR'>A5\YY)NW %&G
ML_9K1C*^CI&-6X!N/\5LB,7#Q,21P>9UAC:H[GYO?2'UT[:C)89-JG(F$HP@
MRD5,!8MZ/[R6ERV_<6F:*LG>-;$5MHS'Y%'*\)X&==?Y)_;];J#A2ZJOJOO.
MML^@3K6A"U(8!?<(/D%_8V@I4)6@N<$/MCGMW,J(X1,A0O?/@'L9-C<Z+;CT
MQ<]TS*-Q98S6<L@+Y_>'Q;Z5-I5,\45VB3.BV+S&O.ZUB%#6IM-;(%Y&8Y&O
MWLN^><+X%K S6Z8(K^<(^=%[@&GE,0=SBG.#<90=W0*T&&X,GW:44+W?GDJB
M7\#E! <86DL+5[N]8I=_:\2>R[]F; CK.4DDJ.!_V7@";II\I'BA50S=9121
MC+OY+;),E(ZH#@7;('2NJSI($32S5I,R9EO2!,+Z85\=2$9\>*@-;,XGR7RC
MW)-QKUXJH:JQH+T9/K$X9ZE>0+K"M\&"U[4=),&6$)'GC*=Y;ZVF16->I/M7
M[M6W-J;H,HA']TXP^0+IB\5-Y.]1\[,N(,%?FK:\WV-9"K#8S5W(*]@[#'CT
M?70V+FR/VBP#VYT6K3>U9(F_1=A9E#I6NL^Z5V;H=:6IF,LRJ]K[X=RK>4\F
MP!*A(+$;+ T/"<:!J-2XE1K[WPRO'KAKY&@L;O:3?;."#Y7%@Q*E'XL+L'-A
M:@).Z5K/>UO[I,5"<'0:!_66TL)-M]>A>_M3JUG-)B7$X!&[I%:)PPC_K8)#
MF&V') P,]W4T!VX!AQ%^#%A&#X6'/\W![)C!K-R/[Y[WL_12S, *5_'4UG$F
M1^=T ^T2Z+COR]BM)=55#4.RI'"-XVEW=(?6?20_<I*1Z2H#_[V3UHH"86'A
M>:>_OAN(L>86^)35+)UF8J%C)&D53E0PSG1#AB)+CMV"WPNHKLB+TS'> D]X
MO *2*UQ ( FFQ%T.5&.NSL4.O25MLY8N+.G/4K%Y<M- @\%SCV4%1863*Z3S
M/GQDDK_%60L;'[ZZV$\L.WS\[6EAUM/?!MK>(!L]8%F-]CT^'/]")#PWMK(Y
M.QM%\,,]P@==ZR386Q_@$)A>U9 -^L X! @]:1V3R,<C,]"2(UK98O1/P@SA
MK'(W2@',H0E$K@.'OW6D22=TBPO>,0Q\2'#XA6W,1=$R3Q]-:T"BYJ;=@Y88
M:-2"JYB8.3CV0T7M@@R%EQQK,>H]J0-?0+_4-9&2ZJ*GFDYQ0I&?[+4TY/?$
M-G?JA"[U+>!OY ;".K\%#F,MS2@?RIF@SJ^_ZE<['* /VCK-MXGE8LMSVG+H
M%R(DZGPNL?][8N_-4HLS[P]A?"CCZ$UA.&MA]BY1V."TEE>#]#VQ<I;S_<,!
M.AWT7WJ8WY59;IY)XE)*##D'AL4@RE$=N40S/%]-,_CO?JC*G<;W(7OS25[B
M&&3!Y(>X!7HN\A\V//%I)V X;:7^UA^PAU:^?Z)]_E?S'M'!&6]:2CZ33#R9
M_5E7X<Q$/F82CG/D-2C_1L+4U5(L*51_G(XA;_C]D9:R*EVWVLQGE75";-!5
MK-VB9R^'X=+<[EXG3/^<6);LQP+XD3A=<D.NN[LJVO1>([-I>NPKL#FG2Q1U
MOR36R0L?LI25@(<[5.=QOQA60K3I F-1OE!P%*]HJEDHD^G_-XBV_^M4T\]/
MUAPI!PKK4I!YV$G>:--TVI#+^76JQE4<&[7+A;O/A;2-B;A70R&1F?FSIBMZ
MP"NHQ>Y2<C/5=OJZ5>NX!BP1^OD6B/#=-Z=IA*]1PVAUIQ#\FYK+(^7[ESJ;
MXSKO6@BDI8X%FGK8WS\QU7!7,^0!-[*3K0E^-^8MGOR:\ 49]IUJY;U<O,DC
M:,HK/'A.F0U&?=(VV<AI;7M%[4O>>IZ4F.VK:,>9\\W:T Y!I@F-G)/#10A-
M>B?B#'F5PM[VI6CA'HC5;H"/-@Q(R5+=STIX130J49AI5/0J/_5LG. $*\!J
MX"C!MJF*7S4+RKKDLP/R-3WW-&:84NV%>]7EA5FL1C)5+@2O7(NY^YXC0P4,
M18AH9V([Y2EC;Y,3"T568]KQ1Q<,R-DQZ@A]7#2U07(2RV( L_J Y.!46FFU
MU?&06-K[SEK&(^H-[3@&M ;8VZW]O5GO:T7UU,<_P&4I\R+8UF_BI\-Q'IMY
MQL9](B=+V8#6M&K? NA3IX;)$)/N#K'3QZU!&T$NW(:-,W83?/?%?PQ^5B>+
MX##;?G9_>:)>,+F$-H\)$,NSNDY!J)?YUT"=879^I:-\ZU$*]8T!,DT/=I?Z
M/VL(/'EL:)_C%8']*.(!^F^XUH[JX/B+@,,E&7?90\[IX.^T^J6M^O+\8>NE
M:PU1T:)NT7.,N-XC"[_6\/>)ET8^#9 (77=L/E17_%)!,L'B^5"1G#HIQ:L1
M%S[0U0EC(^K1QH>I+,@Q]<C'(31EU"Y3>(^@LTUGUBE) ;RT:=NHDR2FU=<?
M6\JO[*#O(9C9&_(P3JO#WWTCS_:S5*-%:$<RZ36O/'B_9M=C4+.CA:V,^3'@
MH,\=^E1U-]@7V5^%/AD<0ML_V3?BE.AZ&MTME+TW?94-];M^XQVV,+XYV[BY
M NK+6!S+*'=P*V7+^&2L8JLPCOYFU9NKVJ][GD$OO!I+1S/8[Y1"$!F]:,P,
M=7^"5?3:%#OG?"LYVZ+^]FM/\GMH]=?UY_-4$N.>\F5?0UEA]1MR-9 OT%G(
MR:L&O&Q:6?,G$,.F]/.U1T/WSHK;DB_?&5D/&C['D@WY.-'06JWEMG)V!H)^
MS7Q'@HUB<+SV9B\"1VY!EB#TR2W0Q3%S"VP4MJN4G!UNF"2W1 2N&N\!'[;*
MS#42;^C5(18&Q)M$6-9QSF]UONA)#G&MV<)7^@.W/OA\[%Q/'6F&OH5083'Y
M&Z[;N:Y=!36 7R:68ACO&.Q82&H\ 87@=9[J5]#2*T'+3T.:*C[2XZGF]<RZ
MKSFNJK=0)&7#"UA*@0?N+Q&CA":N6)[(P#;"'V'R%<8/Z>DUQPE^PN4@>$BI
M;>MBVV+.-V7P$I%?ONKVKHJ3"&<13R;&N6B'W.@&M[U??E&ZI\[ZQ!QOB;R+
MN^'MEV4!4)+"X%C0G!9R+$C!^.7#;YCL&:ED9&7[7F=\)ZA:GJUS]A>E(A6;
MXL1_9K;Y%E?WR;U%3!;A5P:5FX5V(WQ^+&-_ZHV6MW<C$E1F@1FN'6]CLAV?
M[D2ZSS-9W6 <#AR*A+G[;7:2(2=:1&_5(8<&,+>MP:T$TH -B<J3;H)DY?('
M?N[-]VI&X2K[A3Z&+IN2&[9H_N-@9SO!C]!*1^5^KCUE>MN5,=HM]K?5-XP(
M$*0SNM*R.>M2;:*FD=:^AJQ=BT6@/98.$_TCE]0]=]5 Q W2-)HPL34=R&5O
M&*FF]Y;.U"^XF1C5K"[[D!=HB'N06M,Z6ZTI9W[ST:N7B1_EUPO*;@2)!B ?
M#:XJ44;(U@\H%I@2+Z/FDE?;!VYPA$L754^U^_P^.L:$B<>P1)K4\&"F<(!?
M+%"[5A(7)VTU9X4X] ]G?RXY,5!;OP76:W1W.D@#WOM85*3KJ$GVY2D2397+
M<L_>8-UTRZ.UFY\:;=Q\J8!Q@P.;/FY<RT'/MN"&5S(+Q4WQVR$5$D]&!"5T
M@'' Z%U8E[FD^>NR&9^P';OGDNMA$>9-A%7KG42K,-M;H!]GXTN.W*H+KTNP
M'1TQGF'\(V:0N%.M+WGW^HL7+ZS(=6]H'.8SPXC+:/,*Y,E"&6!!&WY'&1#*
M[E6JJ>S'I]=1;WS>-#6<;W\H< J*H7/SM=NN9WBZ)4'5SXW4 ,;.?W1X>KE5
MO$8<MB%Y^MM)O21>^B@>V@H>Y65N.Q</$&)BN?*X&%^IJ><3Z:2S9_P<%O/K
M%HB^K/CDWSW5E55WP#/'X)4,#1CU&&+:V'D*!369\%0N94O*Y^35(H=07FPG
M)6V?TD980E3$E!:<Y@#NH[DDWY@I<TZMB]IT^L5DBKKL\<V8Z2B7)W)L:H8U
M7':;:"]\@99/BHR_$8_W":.;;:O.*>M_*]OW9FKL.T$NMI>PF]H"&MMUO4KQ
M4!+X-P;<+W3L7K _3-PCP,9-=.XM0G#W0$JC=[QI&U'EY;+#U?S>.H&YUIUV
M].'5-_Z\<$3(Z<EFV)$XQ$D)XA>]>3H0=Q%OQE=C\;7#:!I<UJ9.7!) HTO7
MO2DF,+);.F<I0%U_/W'F*QYR]O0&\>"T=&W3U,B6$4^K1*Q69C1"G;?@:5Q*
M#(70MCJ5BI$R2Z1B$8O!N/\P,Q;V1^4*X?,]Z/WKIH:UUWD8P9H;;I3I%AMP
MIW@C!0?6IY,7F7/7@%#U;M(X9\A\*@YW^GS23C&R+P<&X[7"5B":QK"9+6JY
ME>N,3^HRW#P"#7YMQ5]V4XP4 "4\=;**1DHBKC3NSU7!+IN'09T,3G(2$-?X
MC6?>880EM\#B,:\WW(JU.HWN7'[A10"YKTK!0K( *:L*T/WFVA3)\ I6_H%P
M@$OO!S+DX(M)943:I@S?=)D'I2=OI_%%9-)_>Z>F[MN=2?+BTZ=\ D?59*^'
ML7I[CD)RRLAK/_KCP[RV2C,V1\SDI-5D5(O+4R#'E)1^8ML#G#HFGLZO%PA1
M*T@DX;N=*J6PUIV;<>%@[1#0B,6&_J;AQ.IZWI4W)28:VZH$K:;SR0??&C1D
ME7G!\G)\UQ_6Y\#K#91RU-,;K4$QFQ9>4 <_DW:=I)(.!YLF6VJ=AP_J-/+E
M19<1YHV)-SAV#ODF#GZDILTQG1OTK>FJ:EL1Y@UBY:QQ! N)+V($?%\,#K"@
M?!%U3(Z/MPGT3 EB9+-O-CZ)V#J]3/2^@.-$/4G:;YY$?Q=2_4.)VY)D33[=
MKMFY#='7LA))#C>!U&SQI6TD+I3UKA%[NUAWN?%'&9\KSQ@2B7SY3O-6Y>FV
MGIR#[6M+Y9-S &7@&R-9F%WZZ0F"M&SC)!;S%9WQ16[%=7/Y,N]A&IQ\=3M6
M+U(KSHQ4Z\IWQ^/2X*2BDUC>'OO"#<:F_?J74H6Q(TUO5B',33?2_K6?X-)"
M:ZX\BP4:U:8)N@-JW:99591SE1;GLT(0._K4@6_GJ;I\%/C+P*I<;K<P]WL1
M$UE%Z?"NVC:3%L6H+DDX]?(PT2.Z$]VCYU)(JUHC>"!S\8VW (FY4RY/HMYL
M(UZ\AC^O*YA"-*#$@8[)R5(Q,E1(?<#+S!Q!BGS.+7<2R=N<X,I ->T^.45H
M69XIYY0\ZZW$:/^J!BR6- ^C;M&=/<US@LR]K4(0K>>X]6;,SE&*&2O']Q?(
MB'G$L'A'LB45NMJ@)Y71QGZ4H2"/*^,+\\C^Y#!UO2F/G#JY:+^\!0B1LWAS
M>@<YLM/0JBK'Y@KGN:P>QU23L:;UM#-+?7Q'R%"C'SGG\ @Q;3/D=R:< \$]
M$TIT,QZ*=5K:+-14:^<XM:92GJ\L,OFUIR?IF"C][-UJ5>1"<KB[O$2GE1N1
MDWS#+0!^?2,!H;J9:I@\H>V5>KVI'M].6D%4VYV"^LTY8_BLT&X@PX5CS[;G
M]R4-6$<6P\Q!4VTH4[<TU3/VQ\L"[GH,50QW2C39!Q<7)ZN=M&'K>6%8"&9(
MYQ9;?3YL2UUJ-]DM7SN$OF:Q)+RR>W=%:9>3O#8J"3_%W0EJJ=V>9_[3Z70<
M:@!S@M!N9O3F*"G#G#:'@IEKE$MDE^?"%HTH6*O0F]8+[)]D[]JA>R1FE'_G
M,A$9>,;]432( 3D#Q2"\S@PFA<L=K)*WG_*(MP7+@9Q2/5Y<NLB(C:,N80A2
MRMF-[PH+^ 6GT2J@O E]'3H8RC.'L(.+P[",(8IM3N)97E@I]MO/^.ZK/W(W
M%4Q*V55[[9F)<X7XWA/!?9:AUMSVY;KL%Q'^S814PI< \M("PNQ/U8WE,79-
MBKT#'9MV5[SX=:!T5>1$%]1@AT[ZVPKNB$ &0I%!UYD7*!N#M!I95_=/;U*A
M!@*J90') L-4*S3R?-@EG TDU2# *M;+6.5^F=-PH:&<"0P<&N:FO7BH?LH8
M6;/QY53^S;WLKQJ3QR+Q5:/)>/#H#[W/WN=QK9#AZ&:"DN[%C4HFPEAQAVX!
M O)-)O/+M\APJS7AN#F]]>07HJ+I.C)4(ICP.B>488T_&A%"A& +_%5K[JC3
M4W*@S+-E<)\#CVI84.^L7NT];2EWZPQY8CSRR2,9R@W3WR :&(%W4A[>^^F;
M%1FYZ$Q)&BD8,&EF4H=#AWI?CU1Z>S&?+@7+S-2%X@O5QW,-GFN<ZX).BUL
M[6;RN5 ]1#SFPB5T^&:VRWM;B\W)?TNPLH:)?3129<S:]35AH%$_8Y/XD=UI
M&=0&9IC5D5<-R[KL,WYS8.Q 8=2<GDC;M".DSL7#,?;28"=*)4548B7K^K'3
MCHV<<;KD-WS<WT%V+3^EY[;9P7Z;\4'0VNO/YM^,\;VD'&@R$" IEW?)0TU8
MSVK]?+C*LAO]6"JG[E<SJVD2#'K%8U[53-"3;U8=!"%]3F)/S:D=-  6!7$S
M18YBB[6'<TU0WUJ03'I@X..S1Z_5,)^KVRG4--QLDSR5 .V=S)=MB&7 =1$A
MD,<%$":"Y_RU9H?BR4J>SK9?V[*\E[LE,EG\IX<XV>ZA2BI;1>&N54F9O_26
MY>\2ZR!]];@YM<<7"GJD);41_#-KGCW=TGW[!$-._XODT)BGTSFWZG7<+>!0
MLU T<'EY"^#LU$U/;E(VT?0ESAO(8'J[U+CYJPRX<9H>X:-($"H,M6AG#H^-
M9DY-BANI"L-#0\<Z&*_?(T+6Q^_Y8Q[J_JBZ\,YR"I)VBK"NS9T;DK-I[QO]
M<-5ZH3(VVQ.>9Q\Z:=[(5K#.N$"I"'M;\(Q>N#>7IZ'.#.3Y]KWS,5]5?-?J
M*-F]Y $VJ@*]0X9MYMBYO4NP1Q'"O]D-WXF1]F3T]YMN,Y-],2]-^QM%)18B
MEERMSW")E3T,]MWDWJ<6C?I^$_)-D?/( "\G#,U6@I@ED(I-18B^<T$XP=U]
MH.!P27(K@P7,8.?);+TS7.F1AYPF'[DQ#LS.A+($:YB 5972=_U=CJI96IO;
M9FPM:30S[3"HBPQM42;J)G$\EW1B9,VA=4@7'0PC58,I5?GG;5S$PDST3U?:
M?Q>?FIHMFRX]7^HCE7D;E=PD]2E=*Q^UAQ#[Q?YAV.EC^*'F^ )W5_J$:4]0
M@ /K+TH'] @E4M&CLP#/>Q(A*:![[G(VLE2DQXRDHE6T/6&$B"?5_I%]C5JD
M6E-\U2?.-V.IUX7H;[(,YF&&R]$CD4STO:2OLH:?L-)\:/HQHZ]7-NZU40-C
M->HW4SS@)T%P3W=,>9$7VQE/^H'RV.@A UZDE,$JD>KW?>*8=O8L0U]@GB#(
MZ[LZG6%>ZV[D(0V; WIY&G!:U=[( V:F#'<0AMQ N(!7.UU\L7C,G^D4<128
MJ"8ROG\-_[&*[KM;8&#E_?8Z40;ZBW"% 4;1$!#2 9I+=]K)$Y)@WP*QG^;7
MH;? PR\5MT#&\!)UE7W3N/MU4BCH>?#CZRP$RB:!LIW3WM3WG-XY(Y4#IQC>
M8B?;G&TN/)%(4N9QIE9J2Z&0P@X1I)7-_%/U9N5MOV1SP]]DS6E ,&;>O Y]
M/D6'R<%'+00L!P_MNBROWY.\WS&LVZA #PR8SHDTI-8N8"X_Z2N,Y=+$Y?BS
M"O%_TQ2AWI3:+SC$^ZT_0')??\8V?J:^'>B]_O'@Y"3Q\4HY0?)9#3@ [FN?
M5_^6/>J7"0=":XMZRX&U[KS[00E(Q5C2E?9#K4OE?0QU17,N,;>KVK#UPK4&
MF55B.:ZW&[,)-]3Z8QUMA$50?!Q?25+J)K06,FH9<=-?->S7L0@4I+-FA3_C
M*]FB-1,W>RFWL&GF*-T2RXO(?D>4IC+7>][M2T+JV-9,I7*==L]U:/G!D;M0
MI_;<>74FJ[9JZP E5T;*_%7-1B+8NY/R%K EHD4\FO 6FVAD)%@Z8/XULJ U
M*N\0L:Q-1;*!5X&5*(EM4(\JIS.P$X:%[$DJG?:)T8I;-\1AD8N,,7*#I. H
M]1\^M'GU&3QD\AGN@4<2 \9P\RW^\&#ITW.H'>QC&<SDP:2,:!DC@>,<YKCJ
MU&;#ZQ$HI;:P)0?&YWP[1F^4Q0Z,/X%QZ(]<5!AAYST6R&KU(IE4#31L'E$E
MM[G#)HA7Q/_[_1KMP^3KZXZESQXZZJ5'6BI;K!3CCV%.R'ZK-NM]0L[W"F+2
MA5?8MB9#V9:>GOKP=["%1I[0L,*9>/H!_%N2!#9,A8N\\X$/K^M(S^^0F=TB
M+\R\LF??YDA7S#1 "53O;')66G#S24:UT5)G.^_+.[O1[H<U[H%!^7VGGU;/
M^Y!6">%:*&SV?[Z[;Y.E)(0C]CE67@++#Y=,F7GPR:I</E*#< >_6P!I(DMS
M#!C?N!ZE[\3*_G/&S@]+]Z_;:(.>49&T2 NS-FB?)<?G6W]D2HW=U9BEXQ(I
MGBW?[& +Z])M_*Z]B2_'"-/>T*0W_EYC.,L=;^;*TC(]DF8@=JJB6\3ZZHU2
MZ[S+,(BD,#</J;8@+/MTKV_6,(RB@[HTU<K'M:[Q:]6;L<S0BMWP2QSZT<3=
MPD^?<=[@+UROXVH%AB%(D"X5G!@IASVRE?V%6_)BC>SYH_O3E%ZCZ>XM,?=?
M&'"1B@BU+EUV^CZ+>8)W,?>V@Q'F-Y#E+!46W4#/;CZUD>-J53]3>;_M#:OI
MIK*J'MI&-KXD]>]==HY^T_)/'N\RA.T4BAS#,0$JP+M&\+J@@T>^B_\U P\D
MZ^&<'XU9]:&3!9H&C0.]Q>NV*+V)&&L]N!JSD.J#+U-%>K'Y*=OXKL[6<(@Y
M5EB7<? 3@IKN<4Q_N^'V5+UIGX^BM'YOPGR3EQ0A'=#!+GX_0K((W*C+ROS6
MXN3*/!X3)J3I3?LV:\CM&:0A ['M6I\.(\[.:*GF=&:.[;RD%",W'2Q]S^;?
M.:G-*K5&?#/:T?TNOR@-A< *3FN@L1"LGDX<?[\'LU4N?#PN1\PM]6TM7[/4
MP9LA7ZPR-3%3]#Z1/Q9+^(K5>=,M1]UQVGE4= K%6WK2F+4YZ32#4M^!<VR3
M2XUC>C:A2?OB# <TVT%T78I0M]MP@W%R.P7FC"]X5_&;GX)7CE[B83,ET$K2
MGQ9Y <3CP-Q#RP^+:EW#&CCU,ZK@3+AQ@T=T!]:@Z3K)*NG,O3V_T5 'U=-+
M4*+29$?Z=5.HO/\KJ M,N]@_NT<LT.5Z9;<1\\.IX^DP)#H79]L254H,T2O)
MWCHH2IB-[!DH,)1/CA2&2<$/&]5=;9[.JC<LC?@_R0G7.U?'5IM.\AQ3^,:2
MA!$PAR#WV[G^$"PB<0LDE\[E?[L%$C4[5CY1U&OTM;)B'OM#_U2&>5W<F(??
M',,C1[;?O$J;P,F>\;3Y]+B(M5"5V@-TU;UG8;!P3A?GE1O%J!@Z> LTSZ;!
ME1U_P#2?_1B/1-A!E=PCI%_#Z6_ZM&X4DM.?> ;OG?EVS&_R6(MN__G6%OSQ
M]-7ZVM' QC@A++773_XTU4'G^7>Q9*?2Y>\\<7,9)#UTGE2(PB/L1?QP.TGN
MAJWO\B_D(\\1!M?E%VXQ4*F0O$@$=Y'9 >7;LF<K2OP+Q:WXM<:5CH.0OAUM
MM@69I*IM*8(R=RU6LJN<!A6#/5[1Y5^W0 )C<UD?8WAG ^O)ZW;UC>_H,.,U
MG=A-Z1$3VKR&90<]S;-V%Y9]6C70?2%WTN\)RH-+67#I 7,R&?GU\<CF&YGV
M:=YC&7ZG%SZ"?DY"4LN]^MZ:>*[8NWHZ3*MH&3I$HN>W (+,:MT(P5OS<LKI
M=_!S\YA@5I:V+&$)<Z&)9.5%3#L#TX<Q?$?"845':'S=G9*EUT4R3A"\]:BH
M&SR5N;9I[D_*O!7&:E,KRTOHR@U3[;676^K/MA^Z7[EQZG!$O8^7L_\(4I_>
M27TK=W,==0LX\<>8-PR\;5=RVI0G_)D5%B42(LF2<JB>H&8#?Y10B#TO<RQG
MHUFGF+BAI[$C?KY6-P[>W\J+76/(V%A+0(B7_6P6OV?V\/-^$^4]9/RC=)[L
MSIK95#I8:I9/PF@OX\K]Z_)HZO3^R#I15R>1OPH*3D?SJ['IO?!CD^P%@<E!
M<TN1V$I4D 0^Z*'^5.)W\T7:QZW7F?)N-3"U9L?/#MI5)K#F\4;[Q8/C20=-
MLT]UY!O%XKZ'M& V4:9C?/I)W=075T7#H1FA$^:4(!CEJ5%?J/#3=-\IWEHG
M;*V?KBQIS-$M^$3I=8-?HIG>K(2K 8@U.,7-*@/;=<$-R#'T'B0T;P,LM/%K
MKF/*5:26A><XCJS7(N49?N6P=9(S$\:;%IED\QO<3@BN%M:&?&0PIPM; ?EL
M:WGC%&OS[X]5X*23!,-5'#EKZ.3]EY<%RVJ+*%>@C>OXDZ-ZN!E"(OULH2&9
MZV?J<_7-I\9$?+1PM<*.M.8 ?[4LIY:9Z%X73+J4:IHMK2#IK]U/&*4TK7XM
M0>M@2WYPN6"BN6"SDJ$2L2_HLY\=9J626-D#;)6MB2N*U+H%1;(-7D5GUZ4^
M9]XP7R+=9/@()X?5;U&4Y=L'^C:6'=0N[0_.-G.7F9DT0),;LFE<P.?:[E]>
MO2&@E.&7R4"0]_13&LKAP\(V[&E0'$+*S0[J&EY>1C;'W]>A5L-]WY:9B+YC
MA 54A.C#N8,E&0F0$W]&%'L"^IW*'HV$W8/%:]3O^)?4N?XK[@*&ZL4ZV.L<
M6"S6?>]>9"]_:=4JJ;V"YIT^&7\+9@C;H#JUMB;HLZ[]"B\ZH5]SZ%>XZ ^I
M*(?]>84M "O9&H]]CG4*OGFUH1E$'_2L_O.?2<.;S/M9ZP^?*9FF'<Q38QVG
MCI-?[O6'Q33)8X22PS+ZYP[87ZDW.8":,>; I/4![LJM3Z G:5N*.VIF2]GA
M'E<3MP#Z">Q!$*1^J[H9XM8WN^_C5O)</:A#TW]2^MK6<Y)RWHKCT8.X3F85
M0WLJ:[KL1)["E3B3=VS)OZL[)SM\KIL[Y/VCH$XPHQ)8=H]OH,WUSFXK80X+
M3:60.G;,1JX*D\I//UOFL:!<@A!B"IG&?H\&*\GQ0W,*9&3SM'-[)5CZ%K!Z
MTGR38C8G*Q__<+_\NG]BR]@/00:"ILS*\ 6KER&X)VO:)2I8HIY&];2]:\H&
MK;*$2=IQOK;FZDU"06=(.\ZK"T.0R3^ZSI>QL%G_ZM7CMG%"8O;L*MV(HOIL
MR7R$SOD<B O_AELD8Y$Y7?["5$ 'P7CD![=&,,%,X%(PS9[GO! WZ/,OI6]G
M6L/W_>JNI(]M,X%TB6>/+9G'J"[I7)B"3Y#EN/6NB^5=*A*I[ V-%OVB*MN?
MB<?6N*YBOS5^ /W(9QGQHEIG2!I[BY;Z/==PCV>UZL/"QBFE%%'C':.9O,]N
MWF3Y(-HV5V:O(Y03<_30F;!3W6O-#:,^S7$L&)'JE&BYB$>S86?GFD10'.J/
M[ON98@%VV#MC?C%DY6=G:VJA,VL-N#=C\E@7YA0#^$9M%5KT":E6[G4!^BN#
M."@+PF>%E9/$[Y;O8U-K<LH##GDHMJ=K1^P0[LVUV*R;PWX&(3%;O*5]TT&>
M//T&#Y&W][?;S_G?:U*C,;V.+_A M]_E!G*<#'H(#X,R7>>W:\,U@MEG9+0W
M@\SXM:?!/A^])QC2T)-[=7DWDDCJU, ?1H.@EY7F2UC0R;KK]S<]&V!NE51S
MB&N1XZ6'R;"QM!,'CG6"@SGZ%Y%RN)6IM2HS3[:1'S+J1<_)<#O:WV1S'[D%
MR+6FZ*JQ^TI*O?:GYCHD1,_D&B$@Q7ID8/':/Z_?G*0X"ZY\NA8C2ON2]1,Q
MAQ-9&D^1+L7*:(V+<[[X\/SUKH*OZ'#KXN<@E8^EB4ZUUTVW@.-7*^VFCL\P
M@>9T/]WB4[,E?WV#%,DB9P%O"TY#_&(7IN1!F;DE!A983,7/6Z ^MVQK[2AR
MXB+;#?=[39CEP8.%*E>*J7$!S:0XC18N?_VY<*>]:\H;W*K35SK38!Z6B7:3
M,I:42CW3<1OGB25.)C</^AXQ8*B[0G!1 7V=T0VVL9DCWK=6%Y;8KE2\'%*C
M.B-#6FYNO'QDLX:?3B(E-RF._Q&+:ER64V._HD"9+5MO&@&_!:)J@XUQ\V%!
M79:&6[M3)ZBI<\!U16H$T>.+7UA'3^ N_FO0!%AM!<RN=]'V9>G\XD_/ P>V
M5!<9STR]3:IO5BS58N#D#E.[A*\5W?*6_$OZ7>;U?MW?37KD0)/!2N7/M2M'
MRBNS9#\(J7QN$%!NC$LI<EVC;5X!844\5@[9.L6"5L)"X*I+@S*<Y:8/*DR^
MN?*)A&@0L1U0M7]_V8^C3K:A+BC]YOR>V&27UK299</]O/9)-_UJ6!>DK'L-
M-9C 9S.1;+6J-!,3%,NAT3 G3,[*_ :'-J?VVT^L436=43G4/_<S/=@:%K]Y
M^$4[JI/@UU>5917V1(W8,;A1^QNRUWY^X:6Z.1FI-.BKKW@_S,HCR+-[C4O&
M^\UQ[/4TQDL684%@ 85/F MVK<GLK.'+"R;V<J9)J-L<+*F_\>#(TE-RN CZ
MTY/7E6!>%SXPV#)5/W><AZ\FSF'O\;-W%"/\(VG _<(W3W0*02-4*UD:>A^6
M*0:OLJ%/KCN#U2%&FPUA!,%^&U2_W$A-M7Q(M"P349I2J(RUV397]9YA$VNG
MDY#0*X*I+3LD(:E]BYU':4@G#$299/=EJ':OLK<TSOI(N/'SL<3M3XHT3844
MLBSLAF0&WP+,J!W?F!FEW<,T7)$!?2B\3RR4K67"^S"1>$'1!>P3X$)<G9^X
M>T6A)X[1FX(J/ :]$+U"AB\8@9-@Y@Z816!Z^F&(#T,1>=^/1)(1.I6%POCW
M]S2*-+DYV'?X>D.V4L3>548X])E>LYJW"7E=E,V]OQF3XY+CN\Z[H3L ES?5
M>WCD/[W^='&,?Z;I_OF3]M<K7J9D4[& 9<* [X'VDL"<O'ZI-)XRF8[ _]=_
ML?$_2:A95ZM6(<O!:P?GN54)[794AS?D5Q]+D(\+)3G!8(*OK:=E?6M1R8>_
M?^$'?QR-TDC7H^_RE=,?$ F8+X=PQ==N-V37FY=J$Q[E+(RCBX/H^Z7T*>8
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MH2> M+W8P[.$8"T4 190ZIR5[+3D]UG<S-QB594[;$W2?/Q4%:*GW?)V5!%
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M^!H(MV,>!S8%>42BW$"8N%3(+3IH,IA#NT]7YC;VIY*9U4EP7$OM_;P-=Q-
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MO>F>N0:\%(-*K1D%9AUIU8?SGC3[Q'M]3OJQFT^304R%)9;OY /4I7R$T__
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MK4+!KF]\S@!RX>\LPD=JO[JZ""O5UKZC?Z=M?)SPSY*\4"ERUI_"?$+4_AG
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M&\.*9I6=A*.!%I*>K%F=1^&CK$*H*<I!F/NXY CHLZ7!F ;5#S9+58DAS&>
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M6R&)#38)KXN.)T&<_9F:8J"1-=/.K<U)@O/^"'DAE13;JT_3U^"R7A=M>*X
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M%!LW3"L*W>-@'DX8E+>QNIQ>'7$]_4E%9='UY(HB88,N(,X(P;%)HCU+(+[
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MP!CE:US1L;Z_73WV9&%]Z5AYT+RA\^Q5IP>6%\380R/9+1&[)L4>2USHY8]
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M;\$!=WSQ8(NJV&MK.?=,) WW5#CE%T>9B[JA(AML(VM&7YDH+D?=)*Z>D=.
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M'R5JX3]D=B/(<:VGV=OJH@?F*!M:-J<75%8C:MY=_;[1;(!7*DQ'U$U5_%,
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M9!#M; (\,B \#RV8]>SJ5J__$#+]-K%!+'S.6!M@_9C*O[J/?_\RW]Q&AJ6
M;CH*0>5.&6L+^(^'YU!+=XB,Y/^D -&/)YJ> QI]26]W):B.Q_^9]/NMTY9G
MV?"+7I@/Z\6E1$G<O<)2AZ&_Q(]PP9H,C[4@Z0.-VMLU-]B-V8U$TQS2]0 P
MF5.>ORUB3)KV*GUN4VU"(6 K>REL_9>/,Q](T5ZJ=76O=43"9?!(&<ZJSDK
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M$+.>,[HF\$J*<HP]2.K.<IC8=?$-> FZ7C8%_TH7G[<1H1F*6$VBLZF/=*Q
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MA/[I \>3O)R#9'SP)HSK=NGQSX'MA>+CU/_8X%<'6+"*UEL!>1VPN]021!;
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M%%4/=2VJ6_57S('@VDT=(5J\(.E=,6@W"XT]TFW]DI0<XGL+TZPBZ&=,V5D
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M3WK>Q;K-'V@[CK4,82V@6OE($?".]I2>E:##AU6(.P-P:2O@ED<65,$LVM3
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MR<5TC<(I",KE8PK<N*X;Z/I5?[P4=KJ2L;:BS6^OW(5A/6"F&A#NL:>"AQ)
MQ'RM"!<DF-NS7Q3>WS^7=S=S7;^KJT BHZ9 F'^J7)5!JU *D,ZZ4!U!3="V
M7JO2?2'$A8N?>']4N]@9?=I'@F6$G0'XKI@OSF 3,?>ZD@FP=3"9#^)#1_&B
M7M 9@/;3\EZLH\'=9<Y/=6350>]F0 D!2=B \\D%:1'_ 6=NC="$BAA2;V+/
MP^MV&@A1=TZU#G"78$,*7 0-]-<6Q-)0L7K;@J-*L?&U+O.H@.^M%!GK<5O?
M7Z2 M6]WTL*DX6#4[9P7N5,ZY'*?B3Y;%4NKPV> UH6A;Q'!\,=O*F)FDH_!
M5_2OO/43-+8L4ZTT8ILZG% KQ.?[RZH.Z/KV3(!,%.@ .\<?_EJ%^==RW6;K
MYHO$>OC&0O\Y@%LL:X#M,'PF._7].TF:_]G4C74Q6D]RZ@+N?5. N9E!LV-@
M^4H[V>')[LDY*/J MX>]10*)JD;@NPOO5P$TYLLEV-;!:212TA\;6#,Y#C3W
MWZRH47&(G+PQYQ<B=^O'JOF<G+-/6MK/NH*K(@EWVPRGP^]9*!FS  YTN!!K
M3:C9UE>YRCDSSX'$R--5; [Q]2]@7)@5B?=C<!U)@F#Q]JD!=2Q!4Z3@]]41
M9R^A]?=&0ARLET/><P6$.\09L;_O%X;.G@%80-[^O-ZK]""/G\89FL.3BFT+
M4"66O0=.R>3W1VM?(UIG4D3OYMQ7]I<M89'[A _;7<<+X]2P85T5MSN5<7GC
M=E7\(:O<WM-'CMZWVS-D&X]Z3V\=7G9^]6CEOKM^3F$$X/"/J?=JLK9(>"LH
M!=X.K?==A[,;4V34AG-M*<H_1M9)7@W/E0Q+M685OQ@:\SPGC7?5M7(W/V9/
M7/.2'\$U<!QU[>C6QS8_(I(BCISL_<:_D=D!.'PM:">.FPNH"=6\\-V,+.*U
MXM\O^JW_C73?D_Q'"/Y%00[T^S\'0V'R07''^FJ+AS./K+!_KLD5U 3/^;7W
MIOA^N=DRKF7*K\1%X4>VF!ZGO#<*,5(CL#:OO6C+0\&3&? MFS65#WK+<7C@
M9R(E-,9Z&MQ5._YS9FD<&[P ,7^^LKR(:]H*#WXK9%SO<A5_\\,1BV*[T@V!
M3W5Y)V[/R1[[(0: \N&3)-H2O#1!_8O8G)8M)N\^>JQ2]GKX[G$6AY=JVP2K
M\_-YM4Z&NZ^%6=3'-#:L"N-@:T]6V\)&&J6C[PR!V;5L4=%*O!E]A<7R\.J5
MFZT)5A<=-:W(XMZH?MUFJ'T;GC0(Q$F8IX$\%1(1X!%S;L)-(<'/$-,S #M/
MHUL+Z4MW 0)B*CARQ!]/_%4]5:UO-D^9[#S;!!QC7II!^1/8V<?*67 5:P=\
M>BA!T1_;>(VM0WM8RT'18/YN4Z-):\3K20'-Q\_E^K5(>Y\D Y@7*Y+ZZ5MQ
M_FM QG!CDP)4M*;NG%Q[O9<_KYU'*DV!N!?=J[A1"S8=<O4!09EG35'([?2'
M)-%P\F%MZ;G*[B3SA2N3#F8KFM7WBER*)7+(X]TM!BZ_LQ)3'Q0K_O[WA27_
M=W2Z]4KKFG&O7/?=U@4>E_YV:;1K H^O7/VHS8TSOHL!I:K87#%GWFDAOM@_
M7->TH%J[:-GS[6D,ZPUE1;I7Q@ =;;?S-=L^_-6P'3&][Y*'AZAQQ(L5;[[H
M77KZEUT]/G5^G%36I<-!]%R\Y*'*I>L_WMZQ>HW&5D34>1=V8D.Y%(T" Z."
M=SBL,-*%.=\FR'0<IFS6 %45L&GS6!A-OQ;D)F8A"^X)3OC=5(@NF!NS*^6V
M,T@(^:"8.S/"%VG:;1[!X3;%*$H%4^&8$/N@*79#X'G59W32X_ZKL$&C?C:<
ML2WF( VBN0:.1V2,%#[:Z6?J['4PO^,3U0(L!)7NY[P\E @6^7;C].&L.HT+
MX-<!3J)/[7?2[O++'^.W>F:UE.MQS;??HJ=S$<_?9)G-\30XTY0][;Y;)&\P
MQ5DV;&@PTTTL?7JQ.C ],#,_"0FF]H*RH)LRD$31Y5T[[3PWRHRREV$N'*SZ
M8AEJ/;(!L=;B^U<WBE?^X<O"_^?HMR%V@Q[,XEV['MM"W/N98$S$MI.*)9"?
M%^$,(/;\"+74-0%:F28M;O^(O$A^.&2.$U6TI6L>"[F3UP%#<FFEPQ9.3D<C
MQFK/H]TBSO2%=Y>=>S7^/D[![+/LID]4O7VOC\UF5_[]2@-1U2I>GLO"<604
M+ 'AS>>8(:Z6$(HI_KG"@:-&XS[XUN,05S3RKL_J+\S>-_/UW6-S#VQQ#=]@
MIZ:C:_ 6>/[$NB+<A413V>3@^?I^>!JJL:"PL>SGM::BYV_WWLACEUO=BZD@
M3?/B8]WB+]_Q"@L-XB^? 0;ES@#(,I)Z>!B*FR";CY'VA'LNU\*&0%A_Q>JN
M B$)_)W=P;Q 37M-PW7U9OB7QQ>%-UBS]:!FT#&2*"X/SP==P(+;3D8$O>2U
M%!ILH\N'---.^.Z]G7JUH'ID6[1^>W/3RS<]D&9X\M+T5DK0[Y%XCG-RNU[Z
MD?SE?TSC_W.H@?H5<3/K!T#HQXIVOUHT^T!Q32/Z9%B(,W'U+J8B(_C%QU63
MIA93QH3T][<&#F5;-K_6^>:QT-V< "U]P1C$]XMZ 6G^6,#S:*FOTQ?.RD,E
M$.'0G\/<2H:)B)/=^=9E'I,2>(CRE(3-;,S*@P>E[0\&I##4!+:DM5ET4PGU
MX\T%"..ZG,)D^>28';3Z2N&J=Z:26/$]]\,SP/S#_'A1]B=#5YP6TG!B2/!(
M1=:JH$(_!20"E]!LBIPALY?XTI_D[XU='X^\_:VK$!86)-!KQBO[\< #DDC^
M<$*K]A=\CZFN0B;TZKNK@AI$T$1SEC8-[@TS@AK['9>!41XZT@M98Z;#68$N
MW&BV[\OBJ@M?$#TTZ QBN=X"^8%W:,.G<+2^OTQVK!"C+8B#(2OB@[,8</:F
M7;-:UZH'7B]Y85.UNO6-Y+H)4U.V:9IL4S8MFBE2->2>@.#G9G?9Z$J#K^G]
MB_.<WK;;4[*R_B10TF;6=+^-;1ILT((B3O6TG\G%)T"7M'S- #Q>'5;!"T<^
M.Y^>TAUG@(3S6$:W36*%MS8C8$@5?!@"^F5;^T!AE_#P$.L2IC[CC8;ASAEQ
MQR0D%,1E=["V0! _Y[;H-'H7U5=RE,V(_KDMCJ7>Z=6<7NA78*\.,)!WX$Z[
M__("M12<Y_A=7?T0B3$+P0LQ?:0MDY7H,CSTI2\+=UW_A3SIRUNMMR38Y.;#
MU=*@TM#F1UG^!27:6U1?(RW^,H7_$2/]79A2P@0Y" E6@0WJ:M.;8]:Q8(QC
M?O5.5EUXVBW6G\4F=!)>=IZT[C;KZ5RY!K%-SH9+A@JBZ,N\T?[KL'0%DA!!
M$'.0^JN%H[C@\7-OOOP&-6D[[F(>OIL,9!2'SYQ8/R\,@,AA:ZU8C2];%;60
MN^B'D<J&H&B4(!G"/GPC8JA2I3)//%#6UN.!;,,M5X4I3AWU\^611->!/']L
M9P#J8" %Y!9ZJP<6B/QYL7WYFHL!5YO<UUN?:"Q1[O%ZF]>%,^R#3DL<BF*!
M:N1X,'3Q=]?>)@P)CZ]@(%#6)5=]F?_]H=G0]Q8VI,M5IL4HDV;N0X^\\9LG
M*3SM#VRLO[&'<V--B;TJ/@[13FAX1L=6QCYO0]/FW+&MB%7FA1-+?<S]R_RB
M]Y1K+N0OQ2QI=Z#!6">< _Y:R806Y1I>D&I_XW*%A;;;AV7](:TA/W>/PO=3
MEET%/,+23%\WLIEFD* X@V%00CDC.KS/X68X3+_MDQYJS(7]E$7<T<GT0[OJ
MU'K@6&#>_)LW#[W%]"QG]:G,O#[_"R=QM,248&O^G"NZ3%L8-S0\?*)&:6)E
MD[NU5^FO_!#ND2!DR7M8)?3 M*30;S>G=";^#-!I,'B0J?'K#7<<(:CF1S$J
M*\^TQVC73TK" 1XD..(Y]\ YIV22\?5%N1@]0-0]SB14,]_W?LI9>94*-N\"
M#:JLA]8SGT,T7^XUHAA^I#H:T;W:+#.0R@U0,FP6Q 7A(PA4N$94,D0=>9!<
MH.03QF^U,F?1V3/W8;@]C4^/M2=54;QA_YE^5<\/*K(!:KBE14DZ^\!R5VC0
M*>84&G*T=<X\*6F(Y;\JN)D9C3&:1B667@]B3+W;3-W>F+! %U_Z8B^*G3_*
M.PP\=;<!U+-7K-P+43*,/L:MGW_A>Z-OF/4E:J;Y]%XJ\*Q-68@TXF]F:NAV
MNEL:QWQK[MF%_QMBHN<^<0V/X,)79<U S,VB,53_44R$ SE\:8*M/0<*',.I
M;!W?@=R;:;[>1'365D[=%)+]PNZ2IJQ^<8S"V7S_<=TAY .RNBO\=S-B!K60
MK'T18O08:X=S_[CTLUQRKJIDE"3N2;EAQY4O?;4 )*?<&7$'$-%+)2\R+&,B
MGK9C_AA. [F&UD26/U[+HFO ?$>8F&1W3.U=R6WK-1;/'#ET- @3?J#KS"&]
M!F D*AC,M3-*3@^;M*5.WFJ-D_'QX3>TNKJ6>IF350Q 27<AG2D6 '#N]SH'
M#"[[_HM)R*&B&_D:*1'4,E($DZ89WA^1D:'U(/2@S^:K+ 3[>J<U+BM#S:/9
MA5;P%-4&43[')9NS6MQ5]EY\S&,'&7:J.;Z][^9^G0&X&MM9_1[M=;C$!ABS
MF3>9 J(?"+PO$0.&D=U[2MQG%MK.FBPNLW\4ITY=O-'/0] &,4#H:W!N$(.F
M\"K;B*(O?:9AV$E\S&%[O+$\=ZB:K^/5>Y;3R@Z>WY4G_K&^#_^9\;+8F9^N
M=TR3M>+H//36^:R;XRYR[Y6@8$O<=C@?J:1?#E(C?-!>E1-L1V>5.QO-'FEJ
M0%?T*JNZ4=5I$1!X"1$81X;\6U-; *YK$,0-Y8-^7.%O\[4;'H:Y=?89^9:M
MM10CCIOD7,MR1A(OE8>FYUM0/^&&NNDZ%.3]+>%[0[701;YV#2Z ^&%*I_+A
M;6-'V8CB>WW;V_IO]'/NI="-<F0K=P3%SA'4SA_\<P(M[DM5&?68J#^5>9T!
M9?Y>84J#5;32QK2J*6T9^9BSY6';5]F+]SYG:SN]?76.^S3/ &X' A-G %K*
MVN%&5>RR#1!Q^9N7W8?=T"#QRBGKA >E-ULZURST+_CB*P%T -P<LCDM!(2[
M&$;@4!Y:N=:.GJZL#F<?%+H9MW^MW+>=J]4TR-7/X42J3&46,,YE/REQMT)N
MLWG!<['/<SQ.YQH-D3$0Q@3EQAFLG22BT.<_F:!9BPNZD<&94%/A]THB1"]]
M4H:XXWHQY[%X?*\OK\N'T)Q<E]LVBN.RE0!\*B"CZ4(!P&^Y-,;@=!^D<3HY
M"D1;-B_-#6EL3N='8U2'HM(":HR")S7?7E_=T@OLC IW32%9\2*VJ877XJBK
M2!\=63#^6=K,N%H=-#"Y9$A;KK_=;:[C656R*T-U7L!II9+\!IO4!UY_1:BK
M'6$48[Y+C5['>A"?DD2\X0*$.U7-(Y/=6WE#697>K=FN*2Q5 <M]ENTSXI\>
MECS2J#+EITK;B@00O=$SZ5? ?-]#$3-)(;X@QT_RM@6"-TQ[,U$KI@WWL._B
MZSFE!]9*.<5>J@P2W(EU_9S0F9IY!6#XG/E'!;].GN!#\>Z^X$=(5[R6].%I
M1*K>D:HO96!I-O/8^4S2CY8:T_ ?@@M,UB]]LP\7/;*(BV8R>F'1YD 9WBPD
MJAUF(=IA2JBQ2!BF53[JVEU%^C.=/V==D'\S_\]R)>.R&T,*E*0VH;Q0/EJI
M-OW$3]/?BE=N*EX)G*3GLO)=,9OK#?0&$%UP!GA=" B'J>RO75-@6\)E(N1J
MPM<D-4M\QW1>^$1<F&0ZN/3^-/EYS/L"@?G:$7!:.1M.#UET? ;@^]FIS??I
M.>,;GYTO8:V5[UPRH+]R.?0?\,7M+;*/0LTAEQ)GL,I_6(T#3OEF3T_>$"+Q
M13&_+6) R*WCLW-FE*>QX6;J<*!<S8Z:OVO"T^V@YY_/O_TD/!>65=&Y&@ME
MA'FM[-A9%<_S&9MAC40'(UY^H#<*%.*YDBH6I3=\F;_2C>S1_;B>WV+H).P,
M3AFS;I>GCP9E[JHX.%RV&MJZU.!1LNGA+ZF9/%N#2-Y=L?&-N;"LRXOM\'U/
M,\VLE6Z]#B1PN&"CT N[T1ACI'D:B;TRW+;VR$]N]V3RD3#\=?&E@O6IGER=
MS3[<$WUK)SPH&@=>: ;@4,,H[EBM:ZA&#9FT:$W[N<8.34^_C^([#+,-J>(6
MAE9D/8/"+G7// S^NIU;_R4QZOA/QI0_;!>.26;LT6:9YVX.<KLX;M:7>2W\
MG.[ _K=TIV6.Q/+?,!Y\'I71FZBD\\XQC(59BF=F<_ZO,9&POT!0KH(-FO9?
M\ZZ+>M@)I^SG$S0P[/PBZZITW^=WQF=[\8)Y5TF6[/;+TR5AN11N7PJV'T(+
M\2X0NX5^D?!>8V)Q/^>,#R@% J:H7V>\3I/PN5Q@UI6F]?WW0+;VEO?;6]FJ
MWY[K1"671E]#CR,SL]"%R-4D N^ST4W/WW+%B.N\=[7B&=I;.>CX#)RG]V)[
MRE)^>)*O9=%")^@QS>M=X\T)0I=Q$QA_.W16/.PU!==)^47VDM4.1$DA-[VX
M22;;37Z 969?N<_!P06"VOFZ,PRB]A+B0G<6^;_X;F?B+*-I''(UXP:;D;.Q
MLNJ6[*ZQLK*B>%Y%!<P#?JKMCU@F'M"< X_66[]K8E@"1_^UX)G"T8PW^>JW
M[XHXD@VA[ET"JW7@0P8_O]JO<]^?T123)=*%^OUL=SK9UNY1^2<ID:;0_V8?
M&C%!""Q=V^X,P@4ZDF$JL+PX*<R03SV<!<<W/6-?L<<4\H$B.@[3)(F?ZTF[
M$,'YY*IR0PQ+N$@I$(Q+6*\W3R218]325"ZZEIA]O++<>!LE$WI'-F>0W?!]
M;#)_LCZY. ,^"%QP!N" K[W6UL!T-IX!: Z&0.3V.X5J)^PVB*_>#XZOZ8?F
MQ]EI<6$2#+<I'F^> :ID%'74G X VAJP04G(#?38UL$8F+8OFAD+S:(H?J.0
MTDP:A+ECO[?2BO6E/73KJKR:0TC(>AB5<EH&\1F$H2T.$,S8J'EW].9)RJ\9
MH6$/U@2YD/K>:#^6(XVIUC2\4=C[X2D9TMO/KC4?+1[N[O[IPXFHQ<Y@M N;
M"-;P_H_!1@X5>ROR.;X)5<Z&:SF^OQ:'GE8'ZR!-+*H2A;=,NJ5^9L6NHHV8
MS^$YH_N<BCF7(QAR8[X1%NX,3Y$+GA-^:L1?<E>BA$[URJ-)<3_>PV<L'.0_
M9^)75('LVIPXM3%Z]^!-#%6:6SV]:LGTY0BT>#^X*!;N1_ ;F%:.=7"X^RFX
M1([Z5NO<E67-:)!9:X)<8Z.<,^L-"L/GEJS<"?<L .0Q $Z_OR4H0:PJS>2+
M!+_S9;':IUP ]\:O(?B#P6A8@4D7A==!H ^;R97%>Z\K'_[D;!!.UTJ3SG<^
M/. %=HX/F3-#/X [N1.#X;&A72S>KW5KO O>F%;5WBX?OJ?<D\CSR?2@)U^X
M<*(P4-(BP,6I\A/(Q]>&M +ODDQ"I]W\M NYB.#<?XX\P0C^LM]O*F!6,DYR
M2GJZKCH7P5+ ZQ$J6^Y#<QK>#L:%@/:**N__1"\1]&?E@Q.ZN5ML3[E#L7.]
MH^(?Q7K%K0T_WGI&2Q/ND-WN?MN"? &TUG8&X*PUGDDZO[=R6^4K\SSV(]8K
M#V4V3$7<N]H5^XWW]>R_30Z,M.3UQ.VMP]=> %\?Q('<83%P)H@!4D2BJ8-Q
M-U*R(^3-(T3[H9TFL=YG:L<_L2/OQ#*=55OI L,&;-!5#(P[A\9T>L+9<(+(
M_(BBLWW:Y,QP*7NYI@?G,36!RUGW#,#P%AD,T;<>LZI?$"-I*22?[%\C];F2
M2V$?$QOD569P$EMIZS1;_6DCVNIM2<-W'-[V =Z.'XA^=M2;_I)YK[./SL*/
MN.M*L[BI);6VO0M:@_'#!M4(YABPQ52Y5L'DG86'*DX>%][3\])U-.>VT50=
MZ97"W[J^CWX&:=Q,_X1#5J[L@-"&YK'S)YUAJM;4HVQFV5_MGVYX;FJTMW13
M1"]D?/F2Q%#%8NCDLP-;Z@_QQXGM-S##J''U6P/CRMY2769E&,++"\T$UAG4
M%.DBCKH9)[D5%4=B^CS2N:?2YW7!]EM2S@,#<-'R=.:^OMR[([%!F</F[P)!
MF:S7,VJ]>,G] >M"YP%'YHB<1)-3Y:!;!0'#"Z:W^/GK@KN%^SQM72+$[&MR
M6+/>.U"\;B/+I6C)BQEJ)"VNHDT54LX [5)[@J@S@& X#(RNSLRJY[_A2U4;
M%5S(VJ":/;3[KF#_&7=*2UQ0[Q6RW\'*F9$+:^<8\C@,^A7,/AU ,V>X,T,P
M]K7.C R 21\#<4',8YDKDF@>P21LPO890-1Z B9 HO\):_OC/1DT$$E<*7OI
M8P?*$1Q!!']2J>=]EGGW7MA=YT$WQP'&FAA0M9[3>QIUZFP].=%MSQG'7^W_
MY;IO]@^;8U.#=Q7$"];D([=W/ES[&\7)U@N$<YX'>1!GN-2=.2T1U SNNI;Q
MY72$S^K2[ _&AURN7J#9C:'^#2O=BH/M4B>"%]YD$?H)UM8\"&*#W#@#));R
M_?Z.^I;P.)S>N).=UN]!#.ED>VQ5+8PNJ(L\;X!ZE>V;N/3TK5/CL@_=#$Y'
MI9C,MS^W0<LRV,S"-8_'OQKI=;JZ^W$EZW4;'PE2'K2Z+'V0FU*Y1G>'N"3+
M1;E,DMSU1"RT<DZMQ\K4UM5VS\FT9C,/;AG;SV7G]BIY/164Q.=R_]MTA*'<
MPA1_U4/6QS&<MB7>]1J[I#$0!20*Q<SMO=K./<YO'-$OBHL33[OQR3VC$L;@
MA0MP-ESJ')INHOK*RTGN'R0^=PGP:V9Q%6M]?DF>N* 0_P8?1I2Y$"YQKP/&
M]G-:;2(H%"?'4Y14).X9]J!*W2/7ZW*B:?TOMI?WZ*X"G.ZX6+2\B(T! .Y\
M_X=3O/_L: !SG -6S%B>=CZ*47K2_E,3'>]N"+]K=YQOIJ!:91S3/"#KAOT]
M)*@#N)>S!EZ2,D<3Q]-]CWUVCI<V$]^/&W3:>@2RW!%/F@K6NZ? LWG"+KK&
M(O"2.H'P9Y/?A""!2PBL^['"6G$;%]'X59Y-$,1M%Y!3Y7R =7=S^YJU^<K@
M2N!+UK*G5HR'S)EPEPJ$&E8HZ2ZF.4[+GPQ=_20C.J+.,_+=:S:)]OAE_I\^
MB3=+.]$O*)4WVL;4N$=*'#7.3U)'\,4A47+*-W"::[_03<]!TP5O?+L70NRW
M;^8760?S:V6G-]V]T0-Y 9EBH_0G.^<-*E 0Z5,A'SA56Q;7N7V]*_?K]3;<
M*VST';O$S^/;>IU+3_?NR,;S;)2KW=C:) ?PD,_#G9IQ%T^R^I4@5NB3H0/@
MHA=)N/=S,;*18$ICK]EM8N%@-F8C=H.C*MYPP7FXG;ED2@Y<FVI\4=QIO1K2
MC#]G!H,:4![HAQ.$5'(CVPD8,_]4L'+AH#:<T)G[]8;TN#]_<IS@I[7+81=N
MT[>0U?^('04\(FGC4I S"23.>2U+5*,S(_OU3T@O?P4_Y585GG'R+7>)_'MW
MV::^OZ*_S+D6N?!8&W!^$GT(.?&U5"_&O>SY1%CUDG?!042M>>W,%8OV]'IA
MG5WJ[,%J Y-G[ZX^Q,-'%1(U%,:8DTBB:/_DY^S?$9N5B/N4&0PY^T#9EPZV
M-UM>6^M+A[9>$HCQ.2SP7P1C6XGE9P"D&MIZ6/TAQ'1ME<?N6D%M5*UJQ845
M1$X@WZAX6+R6TM/-1Y 7]R ?*3+:8IC/5X8X8]*<D#IF.XL 1N/'',6^$*RI
ML6#LM^K]9IC$A]%Z/7$+(R%7JNOBW*S9U4//8U.?*[59_VF"R&?K>P8XCVV<
M#(_ZF?HD= 6<L>/I>5GCM3^SND!.H,5XTL1OIIZZ\+@S@,D\(:S1-R[J@X;6
M\M(@?TLFCV2P+7^$R ;R[FY**/0@"&>^QXFG);BB07O7HC'UV"A5Y6\_U'RC
ML=S="7X-3?LBQ9H3BJ%VM**A'D%'?E;=B)R8V)?L6H7K6X4A#>>_Y4'[LH\,
M?_W/#HQUXG9P1\;F)8[0SD?O<9;9=7S*;4(7ZO-BKM;A#8S. /S0.=KT5UD\
MX=9DL!1"V=6]7Q39RKO,4+@>:;CB]4Q6'SVFS1*WA,G9%<7<.P,L2[5]0N8X
M'FKB"Y_<OS_E].!A0J62;XK6Z')@WF:[DU ;B4X93_<3UKZ !:81F"6R"!*_
M)4KGP[@TXG/U0V3N?9.UO'FZF"M;HV=Q72:Z,NA=O]T&9Q;/^6W_1IA!>REF
M@SJ3';Y>'LV,//E%OG"(5Q@&,87,L)*&^$ QM[^TPUF]08S(V9L:N5H7YG=^
MC22YOK*.5.K9X'PG_4AY%**+7%T,PR83:_J5/:%2Q$J/EO9/P=8='6_Q-['E
M(<?%6FW\X7EF;O?PBTJ:8^^EOE:_6P(W"-D^?/V037'N\)DGX0$0K7<&R) ^
MGYGQ%0/W \\ (O0SI)L-(. Y'-:6@ZBA%9+[K%^%9PWF[B"XBH+JOAGXP(+G
MVB_?/'SSHN,E=4SDZQ\RV+T[S@D4:PR,(WFGY1V;H Y7)^@?7567LAK!$C%S
M9W'IEB'Q(N]IT!_K"N$_MA;"N2 D4^]&.A!':FE>^DUP.K\?"BW^B,<CNX%Y
M:_C6T!AJ LP&*RB#A?Z7&A'HWUZ]B*AL@IE/ LL 1GJ0]M6NX@0*Z$R%H$U>
M.FR(-W:UM"@N9]PBT+:<]X_SI6?YE4]R'='4:UECC1Z&/=\VO/E@\05;M*$]
M^HC9Z2616.HYJACM[F9>XLM^3=A0# X<W;AL-_DJO-#RJ2>)?Q;U.G?W!U_#
M^S. >_P+I9;;EFF @7P3R6WIK"\X=M1F4CJ43V_=U_C6%RW:FM,[YB%>ZSS6
M9KVO4Z5"/+H-'M[L3G]'+\ A_0VM;4XLA:B])"W"^#:(57U@;SBZ<=?*'I14
MSOUYPP@Q6UG&YF#T24DL\XZX4K: (7[ZAF]7["+Y/,S%/!8JC+->(UJ/K+(H
M>'SIE\=]<NO'.!#/23J"/=+?WMX&&\N7_,*I2EA8T<U*,7F(*/R4YAECI> U
M:04)!*A8G\&:_[6:O('?TDQ'N-HH\S)\+6L0QO<#RH1)RK"^A9$LW""VOO.R
MGHMP-BQPU43%?LSCEW$ZY^;/F.RQ46> O"UB(WP%G44J$6]^Y7/DCZ3>6T*#
MAD =!GNLZPYWQGY2)Q*L(!K!45_F%(![8+?7N9<2!VF#I0F0'STSO,U-4 ;2
M$HSZ#."IP.F \Q_0EB-]FV_TY?OMXU+S;=DWUC53-7KN9BK4JY)?]]M1\-H:
M.>)[E17#L\QXCYI_/A-0<OY11]8Y+2]DAL<PX@-\N3W#>3J*?CDL%*Q$FY-[
M\VO594J;3!JQ3IDTW!W\%8@"#NC#H$V%UL] GHK%&;N_35TTBI(U%WY257C;
MKUAOA8QN7P?Q#, 9N-.!A'6< ?9,/?#BA$OF/ ZXR/61N:\_+'8*BJ/?#G19
MY<QNR(E7VSLGH[()KS8ZOPQ0M,9$>2,HW#67VF(3U0$NM?"@Z0B0B<FS5S%&
M+IFU;\-7=YOQ-T%[BF@/8\RO<NZ2H>LDHWE-W@.77ENV2W8@%7$=IJ%W/X]>
MJ&X$<#0M^+O.=/P_]7? PHH.ZEU*S.-A>'OUP9C"$LDX*"RZ#N8MT<#]TS_*
M(^(BK*-%36'3U&]?L,B8G/1D]E2/N]QX"/C:>H\,;PAYU(%)VF,/8FQ*\U6I
MTB@-ZRKX9!KA7O)UV7[<=5-N<& E3.]QP*'\B3APOEG\0+SGX<8C3:'*K.'#
MY[Y#\E^<N?&UM6< >_0SYGR0/WQQWQRQ/!"I4I,44>OEJ#(KGS&:,/UR3J*O
M\Q.%\5.;T>YGOJ^[@_BSG>@3V)2M1QKQM*1Y8+M2./L0F+UX<KB<%5WV8LGK
M9&'.1M/.GJLK93U54]31ZV9 O4+IH&%6$4<7Z'7<YPM,ZZ7;F(/3HX7YK#8G
M +] P;3ZQ(]H#8^NMX (A5'FI>UA( O<H\P8R6??5(BLN^(97*8>9J3>8G.A
MQ,A\6LB2(^?ZLBW)-UY1) /J>@//2%HHYT:;U:+M34VE\<BFKKK1J.AHCRCG
M>7\Q_E U_DW+4 I?-K][)A67ANH3*>&N5M\^"[RWV<@V% C,7"UCLQV7N; &
M4A=)A,WHP,AV=(1$\(+0*0QT$D3^:Y4FNHG^0ZA7U>>0M$FP\NZ1H^&%"CD>
M],L4#J>8DGC[U+I',E\9Y/)'XBG'A;J/"=)V=@#/^PSDX#].HW=V^$G\>2@_
ML[5*TWO'8%R!G= U]>95Z;_;[FBZX+_\AB3LJ^[S3)"+1'S5T2IU 17: 3 '
MB+;U;_#==31H5$@UK"N7M )JW;&R-FSH*CQT>Y#E\31#-'%2HYZ*=6Q7>V<F
M%@(B)IR_"NE\5"6-I#EM+8Q"9LAI#7>7(T.6%8LG5Y/PH6CZZ(67:C352]6Q
ME0Y[<>+\Y?8P]-T/]M?GH(#OQ6])]2\R['4P<DG)[0<,/[^WZ:&8)<&B]O[B
M[VILXKZFB"_RTW0/,/%$.ZSY"WE6L/>)U8:7#"%*[<8>U^FX=< [Q>/>TF4/
M/WKSVLTUA*FAVE:7 L \?8 0PX([B47'60E"DAA@:I\MQA@;_;&C7M/49ZA?
M_K-4?]=LOT$B_:H\3;H[@N6]5MQC"2OA^_?SS>>N[I$LEF9$QC"E0MN/LR:_
M+KR#H>^8/J+/6OI*T&P'^F J1DS!9A]_"6JH/TOUVN:V-!PY"!FYX:U_WU5F
MAL>9\U![...Q?A6++F!#(&OF+4 ZXQ7U_<")#_\DF;__G,KA$N8$JX=FWE-H
M"M?'C^> ?W!!^7S&NSXU[D-G_ ,6Z&+[MM)IH7?X7A]NF.0<^0E8=\SJ""P\
M)O'C7)#[)?(E2##SCB/OG,23&8GRK ><#>8B]VYO6NK(GL-O SWPK16NWL".
M1=;8\CZ8;-Y*OQ.Q%K3VW)&:F*\MY>7(A+&*;?:6BZ@2M#/^("$2R-:^QV#(
M9L0>"NE)$\CHM6#<G%ZMOA+M;&INVOZF?,A7R0MIZSBVLZZ\W&+AJ,[P<+;@
M>FANYL_L@)%'.E=TZ  "9,86O*O>K[,"Q2^0/])V NGF0O.5RMXS N1T)4H?
M&6UQ6HPXO1:H,(,6 5..Z[X_HW'\XW4MG*WCI'X_\W.:7U NOGO<)" R]GS)
M._^8[@S@RJ_S58>^/8"*^F/@SJG%PW59LR_"Z9QB6F' 3.K-/^UUK;[JQ]Y;
M]MS=M<=,;!_7W>6TH)T@;Y3C %C_I9W0<>3?%[>OGJH?L,,6RT+. -7S*GA=
M<-KY@O"7H_]YC>5U+/+I91'#?>JKTX&_KOWPCMV?=;WT,;.Z6]!@>V%'AU96
M;/(BK67ZIAG_$4']]\(D"&WB\ '/0E!SS8 &U5'=0W+SE2UJ1F..-T)_WB:8
M$3LZ-,%IA4 F;1:(8C]N$L6HH!@>%R7WOYA[SZ FHZA=-$B5*KT3I4OO'8(@
M300$I3>E]R8E0" @TIN @( 0$) .(KU(;U*E2 DU5&F24 .$</$[W\P],_?,
MW'/FGCG?_;'_929OLO=ZUO/L=ZUGZ4M<D[&O5=3['ULJ>-)_>FH013J$RZML
MI3,$XY$^O'^G)>[??#@]BE[A0!OR1$F:;+1^_]7N?%/L6@9G7O 8Z^7\I7'<
ML^\I<0C\=/CC<.;2(^<\+!AZ2!GH?>T.<==;N.ZYFCN']MX"R +E!I/:-8JS
M,!.R]D[K4S21QT_;PGPXA7 '='^=)U/?U!7^D0H%3KG55TFML,H__QXI>%AY
MR$ZIAN<:5ONEAB@NGZ]\C9<!EP%WL--.+TR)YB:W@]2I@PUI57$+N$\ "P(U
M5$LB'J9(RFX_'1M]8IKRR#?Q'I\HL^%]H<7<FQZ60%&$/UDAL;KHX#. %[,R
M;MQ[>&)_MWR'>UO+0-"-FIX:X&GC7B4#W?+GC+]+ ;< 8KVZ#Z4%YY$#(K)K
MMKM7KV;^Z^/\?]A?(X-=;25O61=>D%XGAR'<J: /7.>\X?WXD<7)B_8YTMZ$
M\SDF1Z^6NL-((U4?X^%::QCS;-P"@$[6I.W"E6A8/U-N1W*^LU?6WR,AAN3'
M8%R<)PX.-OE\40Z< )('1;@HYK7<P</8:P63O:" NVTD0I^HU';Z-;=^LR8:
M"\1]3D.VE[HX5-ORHB#.?8D69[Q_\ NT5P/:K8SYMJ.%^K.#U]G;YH?Q<@MQ
MK4#?J5Y\&"I],);',WJ%])< 1"[G_>-U_[R]OUY<[G5 ;J=9JB%C4<AU(+LZ
MJR+%^9N[I-G"D]#N[HZ82)"S2D8D-PW_]%S7X3:*&UZ.,8QC_K058*?2_3-G
M%$=+9[BL50UP T#SEX(CC-#2:_)'=)4CZQ55]WK<+3T$^]N_H*HVQ*-C^&(6
M1P73B9L57MO2+DS;6M:6GC*4_!_L7'KEH-KR44CS3CT1KX<*0CR0UETUA$UQ
MD(!J5<08D0YKZ](21YL6/RQ#(I:V*."AN+LA)Y\X"[X-0%ZV>HH.\/T>M ,1
M'#X0=*RQS;_EF=#9V 9'KU\@H-U BIK^Y'C1D*_R/T0YCR5N.$82'+0K,A>9
M*3E3!FQ,Z;?Q&=?37$"?M"HQ;O\,3C7/9^D"5O&P $L*=JQKF+$E2O$]K,.X
MB5OA:?*#2!DE*R'[R[_I9I)7&VN>72"BT D0N>\M@! LKTL7Y/=M66 Z[((^
M[0&NGM<:A9AZ%QX2@/."G:\4@+*. -5:9+#)?4<7WJ7>DO6=?I/0X7.S]#XK
MG:@$FV3'=/=[Z1KP(XY8,\D1]P_JJ?8Y_2"WB06>7FB==?<M(':5KH,&W32P
M2M'PN*2V.?,)<J71K;[)60CQ'GOX '3/F95Z%![Y+=R8Q-H?HXM^B>A,8,.?
MP0#71ZC+_S"EQ%:[)QSW6'Y)X4HXBIT<8)-0$!E?"IJ+ &&H<<^=O7JQM-VR
M#)<-AR^N3[#IT_ P.>$(:"TT+)04O+X_L+W?QR:-#@_8?@HQW-#1W).+_CBI
M <Q@)F'HT:B7M19W%?.<]S?^%;.8HCE.-#$J N6[? -=R[P%U#W+P$4T4WX0
MZ5S,AEDDW )&QBG4#N$=I8Q=$]QA=/_5-=#_BXMB\!: %B2,M_%,M")'KF(X
MX++-T:K1+W3 JNRKS<$Y[Z62'W[@Z&*2^,"O;LI0:W1/@W!"X8[@XGN@$6M0
M(F<X'@H=T$]6TGON^[OA6CO6<^>%5U1 $@(OJ2)RR?BMK9!EK.W5&6ID(SH2
MZM@9W0I+P#B"!7Q'7FX-XCU5[-^L9!YIBI0FF])J^"8'8/Q47B&&H2B'=GL*
M('X+<TPK4>@$?JT<;VRBM^)XH"WP)&D0/#NEIL[_[I5\F!9.#N-#ZM#!?TP<
M]._-AO0A[=H1CBL<^/[ -]'\$.K2/.U6G6IW7.60[D_?XF=1_ZP]*<!X]S=D
MXYH7"U\ANJF6&&FN?Y_S!&65<\_"VDDN@D.+28S7.?^#G3:1O^A1CXC,4FS+
MVU,7$3N#'T1#^83_#__/_QJZ\-^A"B"U?6?C(K;!$Q]#@4Y9%Z3:JO33 ?8&
MI9\E[)-Z&*SS!W)JW6OFF[<G)!7Q\B%2\&630Z<@5J.L*'\K&*[GZK)2][9:
M$*P?8_>]3#ZZ ]QQO?T%RDMQ'!Q>E&O=ZY!% 0=7XV"-:A@K!C0%PO, &"E]
MR%5=A^+HOWKJ8[ZL/*W%$C4PY6.PS6UBKVZ<.)^5;F?N(_V!PO8F*I35Z9_G
MO1TL*@.N6$I2YDQWM;S?^C##M:+9*-#R6T5S:9K-C@!'DN0(/L&/@$'L?>0M
MH.^(8 _+B#)*)V_*M^Y[W5';O&0X7:WZ>/C[]XJ*Q^21AA^C[G4\0FL58_[5
MSP4OFZ/9H,1[G<Q*I!86$K-W@7_ %&*KEV=RP1 9F_M.A3/*R.V-N!?G24 :
MF:MK)QN6(W0YE,:3$,*")"];6XT..@6^GL6RHWN(C&3<BDX*6Z.F?EOV'8Q0
M)GP?>E:7[O<^/5U940-[O[/4A:GIP!BY8K[_L]KC*?TOP;Y1:S=]:PLUTM=L
M4@(N<>7M@ @6XYG'%_0*GP.J@6L3W3>$:]:]EA1=6'KZ^U^<16G?+__<'N.O
M$__)F?BK;NA@Y[4A?M(O OP O@(:WC\$^/^U,Q/^WQ;$^"[<G3+[5I%#02F_
MK$>FUF</=-L>BJ+L& YDO=O8D0LH.O.$D.7UCIEJGO7!WF7F]9W>54JPN%7\
MQ-19A:E B7(L9ZT'D'.2$-](<TF@M(^UBND;HWX8!?=-N"\4WZGSNW'O?C+^
M+LID?M6Y=LG%C=TO\ S08;@Q9.+APQVG1NK3IF](D?& (ANT5L?&A"R"DF!(
MJK7P<\ GUZ^=SS,%$)X.TWWB"L.TFB>47"(LW^295)L\/ZF")^) :Y_OD*'I
MX*+:<A%"C[*\B)'0T0]O:4;.-OO*#L4: YW#=]0$V$S313G;[^GV>)O#<*!K
MGT!4';P0;6M&["]XT>2NC?VU>_ILJQ^9L:E3JC"7V19CC[+ZB^:TL7M4<:6,
M=B\HIJ +)88_YJ".P$BSC.) [](]Z3R:J6HA3Z%B9X<\X[K8/ U_SO^</OPY
M^S3;):3_*H @]W_\;__O&,8D(6T&\*.96C+PS"><U%G>'1.\1]=^L=$T,,9\
M'HPVKT1?]/D'7+1*I?ZJZC,SXTQ;-]V(?%;Q'3?B(<_V'PJS4[[+MUABKG5G
M"=C"\"V@)]LQN@ E'8-]Z.*?1S4E4+V1I$FVU9NA[G/\4/U5+%QZG,XP)B5,
M!U>A#+I6!\-?T%40W.@/653Y^<:N10F&ND"_O0)H>F*4(M9*2<<0UFSE^$.>
MWTP^!.ZF!";/73DN=/PSU0.%DD,>H@-*P/[7W1U U&PQ_9%'PQ&5T^R%L;0X
M+<XG3Z/C#8:>@1)BP$]'H:-C:0R-ZCDSTKBGD_@G2KC+7[67B?3BPSSZ^\"<
M;M,/\V#GZMZ&LR^Z>V]2K.VLG@O%#>U%#">/KN"<Z0U.+*J,]& ?MJ(#D3"M
M%G05RL.$TZ0^E\2^/RE-&&ZP.#KSE1P/A\N&>(?/F(HAHF).%KESSL0FA$[T
M0[T\CY@14.*$J#1+T^U^Z5&8(-N='>U_T_2.L7"5NU^,LC/2.8#&V7C<T^L&
MUNG@"<".8NDS-9!"R>>X8'9WU1?-*5_;.E*HG0+M/8+^OHYOH!FZU@]@.BUC
M*.5/C7]7<%SHU,WR=CY\$1W] _!,\&*@.&8U=W!K Y35C0DFSLMN@2OE?;KA
MDVJ&%\?1 E).O+N.3O/UU+RDR=IB+H1UNJ/$V^Z2D5)4YJ$FO3="]K+-R_MR
MI\D,$2H.YND!4BHQ[E_1)^>_TR.<8++<TPD(YBH2+:+BQ+J.,1>R%SY-T-UB
MT-5DE$3OHZ:Q-* $"45';30K$J0?_O4578?,K(+:6X!!)D@T;FK=F*J?75E9
M3*SULOU+>O<4S=9+A+%XF5$NP\E,JO;8_$VO:V[S4A$=)]].6C@L'^-B_WJ8
MP1'/,27BTG@SLTN1_ESSCC%2 0'@Z37+N5YANCW!1"&2(YK5I?F5VN/SIT)X
MNXVFS%ZO1 ^Y%;^H''#4S/[F+.6IEG\U+"0T6JHKR5Y"Z-M?FH>P73*)5):F
MX\&-&-=SR2A(Y4[1/'EV\J&+K+<&L>1_:&#*WKA%*HMGY_/X[:$U3U,7"&YI
M67=M?/@DK1DC.X4*4]<38R-LF9AM[SVWG^YTAL+YUZ#12NQ N#66$E%)DNI[
MA%;V;:OA^=F2@7O=7></J5KUM94Y3%7$<0DY;2(>57G0)]6#,TX!V2BAY94/
MX_C@FH2V1$S0H/6ZY?QS-BCHH3UOUTT4)AI<HW7B]>CEBQU>/(Q)URDUE.&1
M?SO@;?D^<+Y%5F8S^RY:_X6_<?;>:OU<#QGAJ_9I25!<Q_WI!O['>?"]\:,^
M?V\=O-)^*VGUC[3VKY\8X. ]<,*=*JWANP5$5:,?MP&1S0JX:;^@/?KV:;>
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M5R%TJNJ$Y]#YH\)= B9>U58("?C-J,2 G;,BF*WZZZN7T$&"SG*4H%+S=MP
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MUK95+BO!3[C+7)UI2+9Z.4<Y%[P.E#23EA[O\1_@_'IQ;U)?L6>PN98XS$-
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M= )=H0\P'"%KIZC<R+F$DFNC,EOO\X]U3DJ3'YCH>"VJ^^&F ,!E(M?J@O3
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MIN$!H7UC/V\!D??3YD#S636?"O\-)/WT*QEM*3"6.CR!\/&OG5"PNL:&+A"
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M]3M@[NI$&RD) >'>NZWI9Z?'X]Q&CMGSIF(,;IRB@C_E&01LI"--*C\]S%K
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M+(I=]122[OHCT_Y O<\GZ\F% !Z9Y.R^]3N-;!?3(7JB\V8=<"G'>?1@E#_
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MHIFK8MI7'V(Z;HY^\7"WR_"V=L6\ZQ+6D&3U%.?7.Q)Y_QSP\6[AS-$\B)+
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MLM08\E;P3"=PWE6B+X_^2:30V,_O 2>]3()<'$(. \FT^.RKKRP1E:A _G.
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MI@#Z'> @_R P=)MQ571WOK$R*V-^<F;%CZCV'F-(HN.GNMAXKL=I1/CXWW-
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MJ8O5ASI_=HHV2E-D;I4G2S+[Q[.S#]4^']:I#JY33K>0RMB^+4U6H#J.\G:
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MAO M&Y%R2#7FN1J0H",?B^*C7C>91+Z=PJ&M;5Z^_6QMMA/KTN8T>[4R6>/
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M&--L[_SW&\Y_9<SG,.XJ[QDY;#"ZNC96XT+@*'*:.M[O:8WT'+3=YU"UR"F
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MPM%]V 0,1]XRXA0.UJ'(@K->&Q'K]]"IKX@VN+6:]=PJ!1!VET%6 Y!JT9=
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ML<!PSQ>&NA#(>P)T?OW)^.P88G%@/T =I+!;1&"EBB/#+(,5-Q*;HK& D6T
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M[<;XLHEVVJ>PV?\0@8^9C"#4$8M)4-HB-*)5'=H](7V/!I-4*%![][-@(/_
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MS^U1@[[U!ECVWRE+9[,"W&MZ<E7ERR;59+S!R ,J<_PJB =F-1-Q$<8W5QV
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M:WGVS($>@AZ7K@,B:T>H7F9"CR8FB]1<'W\ASU%J.C5@9I3*3I&6^$/P NM
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M30$6LBK :WBG???8*;)P /E ]S@">.@1#-K5GP"=8G#"F3\)%!0;05\U<R.
ME]NQ". 3-QC"]S=G/W!_LI'"'Y_@@'\UY(!7<8Q@2K2G(9YF\* 1!@0 F"*
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M5F=T)KIG=(7;C #&$Z<KY=[*TZ$,,%>4MFUZ3+0=4GHA@&SV(LT=N+@E OB
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MQ]M\WB3_(L2%UXTY^V>%H#BJ N3W3%&^S4>:Z<S$VS5^.:L N%W &.VH$%V
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M8#0<1CFJH;W!B,I&>_Q)_D)(+*S&HHS_Y,MQ=7?PW&+/ R7J88^*)CFR9PA
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MT7KE "_%X8BS"*//(8-&3-]3BRUG4IF_I8>UK2QNM;E#QV*/[:[Q9[\B!U%
MI]B7HU[/7M+!4K*-HE1?_Z\^#2C O9[>E=00Y,-)2P^&>WJO7K^6CR_/E,*:
MBGW_T78J[JRZ3]33M&:+1AZ?RP:H.+!K.G)#?X&'1NLEMI5:3,V'9,P;MY<
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MO*6MGE RI*AWG2/8_"N*=N+]+9%_J?SAI>Q(.N1)Z/^.+'YUYX()GAU<4&,
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M<Z+5:QY#>^=[KZ<4+MH#7'<$"0C?8LMVM7NS0A?&6"PV=TZ13$)%9\FC$!3
M=WM8*VE3:"RX O_&H,6Q;#%,U%0V'18&U12 4K0KT\>WBV.=&X>/O&6ST]N'
M0PJ/H)Z@" T8W'<YW*GJE3Z3N!RY_JVF\\,I<D'/^S84.3 ]T!Q(_V7C0T3L
MFC_'I1X9U Z+ZK/46S90Y8,W=?Y1R4UK?K> ']N*=_I)+%,8!RI": RM1P]E
M()L6884.I Z9Y0#QY4AL;M^8-JV1E9E[.V.F'MZDRPE[83 J/8=#.;M['=E@
ML^>Y3#8B\F/E-EC1-R+]Q5(:+EX-USM#9]W4)$=L;@_M[-*,@1H"Q_K)VEXQ
MG^F$928=]HL3>*1JI:08[BP51VTZ::5JN_FW$KM1J=4/'>.R>9PPM16.EA*Q
M-X]_CYRW><,EWK$VDW(30?NUP-*0$2&:DH/;1*GC#@V ?>=R>)>/34VPQK2_
MQQX:;5<RHCZIUR]>71TXBI.R:+X0@*TO1\Z2>\RPSR)_6!Q:JC1+%/BB>N*&
M;FXTS?NS#_X5:[GMA&.\O,B<1;ZQH^OD64L$=+W**K$7M'/_:8T +MT,;=#^
M1I^4/$)5&3Y/ ,T<J:.Y(NUTD]$;WN4-,V@Y;XV:UK<HJK-=$D]QX']0%H[1
M+N1Q87Q\G+2XN-U+S\CHA!9?V3_GUO_S*77V7[9"4M>MW]R:JD$!3&6-.Y!B
M>3H: 8M+*^;/]QJ21V"CWJ2/I>TNG9Y=6H31F#B>^)N41"#=XR*09PQ@^756
M?"V3D6GPS.?4BW5L),R>+0+MWP7_Y=@;VGE7T5"^#>Y,_(H"C(O-H0!24)W\
M%&*TW\@OB0*4>,.1(=K>M\'$9\C -M)E S+@PE/DW/[8!+#4Y]L5S.8J=?6L
MT6Z2KU)DVGYE#>B:$COA%ND6W$B^Z1N*J2_DE0@O_[DS5['6T]^;Y+27($5U
MURWF><T(U<NJT8H-YYNFTK#P#4J5GN2F-,'.;YT=Y+PY!L*6":F^UB*""T$#
M(L+9ELJ$$VON.\[,4+MHYS<WN *XQ>0$.\9";] MPDE."[VD1L5:<N6P1N_;
MMYG9/*ZQL[ KN2G@Z7Z+:P_KLBFB7A201O@UMQ@#H;@*)TGA&H/6*Q?JB(45
MZ'18F-%\.\ ^)'^ST6FR;.BSIT^PI'7,IM4J1A2R2!J0W9!GB6]D9R9:_[.(
M,?K>DQN:^L\ 6)& IJ;S2$+S^@;8T Y#74--X.0D9WR"Q8U'X4FE\VIQJSB)
M77(9%BZW^;!O5B:]'S\2$+F@1"@JJP;)["N'//HA]G!3>ZG-[&9S^??!+LMV
M\4QH]SX_V#'WV\_<!!U\G$6.$)B>0JMV0ZDB%\4@JV?FH=D<$1XIN2'$C#7E
M?EX:X;N:&K^^287$O"6_6Y_JH[L7-$B<&5( 7VW?>(*<RJ5'5T2^,;]1*>*N
M$^4,=S00T]ZL8C-9"F/GN*NW.6FX?ZC;;@OC].J<>'!C09W>QN[+_0=TBY8#
M^XV%)Y1%7RPRW!I_:E?5[U^6Z[<P-D599\JV#T(X5QS;9S,:W=(([6%UE8VP
M\,W!1=80=^GUE8"6C @5&2SUD04/P5$O->?Y'79E$BM-T,PZL;(C&W3J-J-S
MC-^KM:0EIB(,BF^%.G,4;N$_FU*PY7BI1A0ZBQ)6%]DTA6^;FF=RYO(3WQ @
M9Z!]=7$H3B<#TLUI\=Q14]E_G"Q6^E1M%G_=%+(JV HITE#^0L'2 ;@AL4G@
M7E3TEW'N,YS+<.V(*_^=ZTTE%IKF:,GN 5U+=@XRM!K*8OW9YB?24(I$E9DU
M9?_GI?\N</NA)PJ0Q34FJ?LS"+Y\?1"6(>[<U9.X(F$NNM8P;>;TS\UQ0\CG
M"/#8;> 10^8OV!B?"CW3Q;][_SEDP_YK+B/4^@-IS&+Q&0EO\?D^^BLIF)6F
M,@2^K#(*WVH&7Y&-@$ZC[IV^'M#"1=QOU\[Y,/52CVMVU,CIL076>N][7V5R
MP_&D*];:8E'$5;VK#]>^344&9P];JZVH!)&_%$G2R,G8 :G+,!W[N8_A$O!C
MO-#CF(P9B[LZO>Q?B:I9!4QOT_X ?PAWO\)W(ES"YU#</_F29^5:,MFP4N]@
MK6'*^$5"6-VDA'NLBGHL3,+$G2]HD<CGMA#^YY((T2]%M_O'J(*&:$=&.D1\
MZ!#W V%7ID\(HB>?/I-RH&>O/-BF$<?RD_9PGMFV'V!Y!HM/_;X:9C&[U[/R
MXX@'81KTV/=Q'>U7JHW2NPQ?2,-;(I^IXS<="+2[8Q>\<MMK$4K)H4TV*Y!B
M&TZUYQ/ ;W]''FHV);@S6C^X^[ANORH<-F7.X"\/CZ,K*\B>XR?&[\/YRE1<
M<\1;!96DYKSD)6K/JW03G^1\_\+]<E,TE ]969-3F8("C)X(LVFU(ZD&.) M
MN9:E4H[M1K?ZJT3Y2;$XEL(%"XM)O9Z7[9]D94QF1O:0KDYDIZXZAT\GX>AE
MK/91D3/E2$;I0N/RC!8$O;1RW,)'U<!@GHC;S^(OC*UO:6AVO%PKIC[W5U\M
MK]D?#9BG@AHK8&E61<OQ'1DM%SQS5L41G+S=SCWLDA]&_K@8!2#,>6ZB;2,,
M;K$:WII:%,V*#X$IT*@NCLXI5/E1L*T0U40_7P_KI.B?%;T??CQ(1VIN)$$Y
M,?R5TGZ#7R15L;IOS]ILLH:.D,IS+E3_4:UX&?UXTT"-P8+YXO%&E*X(7[Q,
M4^7]2.XV*R-HYZ%\9/ +W \MGT3N"B[E\#2$,MHF^C"+5BSYU"'Q3E@YR,TI
MPV-<\[4MG[!EI7W?)O*7%EK.HX(KO;.D M*<FJE<R%6.@$8GZ<3,.&OSF:BC
MU?$.L(760NWU[6_0/.]I.Y^TNB^4SY?P)GJC8@4&T6R.JMCM,L'$6:'Q..H;
M62[?0 $P"_6[NZG\3]PF1E^1:8@KK3IDWGWGOFP_&I-!FI,,A][1R#X^@!_G
MC9LC>?=W&^P9*&TS8Q0I[8PY:VD:.O&PP7>RX<3UM#MWPBQ%NM_50,1Q!,Z"
M#>(1'<7R\Q6LN>R-]!MCSS;C:Z,5<KKA%C5!W=+O0E^_U07DB^)()GP?@/6R
M< 2X>N!.R4]F;6?JM%9NSYF_;6)]@HGEQ[G506J@%79^=.7U\;P5.E2\L>JI
M5UF3/6LY1JE[_^&>S8!QM&CH,ZC?+88WX3+//4;N(U*#EH:*8-AP%. %+'5[
M2/YA9$#,1<;*6NZRL:,N8? C^+Y><9#7\US%80^[$YMQNKD#Y'-E+SXTK#36
MW,D4,O 7(]>F\6C9B2(NFW[Q]O7M:,D4R4@N+IR%U[6@,BL=%.#E@$;LI(?.
MN8Q7(8WDDT[Z1_4Y<HB<5CV/D=TC**Y\=>5K2M&SJ4."#'QFT3:/0FLH,5?H
M$Q7Q(])Y;<*6902=OQUOB)R)T"=^ N*9CP<K&H"=>6/.?EVDGF1:ANG*,NGT
M[B>OOM&]1<4++]&RL6WKG8#M>+_!5UEX [LMQ%I8M.^$4KAD1"U&9[D1@8G%
M%BX^S -/H5 814"]C>U\B8,X3I MMK0;C<<8?[&!A79.LQX7&]^(=9RHO$!.
MI:I<N&)QBI)<G\/M_@V]HJ#]XI9)L@*RC'OZNKV$O7=KHN0SS (QU!U$#T3+
M(8/R26_/XAT%:F.B5[S#&\\/:(25JQNJ&23MJ.27G9M#$Q;J19=$P=K#VU/;
MM3QQ6B_*M;^YB(U9T;JYDR9&^1%V"^)4R>OIB"-&,_B*L<X;0FNE6EUQ;^;G
M$OI!5YZ(O5IW6=X]WM+5#*&)_9Y"/%01<C^HE8\_ $8W3>+V _C=V-I!^,T:
MC4 ?GEH.K=;8$4O6:T?VD$-A-G!["N/@VO#>UP%H^D#%1/1C?C_9E=H>F\?T
M/^WW_+?Z)3(*W8I58[2'G P(IK1YCV>JIF@5KKX]"L$!!*S9T^\?K=''(]KA
M.9N(N0W*HGA'J^+7"E5RKQ)DN./>8&;_P!&@IKYPU&2W+1+A7U*\UZK/,$/"
M+Z0ZI:?[5"I..)18/8#Z7OCL58!J=F$R;&P-^=:99K(QP0MVB<]X&K[TC4DM
MN@V[D+WQVXD*VI14'_>;= "S/4>K/ASW6FG4U(6 ]!XMSCX0J9MA698CLN4*
M4"##25I^+U#,7;._LS/6DL<;6)[TC;UPTM>?#C@!67(!&N2("A85?,MN1P$6
MV3/R3ATPR#Y8QSVA%'@)JIA0>U]-[9OB/S86[32?OLVLGAA=L_$))&6?_/4_
M67S%$5XP."/A,3C?][]V(ZU^ W/:/8NF[TZOT1SDVBX3O3=A\2#RUSS2XDA_
M;;P21RIYC(ESIJ&=^%R@Q T%6$LZ*%Y=CO@!43;,X&_%[$1P!+'#X4]/C"]$
MI)77 %>LVN4BIB(-C_L.&[(SK!Y[DW27EJ( C7H%2N5OK\TY0U/I?O]XO5F^
M6]".)W*&6&;9W6T"IF[FXG[1Z ]56&S 1!*#"96SO'.V9ZT>'GHUG$XV'74>
M'1<YZIP&@[-/4WZ^*-EOZ\L^^4J1<KVSK, X5S*B(1P&ED0<IV2E;VJ=!V1.
M6M<:MDT3KT#,!#H T?:A;Z@1.M4:FJDYEYBD++;[QVAD;##FQ6I5O'[7(OZ>
M''7<A3;NYVKS9=#[EDN@RCO+N)CYB?FQ^Z_'>+_PAHRG/VO2OQG\2/69CXJ2
M'%;H1=):Z!MP\T3U[9/5_;A,'AL4 '$5$Y980C@SE80(FW'K=:J="^>!THG#
M1E0:QALPM]\UBUD$4V!.57I&/'?+Z=%FC:^NR5.8W7:7FCZYNYZ0'618N(G
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MA[]26ZA9TM)D"6\QR>.@=_0U0T64_"B %LNS213@"FSY9619*^919MZ0[N
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MXW](Y<Q0OGLU4!<Y*F'$)2_>4TS#B0T<4AYQ87\X]G*D*S?K203G%V;.V]\
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M5KF)#=569 :]M8PJ'.26 WPS\^+;P8.YDCEPARK=./>NW*R<YO*L3#CQQD7
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M5PCP!M'>BN7N<J$7/R#?"&0>/G%PJE2\FTLDQQ[JQI2%]4;A>Z")R*VIE%#
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M+,B//9C<>W9! 7XS%7X$-<:M'K]UANRE:GU/&)X63 0Q2/G:[^E]W5N'[*3
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M",=@MGDG0327V.'>1@+#_([A;E[[W(W!HQ<-BIS4WJ*JWB(4;BJF)JV57BU
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M?'57)-L8&5<Q8[G]28;?&!, ;8?:)6BKAG\RIRGI&R+H7;$'-\R%&3$FHJP
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M[U_*\OOVJQFD!_"=:,";.=Y,G[6U9_^10T!;X0JY_1Z@0_UPH$9'QT%AKXY
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MJAP],#M-?D+I*^<@+9V4T4TE0K6F,2;/P:'](XTA0?.#TUD-/R,C(Y"[ATB
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M-2/^!WN>@S7<?]_57I(TOR-USB%O']N_A$NZ;V!,GV#DQ<]5QN/M7R-6] J
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M;MW,\C4^[A/"H0$1MK-8$09$)@.N-#4YSJE9<,,,3?4C5?/S'\MY;QFSI<Q
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M,R.["B$V"1[ 'U_>U\G0N?U=J@?BCUF<R8M49)2;,X"Q9Z 2CWL<#/[4^3Z
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M#-9XXD!H+R@Y(#&O(',&)0J7,6E<H?=Q=:]@AZKV)(MOPTTG0:,"C]0T$\5
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M^7VN\>OOY[Q-R@=XD/\]QUM$&ZW\KZ+ZPZ>U02#S*R#U+YY(_3]2&Z(Q+*\
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M._MRNR=)$XN2PW<#,%,XB(^J+=*[7[L&S6FV8YO''<??S%L@Z: *,E<DTSN
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MA[/-D3VZ6(^8\-6X='4[T:@GFYX>B6=)(@*I_-6U-!@6U7(*5;<3M,@'A?>
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M?H6/0S7& 8\;5/(3.BN-#67/+;LH/[-/2C)NNO--.4M8+@Z3B]\6:;P*,!'
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M#Z2IM8CY@S1C4O]$FO$U76#T4S_Y?UKI S%(6R O>,AJS,$,U[TTP>\6H_]
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MI37J_+V1\R/]@.\HHM<S&3X0]MC2%("%V N]?\?%^LY!(4K/^<F!H[BZ(^1
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M/SL@-B(N+MSL_.SL?-]=AS+^J,[V5WTAMK\%NW+!S<8- OX;!\0A;O_DP-6
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MK;8][FLO&ZH2O9P,5%WF*Z"$;\Q&K_6J'QH('QE=]<K'PSSSGM8D+',RJYM
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MM2R;"KBW6C"$6GWUQ[E<M7=S9RV_%JN-0UBG*V?)9IJ(Z\H:PO DN0\R/T[
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M*'%W1SGMZE8B:-KL<CU<55&6[@.I57D9NFB*([+IT8Q,@J;=#.7O&N"65 J
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M:P*<^:.AZI?K_^I![7X_H.S8UR5T3XN-5Q=V&$RN2O78X\("B183--?;$+]
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M.D&I37<K)TIYO$A/T/0*_5A'DU!F*<,\EH(6!Z&'NMQM<1_?U,/\XJQFXM]
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MM1B&60/LFU*WG:#9W".I,E>A"*@S=7-(FC0-&SEIX3<UU&:U5?Z %+540(@
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M2SYDE*?>4L]^^<]6YZGXE3>&?NC/J;]^EDLUM("L-(PV6V)?$$B.)\K1$NL
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MP*FOE:YN.7KUS^!Z&VG[R S$5"8;&3+6(QP81G7OF%&O*JR*0!CL:^96\1)
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MV7E=6&Q&MUKIO58ZM^1.[29_*Y>A.J^2E^]8U,1># 81N,UGN2SC\V7GL?\
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MO+2ACY)(,9/B.*</AM;B58 EXW_FU7[N8OQ;EEO]A)8--VPLH[:[%7/<\TV
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M'<63> <5:LO*ME!G;)9JPM 6P;=MM/$D&R,$+EV);B<7R0DS/"Y7,&(M&(8
MD.(!8@%! T1@/J?[8<!>KJKG>WK[YXOOVWCN[U]VS0+!H 2;6XK**H.AP8>V
M/ADEW-G\$86&%L;6" MH :9CA$WBL@,;929'2!QD>71CR]2Z_P 2<2[MR+6A
MVNW=XRT_;-OJ:]K=MP:'8/5M8>Q$M:8G<$G8J9.N*.1-^_$"^2Q#@>,YZZ[%
M6Q87A=97QBIE?AU'4U,<9JZD\1T43Y R0\0ES26V-P; FPT7J]BZW$-L]L\
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MD$UEYJ$OCD=]]_%.^\O/Y=5S,09&[7'3#=BF5QQ4\)OC=P0T1F >0\,LE'G
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MDDX19%@F)DR(&)$[[T[YKL6/EO %6WK'[VKSJA>3?60Q@TVHQ"1A<,1G7(/
MC$($L3,XB+),'[SSF8WEX_)$"6J1 LAS9&2WBPRC&8S2&=G(/VU%*"D"Y]\*
MZ^0KE"2)<2P$WO3S".91(MC4#J69FK$=; +$%)09@A-Z<&\>8H8P'Y&',ES
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M_%V"U2DS.?EZC$,S[.K&!2D9G50%V9#T.1D!"F4FDJZZ79H_NRD0'YP4T5P
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MNK&.).^SP=3VN<D\SW.IR@Q1?AA!\/8O""_LM4=8?RR)S-\@V\A^_FCWH9/
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M-@)YI73P\!JI.*9,F(KS@\0M3<B^4-F^Q)<WC_BL-.K./'+S7 7FB1$JM1K
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MJ_TO\:]!I[-3J\-8KB6HVG74.[LF?Q]'541/>&G5TD)'-1G]-1U^#CCNF=O
MIO#W/:&CYN<?6%U,>? 5X]3*NK.(;(T[VG"Y1JMV2G^$X/'"7R5GU7-XJL@G
MZT%XW65&RP!/9"(_:'=%E^<-OG#;]["K]JC6LW>?9UY!&O@$FE;.?S/IBOW\
M=X#5&^OHV,31O;S:F#[C&AW,[0@SQ5M6$JO6('Z6Y, =%_)KF?FB1O)NK23)
M9VW23)\G^_&@G&BBW1:+M7G[*%#GS<3@6_L+Y)U,NWKS%HN]K/7_O+\<O75O
M:IVU? 4%D@ L4Z!II*!!2-8>ZB\D#8FV9R]_4=VL0R\Q7\;P=>5*7" S(AJ.
M+QO)8@<+%1@.L&RT.,-%JB0Y$8(WHK%,,9 3-J6H</.$ORS)RH?P9_GOF\Z?
MD/Y,VS5'U!EQ\]FT/M[4:;$!IF5&=0+O:7HVA8DW/1A$^*FEG21S*UXXDCA+
MZSF$.EE)!EUW6+^Z+A1-(@C.SI73 >]0 S<QQ)P*<I[<MB#IDT[J)PB;)6MF
M2?NWK1CN@ V2%WS.%V?X H0>./+L?GO 9'A$1L\F.-I3R-U;1"0C4./VYA^
M=6]=1]SO1:;;;U;V]VMDMHTIWQ(OKYL$ (2;BW ;NK=U.]%*4B]PY%'$-L$
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MW5[4)?T<-[ZA<_X)E=5;8JG#E_^A3/XR^.?!26>;'=$B_WFB+A?'!\^!X@"
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M,&9U'F@T+J2Z!AE8U8\@FLVB(;!J*]/[LJ>$@@DDOF#9D@Z%T'P@ >V&)9"
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M+*1KT9%]?M):3X^%$IM0(4?0:Z-9#W#5_-/:2^*/R'E/?UW4@_6MN*G8JW6
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MH+"@Z74-E73H#:V'.K)\?8G792\NPDD-,S/EE<?UF)'' Q$BH3C(\Z33@*P
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MPI_5NS>X6B'HU4U,>5K'$7"UKP:-K8_VDZLA9/&K(HX5T[<.QZXDG'BQWSO
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M[;5ZO7_Q__Z[V_\4L[?E_P502P,$%     @ >()<5D[.Q5KF$ $ 5&,! !(
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MMK4C&$4F %P'P $PU#]; !- #P !( 'N -<S%3S7G](_S"A D2Z_>41@[>X
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M+3#T4UAKF+N+#>)/\Q*,!/YP\[28?RDDP)\J#J#PLS*_NZ'[L_#.AG ! 74
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M#N^.BYI6&GSOSC5UR1MR4N[FK>(4.W1.J@ :C%0H@^YBN?=CYH6+2L=0%##
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M206VBB$/0Z*BXJ-CN,2&P0\(1Q9H5FKFBJ++S&_,K,>D\V)LD&O:.3DUX.?
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M<* _\:D"4?!&/WSN8>[TQ)RALO95#&=X?5B@G;=_(L<3X9L77IKYAA6<  0
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M9,6*LEO^!FN,52@;&',[LU9B%OG8U*W&W/1AVG"7HWB^WSW*%LN=+[[?;L#
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MC@L\.XN**;[T1"$#U6K#B[0K4P<QO+;:Q=LZHZ=:,8^(7Q(<X##S4-\T@ A
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M-)S;HAT$73,Y=X371<3*;;_PYAT;RILRFM<.A](-;AZ-$RPZ%"#'SA^VECF
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M!79TIX%^0,'TI*31?=<P$7@J^+K1$5>-V>]_4'I>'??E1(RE=3%_;CGQ<8]
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M%RK".(9?)&E4Z;@%E=_+0,WL+"GJB6A[*SX1H/D#5<.*8'^YO)^SL/?-S$I
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M)!MYKK8^/4;J"W0I4A2E0Z9F'YLN50.I<+FJGB,2P%<BU-8Z0%-R)EI'1Z?
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MZ:G/O),UW\_SS\:YF^^=PRVSJ[&[W(X1&N5GG=38?W> C(+Z>+\85)S;BA?
M^B,6RB/EC^(HI.4H9XC9&V;9V838032_ZE*9MM.HJV/=Z4YRPIU/Q%2AXNBO
MZ5]I;),S98HC>M6@FZW<[Q6<3<N@;F8L.([A%REK9&)2C@O-$\BCA?\A<T60
M(?%N)]EOBDI)V;&[7$@UZ_PB&@,Z0AAFJ]QCU%:R/K4ANV'OF?RG/03_2X=
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M8YX7/P!V_' HL;$08#[#?'=]/@.U+!H:,CP?O94!SRI8MJ2+<V4@MG8M\@6
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M7#-EX)!J(OS@N'30BOY&I02*55H3]!Z?-N@H]<!4J\5E=<;#M8=M6^_2,;A
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MXL\:%29C(!S#B!X6[NQEUG75U%-SU\V]FFM4F):93L!Q-&#O=FX\'>$A*&9
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M>G]8S#R*HR3;J3Z3+M,C&RL?K,H1UKA1<%S)/%9VD-U> Z*?=2O50?R4L<&
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M$PTTT0$3K$/UN.RB-&J3]7($.+9U#:\6*=;ORN&H7A?0A0,(#L;]M:/C:;?
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M(JC)T\I$3 9\T5_E3G*3,US3D94MVV=H086M\O>D*2\V^\SNS@JMI"5DAI!
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MR$B^2+X <+))3:_K"$5 /1RA,$8A7GY 7%%#"Q45.&W4R$WVIK^3@!4MDCF
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M?I<F%CLF^R)DG"ZU*F$BFW]F3_30?:QJ;KQL/+;JFJ:JE>"X)/DA5$A40[U
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ML%?REB4W&T&;0UM$?E&FQ$)ON ("0/A064;W^=)NKG&DBIS-#6N"> 4SJ8G
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M,B)LM)\%&GC3T_IUPC'I-3T5,S]OQL=Z>'/VQ"#CS0+H4W*WCCP8QAZ#QD\
MK -9+CV3B%LWYX?O,1?0RO>Q@"H*"D,GP]@CI@8%[!12MR7R>V<.;<24!:[6
ML(J[Q05T!4\$)V'H$LX-(*,,,4K+R[O,UUTC5""O85R"RZ\/$:6BSRXV[;G?
MR\1DC/,AY(9V\RN0=X;P%'W]92%642(MF+V.A!^ *I+#6YZ3]O)5'<"&)Q8L
M?N!2@C3ZYBF1^>SFZE5GSB1:7$.$M+#S)5<Z,O*N!G\/]*YC.WM(.ENB5R?)
MQSO,:9C6,TD<D9M=CPHR0C?P8]RDCS@B@Q-L>A3#VY2U->08&Y-4K#0S)T,)
M%_JH]_I)$C41']%F)</Q;?8\_0U5M%5D)>-R.\+QK[_?6U,V6DRDAP/['@A/
M/0I& !^@QM"%X?<Y,S_]5V_VN!,'IWAK4SM]\#_(X>.MZAICT_Y22[W)51;:
M&48T,?"&\QU_#;.W'8]_T7!IZ/C3:VGTTRR"2=PW.WD24@+[9SY<5AW$DK%5
MUN[@HG\[*JC@)16[)!R-H^U%NRN&'>-8;X61U*Q>O63-3,OG@,](5"@1!\GU
M-ZB@%SA4+&V7'W=QPG7 BQ4M*,^U5K6BO,58:4DBDN4VZMGX->9=0>VEY/ E
M[:@%'@)FXM+''-02 ?A+F14Q*\CM[GCI[1RE$,FB&QZX=_WN([GM]V.8JUM2
MS<08=[Y=[08[N7GSO%[)GM!$P9\HIJ[&;'5R*J*1%JQ"'Q*>R'I0.DV[Z<$G
M3$?3?<V:ZC0H/V)2KO(\MV'Z]EL]Z7N.AR;&'B])!.(BY:=]!O3\;\I IHCP
MJ>5;2D4JX4VW:TR?I]Q&1*D%A_"QC&<12Q?6(6]O'Z<XO:]2:L[E+X#4%KP4
MS:%B$T&(9T):"EUL'CNE^U(9H; 5^,<-520C$I0_[I=-1]<K?K)Z/;B9'4(E
MX"M:1AW]8/S.P_"'K3 G4"LXO^CF/$>ZT^6ER )*MIM+)5/1/0YJF$XPI^FQ
M%X^H@H->+@^]N[D?9/XD\]LEK^SCM;(38-(]**PN=F$== ),TY@<1V[O#*ZU
M7V?X(%$I-AO ,%(41%RO\VU_/&BSYD6+SO\+U-IF_P6UD9:-R>HJH8FP@Z32
MC0P4H8D!_L.%J/M#8:JE^I4/D^TGM 6Y>ZEE68?B,]7O.QF2:94PIU*5\=Y;
MDLVM<[-P%L6@&+]L?J-'M1R],++@P:! C1OSZRXS#KN\(SL:&C%S\ZE,G')&
M&F(*LS)98IAE64DV00N'>Y&3TYJ_TW;K8PL-G-PU&O)UND'U^>.56W7+@IOX
MS(=E,X$WYD6LE?[-AV!G!"'2+--C3SPBW_6JIE=5?8./FQ>O7G;O8YFPIKTG
M]JE:U"*CQYY2UO9A9FE(K1$(U9,'4CS[FE1/U\B*WU+2\HZA1LLRP:[J\63E
M*+?[;I@=GP+]UM'PM;>S(DZH=,N+Z^ZNGQEB10I'",K4LMVY)<>Z7>BB#N_6
ME..E;IIJ=-=CVMVR$M\]<)Z*N!LP3,:<6%4\H&^$@KQEWG&_6Y"GX2%:0B2]
M0+)V:'H'BWQ/!8DMD@3.'@J+'TW40[$:;G?4J"68ZT.Q44:>$F,%^W=:R12?
MHC:[/V'*'0R+,7Q^-R%'%LO7\R6]<'_\H5Q$^U1V<.()8#GDIO&Y_^/T!X/%
M;X['(T<&:^6*!*(M-'""$P"9X-A;JV,G*6 W$&OQP^WCD5A?HR^0YR]:K=VL
M7RJ< ,^*O+^[I0IT&!KZ@Z2PY@3H^];_J< Z[4!$-H.;;X=B,N4#8=!ZD9O<
MWHN*0,Z4Y0 M"Y9R_$F]KU>L]HQ=9#(/HUM>MYR>+]C4"-&+T4A.^RM?8L[I
M):)AY)N.W+N<I5M"!.X*^RJJD_+N2P0P[V>%-_5A[B5.EEEB7_MX-CA9=6N2
M;:N>:\QTD@525F65<4/[<SB_/Y*AL='_O@R:'-SB[$/ZKEU6)E)@*2XK2LW3
M8DWDN*]"JCM!)#S(B-7G$4&:C\0? ;CHJ@,)$ R2!YNZZHZ\[G@ \35U .#5
M8&<$>A+CYI\K@2'PC,<%EZVKG.C[1)R_D*5MJ8?4IH".;NM%U;2BC7%\?E+&
MD391XVR4 #/"Y*2=A4<,->;,&+C--?!">%Z> -E00HK4D0'D]O14I"0,54G3
M[CQ49#K*F=UT<Z7T.:]X_UUK?WKE,EY]$9E&KTF#KB:$%_=0>&9TO-;@4!HG
MZQ/5%<<Y_>(U\7W#0*^U._>X!.DZDP@Y,B\]P^_O=5^H@[K<\"7:5^RBTY(>
MX7]#^K 5?4OF&:^[2_9UE#LU+M?49[F-'9%1>D3 2311,1R2JY(>JY+^,J3Z
M#VBEDA[!\?8JM"HO#\@\D59(F; ;$S$CZQ2/BW2/W*D\]$ZPK7N?QQ>BO1?8
M4^"L3/B!K1?0(WMEE)3 X_8<.Q@:F*.8W0HH*0"$[^F9=//=D9-0E5$4Z -$
M"+J4#=_.N UZ]Y,H^=9KO5/6PEO>% L@$A;+J)C>5_ZCZ"4]VSS+: \#AHX*
MD<>_,=M5T%W17*U&1WAJ(7Y$/7Y8&9W%3QT2=I7U[)]730W=,A8S?%RNL.AW
M!RW#PKGK$Q?ZFS%QQ,8J6\9(UMIKGV6T_N1H:_M#9(]1'KX=-!=WYQOI=5AK
M3E8L";EPBLXY=UI!B:=I<[E]%> 6K]F,.%H1ZL:[55Y=7O[/9*.R+SWAP[I+
MM?+5ZUU&.,31D+QREZJX]@FQ1&C-H:KO%!>.V6NAJBC*I4>L=YNIL2_!I72?
MO1(^RLE237T%DPJSIZ%C\2NA0=M.I+&?6H9(3'OL^^"!Y2);.!\E7.9PC[QA
M9MK[YL!Y6?Z]*.'F1[&VK'$;%)_Q:!O>6K&RC>UR8[-6$WH9++&GB[FIDAUE
MWHCYLHT[;$MYY'W>5J+>#K6QD3%144%T+C/MH;ZHQVP<]?&QB4N+4XV^!'-<
M,Y39-!E+-&;Y(T</^\/&%N4X']RM&$RW,:4+9)#A7*-AU>N^RKW-5S\U8D,F
M[/8(!B"/.=\GF3!_>PWS'2_/C-6]N#H,HE%+.=EL J02W87[>UOO+:-#MX>A
MBBO:+,^_-ETV3H>\^O;$S_T$:'<3^A930_[,?^P$V.JH**K>?6'Z-7EIV"CA
MWUS;?Q#S;!PP(KP;M^5%-M=S:%_1CF;3=UH-UHJ!&WQC>?V-T!S[WLR8"=Q+
M6JI<OEV>.K)!9S%*6A<3ITVOS]D1>L\G;"TQ"0;RO40VHZY59_O)Y?VE@M"2
MZ*=^41,#M%A08BAD,P7WRRA)M92&=;DX6,2>#DU$>6^T0]U,]Q*/"VNDVK85
M.W_(J+"S>BESMX%K8YG73DUN?YQBY\O;6J#7#US0_"( 2D >Y6OE"IT\2EB#
M)WT U\N)]Z/!RKHQ$HCD]3=^@NA/X@LFM2H>1R>(X3=#9OD6AY'N[[(7O#X\
MB.&B\-P(<8V'@#)MG*W(90E9>582N*,DC7PZGW1AL?5_%.FFP=WI)JFIGZIF
MJ:!IU#->MBSK(K--3-)<1"%T^!!J ;(#Q4C);( G&&#7YOH6>M^,M]G1!%1\
MF$\%DUDQW(YX(H!]18..JG"-<N*.LDHONCX612>1R\07PL8IY8 W=?Q8%;QU
ML6)R^')Q$D^\T$I&W)K>^&^^'GT3ZX TN3[L/1BQ(3M2:.YT>EKTY>EFQPE
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MR1<^)82? .\:*[^]P/B$?7-#LPTX 4I((.Z?X/TGP)/W'2W">1:?B$I12CZ
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M-SR V)@9&AI/ 0*"XU^*CE<-W],@D*6)0V @4$RAQT,0C4,K#1Z5_SE_J=(
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MD3K(PLRSJ7$,U(S.O8>XXXYO*VNAM_A0 YA,*D V!^#:/CJ'VH01@[LV/4-
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MIEC6+2I@7B4JL.NU2Y!>ER9#EZM2)MND DI)8%43"P'*  3::*W5_^U,/P1
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M3S$\IMV0P-B#GO6^=1@O=>KA&KZ:S/)/<K9(9+AG^5/"JEC; :D;1CH1!&R
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M#OS^X3S&S/@1ITKW<-L$"CL^6(03%#[*YWVA6#,T,-1$67U@"D*#O[Z>R.P
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MUD&VR'6\$0=VGQ]F33Y.,=*7$='0Z/8R13MNK A_>BEN'A'H(Q:=HFQRSNT
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M$>D["U-.KB$SW8"DBIAN!5IOG3@=.JF04E%\DE;>SDO0<2!SZR*;SHI<0NM
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M<%Q:-=-F@O0!RE5$BM,+SIF@ KL\&:RJGK=[8$*!\D,. 3M@#\D,FED8G6%
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M*M/RQ6A%,92_5ZXAX@/, X8QY:YD5'\\]SK.0.U" PQ1W2^COM16G(C_6E,
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M4*H DYVAYK'C H2ST:JGCRE70X>6)(A;M@@:UOX$?B1N+1#*'_9=>ZRZTCQ
M&&THNK'+Y\K).LXKFKO+?%US:X]B' @;^]<;2E_';+GABN-*G^ ]@3;S'/L
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M4$'"5QSZH  U:6%6(("JQ HFYYAB2.:A)N[@8R!<A83;OGCU*=>%;M9KU7?
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M<4%!P:KXHH\ACKS#%@N&I/KY7JEB@$31,?I7_?>16W51$)"]IBZ;KN\CNAI
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MU,<R&^L6?PBW7NM-/:S9+N[&^'VFSVCK!+V>4VLQX8\OI&N^V6C.%$.L,I9
M:6=1>;'+@&F3=:!XQ@DT8P+Y)O1LN%[UO3FY2 IO:K/MBT[6!'XSA=M5_%4[
MCU-A9\):?Q'A,0F8B6DF.=;%N+Y5,3GVRVAA?(<M\^8UU5M0G,.=#-DZ[ZE1
M657R#;=G)(O0N\B(*$-G1"939G]NE\F$0PX8XP/#'@/UWX!\P4$[(.3@C3-B
MWX-D2FD(<9U7>WS5/-5T1QS&;)!7HYV<AOJS'K+<JD^M_XG,O4%;=HFNR!>A
M]JU)R:.RC9AN80LHV./]K"&,%D*Y:MP%MF?I=1U[S0W%^F,R;2E6!<:0T37+
M-2LQ=<T0%U-EME@^^90A&R<ZJW0#2CIZLBV(E8FEK3P[9 ^+4)I*#/[4_>CX
M GG-S^(W0(H4@8B]=K6;P* >?6G6$+\O)R,RM-U"=?EZ5D2>-$Y51G)_)SPU
M_8<F1QJ[2<Z%KMQ35M=B\I'K>NLRB5IRIZ:.MI3^X4ABOZR?A+AW0,-*M#%U
M%F_;SO>E+!LX:>S'0PIJCZV%(36;/6,+/18\GDR#6$\T\1GPCY^.[%10@]EX
M8TY:=3Q0[BE@<*(6X;Y+K:3>BO?S!+6-YB4VCX]QL*JJU89.3#4.8<2ZQ#";
M[;U>_03-J^LS5;K"\5&N6=]6*D+KVS*;+GAV>[?Y$)V].:5M?H4GL,'"Z*-Y
MZQ=3?H@G-:[F;*?3C\[,9!+I%L;2N\RU"G61UV.EB3WCN"!FW)][2V[7C!?-
ML6I:4D-X&D3KI-@QE!_JIKH:)[Q>C\$+*[VOIQ]<<+[-UZY-):<0#55S.7;=
M/RC(4V4^DA"]=X1"X8Y]ZOSQBH9*/C4R"34)?!SGAD9LB@E8J5Y^=/QF5K,#
M1?W\@<WY.X/7^#N)]- 9KY\:[Z3;/QT&!1V*ZTM/A-6>3W19GI;%#QV*1T-/
MCYHI)(A,<""I1$PK$PMK;WX"2,/>K,+8O(#P+GE=UVS<SAH^UZE-F9BX.*D9
M+7'"]17=L?%0AX*&#XQ!164F0"+?7?9:9)>NE2T?85ZTW(BFZF:^:XZUM9,7
M297I_1_?S@TRJQ4LRC>9 +4\)SF=/!](&I[0?/5/$CNR'_+_,3CS_W[_[<!?
M;)H[[@U/L.>Z2P)5X O:,*<[FN_-Q8Q^/8^%JQOR#I_53$T"DK+&9<EO +Y-
M[C\[]MLUU9[553F6W]YD+LHK_L-;9H"-@VT%5[ [CPA;X=AMNLUH(QY&B?=>
M<2:=0A$%08DM*@G 02SVJ2@%DW/DBOU)X79O\BTDLC#'I ,OQ_O#-#6UJ4BY
M$H!M3DZ-%24//[_ 99*:!3X#'[8?&JH7%I83'6FG=6><4/^'1U#\2D1+^\5@
MB5SOFJBVM'11[RS6+.3"FA?*I&]V>*+2",6%7C/]P_0D?^^[=P_^RD^4+1V1
M06D"81=AC<RL'[ADAU7:9+3Y$_$.C3'K(*#& ,IC0Q^<BK.H@$]!W-^H[+3P
MA"<OHC.#DBTFD A;1,AA992QKEH=PAAK!QS/;7D2C)3%)>6).=BDI3W;:?-M
M66_PCV-!/-$V[!B!MO;LH!\7,;\!!4)!G0[XU<-TU",%I8,?.-F;<[&<#6VV
M*(\]0GG(_2[--5JO>69L(NZK$1'.AE8KD \J@S# ?9UC#=8%9$_K_NWVL/F+
M]?R^-(GAR1@6Y!B([RM*% #7^81=FK%&JA[M,3K5!=NR[I\;?^&ZY=HXICM&
MBPY2%J1H%J4.6;U7%LK[(DTD%Y<BRR+=_M!*N'_<?+W5H=>S&@?EC5/K<>GQ
M"]W)RNG=7FD@I8'ZFE&TZC %1&*$B.*'43B/?X=G0(WG)AJ%A&R;'7*WQ&MC
MIB8R#L'W-^-S9S;GTCFXA2:J(D87_0_0^R(=Q?+VJ;$F*A(?-X8O6*RW0/O?
M"MFJ5-%21PI> RCEA9_,1AI$<]?UA>@IM(':R"WVMG;&A#>TI\P);>T/ZYN3
MZ=K FI6 #MV-'/9XM[.#3SI/NHF[FL#*=(S$C-3 C+0TCS4R.B3^^/0$GFF5
M>UEH(,3TV"!<':$34<S-"< 90]8BXGO[8X35MG'W\XE75?MZZ*(:%[^8Q/#B
M(F<=%P3AW?J8:3374<AA:"VFKIUW@G'#Q!=V<^1QQY3W/WN]^[GNPC/-'3TQ
M; 9#6BM-5(\1G8-6-5=5$CIEY%*UQFUP[I8QQ&+0*1/(8R[RJK(?WYLV($*1
M2#':Z&Z[;:+ .K?R6*W,V?HM'[3F\*"21JA)JLGS8W:XSDDJZ'"8%;6PAN))
M=G1UI8'(H-F1-WZXDG2JQ=EQN06LM^.'SI T*\*6MWA3P"=X!!9A8-"5MKN4
MR^ 9@,'A5@,R6[(G$)T.G\>NJ^2;5.HGRQ]S*:?CO?J]FE;>F>"V#Y55LNM2
MR(X3ZRD)L.^+YGRTN);WQ& W&I[EY)1S#MV;H(LO1S  Q._@B5'A,*,-W#ZT
M7LRU&I0F#C 1GBV9&2,ZV_7_JH,\!G?VW2)HH (W!?V\CGL!9B6H@KVX??E3
M,/$PK72+97]<K,05S[X+<3LO\HFN^D8,NKW%+8?523Y_>!ZH.(>=]7"^R56<
M%?;BJ[ 2/49;%)QOVY3\F>?K2$^,Z1\W2 QWCM9V5>6_5=LV4TOZ"]))>7!U
M_GJ247SJT]M=]3EAYDER/**=E(6YXC-E[F5<,I:+H*&!>HZDT!HI'<T_//RQ
M7^H%5>5G7P*\RPZ=?R;<YT<T>(&':TD(R2%H23+*B!IC#(:T1>A:*2)T=UC@
M,@##6$*RFR(64$%,(1U3\9C<1B6ZL1LR5;?E32*-NV6CB]R*'.78?LU/+"^-
MNC2;,9)VX*-F:^XIS1J<9I3X"SL.\)<IJ66<+%4@^)3]%98__L<O0]2,$Y.Q
M/+.B^\-]J14!QO*W*K/H&K[!P(M 21:I.ABN'3+A20:ZMP S)Z:J-MJ(I*BN
M*_J,!3?C\GRB":9(>HI%7*DAS4BFW@?D^#-\U 2M4I?!<DO.UJ^QO&GE9R0P
M[1X9R]LO>)Q7?KZB+@$# AY.^#]UOW-]:-@0E=,=JZV4R7$;W]P>>#^5'F="
MM5V2,.4,CK7<1*Y*PT.>R70WJ5 ^;[H77\IVP!,;Q5#!9!5K9SR!,W(X:$YY
M,S4UQ&R N&S.S-EA=RS/ !G,-GI27#*JMN@.-1SW?@/HY7>?"#.LRYS2=V@^
M*JXT1WJXITU2T.:<*'M45=LOM)[Q5YVT7SE14KXB$_\&R $_OQN^]6)&^*[K
MDHD7)HFW%RV$;ZJR=.4J;B,\;#:BCQC];9(Y$O+N>ES]>@Q&R[S6UOPO"%O!
MB"@!:@BK 8<,8 YM1K?'SZ,[X:'4.? XKI-(4 <=3V&+O, [$NN]8PI$34Q/
MY4Z EB2(0%ZT/4;APA+;T_Q>3I_3.V814Q0H,9+TV5DT2G0"9=MOV9^KUX=]
MP"%X4ZB?9G:!S_SLXO9G4IZ1'UJ8,0TBG>5)9>S'.FYY55".MM2YI&18^N9)
MI#IKYAKFI0:G0 \EQK2&>+DK_$R$G(0GS4RB$4?19O]$* 4R0_<]$W#UDJ &
MO^![^/,DM?XHS#Y-?<)X]9+OEF@T>KL$$2Y+*R944QB%W39XA?/EV8K^G&43
M#Z.R:.LNTDN+*KSMZQ0: " KWP<X%FFES%C!K]Q*VUTE)T#QBS:U$>OCNDQ;
M^W[78*JR;[<X)S'W$0D> X/%'S'6B772!'^8Y6&_NVSMV\$X3XLCE,T&/<">
MC;<F!*5]O>OR3FI %C;6LM"_J:55@&B"K5D,0??IN"C+(/[>33V!G[K_T"+&
M=F:06^9,*YA*:<[,4U27:Z'"13'RD\"':E0E;<U0"8[.(*[8Z<>^274QXA!B
MW9KB,I=!#.(!*5CDA#*^$3Y@E6V5LS'>\@_<_=7F^45Y>$J6,DA&<Q180A2H
MP#*]9AK/71?3%LVV&<#88=]%PWV[4HI0"Z/GQ8W:)=+?&#*\3+%"D@<6W*[6
M^U*M[9/'HVMVQO_ZDQ^GNI>]J'X06G[/QWB)2V7:0 :(/-J'PWTGTA"/03X(
M[-:;E<S_E$Y)T'X]TVV,/LAY^QM UPZR?XEQSO+DB%D^>=TR_@$U9_6##']_
M#7']O.']_=+LT&=Y;\+.(X@PF&\R7()$(G,OC(DOF!KJX!CUZ\+4U,N(0ON%
MEN$LXE\V1R_NQ=7F9?EY>M"5V*^C(QDD>@SW:+W]+RV,K[8G\#? U*<T\^L#
M]&OC/<^OT1>E?TZP^F-ZVB4<<7[!NAS_!KB> \I;48$.UY<P]2LD\?62(W,W
MROD9]V&SL+ZSCX]QBF$Y;<\;OLMODMTO/S149SB\?"M"B\])AV_**VC^:?/_
M9<-$ X//,2N,D'O1PQWWRJV*;C_/C>[=W67]#A;=&4'ML*MT2I<UBXV$!4Q'
M"=S>=W?6-BX]S7BRV[R:'&23]\\C; [6TD)6#71P,6,\BC;"8'EW<S:: M])
MU%6(@"99T!/3:ME4C[D&LC,"0UT>>4<E^-HRM#BI:DU+,,W-6[59D"VI3\=S
MA<F;7V.RR=(XGE%$E!J'NZ()">C,V1>D$VOMU%;\]-6R<EV)7JW@#\89?_*,
MSH1',_EZ8E1L(%+EJDU?'AC)X;:7'Y$^?_5,5,02(2=IE^,_RL;'-2\-5=7I
MU7WAJV5VJE:[(" X]WWGQU(!I21+>'.EY3#*K GZ!.4!UUA^ !3-9 9'.R4_
M(E4OC"M'P#C#1A(W?#D@_-2H=)OGI,;-ZR@_$VJ&J=[[VOE;9?%5?<9FF!G-
MLO0WE!E4#2A$)PF@_UD:[Z'X!,@N!:8Q.=S#[6KRZ>.KA7UK/F2,H*,Q'IS4
MM-$ROM<_2 [5V]2+;N<H28&J*]*ZZ-@ZFUS3;#_C8?X]5/D@J[ZOL?\!A,SC
M%-!QX['Z 5SG7(]1SZ9X2;!IV61%3'-7/K/!*<Y" 0O^^"[7W6=;4E&%]X8U
M4-=OX9'B&8#.5Y5]/P=.M)68E&=H$$(.E^6/3=%HEE[K?L;C&0R568Y*Q8HG
M?/HHB6^[%I6^7>1IJ5UB&ZU>=<TSTI"*?4NS>6Q[N#SI5%)4."=^6 >QM6IH
MH) A1U)I<"F3$(>=854100XZB.9<;G[</!A(Y[K");E1)ZY?I<%2M#ZU- GU
MBYES"9F7N1J)UUV.,/6PXBL8MT0%HE9XFU.A1\=JF<G!;<H)(Z1Q0,=I (Z/
M+X]K#,FWW4P39^3]A [;X=?7=*%2?(51+<)&E!O?""5:)W24-L83R)T<C N)
M#=AC4<6Q;3$OR*YQ9V)8P\3ZYNN92*:_EJ:-P=4[6ZH0LR/D-$L,01EVO]48
M.=IN)!A52[+[3$5VP&2]H3 QG@*R7KLNEM 7 1RT#RXW-G=W5>BS9K:ANH'/
MY>?V7W_8OR;)RR\*Q>R(_<M&!&/6%0J5F&_36_+@>SEJ[*7@(U!GXUHPYW+1
MU^G+P0^!PQSU'GV_FF#.O5[>UN7YP)_X*U-<-].;]0<KXX/.W^/N3R["2*HE
MF3\C S(5<JI#>+N_Y,9X#UW%NQ.CA':)>." ?OP*\2YW/OSU<"NV\_"*<UWL
MD[OM]R[SUY=/78LSB6\S?5A?9DXUVM/OOWA^IW!X^8GTK"+X^48(5G/I!%"T
M9KF9,LYF_S4E)S@I0D(O78$I?\5OS'QTM(4VFTS)7*9<$K'0#(LN7T%NY*.<
M$9J JH2':>11T=UHK_1L5T>!_P1U73\K3(AQFA\5!=;W&%T<&CQ-+O4A2ME]
M)K)5F?[3:3%_^PUN:([[-2^(]:C$=VW4U$A(0K!7@3,"E1:^^\3P* WL-DNQ
MJ3Y(C;*0PH3&..(]!7F54UT04391YS%W+='F6C/!R6!TC]=/217K#&OM[_D^
MCAK*?5HP0/Y5:TV:B*JMT::OO20*J A\VR^.XB3Z'$HBGT!^2ZJY0^VLH+[&
M*#4>B7/@UZ^3$6&^"-+Q0SA:E4>,NW#P7=\>\*E,UE$"[JO*CIG7<K1UJYVQ
M\^(PO^:DJ'/V376 AIY-87%3[F!Y\@XET@^E6 M]$ZUUZZ_-"S%3;*BT)-C<
M4?(:.VK0,P[CQ-MMBPSZ _H*CF0DJH L;E3PS)%;F0]D[N'89ZY*4N;1/,&X
MJ]S0!PD43U/+/:RKW1\UQ+E(51@Y177'*/&H.$)E9L'QZ+.@K<1P7$!.$3@>
M$X]Y?8@[F?7]%^_DYNY#')YJ9%A=[(S04%Y3::QW")A)QX(9\%^)!N^.2DYC
MYLZ[7K*=-9%%NK4O;)OX-CEF^#LX-+LUZM,*$#SU*M7L5;>$!06N[&6 Y]HK
MB_122Y@>PV9YP/QA><W"R;[D/A+:3GLXV\Q9ORG8C0\: 92R)* ,\7!>='"S
M^M'T!9P: TZ\[&<5(NI0RRU@PBC32MVVLRX/1HW72,9E4T!6K>WW)Y\*<)MU
MU%=YF_-?%.')JC*U"89$62"Y!/E\?\IK.9B5*L_? +AY^QM[^#N U%N@1QS=
M@* [L$DW?94QY3T*OJKA^R@M1FF^HA4N!WEC!S!<5;7$!-TP_OQ$,S&/KVE?
M"L7Z;1"O>7U<D1F)+F;@ZF0,1\%+:DU.&?Y0>'8T 5(KB(4/XK7%3G&$@&QC
MH_<>A:-Q?])I.VEKN@V&##EFA#]\%!7YLAO-C2T(.E;[U9I&.3)0#QWN:&8'
MEZVS:ZBOHUO.CJ;_F@O!50Z"BA3DG"8&$.-8R/2_* W3 .7N+F2J4-[C<6W9
MA6&9WW[0IQ3TZZE4$>]\BHIJFR(J?IO&PV,$39 ;'S@RH420F^&3H(IX\D%>
M"!JW/HUS63F(]S?!JLD7G$H3*&4E.)X)/,+-7U2.@_I@#^&-L%O+1>D.Q)ZX
M.9AIK,:@>;0I+6NGAW<#&1R<4XG\44)J'@R06COM(4'0IJCL<P05=!\\MES+
M->?DWUF2<8S@HS'5.D>G9_?/<IG*YYW56'Y\Z7S]H3;'M6O6Z0S:XL([2*X'
M+3I>&I!SM=5U>SW>/=ZK_F,?ROXQ"I_^!TL@_QL@]%7_W&+LY\EN1,_)-_HM
MN1>ASA\8_YB6LMP/S[F!]-$.6-RD; *^UH]W5Z7N*"X'WG<GUW_</,0-ZG-_
M&/T3DZ3Y]F?M4/2?N;)IHQ3<F@8@+<'\@@IU^*4G%";!6Z52RT7;SN[KJ+#5
M-%6%HTJHVDKUX=3L=C=0,7NCO!%22E071?0K(LI6AXQN2E*RTN.]FZL;:=WJ
MD^#V!U4)8@OM)X('@D.[\_;8VFKMR YRS5))4\4*BIQ "FH>.0# 95HT0%7N
MD!N_G 8,-<\-C,0N@0'8ZQ/9M,@>@CM"ZD&$6X9-W=U==,XY+7M,ISN %%L-
MN\$CO?:QK%,^T\,\0_D-/$L"T/LM&G@6#+=S]+=07F,CJ1/R.IN2FKWIK8R3
M146UF7 FA(3JW<E"^2N'[L_Q:H7CY7UR-/[X)>2Q+U$6<@9\XLH)YM/Q#M 5
MKBKBRK3TQ<B+3UZ_NJ0?-S8@D:*(ID/!<];RAW5!L\JWG-7>4%2J=KUP:9OR
M&1\]P9(T900C3%H8- 5[9#4=^#TK7_JP^^R,VL3P62(37$EM=>Y.J=:0_1:5
MW%'?;Z%O42!][K =DR@C%@*W:4G@O,12E(,/N;.&_=YN?_Y<OCI6":)Q7&[4
MQKB[RI08X2"/C'([A%T@>Y=VPNJ/X'%.ZTP@GJ*H4'^>+:[&L\@3S03T_0U
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MR>$\N@S^-1NT +)2-!07$C^!SB^S%$!Z\GBS;CN?,"CG8E. 0TK62F)>_"9
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MSHR89 @VH]YPJ)V1@-TZ (I#A\/:'P-^:DZNB$(J_Q/-IZ0B<N$B0%6AK0W
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M@>Q@80^W:<8RH_-;F7P&T)O!J$@AS",CJ1$OA,P)2"NH6M^U*R10"'GWCPM
MQ6IKFV/BTSW?+DD+F5TU^))@E%54](33!&\*SVSRA$MV(T#/"WLU7$6_GX:0
ME'J__/##1F(%O/(Y9>)?VXQ_NX+IUL,'5PKV/\^WUO[R0Q:E7*LGC8Q^[OK#
MW'_O0[[];3=:Z9=K#KL\]S72<XL>P:_R 1VM5Z5]<:=@750OG 6?+PA5$U?7
MN,A.;]#TM+!(%!#0(OC(6 JHQ-&62]<FQ3R4/BP:[#Q^ BV[5;_G05<^/G_4
M^C8\(TJ60L#@8JXNZ[!88U$I9M_#+R9"(!>;6]DYN+_2DV"N:_"G[E# FHPF
M=B?#",]01=I:/"8,:R[KVA"\!:ZEPK%,G9&R3RZ.C5,G9$G@<WT1]=%]Z-Q#
M>/AKH<GGBZ_31VLUB*\,='(^+',2)?:OKS]L!_\HW?,<4956K)DN*\ISR'[.
M(CB2]IIP^P=O$Q5.H."+M F!A1Y>H>'N$WQ[U54VA-#$/"RRO:#R2\+J@E.=
ML)2[:,43( 1L%!JMA@!G]NZ6T"RKR3'"QPCH1 ??,MA4FY,>4]X2JPHDT 2E
MJA0]U"@[5)2C]Y^VMV]]5"5_(5\90^03%M@L[2K=Y'WW>THQA6TV9>?:=A5O
MLHG7G6B,[F@JX>BOY0_!D<%OH,GM4#EEH9, FU*+)0+.]\(,)/X>D;/XVP67
M7E78SU%(85O\ ZP:<,*VN9)W1^) BQ$1FR#1N^=<1?O[X.+!TK=_;YGZ(;Q9
M54Y80/_K$5_##(\17N '%74=UO3Q/CU>)&F)&>T;HW"[ X'>S:N+/.7D5!9(
MKU'I6)+*9KYNCD!ACM/H+H9QL]/6TF*Q5_=2!DB*)'$D@C\_ :1<FZPZG')
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M4]ZXY(ZS_8K=V?.[4<,&PP-DMK:^[B:2U14(J1&5HB">I'&AG$\$UXQ^=0U
MX8@,I,0$X@&%9T5FY4UDF'(B4A4\D?HK,%@S;$6J^=:WM0+)R$]$CL=:F#L
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MFT!PG03[<%$3@Z>6&@/+">.X E:YM?F=.5/I$:'T]YV#QECX7*GP']/3A4M
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MNRI%1>.HH(GNCRB8?O/'Z?),/3[1M@2=Z"1ZYC->?-*(Z2N):25;A[QXO]:
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M@-R W(#<@-R W(#<@-R W(#<@-R W(#<@-R W(#<@-R W(#<@-R W(#<@-R
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M_^Z'YMQK9,2DX+'B_\$Y_]\$E;J#<<K: ]'"\5*,D7RQC]V[LY=V+SHGW@)
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M58N&F\$X4;8A7JOPPMP5D10<F,+&VX#LJ"\>6W<+N]+,?K!QZ"[@SE 7G8C
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M+#"JFI 5M8LRT%0UG_H5*OOCR;30^L<IA'7@3EMKNDT"[Q>J_?U>-R*:;!X
MUH22B8M;D;.CX4JX%IEL*+@_;87=GF6[C8U,9@=_UPH;<GQ%- 1/%NZEGH?H
M=<$L^28W##F?M$UG?!Y_F)2@"[QK>/1JF[UI 2#-2X[?=OD:NEY20(':WG 5
M)G$YEU\EFFOD\W?N=JWUL?5+(^H7NL5A\M)C,2E<%$N)CD.K8-Q?[+2V,_W7
M7*]5_"*X^QJ _6/U[FS94IE34YV%.<&JA/]B"Z70J<$Q2Y8!;OB=%W8.G0HA
M')BR9$(M'>+WPN8PHX6J]88F7O^VZ;<EM2GW@VIXDQ@=96.ONX[]W4ILAG"!
MI"X"W9(Z3+-_>?6U$)F\"RO$!\.!&=\A<8_KIE.:8#'*[S6.XWM!)D-@A_Z?
M(L!5,FD :F*?$6T)[2Z1U>X>0):?1J$2^SRCWI/>7[Q\N1S_U.;I48H_SC'!
M:LFW30;:AJ>?"J7T&#716GHGQ0F\U;;O>(L3 /\S07-F>ZV!'D$+[UR =36!
M[APJ9+\/M@Y\IUI6&F3N)1]IE***VSY$^6"#&^=@7&US:OI^-;2O !OY._4>
MJC)$L\@YC+T^05',S"7;:[F7"RL\-(5@G.'*(2((>"<5Q<_3#7YUQ3?!1-HR
M<4Y;V"1^E=4?0.)((WQ!FP,GMO6(:W=:7D=\;+BC701T&8/$7=#*P7.B.]A@
M/=AP*)$3B UM/1,V>>^3&+&UY%=G6%@O<].!]$15J#.2?!W80QJP;M7S"J$*
MKXFN\2-LERF;D(>9LE;6J_UTHQ:OOV>W]7K%M7CZS ;1,OQ6+^\1&JA\MA*F
MLED#_.-VX[EC6LA4ZE_C* MJ"%.LZDAP1(B95Q'$Z#Z4!>HXC%Q9NVP40$21
M%IFNG*K9:7<>9QE(#XO',D*["E%W@9$7@1OO?#UH4/Y6.$K!]SS-]B(/A05Z
M:OE?Y=Y2L2'IOT-"&RZ<PXMM*^S(SQQLO#:(#CW(D/#GP1)OS@ P,/Y$:!V'
MF2,\ROA'H4[:B0@D\_IIYV91Z37 _1I@QPS]12D3LRVFE>:-9L;_G1"V^SVT
MXMN8ZQ71\_4J>KA_8@V0;"1P4U"9.UN;=-&%Z' ^,$"3P.Q577B)+$>6ODIO
M<DMW70LGW<SPBTG_O=">?Y.&TIJD:X##SS\/6,*D4'M@HA],Y!<<]*UIRI/E
M&4@+12@?SLL\11H;&0;;IYP[[._DFBI"<V;?EL'XU!7B.Z;C6 /[5V5D3G_,
M7QD<I::"U\N!>.W4&^H-P89S(29;]:IWKB+L6;*+#1Q(F88$:G^N\^/?'QS>
M,WCIR):#UKN:@&$ZH[@>"61H8:)5-\6G(TL+3=:B%K,&M2UBG/3GG"0%MLH\
M7,=$A_EB5Y9ARVM8%W)HF8LG7T*$X28>91\S[\>>.TO(M.\ZI%=79V:(X'&J
M?7$#6&-3C(WYZB9Q(3@+*G<(5H"-BA& N=20H,M*$#!L/$T)F"!<+221&-\[
MN\B60Y!WY#0:01S^J)CW;-S.CW2[V6*TS76>)J2XD[O3T8)>];*^TUV;!O6J
M%UE=4L+;,G>[=KIR\QJ@WIB@AD"P9U$@<#DSUOP?)URIDS"H+8SGZ[_RL#/?
MVLB".<YV8&/:^JL0QL.F3QYE*T-5*!6Y6..-:7EE5QK)ROV]#Y6'(]R? QR#
M8^YCW8EC/(<A=,XBY2^V'%G5K@&@CADD[()&ZM06R9:)!J] !GHZ&+Y<"'^
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M7<C5*-7^\T(O1/7=O0IB[ 7@U6*K9IEF0#UH6?X(A(G_A<!T(C!Q%P#'E0L
MF RM]:0QTC!![KP4#5J V25M.02FM6PMQ"YLL/*L'&@YCPC/GT63J&F\8E;9
M K1X' )2K+_'M.L?!@9L>JY=&A!I%Q^$K^7P\89M2*/=X2@XR]&,O%ZP^Q@S
M=^B/]]GG1<9,=X,OKW&G)%\'4!2+UXJR'ET ,'K 2)@D_@U,A/Q\PW5/<#?<
M@_13 8'\^WHV&S96=S@O9"+"G0HZNGYB$&57H]4WMA"]@6O"RJW?BD/&1\*F
MYWXL[OKDW0P-CATI&K%_KR=6JBK#ICFCPY(7<ZMU./MQR(?=$&%RH@EAO*)1
MT@MA/5R'N86]?J4N?I;#1<OK/2E]5HTWOXB+7LGKFW<9-4[(#WW&./KO+*>_
M^W[EPMCSAO1#U#8-Z(9UMRM/]=UH6EN-EN18O^/B (<J;T5EYL2S2@KL80/!
M!+9 780'/L<(K3!.G)8O;Y_+;FC7IC)]M9!ZU10@=XWS??;CAXGJ"K.OXL&[
M# =G&)$GY.1@W2713E90KBYH9027<+N@4I\U>;"G/\Q;,/2U2&9D:?$<>5Q;
M-#SM??KKY#&QD1P[@41^S%B?='S$<,^L'9(K(#Y?IU0X:6.@*>5^^89&\GUA
MJB_F%=X]= LV0ZN5?,P88"21JFC883V+1@]SGEF=EE\_>;!1'Y5_4RWD V"4
M!?8(<1^^EH:XK@+&G&[T-<%1\53N*[Q3FYC>'M' [WLUECV3&2W/!>D$BB7#
M'=XMZ,.RZ/_(%P19<(U'2G@-70"<%\<!+"^\WSA\[1_/=C^.)%'K;&L0U"'A
M0IH/L]D:D0L=)NP!;Z56K9G'9A$6&04P50AX'=Q_-(_8B"B KQU=_@6[U6.F
M@+7KS].!@[];W#UD&<0%!(2GY>F$WOUX?I5JI,TH.<EFH)S7R(9A8A69LWX=
MZH4'HL;HSJ/JZ/3++4^T3(X#)8D/:\5BQ3['U#!(U!NC/W4X#KKA%7'TYX5W
M+P!A=I=)\GNC.)EEE_HCE(VP+=*5Z1@](ZG[<R+&891PQ5'-]'Q?P2<Q)]?N
M$E1_0YH3>@N#J]E8O@IB@%0<+Q>U3*V;F40]B=^BJS@<Z),63=-C,Y7@N RH
M'#A:%%R'Y6(8<&^Q 5&NBO.OI1GE[%RQ%LV6B\,.DAW)GJWO Y82GKPSYH&.
M7[WV55-<-R!Q\]7,*0C2H/J1O)C/B<!(HQD5#2S0J-K52D<\;X]Y>.N.3K[-
MJ82@1[/NCR\.]->WO$0,6P+8QT!N=/3#O62F:?CU5T+:W2RC'CY@=4N#)H2(
MSP_]J=OTB(.I0E/SVF8H@_S?2P0^H@3XO5U-?%BM7K0Z7[F_DS_O0WTWR6V+
M0SDY#3&O817[?$Z1Y'"M(8#AV2+AA<N;=@0Y1:AG:K,N$_>:M_.^[]8'L+?[
M=>*"(VMKM3>E.20 3H^\J0$\%),5DKKY7_(S77M5BW:+T$880C<?__F75L_"
M%1<%N3TD?;1_L:OIQ"-6CZ*Z^H!W><9](P6ZGM:.-*)#-=>)6^=91(=*"!RG
M<IYO/_6',V5:+6^QGR+WCD2@T;"[?[7(%0HA?E''LP\T)Z*7(G.A+M@<M!_6
MH5L:4]J30R=DTI@]Q+VLI3.1-GLVG7<SY4!WMK@,)<J;-U]L1/G)EV$"6 ,_
ML(4"">+XEHYLJ4A] R;\$*=0:\:!SQ+O R2+GK%?@C!$R$#%_FVBL@>H;] V
M\\&ICSS:\= %JDZX37R*K\.DZD_7&43 KPM@,QND<3K$AR2^:>G-"'XV@^HH
M^V0'PQ0S^^\<62WO>MQ*L(G]&Z=]E5$*L'MM>"T4D!:?SO$MQ@8"[F;'%>3'
MI.A8?*E)>SB?[80-?P?HX/FKV+U*1YK.J>(K^6[ATDZ;VM-\M<CG]AVK^<'O
M"WH"U<#Z2VXH\]%Q8\Y'<I'<G<=SSM^A]_%8@B74 E^^MJRZWU&#!W4'G'XR
MJ&C>E;9/,D];U_G<=M+HI+$4T*6^G@%8,VU%+IN/RK1OC>%O[QR4;L1_7!&8
M@H:LM5R=VZJ>Y'[:/LG?T1AW.]VB=??S!:!"<IOE>&Y'Z!;3PX7X3Q@R<>2#
MD/K)@(.+P/O3++1^LMKGBMV*,J)UNI<NZO7[["5_^P5 <C[TJWB)-FD7['9>
MT<X/FX#3M@NZO%GMYKT,9H%('^A0KF3P?6GX=5IPJ,?VD5\JV82-B5-;?U%-
M1/XXL">'@33Y[^1,G(JR*XH!H+>>F]_1Q9:CG:-;7:_S*M8Y;:OIY?$= =Z)
M/FMTI%A&U.BS&4LKKD%+ZXFE<^?)/Z62X*?5TW<)7X[*I%]:H"O*YU6,-(<X
M;<R]C4.O/;A?289 K['P/:PRS@'[^?9X'2[JVISGK6S48\:03+DGODU+E@RU
MWTHOR_&/KEPG@+KA% W=1Y$K'!C$(MO971NQN2>$A]'#S$%W\A\]3+-/N_YT
M7'NGW,LM_4%%7>&RZ]_86O99,\-:H\4E3:&X5_;J@N*O;JBIF$F\0AW&-6GH
M6.1\6J4F@:3#$6LY%P 6HH!_Z;Z^89V>.YU\893C.[0\Y54];9T!_?'%U:I+
MSZ2_E!7]]!:/PKN_\",H$!_C*;"77T^_I@/9A,N+$_:'->_<O85#K6P^CE#U
MLQ\?3%Y!X]X.M_BB>!UP[OBQ7'QT#YS^-9@2GV<V_FKN;;R1$L\XTNWYXMDL
MQOJLK#'V^E,TJ6$8V;]S9A*)S,$\RUFHWN\%4A*O0"F^NB'SLV\DOQX. >J.
M#-_*D-#A#(F4_3DPO@A09Z+0WN0!VZZXG.\P2)P9'4#16-U>D.L1_O82B3OY
MT$K#T]S5U\(ME4E3M?<%(\'M\;.&Q$KA\N&^X0:_(8X#$<$] [S85G,_00GO
MXYW')]Z _'XG[YS^J/C(VHS('+_.'N<)DX%JXZ,VRD6LQ_TS]AVXLQPT$@?K
MJ+T.]7NFM!H%*OAH/U._=7KJW0@V(I?(=(ABCZHJGG/]'-2M=+4()?X;J\+<
M5I'L<BI;]FCR@/,ZOXB7;LQ&Z?6Q--&"":[CAJM_:ZC6A#[F8/1L3!8^+*Z#
MF9)JT<@K#0N7VMK>8&W]R&HW*O6GP<=*W#M^PX+[\SU)%P#@6VS+%NCV7F_P
MW $"4VHZC7BA+!WY=TFQG6U&7E+.?'*''4>;A#S_AMH-RE9_J]/S+C3S%:,=
M$Y&[X;R S*JDF=T37$"T?R35ZJY]C3OFCF7:,*I-Z,OO%3!PZPZ6VI,MO6E-
MQDIIZMH]>1__L*H_[$16!T;2F"KGRD,0YO.BPVU5!YQX9T+1/8HX&60SF>"+
M4(7^#A'$66%(=46NL[CFR@^WFG*,VFC2I)Z8&75S>.QL&6L\"P,X#G0ZB22=
MM[>*8RE09@=%:S00HC"\&-];9\5=;J6%0;<LG2=N'+ _>D'X>@%HL<B\A=$]
MOO_G#V)>J[NY,@SN:$?IRG68%ISG5H\ ,R_8+>I<V;7\NSXGTT@KF\_8_TA<
M%;QL/I=ZFJK*>)[Q.T,?2+KN$UBTA]%ZX>"*LKNAYNGIR?$XG$G\C_&S>]=N
M4 (8/M/2-P'+^Q RL&O0V]@^\MQ2\DU#C>!KR[#^;EE(1H]<[,L=_11E ]')
MWYHD'YL,ZV9TYXYWY53KZY*RJ?G7+S>:SOY9/6$7@'2]"X /^+RF\CO(,2>"
M!)R .ZY>=653DD^8^M-V>?3D>2B$.(U(W%Z@ZWY:<2UD,2T@6^&*6IW)P[,-
MTO4LS%$OXD;&^EM,0[@_@BDDGO!L&>ZP-V5SQDT:8(?$FL>@/>#-[OMV"Z31
M(W4\(V:EBS2$&B7-=2MYL+,E50R^2)9\IB2;>,U>#6BH/WSJZL\4?\1]"".3
MY$X1!T/"8_=.AQ@&O$;%*^=YQ12"39%P<](@#^Y!U? %8*W,[MB;!+P 5#U=
MO #H2>V7D./8B2B*172OQG-M70"BB+R5D$"#I&[V&^4KI84C[LS:7FAS32X-
M0#UK')7C77CGDW86_"J*O3^6_@+0S4<_UZI1U+\>#;$\TIUR:HYZQ1[XQ$&2
M*X&;MHBJYCJ9NK<AU'-(-I;]9,5#Z3OE)31)8G5C++M\SW'ZA7^B=D^U2JG'
M,$?LE_M4P[[FE[\/O/MA0>=-%M3H7C+G4SS8 [YM?; FWB9B]KK*)2^%QK]V
MHL?<R=TT)G&>\SV@"BCE).*\Y)5$NCY3N'?L3KHV8]:C+Y6'LR@O&J?K'OAA
M=4@KE?=009,WK%^PA8+_(_]W:)'XB#Z6L %^+S^\RJE'D,7;J4V7C<P6^:-T
M5"B"KU3).8\F5ZAT+'B;MQSN/D4%#<>829CKH1(/R.M$37R ->L&+C1T_W6.
MYK.R&E- _5W52Y]@<J=Q_=+<M:7C%/!R*JM#]@PEF^<(%22G<S_&-G;##BF&
MTG<V:"#+N]]1_B$JR_Q@@2TIR0DGWNAW-_EO/*HNE>(T23T$S_?C:H%U6A&M
M#\&OF;_NMP,5]N"XH"<I4VF&6"&K'[MZ&B(#@93/PW[ZM8"'5S%/5L-5%?'!
MV UK!!845G=$OW<,L46QM,R\7BA_Z4JW7,(8\<F8K:NJXZ"P)B;3^*BI[%O^
MNF<L""]>GT%748)I)BE#V/YN2^IR@EDOCYJ":KZDOGG;:SPB=>D>GP,FL!ZR
MNAC6,X?+J=XYZ,[5>EVUI_B7QRS)0E8\*$G#P97',U$QMFIIK&L]R+/S1^.?
M([Q88#>"C?@(' '$1./-K+ B\Q> VI$YG&J6_.HGQ,&[P \S'T9G^PF%S?"8
M"T -\$.[ JSW D#WVHK&>(H8N#["K9_.[?F<,BZ(5V+V?EE@.RWEHJO0&GO$
M'>\[ ^NW":U=F8Y'OCGWB4SG7Q$N!N__W=K&W &_G*?*ZY*"$I]O%?^^U+:O
M1(&+3!;N^=DA/=IHT\)Z^1N '2>)8>^EX\9U3$#UBO$,/:K4$_(Z_J)D_6?#
MMF$PN1&[EC6K8/J0#72GLUHA #G1']?C#F%&-:!="2KXEZ!+B&[W55;+O2'!
M^F;$>$4=:P0%</BR@;MTJICHZ%7S"E38UC7F7?@"L!]1"^IEB.):J<."ND\@
MX$Z:5Q,6KC5[[O:""-/Z;B'?[=T2S2^'3J*-C6,TH8\[SKHW @].L1EK#.@'
M(5BK#B66=O'ZYEDO>66]<F4#]V]<.Z,GGLYUSQV1C/GJ8IZ/^ 1XA>R9D1<
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M90Z]#-;YH';3O@] E#TTX5X-;(2-PME KHAH./?O**+S>A24=XW;?%/?MI_
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M?U<TYL";U)5[2-GSDB)M1LW\K=QF-5K,X/Y9WAJ\*YY[#X0Q/%?O-2/1S1U
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M3)^IB<$67*?CE.S_[&JUJY:>)U\ 7*3C@*RJ@JM[=DPDGGBJW3N[QROJQ1<
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MU!^:W+0)ER:REG;"^":A)FL&-RQ<ZP-(-^<$VAJFP<:L[KF >O- VK7FLH)
M6AF;KXG?OT+Z#]P#L4G=BJIWL/&= Y+^)P7J7NFC[V1K:':%](H^?% 9^!G+
M&869:,AHN421'Y=7-]U^'1IRWJ J:[4/D\$<D*@:S#W+I"K =P?O$MQI3&2U
MV3B<5#VGO)@4*3\.\M-.2"DL-[GY*;S*D5<UCO/#H;#M396N\$NUYWI&28;O
M8+Q[Z152D5ERUDOBDCUH<>*QW)GI>O1FC-<O=([NOYT81H(6WJJ+K9UV$N%L
MY:(B25=2$Z_/1S.#%!7LI$T\S#RD2VIMUTOL.5S2#\Y!KQ. OU8Y5>37Z8S6
M1U,+N\L@+X$'OR>_1G ;^3CU/A;E08B%A[FSA']X\@2_.-$:W$U>@2)T&.9(
MJPXST_]_V.M!-(M81U!(_5QP4!E.V:X.V_YQA+\5WXWXD$V)'T8)8X'A1,/U
MD:L;:KXCI>;62.2(;^HSCN3H=]S:)3LW?!HEXO+NO82>DEBI^@WF@:B4(E0E
M'1X*J=2*&-V>_C4Q_V Y!@E1$]?Q_H1(\S!)9/.H?K?YPS39+*<6X6#'#O7&
MEL&D9V&RYCKY\W9Z-"Y*4)S,@HH8WYJU)O_]+&/6#Q0*>E*3^2<Y6631CU@4
M7/^9FB[5AIDU8%W1XD_V%X7*R8]?'\K7XJFG3:A^VZ:Y3=N?"+CDMBUE,A <
M?]! <(+0D EF12ZNDG8>HH<20'Z1Y'-B9[9=H&2^>V?IRZ<<A\O;/ Y>0L\Z
M5%<K3NS2[:J !X-8I9.-'A 'C!^IOUX;Y[ZL[E3B4;7J%IBJ"O6#Y]ES^U])
ME3!1?'GGH[H3:')BI:K44?SQ;@',:H#XK^>;BY>R Q!?8RKC?P>'3VS/E<\:
MU"Y::TM3_LE)H1THNBQPT]V;2^X"(&&><.W*_'FIBJLKP00VM7JU53!?[[MB
M!+CL]6)T!HVR(>]6[C27<M120@5G^-?Z (]6%Y;-M[;M.>1G?(3RM.-+,-05
MOY7%LPQZFB5_LYNFX-[XM#1G"0EP2H[?7OD [4D;"C58F!/,M<L&V8-"+P W
M#A$NHJW.6(K.].U4^LCU7;0'6-Z*?0H!2^AU]7AG]2+#L\RO#V(OE]JM=']%
M[JEH>Z1*KK!"RL]UA",P-C7G*HP2-I[-/BLR<]?3MJ^S<*J,/SROM;8U>>3]
M2=!;<<U!N7DORNH6B_%7]RK-R(-\2I2U^X&?0K'V]6>[QQ_H/1).T(W)%6FF
MU$$.G-5T7DEP\%][U1 'FUFM6>U!T!#A^'05WG4@B_L*%]:>/>)P3#_DH77^
M\>+RW1=YL:VYO,N(H1S![YIRC?<D_[(3!(C*K7@[@B(1-.[/["_U-07HV11W
M+$>+T?$17^;@U7M5ZV1W.^GTXV6?<>;,(*MXPRZ&--'7JM?/OX*V1-/MSF-A
M9)B;,&7=A6/,*C\3Q3JO?'?KG L-V.XY?O.G7S#[C:EB/T,XGR(9%//^PC]Z
MJ'!7KD*<0,R0-WYE5J[5@ZY; A;4P%&:FFN&#:^PM7.U\$[M?XYH-NC+?P;M
MU?\P:&=SIN^.Y"T*P3Q2CK\I/VWY(M<<\IDRED(N+8Z*151H3=II5>8WP\$0
M*\+9+OR]E ZF/J6(XEVT\<#O#9%L?.5(#C*LF\LN&K168)#KAML^U9VI.[\\
M>GPUP$Y&J*$Z=LXWP5CVSNBD^"[#? ,*@:91:%M#1&9+XN$*G]:R1 P@4G6Q
M!FI-U4T?9Z_I+A:E"99Y+1*+.\R':X->RI9MC)+N_;-KE/^S:TP1C5ZL+<,(
MW3+XC.Z3K)>+^BEZ!J), ]HD;YNW-S67D_JF#"E=?XV(W5W_IDJ65*%A$ >=
M'^>Q4+LK2IZ9 7_!./ \?QS@$]*S)93E>,:G@;%&9#BF1/STJ?@_SZ/A8L1Y
M-E'31/!ANVBSAK&UJ%T5\L8=O]I7V51/LIOD]^T: B/][3AA0^WRDW<E94\M
M9KS:._BK?]0G!BV5_VFI%WQHOJXF$O=VCHJLW8<QX ]0"HQT#U=@5"V=07?#
M$2IH1\_&= 9=X!);\)7IBC?]4@1GOXF\RFKS%E?\45!\Y0-Q+&$=\>XU\ ,<
M\QP=J(FESZ(O+UB"(&R"RBJ,OVS)R$]/1':>);\*MW+E>$"OQ4J@6#+;ENXD
M1\"]23@Y N(_5A*Y*^?Q3@;,D B?,NN]ZG[7+27;#ZNCXC7T-@%K)XW&4] &
ML6^^/E6_5C$F:*89&!7>S.C.0S":J,5;RZYYP_'C?<D*KL>F)%8'KL/%V$7F
M^T@94(>RHQU>>+1<MI]KD$S'BZ*H11)\A/>L?PO1?;V43<5;FOO?W5#LZ^?*
M_W<WE',GB H2K4N^Q<O-EJ,-0RIQ1+FJ2*.NF6DTU4$J:1,?K$>I%%YJN.??
MT7^?U7IE*^;,KA:A/@A?2P">F"(.F8F5X@/$^]CHQ^=I<#!#%$D(^_2]__!]
M>4];<;N#0?ZF]-ZBQI,GXTR]IH_R\S_:RF:[E[YXIWZ4@]%C^%_LW%POZDCS
M4X6U)[B0RH!.@9)[2TT7 (C98#;GC#_B$FE\E?&@G<\%E\/SHBGQ>&2TI,B@
MHA_NB&MT)CS^_H[+3.NQD;C3K00O37L'^?$\3N/D>IE X_60T;G>=NG&\QJ0
MIS2M&UF.U2HCKJ]TXSB%IS>K0_6^T#*+#Y8L]7 /OV _W+BTE,K8\S5'YD;(
MOT_!6X8!:^8BTT)+X5UF'FJVOJNO6G9XFS]]FD/PF(6[@.I/>U87?A$,JN?:
M*2"!G;9\K8GN]5,>K[G+*0^=&"F=X[0D8@:@;]%;"B8/.3;XL 2XQG=BT'DR
MD?H[1+P[?;8>F5WI4-9?M+ @/[)D>FQNW5S33T\,^?U<33R%0IY!-Z&]+]K2
MMW['B!S ZQC;^'S8, PX^QNMM#)G@KW28/0K,-=/>/#C+X@#72;Q^X?O-^QI
MFS@D>HAP@N*>PAL0D05U]'1J+:ZK:ZJGG3\4B5RY$W5=2/%7\5?OXO]FP0K\
M?U9J&O]=J1EB]?]_E5I1FJ)L$XRBDR3E;BN$5417;?#J@FBE>VQL5WM29V=7
M^!JGLK>Y!]!IW\*%(FYI?7K.;:_[&RZ4NE+0_;>R;RQZM3:P_RCR=(46J]CA
M.F70^ E,.9/S7EXXF_-EJF_MTX-UWFD/$:^ E@J8QYP_P0PV!&)ME2&HVT!?
MXM6<=PS$+@"N=]\P];K[.:NX1LWW/)6"GC1]# ],&-H=CDD3=UNM.T4'%N^=
MFHY#N9NF"E(4XY1;X%2_/"4HW_U_S+UW-)QOUS8\(8@20O1>0]00T1DE6D3O
M=9(@6A!$#48GH@NBBQ*)&KW&Z+UWHX[1&68(!F-\\KOO^UG/L]:WWN][W[_>
M/ZY9L]9<UUQSG><^CGWL<\Z]-XXRA?0WVU%Y3UM.DG+0MU%XP&C\F1L:#YX;
MM?HK/AY+APYS9*:8J3A=($UCB2I_&R%1H._P_IMN[\:G;5-W \:G+7@"'2A(
M.) F4 S< 81/B]ZJ%F JO).&9F+(C6E#151<")_*V76=[*&P&HR_Q8:(S1:/
MP4MN/AE+?Q?;_S%(";4FD@"8FCZ\\I;<=[X!,*=C@(N5B1CKJ^>!LW)B:-<?
M:%4=M&;)G1\F 2'[AI&=-.N'-J^KWWA\G>Y/-^+Y',SW[IZAVM?ES!=]BZ#J
MAE[@7VU!-?I[;8A!]J'NQ]FFN=JH_%CNAFE.;O_J \,3DN! TZAE]NN#)[:@
MT!O VA<^3G M,"KIN7UW('4CM!MFJ+R<A\O<R)U;'J!T:XM7U^G^IDC<KL#'
M,ZUVE-128U%%#2P+.H/5F2;E,1UFZL:\&G1C_<1X)ATDZM!<5A\[&+CO:+[E
MGWW\J[B..8_XJ$9:C5$[DZ#%O51-Z7"1@.SL;V_M)U_%LOJOO?)?A%;KJX?.
M]-0&MAX*;F\0.'#;=W#$!#8]:B3[5RYFY+]S,=61##W,(JCBSEA<4]39)Y9(
MC&$ \9+%[B_% 48>&S G+53U52][>$+]YKL(0(SNU0OP0"M&YS92U3:Z 4RJ
M\Z6NG,:57C7($=^RWTLTM\)TJR:\DL)J5VQ.:B6>*L8O8/K;9R6F/BA)+,6V
MRWI5'@7><H/[3Z*#Q^"U<BMBY%GR>B6.3\B09DT#BK2)"M%6X)=7:GD/K[JK
MT0YOQI:O\74TXFZ*(6XOT-H<$I-#UX2*C DD57"JS.9E^##[@3#E*TB!W5+F
MN<*6BHW]L'9$;.OR_#TF3D^FBB*D/OP(T81*6C5'Q4?:(66;NYQ?>WKX?E<O
M7G0X*[%)X!=^Z;_X?8G3A9@J29XNW\+YH$% Z^THGJ"CE]HI>-%;MVD&\@H4
MD@:-76KP3M/;F7MH8?F",\D[0,3(EVY59O/KQNF(5RY2>W6A&#;:<"6SD_-D
MUI^[R"?9'(6[]&SI\CK+>UTT8LN$0L)(_OD+(YDL=PWW%R4EA^ .53G&O<L;
MP,$Y#$2&YN@\S_A6C<*#I'W?$1,26D!,CNXJD"N*<+"P7]D8%]Q2"^,_U(+^
M-[48UEWYY QBH6K<BG-SI$VQ[:]36..DR$T]L(?+6CD:,UM 6;!KK+DA"H@H
M^NF0M#NR7GDP=G E\/2YDUVBB[7/Z]R#=L7G<9RI#I=B&#G*V-*:WZCB/E>H
M4A^(U!-X!Q0XEFCNXZTSU9M37Y]#/(UIT0C(U%&,95/VB:,+?/E8#4DZ$6]\
MW0RQ 4:!*-JX=R 4<K0=C!G=.EU.'M9VHD;BGT5%TN+0+X_94_GJQ%U,*15(
M)SVBT.4<9VW7%7^6Y6:AX%!OJ9@JE<0!;[<UA*9MU@] ?Z?X<Y+Y@7LE3=S$
MAL--^D_?NQB)@==R@/@8DU52[%.?IWW-W)]:!?+0(9,KD[3/^$S+*2^0RTIN
MG.3#+=X'QPI<VLLO4P%WMG.1+R%,N1% &AE?6#SED .L5+J<KJ)BSF39[EEV
M3UBDOV3"CPOVG,W<S7YR.[ZJFK.Y@^  E+4!VN@<0C<\@<X_1(XXW9^F/CLN
M^A2";XGJQ.\EF<2IP T]#ZH,ASB-+1RMD]U*>H=X2G0H;#7TU-E8 \65-0>V
MGWC'/<T!JE?BITD<[&'DKQ;.0M 1);/IW=/)3_J2\6H-3CFGI(HEW(0A5.$@
MA.$Z))J^D/FEGQVTCI"^T]#<\W>K+SG'<5;-A8IX"V\>JDJD#RA>@AW/K6^+
M13; BS^)DD7DWA<%/_17^:)PJY_R>(=D>X9HOT##&D!2KW#ZF%>%U9(>X8&]
MQ"_!F(<-:[]7.^.#70/*',[I7:/J$"KKA\?W5;6<G.:M581523*#?%6L?8/9
MWKLPX":9;U;&L> $BF#'('5.F!=(ELAG9#1*'TN6G5+%I=Y^F>O__!0(Y3_D
MD!^.,7H;'ZCP7JG Q7C>0S6G@V= 9>>8!;JX7ME#%NW7%W$J]&F5K!Q#['U7
MK\?6OUEY-//9>B@#I9!T:L)S<[X0G(NQ!/$L;!P"B#R<??]-R9_W*N^8[ P(
M>$! >U89";;7OO<W7:'6./+/$8-/7_OY0+&"3[T?*/)/["/EYOH3X-S(!L_'
MH-R=SXVC!O%20'[&K #$K7@[*[T!D+#<OCDZLSPZNP%@^, 'M^""U "A;5/7
M*9L7<D;B%YEMEE^7<X25U;E?ZX7&'DVC:["$V^NW^H38G^FZZ!3!NZMO.OE!
MS9-8\BLA-1T\5,\^=XOSR6 E%0Q2O1HCQXJ108D5K&M'0NZ_1ITU.;^K/[88
M*[#<HW#XQ)H NTO!$]-($OY5F,W2,/((-^"6_^_VH[77A>[/^YM.8=S61O35
MJF8*IJPUP \</!28#EY9$3[@W!/G6;G#@HB92]H!XH'MC^;!ZX\J?Z+)%)M0
MJ:&>;F><.8/<D/J9Q +O3T4UT4K\CYXFMX89NN]QVB:?-PPW+3<G]E^PNT%J
M#?OZ(%!S_0E/,DH,W71MN=)+=0$CN HR'*/I7J:DPI6DQ"'R_&H!7\+!(DXS
M(/9*Y[XI9"V3C+FY(=3"DD A0,&3Y@:@?J4*Y8_)5\1<9#;@YFRUAH"A3\\&
MT9_YZ<7"D7O[G0U)58F>M*W2 OGAADO6#D)#[=%^MD'^-P"J ,TK#Q]7$U3D
M025<D^7YE.NS;*VU^7O\M5?&31D6('-IEL<*[\*-)/Y09:8<.-&Z;OFX8BA"
MV^DIP408[?7Y/SM &+NSBS,/J)I,V)F:V/0Y\8)!2XW8N'AV>,WF]U4B])RU
MZ]^N)#JUZ'<">75QVK3V#V7>=R?^3#*H<K"1T$_UXHK7_IH\G0RZ#7X[1# ,
MZRP ##$*/WO=&5<?B<#D<.=\J)MQ9H8:14'-[K"J A#]K[,\]:UP41"8:MPS
M5S3/6?9Z)AG^_OD*77SW"G/6/C7T7;69KUJJHNI)R$$GI?."C+/H19I,@GN;
MVKDD$-K%0@Y<*Y 2"L<H",_4LB TB96O<'G"J4?U78Z[ME2HXLP.W]Y/6'B'
MXQ4+^8YE1;O"P-0^@OL=S3F1=IZP3^6!O1^^ 1[T/0#P]C7@R#;BB:U5T+B(
M1:,SSXZO$_Q?KVM'D?N;HQT<H:E5C&Y#/TU,7J! A;,[_J7]3[E'.R4*%!@5
M0/Z.@XS]B[[::'NR189UHY 5TCJTJV?AJI7)=2)&!<HUF^O^HL)*6\Y.XZ-W
MPGL3GH[1]N+7ZH[[*GH!$SVWPZ1-[L^!HH'U!?W)KP^D0MX PE_3>Z8NCS@_
MU.!J"4_)''[7XWI/^NMUNXIIORQ9Y W /AX*[%QY4(=\FW(EM:@ LW?6S/*S
M1UI53*@SW[-)^[#]_MV_]T>M.\V"G2KGM_M8J+ /_85_3VS6H@BZM0EWWSMD
ME(ZPBNS3J4T/"FY")RD3N3Q-7X0(VEI'7(!&98!7ZMAY(.F?CR"2)7_^:1D-
MP2\CUH+%/WP<L6<.7A_P?;@,,J_R/?M?B1R,I(H5-@D^S[LHD\82%B"/UKF#
MY9[Z?/)7A8$I?3P4&L<M:ASK:<3J:RR*IO&YWJRI3/)>=#.Z$'/\&*7-G9*=
M.=X^<%X_BF,6B^^EG^LU)Q3-)-Y][4R@G=,KS1VLM$0<U4WPM"2D"O!VP!9J
MD.-QR@R4ZG0Y/%C)\C6,[\\EVW'#>-VJG11'/_#G0NSX9.2G4]H5ZHA'$?8'
M%&L*#Q^-A+]8[*YLI+;IU3)Y%A@>.-M&/.YO=R6)/ENU^-4P33VDW#K-;YNB
M];HY!*H:;<"KQ(?;<IAC[)=<]Y4E">QXM*"]_K<>G#T?Y.]?167*PU,_I[_:
MYQC^7@Y#]?Z4/)Y?AX]U21J0'(O&Q112C(Q@Y/]=)X*Q$<F-X3,?(S'=^Z[<
MVEPU?O@'YN%"]:DA=?U0+[%W+7:H2</ZK=?3R)GEA>\V&7MQ+5A"NA+0DOT-
M@%+TO+$Q63/"4LKGM8A4%V5%&KMEUL$H>[BZO B5MPU>7_JMU9B("R$(8:=[
M#)VSFP,R5.+>KV)_/PV2/*MLO@'8Q"]XK9XYH.VN$P4VZ',_/9-,/3&=9@\6
M&V U),:1U$%0OGJBM\TYP $31X#B;P7R=Q"1C"N*&-X;"8;]38-EGX(C>UJ%
MO(L<:BR?5Q.W?!=.C37![WK<<=!9(F(U>8W' [3;"DPO;ZE89^%&NY.Q6/GN
M.?9P";B+>Y3SX5'JJKW^7W7TU1$5H>)E".T[5[P*DMP_TI^0?Q"0=1L7A]P!
M;$N,W0!^!-9R\J=+6%31;?\ZFDH^Q>SY\>R_WWU38U:_R3:/USO1"*^4/(5/
M9_SRB#;CP3VI@0$/2E%\7<"&WF\H;CWDH,+:?OR#??$^'6?%V9>+8TQ0>:Q:
MFM^12"5RNT*^<OP'8OF)G&7>*^8;P$OK8C.?L),LCZP43F;PP)&^?K*[0UN8
M"M'CHNF7NO6IT9G4JK679%<[$_^\3G_1ITK(FG%S7/R:]H9!.@(>UVH]%:_(
M.Z(XIQ9]H$7UG_KI\OWK-<*=#Q#<TI\%5;9.92^#E[;;'&>4S\*62L?_75F8
MUPQ0RI6;?N?E(VS)L CE27P@X8$J['GJ&\V6+Q*,_J,+C.2)1XL[VG+U/_*(
M8NT/\$TM<NC2W=WFXY8CF:2G9I?GO-G</5+:$3$?;@ L@_^N;.=]:? EW-E%
M8>/7P!UUN>+B8HDQ10=Z.O%4/+5^J(CJ-+8XQL\P^G%X:CBX)H?4_?T=R5ZW
M&\!^T140O#[J=[4]=;JO/Z'Z/&00D0)=;A&^:T/J$7,#N P7?J<(4S/2/0<O
MM+?WP7("1LSSXQI8GD=#;-U8WY5:YWZUV=Y?C%=8+#>1+-:5?R"JY\))Q<&!
MRQF@CAFC_?.S2D.9^?5DIR&X!I@UB5/:2++FD9/],8APCW>$DJC'_F &WRL(
M$Z0@8[,-U)^^.I=U.NGJR:T>ZZF,R:V?EGN*RHETI0E">'XY+L[8@^XMUPZ]
M%7")6"@6X1W5V91O=RAT+_CB.A$=IN@[*CGZ(HD,N'%>&K/DQ:ZC;V1-38A3
MDDIK):OT,<%W_PB4RT(#MH5\:N.]_GT@Q^G0QF >C]^U?I_ZH@[W!_3GL<#D
MA)T;^1<U1=I,M+M/NV3E!%%8IT^O1"\QA3;+AG<1G838G.X@D0/WN$V"3#J!
MRZ34^:4UDY1>GR-5)-&WP)V7P6,_CDY+*0W^5!6;IP3V3;%I+5&Y7.!6J C_
M8<;6!J1@VJ]2@K9)1#Q.$7UYB-ER795\7@95B2&^Y*ZG@EK2Y(N_X-]]BZ[X
M+H(;^.Z,#?_KO%(#G2?YT3SD1AI/'QW\8HM[\:N_?4?X<KL"S*M2O=3?8^UE
MM%2V,)CS7F'CCT0?(_5ICWE^]OR'*K($;=0#>3:M?^8P<E_3R=L6JO9>G1O,
MZLWH3=?G5Z7,RE<KU)A DQN8DP67'1$U^V4G9\UTL23.Z EGSO(C-_J1)TV5
M.A^!%S0JHB;1\6>WGS-Y;%/KV'Q+0D^;,>?O180_=_+N&3VL,_PEWR&3W']Y
MC:>I3'F'8*%_VXTSB'#TZ2V_F%X_IJ##"7_;S^BYQ+ 4.@:ZO3%#,*[RHW4%
M/1&QF,13[@:/7ED>D\(E0EY\+5A28)C7@41?N;8RG\,K.>;K!HCU$0OF+3K\
MF[\"DKK&UKG4'FK6P?1YA*M\<,S9C1,E6U::N"49D"<IGV.6L,WMFN(3";L!
M('I0'*HMR.*H"NAB%W1"0WIW&*I<K8P;G[[AY+9U8<)@J2/,E](KPO>G64/G
M0(LRXJHCF./6A/=O'R_K"2[Z_3V.Z6V9:V%SWB1UP5ZM+^:N32>J!]I7['O
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MF5(U2OL?YC+-#\__Y=E$\ ]F6#VR[&X TX^I);TCN.0'^@> 2HAQMWBS*F6
MD=A15= [YA>)P34Q)._MS?6HOB!I/4ZH^QB#<U:#+@TS>,SX"&ZQ/\9>)B^'
M^.V=E1R\?\J</2+[VKFD^*Y;COHV"L/KQT/:X]7@95D8>3?)^YC K2_0;25M
MP$6-2/U45E:RU^_A+0MKW'Y+ZG3$&YLW+%XJ_W8UCSEJ'M]3:I D,55@R)P^
MWR/PR+FX90<&JL#!X2K,BJE^;LJG_<7=7-TX*3\^LRI;=I4[7FNWUC,:X'/Z
MJ&Q"7E8%4> L%0VH9"1I">95=47!6;9_<R]L&L;P'2Z>-^1H$51.>S.-F.:G
MU/X=BR]+C#P<<60@*[><(#V!EA+$7=:[Y#5!'W.D2;9_F^1__=_9Y?G?#ZJ1
MIK5M;L##+#L6;#/U+3?P/Y'83UC9ECD]+Z74WWUM:K4)JKH,EWYOV+)!VFK-
MY$<&-E.PATO8*DH8&7;T^9\=^NS>FC25G+R/'2+]5C-WLU!#WJ[2H,T[H1Z.
M?EMY_-@1YZV^!\FV&WKBHP>4_E55&Y?&Y+>QX#5:&JX=PH+O.4+<>RF3(5CN
MN4Y8F5]G_D.082")^,.*&;?GU<YV#..=Q(S+3WD!952_W%_ <>UH:==N +P@
MKDP7-3Z,1IST26BNRU.SQW7,5F$2W(*O/]OO9XE\8^3C78,WR;;D2-EE_%*6
MB@Y5;#%O$9PT[*+0PLH?2AP^C3L5G-H!'A5HYP>QVF^LJ-U2PT227.'MT_05
MB1\<B_03(Y:G7F_8^%VK[T@3U2@##/\Z@G,^ZZPG V-S#<RA#68UH2]-4VJ"
MM$@E,,#>PL*9GE^&7@T"7:\C/ 9V1P.DW>+ O%7*PBG40T[2SK%TF1Y/1DU0
M2=I6H;3;06U?BP=<CFV8&CF._@5#X'^:<\=)ME]._'=QPK.P),YA;J<#D>!2
MER'!(7LC.38W=USHY$OW(JF"]K\LMESW!;1X7LHD=.!U<C@G:F!W=_3I> 8U
M-;1DOKW7ESOQ]-;0'T<O4F%'?:0_20!.8N W@%GP"XI_33@6Z>I.)ANPUT/Y
MX=?ETO\_B[0L7TYS8.O@S,8$+[DMV3'M^J=>Q%$F]W'_HW0<_1X'+=<1F[?-
MWOFO:9N)_D<\5LYWJ91TJ!D1),X1A.X>355N6SE<*77!/^:&8/E#82.9%NC!
MP[F#63G+_OKWMFX,:LDTFA6)J1^<NTA*$^/X9AQ;Y*],^%YMI/3BCSX1[L :
M3-4T9KQ$#V$)X5>"/J5KLO&?GXTQ[I([R'%.5W#4U-7WU'6CS 2M5!\J<_ 6
M5O>73?Q@7"QEZOD%T<"X3[AB3)%V?1G4R?9S?A4_80B5WM$E*;94!X%E\CMO
M  ,</W%:P/_3UM2Y?GAQ$RD%K+4GWNJ&T^+'DM)5/#]*.=9ST=S:!_OPU> G
MZ$LA)I\ 4>,98$U&3]N,JWN%-0U7_86>&$ZZBHA"WTMCZ- [X^!PG;\,Z@N'
M_&50P_ T6=*CWVFN[^!3O[5?Z+E[OXDQ,$PT+5]UPGO'F%3XZAT<EY&>>AIA
M*X//B.FIZF.U:UB32WD;;<D/,D]INZ6XUR"OE98Q;MRXP#Q/IA&<F09A!]K#
M497_4L:4GHT?JLP/CGE[<0\7YWPWUMS&_DZG28_ /Y\0)*T^[@R1_1?#Z-./
M7T3OR;-Y'4HNQ\%E:_HXQCT1CM'4T>V&<6-#RW6*.&['+39(?&V(:Q[CI21K
M@N#D$JG4AG@304[;Z9MH*1.II>!OSF4%M-N,B0.7@:(#_,,)E&SBIT:O$XH;
M( 3C\9WENJJO> ?><BXV*06YG4CVK\7$!ZXJ^IXF_G.99!^G>V"NOKZ!E=]A
M^\:UBA_\8F(6-MEU:V-:E.1]!)65$F/RCZF79[Q"'N#<6VB7'6.*\%C)J8E9
M*WV,Z/68RI'R/-IQ- .XK*10="X::@G?8J!X;N>6['%J_CL1'(W]YD]M>RM]
MN;&]XQ;72C9;IJNJ0=3-8B=7R/A <O3I#6"/I3SPM3VX:A4A?B7L$W&X#5-I
MLBU5^,$_>R*6+5NK^Q6>4"NR9+["H\"V=.\V?%_F/6+=P.8;W"<6D[H/\29=
M08]5.C:.](@V)_*Z)6O^ 3ZIRYT_.LNZ+I;1L/- V753^]G69TRHNCXJ$J@M
M^=7Z;7FMOD;_8:/A1</7(<3GK3L*H$DA/+38:GL.X7BK</&8Z*R96"Y^MJO
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MWLIOA\BCAISME\T=: M2H+#A2NM=_XF,$^T04"TP!&PO@+^MA_0J/'>UVQ3
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M[)X<VF1.$E-&9\J(;V2D=^>NGL]<'Y2F*Y=P+_ 12O ;<_PWAU_I%96"D@:
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M*B', B:."T->"O04PEW0C^2U!BBKMY/NV=KREY4%&B/!GR%O;P#TV(6&_UK
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MZZ?PD 'USCF]GGS"R1$%"9.M\!O6K_8/>]>9C(&?VIUL%@K[.&J=^CRX_YG
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M6B^CN1O&$!*,(1(]VJ4V7KMD,=(XZ]XJS=10[?81%W>A@U'@)F%R<41XSB!
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MU?J?222QN3;<OQ1'Y]R->>78-N#<QG"3ZM25O^&R298%.@IY=4^^':-2/CT
M^\!1M\3>_EQASTY@NK&8B=]?L1[3?O4 ^QC)>]"R?JC8U]%L?_Y4)-K+2^AL
M*,?/0V^,5$1LV/,#D706E6G8\Y1T.,U&90YP-;=-9A9+@0Q OYO^<S(E'?VV
ML<Y*JA.U=/A^T&)%]J$6M'VCNSP"QL]'*I40>GRE02-R<(Q2LQ67QCYH+GU'
MK"4JE1H&.,Y?,<?8W1#9K.5)]RRS858^[66T>::5F>^BI?4B[,0Z> )B^>WQ
M>N^GI.SK,RTS9_+!S5EA6)K@U9MT5.&Z6B+6!N&=S^O!/BLM%;3*X.;CYW]*
MXR=\_C#K'W&R:GS2R>-^OJB6%<SCS%^0^QB.M>,H>8>U1.*AKJ<-Z.]!+ZN<
MQQ_6?4=JX)X(,$X\CS8DQPW[S#?,>#W2IG"G(RL,D-4\()7D^5PKE<\WD./-
MJIF-8F^\]K2#TM;$H8A\/;R#Z-5';I<4=DD_,O;C'MW$=IKVU8*@WLC5%4(0
M]Q5'UZRTZ*)U5-JA%-)2)MU@ZVBWP(:?BGBH[CGU 8^EYK*I5?GQ\6>&<_FQ
MAO;7NE1W4?!U:AO[LFL#F8\?6^YLS(*1E6U]4P:A">$GJ=^(6-\D;XT!R8NY
M.VMXBI%;@R6LU.+ZMSVN]M#I4YYTG"FHR?K0X\NO2^I<<Z]= I3Y2#ZL!__@
MFSVP#(:G2+G[]T4T/<BW(]N][:VY=FGW.<E/X_4W 2-/5 ,>;VF.<2EUD_T>
M%3AUNR%2W.<X)%O'Y[ES[O&67]. CX%N=0K@L%D?U\FJHK1S;1B&']@)) B1
MFU9DL<*X=3'K1CE,%[8E'5\]FGBM04_C.1'.O/YD/OV4TZJ/*/? ,N@F_DH
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MXS]+XE>J\56P1IQ450@1Q9LR^,?(VVU?-R:[MW"=X_=43U!ON[-$>=#Q+^F
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MMD;\37:/;(,A*.:!?>QL,^6M(P+&<R+?/<O?V 5RIO;"91G"&D=-\>E.3;J
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MS".*" OEZLNB=DRF2MQS]3)>XS__7VXE<)VA53!ZEYXWV&Y/.N]@>3\E<HQ
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MVV1OY%.I_RE5WK$A1G.4NYIN]5:&YP9T$%FUUPD"D+N!')J,RT:,I9K6Y1_
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M6VFQ$?@P_2E:H\OD!49S(^Q@96] T.,?;YW#U#S<GEA,:9RW'Q=8S0@K9R(
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M?)>-^4.?K<'8"6(';8VG9;.V=ALAJJ;V<M?X2K\;LTA)>K]F;&/^8.__1OD
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MU45$4A/BVJ ,V,\ILEF>K1+5MA'SMS%Y;ZSXGK3G@0^/--H"02[=VA"AU?B
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M]W^Q]QY 37[=WF@ %0$50:J4** H+4KO$9$F H+2FXKT)B 0(! $Z24"?T!
MB#21+KU*Z 'I74)-:$I-1$(@(;GXGO=\]WW?<\[<;^;.G?/=F3//[)EDS;/W
M9*]G[=]OK9UGKW5.C);#-@.D?'$E6 Z5 \#M11]L[3% 9E;$ITZH@/@#YO/S
MT1)NV(ERII_3'#X7"EAZRZKZ,"^3[W,%%-XR>;8+KPSAAP!UB+;+V?2=@;PN
MF:IP9[XR_;Z27Y*X81+[T[Z=?8Y>\_<Y1<+5E8"3%+)U!22EDR([>O#UOOM+
MB%)/9GK$LTE?@%!K4VW#]^=R$N=9'W$\9@J5>Y.2=B-K*?-+( _*<-)0@^Z_
MJY .MRTK64\)MOSYU.UY#\7:,@ZK7_C]JTX9H&63T(]:Y)\B+,I7)E(!S@9G
MB%F=L-J]KJ7$J\R1,G^.;8BG_&RN3\_KK+:=R^<6T'FA1UH3:QCGB\TR[7LQ
MV/*K67/A45%()'AGM,WS-!P2C8^:Q>9GH^)/*O6Y>P-6!.DF9^B6D7 J@$<"
M[#;":P$*/;AH:QBN%5- A%"D&BSU;HJGN1,:U^Q_97P9(W_^2 44-N0[MN'Y
ML[!P]#XAE&A=-DND[[$!X"J[YL++K)<@(_HDWO3DUB3MM-%VLZ.$YBEO3.]"
M=_V\YLW!:0FH+LZ 0"2^P3,>8F826HTQV8Y=TX3 USFLXY:/%WO$_JKJ.JM7
M[GI+I!L\[]YB;O:S,+YLQ!1ONV-?N@0UFB8SX%"8D%R\G"$.NV':IO<0W=L[
M^^U3WTJC^^;X.4=-K>\=^2F M]ZM1=&PY8_-_ B2W \D6ZTMTU!9OV\%"D-:
MX,<>;I<_]R7X9]?<B>F.S64K9MH7BVL4]3#$4J1//M0B:4)&P2PR!C'@\\J&
M>--.BN#DS2EI<=U.EH?[%GU[&T,7OLSI)\3/O^].N6PP._-"[OV<"]2#J.-?
M&=(GV^S8106$A=S Z=5 ]DF:,UUK'KY,1Q\YI'I!-]^F.\E5E^GQO&+</?LV
M]F'MV:''OX%SKM@+(:"3S-?6=EAPU\AEB,,XC%/S]<(-WY8@UXWP;5-6#2^O
MN(#N!\6^07[6?>WV^*% VQBDFWB0+O$$"W_;QD:T#5X1]]2ICPUR=CMP6HXY
M[#E3OL$99]_ZL#KU@GF_;X)71HB5 ?&VXQNHQ@K\C2KOA++,1Q=^022\&V<U
MX%XP^W4PBV-\?\-IE&.N\>.(T*IC.:@+>08297 ZDW?01WCQX?!B"^(+4M<=
M#=?RK_DGB0&TSI@\\ZJZ1,-&97+E4OYA@ <X*!-50!D!UOG%X6<Z0VZV3;[^
MJ<Q<#K$PA7<K.E1>-]@>E:/@/_G>8W_@(^K!:)CWJOT"QZ_#DS9?5P3] E1]
M(H39]0E9L*8E<=J =<%ENGZB.L,N9E%)DOF]B<FOR8(([C<7-HW#L"$CR'.^
M.ZZ]MG7#\/*?BNF1;E#[$BL+LTW_3&@,[X!0<Q@#9M'8P=A< /8NT<!M)AK"
MN5P9T<9+Y+#FQ!IL#^"9NJF RV(F+V0N7EB8=VZ.//!_*TW8/W)B __5P?J8
M]ER'@^@3)\X 1%Z(&#'#\1.4;XHB\/,R%>#ZL_[X#/J@<9YP^CE&?!!?+-;R
M3C*P0C. KW05/IM.>(7;VWF^'#02!^9V?XF/+,;JSB5]LH2Y6I=7I-KS_M)T
MQ][;[#O3^8PSJ**#?Z&P@/W +P5'&>F&T8I#KP3G+T#T>_>Z7/,&"BQM8PHG
MKB=/WG.?#H&B-.3WSRL(^LOL"[<#H_G!I]!V-80+LK>\%R=#E,ZP1VA-D9F*
M8*YJOAZ'5Z08SOM^Q_SJLW2M]7B3;Y3A&]+E7#/F2P7$9'INQWV$7%G>BY2&
M7R8_P4=LN[OG.1_*C<J,S+[-.+?Y"NS#6#J8U/#79?$:"</'7SW(HB?%H%9S
M_/T53&4BE#X(-X<2&-TTF?:_&B]7[Y\V:_C>XXESLE7 VY)B@,9-RU4W"**;
M"13C#^0(8::,I4#O3A=:\DFXJOAW6$#[?8N_=^XI&S[B7 M86&G;O\#$^)Z<
M73'PH6(C#"J%W4-?(7P;;0,M$$'=JG0XQPCI@-<MQGB-O+G%3<Z+;"7M<QP7
M6:F HJ9%NER2A"03YM)3WG%%Y*G*VV9@SMD6"M(CD?YHAPA7?[&K:;6^9FMU
M-52 EOGS\Q8RSFM^\XFQ=UEK'U2)O^D@NE(8N;%+5Z'*,\KN'Z%,4S)Z@FH9
M*6:-4::&GIX<E_=BU0$!5K3KQD\%+B=5N4FQ__A3.)X>S_FF[1P1KH^7#?],
M]-LAZRE7S6Y.>WH*=KOM -+M(N1O6/'37V^>&8#5 +L]V7[85H.[1\XY+3&V
MZF$/\.(+)Q$YQ;ES6='N&\G#YX5U(S06./_ZQ*DY%Z-[YUNJ'^< ,*@/E1FR
MET$ 1X,]+G(L>H;YJ_*/"<U(&\2@DR:PK9D_RQTF'HZ<N60#$N^.K]:[)7\=
M[/MN];)KV2DH7H4JD9Y M)9G<7MS5[HMU%WLS$A>QO6=UBG I#7LO9#^&0BX
M5?G9!7(-_@KA]:GKW;!,!6S_+'%"LZ/B#FPC#T>*-S,OIF#QB^O'3/FTY[MB
MC(2UHIM9O5D(;&*FN>.[RG9X.P*9Z+6R073&[IV'Z,]HY@PKU"VH8-W#F Y8
M'[&Q-_B(E87)NO=P<"X_S$L7TE,I@)M-@5UW#(R(V=C*2Q!Z3&3QRHE@QX0&
M?;2,KA+1W4.\8 'T/HW@'7KH%G?AC;&^C4;[<E1ED<FFG/$S;1/NLY'S!P?'
MIAO,.^*X@SIDM$7/X2FHOJ4"KD!Y\*EUSN([RCJ8SZU?>0SW[9^2GBR4O;%C
M=GOIQ["6FN9\ION-(&(4?.8G>@T>]ON\LHZ_>Q#6J:R\M]37Z7QD4-75F.QS
M4T>ZD8)KO"SM96L>D>^\25IK<MNVF+W9AEY^OE.4*&]>@MZ;\D5N[\B>SS(R
MO-':[\Y[NVVVM6XPT52L/;&(+I,$/@61>@YD 3D$K]5IP B]TX9/:RB8TU"I
MG0ZL??6 A TSV8_KJ5Z\8?XP4FRUN;=Q$ F*#ND!LK9JD>2AHI.M4EC/<" [
MR)<IV\-=QWZ,?%NT>ZSVCB8=-[>9[ NWT+MA"I5/B4'+\,L_J0"<$7-,SHVF
M45]1VPNV$(?SY;X-M;"JD6MZRM(ZLK)5W^3H$:DC-ED&:9;ONS*5^!P[J8"Y
MH$Z*/-%RI9*-&*[;@HLL6DXX%1[?F'-P,JN-8>S>%;PHE,"6).;&0NYA?.IA
MM"04@@8"6ZWQI00?7/E2-(7=9?'<N R?A[BZUA3_D<=R:X)XQ;NC^*K>Z=U.
M;?2UQS%LVGT/0RW+)Y".>]&J2A-4@)LUZT179F2Z+Q9\6<TG7[:4#JU6<J08
M,=1Q64\@="[I\3FL\K?\5T#)7V#>/]S*@;2'1=DRN[6=)6[V[G>FF,TM+5@Y
M>R>)=KC*U/(_"F)J;MSG6TAWTWHF!NVV\XI_\5O R'N>Y+]2M".&. ]5PR#.
M.^5P?<6CX%#-;>FA2YT0K))AJ+.'=8Q3_NWURR1&"M;J':=,SW?*;+JB^V%<
MJ]P*(DIND0X_'//1&I*XI-LTB6FJG=S!Q$&T/=Y=:!+0Z[![5LKV]D/^V8U3
M-\N3AIC2B:R=Z4(D7J6/J /R_,R\A+B96N)LP?MP9KIDW6P<DN*?<=>^S6<M
M+_0,O<_G9Z9#(4(04.]2+:H'S@9]'-6><P.'B%(&+_-9:DVX0=5>"$[6!155
M-\$'=!_M/<HB=# )5#4PO1NI5W[ZXE F)?/[3NXIWT9 P@RBFDV[8RB,FV-0
MI;0?%BZJUZ*,XT\RR(3[N-QX[GRT +]=@,Z&1Y3?/>'J*,(,';8H3%J)"@ L
M_J#0X.NVTW+X\!$GQZ6;/'X"VO5,W$F"R>;/'TBRW[AAKDUW+0!&%H5Q4@%=
MY3 ,^^FBLK/Z4WE+@=)-8EORF#NIV[#KGT.>V"J@YH]*P'_;L"F6VS8DV%[8
M\M?-A3EFO](J>M1E</LDJ]'JU9EK;N^A*WF(W>66>PJ?@D9Z0.AD4B?R"H;H
MNFQ+LTC6QL_,]IP,I=;G7\PNS*X2W]?S)K46W_T2X0N($>RR'Y4;L>4_-1PX
M.V1_F3,^%S<3?F# 2$SO.BPM(C83!KJ9>!>O^GY]>^]YVIWRUPT\#O'O'Z;>
M;3!^Z9=.2#K)L:LY*:X#1=N 3G$)' >^1%8KZG$5KXRDR_JJB']Q_JWZA6*A
MDK,?E;)<;C=C8NY=32S%I<UU+]6 4!=!&$3[""ODG.A809QK<"#6!U8:YYP6
M !M=]W=J_6OQ:?[=]U_HQ&3I=^.6% =@<X(HV#DJP&&)@=C2:\LD(;&S%J4]
ML>VK!+_2)9TYFS9L;G&L:9:=/S*+[7OG,82R3?L<,@>^G(^/VI[(VP*R4/@A
MX5TF*<1FJ4\_1<OGYFR5@2\:DT7CXBV'!6[HELY5[VK2@1)=0XF[% EB$XF7
M".RX"NY$1)M8_-E\EK;4_5P'O-3,#?VJNJYP,_2ZPVN3!!J)_).75MY>.W_0
M8826&(<"TD*5/D%<[TTJ:\& ,<M-:7,Z-4$9C.+9&\-C'\4;O-1R=.9IMC2P
MHMJ'H#@$*]1NN318!'@6*M]*C"FQJ1V7OKMIZ#S]3HU'8"\HXXVA(/>3EY ;
M[>\26:*// EA)_EB;2HAO<BKKTG9?&30"I!IDR/0,UI9Q4O$.DX!7+N28/;H
MH]!G:-%1I$)"[QT:=^"<01?E%IX350G0P(+H($@4XJQ[[9''GC2,<?9K=T(Q
MC>)15%^2-=^CM#G=QK/0T8S!NF7^LT2M%3N24L@X80PJ@=>*BFSRRI.-PVPE
MJ.[J/*![[']'H^WNC?9(N<>#-$*T01/Q=@-^5_[ZJPP^YCE;+4L%1$*(YA'&
M=)V9YFAF@]_RH8!0^2UTF_&X-)CHOH=.P6HB5B"?@!<IO$B"$<1$Q00K[^%Y
M"IKY+>\ G'YGQY9X!&^975E_O-962Z1Q],^#,A ]G\/LO1QAKIAL6:8XW8A9
M,<G"$GI-([4+YP7YZ_95D)%D=])URACXLK)A$5EU.N0:61I_@%VTMH+XZNV6
MV_MI#'8S>=7^M?\R(]!]5DQX:+X,GCTD%D0?&7+I!ZRZ,@+Z/!@WIX[G:&[.
M0O,8T'=]9OAH&5\&Z'18OWX=@@YXZ8".R>&XDQ?598N.>CK5)J6%Z\)R=OUL
MXX64&IUB;NWOSZ9/PY_&'LM(!N2NOKG?2XR]3[,IZ*'UC0<%<QZ)07*&J$#/
MX%^J7CCE A"CL]?F=&#PH&($,K5XZ^KK)!U"+8G+5N:%^57 (XV!_"]*]S+H
ML\C,1#L^^,[7Y07'#O Y94?<7+OL8^L'OR!Q!JV##1?M?3,6=>+*7K84/*?[
MHFK1</9;;#RG^"QKUGJM03[2P0!-LCGY5.>T.J'*O>2<R5X^_\7%8FS*+FUZ
MX(3/_NUUIZFBU#EOQ5O=#_&LW?7GTF.1+CL.5 #V4\TR.!+,5$FYZ6+#9[7%
M65IB\=T,K<!0+;\+#*S-C8\>JY^^R/;^C"!+/ZQ#6ID9"Z(E7\3S9V/=Z0UQ
M._,Y-W/,R@Y<Y1J2L+)IH;I5G1]8*YCU_7TKM#I,;6Z=I)P".B@^90FJB$]/
M5%98L?Q\T*+RI.,8A(Y-3W.&)N=^>5@WV6>^8,7TVA/DUEZR!I=.?[YOD 9J
M0N*>=)_B*7#G!$]+6.IL7HS#QB'/6UA;CY0N/CCCI7/N?>=L.0??V,.,Z#M2
MC6=YN.=EUR&>%$8^+.+4,YLB>WV$LDS*Z/%HI$Z8-D59&-3,]=3QV0C_\TL)
M Q+I'4!&8J?MW#Z6/NZ "CCGLLA7/:DL[!*)-<O>QC0%!=\NK+>L,^3K$D2)
M[!G!IL"%WDO5GEU(#H@CX0JQ!S/TI,MB/:72EL]Q6U%C(7[Z,)W?(8,1E,YS
MRV_AYK8[7<Y9\.LL;0+\:L@</]-8VT6B+NJ8+S$?J]/J*&7VXRI[7IG_84-H
M<P"(6ZD3)7DD,1;55;U\YYDN5)1DZBH+9/OM24/6)UK#<"-&>-8-K:_N1M.4
MWIU)5>)JHUYL=1I+7F_+^]JJ5<"FP5 :C#9$ $62H0S;@":@@J4N_$)$G[*E
MS4SX6X\\V?3Q.1Y""Q60EF4).Y868=,21")2Z>G]<XEM2SV(.M0.#0[^9**5
M!@NG(UJV!X9.@7Q!7#^+G:6K.76FN3".\VJR.MS)DFO0_2;. ?X7M;KK[_<N
M4@$=#Y2?K!A$!2(3I9G#KD86Y_^H;G8YO+.E0PB"U.>7]@B_$THEI#L;/XY.
M%?1SKS /9+Y,62($NL,C6RT=ER\^-(BP^%3H7*B[(OX0+QXR](KH'&:1UW^C
MLSWGF03R=AJ#L4YG%0;Y<BDJ1 PWLBV,C^IJ+HJL&Q*U:5,<^?XZKH6[?$]"
M>4B2S59"]O%.L]YW-+TRX[*J %D8OT8%D*]48FRCW,G 2AMBVD#WQ(!_OE;1
M0T_Q7$F7!PIQ3N\ 0H_OR%^B_ZIT;R0S]]"T9R3&YBY.KRV5.:R-UP:J,06R
M<+[*=2!?NZ5]+2')_^M@^^>D^*IM^)E&5I;.NUQ+-<@=H#-^<ZGGJF\O7#A2
MV1%CK5:[ [N7C/&X^LUH-[I?,2'Y-LLWNDN?9'?"H%<(XZ/*AE@0W 80UVUS
M#@^#JS+..?]:6'2BL-<$Q? 8T?KN,T0^>.TK:>DNL<R^?]]1<A*,TT.<V:*P
MXX5[F89,VP.7WDB7/\3VZHGJ3HOO"K+,1;8*G E(LC#D>FF]+>G-L#K6UP0*
MUB7 <Q:86S[GQ;;_^+=-KH*/YPXJ0Y'+^5W\MT>U3A3G8#_\?0]_[/PMJ8=6
MG^JMT4OZ>F6\;AYW#A44>I5F*E/J>'UO2Y4RD9T0[&.:TQ0,&44<JT,VPNY2
M9$C MN#$KYVQL@V'S.O@WH3RDZX_N^I+%V'O;^6[PEY1[,A.Z*5Y\'LJX*H*
M;N8H['_N_#_GSB!$/A*G#SP2#+E&!51%KE !.N6N6^!FT54D49B)!N=I2UKZ
M=6>$+/SU:T-#7;#3PL40J2Q5-U_3=:B'*'%<V7.EDVP\B<1PCX9P!L,?*F;O
MD?65S3]S;5#ZZC1,%MA;HR3[A44:ST#+N'*]Q"#@+^G1,IY<(0/\]-,R7XWV
MS:<DSE(!V;#/\RH]W;F>11H+@LG=$<9\0::MDBQA3'1AWEJ//AP['@ CH'M4
MP)G=)!@F,01XY]G3!/4+BI=]F>)Y9[()'E[!I9QD#=)-6*<.-MC@Z:FOUH/W
M>60YT%]!Z2HBEN?71D%S'--9N1(GU7^5G#LR:41^/[?4$X@*AYJO\-GVY-S"
MTT<>+.B5DZ7H8RN'=M#FEJU5<5'/1<\$\,WRL=V<<&,643=5([E")HP;<#8I
MN(G.I("<.\04/_19Q.["2F1?A%R#9.II7.>7U&@"%A7Y]DL"6F,SA1O!)";@
MBMHSF=]"P<RST@G\PTK:]U%7E7N>THF]87G:U^WIP"C9G;/ZI"V=O:XJ"5^#
M34/@'#%1,<K.Q2*U@<:(3/'!^$BLOZ?$(NV/,E-H6=4J7=@\WN;V,A4PFX[U
M:\I7Q]IR0?WP/5'=#,N1&]N!=AV74NQ?55V_W/^R!=OX-,E*IRK?7,M^WKSV
MU+N_Z*-/'"/QDW4]:5TM;&-WRG>PC6E;&I//<Z03%R$2$IR#)B+<S[7<'/T7
MT S73-.@&B=9(72P+N4M)&?K[6!?B9IS[WR'E'I_;1UJ;FX]CC]*TI-[3SKS
MR^IBHG+A.^G$DL]$1NR#6I4KA&9WL#$Q!@?KXI=KM 2]M>A9+*8"&*Y_;0Y2
M437/K6,U$YMYV%]S6/I50")W5NYYYO4&>@RP=P47MPQ,](V*W>H)E$U?$=VA
M:P]\)'64O.G7YGTCH?Q#E,_\-=A=.M#[;^^TV>2CQ8,J(Z<G>FP!M4SP6).K
M;C]!465[4'7F:+<\[>?9SW1N!D4+/:YZ^UI,_2Q#3=[.RMI2G,W-*4%B4#DY
M8+1VRYVGRX:I.OR42UV]'-SC_0X]V5/7"]SO,)@F3%H*DB-H6]22"S]8O$@=
M^SW2CGC; +RX?;!@VRV'W^)7Q!O_G*K[>I_KNV9R-4("S?'*GN-+Q0_L_J5[
M"Z$M8: OI@-(!KOI-A;*A*DMPU*OC2"^,LI36?A4!Z8([!:R84G-#Z11(^83
M<>_+7R*]DI>XSNDU!2\]GG8W6Y3 CFFPW_@OC_B8DN[:TR2^TI^G IBM6/;Z
MR"4];#3&VUV2LI-^)O-ELV<-Y*_]"N2U2V0*Q!9H6R@P,6<)T@OS26H![(IE
M9-AHK-T7_*'D'/)Q"H7_+X2C%Z)9ZYX<"VH@I;U7C;X!*S+$1F-8IGY44!+I
M%7XJX>Y3]H$;//2J!4M<\EO^]<J2+E3[<..K>5YVSTM3TNU]N2/XC)+_![L*
ML"I,_\,3NYI?A^Z/0_&_FOJ7+R!"ENXI_*[3T(L5"8XO"6W1I@)<50+I4(]\
MVP]VI@N<7KI!5^V _KF"N!\A7Z.^&FB<257]UG'H;M3^:M!;/Y!  +[#1E2C
M!SOL-!WF!YL&^"5UMD;M>'&<$^P>L9[&S[=WC4G\LIBJA<1SEI7TB1]2#C:F
MLPE/:FEG473@P95B<G-FE09ME9DY5@MV=WAEPJO]Y]X/^JU-)UT'4V&1$OGS
M2/^M;7T]\[S0:M'@](OO/G+,6S=<]K['=298D=!.YEN5W?N*FCS>F %NX(I_
M?+1_V6#_PKLD/S3N,'A$GZ'_4YP6=Y<(2V=UQ26EC08?U*-]DQ^?SL)JJFN:
MWU7?(<TCVH]7R ?28PX<LH_9S@GAYX23E8)^;QU-E8BXEZ/&NVT,A[7Z]!DZ
MA"<$?Y^X*(C37=@Y2SR3'- Q')+_^7!7<2KS=O3GZ>OD<6,Z^8Z5:^'QJ_P*
MJ*+"A\^4TI/9 Y\=""N,'.T],=3'--EN%SZ-<'N9L+3SNE^5#!Q.V=[;D'Z3
MZD_SX9+/1.4K&A6-TSE>)RFP!H0F'/5WOFGYCACXQ=;;X"/0ILXRHN(S,5$D
MW%!HGO>.O;4X0/DVO>#%#X<=?<LO<W*F)"9^@/?RC0QU1/]DA6G?!Z+OP7K2
M\9SC?_Z3%ZA,1V)FY<"_#4U/L1EYTM:6]Z?T>QSQWTN_?YHVOMU;V)2&RHH?
MP!$IMAZ5 T%0*@ #?_NG'_"W(8K" ";EP8E^>J@3-B\J(,R \J.RQ:F8P$;B
M=SQN2H.-5/8@&&!=U1[@'_EP,BOL4 .(V\Z"']\Z):HSB),Q6[\QK2]%W\%3
M@S64X! QHBZ%+^5T' U>V/)II-'\IW;\RWG8F!:0*$0%[,:2ZF-5(E0[*!7V
MB/TMO&.G[>E@B0A<52]XFX$*6&!O6H81A8-'PEOM,2?N;=>"J_F$#<,-.9"S
M_.:I>4G6QA_T]56M7N_9.HW=S]53*K"2ATD4W9"?F%**E@>8^!7F6;I>#5Z(
M."@L7TN8U_-4J>M^H;T6,^.:7]QG;[]<S"50^[E\)$\UY#0^9B"RG+3)Y.((
M0YYMTS,M)KNKED<1ATD$F-2W7_TKWV;7=H[\=K!?#;#,G:<KG?P4EY:+\61S
M[O],#'K\?4;65;3KZ[BA2/V/;U^4ILS>S:_0QV]4Y&5WI\;;7H28H#HHP EI
M<8&S-6._Y\S*RMT/:[@PL7=YG7C)*,;\]1>6BS4'(Y$A_'CAN%8I;+FNOB7B
M,M%U1UBG=;_0MOHD#RSA=NM9>9.J[7M>OQ[?IT;\&S>PL$@+^OBZ2F:7S,6<
MYNSA-Z]GT"Y#7K<BF>(!R5SJ 1X_X_.;4[C77NG(F&+].T88R"]Q61#'7D5E
MQ<78<3&D8^H"MQFMG&"NJ>:UZN0R!E-?8=<O*E_9=D<SFX8@PNV*<ET(II^J
MO+AUQ*74O)])Y]W+,<*WFOH'>&N2 QQ>F/>+=2?K_#P_),[6P'5JB8#_KA9J
M#*OY-G!-TGUAXOGJ2Y^120)?Q.GJ$OF:N\_^5^C]G7F?%K[>(,=$K8];WQ,'
MM5I<WM+3K?FDM'.KGK2%^OQTB?5GCQURLXSLNK"1,O'AV&^%E_)TNE8\I<[T
M8F=I=EDC2O!-3J#/: C'CP(.#8<&/^N"J#/)_K_HO7H5-A;3MPO_.J=P+1NY
M?=#!3X9_*S/4TF4N_S;@@=6$1@CG*&X4%>G3>UH8US\;?)2HOMNWZ#43'^CU
M0\,L+U04Y<+RIC,4^?K6-9]-I1-GU6&*CS9CQ;+4FWW'(IMEVL#8&@V "4EB
MS1[6#$&7W:.KOQO/3S]1]8\HES+7M/(IH/3UD\:RV'Z/S1;U,XQJ//+T32N\
M/GLVSTFJIW$F\"2K5= ?,W)A\VK=043/ELLY:PNL@CTK5WZ<@UV"9&R5!)UC
MFFHX?Y6&J@.'10![VL*$R^YB=I<<%6"60D3@/IU$>WC<X=J/<LL!C%2M *?+
MQPQ?Q&(74K.[SB9%+:Y2Z$_1N+B4S?#1@R#+4=B29OX?/LR2%_8DJ;S20@K^
MR2'#=#\/+3M:1!-B=+_A%3U7[UV4FY%,5D#$Y%I6LBY__I??]%O?7WF[K+&=
MB_"LZ?N79RE3;IU_BS'46RJEO8,+Q6O'Z[7T8:KY]AOZ=W-MA\ G6P@K&*(S
MO5\I_4R$S7L5G6$?2M#DI!%M<9U/?'63PH7!)OEM+8^N>#OER3B&A$EX5EJ_
M7?S+C8]<5(#*ILLMVG.QFNW[YWN9^1B D:_^L)Z@98O$N'J8CM(17>-*X[#2
M5.PMVA(+X-V,/J&*A2ZET&VI)=Y?P0;Z*Q;U4S_,?1*]9A);DU"%%GG))B:7
M&JZ9O61DSWJ#.@P/>A>PM?=(ML(KS53X>D:Z,%_TSG>O>,?,.HT[HCPFSDR[
MO0$J^YL*P_3Z.7^M1>1[FZZ/T'NABG^<4TQY,J;UKGF^I'ZWA.WR&VU!1\"A
MLM_&8O0VN7KNZ35YH&B] > EB7!,,U)8<FL?^""V=V'.[H[15I_"6N#+U[M:
M-O+2I1Y;+1NKAQN3"-SOTP=PUJ%FH4&LK&0NK)J6!N@/U%<A;CVL7]/D9)3*
M8;;Q^9D3, +._F.3XC45>XB4)801K&L<L?IAE>_M\@?68"ERB<LM]B1C=^;W
M@STZH@VOAI>5+ARBE!%/)EHHP[!6M0[ AOP(%? YI$Z%[9\JSWJ(KL'1ZLO2
M"&";F#G1U[=PS&9.0T_'P[Z.4UW42\3MN[FFJM=2567QHW:[:W ;+?ZO6T/A
MCH2_?L!6C;82P2O[TW6%1D\=2M1?6]W\V?]0*7_M3Y8P92K@M^',O_&-%EF)
M'W9\:^M_457E$Y(='Q4 !@M6;M6U_.&JJ@TJ("\1^6^$ \9\WZ<"QK1L_\9=
MP7,:P#FNO:.C(_H95W]5UE-VLCN=B 8?#*=S2C]L_]+YE*W ]7>7]O=_,5=,
M[T)O4 &74 A*K"(5\+_([1^[LQ^ZL\'<[) ;&ZM Z_+Y/UP(!Y^P^9Z&]*>>
MYVO#?^DNNHN^1?F.@HV,]*FV6#;ATO]I:OG_W-ETH=;PI.K/63W$NV"_!A\,
MZ/]!+_E_5\NUXQV/C3\\&T %_,BO_'>^_\>^?SB<T*M$"0E1.T OC)SZ!O^H
M,^ _=6W;R8/OQ/N3R>3P_U'W_ZC[_R-UHY .5$!H,ID&I[$1E65A[5PAPSFI
M-VF2-^GAM**717<'M=N_-6]:B<W6"# 6>5B[H+,[K-,_F?)7@V,FU.8D&WH6
MOT$2IEPI/^L[LETIMXWXF<Y!,4P96**4: Q#/U,(7@V)GYHJHY!5L$Y@A*K4
M1*LIQI9!(KW2F409>>W+TT_P".T,T;EI3WJ;F+T_DWG(*"*Q8Z<D.H^M0[S-
MX9]INP8)ZFV83A[!@IA1TA8O=X*\5N?*^G[>-:,[4ENP"EO3?79KF/W>]N2+
M; T:^Z /])V(-Y3+1.%<ZQ\Y%\<U4PH6;++OFUW=# H[/&MH<7^\Y9T7&_0"
M3<-BXP(S 414P2#X+2%=CW#B"6TMKKXW#EI[L7ZQ/)$;@?>&7UCQLM/<B6#[
MR*.ITAL+'6+HD<K -X1*(Z-MN">AX'*4^'#*Y][1!77VR?H=(<>2@"3)MO-'
MVA?D!!4_1 J44P&=@H6P3M5C.N<TR1_BK@3P]JSXZ%R DBQ7:YG[=].PQEYY
ME$R#AGY7M6,V] :1;AG^)M">@EAV9Q1G15.\O+Q[ SR$DMK;3U;+A@%G,.KN
MUH/W$X80&GFQ_HTWGOUGI<C_JZ8WZ?&9W'-*KE4C'DL)VE[WF/X]4Z9'ON^#
M&4,)\A?KCU5B][CX#%0BM51_MP5N<*E(]:%^!!R0$\0U=9H3IBXW)]2$=E?(
M22@\UE03+!>9%WK#K?K:([%Q;N+:1EOPYTD&I[S8%__T?J&(['N)^? T>3K<
MR&]PJHQ$LL8%YF^!LFK\V6H'V-";_UIP:Q#I3(<(HPA0 0U_WG;^"GI5*752
MP$PVA[$$B_\M#PR^D@BA KH^X#]"\H$'6^Y40#^[Q$,P2U=,+^:+WW'WI.?\
M\8"T0]OCT_7T#BI+!7SDC$7B..:H@.1;_U$D"G;7/4IDWAELH,"ZCY'_V_UN
M$2:1[\$-DDM'5,"53?)8YI$ZA5\--T<)M1&A MHM/2G:^?]!,&=$>4:9'X!M
MD U*P\-CK6: N"*L318^J#W0-D[ZO41Y[8GZT*^\KQKFI@-)*^X=YE%/Y3N4
M6:P]=KTL%C=_$')EC$2\9C=C;GTV6;.X'_YY[QBF?F1(^$P\JLK)H"?CE\9+
M!DO_),PHX'.A;TW0!SAL)>0KH&P4CT/L^%RLCYG=!Z2? EW4/W@H63K+R_/2
MS4S0EX/0E^MI%H8O,2^L*%,0V5?_Y*F #W,-T+8N>Z"45\IU'CW_KQ(Y_3>U
M4WN5 ;Y7Q$0&>LW@/O>LN@VRQ[$KF=WJ/Y,4JK6"*%*Y?<QT.E-#C;\GIGGJ
M>L<#I8)"%@)T--A&Y#WHZ(634$#$RCWF_]ORXG8,V86T"R[0]:W(H_:![S_^
ML>3399-GWB7A]V7X[NC&S_![K&.&P26@HQ]?I3[@X19I?S=P4)U6XZUGMO)H
MQ42ION.GM?\4/F5]7KC7H[5^>R-I)S&(0+[%;*0W66>VV)W?M"N_*;\:>$ .
M<B@2&I^4#KITNI9#3V_7N#_C572Q"^9_+><$L E14;DHKFF@P?;D\M^'I.DG
M#F"046080:K2F0KPD&TA5_Z.$9QM?=Z&X2:[AN(08=*>9RBC%XN<IN]_ZVF5
M]+@0XI8,E-I!!(EU4_A$T2IGH1A\RTID# ZX8ORII0*]R>F7;@/49=.3E?:_
M-",I+Z3T<2XZJ\U;BS_S_H>2@62>JEX)O1M-OQ.=AJ#9I\&YT)^,BO= [+!E
M\08J0,CP/XI,BTY2X*?L(JD84FI[Q%SFH^FZND<,$.ZR/::!E%(!-.[((P'X
M?Q!L?X"1C]X%FR!_ <W6XV?ZEW"_#"*1OVGQIA3:.=BO4Z[^E^^S\E3 T?ZU
MXW+8JFK5$'=E"A*S^B=S[EEL)?GLGS1KIXS]KX)J+RI@?UWMP((*Z NVRY2R
M%89U]:M>I0)&F7ILB4Q_\(3M/Y&\7*$"-@;#-^NH@'?'J%.<T#\%A62HS+_B
MQ+^**/TH*F D@W[J5$'7#_[W56CX=PTRE\Q0U+=X3P%&B<*O@YOY9X#Y%P%)
M&$@%J+X$&E>2HZ85\F5^^9.54S"5)X!6XU-^KU\B)VG]!P%!'TR!]JG^SW/Z
M_]%S\C=L;E5:3M_QP@ 3*;=;1E_SR5G4M-;7!J&"-;F,)&/QN8"""I\,TP:[
MD<I&YN'6;[4EH^DWS'[5,&ATH-4_?Y)^X]7%BV\?NBA9H0LM/5E?AB'P97U
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M9UPV4M;X:=+8RG<!B<_EMX[.T8Q+3SAX%\M4'6?CE0C-N*(N!!^LD],Y%X)
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M4P$9AK)_(8WLO^&^Y+?_'T8%30Y(M(%8^K[)H@'E*5#-9T0Z_!^8*Z!P9ZV
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M<>4D'/=\\B_;R)I-CYF V(WH94N]8'&P>1Y?IVA&QS"8:K#S\?V65/*%KU2
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MP&5JNVMW#8L("AS;G:F=223D]E@!:5KD(MPZ\SL1=+LZK6/PW+R;BLG<._]
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M;^CY,1J, ;.[MK+@?GZJ<)L!.HX_';3T]MI65HAYE\C8Y'GO(?I!'L  FT-
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M.0>5X.NVFPH%1ZS.I]72L1Z(_$O+Y G;54&>UOB#;7+1_M+I&U)*FSMT"U2
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MP[8T!];!IG>_=-V-=]#.+[US;ZAH<7[=AJ.!EWZ]#U/FH@S.(;V_^Z$:>K.
M\[W'M?OEY7$G>C4#EH',2]#W<UW(ZQ>R?#'J^@G*LT.9*;E]#I?;;^=Z[=NH
M[WNO>%L-X8/:E^BAQ'M)5$#7(C,M)HRI>)_X*&G-;'RY,>,Q?=S;8):8>R/8
M%_/$O(/T>YQZFACO$[_L5"KC!KMR.#,PC*H_]Z:7'E0G;<A=,K^W47[&?+;+
M^>N7G1RE43IH2-=L4@:\U.6Z>4EPX>":*Y*KSG=8.B';U([+251Y0$PRN5[R
MW?LW'7UKTC @ =;;G0430W[=_QBJ$W0Q+LQ6RL&ZX0'@G=4]E2KTO4=YH?$V
M2)("N.,I"Y9@OUP7,!?ES3Q[<C?U 1[X&%Q\WRY;A^OQC[OB[^-T!!V(^BHD
M2_A%*F .14G7@606+WMW>?UY.=(4M,WH3QNJQ88%%D@%"$.Z( <[?[W.65 7
M]-1[Y$N9MEGM,5 M=W5_SP[LKB)H/3M I#E0P$0J />>(D0%C&GA+2AGO>"$
M.!!:AZ1'!;P/PU206.>I #P'40QQX*I &?8/,Q)D.,ZFN5>(<6(*88X*.">+
M 9'9=CC@RYEK-!D74-@A7?!CL44)*J!=>I0*8(%465(!3Q*H@&J]R:_P3Z_A
M1V39-A+-X8L$XGD>1- FIEN(LHP$D73"DFEN-AYG$:O!)IL,1U_&;9>\"WO[
M,!@X:^YG?30'FZ@OQRDD=NY55'W#;BC<\SRO>C9MXSH\+V>:V^RL?]>^'X6W
M*.NQ4&S"?!DL_G.E7W/!00)!K9SD0W -6";S]:1"KZBO^X8%T\<TJ@06"3.Y
M#=B>L9"*C/LB];E/V^)1F%5FXVBEUN,)N#,XZ5@S,3$R&@ND3T(X\'9ZNKKC
M#HV2Q-^;G:O\'-UF=D_YQ?,S C>ZGVDUX**[<HI[DYD)NW.]QTD(]+!R=YE,
MLP!W^BRD[_;*J)_(.?[@_O9$U&2%IO)Q+8?-4/Z#Y+Q:^/<U#+DBKEF;INVS
M7/>_/O6THAAI*[ZQZ#PX1GW[WC;D,Z@0P7]'KY_U^>>W)WB038=+]'#GG0NA
MC!,!AF$<Y;4">F8-[BV&=M.B7-<S"ZXZ>\ZP>?+5[:@"Z-X,^8VL'H>Q^U_[
MH9<-E5VNIP6.8&X"%6 ^A:)!C']_3>6>])!KH>N8!+8VVK]AL%Y^H.US']&X
M>\XN )/\;1'$ HWN4C8A]&P,HN%Q2MKEA/CVJPY\?$3,IG!25M<1KC!5YZ3\
M557&2[HW-JO7)<1-7?COLV;^-U/H_[\HUYIUT)J@'MZ[L\9-1>NS(QFJYCF#
M)B^\+J5D='X@S%]$/Y0\OT*OS8UECJ0M6WA;COOZ(O?7_=$+KKMWG$-L1<?5
M'Y(ZWAEB$V^( ?ST[-=M!=BE.2*=0O+,=MI1]&Z+XEHB*%S4BP ,2/EJ3YE,
M[DG;6"' ;<SCW,Y+YSA>S)\H/],M*$-06ZX NK$L$7+;*4 \Q[Y)*<O\1J,-
MEVGIC<H'S%?DSO$L?%%'^.=/QP5Q2:AA0]J>,<0I"<B:3NUK2II-UC0TD[4V
M[U4G80QYY N;I=I>S\GU^!7ZQ868VD(9.@\7Q>OP(B,11?/0I'$AIKI*D<(G
MN]Q]/B:B<RU<%\A\A+GI1@EQ@93A7RCF9A"Z[-;]245/1H-Q)0'3%6S082 G
MRRV1^265'5$GND+O?'!V$BQP+><'%? 'UC[W(M'1X=]GO+@)?X>UIK_!FGB3
M,7J@S"$=']W)S!AZPS  KQ*U#V&)]^NAGZHAE)M?^;;X0+\L 7OW10*6YX-M
MJ#2NB)0/#*E@= F2?DO/:Y#3(489FOLB7CM 6:7C?22JA3FVL-61CFX86?B7
M(4G_WT.J_N<AY9:'@KYJ& 07+;HU<F:5V*W['1UP61SX#HH4Y@G@Y6S>#>@=
M^AXRO.TUT)'Y=,"969GUV45Y=AKA:_]Q=LZ-4\5\UVK!VE97.,[EC?Y3QT=M
M)2?#BR^%:S.<:" FOQ1D;,:U%$?):/"@^T/EG.7REW0]Y=F<V5]6R@NK*TNR
M"4>_(!F15VR+V#OZ5FL@D;"+N.GFX\5DM!&SX51A;5+[3NG6E:C VMNW'VIT
MWPO]4GGS%/SIF9FDTY?P>NVHDX2Y!T:WNNR8_@(H4SE6FXU9#Q7YSPS.9P3&
MDK[:]MDL<WKO\&+%BP,Y]<2<<<@.Y>MU*9_;T487I*WU:JR9U.\E@R.=JY!F
M3OKV/ME)U\HW./3O<3\'")OE0J(I@I5XG9U8SZ<"\C-=05]C9'['>*;(BB6<
M8N0;8E>_Q/*!#M16.S:F+Y6D<(\ 6BZS[KZ*,;K5GL\_J7&+OW)4L-*_J.TP
M!H_=_7:GS]IORT99FT_WNOEH3*C8!VBU+D)OYNF<@+]!O;A3U:1GJHNU.X.I
M2:>DIY,Y#S_'_?^+O?>.:JKK]H6C"$@3I/>H((@TZ4B+BG05400$(2*]-Y$@
M(1&07B(@'8F = 'I2N^1WGL-H2@UH092N/@\[WO.N>><;XSO^\:YXY9Q_]@9
M8:RYLN;:>\TY?S_VFFN.VE;GY[)KL=EAO5K>\+./0F7<T(R,9GBOQTG]M4/H
MX>+AX=4'-_:NOQ>:<(M3,P$>./T.X @E4Q%!V,2R2\69$)XV)?DB*FBTNO[0
MUF*&6-%5VO5W446U6*WNY==R<P9Z.8'=1[<7:/%T=[#\R.N(D-?BDFV'GMVV
M<3-ZE3'30A^"*0^O4"@:'-/VXN!G4(!X9_3SJ(K>F0[XP!/.^H_?QUY_E_AB
M2/_<4#;,S-[V%2N3VJNW$TX:W/.8X?';,R  WD\?9[X0(5[))P%DME!??K&.
MF]:LB>\\_PYQRWS[L^!+*N%S',.%OQ;HH +H!BK"O6$5D4P'TTN?S;9JS1,_
MT<M/*(]8'<?>#/;O/O^I>9FQM;;[!EO,6U3S6ZHT- *O);;/(#'2UAO7>:+"
M_C/1.2YQ[W$[AY.HF^==3L'T@\*,RWACM"2 )P];$[P/IE.=>NI-BK9D^_9]
MZKO6JO.SN4H9*Y6H#Q?YWG;?H!.('R*S0[3:WC(<!G^!/+TW7,EWIV;F=9VX
M$J=+B4\N:N^:(2WA(Z5RP$]@\%V%EK,P.P>Q&&A3X*?''J!"G)=ES.S+';Y5
M?63F6RZ_\_15^D]B -'%_!/K]MF2KC?'-K4N,#6VG0)HP"&R^LS^H?"I":.1
MI5J3'K99X]ZG-<H<5X!HKGXJOL6%$#4VO-]A&QI.]PO&[=2'=' 1T \9G77N
M;Q-.C*QS7>WTUW^0NOXK:WN<XV9#:\2-+X__F7PSU["!1LSLM9JN1=4[9$W_
MXI;/++'0LJ3O<\LSK=\ILU@3IF4\"O;O%52!AB+S@,6^7LU([#!MA_D;B%[X
M)= :-H:$U5\S5X1JC3EV%LYQCQ1L+G^I!28!S\"-('P(A-/_5VRC?89MX$O(
M?V(;23RMS*;H.GR\L*D+V)!1>OCE%/"1:'^&4#AP N3P4T $'*OW!UL9_ 5W
MM$@LIP#64\#?@*=T"DHXZW[C%&!:> :[8(? Z7CR4]Q?. AQ(DP6^2<.TB+>
M: H'[NL3_VR"-D.2KS79[&W>&/B637(L(L82)N&.^L?ZG0B\ 9P9] OYI_+*
MA3^@Z-_K3THZZZ+6BC@H+-W5VK$D%8!60-S_85*L\-9(?.PIX/X9N@+AK_\X
M!2R)'H+56J,(M*"_IQGZ?V?YO_DL$<T&Y*IG9&W2)JA*F)B'^1>E#/ZIE![(
MJ@'X&#NQN8,6ES$>V=XOUF3Q734%WQE\D%*7$F+0;)EP)4;ILL7(-_AK0Q<Z
MQ9?:C^?<40*YMS09'TRD)-NQ>='JIG_.MH,/$/L?:$J;A.W^+!=M(ZM!&?'!
M.$^]+>4SG\ .0M-B$_-RU%(*["/1/4X[E2ETX39[GX(*[*>LFA4!=L5^T6R+
MQ7P#JD5%_'Q8QD5XN^1[-YL\2-!2,Z[T?>6<B&R?PGVW2V8FI.3.QQJ2Z5'F
M$9W%_#0MU*I.Z6,@&S@W!([*$!@G<Q#-?^#]<B QFXZI&0BO+/6O]]VZ2)O8
MX^T+%G;N5%X+]M$")T\BH ,&GL4J"'ZLVR;:$CN#!D;4<Z'!EYV,:A%AE <=
MJ/ JT9K:48:#;C:%J,6\'>JN;F?AE[=G]=(WX._(2M_PXNBSA6%*!(\_[512
MG:U1[V2>H0NI9U8YCEF=MOOP()*5<*^"A,^&HV<L5C1X^X\N/7,"JN$%#FUP
MDD3A-S 1? Y.>F\IZD0_00B1JY;&GY([_>)J$L=#)YY*SQ?G1.A$N%ZL<1F*
MS$-=\<_\<:'HE;4@-(ZUD?O;Z/8U<]WU;F97FS)FJM1YH4M9\@F:K9M\;^H"
MH^L0FEDQMKSYNW_6[_G736$9U,.O1:D0K4<P8%WU:+UROLF]G-=U/3:B+E?>
MH:]'&].^<J6-._>$+1@<> J@D&CD&EAB\ 'C9.=E< MAR\$'_C ]F[*8UP&F
MRO;#XP(KG66=<YK/)^/,>-A4'2-N)WL6_3F&+B[PO^1\>T3?QJX"_P(82]+@
M=]./_7%X D?\LC^O^^\!^DW)2J%5BQR_2X\4UR@V'CVGL OAQ,1& /S9@.F*
ME+J)ORY)P\&='UY(NANKY%OVT'M3E/Z^PSST[RNE/:X:OE;'$OQ@6_ =%94?
MX>GXG2ETB.+RJW? _WX3V,=SJ^"_-W'"_^+2%A^&8NHGTLA#:V2QIK"FK853
M@.ZUTOL$0[.R>HIG9;SKRMT3PEF?"=;@O3&0DMH4!_% OS_WUPLLV5I?X^[A
MSZ:U0MAK_W+)XW7D)XZ[ XRK]V<>*0H^H13()]V4K+X/CTFOH>T]OXTJN<@*
M;95^CZR[UL'Z<4"A].>LGS^\[8"5F]G@<?&P4C9% M3E2N E33\_PU' GT)S
M"M('HI.>'BA%H*F7+IOZRPR_QQ2_\A,]TMEL5+_WO_5"/6H@,0A/&U(I@FYN
MMS23X>/_H;[L_UI7IM,7C3?"M"FS.@!Z^J/#/-GN[S\%A'G)(/0=9@.#\,&U
MC)2?V[>T!WXYZ@)N9&6S9 ZHRL3.OHQ%#@Y>^&@(<U]DNVGV6;&+!.>^Z][0
M\F(W,U1,:O124PY [Z\GJW'X?K9GM-2R"\6[Z._ _?NR>7AKK@_S'0H*55+^
M>4>1R"O.V#9>3RG]?\G2%5D0'>'Y+JRJN'$*6"^P/],RO(3-X 6V>$#PDM(:
MTA%P1FY!BNZT">*#O-;DIFB CL9]"8[OHAF&MU9"E (F]K.W:'XD%5BTQ<?<
M;CX9O%!I"+9_V-U ]T:%UZN?<3CGGX;0#TZJWD:"=>/^'QCJE\^7J)>,0C$-
M3PFW\**F94.ZOH&XDE@=Y\VI&BF=$<;?H\:4V 4=G&T\;GH5Q+%>?5)22.9>
MX!UO>7.1/,2]&, *W396/7/H>TC3/6ID#^E+$.>L"#91P2-ZP1DDX341](SO
MAXO[RNH;5747'D=@I19I76T(>%3@V=BVDO3*I=(E'W;V9S[A/GP^.^&03J],
M?EI^%&2/((SZ9X%V#+H)E#F3:?^V9_Z*?^#PYL/JZ"K&:0'R ?"/J&=CB\,;
MH1G-Z="MRZ> MX@_LK?!+ROK6%RR7=0/PTX!#5I_A'E+OYF:AU</56?^-=Y?
MPC'&D^(2[3/V,X])?P;\6UATD_V_5KGKA%&7_?SZ?8M29&?8=J(F@(H"F1Q(
M_<((VN2H#2WU8[^1E3Q,B:+W0E'(62.RDLNI!NBE4 *L&6[@V.^')Z> T/4;
MYW7_S4*Z,*>Y'OWE6>==+L4UW%G\<,O(RRK#"%S@)5>>4V7M^" /L8RYS9D_
MO<51!KIU-\I3'X.RV#]K^:\Y)@NH"AL!5W;L-(,N0Y4']W<H$9SK,.GZU-;.
MV76=5U;?C0($[@SPE)CT4IGD<ZKLLR5@FPY_U$VHR3[$UJ%. 8RN9&Y\[M+,
MEJFGCC\?D6/]\G+2T5!6_M7+,P*BR=9/NA<%?/6)K"+>-O@N@CP#E:C45[C;
M [&)QQ+5 XH_OMVB>6\%CP.>^R8M?8O!ELAX"G@?W[Z ?<Q@NH=YUI"1A/$'
MWK57$;?);7XUDO/>U3AU^,U'%4)VZDJU](^6-)^/+JWC0U$O7+UT/9^4'?U*
MYT,YN?"Z+@;U*W.K#2I03C>O42MR8@XV%0]*?[J=@SAU(JOR0HC^F+2=]T=P
MEBJ2YOIZSZ.)'%S6\VG(&W6NC!O%6S8O-V/E!MUC"&_>W^$X2FN +Y'S<&H+
M:.3F##9^B:JT\-?)0&15SR>%=J\9BRN-WZO,OE1KS]NG9"58T'782?#6%<J<
M]PF!]<)&"4D88"<#<!'1Y@_NG%[)S?3]\MN644U57C#.EGF ]Z:A3.$'^@!$
MWR _GMJMQ4*V'+<6]%J2Q41+5@E6D3>S;O3;G56[["'WSX#6LG/?9A=C/_C*
M_4D4#24 H;?P8((BOJ*]D7.XM+)N3G*S::JZW#'IR8S)@/CRY=D^5D]MK119
MF*%S7T*[%-L9HOO99+\3!&/ NQ#HH;<GB#)9IP [1[(H4KUQ7.)Z;<KXJMMF
M7:=/>YSEQ;U596/'#[.7J%A?)NMF:ZT7SFLNO%YIJOO Z/IY7R6F,2N]YB*A
M>N4=2B!/Y10@9MR^4&.*P-M+3AG613&RN9L)LBN\M:>FF,$N[Y=(Z+]7 IY!
M61&%#C@COF+KZ.VU7^PU,I,SLUTN;$M?3"UC:$REN6*M/41>+-=[\$W2YWBR
M;3$.#KESEK!%?/MI&:CV"=Y_0X'V.X^9!]=,#/R$B,G++^W>"6VB=5'16$1.
MF[6\)9>6;&2PXG6]=>J%<\WG*Q^WO%YP/@N_']0K^F)AW;?RSES#%_U=V$'9
MH<^FZ!*?7@>PW*YMIL]H8XNEPTDNKJ?JJ;/1A,Q=6F+AN1E>J1+M-:[;0N'W
M6KB3Q&'#"Y5S YNG .K0S]^P[S-NC56%'="U5Y%'8CHYBYTS66:[1Q2M?KQR
M0=_[<-]5^M+@?# 6L429UZ$?RL^%\TZNF2F<;',?,ILEY;@(V?![__AP;D\3
M'5M^COX]T\4.J#%.%!/:FM_DUO#J#)9+5>G3X^U:!SZW>(MY+<ST^<LPRLO'
M"%KV&ONXJ[CF^&C>/?[&#IHL.GQW9B3ZB^!.T,5?)\4QU3#^J77NII"2DDS"
M[<9O'6W9#9_;>X!IG&]>]6*V+!^U4O)FK"4WY#6YAHZ#JR0[HJT6$<UN+)"9
MNS55]:/[I>7)Z,;P>6I&+WH)6H$B]Q)4_FHM_/V\=!T.]=<.A$-E/Z<Y*_6*
MT>U7-7.\!EURM=TMGC2T=+S,;XU7_0>:&V@)9)JM0JBY4[$K'.B8E+7Q>-3,
MT([CW7H6BYN8VT>ID//.WZ5]BSY-MB(U29GU=DO:<#OPE%>S&F_<[V+H\]Q)
MT]F[7\[PDMT+Q\O^<>.SSVG2I+YZDKX&"AJ]R&*^E:>PV77XE<2O$"OZ,IU)
M6NM"%!8D\T$M)%WXR9TVNURI=(\,#W"* I@:)D24J\<U5GTFBM7BU;&KF!;N
MCNJZW+S(*^/7?B2(N2Y'V,ZNWFE5OZ@ON?UN[E.'YV,B]: +?!'Y%M2I75J%
MQLSQ[\_]G@YTE!9XGG>8/7/,=$/P7E"O[^X[4(:/:XM4PN:$!\$(5N:?HQ#<
M1K^ON-%_\10 PFA-QSN % #I+K>O>#>O.^WU=&9<&X/;NT4B*Y+:]#DW.$8@
M6NWS#%4XCC#QK\)^S\;LXJ:= I,N1J\<FVU:31>^RSW6_:!;_CJ#:6BKR=9M
M!M6VP%!_<4()_J[>/%.OP/Q7DD)YCXN35S5\OODKQND4\+FU#NG;'I/2V1R_
MV7T8.@=RC 0D=FJB?\<H[V^+<&^QRULF3;?HY@D+<P)CM-92B?ND6!CS;U U
M=2C4' =:DMMN\L)(;A$BS84?5XR5%*-"J[_XT#JK:[]A35Q)H=BYOSM*"50C
MNDT[KK6!N%3<<!E';0MT<OKAIC5!F_,CCW'F:^'1[RWX[1>]IQRLWQSC[F/U
M19XFQCU5DT9<MME<D O>,A8?&-:HCXY1>^F!K(6=F; #;)3>;\CT;E3T=^7&
M4,53P '):7?A\!VNI )'1Z:IP,:_P/'GJ#44=BWI7$T]_+7DD'A]%*UI^X+Y
MGN;GIGEGYIEP9X+D5NA+N#5RREMV(#1INB0E'Y_6/OZ[P*EBW4>R8.Y%O>WS
M;?(@)UOJ4]NT:K2VKWMD!O **?, U D.XQYH X9R-X552M):X&>,RG8?</.G
M-92XUCR(E>*Y/+FE=<D]])Q^CC.$Q;0)IQ"TSV#W9&AU2$YT2VU^VU]Z);G'
M2BRVJ)[^N;J-SK3GN0N\ 6?&2S @=S>=!2R[4\"4&VHZ-! S]KHGWB'O.=@W
M-2I>/;^'E&.+&Y 5>^/[JZ6[_.;-R!3W6W<L1#&'$>3KV)U-A>R<^<Q<^4P7
M*S=27NZ+8X4W-IT?<[6_W-3]><Z6WJM[+SU5-45ME"3Y?*SV+:9*=DY3P1KC
MJASCJ0TLAM*AD>>GR'U-V,<+U'AA].;1B7 0\1GZ6.+@(6?O!/NNK(>%KSWW
MD[XVT_!S@K45/]E:E:]VD)(:Z2%>A^-8> SL*M&4._''DE.T+>91]>Z!SK X
M-_#&@TC'M$E*HUKE)_I2'*^.%KXOBTX#LR(]HRO?=9C8F- ''<,S'/BW93]H
MP@@O@Q>M[7CM2D #!N /8*;&ZY#(I20BRT1;.20+=U WI["D</C:.*E"3[5O
MV#]B:9$C3LM*@"JY1 HA<>L[QMN/&K40* ^JV$'M!%$W-PKB- /R\;O;+A3M
MJ96FH6F^^>&YU3%.U3Y&UQS4!GO->-@UPF,O)WF#;/6K0%K!W>4AC_L9/Y]X
MG0R3,KVB>$]@8 SX/)&6W$;Z!'?1C^'G'#: JF(Q.MAZI:V^"BX)7<YKU;&Y
M\X258XVQB>XO:Q#,1U0_D-D;@;]/Y$ C(Y&,:KQ.&9=JXRTLSZCX,USH3)7J
MLZ0M.JD?Y5TF*PFQT_H?.G5KF;N$>S$ZW[SC0%;Y7W*^7@KJA3N<.P6PV[5;
M)->< H;#BG8I\+Z&<^2E4T PK!DV#-S5(&KL_]V$(]B7*G!.KU3,$B>B;&X0
M+AF[G +HX,DI;MMG, HJB3=()&_"CUK/NDH,:0Y9@&7KD"F$YT>O;)KJ@"1L
M$UK3C%!V"EB@([/6:?!H\ YO\X_[3\K[73@%-'(010^T#J\:G0)"'+!^:R&$
MESPQCRAGFZU) &+1;IU]Z9C^)(+\$-&"/"3\57\1QOZPNY?0R%R@E-S5^; R
M&][!OU=;+[/$T8D .L"D&[%_RFG2;EC(<ALG'#8\.B$O:)>[R=_"I>GDSDK(
M$WN$ ).3U,5^<1,R&#=.>_ EHE0^'M&>^O'MH_ <U.KL7)_ S<X?K<3L)%OG
M:_F4Z>7O.#\P?OL*JQ!-%VYN0NCC_.OULC?X>>JQ=M'U,I[5)^,!OE>29U+.
MW>IB73_?71(0=L7K'6PC&U1F/  L/P4$$1_*H6(:;T)&-./;U*[C WR<O$X!
M%W=[=^%VDV9M*Z9?PPQ9/\6F=R$.:0Q=?C86X<R6!D+)EZ"@"16K)1';A\):
MX=:?7++VA&Q?L2N.2:O9O;G/$\9E&4<MN_QU\T9=4884X0ELFAU8X3S^UKLF
MN%3%LD3'B53D[41?ZN9FE9<"_?@C%7[S8=J7JZR7NY[07/@,PQR&X:M\L<@V
M)9'AR@V_'69\FE$5=CZ:#U-NIN'K#NY)]/QA2>M\/8%"AI@O]6D,5]/1Q 3Q
M=)N27 JI*L;OM+Z=Z 3R]>3.;;Q]$UX\8RYXC^Z71D-"O=2/GR$,W9/24FXR
MTK6%5?Z?< +-\T!2MAKPM^<O-8'HC(''B.?8G?!]A^SZP)$G-3XFV_(A4K,W
MI3[(NB6X:C[#MJ8_$9)V[L6SX,S:^:5Q'#'0RQ@G!OD!E 53ZN"ZC+WT@VEK
MW/Q]VQK(!4ROT<6Z%TR&THGT/M+% ^^;V.7@D?Q*.)OQ)!<[X=8MJ?A'PW(_
M#59=''&^WU-IZ(+9L=]N+6MN"!1)][3H'N\L*81^P=)G"&"]%Z+L)E3L, ^E
MO'?"+>2_?XN9-,4_&E:H\7*AM\R.N1>,B1+TDK)+F;&UFOE]"J!04U67+UU$
M4H&):J,J%&B2E_;"HFA=M"[?_?54_TIM@HU)3T-=<=V=9FVSV^[6\U1["=0R
M:BE9$:(RC_^G___A/[\H>DX!9S%_ $NWN-V$R<Z1J)9%5"#+_+-_RO@FT5!+
MNSC#OU)O9X1.U\-;@-4E1:#P1O[?9%6\D_<B'R,*=^8!+FY7\)>QY_"U#XM1
MW9A77#(*YQW@IG*_M,9%*ZVY0&15?8\LVT$$IH=P0^AO W>9JD\!W,<\J&EX
MM!H=41Q/@7/J4%I!=( 8'>1KW_Y68C@(^NWI(&0&D?B@)5<?-* L1FR2]E]D
M^A'SL*_&1$-7P4Y5YWOW3P)%RRD 6*^UY#:CC@)2KU6,6&('0E\K5BE*"NBH
M38F55%L7?2+(GR%H$/:0;5]ZX5X'P".))REVCSX@=EW-<F34N -)9U)*9)/!
MT-QL5GB_A9W$7%.5C#K9!2D=CV 2R[*@&EA4.R)B@;&1Q\EXR,0I[!7^!WRI
MZU5=39U9LK7F0]D$ZYCKB8JO,)ZHE<1I@S*+7M6"D^8)W;*=-M:-V-\H4(G3
M&O@B;-#B*DYX"XF!OV>9=OB&MVN;ON9H=.3 FK7KH&M2(<H\0XNHRHC\O0-6
M@MX;+8$[2$;!*T!MI3QS W!TL5GKFWF)4?9Q=5<YT2EQNT3-#T*&DB>W#%8*
M63FDMRQ_>*0LJJHM'/J0RN#V&MC1"0XLQ J]?W3(?M*[^\*7CJ$1*<O$(>P1
M(E7%Y#I[&2!(6E=-;BA2ZR45P,2<@!=@%)"TSFF&AN+5O!S_CRB&_4=81;]D
M2W<#/K/@-ZI:<B-$(5S"0HP:"UZF/:EL9L9B@YLO(\^+K?'74HQ.\;@1W0?M
MQR:+\<--,MLPRE_&"UA]EZ=+&^9.7GB"80.':4C6=+9B/?4SIC1?*VAFU"T6
MFY;XOA?;G:PG"EL,&!"S.D&)W)-Q#KN<]-!I:4Z^=7R)0>A/E66,0>1F8O72
MSP=3T59)6]:7KY6O,,4&WX;UJA:!M%)WKSNS[ %H>)EEFHG]6HL.?>Z1J-Z^
M?C9-KPAB5SW^-DX!7;P6?5!,C;:9: 6&*O!?'!>OFI-3>4Y5QM9;8.4C^%1^
M39J*F?.>+_PUU>:VZ QH,6V!&GK["_0R=JW]6HV/A=!HL=OKU=KZ^MBLP#ZW
M+Z< S0BQL"&5GRH#M6;0.+Y)_ZSKCX8:>J+UNE$EL+&%RM?(,U_?5JS<(8X>
MPTG5C66/4")G^O+-<7U7XN%)5W]>MN)<?WM4@C@,P=>? @"-ES;(2DI/-JRT
M";<)'-,J00HI[A^\A,91)\VPW[_\B]; ^)O+&6Z;Q^@OSZP$((63FP:)J\/8
MUVR_D%@#$6JBU!IB%-ONL"ARQ8XL)-^&V)LUX,SK6;WTT,N7OP,[T-&'&0B=
MY\"I3_F'N%AI5XRIH=9\^]S6VDNL& ,^R$3/7F)$CQ</E]TV>JS8Q4<",?90
MRQW["P=4G@+"P96EFPUH%Z/U$P8A MHUM4++1OGN]=[SG<2><]YMOJZ% M#T
MCZEW:..X_.TPJ\'4$4V.C$' BHV&+43K9*64CUI*WOS#R_4Q;)\R0VP7]@I)
M@7Q?96Y(:]^E3!A<9K3W'SK\2?)M4?;HHACT!@7[(EOATZ)M2,YZ&QQ%FZE<
M3)&3_V*Q.D'A<=S)C401ZSU;Q.OK@J^,7S/V!"L*Q'P_UIQH?BO9XC9CA%I<
M"\FN#T7[M#/2O:@N0O\XX)H>9H_CPL1^YFD3C*HVD$S64]SCNDOQ\A'\4)R4
M0:3^2AX\<SRG@$JHXC"0 E\HA-TYL4&=,.G5M7$=6_/;JKP'UB_$):LLLW6'
M'T:=Z!\*DC)5M B:4-$QHL92))^"?E/%^,I(W,)#G<L7'"CK4VQBYVJV4^KV
M9\#WCS'IV5'RLULD&!(#CENH*-W<0X/#D67(#GUVIX7I)&Y4Z,JHS7!6S#&Z
MYEL<W0T[.^W&WP[E!<+)]5G7HNO4^1;"D)R-5R +A[:D-*C\=&[>5S!DB6!0
M-LJ0D7E(1WK"Z1J=+F^+4;.8B%ASJBQ<3M!Z^8@TK9NZ6JE!6Q.]#,O]VMU1
MEDX1=:B".8[ (]%V6W4XZ@YP11T$3Y0Z8]TS%F<?:00&61!=FQ?'"6CJPM+&
M.0D>5TR-8N?%U1]G1&!@,:F]-!14&9+VU1Y.L]W(3)1K*'=R@>O!V<TVI%[4
M.[EC^UN^.% <(YC.<="$M/!;)^R&4!.5)RC9ULZ07][1HQ5^MT,CKX %_E'-
M3ZW/G&$C_CE*7K%=P+DCN>5_\/?0YE)FR,B]ZJJZT?VF\F./A?8=U_M)CUN/
M[WN_.O]#A1N'G!$UPB(CU:Y"&-$=.T%R;N&--^OU&NX-M,J?;-9*("N+8GU4
MFDM3;K#OHKC7[)]+T*S$^W2_A8=5_0#9 J?C6[C?R_Q6 H5418LX0R6O_VH@
MM\<>&#&;%K=<J'_9C+RM*,:%ZA-(31[YKEN,&-EY#[O9A%MHA5/B8_[*5[!3
M_Y.O4/6/?(7/RUOT\PVB/8TW8:-',!9\&F,;^#R>>V,)C&CLKHWN3'$J:'-P
M<W#46\G]=,1I3=&M;/V,7BA*E+G9V(,@IW<*X,1A:Y:=3P&MPCG[+13LL1X?
M/!;&&^U(D9MB^XCID<.TFE&Q:^4XWFGT]ZJ:VH=);O9'QI=VVWFW=U-,^R9+
MNWUFTHD_ST<]7=V5]83MI.R#6YHB^<7Q 0IA7U5LL#,&>(^B7WOWZ'V,"WQM
MO'D+FEXK:!>6*^4?CVER> :V;]-MT"E5;]K]8U5@03.B*#(SW@<K8)+4L57T
M,,_QJ7H.*N^W@KB35\%/<"^[B^)Q=H1AA$;L'E)DA2[1AGI%,N#-VXF6@9F@
MU@S6$1C0'"HT1-3+T9U&A%"'39A%/M:VJD\4S?V0.#DS0ENH.1<=J#+RP_.W
MQY[?.$AG_#?WG?0UR@:LU$SI6[4)#BYG:U>N7UI\)SYLQRNG@ NU>(U,2&1S
M#;_JZ,+C43F2,+BN>H3=*4_^D'[<0S!>S''>3*5 @BN9Z=[]>T4BU^'6X/>U
M^EM!Z 4.J#X^VJ]T%M]#>+LTH3,J=N!4Y('>*N!K36,:Y@N^_N-5P%'6L>-Y
M!-+OT.^894L-*+-A3KTT$%;%.$W7#F1T50.NI]J%[/?)N6[56UY--EF7_EAS
M;?K68%@;H]*+X(_(67XES%@JCEWSWL4K=M52J-M;72B5=-[7I>&-'!HU9-H4
M7.BM185@2\JR%BIQ09<3W,:L<=\?H_^-U@]O*BOM@',X89X@GV-)_9G>.?=J
M^A/'O<RFU-U?W'//S"7-/JD([%1\1?LXW_$VQ32P&&G/$[CUTBLHG=[CY/#W
MQKU9S<DUZJ"0"Y<S4JAS8);XH*6:2+(0]!PI"<I7!,DVW(7ZEEHXI*[FV=V.
M.%F?%MTI"UOVV/U9RM"_)IW-87WF&!;G@W'"S4J@33A!%TH'HLUN')1%<CGN
MY&S42LYL"U74D98??XD3N/W&QJQKBH*%N]*^Q7AMWI.Z4@WOU/Z<Z^*5@(Q)
M%.^:BJ?'@# UGPALL$GB[I.V*[STN'1_=\85<!S\;*X;?\VUYI]S'93PIOMT
MDZWQ=75%XGPW3^ 22S"#0A?KU\6R&,[ CS>YXY?D*G'DKE, +0PTZYB:48HS
MU6=N<^%O*#"OW')SLST*O)$=AA"[ZG17E#EJ>U>[?Z"APF*@%^$(JR;]<2-'
MH4?^?4![7DO.H S()JP*M[.55 31[T RU5-CEXY:4FO:%]@LKL]GVJ%Y_-^8
M\^A//_M9E_'2N/<CG:]5M%>E6-*%W:ZZC#-VZ &)-'>QPE '219ORWYB;$OM
MM=+'SB8505/%$'(_$\>5 VD2S@5?VEPLKT"DS*8<PK;Z5+-6RXX>LAH\Y_YG
MP@?]/AN6D<CJ^P:/5+_ZU+>RAEK@-I5>EN9;S!7CA85VT440_BQ.1YLRDM[.
MP'_Y>*^OZ*B8*S;F6; )FRJHB>WQ_),1^T:3)D\!.\%G-T97]. 48*5W;' P
MW\\7_)^+W#B4;4I@G&K[UF@%?P,BH.&M"*E_L&P=#?[.I-W/A^Z;DLD+<P@R
M'HS-[OTG17]BH%660\Q735>F6U4XLOJ+>=_XUR$^&FPZP&\RVEUJ/?[7P50Z
M_TGKK[/Z<8.[@_[/&I:C(M02^B]CP0K)[3?AZ!0B_V(&;)(*$W>G+IT>^9GM
M^"FX"/3M%$!,^W/0\-;>*4!/N#1V2=<]AITYHF*U9M7W>:I!5IQ6?006,0TZ
M_()=V#QR8ZCJB]X)JW_F[^3AY9+YF];"B_Y6U]7OZ8A44>^+ZFIT]%*TW3'&
M<^/U;H<QV'[$V:1]EF+J7_=PR2W@[\D]5%EG-LM#'H(K>H3C!MZUJJ*4:6CU
M%?M@WGSFB.1XAQ=;:IR0 O(5J JV-"*USSGM^;"+G)2SK30).1!N+15ZDP[
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MW)(_D3Y]EENR7A=M7BPD\I@1[K(.!1[P^GQN>/ZV+;_YXI(\48?,'MW? >;
M*(I&871(XNWUWVM"=B=3Q+59G%5SJE.G?UY-*D[=EUL[FK<;NB[TVIMV2Y[
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MI*R#F3BQ^!U?44) _3/O4$WU*"ZCFF[A#YE=WBTF%N4=K:?E='=,.3ZGG.%
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M#V[2>D*_2H(V*W**H^-Z+TEMRUV9?1A9EIB@&\3X\4/606#)!(?NCRWWOQ&
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M&HFR]!K#P(@=_JP=B6ELI*U6BM3DHR&,SM<)-8,YH><Q[XDR4\L&MT]W+FZ
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M*AS+(1D\8:JX7G#T%,C"PP*0$E=7T:$U:?1_I':B]'Z.K=\$PKFX)3E<G<K
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M L M/M0KPUEQ_C';4U 7;WIU_G;VG&G5B^;OYI1ZO_-5M* JL!$4E4-'X)!
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M$BF/.']K89++YZXW4P')T=BR)BE]G\](*(KS3,FSV[Y?JQ+MU8=+KP/2AW
M_0C8ST/*D]]03Y'UUNM=K)SJ9]L^:NMN9"8K?%P,7NCWK'WW*OZKW2FML$N)
M7#UM'ST?'3(3Z<;%Z NZ)#ZQO-41+#6\J[ E&%.@,H7C"3@\0M$!A[MJ1SDG
M>F>HSSL0VC;#\H/"F[MF;+'&4=WI7?>Q>8!;V37'Z8IXAP!,%LHO>S\JBDY&
MUD]D-QGH(*\;DX4;2#FM0:Q8("#+6<YI_D_T8<1651LKPM:%WT2'3R=-PK^[
MBOON_GOQ-R7:L$KH<'6S!FEI+[)470E1LEH!Q T(: R@V1=A_F>>B3(+"=1<
MG?^Q_)AVH'%;KKSF7G\PW0<'6JX]SJTXB Q<@*(P\MSAA,7$46"#.:29%->"
M<<"9(\5&UVUB>U..#Q.QR*@23B.Z(W$+ZZ.RGZ[Y-SC3;M=1)E4$R4&&M,?2
MMF2<3KQ'^K33G*709I65K*"SF/0X&G_X_<ZS!%TNW'NA!]S)M\NOQ&AD0VXC
M2;Z/62OGYM#XTGQY__4&VI _7.OH%;@04+$[_X0$F\=%4GCGT35^6,+9X313
M]/SA87%\AT<Y)Q_TG51GK)3B]=N#'+JG^@*LA$90?^7G&Q1'(\\<)J8>%FJ#
MZS2F#P2;DV)JM#DW3XD]\<MCVK1P<F53VAP\T[NC.3JN7E3B%6CS;SH KX&5
MT=L-/1M.EC;IPM>\I.R2:(GQA[<H!H T 15QP!RB?E8X:=Y\)6"_A'N)H2P;
M*E1XQ@8U$RPGE* SH-YR-6*XG#TQH'VV!HKVFCT#J!%RL6]^!X+G-<N^3#K)
MC5OWC+X<+JZ:6',)3+C+X!["V">Z_+8CTTSL3+KIT;N(W4'--8Z;*W2XF)C'
M*W]R.6B4Q7H"W'^OQ'T,.. FPR<$<3-*),:,""IK/4DJ+,48MEOL@IM(GQB[
M8XQ(>1[)0^MD?W9,N>MN\/U@:_>!H&YX9>@6K@OI_FG=-,W9+['U9615P[ Z
MY(7=D'2.;]+3VBJIOF\L--Y=ZLHJ/G<SK*6_E[BZ#A_<B[I>(/_?@W'QU#>;
M'.4T*S./[Q$ZXAJ.(H\JW2KO_*#VI-B/G0V(O*)Y%.,9D5[C_@?\\&_TG5<G
M3/43>%O!$?)GW?48E#4]FI5B%/O\OBC,WFM^[HM)C%V%/&I^>84:B:.:00XS
MT(!_W3$HV_T8E(2GKI2&%90.0;Z^ '=1=P-%AAU]-)>.0>'IF ,1\+[5,6CS
M)>3?_+69.QNSRT2S#YYI6Y-7 WN<:)1^_!$KFE*"VM, DW8\CT%W%HY!XI@C
M/)SQ ?2_BOX_+ZIW2'N*@MYZ\H>;%UUW\KAP_]KG44<?@I0Q$_0M2O4KN_R#
M=TNRA#-<,S:F%L6T#_<VC!.N\=:'_"GMICLZ,8W!B&-0-\_H,6CC2>V)-G*Q
M(,E]**4/:?OR+J?T<T=,ZX\<6!J]\;I%Q#2_\HH*OWNG=L#NZDQN:?0QR+E8
MI.WE* Y_;A+IT-A0"0A()0>U-1-TO/:1=X66[O@BSI^3E7ROJA[S^@ZBZIML
M(?*."?YC8MFNQ;2@H@HM/Y_R"N_AGQ--@X-72+_Y#3E/_3XC\:.9V5H_D*1W
M>(DG?;D*J_3R.?=^D@_.53Q90K_:PI@',FL2'S86'_29C(LNHM#,]0>TU[_Q
M['^2X[3'G=3NTU,L#F5P%7S#<%/B]H?3-_'N6J8^;-8_^[UKS1ZSL0XPT1HT
MH<0*O[A,!$7F33NKADXIJ@9^TM?HGQZ.9KO16=@T/1U!]Z7NJ>XW4,9/$N*U
M)A>%!4!G3?J-GG1[G#RO)ZY9H"+:).7^3Z35R%=''U^IO1N6%JU#G[Y"%ZW:
MMM64SWS,IY7< %<AWJQ\;V8$F"9,A[WQ=(!+>YK&:-2F])7I?M^<R14B!T=!
MCA)]G9'Y*>V!3H]:JV+E;%MA?'8EF-,Q0VR(^$>2U:1BQ&L]N)=]&:.*IT_R
MB*')$G_;\IJK2VPF_,(QZ$)8%%+W&'1^;<W'M?3H[2S*[BA+\^?NBQ;UV>L?
M)Y4N-I2]TCD3K!VD#$#(6FW'($9\)R+"YO*/","\:&HU.8AFL-AUL;QZQ)N]
MPF\IN!-O_\=?^ */:L?._K/85EG:)LI9P/:SG\&H!=DW:I/[Y*^R"3,[[1*Y
MEV>FLZ.?*QK>*5E?:N&2\0]-710;Z//(,KN^()[1>Y?M(?=9M@<W_U?2%6:<
MY.5C4 ?F'-(_RTDQUO?+6@;?\//GQ+9L+ON$Z<&+E_D9$E3?BA,D1>;P1-I2
M:E^:V3<N3>[5^K/O$BIF@ H3\MG&R*7T_*9OP8S;MZFVV@W'(#]-K>W@EI3?
M!GJ&&P9L88<MKP71MR;7;X:6A6S_5F'P7Q&9_?,EYK_YP!%F=YW(J+!CD LL
M^.52W(?ZTA *Q]S[1K5 PEF_)Z*REC9W0"']LDN-7>C>VNMO'V?H#!U]^;M
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M?QM!MB./0=-LJ+;RY1/%'G\,>@>C_BIA_CRB"3ZR[,.N3!SBP[^Z?PS? 2_
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M];ZOG/^RE+-BM;H6QA]S(#OA>[_Y^R,PPMQ]/IW<'Y,:.!XQUXW=.?F"]<;
M3B+/TWB_7P ^N0YU$KC<J)0]+P W,NH:JC45TN/H#@K3:8-5Q>KA<JT=EWF@
M(G%>F<((:/MRF#>P#A2DP&F.9QDGT&$U!N%.#LY'9LTD%BY"M)H/WD^U!&V2
M&G.<ZI&@U\X/3P+%:CW240/SLZ#-<$4R*Y+U7V\8#T=U8#NJ-9:[2/\LP0M
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M51EO!%[UK&@Z:KVUK#3I(GXNN<3"0B:=1.:DZ=.I3.XH^>W;N\M%YH"2=P#
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MQK&#^FAJ DAGH-+3_2>S3_@R#6QEE_LIG=++3']]P7;GVV6_O=^N!;(Y#5X
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M^&D@&'L'W)44?W#0IXAI*T$("!0Y[\M9VB"V6#1JO0^@,[)47*C#28Z^A@O
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M:K,[TEGQ5YY.*P<0U_BM16S*!4"Q@O0"L/)B[%]*/?T;F<T?V>PV<)X)BB>
M8TZ!!L?#H,.LNWI@0R)6KP_D@_YPZH1AF3S^I:S5/PB<;2X AZ>!H#6@>=<%
M0.8@D>[8#2_KO6IW?KWEWP#[?Q"<](*)&T\RDJ#X7\K^'U 6&$TT,"DB9XLB
M$KN3!PO0+8DR'V^\+'35C4C'!(GJO(GJP":$ >B5X^7W"I>FCK0"]W6:FINF
M;=I4)_/CD%0U#[*O-G$N?IFO>Z J<9BR81G4C7C^4&S#6P[ORI6H85Z95-AX
M4A%/$,'J4\*;D72S[[@_ ,F5T' 7D$$S1O>#4FF/MT>=3X)6(ILAW8%5K-S$
M_N7'#:%?9A2/OSKU*/ %#@8R8*-69S">;8456)9>CT=)R9E<:->BLX!%5--[
M7,IWTH?QW+(GIQ\'0EWAS4XKN6-I\7)(!%]($6$8QIJ+MJ@L6?19!84E+(*W
M"+Q-45F&0;LOF:K;$N=:L(8+JNL:06IQZ^S&MTAQ4JAKEKZE$#)L7*'QG":T
MR +KIE=76_7^:8+Y\$S5O=Z(#\:5*X"6S.GWZ,D3 S2L*XN^(J)<0A[:IR 6
M3%);C6&(K%6=$MHM^PE<Z(HM"K\9NS^_ 7RHU^SD4O:"[,3SAYPLYK ;Q"#H
M5BN%86]\*3X?H1F6YR^-(',&O7U_Y2[(.J(D;LA]DF$XK3$U0J-O-.OJ!< &
MMQ\&O"3'5C&'#\0&.07X9YOUV+8!9ZZ5)UA6T47?T9^1\P HAVM-D'A%ZVO(
M0MH:<;([^H%3T"J=D+TVWJTZO[G9TCU!3VD*6#+;8(\'CP!?#Z[J01C/H$O7
MP?L'M'8O CL(-YF_%I['K0(9L> NYH+Q)AC:+>2XRR9WP>V9>IX]]8,.WB?P
M#G.V4CV-.[KRAP2J"'\090:WALV/E]$_3$TDT\C5G.ET\P,U1,6M7H+NW'EF
M=4UM->M!'OMFSY(D>OG3KC-><05VQ<>6%JN('N#'Z(3-C"(R0;=W),=;!G(7
MU!]8BGZ[_V988ZS>FNJ5&"/=+.0.MAG#H(D-0D<+,V+CNWI.@/0US1FFD]HA
M3V-T+@"?W'-K-<>$9.@R]I[EY]Y7/V0+GR>@H=D*[!!&]'(7.,@/VK4HIA,-
M)3>%R^<G^;W':9B7!D6N/K>L_12TQON:9I/CCB[MFV5RXOQFD>-%,0]W=+<S
M.3!7D^ZA[27;N*;9"<N/ZE]>4;*.%J-.?/8T?JR*EZ4Q8&#@<E",76ZX /?K
M_^C"QU]7)HL*7K)\W-'\J*E,SY@^/B)(V\TO[J&I#."C8!2OT?_>G9L4?I]3
M)B_5].Z[OWX&?!%_.3&NT44=;GKG>S JS^5A^$M>6N(_;XZP3HP_O;H1[6"?
M?7WE3_VH=S2I,@7_/=YC#'\72A4@^-<-G".84,OLW[/5%_S)&&*1IM+.!Y><
M&']$M7MT.9W^'XI-\8M3:?[G5U[[9]O?IO+??O)1\%&6/0PW9"12XG^9Z?_Y
M[/U_/_\UCD;#],YEP:&:C*[U42CIH=MIXWTDP4:XCP"2%\C#)+^#(1XXB9TW
MEMI_G8?BW^^UQ$CY;'H]F\W$JG92(( Q**OSVA*G1UCP&$ZEPHL_&>2,:ZZ+
M27HG7^'"XC"E*\#Y5]3.%Y._10!=BUVL<2G4>_3/?24G]7^O,OG3X%>^2+/6
MP_"[IEU_0EP^74Z@W?Z_5LG[,F^#"EPV(=)]GT!2(.+&;9F5QM3N;,W^:%1U
M]O2,^=3[9 )[6@'A2D/T!<M)E9A@'9&]S.W531B+'.8%U?QYE9.M^SD\IV*X
MXU<OWMUDS2"[R?US5CPK'$A!N(Y_ :7'*X?T&HGXO-G#J<V4B1^-5Y1]-3/Y
MG7?_2>ZWW;!X\_V%";M+U&4JVQMO$@NL?NU+K??K!ZBR&@1.P.X^MR4I9@L6
M2S@+]#P [<)PJC[03F 5K+/5:I4_4LA-HH)Z<6GKA,8\H-!@2D*F;?&A2E%1
ME0;^QB0WAUAOX] =>;>/!#XG>#TJ!UE!8NYS 5"=@DA]M1^W,/-186&B/^E]
MG.0\.2!3=V/PR=[KZL;S,T@>B3W2LI@O@#/5]!2N@[W#WR[^/1CM0^#_8!8F
MJ)K\=4D\_%=<,WVD4HL0[U,9%N,]0'Q4_9+XB%^7Z21J?U<(T?*],<B5H[D^
MD2?<^(NK.MWGV.?)&^32W*EI$HWJA96>7Y^SIK-_\N0N+)S2_U.V@XE'<K+W
M 71L:TP#^]L<NXBY@IQ%T97A);'*JXQRW(@+P,W>H54@S0M[+6_A>6IU+B?C
M"<.#_@6K#AM#M^KA_N%W)+NE! XB,*@6"BO;!K&W\6RE[@>7U[+X:]%TTS=I
M=OAN#%QA*MNLKPM+I!6WSC&TE8OONE=LWN0;-U)P!M28>HRXY;N5'HV\&DD(
M;HAAA[Q&@[M U#Y&CS!"->(C9CU262_'45$M52S%OU6:I;@>**7DXM951P76
MM2@)I%H(V;&83,[Q8T$K[5JLIETA3Y,KC#[%;]:;P<9E(/H)J5?AB/M )&6L
MQ^ >-WVG?N5O2?M%"R.,TTDVU@8MK#]9L\_B\Y6-07>*2\P,3N9;SF??AZEZ
M$MV?'P+X?BG2];I&.G\8R%$X6($&ZY"'?SS58D"-E3+TC!XSJJ_-7)7R,F%Q
MH,H3_4ZEQOC@F@EI'<OE^ B6>+/,,F5?RG<P)]"G"P -WEWJ(UX$*2!OUBW"
ME+P;QAI:]26:YZ# DVHDDEJNSF603.@9_2UL#LX8<A<K5MSS%0OK-4RUS=]T
MFNNBK4\PRRCJ&E6C&C;[%)>X7.^%J!?_\_I3N9ZY;1;F8X=?\CN7%G=@V-%/
M"*<[Z0)?K??KNI,.ICJ*?<X7(="!6K32Y89^K@80@  '7VOC=YHYXP]I\;?Q
M^+:P8F:ZV"$?U_!JL(35]NVCO>'MRY>-#]]W=!_TR\2ACHRNK>A$LY-B4U9U
MZ.S9F6>""TM\3 ]WF7N^UR>).2EL,=AN*AO)!%OH?C^EL,)ZGV1B'58K@OWV
MN]FDNC$#" IJU7"<?N:2_=4W][AW;W()5(L.T?_XYIU"*Z3>PUIUR]KOZW8,
MZN:!'3?T:7$Y"0+4MW\)XCZQOX^GK.@K-_O9S]7X/%B--RKF:<^]O" YQ E*
MVIFFMO*P#[6/25B%=H%NX^^/*S!N([6F6YY[^-J=&-;4?EEZ6N8<VTN^_5S;
M1D;F"E##/>+-]X72\H#0V4LJ7@H*F7-;4V<&J2]+2SZH'^W*.VUD?8+6G&<V
MXMCY>UYX;70&@-4F-YG3J<'*5 FZ]8/.]V_?R,_XH%9YZ@MT>)13U7A ^3,/
M6=^3Q8J'3.&!&)J>[SNI?EAM(-6C6)/YQV*OZ\2ZY_.";AG*?B]MO7*]X^4E
MB4$AS\*4WR,JU=<7W_4!QR;G,<<5-)C?J!(T&)$5QO=#X@+ 9JI48A:,TVI-
M;/D-L[VWSF1CS^T9-1W,Q!AL_N'15>8#'5:(VK0$)?:.3J>6@!K&9@<K:X3N
MGAWY"E]N=IC]]G**U)SQ_<^555&6'*KBJ\B@/V_\V8Q;2&'$3MJPZFC_GC<^
M3CUM(B%:L]SA,@75X1.K6PC5 27^!)9//.2(4.E[[L'ZGGA?G 9$ OL*(K3$
MCW%)2G1;=7V;UDO)6SM(V-\4XZIQ_\H75M\_V&PFT\[#6BH3MY56M&AAADX[
M2<?:8 9_ZU:C=<)?SKCN<M$LF'WAJXNS6M)M,(DC*[+\,!3;G"R]T-A%''4!
MV@@1W>J>ZQ/1EV0(+ZM3'BG+IUE*\R(?'.]_&=7YL.K!'37+7E7N>\/EUOX!
M=!L6DN?Y;2P0>;10!E++J<?+"2&O\LMX;OO,QQ\KQ,^E$T?1U&],V%",%4GD
MEBF%D@7^!)- '%:C-+O@H!CQ^3(='<TPNR6>8$JA6[9O,Y6-\Y5UQQH9/X3N
MB7[K5C#4$95/"C\4_G@!J GI@L5DP;O:,SD)BP_50RUB*LW-3A7L4M8W1Z+$
MLNZ>V643T&,@Q/*\TLIL.-Z=Y--;&*OI"Z=DABA+\E=+GA\<NEQ($SY3*2#?
M!9F'+.1H6NL1+P+[O#+MLR3?9!0'='4(&T%8_ M(K8$030KDT!_P9:Q@\P4
M^7PV< )XH"*G_%<)B#,]NL!'B%809I]0Z[[JI!'5Z)?%V<W4:EXRY\_3NK.\
M[G8(>@9%-+:107\L0=$FOA> 7OL+0/ &E@C3E(C?.FPV+P!,%8.+^^<]>.+Y
MIMR@>\)$T4RY3GE;7S^T[.?^6AC.8 4<RBS5'4,&]PGI.FP]B7MK?7O!5XL=
M%=W?Y_0N\(!JHHFC??8#H5MM!">*%4GY?<=IL3!C&8,#Z:NC+-"UVXJ'RE)3
MYYHDAL_11]M#7@FXZ6ZG(..AV)],_5?X8RP'0!J*;UJ[A'POA?!8%;$Y;>K
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MN'"W,KL [4\9ZK.KK0J6GETA ^2 "[4N/ZF-'P[1&!N?=1%7'.C_J5TY8AV
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MRF'?/ERC2^9Y;]"GYH&F?KW/1&,%R4#U1 2@&:P'!G]_(MJ*3HW>\= [+/Y
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M^'(6.I#I/I8/P9-G7S]1+M0$'Z(U5)^Y&/Q<G]]/O>Z9L7RF1Q56>XN M=/
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MR[[^JR  9F"Q"+X,IG.679K[DK4QO?;M]F&I7YN3_6R^UU5:3J7;=@FSM20
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M &HHJR,JH)5^#J+=>4CD^OQ&SS.OM_!FO?==+E/5CHM"2H\8[V[$$&9C.DF
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M8[&K=69YR2FIU!\^)K&05?F/&X;^._T[_3O]._U.(-+,_P)02P,$%     @
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M(]DYSB<48PSIG3#SZ:#-G<UB5M&GF^%(8:6S)'CK0C:LQA\_FJH:M_LH47)
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MT-X9Y.+ESB;!\Q>!_VW;0<"?IKO"H)#+6 4!>< 0L!/8V<,=;C[?7\T' <6
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MW;!Z/!!ED4)U$9IMU#+9X[A]3[8A,?AIY83*7,V["3$/ ,K2U#IBO57X89,
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M 9:6(^,CXU1(\OSSWL.$V>I?1BHKQS\>''M_X]OO*^#;?TOUE&]M),;GVSF
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M<L<AFH(BNE%8M_I@VDDHJ3Q5M=38L7[),%H^(Y:Z.@]IKBSDK4)I4F=?:B2
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M IMR_K-N>1T=YI>^N2"UI9PNJV8.)*>3AE:=6,?9)'L*$U%3(5\<[%-BF$G
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MKZWHL/O*X=IT FY>PX(ISU(V#*^X?JF0-$PL5'0[,&3!GELH%3_9>^!^JLG
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M!\!#CO)NV%)G80[]<KV;$Q\V["#L@&/0 )9BD"TN+OJ4F;S4NW&J@/@T/ 9
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M,1.Z^,K2E3O2!+[[7E(0" _:4VKU^YE1230K^4CQ6,/M0A@JK\:Q%7I..7)
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M'_/+H=U'7W&>2+S^W(U&.[.M 9ZJN#&1\P&$PYIHN4PJA7JX$"EYB"QY/1B
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MD52)X/?$C!BE!%Q5#0H^;R<&6\+K8J7VXR6Z]$$H*\]6-!8:^>O/I_@Q%A
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MS0LYO$P:)1N")"6G;WE,R*BJVE-GVS.*2) _,8N]31\0J?D+SDTW>1Q*"[G
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ME12A90]%0%WMH3 :/DYN@+",LCH:&N"TD1HUZMG\W@684P!- *C7&14I4
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MR8#_*B<#M]'3AR 4Z'7 ", O309L0_-W=!U7,.*<KN4)EK+5,?B-C.T.LD9
MX7*6",N?6:%EI^7Z(RO.SG_[ECT/ L@6\7?F]4X7R-_1=:W!W^E:<&LIXY]D
M@M.E #.T!YU.[NE\.4#L?D0,[XRA<^J3#!2!@#J#H1"[WU1P?W#.7/B%?OD'
M7<?!SOY7!LX/QJEO/\EGF8.Z^MT'U*:O J=+%>7']WE6,9WS\'X?@:3?=RVT
MR^?=L]7^?35>^]FG.K>Z==Z_]$,/>*YU@^![F'],_W<4U)WS<R4 EZWM*0=\
M>L3X3>D[)?U)XD\*[_G1Y/3X@R)P?N3XG7)N<__\_'0E??O;AOKYC/W?YYW'
M NM[1,_] J!(??_\QJ/Z&:?O??*S,U2!G]Y_'\)IEJ'Q_PS=7]LOM#,YH.L_
M$?C9?B\, (@;^"S!4,Y@K:!N$!O7/ZU+:P3/#S?/DOF71 +\*>, ,C\S\[L;
M.C\3[WP(&*Y@!VN0JP%8[8P+_ ,.^CGO](3H](-YWE&6^\4VIAT<Z@;[ PD#
M"G>P<_A9%>5USY0TSVFG_<N6;@BH(@@"@ELB0#;GWGO!?A1U[._"9Y0SCK*S
M'<W_A?&CNL'!?[@TG ?_CQ1U5[L_7CXP+,$(/4N[/]#PK$&G>B!/A+*KDIZZ
MVH\"A?6#_ ?A2_90N+<TV,'N1Z3POP]>Z0?Y++HV(%M+M_,*=<D=!$?\C;C!
M#_(?Q7&L[&2A8"C\E^ 2?E>04?S).'-# PHY^[Z$@,).+T.NH%\#APT^#>1?
MJ+A6YZ7N+W0<^%E!^Q/Y? 4Q?]<[2V?)+X#?Z83GI\#OE0>-Y+QW-J%HYWW<
M<Q<F?PM8VNE'Z/1T!@ X2PKL)@ 9 /AM[-LJ %?:!FH%LI!5!Z!\6P/@G?<
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M3^\_01+\8EQ_1_ZG3G^GZL@I2&"?#OC'0XF_R^O_?KL N0"Y +D N0"Y +D
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M(T5)$TF9N <%O3Y$/(['JAY@#7.MX0?C7%(.NJUOJ-38_>!.=N<;.KT':70
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MP /F1DEZ:^[['^^C=E$WW#B6^GH758LY*,W?=];O-M[EH_4#6C^'>?QTS&^
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M> AWUI?C$AH;.)S@[^?&?"XWWVVZ^@U T-%8@G^ZEX"555;NU!U#-P18);0
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M5AL/);W18WAM;]#2P43[6B*H9$Q9IL>0G< ]+J7Z410\(M37EX.%%D3Q.H"
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M@H*ZAR^,J63JM+3;U5GC^OQ945+OJ^KB=O;92910'7>,,-*Z9\P?27QUQ!/
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MN2:W\7QVE77<Z!IZ(_89*RC\"* PN9R^\MDS'EY^!\!ZKJ\RTY&5O0*H[YX
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M.F(70/H%=_N =]?5/"IH3#F(-Z"N0QEQ+M?_5^0[X(6MK+M\+<A*?=#\+Y?
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M-N.KT[Q^-7IG2UVTJW%LC?-1?JH/M/*'LS94]DWUEHR^VD6B*M".#W/CL9G
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MA4VS?P5LO^I.$6!,R__C*J M >N!^Q[I-XA#FZ^BHD<?G\>9WB#C!.^ X-"
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MO2_)(24G8\4=^;A- 6#'57VKO3MM?<.R&B[PR_?7E;',\/^EC>R_/2(@RE5
M+&=E>Z0T9/<4#^@;&='-(G$/E">4^>5-X9 !>S@ Y*^#6#  #LW:#LZ^**\%
MWL;[,(^4 ZA7/08IJ\S"#9Y<Y(@_F+VQW%B#(:Z\>?\Z0K%22N&LI*0XN[U
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MD,>.MN-*+J>BXU3ZD_2)O9EBY^)LFD_/2H7F:@TGFQ_SM/%GFO9QA'M8GW<
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MM#79@WK]G&#K3YTKU59DO;N-<)42I4975T]]7O<I#R8ZB#O8=D"KV8KL+M>
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MBMF%B-CXW5O,D(*%)])"X7L3:"QKKZZOSWX]_EY#RZ]4%_)HSL:KB.=@]3<
M*T6J*Z9B*&LQ/^L+^'YV3/\#WQKD;V-U.!!NI^&\&C!:O!0+GS^A=32HW"=)
MXH4)<]V__)Z6JW+EV-\"N6Y->LS#^FK8U5DL4V=ILI@5'RI(XL-EP-NG,2F$
M['V9R;$(->6Z=I",:=8O77+G[G5NCC7:/N&SVR0*2:TT<MBF5S4P,:LLR1V;
M9B 4I'\L4:]2"W@SUIM@'] 'BG@F']H_1E1\RX!]1J0S/2I]RW"']=_<H&)8
M'ZYT=[K=!SMR*\MF.H1#3-NJ93&MH88%@7@K%ET7QUL\GA8"4/(3U>&;^)JR
MA?<_AL42-1H+-\TZT&ZA-PL0@XE:[OPA5@_\(UT"=Q^"T/>'O\>B]0TJ+=LP
M5EN>F75E<,/3T%H]K!Q]XL!:I1@ *;UO-AROY-62U=I1][]S,+0/ H@"1R;]
M@;P=NJW**L;MVDFG%74F];IBGM%';^/*Z&EY&6W>O<\TP;I]KKUF"@+[DT$\
ME9U8!\H77H#F##+?!^'Z1BC31UH<VFQ )%],:Q=$JU4$23X^)B_6/9<4@,V*
MQ@7ADBXZV6\M(J1HR7!R13-O_$?2 JC2U7C9[-/SH.P8;X6]2$\$2)AP[F_W
MSK9?ZVST^1X" -+6)$3U>1M@BM[G+$^1&!\$\H5YGBZ&J[!FQ%B:?OPZ&P\:
M;,ESMZWJBA7*1NMW2C%=WD154JPK)VDS5W]^PHY15)NN+4X5O8M4D2A5&:6P
M3EHK_.XS\;14_E<]JI!BUR?2(JH/]D9,_C,L1BM>E;]"5[:[M(J3=CGV54\%
M6D0*YJ67K&40NA?=?4I&$*%:Y#$5ALQ^!7Q.1<QT:L2?5_PF_+AW^>BN,EWH
MA.=%>H1E T3[R-IK\KC41>TWC5A[]SNF\9\60Y)V["O-];ER+K6< *TW*5LX
M[SQ0'<=R@?M] MH"-5T7[G.&48Y"#M/:!^V%VOVK-0?2S8:VJ6^0"<-70X?C
MYF$6B<[#(*XZ-WML?0,J<2=WA^?K*^Z&9CWQFMV&3PJ#\&O:&/2(7@[(;0#?
M79Z/,@9Z=O#C\,[7RU57TQ;2;);9GS1?.\OX=F^==*5W^]<<018>W(;I!X(G
MMQ9-1&,:5<>R%B!I=>7?X<0.ALXM&=\^^'(Y+X*_J8<7;K81!(*..&2:A+AM
MEL%^2Z+9<=4MME\S4S^PST1RE)4JZ9C:1>O[[BFPZ7W0X=HDAWE=6"IL(>BY
ML$T/%ZK;3U%2)Q-3;SHTOP;2%3+XR_C;O;'$S<BCR,BMZ5$B9ZU+8E16JN0Z
M%[:SU.)9HU,5\NMN(S3^J-V\V^?GD<\MH]M_8@F'BUT=\\PS3[M7JSNW,+FQ
MIR4U&!@O9L2]QHDFO=Y_]^/ET/%W-K>$L?'I/-=--MLP\O/ZUYL"7_IR_K$E
M_S] 8'%.L31N//H5"8 .;>K48E5K]ND0SR)F(6)Y+5^]37<&))K1HEG3T.++
M&OSH1M^>W<R+CK6@-\E-9 KELY7&%R[+R7%1<T?:-U*-U![0W,9E:)M50^$>
M#V7&+SD;C,=FZW1%H'[P*'B=6TK 4TD=B!OG_7<0GGOPO5ETKY43:)[JRWQ;
MV+//2U1&GP7 M-"9R[UIH1<&$Q9F5@N;KN155/'UD(_]'/L:.^$B!=(\^JP1
MRDDY(XTJ6$EZEU035+'EBO%O!:,8[ JTL%W[)+'ZEULFK<SS6BTJC14&%90F
MIJ3! \-"PSF#K;?MGPB2E U2,_UP(T@HP)-KTEZ;RK3%\0F(/$=TX@OA5RDD
MM&5AV37M41R'$U.;#1W!1@$)R"<+*6'*%5T1;:[[!&&@)L'BS@X=XW*2I?F7
MI;:>N*8V-#I244G^GL7Q_!=,CNA6NMPTL[E Y<I&/<%.4WM\%IJ:D^TW:4Q5
M9=F$12 0SZ&&GH;"UBDK&QNKA60J+,UGYV'O!7V'B5TDZ@=A?GB/ C2^'+4R
ML[EJ>N(=]<&7T%AY8JK'HQ_(UR.NR$Q0D-C]!V"MA%?#W)^0V4_*4<7.JKX%
ML#ESYL\XEX8%A1<%ONA;S""PL,E:-".M]T((TON&I^0KNE.=E.AXK#6W/D9
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M^T,37"X,_U[55,\5:=T8F4J:6GZUATS^ T#^ >"CA_^_9)+[L_PO4$L#!!0
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M$2R U!#>$45-)#9&PZU5QGM]4VI\;*RU=X/2C%^ /5BT3_MT_.GP[0L0L:Z
MN=>_OJ!7)<IP<N;+\?3RB]]D*E^J7+VD7,P8<C:A9U+1#YO\ -'_^V08$D%?
M)IQR_C)IE18TXD%Y&(.*"K<(_C)E$O[G]V.%QOY/W*"L45,9@1!KV.M_,RS:
ME33E2=$L;M]S6S<YN'1E:-<+LO5R\(%R$ C>@F8"&S/=3?CI;NE73L:-XPYW
MMB6@=\%6$P/*)Y>P4\^#-X#K&X'>R_-;Y3F-(0JI4I+G A,#4@$&C](DHX91
MGPN:6G==GHLL,&Z$):G$"L!:>&)I *40GF6]L5F6N245ZAL";(1#VUE[_Y(&
MKPCXED2_0<;SES3/7RJ=/5,1O[5L&AT<YVJZ +*;T7#?*-R7MZ;=O'U_N[_S
MZ?WNAZ/#9._#SO[!Q_V#[:/=M\GO?TL.=M_M'NQ^V-F]MN*^.+\E_T?RR)0,
M)&-@O<F44V*H34D6C6)&2</5#;7M6XV]MZ6;-!Z6O:$K*U -, /]]PMX6JC"
MT(4C>/3O V#_%TFHG1DA8523\)7CU4=6 OX^J<=%O-A\0OF(IR;3JKV+A7S/
ML11]^>7BTD$Y;XFR3$7@B)=F.)R OG@60G-",M,K3LN!#U7],H&INE/T?"RV
MD\$3PP*=MVV/E<3$\=1;$D")_(I-%@N@A$%R$4R5M(>3;X,+C48CV$R910]>
ML4!3J*M6,ZK"0Z4R^6BJ<;*WMS<OR_\.%CQAE/SU)0YT?OPYAK6I7578UCTS
M^]HF2MB;#@;D_J_+W1&86K"K,XY@CQ07."V+//V,;_%T! M?@D$7[L%_=T0X
ML)MC6F6(0\>:-J]_,4[GL>(C<Q+:,!K2,/AK,_@,W/[F1?*J7[:.T-#3Z3[7
M^DFO=DF/FCKM(,QWVH_J;JQN-TEM0XO:@Z*?Z[N*VBNV);.[JLBG6[G([UM%
M7GU3J@M/TY>S_X$K9@ ZI296#!\07'A6> ^(.'MFNZ[3I]XWZ% ]"8VO1A52
M*U6%'A(9^IB[VJYKOZO/<E>O:K:TU6SK<E#XY.HZ+MW^)?NQ)G)8FYJP4FKY
M" KI-R8Z3N%X0?S?NQ1GUZ'@$?4=DYQ6Z!3ZYWIR!E^Y.*Z*^L_C:-RX?& +
M[>EBWH^,FI'YX- -4)3#UTV4Z* 8AD?3MPX_O7^_??"WY&#O\*_)N^V=H_V#
MPSG%F0X*J+ODSB7CKXNFFI&MQ>>V6M)@ST/R8(9+]\7.*&"@Y?&P'#\L3JCK
MXN;C[L[>]A_)A_VCW>1@]R_;!V_W/OPE>;=_\%_P8_+'_OY?\??#H^VCW>9D
MH)=%O2R"\8L'RZ)>_GQ-_HQ,]; .M!V7.Q^W#XZ2O6X*DRX3R%>LZ?ON^"-+
MAJX;U#U&/!4EI.O&B,5]R[94"@]_9*FPZ N?OK$#@F(#:6=O',X2MM4]*=)E
M<)AK#S"-LV-V;&=%<9]"D9@2Q-.K$K/2O]U4)GK4Z5&G1YT-H9T6=;9[V'D(
M[)BG]]6O#7L.8*;)NW:F/?[T^(/X0WL Z@'H00#T>P] #P$@>SP95J$N!^?!
M']=C$^,QYJ)A4-_S1J-/\VDGASCM9&<Z[1Z:>FC" V0J>VSJL>DAV,1[:'H
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MZ?$$]'+3'IFB:5'4Z'4X0UZ'A9CJ!=-@A6$X,4T-:]#+71C--?-Q:V2!;N]
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M(62&CL$/\'^C-!J&G>#-Q2\=LD7Y\%,G>)7$P;M8$+(C\CS8 '2"ES&:,R*
M+&ULT G^W9T=#XK:+R_"E%\$*'_1J\:_-PBODX0?*5[Y*[?"R4)+O:<8H9-?
M#-G*6L&L>)TGM?AH%$5SN= B5J6$6N<;6@BZ4UCB89X5A4VG:@+69%*'!GFO
M>5F#_0QM1Z!MX>S47SU9:UK "UT$C?26WL+6;?6%=3!OK3?S=3]$EN$VA_1%
MKN*%JCJW\<*F+H%O$"] T%N$J@"@A9DPP<$@SN85<VQC"P\ON7K@=NI6:<T!
M#&0^O,TH4=%J/6J-UCB?AHOL10M'_/Y+97-J]#\.,<NQ\+Q_$;'#8&E:<(3Q
M1.BY&ST,=B2$#4"(MWW><O3KIQ1CBE 4>^@BK2#>NRHH?58X:N>A%.1_C1Q5
M1DU1S",;MWHP\96XENJS&:(%VZF@K3["/S#P-2+K4G2=(!Y;P;&.I<P80ZTC
MRHUWZ\KZ-6>VK>QOQ?)JH'TQO;AKU?I\-@K5>]$>FFP>T:$8#B@<=MI]U<8:
MOBIM<CJG(Z_AN';-J!L5]!4U"3 4KL..+\.Z=;Y40%TYRSP7.0EY&=O80UAW
M''6&9=60*M5=1/I:B,/]+,7#%N+PC<G-6Q?UJ[R(*XI"I.OYQ30>T=1ND-.Z
M$<[J/1N.SZJF,L61+T.SH*/E]TSD4#79680SU^19E /,P5S$;>K*L+<?,FN/
M0D\L=IU"[<K0K4XKGT)&PK7#0L\>\++Z?#)J3UM.ANW#(\2G-S*(_N%;5;2S
M5'.-)[NH\JY[F)I\FB=.R+G5!:2LW9BJS"!W'!FK*EGI1ZNBV5?7Q0G%PBE.
M:5$/OY-N;6,>M%&8V:JL=T40O0E4NQ/\$^4"N6*$VB=NYP^_HP,.BZ+$CD)6
MA!9U$?U6XN:UTIH_TC6T:](([7]/1/G<&A0R!#)ZFJ#68H8A,FB0EMQI>R,V
MQXQNSI'UX^59C+CC8DJCGTR;LR849M<K2M\OXN9I>9#Q]OT6$FZ)MA]*0L%/
M6-F%K;DFUG(D*],=)G0R=6Y-77$JOVM2^6![X5/>2U*)TK7'*5OC^N.451/A
MGSUC SUC5R6#AZZ:*@@:G_//$.S651!K,MZ2+=$,B?6&UOJ'1N#;^E-F]NQT
MWI*@6&20HE1R.N^[X%=JTH=VG1S#:0BF,WJTWR69U]3%0RN)SO6%R_8U('PQ
ML3[CK Z!9Z8FE<W:OCF #"-/X]-LCEMF2.6WG8#N'YB/V_1SQ7$,4Y-5ZO\9
MAS\P$M]?=[BJ(,Y#==KB=QEFR+@XI+HT$W:KM'P36?-7>H1;(X7&];I]0N,/
M7F=<J"&QHCQ1\-59=<Z-%!"L-#B )IFHV:X:@/L3#3^Y?/-])<&/G=9W4-HX
M;D9K5B1C%QF=Z]]3_ML7+3<,UJQ&7,T:U-=D.,K*17V3W:+@[,7V'<&@@84T
MGN-Y'94GY)SGW"Z"P#&;14U9_+ID=-/JV&O#S0UR%-MP\]M''R>9TW4/O1+_
MEVFX/Y XA8\2D[ZJ"R2PE(3A$S<,HP5'WY4I6J<1WNK<MSKWM^C<=U3$P;CK
M3<NB'HGLB=]&LX:V&KP!"T2&\D<\! /V'=+9[*!B-="<!<?NMV8>:SCHX"3;
MZ03O%J,=_B)/-.>#:85)[&:'@4PT-&4I!&;4P!X%>E6GC5=X[52N>NYAA0XX
M^&MOYR"@G9[@$1ZCW'GP4W]WU_SJR<H<D/>SY(7%ZQ2/,Q)[QTP5PRED.^S"
M,TEW']1-D<\$Y."FI\9;459IP#EM%L_.ATCOZ"<T.QVYR>9']U$*>QV'1)1W
M>!63W0+^4!%3ZS1'S'JKLOU*;L)?]JH-P[@JB@!HK#;EL,98.7T';]T:B1,/
M8R3>Z<"$>)@A%S70/ P1;R:A%_YCK5LC@!:C2:G\[-DU/&+[=1I%OE1SM_HP
M7%9@ [43M'Q*&W2*MD[<=U#G%<N+_6R0>XCS#9,QG7G5EH\'XZ[=&V]^G7O=
MDN=76>OOSGL?6X&IYBMI3,WD[;;<6I.K8%[V3*4LY."$)B!B?':Q4,Q%/,]Y
M.A:TH$>$ #%>>D)/CH5AQL>OC<TKLC6K4G2FW\?1,/B*/WY.?86-X=>(M3(X
M_\<2:1Q@U I530N5&:8J'4WN7K9Q;76H];<_GR=+JS#40DZW82O[7/"**V@A
ME?<SU<];2&4+J=S&I=M"*K^OX5!B1ZMHT:1^,?:D>=:(7?ARHOB(E?GBZ@9+
MV*B"C74=X/LH)U1![RB,I6$%IT1"_E"7LPP^393IOE^1);0E/.NYK#8AW\[]
MW58,-FA1;HX!^'&"S8\F*"F,P\U9W,ATRD+P5_KUBFD\YXT\"V]8MT\"EY*V
MN<M&&T-A=B\V=0U(\D!\7.DQYK@L2$M&OK!V:M2-;F*IGC,F0'"RXS'@3W[
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M*2J*I!K@J](R0ZWD74#L*R!46N'8M;?YVQMW6+3<F-^.04M3_2W-Y::OA&_
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MYE<1A6S#MN(H32H2VH[3IN,U?%=)5EBKU6A35EE6=#VL.9C:AK\_V_#7KT6
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MA$VR9NT9^>W/R-><+67F[P^ W>$4>*,U];>.M/O!9!!>^I+%R(=V(SQD$A>
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M6141<X)O/9$=C5!FZ;;RT4&5%Y:V=413-?*I-=B5#"4MB2U>L*>UN-T,6!-
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M[7=EV+-;U4VWW3XNP'979'SL4PH0+EY=GO9%M_CX]*!WXM]+,UG^AM+O"8[
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M,*(70MZW63"=%N/Z7:4X6PK.+7ME5G)S)<#FHAK8!^)\QOW>47#QCF*Q1#S
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M@&&<X@+TR:,#;XC3C)/HL0BJ6=("X6\113/EI\J;,CZ5X-M*DT$3>DW,+>P
M=D;K$T#?G,6CKA_X]7>"]][+6VGMUOA=F[/G\RC,.902?4'@R6W[\(Z*T7"0
M*1%5L5!&!B<]U^4. TSIZ(J"8[Q"8=VBN"PLD%"@=4H>,U[J3O 1D/[^_D[_
M$>M[^;E4]4":I\+-%@60M-@C+H95DP&6XJ'I0_LV@^!C _QU+I0-X@J-2DE.
M#.NAN@;\7CQO8];53"''NVD>8^CV"A6.;KJ5C8#-(I7"G!"$TW26\Y%D?5:&
M*L!'KMKL[ST*3EZ>6W4UY@(?<Q\\)TB0NBA8.=!)!N(93>T1C?"@RT %4%)M
M1G9N#KB$P.<X_0<Y=KPV>\U<-V%O_Y&\@#"8G;V^X%\=Z,7PF#Y?A\ZBB?3-
M7%DV))JL K:^.TQ"^IP7ZOOY)=FN9D#T^)6R*8=FM21E, [C!&W[G#8Y?/2P
M'-SV4/RCM)>^@:SLSSP;T .[O.Q*75[994P_T^/T[_W=)QWO(C#;AP>\.W5)
M^I*>M3:C];NK?["RN_9T=YEM4!F(,2;S;%YJS@MK?AJ%5S#)-.%&\I$3T!8$
M$ ;3,.>S@?_N??^%=VKO/F+X-EWEBLEXG%%I(B;C6SQ'8A8G_!R72\L9GC$N
M%F&ZD ?P\JOV[(4IMPD_,R<=K>"Q&D/HYHHY#CR%S\$R.']U\O;B,NCM] )H
M:=%ZT$,"%S8V7GZ6JN;)<;?7/W#3SX!A,Y?\;)Q:1YQ<@&JG-2 _K@&YM$ZP
M>(QF$XFOE*"$0:9#:5CUX.,E1&N4CB&_OF@<9>>?*GCG//;/_1U#W6Q\!._*
M@VB9:4>GW3[Z)]K1 ^'@\\L2S"!SWM6F2%;1-=V3N+?;5;Y8[,H57YZ?')/W
MWPDN7EV>]GDOG1^?'O1._'MI7=.WF_H]D=!V0WV<!G\/]@Z?=&H6$+:+' S#
MNJ6/=YW=:HW=5N?*/G]"6,'L!Z9@BV6O,1I^"HK?2K+'9,^XKW)(P4%,TZTF
M8T9N+GYJ>!C3KF*H<OCAK#IX(>59' #L=CQ_M/X2:S%;+.C[[N/KCD[1?N,4
M'3W2V3&!CV\ 36?P4[JD[1)V1I6]*\PHN69X)\XQ18L.+0VW)+C6ZW4)5PRD
MXV S9Y'I-*;A\[$1!DE8L>?_X3.6#\=ZA"._/=A71Q+KW9PU<FRHVR<]L_Z,
MFCORG-/2D9>(LY,7TZ$Y/"^81VJ(&:O39]$9$G,MGIX%>T-> *VO:!;!R$U0
MR"5[]XF&.!8N2QH'GIP.K"ERLKQO8^ZA8G9BG^]S0$8"!52*C?C '9<Y5R<E
M8N +VB?BR"N)/Z':S,K5$DMP,%[IN*Y[P;+H[5.8"?$:MNB*BOEZ3![Q$S9C
MH9)W+=P$5Z\('CUW5;-Y>P>/*(;^KT$>//WO!P('V2C>VX=37-MKBVO?<2'^
M<(TC:WOFSKK/]G:?=0(0*7Z@X"OI!*\!14+NX81S#V>_O/_W9<^I7+7](U_?
M3-R]O/"1SLNK.+INFT-^N$6R;DK_*40GS(2:40!&P56^[ 0GYV\OSLZ[ M"]
M^/#V[/P&0?LP8\@:DA" ) I*RB$^=;>S4*22I$Y%@SL,3DX^O.IU\?WHQG84
M7[Q30IX=\UU@U8)/<8I,/Z/=YM.LH/_E2WB]17!R^DNO(TC& ;E>M/Y,9G^X
M1+HY>-G%1S3O<2-LC8;U)0K$-R]IP(E\":%*C!QO.%H*XA,>\XQL%464.X&:
M.'Q$B&E&Y',FV5PRPX+W1T*('5-![$5<;D U2)_(VCYYGCP22+.XL4*KZE.&
M^E.$G KF3<H+ME>?QJE7Y8<0>@!.1%.$EE&,D(>I\"7+K$,)4]Z0^IH^(?S3
ML]/_J=#@"J5.1UM\^%W20)#JF9B'K"%=36*=@FID[+QYF_+W'5S1O\_9+Q;7
MZ-%K@E'69;+AQH_R<M+%_PEO?CC4J/AX[CB<%=C1HL2WPNA(ZB;"WX3"G->#
M6 )>,IY-4<PIXD<__Z()&]T=LKZ'9C6JX&R9QA2<(N9C0"PO0*0UC=OB@GW=
M%OQ-!CPC@<"UT9?_\^MAX-(((6_2+FP-0O )LKMF9]N6AW@F"],8B4_1DA\
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M93R]V!,?DE9^;O= IPKSNX!F 7-8[?BO8DC]]O]I2#,TS#[%T@UM+DW7LTC
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M?B$$ARV<_.MSVSD.H"I'MR*V"F80$-S&C%TEQC"&J[ NP"D9@3:-YSY9-X;
M*L8/94<^E/WW63K1:V#]Z/=HLH]&AO",Z7R0%!]%P<GYVXNS\S5?4'QJ.>@.
MEXN,8:[X(WPA0P-$9GJ%;)D]P"9J3[.,&M:IAW_<T6^0$_DI!8F0 (4,/$U(
MMJI9)\%=?;@X>7?2">"I3@0.ZU^+WNBKO6XYB'\KZ>9I *Q7H11$TD]1!"=+
M'$7!JU[PV$,M"[*6GCMCRB\A.1B1QQOJ6358&G*1191Q@P:&8^'B0H4D3Q$:
MICKM>41"*5(L71[1A2/64P6Y'PC!&/&\R/% IB4$L^50?PS:K&UDB]HRVU<1
MF4N/<*3*IY0Q94J9*DVJ1Q-KC^9R(7 PE\?Z6M%6:\S=QOW:I >63.Y6R@/=
M(RE_6V!\EN;TCW(?K"4[$,B\1QRRGK^@C>>_:R^V37&_5].K(O9M'_8?LEO/
MUB^J-8%X;VT@WOLL7>_1\Z9 ?".-GKZ/.]3_VA1W6VOY8Y[]45MK^:XIL&V2
M@_[FV9%341ND\_:2^0=;Q_IK+V;R88_G>9P$_=U^3VC(*=B)V:MA$NYYE':3
M<! EAKP\H-#IY[<GMPC<<"//S-&%:C\4?RPNG%P1 BH%5'!(E4D(7'%Z;]/-
ML>VL3D!'JVR HRD#WB*8TM5HYB=HZXVKA;A1M)"6FT:]#/+<Z.^"NVVB++<]
MIYZP19L(VHIE+QSE'8ZI) .82_\W?9["Q#RSC> J!\4<C2R+D;.$2CPRI-!%
MR6SEV\,HMS&QXX.RHFS 1+/+MWV"<8H*VI]BT"RU"*RKFE*G <'B%6(3#1>#
M(HKS:$(C4VGZ<!Q5,TYL8?VK<4-AFF=)XE'G%ZS4($P03*&X8CB'TQ!D ?01
M=*$.EFLU7\3:-4H1R7YJE4ZW9O4V9=;PNU'LM:,:P:BH(A?UZ\J2I644"=P<
M(,)B.(U&$!X$.)W7!>=.PWE!OQ0ID0E=,V4RC#2"(0WS94?H\>$KU':/R#,$
MH@L3SR#_E0W^H_K3,3=+D[$.!TE<3.7+O%_,*+P4&O][7.:\CLU#TR#\O<ML
MN44!IH#_Q]Z[-L=M9-N"?P4QUWU"B@NR1>IANQTS$30EM77:LM6B?#KZ3LP'
M5%46"0L%5.-!BOWK9Z_]R <*15%NR=8#7VRJJ@!D)C+W<^VU:3FJDA803]3C
MQY'@F(X[,E!&/0"W%4 YTB-,SW0R+>$G*IEMP+W95DV410BSD,>6<8\L:8O%
MT=$"/,5&5HV'O%4*Y1P)E9,L_-Z2Y@@6("P=MV@'S)H,Q&,>QV-Z3=QE0$U&
MXQEO'1J+H7V'\- \?_;3SZ].?GG)%ST_^>M/3UZ9="(I$1M_T_A/#<%:M7Q:
M:S?!J_V\D$&.K%B+]-(>;X=2&&08=%/3*2G:C16/WVC>^B; -YBO^[;%7H!K
MM@,OVV_BIHPMJF_6#?9O]B]Z/[UT??#SASG#H<@U]RDFH?Y:1[X33)X<55S6
M.,G 4]"!ZD>C'55<Y@'?3'^8K6SI*F'[&:"$NI)1Q:/"S,/,M^+8DK(J.Z&/
M2?L2<"\._IE6H]Q_0 -Y\O/+5Z<'/YT^.S@Y.7V9G5UOMJ1%Z5DTU9^7?:.[
M]]CK7&M4(V_$'E#6EV 0.B^8]H;>M^VJ:'<X;D[#\@LM;'AIZN1*DNST@AN
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M&F::-(O)UP]/[+8]?3_%>>4U^HI.1&!16U9H\<#C1*?XH6TE&+%V;<M;SUZ
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M^ZQV^@R]NO5ZGK&.@LA^7K2O&0+X<2&J9OS4[W:V_EJBW0YS7IEWD1C8YJ7
MCK@F^P8 "))PW06[0)%9T+3G1>VC;"V8\/JV7 R"%2ZV@@4NE66?[YG>Z^JB
MJ:KK@^8*R .FQ0.BHUR5!?"GVJ*0!#0M$#.*==DO9R?9LWIY2 9^]MA5Q968
M&^TV:;"(*(/O]8X>AXNV7)T[L#IU'<E3L@9Z+G9HZ(%;NK:75HW60CYI"*]
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M].D C<YR#QG_I<;?A$\#7\7P37:[^'L\<&/(!.^/)=F"6FR6P^P,$2,$1-4
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MX6<L$A(]H3?A7.I 5BF@DVVQ*HO@)W*H3'3-=2PHD!AM_.<7M+SP,?P'"W9
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MJ3N$!KQT;<V%.O\:H'^Y9G>!?D<<RU*#:!S:DDW"E55<QMN-2V&8!U)J<Y@
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M^?? $&&2Y)::4Z_3AM#%/EZSA2 =:G&CN"$ <OT"RMU3%J3"LW?%)M3+<!8
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M+\W!,:1*B[[;\G8%ER#^0<J=%VO%R%)BF$G 6WA-L7(;;(K69[9_=8;4N"I
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M!D\D\L/1 5#86@U-4NK#GI!%SCU1K(4' G,WVT/2ZU5;G,H>_[M>JORXOH$
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M*= L 7P@<?\NV6+L5"&29B$Y/F9XV2(+^Z+51GM)T(EV#R* %1T^=5JG:*9
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M$GBJHN,$2GC0H' ;5&0(],[KRJ@SX^S"ZL&[$K*>!9^O&E>Z&X1@^,N'1\+
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M':F4_+.3MKB!U .%AAS518D>$3Z:IL>%Z+I8'Y4YD X-(A.<Q3S8V;Q>/%>
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M,V$F =ZWD_"*E !Y0LO_%Z#F: FO@;6.0'*_J=<]P3 'JQZ[<YO"=9A?G[
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M!P+7[07U,\ $^=I-!.SF$(NG6@(HZZV-%;S*0J^Y+K-B/]3[Y4 G&K!E< R
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MEWYB3>K4 /K4]VX4DV?*6]@IN45D*829H^5-B<"EY2TAEI1&J#J&+5/SRSO
MR.$.W_382<T:L?'^CQU$1[.$QRV72M@R>R_N-..B]L]]4[0YHV=,T^?]^Z2.
M$['OVC5$*^K[.8;2N/Q(Z,UWV+U$C3]KJLS?PJ"<>3R]\ZAEAHC".D;.DW)L
M<X,-6?0 X&<7O,.,FP#T_0UF7Y^;6!J8AP&!\[1K\&&J-.*EEBH%R, W@S>C
M0Z7!9R4N@[ZB0LMOB]]Q5R']IO&7$:(Q&L[UVVLC44ZKC7[F.Y%$;H:#FM\6
M<DEM@L-9@T,;H0G<IS##ND/MOKY7RC.A,X[WT#=MCST"R$51UZ:K3>]..8R_
MO7B]U*7 ?6;//<ZC//JY#%GK :^&U(6)#]JN>_1*BS7K5V-:/)#PQ.+M,-(6
MG5GL]25V@%N2G%XN]K #X?+:N^YZ\1T1Q9P^&*CI2P7B_0JQXQOTI-&!H1?5
MN0_QJ;< LU;P)9<U#K3,;KV8I%[#VI^N?O->HU;1T&Y]2G<>1;?!L&$)1+9-
M&!OIWH(QW&0-"7%3QUK6Y#0P L_ I7FX$:ZNQCDL]BM8(5S?(.LDY>DKKSR-
M"XQHB$;-D/A<V#Q#97NMZZ.MP=_1^]1I^8 ^6!%U/@CW$MH8[9L-JYZMD-P(
M.S7[)F.6*NG3_8!;T>8P<B)F-UYYIM'>.U@<]C7!<OO@B<AKUUHWQT_'$LG3
M;P?M>T1VY:35R."T])5QV[+/O:SK%@]#\L'@2,7#LNWW9'745$6?9NB7;Q"<
MX7B4=*E*UN.(N;LIVJ8W? (-6B%EX'.SE\*3%)Z<:ATL"%:?.R[:HN? +#5@
M8!4NK[S(ME5-'!*T]:*!"#^=>#E]I:<VF!="@S<]^@FZF*<OA6MY5=3DC#1B
M!8XOI =<ZTJW]BA'PV-E6_<"IU5>T^9=^Z&Q%7$YF=U3)F.=H-"9;2-.$=#3
ML9W'SEXMWCD^><"-#1P8@I XBM/FV-TF<L&-6?%@'G5)7?$,YQLM\M.][,S;
M2/$ MK0.KJN6&!8WGDO*S;@D8W/O,\0;+M%MR5@.]8J[\ G4GU6NI).63LL2
M["8_SEYO&L]('7(!H\'>&S)1F-'*9F":!P:T(B?V"$,M<8+@@C@,N*T>'%GT
M_# M2"#E!7AO\ !%NYO(++)K8!54G'C7N^+0^CYI\G<V2(!A&97)Z?'P:7G"
MX0TY[QE/T/7BKWV#W]L3HR1F02E9:>>,V9M/O0@-(64;%CF+@7.*2/&.B#YI
M^HA&?*5//\%W]/0]AY2J_^ YY6"!XG*D0B$^*HQ_"'8\-$1OH\H:H.D M!E8
M26B8Y,C_A*GX*C8!O@0Z]6;)BX82F-W$\@ZBS8W+A<_+;!.81,54?K:N\V.5
MH72S^2V%B28;%7;=;9/MP^XQN*<\A>4(,1?]K;O>7B]]CF=",?IW$N04*!?%
MX <*)TMW0R$8/(I&B.61>4KH5]UBR@HO>$'=WT6!A[PINJ9^8@\XNPO!"WYB
MC_+ =W7SV;RJ?0UA ]CZ2TH^@B4>.;RI\E@_'D]US!:L* ^KD7J#[$HB+Z][
MD3@4NME1(!*(MOU6<<6<5+%O86LQ?:/D39N2>)*&%--1VD\RR"O*N')K)WBA
M==/@5YD$&Z9_>[Q>O)[8MH*[H;M;'N]#T>X;MBT87OB"LF(/$US)>_@5>P\?
MG5:8<Q.$Z#EKF/'R8Y(/<_R%<:IA,KW@$WO"AEIJ%O?^/(E<QAI\=&JPGLE(
M0RW,6=L$"-<R]!*W=?..- JR V[IH43'R1#/B!H(XW'#V%-9K0B41]RJRD2'
M389@?9,.A9T@'V1#\Z+LE611A#%Y7#4[9 4\&)8!AXA_V)*0RQM_;O 543GQ
M\]I(4M?! [H._B-U'3R:XDPZT3XF'IZ.@^T1XZ6[YE(WH<9K*T"X35/B*J/#
MC$ER!-;;]H=#2?5;25:%VSW]33)5>1XO>D-78P,+#X][FQZ4U.U$[B]PZ4[Z
M)*B((TM\F =F1%I8T(2?D+\*R)-H49':]VY*7ZL0-!! $'?O3B98'6%7<)::
MNN>G9!;&T%)&U+&/DJOM!A7PR;E)%:,G9(>/?VAX9*8I#C!N809^(S]VGWDN
MZ3/*^\W$M*V'J4&45ZQ]_@CK1V7Q#H/& 4)P %QBL* GF]3X=Q(U?$K^,Q)U
MX\#.K+UUZ3)& =4&[G5H"LQ7UV.X"=4(/R*X/Y19Q1?6X-[IHQ5-KJ']5'5P
M2<<.DPGG TXRWU4P.8;E"*?(IUO.()M#IX?(U)'H)ZBU,V2PU]&91![:Z=%<
M+U!:R,+$;%\[GU=X6INCFL^L!XS-QN8?=.P.6><_Q<E+M*@.V5>IU>-0ZX/Y
M=_" 9_02R(]Z!E]"RB!%:@^:T[]:K .ND(EJG%>_Q"?C+0I6._*A$7I/"=B>
M__C=HJQ;+@R\>/']-U\N\+J^OKFD;_85BT\21+H;W B-%Z$6OM.YP.!MU;I(
M*Q*KC^):A]3>&G7QVB!#R8G-D'GW'!P3A0'UP'%\7'* ![M>O!UA'%"$G$CE
MD"R*51O8JKR#KX&I8R->(:\<'N&ATD&;JWGF#+'7B IE*$Q]Z(H]"HQ1/6*
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MUPN_N"XK*_B+I\V?4E+PE\^:4Z*MPC[E>*?*)\,^;8L9M_J@NUTQP9W+ W^
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MGUKTQG4=;YU4>NI%TVJ)'O:&6&NHM4A^A<C,&X/OOG_Q[%F(T0CUXA*<R)F
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MQG2HT/4F)HAD"6V\H\WHCY W9:\Q)I*>=?C-G%)$%.OD%TT3Z-<#8L"@6(%
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M#V0AS1)47*W.-\RDA!1)E!)$UR958V%,K[T_Z"TPL*N0\J$_1#V]$+@1J\!
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M)*'3<CQ&A$#C0=HU%P\MH9BJ"[]8.^T&6@>X5C<];7QJ\5J[[O.6!+7"0Y6
M^2.00T&PG5F.^68#U SW6=U[9:)HQ:0X-0,Z+(1DYRI-0&%^&$>LRT:KTGR8
M0WM= V9>Z.XM*8]KL5BUTP.BA-1.I/4U9!/,"K,]7S0>?TX?R5&@RXD5T2QR
MLGC^HVGCSDK+H8GTK$U'IQMD<FWG6C-V;S.MM6Y;!9&)%:/%R  ]*.["!0%=
M#F6*:])=M(;%(NJU$64;:$,#9ZA\>NW"\XJM$.Q\3&\.2O_R(MG%2<!J<'?H
M0LR0G+I>2N_7A#N\UTFEQ"#CRTW.KR36\[)-X%>9M709IU :I1<4P^=?IE\8
M=.7!D\SO.<Y#I.1J=H;@+&:VRAV6:.=G>J$]^]3].GL.!3 C<5T[DS],@#R1
MMQFKE"C">CYVQBFZP=X54D[8<2$%ISWB_$IO3FX,##*.UI1G%98RC?<)<#K(
ME?'5,ZT"Z7"U!42*1M[ >*L'IDOEG\ZO<X*<3D#[E?:E:!B<G+?4-JA]?L8+
MY',>9W#JZHWIKC.=YW1^V30<H%S'9K/K_>8]A;)@F[8<A.NF)%+*6QX>S@*P
MD)UA#(P_>,-\F^>8> +_4@5(VZ9G\\=E0!9<QCO@,OZTX#)^55S&DM/[H,U;
M@Q0&:&M@8\4A#1GKM^ B$XH/^J?23F31;_+N]G[M)[-A6.*Q]/<*83!#/$ ]
M2W_9-[4C]Q+Q9\!SC#S-"0!FYX0J+@9D')48)]/4]W"4X+CQ9]6>P",;89KP
M>[#6,HXTTJL3SVT@H?4C'BX1ET"334?!1CM.E.TS@G=#=@ MZA^L"+_D$A_[
MJ3'>B++?E#/ [+N[<X?"/O4-7^)92E7XTGZ+&6;!"]VEUR."3J0RP74J6\9?
MHW!QNZ=AE]S&M;&)#9=_W8(@YV082B/<]\?M5B@ROQ5#\ZP#3>CS8%W"A?03
MS]FFK%XH!%KIS)_^^8]_M+UT".V^??[BF;E(, %KRM^TIT <#O^M9!;TU=,_
MX=//KU9T./WQ*V)*S^PCY3YRI=O*+U\]6[UX]OKE]S^^YE\:*Q%J?\'4P/SI
M[>^PA[&!2;@V N$PZB&U\!9%D/5KO*) "21Q,-!LXD?ORC6Q2U;'YMH)G:D#
M:H$[P%$A-!F826(RJW85L0$(JZD= (G)H[1%A+'SM%#ZICPV_(MAQCMHT].8
MCG[WNR-G9"U!K3EN1&&!8>XHF4)\UR%!=3#8$"Y\T@-JA"*?Y/2/]L83!&)\
M:@G_D!^Y'P7:!:B^*JFA,*.0%ZW+F)<O31R70??IR!A'1:/8=9)B_K@WD--D
M_V+-./\;Q"49ZX/SOUH)W?"3;9TD !O_1-3Z'#U%@GY.^('&=N4J#B=O\HIC
M4?^U\L#H1%E]C.'@NW%?3>?H 0*L3\@6QFGY80_W>9H:Z 94E24]((0D3?:J
M@0= "2LB0,TGLNF'7=XQU?1_L/B8@":C\-2!>*&.Z&O82##.W"M@IE(+F;R6
M"6Z%+CPV,DU(#?)DVXGG]:+X)&Z,V((P51+A,<1/636"/IB_6/RUCQBVW@%!
M.&]4$_J:2- [V6EQV$U[[9?BO]2)$I]F(N_+QD42JIH\*"OVKTRA1_*2[[F>
M$Q"D) S\ 0=@4!6ZJ/XE68*;(#="';:5*QCVQ;EL8^H(K31NE)K,"0Y %&?2
M@QM_>3YN@_,WV1I#FZKL.'/*AT#5<+U83FY:"WQ@TZ8I_8PR'9SWC^4[^=L5
M'8U^'79B/6.S9:AW<1M)WA=),\ZH$2>=^NB0?FJ)B$\NV)N;SY=E]X94LSD#
MZ*TAE72_1CL\+0S".;R&N7[!YOJR@I'?'/GSF&*1WSY)T+I*F-^4Y)M)/,M:
M70:(R-2I!V#=.WH/O/:.T2DHZQORQ:_EC%";1ZRB>G2H.T7(Y$QN"Y^7?007
MKM4=^T(_// Z0!?%>8/40Y&32+ ^VQY%7^2QA5>@3&']1:_8HKUS1YD+T/#F
M1<5E)<.KM([@7O%$IHB:P "9@@/<'.L33+RM>EJ@M$$)TX'@?=G+VM)+?N%A
M\POPJUK"512K_B!LO9 0G=C,_(D/MIN3SH-?L+/1^0(=J\D6H)D> QY"L_(1
M-P6BRFA)$0R@WDK*JDU&=C#)("))A]A(00\2[-T$0:("$9% ]WRZ3-D)D %J
M:K).DPK399OXQ?]#M#S^UQ4H4 2.''KZQ?%'(Q4'WCX\5K>31F='I-/<Z=OA
M],APSD&19UNOFF/CMT$F>5KCC4^^BVY3,BO,)J9TLV#M:,WFXK),6W''%#BM
M@(;Z$*XD-S6<!EJ[U%O$"YYL/!-.'IG!V+AFH0C735.D +W0F4_T%']_T7%.
M*LP//]K?GK\8=KZPJG#KTKP:U3C[DO2N* R1]HN08OOVZV?:N>+'KW$=\F3V
MN#&(&\!]JBHN1@FT"2NF"] @,ZXT8SB\CHQ$W@D]ISZ7D2B&_)Y_KV6-%:N!
M6F(19&G18O17T?67"9>/T+YUF=(\C4U-6*DK'PF[3N@AF3QQ\%'EE.1GUWZG
M.5MU1YM3\LQ92D0$2Z+=,-RNTH_S(8+&*AR1A?AH'FL=$"F!=M+K9??@GF^7
M(UO+'N'? 2LP61V L0&:R-:L2:+%B:^B'4.Q?TAF(LDQ@%"2":M/3<_&!6=)
M7 "T<I5]=^(A3B+E-O4G)DZ(!-^<VHOO\Y[/-?\ZL6.Q,4T)*M78G7J+I(2[
M=L9&XM*RL^S!J7""^+>#$8<\T\VZ^=L/@U%1/+<]!XX:0K#25='Z YQUR>XQ
M8VJ;;N%O>E.4L_&9<FB%\N3C2CPL$*KW(03( DPOVM0LM<CI$4O6(X4_"240
M]OT@J!+'* NB;'G-1.5LRT6W&#H(W#4J.-6DZN"?3A?WD53)I"%18%@S,=A4
M?&E=XG//V\BIHT=+Z(!$<IAST:;?';AV PA/#VTS,&4>%KD"MODP)<RVI(X5
MR&M86)-VL9PM*"ZH9IV(-]!)\U%MX@7&] XPIC\O,*9%;^L25F)P+(;]^9'>
MLCY-66K38T[F<X(\3X"T-ALA!6Y#HR)N4R=^4Z X$3-\(!W3'%+&ANRR2=,
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MY\T57!G_IVQU\.Y\+^Y2B')HS=,7V<[2!85>3&\4P$0Q?[TU5F"J[1VLZ62
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M_6!NV-;\4BF]V?L)*MM-OR<=T8U+$S*<%MS)F:L<S- )Y@9STK3ER?/O+4C
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M_;8I_@WQXBW/F0!)N?21A,B@%TN"9*%<,=M4;XE,XIWWQ3U9'3C\7H!7*M_
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MM'BFF9--WFD1,$L@O7LG8)YF78E821!-1![IFL[8&A%PJ;DN?(+R#!$G'+'
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M3R#QD,G$4:4F@AYVZEF5XP'!@3)<@";B/2(#697>.8*UA+5:N]IMRZ.U30-
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M==Y'/'@GH=[F-TV+KX/S(.>WRJ; 9"SZ>N#!IB;H'J-:!(R6$_-]3TPN0:W
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M 24':4=\U0\5_]_EA='F.7<RG*&K3^C3Z EJLEV,/4I-DB84=,HZ-K:2\0U
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MB&*L[R^Y4*1!\S;%S\.W;%FTEPYGZ!,\^O3>9UQCN(<KC PIY^(Q"5'N7'Q
MG6([_Q.S+ M""Y<-ZZ[=)S+K%H),X#:&B_&WJ*8C'[3(M7^VL)I8PX83+3H3
M*>H>>036GW)43OBW*.%#M>3!'UP^12ZPA3D\W]NJMCI3@)>1KD+'9X@6NT^8
M2(K?F^TOJW/O_ A=K5,JHTL);V:'-)&R_7+&_2S,98+LXC%U+Y+(-Z.4T>=
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M[LQZ0HZ<99,,N[9A.C2J.*P]PST_)1@6SB<&WZ73LS\]V,^H9 .1 R936[0
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MG4V5F59MUF@M56H0NRRIJ,\('B8RM\+DH[RLT^*-\G)/\I+CR<1\P,AK98(
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M5@0FBHFW7++$2HN*@>YRW=>ZSRE:0.]%H6)'$;0X#KXJ<TK-2.-=/$V;Y8!
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M-+'K[C@3RG7M>?JWLAKRX4;7Z-NY1A_#0 P32F5U B:)X3P?Q6%E+6OI(X!
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M9)D3[Y5/#D.$6]*&BY[*8<"BI#8^BX5)B+[&Y+5ABAD*<L'P#HL"XVO'!EM
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M_K&E9; Z<FO2W3MR:X+NB%:;FKBM"Y/T+.$4YS"GFG20N!SY-.<N'?GL@7S
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MM/@X1:K^I:#@)_-%),EFH3 ION07:4KG335@[-UD>1&$^ESZEWD*=Y'= J$
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M$8S(U[&C<ZBY2+5SK)74N%]>W>G+$R/\/F[S':82A_Y&L/^WC&6J6+S-'ZZ
M':@4F*9AT/:'VRI%> M-9/SR,&@;?!%5?%$I4\B_LQ %_B(- 2[P061/$GA8
MLI3(&R,2_*04V(F4F8C@:;3R)DE<9/0#? V^#S]E,P&G15.)(]CP)6&\+5H@
M51:VLK(JM32@-V5A0-)V*K.,V3 <^BKTJXF=D;P440O58ZREU_Q?P!]S\[SU
M>3PV: GXW%1*JC(HRWA:J@0B2=4K&#4$8Q0^EQ6I0)FD-XE;N ()1Z(6Y$TQ
M 13GPU$QACE,^>E+?2FU%Y(=O@QPEL.#85I3ZH,JS>6==+R::%TI1U%U))52
MMID4 9$*E[PM%DG*WRI-S=KLR96TQ]L5=%"UDHVU2V4E'-6_P"H5K<L0<HNI
MN*5)O%1E6ZQLA421M+.[R%;9-B6SV99Z5TP@T+P1_F0<@3&E7L3=@"+:<<H1
M4,HDB8)GU!X^$V_]%).5_49I0V];L'"^,X;ZS$=R"M'.^2MC2:BP1!HLB66^
M01,"CAG!/@)5A&+^>2G"F-E,E% E+F@W6/0+\,(@$GE44#G(P<;.<OU)X*=H
MCF(]K,@XB9Q^0 OT2D1<NDA!+$R]8"^?!-9(S+=E*1&&,V58O$F,3'T)GYF(
M^ =Z==++:I,@)Z9W@T9?'X$4&L_NA5SDRYH!^^&D 84Z>FGVHOA8'QLG5 @L
M2S7;EX!9Z&$TRC%@N%CBK^@W*8KZ&C55UVF#>#49"I;@+"5@1#J%]=AQ:;"N
M*/4^1:G#%9"ZHM3G+$I]<?KA9@9M6@]\9D8%3+=9>N"SNU8/20U\9DW[ @VW
M-,S89X^&\S]!4\N\CP#:P/L ,G0^ 9$XZ+4\##F3E(0?>LW"J.9;%DI4'J5.
M^)VZ_NBPN]+=BSE:$G^B)LCM@TQ#%,.53,N@):&<O /E#K9<74%DG9>)(D]T
M/V#<+H#O7?<]/=Z.Q#(I<ECY1@;O^2N]+G$Z]0(E#BTR^2Z30,&@^&J,HW9@
MO/:KU>ZY5V$6<I>>=_K]FAZZ_+G1N',VZF&^26VC-;6GSN!D?.<SW;N>Z';.
M>CM8IC,X/=G)9LX.>"^W=$UF+>G9IS&M-\W3NN=6+?-.=Z[ZUIL==RB_ZRKF
MH8P=V%'OS]W?PP-,D.>\!=/Y<WQ7Y\\G'1:PU0C#1E+4,RC(.\6'?WX\_^I]
M_.W#QP__-4G!.O_P\>+CKS]]_(K*2#-H]5@PHT%4WJ3[>_ALGI?+G.]LR^S4
MF!=!6NY>'CE3Q5D'S;\^9QTTYA;V)H".10<\-.L O9'-H,ECP8 &47.3[F_=
M"G 7Z=BR8\L;V7+O(,CZ8#"@0=3<I/MSSAG'A!T3WI!'\C_GO_WWQX,@XX/!
M@6;0LW,8'?3U.8=18V[!",5>UX4L#EK:O:$BPZ3(1!QD;YM!=DV_XV80HALI
MOPW3/, DU*_R2L:%?/= 8G3CE)MG&KJ9O6Z<LKL:Q\F:>@^.DSER<5=S,%?C
M.)GC9(Y<W-4TV*50=0G9,%8K[<[+8-<A]BQX.\?#?2-?E0;NXC*5/+VD&5Y!
M)_2>Z1[BY'!NX0%4]HP$];H9E--\^7> S+(WZ+5.!UU'DVN7>11,T FC9MS#
M(2&^$T9.&.U'&)VTQETGBIPH:@#(G2AJPBTX4>1$T9[LHOZPU7=V42.$D4L1
M.U)/[6?3N%DW?7;98DU71EQDLNGA+Q>9=%?C.)GC9(Y<W-4<T=4X3N8XF2,7
M=S4-]BZX;+'#\T%\-9,EJ^,D>1 ;CN 0-YZ?RB!T&62-%X3.*WO0 #]XD7:
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M[C2FU[!;. J NZ*NY^=S;WIGK9.SARH=QTQ2S6YT_[89--FP.W/"J FW<!0
M=\)H'\*H>]H:-Z,VIV$TY:21DT;-88Z'1#E' 7 GC9Y?&IV>MD['0T=1#: H
MEQA\I&[6S_E,IEX8^\E<>F]46O!;:O3[T+E#+CGXN43<]CWN7UQ[IR9=D[L:
M=S6.DSE.YLC%7<UQ7(WC9(Z3.7)Q5]-@-X-KJWEXSHBO$H[SIPRHKV81I_J?
MER*,O3=1DF5OO23VIDD*VXD]>>//1'SI>FXV728Z3^U! _S@I=L!LL)!]]21
MTXLDIX:!W,F1)MS"40#<R9%]9'0-703=97,Y2=1DQGA(E',4 '>2Z/DET7#4
M=^34 ')RL]U?M(_U$_(SF>4JYZL9 9*&$>7A:!INJEO# >XTC>=G<:/6>-!S
M!/4B":IA('>2I FW<!0 =Y)D#U-[1F[<[LLDIX:!W,F1)MS"40#<R9%]6"2#
MDX=Z/QU!-=3[Z3),#X\0N=Q5E;E2E6LS(DX-H\O#43?<G+"&JB5ND-_QJ"]O
MAFYRK<LU<J-OG<0\$I(\BHMQ$K/)$O.A 4A'GDYB.HEYT(SY&$GR*"[&2<P&
M2\Q&9 <?*'4>H,!T'26/U,6N1LU;?24?XV=W8?UFB%HWW:RA.I";/W@\.M"H
M=?K@24".0!V!.K/?B3Q'44[D'9#(.WEH=PI'G8XZG;QS\LY1E)-W!R3OP,3K
M-R(3W!'HOC/&G:.Z 1/F)Q*[">L!2+FXD6[*_&&K,:Y;4,,![@K0]M$&<M Z
MZ[JYOD<1.G?"R FC!MS"40#<":,]39D?G3XTTGG,-.6DD9-&S6&.AT0Y1P%P
M)XV>7QJ=#5MC)XL:05&N-?&+=LA^,DY8;R)C"7\L)](W(W36, H]',W#A:X:
MJJ&XV/+Q:#)O>G")PQ-'HL[\=AE93FH>!TD>Q<4XJ=E<J=EKC4\>.FO5$:@C
M4"?RG,AS%.5$W@&)O#>]<>NT/W(D^I(,19?'?*1N\]]D[D5)YO*6#UOS><(^
M1OU.'_EJD!232#K&^O +?MT,&MO^=IWZ]"2MRLY:W0?[V1V=-Y_.&Y+H=N?M
M.L>#$[\OB"R=^'7BE]+'QZVS[D-]]H[0FT_H3OXZ^>O(LG%DZ>2OD[^O_GYR
MTCH=-W"\Q0&1^?Y2Z^&_ L!#/]9FL \[H\'@+ZL9['^Y%4:]T\<"Z5]%EH?3
MY0%1![^/VWP7YG (?^.E?)57,BZD=2L5X-N05L"_%=;]EP?K.R#K78O,>]T;
M]#JG'BP9A4GL39/4RV?26TJ1>A*@&W@?I"_G$YEZ@U[+ZW?[_8[W>0H/A9DG
MYG#NO 6+],:=L5DDE9'(X<T\H;52Z2>7<9CCGY(I_)._+K(L\4-Z\#K,9_3H
MU\2'_SV_3*6<2UP9G@=H^3/X1'?4&6SZQ&4JXAP?QG_XR7P2QO!'P"XL@LA@
M@_W.R:9W_2B,D4=Z>1K"_\[A;_A#!O\6<3:5:2J#EB?BP'M]NOF0"P&<%EY?
M.6P@>0%S:@1P*C, +QP*%PW@#U&RP./BM5W!GC-O(5-X<$[+7XLTR/3!%I'4
M2^-O+N!.P[@(XTOO.V\Z*%+\%VT)SI$$'4= .R>@?P#V1EFB+_M/N*?7O5&G
M?R\R @*XE19^^O5;20EU--?OC%:P,=M <FM8:"%OD!:7ERC;O!RN3^89[NNG
M-,SR)/)^7<HT\[[]NP@G$V 7X16\$\(CI)/1U^2-3/TPDUZRP*]E=/3U-8,0
MMH1?%+F77R< 7R 8V((7R0Q?4P1FDRER)X&T4D2&M#=0&?YIG=+29+X.R)87
MQMXB319)2F\K@$5(A<R=MJ=-1VO/+:Q.+ :\!8WU:LAFO$8UFP359HPR2#]9
MUI,*XV28*JHH7[B;.K)E#*^"U@XXF<\ UYE"6MZB2+,"Q9S:+8BI>::Q?P7'
M$7GY1'Q M8VIE,AS?(F$K$BNU^D=!<G9:-Y$//8V\09G13RM%6$AUP<+N3YR
MA2Q('DP$ C3\+FZ\"\!FD&]-PZGMC[L1R^XI@<8O#Z>VPB";/:D:Z\R[EJE$
M&^C,8J7;:( MTNA%RA+H]1EL^Y[2[?N,>G"F4J &-@4%RMY#&&_FK>7F@><O
MTA"N$^ $_!4$2_*N:02P+;H'X=4FMGI2PU:#,%M$8OEN&LF;=>Q7**P_1T\!
M%8(\?$\XWH:SS[-W$X ]F)"REB+*C=M[."X2J8#5P#2,$2AM NVMWUUE++>
MW8;FR:@_[H_')_U>;W#:!7:&;KP;)"OCR+.PH;JK@P?YJ[\+]-Q4:%UQ 2!Z
M5B>!Q$%%C$%U\Y,,;;:JLBN"*Q'[I*!I?>[KE_9XT!VCKG:9BGFI1JX\"^<U
M3A/U; ;?A84__?:A+6/0;5%)R_(B"&56^E7A/M3_;A1-=VL[CS:-RHC&@:-
MKS=:87\SDZ&^$)>2(P1M,87COA/1M5AF[U]Y?WT$\(\PUNJDAI,:+TMJ]"T?
MBBTUP)[.DCB645M+"I(;:+W[$7!RX.CP^M!RPMMO9S/08]N(U0%IM:!<BIS]
M%D:YM"20?C7P9E($/OIF:)5B@5X"%#))D8(@R_SD2J;+-?55^'EX%>8H7KP-
M\L51M:/J%T/578LL UF2920F22KR!$@(:2L"@B%:,G:A"7>]I]\[6FK.Q3I:
MV@\M#:P@E"WB>#;W1H_*FK3,4P%_;<%#:#"%2AQ.A1]&)+G8OEJQTN($!>%5
M$E&H+;;MLI;GBWD29YC3,_&4?^A1IEGG+M/,^::?TEG[WS*6*5P4HL%Y $^%
M&> ,*#;2>*>;YHASGN@]\B8;7T057U9\T8/^_0*EJZ[H_OA^R0QUKNAQ9VA[
MHB^WV#P<-8-?8\!R>H0^Z/ZITY6.35?JG9R.AV?]P<GPI#]Z@<K2T(I9U7H3
MO-N\"78*TXZ]"0)YH9>!(B2)>R7II8C#/VF932YI1[J.=%\.Z?:MO-\*Z:;)
M5&:8= 3BFE*&-J?JPM&4BP%7T?$BF6&V?)C-M%F"SCR1M^%O;4#S'S+79M!2
M6RF\\$5R+7F9"U1'XF7+^^67BQ83<Q3A?_-PCLP#%A7 1G)Z^)M()R*66?OS
M3227WKE/'^UWNWV+^\P748BFDB>GH-'D&^-2C@DX)O!RF$!W Q-@9\<V2OM<
M #PJXKAT<="+G[ZS["</HR.ZYB" ([I]Q> LZ]KVUJ.8_/"?8KYX_QG^F14I
MR2O8Y#PLYLY9MU=_UF=BB&K6RAOEGWM+V:--\U0X)]T>R9OQA >CM[P85%VJ
M7!AUSA[CD.O>+[6TSA\WJDAZ)>#5 /=J$JC(\S2<%#G7*"3>#. &SV8%Q1*N
M)'GH8 E?9!P&H1_DOXOP"JSM.&>QSXH^K9%)OTB50E!J\FK9$-.Q8$T/ZX&R
MC24TCKL])2-0? USX UO\W[B:5*.O3GVMHHH.&Q,60"JC'AT[^3WU:QSKFH2
M-\0R%&-22M'OG6\=X#^3+ Q"H=*!BAR,#/;G(7^;RL"8*J!TYG)SI!8W[U.E
M!W"N%):#_5*5K:O?>Y;I=(PP5I1]&XE6@R^$%0^Z]TQ9MCF6P273:09B>K+<
M#OD<DNP>2;Y3-:&EK/3&56TEGYE;6<4D"RW2\$K&=)$SEF47A5)&_C>99.07
ME-.I],F!\;\B+I"7Z'+L%!48JB[TQ8($RY^E5U/,L7BQY#8"5)A/7R^\WLE0
M)6ZL^DCORA.QL XVNR]F=EQJTR2)@B?#T5]"P(\ 7=;DGV8<\;[*#'B$O\-,
MC2<]A-.(=@[2;R$Z:5!0X \+#E->2V\F@,E@.I?5)4+$RVJQ]")-@@+84@:&
M$W,J>@U6*JBR.EF@E$*FA*WJU2.QO&0?+-E=TRBYSG@UW(1Z(XFSCO</:Q=+
MB:QG/L="=.1M:C=Z [@N;#I(Z&%4[7RJ--=RLKIMWB[RP7();OV0P6/(N5"4
M8[1WBC7MP"T[WN?8^]\BEEY_0 RW2T!2+4WPI+#W3U\^>]=@$TK@BO#',,L*
MVJ8G+B]3/#0)AUZ_-1[!Y7>[=*!$A8OA:]PJAB/,,JN6ZH,0F191I&N= ,-D
M>@U&J4PS\C[VSM[K,GDX]@)H>H;"J%C@/W$+04#%[W"VWJ;OXU'AU0G8),C?
M)4D3D$^^*LX$O.MB9)Q?8!N]/!KZ"@"6OI1!6:6/ J+(RLIZ A'E^/0'_3+V
M#M_&,A^0#'@5^%ES0))HL,\PLSIMF-T9-SYN<%#Z)3O>I]C[+;EB)8P5L,I]
M";CN"%"O31)+K;9^></6N%L+*RM/LNZ:M%RTKFFMJ\+Z/>EO69=USROJ5ZZH
M13A=N1A\ZLRJ@M@>\K;OHQ[^5C#F\/L:N+*^AY;UC5U9WR[*^IQAM@OKW3LO
M+N$XRF<#C)WHC!S *!@Q40/YZS?BK]XW3+>R^[>Q8?^-] 7K][=D>R![5.K0
M)3UK-[YA"0^[F(LEBQBVD9"M5CB]DICAG#U+(3KCU6;.O_^JMLL2N/PW/CJ1
M.$@K8"Y>O_F0]!X\! HJ2T\)^%5[PZC69#,989N;2Q4]QTVB4<?9,;'W,]RA
M]ZT]\-[\' +X?DLZWF P:/=')^/QZ=N6UD'@S#?AO)A;*@-W-6*+N3\JU8$.
M+*(!01K@1 *DU3XWGHP%$[?V4;H6]4XZC\%21E.':_/4AGO=]O_M?"&[)[DO
M:8B(FFB-6!D3 >A%Y!FK*OF6^R.?P4$O.1 #5NHTC$7L@XX!6@_@ "H;J0BS
M&H5:+$"[ =2"?\(RKWL#NY4=_!T F&6E!F1T4:12G=T%D%+-H!3:<7,I"R=O
M6PDQDV+=N!OO6J2I(A_AHU.&S:L*?9?&#77BPRY5,;$EXBR?XX0T-WSM2Q*!
M@C^8G+X'EC4+)V&>I";K#'=9V\'KUCZ-6&B3X'5A8ZP8KE=;43X\&0;4B4_[
M-'.0UKE^R\=#IJH"3RGX(3;5@G6*!8 CSE6NC=%?%V(YIYC:^D6-NY7T6:X'
MTA=+"CP;7!LX]WKNGFJ8"8MHCD#0Y%0_/)!=@&2,U;63F"V7G*;2K*SZX=6-
M5YC:8%@6,CAF\R2=+$M;G[P.7@8G#*>A+^PN060SKOHB-(K#?X%2)+G.IT5>
MI%)E7ZOB-,4@UDA$,RR[:(W"R?H?%LWA0>0/%*)%Q/6L1 Q7ZA42N;+BX"A]
MM;%^&'"T9AO*]4'2'"$3QAQ>8'!43,DZ1V\)%NJ>IVQ+GS4:8E,:PC,P/A$4
M&_D*_ON6E#O^/NW33M7S,<_>I]/RAA#:D8AC&=SR*5- ?UR6IJ/_>\'T)U!*
MXQB1%Q")!<7FV GE5/=./!EA#K8B86EY8]@'0@$S5;QQ>_\QH*P"=04E LCG
M"7^;AEBVP=% %I6D!&08ZP#9@E(:!1B'9*BZ8^YAFPAX\8J#B%E%!_\4JQ);
MW4OT(@E ^54TTSL9HAT0DEYR%:*K!N1:9A65($%1B(C\K;9 +D-2L#N+<6(2
M35;)X.&DG/,HGQ'+NTAB$'>@"X6JZBU@=U"$1D+$K(OXQ7521 %WVF0Q:0>B
M%& X#I1XF(";:L]KZ8%&CJ52"6E):IYICJJ-F%0N).AS 5I)E!MTC>ZX>1+
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M+MX_0I/.C'GK?._P<IB26"L(B,H@H0(9LU\LJE&;9(UH+F[8!DD0"5$P*AL
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MUKXV-P,P'M-:+9IV6(U.M,Q<"HP_K'M"-%B,ZJU_ :#03JJT?-PHN5I[,[]
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M9G4*FV8$M"GF),9Q<D>)2;F9+%%9+9%1>=20CJ/B'"XIY#Y)(7V7%.*20IJ
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MK)%WW??T>#L22S!_8?D;&;SG3_6Z!$'U G4,7&3RG6X:J8%#31!Y[5?X?=B
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M[(Q-NL$U90]$B4F1)4=__;66GGC83Y@R"/ "LE(?R90^0M_+UG(,7O>ZH\[
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M_GDVV[SOY9B!L'ZJN6VR.$P@-DP0H_0820**)I($#U42\"*MC)Y#0L=!2:?
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M\&C,M\-1>I0\;U3I447P!J4W0-S\\;JEZZ18SQ6K%U875 9B"*;KB5(070[
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MF0-/!-(,H7;.XSSI*_5'/7EM"$HZ\#A>24E'V2G]]U#$,5H7?!(&DL@(2L@
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M2(1(A&[Z]DB$BI3WVRB$.D5MZU48Y4$56[HB900K2N96>A3QRL!:QJQB(EE
M%S0H$;<ES@!&8HG">5[P^G[N>R]2*F4IG]@>'M$N@KTD>0\,,-NF/XBA!F\%
MC)-37*S#%FGP7?<UMG$FJ2TO#T:.]7K2I2T?C,'<]$P_L&=ZBJ<AQU-;!B<2
M.;P/QF!N(A$B$8HG(A$B$;KIVR,12@S?:V+82Q=%-A%8*0548!P<\P5\<4J*
MU'6?ICXZ3H_R_YRM-R?UHZQ?+X]RGG6?(<Q?AEE^OG@23F>;,-]FEK:)I2>7
M\DJ_XS_/9NMJNE>X>CM+N,LH_XYI^6:Q?9=M<KF?N>5^:GR;4T,(P8BVB;;I
MIF^5MNG9CY[]*)[:-CB1R.%], 9S$XD0B5 \$8D0B=!-WQZ)4 +Q7A.(LF!
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ML$'$DD&&@J!D["0?&@C>)ZZ1EQ3+G<=[7M5[%TA^M,A//^+XZ_#NR0[%?_\
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M0S&JC]95LJ,B:2T_F0W&H\UB1:BNS'L'4'@]!%5:I0(]C-A6J0Y2&!UI+B=
M#U3$\O.+X!]?\EQI1LF,G@QBU"1'Z%EY[K7T4S$3PU66?]#5Q-M=0/!WG25@
MO&C& -%5N3C:TAI:HX55IJH7#19C"Z[@H 11;-_\-"6X+U4_(F<-+MS]?0=L
MZB8RD/9+K%L=-@,CJUXN#5*8_MT4F!U$,A->L)C&)( >FBJY?UVVCAS?"3M^
M;(:G:&;ON<S")6V0G^1I][G_1\W]IS[W?QZY_UX>CVSS'8NQU@::LQ$#=-Q6
M .*;SY7#QBS<!V>F"3D:.(R-THFS#2!$Q>K69).Z\JZZ"[CKB=-P>,'W6D;7
MJYN-[C R9+#@'BC7V,8TF0:!_'8%2UW"9DJ;IZ%=JRY10TW<U>.V9>;&Z*EM
M%0"W#E,_3$)*;7-;[9AOIT)L$Q5XY6O,!_CWT.<'O<1J%'V\KC?79AVC<4M;
M7D>$7RULD_/W_F ]R3]>!'],WV?(.X$';$/&[8P3\U8[]SQ)E>4%PC%-'^-0
M[R;<B18+3J0VV50]:^J@_FHL..IQHK4-!B$/Z%A'9ZP(N+^T30+0B;_N,X''
M=QKPF&!MJP-"QD.$C\ X#?+(>XS(@PQ ]%>;Z=A]],%ZZA'EP8Y<!"]T$&JE
M3(<Z//T*O[;50PM?RZ2E7RDK4-#\$LMZ9:8\#.^.]I$)86!\2>=)MTK6ZYX)
M7?@$0PY-"R+*B=LA\6QM(VQ&PHUN/MG'Z1XN=.,R%^&P&6XV;<)B6LOWMYAN
MS]QG@#16XM84,[DN2'WCHJX/^]B@2A_N&M]O@4O!QXS?"[86GUIW-K_#G(,M
MTH[WQC0FZ\S.VVGEPWG2[L%JV7SH;$<SLPQT-C9+&^.S0:+1B]:=21=OAT5O
MG3SN&IB,OV?7_H7+N.^PZT<N]KZ\H<(*/;7-!YT&@Z;S] #5W: (7#K-^$[-
MGKS!25;HH@]FVEZJEH/Z_F"'#MRA=S%9CC7L<]V:X+ . CJ&[,^,7:5]@7<K
M?9M>Z4Q5*;[*) "G'W['MDR1 B8A8><^D\>#5_]@NY*U@#N DC]N[;[-*'6+
MZ55?7^R'7?JM0/GDM,S@MV%MP)GM.UR:ULKKK??1OI^QR!GBIWIPC#U=M?6T
M& &[BZ>V3OZJ0H)(E#GZ :JV QKMH:EU][, 1PUK#.:<.LVD?D,7I& ?<-V7
M97V:8.";I2OQLF*ABDFL1$ZHBE/"$RJ)%!&-4IIS47Q5_>*HC0J:Q^;D_5%W
M?S[7QQM_VG*XZX?5JXV2E^M/7>$_(^^G_UK;:D0?TX#%R!^DD!;[+ZN*_&3E
M]&N=O8\?>5?^,:MW^G0?%,'M9E2==M/@-;6=GHFYJ=L-)\4.!:T&:9&"SD$Y
MM']U:.'S.JQ>!"\W[7Z;6RO(&O7);A!T\3GF^)YG8&#.P(*)P3_9IF;T"7G7
M,JEV@@]Z0BG_;U<)T1@ U;Y7?0]876R(N6.@:IC.S<% -&HL+,=?NKH,V;D6
MIALSQ;1OO;FO[,$SQ]%SNPUYL+H&>,&<"N.GD/4T<0Z/2+W>&*8P!HOZB"-G
M\!-=$F2.U5;+Y?ZVF.F%W(%6U/Z;[J24::<[)C(X#M25S>O;OC<SXLXACTMJ
MRVCP@>ABUKX?D7:SN ;0]A&V1-;( 7U>\0Z;U:9#!_^8[;FZ;6SYK"'/Y%.P
M?!I1:XBHV6-(-]<9#HBX-#S&U[RJ;WP@S+/>X.#0IP^+JK&QMBUJ&VK2\'C5
MXV[C(SNK6FXP%&6XAZOU!^6,"[9BLH:MLD62KO)[5#BIV10KM>%_KN,)\N;6
M5QVKXV7=1DO\\3J'PLWQ4LQ91R^',<718A3:9G+5>?;#T7I,\'A/GJZSS<^N
MI\I,V$F;,]948*/Q#9]L+HQ)\5#&E4B+.(D$B7,<W5U5A9F F/.R$"R-J1+R
M@8VK'E*^&* 2('D+Y#6.US;8_A>(JTK1D&=$%ADCE,.*8-DI";,\P8S7*HQW
MK,-*R%C0BI(H34-"<8@&SU1!1!:7>1YR%<?J05[@Q(7LY3G-+-OMNH*R'+N:
MG,D+[HX-6C5Z#(LK^FC 7)X6NZ-.7%ATU^VJ3)>C@4%!,W*Y_\O(*6^_=:7D
M.^T=;UO\LAF^T<ON;;F]_?MPV5B [IT%,\>]GRBI1\CV3\J$)D6! PEP6EPL
M" ]!GF>1%)*F298R?API/G(PO]!N75^2_0B.K[%;'QWBWFI_L.W5P0P;S^]T
MR$+_93S(T\1:AKC*':D*QO(VP4P;7!MW3-%!6UA)<PVLC-5OZZV&(>A$TW;O
M^!D7P<L#X1[G0]-Z>C.D90R6^YZ QP$GVIMF;8:-;S]#IZ+"5I@X<.>L"&4<
M![IIONUG=5\+CGVS7_;$L$Y2Z'^K:$D9)8SQ,"%1% &VC:.,%)6*B$S#D(N\
M4GF^,VSTB[IIL;K]7QC@_,?0?<7K@H?OGH6!9;WOP6CCO4(XJD*P7?D.]%+:
M;K^N9X6U;;V=7F?+=/LB\(O@UTE6@.MG8:L!>I2MT^J,XOB@"WAU\:]0M1NB
MQ^S2$'/?L-KD9:!:P3)?UJ_U-OB!(7BO;:;>CWVIK9EB@$'\-KC6R4,2JY#9
M.]5LNCXH8A,C^D<-]\6]6068)]#BD+Y!H_6N,I<AR-IUC8_2LMX\?=RMR32P
M^E\Z-4@G#REQM:K_M8%=WEBWL;U\O*_7<-+@"1_K:Z"]B>Z;;@@[R8LF2%2O
M=J[<K':NO1C-&SE ^?UD9L;!R*=%("MYDFIK#NG 9Y2DGOHD]7DDJ7OUUN_O
M!)QC>8U5:%6#N50FA1)KZI;89*-7=^/\S!H0>RNN;A?X8=^N(:CJ%K.R/C1&
M)]J<3$R>&F2MBY<LL8ZM[L97C67RTY,4GOW1M&<)6>EI>I&ER5^>C4\K22]"
MFO_EV0W."5V],]?1BS1)_"'^="%!RV?_UV]X1H/(=N).G@7_TU0HF-($$W'7
MB10&D!CC%9.D=5,QI^='X&;<%-F?/7_V[CU[\7#V7N[ SQ]&SAQW5/\U/J$_
M#M[V?WW"R>T R.JH\[YSN]B]A?ONI!^XO>^4$^Z_>>_@M^_6WW,DW3&EV.0<
MB:9M&V['1?';\476-@#LSSRK>5;[=%9+!E9[NVN_#0>RV]S8@C..&7GKM3F9
MJ\8=/<T!O7=6?V44%@-;3BJ<>FTZ .P6YO16\2Z3&,>QG?XI= .!1@**6O1U
M:$H.%1"8"W[52&R0Z7J/.28<+.$3YQ&?T?2E&4W-I)3)59:\[YTEX[)-<\KP
M.&XS@ZX]F8KH+>?':,K(PE9EF=/?-S\<'?^AD6$#-__OC=1-:7>+4.$F.*0>
MO^TNPND7K:B[H6IF&)<QX;AI\8SI,] 9A]0XFQ:KH-XUK2N!L3+B$]PX6_TZ
MS [4..1D#:^VOAVV55LJS0=\NK:&]/P5W."^/F=+<&P)BY&OR[/Q]\G&ERM]
MKM9FQHVX:G1>_,BON3>A7D?"K!O:HBY=&+WE>>Q[2L)Q54M;@2E-9\?7&V!R
M4"!P,#=W%&BC(-&WKG2)4V_+CS2>2?7H@WO*%NE]J)=+XYL>RKL5:Y&%O=+Z
M3D\[IN&Z/I]R=(BVHR;C(N0#!1X+70_*M U1ZSD/?7=856O=M>B[J+J_]-T*
M1I*_3U._8;>]"\IUE1UF#][<M,U'O6ZK#?KJ:/,"1ZB4\ ?EBQH7'0RP+7K4
MH R9304F"%=GFELPY";(['%APBTZT=8<[\";]^HT!=>W2C:(BC++:9R3A,J2
MT%PJ4N0R)B7E.1=Q$I:T/$:RP:L6LT36MZ^6@+,N5Q*;GMX,&0?SRS5X1$9]
MX('W9N.UT.QW?0&W63]NAF,>\Y#%5)&PY!&A22X(2UA)DHPRSLM*YGGR]4-,
MQ962F^5H:H%\VZEJL_RM?J^ZEY7;C?$)?(/BZM@'\',]0%:SG*6FF!Q!Y;9=
MVUYKC3) )XP:L)M&'IBWAQ7^HVY#4NFI)*;8)?AY])N.0[&EL!<.\ZL CS/=
M.5XW*3'.FJ!QW5H&G+/1AP1LS/<#T#$(9#$J\M$9U1ABZTXRNN7"U\%_6@V]
MZP-EFW7SC.N\$+UHV,>GX3-].5FRVV:SAOM_5/*9>584:D:P7]!H[Z933SLS
M>$&Y,ZZ;]YM[/QE6 <OHP^C8H\*DICQU=YE<"M?*/I2M'TW+"UH6?T'V^.M:
MWGEI=!&&]).N/'A3^+7=O_(K0T:C;PXM^1ZF_0#[9Y((GII4 OS#_J,#1U>[
M^ZV0,-+#$:#79>D-V)68K?GL#@'F#ID^=<6C9"$\@O;<5?Q?52Z#F5//C9MJ
M,I3Y\$EZ,%H#50X3.M!/B=-TX?X'!('MFQ?][\E".2KM]B2A/#[-/'\^*'_V
M("\P*"_0,.]HNODAEQX</IGW*AL+$3Y/V\0A7<1)H65#]+5RZ%./[2-EMYT@
M*$;7R0:[+_> ^&M$U3D3]UNG+GXK4EC=,3-J/)0?*E)AS-.*\*Q@A)9Y"C^Q
MD*1,IERE61:6\;9W0,(WHBI1),ID1BBE$2E3^';!61BIJ,Q$%GVR'\JY"2KU
M)#!S4__VI(:=Z)1X*C<M-C _?:&3'*S>/8MZ:<.\2*KNL;7KD?#]S)C]!,_
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M(EOO5]=9F"T"1QJ=RO:\=Y7HBY[#!C7 GEWP@[%QQ#/[/?.K?/8CBD'3G0X
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M-]@CS\Z8!\W0]7K.G@J+P\$($':W;&7(H=<>.XKWKPC@YT&"V/I1PQ\KQ <
MP[%=C%:.S<86)J)"NNF=)T,=ZT"3\3(F_8S&E%78I<_D4>O/-JO>^MM_J];H
M7&N#PY?13-(6C:GUM$;;@55-'"8F]<HEK2/S65[59[??E]V[&!_:D('@/&0
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M#C]:=!R,\?I6<"O!OL(]"O?HK7H6[G%\W$-3&DFR#&[ $^*!$F28<BCZ7._
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M3]W<UI/\L!58^7& D8BC:C:]M./Y)7+1SNK)IU$5O_CQHH&+KA\/1)E#^,
MX/SJW.91ZX+[?P [0*?3S]4T[7NB_!RK8O"C527X]D0_/0.(]37,I/^->=]N
M6'BXII]>M./C+JMF 8^_?(*PNNE)]7'CA>H&KOZO19W/@#N=V\N]#V%S^\#)
MPHXK@'8TBPG>)YO>]?NE"./0C1=<TL/EZM8V@US@A9LY3(4YX' %TPQ$/)W$
M3MS=P.7;GMWIV>P9* 6\Y.(\?V//X:V_ ,N;1Y@J_[X/=@JQ7UK@8 T76E&4
M, :2;KE CNB$#,=6."^]E3LU-JG6PBFPU2&J!'3>4*0-CRAISC5S%!NI;[7
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MXI&!O[@,(O<;NF[ DP_4\\01$0*#T><:.1DU\I(:I;"+E,8G,^ $DV+ ^VS
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M20&*F2]F?FAF7BHGN2 >1:S!9(-51S8FBP*E1AAFJ([V$"&>YS;S?"3-0>-
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M3Q_R%K9\W%OP-B?!SG(WP"TP.%]LI/4ANHD*M]<4),,-1GV_VK8\;ZO[WF1
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MF1M  ,H84.22,J1H85#A4IP*E1<XV^E!_\(P8"L?_Z<FBOK1QT^/DXI_&X+
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M8V*E0;GE&E%.*)*I+9"314%R0@ASWP1_%_/EU[<_P^$,LO_7H@X+-.KB**J
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MULR@*/%BOL"A<\RIJ<#O2M_A=K:JU-16WP^'^X9.Y^'PXQU*KHG&/DC+'6N
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MEVK0UX$'X$:U-%O"\^&DAB,\=1? 9DWBP\5L9I-"=7+6,Z>K6OE32\%:CLY
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MH5P8DJ6ISE)KMY&HI,I0IS0J.,?P'>Z0LIE!EA&%K;*IQ.(%HL49'7%RN!_
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MV0&, U:EFE[4+1=JO33[DE3EUZ0H+U8+;S>ZN6N41GW!5(%1T76% >L';)+
MCLW#QH<42S4+C56"U>[WL7[S8.J$WVLOGEN$3SS=T&J^-NMJ@^@27K:Q.N!]
M' I]$%K>[ZT@$*I;PQQD4?=V6_L8WFO/9H)T\;]%87+[J"M*I,X$DKDAB-)4
M(T4%1UQ)FW*IK#%X5YA@7J2:H%3Z[[A4(NVX0UGN!"V(S*W9J0KO2@2NX&S
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MK'_C:KF 4PA<O@5BZQ**4-G==J,]T%EQU>7+].^[&4^MZ]FN=#G=R/QO"V^
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M!6&Y9!P14H#9PSA QA1NX9Q46*>8<OZ"<OQ5=$2(<OPA83(FTYP2I+BOX"M
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MD=0\1QKG1OO2J\(63XGDQ..HR0R7(KGJF)$J)42E($VH:J*6U4K-LU-5;8]
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MC4<@]$3/QH>;M],S 6R*&^61,IXB)JE#0GB+J#2&>^PPTP?T[.DU93H,_R%
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M^7K5F="\.@?^V$TZX)15;=L$@H.#(-BQ6<][*8/,]\"JS].0K]L. N97&S:
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M(*:T1E(S@DJ&C1"Z--P>-' ;F(M5?D JEL)B<8-1"HM-G(K]M*L)TE5ZBR=
M$)EJQ\7*!EV3#GUT?]* &=VY[MO.YB>6%PO\WE$!-B<J]U(BK M@;(5G2!2*
MHY(K[[&33NB#"K!#LKPWH83AL$2OR*.-N7UU880$="E(-WUF^+%>J7D\08K(
M%#HN/CCHPO@Z7M(3&@#3UNM0_"UJ1IC.DCZ*4MZGX40J(T3N.TAE88 +,H>
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M$@>(1!.) R0.,#4.H$ANP(M[Q$VH?.F\0H+E GENG"WSHC3.W.0 DI;$ 0D
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MY_^4_S1G:G'JVG]6BW_:JKV*N_TS6.,_E3'/7[QN6 W\#./,Y$GVMA]H@([
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MA"]O0J@K$-'FL6W6+F$5[:NK "O<?*]+ZGKN^N&' 6WBK=U+M6MS=FV<\$)
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MKWX71N];RBT6T:L!1+E]0 4?;:#N''X.<N_7N';M.GAO&A@B_,\W:FV[ =8
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MAR+#T836O 3BH=9>>K3I/%-$YA@0#T6&HPE?!\$G^ 2?1 \XP $.<( #'.
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MN2;,24@,B6%.0FDHK<1*>_E!)")#9"47&>XDIG (/L$G^#3ZX  '., !#G"
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M^)C0&!K#QX324%J9E:;/AL;0&!K#Q\1DC\.3/02?X)<K^#3\X  '., !#G"
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M]PIGTSN9*_%17>K+Q_WQI3$_&7?3BM]K]Y77VLUL3T>JFUK?4[V%[XG\E9]
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M1G1OIU%K-!J_.+T/QM?CN=9B]S_C+(_.)R48H_]FA^!],5"INH[R08T KSC
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MSN,Z''QM?S,@5/!MST.NNQM<.Y[EV8[E#N;I1_\]N/'LD\'$=0?WA"H8W*,
MX2>T/(G[= '!.S>%\1(X[P)[C3;6K6]3]BZ'!3PO#]@]\?'CZ?G9V<5I1L5M
M0?XV2IN-R$^C\?GH8GSR$BR' Q@-+Z#?%OA(VOREUO[Y@K8>OWW[]I3^:]8T
M<%@-H=OQZ6^?;N<4YPA&* 2IH>%/7PT&L3BP[Z)[M!J0_W^YOREU@M'6P@B_
MT-$$\9^/SR_&IZ'UXGO^9G=*2$[OX3^_ST,85Z(25S[1 6<)?UV^MUSRK?D:
MH3  /NGGUABM+H=X&[Z,T@Z)@/XIV4VXVZ++8>!LMBX:GO:')E?\6P0#$<RC
MS<;"N]GJ.@KAQT^.YVRB#?VW.VM'6 V^>$N$9UN$086\QYALBD++<8/S-M0'
M^MRAI,,?I.S'8+9*F(-_G7C+*W^SQ6B-O #,RJT?=% $^6^HE<.5%:RO7?^Y
M)\BU[@Z*+M=,\ETB9/C?A_]&SI/E$G[@ET\6_A,4[\%%<V1'V F=@@)+427Z
M*R0GE8P=2>)WV ?U#G? %&%Q2Q3@,PJ)#5]&+IJM. WV$V-/7SN2;":VC2.T
M_/"RA>F.R+C-PC7"5Q'&P-:M8STX;CS@&?_")/O)[X@<'4G&E;6(_O7*#\(]
M!23:G1IT>ZVTW230Z9-'DA)XTOX&+:R7XLC!TOH>K7QJ,YX<$EE<^[C0<C_I
M]/&IP_N#+"Z[B:&/OA5JPSVR?0C 7(?Z85V%<; /*IXO*  K[V#4[]3@]*H0
MZXWWA(*0&#'X'<+]I1/VCESX&PKE,$4K!*OX$GZ=P#CMNV;NT_6QX@%_LW'H
M*,2QET>6*@03L^CA%!HM_#D*0Q>1EMBRP\AR9P^N\QB';WNZ_H?D@2='VW+M
MR*4D9"NLU!J]A C6[F7:!Q'<P;92"$L,IB;8+O%D83ME!_Y8XZB\]92T. V(
MMI'>1@ZPD=*OL+^Y'$;!Z-&RMK\7'%20_CST[3_7O@N>2T#B@W"7"=)GT@P'
M/H;&E\.SX> 9D8VZR^%X.(@"X,_?DF];;BQW34 F?CD+%GCR?@0*!@X<B1RS
MEB8@C(U( SA.J!Q>61CO8,+]8KD1,@-K2?T:M=/ (60J9GEP30 C9DCN<+(,
MTN9FJJ"PU6Q8YS+08T- -UM1LA]2EA#=$F$M&UH#;C6JK&W&ZC35&F&+*2WO
M7J2-=Y\A=#,))=^RIMNA=^"2A94]43.PB=L>WV-86:VQ[6-E6:T2K.>&8&TP
M.)P)6;4Y6B/E6E42*?Y.3OFA-^*K3M$3<OUM>8_@'MD(O%<PN6:@;;&P:1#[
MJQ.NKZ(@]#?Y.LFRLUICY=M9&-40.S9$OR0 ,0V7F.69+$$_*<=WEK.\\:ZL
MK1-:;L'TFH%6S!(U*F[5'EWHC+?5R\OV[QBVQP!D[>L(3;":K;X$B%*8 4YP
M4MIVM"&LH>18MIA>$@\LV8,'=V^V@A$V [I4(%;8?:Y.RV]U!MDZ+?/9&-SZ
MWN,"X4UJE((9!L_^$5N;P"2PS)E*M#;^9\:RJ34HL1EZ3S;L/;3\8&$/#%)0
MF+%3M')LQQ"TK?I*1[*@M!FL[_2'Q<*3'F%E!B;1TL("8@"RA@&[(^<\3IK9
M4S6>WXMB<_TR()<D*/NX?$I&$ 4 B<)96<$#Q91P0L^83I$;!NDO]$"-'J;)
MQLJN]8!<B1!;+91VKA4S6%$?/I]I0P7L\LZUF"QS&JM@FS4_J]R6VBA@4O!8
MC<F\&*TRR3>*7 5;PD9-#S/&/-QB\LMJJ4*7FPZHV!K<0*'&T(D</?'LG@"M
M E"-9TQ,*$T4"@ ('"(Q8;33*9G430=&G-G=0*)HFI?/@KASN]1,']5I5O\6
M(GD8]0PVZ9.*$J.RU$IT1/!8@J,Z8M0*@/$/(IA(N,U5K&X"YPOLI:V=4#<5
M:Y[A0J0*(#$/"I@(6"V5V]?:,8" >:W2J/'ZY+;X>?Z?5"_JW%O6AGZ32\MH
MK\3PBNW6<\RP$+&*&<3>GF?/'&9;)6/1ON7.&8=60E5C4-I8YXN_V$P!JTU[
MYDRF&PC4;&FP=L1YFQJ,MO$5#%H<HWH'XXB7,_HNU:#Z*.,6@58@3N"3(ICF
MH5XI7;Z)%E"#J,B&,+GA;$/3R8;\S9 L[0YBX5#))TX>Z4A"$FKUH$*47#=H
M? 65Q\GM2[EG7E _F2T/3:RM6$F4EBHPJFU))N(\%F@T&VD]"):E'.EG*D5B
MGCL?4Y["$#L/$=U@7OAW5F.^ Z?+R1,LG*2#:Q_/K>)&]63Y1Q3?"Z[E9&F]
MUC &OBX2]J9?0F$&3HA<_/)4R-BOX\TO><=-B[DA>J-$8?,\S_SQ!/U[Y$$
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MMZELV9 NNZS2"(I;K.+$*K+;VLTL<\%MI^M;^&*VD"M^(7)%*1A-YHV;:M%
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M "_0]7F-O:/#44+03Y\'0"?O0#3ADN[MT(B*KH PXP4B?29'?8F7F2(U:GV
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M!)8&=<&BD#I@E8JD7F\9"XL$+*C0W3WXY"O#4WH?$3_?0M+F':'H]9*1D'A
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MNX] 85HXYA<:5X2\7]_%.-T>\A_A+>@MO@K2LYE?WQ&TVA2<6'G5FE8%EY;
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M;>2$ 'HV-2.8PX+5+.HTH*B]B *@)<)Y"N0+"A/45KPVC&&(2+VAYV).<)_
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MMZV?Z=-9Z(3H4RH9WR9PTO_D'NDLX+!XLX9:H(3O&M.*J+D;/D=AO YV>]I
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MW4S8^NPH;6(?K>.^W;8B"JJTMECYT&[>AFA.,W$S1,XTN,G,Q*Z/L!E9PHS
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M'K\$T3;YPOGZ^$D<R?^!/_G;1<A@7F'$!X$AJ?^*(^7F7-G4VEQFJY6_H-,
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M=V'R*TU2;=?T4I5\I6[&=H]5+)0WD<Z+6G,Y^&-IT][!VRL$@H*&]NSF*4I
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MW(>=HCQ5L=99T*1K_U4_:F/Z1-18E GQJ^/=[ACVLDI4 B0/HKD684NIQ:?
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M!GT)G7!\!N((5;YZY>V[C=NZ$,[8NG@MU:Q/GP8O91_?H@G^4^7:5O7H$4%
M)GM6JW,EC>V#2G @IJQH8OA7CP"4.(I0'Q=2:97'+.A0V174M/MP[)CB*K00
MYEY%:$#NVNDJH=&I>3ZYSM8.FH&MBSCQ_#1+S;/: =FLX[#,;\<;VRP:%X(
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MQUL8S6$5^\. '0O.\W_[,/@)'QA:<V%2CMS@EKEH&BB5('&'(IK -+(>)"4
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M.D1#LL=% =1Z=ZRH-^XIB*@HU?*CYP?X0,^"2]B8KQS)N=4]G)(F2%M)3K.
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ME';+.%,\2P0#/0PQQC'BA2<\:DJ,-4J&#PH_J'!NQ??6X#N-+>;1"1X?T6&
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MHH/FMV'D.-/? 6LYCY40I11QHX['1.5+.%1R7SV?H8QS'48(]W!)GQ-#5UW
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MY,4+<NOL;+&X1#%_H4\!#!/%<$'-5G/ZQ8L_7TX1*S$.0=*%%R*Z@/G1J+U
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M"W[.]\"6W"+*@,?Q.<D*!B7IJ"0=]M! BV8=Y^LAZMW/5E=?%B^X8['4_2Q
MJ)$<F E(@0GL.-B*$NPD^P.C9:L0'#X=M&)0.2&"=8/(BNT6R4ZN% ]@B%_(
M"V4.+Z !K S++XJ:"\')$![9$K],"I!ATBG()J(V>N:'V1Z%F[+7RFUX8FQ
M,9LXW\(MT(5!Q36C/PA& [KF53'?,ZL'!O$&-0<U(#+:8N#D.,6+=KV9S0"!
M4[EW%CS +1)SNL$*;]%>1)%AO'$\6\&=PC,VPV >^>LUC3[[@;_9;7Z,L+9K
M%"XH7?)W^ ;S'SQVOWMF_F(&UUT$]U KG_T+S!;+*9,UC@5RJQ@,%\,7@Y$M
M'PU^(H8CR8N7D$1,E-<7"M%DOD#,%LD%]H:UEM"2XN>)S]';9>6@( GQR*45
MC=[Q>LOSJ*>B0BKY9- 1DTZ'R/D0.2'"9T34E C.B<A)$3$KHJ;UCE<P9VA+
M5Y+R.4UX5@3?L^D>G*@M.B$;N9BY+<YES))-[M!.!S=/A)A<EU3\>1,H$%9#
MEF[WO&E45[0\\C"<L;!SH!-PFN1K1?T;U/DT>]V$IJ3U)]/T V$Y;G/S=ES5
MTAX3K&+^W4(MILD-1IDM;D&(9VD]NG8I&MG*6X(X,:B/A:N"_(WN62M Q!9!
M=Z70!>WN0?0Z/7NQ'PN!1(PAT-!UF1VX3T"%IK%X/KPHVJ.,P^LJ.CR.#E:@
M O);1396PCCT4R;&AN(ZZUR#<ZBV#415<ZV?#4@G$[5Y@:/("Q8O[6IQ"%HX
M[412&^BD66:^H(3,ASW??.3(P3H[E-@SP3 VHI6&.M6"B+&!3I6EL\S<&GUE
M-J=E[' :]Z'(K5&;7OW;TM7210F\7MC5LDN#:FY&X4 >):<&G9!TH?1$.L .
MXSC;&ES5 DIZBB+&N [,S##FA0Q2YI&K+L%7[/+'\JQQJADH9.>HZ@>B]TW
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M=YU'.L9\6XW_;NR4*A:DC T(R="D'YW6S*=-FC-VENS#KEX-F4'#/[/ -+K
MGW1@\';/F/A,%= )'3ZNAOU2 E)>(K,U<:I2#41#$:TCQ91?V)4L]8@W\!XO
M=BGBRN_(Q6T%_: <X((8(38>IJM<ZXRWVHZ4/(9J#)=UL8=4(N3&^:9K=$,*
MB#+1:Q[RZH-#,;<U)ZERG#[P^H6LJ'H=-N&/NFY2U!FMKB.?<6#P5E\%:MZU
MPI)\ZFYD\EMQ9""T^=S73I!P% T^=);5"M2.)UN:=[@M!D)@!F88L3V$!3T
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M5LVS$Z=8FA10F.$D;5G_&Z?3?0'A8;E]S1!#K5J^Y2&.4?00WXGZ1?3[6O
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MQG&LILI -/I!#!5LZ5C!P_/R KFJ&(L:/&$-7ZR"- <Y"IB/'QRXM2T1,[C
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M-=8K5@-T:5FAIV%/'7)?/%=*5L- >N$F86"]JEM8W==Z<<4[.9_MB^2WAC/
MF:8G(L+9(<D@8<)6<\EAI9C-!C(S,@'?)RR/0W:QI!@(DBI=V?E6'8F7JE6<
M\W+@).<^=]+Q"=Q:L4UERYYIG_?PC(+=%MNU^7P$!SF,*P^T"Q9K#@ESA;Y
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M%>6M9Y=9J''*M=BV$RU-9\% H[8,N\.TRG6M:FE[5]^6Z<:K#J:8-.,RV^I
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M=HLV^7)[]VW#\-5?PAPMXT'EU(P16.,/XU_HZHIUUE,%+5+5*22\@EY4T5C
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MF(=SC2IQUHG[]V.R$@MI\H$CP,1[S2#60ED7%YL<?W#O7DL^R>E4?$M-<#D
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ME)>90MQ81V59#;S5&)4Y[0Q\'YJ!(:BGQYK^-&I<POG3\/W$]D$[Z@##[$_
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ML#R%L2V4JZ.]=VVSBGW4,SV]1S??C&F>J)JP#-)E*:J<DJ-S$BFOL6;52&9
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M$FRST!KY6YZW>)?-F4EB2A]\_S6(4-IVN%#4XCHY%O_VLUXL8A0.'@E&2*E
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M-50OZM=\6/*?WMA,A>80 2%7*/O_$J[Y_27!^BD,,(CI/1!+!"^N<JOH^IW
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M9184\;%]MY;3L4BJ"=$)0)I=)!'V413-%@N<3;*TF:]0[&#/\&DI(/R.<35
MK6]/=S2(NS#<YM=<KIPX#SD=?L6\O2'L:,*%XAP**=P[&_AG*4>)>AE%H:.!
MZ=P^S*F)U<V_]V0@/9+<+\H=H^K?^B2&BD_]KST1]-5YQYMDPR2I^G<3VR-Y
MC? ".^&^Q.^4Y12W-T%\D8F;U50Y!G)Y$^#V,3")&AU<F41O:^2VW&:3W\_E
MBJ-F.VVVH.#4I%V/DN\WW7;2<MM)PPX'SED''FB]4<;\Y-EDT%?3/SQM/<RT
M@B1ZFEAEH(%<J4Z=:-G5=NX&8K?OZP3#/O\$J_Q]$"QR'\2E5<Z*MD7DSCSA
M\4_2_"(81IL@NPE@?=_FL/G : -[D7UQCM'2%.C92XY7"2$E*PB0%<.[1V_I
MG]A'L%1G;0!_"4G0/@Q<A!81"3_=DO?6'>\A>?6P6X!) URRIYDJ_D>B\E>5
M9::EWM^(=E'LM5S!S%@C+[^(%JP]+.YG8C*D>-]\^;M#KLG$\_ 1K];Q?4)V
M+E!Y"(]>.IZ'%A?[O%V4-V36$CAQ5 - /!(_C8\61;QWYKK))DG+F%RA)7:9
M1[E$1Q,B,.6M3(P]A-A%1?R:)?68[0<B/M),V$);5Q ;U7[:I/:+#T?Q&V%C
M?Y7&':,HK0/D+PY/CQ8RJJ@$3Q/A;88Q&N]1]216KZ:+?7>6IZS(^_LJK\<?
MW6J6XD/UU16A^8K?S+Y;Q@S78#'[FI/.4@:0]OA5DKHD=I/M>,DX&<N8,1QZ
MEL/$=6-6KY8W7(>60J/LIJR(XZGRAF+E#06X1\QP5/U1R=UJ^>6W=@HDQZ]K
M*5XBI:KJ-[84A%8B7E*S&#%DBD)*Y/"W_(JIFL3BQAPL1>JT;<HVF$8,EWB+
M2H2'NKBU/(AJ7:T83A%V2Z]\MV8^I5B?I3>^3]ZY"G'%+FY[G\WFY8(H$;_,
MP?OS!%X#O%/CI3FT?YFV=A58F?AKCMVO$W8UA88=[,TA^VV"3'R2U$+,A84[
M^>'**DRKP'<!I59O0<E1;/)2T*&@SQ->^1@D%<A[$%Y!DEX_?@A *X$#80!W
M@TY.RZ#,BI_8R^E@),,'OHU=\BZ1$ZU)G>#TTBH[KX?1W$S*F8O(_73"$^2.
M;58OBOSK$'ZX]8'>9)-5BEM>.!X1:4]KA-)F[)RT4P<V<<UHLW5PF/JRE[4[
MBL_!!8*]N05-$^008];R_4UE;C4?NCJ6L;[8TQ^$NX$YD8?@4.D1."*""0M?
MX1U>@-PHGN#B98%U_FW3'DFQ'*LJIBRQ87TU=S6@= @I2Z,*[0!5$'.6NGK;
MX=:3!+7]/4$YQ;94G*S0_U\BM$P\PJVPR<'0VJ(PWA,#X8\$;PEX9Z;W%E,@
M3]W&Y7DTK*1F/K*HHYGL:CI5Q;HM64GB,CT-3.C,[9+C#F+B*_>:GJ#[D%CM
M8O\,G^5<A);I.:0)$:*XEZ-E>IJY*KU-X-0YD".Z,$UM/:25H!U#JFM"'</$
M?=PE'+M(;FWH;0V5#!"3.P!"[Q H@"15!Q3M,-AEN9M<HGD]3.O(\EI*S0\N
M5@8L34AM:5U(']>6PZ:JMTBQ75DQL!P_!>5("KJR"C)6Z)IJ6.UR!UW9&2M<
M[8X&NH9EN>NN$VEWU\B7LQ6^ECN6H0!/8-' 8L%DJU>X)4Q<M=]VI^[!Q?T5
M4("?T\E3"C/3'M3)NRQF\6&4N?](<MY(M@=YBR(Z,\_N81Y'@$2^0VX7 T9L
M.6;!7+'2,F5/)(>55>.Y%_6-;R)1X/C&%GSE$G26%>SI+.N)7ZA4W-' =%Z>
MGL,4\?1.471,-^7.1=3+^+IPW,"4AB8"#"GK4W:^*,X@[#>DR:A.PJBTN]@?
M_OEWC$)0&M;[.[1#'H>9)#N;G%;Y5&[2R TPJ(UA_J2BG!WI8?'B!Z\1"G?D
MS+CUP5ZO/M!YL4^[IWGX<GCH_IRV&E)? Q_MOSKA=Q3?)/XBNO6S-ZAN?9)I
M1)ZP@?\C2NW.\9BNZ5-&,KN!C\#*[=E:>_,<W$H7:KA<.M"W[DRF%Y16K"2)
M;D+T1T)>B)%;:V;/@0CG U'*(KG>T^2$4GD7I2??)ZX*R>LQD!6)#CM";B:\
MKD95^POL><J:/;63OH,J/5G("2D@3-1Z(,S^69G9/P\DR"OCL"C[NC1Z!RR/
MD<B["LKX"BWR4:'&"EG*8&LY4-(NA#)N'%/=<KC4['RJQ),SI<>"8T<V]^%:
M:%M;=BSXL\Q=SF&M<;'&@K).NUQ*$!^E]P2Q6IB)RO@\E\%8 !:[343'7<,Y
M,1;H5+SG5!!I#I$1@L?P;@G5K(8+QG+L3K49Z:X>RY.;^E-).5ZK+C >1N'J
MO@[JNCH[%J[5><9\'N>6[XPGN:X"RY,A.\68YN:SM,!GOSRKQV#MHUSHX))6
M;:BH93[_E/7J9Y5!TY+=P#S1!8K?$/)GGI=*5NJ;9M)]![/%!<$T143Z,'I,
M[D:Z0Q=^0U.X#T5$E'J=V38^, -,YPEL%NR"D"XETY>J'I'S,Z+_B9M*HO43
M)NH,R&>T274QG_TUHOS%DZ&K1X>XZ\YH/"4KJA%_A5[CHT2=[4"@$AZY"4+R
M4 3ORH=,S\&($,YR<#H8+S_:I*N%A#QI2*/7/B+"8_F5O7A?8C:^\JLP@-%"
M3O4]<Z2O$69D5G.2&</$]9$:635AL0G"&/^+5-Z+XO1\8MTJ41W&A/AO:E \
MX<]H;3295#F1=$HB;<'TQZ<*T@=>7GP TR/L^P7TK0NT#$(X-=_;[03)L4>;
MLJQ%K1#:(>?'>G?P4U>L5QU[ *"4/0?E*4C.F]G=M(>J"\="I2#.E)O7;2!:
M9 "/!6+[TA^'$>U7,/+5XO@68B7V'[#+_JN:ZY;O:W5#O@RM%--:CF K7T$E
M)5G9#N\$T2!VO&$@*K#6R]CI5:OLE9A=JY\\/\6X4J+LR8(<$,8ME2.>GF Y
M8EV?2K*.,LMA[D^N<C/,1Y(*V:EA7_8>6@YK6UN3I9=U =<P]"9C8K3F]-6*
M\&\9PCY:D0^?-4LJKH_EF<[:N97MC;>]NJY2DJ,-"<R69W1,P3?EQ+(JH0]!
ME/+X?4)4I/FR^)D5F=,SMHD,1\H&9^4WTIJ:>38O3$B%CF('WOH@Z1!HP0CO
M..F!XGYGPI2E/49^K9$EZR.;R,ZHV-:$BCD<+B&L4,QY$4W4:W K._.\X(T\
M(@P_9^\-$Z+O@_@A1#L<))&W)V9=2(['-NNK,KYI1>ZTJ(Q>F\/>1[&[C'U)
M'YZ6.\A.PYA^%EONG3EQ\XMU <NMX/ZW=4/]Z.,:[]DB+-1G<O3^;4)/F3^5
ME*@<YS_;ZL.A/5A_C^+F^V^U!F?FN1G+H_:IMJHZE:S3D*8!#";PI$EUG9ZW
M[V6UIN?MI^?M3W;.%<KA%8)#Q,5Y>&#KH53K\!=YCE_Z>R;\;!^>GN$-0,-X
M$Y0Z3WK;(>TLD,XM!+J)*<@A/@"L#P]\IH65>*]]4F<@W=VT2:#Y6>=<4[(\
M\5I%PZ+G#(C4&,L![.0A[++"9#E^"DJC%'1EU6RLT#75TTJ.'DL)'"M<W/-!
MG^:I-4@QQ/2S3D3A72/QS-8H3\OMS-#_QPI6.V4O-3LZ"8D-YT982_YB<9:M
MD<.6,,E;6=9E?2H$"\I'Z/7[%OD1":H&*Y]$LJ:0@<F007EIF+E!I29&"J:1
M*/P3\$*ZH^[(1XA@8#N6>3V&,P&N*YG?9V"^NRDH,[2@S"-(3SC\2![^%:G(
M'*3DY+)75$Y1V-/ A+X@'X6.1^RNQ0;[F' -R7F0F9)<W\%J(%S=MBJ_+;?E
M)4Z"ZH,-7+EK.5B3C]>@8X/+J9;C)J7NU*H,B0\KRT&;O&C]\IRD/M$';";S
M_/*4YWS6Q(DQC]<HO$S",.6?PWL\I?NQLEW.S;!W]F2#D0FE4W0\T;5-7@\3
MJ0F;K1?L$7I$63KU<27RM6$E*PC[:2M_G/,.5^#3B57N;NXN(8CC)8JB5#;<
M(!'Z@DZZH:?YZAX2 -.)&O?AY/N92( B0D>:QUFM=<-;EXI" A4[FSYG)81D
M)8H@%DF6ZW62@*E+1\L5.D5&$XE>VZ-7ZEPF. @LO^BFR%Y,66[Y;;46?"5S
M G9R2ZT6<C=I5=UAEV P6X5(^$QG3^810VUI4DHW>02-C09O+@,/J PR^WT6
MAHZ_RLE+'XQU&7].ZP\"\>0NN5R81]N'#,!%TAC =C]2Q0F?TMN:,*@:&#MT
M6+GA']51C-S0.9FS&E&BQK4>C9_09C;51<I7#*=-'/@(J'H,]HX7[^$,2NE\
MV9+;XFN,LL0:V(Z@OCC8OX2O8#=UY5T&FPT*29G%PSA4F[:'KVI#Z!Z]_3,(
MO[_XL"YA!$?ED6KFNU'"/GK-7L=[".!<BLL(-)%D&KZ2W4WI0G+G)#V"IN]H
MLMQ,YAY/%4-/]4BP'+@N3HZ#2M^'=+9\?;I34RMO.="WC^78ME0/#^PM/EHM
M![!3X:&D&G3AS1Q4P;1^Y(#>!;4]^)WFZUM1@?@I>8W0'PD)$^R01*$*=GL3
MGIPJ,5Q;GMY6%]%1&)<(AI^.Q,(/WY[0*KTBCH)5Z&S71*VAHLQO>R*Q$7)_
M6@6[CU&\#3-BR;]*A,)/WRYG/_Y_EW6JCG\P4HX@BE"VXZY0Y(9XFV\BKM-"
MU$N?E9U7EYQO$9&._BJ3#53CFM'4A-LH+5-VXY#G.N(]=\=3FYK8[+'C+U[W
M=R@F)P&<ABE=_#W/ZV(<=8X?E=+05"$042I3K=%@! 3/,<_KT=>)4"0<EN4\
MA2/X;8=TFV<JVC60HET4%8VS*JS6V@[([+XYN>2:&1!!N'_:.B[]XHU,CS[4
MH*\SF@X$OS4FWZI*PS4L$=@,+B+:1"J\@F<4;K /DH(K]!2&Z4D29JM]D8 !
M#&11N8+9;""K03 CYKG//RB%'?4%QZAKO<5A:H!^A>^1'+%_(H>Z_Q1Z#V0!
M*'Q\G=K4I^V%?(R!3++US,Q/YX'X6/#BD9UF6VXQ$+R!%O3F>&2/*H!=[J5M
M/]]NMAYV<7SK@R&#HOBQ*>;9[4RD6%<@*1*Y]JP4:T9KXYY7D6^L$KJE^Z(L
MC0-(.;4(/&6GDJ58*#JJCD$DEN?(<IQXOJ?*CN(Z?$8%$BNG@0ZEY=#0W5+5
MVDH<CY#UZ B]86P.LCKX+^5V2\\L_N%F*3PM''Q3@56APLB"BZ-;=@&2-PA\
M%$OE2;D/+64I-06;N"LMO]:GH%VW=YR.$D/V.^\L<=8%3&<IH=C^ZU%RDO)N
MK#O.+;]LJ[C_5,K]CPLRME-%)?)A^4UE26X3F$6C!$F'6E&$:2R_Z*THTX1X
MCQ(N97YC,)FMK[>V0*T2<NSCT=7S@D<8\,PA^\L$&2<"FX/TZP22,/*;0_6;
MW5="GI+-Q@GW\V7ZXV40Q>=6S/!LDGYS?&4HK;0SG@Y!J)'*A$@;FD@@70=A
M3$X!$;F4A@;(_8<38J)NBJAMMC/)MR)^'8#P%X=9&WO04F^\4.JPC\!LK2=<
MZ&+%>C>I!"X4^66]4T\"EB8<>GU00ZKZ5M4=T^IW52EROA>,ST2?K,+-J#PD
M:&SBM1Z\6L?SY4N$9F"JQ?-74CD%+6[]ZW=W32[IWP2A6C+N*2,:7[??$:$>
M+68[^.T*/2(2L"L'FSY)K:C$,$.;*A$F0>*G?HD'%+KL3'OE809Q6O"+K#(V
M[QBT+BXP)XD'ZRNKJ#*6C'09@^;6'C*JE++N?5.^=G>3Q/#+K\ YFV13$5@O
MH*+5MN/D/>SMNM=!\A7+<96@>X#R^0UY.Y1F#O"+C;08;L!3)RD2SV_!B3,N
M1AGZ1.&;*O>F^>,,>+(GSG%P4P.1F1\II'Z\"TUG&_)3FWDRQS*NZY_K!4K9
MFSIM!/'H=7ME03X&7ZL^Q+(38?3JO/S!TH>3]GRA8A]46A/>?LMP\]$J?37K
M3) 3N2 Z36LS:1I>!CX8QC%^]=!#,8FG-8PRW-JB@FH^C\2KQ*AC=OQ;3Z6%
MT@\R*PJ5_]H305^==V+U,TFJ_MU$A4+/B:+Y\BD.W._\JI#-AB8R55"(8:\<
M]PXAAU\2DM/#Q,NK?R3DVC7?7U)K9.(-(+39!J$3[C-2+O;EY>=56I3H:*:4
M:';=(:/J,@ B?:+(\.KD<?L88YT#'=S=2F]K$ODR'\B@WFAOY*VES2;PQ3*F
MV<X L5?H-;[U060D@C>[* V-DWOO;/BE-YG-S0O'.T%E:F9S;=7":E_(%<HD
M7H,&_2^T>/$]O,%@'M0(5.NKC=H;'$;I.P+NFE,3E-*J+YTMB]2P=;;*WXTI
M01?*2A"]A_D-]."$\S 5_(M_.%Y" H4I&\KM)V9O;0S[A-S 7P@YEM:LLRU.
M%O VBA*TN$I",*1AUCC(3<E[]);^B5J3OMU VJOGYS!QR^8?VI@I$NTBM(AN
MPF!#,'#2JYY4\YT@R&!5U5%,3#1WZ>6J5D%E>I.%-2M>%R,Z)I6'4VF084V>
M^:[@#GL56I*7AIEZZ"EC#@>$;"-K1D%V4.-J98FL"^2C)29/RAWIOD$.2<V0
M4CDEAS)BI1S7(5VP\O+ J<A*@13WTR;UJV*./"^5;!(O?5OJ"N_P OF+4H:0
MLZ+6NE4?Q$SAXQ*11X@OG(CS3@*O3U<J!,E?BXJ=2S[W'.+5"H6Y>OL08O>@
M2]WZMSXF+[,])*\>=N=+H!>D@81^H>,KAA#X$@915#G!N\% \COZ-N-A@\R7
M?P^\15IKM1:-N/:0FQ4<R,5![>_4_:ECW$YF>8=A'19IO"1-D(U^=T!H+"[V
M&9D-*D6S4Q[/9%&Y1H"FJ %3"998FEW!" H5$-3",Y:"(([U5&[M\4(LEB-$
MC\Y4GL^5"(Q8#I)4,*6,&2-P,1:86)&/2E5FRM:T'!_Y$&.M1CP+5<OQXH;_
MJB_[-J)6ED/##GV5<6%'G"R'1Q2O.M0\DH\C68Z8*#AY0(P6R[(4&Y$J78V:
M69Y[K*)*,P)UEB.D=KS7#-5Q84,5R,JQ4LLQDQ;)U&BMY>"TTZ5I:I/E]Q]:
MJT*2\?9QP:=JL]$=!I87G)9FN69JQ+B0D>0F-IZ65Y)6T1J4TU<F[.326VPO
MO*T"U(EY-Y;7Z-: I'3RCN6UNU6@;)< 9'E=;Q4 )=*)^BCM/7"TVJ8U%8:H
M;=[!=DH*-U>J@&HD1KNT+:HE<:L =R26JBYP97/""GA'8KIQ1*269+,"SC&;
M)QJRV@H81UA>X5"-K_;[(5184,GUGJ[K3]?UQW-=_QPOC9N[':R;]$Q"9FX)
M.>HK/::;L9I68)[$4>SXB^9M ^ENYJ=RZ83A'DC)JF#-XCC$KTE,),QS\) J
M2')SDQC'_&1+JEG&6>2E4%D!0.MJ[%H9)5A0WN0OV\ _VDHL7:3%2*8U\BE7
M?LJ5GY+ ^S9\IR3P[C+'JMJ<Y3A-^9F&DB]& I?ZQJLH\1-8)ZCW(TNR4T&/
M87>,*X^,"U@KJZ:/Y*A>W>9'CWDZ[746F,DU^J$6(E;Q SD>RH\RDBF>Y51&
M3AIEXKK-)3J:>!P".''F>4%,=-YYRG!<IQ:[?9]UF*>BT.=:%/HI>8WP H-$
M+>T'GO^=V7X*V3 Q=M=HD1S0RO5O7JR&UV.JJ3RBFLIG59:X;%8V-#-.T/K.
M9"",J24VTH-47=[- ?35U0W@R'^;^T46$J>V+KVE\7)I$@%'3@=]]5[A$(MF
MJQ"EHHI3\)76;B @BF.&HEYF!=L_ O(\3);7)!9OE=8FJD[FV;Y1B:9+)UHS
M*&<V'UK=4%8E8<7.)J95D@R5C%C63)CM!U1\^, LS"TMZJ=-1J9/U[Z1^R?^
MBGP 1^0PBV;^XCJ*\8;<3R].E^OW+?(C>E6]-L,,9Y.D-YU:[I%:7],^-'F/
M2>4=+[9CPM( TU11<:JH*./XH$4;);:8Y7B)<T:X;A'+T9D**\K!)/:<J5>?
ML!6LJ6J@5(Y(PS,E%3.D>(.ZP,P;!%QJ&B+7(V5Y^H.J@&(K$98#);T#>6Y"
MRS%JL>WH_DO+LV8D-QV]T*"MH)RTP6@9:[8"I2BR&;A:GF>EH# Q_/A= #0,
M[4@:&W:HH(LLLS,#1[',HM9[[*#"OP9GM]4X<0[+ZVLIG&W":(KE];.$4+4/
MZ5A>..M4R56/$'51.:LIN$SF$K\Z$5H0?Q,P2+92-N03@XF._DB($W$'_WF&
M3_'3B)GM#65SEHCA7X>GMC41 O<<7_@H?*V1OG<"WX+G=9!$8/P\OP$,^^O-
MU@OV*./PAR1TU\#EY.OLY"#E,4QPAEUI\@>$A9F1M)9&TH8*T9GJ(P>1^8@\
M<MJF%6>/0K6H2RM(;3YQ4+.IT(2NB\8)$H;$8Y/2>;$_MLEIG[TYX4(R<?K$
M\:?K$U1RINL3]ER?^ >*B ' (;?<PAR!W/.IVF:Z'#&BRQ'M17PFYX$TL'BE
MU,]./F4 LD?8+2%VX]S[_^+C.'I\>N%J4/P^TZ48/K'']6>+@VJ;(>XD%G<W
M'"6J^T8\\#G!4;SK4G].43<ZS.\8--\Y_%UI,ISU3'==]@+/W*?KO6U&,._W
M$8@;5FMM3I7'U)?XO$:ALT5)C-WHUG>#D%1N(+!EV>-\GXKJ$'T9)-6G+YL&
M2>7O^JZIB04%6SQ<(M+Q"[2-FU?$M \_R.W]_!:<N+V/(W3H>DP5:^!S^ 'O
ME)V.S-[:**[$L;<X=KP\)IE5QO?VH"JB<(<6-T%XDY#G5HH@'&T&)XQF5NFL
M4"L[Y?;C:%N^F>\G)#3CAF3+WOHU+6+G8(^XOH""XMNSJ%2%WB]E">5I0^70
MZMR_P;[C73E9Y747D7:7CH?\A1/^$SE4+C9-DD%L<]]5T;!$-O56=%=?T8;
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M3LR,('8\\SF -'5G4G(&H>3D^>OYA@>RKM^WQ,"[0#Y:8M8D1+T,/@>8TW2
M66H^DIV-*2&R\Y B?/AR5LB4TP%/NSHA8OWI,&\>YFR8[#F()9P/Y,Z=[Z9E
MTU,OUG0Z#^)TMM@$[0? Z^42D9CQD=Y')T95;I_%-PAV?);]D)#782J-&4#I
M&-FD/E&EE"$,VT&C]QO# 0E^<0D"'S,?+A;WTY:1R>$ZV'T@;A-@SE</Y5C/
M7)>48(#=>+DFP:WZ#/2,V<'L*E1<.EL,Y^@7!^?,=*P#"P3E%3UX\U(>;3C,
M1UN!)\ =73@16I2)O@P$TOW4L;M>YC0++3U:%%:SU&DXBS:/URB<+?XKB>*\
MM)S*LC1Z#V=BL./]%1Q]A>D!#691A.+H'XZ79&>?YP5OY#:GVIQ5!I[,<7O<
MGI,IKT]?G>Q\JIVO1^.U-!M(+[AE35EKAM!O&6 ^6I$BA6<%F2:UW=(\HM/
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M/$F5=#;&A%1&&,($;_V','!1=$C/F_F+4J*L["Q%PPQAJH3+\M_E50O*Q5F
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M9?]_Z]._G*=+LNJ\JXUA>M?+K4BY4JXB1GT<.":W*E&!<'H[BCS?<AGXY.8
M\EV0;$>)6FKT'#RA&'8I:4D@3AQO_NKA54K;N>6E<28O7=)';0P#GA[J2ETE
MP/OW /WS&_)VZ"NT6;/<7 H##&IZ<$8'_H+RW+M2UT%-Z7F-PW8S.O8<U(1(
M><9XW6I&I:[#FA)>MIW1H>> )C1;PG'5=DZUSD.9ELHLC*LXK0ZILMVB<@!8
M;E]WB&7YM+'<U.X0Q=(!9WEU@PY!+!^JEM<YZ!+%XYEG>;6#SD"LZPZ65TSN
M!D?[G_/AX#8TKV&$W)]6P>[C N%,^X1_')5.^.';'5HYWC5,(=Y3<H9H+4[4
MBL4D9=^B9N\T_FQ 16?X\,+0 2[(+FYGV^(Y>$ AX8*;($Q+,T3/0!8W*TG/
MV-I\M \A<J$5=AWO*4X6V9O)E_EOGD/L>)R$%/G.VNB5DFBT?$+5WN?%=A=[
MPAR<E$ ]8QLQEX?O$3V%5^\8*7UM1C"P/'>!OWI&X::<P)!1S$W($W;3M@C/
M:_3BXQWP,1PI\^4S>G>BKU<S$HZ. O^2! +#2T0>B6?+.>4QM%'_M$4NB-%X
M_^2&")'H[1,*=]CEI0D*^VAD<(IV".(#!_4KF,+FVFBZ" -G<>M'H$$D,7GD
M@0T4JVFW^$0/#I:')VO=+479EH.%H/A397N9LG0X"BZQ8YK*9A?^1&\0QIY6
MK?40H%90$"UUU;;4.\MFM";-SE* 3_96**^0Y4!J-20T\7%9Q%@*_PE*?QED
ML4IM*7XLS]!ABZOK\I8BU>V1+S8Z+ TGGG#24_70+F RJVN>*.+$5J.EG"44
M;4RSU5) 3MAJK7C0TMA]9_LQ]U)T 9NE$JSF1>DCS<%HB#0!LGUW_XBC[\>\
M[!OL@Q8&RL-#$*5ATNOW;=J\WP@IP_L%R@_"*[],.C-4Q&QKP,E^X7A$MWU:
M(U(GQ<W8C1WK838?".G<^"BG@XGHDQ.MJ0YD2@-M3EH*ZS5DD8!5[TS&A&KT
M7(%JMW/('36BWX1)*G;O@_@*1="*7!6<17]'BQ6(X%*#M#KS++YQ<$@*6[/*
MPW3SK2Z7DA&K%#;71A,8C7&(7<""R=WL=N?*3H=71WIB*>KW="XAQ>X_OB;U
MB%P$1,-QQ5U>M3'.=>E+*\!^6;"++^FK%T,\-L?UX)6(H;<T4<['=8D^#';$
MGLF'_+;:X*._HI,M=5RJ_\^&57$$;917'DSB4LAH:=3*$JG;9:<W6\6UW(4K
M5I K^;BE$]M28*15X#(N':F<(X.8&5ME[V1+$9*UO$4B; P13QDQ+[&I+75T
MJ\EYCH%F*3[FQ#W=)-0*\Q ?S%)C1$4ST^8PBQF=I&:\6@IP"^9D&<66WR]5
MLQ<85KCEUT<5N$C5-V#YA5$%Y%B^B4[NA@XT\#F RZ!G%'AX0*%+(%BA^?(*
M 2 N3N%X>;J:K8#%HOC2\9T%=H#E/(]^%4%Y# .NSR] !WG.8NYK40$83E/=
M7QF:;L5T1JBST<BL;]Z%?NV\:7OET$?DD<D_.&$\P-O_[:X9'V:T?PX=/P)6
M(1E?%_OR7[AWB:4','*+^DB#X"9^H^'H$F38$;.RV0!JL988VFECZEJ<*(Q+
M"P,_'1<%?O@V6R[ANX0SLH1=ZHPX#0VS?&E#JF_A(>S9$CG2V[?91WNJ17$%
M MCT$=B3I,>*<RO8G88#<B2L%BWH9O3E,;FS2.Z!,96QAK-^#1^DW/K=F<P0
M9-!4%+DFE>O+"_ [CM?E+FHSE1YU(*?_F63V7B7H.:AJQ_G1S2">T\&TVTM=
M):[>BFUJG)::G.T\K"?JDI9CR398"(8\E71$P##46M8VI"B1XP1+$-GE:+7C
MQ*NA#=,? %12.\>)9$,OE=BK\@J@Y9@..>]L&-6.3C(!)5AQ%,G';;8N3^_O
M(AC0?,S>8JZC6AR69OYIQU1XA\"B:^Q],>1=(T'7VAOM7U"P"IWM&KNEV-X1
MWX<PV"*R)_W%]1\)3E,A[U%\L3^<N0,( PIB&T]H1<@^SM3QJ#YV?EM-Y<%3
MMT"XS^C-?SB2F__BV^6L1EOI#T8]SSD^CV@;A'$:%3\PS<4^_Z.<WUE^I)Y"
M8$_ KJB^^!2W)+^MB=5A(RERDTMU-3"E0NP\P-D6UV0/8RK<+@-8%4' B=F\
M5[GS\L20._ '4X>^E @GAWI9>%INPIP@D OW*D?<60J>E) _P,/F.$OA:7.<
ME'5IOLP>&6AR#E6%S6LI?LK"G9Q0HW$-M!+N:OO8]DQ6@7W[B%?K>+Y\B5!Z
M#SZ:#-O)L)T,V\FP[6I*<U"1'$)0>I&L)GT8<^'W&<"Z3*;M9-H.1?N93-O)
MM-5NV@JD]LA0FVS;R;:=;%L3MJW K!WL/4W[[%AI;;(](=/;UI.=/]GY9VKG
M/Z(=\A/$OIZ6_WD :/=GO3,?K\51''A?]W"T/OV1X-?7RV"S=7SZ)62I+OWZ
M-/_.\FG^71](?P^6RXWC^W?.8P BZ-9W9_[BIO;;NYAS/5=QA'/4FFVS(*9W
M?G49#KR7ZBQ":\A^H('P44L7T/% MU36G+6WQRQO2;QS*-!P+.4I]?C&WR</
MF([XAD6/KPHWEZIF/*+K6OWY6+NZ9&0R=>@I>8W0'PF,?@UG?VQ%&;S:G)[W
M]?>PZ]8_L[T)ST65&.[K2O2V)JXR>(Y_[VSX,-<::?,:/+\%S^L@B1Q_\?P&
M,.Q)4FZ\!QD)/^ =(M]E>PP4>O?EXH0O.R!G7OR(/->^Q&C!CA0PV_9,+*DY
MZCH1G5\Y#<WO,%&5-&9S\Z1S??BTIGT[Z8M%%SGH*^U,X+J&<_/"B=""V"S(
MCW)5)G3\54I@!*K$H<V#LR>_F[TYX2+]#SDQ0!^3DH*=?,H 9->;K1?L$7J*
M _?[/%6"N&<5N[V))PP/4+(KLE7;&#Q4.316F@Q 'O$19;4V3WC#*\:G_(X>
M=3-A!HE4W8JQ0U<M+?7+\'73@V6MHCU:BI24TGGPRS 4/DNQD54:.?ML! F
M/'VOSC@4#K,4FCZTRS+?<50RRQ&FZG.5+=G)$EB.*L_:K%R*KBBJ(P.%QW1L
MY<QRD&BF"XUC1@*'[$:JB3';@X22J#!WG.4O9HKPX6A>EK^4V9)S[AH1O4Z?
MR62&]?(_D/^\@KKQ'_\_4$L#!!0    ( 'B"7%:J8I2<6@T  #6I   0
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M!P]7&?E,9V _?Q@&Q_8=\#:__KP'.Q;?=<5ADJ/LQ[?#=\<GQQ?'IR?G[FS
MPLA_'XF,^G8>P058NY,TCM-K-*?U9S2E<_(*KM'2!GLE*'.PB\7LSJ=@3F/\
M69.!7WUSIE4"_^;?3(!Y1^5/";$.[-:W%T'[N_OK(WP>1,3\[:^?#_;VQZ\&
M;]^2D!E\",Y #V^.JW_?J4:O.A#'0&F3DP1"YPE5DXJ##/X6S-6"@"B2Y_P
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M1P='SUX\V7MR\.3PZ0]8#+#=<5.$3Y@7D)A0EUU1CYGV?ET=#+-Q#[S&\8Z
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M>OT*)6M_R-;D'5B#0]9UE_J.APR/SNF<^KR"6AI*EUCRO-#SY3S4C?'>IWS
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M2X\=T4;HLS.%K?1,;*4VI2/&+F2.E1VZFLJISKFP&_R&XZ\M,XX*[XW_)(M
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MB*1S^(C3D^'.Q6_##^\NW@=;^__8/R!P!%E5%<:CA5;#9U).^7I\[FX DZ;
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M3GWY9*7]! 3L($BDC'H#5=SL*U 4]<:6KGME0?U?I/<?@TTY8H4%Q!2[PQ3
M1(TQET>%.3IC#MQ+UVH/OY2D,BBY50_YZH:(ZSH!UM)9C#0V3I+\GZN*\P@C
M!;O-W2&K<TOGV'5B=Z?MDYX71)]%_1$,]5K%2"VSP3@)<PW_H>;V<3E+\*QC
M.XB0>24S,\8N'RK1<46V,DOA%L(OP ^S2<RE07TFNF!L+T'1ZH)!VEF:SFR_
M)Q4AT(EE,^&<Y*O(]Y7W)[D;)[GK_%,W:E7C=YO--.5:6LHY7'\6S@."0XCJ
M7"X0NG;6[7=NUQM*;[(TP]0WUL6.V;6FCXC[7%J^P7W 5,AK]L$8'I10PQJ7
M+^>.@3"#68)<X_AYLX\+62_T!Y7-XEIGOSG<+L8)SK@,=X)1\ZJY#0@$0Q4J
M^ 7.2R( D$T!60#.YGWYI$,[XV9G;6N5L#'BY2*UY'T=('-WI2O5HQA[%..=
M4(Q/-W\./<OLAJOFKA<D77@96LJ_7FJKTOSFKE?.36VP&8HYZMGC9)F& KVX
MAJ\O=B9IF05;!T^V01V666ZA* TX8=CDKV4[OG! Q*7: _T9II[P<!RNPP8O
M_.Y\[/\*GWP-PJ;AT%3]Y5L:CJS68_U1WJRCW/42J24K&PUJ:M)(6#77&1$.
M)YB8&9BO,RW]%E7D*I33ML.&$.)[W,-6.8\TU2V:K G'"#Q(+!?2+.%!J+J)
MNRA(1V3G8<-G>>&"E,$\+G,JBHQ@90SSVF"G8DU)1,L]A5DC=/"W]I_^X+HY
MJ$LPVR^%>HK;2M"MW>BP0^@EPUDL]B\/!I%K]^UJ@NH0WU86+-?$QK%YOA64
M7A.A!PZ$0T_#4C*\NG?VNR&&N@X/D[9L*'.:[S5R31LXQU55LM.\-_'8-Y%D
M2U7.(N0BYJC2TH6'L@6.5 N;GT8&7E0,Q2^U+Y4<"K$>5%_F\L9*0MG"!#Z?
M55_[2-(-7J'@<B4#H]8GGD-/+5!GX/;G G6=UWBZ+337+AF+ >G,8V?*SZC/
M3JC!D#&7X>]Y*@UK44#.L%TMO' (25YJ^>75BEHZ_3[*V!'!TW7HG&?_D/,Q
MTG!(Z)!>J\R59=L#A6<$H=V%II#7"L,GM)S$5KU[KH++N\[F6,TS*:O&XCYM
MD>_D5'WVV';ICU8WCM;SCA\M3Z??[_RTN0"N]WBB+ZW&:K2,60HS<X\'T&FQ
MNO:CS*TT 68VPE;C-6]BV6JWCH0MWR=UN\IB^5H^AGL0^1G+_2U[UV!=#\%#
MB)$7'1<CGH;V^R7FE711L0)[?\LDX[B,B 8$H;,8R(C!<.7JYA#.&U*^X:4A
MUYS.P5_X%&/BD+XO9635Q_DBAQ=VVV_QTA14E]C$>4*&M(BR6^54K9FG)X%(
MYE7,))3'JV($]?Q@J[3B;U!S5Y(2^C,Z"6B-8,,3!"-06"*O5Y!5+1/(NL T
M82\8NB$8]O<Z+AE^08-]Z/6'S@*MLM@T:CI] %V+ZL_+3  $5VJ,!-KS%/Z:
MYS<S&-6KQ@D;Z)()H9_9N(8A<>  ?R"<GOX\UG,J]T18 @(1@Q'"=W;R:T07
M>?>AQ+]8 *RU&]Q /71_[7'D#P?=[Y'[/G+_I\'9Z\%/P^!L^//IKX,/!-H?
M_OMB>/;S\<G@XO3LO%=S'5!S^WN/#[6/EBW,;DP^+ZB/*^Z>9P/1''_&OT=\
MP829E.%G"G$1; Q6S_53^0Q"VOCM]^K:3@SCCXJA[P-0;FQ!1WJ4&3 L+U4V
M0O@^\10A4:AH..+9P-9&RWDZV(JY'F-HBU/_^.RY&7^"$9*RC#1H82/M:Q6J
M4S2!,1"V="^X8$XP/V1VAJ<J*G%U47&\FRP&X^-583'MS6KO!A\CW-+ @J,2
MEVDA=P;/-:SB_75H,$70>3S$-3C)P G(:-@XC6I<C6<OEV:HA:.V<!$'6'0W
M %Y]\0=H>+!AZ96*B2>:F);:4JHUGA%<B\: 9F5BQF9.M$DN%<&N@_6YEBZ3
M>P@MMWV^6U!;0U%O(^I(;"DKL6CK$%+5+?KYF] O";&-=0\.=_=#FBSR)*&C
M1!MDBK(B]G",0X2B9N^(WS:3DSO%:>D:74IK\G:5A]2#%'N0XIU BL\V?P[?
M#J38>QR;XW$<KX7M]?V7G%V.X<FOQV>G)S\/3R[ X7AS>O)F>';2^QF=\#/V
M'Y.?06>G4)^T9)LH-%UCZZRY""]O?\7E)41GY.7^X>Z39X<_O%IZ[1^TQ=31
M[K.]@[[%U/T.0O74Y[M'SY\\>[[_[,4S^/?)X;,?Y)1T_YPLNRS#Y,IDJ2T@
M^Z"N<\MD*T5KZ(%(<546P!LJC:GML;) 4JRR0D<,,:QZAH6K&H\@X^O#)7!]
M53K.Q)"Y8X8TKO;;Y<'][!)X8O"HT.%E\Y)(#+&T:PR;G\[HQ\;C,(AP!:M^
MVX._W+8]>/KT3^[QP=>R;C??0(>M%X)*J@->A;608@<*" G Z [= 7MQ_FC$
M>?<9 T :)MJ0.#.(&\@>3/[:9[7+7R=N'55M]5/; __\B;<Q1XR3ADR=@CCI
M(@7591)D' N%!!R_O(K7);1Q7ZJVQL:_!/(B+;FL(3F&/%7_55F4EGDP0Y(4
M(YS?A.I./YMQ&$0JN=097H'Q91695#'C?%Z.I"4@+I5@/Q@U/84!(<E"M5Q9
MBGCK7"[DN#).(=(3DQB;)V;(U/A5RZA"_EOTJN6B:Y47NN4">'-C?XHKKOM/
M"0;!SJV7T7KXLUYQQ3R-X[+ (O/E*_"UQ_*W]K_>]$TL/9^4L5O)ZHHT$Z9D
MVNC<P%D$(V>F54+%X$*JOO0"!%OX[L%0,#Z*(6R=95PTHW+WU(=2PQ1!^ ;"
MY;W;U)_MB[3YEH7=^6TA^$>@] A&CZ6=:;)"ZO VXU_>(/<*O,!$K/(6EN4.
M@*/>WG@T]D;W>4V(OR1<$R=OV<CX)J9%0=56F+RNBK<H<^F 4L*UAIH== =Z
MS:P[QN,TBVXR)&HU2EQDGG]";1YK]8G&E,]-''ND*2U2F6C4P@#V@+.UF$M,
M2FS!7F:<1R=KR-D-2Y#U6J4JUW]@-E*TW[4B5C?6O45K8^#>ZUJ7,[H.4K#[
M%!(^BQ,8M;:&,C:,=5AU1LFY4%FV(!I&I$A&Y@GT"$A2A=AN"$Y<& C:8,G:
MD!X?V%U$RL%1F-40G<0 ,4?T ?H05!P9++3*^B.Z+B_0.AS1[E-#</,N4XC3
MQPK>)(7]C4%EBF;4'A!8I6TKZE:ZY<2QL90<#<=#/;)E3:CJ"2O$5.:N<#H3
M&O.QJ].\Y5&6F/:& 6-Q!IM,2:/Q+!DV%I!D!083360+1]3.O7T$MT7F%P7V
M6P<F?=C8#J(VM602?A[',/,K+3"R8F%OU_877BIGSP54P@HR=8)_LH:AX+-R
MB\SR:2:Y#=$XG6F[ON[./N2JN1H6.)A03I#M'?RL;:*I%W\A(\A0]\*V2Q4%
MG I]R9 YL]*;;-D@'E*S&F"QLA9@E33O45P]BNM.**ZCS9_#32BNWI1Y-*9,
MU^EER)0A\/M]%$3H'!3R)E@Y$VPX9*RUMNAA0I-+G5:K6I.N9!A#0*1\%=,1
M?2BAF*5HQPIP0;WY2QM=5MH[*VOS_JW#">\^C\OF9'&_28#URVR1_:>A_/]W
MW<6[1TM16%Z9-'92>UE*]@)P78[G.@C KK/M7*1,%M6LC4,F*>E80]"(M,&"
MO\K"H.!/[N<OJ(]JU;E>U[Y4,>G"8_]3<EW8BH)"$K@\G*I BT((H=>S3N6Y
MXG;31._GLU:$TG^9ZMHLYRZ(WQS1)R2:.?L32==7J4NKS3ULLOS!KA5P&4R8
M^/&I"K!*6DMBAR,E><4.AB6 O:!9EV.P#H*F\WP\*3H_.EIXS)8PM\9QKAI/
M6=J;.QMDX<V6TAT,LKO98S?;?7_>( NE"X_'-T:TGK0:V)\3GE 6/$]+%?@M
MQ!X\MC>1-N5<K8/DZCQA$(@N6ZKNYS8H,(1!%)T7UBQ 6K$K96*"II@$"T.K
M0G(B/TC')=>+U_O++Y/BW@Z%1<0CIFFPYLI4?.I_VL+R\+"AD]+$A2:<P<S)
M&.LKY#ORQ@>2.,T*9_Q5*U";VJL[D [U8N/QB(U'4/!U::YJ9'NH]AMVBS31
M;&$HX?9=-YH1(H(\,)RA)IS8X@29N&OD&? 7A)9=X: 7-38,O"(=P<O="&;3
M=WR8G&L6;ON,KA)>%;*&[25'\(TR2[A%J!LKMS'4(\;U-<84E5DE/2<D:K%!
MN2U[D[7!U#KF_76MF4J-LZTA50D$Y&RG:N9@^Q5F7K*_RC#S5_CL7FZMR:%:
M"[G5^<JFV_H*NG:"ZA+MCB)0QXX^%"R"D?0(#H5 F$4 =QPD@> D (B2,EO*
M0 FR1:RCR" S3[Q@#)'[#>L]0!@E:=*TDUJK1M@[O.--JU:'A,VI6"O".E[W
MKECLK^^9!@_MFMYB&,;Z4LDK$&S] 1=2BUP<#AS83.W8C[8I$PHWGM!ZN7?"
MD<VZ_I->]QW<" H=X#VQDW:0:!UQ1!'>6K2Q[5R6][WG7.K1.E^$UGF^^7/H
M&T-NL$E"5D?730[B,=STHDTV"CH@+AK<\6C'373"G)@Y&A#. "PZLFUIUH%M
MFXCI[*SR9.$09&*=4U^PG)I_C<&&PD+KALGN.</P%Z(T=W9\S6![8)-/$K^?
M3!)9"S516&37 .K#>B3"[4G&*[L$,(V,N%1E:<CLK_L>_6N\)J]QDSB,>NIB
M _FJ?SS]E*$#!F_9)5K[MHF\O.*NDL)\TER_"1^,.-EXF<*K8ET$58(SDV%(
MG'DJVIW'RG\#AS"+R#=:N,-42_TW(98NQH_I/1@\_(SC89>N]KHZYW5%_!Y.
M2,&4&MQ9)&1&#?@G^D.-N:(B!-=(P4*-L?HL2VA!\+10#P!;[+ ZZM_2 &5E
M?4R:>5@KB=']@WUL6\LR,Y<6,SO&PT;E,#('C%R&5*A1S8>V(+1?X\P(Q4%Q
MO59/]K8)BF0!7WIB,CS\8SGY?AM(*?*-;B(<8-ANLV^T)#TDFND(M8MNB99.
M&#8B%;QHM(2Z^QU:GQU:$5-C%);?F[FE:9L?.W.-W:3-.@MX*OMU0E^$6);&
MW[Q[44]/O$'TQ#T_L<]/_'%P]C_')S\%@[/AH&<E[D)$Z:#[;*L5^!:336CS
MS<%EA'D%6R^VT8*GKB0TMMRRL_PW3;37, 0^/1]/=52"-K',8F\LBQ6C\_ +
M6_N-^]G;@4V)?<'JCQ*+XV1X^O/P;7!\<GYQ?/'+Q3 D55;3??0 2FZ#SN-6
M'RUWY'IPRNM("Q=EN&=)G5NFI2LIVK_.W9X@%F$*NXN6\=LTCA4HVJW_\W1O
M;QLMVF &3YXVK=^^C]C:B_ [2I,_I2770TTN"Y'E]!LO8",)YU;U;IR^O<K;
M9)5W^ A4'I$I6I95E,\M?2N)40VO0>U"E*V&8/=C;8N5\S26*"Q'<ZET^?Y<
M_8>'WQT#]6SWV;.C'@/U9S%01[O/7AP\>W9P=+#W].#HQ8OG/\A!ZOQ1&B3.
MX*,V[R;_E#OB6H/<_(0WFJ>@=Z7?VC7").,8HYV1LYX.PKV]/?S?MDL]8#_I
M,,#2^SD%%@EY0IW9)"P%YA7G7?QR?PHU"\U@'&,]WI66Y(54J?%8B'& CCFI
M.KK,&FR3DCK6$ULS/?I*Q66CS;2'X(1?"V<9+\6,*<A+P+!JE&:&,'EIAS93
M4:-3WBK $5BFUQJ&AFW_,-9/]Z+'>^5 WFU,SLDG:I17B_>X,<.;',?-;GD4
MQ6>R),MUQ)/[*.1%]R>4[65<=V5<US$7@V!>CD!FN/SO8EFR.?DQ2B-X$ESP
M1YDMPHKNBY.W7!E2W0?.83E;.G[S,LM+K!P1\D1;$N-]S\N0^1!R)&XTF%P!
MLZ7AU<H]?-3C2IE%Y7283(;KT+EK$Q"2)/3OYR?(+*[2Q9UOE4NAK87V>Z?>
M)G'F;?+F@(3+M\4A[G70N4#+&/9&7FG7=Q4-X81>*09.\"X33QZE/W&ODC00
MG OV/;U-Q4^(&@@SP92#-LE5&E^UG)Y(JV(J]';U8V1)1 /L 8!:< 9+7-AJ
M3_ZM6<_AU70*HT\HO4@QKXDZ%_[=78T [%7:HU%I7>=('U3DG\@&F67EG. '
ME5X#6<SV,ATEMCT-F<5F1KU\:ZV&X81Q;8!?)T#6.0H'K3)N5:&*(C.CLK E
MC]03!08:Y_QDT#,]"KU'H7\)"OW%YL_A'IR1RSJH5T!?O .826([^^741+"L
MWULE=5P9V8!/W<5 WT=P;I57L5Q2Y90,)>K8)J0JW')&JB4E*B2!:-N"?JP7
MWCK<YE1=5?GD+^&:K=']&0%Z\[2[YFG7FU<,J*K"FJ*.?I7*&!&^7@?^4M"Y
M#TFNR_:MPP'I>NN(@8N\+44BVY@L[AGYZ-/WFWHVZ/7O?#R^IAWHM<?8-\<K
MM\PV$R8$5.Z>@Y&83P@-O:@W(0KA4KZ6\GP1EY5P&"++_2.#+ #SHDG3A'?
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M08$][3RJ]*)22Y@P\FG]L:: (CM8SP[OC.5WPT@,Q=C% 'UMPW+X45*1O#:
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MA,K@VXL.GUSJB 7J>G+)L4#:YJ0Z(&7 2QPA_.X>5Y"86*:;4&2T6839\2]
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MVI F]2+H2D(=TVO&J>'KH;2XPIFF)GK&LK\516W!+I\K*$Q7L-/C'G*(S8K
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MLON7*#+CNHD'Z:+CJH0T0N%$D6*)BAO?DXS**,8WY?,<EJRA;6"M'L.#=P3
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MY$*RP3=)(C2!46$A-"(T\0NVG07<RD&&S B7DL:^!9(;'&C  W4,722,A21
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MI"UO8E ?4^F2Z4EN/YG(O@]&F [-"%;[8J74#<R5+F.MW%SZSJ5MZ\(YJ#0
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M"O>BQ?0T]+M8H-AY](<[*Q9YRJ"AX;,U?@5C%#L:( S@5QJHRE4E!DH2DR<
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MNB;^/U!+ 0(4 Q0    ( 'B"7%:^JC[T<7H" *-* P 2              "
M 0    !I;6<Q.3(S,C$Q,CA?,"YJ<&=02P$"% ,4    " !X@EQ6?Z4=S!JK
M 0"V%P( $@              @ &A>@( :6UG,3DR,S(Q,3(X7S$N:G!G4$L!
M A0#%     @ >()<5JVM)AA&'@( 6;$" !,              ( !ZR4$ &EM
M9S$Y,C,R,3$R.%\Q,"YJ<&=02P$"% ,4    " !X@EQ6=\DG\$DN 0#M: $
M$P              @ %B1 8 :6UG,3DR,S(Q,3(X7S$Q+FIP9U!+ 0(4 Q0
M   ( 'B"7%9<%20IM.X  #U# 0 3              "  =QR!P!I;6<Q.3(S
M,C$Q,CA?,3(N:G!G4$L! A0#%     @ >()<5A.'U2P4:@$ 190! !,
M         ( !P6$( &EM9S$Y,C,R,3$R.%\Q,RYJ<&=02P$"% ,4    " !X
M@EQ6]U'-NZ$;  "D'P  $P              @ $&S D :6UG,3DR,S(Q,3(X
M7S$T+FIP9U!+ 0(4 Q0    ( 'B"7%8H"F+("&L  %VZ   3
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M9S$Y,C,R,3$R.%\Q.2YJ<&=02P$"% ,4    " !X@EQ67;5Y-HYZ 0 VG $
M$@              @ %+'!, :6UG,3DR,S(Q,3(X7S(N:G!G4$L! A0#%
M  @ >()<5F'/*J.#?@  B9   !,              ( !"9<4 &EM9S$Y,C,R
M,3$R.%\R,"YJ<&=02P$"% ,4    " !X@EQ63HC?*N$[ @ ;R0( $P
M        @ &]%14 :6UG,3DR,S(Q,3(X7S(Q+FIP9U!+ 0(4 Q0    ( 'B"
M7%9ODYM9V8P!  WF 0 3              "  <]1%P!I;6<Q.3(S,C$Q,CA?
M,C(N:G!G4$L! A0#%     @ >()<5CT#_Q5'0 $ K)D! !(
M ( !V=X8 &EM9S$Y,C,R,3$R.%\S+FIP9U!+ 0(4 Q0    ( 'B"7%9.SL5:
MYA ! %1C 0 2              "  5 ?&@!I;6<Q.3(S,C$Q,CA?-"YJ<&=0
M2P$"% ,4    " !X@EQ64Q@&7^=M 0!+T@$ $@              @ %F,!L
M:6UG,3DR,S(Q,3(X7S4N:G!G4$L! A0#%     @ >()<5JN7VWY, @, A:8#
M !(              ( !?9X< &EM9S$Y,C,R,3$R.%\V+FIP9U!+ 0(4 Q0
M   ( 'B"7%;BR0CZEDX  +1;   2              "  ?F@'P!I;6<Q.3(S
M,C$Q,CA?-RYJ<&=02P$"% ,4    " !X@EQ68\V4 OBM  #9_@  $@
M        @ &_[Q\ :6UG,3DR,S(Q,3(X7S@N:G!G4$L! A0#%     @ >()<
M5LO K,CYH@  &O,  !(              ( !YYT@ &EM9S$Y,C,R,3$R.%\Y
M+FIP9U!+ 0(4 Q0    ( 'B"7%9&LC,A2 P% %T'10 1              "
M 1!!(0!R<'1X+3(P,C(Q,C,Q+FAT;5!+ 0(4 Q0    ( 'B"7%:_%<R4\QL
M *%; 0 1              "  8=-)@!R<'1X+3(P,C(Q,C,Q+GAS9%!+ 0(4
M Q0    ( 'B"7%:Z3B=9QQ,  !8J 0 5              "  :EI)@!R<'1X
M+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4    " !X@EQ6:,('\J@]  #*<00
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M>#$P7S,Q+FAT;5!+ 0(4 Q0    ( 'B"7%9\R*'%UJ   '/6!@ 0
M      "  9 ** !R<'1X+65X,3!?,S(N:'1M4$L! A0#%     @ >()<5EP
M$V?2"P  ='0  !               ( !E*LH ')P='@M97@Q,%\S,RYH=&U0
M2P$"% ,4    " !X@EQ6CPWHZB4#  "!$P  #P              @ &4MR@
M<G!T>"UE>#(S7S$N:'1M4$L! A0#%     @ >()<5LWM_19("0  854   \
M             ( !YKHH ')P='@M97@S,5\Q+FAT;5!+ 0(4 Q0    ( 'B"
M7%8O.GRX6@D  )M5   /              "  5O$* !R<'1X+65X,S%?,BYH
M=&U02P$"% ,4    " !X@EQ6XO3\6W &   M7@  #P              @ 'B
HS2@ <G!T>"UE>#,R7S$N:'1M4$L%!@     D "0 !0D  '_4*     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
